LOINC_NUM,text_representation
25138-9,taurine/creatinine [molar ratio] in urine
25138-9,tauie/reatinne [mor ratio] in uin
25138-9,taurine/creatinine [molar ratio] in urine
25138-9,taurine/creat ur-srto
25138-9,ur-srto taurine/creat
25138-9,taurie/ceat ur-srto
25138-9,taurine/creatinine (u) [molar ratio]
25138-9,ur taurine/creatinine (u) molar ratio]
25138-9,taurie/creatinine (u) [mol rt
22100-2,avian paramyxovirus 3 ab [titer] in serum
22100-2,avian [titer] 3 ab paramyxovirus in serum
22100-2,avan autoantibodies prayxovirus a inserum [ter]
22100-2,apmv3 ab titr ser
22100-2,titr ab apmv3 ser anti
22100-2,abitr av3 ser
22100-2,avian paramyxovirus 3 ab (s) [titer]
22100-2,aian 3 aramyxovirus ab (s) [tier
22100-2,aan paramyxovirus 3 apmv ab (s)[titer]
62549-1,phenx - alcohol - maximum drinks in 24h protocol 030401
62549-1,protocol - alcohol - maximum drins in 2h phen 030401
62549-1,phenx - alcohol - maximum drinks in panel.phenx 24h protocol 030401
62549-1,alcohol max drinks 24h proto
62549-1,max alcohol drinks 24h panel proto
62549-1,alcool max 24h drinks proto
96252-2,arsenic.methylated [mass/volume] in 24 hour urine
96252-2,arsenic.methyated 24 i ur [mas/volume] hour urne
96252-2,[a/volume] arenic.methylate in 24 hour urine quantitative
96252-2,arsenic.methylated 24h ur-mcnc
96252-2,ur-mcnc 24h arsenic.methylated drugs
96252-2,arsenic.methylated 24h drug/toxicology ur-mcnc
96252-2,arsenic.methylated (24h u) [mass/vol]
96252-2,arseni.methylated [mass/vol] u) (24h
96252-2,arsenic.methylated (24h u) [mass/vol]
43423-3,sodium urate [saturation fraction] in 24 hour urine
43423-3,in rate [aturation frcion sodium 24hou urine
43423-3,urate sodium [saturation fraction] in 24 hour urine
43423-3,na urate 24h satfr ur
43423-3,na satr 24 urate ur relative supersaturation
43423-3,quantitative na urate 24h satfr ur
43423-3,sodium urate (24h u) [saturation fraction]
43423-3,sodium (24h urate u) [saturation fraction]
43423-3,sodium urate (24h u) urn [saturation fraction]
26595-9,hydroxylysine [moles/volume] in cerebral spinal fluid
26595-9,hydroxylysine [moles/volume] in spinal cerebral fluid
26595-9,ydroylysie [mles/volume] in cereral sinal fluid quant
26595-9,oh-lysine csf-scnc
26595-9,csf-scnc oh-lysine quant
26595-9,cerebrospinal fluid-scnc oh-lysine
26595-9,hydroxylysine (csf) [moles/vol]
26595-9,(csf) hydroxylysine [moles/vol]
26595-9,hydroxylysine (f) [mles/vl] quantitative
63524-3,carboxyhemoglobin/hemoglobin.total in venous cord blood
63524-3,carboxyhemoglobin/hemoglobin.total bld venous cord carbonmonoxyhemoglobin in
63524-3,caroxyhemoglobin/hemoglobin.otal in hbco venous cord lood
63524-3,cohgb mfr bldcov
63524-3,hbco mfr cohgb bldcov
63524-3,cohgb carbonyl haemoglobin bldcov mfr
63524-3,carboxyhemoglobin (bldcov) [mass fraction]
63524-3,factin] (bldcov) [mass carboxemoglobin
63524-3,carboxyhemoglobin (bldcov) [mass fraction] quan
15059-9,dopamine [moles/time] in 24 hour urine
15059-9,dopamine [moles/time] in 24 hour urine 24hr
15059-9,dopane [oles/time in 2 hourrne srate
15059-9,dopamine 24h ur-srate
15059-9,24 hours dopamine ur-srate 24h
15059-9,24husrate quant dopamie
15059-9,dopamine (24h u) [moles/time]
15059-9,[mole/time] (24h u) opamine
15059-9,dopamine [moles/time] u) (24h
82416-9,deprecated histone ab [presence] in cerebral spinal fluid by immunoblot
82416-9,deprecated histone ab [ql] in cerebral spinal fluid by immunoblot
82416-9,deprecated hison ab [resence  cerebrl spial fluid by immunoblot
82416-9,deprecated histone ab csf ql ib
82416-9,deprecatedhisonea csf immunobl ql ib
82416-9,depeated histne ab ib blt l csf
82416-9,histone ab ib ql (csf)
82416-9,west blt histon a ib ql (cerebrospinal fluid)
82416-9,histoe cerebrospinal fl ab ib (csf) ql
47074-0,pcna extractable nuclear ab [presence] in serum by immunofluorescence
47074-0,pcna extractablnuclar ab [presce] in srum byimmunofloescence
47074-0,pcna etractabl nular ab [presence] in seru by mmunofuorescnce
47074-0,ena pcna ab ser ql if
47074-0,a pcna ab ser ql if fana
47074-0,ena antibody pna a ser ql if
47074-0,pcna extractable nuclear ab if ql (s)
47074-0,pcn ifa extratable nuclea ab if ql (s)
47074-0,pcna ql eractable nucle ab if ql (s)
626-2,bacteria identified in throat by culture
626-2,bacteria identified in by throat culture
626-2,bacteria identified by throat in culture cultures
626-2,bacteria throat cult
626-2,throat bacteria cult
626-2,bacteria cult throat
626-2,bacteria identified cx nom (throat)
626-2,bacteria identified cx point in time nom (throat)
626-2,bacteria identified nom cx (throat)
13502-0,borrelia burgdorferi igg band pattern [interpretation] in serum by immunoblot
13502-0,borrelia burgdorferi igg band patrn pattern [interpretation] in serum by immunoblot
13502-0,borrelia b burg immunoblot igg band pattern [interpretation] in serum by burgdorferi
13502-0,b burgdor igg patrn ser ib-imp
13502-0,b ib-imp igg patrn serum burgdor
13502-0,b burgdor igg patrn serum ib-imp
13502-0,b. burgdorferi igg band pattern ib (s) [interp]
13502-0,b. burgdorfri igg band pttern patrn ib (s) [interp]
13502-0,b. burgdorferi igg band patter b (s) [intep]
31418-7,heterophile ab [presence] in serum
31418-7,ab heterophile [presence] in serum
31418-7,heterohile b [pesence serum in
31418-7,heteroph ab ser ql
31418-7,hteroph ab qual er l
31418-7,ab heteroph serum ql
31418-7,heterophile ab ql (s)
31418-7,mono test heterophile ab presence (s)
31418-7,heterophile ab presence (s)
87324-0,porcine circovirus type 2 [presence] in specimen by organism specific culture
87324-0,porcine circovirus type 2 [presence] in specimen specific organism by culture
87324-0,prcine crovrs pecifc 2 [presence] ispecimen by orgnim type culture
87324-0,pcv2 spec ql cult
87324-0,pcv2 spec presence ii cult
87324-0,pcv2 spec pork ql cult
87324-0,pcv type 2 org specific cx ql (specimen)
87324-0,pcv tye 2 or speif cx ql (specimen)
87324-0,pcv type cx org specific 2 ql (specimen)
31378-3,equine herpesvirus 1+4 ab [units/volume] in serum
31378-3,equine herpesvirus 1+4 in [units/volume] ab serum
31378-3,qune herpesvirus 1+4 ab [unisolme]in sru
31378-3,ehv1+4 ab ser-acnc
31378-3,sr-acnc ab ehv1+4
31378-3,ehv1+4 abs ab ser-acnc
31378-3,equine herpesvirus 1+4 ab qn (s)
31378-3,qn antby herpesvirus 1+4 ab equine (s)
31378-3,(s) herpesvirus 1+4 ab equine rhinopneumonitis qn equine
94571-7,branched chain amino acid panel - dbs
94571-7,branced dbs chain amio acid anel - ds
94571-7,branched chain amino acid panel panel.chemistry - dbs
94571-7,branched chain aa pnl dbs
94571-7,dried blood spot branched chain aa pnl dbs
94571-7,branched chain aa pnl dbs
94571-7,branched chain amino acid panel (dbs)
94571-7,branched chain panel acid amino (dbs)
94571-7,branched chain amino cid panel (dbs)
3119-5,valine [mass/volume] in urine
3119-5,valine urine quant in [mass/volume]
3119-5,valine [mass/volume in urine
3119-5,valine ur-mcnc
3119-5,ur-mnc quan valie
3119-5,ur-mcnc level valine
3119-5,valine (u) [mass/vol]
3119-5,(u) valine [mass/vol]
3119-5,(u) valine [mass/vol]
62878-4,deprecated phenx measure - conditions relevant to immune response - screener
62878-4,phenx deprecated measure - conditions relevant to immune response - screener
62878-4,deprecated henx meaure conditions pnl - reevant to immune resose - screer
54031-0,smith extractable nuclear d ab [presence] in serum
54031-0,smith extractable nuclear d ab [presence] in serum qualitative
54031-0,smith extractable nuclea d ab [preence] dextro in serum
54031-0,ena sm-d ab ser ql
54031-0,ena sm-d ab serum nuc ql
54031-0,enasm-d ab ql ser
54031-0,smith extractable nuclear d ab ql (s)
54031-0,sm mith extracalenuclrd a ql (s
54031-0,smith extractable nuclear d ab presence (s)
62355-3,chromosome analysis panel by banding
62355-3,banding analysis panl by chromosome
62355-3,baning alysispanel by chrom analy pnl chromoso
62355-3,chrom analy pnl banding
62355-3,analy chrom pnl banding
62355-3,chrom analy banding pnl
62355-3,chr analysis panel banding (bld/tiss)
62355-3,chr analysis (bl/tiss) bani anel
62355-3,hranalyis (bd/tiss) bandin panel
20651-6,methionine [moles/volume] in serum or plasma
20651-6,ethionine plasma in serum o [oles/volume]
20651-6,methioine[molesvoume]in srum or plasma
20651-6,methionine serpl-scnc
20651-6,quan ethionie serpl-cc
20651-6,methionine serum or plasma-scnc
20651-6,methionine [moles/vol]
20651-6,[moles/vol] plsm methionine
20651-6,serum methionine [moles/vol]
9424-3,intercellular substance ab [titer] in serum
9424-3,aby intercellular ab substance [titer] in serum
9424-3,intercellular substance in [titer] ab serum
9424-3,ics ab titr ser
9424-3,ics ab titr antibody ser
9424-3,ics ab ser titr
9424-3,intercellular substance ab (s) [titer]
9424-3,intercelular (s) ab sbsance [iter antibody
9424-3,titer intercellular substance ab [titer] (s)
29672-3,bordetella pertussis iga ab [presence] in serum
29672-3,serum pertussis iga id ab [presence] in bordetella
29672-3,borete point in time petussis iga ab presene] inserum
29672-3,b pert iga ser ql
29672-3,ql pert iga ser immunoglobulin a b
29672-3,b pert iga serum pr ql
29672-3,b. pertussis iga ql (s)
29672-3,b. pertussis iga presence (s)
29672-3,pertssisiga whooping cough b. ql(s)
16749-4,propoxyphene + norpropoxyphene [units/volume] in urine
16749-4,propoxyphene + [units/volume] norpropoxyphene in urine
16749-4,propxphene + propoxyphene [univolume] in urine
16749-4,propoxyph+nor ur-acnc
16749-4,ur-acnc propoxyphnor qnt
16749-4,ur-acnc popoxyh+nor
16749-4,propoxyphene+norpropoxyphene qn (u)
16749-4,random qn ropoxypene+norpropoyphen (u)
16749-4,qn propoxyphene+norpropoxyphene (u)
29721-8,influenza virus c ag [presence] in specimen by immunofluorescence
29721-8,influenza by c ag [presence] in specimen virus immunofluorescence
29721-8,immunofluorescence virus c ag [presence] in specimen by influenza
29721-8,flucv ag spec ql if
29721-8,flv sp qualitative ag presence if
29721-8,flucv if spec ql ag immune fluorescence
29721-8,flucv ag if ql (specimen)
29721-8,presence ag if flucv (specimen)
29721-8,(specimen) ag if ql flucv
89503-7,rna polymerase iii ab [units/volume] in serum by line blot
89503-7,rna polymerase ab iii [units/volume] in serum by line blot
89503-7,rna polymerase ii ab line nseru y unitsvolume] lot
89503-7,rnap iii ab ser line blot-acnc
89503-7,rnap iii ab serum line lt-acnc
89503-7,botacnc iiiab ser qnt line rnap
89503-7,rna polymerase iii ab line blot qn (s)
89503-7,rna polymerase iii ribonucleic acid ab (s) blot qn line
89503-7,rna polyease iii ab line blotqn (s)
57289-1,neisseria gonorrhoeae rrna [presence] in nasopharynx by naa with probe detection
57289-1,neisseria gonorrhoeae rrna [ql] in nasopharynx detectio a wit probe y
57289-1,neisseria gonorhoee rra presence in nasopharynx by naa detecti prob wih
57289-1,n gonorrhoea rrna nph ql naa+probe
57289-1,gonorrhoerrna n nphql point in time naa+robe
57289-1,n nph rrna gonorrhoea presence naa+probe
57289-1,n. gonorrhoeae rrna naa+probe ql (nph)
57289-1,n. goorhoee rrna naa+prbe q strand displacement amplification (nph)
57289-1,n. gonorrhoeae rrna (nph) ql naa+probe
11238-3,hydroxyalprazolam [mass/volume] in urine
11238-3,hydroxyalprazolam ua in [mass/volume] urine
11238-3,hydroxyalprazolam [mass/volume] in urine
11238-3,oh-alpraz ur-mcnc
11238-3,ur-mcnc oh-alpraz
11238-3,ur-mcnc oh-alpraz
11238-3,hydroxyalprazolam (u) [mass/vol]
11238-3,hoyalprazolam (u) [mass/vol] level
11238-3,ur hydroxyaprazolam (u)[mass/vo]
44992-6,chlamydia trachomatis c igg ab [presence] in serum
44992-6,chlamydia trachomatis serum igg ab [presence] in c
44992-6,n trachomatis c igg ab [presenc] chlamydia serum screen
44992-6,c trach c igg ser ql
44992-6,ctrach c antibody igg serum ql
44992-6, trach c igg serum ql
44992-6,c. trachomatis c igg ql (s)
44992-6,c. igg c trachomatis ql autoantibody (s)
44992-6,c. tachomais l igg c ()
100962-0,"dengue virus ab.igg panel - serum, plasma or blood"
100962-0,"ab.igg virus dengue pl panel - serum, plasma or bld"
100962-0,"denue virus ab.gg panel - serum, plasma or blood"
100962-0,denv ab.igg panel serplbld
100962-0,denv serplbld panel ab.igg
100962-0,ab.igg serum or plasma denv panel serplbld
100962-0,dengue virus ab.igg panel (s/p/bld)
100962-0,dengue vius ab.igg pael (s/p/bld
100962-0,dengue ab.igg virus panel (s/p/blood)
31021-9,interferon.beta 1 neutralizing antibody [titer] in serum or plasma by neutralization test
31021-9,interferon.beta 1 neutralizing antibody [titer] in serpl serum or plasma by neutralization test
31021-9,interferon.beta 1 neutralizing antibody or in serum [titer] plasma by neutralization test
31021-9,inf-b1 nab titr serpl nt
31021-9,inf-b1 nab titr serl nt
31021-9,inf-b1 nab ifn titr serpl nt
31021-9,interferon.beta 1 neut ab neut test [titer]
31021-9,neut 1 eut ab interferon.beta tet [tte]
31021-9,interferon.beta 1 ifn neut ab neut test [titer]
100673-3,aspergillus terreus dna [presence] in blood by naa with probe detection
100673-3,aspergillus terreus dna [presence] naa blood by in with probe detection
100673-3,aspergillus terreus dna probe dna [resece]in lood by naa with probe deteion
100673-3,a terreus dna bld ql naa+probe
100673-3,a terreus naaprobe bld ql n
100673-3,a tereus na bld ql naa+prbe pr
100673-3,a. terreus dna naa+probe ql (bld)
100673-3,a. naa+probe dna terreus ql 3sr sr (bld)
100673-3,a. terreus dna (bld) ql naa+probe
27032-2,zirconium [mass/volume] in serum or plasma
27032-2,in [mass/volue] zirconium sermorplsma
27032-2,zicnium [ms/vlume] in serum or plasma quant
27032-2,zirconium serpl-mcnc
27032-2,serum or plasma-mcnc zirconium
27032-2,ronum serum or plasma-mnc
27032-2,zirconium [mass/vol]
27032-2,zirconium [mass/vol]
27032-2,zircoim [mass/vol]
40968-0,deprecated streptococcus pneumoniae 43 igg ab [mass/volume] in serum
40968-0,deprecated treptococcus pneumoniae 43 serum ab [mass/voume] spn in igg
40968-0,deprcatedstreptococcus ser iggab [mass/volume] in pneumococ neumniae43
40968-0,deprecated s pneum43 igg ser-mcnc
40968-0,deprecated s pneum43 strept igg serum-mcnc
40968-0,deprecated ser-mcnc pneum43 igg s
40968-0,s. pneumoniae 43 igg (s) [mass/vol]
40968-0,s. igg 43 pneumoniae (s) [mass/vol]
40968-0,streptococcus pneumoniae 11a s. pneumniae igg 43 s) [mas/vol]
74130-6,"6-monoacetylmorphine (6-mam) [mass/volume] in serum, plasma or blood"
74130-6,"or (-mam) mass/voume] insrum, plasm -monoactylmrphin blod"
74130-6,"6-monoacetlmorphne (6-mm) mass/volume] in serum, plama or lood"
74130-6,6mam serplbld-mcnc
74130-6,illicit 6mam serplbld-mcnc
74130-6,serplbld-mcnc qnt 6mam
74130-6,6-monoacetylmorphine (6-mam) (s/p/bld) [mass/vol]
74130-6,(s/p/bl) (6-mam) level 6-monacetylmorphie [as/vol]
74130-6,(6-mam) 6-monoacetylmorphine (s/p/bld) [mass/vol]
50771-5,ganglioside gm2 igg ab/igm ab [ratio] in serum by immunoassay
50771-5,ganglioside gm2 igg ab/igm ab [ratio] in serum iaa by immunoassay
50771-5,ganglioside gm2 immune globulin m igg ab/igm ab [ratio] in serum by immunoassay
50771-5,gm2 gangl igg/igm ser ia-rto
50771-5,gangl gm2 igg/igm ser ia-rto
50771-5,gm2 gangl igg/igm ia-rto ser
50771-5,ganglioside gm2 igg/igm ia (s) [ratio]
50771-5,ganglioside gm2 quan igg/igm [ratio] (s) ia
50771-5,ganglioside gm2 igg/igm ia (s) [ratio] antibody
60074-2,fexofenadine [mass/volume] in urine
60074-2,[mas/volume] fxofenadine inurine
60074-2,fexofenadine [mass/volume] in urine tilfur
60074-2,fexofenadine ur-mcnc
60074-2,ur-mnc exofenadie
60074-2,fexofenadine ur-cn
60074-2,fexofenadine (u) [mass/vol]
60074-2,exofenadine mass/vol] (u)
60074-2,fexfenadi (u)[mass/vol]
20941-1,deprecated phosphate [mass/volume] in serum or plasma
20941-1,deprcated phosphate serplas [mas/olume] r serum in plasma
20941-1,deprecated in [mass/volume] phosphate serum or plasma plasma
20941-1,deprecated phosphate serpl-mcnc
20941-1,deprecated serum or plasma-mcnc point in time phosphate
20941-1,serum or plasma-mcnc phosphate deprecated
20941-1,phosphate [mass/vol]
20941-1,[mass/vol] phosphorus phosphate
20941-1,quantitative phosphatmass/vl
98124-1,neutrophil.pma stimulated dhr panel by flow cytometry (fc)
98124-1,neutrophil oxidative bursts neutrophil.pma by dhr panel stimlatd low cytometry (fc)
98124-1,neutrophil.pma stimulated flow panel by dhr pan cytometry (fc)
98124-1,neut pma stim dhr pnl patient fc
98124-1,neut pma fc dhr pnl patient stim hematology/cell counts
98124-1,neut pma sm dhr pnlpatient fc
98124-1,neutrophil.pma stimulated dhr panel fc
98124-1,nutrohilpm stiulated dhr ael fc
98124-1,neutrophil.pma stimulated dhr fc panel
14836-1,methotrexate [moles/volume] in serum or plasma
14836-1,mthotrexate [oles/vlum] in serum or lasma
14836-1,methotrexate moles/volume] in drug/toxicology srum or plas
14836-1,mtx serpl-scnc
14836-1,serpl-scnc universallaborders mtx
14836-1,serplas mtx serpl-scnc
14836-1,methotrexate [moles/vol]
14836-1,methoteate [moes/vol]
14836-1,[moles/vol] methotrexate
17056-3,legionella longbeachae 2 igm ab [presence] in serum
17056-3,egionelalongbeache 2 igm antby ab [presnce] in serum
17056-3,legionella longbechae 2 igm ab [presece] in serum
17056-3,l longbeachae2 igm ser ql
17056-3,ql longbeachae2 igm ser l
17056-3,lngbeachae2 l igm ser ql
17056-3,l. longbeachae 2 igm ql (s)
17056-3,l. longbechae 2 im ql s)
17056-3,l longbeachae2 l. longbeachae 2 gm presence (s)
97650-6,desmethylcyclobenzaprine [presence] in urine by confirmatory method
97650-6,[ql] desmethylcyclobenzaprine in urine by confirmatory method
97650-6,desmethylcyclobenzaprine [presence] in urine conf by confirmatory method
97650-6,desmethylcyclobenzaprine ur ql cfm
97650-6,desmethylcyclobenzaprine ql ur cfm
97650-6,desmethylcclobenzaprine r presence cfm conf
97650-6,desmethylcyclobenzaprine confirm ql (u)
97650-6,cnfrm desmethylcyclobezaprine conirm ql u)
97650-6,l demehylcycloenzaprinecnfirm (u)
40524-1,macrophages/leukocytes in pericardial fluid by manual count
40524-1,macrophages/leukocytes fluid pericardial in by manual count
40524-1,macrophages/leukocytes fluid pericardial in by manual count
40524-1,macrophages nfr pcar manual
40524-1,anual macrphg pcar macrophagesnfr
40524-1,macrophages nfr percent manual pcar
40524-1,macrophages/leukocytes manual cnt (pericard fld)
40524-1,macrophages/lukoytes pericar cnt manual fld) macrophage
40524-1,macrophages/leukocytes manual cnt fld) percent (pericard
21368-6,levofloxacin [mass/volume] in serum or plasma
21368-6,levofxacn mass/volme or serum in plasma
21368-6,levofloxacin [mass/volume] in ser or plasma
21368-6,levofloxacin serpl-mcnc
21368-6,serpl-mcnc levolxcin
21368-6,serpl-mcnc levofloxacn
21368-6,levofloxacin [mass/vol]
21368-6,[mass/vol] levofloxacin
21368-6,[mass/vol] levofloxacin
55423-8,number of steps in unspecified time pedometer
55423-8,number fsteps n unspecified time pedometer
55423-8,number time steps in unspecified of pedometer
55423-8,# steps ?tm nrate pedometer
55423-8,# pedomeer ?tm nrate teps number rate
55423-8,?tm steps # quantitative nrate pedometer
4538-5,erythrocyte sedimentation rate [velocity] in red blood cells by wintrobe method
4538-5,erythrocyte sedimentation esr rate [velocity] in red bld cells by wintrobe method
4538-5,erhrocytesedimentation rate [velocity] in rd hematology/cell counts bld cells by wintrobe metho
4538-5,esr rbc qn wintrobe
4538-5,qn rbc esr wintrobe
4538-5,esr rbc wintrobe qn
4538-5,esr wintrobe method (rbc) [velocity]
4538-5,(rbc) point in time wintrobe metho sr [velocity]
4538-5,(rbc) wintrobe method esr [velocity]
74920-0,gamma hydroxybutyrate [moles/volume] in blood
74920-0,point in time gamma hydroxybutyrate [moles/volume] in blood
74920-0,gamma hydroxbutrate [mles/vlume] lo in
74920-0,g-oh-butyr bld-scnc
74920-0,g-oh-butyr bld-scnc
74920-0,bld-scnc g-oh-butyr
74920-0,gamma hydroxybutyrate (bld) [moles/vol]
74920-0,substance concentration gamma [moles/vol] (blood) hydroxybutyrate
74920-0,gamma hdroxybutyrate (bldmoes/vl] substance concentration
53709-2,glial nuclear type 1 ab [titer] in serum
53709-2,glial nuclear ab 1 type [titer] in serum
53709-2,glial nuclar lambert-eaton myasthenic syndrome type 1 ab [tie] in serum
53709-2,glial nuc type 1 ab titr ser
53709-2,glial nuc type 1 ab titr serum
53709-2,glial nuc type ab 1 aby titr ser
53709-2,glial nuclear type 1 ab (s) [titer]
53709-2,glial nuclear type [titer] sox1 ab (s) 1
53709-2,glial nuclear type 1 ab (s) [titer] ttr
95865-2,lcds v4.00 - swallowing/nutritional status during assessment period [cms assessment]
95865-2,lcds v4.00 - swallowing/nutritional status during assessment period [cms assessment]
95865-2,lcds pan v4.00 - swallowing/nutrtional status during assessment eriod [cms assessment]
2659-1,deprecated nitrogen
2659-1,deprcated nitrogen
2659-1,nitrogen deprecated
2659-1,deprecated nitrogen 24h stl qn
2659-1,qnt deprecated nitrogen 24h stl qn
2659-1,deprecated 24h stool = fecal itrogen stlqn
2659-1,nitrogen (24h stl) [mass]
2659-1,(24h nitrogen stl) [mass]
2659-1,nitrogen (24h [mass] stl) quan
2108-9,choriogonadotropin.alpha subunit [presence] in serum or plasma
2108-9,choriogonadotropin.alpha subunit [presence] in serum or plas
2108-9,choriogonadotropin.alpha subunit [presence] chorionic gonadotropin in serum or plasma
2108-9,a-hcg serpl ql
2108-9,a-hcg screen serpl ql
2108-9,a-cgerpl ql
2108-9,hcg.alpha subunit ql
2108-9,hcg.alpha ql subunit
2108-9,hcg.alpha subuit presence
50333-4,tetradecanedioate/creatinine [mass ratio] in urine
50333-4,tetradecanedioate/creatinine ratio] [mass in urine
50333-4,urine [mass ratio] in tetradecanedioate/creatinine
50333-4,tdecanedioate/creat ur
50333-4,mass concentration ratio ur tdecanedioate/creat
50333-4,tdecanedioate/creat ur
50333-4,tetradecanedioate/creatinine (u) [mass ratio]
50333-4,tetraecanediot/creatnin (u) ass ratio] ucr
50333-4,tetradecanediote/creatinne () [mass rtio]
5845-3,herpes simplex virus 1 ag [presence] in skin by immunofluorescence
5845-3,herpes simplex virus pr 1 ag [presence] in skin by immunofluorescence
5845-3,herpes [presence virus 1 siplx in kinby immunofluorescence
5845-3,hsv1 ag skin ql if
5845-3,hsv1 ag skin ql if skn
5845-3,i hsv1 ag kin ql if
5845-3,hsv 1 ag if ql (skin)
5845-3,ql 1 ag if hsv (skin)
5845-3,(ski) gif presence hsv
20703-5,border disease virus ag [presence] in tissue by immunofluorescence
20703-5,boder dseas virs ag [presene] in tisse by immunolurescence
20703-5,border disease virus ag [presence] immunofluorescence immunofluor tissue by in
20703-5,border dv ag tiss ql if
20703-5,dv border ag hairy shaker disease tiss ql if
20703-5,ifa borderv ag ss ql i
20703-5,border disease virus ag if ql (tiss)
20703-5,border bdv disase virusag ifql (tis)
20703-5,border virus bdv disese agif presence (tiss)
3503-0,clostebol [mass/volume] in urine
3503-0,clostene in [mass/volume] clostebol urine
3503-0,clostebol in [mass/volume] urine
3503-0,clostebol ur-mcnc
3503-0,ur-mcnc 4-chlorotestosterone clostebol
3503-0,clostebol 4-chlorotestosterone ur-mcnc
3503-0,clostebol (u) [mass/vol]
3503-0,[mss/vol] clostebol(u) random
3503-0,drugs (u)[mass/vol] clstebol
91722-9,promis item bank - physical function - version 2.0
91722-9,promis 2.0 bank - physical function - version item
91722-9,promis item bank - physical function 2.0 version -
50977-8,echovirus 5 ab [titer] in serum
50977-8,echovirus 5 ab antby [titer] in serum
50977-8,echovirus5ab serum in [titer]
50977-8,ecv5 ab titr ser
50977-8,ser ttr ab titr ecv5
50977-8,ecv5 ser titr ab
50977-8,echovirus 5 ab (s) [titer]
50977-8,echovus 5 a (s) [iter]
50977-8,antibody (s) 5 ab echovirus [titer]
90298-1,entamoeba sp dna [identifier] in stool by sequencing
90298-1,entameba sp da [idife] i stool by sqencin
90298-1,entamoba sp dna [entifi] in gastro tool by sequecing
90298-1,entamoeba dna stl seq
90298-1,entamoeba dna stl seq
90298-1,entaoea seq stl dna gi
90298-1,entamoeba sp dna sequencing nom (stl)
90298-1,dna sp entamoeba sequencing nom (stl)
90298-1,entamoeba sp dna sequencing nom (stl)
13717-4,calcium/creatinine [mass ratio] in 24 hour urine
13717-4,in ratio cal alcium/creatnine[mass 24 hour urin
13717-4,[mass calcum/ceatinine ratio]in24 hour urine
13717-4,calcium/creat 24h ur
13717-4,r calci/eat24h
13717-4,calcium/crat ur crea 24h
13717-4,calcium/creatinine (24h u) [mass ratio]
13717-4,mass ratio (24h calcium/creatinine u) [mass ratio]
13717-4,calcium/creatinine 2h [mass u) rato] crea
40926-8,streptococcus pneumoniae danish serotype 9v igg ab [mass/volume] in serum by immunoassay
40926-8,streptococcus pneumoniae danish serotype 9v igg ab [mass/volume] eia in serum by immunoassay
40926-8,strptococcus pneumoniae autoantibodies danish serotpe 9v igg a [mass/volme] in serum byimmunassay
40926-8,s pneum da 9v igg ser ia-mcnc
40926-8,s pneum pneumococcal pneumonia ser 9v igg da ia-mcnc
40926-8,s pneum da 9vigg serum ia-mcnc
40926-8,s. pneumoniae danish type 9v igg ia (s) [mass/vol]
40926-8,sr s. pnumoniae dnish type (s) iggia 9v [mas/ol
40926-8,s. pneumoniae danish type 9v igg ia (s) [mass/vol]
96762-0,barthel index panel
96762-0,index barthel panel point in time
96762-0,barthel index panel
96762-0,barthel index
96762-0,point in time index bthel
96762-0,barthel index
53025-3,gliadin ab [presence] in serum
53025-3,gliadin ab[resnce] i ser f98
53025-3,serology gliadin ab ser in [presence]
53025-3,gliadin ab ser ql
53025-3,gliadin ql ser ab
53025-3,gliadin ab autoantibody serum ql
53025-3,gliadin ab ql (s)
53025-3,serum gliadin ab ql (s)
53025-3,(s) ab ql gliadin
5681-2,manganese [mass/volume] in blood
5681-2,manganese [mass/volume] drug/toxicology i bld
5681-2,manganese in mass concentration [mass/volume] blood
5681-2,manganese bld-mcnc
5681-2,bld-mcnc manganese qnt
5681-2,mangaese bl-mcnc
5681-2,manganese (bld) [mass/vol]
5681-2,mangnese [mass/vol] (bd)
5681-2,(bld) wb manganese [mass/vol]
58441-7,other elements in urine sediment
58441-7,urine elements in other sediment
58441-7,other sediment in urine elements
58441-7,other elements urns
58441-7,other elements urn
58441-7,urns elements other
58441-7,other elements (urine sed)
58441-7,elements other (urine sed)
58441-7,other elements panel.urinalysis (urine sed)
91066-1,enterovirus rna [presence] in lower respiratory specimen by naa with probe detection
91066-1,enterovirus rna [presnce in lwer respiratory specimen by aa wit probedeection
91066-1,enterovirus rna [presence] naa lower respiratory specimen by in with probe detection
91066-1,ev rna lower resp ql naa+probe
91066-1,transcription mediated amplification ev lower rna resp ql naa+probe
91066-1,v ra lat lowe resp ql naa+probe
91066-1,enterovirus rna naa+probe ql (lower resp)
91066-1,n+probe infectious disease na enteovirus ql(loe rsp)
91066-1,enterovirus rna ql naa+probe (lower resp)
16127-3,helicobacter pylori igm ab [presence] in serum
16127-3,anti helicobacter pylori igm ab [presence] in ser
16127-3,antibodies helicobacter pylori igm ab [presence] in ser
16127-3,h pylori igm ser ql
16127-3,h pylori igm ser presence
16127-3,autoantibody pylori h igm ser ql
16127-3,h. pylori igm ql (s)
16127-3,h.ylori igm ql (s)
16127-3,h. ql igm pylori h pyl (s)
66767-5,vanillylmandelate/body weight [moles/kg/time] in 24 hour urine
66767-5,vanillymndeate/body weght mole/k/me] hour quan 24 in rie
66767-5,"vanillylmandelate/bodywegh in [mols/kg/im] 24 our 3-methyl,4-hydroxy mandelate urine"
66767-5,vma/bw 24h ur-relsrat
66767-5,ur-relsrat 24h vma/bw
66767-5,quan vma/bw 24h ur-elsrat
66767-5,vanillylmandelate/body weight (24h u) [relative moles/time]
66767-5,(24h weight vanillylmandelate/body u) [relative moles/time]
66767-5,vanillylmandelate/ody eght (24h u) [relative oles/time]
40585-2,drugs identified in specimen by confirmatory method
40585-2,drugsidentiied inspecimen confirmatory by ethod point in time
40585-2,drugs nominal identified in specimen by confirmatory method
40585-2,drugs spec cfm
40585-2,spec drugs cfm
40585-2,drugs spec cfm
40585-2,drugs identified confirm nom (specimen)
40585-2,drugs identified confirmo(specimen)
40585-2,nom identified confirm lc/ms/ms drugs (specimen)
35166-8,oleate (c18:1w9) [moles/volume] in serum or plasma
35166-8,[moles/volume] (c18:1w9) oleate in point in time serpl
35166-8,chemistry in (c18:1w9) [moles/volume] oleate serpl
35166-8,oleate serpl-scnc
35166-8,erpl-scnc sr oleate
35166-8,olatesepl-scnc
35166-8,oleate (c18:1w9) [moles/vol]
35166-8,oleate serpl (c18:1w9 [mol/ol]
35166-8,oleate (c18:1w9) [moles/vol]
2611-2,methcoproporphyrin [mass/volume] in serum or plasma
2611-2,pl methcopporphyrin [mass/volume] in ser or plasm
2611-2,methcoproporphyrin [mass/volume] serplas in serum or plas
2611-2,methcopro serpl-mcnc
2611-2,serpl-mcnc methcopro
2611-2,methcopro serpl-mcnc
2611-2,methcoproporphyrin [mass/vol]
2611-2,[mass/vol] methcoproporphyrin
2611-2,methcoproporphyrin [mass/vol]
93149-3,phenx - bone age protocol 220301
93149-3,pt phenx agprtocl one 20301
93149-3,phenx - bone 220301 protocol age
93149-3,phenx bone age protocol
93149-3,px protool age bone
93149-3,bone pan phenx ageprotocol
15488-0,mycoplasma meleagridis ab [presence] in serum by agglutination
15488-0,mycoplasma meleagridis ab [presence] in anti serum by agglutination
15488-0,mycoplasma meleagridis ser ab [presence] ser in by agglutination
15488-0,m meleagridis ab ser ql aggl
15488-0,m meleagridis ab ser ql aggl screen
15488-0,m meleagidis ab ser qlaggl
15488-0,m. meleagridis ab aggl ql (s)
15488-0,m. meleagridis ab aggl ql anti (s)
15488-0,m. meleagridis ab aggl presence (s)
74100-9,nitrate+nitrite [moles/volume] in serum or plasma
74100-9,nitrate+nitrite [moles/volume] in plasma or serum
74100-9,nitrae+nitrie [olesvolume] plasa seru or in
74100-9,nitrate+nitrite serpl-scnc
74100-9,serum or plasma-scnc nitrte+nitrite quant
74100-9,serum or plasma nitrate+nitrite serpl-scnc
74100-9,nitrate+nitrite [moles/vol]
74100-9,pt nitrate+nitrite [moles/vol]
74100-9,[moles/vol] nitrate+nitrite
86330-8,adenovirus b(11) dna [presence] in specimen by naa with probe detection
86330-8,adenovirus b(11) dna adeno virus [presence] in specimen by naa with probe detection
86330-8,adenovirus b(11) dna [presence] in by specimen naa with probe detection
86330-8,adv b(11) dna spec ql naa+probe
86330-8,adv b11) na specql naa+probe
86330-8,adv amplification b(11) dna naa+probe presence spec
86330-8,adenovirus b(11) dna naa+probe ql (specimen)
86330-8,adenoius naaprobe screen b(11)dna ql (specimen)
86330-8,pcr presence b(11) dna na+probe aenovius (specimen)
47819-8,3-hydroxysuberate/creatinine [molar ratio] in urine
47819-8,3-hydroxysuberate/creatinine 3-hydroxy suberate [molar ratio] in urine
47819-8,scrto 3-hydroxysuberate/creatinine [molar ratio] urine in
47819-8,3ohsuberate/creat ur-srto
47819-8,3ohsuberate/creat ur-srto quantitative
47819-8,crea 3hsuberate/creaur-srto
47819-8,3-hydroxysuberate/creatinine (u) [molar ratio]
47819-8,3hydoxysuberate/creatinine (u) molar 3-hydroxyoctanedioic acid ratio]
47819-8,[molar (u) 3-hydroxysuberate/creatinine ratio]
49260-3,cryoglobulin iga and igg and igm [interpretation] in serum narrative
49260-3,cryoglobulin iga and igg immune globulin g and igm [interpretation] in serum narrative
49260-3,impression/interpretation of study crogloblin ia and igg ad ig [inerptationin seru narrative
49260-3,cryoglob iga & igg & igm ser-imp
49260-3,cryoglob iga & igg ser-imp igm &
49260-3,cyolob iga& igg igm & ser-mp
49260-3,cryoglobulin iga and igg and igm nar (s) [interp]
49260-3,cryoglobulin iga and narrative igg and igm nar (s) [interp]
49260-3,cryoglobulin iga and (s) and igm nar report igg [interp]
41453-2,human coronavirus ag [presence] in specimen by immunofluorescence
41453-2,humn oronavius ag [prsence] in specimen by random immunofuoresence
41453-2,human coronavirus ag immunofluorescence in specimen by [presence]
41453-2,hcov ag spec ql if
41453-2,spec ag hcov ql if
41453-2,hcov if spec ql ag
41453-2,hcov ag if ql (specimen)
41453-2,ag hcov if ql (specimen)
41453-2,hov ag l point in time if (specimen)
103834-8,norbuprenorphine [presence] in meconium
103834-8,norbuprenorphine [presence] in meconium
103834-8,norbuprenorphine meconium drug/toxicology in [presence]
103834-8,norbuprenorphine mec ql
103834-8,norbuprenorphine mec ql
103834-8,screen ql mec norbuprenorphine
103834-8,norbuprenorphine ql (mec)
103834-8,norbuprenorphie ql (mec)
103834-8,orbuprenorhine mec) drug/toxicology ql
90813-7,ampar2 ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
90813-7,ampar2 ab cerebral in [presence] spinal fluid by cell binding immunofluorescent assay
90813-7,amar2 b [presence] in ceebral sinal spinal fluid lud by cell binding imunofluoescent assay
90813-7,ampar2 ab csf ql cba ifa
90813-7,ampar2 ab ifa ql ca csf
90813-7,apar ab csf ql ampa receptor ba if
90813-7,ampar2 ab cell binding immunofluorescent assay ql (csf)
90813-7,ampar2 ab cell binding glua2 immunofluorescent assay (cerebrospinal fluid) ql
90813-7,aar2 ab cell bindg imunofluorecent asay presence(csf)
42513-2,ige [units/volume] in cerebral spinal fluid
42513-2,ige [units/volume] in cerebral spinal fluid
42513-2,ge [units/volume] n cerebral pinal immunoglobulin e flud
42513-2,ige csf-acnc
42513-2,ige cerebrospinal fluid-acnc neuro
42513-2,csf-acnc ige
42513-2,ige qn (csf)
42513-2,(csf) qn ige
42513-2,(cerebrospinal fluid) qn ige
45081-7,deprecated chlamydia trachomatis rrna [presence] in urethra by dna probe
45081-7,deprecated chlamydia trachomatis rrna [presence] dna urethra by in probe
45081-7,deprecated chlamydia trachoatis ra [presence] i urethra by dna probe
45081-7,deprecated c trach rrna urth ql prb
45081-7,deprecate c trac rna urth ql prb
45081-7,deprecated c tachrrna rth presence prb
45081-7,c. trachomatis rrna probe ql (urethra)
45081-7,trachomatis c. rrna probe ql (urethra)
45081-7,c.trachomais probe rrna presence (rethra) dna probe
7794-1,normocytic/normochromic polychromasia [presence] in blood by light microscopy
7794-1,in polychromasi [presence] normocytic/normochromic bloody light microscoy
7794-1,normocytic/normochromic polychromasia [presence] in blood microscopy light by
7794-1,normocytic/nc polychr bld ql smear
7794-1,normocytic/nc ql bld polychr smear
7794-1,l blood polychr bld nomocytic/nc smea
7794-1,normocytic/normochromic polychromasia lm ql (bld)
7794-1,normocytic/normochromic polchromasia lm l (bd)
7794-1,normocytic/normochromic polychromasia ql lm ql (bld)
16203-2,alprazolam [presence] in urine by confirmatory method
16203-2,alrzolam [presenc] by urin in conirmtory mehod xanax
16203-2,confrmatory presence] i urin by aprazolam method
16203-2,alpraz ur ql cfm
16203-2,alpraz pr cfm ql ur
16203-2,alpraz cfm ql u
16203-2,alprazolam confirm ql (u)
16203-2,alprazolam confirml pr (u
16203-2,niravam ql confirm alprzolm (u)
13699-4,5-hydroxyhexanoate/creatinine [mass ratio] in urine
13699-4,5-hydoxhexanoate/creatinin ratio] [mass in urne random
13699-4,5-hydroxyhxnoatecreatinin in rtio] [as urne
13699-4,5oh-hexanoate/creat ur
13699-4,5oh-hexanoate/creat ur
13699-4,5oh-hexanoate/creat quan r
13699-4,5-hydroxyhexanoate/creatinine (u) [mass ratio]
13699-4,5-hydroxyhexanoate/creatinine (u) [mass 5-hydroxyhexanoic acid ratio]
13699-4,ratio] (u) 5oh-hexanoate [mass 5-hydroxyhexanoate/creatinine
4104-6,acepromazine [mass] of dose
4104-6,random acepromazine [mass] of dose
4104-6,aceromazine veterinary [mass] of dse
4104-6,acepromazine dose
4104-6,dose acepromazine
4104-6,aepromazine dose
4104-6,acepromazine (dose) [mass]
4104-6,(dose)[mass] acepromazine qnt
4104-6,[mass] (dose) acepromazine
44264-0,influenza virus a h5 rna [units/volume] (viral load) in specimen by naa with probe detection
44264-0,influenza vrus a 5ra [units/volume] detecion load) in specimen by na with probe influenza a viral
44264-0,influenza naa a h5 rna [units/volume] (viral load) in specimen by virus quan with probe detection
44264-0,fluav h5 rna spec naa+probe-acnc
44264-0,fua h5rna spec 3sr sr naa+prbe-ac
44264-0,flua fluav spec rna h5 naa+probe-acnc
44264-0,fluav h5 rna naa+probe qn (specimen)
44264-0,naa+probe h5 rna fluav qn (specimen)
44264-0,fluav h5 rna naa+probe qn (specimen) probe with target amplification
55096-2,nocardia sp identified in isolate
55096-2,nocardia sp intified in isolate
55096-2,nocardia isolate identified in sp
55096-2,nocardia islt
55096-2,islt nocardia id
55096-2,islt nocardia
55096-2,nocardia sp identified nom (isol)
55096-2,nocardia s ideniied nom (isol)
55096-2,nocarda sp identity or ql identified om (isol)
90766-7,hedis 2019 value sets
90766-7,edis 2019 value panel sets
90766-7,hedis 2019 value sets
90766-7,hedis 2019 value sets
90766-7,sets 2019 alue hedis pt
90766-7,heis 2019 vaue random sets
90766-7,hedis 2019 value sets
90766-7,hedis 2019 sets value
90766-7,heds 2019 value sets
13611-9,6-beta-hydroxycortisol [mass/time] in 24 hour urine
13611-9,-beta-hdroxycortiso in [mass/te] 24 hour urine
13611-9,6-beta-hydroxycortisol urn [mass/time] in 24 hour urine
13611-9,6b-oh-cortisol 24h ur-mrate
13611-9,24h 6b-oh-cortisol ur-mrate
13611-9,chemistry 6b-oh-cortisol 24h ur-mrate
13611-9,6-beta-hydroxycortisol (24h u) [mass/time]
13611-9,24 hours 6-bet-hydroxcortsol (24h [mass/tim] u)
13611-9,ur 6-beta-hdroxycorisol u)[mss/tm] (24h
53374-5,francisella tularensis ab [presence] in specimen
53374-5,francisella larensis ab [presence] in specimen anti
53374-5,in [presnce francisellaularensisab specmen
53374-5,f tular ab spec ql
53374-5,f infectiousdisease tular ab spec ql
53374-5,f tular ab spec presence
53374-5,f. tularensis ab ql (specimen)
53374-5,f. tuaenss a ql (specimen)
53374-5,f.tlrensis ql ab (specmen)
101727-6,jc virus dna [log units/volume] (viral load) in urine by naa with probe detection
101727-6,jc virus dna detection units/volume] (viral load) in urine by naa with probe [log
101727-6,jcvrusdnlog nts/volume] (viral load) inurine by naa with probe detection
101727-6,jcpyv dna ur naa+probe-log iu
101727-6,3sr sr naa+probe-log da ur jcpyv
101727-6,iu ur naa+probe-log jcpyvdna
101727-6,jc virus dna naa+probe (u) [log units/vol]
101727-6,(u) virus dna naa+probe jc [log units/vol]
101727-6,u) virusdna naa+proe jc naat [log unts/vl]
11060-1,reducing substances [presence] in stool
11060-1,stool substances [presence] ql in reducing
11060-1,reducing substances [presence] in stool
11060-1,reducing subs stl ql
11060-1,reducing subs stl reduc presence
11060-1,reducing stl subs ql
11060-1,reducing substances ql (stl)
11060-1,reducing substances presence (stl) qual
11060-1,reducing substances feces ql (stl)
73828-6,"flunitrazepam [mass/volume] in serum, plasma or blood"
73828-6,"blood [mass/volume] in serum, plasma or flunitrazepam"
73828-6,"or mass/volume] in srum, plasma lunitraepam bld"
73828-6,flunitrazepam serplbld-mcnc
73828-6,flnitrazepam serplbld-mcnc
73828-6,serplbld-mcnc flunitrazepam
73828-6,flunitrazepam (s/p/bld) [mass/vol]
73828-6,flunitrazepam darkene (s/p/bld) [mass/vol]
73828-6,flunitrzepam (s/p/bld) pl [mass/vol]
22424-6,mycoplasma meleagridis ab [presence] in serum
22424-6,mycoplama ab meleagridis [presec] n serum
22424-6,ab meleagridis mycoplasma [presence] in serum
22424-6,m meleagridis ab ser ql
22424-6,m meleagridis serum ab infectiousdisease ql
22424-6,ql meleagridis ab ser m
22424-6,m. meleagridis ab ql (s)
22424-6,(s) melagridis aby ab ql m.
22424-6,m. melagriisb presence (s)
18465-5,3-hydroxyoleoylcarnitine (c18:1-oh) [mass/volume] in serum or plasma
18465-5,3-hydroxyoleoylcarnitine c18:1-oh (c18:1-oh) [mass/volume] or ser in plasma
18465-5,iii 3-hydroxyoleoylcarnitine (c18:1-oh) [mass/volume] in serum or plasma
18465-5,3oh-oleoylcarn serpl-mcnc
18465-5,srplmcnc 3h-oleoylarn
18465-5,serpl-mcnc quantitative 3oh-oleoylcarn
18465-5,c18:1-oh [mass/vol]
18465-5,c18:1-oh pl [mass/vol]
18465-5,[mass/vol] c18:1-oh
53171-5,3-hydroxyisovalerylcarnitine (c5-oh)/carnitine.free (c0) [molar ratio] in dbs
53171-5,3-hydroxyisovalerylcarnitine (c5-oh)/carnitine.free (c0) whole blood [molar ratio] in dbs
53171-5,db (c0) substance concentration ratio [molar rto] i 3-hdroxyisovalerylcarnitn5oh)carnitin.free
53171-5,3oh-isovalerylcarn/c0 dbs-srto
53171-5,dbs-srto 3oh-isvalerylcrn/c0
53171-5,scrto 3oh-isovalerylcarn/c0 dbs-srto
53171-5,3-hydroxyisovalerylcarnitine (c5-oh)/carnitine.free (c0) (dbs) [molar ratio]
53171-5,ratio] 3-hydroxyisovalrylcrnitiec5-h)/carnitine.re(c0)(dbs)mola
53171-5,(dbs) (c5-oh)/carnitine.free (c0) 3-hydroxyisovalerylcarnitine [molar 3-hydroxy-isovalerylcarnitine ratio]
101528-8,mycoplasma sp dna [identifier] in isolate by sequencing
101528-8,sequencing sp random dna [identifier] in isolate by mycoplasma
101528-8,ycoplasma sp spp na [dentifier] in islate by equencing
101528-8,mycoplasma dna islt seq
101528-8,islt dna mycoplasma seq
101528-8,mycoplasma dna islt islt seq
101528-8,mycoplasma sp dna sequencing nom (isol)
101528-8,(isol) sp dna sequencing nom mycoplasma
101528-8,mycoplasma s dna random squencingnom (isol)
22078-0,acanthamoeba sp ab [presence] in cerebral spinal fluid
22078-0,acaamoeba sp ab [presence]in cerebral fluid spinal
22078-0,acanthamoeba abs sp ab [preence] in erebral sinal fluid
22078-0,acanthamoeba ab csf ql
22078-0,ab acanthamoeba csf ql
22078-0,ql abcsf acanthamoea
22078-0,acanthamoeba sp ab ql (csf)
22078-0,aanthamoeba sp ql ab (csf)
22078-0,acanthamoeba sp ab ql (csf)
25964-8,normetanephrine [moles/volume] in 24 hour urine
25964-8,normetaephrine normeta [molesvle] in 24 hr urine
25964-8,in [moles/volume] normetanephrine 24 normeta hour urine
25964-8,normetanephrine 24h ur-scnc
25964-8,normetanephrine level 24h ur-scnc
25964-8,1 day normetanephrine 24h ur-scnc
25964-8,normetanephrine (24h u) [moles/vol]
25964-8,normetanephrine (24h u) [moles/vol]
25964-8,[moles/vol] (24h u) normetanephrine
75360-8,date of supracervical hysterectomy
75360-8,hysterectomy qnt of supracervical date
75360-8,date of supracervical hysterectomy qnt
75360-8,date supracervical hyst
75360-8,date random supracervical hyt
75360-8,date partial hyst supracervical
13879-2,collagen type 2 igg ab [units/volume] in serum
13879-2,collagen type 2 igg ab serum in [units/volume]
13879-2,type collagen 2 igg ab [units/volume] in serum
13879-2,collagen2 igg ser-acnc
13879-2,ollagen2 ser-acc igg abs
13879-2,collagen2 ser-acnc igg
13879-2,collagen type 2 igg qn (s)
13879-2,cllaen type 2ig qn (s)
13879-2,ollgen ype serology 2 igg qn (s)
26454-9,erythrocytes [#/volume] in cerebral spinal fluid
26454-9,erythrcytes [#/vlume]in spinal erebra fluid
26454-9,erythroyes [#/olmin cerebal spinal fluid
26454-9,rbc # csf
26454-9,absolutes rbc # cs
26454-9,rbc cerebrospinal fluid #
26454-9,rbc (csf) [#/vol]
26454-9,rbc /vol] (cs)
26454-9,erthrocyte rbc [#/vol] (cerebrospinal fluid)
27147-8,deprecated streptococcus pneumoniae 19 ab [mass/volume] in serum --2nd specimen
27147-8,deprecated streptococcus pneumoniae 19 ab [mass/volume] in serum --2nd specimen
27147-8,deprecated streptococcus 19 pneumoniae ab [mass/volume] in serum --2nd specimen
27147-8,deprecated s pneum19 ab sp2 ser-mcnc
27147-8,pneumococcus deprecated s sp2 ab pneum19 ser-mcnc
27147-8,deprecated pneum9 sp2 b ser-mcnc
27147-8,s. pneumoniae 19 ab spec 2 (s) [mass/vol]
27147-8,s. pneumoniae 19 ab spec 2 (s) [mass/vol]
27147-8,s. pneumoniae 19 ab [mass/vol] 2 (s) spec
62768-7,deprecated phenx measure - global mental status screener
62768-7,screene phenx masre - globl metalstatus depreated
62768-7,deprecated phenx measure - global mental status screener
18452-3,decanoylcarnitine (c10) [mass/volume] in serum or plasma
18452-3,decanoylcarnitine (c1) srum in serp [mass/vlme] or plama
18452-3,decanoylcarnitine (c10) random or in serum [mass/volume] plas
18452-3,decanoylcarn serpl-mcnc
18452-3,serpmcnc deanylcarn
18452-3,serpl-mcnc decnoycr
18452-3,c10 [mass/vol]
18452-3,[mass/vol] c10
18452-3,[mass/vol] c10
1873-9,apolipoprotein b-48 [mass/volume] in serum or plasma
1873-9,apolipoprotein b-48 [mas/volume] i ser or plasma
1873-9,apolipoprotein quant -48 [mass/volume] in erumor plasma
1873-9,apo b48 serpl-mcnc
1873-9,serpl-mcnc 48 apo
1873-9,apo serpl-mcnc b48
1873-9,apolipoprotein b-48 [mass/vol]
1873-9,b-48 apolioproten mas/vol]
1873-9,[mass/vol] apolpoproteib48
22120-0,borrelia burgdorferi ab [units/volume] in body fluid
22120-0,brrlia burgdorferi ab fluid n body [units/volume]
22120-0,n burgdorferi ab units/vlume] borrelia b burg bdy flud
22120-0,b burgdor ab fld-acnc
22120-0,b bodies ab burgdor fld-acnc
22120-0,b fld-acnc ab burgdor pt
22120-0,b. burgdorferi ab qn (body fld)
22120-0,b. burgdorferi antby ab qn (body fld)
22120-0,(body burgdorferi ab qn b. fld)
46105-3,problem conditions set
46105-3,conditions problem set
46105-3,set conditions problem pnl
35231-0,triiodothyronine (t3) [mass or moles/volume] in serum or plasma
35231-0,in (t3) [mass or moles/volume] triiodothyronine serum or plasma
35231-0,ser or plasma triiodothyronine (t3) [mass or moles/volume] in ser or plasma
35231-0,t3 serpl-mscnc
35231-0,t3 serpl-mscnc
35231-0,srl-mscn t3
35231-0,t3 [mass or moles/vol]
35231-0,t3 serp [mass or mole/vol]
35231-0,[mass t3 or moles/vol]
68381-3,ph of synovial fluid by test strip
68381-3,ph of strip fluid by test synovial
68381-3,ph testsrp sovial fluid by of
68381-3,ph snv strip
68381-3,joint aspirate ph snv srip
68381-3,ph snv strip sf
68381-3,ph test strip (syn fld)
68381-3,fld) chemistry test strip (syn ph
68381-3,ph test strip sf (syn fld)
89732-2,communication [cdc emergency operations centers]
89732-2,communication [cdc emergency operations centers] pan
89732-2,communication [cdc emergency operations panel centers]
75213-9,malonylcarnitine (c3-dc)+3-hydroxybutyrylcarnitine (c4-oh)/decanoylcarnitine (c10) [molar ratio] in dbs
75213-9,malonylcarnitine (c3-dc)+3-hydroxybutyrylcarnitine (c4-oh)/decanoylcarnitine dbs [molar ratio] in (c10)
75213-9,malonylcarnitine (c3-dc)+3-hydroxybutyrylcarnitine (c4-oh)/decanoylcarnitine (c10) dbs ratio] in [molar
75213-9,malonyl+3ohbutyrylcarn/c10 dbs-srto
75213-9,iii malonyl+3ohbutyrylcarn/c10 dbs-srto
75213-9,malonyl+3hbuyrylcarn/c10 db-srt
75213-9,c3-dc+c4-oh/decanoylcarnitine (c10) (dbs) [molar ratio]
75213-9,c3-dc+c4-oh/decanoylcarnitine (c10) dbs (dbs) [molar ratio]
75213-9,[molar (c10) (dbs) c3-dc+c4-oh/decanoylcarnitine ratio]
84910-9,positive affect survey - fixed length form - ages 13-17 [nih toolbox]
84910-9,positive affect survey - fixed length form - ages 13-17 [nih toolbox]
84910-9,positive affect survey - fixed length form - ages 13-17 [nih toolbox]
88468-4,types and sources of assistance - discarge from agency during assessment period [cms assessment]
88468-4,types during sources of assistance - discarge from agency and survey assessment period [cms assessment]
88468-4,types and sources of assitanc - discarge from agencyduring assessment pnl period cs assessment]
74429-2,metamyelocytes.eosinophilic/cells in bone marrow by manual count
74429-2,mnual in bone marrow by manl metmylocyteseosinopilic/cels count
74429-2,bone mtmeocytes.eosiophilic/cellsin arow bymanual count
74429-2,metamyelocytes.eos nfr mar manual
74429-2,manual nfr mar metamyelocytes.eos
74429-2,fr metamyelocyts.os mar manul
74429-2,metamyelocytes.eosinophilic/cells manual cnt (bm)
74429-2,metamyelocytes.eosiophlic/cells (bm) bm manualct
74429-2,metamyelocytes.eosinophilic/cells manuacnt (m
28609-6,alpha aminobutyrate/creatinine [ratio] in 24 hour urine
28609-6,alpha ainobutyrate/creatnine [rto] in alpha amino-n-butyrate 2 hour urine
28609-6,alpha aminobutyrate/creatinine [ratio] in quantitative 24 hour urine
28609-6,a-aminobutyr/creat 24h ur-rto
28609-6,24h a-aminobutyr/creat ur-rto
28609-6,ur-rto quantitative 24 -aminobutyr/cret
28609-6,alpha aminobutyrate/creatinine (24h u) [ratio]
28609-6,[ratio] aminobutyrate/creatinine (24h aanb u) alpha
28609-6,alpha aminobutyrate/creatinine (24h u) [ratio]
101750-8,adeno-associated virus (aav) serotype rh74 [presence] in serum by immunoassay
101750-8,adno-associatd virus (aav) serotype rh74 [presence]insum suds byimmunoassay
101750-8,adeno-associated virus (aav) serotype rh74 [presence] in ser by immunoassay
101750-8,aav serotype rh74 ser ql ia
101750-8,aav ser rh74 ql serotype ql ia
101750-8,aav qualitative serotpe ser rh74 q ia
101750-8,adeno-associated virus (aav) serotype rh74 ia ql (s)
101750-8,adeno-associated virus (aav) (s) rh74 ia ql serotype
101750-8,adeno-associated virus (aav) serotype rh74 ia presence qualitative (s)
13400-7,hydroxylysine [mass/volume] in amniotic fluid
13400-7,fluid [mass/volume] in amniotic hydroxylysine
13400-7,hydroxylysine random [mass/volume] in fluid amniotic
13400-7,oh-lysine amn-mcnc
13400-7,qnt oh-ysine amn-mcnc
13400-7,amn-mcnc amniotic fluid oh-lysine
13400-7,hydroxylysine (amn fld) [mass/vol]
13400-7,hydroxylysine (amn [mass/vol] fld) quant
13400-7,hyroxylysine (amn fd) [masol] quan
105078-0,human coronavirus oc43 rna [presence] in specimen
105078-0,in coronarusoc43 rna [resence human pecien
105078-0,human specimen oc43 rna [presence] in coronavirus
105078-0,hcov oc43 rna spec ql
105078-0,hcov hcov spec rna oc43 ql
105078-0,rna oc43 hcov pec ql
105078-0,hcov oc43 rna ql (specimen)
105078-0,ql oc43 rna hcov (specimen)
105078-0,hcov oc43 rn ql (specen)
63479-0,platelet glycoprotein ia/iia ab [presence] in blood by immunoassay
63479-0,platelet glycoprotein [presence] ab ia/iia in blood by immunoassay
63479-0,eia platelet glycoprotein ia/iia ab [presence] in blood by immunoassay
63479-0,plat gp ia/iia ab bld ql ia
63479-0,plat gp ia/iia ab bld ql ia serology
63479-0,plat gp ia/iia ab bld ql antibody ia
63479-0,platelet glycoprotein ia/iia ab ia ql (bld)
63479-0,platelet glycoprotein (bld) ab ia ql ia/iia
63479-0,ab ia/iia platlelycoprotein ql (bld)
98121-7,protein/creatinine qualitative in urine by test strip
98121-7,test qualitative in urine by protein/creatinine strip
98121-7,proten/crtinine qalitativ n urine by tst stip
98121-7,prot/creat ur ql strip
98121-7,prot/creat ur presence strip
98121-7,prt/crat urqlsrip point in time
98121-7,protein/creatinine test strip ql (u)
98121-7,test protein/creainne strip l (u)
98121-7,protein/creatinine test strip presence (u)
56550-7,pca-tr ab [titer] in serum by immunofluorescence
56550-7,ttr pca-tr ab [titer] in ser by immunofluorescence
56550-7,sr pc-tr ab [ttr] insrum by immunofluescence
56550-7,pca-tr ab titr ser if
56550-7,pca-tr ab titr serum cytopl if
56550-7,abitr ifa pca-tr serif
56550-7,pca-tr ab if (s) [titer]
56550-7,pca-tr ab if (s) [titer] ttr
56550-7,pca-tr sr a i(s) [titer]
76597-4,streptococcus agalactiae cfb gene [#/mass] in xxx.tissue by naa with probe detection
76597-4,streptococcus agalactiae cfb gene [#/mass] in amplif xxx.tissue by naa with probe detection
76597-4,streptococcus agalactiae cfb gene [#/mass] in xxx.tissue by naa with probe detection
76597-4,s agalact cfb xxx.tiss naa+probe
76597-4,naa+probe agalact cfb xxx.tiss s
76597-4,s agalact cfb xxx.tiss naa+probe strep group b
76597-4,s. agalactiae cfb gene naa+probe (unsp tissue) [#/mass]
76597-4,s. agalactiae tissue) gene naa+probe (unsp infectious disease cfb [#/mass]
76597-4,s. agalactiae miscellaneous cfb gene naa+probe (unsp tissue) [#/mass]
13816-4,tiglylglycine/creatinine [mass ratio] in urine
13816-4,igylglycn/ceainine [mass rati in urine
13816-4,tiglylglyine/creainine [s mass concentration ratio uie in ratio]
13816-4,tiglylgly/creat ur
13816-4,ur tiglylgl/ceat
13816-4,tilylgly/cret ur
13816-4,tiglylglycine/creatinine (u) [mass ratio]
13816-4,(u) mass ratio tiglylglycine/creatinine [mass ratio]
13816-4,tiglylglycine/creatinine (u) ur ratio] [mass
100746-7,glucose [moles/volume] in mixed venous blood
100746-7,blood [moles/volume] chemistry in mixed venous glucose
100746-7,glucoe moles/volume in mixd enous blod
100746-7,glucose bldmv-scnc
100746-7,blmv-scnc glucose
100746-7,bldmv-scnc glucose
100746-7,glucose (bldmv) [moles/vol]
100746-7,mols/vo] (blmv) glcose blood mixed venous
100746-7,glucoseur glucoe (bldmv) [moles/vol]
35026-4,monocytes [#/volume] in cerebral spinal fluid
35026-4,spinal fluid monocytes [#/volume] in cerebral spinal fluid
35026-4,monocytes [#/volume] in # cerebral spinal fluid
35026-4,monocytes # csf
35026-4,monocyte monocyts #sf
35026-4,monocytes # cerebrospinal fluid qnt
35026-4,monocytes (csf) [#/vol]
35026-4,ct (csf) monocytes [#/vol]
35026-4,mooytes (cerebrospinal fluid) mono #/ol]
11271-4,hematocrit [volume fraction] of cord blood by automated count
11271-4,ematoit olume by of cord blood fractio] autated cunt
11271-4,count [olume fractin] of cord blood by automated hemaocit
11271-4,hct vfr bldco auto
11271-4,vfr erc hct bldco auto
11271-4,hct vf volfr bldco uo
11271-4,hematocrit auto (bldco) [volume fraction]
11271-4,fraction] auto (bldco) [volume elec hematocrit
11271-4,hematocrit auto (bldco) [volume fraction]
103686-2,pneumocystis jirovecii dna [presence] in cerebral spinal fluid by naa with probe detection
103686-2,neumocstisjirovecii dna [presence in cerebrl spinl fluid by aa with probe detection
103686-2,in dna [presence] pnumoctisjiovecii cerebral sina fluid by naawth tma pobe detction
103686-2,p jirovecii dna csf ql naa+probe
103686-2,p csf dna jirovecii ql naa+probe
103686-2,ql jirovecii dna csf p ordinal naa+probe
103686-2,p. jirovecii dna naa+probe ql (csf)
103686-2,p. jirovei dnnaa+robe presence (csf)
103686-2,p. jroecii dna ql naa+pro (sf)
94815-8,cv2 igg ab [titer] in serum by immunofluorescence
94815-8,v2 igg ab [titer in erum by imuolorescene
94815-8,cv2 igg ab [iter] nerum by immunofluescece
94815-8,cv2 igg titr ser if
94815-8,serif acif igg titr cv2
94815-8,cv2 titered igg titr seri
94815-8,cv2 igg if (s) [titer]
94815-8,cv2 iggif s)[tite]
94815-8,cv (s) igif [iter]
42774-0,multiple drug resistant organism identified in wound
42774-0,multiple drug in organism identified resistant wound drugs
42774-0,multiple dru resistant orgnismidentified in wound
42774-0,mdro wnd
42774-0,mdownd
42774-0,mdro wnd wnd
42774-0,multiple drug resistant organism identified nom (wound)
42774-0,multiple drug resistant oraism drugs identified nm (wound)
42774-0,multipe drugresistant identiied rganism nm (wound)
12215-0,fatty acids.very long chain [moles/volume] in serum or plasma
12215-0,fatty acids.very long chain [moles/volume] in ser or plasma
12215-0,fatty or long chain [moles/volume] acd in serum acids.very plas
12215-0,vlcfa serpl-scnc
12215-0,serum or plasma vlfa serpl-scnc
12215-0,serpl-scnc vlcfa
12215-0,fatty acids.very long chain [moles/vol]
12215-0,sr fatty acids.very long chain [moles/vol]
12215-0,fatty chn acids.very ong chain [me/vol]
2709-4,oxygen saturation in capillary blood
2709-4,in saturation oxygen capillary blood
2709-4,oxygn blood satn in capillary saturation
2709-4,sao2 % bldc
2709-4,sao2 o2 % bldc
2709-4,sao2 % bldc satn
24215-6,influenza virus a ab [titer] in serum by complement fixation --1st specimen
24215-6,influenza virus a ab [titer] in --1st by complement fixation serum specimen
24215-6,influenz virus cf a ab [tierinserum by compemnt ixatin --1st peimen
24215-6,fluav ab sp1 titr ser cf
24215-6,fluav ab sp1 titr ser fowl plague cf
24215-6,fluav ab infectiousdisease itr sp1 serum c
24215-6,fluav ab spec 1 cf (s) [titer]
24215-6,fuav ab spec1 point in time cf() [tter]
24215-6,fluav ab spec infectiousdisease 1 (s) cf [titer]
105980-7,igg.kappa [presence] in serum by immunofixation
105980-7,[presence] igg.kappa in serum by immunofixation
105980-7,igg.kappa [presence] in immunofixation electrophoresis serum by immunofixation
105980-7,igg kappa ser ql ife
105980-7,igg kappa qual ife ql serum
105980-7,igg kappa ife ql ser
105980-7,igg.kappa immunofixation ql (s)
105980-7,igg.kappa immunofixaion ql (s)
105980-7,gg.kapa immunofixaion ql (s)
28593-2,gamma aminobutyrate/creatinine [ratio] in urine
28593-2,gamma aminobutyrate/creatinine [ratio] in urine
28593-2,gamma aminobutyrate/creatinine chemistry [ratio] urine in
28593-2,gaba/creat ur-rto
28593-2,u-rto chemistry gaba/creat
28593-2,ur-rto gaba/creat
28593-2,gamma aminobutyrate/creatinine (u) [ratio]
28593-2,gamma aminobutyrate/creatinine (u) [ratio]
28593-2,gamma aminobutyrate/creatinine (u) [ratio]
55975-7,igg [mass/volume] in body fluid by immune diffusion (id)
55975-7,id ig [mass/volue] n boy fluid by diffusion immune (d)
55975-7,igg [mass/volume] in body fluid id by immune diffusion (id)
55975-7,igg fld id-mcnc
55975-7,id-mcnc fld igg
55975-7,igg id-mcnc fld random
55975-7,igg immune diff (body fld) [mass/vol]
55975-7,igg immune diff (body fld) [mass/vol]
55975-7,igg imune dff point in time (body fld) [mas/vol]
17672-7,sulfide [mass/volume] in urine
17672-7,sulfide [mass/voum i drugs urin
17672-7,[mass/volume sulfide in urine
17672-7,sulfide ur-mcnc
17672-7,sulfde ur-cnc quan
17672-7,level sulfide ur-mcnc
17672-7,sulfide (u) [mass/vol]
17672-7,(u) sulfde [mss/vol]
17672-7,[mass/vol] (u) sulfide
75150-3,inosine [moles/volume] in serum or plasma
75150-3,inosine [moles/volume] in ser or chemistry plasma
75150-3,inosine [moles/volume] in serum or plasma sr
75150-3,inosine serpl-scnc
75150-3,insine serp erpl-scnc
75150-3,serpl-scnc quant inosine
75150-3,inosine [moles/vol]
75150-3,[moles/vol] inosine plasma
75150-3,[moles/vol] nsine
82178-5,chlamydophila pneumoniae dna [presence] in nasopharynx by naa with non-probe detection
82178-5,hlamydphila numonie dna [pesence] in nasophaynx naa by wh non-probe detection
82178-5,chlamydophila pneumoniae pr dna [presence] in nasopharynx by naa with non-probe detection
82178-5,c pneum dna nph ql naa+non-probe
82178-5,c pneum dna nph naa+non-prbe presence
82178-5,c neumdna np presence naa+non-pobe
82178-5,c. pneumoniae dna naa+non-probe ql (nph)
82178-5,c. pneumoniae (nph) naa+non-probe ql dna
82178-5,c. pneumoniae naa+non-probe dna tma presence (nph)
27922-4,echovirus 4 rna [presence] in cerebral spinal fluid
27922-4,echovirus 4 rna [presence] in cerebral spinal fluid random
27922-4,echoviru 4 cerebra in rna[preence] spinal fuid
27922-4,ecv4 rna csf ql
27922-4,ecv4 rn csfql
27922-4,ecv4 id rna csf ql
27922-4,echovirus 4 rna ql (csf)
27922-4,echovirus 4 ql rna (sf)
27922-4,echovirus 4 na ql (sf)
35394-6,legionella pneumophila 1 igg ab [presence] in serum
35394-6,gg pneumophila 1 ordinal legionella ab [presence] in serum
35394-6,legionella pneumophila 1 serum ab [presence] in igg
35394-6,l pneumo1 igg ser ql
35394-6,pr l ql igg ser pneumo1
35394-6,q pneumo1 igg philadelphia 1 serum l
35394-6,l. pneumophila 1 igg ql (s)
35394-6,l. pneumophila 1 (s) ql igg
35394-6,l. ( serum pneumophlaiggql
49198-5,bartonella vinsonii berkhoffii igm ab [titer] in body fluid
49198-5,bartonella vinsonii erkhoffii igm  [titer] in boy fluid
49198-5,bartonella vinsonii berkhoffii igm antibody ab [titer] in body fluid
49198-5,b vinsonii berkhoffii igm titr fld
49198-5,b vinsoni berkhoffiiig titr fl
49198-5,b vinsonii igm berkhoffii titr fld
49198-5,b. vinsonii berkhoffii igm (body fld) [titer]
49198-5,igm vinsonii berkhoffii b. (body fld) [titer]
49198-5,b. i berkhoffii vnsonii (bod fl) [titer]
96939-4,social contact panel [r-outcomes]
96939-4,[r-outcoes] right contat pael socal
96939-4,contact social panel [r-outcomes]
96939-4,social contact panel
96939-4,socialcontactpanel
96939-4,social contact panel
44501-5,herpes simplex virus 2 ag [presence] in throat
44501-5,herpes ql throat virus 2 ag [presence] in simplex
44501-5,screen herpes smple virus 2 ag[ql] in hroat
44501-5,hsv2 ag throat ql
44501-5,hsv2 ag throat ql
44501-5,throat random ag hsv2 ql
44501-5,hsv 2 ag ql (throat)
44501-5,ql 2 screen ag hsv (throat)
44501-5,hsv 2 ag q herpes simplex virus type 2 (throat)
50881-2,molybdenum [moles/mass] in hair
50881-2,molybdenum[moles/mas]  hai
50881-2,in [moles/mass] molybdenum hair
50881-2,molybdenum hair-scnt
50881-2,molybdenum hair-scnt
50881-2,molybdenum substance content hair-scnt
50881-2,molybdenum (hair) [moles/mass]
50881-2,molybdenum (hair) [moles/mass]
50881-2,(hair) drugs molybdenum [moles/mass]
98687-7,motor nerve conduction panel right fibular nerve
98687-7,nervecondutio motor panelright fibular nerve
98687-7,right nerve conduction panel motor fibular nerve
98687-7,motor nc pnl r fibular n
98687-7,motor nc pnl r fibular panl n
98687-7,motor r pn nc fiblar
38643-3,calcium cyanamide [mass/volume] in air
38643-3,calcium [mass/volume] cyanamide in nitrogen lime air
38643-3,calcium cyanamide [mass/volume] in air
38643-3,calcium cyanamide air-mcnc
38643-3,calcium carbimide calcium cyanami air-mcn
38643-3,calcium cyanamide air-mcnc
38643-3,calcium cyanamide (air) [mass/vol]
38643-3,quantitative calcium cyamide(air)mass/vol]
38643-3,(air) yanmide calcium [mas/vl]
1715-2,acid phosphatase [enzymatic activity/volume] in serum or plasma
1715-2,[enymtic phophatase acid activit/voum]n srum or quant plasma
1715-2,point in time acid phosphatase in activity/volume] [enzymatic ser or plasma
1715-2,acp serpl-ccnc
1715-2,serpl-ccnc acp
1715-2,serpl-ccnc acp
1715-2,acid phosphatase [catalytic activity/vol]
1715-2,acid [catalytic acp phosphatase activity/vol]
1715-2,acid phosphatase activity/vol] [catalytic
50879-6,methyl ethyl ketone [moles/volume] in body fluid
50879-6,methyl [moles/volume] qnt ketone ethyl in body fluid
50879-6,methyl ethyl ketone body in [moles/volume] ethyl methyl ketone fluid
50879-6,mek fld-scnc
50879-6,fld-scc mek
50879-6,mek level fld-scnc
50879-6,methyl ethyl ketone (body fld) [moles/vol]
50879-6,methyl ethl ketone (body fld) [oles/vol]
50879-6,fluid metyl ethyl ketone (ody fld)[molesol]
70871-9,additional concerns - fact-c [facit]
70871-9,additional concerns - [facit] fact-c
70871-9,additional - concerns fact-c [facit] survey.gnhlth
34641-1,protein fractions [interpretation] in serum or plasma
34641-1,roteinfractins [iterprettion] in serum plsma or
34641-1,protein fractions or in sr serum [interpretation] plasma
34641-1,prot pattern serpl-imp
34641-1,serpl-imp pattern prot
34641-1,prot patten prot pattern serpl-p
34641-1,protein fractions [interp]
34641-1,pr protein fractions [interp]
34641-1,protein [intrp] fracions plsm
5149-0,echovirus ab [titer] in serum by complement fixation
5149-0,echvirus ab [titer] inserum b complement fixation abs
5149-0,echovirus b [titer in ser y omplment fixation
5149-0,ecv ab titr ser cf
5149-0,ecv ab titr cf ser
5149-0,ec ab tit ser cf
5149-0,echovirus ab cf (s) [titer]
5149-0,echovirus ab cf (s) [tier]
5149-0,cf ab echovirus (s) [titer]
56973-1,proline/creatinine [ratio] in 24 hour urine
56973-1,proline/creatinine [ratio] in hour 24 urine
56973-1,prline/cretinin ato] in2hour urine
56973-1,proline/creat 24h ur-rto
56973-1,24h proine/creat ur-rto
56973-1,roline/creat 1 day 24 ur-rto
56973-1,proline/creatinine (24h u) [ratio]
56973-1,proline/creatinine (24h u) [ratio] crea
56973-1,u) (24h proline/creatinine [ratio]
43247-6,catecholamines/creatinine [mass ratio] in 24 hour urine
43247-6,catec catecholminescreatiine [mass ratio]in 24 hour urine
43247-6,catecholamines/creatinine [mass ratio] urine 24 hour in
43247-6,catechols/creat 24h ur
43247-6,catechols/creat 24h ur
43247-6,ur 24h epinephrine+norepinephrine+dopamine catechols/creat
43247-6,catecholamines/creatinine (24h u) [mass ratio]
43247-6,caecholamines/ceatiine u) (2h ass epinephrine+norepinephrine+dopamine raio]
43247-6,ctecholamines/creatinine urn (4h u) [mass ratio]
55231-5,electrolytes panel - blood
55231-5,electrolytes blood - panel
55231-5,point in time electrolytes panel - bld
55231-5,lytes pnl bld
55231-5,blood pnl lytes
55231-5,lytes bld pnl lytes
55231-5,electrolytes panel (bld)
55231-5,(blood) lytes panel electrolytes
55231-5,panel electrolytes (bld)
6569-8,varicella zoster virus igg ab [titer] in serum by immunofluorescence
6569-8,in zoster virus igg ab [titer] varicella serum by immunofluorescence
6569-8,varicella zoster virus igg ab immunofluorescence in serum by [titer]
6569-8,vzv igg titr ser if
6569-8,igg vzv titr ser if
6569-8,vzv autoantibodies if titr ser igg
6569-8,vzv igg if (s) [titer]
6569-8,vzv igg if (s) [titer]
6569-8,vzv igg if (s) [titer]
53868-6,glucose tetrasaccharide/creatinine [molar ratio] in urine
53868-6,glucoe tetrsaccaride/cratiine[molar ratio in uin
53868-6,glucose tetrasaccharide/creatinine [molar ratio] in urine crea
53868-6,glucose tetrasaccharide/creat ur-srto
53868-6,gucose usrto random tetrasaccaride/creat
53868-6,ur-srto tetrasaccharide/creat glucose
53868-6,glucose tetrasaccharide/creatinine (u) [molar ratio]
53868-6,quant lcos tetrsccharide/creatinine (u) [mola raio]
53868-6,glucose tetrasaccharide/creatinine (u) [molar quant ratio]
16458-2,bethanechol [mass/volume] in serum or plasma
16458-2,bthanechol [mass/volum] in ser or pasma
16458-2,or [mass/volume] in ser bethanechol qnt plasma
16458-2,bethanechol serpl-mcnc
16458-2,serpl-mcnc bethanechol
16458-2,serpl-cnc level ethanechol
16458-2,bethanechol [mass/vol]
16458-2,ser or plasma bethanechol [mass/vol]
16458-2,[mass/vol] plasma bethanechol
55563-1,paraldehyde [moles/volume] in serum or plasma
55563-1,[moles/vlume paralehyde in serum or plasm
55563-1,in parldehyde[moles/volum] serm or plasm
55563-1,paraldehyde serpl-scnc
55563-1,paraldehyde serpscnc
55563-1,serpl-scnc paraldehyde
55563-1,paraldehyde [moles/vol]
55563-1,paraldehyde [moles/vol]
55563-1,parldehyd [moes/vol] plsm
91788-0,neisseria meningitidis [presence] in upper respiratory specimen by organism specific culture
91788-0,neisseria ql meninitidis [presence] in upper respiratory specmen by organismecific cultue
91788-0,neisseria meningitidis [presence] in upper respiratory specimen by culture specific organism
91788-0,n men upper resp ql cult
91788-0,n men upper resp ql cult meningococcus
91788-0,upper resp n en uppr resp presence cult
91788-0,n. meningitidis org specific cx ql (upper resp)
91788-0,n. eningitidis org specificx ql(uppr resp)
91788-0,n. meningitidis org specific cx presence (upper resp)
82183-5,haemophilus influenzae dna [presence] in cerebral spinal fluid by naa with non-probe detection
82183-5,haeophilsinlezae dna [resece] ncerebral spnal fluid by na with non-probe etetion haem influ
82183-5,haemophilus influenzae dna naa in cerebral spinal fluid by [presence] with non-probe detection
82183-5,haem influ dna csf ql naa+non-probe
82183-5,naa+probe heminfludnacsf q naa+nonprobe
82183-5,haem dna influ probe with target amplification csf ql naa+non-probe
82183-5,h. influenzae dna naa+non-probe ql (csf)
82183-5,h. influenzedna amplification naa+non-poeq (cf)
82183-5,h. influenzedna a+non-probe q (sf)
54345-4,acetylcarnitine (c2) [moles/volume] in semen
54345-4,inemen gu (c2) [moles/vlume] aceylcarntine
54345-4,[moles/volume] (c2) acetylcarnitine in semen
54345-4,acetylcarn smn-scnc
54345-4,smn-cnc acetycarn
54345-4,acetylcarn smpls smn-scnc
54345-4,c2 (sem) [moles/vol]
54345-4,(sem)[mole/vol] c2
54345-4,gu c (sem) [moles/vol]
13508-7,hematocrit [volume fraction] of cerebral spinal fluid by centrifugation
13508-7,[volume hematocrit fraction] of cerebral spinal fluid by centrifugation
13508-7,hematocrit [volume fraction] of random cerebral spinal fluid by centrifugation
13508-7,hct vfr csf spun
13508-7,hct csf vfr spun
13508-7,vfr hct csf spun
13508-7,hematocrit centrifugation (csf) [volume fraction]
13508-7,csf centrifugation hematocrt vlme frctio]
13508-7,hematocrit centrifugtion [volme (csf) fraction]
54279-5,glutarylcarnitine (c5-dc)/creatinine [molar ratio] in urine
54279-5,glutarylcarnitine cr (c5-dc)/creatinine [molar ratio] in urine
54279-5,in (c5-dc)/creatinine cr [molar ratio] glutarylcarnitine urine
54279-5,glutarylcarn/creat ur-srto
54279-5,u-srto utarylcarn/creat
54279-5,ur-srto glutarylcarn/creat chemistry
54279-5,c5-dc/creatinine (u) [molar ratio]
54279-5,c5-dc/creatinine [molar (u) ratio] ur
54279-5,c5-dc/cretinine(u) ratio] molar
57005-1,glutathione [moles/volume] in serum or plasma
57005-1,plasma [moles/volume] in serum or glutathione
57005-1,glutathione [moles/volume] in or ser plasma
57005-1,glutathione serpl-scnc
57005-1,serpl-scnc glutathione
57005-1,serpl-scnc glutathione
57005-1,glutathione [moles/vol]
57005-1,glutathi [moles/l] substance concentration
57005-1,serum gutatione [moles/vol]
44720-1,methylmalonate/homocystine [molar ratio] in serum or plasma
44720-1,mthylmalonat/homocystine or ratio] n ser [molar plasma
44720-1,methylmalonate/homocystine [molar ratio] in or serum plas
44720-1,methylmalonate/homocystine serpl-srto
44720-1,random methylmalonate/homocystine serpl-srto
44720-1,serpl-srto methylmalonate/homocystine
44720-1,methylmalonate/homocystine [molar ratio]
44720-1,thymalonate/homocystin [moar scrto ratio
44720-1,ratio] [molar serplas ethylmaloate/oocystine
17907-7,bacteria # 5 identified in tissue by aerobe culture
17907-7,idetified bacteia#5 in tissue by aerobe ulture
17907-7,bacteria # 5 identified in tissue by aerobe culture
17907-7,bacteria tiss aerobe cult org #5
17907-7,org tiss aerobe cult bacteria #5
17907-7,identity or presence bacteria tiss #5 cult org aerobe
17907-7,bacteria identified # 5 aer cx nom (tiss)
17907-7,bacteria # identified 5 aerobed aer cx nom (tiss)
17907-7,bacteria 5 # tissue identified aer cxnom (tss)
4032-9,sotalol [mass/time] in 24 hour urine
4032-9,sotalol [ms/time] n 4 hou betudes urine
4032-9,urine [mass/time] sotacor in 24 hour sotalol
4032-9,sotalol 24h ur-mrate
4032-9,24hur-mrte solalex sotaol
4032-9,24h mrate sotalol ur-mrate
4032-9,sotalol (24h u) [mass/time]
4032-9,sotalol [ass/time] u) (24h
4032-9,[mass/time (4h u) sotalo
8851-8,left pulmonary artery oxygen saturation
8851-8,left pulmonary artery oxygen saturation
8851-8,left pulmoary artey oxygen satration sao2
8851-8,sao2 % pa-l
8851-8,% sao2 pa-l
8851-8,sao2 % pa-l pulmonology
92700-4,trichomonas vaginalis dna [presence] in vaginal fluid by probe
92700-4,ichoonasvagns dna[rsence]invaginl fi by prbe
92700-4,fluid vaginalis dna [presence] in vaginal trichomonas by probe
92700-4,t vaginalis dna vag ql probe
92700-4,t vaginalis dna vag presence probe
92700-4,t ql dna vag vaginalis probe
92700-4,t. vaginalis dna probe ql (vag fld)
92700-4,t. vaginalis dna probe ql (vag fld)
92700-4,t.vanalis ql dna probe ql (vag ld)
69350-7,temporal orientation and/or mental status - acute [care]
69350-7,temporal orientation and/or - status mental acute pnl [care]
69350-7,temporal orienttion and/omental stus - ute [care]
40626-4,codeine [presence] in specimen
40626-4,codeine inspecimen [presence]
40626-4,odeine [presenc] in specimen
40626-4,codeine spec ql
40626-4,miscellaneous denespec
40626-4,codein pec morphine methyl ether presence
40626-4,codeine ql (specimen)
40626-4,(specimn) q codeine
40626-4,ql codeine ql (specimen)
53947-8,escherichia coli stx1 and stx2 toxin stx1 and stx2 and h7 flagellar flic genes [identifier] in specimen by naa with probe detection
53947-8,escherichia coli stx1 and stx2 toxin stx1 and stx2 to be specified in another part of the message and h7 flagellar flic genes [identifier] in specimen by naa with probe detection
53947-8,escherichia coli stx1 and stx2 toxin with and stx2 and h7 flagellar flic genes [identifier] pcr in specimen by naa stx1 probe detection
53947-8,ec stx1+stx2 + h7 flic spec naa+probe
53947-8,e sx1+stx2 + h lic spc naa+prbe
53947-8,ec stx1+st2 + h7 transcription mediated amplification flic spec naape
53947-8,e. coli stx1 and stx2 and flic genes naa+probe nom (specimen)
53947-8,e. coli flic and stx2 and stx1 genes naa+probe nom (specimen)
53947-8,coli e. stx1 and stx2 and flic genes naa+probe nom 3 self-sustaining sequence replication (specimen)
92854-9,adenovirus dna [#/volume] (viral load) in cornea or conjunctiva by naa with probe detection
92854-9,adenoirus dna [#volume]viral load) in cornea or conunta by na with quantitative probe detection
92854-9,adnovirus dna [#/voume (vral load) in ornea naa by orconjunctiva with probe detectin
92854-9,hadv dna # corn/cnjt naa+probe
92854-9,adv dna # corn/cnjt na+pro
92854-9,hadv naa+probe # corn/cnjt dna
92854-9,adenovirus dna naa+probe (corn/cnjt) [#/vol]
92854-9,adenoviru dnaaa+proborn/cnjt)[#/ol]
92854-9,adenovirus count dna naa+probe (corn/cnjt) [#/vol]
45161-7,hepatitis b virus dna [log #/volume] (viral load) in serum or plasma by naa with probe detection
45161-7,hepatiti b viru dna [log/volue] (viral load) in ser or lasa by naa wth probe detectin
45161-7,hpatitis bvirus dna [log #/volume] (viral load) in ser or plasm by naa with probeetection
45161-7,hbv dna serpl naa+probe-log#
45161-7,hbv serum or plasma dna amplified naa+probe-log#
45161-7,hbv serpl dna naa+probe-log#
45161-7,hbv dna naa+probe [log #/vol]
45161-7,dna hbv naa+probe [log #/vol]
45161-7,naa+robe dna nasba hbv [log #/vol]
34412-7,mitochondria m9 ab [presence] in serum
34412-7,mitochondia m9 in presenc ab erum
34412-7,tochondri m9 ab [presnce] in serum
34412-7,mitochondria m9 ab ser ql
34412-7,ab m9 mitochondria ser ql
34412-7,ab m9 mitochondria ser ql
34412-7,mitochondria m9 ab ql (s)
34412-7,mitochondra m ab ql (s
34412-7,mitochndia m9 ab presence (s)
29806-7,anaplasma phagocytophilum igg ab [presence] in cerebral spinal fluid by immunoblot
29806-7,anaplasma autoantibody phagoyphilum igg ab [presence] in cerebra spinal fluid by iunolot
29806-7,anaplasma phagocytophilum cerebral ab [presence] in igg spinal fluid by immunoblot
29806-7,a phagocytoph igg csf ql ib
29806-7,a ql igg csf phagocytoph ib
29806-7,a csf neurology igg phagocytop qlib
29806-7,a. phagocytophilum igg ib ql (csf)
29806-7,a. ib igg phagocytophilum ql (cerebrospinal fluid)
29806-7,a. phagocytophilum igg ib ql (cerebrospinal fluid)
99026-7,providencia stuartii dna [presence] in urine by naa with probe detection
99026-7,providencia stuartii dna [presence] in 3sr sr urine detection naa with probe by
99026-7,providencia stuartii dna [presence] in urine by lcr naa with probe detection
99026-7,p stuartii dna ur ql naa+probe
99026-7,ordinal p stuartii nr l aa+robe
99026-7,naa+probe stuartii dna ur ql urn p
99026-7,providencia stuartii dna naa+probe ql (u)
99026-7,providencia deoxyribonucleic acid stuartii dna (u) presence naa+probe
99026-7,stuartii providencia dna naa+probe presence lat (u)
14278-6,neutrophil cytoplasmic ab.perinuclear [titer] in serum by immunofluorescence
14278-6,neutrphl ytoplasmic ab.perinucear [titer] in seum by acif immunflurescence
14278-6,seu cytoplasmic p-anca ab.perincear[tter] in neutrophil by imunfluorescence
14278-6,p-anca titr ser if
14278-6,-anca titr immunofluor ser if
14278-6,p-anca ser titr if immunofluor
14278-6,neutrophil cytoplasmic ab.perinuclear if (s) [titer]
14278-6,neutrophil cytoplasmic (s) if ab.perinuclear [titer]
14278-6,aberinuclearif cytoplasmic neutophil (s immune fluorescence [titer]
38715-9,phosgene [mass/volume] in air
38715-9,phosgene mas/volume] n air
38715-9,phosgene air in [mass/volume]
38715-9,phosgene air-mcnc
38715-9,qnt phosgene air-mcnc
38715-9,armcnc phosen
38715-9,phosgene (air) [mass/vol]
38715-9,[mass/vol] (air) phosgee carbon oxychloride
38715-9,phosene(air) carbon oxychloride [mass/vol]
22534-2,sarcocystis neurona ab [presence] in serum
22534-2,sarcoystis neurona ab seum in presence]
22534-2,arcocystis eurona ab qualitative [presenc]i serum
22534-2,s neurona ab ser ql
22534-2,s neurnab ser ql
22534-2,s euroa b ser ql antby
22534-2,s. neurona ab ql (s)
22534-2,s. neurona ab l(
22534-2,s. neurona (s) ql ab
99674-4,temporary pacemaker panel
99674-4,temorar pacemaker pnel random
99674-4,pacemker temporary panel
99674-4,temporary pacemaker panel
99674-4,panel pacemaker temporary
99674-4,panel.devices temporary pacemaker panel
73365-9,gentamicin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73365-9,gentamicin induced platelet igg ab [presence] in ser or plasma by flow cytometry (fc)
73365-9,entamicin genj iduced platelet ig a preence]in seum or plasmaby flow cytometry (fc)
73365-9,gentamicin ind plt igg serpl ql fc
73365-9,gentamicin id plt gg serpl ql fc
73365-9,gentamicin ind plt igg serpl serpl ql fc
73365-9,gentamicin induced platelet igg fc ql
73365-9,gentamicin induced platelet igg fc ql serp
73365-9,gentamicin induced ql igg fc platelet
87591-4,sulfathiazole [mass/mass] in specimen
87591-4,sulfathiazole [mas/mas] in specimn
87591-4,sulfathiazole in [mass/mass] specimen
87591-4,sulfathiazole spec-mcnt
87591-4,slfathiazole spec-mcnt
87591-4,sulfathiazole mass content spec-mcnt
87591-4,sulfathiazole (specimen) [mass/mass]
87591-4,sulfathiazole unspecified (specimen) [mass/mass]
87591-4,sulathiazle (specime) [mass/mass]
73467-3,ceftizoxime induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73467-3,cetizoxime induced plateletig ab [pesence] in sem or plasmaby flow cytometry(fc) immune globulin m
73467-3,cftizoxime induced plateetigmab [presence] in erum orplama by flow platelet auto-antibodies cyomry (fc)
73467-3,ceftizoxime ind plt igm serpl ql fc
73467-3,ceftzoxime qualitative ind fc igm serpl ql plt
73467-3,ceftzoxmind fc serplql ltigm
73467-3,ceftizoxime induced platelet igm fc ql
73467-3,fc ceftizoxime presence platelet igm fc induced
73467-3,ceftizoxime induce platelet igm fc ql
89657-1,microscopic observation [identifier] in lower respiratory specimen by toluidine blue o stain
89657-1,microscopic observation [identifier] by lower respiratory specimen in toluidine blue o stain
89657-1,microscopic observation [identifier] in lower respiratory specimen by toluidine blue o stain
89657-1,tbo stn lower resp
89657-1,tb stnlowr resp
89657-1,tbo stn resp lower
89657-1,microscopic observation toluidine blue o stain nom (lower resp)
89657-1,micrscopc oervaton tolidine blue o stan nom (lower resp)
89657-1,microscopic observation toluidine blue o stain nom (lower resp)
49814-7,2-hydroxyisovalerate/creatinine [molar ratio] in 24 hour urine
49814-7,2-hydroxyisovalerate/creatinine [molar in ratio] 24 hour urine
49814-7,urine rati]in 24 hour ydroxyisvalerate/ceatinine[molar
49814-7,2oh-isovalerate/creat 24h ur-srto
49814-7,chemistry ur-srto 2oh-isovalerate/creat4h
49814-7,2ohsvaleratcet ur-srto 24h
49814-7,2-hydroxyisovalerate/creatinine (24h u) [molar ratio]
49814-7,2-hydroysovaleratcreatinine (2h u) [molar rato] ucr
49814-7,2-ydoxyisovalerte/creainine(24hu) rtio] [mola
76702-0,promis short form - physical function 20a - version 1.0
76702-0,promis short form - physical function 20a - version 1.0
76702-0,promis short form - physical function 20a - 1.0 version
103615-1,erlotinib [mass/volume] in serum or plasma by lc/ms/ms --24 hours post dose
103615-1,erloinib [s/volume] inserum or plasma by lc/ms/m --24 p dose hours post dose
103615-1,ser [mass/volume] n erlotinib or plasa by lc/ms/ms --24 hours pot dose drugs
103615-1,erlotinib 24h p serpl lc/ms/ms-mcnc
103615-1,p erlotinib24h serpl c/ms/ms-mcnc
103615-1,erlotinib serpl p 24h lc/ms/ms-mcnc
103615-1,erlotinib 24 hr post dose lc/ms/ms [mass/vol]
103615-1,erlotinib point in time 24 hr post dose lc/ms/ms [mass/vol]
103615-1,point in time erlotnib 24 mass/vo] postdose lc/ms/ms hr
103947-8,long-term care hospital (ltch) continuity assessment record and evaluation (care) data set (lcds) - unplanned discharge - version 5.1 during assessment period [cms assessment]
103947-8,long-term care hospital (ltch) continuity assessment version5.1 and evalution (care data set (lcds) - unplanned discharge - record urig assesmentperiod [cms assessment]
103947-8,long-term care hospital (ltch) continuity assessment record and evaluation (care) data set (lcds) - unplanned discharge - version 5.1 during assessment period [cms assessment]
26015-8,cholesterol in hdl 2 [moles/volume] in serum or plasma
26015-8,cholesterol hdl pl in 2 [moles/volume] in serum or plasma
26015-8,cholesterol in hdl 2 [moles/volume] in ser or plasma
26015-8,hdl2c serpl-scnc
26015-8,cholest serpl-scnc hdl2c
26015-8,quan hdl2c serpl-scnc
26015-8,cholesterol in hdl 2 [moles/vol]
26015-8,cholesterol [moles/vol] hdl 2 in serum
26015-8,substance concentration cholesterol in hdl 2 [moles/vol]
14835-3,methanol [moles/volume] in serum or plasma
14835-3,methanol [moles/volume] or serum in plasma
14835-3,methanol or in serum [moles/volume] plasma
14835-3,methanol serpl-scnc
14835-3,methanol serpl-scnc
14835-3,serum or plasma methanol serpl-scnc
14835-3,methanol [moles/vol]
14835-3,methanol[moes/ol]
14835-3,methanol [moles/vol] qnt
53578-1,alkaline phosphatase.intestinal 2/alkaline phosphatase.total in serum or plasma
53578-1,alkaline alp phosphatase.intestinal 2/alkaline phosphatase.total in serum or plasma
53578-1,alkaline phosphatase.intestinal 2/alkaline phosphatase.total in ser alk phos or plasma
53578-1,alp intest 2 cfr serpl
53578-1,cfr intest 2 alp serpl
53578-1,ap serum or plasma itest2 cfr al
53578-1,alp intest 2 [catalytic fraction]
53578-1,ap 2[catlytic intest rton serplas
53578-1,fraction] intest 2 [calytic alp
94383-7,glial nuclear type 1 igg ab [presence] in cerebral spinal fluid by line blot
94383-7,glial nuclear type 1 igg ab [ql] in cerebral spinal fluid by line blot
94383-7,glial nuclear type 1 gg ab by in cerebral spinal fluid [presnce] line blot
94383-7,glial nuc type 1 igg csf ql line blot
94383-7,line nuc type 1 igg cerebrospinal fluid ql qualitative glial blot
94383-7,glial nuc type 1 igg cerebrospinal fluid ql line blot
94383-7,glial nuclear type 1 igg line blot ql (csf)
94383-7,glia uclear ype 1 igg lin bot ql csf)
94383-7,glia nuclear type 1 iggline bot ql csf)
29973-5,strontium/creatinine [mass ratio] in 24 hour urine
29973-5,24 [mass ratio] in strontium/creatinine hour mcrto urine
29973-5,strontiumcreatinine hor quantitative 4 [masstio]in urne
29973-5,strontium/creat 24h ur
29973-5,strotium/creat 24h ur
29973-5,24h strontium/creat ur
29973-5,strontium/creatinine (24h u) [mass ratio]
29973-5,strontium/creatinine (24h u) [mass ratio]
29973-5,trontiu/reatinine [massrato] u) (24h
43873-9,aspergillus sp igm ab [presence] in serum
43873-9,spp aspergills p igm ab [presence] in serum
43873-9,immunoglobulin m aspergillusp [prsece] ab igm in serum
43873-9,aspergillus igm ser ql
43873-9,aspergillus igm antibody ser presence
43873-9,aspegiu im anti ser ql
43873-9,aspergillus sp igm ql (s)
43873-9,sp aspergillus igm ql (s)
43873-9,aspergllus sp igm ql (s)
103139-2,systemic lupus ab panel - serum or plasma
103139-2,luu systemc ab panl -serum or plsma
103139-2,systemic - ab panl panel lupus ser or plasma
103139-2,sl panel serpl
103139-2,sl point in time serpl panel
103139-2,panel sl serpl
103139-2,systemic lupus ab panel
103139-2,systemic lupus panel ab
103139-2,pnl systemic lups ab pane
48155-6,"threo-4,5-dihydrohexanolactone/creatinine [molar ratio] in urine"
48155-6,"[molar threo-4,5-dihydrohexanolactone/creatinine ratio] in urine"
48155-6,"ratio] [molar threo-4,5-dihydrohexanolactone/creatinine in threo-4,5-dhl urine"
48155-6,"threo-4,5-dhl/creat ur-srto"
48155-6,"threo-4,5-dhl/creat ur-srto"
48155-6,"threo-4,5-dhl/creat substance ratio ur-srto"
48155-6,"threo-4,5-dihydrohexanolactone/creatinine (u) [molar ratio]"
48155-6,"ratio] (u) [molar threo-4,5-dihydrohexanolactone/creatinine"
48155-6,"(u) threo-4,5-dihydrohexanolacon/cretinne [molar ucr tio]"
100976-0,eosinophil derived neurotoxin [mass/volume] in serum or plasma
100976-0,eosinophil derived neurotoxin [mass/volume] in serum or plasma quantitative
100976-0,eosinophil derived serum [mass/volume] in neurotoxin or plasma
100976-0,edn serpl-mcnc
100976-0,serpl-mcc en
100976-0,edn plasma serpl-mcnc
100976-0,eosinophil derived neurotoxin [mass/vol]
100976-0,eosinophil derived neurotoxin [mass/vol]
100976-0,neurotoxin derived eos eosinophil [mass/vol]
104652-3,synovial lining cells [#/volume] in synovial fluid by manual count
104652-3,synovial lining cells [#/volume] in synovial fluid by manual count
104652-3,synovial lning clls [#/volue]in synil fluid by mnual manl count
104652-3,synoviocytes # snv manual
104652-3,manual synov # snv synoviocytes
104652-3,synoviocytes # snv manual
104652-3,synovial lining cells manual cnt (syn fld) [#/vol]
104652-3,cells ning synovial manual cnt (n fld) point in time [#vol]
104652-3,synovial lining cells manual cnt (syn fld) [#/vol]
82932-5,sp100 igg ab [presence] in serum by line blot
82932-5,sp10 erum ab [presence] in igg by lieblot serology
82932-5,serum sp100 igg ab [presence] in serum by line blot
82932-5,sp100 igg ser ql line blot
82932-5,sp100 anti igg ql ser line blot
82932-5,sp100 igg ser line ql blot
82932-5,sp100 igg line blot ql (s)
82932-5,sp100 igg line blot serology ql (s)
82932-5,ql(s) i line blot hepatology sp1
73385-7,fenofibrate induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73385-7,fenofibrate induced platelet igg ab cytometry in serum or plasma by flow [presence] (fc)
73385-7,fenofibrate induced platelet by ab [presence] in serum or plasma igg flow cytometry (fc)
73385-7,fenofibrate ind plt igg serpl ql fc
73385-7,fenofibrate ind plt igg serpl immunoglobulin g ql fc
73385-7,fenofibate ind t igg serum or plasma ql fc
73385-7,fenofibrate induced platelet igg fc ql
73385-7,fenofibrate induced platlet ig presence fc
73385-7,fenofibrate serp induced platelet igg ql fc
100892-9,orthopoxvirus igm ab [presence] in serum or plasma by immunoassay
100892-9,orhopoxvirs igm sr ab [presece]i serm o plasma b imunassay
100892-9,orthopoxvirus igm ab [prsece] i serum or plasa by immunassa
100892-9,orthopoxvirus igm serpl ql ia
100892-9,orthopoxvirus autoantibodies igserpl ql ia
100892-9,ortopoxvirus igm serum or plasma ql ia
100892-9,orthopoxvirus igm ia ql
100892-9,gmia othopoxvirus ql
100892-9,ql igm ia orthopoxvirus
106562-2,trichomonas vaginalis dna [presence] in throat by naa with probe detection
106562-2,trichomonas vaginalis dna [presence] in throat by naa with probe detection
106562-2,trichomonas vaginalisda esnce]in throat b naa wth probe detection
106562-2,t vaginalis dna throat ql naa+probe
106562-2,t vaginalis dna sda throat ql naa+probe
106562-2,naa+probe vaginalis dna throat ql t
106562-2,t. vaginalis dna naa+probe ql (throat)
106562-2,t. vaginalis dna ql naa+probe (throat)
106562-2,deoxyribonucleic acid tvainalisdna naa+probe presence (throat)
67453-1,treatment duration
67453-1,point in time duratin treatmen
67453-1,teatment duration random
67453-1,treatment duration
67453-1,duration tretment
67453-1,duration reatment
2695-5,osmolality of urine
2695-5,osmolality f urine
2695-5,urin of osmolality kidney
2695-5,osmolality ur
2695-5,omolalty random ur
2695-5,ur osmolality
2695-5,osmolality (u) [osmolality]
2695-5,ur osmolality (u) osmolalty]
2695-5,osmolality (u) [osoality]
8850-0,inferior vena cava oxygen saturation
8850-0,inferior vena oxygen cava saturation
8850-0,infeiorvena lung cava oygn saturatin
8850-0,sao2 % ivc
8850-0,qnt sao2 % ivc
8850-0,% sao2 ivc
87820-7,zolpidem [presence] in saliva (oral fluid) by screen method
87820-7,olpidem [presence in sla (oral fluid) by screen method
87820-7,stilnoct zolpdem [presence] in liva (oal flui) by cren ethod
87820-7,zolpidem sal ql scn
87820-7,adormix zolpiem sal presence sn
87820-7,scn sal ql drugs of abuse zolpidem
87820-7,zolpidem screen ql (sal)
87820-7,zolpie q(al screen
87820-7,ivedal zolpidem screen ql (sal)
13324-9,herpes simplex virus 1 ab [units/volume] in serum by immunofluorescence
13324-9,herpes simplex virus 1 ab [units/volume] in ser by immunofluorescence autoantibody
13324-9,erpes simplex immunofluorescence virus 1 ab by in serum [its/olume] immunfluorescen
13324-9,hsv1 ab ser if-acnc
13324-9,ser ab hsv1 if-acnc
13324-9,hsv1 b f-acnc er
13324-9,hsv 1 ab if qn (s)
13324-9,hsv 1 ab if qn (s)
13324-9,hsv if ab 1 qn (s)
63303-2,parietal cell ab [presence] in gastric fluid by immunofluorescence
63303-2,parietal ab ell trf [preence] i gastric luid by immunofluorescene
63303-2,parietal cell fluid [presence] in gastric ab by immunofluorescence
63303-2,pca ab gast ql if
63303-2,pca b gast presence ordinal if
63303-2,pca ab gast antby ql if
63303-2,parietal cell ab if ql (gast fld)
63303-2,immunofluor cell parietal ab if ql (gast fld)
63303-2,parietal if ab cell ql (gast fld)
40931-8,yersinia sp ab [presence] in serum
40931-8,yersinia p b[presence] in ser seru
40931-8,yersinia sp ab [presence] in qual ser
40931-8,yersinia ab ser ql
40931-8,yersinia ab screen ser presence
40931-8,ql ab serum yersin
40931-8,yersinia sp ab ql (s)
40931-8,ql sp ab yersinia (s) antibody
40931-8,yersinia (s abql sp
26446-5,blasts/leukocytes in blood
26446-5,blasts/leukocytes blood i
26446-5,blod in blast/leukocyte
26446-5,blasts nfr bld
26446-5,blast nr bld
26446-5,nfr wbcs blasts bld
26446-5,blasts/leukocytes (bld)
26446-5,wbcs blasts/leukocytes (bld)
26446-5,(bld) random blasts/leukocytes
45310-0,mesoporphyrin [moles/mass] in stool
45310-0,mesoorphyrin [moles/mass] in stool
45310-0,mesoporpyn heme [mole/mass] in stool
45310-0,mesopor stl-scnt
45310-0,mesopor sl-scnt
45310-0,mesopor stlscnt
45310-0,mesoporphyrin (stl) [moles/mass]
45310-0,mesoporphyrin (stl) point in time [moles/mass]
45310-0,(stl) mesoporphyrin [moles/mass] random
105536-7,phenylacetyl fentanyl [mass/volume] in urine
105536-7,fentanyl phenylacetyl [mass/volume] in urine
105536-7,phenylacetyl fentanyl [mass/volume] in urine
105536-7,phenylacetyl fentanyl ur-mcnc
105536-7,phenylacetyl ur-mcnc fentanyl
105536-7,phenylacetyl entanl ur-cnc drugs
105536-7,phenylacetyl fentanyl (u) [mass/vol]
105536-7,(u) fentanyl phenylacetyl [mass/vol]
105536-7,(u) duragesic fentanyl phenylacetyl [mass/vol]
35278-1,neuronal nuclear ab [presence] in serum by immunoblot
35278-1,neurnal nuclear b [presece] in serum ab imunoblot
35278-1,neuroal nuclear ab [presnce] in serum by mmunoblot
35278-1,hu ab ser ql ib
35278-1,ab h ser qlib
35278-1,ib ab immunoblot ser ql hu
35278-1,neuronal nuclear ab ib ql (s)
35278-1,neuronalnuclarab ib ql (s)
35278-1,presence nuclerb ib hu nernal (s)
92750-9,glucopsychosine [moles/volume] in serum or plasma
92750-9,glucopsychosine [moles/volume] serum in serum or plasma
92750-9,plasm [molesvolume] in serumor gucopsyhosin
92750-9,glucopsychosine serpl-scnc
92750-9,serpcnc random glucopsychosine
92750-9,serpl-scnc glucopsychosine
92750-9,glucopsychosine [moles/vol]
92750-9,serum or plasma glucopychsine [mols/vol]
92750-9,serp glucopsychosine [moles/vol]
17327-8,neisseria meningitidis serogroup b ab [units/volume] in serum
17327-8,neisseria mningitis serogoup neisseria meningitidis type b b ab in [units/vome serum
17327-8,neisseria meningitidis b serogroup quantitative ab [units/volume] in serum
17327-8,n men sg b ab ser-acnc
17327-8,n men ab b sg ser-acnc abs
17327-8,nmen g b ab serum-cnc
17327-8,n. meningitidis b ab qn (s)
17327-8,n. b meningitidis ab qn (s)
17327-8,n. menngitidis b ab qn (s)
54456-9,urea reduction ratio in serum or plasma
54456-9,urea redution or in serum ratio lasma
54456-9,urea redution rtio in ser or plasma
54456-9,urea reduction ratio serpl
54456-9,urea reduction serpl ratio
54456-9,ra reducion atio sepl
54456-9,urea reduction ratio [molar fraction]
54456-9,plsm urea reduction ratio [molar fraction]
54456-9,urea reduction [molar ratio fraction]
53177-2,octanoylcarnitine (c8)/decanoylcarnitine (c10) [molar ratio] in dbs
53177-2,octanoylcarnitine (c8)/decanoylcarnitine ratio] [molar (c10) in dbs
53177-2,octanoylcarnitine (c8)/decanoylcarnitine dbs [molar ratio] in (c10)
53177-2,octanoylcarn/c10 dbs-srto
53177-2,octanycarn/c10 dbs-srto
53177-2,dbs-srto octanoylcarn/c10 chemistry
53177-2,c8/decanoylcarnitine (c10) (dbs) [molar ratio]
53177-2,[molar (c10) (dbs) c8/decanoylcarnitine ratio]
53177-2,c8/decanoylarniie (c10) (dbs) [molar atio] blood
10540-3,glyburide [mass/volume] in serum or plasma
10540-3,glyburide [mass/volume] in micronase serum or plasma
10540-3,glyburie [mas/volume] or quan serum in pama
10540-3,glyburide serpl-mcnc
10540-3,glyburide quan serpl-mcnc
10540-3,glyburide serpl-mcnc sr
10540-3,glyburide [mass/vol]
10540-3,[mass/vol] glyburide
10540-3,[massvol serplas glbuide
44025-5,aspergillus flavus b ab [presence] in serum by immune diffusion (id)
44025-5,asergllus flavus bab[presence] in serum by mmue antby dffusion (id)
44025-5,aspergillus flavus b ab by in serum [presence] immune diffusion (id)
44025-5,a flavus b ab ser ql id
44025-5,a flavus b ab erql id
44025-5,a sr flavus b ab serum ql id
44025-5,a. flavus b ab immune diff ql (s)
44025-5,a. anti diff b ab immune flavus ql (s)
44025-5,a. ab b flavus immune diff ql (s)
82274-2,estimated metabolic rate/predicted rmr [relative energy/time]
82274-2,estimated etabolicrate/predicted [relative rr actvty energy/tim]
82274-2,estimated etabolic rate/predictermr [relativ energy/tm]
82274-2,est act metab rate/pred rmr
82274-2,est act metarate/pred rr
82274-2,est act meab ate/pred rmr
26697-3,clostridioides difficile iga ab [units/volume] in serum
26697-3,clostridioides difficileiga  [units/volue] in eum
26697-3,in infectiousdisease dificile iga ab [units/volme] clostriioides serum
26697-3,c diff iga ser-acnc
26697-3,c diff iga se-acnc
26697-3,arbitrary concentration c iga diff ser-acnc
26697-3,c. difficile iga qn (s)
26697-3,c. (s) ga qn anti difficile
26697-3,autoantibodies c. difficile iga n (s)
65759-3,t-cell subsets cd4 and cd8 panel - blood
65759-3,t-cell subsets cd4 and cd8 panel - blood panel.cellmark
65759-3,t-cel sbsescd4 an cd8 panel - blood panel.cellmark
65759-3,t-cell subsets cd4+cd8 pnl bld
65759-3,t-cell bld cd4+cd8 pnl subsets
65759-3,cd4+cd8 subsets t-cell pnl bld
65759-3,t-cell subsets cd4 and cd8 panel (bld)
65759-3,tcell subsets4 ad cd8 pal bld)
65759-3,random t-cellsubset cd4 and cd8 panel (bld)
21058-3,albumin [mass/volume] in serum or plasma --2 hours post peritoneal dialysis
21058-3,albumin [mass/vlume] in ser orplasma dialy --2 hours post peritonal dialysis
21058-3,hours [mass/volume] in ser or plasma --2 albumin post peritoneal dialysis
21058-3,albumin 2h p pd serpl-mcnc
21058-3,albumin pd p 2h serum or plasma-mcnc
21058-3,p 2h albumin pd serpl-mcnc
21058-3,albumin 2 hr post pd [mass/vol]
21058-3,albumin 2 hr post pd [mass/vol]
21058-3,albumn 2 hr post pd [mss/vol]
75024-0,coproporphyrin 1/porphyrins.total in stool
75024-0,copro1 in 1/porphyrins.total coproporphyrin stool
75024-0,in 1/porphyrins.total coproporphyrin stool
75024-0,copro1 sfr stl
75024-0,copro1 sfr stl
75024-0,opro1sr st coproporphyrin i
75024-0,coproporphyrin 1/total porphyrins (stl) [molar fraction]
75024-0,fraction] bowel movement 1/totl pohyrisstl) [moar coprporphyrin
75024-0,coproporphyrin 1/total porphyrins (stl) [molar fraction] stool = fecal
72318-9,centromere protein a igg ab [presence] in serum or plasma by immunoassay
72318-9,autoantibody centromere potina ig ab [presence] inserum or plasmabyimuoassay
72318-9,centromere proteina igg in [presence ab serum or pasma byimmuossay
72318-9,cenp a igg serpl ql ia
72318-9,igg a meia cenp serpl ql i
72318-9,cenp a serpl autoantibodies igg presence ia
72318-9,centromere protein a igg ia ql
72318-9,centromee protei ql igg i a
72318-9,centromere igg a autoantibody protein ia ql
19471-2,fluoxetine [presence] in urine by confirmatory method
19471-2,bycnfirmatry [pesee] i urin fluoxeine drug/toxicology ethod
19471-2,fluxetine [presence] in rie by conirmatory method
19471-2,fluoxetine ur ql cfm
19471-2,fluoxetine ur l screen cfm
19471-2,cfm ur ql fluoxetine
19471-2,fluoxetine confirm ql (u)
19471-2,fluoxetin ql conirm (u) ordinal
19471-2,fluoxetieconfirm u) drug/toxicology ql
92773-1,streptococcus agalactiae dna [presence] by naa with probe detection in positive blood culture
92773-1,stretcocusagalacae dna [presece]y nawih probe detction in positivblood culture
92773-1,streptococcus agalactiae dna by [presence] naa with probe detection in positive blood culture
92773-1,gp b strep dna bld pos ql naa+probe
92773-1,gp  strep dnabldpo ql naa+re
92773-1,gp b strep dna bldpos q naa+probe
92773-1,s. agalactiae dna naa+probe ql (pos bld culture)
92773-1,ql s. agalactiae dna naa+probe culture) (pos bld ql
92773-1,s. agalactia dna qbr naa+pob ql (pos bld cultur)
16594-4,chlamydia trachomatis iga ab [titer] in cerebral spinal fluid by immunofluorescence
16594-4,spina rachmats iga ab [titer i cerebral lamdia flud by mmuoluorescence
16594-4,chlamydia trachomatis fluid ab [titer] in cerebral spinal iga by immunofluorescence
16594-4,c trach iga titr csf if
16594-4,c trch iga titr csf time resolved fluorescence if
16594-4,c trach c trach iga titr csf if
16594-4,c. trachomatis iga if (csf) [titer]
16594-4,c. trachomatis iga if [titer] (csf)
16594-4,trachomatis c. iga if (csf) [titer]
51586-6,other cells/leukocytes in blood by manual count
51586-6,other cells/leukocytes in blood by manual count number fraction
51586-6,other cells/leukocytes manual blood wbcs by in count
51586-6,other cells nfr bld manual
51586-6,other hematology/cell counts cells nfr bld manual
51586-6,blood cells nfr manl other manual
51586-6,other cells/leukocytes manual cnt (bld)
51586-6,other cells/leukocytes manual cnt (blood)
51586-6,(bld) manual cnt thercells/leukcytes
39014-6,suberylcarnitine (c8-dc) [moles/volume] in serum or plasma
39014-6,suberylcantine (c-dc) [moles/volume] in serum or pama serum or plasma
39014-6,sberylcarnitine (-c) [moles/volum] in quan serum or plama
39014-6,suberylcarn serpl-scnc
39014-6,suberylcarn serpl-scnc plsm
39014-6,sepl-cnc suberycarn
39014-6,c8-dc [moles/vol]
39014-6,c8-d [moles/vol]
39014-6,[mos/vol] c8-dc
5154-0,epstein barr virus early ab [presence] in serum by immunofluorescence
5154-0,eptein barr virs early ab [ql]n serum by mmunoflorscence
5154-0,epstein barrvirusearl ab ql] in serum by immunofluorescence
5154-0,ebv ea ab ser ql if
5154-0,ebv ea  se presence if
5154-0,ebv ea ab ser ql if
5154-0,ebv early ab if ql (s)
5154-0,ebv if b fa earl presence(s)
5154-0,ebv early ab if presence (s) presence
22336-2,deprecated herpes simplex virus 2 igg ab [presence] in serum
22336-2,deprected heres siple virus2 ig ab ser [prese]in
22336-2,deprecated herpes simplex autoantibody virus [presence] igg ab 2 in serum
22336-2,deprecated hsv2 igg ser ql
22336-2,depreated hsv2 igg ser q
22336-2,deprecated hsv2 igg ql point in time serum
22336-2,hsv 2 igg ql (s)
22336-2,hv  ig ql (s
22336-2,presence 2 igg hsv (s)
95147-5,hepatitis b virus dna panel - serum or plasma
95147-5,hepatits b lasma dnapanel - erumor virus
95147-5,heptitis b virus dna pane - erum or plsma
95147-5,hbv dna pnl serpl
95147-5,serpl dna pnl hbv
95147-5,hbvdna nl hep b serpl
95147-5,hbv dna panel
95147-5,panel da hbv hepb
95147-5,hbv na panel
13115-1,deprecated neuronal nuclear type 1 ab
13115-1,type neuronal nuclear deprecated 1 ab
13115-1,deprecated neuronal nuclear type 1 ab
13115-1,deprecated hu1 ab ser
13115-1,deprecated ser ab hu1
13115-1,ab h autoantibodies dprecated ser
13115-1,neuronal nuclear type 1 ab (s)
13115-1,neuronal type nuclear 1 antibodies ab (s)
13115-1,i neuronal nuclear type 1 ab (s)
70911-3,cryptococcus sp ag [presence] in cerebral spinal fluid by rapid immunoassay
70911-3,crypococcus sp g pr [prsence]in cerral spinal fluid by rapid mmunoassay
70911-3,cryptococcus sp ag [ql] in by spinal fluid cerebral rapid microbiology immunoassay
70911-3,cryptoc ag csf ql ia.rapid
70911-3,cryptoc ag csf ql ia.rapid
70911-3,random ia.rapid ag cerebrospinal fluid ql cryptoc
70911-3,cryptococcus sp ag ia.rapid ql (csf)
70911-3,crptococcus sp (csf) ia.rapid ql point in time ag
70911-3,ag antigen s cryptococcus ia.raid presence cs)
8737-9,left ventricular cardiac output by indicator dilution
8737-9,left cardiac ventricular outputb cardiac indicator dilution
8737-9,left ventriculr lv cardiac utut byindicator dilution
8737-9,lv output indicator dilution
8737-9,lv dilut output indicator dilution
8737-9,dilution output quantitative indicator lv
4623-5,hemoglobin s [presence] in blood by electrophoresis alkaline (ph 8.9)
4623-5,hemglobin s [prsence] in blood by eletrophoresis alkaline (ph 8.9)
4623-5,hemogobin s presence] in lood y 8.9) alkalin (ph electrphoresis
4623-5,hgb s bld ql elph alk
4623-5,hgb s ql hbs blood elph alk
4623-5,blood s hgb ql elph alk
4623-5,hemoglobin s elph ph 8.9 ql (bld)
4623-5,hemoglobin ql 9 phph (blood)
4623-5,hemoglobin ep s lph ph 8.9 q (bld)
105971-6,ecgonine methyl ester [presence] in urine
105971-6,ecgonine mthyl eter [presence] cocaine metabolite in urie
105971-6,ecgonne point in time in te [presene] methyl urne
105971-6,eme ur ql
105971-6,em ql ur
105971-6,eme ql ur
105971-6,ecgonine methyl ester ql (u)
105971-6,ecgonin methyl ester q (u) drug/toxicology
105971-6,ecgonine ql ester pr methyl (u)
25247-8,chloramphenicol [mass/volume] in specimen
25247-8,chloramphenicol[ass/vlume] in specimen
25247-8,chlramphenicol [ass/volume in pcimen biophenicol
25247-8,chloramphen spec-mcnc
25247-8,spec-mcnc chloromycetin chloaphen
25247-8,spec-mcnc chloramphen
25247-8,chloramphenicol (specimen) [mass/vol]
25247-8,chloramphenicol (specimen) chloramphen [mass/vol]
25247-8,chloahenicol (specimen) [mas/vol]
96411-4,pancreatic polypeptide [mass/volume] in serum or plasma --10m post sham feeding
96411-4,anceatic popeptide [mas/volume] in erum o post --10m plama shamfeeding
96411-4,pancreatic polypeptde [mass/volme]in serum  plas --1m post shm feedng
96411-4,panc polypept 10m p sham feed serpl-mcnc
96411-4,panc 10m polpept psham feed serpl-mcnc
96411-4,panc polypept feed p sham 10m serpl-mcnc
96411-4,pancreatic polypeptide 10m post sham feeding [mass/vol]
96411-4,post polypeptide 10m pancreatic serpl sham feeding [mass/vol]
96411-4,endocrine pancreatic polypeptide 10m [mass/vol] sham feeding post
23333-8,ovine progressive pneumonia virus ab [presence] in milk by immunoassay
23333-8,ovine id progressive pneumoniavirus ab [presence] in mlk yimunoassay
23333-8,suds ovine progressive pneumonia virus ab [presence] in milk by immunoassay
23333-8,oppv ab mlk ql ia
23333-8,enzyme immunoassay oppv ab mlk ql ia
23333-8,oppv ab k ql ia
23333-8,ovine progressive pneumonia virus ab ia ql (milk)
23333-8,ovine prgressive pt pneumnia virus ab i ql (milk)
23333-8,ovine progressive pneumonia virus (milk) ia ql ab
96451-0,alpha-1-fetoprotein and alpha-1-fetoprotein.l3 panel - serum or plasma
96451-0,alpha-1-fetoprotein and alphafetoprotein alpha-1-fetoprotein.l3 panel - ser or plasma
96451-0,alpha-1-fetoprotein and alpha-1-fetoprotein.l3 panel - serum or plasma plasma
96451-0,afp+afp.l3 pnl serpl
96451-0,afp+afp.l3 serum or plasma serpl pnl
96451-0,afp+ap.l3 pnl serpl
96451-0,alpha-1-fetoprotein and alpha-1-fetoprotein.l3 panel
96451-0,alpha-1-fetoprotein.l3 and alpha-1-fetoprotein panel
96451-0,alpha-1-feoproten.l3pnel alpha-1-fetoproteinand
3072-6,tryptophan [mass/volume] in urine
3072-6,tryptophan [mas/olume quantitative in urine
3072-6,level in [mass/volume] tryptophan urine
3072-6,tryptophan ur-mcnc
3072-6,tryptophan ur-mcnc
3072-6,ur-mcnc tryptophan
3072-6,tryptophan (u) [mass/vol]
3072-6,[mass/vol] (u) tryptophan quan
3072-6,tryptophan (u) [mass/vl]
16585-2,chlamydophila pneumoniae rrna [presence] in serum or plasma by probe
16585-2,chlamydophilapneumoniae plasma [pesnce] in serumor rna y probe
16585-2,chlamydophila pneumoniae rra [presence] in seu c pneumo or plasmab probe
16585-2,c pneum rrna serpl ql probe
16585-2,c srpl rna pnem qlrobe
16585-2,cpeum rrna serpl pobe ql
16585-2,c. pneumoniae rrna probe ql
16585-2,c. pneumoniae serp ql probe rrna
16585-2,c. peumoniaerra l probe
105978-1,desmethylzopiclone [presence] in urine
105978-1,desmethylzopiclone [presence] in urine
105978-1,desmethlopiclone [prsence] ua in urne
105978-1,desmethylzopiclone ur ql
105978-1,desmethylzopiclne ur ql pr
105978-1,pr desmethylzopiclone ur ql
105978-1,desmethylzopiclone ql (u)
105978-1,drug/toxicology ql desmethylzopiclone (u)
105978-1,q() desmethyzopiclone
23606-7,tritrichomonas foetus [presence] in genital fluid by organism specific culture
23606-7,tritrichomonas fetus[pesene in cult gental fluid by organism specfic culture
23606-7,tritrichomonas foetus [presence] in genital specific by organism fluid culture
23606-7,t foet genital fl ql cult
23606-7,t foet genital fl ql cul
23606-7,t foet genital f infectiousdisease presence cut
23606-7,t. foetus org specific cx ql (genital fluid)
23606-7,genital foets org specic cxql t. flid)
23606-7,t. genital tract foetus org specific cx ql (genital fluid)
44017-2,blasts [presence] in blood by light microscopy
44017-2,blasts [presence] in bld by light microscopy
44017-2,blasts [presence] blood in by light microscopy
44017-2,blasts bld ql smear
44017-2,blood blasts ql qualitative smear
44017-2,blasts sear blast bldql
44017-2,blasts lm ql (bld)
44017-2,blasts lm ql (bld)
44017-2,ql lm blasts (bld)
71661-3,eosinophils/leukocytes [pure number fraction] in cerebral spinal fluid by manual count
71661-3,eosinophils/leukoctes pure nuber fration] in erebral spinal flud by maual count spinal fld
71661-3,eosinophils/leukocytes [pure by fraction] in cerebral spinal fluid number manual count
71661-3,eosinophil nfr.df csf manual
71661-3,eosinophil nfr.df csf white blood cell manual
71661-3,eosnophi cerebral spinal fluid csf nr.df maual
71661-3,eosinophils/leukocytes manual cnt (csf) [pure # fraction]
71661-3,eosinophils/leukocytes manual cnt (cerebrospinal fluid) random [pure fraction] #
71661-3,eosinophils/leukocytes # cnt (csf) [pure manual fraction]
43163-5,quaternary ammonium compound [mass/volume] in specimen
43163-5,quateray ammonum compund [mas/volume] in specimen
43163-5,quaternary [mass/volum] compond ammonium nspecmen amm
43163-5,qac spec-mcnc
43163-5,drug/toxicology spec-mcnc qac
43163-5,spec-mcnc miscellaneous qac
43163-5,quaternary ammonium compound (specimen) [mass/vol]
43163-5,quaternary ammonium compound (specimen) nh4 [mass/vol]
43163-5,(specimen) ammonium compound quaternary [mass/vol]
30523-5,mycobacterium sp dna [presence] in urine by naa with probe detection
30523-5,urinbaa dna [presece in mycobateriumsp wi probe detection
30523-5,myobacteriump dna [prsence] in urin by naa wih probe tection
30523-5,mycobacterium dna ur ql naa+probe
30523-5,mycobacterium naa+probe ur ql dna
30523-5,ycobacerium dna urql na+proe
30523-5,mycobacterium sp dna naa+probe ql (u)
30523-5,mycobacterium sp dna naa+probe presence (u)
30523-5,mycobacterium sp (u) ur naa+probe ql dna
82770-9,patient reported outcome computer adaptive testing used
82770-9,patient reported computer outcome adaptive testing used
82770-9,patient used outcome computer adaptive testing reported
82770-9,pro cat used
82770-9,used ql cat pro
82770-9,cat ro used qualitative
43070-2,burkholderia pseudomallei igg ab [titer] in specimen
43070-2,burkholderia pseudomallei igg abs [titer] ab in specimen
43070-2,bukhoderia pseudomaei igg a [titer] in specimen
43070-2,b pseudomal igg titr spec
43070-2,b igg pseudomal titr spec
43070-2,b pseudoma unspecified igg ttr spec
43070-2,b. pseudomallei igg (specimen) [titer]
43070-2,b. pseudomallei igg (specimen) [titer]
43070-2,infectiousdisease pseudomallei b. igg (specimen) [titer]
91054-7,drugs of abuse panel - body fluid
91054-7,drugs - abuse panel of body fluid
91054-7,- of abuse panel drugs body fluid
91054-7,drugs of abuse pnl fld
91054-7,drugs of fld abuse pnl fld
91054-7,drugs of abuse pnl fld flu
91054-7,drugs of abuse panel (body fld)
91054-7,drugs of abuse panel bf (body fld)
91054-7,drugs of panel abuse (body fld)
46980-9,n-desalkylflurazepam [mass/volume] in serum or plasma by confirmatory method
46980-9,n-dealkylfluraeam [mas/volume]  serum r plasma by onfirmaory ethd
46980-9,[mass/volume] n-desalkylflurazepam in serum serplas or plasma by confirmatory method
46980-9,desalkylfluraz serpl cfm-mcnc
46980-9,desalkylfluraz sepl cfm-mcnc cfm
46980-9,cfm-mcnc serl dsakylflura
46980-9,n-desalkylflurazepam confirm [mass/vol]
46980-9,n-desalkylflurazepam [mass/vol] confirm
46980-9,[mass/vol] confirm n-desalkylflurazepam serp
33254-4,ph of arterial blood adjusted to patient's actual temperature
33254-4,actua o ateral blood chemistry adjusted to patient's ph temperature
33254-4,ph actual arterial blood adjusted to patient's of temperature
33254-4,ph temp adj blda
33254-4,ph adj chemistry temp blda
33254-4,ph blda adj temp temp
33254-4,ph adjusted to patient's actual temperature (blda)
33254-4,ph aduste o arterial patients actual tempeaur (bda)
33254-4,ph adjusted to atient's actual temperatue (blda)
39572-3,west nile virus igg ab [units/volume] in cerebral spinal fluid by immunoassay
39572-3,west nile virus igg byimmunoassay [uns/volume] in cerebral spinal fluid ab suds
39572-3,et elfa nil vrus igg ab [units/volume] in cerebral snal flid by immuassy
39572-3,wnv igg csf ia-acnc
39572-3,ia-acnc igg csf wnv
39572-3,ia-acnc igg csf quant wnv
39572-3,west nile virus igg ia qn (csf)
39572-3,west spinal fld nile virusigg iaqn (cf)
39572-3,west nilevirus gg ia qn (csf)
1740-0,alanine aminopeptidase [mass/volume] in serum
1740-0,in aminopeptidase [mass/volume] alanine quantitative ser
1740-0,[mass/volume] aminopeptidase alanine in serum
1740-0,aap ser-mcnc
1740-0,ser-mcnc aap
1740-0,aap ser-mcnc
1740-0,alanine aminopeptidase (s) [mass/vol]
1740-0,alanine aminopeptidase (s) [mass/vol] sr
1740-0,alanine aminopeptidase (s) chemistry [mass/vol]
51659-1,hepatitis b virus surface ag [presence] in body fluid
51659-1,hepatitis hepatology b virus surface ag [presence] in body fluid
51659-1,hepatitis b virus surface ag microbiology [presence] in body fluid
51659-1,hbv surface ag fld ql
51659-1,hbv surface liver ag fd ql
51659-1,hbv body fluid srfac ag fld ql
51659-1,hbv surface ag ql (body fld)
51659-1,hbvsurace ag fld) presence(boy
51659-1,bv suface fld) ql (boy ag bf
7836-0,coxsackievirus b1 ab [units/volume] in serum
7836-0,coxsackievirus b1 serum [units/volume] in ab
7836-0,coxsackvirus b1 infectious disease a [units/volume] nserum
7836-0,cv b1 ab ser-acnc
7836-0,cv b1 ab ser-acnc coxsackie
7836-0,cv b1 autoantibodies ab ser-acnc
7836-0,coxsackievirus b1 ab qn (s)
7836-0,coxsackievirus b1 qn ab (s)
7836-0,b1 coxsackievirus ab qn (s)
38671-4,m-cresol [mass/volume] in air
38671-4,qnt mcreol air mass/voume]in
38671-4,m-ceol [mass/volume] in air
38671-4,m-cresol air-mcnc
38671-4,m-cresol drug/toxicology air-mcnc
38671-4,m-cresol air-mcnc 3-methylphenol
38671-4,m-cresol (air) [mass/vol]
38671-4,m-cresol [mass/vol] (air)
38671-4,m-cresol level (air) [mass/vol]
5327-2,bartonella henselae igm ab [units/volume] in serum
5327-2,baronella heselae igm ab [units/voume] in serum id
5327-2,ab[nits/volume] henselae gm infectious disease batolla in serum
5327-2,b henselae igm ser-acnc
5327-2,b henselae igm ser-acnc
5327-2,immune globulin m b henselae g ser-acnc
5327-2,b. henselae igm qn (s)
5327-2,b. aby henselae igm qn (s)
5327-2,b. henselae (s) qn igm
6906-2,sertraline [mass/volume] in serum or plasma
6906-2,serum [mass/vlme] in sertrane or lasma
6906-2,sertraline [mass/volume] drugs in ser or plasma
6906-2,sertraline serpl-mcnc
6906-2,sertraline drugs serpl-mcnc
6906-2,sertraline serpl-mcnc sr
6906-2,sertraline [mass/vol]
6906-2,sertalin [mass/vol
6906-2,sertraline level [mass/vol]
9428-4,benzodiazepines [mass/volume] in urine
9428-4,benzodiazepines qnt [mass/volume] in urine
9428-4,benzodiazepines [mass/volume] urine in
9428-4,benzodiaz ur-mcnc
9428-4,benzodiaz ur-mcnc universallaborders
9428-4,ur-mcnc benzodiaz
9428-4,benzodiazepines (u) [mass/vol]
9428-4,benzoiazenes quant (u) mass/vol]
9428-4,benzodiazepines (u) [mas/ol ur
49776-8,hepatitis e virus ab [units/volume] in serum by immunoassay
49776-8,hepatitis e virus ab [units/volume] in serum by immunoassay
49776-8,hepatitis e virus ab [units/volume] inserumby immunoassa
49776-8,hev ab ser ia-acnc
49776-8,hev ab ser ia-acnc
49776-8,hev ab sr ser ia-acnc
49776-8,hev ab ia qn (s)
49776-8,infectiousdisease hev a qn ia (s)
49776-8,hev ab q eia ia (s)
91844-1,trichomonas vaginalis dna [presence] in genital specimen by naa with probe detection
91844-1,trichomonas vaginalis dna [presence]ineitl speimen by naa it probedetection
91844-1,trichomonas vaginalis dna [presence] in genital by specimen naa with probe detection
91844-1,t vaginalis dna genital ql naa+probe
91844-1,t dna vaginalis genital ql naa+probe
91844-1,t vaginalis dna naa+probe ql genital
91844-1,t. vaginalis dna naa+probe ql (genital specimen)
91844-1,t. vagnalis dna naaprobe ql(genital specen)
91844-1,. vaginalis dna naa+probel specimen) genital
35631-1,phenobarbital [mass/volume] in serum or plasma by screen method
35631-1,phenobarbital [mass/volume] quan in ser or plasma method screen by
35631-1,qnt phenobarbital [mass/volume] in serum or plasma by screen method
35631-1,phenobarb serpl scn-mcnc
35631-1,phenobarbserplcn-mcnc
35631-1,phenobarb serpl scn-mcn
35631-1,phenobarbital screen [mass/vol]
35631-1,screen phenobarbital [mass/vol]
35631-1,screen phenobarbital [mss/ol]
3738-2,maprotiline [mass/volume] in urine
3738-2,maprotilie urine in [mass/volume]
3738-2,maprotiline [mass/volume] quan in urine
3738-2,maprotiline ur-mcnc
3738-2,ur-mcnc mprtiline
3738-2,ur-mcnc ua maprotiline
3738-2,maprotiline (u) [mass/vol]
3738-2,maprotiline (u) [mass/vol drugs
3738-2,quant maprotiline [mass/vol] (u)
17820-2,albumin/protein.total in body fluid by electrophoresis
17820-2,albumin/protein.total tot in body fluid by electrophoresis
17820-2,albumin/protein.total in body fluid by electrophoresis
17820-2,albumin mfr fld elph
17820-2,mfr quant alumn fl elph
17820-2,albumin mfr fld elph
17820-2,albumin elph (body fld) [mass fraction]
17820-2,albumin elph (body fld) [mass fraction]
17820-2,albumin elph (body fld) mss fracton]
62996-4,phenx - stuttering protocol 200901
62996-4,stuttering pnl - phenx protocol 200901
62996-4,phenx - stuttering protocol 200901
62996-4,stuttering proto
62996-4,sttterin proto
62996-4,proto stuttering
13548-3,chlorpromazine [presence] in serum or plasma
13548-3,chlorpromazine [presence] in serum serpl plasma or
13548-3,chlorpromazine [presence] in ser or plasma
13548-3,chlorpromazine serpl ql
13548-3,chlorromazine sr serpl l
13548-3,chlorprmazie srpl l
13548-3,chlorpromazine ql
13548-3,q pl hlorpraine
13548-3,ql chlorpromazine
88715-8,norquetiapine [mass/volume] in serum or plasma by confirmatory method
88715-8,norqutiapine[mass/vlume] pl in srum o plasm b confirmaory method
88715-8,norquetiapine [mass/volume] in ser or plasma by confirmatory method qnt
88715-8,norquetiapine serpl cfm-mcnc
88715-8,level serpl norquetiapine cfm-mcnc
88715-8,norquetiapine serpl lc/ms/ms cfm-mcnc
88715-8,norquetiapine confirm [mass/vol]
88715-8,cnfrm quan oruetiapine [mass/vol]
88715-8,confirm orquetine pt [ass/vol
3321-7,amikacin [mass/volume] in serum or plasma --trough
3321-7,plama [mass/vlume] n serm or amiacin --trough
3321-7,amikacin r in erum [mass/volume] plama--trouh
3321-7,amikacin trough serpl-mcnc
3321-7,amikacin pre-dose serpl-mcnc trough
3321-7,rogh aikaci serpl-cnc
3321-7,amikacin trough [mass/vol]
3321-7,amikacin mass concentration trough [mass/vol
3321-7,amikacin [mass/vol] trough
2230-1,epinephrine [mass/volume] in plasma
2230-1,epinephrine [mass/volume] in plasma
2230-1,pineprine in [mass/volume] plasma
2230-1,epineph plas-mcnc
2230-1,pnep pt as-cnc
2230-1,epineph pas-mcnc
2230-1,epinephrine (p) [mass/vol]
2230-1,epinephrine [mass/vol] (p quantitative
2230-1,adrenaline [mass/vol] epinephrine(p)
82862-4,11-deoxytetrahydrocortisol/tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [molar ratio] in urine
82862-4,11-deoxytetraydroortiol/tetrahydrocrtione+tetrahydoortisol+5-alpha tetrahydrocrtisol urine ratio] in [molar
82862-4,11-deoxytetrahydrocortisol/tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol urine ratio] in [molar
82862-4,ths/the+thf+5a-thf ur-srto
82862-4,ur-srto ths/the+thf+5a-thf
82862-4,ur-srto ths/the+thf+5a-thf
82862-4,11-deoxytetrahydrocortisol/tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol (u) [molar ratio]
82862-4,11deoxytetrahyrcortisol/tetrahydrocrisne+tetrahydrocortisol+5-alpha ttrahydrocortisol (u) molar ratio]
82862-4,11-doxytethydrocortisol/tetrahydrocrtisone+tetrahydocortisol+5-alpha (u) etrahydrocortiso random [mar atio]
33962-2,melanoma inhibitory activity protein [mass/volume] in serum or plasma
33962-2,melanoma inhibitry ctivity proein [mas/voume] in seru or plas
33962-2,meanomainhibitoy activity prote [mass/vole] i seru or lasma
33962-2,mai protein serpl-mcnc
33962-2,mai mia protein protein serpl-mcnc
33962-2,mai actvty proteinserplmcc
33962-2,melanoma inhibitory activity protein [mass/vol]
33962-2,melanoma activity inhibitory protein [mass/vol]
33962-2,melanomainhibitoractivity mass concentration prot[mas/vol]
76026-4,phosphomannomutase 2 [enzymatic activity/mass] in fibroblast
76026-4,phosphomannomutase [enzymatic 2 activity/mass] in fibroblast
76026-4,fibroblast 2 [enzymatic activity/mass] in phosphomannomutase
76026-4,pmm2 fib-ccnt
76026-4,fib-ccnt pmm2
76026-4,fi-ccnt m
76026-4,phosphomannomutase 2 (fibroblast) [catalytic activity/mass]
76026-4,phosphmanomutase [cataytc random (fibroblast) 2 atiity/mass]
76026-4,(fibroblast) 2 posphomnnomtase [catalytic actvity/mass]
105716-5,deprecated fluorexetamine/2-fluoro-2-oxo-pce [mass/volume] in urine by confirmatory method
105716-5,deprecatdfluorxeaine/2-fluoro-2-o-ce [mas/volume] in urine qnt by confirmatory metho
105716-5,deprcate uretamine2-fluoro-2-oxo-pce in 2-f-2-oxo-pce [mass/volume] urine byconfitory method
105716-5,deprecated fluorexetamine/2-f-2-oxo-pce ur cfm-mcnc
105716-5,deprecated flurexetmie/2---oxo-pce fluoroeticyclidinone ur cfm-mcnc
105716-5,fluoroeticyclidinone deprecated fluorexetamine/2-f-2-oxo-pce ur cfm-mcnc
105716-5,fluorexetamine/2-fluoro-2-oxo-pce confirm (u) [mass/vol]
105716-5,fluorexetamine/2-fluoro-2-oxo-pce [mass/vol] (u) confirm
105716-5,fluorexetamine/2-fluoro-2-oxo-pce confirm (u) [mass/vol]
89983-1,olanzapine [presence] in serum or plasma by screen method
89983-1,olanzane presnc] in b or plasma serum seen mehod
89983-1,olanzapine [presence] in sr serum or plasma by screen method
89983-1,olanzapine serpl ql scn
89983-1,olanzapine serpl serplas ql scn
89983-1,olanzapine serpl ql scn zyprexa
89983-1,olanzapine screen ql
89983-1,zyprexa ql olanzapinescreen
89983-1,drug/toxicology screen olanzapine ql
99269-3,clonazolam [mass/volume] in urine by confirmatory method
99269-3,cloazlam [mass/volume] n urineby confirmator pt mehod
99269-3,clonazolam confirmatory in urine by [mass/volume] method
99269-3,clonazolam ur cfm-mcnc
99269-3,ur clonazolam cfm-mcnc
99269-3,clonazom r cfm-mnc
99269-3,clonazolam confirm (u) [mass/vol]
99269-3,clonazm confirm [mass/vol] (u
99269-3,clonaolam confirm [mass/vl (u)
71315-6,emotional well-being and illness experience - fact-br -peds-adoles [facit]
71315-6,emotional - and illness experience well-being fact-br -peds-adoles [facit]
71315-6,emotional well-being and illness experience - fact-br -peds-adoles [facit] survey
3611-1,ethchlorvynol [presence] in urine
3611-1,urine [peence] in ethchlorvynol
3611-1,urine [ql] in ethchlorvynol
3611-1,ethchlorvynol ur ql
3611-1,ethchlorvynoluql
3611-1,qual ethchlorvynol ur ql
3611-1,ethchlorvynol ql (u)
3611-1,ethchlorynol (u) ql
3611-1,screen ethchlorvynol l ()
72325-4,arterial blood functional shunt volume adjusted to patient's actual temperature
72325-4,temperature blood functional shunt volume adjusted to patient's actual arterial
72325-4,arterial blood functional fshunt shunt volume adjusted to patient's actual temperature
72325-4,blda fshunt vol temp adj vfr
72325-4,bld fshutvol temp adj vfr art
72325-4,blda fshunt vol temp adj vfr volfr
47651-5,hydroxyproline [moles/volume] in dbs
47651-5,hydroxyproline hydroxy-proline [moles/volume] in dbs
47651-5,hydroxyproline dbs substance concentration in [moles/volume]
47651-5,oh-proline dbs-scnc
47651-5,dbs-scnc oh-proline
47651-5,oh-proline dbs-scnc
47651-5,hydroxyproline (dbs) [moles/vol]
47651-5,hydroxyproline [moles/vol] (dbs)
47651-5,whole blood hydroxyproline(dbs) [oles/vol
88162-3,acanthamoeba sp identified in cornea or conjunctiva by organism specific culture
88162-3,aanthamoeba spidetified in cornea or conjunctiva by id oansm specific ulue
88162-3,specif sp identifed in cornea or onjnctiv by organism acanthamoeba culture
88162-3,acanthamoeba corn/cnjt cult
88162-3,acanthamoeba corn/cnjt cult
88162-3,acanthamoeba orn/cnj identity or presence cult
88162-3,acanthamoeba sp identified org specific cx nom (corn/cnjt)
88162-3,acanthamoeba sp random orgspecfic dentiied cxnom orn/cjt)
88162-3,acanthamoeba sp identified random org specific (corn/cnjt) nom cx
58371-6,carisoprodol/creatinine [mass ratio] in urine
58371-6,n [mass rato] isoprodol/cretnine urin
58371-6,carisoprodol/creatinine [mass ratio] in urine
58371-6,carisoprodol/creat ur
58371-6,ur carisoprodol/creat
58371-6,ur carisoprdol/creat
58371-6,carisoprodol/creatinine (u) [mass ratio]
58371-6,urn carisoprdlcreainine () [ms ratio]
58371-6,carisoprodl/ceatinne(u)[ms rato]
46079-0,resident assessment protocol summary section
46079-0,section assessment protocol summary resident
46079-0,survey.mds summary assessment protocol resident section
19553-7,methadone cutoff [mass/volume] in urine for confirmatory method
19553-7,metadonecutff [mss/volumn rine method confirmaty for
19553-7,methadone cutoff [mass/volume] in urine for confirmatory method
19553-7,methadone cto ur cfm-mcnc
19553-7,methadone cto random ur cfm-mcnc
19553-7,cfm-mcnc cto ur methadone
19553-7,methadone cutoff confirm (u) [mass/vol]
19553-7,metadone cutof confirm (u) [mass/vl]
19553-7,methadone cutoff confirm (u) [mass/vol]
91030-7,methadone+metabolite [presence] in meconium by screen method
91030-7,ineconiumby [esence] metadone+metaolite screen metho
91030-7,methadone+metabolite [ql] dolophine in meconium by screen method
91030-7,methadone+metab mec ql scn
91030-7,potentialforabuse scn ql methadone+metabmec
91030-7,methaone+metab presence ec scn
91030-7,methadone+metabolite screen ql (mec)
91030-7,(mec) screen ql methadone+etabolie
91030-7,(mec) screenql methadonemtabolite
70885-9,additional concerns - fact-o [facit]
70885-9,concerns additional - fact-o [facit]
70885-9,addition cncerns - a-o [facit]
54512-9,psychosis in last 7 days
54512-9,psychoss past i lst days
54512-9,pychois das 7 inlast
14855-1,norfluoxetine [moles/volume] in serum or plasma
14855-1,norfloxetine [moes/voume] in serum or plsma
14855-1,norfluoxetine [moles/volume] in serum plasma or
14855-1,norfluoxetine serpl-scnc
14855-1,erpl-scnc norluoxetine
14855-1,norfluoxetin serpl-scnc norfuoxine
14855-1,norfluoxetine [moles/vol]
14855-1,norfluoxetine [moles/vol]
14855-1,norfluoxetine [moles/vol] quant
39460-1,bicarbonate [moles/volume] standard in arterial cord blood
39460-1,bicarboae [moles/vlum] stadrd in areril cord blood
39460-1,bicaronate standardin [mole/voume] arterial cord bloo substance concentration
39460-1,hco3 std bldcoa-scnc
39460-1,std hco3 bldcoa-scnc bic
39460-1,bldcoa-scnc std substance concentration hco3
39460-1,hco3 standard (bldcoa) [moles/vol]
39460-1,hc3 andard [moles/vol] (bldcoa)
39460-1,hco3 std standard (bldcoa) [moles/vol]
4320-8,methapyrilene [mass] of dose
4320-8,methapyrilene [mass] of dose
4320-8,[mass] methapyrilene of quan dose
4320-8,methapyrilene dose
4320-8,cope dose metapyrilen
4320-8,methpriene dose
4320-8,methapyrilene (dose) [mass]
4320-8,methapyrilene paradormalene (se) [mss]
4320-8,methayilene (dose) mas]
90902-8,"hiv 1 rna reverse transcriptase gene [nucleotide sequence] in serum, plasma or blood by sequencing"
90902-8,"hiv 1 hiv type i rna serum, transcriptase gene [nucleotide sequence] in reverse plasma or blood by sequencing"
90902-8,"hiv 1 rna in transcriptase gene [nucleotide sequence] reverse aids ser, plasma or blood by sequencing"
90902-8,hiv 1 rna rt serplbld-seq
90902-8,rna 1 hiv hiv type i rt serplbld-seq
90902-8,hiv 1 rna rt serum serpbld-seq
90902-8,hiv 1 rna rt sequence nom (s/p/bld)
90902-8,hiv 1 rna rt sequence nom (s/p/bld) aids
90902-8,point in time (s/p/bld) 1 rna rt sequence nom hiv
49406-2,herpes virus 8 dna [#/volume] (viral load) in blood by naa with probe detection
49406-2,herpes virus 8 dna [#/volume] (viral load) in bld lcr by naa with probe detection
49406-2,herpes #/vlume] 8 dna virus (irl qbr load) in bld by naa with probe detection
49406-2,hhv8 dna # bld naa+probe
49406-2,hhv8 qnt dna # bld naa+probe
49406-2,hhv8 dna # whole blood bld naa+probe
49406-2,hhv 8 dna naa+probe (bld) [#/vol]
49406-2,hhv 8 naa+probe dna (bld) [#/vol]
49406-2,hhv (bld) dna naa+probe 8 [#/vol]
79298-6,d- and l-2-hydroxyglutarate panel - dbs
79298-6,- pael pt l-2-hyroxygltarte nd - bs
79298-6,d- and panel l-2-hydroxyglutarate - dbs
79298-6,d2hg and l2hg pnl dbs
79298-6,and d2hg l2hg pnl dbs
79298-6,and d2hg l2hpnl ii dbs
79298-6,d- and l-2-hydroxyglutarate panel (dbs)
79298-6,d- and panel l-2-hydroxyglutarate (dbs)
79298-6,d- panel(dbs) l-2-hydrxyglutarae and
43164-3,silica [mass/volume] in water
43164-3,silica random [mass/volume] in water
43164-3,wat silica ater in mass/volume]
43164-3,silica wat-mcnc
43164-3,ilica wat-mcnc drugs
43164-3,drugs silica wat-mcnc
43164-3,silica (water) [mass/vol]
43164-3,(water) silica [mass/vol]
43164-3,silica (water) random [mas/vo]
14886-6,pregnanetriol [moles/time] in 24 hour urine
14886-6,pregnaneriol hou in pregntrl 24 mles/ime] urine
14886-6,pregnanetriol [oles/tme] srate in 24 hour urine
14886-6,pregntrl 24h ur-srate
14886-6,1 day pregntrl 24h ur-srate
14886-6,2h pretr ua ursrate
14886-6,pregnanetriol (24h u) [moles/time]
14886-6,pregnanetriol (24h u) srate [moles/time]
14886-6,qnt pregnanetriol (24h [moles/time] u)
2815-9,porphyrins [mass/volume] in serum or plasma
2815-9,porphyrins[mas/volume n erum or plasma
2815-9,porphrins [mass/volume] in serm point in time or plas
2815-9,porphyrins serpl-mcnc
2815-9,porphyrins serum or plasma-mcnc mass concentration
2815-9,rphyrins serpl-mcnc
2815-9,porphyrins [mass/vol]
2815-9,mass concentration [ma/vol] orphyrins
2815-9,[mass/ol] serpl porphyrins
41628-9,burkholderia sp dna [presence] in specimen by naa with probe detection
41628-9,urkholdria sp dna presenc] n speime bynaa wih prob detctin species
41628-9,burkholderia sp dna [presence] in specimen naa by with probe detection
41628-9,burkholderia dna spec ql naa+probe
41628-9,burkholder qla+pob spec amplified dna
41628-9,q dnaspec brkhlderia na+probe
41628-9,burkholderia sp dna naa+probe ql (specimen)
41628-9,burkholderia sp naa+probe dna ql (specimen)
41628-9,burkholderia sp (specimen) naa+probe ql dna
5198-7,hepatitis c virus ab [units/volume] in serum by immunoassay
5198-7,hepatitis c virus ab [units/volume] in hcvab ser by immunoassay
5198-7,heptitis c virusb [units/olume] anti in erum by immnoassy
5198-7,hcv ab ser ia-acnc
5198-7,arbitrary concentration hcv ab ia-anc ser
5198-7,serum ab hcv hepatit aacnc
5198-7,hcv ab ia qn (s)
5198-7,hcv ia ab qn (s)
5198-7,hcv ab ia n (s)
103184-8,human rhinovirus 1 and 2 rna [presence] in respiratory system specimen by naa with probe detection
103184-8,tma human rhinovirus 1 and 2 rna [presence] in respiratory system specimen by naa with probe detection
103184-8,huan rhinovirus and 2 rn ii [presnce] i rspiatory sstem specimen bynaa withprobe dtection
103184-8,hrv 1 and 2 rna resp ql naa+probe
103184-8,sda hrv 1 and 2 rna resp l naa+prbe
103184-8,2 1 and hrv rna resp ql naa+probe
103184-8,human rhinovirus 1 and 2 rna naa+probe ql (respiratory system specimen)
103184-8,human rhinovirus 1 (respiratory 2 rna naa+probe ql and system specimen)
103184-8,human rhinovirs 1 and 2 rnnaa+pobe ql (respiratory sstem spcimen)
8031-7,streptococcus pneumoniae igg ab [units/volume] in serum
8031-7,stretococcus pneumoniae igga [units/volum in ser
8031-7,in pneumoniae igg ab [units/volume] streptococcus serum
8031-7,s pneum igg ser-acnc
8031-7,s pneum ser-acnc igg
8031-7,s seracc igg pneum
8031-7,s. pneumoniae igg qn (s)
8031-7,igg pneumoniae s. qn (s)
8031-7,antby s. pnumoniae (s) qn g
94112-0,7-aminoclonazepam [presence] in urine by screen method
94112-0,7-aminooaepam [presence] n urne by screenmetod
94112-0,screen [resence] in rine by 7-aminoclonazepm method
94112-0,7aminoclonazepam ur ql scn
94112-0,scn ur presence 7aminoonazepam
94112-0,7aminoclonazepam ur ql scn addiction
94112-0,7-aminoclonazepam screen ql (u)
94112-0,7-aminoclonazepam screen ql (u) pr
94112-0,ql screen 7-aminoclonazepam (u)
4092-3,vancomycin [mass/volume] in serum or plasma --trough
4092-3,rplasma [mass/volume] in ser vancycin --trough
4092-3,predose vancomycin [mass/volume] in serum or plasma --trough
4092-3,vancomycin trough serpl-mcnc
4092-3,vancomycin serpl-mcnc trough
4092-3,drugs vancmycin serpl-mnc trough
4092-3,vancomycin trough [mass/vol]
4092-3,[massvol] trogh vancomyin
4092-3,vancomcin trogh [ass/vol]
50819-2,barium [moles/time] in 24 hour urine
50819-2,brium [mole/time] i 24 quantitative hour uine
50819-2,arium substance rate [olestme] i 24 hou urine
50819-2,barium 24h ur-srate
50819-2,ur-srate 24h barium
50819-2,ur barium ur-srate 24h
50819-2,barium (24h u) [moles/time]
50819-2,arium(24h substance rate u) [moles/time]
50819-2,barium (24h u) [moles/time]
96640-8,hla-dp and dq and dr (class ii) typing panel - blood or tissue by low resolution
96640-8,hladpand d and dr(class panel typin ii) -bld ortisseb low reolution hla antigen
96640-8,point in time hla-dp and d addr (class ii)yping panel blood or tissue by low resolution
96640-8,hla cls ii typ pnl bld/t low res
96640-8,typ ii hlacls pnl bld/t lw whole bld re
96640-8,hl cls ii typ pnl bldt inherited low res
96640-8,hla-dp & dq & dr (class ii) typing panel low res (bld/tiss)
96640-8,hla-dp & dq & dr (class ii) typing panel low res (bld/tiss)
96640-8,hladp& dq &dr lassiitypng panel lw re (bld/tiss)
93188-1,irf-pai v4.0 - administrative information - discharge during assessment period [cms assessment]
93188-1,irf-pai discharge - administrative information - v4.0 during assessment period [cms assessment]
93188-1,irf-pa v40 - administrativenforation- discharge durig assessent periodcms assesment]
66853-3,myeloperoxidase [moles/volume] in plasma
66853-3,plas myeloperoxidase [moles/volume] in plas
66853-3,lasma [moles/volume i myeloperoxidae
66853-3,myeloperoxidase plas-scnc
66853-3,myeloperoida chemistry la-snc
66853-3,mpo plas-scnc melpeidas
66853-3,myeloperoxidase (p) [moles/vol]
66853-3,myeloperoxidase [moles/vol] qnt (p)
66853-3,(p) myeloperoxidase qnt [moles/vol]
52477-7,largest ulcer measurements
52477-7,largest ucer pressure injury measuremnts
52477-7,measurements ulcer largest
47827-1,adenosyl homocysteine hydrolase [enzymatic activity/mass] in red blood cells
47827-1,adenosyl homocysteine hydrolase [enzymatic activity/mass] in red blood point in time cells
47827-1,adenosyl homocysteine hydrolase [enzymatic activity/mass] in red bld cells
47827-1,adenosyl homocysteine hydrolase rbc-ccnt
47827-1,adenosyl homocysteine hydrolase rbc-ccnt
47827-1,adenosyhomocysteie quan hydrolase rbc-ccnt
47827-1,adenosyl homocysteine hydrolase (rbc) [catalytic activity/mass]
47827-1,(rbc) homocysteine hydroae red blood corpusles adenosyl [caalytic activity/mss
47827-1,adenosyl homocysteine hcyst acvity/mass] (rbc) catalytic hydolas
45349-8,condition of tick [identifier]
45349-8,conditon [idntifier] tc of
45349-8,id condiion of tick [ientifer]
45349-8,condition of tick
45349-8,tick of condition
45349-8,tick of condition
45349-8,condition of tick nom (tick)
45349-8,conditio (tick) ticknom nominal of
45349-8,condition of tick nom (tick)
8212-3,opiates [presence] in gastric fluid by screen method
8212-3,opiates [ql] in gastric fluid by screen method
8212-3,qual opiates presence] n gastic screen by flud method
8212-3,opiates gast ql scn
8212-3,opiates gast presence scn scn
8212-3,opiates drugs sn ql gast
8212-3,opiates screen ql (gast fld)
8212-3,opiates screen ql fld) (gst
8212-3,(gast screen ql opiates fld)
78764-8,7-hydroxyquetiapine [mass/volume] in urine -- adjusted for lean body mass+urine creatinine
78764-8,7-hydroyquetiapine [mass/volume]in urie reatinine adjusted forlean body mass+urine point in time --
78764-8,7-hydroxyquetiapine [mass/volume] in urine ucr -- adjusted for lean body mass+urine creatinine
78764-8,7oh-quetiapine adj bodymass+crea ur-mcnc
78764-8,level urmcnc ad bodymass+crea 7oh-quetapine
78764-8,urn 7ohquetiain adj ur-mcn odymas+crea
78764-8,7-hydroxyquetiapine adjusted for lean body mass+urine creatinine (u) [mass/vol]
78764-8,7-yroxyquetiaieajusted adj bodymass+crea for [mas/vol] mass+urine creatnine (u) leanbody
78764-8,mass+urne adjsted for leanbody 7-hydroxquetiapine cratinine (u)mass/vol]
58756-8,parvovirus b19 igm ab [units/volume] in cerebral spinal fluid by immunoassay
58756-8,parvovirus b19 igm ab [units/volume] immunoassay cerebral spinal fluid by in
58756-8,rebral igm ab [unts/voume] n prvovirusb19 spinal flud by immnoassy
58756-8,b19v igm csf ia-acnc
58756-8,ig b9v immunoglobulin m csf iaacnc
58756-8,b19v igm csf ia-acnc
58756-8,parvovirus b19 igm ia qn (csf)
58756-8,arvovirusb9 infectiousdisease igm i qn (csf)
58756-8,parvovirus b19 igm ia qn (csf)
88911-3,taenia solium larva dna [presence] in tissue by naa with probe detection
88911-3,taenia solium [presence] dna larva in tissue by naa with probe detection
88911-3,"tissue, unspecified taenia solium larva dna [ql] in tissue by naa with probe detection"
88911-3,t sol lar dna tiss ql naa+probe
88911-3,t sol 3sr sr lar naa+probe tiss ql dna
88911-3,sol t larda tiss ql naa+probe
88911-3,t. solium larva dna naa+probe ql (tiss)
88911-3,ql solium naa+probe larva dna naa+probe t. (tiss)
88911-3,t. larva oliu da naaprobeql (tss) nucleic acid sequence based analysis
20449-5,borrelia burgdorferi ab [presence] in serum by immunoassay
20449-5,boreliabugdorfri ab [presnce] immunoassay by iserum
20449-5,borrelia burgdorferi ab [presence] in iaa serum by immunoassay
20449-5,b burgdor ab ser ql ia
20449-5,ia burgdor ab qual serum ql b
20449-5,burgdor ab presence se ia
20449-5,b. burgdorferi ab ia ql (s)
20449-5,b. burgdorferi ab ia ql (s) b burgdor
20449-5,b.bugdrferi abia q (s)
18396-2,hiv 1 p24 ag [presence] in serum or plasma by immunoassay
18396-2,in 1 p24 ag [presence] hiv aids ser or plasma by immunoassay
18396-2,hiv 1 p24 ag [presence] immunoassay ser or plasma by in
18396-2,hiv1 p24 ag serpl ql ia
18396-2,hi124 agerp ql ia
18396-2,hiv1 serpl p24a ql ia
18396-2,hiv 1 p24 ag ia ql
18396-2,hiv 1 p2 a ia presence
18396-2,ia 1 p24 ag hiv ql
2839-9,progesterone [mass/volume] in serum or plasma
2839-9,progesterone [mass/volume] in serum plasma or
2839-9,progesterone [mass/volume] in ser or plasma
2839-9,progest serpl-mcnc
2839-9,proges sepl-mcc
2839-9,proestser-mcnc plasma
2839-9,progesterone [mass/vol]
2839-9,[mass/vol] progesterone
2839-9,plasma [mass/vol] progesterone
29680-6,rickettsia akari ab [titer] in serum
29680-6,rickettsa akari b [tter] in serum
29680-6,rickettsia akai r akari a [tter] in serum
29680-6,r akari ab titr ser
29680-6,r akari ab titr ser antibody
29680-6,r akari ab titr dilution factor ser
29680-6,r. akari ab (s) [titer]
29680-6,r. [titer] ab (s) akari infectiousdisease
29680-6,. ab akari s)[titer]
32350-1,basophils+eosinophils+monocytes/leukocytes in blood
32350-1,basophils+eosinophils+monocytes/leukocytes in blood
32350-1,in hematology/cell counts basophils+eosinophils+monocytes/leukocytes blood
32350-1,baso+eos+monos nfr bld
32350-1,nfr baso+eos+monos bld
32350-1,bas+eosonos ld nfr eosinophil
32350-1,basophils+eosinophils+monocytes/leukocytes (bld)
32350-1,basophils+eosinophils+monocytes/leukocytes (bld) bph
32350-1,(bld) basophils+eosinophils+monocytes/leukocytes
85986-8,streptococcus pneumoniae danish serotype 12f ab [units/volume] in serum --2nd specimen
85986-8,strptococcus pneumniae danish pneumococcal serotype 12f ab [uits/volue] in serum -2ndspecimen
85986-8,streptococcus pneumoniae danish [units/volume] 12f infectiousdisease ab serotype in serum --2nd specimen
85986-8,s pneum da 12f ab sp2 ser-acnc
85986-8,s ser-acnc pneum da 12f ab sp2 pneum
85986-8,convalescent s pneum da 12f ab ser-acnc sp2
85986-8,s. pneumoniae danish type 12f ab spec 2 qn (s)
85986-8,s. a antibodies anish tye 12f pneumoniae spec2 qn(s
85986-8,spec pneumoniae danish type 12f ab s. spec 2 qn (s)
23173-8,leptospira interrogans sv canicola ab [presence] in serum
23173-8,sv interrogans leptospira canicola ab [presence] in serum
23173-8,leptospira serum interrogans sv canicola ab [presence] in serum
23173-8,l inter canic ab ser ql
23173-8,canic inte l ab autoantibody serum ql
23173-8,l inter canic ser ab ql
23173-8,l. interrogans sv canicola ab ql (s)
23173-8,l. sv interrogans canicola ab ql (s)
23173-8,canicola interrogans sv l. ab ql (s)
2055-2,catecholamines [mass/volume] in blood
2055-2,catecholamines in [mass/volume] blood level
2055-2,ctecholamnes [mass/vlume] in blood
2055-2,catechols bld-mcnc
2055-2,catechols bld-mcnc
2055-2,bld-cnc whole blood ctechols
2055-2,catecholamines (bld) [mass/vol]
2055-2,qnt catecholamines (bld) [mass/vol]
2055-2,catecholamines (bld) [mass/vol]
4376-0,paraldehyde [mass] of dose
4376-0,pradeyde ofdose [mass]
4376-0,[mass] paraldehyde of dose
4376-0,paraldehyde dose
4376-0,pt dose paraldehyde
4376-0,dose med or substance dose paraldehyde
4376-0,paraldehyde (dose) [mass]
4376-0,paraldehyde (dose) [mass]
4376-0,[mass] (dos) araldehyde dose med or substance
81097-8,west nile virus kunjin strain ab [presence] in serum
81097-8,screen strainb nile vrus kunin wst [presence] in serm
81097-8,west nie virus kunjin strain  [presence] i ser
81097-8,wnv kunjin ab ser ql
81097-8,ql kunjin ab ser wnv
81097-8,qualitative wnv presence ab ser kunjin
81097-8,west nile virus kunjin strain ab ql (s)
81097-8,west (s) virus kunjin strain ab ql nile
81097-8,west nile antby virus knjin strai ab presence (s)
13560-8,fluvoxamine [presence] in serum or plasma
13560-8,flvoxamine [presence] or inserum pama
13560-8,fluvoxamine [presence] in or serum plasma
13560-8,fluvoxamine serpl ql
13560-8,fluoxamin qual serpl ql
13560-8,serpl fluvoxamine ql pr
13560-8,fluvoxamine ql
13560-8,fuvoxamne ql
13560-8,presence fluvoxamine
14165-5,lactate [moles/volume] in body fluid
14165-5,bdy [molesvume] in lactate luid qnt
14165-5,lactate [moles/volume] body in fluid
14165-5,lactate fld-scnc
14165-5,fld-scnc lactate
14165-5,lactate fld-scnc
14165-5,lactate (body fld) [moles/vol]
14165-5,lactate [moles/vol] fld) lact (body
14165-5,(body lactae fld) [moles/vol] flu
71428-7,cms - history of present illness panel
71428-7,panl hisory of present illness h/o ms
71428-7,cms pan panel history of present illness -
38583-1,"1,2-dibromo-3-chloropropane [mass/volume] in air"
38583-1,"1,2-dibromo-3-chloropropane [mass/volume] in air"
38583-1,"1,2-dibromo-3-chloropropane [mass/volume] in air random"
38583-1,dbcp air-mcnc
38583-1,air-mcnc dbcp
38583-1,air-mcnc dcp
38583-1,"1,2-dibromo-3-chloropropane (air) [mass/vol]"
38583-1,",2-diromo-chlororopne [mass/ol] (air)"
38583-1,",2-dbroo-3-chloropropane [ass/vol] drugs (air)"
53941-1,vibrio cholerae toxin ag [presence] in isolate
53941-1,vibrio cholerae ag toxin isol [ql] in isolate
53941-1,vbrio cholerae toxinag[reece] in isolate
53941-1,v cholerae tox ag islt ql
53941-1,v holerae to g ist presence
53941-1,v cholerae tox ag ct ql islt
53941-1,v. cholerae toxin ag ql (isol)
53941-1,v. cholerae toxin ag infectious disease ql (isol)
53941-1,v. cholerae toxin (isol ql ag
16548-0,carbamazepine [mass/volume] in urine
16548-0,[mass/volume] carbamazepine in urine
16548-0,carbamazepine urie tegretol [ass/volume]in
16548-0,carbamazepine ur-mcnc
16548-0,carbamazepine ur-mcnc crbm
16548-0,ur-mcnc carbamazepine
16548-0,carbamazepine (u) [mass/vol]
16548-0,carbamazepine (u) [mass/vol] crbm
16548-0,[mass/vol] (u) carbamazepine
78433-0,soluble liver igg ab [presence] in serum by line blot
78433-0,soluble liver igg [presence] ab in serum ql by line blot
78433-0,souble lver igg ab [presnce] in ser by lineblot
78433-0,soluble liver igg ser ql line blot
78433-0,soluble liver igg serum ql line blot
78433-0,soluble liver ser igg ql line blot
78433-0,soluble liver igg line blot ql (s)
78433-0,soluble liver igg ql blot line ordinal (s)
78433-0,soluble liver (s) line blot ql igg
90820-2,contactin-associated protein 2 ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
90820-2,cotactinassociated proein 2 b [prence] in cerebral spinal fluid by cell binding immunflorescent assay
90820-2,contactin-associated protein 2 antibody ab [presence] spinal cerebral in fluid by cell binding immunofluorescent assay
90820-2,caspr2 ab csf ql cba ifa
90820-2,caspr2 ab cba ql spinal flu cerebrospinal fluid ifa
90820-2,caspr2 ab csf cerebral spinal fluid ql cba ifa
90820-2,contactin-associated protein 2 ab cell binding immunofluorescent assay ql (csf)
90820-2,protein contactin-associated 2 ab cell binding immunofluorescent assay ql (csf)
90820-2,contactin-associated protein 2 ab cell binding immunofluorescent (csf) presence assay
16175-2,bartonella henselae igm ab [presence] in cerebral spinal fluid
16175-2,batonellahenselae igm abs ab [presencein ceeral spl fl
16175-2,bartonlla henselae ig ab[ql] in cerbal spinal fluid
16175-2,b henselae igm csf ql
16175-2,bacillary angiomaosis b henselae igm csf ql
16175-2,henselae b igm csf autoantibodies ql
16175-2,b. henselae igm ql (csf)
16175-2,(cerebrospinal fluid) enela igm ql b.
16175-2,b. qualitative henselae igm ql (csf)
48944-3,carboxy tetrahydrocannabinol [mass/volume] in specimen
48944-3,carboxy tetrahydrocannabinol [mass/volume] specimen in
48944-3,carboxy tetrahydrocannabinol addiction [mass/volume] i specime
48944-3,carboxythc spec-mcnc
48944-3,caboxythc pec-cnc
48944-3,spec-mcnc carboxythc
48944-3,carboxy tetrahydrocannabinol (specimen) [mass/vol]
48944-3,cbox tetrahydrocannabinolspecimen) [mas/vol]
48944-3,carboxy tetrahydrocannabinol (secien) thccooh [mass/vl]
104370-2,clostridium butyricum [presence] in specimen
104370-2,clostridium point in time butyricum [ql] in specimen
104370-2,misc clostridium inspecien [presence] butyricum
104370-2,c. butyricum spec ql
104370-2,butyricumspec c. ql
104370-2,c. butyricum spec ql microbiology
104370-2,clostridium butyricum ql (specimen)
104370-2,buyicumqlspcimen) clostridium
104370-2,(specimen) butyricum ql clostridium
93706-0,ethyl sulfate+ethyl glucuronide [mass/volume] in urine by screen method
93706-0,ethyl sulfte+ethyl glucuronide [mas/volme] in rine bscreen method
93706-0,ethylsulate+ethyl method in urine by seen glucuronie[ass/olume]
93706-0,etg ets ur scn-mcnc
93706-0,et ets gluc ur scn-mcnc
93706-0,scn-mcnc ets ur etg
93706-0,ethyl sulfate+ethyl glucuronide screen (u) [mass/vol]
93706-0,ethyl sulfate+ethyl glucuride chemistry screen (u)[mass/vol]
93706-0,ethyl sulfate+ethyl glucuronide screen sulfovinic acid (u) [mass/vol]
31183-7,deprecated streptococcus pneumoniae 5 igg ab [mass/volume] in serum
31183-7,dereated strptococcus pneumoniae 5 igg ab [mss/volume] in serm
31183-7,deprecatedstreptococcus point in time pnumoie igg b [mas/vole] in erum
31183-7,deprecated s pneum5 igg ser-mcnc
31183-7,deprecated s pneum5 ig sr-nc
31183-7,deprecated pneum5 s igg ser-mcnc
31183-7,s. pneumoniae 5 igg (s) [mass/vol]
31183-7,s. qnt neumonie 5 (s igg [mas/ol
31183-7,s. pneumoniae 5 igg pneum (s) [mass/vol]
16843-5,ethanol [mass/volume] in body fluid
16843-5,ethanol [mass/volume] quan in body fluid
16843-5,ethanol [mass/volume] body in fluid
16843-5,ethanol fld-mcnc
16843-5,ethanol quantitative fld-mcnc
16843-5,fluid ethaol fld-mcnc
16843-5,ethanol (body fld) [mass/vol]
16843-5,ethanol (bod [mass/vol] fl)
16843-5,ehanol (body fld) [mass/ol]
48358-6,herpes virus 8 igm ab [titer] in serum by immunofluorescence
48358-6,herpes virus in igm ab [titer] 8 serum by immunofluorescence
48358-6,ab virus 8 igm herpes id [titer] in serum by immunofluorescence
48358-6,hhv8 igm titr ser if
48358-6,hhv8 igm er tit if
48358-6,hhv8 igm titr ser immunoflour if
48358-6,hhv 8 igm if (s) [titer]
48358-6,hhv (s) igm if herpesvirus 8 [titer]
48358-6,hhv (s) igm if 8 [titer]
101628-6,thyroglobulin heterophile ab interference [interpretation] in serum narrative
101628-6,thyroglobulin heterophile abinterference arrative in serm impression/interpretation of study [interpretaton
101628-6,mono slide throglobulin hetrophile a interferenc [interpretation]in ser nrraie
101628-6,tg heterph ab intrf ser-imp
101628-6,tg heterph ab intrf ser-imp mononucleosis test
101628-6,tg bntr mono screen heerph serum-imp
101628-6,thyroglobulin heterophile ab interference nar (s) [interp]
101628-6,thyroglobulin heterophile ab interference [interp] (s) nar
101628-6,thyroglobulin heterophile ab interference [interp] (s) nar
70862-8,rabies virus igm ab [presence] in cerebral spinal fluid by immunofluorescence
70862-8,rabies virus igm ab [presence] in cerebral spinal fluid by immunofluorescence
70862-8,rabies vrus igm b presence] in cerebalspnl fluid by immunofluorscence
70862-8,rabv igm csf ql if
70862-8,rabvigm csfl if
70862-8,rabvim csf ql if
70862-8,rabies virus igm if ql (csf)
70862-8,rabies ql igm if virus (csf)
70862-8,abiesvirus igm if ql (cerebrospinal fluid)
27146-0,deprecated streptococcus pneumoniae 12 ab [mass/volume] in serum --1st specimen
27146-0,derecatd streptococcs peumoniae 1ab in pneumococcal [massvolume] serum -1st pecimen
27146-0,deprecated streptococcus pneumoniae 12 ab qnt [mass/volume] serum in --1st specimen
27146-0,deprecated s pneum12 ab sp1 ser-mcnc
27146-0,deprecated s infectiousdisease a pnum12 s1 er-mcc
27146-0,deprecated ser-mcnc pneum12 ab sp1 s mass concentration
27146-0,s. pneumoniae 12 ab spec 1 (s) [mass/vol]
27146-0,1 pneumoniae 12 ab spec . (s) [mass/vol]
27146-0,ab pnumoiae 12 s. pe 1 (s) [massvol
6305-7,plasmodium malariae ab [units/volume] in serum
6305-7,plasmodium malariae id ab [units/volume] in serum
6305-7,plasmodium in ab qnt [units/volume] malariae serum
6305-7,p malariae ab ser-acnc
6305-7,p malariae ab se-cnc
6305-7,malariae p ab ser-acnc
6305-7,p. malariae ab qn (s)
6305-7,malaria pmaariae ab qn (s)
6305-7,p. ab malariae qn (s)
4095-6,verapamil [presence] in urine
4095-6,[presence] random verapamil in urine
4095-6,urine in random vrapamlpresnce]
4095-6,verapamil ur ql
4095-6,verapamil ur ql
4095-6,verapamil ur urn ql
4095-6,verapamil ql (u)
4095-6,verapamil (u) ql
4095-6,verapamil ua (u) presence
2586-6,lysine [mass/volume] in urine
2586-6,[mass/volume] lysine in urine
2586-6,lysine [mass/volume] in urin
2586-6,lysine ur-mcnc
2586-6,quan u-mcnc lysine
2586-6,sn ur-mcc
2586-6,lysine (u) [mass/vol]
2586-6,lsine (u) [mas/vol]
2586-6,(u) lys lysine [mass/vl]
95382-8,date and time of symptom resolution
95382-8,date of time and symptom resolution
95382-8,ad dae time of symptom random resolution
95382-8,d/t symptom resolution
95382-8,d/t symptom resolution
95382-8,d/t resolution symptom
85095-8,d-3-phosphoglycerate dehydrogenase igg ab [presence] in serum by line blot
85095-8,d-3-phosphoglycerate dehydrogenase igg ab by in serum [ql] line blot
85095-8,aby d-3-phosphoglycerate dehydrogenase igg ab [presence] in serum by line blot
85095-8,3-pgdh igg ser ql line blot
85095-8,3-pgdh blot ser ql line igg
85095-8,3-pgdh igg serum ql blot line
85095-8,d-3-phosphoglycerate dehydrogenase igg line blot ql (s)
85095-8,presence d-3-hosphoglycerat dehydrogenae igg line presence lot (s)
85095-8,d-3-phosphoglycerate dehydrogenase immune globulin g igg line blot ql (s)
22365-1,influenza virus a ab [titer] in serum
22365-1,influenza virus a ab [titer] ser in ser
22365-1,influenza aby serum a ab [titer] in virus
22365-1,fluav ab titr ser
22365-1,fluav ser bitr
22365-1,fuav abtitr ser
22365-1,fluav ab (s) [titer]
22365-1,ab fluav (s) [titer]
22365-1,fluav [titer] (s) ab
49439-3,pneumocystis jirovecii dna [#/volume] in cerebral spinal fluid by naa with probe detection
49439-3,pneumocystis jirovecii dna tma [#/volume] in cerebral spinal fluid by naa with probe detection
49439-3,pneumocystis jirovecii dna naa in cerebral spinal fluid by [#/volume] with probe detection
49439-3,p jirovecii dna # csf naa+probe
49439-3,p # dna polymerase chain reaction jirovecii csf naa+probe
49439-3,p jirovecii dna # csf naa+probe strand displacement amplification
49439-3,p. jirovecii dna naa+probe (csf) [#/vol]
49439-3,naa+probe jiroveii da probe with ampification p. (csf) [#/vol]
49439-3,p.jirovecii da na+probe (cf) [#/vol]
35509-9,amino acids panel [moles/time] - 24 hour urine
35509-9,amino cids panl [moles/time] - 4 hou urine
35509-9,amino acids panel hour - 24 [moles/time] urine
35509-9,amino acids pnl 24h ur-srate
35509-9,amino ur-srate pnl pan 24h acids
35509-9,amo ua acids nl 24h ur-srate
35509-9,amino acids panel (24h u) [moles/time]
35509-9,amino aids panel (24h u) [moles/time]
35509-9,(24h acids panel amino u) [moles/time]
34422-6,toxoplasma gondii igg ab avidity [ratio] in serum
34422-6,toxoplsmondiiigg ab avidity[ratio] in serum antby
34422-6,avidity gondii igg ab toxoplasma [ratio] in serum
34422-6,t gondii igg avidity ser-rto
34422-6,avidity gondii immune globulin g ig t se-rto
34422-6,t gondi igg quantitative aviiy er-rto
34422-6,t. gondii igg avidity (s) [ratio]
34422-6,t. goniiigg (s) avidity [rato]
34422-6,t. quan gondii igg avidity (s) [ratio]
89263-8,special circumstances associated observations panel
89263-8,special circumstan assoiad observations pan panel
89263-8,circumstances special associaeobservtions panel
89263-8,special circ assoc obs pnl
89263-8,special crc soc pan bs pnl
89263-8,obs circ assoc special pnl
86600-4,preferences for customary routine and activities during assessment period [cms assessment]
86600-4,preferences for customary assessment] and activities during assessment period pnl [cms routine
86600-4,peferences for cusomary rutine an ctvities during [cms perod asessment assessment]
59962-1,propranolol [moles/volume] in gastric fluid
59962-1,ropralol in [mols/volume] gasri luid
59962-1,propranolol ingastric [moles/volume] lud
59962-1,propranolol gast-scnc
59962-1,propranolol gast-scnc
59962-1,gast-scnc propranolol
59962-1,propranolol (gast fld) [moles/vol]
59962-1,[moles/vol] (gast fld) propranolol
59962-1,prpraolol(gast fld) [moles/vol] quant
45024-7,hla typing for narcolepsy panel - blood
45024-7,hla typing panel narcolepsy for - bld
45024-7,hla typing narcolepsy for panel - blood
45024-7,hla for narcolepsy pnl bld
45024-7,hla for narcolepsy pnl panl bld
45024-7,hla for narcolepsy pnl bld random
45024-7,hla typing for narcolepsy panel (bld)
45024-7,hla ypin for narcolepsy panel (bld)
45024-7,ncolepsy typing or ha panel (bl)
45188-0,basement membrane zone bp180 ab [units/volume] in serum
45188-0,basement membrane zone erum bmz b nis/volume] in b180
45188-0,basement membrne zone bp10 ab [units/volume in erum aby
45188-0,bmz bp180 ab ser-acnc
45188-0,bp180 bmz ab ser-acnc
45188-0,mz sacnc qnt bp180ab
45188-0,basement membrane zone bp180 ab qn (s)
45188-0,basement membrane zone bp180 ab qn basem (s)
45188-0,basement (s) zone bp180 ab qn membrane
97026-9,phosphatidylserine-prothrombin complex igg and igm panel - serum or plasma
97026-9,phosphatidylserine-prothrombin complex igg and panel igm - immunoglobulin g ser or plasma
97026-9,phosphatidlsrine-prothrombincomplex igg andigm pane - serum or plsma
97026-9,ps-prothrom cmplx igg igm pnl serpl
97026-9,ps-pothom cmpx igg im pnl serpl
97026-9,ps-prothro cmplx igg igm serpl pnl
97026-9,phosphatidylserine-prothrombin complex igg and igm panel
97026-9,hosphatiylsrine-rothrmbin complex and immune globulin m igg igmael
97026-9,phosphatidylserin-prothrmncomplex igg and igm panel
17403-7,human papilloma virus 31+33+35 ag [presence] in specimen
17403-7,31+33+35 papilloma virus human ag [presence] in specimen
17403-7,in papilloma virus 3+33+35 g pr preence] human specmen
17403-7,hpv31+33+35 ag spec ql
17403-7,hpv31+33+35 spec ag presence
17403-7,hpv31+33+35 spec qual ag ql
17403-7,hpv 31+33+35 ag ql (specimen)
17403-7,31+33+5 pr hv g ql (specimen)
17403-7,antigen 31+33+5agl hpv (spcimen
34592-6,hiv 1 ab [presence] in body fluid by immunoblot
34592-6,hiv 1 antby ab [presence] in body fluid by immunoblot
34592-6,hv 1 ab ordinal [pesence] in body fluid by immunoblot
34592-6,hiv1 ab fld ql ib
34592-6,hiv1 ab ql fld ib
34592-6,ab hiv1 fld i ql ib
34592-6,hiv 1 ab ib ql (body fld)
34592-6,hiv 1 ab ib fld) (body presence
34592-6,hiv presence ab bod ib 1 (body l)
96447-8,we care survey [we care] caregiver
96447-8,survey care we panel [we care] caregiver
96447-8,we [we sdoh survey care care] caregiver
4311-7,mersalyl [mass] of dose
4311-7,pt mersalyl [mass] of dose
4311-7,[mass] ersalyl of ose
4311-7,mersalyl dose
4311-7,dose mersayl
4311-7,dose mersalyl
4311-7,mersalyl (dose) [mass]
4311-7,mersalyl [mass] point in time (dose)
4311-7,mersall dose med or substance (dose) [mas]
58944-0,microscopic observation [identifier] in body fluid by acid fast stain.ziehl-neelsen
58944-0,flu microscopic observation [identifier] in body fluid by acid fast stain.ziehl-neelsen
58944-0,microscopic observation [identifier] in body fluid by acid fast stain.ziehl-neelsen
58944-0,zn stn fld
58944-0,body fluid zn stn fld
58944-0,fld stn zn
58944-0,microscopic observation acid fast stain.ziehl-neelsen nom (body fld)
58944-0,microscopic obervatinacid fast stan.ziehl-nesennm fl (body afb stain
58944-0,microscopic observation acid stain.ziehl-neelsen fast nom (body body fluid fld)
18244-4,niacin [mass/volume] in serum or plasma
18244-4,seruor [mass/volume] in serplas acin plasma
18244-4,or [mass/volume] in nicotinic acid serum niacin plasma
18244-4,niacin serpl-mcnc
18244-4,serpl-mcnc niacin point in time
18244-4,serp niacin serpl-mcnc
18244-4,niacin [mass/vol]
18244-4,mass/vol] niain
18244-4,niacin [mass/vol]
60523-8,carbromal [mass/volume] in serum or plasma
60523-8,carbromal [mass/volume] in serum serum or plasma
60523-8,carbromal [massvolume] qnt i srumor plas
60523-8,carbromal serpl-mcnc
60523-8,serp-mcc carromal
60523-8,carbromal mass concentration serpl-mcnc
60523-8,carbromal [mass/vol]
60523-8,carbromal [mss/ol serum
60523-8,cabromal [mass/vo
61548-4,deprecated phenx measure - fiber intake
61548-4,deprecated phex asre - fiber intake
61548-4,deprecated phenx measure roughage - fiber intake
3606-1,ethacrynate [mass/volume] in urine
3606-1,ethacrynae in [mass/volume] urine
3606-1,mass concentration ethacrynate rine in [as/volume]
3606-1,ethacrynate ur-mcnc
3606-1,ur-mcnc thacrynate quantitative
3606-1,ur-mcnc ethacrynate
3606-1,ethacrynate (u) [mass/vol]
3606-1,tharynate quant (u)[mass/vol]
3606-1,ethacrynate u) [ass/vol] quantitative
83081-0,borrelia burgdorferi igg+igm ab [presence] in serum by immunoassay
83081-0,immunoglobulin m by burgdorferi igg+igm ab [presence] in serum borrelia immunoassay
83081-0,borrelia burgdorferi igg+igm ab serum in [presence] by aby immunoassay
83081-0,b burgdor igg+igm ser ql ia
83081-0,ia burgdor igg+igm ser ql b
83081-0,burgdorigg+igm suds ser a ql
83081-0,b. burgdorferi igg+igm ia ql (s)
83081-0,ql burgdorferi igg+igm ia b. (s)
83081-0,b. burgdorferi igg+igm ia ql (s)
32193-5,monocytes+macrophages [presence] in pericardial fluid by light microscopy
32193-5,peicrdial [presence]in monocytes+macropages fluid by light icroscoy
32193-5,monoytes+marophages [pesence] in pericrdial flid y liht microscopy qualitative
32193-5,monos+macros pcar ql micro
32193-5,lm monos+macros carql micr
32193-5,ql pcar moos+macro micro
32193-5,monocytes+macrophages lm ql (pericard fld)
32193-5,lm monocytes+macrophages ql (pericard fld)
32193-5,ql lm monocytes+macrophages pr (pericard fld)
106011-0,inequality index reporting period calculated
106011-0,inequality clin index reporting period calculated
106011-0,inequality period reporting index calculated
106011-0,inequality index rptperiod score calc
106011-0,inequality rptperiod index score calc
106011-0,iequality calc rpteriosor index
42970-4,pseudallescheria boydii igg ab [presence] in serum
42970-4,pseudallescheria boydii igg ab [presence] in ser
42970-4,pseudallescheria boydii igg ab in [presence] serum
42970-4,p boydii igg ser ql
42970-4,p igg boydii serum ql
42970-4,p boydii igg a boydii serum ql
42970-4,p. boydii igg ql (s)
42970-4,p. boydii id igg (s) ql
42970-4,p sheari p. boydii igg ql (s)
29597-2,mephentermine [mass/volume] in serum or plasma by confirmatory method
29597-2,mephentermine [mass/volume] in ser or plasma by confirmatory method
29597-2,mephentermine [mass/volume] in ser or plasma by confirmatory method
29597-2,mephentermine serpl cfm-mcnc
29597-2,mephentermine serpl cfmmcnc
29597-2,mepentermine serum or plasma cfm-mcnc
29597-2,mephentermine confirm [mass/vol]
29597-2,mephntermne confrm [mass/l]
29597-2,mephentermine confim [mas/vol]
106718-0,scheduled opioid during assessment period [cms assessment]
106718-0,scheduled opioid during assessment [cms period assessment]
106718-0,assessmenperiod opioid uring report period scedled [cm ssssment]
14214-1,histoplasma capsulatum exoantigen [identifier] in isolate
14214-1,histoplasm eoantigen capsulatum [identifier] inisolate
14214-1,histoplasma capsulatum exoantigen [identifier] in isolate
14214-1,h capsul xa id islt
14214-1,h id xa capsul islt
14214-1,capsul h xa id islt
14214-1,h. capsulatum exoantigen nom (isol)
14214-1,exoantigen capsulatum h. nom (isol) histopl
14214-1,capulatu h. exoantigennom (isl)
1678-2,20-hydroxyprogesterone [mass/volume] in serum
1678-2,20-hydroxprogesterone [mass/volume] srum in
1678-2,in 20-hydroxyrgestero[ss/volue] erum
1678-2,20ohp ser-mcnc
1678-2,20ohp ser-cnc
1678-2,20ohp serum-mcc
1678-2,20-hydroxyprogesterone (s) [mass/vol]
1678-2,(s) 20-hydroxyprogesterone [mass/vol]
1678-2,mass/vo] mass concentration (s) 20hydroxyprogesterone
12281-2,bacteria identified in cervix by anaerobe culture
12281-2,bacteria identified in by cervix anaerobe culture
12281-2,bactria idntified in cervix by anaerobe cultur
12281-2,bacteria cvx anaerobe cult
12281-2,bacteria cvx random anrobe cult
12281-2,baceria cult vxanaerobe
12281-2,bacteria identified anaer cx nom (cvx)
12281-2,cx identfied anaer cultures bacteri nom (cvx)
12281-2,anaero bacteria identified anaer cx nom (cvx)
4085-7,tripelennamine [mass/volume] in serum or plasma
4085-7,tripelennamine [mass/volume] in serpl
4085-7,tripelennamine [mass/volume] plasma serum or in
4085-7,tripelennamine serpl-mcnc
4085-7,tripelennane mass concentration serl-mcnc
4085-7,tripelennamine erpl-mcnc serum or plasma
4085-7,tripelennamine [mass/vol]
4085-7,[asvol tripelenmine
4085-7,[mas/vol] rpelennain
97558-1,acetylcholine receptor binding igg+igm ab [moles/volume] in serum by immunoassay
97558-1,acetylcholine receptor binding antibody igg+igm ab [moles/volume] in serum by immunoassay
97558-1,acetylcholine receptor binding igg+igm ab [moles/volume] immunoassay serum by in
97558-1,achr bind igg+igm ser ia-scnc
97558-1,achr bin igg+igmser ia-scnc
97558-1,serum bind bindg+igm achr a-cn
97558-1,acetylcholine receptor binding igg+igm ia (s) [moles/vol]
97558-1,acetylcholine receptor binding igg+igm meia ia (s) [moles/vol]
97558-1,acetylcholine igg+igm binding receptor ia (s) [moles/vol] recept
43740-0,glucose/insulin [mass ratio] in serum or plasma
43740-0,glucse/inslin [mas rati] isrum or plsma quant
43740-0,glucose/inslin[ass ratio] inseum r plasma
43740-0,glucose/insulin serpl
43740-0,plsm gluose/insulin serpl
43740-0,serpl glucose/insulin
43740-0,glucose/insulin [mass ratio]
43740-0,glucose/insulin gluc ratio] [mass
43740-0,glucose/insuin [mass rati]
62523-6,deprecated phenx measure - environmental exposures - exposures from hobbies
62523-6,environmental phenx measure - deprecated exposures - exposures from hobbies
62523-6,deprecatd penx masure - environmntal exposurs - expsus pnl frm hobbes
87952-8,helicobacter pylori [presence] in stool by organism specific culture
87952-8,helcoater pyloi [ql] in stool byorganm specic cuture
87952-8,helicobacter pylori [presence] in organism by stool specific culture
87952-8,h pylori stl ql cult
87952-8,h pylori stl ql cult
87952-8,h pylori stl presence cult
87952-8,h. pylori org specific cx ql (stl)
87952-8,hpyloi org spcificcx ql (stl)
87952-8,h. id pylori org specific cx presence (stl)
6905-4,propafenone [mass/volume] in serum or plasma
6905-4,propafenone in [mass/volume] serum or plasma
6905-4,plasma [mass/volume] in ser or propafenone
6905-4,propafenone serpl-mcnc
6905-4,serpl-mcnc propafenone
6905-4,serpl-mcnc propafenone
6905-4,propafenone [mass/vol]
6905-4,propafenone [mass/vol]
6905-4,propafenone [mass/vol]
33762-6,natriuretic peptide.b prohormone n-terminal [mass/volume] in serum or plasma
33762-6,natriuretic pptid.b prohomonen-termina [massvoume] n b-type natriuretic peptide seum or plasma
33762-6,natriureticpeptide.b prohormonen-terminal [mass/vlume] in erum r plama
33762-6,nt-probnp serpl-mcnc
33762-6,nt-probnp serpl-mcnc heart disease
33762-6,serpl-mcnc nt-probnp
33762-6,natriuretic peptide.b prohormone n-terminal [mass/vol]
33762-6,peptide.b atiuretic ntprobnp prohrmone n-terinal [mas/vol]
33762-6,prohomonen-terminal eptide.b quant nariuretic [mass/vo]
7796-6,platelet clump [presence] in blood by light microscopy
7796-6,platelet blood [presence] in clump by light microscopy
7796-6,liht ump [presen] i ordinal blood y plaelet microscopy
7796-6,platelet clump bld ql smear
7796-6,micro ql plateleclumbld smar
7796-6,platelet clump bld presence smear
7796-6,platelet clump lm ql (bld)
7796-6,platlet clump lmql blood (bld)
7796-6,micros plaeletlump lm (bl) ql
66718-8,rickettsia typhi and rickettsia spotted fever group igg and igm [interpretation] in specimen
66718-8,ickettsia typhi and rickettsia sotted fever group ig an gm [interpretation] in specimen interp
66718-8,rickettsia typhi typh and igm sptted fevr groupigg and rikettsia [interpreation] in spcimen
66718-8,r typhi and sf igg+igm spec-imp
66718-8,r sf and typhi igg+igm spec-imp immunoglobulin g
66718-8,typhi r and sf igg+igm spec-imp
66718-8,r. typhi and r. spotted fever group igg and igm (specimen) [interp]
66718-8,r. typhi and r. spotted fever go igg and igm (secimen) [intrp]
66718-8,r. antibody tphi and rop spoed fever r. igg and ig (specien [iterp]
59276-6,calcium hydrogen phosphate dihydrate crystals [presence] in stone by x-ray diffraction
59276-6,stone hydrogen phosphate dihydrate crystals [presence] in nephrology calcium by x-ray diffraction
59276-6,calcim hydrogen inorganic phosphate phosphate dihydrae crystals [presence]istone b x-ray diffraction
59276-6,ca h2 phos dihyd cry stone ql xr diff
59276-6,ca h2 phos dihyd cry stone presence xr renal diff
59276-6,ca h phos calc dihy cry soe presence x diff
59276-6,calcium hydrogen phosphate dihydrate crystals x-ray diffraction ql (stone)
59276-6,calciumydrogen i phos phshate dihydrte crystals x-ray dffraction ql (stoe)
59276-6,calcim stones hyrogepophate diydrate cystals x-raydiffracion q(sne)
62406-4,phenx - child head circum protocol 020501
62406-4,phenx circum child head - protocol 020501
62406-4,phenx - chid hedcircum protocol 020501
62406-4,phenx - child head circum protocol
62406-4,phenx panel - child head circum protocol
62406-4,pen - hild h circum protocol
9700-6,procaine [mass/volume] in serum or plasma
9700-6,[mass/volume] procaine in ser or plasma
9700-6,procine sr [assvolume in serum pasma r
9700-6,procaine serpl-mcnc
9700-6,serpl-mcnc procaine
9700-6,quan serpl-mcnc procaine
9700-6,procaine [mass/vol]
9700-6,[mass/vol] procaine
9700-6,[mass/vol] procaine
28612-0,legionella sp igm ab [titer] in serum by immunofluorescence
28612-0,legionella sp igm ab [titer] in ser anticomplement immunofluorescence by immunofluorescence
28612-0,legionella in igm infectious disease ab [titer] sp serum by immunofluorescence
28612-0,legionella igm titr ser if
28612-0,immune fluorescence legionella gmtitr ser if
28612-0,legionela igm tir if serum
28612-0,legionella sp igm if (s) [titer]
28612-0,[titer sp igm if (s) lgonela
28612-0,[tite] sp titered im if (s) egionela
27281-5,propoxyphene [mass/mass] in stool
27281-5,propoxyphene cosalgesic in [mas/mass] stool
27281-5,propoxyphene [mass/mass] stool in
27281-5,propoxyph stl-mcnt
27281-5,stl-mcnt propoxyph
27281-5,stl-mcnt propoxyph bowel movement
27281-5,propoxyphene (stl) [mass/mass]
27281-5,(stl)[mass/mass] propxypee
27281-5,[mass/mss] stl) propoxyphene
104390-0,ebola virus igg ab [titer] in serum by immunoassay --2nd specimen
104390-0,ebola virus igg by [titer] in serum ab immunoassay --2nd specimen
104390-0,--2nd virus igg ab [titer] in serum by immunoassay ebola specimen
104390-0,ebov igg sp2 titr ser ia
104390-0,sp2 gg ebov titre ia eia
104390-0,ebov igg sp2 eia titr ser i
104390-0,ebola virus igg spec 2 ia (s) [titer]
104390-0,ebola virus igg spec 2 ia (s) [titer]
104390-0,ebola virus [titer] spec 2 ia (s) igg
23378-3,porcine respiratory coronavirus rna [presence] in specimen by probe
23378-3,prcine respiratory oronavirs rna presence] inspecimen probe y
23378-3,porcne respiratory coonirus ra [pesence] specime in by probe
23378-3,prcov rna spec ql probe
23378-3,prcov ql spec rna probe
23378-3,prcov rna spec ql probe
23378-3,porcine respiratory coronavirus rna probe ql (specimen)
23378-3,porcine respiratory coonairus raprobe ql (specimen)
23378-3,(specimen) respiratory coronavirus rna probe ql microbiology porcine
62346-2,chromosome analysis.interphase panel - amniotic fluid by fish
62346-2,chromosome analysis.interphase by - amniotic fluid panel fish
62346-2,fluid analysis.interphase panel - amniotic chromosome by fish
62346-2,chrom analy interphase pnl amn fish
62346-2,chrom pnl analyinterphase amnfish
62346-2,chrom analy interphase pnl amn fluorescent in situ hybridization fish
62346-2,chr analysis.interphase panel fish (amn fld)
62346-2,hr panl fld) panefish (amn analysi.interphae
62346-2,chr analysisinterphase panl random fish (amn fl)
70854-5,burkholderia mallei ag [presence] in specimen by immunofluorescence
70854-5,brkholdera malei equinia ag [presence] n pecimen by immunofluorescence
70854-5,burkholdeia mallei ag [pesence] ordinal in specimen b immunofluoreence
70854-5,b mallei ag spec ql if
70854-5,b mallei ag spec if presence
70854-5,id b mallei ag spec ql if
70854-5,b. mallei ag if ql (specimen)
70854-5,if mallei ag glanders . ql (specimen
70854-5,b. mallei ag if ql (specimen)
60549-3,deprecated 8-estriol [mass/volume] in urine
60549-3,depecaed [mas/vume 8-estril n urine
60549-3,8-estriol deprecated [mass/volume] in urine
60549-3,deprecated 8-estriol ur-mcnc
60549-3,deprecated 8-estriol ur-mcnc
60549-3,deprecated -etriol r-mcnc
60549-3,8-estriol (u) [mass/vol]
60549-3,level 8-esriol(u) [mass/vol]
60549-3,8-estriol level (u) [mass/vol]
3317-5,amantadine [mass/volume] in serum or plasma
3317-5,aantdine mass/olume] in serpl
3317-5,amantadine [mass/volume] in serum or plasma
3317-5,amantadine serpl-mcnc
3317-5,amantadine serum or plasma-mcnc plsm
3317-5,amantadine serpl-mcnc sr
3317-5,amantadine [mass/vol]
3317-5,[mass/vol] amantadine
3317-5,aantadin[mass/vol
17435-9,pheniramine [mass/volume] in urine
17435-9,pheniramine [mass/volume] in urine
17435-9,pheniramine drug/toxicology urine in [mass/volume]
17435-9,pheniramine ur-mcnc
17435-9,ur-mcnc pheniramine
17435-9,ur-mcnc heniramin
17435-9,pheniramine (u) [mass/vol]
17435-9,quant pheniramine (u) [mass/vol]
17435-9,pheniramine [mass/vol] ur (u)
13918-8,eastern equine encephalitis virus ab [titer] in serum by immunofluorescence
13918-8,ab equine encephalitis virus eastern [titer] in ser by immunofluorescence
13918-8,eatrn in enephaltis vrus ab [titer] equine srum by abs immnofluorescence
13918-8,eeev ab titr ser if
13918-8,eev ab titr ser if
13918-8,eeev fluorescent antibody ab serum titr if
13918-8,eeev ab if (s) [titer]
13918-8,eeev ab fluorescent antibody if (s) [titer]
13918-8,time resolved fluorescence eeev (s) if ab [titer]
89775-1,resources management [cdc emergency operations centers]
89775-1,resources management [cdc emergency operations centers]
89775-1,reources eergncy [cdc anagement pnl opeationcenters]
71616-7,neutrophils/leukocytes [pure number fraction] in pleural fluid by manual count
71616-7,neutophil/eukocytes number [pre fration] n pleural fuid by mana cunt
71616-7,neutrophil/leukocyte [ure number rtion] in plerl fluid by manual lung count
71616-7,neutrophils nfr.df plr manual
71616-7,neutrophils nfr.df plr point in time manual
71616-7,neutrohils nfdf plrmnul
71616-7,neutrophils/leukocytes manual cnt (pleur fld) [pure # fraction]
71616-7,eutrophils/leuocytes manual cnt fd) (peur [pure# frcton]
71616-7,neutrophils/leukocytes manual cnt fld) (pleur [pure # fraction]
2993-4,deprecated testosterone [mass/volume] in serum or plasma
2993-4,depecate testosterone[mas/volme] in ermor plas
2993-4,deprectd testosterone mss/volume] in serum or plasma
2993-4,deprecated testost ser-mcnc
2993-4,deprecated ser-mcnc testost
2993-4,deprecated testost quan serum-mcnc
2993-4,testosterone (s) [mass/vol]
2993-4,(s) testosterone [mass/vol]
2993-4,chemistry [mass/vol] (s) tstosterne
49747-9,cocaine+benzoylecgonine [presence] in serum or plasma by screen method
49747-9,cocain+enzolecgonine [pesene] in serum r plasma by screen method qual
49747-9,cocaine+benzoylecgonine [presence] in serum or plasma screen by method
49747-9,cocaine+bze serpl ql scn
49747-9,cocine+bze ql serpl sn qualitative
49747-9,ql serpl cocaine+bze qual scn
49747-9,cocaine+benzoylecgonine screen ql
49747-9,cocai+benzoylgonine ql sceen
49747-9,screen ser ccan+bezoylegonine ql
21088-0,azinphos-methyl [mass/volume] in urine
21088-0,urine [mass/volume] in azinphos-methyl
21088-0,in [mass/volume] azinphos-methyl urine
21088-0,azinphos-mehyl ur-mcnc
21088-0,ur-mcnc qnt azinphos-mehyl
21088-0,ur-mcnc azinphos-mehyl
21088-0,azinphos-methyl (u) [mass/vol]
21088-0,azinphos-methyl [mass/vol] (u)
21088-0,(u) azinpho-mthyl [massl]
6781-9,igg [mass/volume] in urine by immunoassay
6781-9,igg [mass/voume] by urin in mmunoasy
6781-9,igg[mass/volume]i urie by imunoassa
6781-9,igg ur ia-mcnc
6781-9,igg ur ia-mcn immune globulin g
6781-9,igg ia-mcnc ur
6781-9,igg ia (u) [mass/vol]
6781-9,igg (u) ia [mass/vol]
6781-9,igg ia [mass/vol] (u)
62607-7,deprecated phenx measure - smoking quit attempts
62607-7,deprected phenx attemps - smokng qit masure
62607-7,atempts masure - smoing quit derecatedphenx
669-2,microscopic observation [identifier] in specimen by macchiavello stain
669-2,microopic bseration [idntifier in specimen by unspecified machiavelo ain
669-2,microscopic observation by in specimen [identifier] macchiavello stain
669-2,macchiavello stn spec
669-2,macchiavello stn spec stains
669-2,macchiavlo stn spec
669-2,microscopic observation macchiavello stain nom (specimen)
669-2,mirocopic observaion machiavello stin (spcimen) om
669-2,microscopc observaton machiavello stain (spemen nom
80981-4,"n,n-dimethylarginine [mass/volume] in serum or plasma"
80981-4,"or level [mass/volume] in serum n,n-dimethylarginine plas"
80981-4,"n,n-imethylarginine [msolume] in seru or plsm"
80981-4,"n,n-dimethylarginine serpl-mcnc"
80981-4,"erl-mcc n,n-dmthylarginine"
80981-4,"serp-mcnc plsm ,n-dimethlarginne"
80981-4,"n,n-dimethylarginine [mass/vol]"
80981-4,"[mass/vol] serpl n,n-dimethylarginine"
80981-4,"n,n-dmethlrginie sr [massvol]"
26606-4,carnosine [moles/volume] in serum or plasma
26606-4,carnosine [moles/volume] in ser or plasma
26606-4,carnosine [moles/volume] in serpl
26606-4,carnosine serpl-scnc
26606-4,serplas carnosineserl-scnc
26606-4,serpl-scnc carnosine
26606-4,carnosine [moles/vol]
26606-4,carnoine [molesvol]
26606-4,[mols/vol] carnosine
20692-0,bacillus cereus [presence] in food by culture fda method
20692-0,baclus food presnce] i qual ceeus bycultue fda method
20692-0,[presece cereus bacillus i infectious disease ood by culture fd methd
20692-0,b cereus food ql cult fda
20692-0,food cereus b presence cult fda pr
20692-0,b cereus food ql cult cult fda fda
20692-0,b. cereus culture fda method ql (food)
20692-0,b. cres clturefda metd ql (fo)
20692-0,b. cereus culte fda method presence(food)
77377-0,human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna [interpretation] in specimen
77377-0,human papilloma virus 16 [interpretation] infectious disease 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna and in specimen
77377-0,human papilloma virus 16 and8 a 31+3+35+39+45+1+5+5+58+59+66+8 dna [inerpretation] n specmen
77377-0,hpv16+18+h risk 12 dna spec-imp
77377-0,hpv16+18+h 12 risk dna spec-imp
77377-0,hpv16+18+h risk 12 hpv16+18+h isk 12 da spec-imp
77377-0,hpv 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (specimen) [interp]
77377-0,hpv 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (specimen) [interp]
77377-0,hpv 16 and 18 an 31+3+35+39+5+51+52+56589+66+68 dna impression/interpretation of study (specmen) [interp]
71759-5,rotavirus rna [identifier] in isolate by naa with probe detection
71759-5,rotavirus rna naa in isolate by [identifier] with probe detection
71759-5,rotirus rna [identifierin ioate by naa ith probe detection
71759-5,rv rna islt naa+probe
71759-5,rv rna naa+probe islt
71759-5,aa+robe islt rvrna
71759-5,rotavirus rna naa+probe nom (isol)
71759-5,rotavirus rna naa+probe nom id (isol)
71759-5,rotavirus (isol) naa+probe nom rna
52817-4,nucleated cells [#/volume] in dialysis fluid by automated count
52817-4,ucleated cells [#/volume] cellularity in dialysis fluid autoated by count
52817-4,nucled cells ont in ialysis fluid b automated quan [#/olume]
52817-4,nuc cell # dial fld auto
52817-4,nuc cell # dial auto fld
52817-4,auto cell # nuc dial fld nuc
52817-4,nucleated cells auto (dial fld) [#/vol]
52817-4,nucleated cells auto (dial fld) quan [#/vol]
52817-4,dialysate nucleated auto cells (dial fld) [#/vol]
98099-5,interleukin 21 [mass/volume] in serum or plasma
98099-5,interleukin 21 plasma in serum or [mass/volume]
98099-5,interleukin21 r n ser pl [mass/voum] pls
98099-5,il-21 serpl-mcnc
98099-5,serpl-mcnc il-21
98099-5,il-21 serpl-mcnc
98099-5,interleukin 21 [mass/vol]
98099-5,interleui 21 [mass/vol]
98099-5,iterleukin [mass/vol] 21
5615-0,cesium [mass/mass] in hair
5615-0,drug/toxicology cesiu [mass/mass] in hair
5615-0,cesim point in time inhai mass/mass]
5615-0,cesium hair-mcnt
5615-0,csiuhair-mcnt quan
5615-0,cesium hair-mcnt
5615-0,cesium (hair) [mass/mass]
5615-0,(hair) cesium point in time [mass/mass]
5615-0,cesium (hai [mass/mass]
90546-3,occupational therapy since the start date of the resident's most recent medicare part a stay [cms assessment]
90546-3,[cms therapy since the start date of the resident's most recent medicare part a stay occupational assessment]
90546-3,occupational therapy since the start date of stay resident's most recent medicare part a the [cms survey assessment]
63319-8,ribonucleoprotein extractable nuclear ab [presence] in cerebral spinal fluid by immunoassay
63319-8,ibonuleoproten extractable nuclear ab autoantibody [presence] in cerebral spinal fld b immunoassy
63319-8,rbnucleotein cerebalspinal nuclar b [ql] in exratale fluid ena by immunoassay
63319-8,ena rnp ab csf ql ia
63319-8,ena rnp ia csf ql ab
63319-8,ernp nuc ab qlia csf
63319-8,ribonucleoprotein extractable nuclear ab ia ql (csf)
63319-8,aby boncloprotein extractable uclear ab i ql (csf)
63319-8,ribonucleoprotein xtratabe nuclear ab ia ql (csf)
13219-1,chlamydia trachomatis g+f+k ab [units/volume] in serum
13219-1,chamyda trachomatis g+fk ab [nits/volume] iserum
13219-1,chlamydia srum g+f+k ab [uits/oume] in tachomatis
13219-1,c trach g+f+k ab ser-acnc
13219-1,antibodies c trach g+f+k ab serum-acnc
13219-1,g+f+k trach c ab ser-acnc id
13219-1,c. trachomatis g+f+k ab qn (s)
13219-1,c. trachomatis g+f+k ab anti qn (s)
13219-1,tachomais g+f+k (s) abqn antibodies
33622-2,isotricarboxylporphyrin [mass/time] in 24 hour stool
33622-2,isotricarboxylporphyrin [mass/time] in hour 24 stool
33622-2,itricaboxylporphrin mass/time] in 24 hour stool
33622-2,isotri-cp 24h stl-mrate
33622-2,st-mrate 24 istri-cp
33622-2,24h isotri-p stl-mrate
33622-2,isotricarboxylporphyrin (24h stl) [mass/time]
33622-2,isotricarboxylporphyrin (24h stl) [mass/time] mass rate
33622-2,isotricarboxylporphyrin (24h st) [mas/time]
14550-8,mumps virus ag [presence] in sputum by immunofluorescence
14550-8,mumps virus ag [presence] point in time in sputum by immunofluorescence
14550-8,mumps viru immufluorescence [presence in putum y ag
14550-8,muv ag spt ql if
14550-8,muv a if ql spt
14550-8,muv ag infectious disease spt presence if
14550-8,muv ag if ql (sput)
14550-8,muv ag if ql (sput) immunoflour
14550-8,muv (sput) if ql ag
35143-7,pca-2 ab [titer] in cerebral spinal fluid
35143-7,pca-2 ab [titer] in cerebral anti spinal fluid
35143-7,spinal ab [titer] in cerebral pca-2 fluid
35143-7,pca-2 ab titr csf
35143-7,aby pca-2 csf titr ab
35143-7,pca-2 ab titr csf cerebrospinal fl
35143-7,pca-2 ab (csf) [titer]
35143-7,[tter] (csf) spinal fld ca-2ab
35143-7,(cerebrospinal fluid) ab pca-2 [titer]
92566-9,planned intervention andor services panel
92566-9,planned andor intervention services panel
92566-9,intervention planned andor services panel
92566-9,planned intervention or services pnl
92566-9,pt planned intervention pnl services or
92566-9,planned intervention or services pnl
83277-4,irf-pai - mobility - discharge performance during 3 day assessment period [cms assessment]
83277-4,irf-pa - mobility centers for medicare and medicaid assessment - discharge performance urng 3 day assessment period [cms ssessment]
83277-4,irf-pai - mobility assessment] discharge performance during 3 day assessment period [cms -
20481-8,deprecated opiates [presence] in meconium by screen method
20481-8,deprecated oiates [presenc] ordinal in meconium by cree metod
20481-8,deprecated opiates [presence] in meconium by screen method
20481-8,deprecated opiates mec ql scn
20481-8,eprectedopiatesmec scn scn ql
20481-8,deprated opiates mec ql scn
20481-8,opiates screen ql (mec)
20481-8,opiate point in time scren ql (mec)
20481-8,opiates screen ql (mec)
22981-5,capripox virus [presence] in tissue by animal inoculation
22981-5,caripox [preence] irus in tissue by animalinocuation
22981-5,capripox virus [presence by microbiology tisue in animal inculatin
22981-5,capripox tiss ql anim inoc
22981-5,tiss capripox ql anim inoc
22981-5,capripox tiss presence anim inoc
22981-5,capripox virus animal inoculation ql (tiss)
22981-5,capripox virus animal goat pox inoculation ql (tiss)
22981-5,caprpox viru animal inoculationql(tiss)
56733-9,pcna extractable nuclear ab [presence] in serum by immunoblot
56733-9,ab immunobl extractable nuclear pcna [presence] in serum by immunoblot
56733-9,pcna extractable nuclear immunoblot [presence] in serum by ana ab
56733-9,ena pcna ab ser ql ib
56733-9,ena pcna nuc bser ql b
56733-9,ser pcna ena ab ena ql ib
56733-9,pcna extractable nuclear ab ib ql (s)
56733-9,pcna extractable nuclear ab abs ib ql (s)
56733-9,pcna extracabl ibql antinuclear antibody ab nuclear (s)
31711-5,adenovirus ag [presence] in stool
31711-5,adenovirus ag faeces [presence] in stool
31711-5,adnovius ag [presene] in stool
31711-5,hadv ag stl ql
31711-5,hadv agstl ql
31711-5,agstql hadv
31711-5,adenovirus ag ql (stl)
31711-5,adenovius ag q stl)
31711-5,adenovirus ag ql (stl)
19297-1,opiates tested for in urine by screen method narrative
19297-1,opiates tested for in urine by screen method narrative
19297-1,ua piates testedor iurine by screen thod narrative
19297-1,opiates tested ur scn
19297-1,ur tested opiate opiates scn
19297-1,piates ur tested cn
19297-1,opiates tested screen nar (u)
19297-1,scrn opiates tested screen (u) nar
19297-1,nar tested screen piates u) scn
25874-9,carnosine [moles/volume] in 24 hour urine
25874-9,in carnosine[moes/volume 24 hou urine
25874-9,24 hours carnosine moles/volume] in 24 hour urne
25874-9,carnosine 24h ur-scnc
25874-9,ua carnosine 24h ur-scnc
25874-9,ur-scnc 24h carnosine
25874-9,carnosine (24h u) [moles/vol]
25874-9,[moles/vol] qnt (24h u) carnosine
25874-9,carnosine (24h u) urn [moles/vol]
18427-5,epstein barr virus early ab [presence] in body fluid
18427-5,epstein arr virus n ab presence] early bodyfluid
18427-5,eptein brr virus earlya [presnce] in bdy fli
18427-5,ebv ea ab fld ql
18427-5,ea ebv ab fld presence
18427-5,ebv ql ab fld ea
18427-5,ebv early ab ql (body fld)
18427-5,ebv (body ql earlab fld)
18427-5,ebv early (body presence ab fld)
105615-9,bordetella pertussis dna [presence] in bronchoalveolar lavage by naa with probe detection
105615-9,bordetella pertussdna esnce] in brnchalvolar lavage bnaa with probe detecton
105615-9,bordetella pertussis dna [ql] wih brochoalveolr lavage by naa in probe detection
105615-9,b pert dna bal ql naa+probe
105615-9,amplif b pert d bal q naa+probe
105615-9,b pert dna presence bal naa+probe
105615-9,b. pertussis dna naa+probe ql (bal)
105615-9,b. pertussis dna naa+probe ql (bal)
105615-9,ligation-activated transcription b. pertussis dna naa+probe presence (bal)
90330-2,porcine parainfluenza virus 1 rna [#/volume] (viral load) in specimen by naa with probe detection
90330-2,[#/volume] parainfluenza virus 1 rna porcine (viral load) in specimen absolute by naa with probe detection
90330-2,porcin aanfluena irus  rna [#/volume] viral load) n specimen by naa ith prbe deecton
90330-2,ppiv1 rna # spec naa+probe
90330-2,piv1 rn# spec naa+probe
90330-2,ppiv1 pi1 rna # spec naa+probe
90330-2,porcine parainfluenza virus 1 rna naa+probe (specimen) [#/vol]
90330-2,porcine parainfluenza dna nucleic acid probe virus 1 rna naa+probe (specimen) [#/vol]
90330-2,porine parainfenzavru 1 nanaa+robe (specien) #/vol]
85966-0,streptococcus pneumoniae danish serotype 1 ab [units/volume] in serum by immunoassay --1st specimen
85966-0,streptococcus pneumoniae danish serotype ab 1 [units/volume] in serum by immunoassay --1st specimen
85966-0,streptococcus pneumoniae danish serotype 1 ab [units/volume] in ser by immunoassay --1st specimen
85966-0,s pneum da 1 ab sp1 ser ia-acnc
85966-0,s pneum da 1 ab quan sp1 ser ia-acnc
85966-0,s pneum da ab sp ia-acnc ser
85966-0,s. pneumoniae danish type 1 ab spec 1 ia qn (s)
85966-0,s. neumonie danh a type1 spec 1ia q ()
85966-0,s. pneumoniae danish type 1 ab sec 1 iaqn (s)
97031-9,follow-up panel spine tango
97031-9,follo-u spietango panel
97031-9,panel follow-up spine tango
97031-9,spine tango
97031-9,tango spine
97031-9,ango spine
45362-1,lymphocyte proliferation stimulated by 0.50 ug pokeweed mitogen in blood
45362-1,lymphcteprolifration simulated by 0.50 ug mitoge pokeweed i quant blood
45362-1,lymphocyte by stimulted proliferation 0.50 ugpokeweed mitogen n bloo bld
45362-1,lpt 0.50 ug pw bld-nrate
45362-1,lpt 0.50 ug pw blood-nrate
45362-1,lpt lpa 0.50 ug pw blood-nrate
45362-1,lymphocyte proliferation stimulated by 0.50 ug pokeweed mitogen (bld) [#/time]
45362-1,count/time lyphocyte prolifertion siuaed by 0.50 ug pokeweed mitogen (bd) [#/time]
45362-1,lymphocyte quan proliferation stimulated by ug 0.50 pokeweed mitogen (bld) [#/time]
32340-2,sodium [moles/volume] in specimen
32340-2,sodium [moles/volume] in specimen
32340-2,sodium [moles/volume] in specimen
32340-2,sodium spec-scnc
32340-2,sodium substance concentration spec-scnc
32340-2,spec-scnc sodium
32340-2,sodium (specimen) [moles/vol]
32340-2,quan (secime) sium [oes/vo]
32340-2,sodium (pecimen) [moles/vol
88827-1,symptoms panel [koos]
88827-1,"symptos koos, jr panel [koos]"
88827-1,[koos] panel symptoms
34689-0,sulfatidase [enzymatic activity/volume] in leukocytes
34689-0,sulfatidase [enzymatic in activity/volume] leukocytes
34689-0,sulfatidse [enzymatic activity/volume in leukocytes
34689-0,sulfatidase wbc-ccnc
34689-0,wbc-ccnc sulfatidase
34689-0,wbc-ccnc random sulfatidase
34689-0,sulfatidase (wbc) [catalytic activity/vol]
34689-0,(wbc) sulfatidase [catalytic activity/vol]
34689-0,sulfatidase (wbc) [catalytic quan activity/vol]
29241-7,mumps virus igg ab [units/volume] in body fluid
29241-7,mump irus igg bod [unit/voume in ab fluid
29241-7,mumps virus igg ab [units/volume] in fluid body
29241-7,muv igg fld-acnc
29241-7,muv fld-acnc igg
29241-7,immunoglobulin g muv igg fld-acnc
29241-7,muv igg qn (body fld)
29241-7,muv igg qn (body body fluid fld)
29241-7,antibodies muv igg qn boy fld)
31635-6,deprecated streptococcus pneumoniae 1 igg ab [units/volume] in serum --1st specimen
31635-6,drecated streptocus pneumoniae 1 igg ab [units/vome] in serum--s specime
31635-6,acute specimen deprecated 1 pneumoniae streptococcus igg ab [units/volume] in serum --1st specimen
31635-6,deprecated s pneum 1 igg sp1 ser-acnc
31635-6,deprecated s peum 1 ig sp1ser-acnc
31635-6,deprecated s pneum pneumococcus 1 igg sp1 ser-acnc
31635-6,s. pneumoniae 1 igg spec 1 qn (s)
31635-6,s. spec igg pneumniae1 1 qn (s)
31635-6,s. 1 pneumoniae igg spec 1 qn (s)
69781-3,2-hydroxyisovalerate [moles/volume] in serum or plasma
69781-3,2-ydroxyisovalerate [moles/volume] in ser or sr plasma
69781-3,2-hydroxyisovalerate [moles/volume] plas serum or in
69781-3,2oh-isovalerate serpl-scnc
69781-3,serpl-scnc 2oh-isovalerate
69781-3,2-hydroxy-isovalerate serpl-scnc 2oh-isovalerae
69781-3,2-hydroxyisovalerate [moles/vol]
69781-3,[moles/vol] 2-hydroxyisovalerate
69781-3,hydroxyisvaleate substance concentration [moles/vo]
32361-8,west nile virus rna [presence] in serum by naa with probe detection
32361-8,west nile virus rna [ql] in serum by naa with probe detection
32361-8,wst nileiru pobe [presence]i seru by a with rna detecin
32361-8,wnv rna ser ql naa+probe
32361-8,wnv naa+probe pcr ser ql rna
32361-8,wnv rnaserql naa+probe
32361-8,west nile virus rna naa+probe ql (s)
32361-8,west nile virus rnanaapro ql (
32361-8,naa+prbe nilevrs rna wes ql ()
86034-6,streptococcus pneumoniae danish serotype 19f ab [mass/volume] in serum --1st specimen
86034-6,streptococcus pneumoniae danish spec serotpe 1f ab [mass/vlume] in specimen --st serum
86034-6,streptocccus pnemoniae dansh erotype 9f b [mass/volm] in srum -1stpecimen level
86034-6,s pn da sero 19f ab sp1 ser-mcnc
86034-6,s 19f da sero pn ab sp1 ser-mcnc pneumonia
86034-6,s pn da sero 19f ab sp1 ser-mcnc autoantibodies
86034-6,s. pneumoniae danish type 19f ab spec 1 (s) [mass/vol]
86034-6,s. pneumoniae danish type aby 19f ab spec 1 (s) [mass/vol]
86034-6,s. pneumoni anish type 19 ab pec 1 (s) [mas/vol]
40616-5,campylobacter sp iga ab [presence] in serum by immunoassay
40616-5,campylobacter iga sp ab [presence] in ser by immunoassay
40616-5,camloacer sp iga ab [presence]in serum meia imunoassy
40616-5,campylobacter iga ser ql ia
40616-5,campylobacter ser iga ql ia
40616-5,campylobacter meia iga ser ia ql
40616-5,campylobacter sp iga ia ql (s)
40616-5,campylobacter sp (s) ia campy ql iga
40616-5,campylobacter sp iga ia ql (s)
73943-3,cannabinoids synthetic [presence] in blood
73943-3,cannabinoids synthetic [presence] in bld
73943-3,cannabinoids ql [presence] synthetic in blood
73943-3,cannabinoids synthetic bld ql
73943-3,cannabinoids drugs synthetic bld presence
73943-3,cannabinoids cannabinoid synthetic bld presence
73943-3,cannabinoids synthetic ql (bld)
73943-3,cannabinois synthtic presence (bl)
73943-3,cannabinoids synthetic ql(bld)
30021-0,borrelia burgdorferi 23kd igm ab [presence] in synovial fluid by immunoblot
30021-0,borrelia burgdorferi 23kd igm ab [presence] in synovial fluid by immunoblot
30021-0,borrelia burgdorferi 23kdigm a [prsence] in ynoval luid by immunoblt
30021-0,b burgdor23kd igm snv ql ib
30021-0,l igm snv anti bbgdr23kd ib
30021-0,b west blt burgdor23kd igm snv ql ib
30021-0,b. burgdorferi 23kd igm ib ql (syn fld)
30021-0,ql burgdorferi 23kd igm ib b. (syn wblot fld)
30021-0,b. west blt burgdorferi 23kd igm fld) ql (syn ib
6769-4,deprecated alkaline phosphatase [enzymatic activity/volume] in serum or plasma
6769-4,depecated akalin phosphatase [enzymati activity/volume] inserum or plas
6769-4,deprecated plasma phosphatase [enzymatic activity/volume] in alk phos serum or alkaline
6769-4,deprecated alp serpl-ccnc
6769-4,eprecatd serpl-ccnc random alp
6769-4,deprcated serp-ccnc alp qnt
6769-4,alp [catalytic activity/vol]
6769-4,activity/vol] [catalytic alkaline phosphatase.total alp
6769-4,alp [catlyic activity/vo]
21419-7,neutrophil cytoplasmic ab pattern [interpretation] in serum by immunofluorescence
21419-7,ab cyoplasmc neutrophil pattern [interpretation] anca i serum by immunoflorescee
21419-7,neutrphil cytoplamic b patter [interprettion] bimmunofluocence ser in
21419-7,anca ab pattern ser if-imp
21419-7,aca ab patter ser if-imp
21419-7,serology anca ab pattern serum if-imp
21419-7,neutrophil cytoplasmic ab pattern if (s) [interp]
21419-7,neutropil ctoplasmia attern impression/interpretation of study if ()[intrp]
21419-7,neutrophil cytoplasmic ab pattern if [interp] (s)
12504-7,hemoglobin.gastrointestinal [presence] in stool --5th specimen
12504-7,--5th [presence] in stool hemoglobin.gastrointestinal specimen
12504-7,in [presence hemglobin.gasrointestinal tool--5th specmen
12504-7,hemoccult sp5 stl ql
12504-7,hemoccult stl sp5 stl ql
12504-7,ql sp5 stl hemoccult
12504-7,hemoglobin.gastrointestinal 5th specimen ql (stl)
12504-7,hemoglobin.gastrointestinal 5th specimen gastroenterology presence (stl)
12504-7,hemogobin.gastrointestinal 5tspecimen q (stl) pr
81688-4,barmah forest virus rna [presence] in blood by naa with probe detection
81688-4,barmah forest virus rna [presence] in bld by naa with probe detection
81688-4,barmah forest virus rna [presence] in blood by probe with naa detection
81688-4,bfv rna bld ql naa+probe
81688-4,bfv naa+probe bld ql tma rna
81688-4,bfv rna probe with ampification bl ql napobe
81688-4,barmah forest virus rna naa+probe ql (bld)
81688-4,barmah forest virus rna naa+probe ql (blood)
81688-4,barmah foest naa+probe rna virus ql (blood)
57968-0,ganglioside gd1a igg ab [presence] in serum
57968-0,gnglioside serum anti ig ab [ql] in gd1a
57968-0,ganglioside gd1a ab igg [presence] in serum
57968-0,gd1a gangl igg ser ql
57968-0,angligg random gd1a er ql
57968-0,gd1a presence igg sr angl
57968-0,ganglioside gd1a igg ql (s)
57968-0,ganglioside igg gd1a ql (s)
57968-0,aglioside d1a ig ql (s
22818-9,avian infectious laryngotracheitis virus ag [presence] in trachea by immunoassay
22818-9,avian infectious laryngotracheitis virus ag [ql] trachea in by immunoassay
22818-9,avian nfectious layngotacheitis vius ag [resece] in rachea by immuoassay
22818-9,ilt ag trachea ql ia
22818-9,presence iltag trache presence ia
22818-9,trachea ag ilt presence ia
22818-9,avian infectious laryngotracheitis virus ag ia ql (trachea)
22818-9,ia infectious laryngotracheitis virus ag avian qual presence (trachea)
22818-9,avian nfectiou pr layngotracheitisvirus ag ia ql(tracea)
17936-6,bacteria # 3 identified in blood by anaerobe culture
17936-6,bactera #3 ideniiedin blood by anaeroe culture
17936-6,identified # 3 bacteria in blood by anaerobe culture
17936-6,bacteria bld anaerobe cult org #3
17936-6,bacteria anarobe bld cult og#3 anaerobe
17936-6,#3 bld anaerobe cult org bacteria
17936-6,bacteria identified # 3 anaer cx nom (bld)
17936-6,bacteria identified nom 3 anaer cx # (bld)
17936-6,bacteria identified # 3 nom cx anaer (bld)
59978-7,venlafaxine [moles/volume] in gastric fluid
59978-7,gastric [moles/volume] in venlafaxine fluid
59978-7,venlafaxine [moes/vole] in gastric fli
59978-7,venlafaxine gast-scnc
59978-7,venlfaxiegast-scnc
59978-7,gast-scnc venlafaxine
59978-7,venlafaxine (gast fld) [moles/vol]
59978-7,vnlaaxine (gast fld) [molesvol]
59978-7,venlafaxine substance concentration (gast fld) [moles/vol]
73179-4,quinidine induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73179-4,quinidine induced platelet igm ser a[presence] in srum or lasma by flow ctometry (fc)
73179-4,quinidine inducedplatelet igm ordinal ab [presene] yomtry serum or lasma by flow in (fc)
73179-4,quinidine ind plt igm serpl ql fc
73179-4,quinidine ind antibodies plt igm serpl ql fc
73179-4,plt ind quinidine igm serpl ql fc serplas
73179-4,quinidine induced platelet igm fc ql
73179-4,uinidineindued platelet igm f ser or plasma ql
73179-4,fc induced platelet igm quinidine ql
53446-1,carnitine palmitoyltransferase 2/citrate synthase [enzymatic activity ratio] in red blood cells
53446-1,carniin palmtoyltransferase 2/citrate ynhase[enymatic ativity rato] in re blood cel
53446-1,carnitie palmityltransferase 2/ctrte synthase [ezymati erythrocytes acivity ratio] n ed bood cells
53446-1,cpt2/cit syn rbc-crto
53446-1,pt2/ctsyn bc-crto
53446-1,carnitine.total cpt2/cit syn rbc-crto
53446-1,carnitine palmitoyltransferase 2/citrate synthase (rbc) [catalytic ratio]
53446-1,(rbc) 2/ctratesynhase canitinepalitoyltransfrase [ctlytic quant atio]
53446-1,caritne palmitoyltransferase 2citrate synthase(rbc) [catlytic ratio]
22608-4,escherichia coli verotoxin 1 ab [titer] in stool
22608-4,schrchia antibody oli verotoxin 1 i [titer] ab stoo
22608-4,escherichi coli stool 1 ab[titer] i erooxi titered
22608-4,e coli vtn1 ab titr stl
22608-4,faeces ecoli vtn1 ab stl itr
22608-4,e vtn1 fecal coli ab itr stl
22608-4,e. coli verotoxin 1 ab (stl) [titer]
22608-4,e. col verotoxin 1 ab stl) [titer]
22608-4,e. coli verotoxin 1 ab (stl) stool = fecal [titer]
86733-3,porcine parvovirus [presence] in specimen by organism specific culture
86733-3,porcine culture [presene]in secien by organism specific parvoviru
86733-3,porcine parvovirus [presence] in specimen specific organism by culture
86733-3,ppv spec ql cult
86733-3,pv spec ql pr cult
86733-3,ppv ql sec cult
86733-3,porcine parvovirus org specific cx ql (specimen)
86733-3,porcine parvovirus org specific cx presence (specimen)
86733-3,orcin arvovrus org specificcx q (pcimen
49813-9,2-hydroxyisocaproate/creatinine [molar ratio] in 24 hour urine
49813-9,2-hydroxyisocaproate/creatinine [molar hour in 24 ratio] urine
49813-9,-hdroxyisocaproate/creatinine [molar atio] urine 24 hour in
49813-9,2oh-isocaproate/creat 24h ur-srto
49813-9,2oh-isocaproate/creat 24h ur-srto
49813-9,24hur-srto 2oh-icaproate/crat
49813-9,2-hydroxyisocaproate/creatinine (24h u) [molar ratio]
49813-9,[molar (24h u) 2-hydroxyisocaproate/creatinine ratio]
49813-9,creat 2-hydroxyisocaproate/creatinine [molar u) (24h ratio]
57708-0,organic acidemias defects newborn screening comment-discussion
57708-0,organic acidemias screening newborn defects fp comment-discussion
57708-0,organic cmnt acidemias defects newborn screening comment-discussion
57708-0,oa defects nbs comment
57708-0,oa defects nbs comment
57708-0,oa defects nbs comment
57708-0,organic acidemias defects newborn screening comment-discussion nar (dbs)
57708-0,acidemias organic blood defects newborn screening comment-discussion nar (dbs)
57708-0,organic comm newborn defects acidemias screening comment-discussion nar (dbs)
80827-9,clostridium botulinum and clostridium baratii toxins gene panel - specimen by naa with probe detection
80827-9,clostridium botulinum and probe polymerase chain reaction baratii toxins gene panel - specimen by naa with clostridium detection
80827-9,lostridium botulinum and lotridiumbaratii toxis gene anel - specimen by naa witprobe sda detecion
80827-9,c bot + c baratii toxn pnl spec naa+prb
80827-9,cbot + cbaratii toxn pnlspec naa+prb
80827-9,c c baratii bot + c baratii toxn pnl spec naa+prb
80827-9,c. botulinum and c. baratii toxins gene panel naa+probe (specimen)
80827-9,baratii botulinum and c c. toxnsgene panenaaprobe miscellaneous (speimen)
80827-9,c. botulinumand c. baratii toxins gene anel na+robe speimen)
44336-6,magnesium/creatinine [mass ratio] in 24 hour urine
44336-6,magnesium/creatinine [mass hour in 24 ratio] urine
44336-6,magnesiumcreatinine hor in 4 [massratio] urne
44336-6,magnesium/creat 24h ur
44336-6,ur 24h magnesium/creat
44336-6,magnesim/ceat ur magnes 24
44336-6,magnesium/creatinine (24h u) [mass ratio]
44336-6,magnesium/creatinine [mass renal u) (24h ratio]
44336-6,quan magnesium/creatinine (24h u ratio] [mass
20416-4,hepatitis c virus rna [#/volume] (viral load) in serum or plasma by naa with probe detection
20416-4,hepatitis c virus rna [#/volume] (viral cnt load) in serum or plasma by naa with probe detection
20416-4,hepatitis c with rna [#/volume] (viral load) in serum or plasma by naa virus probe detection
20416-4,hcv rna # serpl naa+probe
20416-4,hcv rna number concentration (count/vol) naa+probe serpl #
20416-4,hcv rna naa+probe universallaborders serpl #
20416-4,hcv rna naa+probe [#/vol]
20416-4,random cv rna [#/ol] naa+probe
20416-4,pcr naa+probe rna hcv [#/vol]
98957-4,coccidioides immitis igg ab [units/volume] in specimen by immunoassay
98957-4,coccidioide immitisig ab [unitsvolme] in specimen by immnoassay
98957-4,enzyme immunoassay coccidioides immitis in ab [units/volume] igg specimen by immunoassay
98957-4,c immitis igg spec ia-acnc
98957-4,ia-acnc immitis igg spec c
98957-4,igg immitis c spec ia-ac
98957-4,c. immitis igg ia qn (specimen)
98957-4,elfa qn mmitis gg ia c. (seien)
98957-4,c. immitis igg ia qn quan (specimen)
23969-9,echovirus 7 ab [titer] in cerebral spinal fluid
23969-9,in ab [titer] echovrus7 cerebral pinal luid
23969-9,hoviru 7 ab [iter] in cerebral spial fluid
23969-9,ecv7 ab titr csf
23969-9,tircsf ab ecv7
23969-9,cerebrospinal fluid ab dilution factor (titer) titr ecv7
23969-9,echovirus 7 ab (csf) [titer]
23969-9,echovirus 7 (csf) ab [titer]
23969-9,echovirus 7 ab (cerebrospinal fluid) [titer]
100065-2,satisfied with treatment
100065-2,treatment with finding satisfied
100065-2,satisfied treatment ordinal with
100065-2,satisfied with treatment
100065-2,saisfied withtreatment point in time
100065-2,stisfied tratmnt wth
6406-3,flavivirus identified in specimen by organism specific culture
6406-3,flavivirus specimen in identified by organism specific culture
6406-3,flavivirus identified organism specimen by point in time in specific culture
6406-3,flavivirus spec cult
6406-3,flavivirus cult flavi virus spec
6406-3,flavivirus id spc ult
6406-3,flavivirus identified org specific cx nom (specimen)
6406-3,flavivirus identified org specific cx nom (specimen)
6406-3,specific identifid infectiousdisease org flavivirus cx nom (speimen)
17729-5,treponema pallidum igm ab [presence] in serum by immunofluorescence
17729-5,teponema plidum ql igm ab [pesence] in erum by immunfluorescence
17729-5,anticomplement immunofluorescence treponma pallidum igm b[preece] in ser by imunoforescence
17729-5,t pallidum igm ser ql if
17729-5,qlif gm immunoglobulin m se tallidu
17729-5,t palidum igm ser l random if
17729-5,t. pallidum igm if ql (s)
17729-5,t. pallidum ig ordinal ifql s)
17729-5,t. pallidum igm if ql (s)
21489-0,rickettsia (proteus ox19) ab [titer] in serum by latex agglutination
21489-0,rittsia(prus ox19) ab [titer] in by serum latex agluinatin
21489-0,ricketi (proteus aglutintion itr] srum by latex antibodies ox1ab
21489-0,proteus ox19 ab titr ser la
21489-0,prtu b random ox1 titr ser la
21489-0,proteus ox19 ser titr ab lat la
21489-0,rickettsia (proteus ox19) ab la (s) [titer]
21489-0,(proteus rickettsia ox19) ab aby la (s) [titer]
21489-0,rickettsa (proeus ox19 b la (s) [titer] infectious disease
24047-3,alpha fucosidase [enzymatic activity/mass] in leukocytes
24047-3,alpha fucosidas [nzymti activty/mas] in qnt leukcyts
24047-3,pha fcsidase [nzymatic quantitative activity/mass in leuocytes
24047-3,a-fucosidase wbc-ccnt
24047-3,a-fucosdase wbcccnt
24047-3,a-fucosidas wbc-ccnt catalytic content
24047-3,alpha fucosidase (wbc) [catalytic activity/mass]
24047-3,alpha ucosidase (wbc) [catalytic acivit/mass]
24047-3,[catalyti (b) alphafucosidase activity/mss]
23770-1,porcine parvovirus ab [titer] in serum
23770-1,porcine parvovirus in [titer] id ab ser
23770-1,parvovirus titer porcine ab [titer] in serum
23770-1,ppv ab titr ser
23770-1,titr ab ppv ser
23770-1,ppv ab r ttr
23770-1,porcine parvovirus ab (s) [titer]
23770-1,orin arvoirusab dilution factor (s) [titer]
23770-1,porcine parvovus ab s)[tite]
54033-6,rickettsia spotted fever group ag [presence] in tissue by immune stain
54033-6,immunohistochemical stain immune spotted fever group ag [presence] in tissue by rickettsia stain
54033-6,rickettsia spotted fever group ag [presence] in tissue by immune ihc stain
54033-6,rick sf ag tiss ql imstn
54033-6,rick sf ag tiss presence imstn presence
54033-6,rick sf ag ricket tiss presence imstn
54033-6,r. spotted fever group ag immune stain ql (tiss)
54033-6,r. spotted fever group ag immune stain presence (tiss)
54033-6,r. spotted (tiss) group ag immune stain ql fever
93405-9,bacteroides fragilis dna [presence] by naa with probe detection in positive blood culture
93405-9,bacterides 3sr sr fragilis dna [presenceby naa with prbe deection npsitive blood ulture
93405-9,bacteroides frailis dn i by naa wth probe deectio [presnce] positiv blood culture
93405-9,b fragilis dna bld pos ql naa+probe
93405-9,fragilis b dna bld pos ql naa+probe
93405-9,b fragilis dna bld bld pos pos ql aa+probe
93405-9,b. fragilis dna naa+probe ql (pos bld culture)
93405-9,b. deoxyribonucleic acid fragilis dna naa+probe ql (pos bld culture)
93405-9,b. fragilis na naa+probeql (pos ld cultre)
100688-1,parvovirus b19 dna [log #/volume] (viral load) in blood by naa with probe detection
100688-1,parvovirus by dna [log #/volume] (viral load) in blood b19 naa with probe detection
100688-1,(viral b19dna[log#/vlum] prvviu load in bloody naawith proe dtection
100688-1,b19v dna bld naa+probe-log#
100688-1,naa+poe-log# dna bd b19v
100688-1,b19v dna 3 self-sustaining sequence replication bld naa+probe-log#
100688-1,parvovirus b19 dna naa+probe (bld) [log #/vol]
100688-1,(bld) b19 da naarobe parvovirus og#/vol]
100688-1,parovrus b1 #/vol] naa+obe d) [log dna
32578-7,bartonella quintana igm ab [presence] in serum
32578-7,bartonella quintan ig point in time ab [resence]in serm
32578-7,bartonella quintana in ab [presence] igm serum
32578-7,b quintana igm ser ql
32578-7,ser quintaaigm ql
32578-7,ql antibodies quintana igm serum b
32578-7,b. quintana igm ql (s)
32578-7,b. uintana (s) ql igm
32578-7,b. quintna i ql (s)
92133-8,chlamydophila pneumoniae dna [presence] in respiratory system specimen by naa with probe detection
92133-8,chlamydophila pneumoniae dna [ql] with respiratory system specimen by naa in probe detection
92133-8,chlamydophila pneumoniae dna [presence] in respiratory system specimen by naa with probe detection
92133-8,c pneum dna resp ql naa+probe
92133-8,c pneum lcr dna resp ql naa+probe
92133-8,c pneum dna resp lat presence naa+probe
92133-8,c. pneumoniae dna naa+probe ql (respiratory system specimen)
92133-8,c. pneumoniae cpn dna naa+probe ql (respiratory system specimen)
92133-8,c. pneumoniae dna naa+probe presence (respiratory system specimen)
38553-4,narcolepsy associated ag [presence] in serum or plasma
38553-4,narcolepsy associated ag [presence] in ser or plasma
38553-4,narcolepy associated presence] ag in serum or assoc plasma
38553-4,narcolepsy assoc ag serpl ql
38553-4,ql ssocg serum or plasma narcolpsy
38553-4,narcolepsy asso a serpl presence pr
38553-4,narcolepsy associated ag ql
38553-4,g random associted narcolepsy ql
38553-4,assoc narcolepsy ql ag associated
41222-1,yeast [presence] in body fluid by light microscopy
41222-1,yeast [ql] body in fluid by light microscopy
41222-1,yeast [presence] fluid body in by light microscopy
41222-1,yeast fld ql micro
41222-1,fld yast lmicro
41222-1,yeast flql micro
41222-1,yeast lm ql (body fld)
41222-1,"yeast lm ql (body fld) body fluid, unsp"
41222-1,yeast lmql (body fl)
13237-3,epstein barr virus early restricted ab [presence] in serum by immunofluorescence
13237-3,epstein barr restricted early virus autoantibodies ab [presence] in serum by immunofluorescence
13237-3,epstin barr irus ealy restriced ab [ql] in serum by immunofluorescence
13237-3,ebv ea-r ab ser ql if
13237-3,ebv ea-r ab ser ql hhv-4 i
13237-3,ebv ea-r ql ser ab if
13237-3,ebv early restricted ab if ql (s)
13237-3,ev earl retricted ab ql if s)
13237-3,ebv early restricted ab if presence (s)
9691-7,cobalt [mass/volume] in specimen
9691-7,cobalt specimen in [mass/volume]
9691-7,cobalt [mass/volume] in specimen
9691-7,cobalt spec-mcnc
9691-7,miscellaneous cobalt specmcnc
9691-7,cobalt spec-mcnc misc
9691-7,cobalt (specimen) [mass/vol]
9691-7,cobalt mass/vl] misc (spcime)
9691-7,coblt (specimn [mass/vo]
105084-8,trichomonas vaginalis rrna [presence] in specimen
105084-8,qualitative trichomonas vaginalis rrna [ql] in specimen
105084-8,trichomonas vaginalis in tric [presence] rrna specimen
105084-8,t vaginalis rrna spec ql
105084-8,ql vaginais rrna spec t
105084-8,t vaginlis ql spec rrna
105084-8,t. vaginalis rrna ql (specimen)
105084-8,t. vaginalis rrna (specimen) ql
105084-8,qlspcimen) vaginalis rrna t trich
81333-7,thoughts on antibiotics narrative - reported
81333-7,thoughts on random antibiotics narrative - reported
81333-7,thougts on antiiotic narratve -reorted
81333-7,thoughts on antibiotics reported
81333-7,thoughts on antibiotics clin reported
81333-7,point in time reported antibiotics toughtson
92147-8,human coronavirus hku1+oc43 rna [presence] in respiratory system specimen by naa with probe detection
92147-8,human coronavirus hku1+oc43 rna [ql] in respiratory with specimen by naa system probe detection
92147-8,rna coronavirus hku1+oc43 human [presence] in respiratory system specimen by naa with probe detection
92147-8,hcov hku1+oc43 rna resp ql naa+probe
92147-8,hcov naa+probe tma rna resp ql hku1+oc43
92147-8,hcov hk1+oc43 naa+probe res q rna
92147-8,hcov hku1+oc43 rna naa+probe ql (respiratory system specimen)
92147-8,strand displacement amplification hcov hku1+oc43 rna naa+probe ql (respiratory system specimen)
92147-8,hov hk1+oc4 rna naa+probe ystem (resatory ql qbr specimen)
25488-8,nicotinamide [moles/volume] in serum or plasma
25488-8,nicotinamide[moes/olue] sr lasma serm or in
25488-8,nicotinamide pl [moles/volume] serum in or plasma
25488-8,nicotinamide serpl-scnc
25488-8,nicotinamide qnt serpl-scnc
25488-8,serpl-scnc nicotinamide drugs
25488-8,nicotinamide [moles/vol]
25488-8,nictinamide [moles/vol]
25488-8,drugs [oles/vol] ncotnamide
19174-2,choriogonadotropin.beta subunit [units/volume] in amniotic fluid
19174-2,choriogonadotropin.beta amniotic [units/volume] in subunit fluid
19174-2,choriogonadotropin.beta amniotic [units/volume] in subunit fluid
19174-2,b-hcg amn-acnc
19174-2,qnt amn-acnc b-hcg
19174-2,amniotic flu b-hcgamn-cnc
19174-2,hcg.beta subunit qn (amn fld)
19174-2,hcg.bet bunt quant qn fld) (amn
19174-2,fd) subunitqn(am hcg.beta
18240-2,"1,3-dichlorobenzene [mass/volume] in blood"
18240-2,"1,3-dichlorobenzene [mass/volume] bld in"
18240-2,"blood [mass/volume] in 1,3-dichlorobenzee"
18240-2,"1,3dcb bld-mcnc"
18240-2,"3,3'-dichlorobenzidine ,3dcb bld-cnc"
18240-2,"m-phenylenedichloride blood-mcnc 1,3dcb"
18240-2,"1,3-dichlorobenzene (bld) [mass/vol]"
18240-2,"1,3-dclooenzene (blood) mss/vol]"
18240-2,"1,3-d 1,3-dichlorobenzene (bld) [mass/vol]"
2261-6,estrone (e1).unconjugated [mass/volume] in serum or plasma
2261-6,estrone (e1)unconjugated[mass/volume] quant in serum or plasma
2261-6,estrne (e).unconjugated [mass/volume] plasm erum o in
2261-6,u estrone serpl-mcnc
2261-6,u splmcnc chemistry estrone
2261-6,obgyn u estrone serpl-mcnc
2261-6,e1.unconjugated [mass/vol]
2261-6,e1.unconjugted [mass/vol]
2261-6,[masvo] e1.unconjugated
3911-5,penicillin [mass/volume] in serum or plasma
3911-5,[mass/volume] penicillin in serum or plasma
3911-5,penicillin [mass/volume] plasma serum or in
3911-5,penicillin serpl-mcnc
3911-5,serpl-mnc penicilin
3911-5,serpl-mcnc level penicillin
3911-5,penicillin [mass/vol]
3911-5,point in time penicillin [mass/vol]
3911-5,penicillin drug/toxicology [mass/vol]
44924-9,normetanephrine/creatinine [molar ratio] in 24 hour urine
44924-9,in [moar ratio] normetanehrie/creatinine 24 hr urine
44924-9,nrmetnephrinecretinne ua [molar rtio] in24 hur urie
44924-9,normetanephrine/creat 24h ur-srto
44924-9,normetanephrine/creat qnt 24h ur-srto
44924-9,substance ratio normetanephrine/creat 24h ur-srto
44924-9,normetanephrine/creatinine (24h u) [molar ratio]
44924-9,[molar (24h u) normetanephrine/creatinine ratio]
44924-9,[moar (2h u) normetanhrinecreatinine ratio] crea
18291-5,hemoglobin f/hemoglobin.total in blood from newborn
18291-5,hemoglobin f/hemoglobin.total in bld from newborn
18291-5,hemoglobin f/hemoglobin.total in bld from newborn
18291-5,hgb f mfr bld nb
18291-5,hgbf mfr bld nb
18291-5,hgb f mfr nb hematology/cell counts bld
18291-5,hemoglobin f (bld newborn) [mass fraction]
18291-5,hemoglobin f (blood newborn) wb [mass fraction]
18291-5,hemoglobin f(bld nebrn) [mass fraction]
98967-3,nutritional risk screening 2002 panel
98967-3,nutritional risk screening 2002 asymptomatic panel
98967-3,panl ris nutritioal screing 202 anel
98967-3,nrs 2002
98967-3,202 pnl nrs
98967-3,2002 point in time nr
5244-9,measles virus igg ab [units/volume] in serum by immunoassay
5244-9,measle vius in b [uits/olme] igg seum by immunass
5244-9,ab virus igg measles [units/volume] in serum by immunoassay
5244-9,mev igg ser ia-acnc
5244-9,mev ia-acnc ser igg
5244-9,gg mv meia er iaacn
5244-9,mev igg ia qn (s)
5244-9,mev (s) ia qn igg
5244-9,mev igg ia qn (s) point in time
16411-1,aspartate [presence] in urine
16411-1,spartate ur [resene] inurine
16411-1,chemistry aspartate [presence] in urine
16411-1,aspartate ur ql
16411-1,u asartate chemistry ql
16411-1,presence ur aspartate
16411-1,aspartate ql (u)
16411-1,ua aspartate (u) presence
16411-1,aspartte ql aspartic acid (u)
78749-9,glycolate [mass/volume] in serum or plasma by gas chromatography
78749-9,glycolate gas in serum or point in time plasma by [mass/volume] chromatography
78749-9,glycolate [mass/volume] in serum or plasma by gas chromatography
78749-9,glycolate serpl gc-mcnc
78749-9,glycolate serpl plasma gc-mcnc
78749-9,glycolate serum or plasma serpl gc-mcnc
78749-9,glycolate gas chromatography [mass/vol]
78749-9,quantitative glycolate gas chromatography [mass/vol]
78749-9,glycolat gas hromtoaphy [mass/vol]
35170-0,nervonate (c24:1) [moles/volume] in serum or plasma
35170-0,nervonate (c24:1) [moles/volume] in plasma serum or plasma or serum
35170-0,neroae (c2:1 [moles/volume] random n erumorplasma
35170-0,nervonate serpl-scnc
35170-0,nervonae serpl-scn
35170-0,serum or plasma-scnc nervonate
35170-0,nervonate (c24:1) [moles/vol]
35170-0,level nervonat (c24:1) [mles/ol]
35170-0,[moles/vol] (c24:1) nervonate
34910-0,immature basophils [#/volume] in blood
34910-0,immature baophls #/volme]in number concentration (count/vol) blood
34910-0,immature random [#/volume] basophils in blood
34910-0,imm basophils # bld
34910-0,imm basophils # whole blood bld
34910-0,imm basophils # blood
34910-0,immature basophils (bld) [#/vol]
34910-0,count immature basophils (bld) [#/vol]
34910-0,basos basophils immature (blood) [#/vol]
101346-5,"mds v3.0 - rai v1.18.11 - special treatments, procedures, and programs [cms assessment]"
101346-5,"mds v3.0 - rai v1.1811 - special teatments, prodre,nd progrms [cms assesment]"
101346-5,"ds rai v.0 1.18special treatments, panl procdures, and prorams [cms assssmet]"
16606-6,chlorine [mass/volume] in dialysis fluid
16606-6,chlorine fluid qnt in ialysis mass/volume]
16606-6,in [mass/volume] chlorine dialysis fluid
16606-6,chlorine dial fld-mcnc
16606-6,chlorine dial fd-mcnc
16606-6,chlorine drug/toxicology fld-mcnc dial
16606-6,chlorine (dial fld) [mass/vol]
16606-6,chlorine (dial mass concentration fld) [mass/vol]
16606-6,chlrne (dial fld) [mssvol]
90337-7,cryptococcus sp rrna gene [presence] in cerebral spinal fluid by naa with probe detection
90337-7,cryptococcus sp rrna gene spinal fld naa spinal flui by [pesence]nerebal with prbe detection
90337-7,cryptococcus sp rrna gene[resence] infectiousdisease in cerebral detction fluidy aa with probe spia
90337-7,crypt sp rrna gene csf ql naa+probe
90337-7,crypt sp rrna gene csf ql naa+probe
90337-7,crypt csf rrna gene sp ql naa+probe
90337-7,cryptococcus sp rrna naa+probe ql (csf)
90337-7,(csf) sp rrna naa+prob polymerase chain reaction ql cyptococus
90337-7,crypococcus sp rrna naa+probe ql (csf)
73188-5,propoxyphene+acetaminophen induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73188-5,propoxyphene+acetaminophen induced platelet igm ab [presence] in serum abs by plasma or flow cytometry (fc)
73188-5,propoxyphene+acetaminophen induced platelet igm ab [presence] n-acetyl-p-aminophenol in flow or plasma by serum cytometry (fc)
73188-5,propoxyph+apap ind plt igm serpl ql fc
73188-5,propoxyph+apap ind plt fc serpl ql igm
73188-5,ql ind plt igm thrombocytes serpl propoxyph+apap fc
73188-5,propoxyphene+acetaminophen induced platelet igm fc ql
73188-5,tylenol propoxyphene+acetaminophen fc platelet igm induced ql
73188-5,propoxyhene+actaminopeinduced platelt igm fc ql
51984-3,meperidine+normeperidine [presence] in serum or plasma by screen method
51984-3,meperidine+normepridine[resence] or inserum plasma serum or plasma by scren method
51984-3,meperidine+normepeidne [resene] in seum or pasma norpethidine by sceen method
51984-3,meperidine+nor serpl ql scn
51984-3,serpl meeridine+nor ql sc
51984-3,meperidine+nor serpl ql scn addiction
51984-3,meperidine+normeperidine screen ql
51984-3,serum meperidin+nomeperidne l screen
51984-3,meperidinenormperidne scree screen q
95700-1,murray valley encephalitis virus iga ab [presence] in specimen by immunoassay
95700-1,valley murra encephati virus iga ab [presene] n spcimen by immunoasy
95700-1,murray valley encephalitis virus iga ab [presence] in specimen antby by immunoassay
95700-1,mvev iga spec ql ia
95700-1,mvev iga spec presence ia
95700-1,mvev iga spec ia ql
95700-1,mvev iga ia ql (specimen)
95700-1,iga mvev ia ql (specimen)
95700-1,autoantibody mev iaia presence (secimen)
87924-7,rickettsia conorii igg ab [presence] in serum by immunoassay
87924-7,rickettsia conorii y qual ab [prsence] in srum igg immunoasay
87924-7,in conrii igg ab [presenc] rckettia serum by immunoasay
87924-7,r conorii igg ser ql ia
87924-7,r presence igg ser conorii ia
87924-7,presence random conorii igg se r ia
87924-7,r. conorii igg ia ql (s)
87924-7,conorii r. igg ia ql (s)
87924-7,igg conorii r. ia ql (s)
35721-0,chlamydia sp rrna [presence] in anal by probe
35721-0,chlamydia sp rna[ql]i aal chlam brobe
35721-0,hlamydia sp probe [presece] in anal b rrna
35721-0,chlamydia rrna anal ql probe
35721-0,r microbiology hlamyda analq prob
35721-0,probe rrna anal ql chlamydia
35721-0,chlamydia sp rrna probe ql (anal)
35721-0,ql sp rrna prob chlamydi (anal)
35721-0,chlamydia screen sp ql probe rrna (anal)
74743-6,deprecated enterococcus faecalis hsp60 gene [presence] by nucleic acid capture and probe detection in positive blood culture
74743-6,deprecated enterococcus faecalis hsp60 gene [presence] by nucleic acid capture and probe detection in positive bld culture
74743-6,deprecated enterococcus e faecalis faecalis hsp60 gene [presence] by nucleic acid capture and probe detection in positive blood culture
74743-6,deprecated e faecalis hsp60 bld pos ql prb mag
74743-6,deprecad e faecalis hsp60 bld pos ql prb mg
74743-6,depecated  faecalis hsp60 bld pos q rb mag
74743-6,e. faecalis hsp60 gene nucleic acid capture and probe detection ql (pos bld culture)
74743-6,e. fecalis hp60 gene nuclec acd capture ad (obd detection presence random probe culture)
74743-6,e. faecalis hsp60 gene nucleic acid qualitative capture and probe detection ql (pos bld culture)
55371-9,hemoglobin a2+e+o/hemoglobin.total in blood
55371-9,hgb in a2+e+o/hemoglobin.total hemoglobin blood
55371-9,hemoglobi in a2e+o/hemoglobi.total blood
55371-9,hgb a2+e+o mfr bld
55371-9,percent hgb mfr a2+e+o blood
55371-9,hgb a2+e+o hematology/cell counts blood mfr
55371-9,hemoglobin a2+e+o (bld) [mass fraction]
55371-9,hemoglobin a2+e+o (bld) [mass fraction]
55371-9,emoglobin a2+eo(bld) [mss frction]
59844-1,methylenedioxyethylamphetamine [presence] in urine by screen method
59844-1,methylenedioxyethylamphetamine [presence] in by urine screen method
59844-1,methylenedioxyethylamphetamine [presence] in method by screen urine
59844-1,mdea ur ql scn
59844-1,scn ql deaur
59844-1,mdea ur scn ql
59844-1,methylenedioxyethylamphetamine screen ql (u)
59844-1,(u) urn screen ql methylenedioxyethylamphetamine
59844-1,ethyeedioxyethylamphtamine screen (u) q
6465-9,microscopic observation [identifier] in duodenal fluid by trichrome stain
6465-9,microscopic observation [identifier] in trichrome fluid by duodenal stain
6465-9,microsopicobservatio[identifer] in duodnal fludbytrichrom stan
6465-9,tri stn duod fl
6465-9,stn tri duod fl
6465-9,fl gastro stn uod tri
6465-9,microscopic observation trichrome stain nom (duod fld)
6465-9,microscopic observation rihrome stain nom (dod id fld)
6465-9,microscopic observation trichrome stain nom (duod fld)
68932-3,iga.secretory [mass/volume] in tear
68932-3,siga iga.secrory [assvolue] in tea
68932-3,iga.secretry mass/vlume] tear in quant
68932-3,siga tear-mcnc
68932-3,tear-mcnc siga
68932-3,siga tear-cc
68932-3,iga.secretory (tear) [mass/vol]
68932-3,immunoglobulin a iga.secretory (tear) [mass/vol]
68932-3,iga.secreo (tear) [mass/vol]
73076-2,neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73076-2,anti neutrophil g ab [pesece] in seum flow lasma by or cytoery (fc)
73076-2,neutophil im ab [presence inserum orplsmaby fow cytometry(f)
73076-2,neutrophil igm serpl ql fc
73076-2,igm neutrophil serpl ql fc
73076-2,fc igm serum or plasma ql neutrophil
73076-2,neutrophil igm fc ql
73076-2,neutrophil igm presence screen fc
73076-2,neutrophil plsm igm fc presence
77741-7,streptavidin [presence] in serum or plasma by immunoblot
77741-7,streptavidin [presence] in ser or plasma by immunoblot
77741-7,strptavidin [presence] plasmab serumor in immuoblot
77741-7,streptavidin serpl ql ib
77741-7,srpavidin serpl ql ib
77741-7,steptavidin srl ql b riba
77741-7,streptavidin ib ql
77741-7,streptavidin ql ib
77741-7,streavidin ib serplas ql
96748-9,interventions or enabling services provided
96748-9,point in time intvenions or enabling serviesprovided
96748-9,inervetions renabling servicesprovide nominal
96748-9,i/e services provided
96748-9,i/e services typ provided
96748-9,prvid i/eservices
78971-9,phosphomannomutase 1 [enzymatic activity/mass] in fibroblast
78971-9,phohomanomutase 1 [enzytic actiiy/mass] firolast in
78971-9,1 phosphomannomutase [enzymatic activity/mass] in fibroblast
78971-9,pmm1 fib-ccnt
78971-9,fib-ccnt pmm1 chemistry
78971-9,pmm1 fib-ccnt
78971-9,phosphomannomutase 1 (fibroblast) [catalytic activity/mass]
78971-9,phosphomannomutase 1 activity/mass] [catalytic (fibroblast)
78971-9,phosphomannomutase 1 (fibroblast) activity/mass] [catalytic
86695-4,porcine epidemic diarrhea virus ab/positive control in serum by immunoassay
86695-4,porcine epidemc darrha virus a/positiv control in serum b pedv immuoassay
86695-4,seu pidemc darrha virus a/ositive control i pcine byimmunoassay
86695-4,pedv ab/pos cntrl ser ia
86695-4,pedv ab/pos cntrl ia ser
86695-4,pev abos cntrl ser a
86695-4,porcine epidemic diarrhea virus ab/positive control ia (s) [relative ratio]
86695-4,porcine virus diarrhea epidemic ab/positive control ia (s) [relative ratio]
86695-4,porcine abpsitive dirrhea irus eiemic contr ia(s) [relative ratio]
82371-6,norbuprenorphine [presence] in urine by screen method
82371-6,norbuprenorphine [presence] ordinal in urine by screen method
82371-6,norbprophine scren in urine by [presence] method
82371-6,norbuprenorphine ur ql scn
82371-6,ordinal norbprenorhine scn urql
82371-6,norupreorpine drugs of abuse ur ql scn
82371-6,norbuprenorphine screen ql (u)
82371-6,norbuprenorphine screen ql (u) buprenorphine metabolite
82371-6,screen norbuprenorphine ql (u)
804-5,leukocytes [#/volume] in blood by manual count
804-5,leukocyte #/volume in blod by manual ount white blood cells
804-5,blood leuocytes[/volume]in by manual coun cnt
804-5,wbc # bld manual
804-5,bld # wbc manual
804-5,# wbc bld manual
804-5,wbc manual cnt (bld) [#/vol]
804-5,[#/vol] number concentration manual cnt (bld) wbc
804-5,cnt manual wbc (bld) [#/vol]
13712-5,azelate/creatinine [mass ratio] in urine
13712-5,azelate/creatinine [mass urine mass ratio rtio]in
13712-5,azelat/creatnine inurine ratio] [mass mass ratio
13712-5,azelate/creat ur
13712-5,ur azelate/creat
13712-5,ur azlae/creat mcrto
13712-5,azelate/creatinine (u) [mass ratio]
13712-5,drugs (u)[mass zelate/reatinine ratio]
13712-5,azelate/creatinine [mass (u) ratio]
4458-6,valproate [mass] of dose
4458-6,valproate [mass] of dose quantitative
4458-6,divalproex alproae o [mas] dose
4458-6,valproate dose
4458-6,quan valproate dose
4458-6,valproic acid valprate dose
4458-6,valproate (dose) [mass]
4458-6,valproate [mass] (dose)
4458-6,[mass] (dose) depakene valproate
44584-1,iga ab [presence] in serum or plasma
44584-1,iga ab [presence] or aby ser in plasma
44584-1,iga or [presence] in serum ab plasma
44584-1,iga ab serpl ql
44584-1,iga ab serpl antibody ql
44584-1,iga aby ab serpl ql
44584-1,iga ab ql
44584-1,ql ab iga
44584-1,ql serum or plasma igab
2480-2,inositol free [mass/volume] in serum
2480-2,inositol free [mass/volume] in random serum
2480-2,inositol free seru inositol free in [mass/volume]
2480-2,inositol free ser-mcnc
2480-2,inositl free sr-mcnc
2480-2,ser-mcc free iositol
2480-2,inositol free (s) [mass/vol]
2480-2,inositol free qnt [mass/vol] (s)
2480-2,mass/ol] free(s) inosiol
49596-0,uroporphyrinogen decarboxylase [units/volume] in red blood cells
49596-0,cells decarboxylase [units/volume] in red blood uroporphyrinogen
49596-0,in decaroxylase [unit/volume] uoporhyringen red blod cells quan
49596-0,uro-d rbc-acnc
49596-0,rbc-acnc uro-d
49596-0,rbc-acnc uro-d
49596-0,uroporphyrinogen decarboxylase qn (rbc)
49596-0,uroporphyrinogen point in time decarboxylase qn (rbc)
49596-0,uroporphyrinogen decarboxylase qn upg d (rbc)
95561-7,etiocholanolone [z-score] in 24 hour urine
95561-7,etiocholanolone urine in 24 hour [z-score]
95561-7,[z-scor] etiocholanolon in 24our urne
95561-7,etiocholanolone 24h z-score ur
95561-7,etiocholanolone 24h z-score endocrine ur
95561-7,tiocholanoone 24h zscre ur
95561-7,etiocholanolone (24h u) [z-score]
95561-7,etiochoaoloe (4h ) [z-score]
95561-7,etiocholanolone quan [z-score] u) (24h
43622-0,aconitate [presence] in 24 hour urine
43622-0,aconitate [presence] in qual 24 hour urine
43622-0,aconitate [presence] hour 24 in aconitic acid urine
43622-0,aconitate 24h ur ql
43622-0,aconitate qual 24h ur presence
43622-0,aconitate 24h ur ql urn
43622-0,aconitate ql (24h u)
43622-0,aconitate ql ur (24h u)
43622-0,aconitate l 24h u)
103193-9,mycobacterium ulcerans dna [presence] in wound by naa with probe detection
103193-9,mycobacterium ulcerans dna [presence] in wound by naa with probe sda detection
103193-9,mcobacerum ulcerans dna[pesnce] acid fast bacilli in ound bynaa with probe detectin
103193-9,mycobact ulcerans dna wnd ql naa+probe
103193-9,mycobact ulcerans dna wnd ql naa+probe
103193-9,mycobact naa+probe wnd ql acid fast bacilli ulceransdna
103193-9,mycobacterium ulcerans dna naa+probe ql (wound)
103193-9,mycobacterium dna ulcerans naa+probe ql (wound) ligase chain reaction
103193-9,mycobacterium ulcerans dna qual naa+probe ql (wound)
29945-3,alpha 1 globulin [presence] in 24 hour urine by electrophoresis
29945-3,alpha1 globulin [rsne glob% n 24 our uine by electrophoresis
29945-3,1globulin pr alpha [preence] i 24hour urie b electrohoresis
29945-3,alpha1 glob 24h ur ql elph
29945-3,alpha1 glob qlelph ur 24h
29945-3,alpha1glob qllph ur 24h
29945-3,alpha 1 globulin elph ql (24h u)
29945-3,alpha elph electrophrs globulin 1 ql (24h u)
29945-3,presence(24h 1 globulin eph alph )
2426-5,homocarnosine [mass/volume] in cerebral spinal fluid
2426-5,homocarnosine [mass/volume n cerebral snal flid
2426-5,homocarnosine [mass/vlume] in flid spinal crebral
2426-5,homocarnosine csf-mcnc
2426-5,omocarnosnecf-mcnc
2426-5,cf-mcn homornosine
2426-5,homocarnosine (csf) [mass/vol]
2426-5,(cerebrospinal fluid homcanosin [masvol] quan
2426-5,omcanosie (cf) [mas/vol]
22461-8,reagin ab [presence] in serum
22461-8,ab reagin [pesence] iserum qual
22461-8,reagin serum [presence] in ab
22461-8,reagin ab ser ql
22461-8,presence ab ser regin
22461-8,reagn ab ser ql
22461-8,reagin ab ql (s)
22461-8,(s) ab ql reagin
22461-8,reagin ab (s) ql
73577-9,anion gap in arterial cord blood by calculated.4ions
73577-9,quan anion gap in arterial cord blood by calculated.4ions
73577-9,anion gap in rterial ord blod by clculated.ions calculation
73577-9,anion gap bldcoa calculated.4ions-scnc
73577-9,calculated.4ions-scnc gap bldcoa level anion
73577-9,anion qnt bldcoa gap calculated.4ions-scnc
73577-9,anion gap calculated.4ions (bldcoa) [moles/vol]
73577-9,[moles/vol] calculated4ons (bldcoa) aniongap
73577-9,anion gap calculated.4ions random (bldcoa) [moles/vol]
19048-8,nucleated erythrocytes/leukocytes [ratio] in blood
19048-8,nuclateerythcytes/leukocyte rato] inblood
19048-8,nucleated erythrocytes/leukocytes [ratio] in blood
19048-8,nrbc bld-rto
19048-8,blood-rto quantitative nrbc
19048-8,leukocyte blood-rto nrbc
19048-8,nucleated rbc/leukocytes (bld) [ratio]
19048-8,quan nucleated rbc/leukocytes [ratio] (bld)
19048-8,rbc/leukocytes nuclated (bld)[ratio]
28042-0,organophosphate pesticides [mass/volume] in urine by screen method
28042-0,in organopophaeesticides[mass/olume] urine mass concentration by screenmethod
28042-0,organophosphate pesticids massvolume] in uine creenmethod by
28042-0,op pesticides ur scn-mcnc
28042-0,cmcnc pesticides quant r op
28042-0,quantitative op pesticides ur scn-mcnc
28042-0,organophosphate pesticides screen (u) [mass/vol]
28042-0,organophosphate pesticides screen (u) mass concentration [mass/vol]
28042-0,op pesticides pesticides organophosphate scren (u[mass/vol]
81209-9,clomipramine and norclomipramine panel - urine
81209-9,clomipramine norclomipraine and pael anofranil urine
81209-9,cloipramin norlomipraminpane and urine
81209-9,clomipramine+nor pnl ur
81209-9,pnl clomipramine+nor ur
81209-9,clomipramine+nor pnl ur
81209-9,clomipramine and norclomipramine panel (u)
81209-9,clomipramine clomipramine+nor pnl and norclomipramine panel (u)
81209-9,clomipramine and norclomipramine panel drugs (u)
79313-3,gamma butyrobetaine/trimethyllysine [molar ratio] in urine
79313-3,gmma btyrobetaine/trimetyllysine ratio]nurin [moar
79313-3,gamma butyrobetaine/trimethyllysine [molar ratio] scrto in urine
79313-3,g-butyrobetaine/tml ur-srto
79313-3,ur-srto g-butyrobetaine/tml
79313-3,butyroetaine/tml tmlhe r-srto
79313-3,gamma butyrobetaine/trimethyllysine (u) [molar ratio]
79313-3,butyrobetaine/trimethyllysine ua gamma (u) [molaratio
79313-3,gamma butyobeaine/rimethllysine [molar () rtio]
9432-6,isobutyl acetate [mass/volume] in specimen
9432-6,isobutyl acetate specimen point in time in [mass/volume]
9432-6,in acetate [ass/vlume] isobutyl specmen
9432-6,isobutyl acetate spec-mcnc
9432-6,acetatespecmcnc isobuty
9432-6,isbutyl spec-mcnc acetate
9432-6,isobutyl acetate (specimen) [mass/vol]
9432-6,isobutyl [mass/vol] (specimen) acetate
9432-6,acetate isobutyl (specimen) point in time [mass/vol]
24304-8,coxsackievirus a7 ab [titer] in serum --1st specimen
24304-8,coxsackievirus a7 [titer] ab inserum --1st speimen
24304-8,coxsacievirus7 b in [tier] serum --1st pecimen
24304-8,cv a7 ab sp1 titr ser
24304-8,cv a7 ab sp1 titr ser autoantibodies
24304-8,ser a7 ab sp1 abs titr cv
24304-8,coxsackievirus a7 ab spec 1 (s) [titer]
24304-8,coackievius a7 ab spec1 (s) [titer]
24304-8,coxsackievirus (s) serum ab spec 1 a7 [titer]
75237-8,erythrocytes [#/area] in synovial fluid by microscopy high power field
75237-8,erythrocytes [#/area] hh snovial joint fluid fluidby miroscopy in power fild
75237-8,eythrocyte [#/area n synovialfluid by microscopy high power fild
75237-8,rbc #/area snv hpf
75237-8,rb lm #/ara snvhpf
75237-8,rbc #/areasnv pf
75237-8,rbc lm.hpf (syn fld) [#/area]
75237-8,lm.hpf rbc (syn fld) joint fld [#/area]
75237-8,#/ara] (yn ld) rbclm.hpf
62919-6,deprecated phenx measure - disinhibiting behaviors - impulsivity
62919-6,deprecated phenx measure impulsivity disinhibiting behaviors - -
62919-6,depecatd henx measure beaior -isinhiiting -plsivity
105616-7,bordetella parapertussis dna [presence] in bronchoalveolar lavage by naa with probe detection
105616-7,boretella parapetusis dna lavage b parapertussis in broncholveolr [presence by naa with pobe dtection
105616-7,bordtell parapetusis dna prsence] in brnchoalvola lavage b aa th probe detection
105616-7,b parapert dna bal ql naa+probe
105616-7,b parapert dna amplif bal ql naa+probe
105616-7,b araprt dna bal qlnaa+robe dna probe
105616-7,b. parapertussis dna naa+probe ql (bal)
105616-7,b. parapertussis dna (bal) ql naa+probe
105616-7,b. microbiology parapertussis dna naa+probe ql (bal)
12406-5,nadolol [mass/volume] in serum or plasma
12406-5,nadolol plas in serum or [mass/volume]
12406-5,nadolol [mass/volume] in plasma or serum
12406-5,nadolol serpl-mcnc
12406-5,nadolol serpl-mcnc ser or plasma
12406-5,pl serpl-mcnc ndolol
12406-5,nadolol [mass/vol]
12406-5,[ass/vol] nadll
12406-5,nolol[mass/vol]
47620-0,glucose [moles/volume] in stool
47620-0,glucose [moles/volume] in stool
47620-0,glucose [moles/volume] in stool
47620-0,glucose stl-scnc
47620-0,ucose stl-scnc
47620-0,stl-scnc level glucose
47620-0,glucose (stl) [moles/vol]
47620-0,gluose (stl) [moles/vol] feces
47620-0,fecal glucose [mols/vol] (stl)
81801-3,16-alpha hydroxydehydroepiandrosterone/creatinine [molar ratio] in urine
81801-3,hdroxydehydepiandosterone/creatinine 16-alpha [molar ratio] i ua urine
81801-3,quantitative 16-alpha hydroxydehydroepiandrosterone/creatinine [molar ratio] in urine
81801-3,16a oh-dhea/creat ur-srto
81801-3,r-sto oh-dhea/creat 16a
81801-3,r-srto 16aoh-hea/creat substance concentration ratio
81801-3,16-alpha hydroxydehydroepiandrosterone/creatinine (u) [molar ratio]
81801-3,16-apha hydroxydehdoeiandroserone/creatnine raio] (u)[molar
81801-3,hydroxydehydroepiandrosterone/creatinine 16-alpha substance concentration ratio (u) [molar ratio]
49821-2,3-hydroxyglutarate/creatinine [molar ratio] in 24 hour urine
49821-2,3-hydroxyglutaratecretinine [molar hou in 24 ratio] urine
49821-2,3-hydroxyglutarate/creatinine [molar ratio] in 24 hour urine
49821-2,3oh-glutarate/creat 24h ur-srto
49821-2,24h 3oh-glutarate/creat ur-srto
49821-2,3oh-glutarate/creat 24h ur-srto quant
49821-2,3-hydroxyglutarate/creatinine (24h u) [molar ratio]
49821-2,3-hydroxyglutarate/creatinine (24hu) ratio] [olar
49821-2,3-hydroxyglutarate/creatinine (24h u) ratio] [molar
104782-8,order start date
104782-8,quan order start date
104782-8,order start date
104782-8,order start date
104782-8,date start order
104782-8,pt order start date
17790-7,leukocytes left shift [presence] in blood by automated count
17790-7,leukocytes left automated [preence] in bood by shift pr cont
17790-7,leukocytes leftht presece in bld by pr automated count
17790-7,wbc left shift bld ql auto
17790-7,wbc ft shiftbld ql uto
17790-7,wbc auto bld presence lftshift
17790-7,wbc left shift auto ql (bld)
17790-7,wbc left shift whole blood auto presence (bld)
17790-7,wbc left shiftauto ql (bld)
3601-2,etafedrine [mass/time] in 24 hour urine
3601-2,etafedrine [mass/time] in 24 hour ua urine
3601-2,etfedine hor 24 [mass/tie]i urin
3601-2,etafedrine 24h ur-mrate
3601-2,ur-mrate 24h etafedrine
3601-2,24h etafedrine ur-mrate
3601-2,etafedrine (24h u) [mass/time]
3601-2,tafedrine (24h u)[mass/time]
3601-2,u) (24h etaedrine 24hr [mss/time]
30030-1,iron [mass/volume] in 24 hour urine
30030-1,iron[mas/volume] in 24 quantitative hour urine
30030-1,iron [mass/volume] in urine hour 24
30030-1,iron 24h ur-mcnc
30030-1,iron level 24h ur-mcnc
30030-1,iron 4h u-mcnc
30030-1,iron (24h u) [mass/vol]
30030-1,u) (24h ron [mass/vol]
30030-1,iro (24hu) [mass/vol] ur
23507-7,trypanosoma brucei dna [presence] in blood by naa with probe detection
23507-7,trypanosoma blood dna [presence] in brucei by naa with probe detection
23507-7,trypaosoma brucei dna[presenc] inblodby naa ith probe detection
23507-7,t brucei dna bld ql naa+probe
23507-7,t naa+probe brucei ql bld dna naa+probe
23507-7,t brucei ql blood 3 self-sustaining sequence replication dna naa+probe
23507-7,t. brucei dna naa+probe ql (bld)
23507-7,dna brucei t. naa+probe ql tma (blood)
23507-7,(bld) deoxyribonucleic acid brucei dna naa+probe ql t.
53390-1,trichothecene igg ab [units/volume] in serum
53390-1,abs trichothecene igg ab [units/volume] in serum
53390-1,trichothecene serum ab [units/volume] in igg
53390-1,trichothecene igg ser-acnc
53390-1,seracnc gg trichothecene
53390-1,trichothecene quant igg serum-acnc
53390-1,trichothecene igg qn (s)
53390-1,trichothecene qn igg (s) random
53390-1,(s) iggq triothecene
31910-3,neisseria meningitidis serogroups a+c+w135+y ag [presence] in specimen
31910-3,specimen meningitidis erogroups a+c+13+y ag [presence] in neisseria
31910-3,neisseia spcimen infectious disease a+c+w135+y ag[ql] in eningitdissrgrous
31910-3,n men sg a+c+w135+y ag spec ql
31910-3,sg men n a+c+w135+y ag pc qualitative q
31910-3,men n sga+c+w135+y ag spec qual ql
31910-3,n. meningitidis a+c+w135+y ag ql (specimen)
31910-3,n. meningitidis a+c+w135+y ag ql (specimen)
31910-3,n. meningitidis ag a+c+w135+y ql (specimen)
10894-4,aspergillus niger ab [presence] in serum by immune diffusion (id)
10894-4,aspegillusnier byiune [presence] in seru ab diffsion antibody (id)
10894-4,sperglls nier ab preence] in ser byimmune diffusion(id
10894-4,a niger ab ser ql id
10894-4,a niger ab ser id ql
10894-4,a niger ab serum ql id
10894-4,a. niger ab immune diff ql (s)
10894-4,a. niger immune ab diff aspergil ql (s)
10894-4,a. niger ab immune diff presence (s)
17423-5,deprecated parvovirus b19 igm ab [presence] in serum
17423-5,deprecated parvovirus in igm ab [presence] b19 serum
17423-5,deprecated parvovirus [presence] igm ab b19 in serum
17423-5,deprecated b19v igm ser ql
17423-5,infectious disease deprecated igm b19v ser ql
17423-5,ser b19v igm deprecated ql ordinal
17423-5,parvovirus b19 igm ql (s)
17423-5,parvovirus presence ig b19 (s)
17423-5,parvovirus b19 b19 virus igm ql (s)
641-1,microscopic observation [identifier] in gastric fluid by acid fast stain.kinyoun modified
641-1,microscpicoservation [identifie] in gastric fluid by acid fat stai.inyoun microbiology modified
641-1,microscopic observation [identifier] by gastric fluid in acid fast stain.kinyoun modified
641-1,acid fast mod kiny stn gast
641-1,aid md fast iny gastric contents sast
641-1,acid fast mod stn kiny gast
641-1,microscopic observation acid fast stain.kinyoun modified nom (gast fld)
641-1,microscopic observation acid modified stain.kinyoun fast nom (gast fld)
641-1,mirocopic observaionacid fast stin.kinyoun modified no (gast fld)
35441-5,hiv 1 gp120 ab [presence] in saliva (oral fluid) by immunoblot
35441-5,hiv by gp120 ab [ql] in saliva (oral fluid) 1 immunoblot
35441-5,hiv west blot 1 gp120 ab[presencein saliva(oal fluid) by immunblot
35441-5,hiv1 gp120 ab sal ql ib
35441-5,hiv1 sal ab antby gp120 qlib
35441-5,hiv1 gp120 ab sal presence ib
35441-5,hiv 1 gp120 ab ib ql (sal)
35441-5,hiv ab gp120 1 ib ql (sal)
35441-5,hiv 1 autoantibodies gp120 ab ib ql (sal)
31562-2,pm-scl extractable nuclear ab [units/volume] in serum
31562-2,scleroderma pmscl b nuclear extractable [units/volue] in srum
31562-2,pm-scl extractable nuclear ab antibodies [units/volume] in ser
31562-2,ena pm/scl ab ser-acnc
31562-2,scleroderma ena pm/scl ab se-an
31562-2,ena ab pm/sl ser-acnc
31562-2,pm-scl extractable nuclear ab qn (s)
31562-2,p-scl extractble nclear ab qn (s)
31562-2,qn autoantibodies extractable nuclear ab pm-scl (s)
54143-3,gardnerella vaginalis dna [presence] in vaginal fluid by probe with signal amplification
54143-3,gardnerella vaginalis dna [presence] in vaginal fluid by probe with signal amplification
54143-3,gardnerella vaginalis dna [ql] in g vaginalis vaginal fluid by probe with signal amplification
54143-3,g vaginalis dna vag ql probe+sig amp
54143-3,g vaginalis dna vag ql probe+sig amp
54143-3,g vaginalis amp vag ql probe+sig dna
54143-3,g. vaginalis dna probe+sig amp ql (vag fld)
54143-3,l vaginaidn probe+igamp g (vag fld)
54143-3,g. vaginalis dna probe+sig amp gyn ql (vag fld)
97148-1,guanidinoacetate [moles/volume] in urine
97148-1,guanidinoacetate [moles/voume] n urin
97148-1,guanidinactate [moles/volume] in urie
97148-1,guanidinoacetate ur-scnc
97148-1,guanidinoacetate ur-scnc gaa
97148-1,gunidnocetate ur-scn
97148-1,guanidinoacetate (u) [moles/vol]
97148-1,(u) guanidinoacetate [moles/vol] random
97148-1,guanidinoacetate (u) [moes/vol]
90289-0,norovirus genogroup ii rna [presence] in vomitus by naa with probe detection
90289-0,norovirus genogroup ii rna [ql] in vomitus naa by with probe detection
90289-0,norovirus genogroup ii rna [presence] in naa by vomitus with probe detection
90289-0,norovirus gii rna vom ql naa+probe
90289-0,norovirus gii rna naa+probe presence vom
90289-0,norovrus gii rna ql vom naa+probe
90289-0,norovirus genogroup ii rna naa+probe ql (vomitus)
90289-0,(vomitus) enogroup ii rna na+poe ql norovius
90289-0,nroius enogroup i rna naarobe q (vomitus)
105040-0,hemoglobin [mass/volume] in mixed venous blood by calculation
105040-0,hemoglobin [mass/voume] level in mixed venousblood by caculati
105040-0,hemoglobin [mass/volume] in mixed venous level blood by calculation
105040-0,hgb bldmv calc-mcnc
105040-0,gb bldv calc-mcn
105040-0,calc-mcnc bldmv bld mixed venous hgb
105040-0,hemoglobin calc (bldmv) [mass/vol]
105040-0,hemoglobin calc bld mixed venous (bldmv) [mass/vol]
105040-0,hemoglbincalc (bdmv) [mass/vol] haemoglobin
106809-7,igg subclass 1 [mass/volume] in cord blood by nephelometry
106809-7,igg by 1[mss/volume] in cord bod subclass nephometr
106809-7,igg subclass 1 [mass/volume] in cord blood by nephelometry
106809-7,igg1 bldco neph-mcnc
106809-7,cord (umbilical) blood igg1 bldco neph-mcnc
106809-7,bldco igg1 neph-mcnc
106809-7,igg subclass 1 nephelometry (bldco) [mass/vol]
106809-7,[mass/l] 1 nephelometry (bdo) iggsubclss
106809-7,iggsubclss  nphelomety (bldco) [mass/vol]
86685-5,oral/dental status during assessment period [cms assessment]
86685-5,oral/dental status durin assessment peiod [cms asssment]
86685-5,orl/dentalstats during [cmsassessmet] period asessmen
72730-5,mitragynine/creatinine [mass ratio] in urine
72730-5,mitragynine/creatinine [mass ratio] in urine
72730-5,mtragynin/cratinie [mass rati] ua in urine
72730-5,mitragynine/creat ur
72730-5,ur ur mtragyin/crat
72730-5,ur mitragynine/creat
72730-5,mitragynine/creatinine (u) [mass ratio]
72730-5,mcrto mitragynine/creatinine [mass (u) ratio]
72730-5,[mass (u) mitragynine/creatinine ratio]
46128-5,tissue transglutaminase iga ab [units/volume] in serum by immunoassay
46128-5,tissue transglutamnase iga ab serology [uits/volue] inserum by immunoassay
46128-5,tissue transglutaminase iga ab [units/volume] by serum in immunoassay
46128-5,ttg iga ser ia-acnc
46128-5,ttg igaser ia-acnc gi
46128-5,ttg iga ser ia-acnc quant
46128-5,ttg iga ia qn (s)
46128-5,ttg iga ia qn (s) eia
46128-5,ttg iga ia qn s) arbitrary concentration
2232-7,epinephrine [mass/time] in 24 hour urine
2232-7,[mass/time pinphine in 24 hour quant urine
2232-7,pinehrine [msstime] in hor 24 urine
2232-7,epineph 24h ur-mrate
2232-7,epineph 24h ur-mrate
2232-7,epineph quant 24h ur-mrate
2232-7,epinephrine (24h u) [mass/time]
2232-7,epinephrine (24h u) [mass/time] quant
2232-7,epinephrine u) (24 [mass/time]
106578-8,monkeypox virus clade ia dna [presence] in specimen by naa with probe detection
106578-8,monkeypox virus clade ia dna [presence] in specimen by naa with probe detection
106578-8,monkeypox virus clade ia dna [presence] in specimen by qualitative naa with probe detection
106578-8,mvpx clade ia dna spec ql naa+probe
106578-8,mvpx spec ia dna clade ql naa+probe
106578-8,mvpx clade ia dna probe dna spec presence naa+probe
106578-8,monkeypox virus clade ia dna naa+probe ql (spec)
106578-8,monkeypox ia probe with ampification clade virus dna naa+probe presence (spec)
106578-8,monkeypox ius clade dna nucleic acid probe ia dna naa+probe presence (spec)
14611-8,nuclear ab pattern [interpretation] in serum
14611-8,nuclear serum pattern [interpretation] in ab
14611-8,nuclear ab pattern interpretation]in serum
14611-8,ana pat ser-imp
14611-8,ana ser-imp pat
14611-8,ana pat ser-imp
14611-8,nuclear ab pattern (s) [interp]
14611-8,nulear ab (s) pattern [nter]
14611-8,point in time nucer a [nterp] (s) pattern
53988-2,atypic speckled nuclear ab pattern [presence] in serum by immunofluorescence
53988-2,tpic specklednucar ab patern [presece] b srum in time resolved fluorescence immunofluosence
53988-2,atypic na speckled nuclear ab pattern [presence] in ser by immunofluorescence
53988-2,ana atypic speckled ser ql if
53988-2,ana atypic speckled if ql ser
53988-2,speckled atypic serology ana ser presence if
53988-2,atypic speckled nuclear ab pattern if ql (s)
53988-2,(s speckled ucr ab pattrn if presence atypc immunofluor
53988-2,atypic ql nuclear fluorescent antibody ab pattern if speckled (s)
73151-3,simethicone induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73151-3,or induced thrombocytes platelet igg ab [presence] in serum simethicone plasma by flow cytometry (fc)
73151-3,simethicone (fc) platelet igg ab [pesence] in serum or plaa by flow ytometry iued
73151-3,simethicone ind plt igg serpl ql fc
73151-3,simethicone qlfc plt igg serpl ind
73151-3,fc ind plt igg serum or plasma ql simethicone
73151-3,simethicone induced platelet igg fc ql
73151-3,simthicone pl induced lateletigg fc presence
73151-3,simethicone induce pltelet ig ql fc ql
2269-9,complement factor b [mass/volume] in serum or plasma
2269-9,complement factor b [mass/volume] in serum or plasma cvfbb
2269-9,complement facto plsm b [mass/volume] in serum or plaa
2269-9,comp fact b serpl-mcnc
2269-9,comp serpl-mcnc b fact
2269-9,comp fact b serp-mcnc
2269-9,complement factor b [mass/vol]
2269-9,complement factor b [mass/vol]
2269-9,compleen comp factorb [mss/vol]
29737-4,rickettsia rickettsii ab [titer] in serum
29737-4,rickettsia rickettsii ab [titer] in serum
29737-4,rickettsia in ab rocky mountain spotted fever [titer] rickettsii serum
29737-4,r rickettsi ab titr ser
29737-4,rrickettsi microbiology b titr sr
29737-4,r ricketsi ab tt serum titre
29737-4,r. rickettsii ab (s) [titer]
29737-4,r. rettsii dilution factor (titer) ab (s) [tter]
29737-4,(s) rickettsi dilution factor ab r. tter]
18439-0,butyrylcarnitine (c4) [mass/volume] in serum or plasma
18439-0,quan plasma (c4) mass/volume] in serum r utyrylcarnitie
18439-0,butrlcarnitine srum [masvolme] in (c4) or plas serplas
18439-0,butyrylcarn serpl-mcnc
18439-0,sr serpl-mcnc butyrylcarn
18439-0,butyrylcarn qnt serum or plasma-mcn
18439-0,butyrylcarnitine (c4) [mass/vol]
18439-0,[mass/vol] (c4) butyrylcarnitine
18439-0,(c4) butyrylcarnitine [mass/vol]
42222-0,manganese [moles/time] in 24 hour urine
42222-0,manganese [moestime] in 2 hur urine
42222-0,manganese 24 in [moles/time] hour urine
42222-0,manganese 24h ur-srate
42222-0,ur ur-rate 24h manganese
42222-0,manganese drug/toxicology 24h u-srae
42222-0,manganese (24h u) [moles/time]
42222-0,manganese (24h u) [moles/time] drugs
42222-0,mnganes [moles/time] u) (2h
33253-6,nuclear ab [titer] in serum by hep2 substrate
33253-6,nuclar ab anti [titer in erum byhep2 substrte
33253-6,nuclear substrate [titer] in serum by hep2 ab titered
33253-6,ana titr ser hep2 subst
33253-6,ana titr hep2 ser subst
33253-6,ana titr hep2 ser subst ttr
33253-6,nuclear ab hep2 substrate (s) [titer]
33253-6,nuclear anf ab ep2 substrate (s) [tter]
33253-6,nuclear ab h2 ubtrate (s) titre [titer]
35505-7,lipoprotein.beta.subparticle [type] in serum or plasma
35505-7,lipoprteinbeta.subparticl [type]in serum orlasma
35505-7,lipprotein.beta.subparticle insrum [type] or plsma plasma
35505-7,ldl serpl
35505-7,serum or plasma ldl
35505-7,serpl ldl
35505-7,lipoprotein.beta.subparticle nom
35505-7,nom lipoproeinbeta.subpartcle random
35505-7,lipoproein.beta.subpticle nom
92605-5,promis short form - upper extremity 7a - version 2.0
92605-5,pois sort form -per extremiy 7a - vsion 2.0
92605-5,pomi short fom survey.promis - uper - 7a extremity version2.0
31760-2,candida sp ag [units/volume] in serum
31760-2,infectious disease in sp ag [units/volume] candida ser
31760-2,candida sp ag [units/volume] in ser
31760-2,candida ag ser-acnc
31760-2,ser-acnc id ag candida
31760-2,ag sr candida ser-acnc
31760-2,candida sp ag qn (s)
31760-2,candida infectious disease sp ag (s) qn
31760-2,candida sp (s) qn microbiology ag
71767-8,ebola virus igg ab [titer] in serum by immunoassay
71767-8,ebola virus igg ab by in serum [titer] immunoassay
71767-8,ebola virusgg b [titer] in serum by immnoassay
71767-8,ebov igg titr ser ia
71767-8,ebv igg titr serum ia autoantibody
71767-8,ebov ser titr igg ia
71767-8,ebola virus igg ia (s) [titer]
71767-8,ebola (s) ebo ia viusigg [titer]
71767-8,igga vru ebola s) titer]
13770-3,malate/creatinine [mass ratio] in urine
13770-3,maate/creatinine quant [mass ratio] in urie
13770-3,mass ratio malate/creaiine [mas ratio] in urine
13770-3,malate/creat ur
13770-3,mlate/creat 
13770-3,ur malate/creat
13770-3,malate/creatinine (u) [mass ratio]
13770-3,malatecreatinie (u) point in time [mass rtio]
13770-3,malate/reatnine quant (u)[mass ratio]
60292-0,chloral hydrate [moles/volume] in specimen
60292-0,chloral in [moles/volume] hydrate quantitative specimen
60292-0,chloral hydrate [moles/volume] noctec in specimen
60292-0,chloral hydrate spec-scnc
60292-0,hydrate chloral secscnc level
60292-0,chloral spec-scnc welldorm hydrae
60292-0,chloral hydrate (specimen) [moles/vol]
60292-0,medianox chlr [moles/vol] hydrate(peimen)
60292-0,chloa hydrate [moles/o] (secie)
100693-1,pneumocystis jirovecii dna [log #/volume] in respiratory system specimen by naa with probe detection
100693-1,neumostis jirovecii [log da #/volue] inrpiratry systemspecimen by naa spec with probe dtection
100693-1,pneumocystis jirecii dna [log /volue] in esiratory sysem p carinii specime by naa wth probe detectin
100693-1,p jirovecii dna resp naa+probe-log#
100693-1,resp jirovecii dna p nucleic acid sequence based analysis naa+probe-log#
100693-1,jovecii dna resp lat aaprobelog#
100693-1,p. jirovecii dna naa+probe (respiratory system specimen) [log #/vol]
100693-1,p. jiroveci dna naa+prbe (respiratorysyem pecimen) [log #/vol]
100693-1,p. [log dnana+proe (respiratory sysem pecimen) jirovecii #/vol]
34958-9,eosinophils [#/volume] in cerebral spinal fluid
34958-9,eosinophils [#/volume] in cerebral spinal fluid
34958-9,eosinophils in # [#/volume] cerebral spinal fluid
34958-9,eosinophil # csf
34958-9,eosinophil # cf
34958-9,eosinophil # cerebrospinal fluid
34958-9,eosinophils (csf) [#/vol]
34958-9,eosinophils spinal fld (csf) #/o]
34958-9,onophils (c[#/vo]
10673-2,hepatitis b virus core ag [presence] in tissue by immune stain
10673-2,hepatiti  virus coe ag [prsence] in tissue y mmune stin
10673-2,hepatitis b by core ag [ql] in tissue virus immune stain
10673-2,hbv core ag tiss ql imstn
10673-2,hepatology hbv core ag tiss ql imstn
10673-2,presence core ag tiss hbv imstn
10673-2,hbv core ag immune stain ql (tiss)
10673-2,hbv core ql immune qualitative stain ag (tiss)
10673-2,hbv core ql immune stain ag (tiss)
17970-5,bacteria # 2 identified in urine by culture
17970-5,bacteria # 2 identified in urine by ua culture
17970-5,bacteria   identifid in urine by culture
17970-5,bacteria ur cult org #2
17970-5,bacteria ur cult org point in time #2
17970-5,cult briau org cult #2
17970-5,bacteria identified # 2 cx nom (u)
17970-5,bacteia idetified # (u) cxnom
17970-5,bacteiaidentified # 2 cxnom (u)
104719-0,direction repetition timing [time]
104719-0,repetition direction timing [time]
104719-0,[time] repetitin timin direction
104719-0,direction repetition timing time
104719-0,diretion timing epetition time
104719-0,direction repetition timing quan tie
38897-5,fibers [presence] in stool by light microscopy
38897-5,fber [presenc] n stoo byligt qualitative microscopy
38897-5,ibers [preence] in stool by ight icrocopy faeces
38897-5,fibers stl ql micro
38897-5,fibers ql stl micro
38897-5,fibers ql stl micro
38897-5,fibers lm ql (stl)
38897-5,fiberslm (stl pr ql
38897-5,fibers lm (stl) ql
43589-1,shigella sp ab [presence] in serum
43589-1,in sp ab [presence] infectious disease shigella serum
43589-1,shigella sp qual ab [presence] in serum
43589-1,shigella ab ser ql
43589-1,shigell aby e a ql
43589-1,shgella ab ser aby q
43589-1,shigella sp ab ql (s)
43589-1,anti sigellap ab ql (s)
43589-1,spabql(s) shgela infectiousdisease
2620-3,methionine [presence] in blood
2620-3,[ql] methionine n bod
2620-3,methionine random [presence] in bld
2620-3,methionine bld ql
2620-3,methionine bld ql point in time
2620-3,ql blood methionine
2620-3,methionine ql (bld)
2620-3,ethionine ql (bld)
2620-3,(bld) ql mthonn
71625-8,neutrophils/leukocytes [pure number fraction] in synovial fluid by manual count
71625-8,fluid [pure number fraction] in synovial neutrophils/leukocytes by manual count
71625-8,netrophils/lukocytespue number fracion] leuk insynovil fluid by mau count
71625-8,neutrophils nfr.df snv manual
71625-8,neutrophils nfr.df snv manual
71625-8,joint flu neutrophils nfr.df snv manual
71625-8,neutrophils/leukocytes manual cnt (syn fld) [pure # fraction]
71625-8,nutrophils/leukocytes manual cnt (synfl [pure # synovial fluid frction]
71625-8,nutopis/ekoctes manual nt [pure fl) (syn # snv fracton]
29956-0,lysozyme [mass/volume] in body fluid
29956-0,lysozyme [mass/volume] bod in fluid boy
29956-0,lyszyme [mass/voume] in body fluid
29956-0,lysozyme fld-mcnc
29956-0,fld lysozyme fld-mcnc
29956-0,lysozyme fd-mcnc
29956-0,lysozyme (body fld) [mass/vol]
29956-0,quantitative lysozym fl) (body [ass/vol]
29956-0,lysozyme (body fld) [mass/vol]
34190-9,thermoactinomyces vulgaris igg ab [mass/volume] in serum
34190-9,thermoactinomyces vulgaris igab [mas/volume] in serum
34190-9,hermoactinomyces vulgrs iggab [masvolue] in srum
34190-9,t vulgaris igg ser-mcnc
34190-9,t igg vulgaris ser-mcnc quant
34190-9,t vulgaris igg serum-mcnc
34190-9,t. vulgaris igg (s) [mass/vol]
34190-9,point in time t. vulgaris igg [mass/vol] (s)
34190-9,t. anti [mass/ol] igg s) vulari
50866-3,indicans/creatinine [molar ratio] in urine
50866-3,indicans/reanne [molar atio] n urin
50866-3,indicans/creatnine[molar qnt ratio] n urin
50866-3,indicans/creat ur-srto
50866-3,ur r-srto indicans/creat
50866-3,ur-srto indicans/creat
50866-3,indicans/creatinine (u) [molar ratio]
50866-3,indicans/creatiine () [molar ratio]
50866-3,indicans/creatiine ato] [mlar (u) quant
4429-7,sulbactam [mass] of dose
4429-7,sulbact ofdose [mass] sulbaam
4429-7,of [mass] sulbactam dose
4429-7,sulbactam dose
4429-7,dose sulbactam drug doses
4429-7,dose sulbactam quantitative
4429-7,sulbactam (dose) [mass]
4429-7,sulbactam quant [mass] (dose)
4429-7,[mass] (dose) sulbactam
4251-5,fenetylline [mass] of dose
4251-5,[mass] amfetyline fenetylline of dose
4251-5,fenetylline [mass] of dose quant
4251-5,fenetylline dose
4251-5,dose enetyllne
4251-5,dose fenetylline
4251-5,fenetylline (dose) [mass]
4251-5,fenetlline dose med or substance [mss] (dose)
4251-5,quantitative (dose) fenetylline [mass]
34640-3,bile acid [mass/volume] in body fluid
34640-3,bile acid fluid in body [mass/volume]
34640-3,bile acd flu [ass/lume] inbody flud
34640-3,bile ac fld-mcnc
34640-3,bile fld-mcnc ac
34640-3,"ile ac fld-mcnc body fluid, unsp"
34640-3,bile acid (body fld) [mass/vol]
34640-3,bileacid(body acids fld) [massvol]
34640-3,bile acd body fl fld) [mass/vol]
17259-3,methadone.long acting metabolite [mass/volume] in serum or plasma
17259-3,methadone.long in metabolite [mass/volume] acting serpl
17259-3,methadon.lng ctingmetaolitemass/vlume] in serum or plasma dolophin
17259-3,la methadone metab serpl-mcnc
17259-3,l methadone metab metab serpl-cnc
17259-3,sepl-mcnc mtab la methadone metab lamethadone
17259-3,methadone.long acting metabolite [mass/vol]
17259-3,metabolit cting mehadone.lng [ass/vol]
17259-3,methadon.long la methadone metab cting metaboie [mass/vol]
25845-9,aldosterone [moles/volume] in 24 hour urine
25845-9,hoururine moesvolume] n quant 24 aldoterone
25845-9,aldosterone [moles/volume] in 24 hour urine
25845-9,aldost 24h ur-scnc
25845-9,24h aldost ur-scnc
25845-9,24h aldost ur-scnc
25845-9,aldosterone (24h u) [moles/vol]
25845-9,(24h aldosteroe u) [moles/vol]
25845-9,ldsterone (24h u) [moles/vol]
2111-3,choriogonadotropin.beta subunit [moles/volume] in serum or plasma
2111-3,or qnt subunit [moles/volume] in serum choriogonadotropin.beta plasma
2111-3,chriogonadropin.beta subuni moles/volum] beta human chorionic gonadotropin or eru in lasma
2111-3,b-hcg serpl-scnc
2111-3,b-hcg serpl-scnc
2111-3,serum bcgsepl-scnc
2111-3,hcg.beta subunit [moles/vol]
2111-3,[moles/vol] subunit hcg.beta
2111-3,ubunit[moles/vol hcg.beta
13348-8,monoclonal band observed [identifier] in serum or plasma
13348-8,bands monoclonal band observed in [identifier] serum or plasma
13348-8,monoclonal band obsered [identifier] in serum r plasma
13348-8,monoclon band obs serpl
13348-8,bands mooclon srpl obs band
13348-8,monoclon band obs nominal serpl
13348-8,monoclonal band observed nom
13348-8,nominal ban onoclonal obseved nom
13348-8,nom oberved mnoclonlban
39315-7,influenza virus a n5 neutralizing antibody [presence] in serum by neutralization test
39315-7,influenza virus a n5 neutralizing antibody [presence] in serum test neutralization by
39315-7,influenza vius a n5 sr neutralizing atibo [peen] i serum byneutralizatin tes
39315-7,fluav n5 nab ser ql nt
39315-7,fluav n5 serum nb q nt
39315-7,fluav n5 nab ser fluav ql nt
39315-7,fluav n5 neut ab neut test ql (s)
39315-7,ab n5 neut fluav neut test ql (s)
39315-7,fluav n5 neu ql neuttest ab (s)
55095-4,adenovirus [presence] in specimen by organism specific culture
55095-4,adenovrus [presence] pr in specimen by orgasm peific cultre
55095-4,adenovirus [presence] in specimen by organism ql culture specific
55095-4,hadv spec ql cult
55095-4,unspecified hadv spec cult ql
55095-4,cult spec ql hadv
55095-4,adenovirus org specific cx ql (specimen)
55095-4,adenovirus org miscellaneous specific cx presence (specimen)
55095-4,ql specifccx denovirusorg spcimen)
5052-6,aspergillus sp ab [presence] in serum by immune diffusion (id)
5052-6,aspergillus sp ab [presence] in serum by immune diffusion (id)
5052-6,aspergillus presence] ab sp i serum by immune dffusion aspergilla (id)
5052-6,aspergillus ab ser ql id
5052-6,ql ab ser aspergillus id
5052-6,ql ab ser aspergillus id
5052-6,aspergillus sp ab immune diff ql (s)
5052-6,immune sp ab aspergillus diff ql species (s)
5052-6,aspergllusp b immne diffql ordinal (s)
50113-0,3-hydroxyoleoylcarnitine (c18:1-oh) [moles/volume] in dbs
50113-0,3-hydroxoleoylcanitne (c18:1-o) [moles/vlume] in bs
50113-0,3-hyroxyoleoylcarnitine (c11-oh) [mole/volume] in dbs
50113-0,3oh-oleoylcarn dbs-scnc
50113-0,3oh-oleoylcarn dbs-scnc
50113-0,dbs-scnc 3oh-oleoylcarn
50113-0,c18:1-oh (dbs) [moles/vol]
50113-0,c18:1-oh (dbs) [moles/vol]
50113-0,c181-oh (dbs) [mols/vol] 3oh-oleoylcarn
50660-0,herpes simplex virus 1 dna [#/volume] (viral load) in serum or plasma by naa with probe detection
50660-0,hepes simplex virus 1 dna #/volume] (vial load) in serum or plama y naa with prob ligation-activated transcription detection
50660-0,herpes simplex serum 1 dna [#/volume] (viral load) in virus or probe with ampification plasma by naa with probe detection
50660-0,hsv1 dna # serpl naa+probe
50660-0,v1 dna i # naa+pobe serl
50660-0,hs1 dna # sepl id naa+probe
50660-0,hsv 1 dna naa+probe [#/vol]
50660-0,hsv 1 naa+robe infectious disease dn [#/vol]
50660-0,hsv naa+probe dna 1 [#/vol]
27153-6,deprecated streptococcus pneumoniae 3 ab [mass/volume] in serum --2nd specimen
27153-6,deprcatd streptococcus in 3 ab [mass/volume] pneumonie seru--2ndspecmen
27153-6,deprecated streptococcus pneumoniae 3 ab [mass/volume] in ser --2nd specimen
27153-6,deprecated s pneum3 ab sp2 ser-mcnc
27153-6,ser-mcnc s infectiousdisease pneum3 ab sp2 deprecated
27153-6,deprecated spn ab pnm3 s sp sr-mcc
27153-6,s. pneumoniae 3 ab spec 2 (s) [mass/vol]
27153-6,s. pneumoniae 3 anti ab spec 2 (s) [mass/vol]
27153-6,s. pneumoniae 3 ab spec 2 (s) [mass/ol]
30348-7,glutamate [moles/volume] in urine
30348-7,glutamate urine in [mols/olume]
30348-7,glutamat [molevolue] in uine
30348-7,glutamate ur-scnc
30348-7,lutamate random r-scnc
30348-7,level ur-scnc glutamate
30348-7,glutamate (u) [moles/vol]
30348-7,glutmte [mols/vol] ()
30348-7,urn glutamate [moles/vol] (u)
96291-0,pregnenolone sulfate [mass/volume] in serum or plasma
96291-0,pregnenlone sulfate [mass/volume] in serpl
96291-0,sulf pregnenolone sulfate [mass/volume] in serum or plasma
96291-0,pregnenolone sulfate serpl-mcnc
96291-0,sulfatserpl-mcc pregenolne serpl
96291-0,sulfate serum pregnenolone serpl-mcnc
96291-0,pregnenolone sulfate [mass/vol]
96291-0,pregnenolone [mass/vol] qnt sulfate
96291-0,pregnenolone [mass/vol] sulfate
66133-0,mononuclear cells atypical/leukocytes in body fluid by manual count
66133-0,mononuclear cells atypical/leukocytes body in fluid by manual qnt count
66133-0,mononuclear manuaount atypical/leukocyte in ody fuid b wbc cells
66133-0,atypical mononuc nfr fld manual
66133-0,quantitative atypical mononuc nfr fld manual
66133-0,atypical mononuc white blood cell nfr fld manual
66133-0,mononuclear cells atypical/leukocytes manual cnt (body fld)
66133-0,cells mononuclear atypical/leukocytes manual cnt fl (body fld)
66133-0,mononlear cellsatypicl/lekocytes manual ct (body qnt fld)
29992-5,eosinophils [presence] in nose by wright stain
29992-5,eosinophils [resence] eosino in ose y wright stan
29992-5,eosinophils nose in [presence] by wright stain
29992-5,eosinophil nose ql wright stn
29992-5,eosinophil nose presence ordinal wright stn
29992-5,q nose esinophil riht stn
29992-5,eosinophils wright stain ql (nose)
29992-5,eosiophils ql(ose) stain wright
29992-5,wright eosinophils stain ql nose)
43609-7,adipate [presence] in 24 hour urine
43609-7,adipate [presence] in 24 hour urne
43609-7,adipate presence [presen] in 24 our urine
43609-7,adipate 24h ur ql
43609-7,adipate 24h ur ua ql
43609-7,24h hexanedioate adpate ur presence
43609-7,adipate ql (24h u)
43609-7,adipate ql urn (24h u)
43609-7,adipate ql 24 hours (24h u)
32717-1,sodium [moles/volume] in arterial blood
32717-1,[molesvolme] quantitative sodium in rterial blood
32717-1,sodium [moles/volume] arterial in bld
32717-1,sodium blda-scnc
32717-1,arterial blood blda-scnc sodium
32717-1,sodium blda-scnc qnt
32717-1,sodium (blda) [moles/vol]
32717-1,sodium (blda) [moles/vol]
32717-1,sodium [moles/vl] (blda)
6514-4,human papilloma virus rrna [presence] in genital specimen by naa with probe detection
6514-4,human papilloma virus rrna [presence] with genital specimen by naa in probe detection
6514-4,humn enitalpeimen irus rrna [presence] n paillma by naa with robe deection
6514-4,hpv rrna genital ql naa+probe
6514-4,hpv rrna ql polymerase chain reaction genital naa+probe
6514-4,hpv genital rrna ql probe with ampification naa+probe
6514-4,hpv rrna naa+probe ql (genital specimen)
6514-4,probe amp hpv rrna naa+oe presence (genital spcimen)
6514-4,hpv rrna naa+probe ql (genital sda specimen)
77447-1,nordiazepam [moles/volume] in specimen
77447-1,nordiazepam[oles/volume] stilny i specimen
77447-1,nordiazepam quantitative in [moles/volume] specimen
77447-1,nordiazepam spec-scnc
77447-1,spec-scnc nordiazepam
77447-1,spec-scnc nordiazepam
77447-1,nordiazepam (specimen) [moles/vol]
77447-1,[moles/vol] (specimen) nordiazepam nordazepam
77447-1,[moles/vol] (specimen) nordiazepam
90832-7,ma+ta ab [presence] in cerebral spinal fluid by immunofluorescence
90832-7,ma+ta ab presence] in ceebral imunofluorescece luid aby by spinal
90832-7,ma+ta fluid [presence] in cerebral spinal ab by immunofluorescence
90832-7,ma+ta ab csf ql if
90832-7,ma+ta ab presence csf if
90832-7,presence ab csf ma+ta if random
90832-7,ma+ta ab if ql (csf)
90832-7,ab ma+ta if time resolved fluorescence ql (csf)
90832-7,f ab ma+a l (csf)
94380-3,acinetobacter baumannii dna [presence] in lower respiratory specimen by naa with probe detection
94380-3,acinetobacter baumanii n [presene] in lower respiatoryspecimen by naa with pobe deetio
94380-3,acinetbacter baumannii dna repiraty in lowe [presence] secmenby naa ith proe detectin
94380-3,a baumannii dna lower resp ql naa+probe
94380-3,abaumanni dna lower resp presence naa+probe
94380-3,naa+probe amplif baumannii dna lower resp ql a
94380-3,a. baumannii dna naa+probe ql (lower resp)
94380-3,a. baumannii dna infectious disease naa+probe ql (lower resp)
94380-3,a. baumannii dna ql naa+probe (lower resp)
43635-2,2-hydroxyglutarate [presence] in 24 hour urine
43635-2,2-hydroxyutart qualitative [pesence] in 24hour urine
43635-2,2-hydroxyglutarate [presence] ua in 24 hour urine
43635-2,2oh-gluterate 24h ur ql
43635-2,2oh-gluterate 24h ur ql
43635-2,2oh-gluterat alpha-hydroxyglutarate 24h u l
43635-2,2-hydroxyglutarate ql (24h u)
43635-2,2-hydroxyglutarat presence 24h u)
43635-2,2-hydroxyglutarate 2oh-gluterate ql (24h u)
54097-1,organophosphonate nerve agent metabolite panel [mass/volume] - urine
54097-1,organophosphonate nerve agent metabolite urine [mass/volume] - panel
54097-1,pnl organophshonate nerve agent - anel [masvolme] metablte urne
54097-1,op nerve agent metab pnl ur-mcnc
54097-1,op nerve agent urn metab pnl ur-mcnc
54097-1,ur-mcnc nerve agent metab pnl op
54097-1,organophosphonate nerve agent metabolite panel (u)
54097-1,organophosphonate nerve (u) metabolite panel agent ur
54097-1,organphosphonate nerveaent metaboitepanel metb u)
33697-4,bacillus anthracis ag [presence] in isolate by immunofluorescence
33697-4,bacillus anthracis isolate [presence] in ag by immunofluorescence
33697-4,bacilusanthcis ag [presence] in iolate by immunofluoresece
33697-4,b anthracis ag islt ql if
33697-4,b anthracis if screen ist ql ag
33697-4,b anthracis ag islt presence if
33697-4,b. anthracis ag if ql (isol)
33697-4,b. anthracis ag ql if (isol)
33697-4,b. anthracis ag if ql (isol) immunofluor
32270-1,serine [moles/volume] in body fluid
32270-1,serine [moles/volume] body bf in fluid
32270-1,serine [moles/vlume]in body lui
32270-1,serine fld-scnc
32270-1,serine chemistry fld-scnc
32270-1,body fluid flscnc serine
32270-1,serine (body fld) [moles/vol]
32270-1,ein [moles/vol] (bodyfl
32270-1,serie flu (body fld) [mols/vol]
19483-7,hydrocodone [presence] in urine by confirmatory method
19483-7,ydrocodon [presence] inurin by cofirator mthod
19483-7,hydrocodone by in urine [ql] confirmatory method
19483-7,hydrocodone ur ql cfm
19483-7,hydocodone ur presence fm
19483-7,hydrocodone ur ql cfm
19483-7,hydrocodone confirm ql (u)
19483-7,hydrocodone confirm ql (u)
19483-7,(u) confirm ql hydrocodone
96911-3,delta aminolevulinate and porphobilinogen panel - serum or plasma
96911-3,delta aminolevulinate pan anel andporphoilinogen - serum o plama
96911-3,delta aminolevulinate and porphobilinogen panel or serum - serum plas
96911-3,d-ala + pbg pnl serpl
96911-3,d-ala pbg + pnl serpl
96911-3,serl pg pnl d-ala+
96911-3,delta aminolevulinate and porphobilinogen panel
96911-3,elta aminolevulinate and porphoblinogen panel
96911-3,delta ainolevulinate nd plasma porphobinogen panel
17925-9,bacteria identified in wound deep by anaerobe culture
17925-9,bacteria identified deep wound in by anaerobe culture
17925-9,bacteria identifed in wundeep y anerbe cultur
17925-9,bacteria deep wnd anaerobe cult
17925-9,wnd bacteria deep wnd anaerobe cult
17925-9,bacteia cultures cult anaerobe deepwnd
17925-9,bacteria identified anaer cx nom (deep wound)
17925-9,anaer identified bacteria cx bact nom (deep wound)
17925-9,bacteria anaer identified cx nom (deep wound) pt
15119-1,cobalt [moles/volume] in blood
15119-1,cobalt in [moles/volume] blood
15119-1,cobalt bld in [moles/volume]
15119-1,cobalt bld-scnc
15119-1,ld-scnc cobat
15119-1,whole blood cobalt bld-scnc
15119-1,cobalt (bld) [moles/vol]
15119-1,[moles/vol] (bld) cobalt
15119-1,[molesvol] (bld) whole blood obalt
86876-0,deprecated mds v3.0 - rai v1.14.1 - swing bed pps (sp) item set [cms assessment]
86876-0,deprecated mds - - rai v1.14.1 v3.0 swing bed pps (sp) item set [cms assessment]
86876-0,deprecated ms v3.0 - rai v114.1 -swing be pps(sp) item set [cms assesment]
56529-1,ma+ta ab [titer] in cerebral spinal fluid by immunofluorescence
56529-1,ma+ta ab [titer] in cerebral spinal fluid by immunofluorescence
56529-1,ma+ta ab [titer in cerebral spinal fluid by immnofluorescene immunofluorescence
56529-1,ma+ta ab titr csf if
56529-1,titr ab ma+ta csf abs if
56529-1,ma+ta i tit cerebrospinal fluid ab
56529-1,ma+ta ab if (csf) [titer]
56529-1,ma+ta dilution factor if ab (csf) [titer]
56529-1,ma+ta (csf) if ab [titer]
40505-0,chikungunya virus ab [titer] in serum by hemagglutination inhibition
40505-0,chikungunya virus ab [tier] antibodies in seum hemgglutinaion by nhibitin
40505-0,chikungunya virus ab [titer] in serum by hemagglutination inhibition
40505-0,chikv ab titr ser hai
40505-0,chikv ab ser titr hai
40505-0,chikv ab titr serum hai
40505-0,chikv ab hai (s) [titer]
40505-0,hikv ab hai (s [titer]
40505-0,hai ab chikv (s) [titer]
71598-7,neutrophils/leukocytes [pure number fraction] in bronchial specimen by manual count
71598-7,inbronchial number pulmonary fraction] neutrophils/leukocytes[pure peimeby mnu count
71598-7,neutrophils/leukocytes [pure number fraction] in manual specimen by bronchial bro count
71598-7,neutrophils nfr.df bronch manual
71598-7,neutrophils manual bronch nfr.df
71598-7,neutrophils nfr.df bronch manual
71598-7,neutrophils/leukocytes manual cnt (bronch spec) [pure # fraction]
71598-7,#fracin] anual pulmonology cn (onch sec) [pre neutrphilslukocytes
71598-7,fraction] manual cnt neut (bronch spe) [pe # neutrophils/leukocys
42949-8,toxoplasma gondii ab [titer] in serum
42949-8,toxoplas gondii ser [titr in ab
42949-8,toxoplasma gondii ab [titer] in id serum
42949-8,t gondii ab titr ser
42949-8,t ondii ab titrser
42949-8,t infectious disease gondii ab titr serum
42949-8,t. gondii ab (s) [titer]
42949-8,t. gondii ab s) infectiousdisease [tier]
42949-8,t. microbiology (s) ab gondii [titer]
57458-2,neisseria gonorrhoeae rrna [presence] in anal by naa with probe detection
57458-2,neisseria gonorrhoeae rrna [ql] in anal amplif by naa with probe detection
57458-2,neisseria gonorrhoeae rrna [presence] in anal by naa with probe detection
57458-2,n gonorrhoea rrna anal ql naa+probe
57458-2,gonorrhoea ql ana rrna naprobe
57458-2,n gonorrhoea rrna anal presence naa+probe
57458-2,n. gonorrhoeae rrna naa+probe ql (anal)
57458-2,n. gonorrhoeae rrna probe with ampification naa+probe ql (anal)
57458-2,n. presence polymerase chain reaction rrna naa+probe gonorrhoeae (anal)
10533-8,propoxyphene+acetaminophen [mass/volume] in serum or plasma
10533-8,propoxypene+cetainophen [mass/volume in srum or plas
10533-8,algaphan ropoxyhene+acetminophen plasma in serum o [massvolume]
10533-8,propoxyph+apap serpl-mcnc
10533-8,propoxyph+apap serum or plasma-mcnc
10533-8,serpl-mcnc propoxyph+apap
10533-8,propoxyphene+acetaminophen [mass/vol]
10533-8,propoxyphene+acetaminophen dextrogesic [mass/vol]
10533-8,[mass/vol] propoxyphene+acetaminophen
39023-7,vesicular stomatitis indiana virus rna [presence] in specimen by naa with probe detection
39023-7,vesicular stomatitis indiana virus miscellaneous rna [ql] in specimen by naa with probe detection
39023-7,vesicuar somtitis inin virus rn [prsen] i secin by naa with probe detection
39023-7,vsiv rna spec ql naa+probe
39023-7,ql na spec vsiv naa+probe
39023-7,sv rn spec ql naa+probe
39023-7,vesicular stomatitis indiana virus rna naa+probe ql (specimen)
39023-7,vesicular ql indiana virus rna naa+probe stomatitis (specimen)
39023-7,ql stomatitis indiana virus rna aa+probe probe amp esicula (pecimen)
32727-0,urobilinogen [units/volume] in urine
32727-0,urobilioen [unt/volume] in urine chemistry
32727-0,urbilinoge [unitsvolume]in quantitative urine
32727-0,urobilinogen ur-acnc
32727-0,urobilinogen r-acnc urn
32727-0,urobili urobilioge ur-acnc
32727-0,urobilinogen qn (u)
32727-0,urobilinogen (u) qn
32727-0,(u) q urobilinogen arbitrary concentration
8230-5,phencyclidine [presence] in gastric fluid by screen method
8230-5,phecyliie [presence] in pcp gastricfluid by scree metho
8230-5,pr phencyclidine [presence] ingastric fluid by scren method
8230-5,pcp gast ql scn
8230-5,pcp gast gast scn presence
8230-5,pcp presence gast sc
8230-5,phencyclidine screen ql (gast fld)
8230-5,phncyldine scren ql (ast fld)
8230-5,fld) screen ql (gast phencyclidine
93915-7,rh antigens and k ag panel - blood from blood product unit
93915-7,rh antigens and k ag panel - blood from panel.bloodbank blood product unit
93915-7,rh blood product unit antigens and k ag panel - blood from blood product unit
93915-7,rh ags+k ag pnl bld bpu
93915-7,rh ags+k bld pnl ag bpu
93915-7,rh ags+k ag pnlbld d phenotyping bpu
93915-7,rh antigens & k ag panel (bld bpu)
93915-7,(bld random anigens & k ag pael rh bpu)
93915-7,rh antigen& k panel ag (bl bpu)
53438-8,carnitine palmitoyltransferase 2 [enzymatic activity/mass] in fibroblast
53438-8,carniine almitoyltransferse 2[enzymatic acivity/mass]in fibroblast
53438-8,carnitine palmitoyltransferase [enzymatic 2 activity/mass] in fibroblast
53438-8,cpt2 fib-ccnt
53438-8,fib-ccnt cpt2
53438-8,fib-ccnt cpt2
53438-8,carnitine palmitoyltransferase 2 (fibroblast) [catalytic activity/mass]
53438-8,carnitine 2 palmitoyltransferase (fibroblast) [catalytic activity/mass]
53438-8,carnitine palmitoyltransferase [catalytic (fibroblast) 2 activity/mass] quan
93225-1,coccidioides sp ag [mass/volume] in cerebral spinal fluid by immunoassay
93225-1,coccidioides level sp ag [mass/volume] in cerebral spinal fluid by immunoassay
93225-1,occidioidessp ag [masvolume] inerebra pinal fuid by immunoasay
93225-1,coccidioides ag csf ia-mcnc
93225-1,coccidiodes spinal fld ag ia-mcnc csf
93225-1,ia-mcnc csf cocidioidsag mass concentration
93225-1,coccidioides sp ag ia (csf) [mass/vol]
93225-1,coccidioides sp ag ia (csf) [mass/vol] spinal fl
93225-1,coccidioides (csf) ag ia sp [mass/vol]
70506-1,functional assessment of chronic illness therapy (facit) - cancer specific symptom indexes panel
70506-1,caner assessment of chronic illness panl herapy (facit - fnctioal specific symptm indexes ael
70506-1,functional assessment of chronic illness cancer (facit) - therapy specific symptom indexes panel
42375-6,neisseria meningitidis serogroup z ag [presence] in isolate by agglutination
42375-6,neissera meningitidis n men sg z serogroup z g [presenc] isolat in by aggutination
42375-6,neisseria meningitidis type z' neissei mengitidis serogroup z ag [presence]i isoate by aglutnaton
42375-6,n men sg z ag islt ql aggl
42375-6,n men sg z ag islt ql aggl meningid
42375-6,n z sg men ag islt ql aggl
42375-6,n. meningitidis z ag aggl ql (isol)
42375-6,isol) menngtidis z ag aggl ql n. n menigitidis
42375-6,a meningitidis z n. gg ql (iol)
11255-7,haemophilus ducreyi [presence] in specimen by organism specific culture
11255-7,[presence] ducreyi haemophilus in specimen by organism specific culture
11255-7,haemophilus ducreyi [presence] in specific by organism specimen culture
11255-7,h ducreyi spec ql cult
11255-7,h ducreyispec cult ql cult
11255-7,h spc ucreyi ql clt
11255-7,h. ducreyi org specific cx ql (specimen)
11255-7,h. ducreyi org specific ql cx (specimen)
11255-7,. ducreyi org speific cx ql (specien)
88261-3,gram positive bacteria identified [interpretation] by probe in positive blood culture
88261-3,in poitve bacteria identified[interpretaon]by probe gram positive blod cuture
88261-3,gram positivebacteria identified nterpretation] by probe posiive in blood culture
88261-3,gp bact bld pos probe-imp
88261-3,bact gp bld pos probe-imp
88261-3,gp point in time bact bld pos probe-imp
88261-3,gram positive bacteria identified probe (pos bld culture) [interp]
88261-3,gram ositive bacteria identifid pre bld (ps culture) [interp]
88261-3,gram positive bacteria identified probe [interp] random bld culture) (pos
67126-3,cannabinoids synthetic [presence] in urine by confirmatory method
67126-3,cannabnoid synthetic [pesence] urine in by confirmatory etho
67126-3,annabinods by [prsece qualitative inurine sntheti confirmtry method
67126-3,cannabinoids synthetic ur ql cfm
67126-3,cannabinoids synthetic ur ql cfm drug/toxicology
67126-3,cannabinoids synthetic cannabinoids synthetic ur ql cfm
67126-3,cannabinoids synthetic confirm ql (u)
67126-3,cannabioid synhetic cofirmql ()
67126-3,(u) synthetic confirm ql qual cannabinoids
22484-0,rickettsia sp ab [titer] in serum
22484-0,infectious disease rickettsiasp ab [titer] in serm
22484-0,riettsia titre sp ab [tir in serum
22484-0,rickettsia ab titr ser
22484-0,rickettsia serum titr ab
22484-0,rickettsiab antibody titr ser
22484-0,rickettsia sp ab (s) [titer]
22484-0,rickettsia sp ab (s) serum [titer]
22484-0,rickettsia sp ab (s) [titer]
42909-2,hemoglobin.gastrointestinal [presence] in gastric fluid --1st specimen
42909-2,hemoglobin.astointestinal [resence in qual gasr flid --1st specimen
42909-2,[presence] hb hemoglbin.gastrointestial in gastric fuid --1st specimen
42909-2,gastrocult sp1 gast ql
42909-2,gastrocult sp1 gi gast ql
42909-2,gastrocut s1gat ql gi
42909-2,hemoglobin.gastrointestinal spec 1 ql (gast fld)
42909-2,hemoglobin.gstointestinal spec 1 l (gastfld)
42909-2,hemoglobin.gastrointstial spec 1 ql fecal occult blood (gast fld
17921-8,bacteria # 2 identified in nose by anaerobe culture
17921-8,bacteria#2 idenifed in by ose anaerobe cutur anaerobe cult
17921-8,bacteria # 2 identified in nose anaerobe by culture
17921-8,bacteria nose anaerobe cult org #2
17921-8,bacteria cult anaerobe nose org #2
17921-8,bactera nse anaerobe org ult #2
17921-8,bacteria identified # 2 anaer cx nom (nose)
17921-8,bacteria idenifid 2 smell anaer cx no(ose)
17921-8,bact bacteria identified # 2 (nose) cx nom anaer
104344-7,borna disease virus rna [presence] in specimen by sequencing
104344-7,borna disease virus rna borna dv [presence] in specimen by sequencing
104344-7,borna diseaseviru miscellaneous rna[prence in specimen by seqencin
104344-7,borna dv rna spec ql seq
104344-7,borna dv dis rna spec ql seq
104344-7,rna bornadv spec ql se
104344-7,borna disease virus rna sequencing ql (specimen)
104344-7,borna disease borna dv virus ql sequencing rna (specimen)
104344-7,ribonucleic acid borna disase ql rna sequening virus (specimen)
58435-9,microorganisms panel - urine sediment
58435-9,panel microorganisms - urine sediment
58435-9,microorganisms sediment - urine panel
58435-9,microrganisms pnl urns
58435-9,icrorgnisms pnluns
58435-9,microrganisms panel.urinalysis urns pnl
58435-9,microorganisms panel (urine sed)
58435-9,panel miooanisms (urine urine sediment sd)
58435-9,micoorganisms ane (urine sed)
30027-7,dimethoate [mass/volume] in serum or plasma
30027-7,or [mass/volume] in ser dimethoate plasma
30027-7,dimethoate [mass/volume] or serum in plasma
30027-7,dimethoate serpl-mcnc
30027-7,serpl-mcnc dimethoate
30027-7,serpl-mcnc dimethoate
30027-7,dimethoate [mass/vol]
30027-7,[mass/vol] dimethoate
30027-7,dmethoate [mass/vol]
43068-6,campylobacter sp iga ab [presence] in serum
43068-6,[presence] sp iga ab campylobacter in serum
43068-6,campylobacter sp iga ab [ql] in serum
43068-6,campylobacter iga ser ql
43068-6,campylobacter iga ql ser immune globulin a
43068-6,ql iga serum amplobacter antibodies
43068-6,campylobacter sp iga ql (s)
43068-6,campylobacter sp iga ql (s)
43068-6,() sp igaql campyobactr immunoglobulin a
88018-7,alanine/lysine [mass ratio] in dbs
88018-7,alanine/lysine dbs ratio] in [mass
88018-7,alanine/lysine in ratio] [mass dbs wb
88018-7,alanine/lysine dbs
88018-7,alanine/lysine quan dbs
88018-7,dbs alanine/lysine blood
88018-7,alanine/lysine (dbs) [mass ratio]
88018-7,alanin/lysine dbs (dbs)[mssratio]
88018-7,blood alanne/lysne (dbs) [mss raio]
86456-1,brucella sp ab [presence] in serum by card agglutination
86456-1,brucella sp ab [presence] n cardagglutnation y srm
86456-1,brucella sp ab [presence] in ser by autoantibody card agglutination
86456-1,brucella ab ser ql card aggl
86456-1,brucella ab serum ql card species aggl
86456-1,brucella ab sr ser ql card aggl
86456-1,brucella sp ab aggl.card ql (s)
86456-1,autoantibody brucella sp ab aggl.card ql (s)
86456-1,rucellasp ab s) q aggl.cad
21577-2,transferrin.carbohydrate deficient.trisialo/transferrin.total in serum or plasma
21577-2,tranferrn.carbohydrate plasma in serm or eficent.trisialo/transferrin.tta
21577-2,transferrin.carbohydrate deficient.trisialo/transferrin.total in serpl
21577-2,cdt trisialo/tf mfr serpl
21577-2,cdt trisiao/tf mr serpl
21577-2,mfr trisialo/tf cdt serpl
21577-2,transferrin.carbohydrate deficient.trisialo/total transferrin [mass fraction]
21577-2,transrrin.carbohydrat deficient.trisilo/tota transfrrin mass frction]
21577-2,transferrin.carbohydrate transferrin deficient.trisialo/total [mass fraction]
8222-2,opiates [presence] in urine by samhsa screen method
8222-2,opiates [presence] in rine by samhsscreen method
8222-2,piate [presene] inurineby method opiate sren smhsa
8222-2,opiates ur ql samhsa scn
8222-2,ur opiaes ql illicit samhsa scn
8222-2,oiaes u presence samhsa scn
8222-2,opiates samhsa screen method ql (u)
8222-2,opiates samhsa metod scren drugs ql (u)
8222-2,opates amhsa sceen method ql (u) opi
31461-7,legionella pneumophila 4 ab [units/volume] in serum
31461-7,legionella pneumophila 4 ab [units/volume] in serum antby
31461-7,serum pneumophila 4 ab [units/volume] l pneumo4 in legionella
31461-7,l pneumo4 ab ser-acnc
31461-7,l serum-acc pneumo4ab
31461-7,l pneumo4 a ser-acnc sr
31461-7,l. pneumophila 4 ab qn (s)
31461-7,qn(s) infectious disease pneumophila 4a l.
31461-7,l. pneumophila 4 ab qn (s) los angeles 1
85124-6,fear-over anxious survey version 2.0 - parent report - fixed length form - ages 3-7 [nih toolbox]
85124-6,fear-over anxious survy version .0 -prt report - fxed length form -ages 3-7 [nihoolbox]
85124-6,fea-ove nxious survey version 2.0- paren report - fixed length fr- ages 3-7 [nihtoolox]
87612-8,brodifacoum [mass/mass] in specimen
87612-8,klerat brodifacoum [mass/mass] specimen in
87612-8,bodifacou [massmass] specmn in drug/toxicology
87612-8,brodifacoum spec-mcnt
87612-8,spec-mcnt brodifacoum
87612-8,spec-mcnt brodifacoum
87612-8,brodifacoum (specimen) [mass/mass]
87612-8,(speimn boifacoum [mas/mass]
87612-8,brodifacoum (specimen) klerat mas/mass
49124-1,coxiella burnetii identified in specimen by sequencing
49124-1,coxiella identified burnetii in specimen other by sequencing
49124-1,coxiella burnetii identified sequencing specimen by in
49124-1,c burnet spec seq
49124-1,c ngs seq spe urnet
49124-1,c id burnet spec seq
49124-1,c. burnetii identified sequencing nom (specimen)
49124-1,c. burnetii identifid sequencing nom id (specimen)
49124-1,. burnetii identifie sequencing nom(specimen) point in time
49577-0,lecithin/surfactant.total in amniotic fluid
49577-0,lecthin/surfactant.total in amnioc flid quantitative
49577-0,ecitin/surfactant.otal in chemistry amniotic fluid
49577-0,lecithin mfr amn
49577-0,amn mfr lecithin
49577-0,mfr lecihin amn point in time
49577-0,lecithin/total surfactant (amn fld) [mass fraction]
49577-0,lecithin/total surfactant (amn fld) [mass af fraction]
49577-0,lecithin/total fraction] (amn fld) [mass surfactant
72924-4,barium [moles/volume] in urine
72924-4,barium quan in [moles/volume] urine
72924-4,barium [moles/volume] in urine qnt
72924-4,barium ur-scnc
72924-4,ur-scnc arium
72924-4,barium ur-scnc ba
72924-4,barium (u) [moles/vol]
72924-4,drug/toxicology [moles/vol] (u) barium
72924-4,barium mole/vl] (u)
73994-6,polychlorinated biphenyl (pcb) [presence] in serum or plasma by screen method
73994-6,polychlorinted bipheny (pc) [presence] in serum or plsma by screen method
73994-6,serum biphenyl (pcb) [presence] in polychlorinated or plasma by screen method
73994-6,pcb serpl ql scn
73994-6,pcb serpl l scn
73994-6,pcbserpl c ql diphenyl
73994-6,polychlorinated biphenyl (pcb) screen ql
73994-6,polychlornaed bipheny (pb) scren ql
73994-6,polchlorinaedbipenyl (pcb) polychlorinated biphenyls sreen l
43595-8,methadone [presence] in meconium
43595-8,metadne [presnce] in meconium
43595-8,methadone [ql] meconium in
43595-8,methadone mec ql
43595-8,mecql drug/toxicology methdone
43595-8,methadone mec addiction presence
43595-8,methadone ql (mec)
43595-8,methaone random ql (mec)
43595-8,(mec) drugs of abuse ql methadone
95669-8,murray valley encephalitis virus igg ab [presence] in specimen by immunoassay
95669-8,murray valley encephalitis virus autoantibody igg ab [ql] in specimen by immunoassay
95669-8,murr valley ab virus autoantibody igg encephalits [pesence] in specimen by immunoassay
95669-8,mvev igg spec ql ia
95669-8,mvev igg spec ql enzyme immunoassay ia
95669-8,mvev igg ia elfa ql spec
95669-8,mvev igg ia ql (specimen)
95669-8,anti me igg ia ql (specimen)
95669-8,mvev (speien) i ql ig
2237-6,erythropoietin (epo) [mass/volume] in serum or plasma
2237-6,erythropoietin serplas (epo) [mass/volume] in ser or plasma
2237-6,rythropoetn(epo) [mass/volue] in serm qnt r plasma
2237-6,epo serpl-mcnc
2237-6,serplmcnc chemistry epo
2237-6,epo serpl-mcnc
2237-6,erythropoietin (epo) [mass/vol]
2237-6,(ep) eryhropoietin [mass/vol]
2237-6,erythropoietin level (epo) [mass/vol]
34631-2,cyproheptadine [mass/volume] in urine
34631-2,cyproheptadine in [mass/volume] urine
34631-2,cyproheptadine [mass/volume] in urine
34631-2,cyproheptadine ur-mcnc
34631-2,cyproheptdine r-mcnc
34631-2,ur-mcnc cyproheptadine
34631-2,cyproheptadine (u) [mass/vol]
34631-2,[mass/vol] (u) cyproheptadine
34631-2,[mass/vol] (u) cyproheptadine
34550-4,immunoglobulin panel [mass/volume] - serum
34550-4,immunoglobuln serum panel.chemistry [mass/volume] panel
34550-4,immunolbulin immunoglobin pane [mss/volume] - serum
34550-4,immunoglobulin pnl ser-mcnc
34550-4,immunoglobuin ser-mcnc pnl serum
34550-4,pnl immunoglobulin ser-mcnc
34550-4,immunoglobulin panel (s) [mass/vol]
34550-4,immunoglobulin panel (s) [mass/vol]
34550-4,immunoglobulin panel (s) [mass/vol]
12488-3,pentobarbital [presence] in gastric fluid
12488-3,pentbabita [resence] n gatric gastric contents fluid
12488-3,in [presence] qualitative pentobarbital gstri fluid
12488-3,pentobarb gast ql
12488-3,ql addiction ast penobarb
12488-3,ql gast pentobarb
12488-3,pentobarbital ql (gast fld)
12488-3,ql pentobarbital (gast fld)
12488-3,penobarbital ql (gast fld
33935-8,cyclic citrullinated peptide igg ab [units/volume] in serum or plasma
33935-8,cyclic citrulinated peptde gg ab [units/olume] in seru or pasm rheumatoid arthritis
33935-8,cyci ser citrullinated r igg b [uits/volume] in ser peptide plasma
33935-8,ccp igg serpl-acnc
33935-8,ccp ig srlcnc serpl
33935-8,ccp igg serp-acc
33935-8,cyclic citrullinated peptide igg qn
33935-8,cyclic cirullinated sr qn gg peptide
33935-8,cyclic citrullinated peptide igg qn
86716-8,actinobacillus pleuropneumoniae dna [cycle threshold #] in isolate by naa with probe detection
86716-8,actinobacillus probe dna [cycle threshold #] in isolate by naa with pleuropneumoniae detection
86716-8,actinobacillus pleuropnemoniae dna [cycle threshold] n islae b i naa probe detectin
86716-8,a pleuropn dna ct islt qn naa+probe
86716-8,a pleuropn dna ct islt isol qn naa+probe
86716-8,a pleuropn dna ct islt qn naa+probe lat
86716-8,a. pleuropneumoniae dna naa+probe (isol) [threshnum]
86716-8,a. a pleuropneumoniae leuropneumoniae d naa+probe (isol) [treshnum]
86716-8,lat a. pleuropneumoniae [threshnum] naa+probe (isol) dna
4438-8,tetrahydrocannabinol [mass] of dose
4438-8,tetrahydrocanabinol random [mass] of dse
4438-8,etrayrocannabinol [mass] dose of
4438-8,thc dose
4438-8,thc dose
4438-8,drug doses thc dose
4438-8,tetrahydrocannabinol (dose) [mass]
4438-8,tetrahyrocannainol qnt (ose ms]
4438-8,tetrahydrocannabinol(dose) [mass]
55815-5,dehydroepiandrosterone (dhea) [mass/volume] in 24 hour urine
55815-5,[mass/volume] (dhea) dehydroepiandrosterone in 24 hour urine
55815-5,hour (dhea) [mss/volume] in 24 dehyroepiandrosterone urine
55815-5,dhea 24h ur-mcnc
55815-5,dhea 24h ur-mcnc
55815-5,dhea ur-mcnc quantitative 24h
55815-5,dhea (24h u) [mass/vol]
55815-5,dhea (24h [mass/vol] u)
55815-5,dhea (24h ) [mass/vol]
86103-9,streptococcus pneumoniae danish serotype 10a igg ab [mass/volume] in serum by immunoassay --2nd specimen
86103-9,igg pneumoniae danish serotype 10a streptococcus ab [mass/volume] in serum by immunoassay --2nd specimen
86103-9,tretococcs pneumoniae ab[mass/volume] serotype 10a igg danish i eum by immunassay --2nd specimen
86103-9,s pneum da 10a igg sp2 ser ia-mcnc
86103-9,s pneum da 10a spn igg sp2ser ia-mcnc
86103-9,da pneum s 10a igg sp2 ser ia-mcnc
86103-9,s. pneumoniae danish type 10a igg spec 2 ia (s) [mass/vol]
86103-9,s. meia pneumonae daish type 10a igg spec 2 ia (s) [ms/vol
86103-9,s. pneumoniae danish type 10a igg spec meia 2 ia (s) [mass/vol]
93049-5,"mds v3.0 - rai v1.17.2 - correction request - sp, sd during assessment period [cms assessment]"
93049-5,"mds v3.0 - rai v1.17.2 - correction request - sp, during sd assessment period [cms assessment]"
93049-5,"rai v3.0 - mds v1.17.2 - correction request - sp, sd during assessment period [cms assessment]"
5918-8,urea nitrogen [mass/volume] in dialysis fluid
5918-8,urea nitrogen [mass/volume] in dialysis fluid
5918-8,urea nitrogen [mass/volume] in dialysis fluid
5918-8,urea nit dial fld-mcnc
5918-8,fld-mcnc nit dial urea
5918-8,dial nit urea fld-mcnc random
5918-8,urea nitrogen (dial fld) [mass/vol]
5918-8,urea fld) (dial nitrogen [mass/vol]
5918-8,nirogen urea (dal fld)[mass/vol]
47994-9,bilirubin.total [moles/volume] in cord blood
47994-9,biirubin.total quant [moles/volme i cord blood
47994-9,bilubin.total[moles/volume]n quantitative or blod
47994-9,bilirub bldco-scnc
47994-9,bldco-cnc bilirub
47994-9,bilirub bldco-scnc
47994-9,bilirubin (bldco) [moles/vol]
47994-9,tbil (bldco) bilirubin [moles/vol]
47994-9,bilirubin [moles/vol] (bldco)
26630-4,corynebacterium diphtheriae toxin ab [presence] in serum
26630-4,corynebacteriu diphtheriae xin ab [presc] n srum
26630-4,corynbacteiu diphteriae toxin c diphtheriae ab [presene] in seum
26630-4,c diphtheriae tox ab ser ql
26630-4,c diphtheriae tox b ser ql
26630-4,serum c diphtheriae tox ab ser ql
26630-4,c. diphtheriae toxin ab ql (s)
26630-4,c. diphtheriae oxin presence(s) ab microbiology
26630-4,c. diphtheriae toxin ab presence (s)
26023-2,extractable nuclear ab identified in serum
26023-2,exactale in ab identified nuclear serum
26023-2,etractable nuar ana abidentifiedin ser
26023-2,ena ser
26023-2,ser ena
26023-2,ena ser na
26023-2,extractable nuclear ab identified nom (s)
26023-2,identified ucearab nominal extrctable nom (s)
26023-2,extractable nuclear identified ab nom (s)
53087-3,calcium.ionized [moles/volume] adjusted to ph 7.4 in nonbiological fluid
53087-3,calcium.ionized adj [moles/volume] adjusted to ph 7.4 in nonbiological fluid
53087-3,calcium.ionized to adjusted [moles/volume] ph 7.4 in nonbiological fluid
53087-3,ca-i adj ph7.4 fld.nb-scnc
53087-3,ca-i adj ph7.4 qnt fld.nb-scnc
53087-3,adj ca-i ph7.4 fld.nb-scnc
53087-3,calcium.ionized adjusted to ph 7.4 (nonbiological fluid) [moles/vol]
53087-3,calcium.ionized fluid) to ph 7.4 (nonbiological adjusted [moles/vol]
53087-3,calcium.ionized adjusted to (nonbiological 7.4 ph fluid) [moles/vol]
59039-8,amylase [enzymatic activity/volume] in peritoneal dialysis fluid
59039-8,activity/volume] [enzymatic amylase k87 in peritoneal dialysis fluid
59039-8,amylase [enzymatic pertonel in actvity/volume] dialys flid
59039-8,amylase diafp-ccnc
59039-8,diafp-ccnc amylase
59039-8,diafp-ccnc amylase quan
59039-8,amylase (perit dial fld) [catalytic activity/vol]
59039-8,[catalytic (perit dial amyl fld) amylase activity/vol]
59039-8,amylas (peritdialld) catalytic concentration activiy/vol] ctalyti
12866-0,borrelia burgdorferi 18kd ab [presence] in cerebral spinal fluid by immunoblot
12866-0,flu burgdorferi 18kd ab [resece] in cerebal pina borelia by mmunolo
12866-0,fluid burgdorferi 18kd ab [presence] in cerebral spinal borrelia by immunoblot
12866-0,b burgdor18kd ab csf ql ib
12866-0,lyme b burgdor18kd ab cerebrospinal fluid ib ql
12866-0,b burgdor18kd ab cerebrospinal fluid ql ib
12866-0,b. burgdorferi 18kd ab ib ql (csf)
12866-0,b. burgdorferi 18kd a ib presence (csf)
12866-0,b. burgdorferi autoantibody 18k ql(cerebrospinal fluid ib ab
41959-8,walking speed in the past week mean calculated
41959-8,walkng sed mn the past week in alculated
41959-8,walkig speed in the past week ma calculatd
41959-8,walking speed 1w mean calc
41959-8,walking speed calc 1 week mean 1w
41959-8,walkin spe qnt w mean calc
44035-4,analgesics non-narcotic [presence] in serum or plasma
44035-4,analgesics non-narcotic sr [presence] or serum in plasma
44035-4,qual [presnce] aalgsicsnon-narcoti n ser or plsm
44035-4,analgesics non-narcotic serpl ql
44035-4,non-narcotic analgesics serpl ql
44035-4,pr nalgesics serpl nn-narcoti ql
44035-4,analgesics non-narcotic ql
44035-4,non-ncotic analgesics presence
44035-4,presence onnarcotic anagesics
85455-4,health and well-being panel [epcam]
85455-4,electronic patient centered assessment method health and well-being [epcam] panel
85455-4,panl nd heath well-engpanel epcam]
48638-1,cryoglobulin type [identifier] in serum by immunofixation
48638-1,cryoglobulin type [identifier] in serum by immunofixation
48638-1,in type [identifier] cryoglobulin serum by immunofixation
48638-1,cryoglob typ ser ife
48638-1,cryoglob typ cryoglobulins ser ife
48638-1,typ cryoglob serum ife
48638-1,cryoglobulin type immunofixation nom (s)
48638-1,noms type immunofixatin cryogobulin
48638-1,(s) type immunofixation nom immunofixation electrophoresis cryoglobulin
82849-1,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [molar ratio] in 24 hour urine
82849-1,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [molar ratio] in 24 hour ur urine
82849-1,in tetrahydrocortisol ur [mr rati] 11-ehydroorticosterone+etrahydrocorticosterone+alo-tetrahydrocortostrone/tetrahydrocortisone+tetrahyrocrtisol+5-alpha 24hour urine
82849-1,11-dhc+thb+5a-thb/the+thf+5a-thf 24h ur
82849-1,ur 24h 11-dhc+thb+5a-thb/the+thf+5a-thf
82849-1,11-dhc+thb+5a-thb/the+thf+5a-thf ur 24h
82849-1,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol (24h u) [molar ratio]
82849-1,[molar quant tetrahydrocortisol (24h u) 11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/tetrahydrocortisone+tetrahydrocortisol+5-alpha ratio]
82849-1,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/tetrahydrocortisone+tetrahydrocortisol+5-alpha (24h tetrahydrocortisol u) 5-alpha tetrahydrocorticosterone [molar ratio]
68392-0,basophils [#/volume] in peritoneal fluid by manual count
68392-0,basophils peritoneal in [#/volume] fluid by manual count
68392-0,basophils [#/volume] in peritoneal fluid count by manual count
68392-0,basophils # prt manual
68392-0,manual # ascites prt basophils
68392-0,mnul # prt bashils
68392-0,basophils manual cnt (periton fld) [#/vol]
68392-0,basophils manual cnt (periton fld) ct [#/vol]
68392-0,random bashils manual cnt(periton fld) [#/vol]
27057-9,serotonin [mass/volume] in serum
27057-9,serotnin in [mass/volme] serum
27057-9,c10h12n2o [mas/volume] sertoin in serum
27057-9,serotonin ser-mcnc
27057-9,serum-mcnc serotonin
27057-9,serotonin serum ser-mcnc
27057-9,serotonin (s) [mass/vol]
27057-9,serotonin [mass/vol] (s)
27057-9,(s) serotonin [mass/vol]
89572-2,"oasis e - functional abilities and goals - soc, roc during assessment period [cms assessment]"
89572-2,"oasis e [cms functional abilities and goals - soc, roc during assessment period - assessment]"
89572-2,"oasis e - functional abilities and goals - soc, roc during assessment period [cms centers for medicare and medicaid assessment assessment]"
93866-2,c4 nephritic factor [presence] in serum or plasma
93866-2,c4 nephitc factr [pesence] i erum or plasma
93866-2,c nephritic actor [presene] n serum serpl or plasma
93866-2,c4 nef serpl ql
93866-2,c4 serpl nef ql
93866-2,nef c4 serpl ql
93866-2,c4 nephritic factor ql
93866-2,nephritic c4 factor ql
93866-2,c4 nephritic factorql
28038-8,gamma hydroxybutyrate [mass/volume] in blood
28038-8,gamma hdoybuyrate in [mas/voume] blood
28038-8,gamma blood [mass/volume] in hydroxybutyrate
28038-8,g-oh-butyr bld-mcnc
28038-8,blood-mcnc g-oh-butyr georgia home boy
28038-8,4-hydroxybutyric acid bld-mcnc g-oh-butyr
28038-8,gamma hydroxybutyrate (bld) [mass/vol]
28038-8,gamma hydroxybutyrate (bld) [mass/vol]
28038-8,hydroxybutyrate gamma (blood) [mass/vol]
47383-5,nuclear ab [presence] in serum by immunoassay
47383-5,nuclear immunoassay [presence] in serum by ab
47383-5,immuoassay a [presnce] in serum by nuclear
47383-5,ana ser ql ia
47383-5,elisa an ser ql ia
47383-5,ana serum ql ia
47383-5,nuclear ab ia ql (s)
47383-5,nulear ab ia ql autoantibodies (s)
47383-5,nuclear (s) ia ql ab
55440-2,cholesterol.in ldl (real) [mass/volume] in serum or plasma by vap
55440-2,cholesterol.in qnt ldl (real) [mass/volume] in serum or plasma by vap
55440-2,cholesterol.in ldl (real) [mass/volume] serpl in serum plas or by vap
55440-2,ldlc-r serpl vap-mcnc
55440-2,ldlc-r serpl v-mcnc plsm
55440-2,ldlc-r serpl vap-mcnc
55440-2,cholesterol in ldl vap [mass/vol]
55440-2,choestroin vap ldl [mas/vol] quant
55440-2,cholesterol in ldl vap [mass/vol]
18330-1,neutrophil cytoplasmic igg ab [units/volume] in serum
18330-1,igg cyoplamic neutphil b [units/volue] n erum
18330-1,neutrophi arbitrary concentration ytoplsmi igg ab [units/volume] in seum
18330-1,anca igg ser-acnc
18330-1,anca ser-acnc igg
18330-1,igg anca serum-acnc immunoglobulin g
18330-1,neutrophil cytoplasmic igg qn (s)
18330-1,anca qn cytoplasmic ig neutrophil ()
18330-1,neutrophil cytoplasmic igg qn (s)
45991-7,communication and hearing patterns section
45991-7,communicaion and earig patens setion
45991-7,mmuncation and hearig ptterns sectin
73752-8,reagin and treponema pallidum igg and igm [interpretation] in serum or plasma
73752-8,reain and trepoemapallium igg and igm pasma in serum or [inerpretaion
73752-8,reagin and and pallidum igg treponema igm [interpretation] in serum or plasma
73752-8,reagin+t pallidum igg+igm serpl-imp
73752-8,reagin+t serpl-imp igg+igm pallidum autoantibodies
73752-8,reagin+t serpl-imp igg+igm pallidum
73752-8,reagin and t. pallidum igg and igm [interp]
73752-8,plsm reagin and t. pallidum igg and igm [interp]
73752-8,reagin ad an tpallidumigg igm iter]
53860-3,fatty acids.very long chain c24:0 (tetracosanoate) [mass/volume] in serum or plasma
53860-3,fatty c24:0 long chain acids.very (tetracosanoate) [mass/volume] in ser or plasma
53860-3,fatty acids.very long chain c24:0 [mass/volume] (tetracosanoate) in serpl
53860-3,vlcfa c24:0 serpl-mcnc
53860-3,sepl-mcnc vcfac24:0
53860-3,vlcfa serpl-mcnc c24:0
53860-3,fatty acids.very long chain c24:0 (tetracosanoate) [mass/vol]
53860-3,fttyacids.very long chanc24: (tetracosanate) mas/vl]
53860-3,fatty acids.very long c24:0 chain (tetracosanoate) [mass/vol]
101285-5,pharyngeal pathogens dna and rna panel - throat by naa with non-probe detection
101285-5,pharyngea athogens dna and rna l nucleic acid sequence based analysis with throatbnaa - non-probe detection
101285-5,hryngeal pathoens dna and rnapanel -throat by na ithno-probe detection
101285-5,pharyngeal path pnl non-probe
101285-5,3 self-sustaining sequence replication haryngeal pathpnl no-probe
101285-5,pharyngeal path pnl non-probe lcr
101285-5,pharyngeal pathogens dna & rna panel naa+non-probe (throat)
101285-5,rna pathogens dna & pharyngeal panel naa+non-probe (throat)
101285-5,pharygal pathogen da & rna pne naa+non-probe (thot)
1962-0,deprecated bicarbonate [moles/volume] in plasma
1962-0,deprecated plasma [moles/volume] in bicarbonate
1962-0,deprecatd bicarbonate [moles/volume] in plsm
1962-0,deprecated hco3 plas-scnc
1962-0,deprecated hco3 plasma-scnc
1962-0,plas-scnc pt hco3 deprecated
1962-0,hco3 (p) [moles/vol]
1962-0,(p)[moles/vol] hco3
1962-0,hco3 [moles/vol] (p)
64137-3,pregabalin [presence] in urine by screen method
64137-3,pregabalin drug/toxicology [presence] n by urne sren mehod
64137-3,pregabalin by drug/toxicology in urine [presence] screen method
64137-3,pregabalin ur ql scn
64137-3,sn pregabalinurl
64137-3,regabalin ur ql scr sc
64137-3,pregabalin screen ql (u)
64137-3,ur pregabalin sreen q (u)
64137-3,drugs of abuse pregabalin screen presence (u)
50815-0,arsenic.inorganic [moles/time] in 24 hour urine
50815-0,arsenic.inorganic in [moles/time 24 houruri quant
50815-0,arsenic.inorganic [moles/time] urine 24 hour in
50815-0,inorg arsenic 24h ur-srate
50815-0,inorg ur-srate 24h arsenic
50815-0,arsnic inog 24h ur-srate
50815-0,arsenic.inorganic (24h u) [moles/time]
50815-0,u) inorg arsenic (24h arsenic.organic [mols/ime]
50815-0,arsenic.inorgani(24h ) [moles/time]
14286-9,carnitine free (c0) [moles/volume] in serum or plasma
14286-9,serum free (c0) [moles/volume] in carnitine or plasma
14286-9,carnitine ee (c0 [mles/volume] plasma ser or in
14286-9,carnitine free serpl-scnc
14286-9,serpl-scnc free crnitine
14286-9,free pl carnitine serpl-scnc
14286-9,c0 [moles/vol]
14286-9,serplas [mols/vol] c0
14286-9,c0 [moles/vol]
14257-0,tetrachlorodiphenylethane [mass/volume] in serum or plasma
14257-0,tetrachlorodiphenylethane serum in [mass/volume] or plasma
14257-0,tetrachlorodiphenylethne [mass/volume] in serum serpl o plasma
14257-0,ddd serpl-mcnc
14257-0,serpl-mcnc ddd
14257-0,dd serpl-mnc
14257-0,tetrachlorodiphenylethane [mass/vol]
14257-0,serpl [mass/vol] tetrachlorodiphenylethane
14257-0,[mass/vol] tetrachlorodiphenylethane
1980-2,biotin [mass/volume] in serum or plasma
1980-2,biotin mass concentration [mass/volume] in serum plas or
1980-2,bitin plas [mass/vlu] in serum rlama
1980-2,biotin serpl-mcnc
1980-2,biotin quantitative serum or plasma-mcnc
1980-2,btin serl-mcc
1980-2,biotin [mass/vol]
1980-2,[mss/vol] iotn
1980-2,biotin [mass/vol] vitamin h
43843-2,brucella abortus igg ab [units/volume] in serum by immunoassay
43843-2,brella aortus immune globulin g ab ig [units/volume] in ser immunoassay
43843-2,brucell abortusigg ab [unis/volum in seru by immunoassay
43843-2,b abortus igg ser ia-acnc
43843-2,b ser igg abortus ia-acnc
43843-2,igg abortus b ser ia-acnc
43843-2,b. abortus igg ia qn (s)
43843-2,b. abortus igg ia (s) autoantibodies qn
43843-2,b. abortus igg ia qn (s)
101428-1,varicella zoster virus dna [presence] in respiratory system specimen by naa with probe detection
101428-1,varicella zoster virus dna [presec] etection repiratory systmpeimen by naa with probe in
101428-1,varicela oster virus dna [presence] inrespratory syte specmen by aa detection probe ith
101428-1,vzv dna resp ql naa+probe
101428-1,vzv dna qbr resp ql naa+probe
101428-1,vzv dna resp naa+probe ql
101428-1,vzv dna naa+probe ql (respiratory system specimen)
101428-1,vzv dna naa+probe (respiratory ql system specimen)
101428-1,v nasba dnanaa+probe ql (espirtory system speimen)
103620-1,lupus anticoagulant aptt screening panel - platelet poor plasma by coagulation assay
103620-1,nticoguant lupus aptt screeningpael - platetpor plasm by coagulation assay
103620-1,lupus anticoagulant aptt screening panel platelet - poor plasma by coagulation assay
103620-1,la aptt screening panel ppp
103620-1,panel aptt screening clot l ppp
103620-1,la ppp screening panel plas aptt
103620-1,lupus anticoagulant aptt screening panel coag (ppp)
103620-1,lupus anticogulantaptt screening panel cog (pp)
103620-1,lupus panel aptt screening anticoagulant coag (ppp)
107343-6,human bocavirus dna [presence] in sputum by naa with probe detection
107343-6,human ocaviru na [presnce] insputum by a with probe detecio lat
107343-6,human bocavirus dna [ql] in sputum by naa with probe detection
107343-6,hbov dna spt ql naa+probe
107343-6,hovdna spt presence na+probe
107343-6,hov dna ql naat point in time naa+probe
107343-6,human bocavirus dna naa+probe ql (sput)
107343-6,human bocvirus da naa+probe naa+probe ql (sput
107343-6,human naa+probe dna bocavirus ql (sput)
60129-4,paraoxon [mass/volume] in blood
60129-4,level paraoxon [mass/volume] in blood
60129-4,paraoon[massvlume] quantitative in bld
60129-4,paraoxon bld-mcnc
60129-4,paraoxon bld-cnc
60129-4,bld-mcnc paraoxon
60129-4,paraoxon (bld) [mass/vol]
60129-4,[assvol] paraoxo(bld
60129-4,drugs [ms/vol] paraoon(bld)
97640-7,thyroglobulin [moles/volume] in tissue fine needle aspirate
97640-7,thyroglobulin[moles/voume] in tissu ine eede aspirat
97640-7,thyroglobulin [moles/volume] in tissue aspirate needle fine
97640-7,thyroglob tiss fna-scnc
97640-7,tiss thyroglob fna-scnc
97640-7,thyroglob tisfna-scnc
97640-7,thyroglobulin (tissue fine needle aspirate) [moles/vol]
97640-7,hyrogobulin (tissue ine nedl aspirate) [moles/vol]
97640-7,[moles/vol] (tissue fine needle aspirate) thyroglobulin tissue
48338-8,histoplasma capsulatum ag [presence] in tissue by immune stain
48338-8,histoplasma in ag [presence] capsulatum tissue by immune stain
48338-8,sue casulatum ag[pesence] in hitoplama by immune stain
48338-8,h capsul ag tiss ql imstn
48338-8,h capsul ag stains tiss ql imstn
48338-8,imstn capsul ag tiss ql h
48338-8,h. capsulatum ag immune stain ql (tiss)
48338-8,stain capsulatum ag immune h. h capsulatum l tiss
48338-8,(tis) capsultumag immunostain immu stainql h.
90994-5,iothalamate renal clearance
90994-5,clearance renal iothalamate
90994-5,clearance renal iothalamate
90994-5,iothalamate renal clearance
90994-5,iothalamate renal clearance
90994-5,iothalamate renal sr clearance
90994-5,iothalamate clearance (u+s/p) [vol/time]
90994-5,iotalamate clearne (u+s/p) vol/time]
90994-5,iothalamat urn clearance (u+s/p) [vo/time]
64129-0,n-desalkylflurazepam/creatinine [mass ratio] in urine
64129-0,urn n-desalkyflurazepam/creatinine [mass rin atio]in
64129-0,n-desalkylflurazepa/creatinine [mass urie in atio]
64129-0,desalkylfluraz/creat ur
64129-0,ur drug/toxicology desakylfluraz/creat
64129-0,dalkylfuraz/cret ur
64129-0,n-desalkylflurazepam/creatinine (u) [mass ratio]
64129-0,n-esakylflurazpam/ceatnne flurazepam metabolite (u)[mss ratio
64129-0,n-desalkylflurazepam/creatinine (u) [mass rao]
53056-8,decanoylcarnitine (c10) [moles/volume] in amniotic fluid
53056-8,quant decanoylcarnitine (c10) [moles/volume] in amniotic fluid
53056-8,decanoylcarnitine (c10) random [moles/volume] in amniotic fluid
53056-8,decanoylcarn amn-scnc
53056-8,c10 denoylcarnamn-scnc
53056-8,amn-scnc decanoylcarn
53056-8,c10 (amn fld) [moles/vol]
53056-8,level c10 fld) (amn [moles/vol]
53056-8,c10 fld) (amn [moles/vol]
13813-1,succinylacetone/creatinine [mass ratio] in urine
13813-1,succinylaetone/creatinin [mass ratio] urn in urne
13813-1,ua succnylacete/cratinine [mas urine in ratio]
13813-1,succinylacetone/creat ur
13813-1,ur succinylacetone/creat
13813-1,quantitative sucinylacetoe/reat ur
13813-1,succinylacetone/creatinine (u) [mass ratio]
13813-1,[massratio] () succinylacetonecreainine
13813-1,succinylacetone/creatinine ua [mass (u) ratio]
760-9,neutrophils [#/volume] in synovial fluid by manual count
760-9,neutrophils [#/volume] in synovial fluid by manual sf count
760-9,neutrophils synoil in [#/volume] fli by anual count
760-9,neutrophils # snv manual
760-9,neutrophils # snv manual
760-9,count/volume neutrophils # manual snv
760-9,neutrophils manual cnt (syn fld) [#/vol]
760-9,etrophils (yn nt manual ld [#/vl]
760-9,number concentration (count/vol) neutrophils manual cnt (syn fld) [#/vol]
43043-9,echovirus 11 ab [titer] in body fluid
43043-9,echovirus 11 ab[titer] ecv11 in body fluid
43043-9,echovirus in ab [titer] 11 body fluid
43043-9,ecv11 ab titr fld
43043-9,ecv1 titr antby ab ld
43043-9,ecv11 ecv11 titr ab fld
43043-9,echovirus 11 ab (body fld) [titer]
43043-9,echovirus 11 ab (body fld) microbiology [titer]
43043-9,1 echovrus b (body fld) [titer]
93213-7,lcds v5.00 - cognitive patterns - admission and planned discharge during assessment period [cms assessment]
93213-7,lcds v5.00 - cognitive patterns period admission and planned discharge during assessment - [cms pan assessment]
93213-7,lcds v5.00 - cognitiv patterns - admissin and pan planed dischae during asesment period [cms asesment]
35069-4,basophils/leukocytes in peritoneal fluid
35069-4,peritoneal asophil/leuocytes flid
35069-4,basopisleukocytes fluid peritoeal
35069-4,basophils nfr prt
35069-4,nf sopils prt
35069-4,nfr basophils prt
35069-4,basophils/leukocytes (periton fld)
35069-4,white blood cell asophil/lekoctes (eritonfld)
35069-4,fld) (periton basophis/leukoyts
76771-5,respiratory pathogens rna 8 panel - specimen by naa with probe detection
76771-5,respiratory id pathogens rna 8 panel - specimen by naa with probe detection
76771-5,respiratoypthogens rna 8 - pnl secmen by naith probe detection
76771-5,resp path rna 8 panel spec naa+probe
76771-5,resp th rna8 panel qbr spe a+probe
76771-5,resp path rna 8 panel spec naa+probe resp path rna 8 panel
76771-5,respiratory pathogens rna 8 panel naa+probe (specimen)
76771-5,respiratory pathogens rna 8 transcription mediated amplification panel naa+probe (specimen)
76771-5,8 pcr ra repiratorypathoens panelnaa+prob specimen)
76633-7,glomerular filtration rate/1.73 sq m.predicted by creatinine-based formula (mdrd) in blood
76633-7,glomerular filtration rate/1.73 sq m.predicted by creatinine-based formula (mdrd) in blood
76633-7,glomerular filtration ate/.73 qmpredictedby creatiine-base formula (mdr i blod
76633-7,gfr/bsa.pred bld mdrd-arvrat
76633-7,gfr/bsapred bld chemistry drd-arvrat
76633-7,ld gr/sa.pred mdr-arvra
76633-7,gfr creatinine-based formula (mdrd)/1.73 sq m (bld) [vol rate/area]
76633-7,gfr creatinine-based formula (mdrd)/1.73 sq m quant [vol (bld) rate/area]
76633-7,gfr creatinine-based formula (mdrd)/1.73 sq quantitative m (bld) [vol rate/area]
71641-5,macrophages/leukocytes [pure number fraction] in body fluid by manual count
71641-5,ody macrphg [pue number frctio] in macrphges/leukocytes fluid by manl unt
71641-5,macophags/leukcyts pre nmber fration] body fluid by maual count point in time
71641-5,macrophages nfr.df fld manual
71641-5,macrophages nfr.df fld manual
71641-5,macrophages nfr.df fld quantitative manual
71641-5,macrophages/leukocytes manual cnt (body fld) [pure # fraction]
71641-5,macrophages/leukocytes manual cnt (body fld) [pure # fraction]
71641-5,[pure manual cnt (body fld) macrophages/leukocytes # fraction]
17958-0,bacteria # 3 identified in body fluid by anaerobe culture
17958-0,in #3 idetified bcteria od fudby anerobe cture
17958-0,bacteria # 3 idenified in bod fluidby anaerobe clture
17958-0,bacteria fld anaerobe cult org #3
17958-0,actria fld aaerobe cult #3 rg
17958-0,baterafld anaerbe fluid cult org 3
17958-0,bacteria identified # 3 anaer cx nom (body fld)
17958-0,bacteria identified fld) 3 aaer cxnom infectiousdisease (bdy #
17958-0,bateria ieniie fld) anrcx nom (bdy 3
22930-2,brucella canis ab [presence] in serum by agglutination
22930-2,brucella canis ab [presence] in serum by agglutinaion
22930-2,brucelcans ab [presence] in serum by aggluination pr
22930-2,b canis ab ser ql aggl
22930-2,b canis ab presence ser aggl
22930-2,b canis ab ser ql aggl agglut
22930-2,br. canis ab aggl ql (s)
22930-2,(s) canis ab aggl ql br.
22930-2,sr br. cani ab qls) a
94455-3,arsenobetaine [mass/volume] in urine
94455-3,urine ur [mass/volume] in arsenobetaine
94455-3,asenobetaine i [mass/volme] random urine
94455-3,arsenobetaine ur-mcnc
94455-3,arseobetaine ur-mcnc mass concentration
94455-3,ur-mcnc level arsenobetaine
94455-3,arsenobetaine (u) [mass/vol]
94455-3,[mas/vol] quantitative (u) arsenobetaine
94455-3,arsenobetaine [mass/vol] urn (u)
24191-9,coxsackievirus b4 neutralizing antibody [titer] in serum by neutralization test --1st specimen
24191-9,coxsackievirus b4 neutralizing antibody [titer] in serum by neutralization test --1st specimen first
24191-9,coxsackievirus b4 neutralizing antibody [titer] in ser by neutralization titered test --1st specimen
24191-9,cv b4 nab sp1 titr ser nt
24191-9,cv b4 nab pre immunization sp1 titr ser nt
24191-9,cv b4 nab sp1 titr ser conventional virus neutralization test nt
24191-9,coxsackievirus b4 neut ab spec 1 neut test (s) [titer]
24191-9,1 nt b neut ab spec oxsackievirus neut st (s) [titer
24191-9,test b4 neut ab spec 1 neut coxsackievirus (s) [titer]
14544-1,measles virus ag [presence] in urethra by immunofluorescence
14544-1,measles virus ag [peece]in urethra by immuoflurescence
14544-1,measles immunofluorescence ag [ql] ifa in urethra by virus
14544-1,mev ag urth ql if
14544-1,mev fluorescent antibody ag if presence urth
14544-1,if ag th ql mev
14544-1,mev ag if ql (urethra)
14544-1,mev ag if ql (uretra)
14544-1,mv ag if qualitative ql (urethra)
2490-1,inulin [mass/volume] in serum or plasma
2490-1,ser [mass/volume] in inulin or plasma
2490-1,inulin plasma in ser or [mass/volume]
2490-1,inulin serpl-mcnc
2490-1,inuin serpl-mcnc
2490-1,inulin quan serpl-mcnc
2490-1,inulin [mass/vol]
2490-1,quan [mass/vo] iuin
2490-1,[mass/vol] inulin plsm
33833-5,lymphocytes immunoblastic/leukocytes in blood by manual count
33833-5,lymphocytes blood in immunoblastic/leukocytes by manual count lympho
33833-5,ymphocytes immunblastic/ekocytes in blod by manual cont
33833-5,ib lymphs nfr bld manual
33833-5,manual lymphs nfr blood ib
33833-5,manual random lymphs nfr bld ib
33833-5,lymphocytes immunoblastic/leukocytes manual cnt (bld)
33833-5,lyphocyes immnoblasticleukocytes manal qnt cnt(bld)
33833-5,ymphocytes (ld) maual cnt white blood cells immunolasti/leukocytes
30543-3,osmotic fragility of red blood cells--0.75% sodium chloride
30543-3,osmotic fragility of red blood cells--0.75% sodium chloride
30543-3,osmotic fragilit of r blood cells-0.75% sodiu chloride
30543-3,of .75% nacl nfr rbc
30543-3,of .75% cl nacl nfr rbc
30543-3,of .75% nacl nfr rbc
30543-3,osmotic fragility 0.75% sodium chloride (rbc)
30543-3,osmotic fragility 0.75% sodium (rbc) chloride of
30543-3,osmotic sodium 0.75% fragility chloride (rbc)
46004-8,unsettled releationships set
46004-8,unstled set releationsips
46004-8,releationships survey unsettled set
32854-2,17-hydroxyprogesterone [presence] in dbs
32854-2,[rece] 17-hydrxyprogesterne in dbs genetics
32854-2,dbs [presence] in dried blood spot 17-hydroxyprogesterone
32854-2,17ohp dbs ql
32854-2,17ohp dbs 17-ohp ql
32854-2,ql dbs 17ohp
32854-2,17-hydroxyprogesterone ql (dbs)
32854-2,wb ql 17-hydroxyprogesterone (dbs)
32854-2,ql 17-hydroxyprogesterone (dbs)
54566-5,swallowing disorder
54566-5,survey dsorde swallowing
54566-5,deglutition swallowing disorder
76630-3,amylase [enzymatic activity/volume] in blood
76630-3,amylase [enzymatic in activity/volume] blood amyl
76630-3,amylase activity/volume] [enzymatic in blood
76630-3,amylase bld-ccnc
76630-3,blood bld-cnc amlase
76630-3,amylase blood-ccnc
76630-3,amylase (bld) [catalytic activity/vol]
76630-3,amylase [catalytic (bld) activity/vol]
76630-3,amylase (bl) [caalytic whole bld activty/ol]
67561-1,corynebacterium diphtheriae dna [presence] in specimen by naa with probe detection
67561-1,probe diphtheriae dna [presence] in specimen by naa with corynebacterium detection
67561-1,corynebacterium diphtheriae [presence] dna in specimen by naa with probe detection
67561-1,c diphtheriae dna spec ql naa+probe
67561-1,c diphtheriae dna ql spec naa+probe
67561-1,naa+pre dphtheriae dnapec ql c amplification
67561-1,c. diphtheriae dna naa+probe ql (specimen)
67561-1,c. diphtheriae ql naa+probe dna (specimen)
67561-1,diphtheriae c. dna naa+probe ql (specimen) pr
74138-9,immature monocytes [presence] in blood
74138-9,[presence] monocytes immature in blood
74138-9,immature bld monocytes [presence] in bld
74138-9,imm moncytes bld ql
74138-9,ql moncytes bld imm imm
74138-9,moncytes imm qualitative bld presence
74138-9,immature monocytes ql (bld)
74138-9,presence mature onocytes l(bl)
74138-9,immature monocyte (bld) presence monocytes
74312-0,prrsv [presence] in specimen by organism specific culture
74312-0,rrsv [resence] n spcimen organism by specific culture
74312-0,prrsv [ql] in organism ordinal by specimen specific culture
74312-0,prrsv spec ql cult
74312-0,prrsv sec cult ql
74312-0,spec prrsv ql cult
74312-0,prrsv org specific cx ql (specimen)
74312-0,org prrsv pecific x ql (specien
74312-0,prrsv org specific pork cx presence (specimen)
74783-2,malignant cells [presence] in body fluid by light microscopy
74783-2,malignant cells [presence] in boy fluid by light microscop
74783-2,mlignant cells [presene] in bdy flud bylight microscopy
74783-2,malignant cells fld ql micro
74783-2,malignant cell fdql micr
74783-2,malignant cells fld q micro
74783-2,malignant cells lm ql (body fld)
74783-2,maligantcells lm presence (bodyfld) body fluid
74783-2,aliant cells m ql(body fld)
25374-0,chromium [moles/volume] in serum or plasma
25374-0,hromium [moles/volume] in or serum plasm
25374-0,chromium plasa in serum or [moles/volume]
25374-0,cr serpl-scnc
25374-0,serpl-scnc cr
25374-0,sepl-scnc c
25374-0,chromium [moles/vol]
25374-0,[moles/vol] chromium
25374-0,chromium quan [moles/vol]
62424-7,human bocavirus dna [presence] in specimen by naa with probe detection
62424-7,hman bocviu dna [prsnce] in specimen by naa with robe eection
62424-7,human aa dna [pesence] n secimen b bcavirus amplified wih probe detecion
62424-7,hbov dna spec ql naa+probe
62424-7,naa+probe dna spec ql hbov
62424-7,hbov ql spec dna naa+probe
62424-7,human bocavirus dna naa+probe ql (specimen)
62424-7,human bocavirus dna presence presence naa+probe (specimen)
62424-7,human boavirus dna naa+probe l (specimen)
86033-8,streptococcus pneumoniae danish serotype 19f ab [units/volume] in serum --1st specimen
86033-8,streptococcus pneumoniae danish serotype 19f ab [units/volume] in serum --1st specimen
86033-8,streptococcus danish pneumoniae serotype 19f ppsv23 ab [units/volume] in serum --1st specimen
86033-8,s pn da sero 19f ab sp1 ser-acnc
86033-8,s pn da seo 19f ab sp1 serum-acnc
86033-8,s pn pneumococcal da sero 19f ab sp1 ser-acnc
86033-8,s. pneumoniae danish type 19f ab spec 1 qn (s)
86033-8,s. 1 danish type 19f a spec nemonae qn (s)
86033-8,s. pneumoniae danish ab 19f type spec 1 qn (s)
56525-9,5-hydroxytryptophan [mass/volume] in urine
56525-9,drug/toxicology [mass/volume] 5-hydroxyryptophan n urin
56525-9,5oh-tryptophan [mass/volume] 5-hydroxytryptophan in urine
56525-9,5oh-tryptophan ur-mcnc
56525-9,5oh-tryptophan 5oh-tryptophan ur-mcnc
56525-9,ur-mcnc 5oh-tryptopa
56525-9,5-hydroxytryptophan (u) [mass/vol]
56525-9,5hydroxytrptophan (u) [massvol]
56525-9,5-hydroxytryptophan [mass/vol] ur (u)
35616-2,lorazepam [mass/volume] in serum or plasma by screen method
35616-2,lorazepam random screen in serum or plasma by [mass/volume] method
35616-2,loazpm [mas/volum] in erum or plasa y scree metho
35616-2,lorazepam serpl scn-mcnc
35616-2,loraeam serpl qnt s-mcnc
35616-2,erpl serum orazepm scn-mcnc
35616-2,lorazepam screen [mass/vol]
35616-2,lorazepam drugs screen [mass/vol]
35616-2,[mass/vol] scren plsm lorazepam
61367-9,clostridioides difficile dna [presence] in specimen by naa with probe detection
61367-9,clostridioides difficile dna [presence] detection specimen by ligation-activated transcription naa with probe in
61367-9,[presence] difficile miscellaneous dna clostridioides in specimen by naa with probe detection
61367-9,c diff dna spec ql naa+probe
61367-9,naa+probe c diff dna spec ql naa+probe
61367-9,c deoxyribonucleic acid diff na ec presence aa+robe
61367-9,c. difficile dna naa+probe ql (specimen)
61367-9,difficile c. dnanaa+pob ql tma (specimen)
61367-9,c. iffiile dna naa+probe ql (secn)
51473-7,streptococcus pneumoniae capsular polysaccharide igg2 ab [mass/volume] in serum
51473-7,streptococcus pneumoniae capsular polysaccharide igg2 ab [mass/volume] in pneum serum
51473-7,in pneumoniae capsular polysaccharide igg2 ab [mass/volume] streptococcus serum
51473-7,s pneum cps igg2 ser-mcnc
51473-7,s qnt pneum cps ser-mcnc igg2
51473-7,s pneum cps igg2 ser-mcnc
51473-7,s. pneumoniae capsular polysaccharide igg2 (s) [mass/vol]
51473-7,s. peumonae apsular polysacharide igg2 (s) [mass/vol] anti
51473-7,s. pneumoniae capsular polysaccharide igg2 [mass/vol] (s)
2114-7,choriogonadotropin.beta subunit [moles/volume] in urine
2114-7,choriogonadotrpn.beta urine moles/volume] in subunit
2114-7,choriogonadotropin.beta in [moles/volume] subunit quan urine
2114-7,b-hcg ur-scnc
2114-7,b-hcg ursnc
2114-7,ur-scnc b-hcg
2114-7,hcg.beta subunit (u) [moles/vol]
2114-7,hcg.beta subunit moles/vol] (u)
2114-7,hcg.beta [moles/vol] (u) subunit
11475-1,microorganism identified in specimen by culture
11475-1,specimen identified in microorganism random by culture
11475-1,microorganism identified in other specimen by culture
11475-1,microorganism spec cult
11475-1,icroorganism cult spec
11475-1,microorganism spec cult microbiology
11475-1,microorganism identified cx nom (specimen)
11475-1,om c microorganismienifed cult (specimen)
11475-1,microoganism idtfied c (specime nom
2123-8,chymotrypsin [enzymatic activity/volume] in body fluid
2123-8,chyotrysin [enzmaic ctivivolume] in bodyfluid chymotrypsine
2123-8,chymotrypsin [enzymatic activity/volume] in body fluid
2123-8,chymotryp fld-ccnc
2123-8,fl-ccnc hymotryp random
2123-8,chymotryp body fluid fld-ccnc
2123-8,chymotrypsin (body fld) [catalytic activity/vol]
2123-8,chymotrypsn fld)[catalytic (body activity/vo]
2123-8,fluid (body chymotrypsin fld) [catalytic activity/vol]
86883-6,"mds v3.0 - rai v1.14.1, v1.15.1 - cognitive patterns - no, so during assessment period [cms assessment]"
86883-6,"mds v3. -rai v1.14.1, v1.15.1 - cgnitive assessmnt] - o, so during assessmet period [cms pattern"
86883-6,"ms v3.0 rai v114.1, v115.1 - ognitive paterns - no, asessmen] uring assessment peiod [cms so"
54362-9,bilirubin.total [moles/volume] in dialysis fluid
54362-9,bilirubin.toal[mole/volume]in chemistry dialysis fluid
54362-9,bilirubin.otal n [moles/volume] dilysis fluid billirubin
54362-9,bilirub dial fld-scnc
54362-9,billirubin fd-sc dil bilirub
54362-9,dial bilirub fld-scnc
54362-9,bilirubin (dial fld) [moles/vol]
54362-9,ilirubin fld) (dial [mles/vol]
54362-9,ilrubi level [moles/vol] fld) (dial
16442-6,benzene ring igm ab [units/volume] in serum
16442-6,[units/volume] ring igm ab benzene in serum
16442-6,benzene in igm ab [units/volume] ring serum
16442-6,benzene ring igm ser-acnc
16442-6,antibodies benzene ring im sr-acc
16442-6,ring benzene igm ser-acnc arbitrary concentration
16442-6,benzene ring igm qn (s)
16442-6,benzen (s igm qn ring
16442-6,benzene ring quantitative igm qn (s)
93725-0,heparan sulfate [mass/volume] in serum or plasma
93725-0,heparan sulfate [mas/volume] in serum or plasma
93725-0,hearan sulfate srum in [mass/vome] serum or plasma or plasma
93725-0,heparan sulfate serpl-mcnc
93725-0,sulfate heparan serpl-mcnc
93725-0,heparan serum or plasma-mcnc sulfate
93725-0,heparan sulfate [mass/vol]
93725-0,heparan [mass/vol] mass concentration sulfate
93725-0,heparan pt sulfte [mass/vol]
38394-3,legionella sp identified in urine by organism specific culture
38394-3,lionela sp ulture inurine by orgaism specifc infectious disease identiied
38394-3,legionella sp identified in urine by organism ur specific culture
38394-3,legionella ur cult
38394-3,legionella ur cult
38394-3,legoella legion ur cult
38394-3,legionella sp identified org specific cx nom (u)
38394-3,legonella (u legion og specific cx nom spidentified
38394-3,spcfic legionela sp identifiedor legionella cx nom (u)
104805-7,creatinine renal clearance predicted
104805-7,creatiine pdite clearance enl
104805-7,clearance renal creatinine predicted
104805-7,creat cl predicted serpl-vrate
104805-7,ceatcl redicted pl serpl-vrate
104805-7,reat cl preicted serum or plasma-vrate
104805-7,creatinine renal clearance predicted [vol/time]
104805-7,clarance clearances renl creatinne predicted [vl/time]
104805-7,creatinine renl clearance predicted [vo/time]
22841-1,avian pox virus ab [presence] in serum by immunoassay
22841-1,avian pox virus ab [presence] in ser by immunoassay
22841-1,avin pox irus avian pox ab [resence] i sum by immunoassay
22841-1,fwpv ab ser ql ia
22841-1,fwpv sr ab ser presence ia
22841-1,ia ab ser ql fwpv
22841-1,avian pox virus ab ia ql (s)
22841-1,avian pox virus (s) ia ql ab
22841-1,avian pox visbaql ()
50900-0,platinum [moles/mass] in hair
50900-0,hair [moles/mass] in platinum
50900-0,[moles/mass] platinum in hair
50900-0,platinum hair-scnt
50900-0,hair-scnt platinum har
50900-0,hair-scnt qnt platinum
50900-0,platinum (hair) [moles/mass]
50900-0,quantitative [moles/as] (air) platinum
50900-0,platinum [moles/mass] (hair)
30558-1,sodium [moles/volume] in total parental nutrition
30558-1,sodium [moles/volume] in total quantitative parental nutrition
30558-1,soium in [moles/volume] ttal parentanutrition
30558-1,sodium tpn-scnc
30558-1,tpn-cnc sodium
30558-1,odium na tpn-scnc
30558-1,sodium (total parental nutrition) [moles/vol]
30558-1,point in time sodium parental (total nutrition) [moles/vol]
30558-1,qnt sodium (total parntal nuriton) [mole/vo]
29735-8,leptospira interrogans sv medanensis ab [presence] in serum by agglutination
29735-8,leptospira interroanssv meanensis a[presec] in serum antby by agglutntio
29735-8,leptospira interrogans sv ab medanensis [ql] in serum by agglutination
29735-8,l inter medane ab ser ql aggl
29735-8,l inter medane ser ab ql aggl
29735-8,ab inter medane l ser ql aggl agglut
29735-8,l. interrogans sv medanensis ab aggl ql (s)
29735-8,l. interrogans svmedanenss ab agl q (s)
29735-8,l. interroganssv medaensi ab ag q(s)
6656-3,microscopic observation [identifier] in tissue by acid fast stain.kinyoun modified
6656-3,microscopic observation [identifier] in tissue by acids acid fast stain.kinyoun modified
6656-3,microscopic observation [identifier] tissue in by acid fast stain.kinyoun modified
6656-3,acid fast mod kiny stn tiss
6656-3,fast acid mod kiny stn tiss
6656-3,kiny fast mod acid stn tiss
6656-3,microscopic observation acid fast stain.kinyoun modified nom (tiss)
6656-3,icrocopicobservationacifast modiied stainkinyou nomtis)
6656-3,stain.kinyoun observation acid fast microscopic modified nom (tiss)
97232-3,cocaethylene [presence] in cord tissue by screen method
97232-3,cocaethylene [ql] in cord tissue by screen method
97232-3,cocaethylene [presence] method cord tissue by drugs screen in
97232-3,cocaethylene tissco ql scn
97232-3,ql tissco cocaethylene qualitative scn
97232-3,scn tissco presence cocaethylene drug/toxicology
97232-3,cocaethylene screen ql (umb cord tissue)
97232-3,coaethylene screen ql (umb crd tssue) screen
97232-3,cocaethylne screen  (um cord tissue)
62677-0,phenx domain - ocular
62677-0,ocular domain - phenx
62677-0,phenx domain - panel.phenx ocular
62677-0,domain - ocular
62677-0,domain - ocular
62677-0,panel.phenx ocular - domain
44531-2,hiv 1 ag [presence] in serum from donor
44531-2,hiv 1 ag [ql] in from serum donor
44531-2,hi1ag [presece]in serum from donr
44531-2,hiv1 ag ser donr ql
44531-2,hv1 donr infectious disease serum ag ql
44531-2,hiv1 dor a ql
44531-2,hiv 1 ag ql (s donor)
44531-2,hiv i 1a ql ( donor)
44531-2,hv 1 ag presence(dono)
8013-5,rubella virus ab [units/volume] in serum
8013-5,rubella virus ab [units/volume] in ser
8013-5,rubella in antibodies ab [unis/volume] virus erum
8013-5,rubv ab ser-acnc
8013-5,rubv ab serum-acnc
8013-5,rubv antby b ser-acnc
8013-5,rubella virus ab qn (s)
8013-5,rbel qn ab virus (s)
8013-5,ab viru rubela qn (s)
9786-5,microscopic observation [identifier] in blood or marrow by periodic acid-schiff stain
9786-5,micrscopic observation [identiiei bld r marow y periodic cid-schiff stain
9786-5,microscopicobservation infectiousdisease [identifier] in blood or mrow by peiodic aid-schiff stain
9786-5,pas stn bld/mar
9786-5,stn ps bld/mar
9786-5,stn pas bld/mar
9786-5,microscopic observation periodic acid-schiff stain nom (bld/bm)
9786-5,microscopic observation periodic acid-schiff stain nom point in time (bld/bm)
9786-5,mcrocopic observation periodic acid-sciff (blood/b) point in time nom stai
14311-5,phencyclidine [presence] in urine by confirm method >20 ng/ml
14311-5,phencidine[presene] in ng/m by onfim method >20 uine
14311-5,phenyclidine ng/ml in urine byconirmmethod2 [presene]
14311-5,pcp ur ql cfm>20 ng/ml
14311-5,pcp ur ql 20 ng/ml cfm>20 n/ml
14311-5,pcp cfm>20 ql ur ng/ml
14311-5,phencyclidine confirm method >20 ng/ml ql (u)
14311-5,phencyclidine confirm ng/l > mehod ql ur (u)
14311-5,phencyclidine confirm cnfrm methd >2 ng/ml (u) l
59899-5,ethylene glycol [moles/volume] in gastric fluid
59899-5,[moles/volume] glycol ethylene in gastric fluid
59899-5,ethylene glycol substance concentration [moles/volume] gastric in fluid
59899-5,ethylene glycol gast-scnc
59899-5,gast-scnc glycol drug/toxicology ethylene
59899-5,ethylene glycol gast gast-scnc
59899-5,ethylene glycol (gast fld) [moles/vol]
59899-5,ethylene glycol (gast fld) quant [moles/vol]
59899-5,ethylen glycol (ast fld)[moles/vol]
32170-3,cytomegalovirus ab [titer] in serum or plasma by immunofluorescence
32170-3,cytomegalovirus ab by in serum or plasma [titer] immunofluorescence
32170-3,cytomegalovirus ab antibody serum in [titer] or plasma by immunofluorescence
32170-3,cmv ab titr serpl if
32170-3,cmv titr ab serpl if
32170-3,if ab titr serpl cmv serum
32170-3,cmv ab if [titer]
32170-3,ab cmv if [titer]
32170-3,if ab cmv [titer] pl
23827-9,bordetella pertussis filamentous hemagglutinin iga ab [units/volume] in serum
23827-9,bordetella perssis filamentous antby hmagglutin iga ab [unitvolume] n ser
23827-9,bordetella pertussis ab hemagglutinin iga filamentous [units/volume] in serum
23827-9,b pert fha iga ser-acnc
23827-9,b iaser-cnc fha whooping cough pert
23827-9,b whooping cough pert iga fha serum-acnc
23827-9,b. pertussis filamentous hemagglutinin iga qn (s)
23827-9,b. pertussis filamentous hemagglutinin quant (s) qn iga
23827-9,pertussis b. filamentous hemagglutinin iga qn (s)
74337-7,mica*012 igg ab [presence] in serum
74337-7,n ab [pesence] antibodies mca*012ig ser
74337-7,[presence] igg ab mica*012 in serum
74337-7,mica*012 igg ser ql
74337-7,ica*012 qualitative ig serql
74337-7,ql igg ser mica*012
74337-7,mica*012 igg ql (s)
74337-7,abs mic012ig ql (s)
74337-7,mica*012 (s) ql igg aby
97123-4,covid-19 experiences - employment and school changes panel [covex]
97123-4,covid-19 and -empoyment experiences school cangesanl [ovex]
97123-4,coid-19 experience covid19 - empoyment cangesael scool an [cvex]
47981-6,phenylalanine/creatinine [ratio] in 24 hour urine
47981-6,pheylalnine/creatnine[ratio] quantitative in 24 hour urin
47981-6,urine [ratio] in 24 hour phenylalanine/creatinine
47981-6,phe/creat 24h ur-rto
47981-6,phe/creat 24h ur-ro quantitative
47981-6,ur-rto 24h crea phe/creat
47981-6,phenylalanine/creatinine (24h u) [ratio]
47981-6,phenylalanie/crtinin ) (24h ua [ratio
47981-6,(24h henylalae/creatinie u rto [rto]
27082-7,delavirdine [mass/volume] in serum or plasma
27082-7,delardin [mass/volume] or seru pl i pasma
27082-7,[mass/volume]i delvirdine rescriptor serum or plasma
27082-7,delavirdine serpl-mcnc
27082-7,delairdine serp-mcnc
27082-7,serpl-mcnc delavirine
27082-7,delavirdine [mass/vol]
27082-7,[mas/vol] serp delvirdin
27082-7,delvirine [mass/vol]
27234-4,phentermine [mass/volume] in vitreous fluid
27234-4,phentermine[mass/volme] in addiction vitreous flui
27234-4,phentemine vitreous humour mas/volum in vitrous fluid
27234-4,phentermine vitf-mcnc
27234-4,vitf-mcnc phentermine
27234-4,vitf-mcnc phentermine vitreous fluid
27234-4,phentermine (vitr fld) [mass/vol]
27234-4,addiction phentermne fld)[mass/vl] (vitr
27234-4,phentermine (vitr [mass/vol] fld)
101553-6,aeromonas hydrophila dna [presence] in stool by naa with probe detection
101553-6,aeromonas hydrophila [presence] dna in stool by naa with probe detection
101553-6,aeromonas hydrohila dna [presence] in stool y naa with probedetection
101553-6,a hydrophila dna stl ql naa+probe
101553-6,a hydrophila dna st presence naaprob nucleic acid sequence based analysis
101553-6,dna hydrophila a stl presence naa+probe
101553-6,aeromonas hydrophila dna naa+probe ql (stl)
101553-6,hydrophila aeromonas dna naa+probe ql (stl)
101553-6,dna hydrophila aeromonas naa+probe ql (stl)
48549-0,hiv-signs and symptoms checklist (ssc) panel
48549-0,ssc)panel and symptoms pnl checklist hiv-sigs
48549-0,hiv-signs pan and symptoms (ssc) checklist panel
82196-7,campylobacter coli+jejuni+upsaliensis dna [presence] in stool by naa with non-probe detection
82196-7,campylobacter col+jejuni+upsalisis non-prob [preece]in tool by naa with da detection lat
82196-7,campylobacter coli+jejuni+upsaliensis dna[presence] in stol bnaa ih nonprobe dna nucleic acid probe tection
82196-7,c coli+jej+upsa dna stl ql naa+non-probe
82196-7,c coli+jej+upa pr dna stl l naanon-probe
82196-7,c ligation-activated transcription ol+jej+upsa dna st ql naa+nnprobe
82196-7,c. coli+jejuni+upsaliensis dna naa+non-probe ql (stl)
82196-7,c (stl) dnanaa+no-probe ql coli+jejni+upsaliensis
82196-7,. coli+jejun+upsaliensis da naa+non-probe ql (stl
95522-9,sars-cov-2 (covid-19) n gene [log #/volume] (viral load) in respiratory system specimen by naa with probe detection
95522-9,ars-cov-2 (covi-19) n gene[log #/volume] (iral load) in espiratory system specmen by naa wh probe detectin
95522-9,sars-cov-2 (covid-19) ngne[log #/volume] (vral load) inesiratr syste pecime by naith probe detetion lcr
95522-9,sars-cov-2 n gene resp naa+probe-log#
95522-9,resp n quan gene sars-cov-2 naa+probe-log#
95522-9,sars-cov-2 gene n resp aa+probe-log# qnt
95522-9,sars-cov-2 (covid-19) n gene naa+probe (respiratory system specimen) [log #/vol]
95522-9,sars-cov-2 (covid-19) n gene naa+probe (respiratory system specimen) [log #/vol]
95522-9,sars-cov-2 (covid-19) n gene naa+probe (respiratory system [log specimen) probe with ampification #/vol]
19386-2,chlordiazepoxide [presence] in urine by confirmatory method
19386-2,chlordiazepoxide pr [presence] in urine by confirmatory method
19386-2,urie [presence] in chlordiazepoxide by cofirmtory metho screen
19386-2,chlordiazep ur ql cfm
19386-2,chlordiazep chlordiazep fm presence ur
19386-2,presence ur chlordiazep librium cfm
19386-2,chlordiazepoxide confirm ql (u)
19386-2,() confirm ql chloriazepoxid
19386-2,chlordiaeoxideconfrm ql ordinal (u)
39024-5,vesicular stomatitis new jersey virus rna [presence] in specimen by naa with probe detection
39024-5,vesicular stomatitis new jersey virus rna [ql] by specimen in naa with probe detection
39024-5,virus stomatitis new jersey vesicular rna [ql] in specimen by naa with probe detection
39024-5,vsnjv rna spec ql naa+probe
39024-5,rna vsnjv spec l naa+probe
39024-5,ql rna spec vsnjv naa+probe
39024-5,vesicular stomatitis new jersey virus rna naa+probe ql (specimen)
39024-5,stomatitis vesicular new jersey virus rna naa+probe ql (specimen)
39024-5,presence stomttis new jerey veterinary vrus rna naa+probe vsicular (pecimn)
12324-0,hydroxyzine [presence] in urine
12324-0,hydroxyzine screen [presence] in urine
12324-0,in [presence] hydroxyzine urine
12324-0,hydroxyzine ur ql
12324-0,drug/toxicology ql ur hydroxyzine
12324-0,hydroxyzine ur point in time presence
12324-0,hydroxyzine ql (u)
12324-0,(u) ql hydroxyzne drug/toxicology
12324-0,ql hydroxyzine (u)
89876-7,mtb complex rifampin and isoniazid resistance panel by molecular genetics method
89876-7,mtb and rifampin complex isoniazid resistance panel by molecular tuberculosis genetics method
89876-7,mtb complex rifampin and isoniazid resistance panel by method genetics molecular antibiotic susceptibilities
89876-7,mtb rif and inh resist pnl islt/spm
89876-7,mtb and rif inh resist pnl islt/spm
89876-7,mtbrif and it/spm resist pnl inh point in time
89876-7,mtb complex rifampin and isoniazid resistance panel molgen (islt/spec)
89876-7,mtb complex rifampin and isoniazid resistance panel islt molgen (islt/spec)
89876-7,and compex ifampn mb isoniazidresitance pane molgen (islt/spec)
49935-0,calcium.ionized/calcium.total corrected for albumin in serum or plasma
49935-0,calcium.ionized/calcium.total corrected for or in serum albumin plasma
49935-0,serum corrected for albumin in calcium.ionized/calcium.total or plasma
49935-0,ca-i album cor mfr serpl
49935-0,a-i mfr plsm or album serl
49935-0,ca-i album cor plsm mfr serpl
49935-0,calcium.ionized/total ca corrected for albumin [mass fraction]
49935-0,calcium.ionized/total ca corrected for [mass albumin fraction]
49935-0,calci.ionized/toal a corectedfor albumi [ass fraction]
88290-2,mds v3.0 - rai v1.17.2 - medications received during assessment period [cms assessment]
88290-2,mds v3.0 - rai v1.17.2 - medications received during assessment period [cms assessment]
88290-2,mds v3.0 - v1.17.2 rai - medications received during assessment period [cms assessment]
68413-4,macrophages [#/volume] in vitreous fluid by manual count
68413-4,macropage [#/voume] in vteus fluid by mnual cunt
68413-4,macrophages [#/volume] in vitreous fluid by manual qnt count
68413-4,macrophages # vitf manual
68413-4,count vitf # macrophges manual
68413-4,marophages # vitf manual
68413-4,macrophages manual cnt (vitr fld) [#/vol]
68413-4,macrophages manual macros [#/vol] (vitr fld) cnt
68413-4,fld) anualcnt (vir macrohages [#/vol]
97280-2,morphine free [presence] in cord tissue by screen method
97280-2,morphine free morphine sulfate [resnce] in cord issue by sreen method
97280-2,morphine free [presence] in method tissue by screen morphine free cord
97280-2,morphine free tissco ql scn
97280-2,morphine free tisso drug/toxicology presence scn
97280-2,morphine free tissco presence scn
97280-2,morphine free screen ql (umb cord tissue)
97280-2,fre mophne scree drug/toxicology ql (umb cdtisue)
97280-2,morphine screen free q(umb codtissue)
47603-6,citrate synthase [enzymatic activity/mass] in fibroblast
47603-6,random citrate synthase [enzymatic activity/mass] in fibroblast
47603-6,citrate fibroblast [enzymatic activity/mass] chemistry in synthase
47603-6,citrate synthase fib-ccnt
47603-6,fib-ccnt synthase citrate
47603-6,citrate synthae fib-ccnt
47603-6,citrate synthase (fibroblast) [catalytic activity/mass]
47603-6,citraesynthase [atalyti (fiboblat) activiy/mass] fibr
47603-6,citrate [catalytic (fibroblast) qnt synthase activity/mass]
23322-1,ovine herpesvirus 2 ab [presence] in serum by complement fixation
23322-1,ovine herpesvirus 2 ab [ql] in serum by complement fixation
23322-1,ovine by 2 ab [presence] in serum herpesvirus complement fixation
23322-1,ovhv2 ab ser ql cf
23322-1,ab ovh2 ser qlcf
23322-1,ovhv2 ab se qlcf
23322-1,ovine herpesvirus 2 ab cf ql (s)
23322-1,ovine herpesvirus 2 ab cf (s) presence
23322-1,ovine cf 2 ab herpesvirus l (s)
17759-2,urea nitrogen [mass/volume] in arterial blood --post dialysis
17759-2,urea nitrogen [mass/volume] in arterial bld --post dialysis
17759-2,urea itrogen [ass/volume]i arral blod --potialsis
17759-2,bun p dialysis blda-mcnc
17759-2,p bun dialysis bldamcnc
17759-2,dialysis p bun blda-mcnc
17759-2,urea nitrogen post dialysis (blda) [mass/vol]
17759-2,ureanitrogenpstialysis [mass/vol] (bld) blood arterial
17759-2,urea nitrogen post [mss/vol (blda) dialysis
5288-6,rabies virus ab [units/volume] in serum
5288-6,rabies virus ab lyssavirus in [units/volume] ser
5288-6,rabies [units/volume] ab virus in serum
5288-6,rabv ab ser-acnc
5288-6,rabv ab microbiology serum-acnc
5288-6,ab rabv infectious disease ser-cnc
5288-6,rabies virus ab qn (s)
5288-6,rabies virus ab qn (s)
5288-6,virus rabies ab qn (s)
80543-2,norclozapine [mass/volume] in dbs
80543-2,norclozapine [mass/volume] n dbs
80543-2,norclozapine dbs in [mass/volume]
80543-2,norclozapine dbs-mcnc
80543-2,norclozapine qnt dbs-mcnc
80543-2,norclozapine dbs-mcnc quant
80543-2,norclozapine (dbs) [mass/vol]
80543-2,norclozapine [mass/vol] (db) quan
80543-2,norclozapine dbs) [mass/vo] fp
101912-4,troponin t.cardiac delta [mass concentration difference] in 2 hour serum or plasma
101912-4,troponintcardiac delta [mas concentration diffeence] n 2 hour serumor serum or plasma plasma
101912-4,troponin t.cardiac delta [mass concentration 2 in difference] hour serum or plasma
101912-4,troponin t. d 2h serpl-mcdiff
101912-4,troponin 2h 120min d t. serpl-cdf
101912-4,troponin t. d 2h qnt serpl-mcdiff
101912-4,troponin t.cardiac delta (2h) [mass conc diff]
101912-4,troponin t.cardiac delta (2h) [mass conc 120 minutes diff]
101912-4,[asscon tnt t.carac dela (h troponi diff]
73067-1,amiodarone induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73067-1,amiodarone induced neutrophil igm ab [presence] in or serum plasma by flow cytometry (fc)
73067-1,amiodarone nduced or igm ab [presence] in seru netrophil plasma by (neut) igm fow cyomery (fc)
73067-1,amiodarone (neut) igm serpl ql fc
73067-1,amiodarone (neut) igm serpl ql fc
73067-1,aiodarone (neut) fc serpl ql igm plsm
73067-1,amiodarone induced neutrophil igm fc ql
73067-1,amiodarone neutrophil induced igm fc ql
73067-1,amiodarone serplas fc neutrophil igm induced ql
93751-6,atypical porcine pestivirus rna [cycle threshold #] in specimen by naa with probe detection
93751-6,transcription mediated amplification atpical porcine pestvirs ra [cycle threshold #] i specimen by naa with robe deteion
93751-6,threshold porcine ligase chain reaction pestivirus rna [cycle atypical #]i specimen by na with pob dettion
93751-6,appv rna ct spec qn naa+probe
93751-6,appv a appv ct qn spec aprobe
93751-6,appv rna ct spec qn tma naa+probe
93751-6,appv rna naa+probe (specimen) [threshnum]
93751-6,appv rna naa+probe (specimen) [threshnum]
93751-6,appv naa+probe rna (specimen) [threshnum]
27947-1,coxsackievirus a7 rna [units/volume] (viral load) in cerebral spinal fluid by probe
27947-1,coxsackievirus a7 quan load) [units/volume] (viral rna in cerebral spinal fluid by probe
27947-1,coxsackievirus a7 rna [units/volume] spinal fld (viral load) in cerebral spinal fluid by probe
27947-1,cv a7 rna csf probe-acnc
27947-1,cv csf ra a7 prob-acnc
27947-1,probe-acn 7rnasf cv
27947-1,coxsackievirus a7 rna probe qn (csf)
27947-1,coxacevirus a7 rna prob qn (cs)
27947-1,coxscievius a7 rnaprobe n (cs
72490-6,17-hydroxyprogesterone [moles/volume] in saliva (oral fluid)
72490-6,17-hyroxyprogstroe in [mles/volume saliva(ora fluid)
72490-6,17-hydroxyprogesterone [moles/volume] random in saliva (oral fluid)
72490-6,17ohp sal-scnc
72490-6,sal-scnc 17ohp
72490-6,17-hydroxy-progest 17ohp sal-scnc
72490-6,17-hydroxyprogesterone (sal) [moles/vol]
72490-6,hydroxyrogesterone oral fluid (sal) [moles/vol]
72490-6,17hyroxyproesterone (sa) [oles/vol]
62613-5,phenx - respiratory - arterial blood gas - abg protocol 090201
62613-5,phenx - respiratory - arterial bld gas - abg protocol point in time 090201
62613-5,phnx - espirator point in time - arterial bloo - ag protcol 09201
62613-5,resp arterial blood gas proto
62613-5,blood arterial resp gas proto
62613-5,arterial res boo gas panel.phenx oto
35591-7,creatinine renal clearance predicted by cockcroft-gault formula
35591-7,creatinine renal clearance by predicted cockcroft-gault formula
35591-7,creatinine renal clearance predicted cockcroft-gault by formula
35591-7,creat cl predicted serpl c-g-vrate
35591-7,creat cl predicted c-g-vrate serpl
35591-7,creat cl quant predicted serpl c-g-vrate
35591-7,creatinine renal clearance predicted cockcroft-gault formula [vol/time]
35591-7,creatinine renal clearance predicted kidney cockcroft-gault formula [vol/time]
35591-7,cratinne real clearance predicte cockcroft-gat forula [vol/time]
90544-8,therapies during part a medicare stay [cms assessment]
90544-8,therapies durin prt a micae stay cms panel.survey.cms assesmet]
90544-8,therapies during report period part a medicare stay [cms assessment]
27096-7,deprecated streptococcus pneumoniae 3 igg ab [mass/volume] in serum
27096-7,deprecatedstreptcoccus pneumonia 3 igg ab[ass/volume] sr in erum
27096-7,deprecated streptococcus pneumoniae 3 igg in [mass/volume] ab s pneumoniae serum
27096-7,deprecated s pneum3 igg ser-mcnc
27096-7,autoantibodies deprecated s pneum3 igg serum-mcnc
27096-7,s deprecated pneum3 igg ser-mcnc
27096-7,s. pneumoniae 3 igg (s) [mass/vol]
27096-7,3 pneumoniae s. antibody igg (s) [mass/vol]
27096-7,s. pneumoniae 3 igg (s) [mass/vol] s pneumoniae
57347-7,copper [mass/volume] in dialysis fluid
57347-7,oppe [mass/vlume] in ialysi fluid
57347-7,coper dialysi in [ass/volme] fuid
57347-7,copper dial fld-mcnc
57347-7,copper fld-mcnc dial
57347-7,dia random copper ld-mcnc
57347-7,copper (dial fld) [mass/vol]
57347-7,copper (dial [ass/vol] fld)
57347-7,copper [mass/vol] fld) (dial
104696-0,n-acetylglycine/creatinine [molar ratio] in urine
104696-0,n-acetylglcine/creatinne [molr urine in atio]
104696-0,n-acetylglycine/creatinine [molar urine in ratio]
104696-0,n-acetylglycine/creat ur-srto
104696-0,ur-srto n-acetylglycine/creat
104696-0,n-acetlglyciecreat r-srto
104696-0,n-acetylglycine/creatinine (u) [molar ratio]
104696-0,n-acetylgycin/creatinine random (u) [molar raio]
104696-0,ur n-acetylglycine/creatinine [molar (u) ratio]
64135-7,secobarbital/creatinine [mass ratio] of urine
64135-7,secobarbital/creatinine [mass ratio] crea urine of
64135-7,seobarbital/creatnie mass urine of ratio]
64135-7,secobarbital/creat ur
64135-7,ur qnt secobarbital/creat
64135-7,ur secobarbta/creat
64135-7,secobarbital/creatinine (u) [mass ratio]
64135-7,secobarbital/creatinine (u) ratio] seconal [mas
64135-7,ecbarbital/creatinin (u[mass ratio]
5646-5,"ethylene glycol [mass/volume] in serum, plasma or blood"
5646-5,"ehyle glyco [mas/volumein seru,plama serplas or blood"
5646-5,"ethylene plasma [mass/volume] in serum, glycol or bld"
5646-5,ethylene glycol serplbld-mcnc
5646-5,quan glycolserplbld-mcnc ethylee
5646-5,ethylene serp glycol serplbld-mcnc
5646-5,ethylene glycol (s/p/bld) [mass/vol]
5646-5,ethylene glycl serplas (s/p/bld) [masvol]
5646-5,(s/p/bld glycol ehylee [mass/vol]
6620-9,acanthamoeba sp ab [presence] in cerebral spinal fluid by immunoassay
6620-9,acanthamoeba sp ab [presence] in fluid spinal cerebral by immunoassay
6620-9,infectious disease acanhamoeba pinalflud ab [ql] in cereal p by immunoassay
6620-9,acanthamoeba ab csf ql ia
6620-9,cql a acantameba ia
6620-9,ia b csf presence qual acanthamoeba
6620-9,acanthamoeba sp ab ia ql (csf)
6620-9,acanthamoeba sp ab (csf) ql ia infectiousdisease
6620-9,acanthamoeba sp ab id ia (csf) ql
687-4,mycoplasma sp and ureaplasma sp [identifier] in specimen by organism specific culture
687-4,mycoplasma [identifier] and ureaplasma cult sp sp in specimen by organism specific culture
687-4,mycoplsa byorganism and uralasma sp [idetifier] inspimen sp secii culture
687-4,mycoplas+ureoplas spec cult
687-4,miscellaneous mycoplas+ureoplas spec cult
687-4,mycoplas+ureoplas spec c&s cult
687-4,mycoplasma sp and ureaplasma sp org specific cx nom (specimen)
687-4,mycopasma p and ureaplasma (secmen) org pecifc cx om sp
687-4,mycoplasma sp and ureaplasma sp org specific cx nom (specimen) random
8041-6,treponema pallidum ab [presence] in serum by hemagglutination
8041-6,treponema t pallidum pallidum ab [ql] in serum by hemagglutination
8041-6,treponem pllidum ab [presenc] in serum by hemaggltination
8041-6,t pallidum ab ser ql ha
8041-6,pallum t berql a
8041-6,t plldm aber ha hemagglutination ql
8041-6,t. pallidum ab ha ql (s)
8041-6,t. pallidum (s) ha ql ab abs
8041-6,t. allidum ab ha syphilis ql (s)
12293-7,cotinine [presence] in urine
12293-7,cotinne [esence] inurine
12293-7,cotinine[presence] in urne
12293-7,cotinine ur ql
12293-7,ur cotinine ql
12293-7,cotinine l ur
12293-7,cotinine ql (u)
12293-7,coinine presence u) ua
12293-7,coinine ql (u)
31850-1,herpes simplex virus 2 ag [presence] in skin
31850-1,herpe smplex virus  ag [presnce n skin
31850-1,herpes simplex virus in ag [ql] 2 skn skin
31850-1,hsv2 ag skin ql
31850-1,skin ag hsv2 epidermis ql
31850-1,hsv2 g skin l qualitative
31850-1,hsv 2 ag ql (skin)
31850-1,presence hsv2ag (skin)
31850-1,ag hsv2 ql integument (skin)
41979-6,calories burned in 24 hour calculated
41979-6,24hr caories burned in 24hour calculated
41979-6,calories burned in 24 hour calculated
41979-6,calories burned 24h calc
41979-6,calories burned calc 24h
41979-6,24h burned calories calc
4060-0,tocainide [mass/volume] in serum or plasma
4060-0,tocainide [mass/volume] in ser ser or plasma or plasma
4060-0,tocainide [mass/volume] in serum or plasma
4060-0,tocainide serpl-mcnc
4060-0,point in time serpl-mcnc tocainide
4060-0,erpl-mcnc pl tocainide
4060-0,tocainide [mass/vol]
4060-0,[mass/vol] tocainide
4060-0,[mass/vol] tocainide
87369-5,lawsonia intracellularis vntr pattern [type] in specimen by molecular genetics method
87369-5,in intracellularis vntr pattern [type] lawsonia specimen by molecular genetics method
87369-5,intracllularis lawsona vntr pttern [type] ispecimen y mleular pcr genetis method
87369-5,l intracell vntr patt spec
87369-5,l intracell vntr patt spec
87369-5,l unspecified intracell vntr patt spec
87369-5,l. intracellularis vntr pattern molgen nom (specimen)
87369-5,l.intracellularis attern vntr molgen nom (spcin) misc
87369-5,l. intracellularis vntr pattern spec molgen nom (specimen)
47212-6,chlamydia trachomatis dna [identifier] in specimen by naa with probe detection
47212-6,chlamydia trachomatis dna[dentiir] transcription mediated amplification in specmen y wihprobeetection naa
47212-6,chlamydia trachomatis da [identifier]in dtection by naa with dna nucleic acid probe probe spcimen
47212-6,c trach dna spec naa+probe
47212-6,3sr sr c trach dna spec naa+probe
47212-6,c rach dna spec na+probe amplif
47212-6,c. trachomatis dna naa+probe nom (specimen)
47212-6,c. trachomatis dna naa+probe nom (specimen) microbiology
47212-6,c. dna trachomatis naa+probe c trachomatis nom (specimen)
82846-7,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/androsterone+etiocholanolone [molar ratio] in 24 hour urine
82846-7,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/androsterone+etiocholanolone [molar scrto ratio] in 24 hour urine
82846-7,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/androsterone+etiocholanolone [molar ratio] in 24 hour quan urine
82846-7,11-dhc+thb+5a-thb/an+et 24h ur-srto
82846-7,11-dhc+thb+5a-thb/a+et 24h ur-srto quan
82846-7,11-dhc+thb+5a-thb/an+et 24h ur-srto
82846-7,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/androsterone+etiocholanolone (24h u) [molar ratio]
82846-7,11-dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/androsterone+etiocholanolone (24h ratio] [molar u)
82846-7,11dehydrocorticoterone+tetrahydrocorticoterone+llo-tetrydrocortcosterone/androsterone+etcholanoloe etiochol (24h u [molarratio]
40507-6,jamestown canyon virus ab [titer] in serum by hemagglutination inhibition
40507-6,jamestown canyon virus ab [titer] in serum hemagglutination by inhibition
40507-6,jamestwn cnyon by ab [titer] in ser virus hemaggluinatin ihibition
40507-6,jcv ab titr ser hai
40507-6,titr ab jcv ser hai
40507-6,ab jcv tit hemagglutination inhibition ser hai
40507-6,jamestown canyon virus ab hai (s) [titer]
40507-6,jmestown anyon viru ab hai [titer] (s)
40507-6,jametown ca ir autoantibody ab ha [titer] (s)
39015-3,treponema pallidum ab [units/volume] in body fluid by hemagglutination
39015-3,treponema fluid pallidum ab [units/volume] in by fluid body hemagglutination
39015-3,treponema pallidum a [unts/olume] i ody fluid b hemagluinaion
39015-3,t pallidum ab fld ha-acnc
39015-3,ha-acnc pallidum ab fld t
39015-3,t ha-acnc ab f palldum
39015-3,t. pallidum ab ha qn (body fld)
39015-3,t pallidum ab ha qn (bodyfld)
39015-3,t. palidum ab ha qn (body ld)
74989-5,pentacarboxylporphyrins [moles/volume] in serum or plasma
74989-5,point in time pentacarboxylporphyrins [moles/volume] in serum or plasma
74989-5,pentacarboxylporphyrins [moles/volume] in serum plsm or
74989-5,penta-cp serpl-scnc
74989-5,pea-p serpl-scnc
74989-5,serpl-scnc chemistry penta-cp
74989-5,pentacarboxylporphyrins [moles/vol]
74989-5,serum or plasma [moles/vol] pentacarboxylporphyrins
74989-5,[moles/vol] pentacarboxylporphyrins
25724-6,deprecated norsertraline [mass/volume] in serum or plasma
25724-6,deprecated norsertraline [mass/volume] in desmeth serum plasma or
25724-6,deprecated norsertraline [mass/volume] in serum or plasma
25724-6,deprecated norsertraline serpl-mcnc
25724-6,norsertraline deprecated serpl-mcnc point in time
25724-6,deprecated random orsertraline serpl-mcnc
25724-6,norsertraline [mass/vol]
25724-6,[mss/vol] norsertaline
25724-6,norrtraline [mass/vol]
105892-4,vibrio cholerae dna [presence] in specimen
105892-4,vibrio cholerae dna [presence] in specimen random
105892-4,vibrio v cholerae cholerae [presence] n in speimen
105892-4,v cholerae dna spec ql
105892-4,dna colerae v pec ql
105892-4,v spec dna cholerae ql
105892-4,v. cholerae dna ql (specimen)
105892-4,l cholerae dna v. (secimen)
105892-4,v. dna cholerae ql (specimen)
59982-9,zopiclone [moles/volume] in gastric fluid
59982-9,zopiclone fluid in gastic [mlesvolume]
59982-9,opiclone[molesvolue] in fluid gastric
59982-9,zopiclone gast-scnc
59982-9,gast-scnc qnt zopiclone
59982-9,zoiclne gast-scnc random
59982-9,zopiclone (gast fld) [moles/vol]
59982-9,quantitative zopiclone (gast [moles/vol] fld)
59982-9,zopclne (gast fl)[mole/vol]
17891-3,bacteria # 5 identified in nose by aerobe culture
17891-3,in # 5 identiied nos bacteria nose by erbe ulture
17891-3,bacteria aerobe culture 5 ieified in nose by aerobe #
17891-3,bacteria nose aerobe cult org #5
17891-3,baceria org#5 aerob cult nose
17891-3,bacteria nose aerobe cult org id #5
17891-3,bacteria identified # 5 aer cx nom (nose)
17891-3,bacteria identified aer 5 # cx nom (nose) nose (nasal passage)
17891-3,bacteria identified # cx aer 5 nom (nose) nose (nasal passage)
29537-8,west nile virus igg ab [units/volume] in cerebral spinal fluid
29537-8,west nil spinal ab [unis/volume in cerebal virusigg flud
29537-8,west nile virus in ab [units/volume] igg cerebral spinal fluid
29537-8,wnv igg csf-acnc
29537-8,wn igg csf-acnc
29537-8,wnv csfacnc ig
29537-8,west nile virus igg qn (csf)
29537-8,west nile virus igg qn (cerebrospinal fluid)
29537-8,west nile virus igg (csf) qn
23126-6,francisella tularensis ag [presence] in tissue by immune stain
23126-6,francisella tularensis ag [presence] by tissue in immune stain
23126-6,frncisel tularnis ag [pence] in tissue by imun stan
23126-6,f tular ag tiss ql imstn
23126-6,f ular ag tiss qlimstn
23126-6,f ql tular imstn tiss ql ag
23126-6,f. tularensis ag immune stain ql (tiss)
23126-6,f. tularensis ag ql stain immune (tiss)
23126-6,f. tularesis screen ag (tiss) stain presence mmune
26736-9,promethazine [presence] in serum or plasma
26736-9,promethazine [presence] in screen ser or plasma
26736-9,drug/toxicology prometazine [presence] serum in or plasma
26736-9,promethazine serpl ql
26736-9,ql serpl promethazine
26736-9,ql serpl promethazine
26736-9,promethazine ql
26736-9,presence sominex promethzn
26736-9,promethazine serum or plasma ql
2256-6,estrogen [mass/time] in 24 hour urine
2256-6,estrogen [mas/ime]in 24 hor rine
2256-6,urine [mass/time]in 24 hour estrogen
2256-6,estrogen 24h ur-mrate
2256-6,24hr esrogen 24h ur-mrate
2256-6,24h estrogen gyn ur-mrate
2256-6,estrogen (24h u) [mass/time]
2256-6,estrogen [mass/time] u) (24h
2256-6,estrogen (24h u) [mass/time]
16572-0,cephaloridine [mass/volume] in serum or plasma
16572-0,cephalridne [mass/volme] in serum o plasma
16572-0,cephaloridine plasma in serum or [mass/volume]
16572-0,cephaloridine serpl-mcnc
16572-0,serpl-mcnc cephaloridine plasma
16572-0,cephaloridine serpl-mcnc
16572-0,cephaloridine [mass/vol]
16572-0,pl [mass/vol] cephaloridine
16572-0,ephaloridin [mas/vol]
29338-1,flecainide [mass/volume] in urine
29338-1,mass/volume] fecainide in tambocor urine
29338-1,flecainide ur [mass/volume] in urine
29338-1,flecainide ur-mcnc
29338-1,lcainide level r-mcnc
29338-1,flecainideu-mcnc
29338-1,flecainide (u) [mass/vol]
29338-1,flecainide (u) [mass/vol]
29338-1,fleainide (u) [mss/vol]
55555-7,molybdenum [moles/volume] in blood
55555-7,molybdnum mole/volume] quantitative in bood
55555-7,quantitative i [molesvolume] molybdenum bood
55555-7,molybdenum bld-scnc
55555-7,molybdenum bld-scnc drug/toxicology
55555-7,molybdenum bldsnc
55555-7,molybdenum (bld) [moles/vol]
55555-7,molybdenum (blood) [moles/vol] quantitative
55555-7,(bld) molybdenum [moles/vol]
26840-9,nordiazepam [mass/mass] in hair
26840-9,nordiazepam [mass/mass] in hair drug/toxicology
26840-9,nordiazeam har [mass/as] in hair
26840-9,nordiazepam hair-mcnt
26840-9,nordiazeam quant hir-mcnt
26840-9,hair-mcn nordiazepa
26840-9,nordiazepam (hair) [mass/mass]
26840-9,nordiazpam [ms/mass] (hai
26840-9,nrdiazepam har) [mass/mass]
88691-1,pneumocystis jirovecii ag [presence] in bronchoalveolar lavage by immunofluorescence
88691-1,laage jirveci g preence] in bronhoalvelar pneumocystis ifa by imunoflorescence
88691-1,lavage jirovecii ag [presence] in bronchoalveolar pneumocystis by immunofluorescence
88691-1,p jirovecii ag bal ql if
88691-1,p jirvec agal ql if
88691-1,p jirovecii dfa ag bal ql if
88691-1,p. jirovecii ag if ql (bal)
88691-1,p. jirovecii random ag if ql (bal)
88691-1,p. infectiousdisease jirovecii ag if presence (bal)
82266-8,estimated activity metabolic rate/measured rmr [relative energy/time]
82266-8,estimted activity metabolic rate/measured energ/ime] [rlative rmr
82266-8,esiaed ctivity metabolic rate/measured rmr [elative energy/time] bmr
82266-8,est act metab rate/meas rmr
82266-8,est act metab rate/meas rmr
82266-8,est act metab rmr rate/meas
74405-2,eosinophils/leukocytes in cord blood
74405-2,eosinophils/leukocytes in blood cord
74405-2,eosinophils/leukocytes in cord eosins blood
74405-2,eosinophil nfr bldco
74405-2,wbc esinophil nfr bldco
74405-2,bldco nfr eosinophil
74405-2,eosinophils/leukocytes (bldco)
74405-2,eosinophil/eucytes (bdco)
74405-2,quantitative eosinophils/leukocytes (bldco)
7931-9,influenza virus b ab [units/volume] in serum
7931-9,inluena irus b ab units/volu] in serm
7931-9,influenza virus b ab [units/volume] in srum
7931-9,flubv ab ser-acnc
7931-9,flubv influenza b virus ab serum-acnc
7931-9,flub ab ser-acnc
7931-9,flubv ab qn (s)
7931-9,flubv ab qn qnt (s)
7931-9,flub flubv ab qn (s)
13160-7,deprecated streptococcus pneumoniae 19 ab [units/volume] in serum --2nd specimen
13160-7,deprecate spec stretococs serum 9 ab unit/volume] in pneumoniae --2n speien
13160-7,deprecated sreptococus in 19 ab s pneumoniae [unts/volume] pneumonie seum --2nd specimen
13160-7,deprecated s pneum19 ab sp2 ser-acnc
13160-7,deprecaed convalescent s pneum19 ab sp2 ser-acnc
13160-7,pneum19 s deprecated point in time ab sp2seracn
13160-7,s. pneumoniae 19 ab spec 2 qn (s)
13160-7,pneumococcal pneumonia s 19 eumoniae ab spec 2 qn (s)
13160-7,s. pneumoniae 19 ab spec 2 qn (s)
10837-3,organic acids [presence] in serum or plasma
10837-3,organic acids chemistry [presence] in serum or plasma
10837-3,oraic acds resence] in serpl serplas
10837-3,organic acids serpl ql
10837-3,organic acids ql pr serpl
10837-3,serum organic acids serp q
10837-3,organic acids ql
10837-3,acids organic point in time presence
10837-3,oranc aids ql chemistry
16840-1,ethacrynate [mass/volume] in serum or plasma
16840-1,pl ethacrynate [mas/volume] in serum or plsm
16840-1,thacrynate etacrynic acid [mas/vlume] n serum or pasma
16840-1,ethacrynate serpl-mcnc
16840-1,ethacrynate serpl-mcnc qnt
16840-1,ethacrynate serpl-mcnc serum
16840-1,ethacrynate [mass/vol]
16840-1,ethcrynat mss/vol]
16840-1,[mass/vol] drug/toxicology ethacrynate
22247-1,cytomegalovirus igg ab [units/volume] in serum or plasma --2nd specimen
22247-1,yomegalovirus igab [unit/volume] in qnt serum orplasma --2n specimen
22247-1,cytomeavirus igg a [units/vlume in serm or plasma --2n hhv-5 pcimn
22247-1,cmv igg sp2 serpl-acnc
22247-1,mv igg p2 serpacnc
22247-1,cmv plasma sp2 igg erpl-acnc
22247-1,cmv igg spec 2 qn
22247-1,cmv igg spec 2 qn
22247-1,igg cmv spec 2 qn
13308-2,deprecated dna
13308-2,derecated da
13308-2,dna probe deprected dn
13308-2,deprecated dna xxx rflp prb
13308-2,deprecated rflp serology xxx dna prb
13308-2,deprecated dna xxx rflp prb
13308-2,dna rflp nom (specimen)
13308-2,(specimen) rflp nom dna
13308-2,(specimen) rfl nom dna
9421-9,entamoeba histolytica ab [units/volume] in serum by immune diffusion (id)
9421-9,(id) histolytic ab [units/volume] insrum by imune difusin entamoeba
9421-9,entamoeba histolytica in [units/volume] ab serum by immune diffusion (id)
9421-9,e histolyt ab ser id-acnc
9421-9, hisolyt ab ser id-acnc
9421-9,e histolyt ab ser id-acnc imun
9421-9,e. histolytica ab immune diff qn (s)
9421-9,e. histolytica ab immune diff q (s) immunodiffusion
9421-9,e. hitolytica ab immune diff q (s)
30471-7,levetiracetam [mass/volume] in serum or plasma
30471-7,levetiracetam [mass/volume] ser or plasma in ser or plasma
30471-7,levtiracetam drug/toxicology [mass/olum] i lasma r serum
30471-7,levetiracetam serpl-mcnc
30471-7,serpl-mcnc levetiraceam
30471-7,levetiracetam serum or plasma-mcnc quan
30471-7,levetiracetam [mass/vol]
30471-7,evetracetam[mas/vol]
30471-7,serum [mass/vol] levetiracetam
62744-8,phenx - personality traits protocol 121101
62744-8,phex personality - traits protocol 121101
62744-8,phenx pnl - personality traits protocol 121101
62744-8,personality traits proto
62744-8,pernality proto traits
62744-8,traits personality proto
20515-3,amitriptyline [mass/volume] in urine by confirmatory method
20515-3,amitriptyline [mass/volume] confirmatory urine by in method
20515-3,mitriptyine urineconfmatory [mss/vlme]in methd
20515-3,amitrip ur cfm-mcnc
20515-3,amitrip cfm-mcnc ur
20515-3,confirmation amitrip ur cfm-mcnc
20515-3,amitriptyline confirm (u) [mass/vol]
20515-3,confirm amitriptyline (u) [mass/vol]
20515-3,amitriptyline confirm (u) [mass/vol] amitriptyln
17937-4,bacteria # 2 identified in burn by culture
17937-4,bacteria # 2 identified nominal in burn by culture
17937-4,bacri# culture microbiology identfiedinur by 2
17937-4,bacteria burn cult org #2
17937-4,bacteria burn cult org #2
17937-4,bacteria cult bur org #2
17937-4,bacteria identified # 2 cx nom (burn)
17937-4,bactera identfie  2 cx m (burn)
17937-4,acteria identifid # 2 cx nom (burn)
4072-5,chloral hydrate [mass/volume] in urine
4072-5,chlorlydrate une in [mass/volume]
4072-5,chloral [mass/volume] hydrate in urine
4072-5,chloral hydrate ur-mcnc
4072-5,chloralhydrate ur-mcnc urn
4072-5,chloral hydrae u-mcnc
4072-5,chloral hydrate (u) [mass/vol]
4072-5,(u)[mass/o] hate chloral
4072-5,chloral hyrate [mas/vol] (u)
77399-4,human papilloma virus 16 dna [presence] in cervix by naa with probe detection
77399-4,human cervix virus 16 dna [presence] in papilloma by naa with probe detection
77399-4,hman papllomavirus 16 dna [peence in cevix y detection ith robe naa
77399-4,hpv16 dna cvx ql naa+probe
77399-4,hpv16 ob dna vx ql naa+probe
77399-4,hpv16 dna cervix cvx presence naa+probe
77399-4,hpv 16 dna naa+probe ql (cvx)
77399-4,hpv naa+probe dna 16 ql (cvx)
77399-4,hpv 16 dna transcription mediated amplification naa+probe presence (cvx)
85799-5,bordetella pertussis+bronchiseptica+holmesii is481 dna [cycle threshold #] in specimen by naa with probe detection
85799-5,bordtellapertussis+brnchiseptica+homesii is81 dna [cycle by pt # in speimen threshold naa with probe deection
85799-5,bordetella pertussis+bonchiseptica+holmesii is481 dna [ycle treshold #] in specimen b naa ith obedetction
85799-5,b per+bron+holm is481 dna ct spec naa+pr
85799-5,b naa+pr is481 dna t spec per+bron+hom
85799-5,b per+bron+holm is481 pulmonary dna ct spec naa+pr
85799-5,b. pertussis+bronchiseptica+holmesii is481 dna naa+probe (specimen) [threshnum]
85799-5,dna pertussis+bronchiseptica+holmesii is481 b. naa+probe (specimen) [threshnum]
85799-5,b. pertussis+bronchiseptica+holmesii is481 dna naa+probe (specimen) [threshnum]
23897-2,mesothelial cells [presence] in specimen by light microscopy
23897-2,mesothelial cel [preece] in light by specimen microscopy
23897-2,mesohelil cells [presenc] in specmen by light microco
23897-2,mesothl cell spec ql micro
23897-2,ql cell spec mesothl micro
23897-2,ql cell spec mesothl micro
23897-2,mesothelial cells lm ql (specimen)
23897-2,cells mesothelia lm ql (specimen)
23897-2,mesothelial cells (specimen) presence lm cellularity
62824-8,deprecated phenx measure - physical functioning - objective
62824-8,deprectd funcionng masure- phyical phenx - ojective
62824-8,deprecatd phex masure - physical measure - phys func objective functoning - objctve
88511-1,natural killer cell cytotoxicity.0.9:1 effector to target cell ratio/positive control in blood mononuclear cells
88511-1,cells killer nk cell cytotoxicity.0.9:1 effector to target cell ratio/positive control in bld mononuclear natural
88511-1,mononuclear killer cell cytotoxicity.0.9:1 effector rlacnc to target cell ratio/positive control in blood natural cells
88511-1,nk cytotox.0.9:1 e:t/pos cntrl bld mc
88511-1,nk cytotox.09:1 e:t/os cnl bld mc
88511-1,nk mc :t/ps cntrl bld blood cytotox.0.9:1
88511-1,nk cytotoxicity 0.9:1 e:t ratio/positive control (bld mc) [rel units/vol]
88511-1,nk mc) 0.9:1 e:t ratio/positive control (bld cytotoxicity [rel units/vol]
88511-1,nk cytotoxicity 0.9:1 e:t quan ratio/positive control (bld mc) [rel units/vol]
1675-8,"2,3-diphosphoglycerate [mass/volume] in red blood cells"
1675-8,"2,3-diphosphoglycerate [mass/volume] in red bld cells"
1675-8,"[mass/volume] 2,3-diphosphoglycerate in red blood 2,3dpg cells"
1675-8,"2,3dpg rbc-mcnc"
1675-8,"iii rbc-mcnc 2,3dpg"
1675-8,"2,3dpg biphosphoglycerate rbc-mcnc"
1675-8,"2,3-diphosphoglycerate (rbc) [mass/vol]"
1675-8,"2,3-diphosphglycerat (rbc) [mass/vol] point in time"
1675-8,"2,3diphspholycerate (rbc)[ass/v]"
87662-3,fonofos [mass/mass] in specimen
87662-3,[mass/mas]in veterinary fonofos pecimen
87662-3,fonofos [mass/mass] in specimen
87662-3,fonofos spec-mcnt
87662-3,spec-mct quant onoos
87662-3,spec-mcnt fonofos
87662-3,fonofos (specimen) [mass/mass]
87662-3,fonfos (seimen) [mass/mas]
87662-3,[mass/mass] (specimen) fonofos
101305-1,plasmodium sp dna [presence] in blood by naa with non-probe detection
101305-1,ith spna [presence] wb in blood y aa lasmoium non-proe dctin
101305-1,plasmodium sp dna random [presence] in blood by naa with non-probe detection
101305-1,plasmodium dna bld ql naa+non-probe
101305-1,plasmodium blood dna ql naa+non-probe
101305-1,plasmodium dna bld ql tma naa+nn-rbe
101305-1,plasmodium sp dna naa+non-probe ql (bld)
101305-1,sp plasoium dn naa+non-probe nanon-rbe ql (bld)
101305-1,plasmodium wb sp dna naa+non-probe ql (blood)
19542-0,mescaline [presence] in urine by screen method
19542-0,mescaline [presene] i urine by sreen method
19542-0,mescaline [presence] in urine by screen method screen
19542-0,mescaline ur ql scn
19542-0,mescaline ur presence presence scn
19542-0,mescalne urql scn
19542-0,mescaline screen ql (u)
19542-0,mescaline ql screen (u)
19542-0,mscaline screenl (u) drugs
12227-5,leukocytes [#/volume] corrected for nucleated erythrocytes in blood
12227-5,discocytes leukocytes [#/volume] correted for ncleatd eryhoctes i loo
12227-5,absolutes leukocytes [#/volume] corrected for erythrocytes nucleated in blood
12227-5,wbc nrbc cor # bld
12227-5,ct wbc nrbc cor # bld
12227-5,bl nrbc co # wbc
12227-5,wbc corrected for nucl rbc (bld) [#/vol]
12227-5,wbc abs corrected for [#/vol] rbc (bld) nucl
12227-5,[#/vol] corected fr count ncl bc (bl) wbc
1758-2,albumin.glycated [mass/volume] in serum or plasma
1758-2,albumin.glycated [mass/volume] in serum or quant plasma
1758-2,albumin.glycated [mass/volme] in serum or plasma mass concentration
1758-2,albumin glycated serpl-mcnc
1758-2,albumin plas glycated serpl-mcnc
1758-2,albumin serpl-mcnc glycated
1758-2,albumin.glycated [mass/vol]
1758-2,[mss/vol] alumin.glcate sr
1758-2,[mass/vol] albumin.glycated
82475-5,borrelia miyamotoi glpq gene [presence] in blood by naa with non-probe detection
82475-5,borelia iaotoi gpq gne [presece] i blood by naa ith non-probe deecon strand displacement amplification
82475-5,borrlia miyamotoi glq gene [reence] ordinal inblood by naa with non-prob etecion
82475-5,b miyamotoi glpq bld ql naa+non-probe
82475-5,glpq miyamotoi b sda bld ql naa+non-probe
82475-5,b miyamotoi glpq blood ql naa+non-probe
82475-5,b. miyamotoi glpq gene naa+non-probe ql (bld)
82475-5,lat b. miyamotoi glpq gene a+nonpobe presence (bld)
82475-5,b. miyamotoi ligase chain reaction glpq gene naa+non-probe ql (bld)
43234-4,liver kidney microsomal 1 igg ab [presence] in serum
43234-4,liverkidney microsoml 1 immune globulin g igg ab [presece] n srum
43234-4,liver kidney lkm-1 microsomal 1 serum ab [presence] in igg
43234-4,lkm-1 igg ser ql
43234-4,lkm-1 gg sr presence
43234-4,igg liver lkm-1 serum ql
43234-4,liver kidney microsomal 1 igg ql (s)
43234-4,lkm-1 liver kidney microsomal 1 igg presence (s)
43234-4,ql kidney microsomal 1 igg liver (s)
94866-1,7-alpha hydroxy-4-cholesten-3-one [mass/volume] in serum or plasma
94866-1,serum hydroxy-4-cholestn-3-one [mass/voume] in 7-alpha or plasma
94866-1,7-alpha hydroxy-4-cholesten-3-one or in random serum [mass/volume] plas
94866-1,7a-oh-4-chol-3-one serpl-mcnc
94866-1,qnt serpl-mcnc 7a-oh-4-chol-3-one
94866-1,7-oh-4-chol--oe serpl-mcnc
94866-1,7-alpha hydroxy-4-cholesten-3-one [mass/vol]
94866-1,chemistry hyroxy-4-cholsten-3-one 7-lpha [ms/vo]
94866-1,7-alpha point in time hydroxy4chlesten-3-ne [mass/vl]
40371-7,isoniazid [presence] in urine
40371-7,isoiazidprce] ur in urne
40371-7,urn isoniazi urine in [presence]
40371-7,isoniazid ur ql
40371-7,isoniad qual urql
40371-7,soniazd ur ql
40371-7,isoniazid ql (u)
40371-7,isoniazid ql (u) ql
40371-7,isoniaz isoniazid ql (u)
31075-5,legionella pneumophila 1 igm ab [titer] in cerebral spinal fluid by immunofluorescence
31075-5,legionella pneumophila 1 in time resolved fluorescence ab [titer] igm cerebral spinal fluid by immunofluorescence
31075-5,legionella pneumophila 1 igm neuro ab [titer] in cerebral spinal fluid by immunofluorescence
31075-5,l pneumo1 igm titr csf if
31075-5,l pneum1 if titr cerebrospinal fluid igm
31075-5,l pneumo1 igm itr csif
31075-5,l. pneumophila 1 igm if (csf) [titer]
31075-5,l. if 1 igm pneumophila (csf) [titer]
31075-5,if pneumophila 1 igm l. (cs) [titer]
42373-1,neisseria meningitidis serogroup x ag [presence] in isolate by agglutination
42373-1,ag eningitidis seoroup x neseria [presence] in n men serogroup islate by agglinaton
42373-1,neisseria meningitidis serogroup x ag [ql] in isolate by agglutination
42373-1,n men sg x ag islt ql aggl
42373-1,n men sg x ag islt presence aggl
42373-1,n sg men ag islt presence aggl
42373-1,n. meningitidis x ag aggl ql (isol)
42373-1,n. menigitidis xagagl q (isol)
42373-1,n meningococcus ql x ag agl menigitids (isol)
48354-5,aripiprazole [moles/volume] in serum or plasma
48354-5,aripiprazole [moles/volume] in serum or plas plas
48354-5,sr rpiprazoe [moes/volume] in ser r lasma
48354-5,aripiprazole serpl-scnc
48354-5,random aripipraoeserpl-c
48354-5,pl aripiprazole serum or plasma-scnc
48354-5,aripiprazole [moles/vol]
48354-5,plasma [moles/vol] aripiprazole
48354-5,aripiprzole [moles/vol] quan
17053-0,legionella longbeachae 1 igg ab [presence] in serum
17053-0,legionella 1 longbeachae igg ab [ql] in serum
17053-0,egonella longbeachae 1 igg a preene] l longbeachae1 serum
17053-0,l longbeachae1 igg ser ql
17053-0,l lobeaca1 igg ser ql
17053-0,autoantibody l lngbeachae1 igg sr ql
17053-0,l. longbeachae 1 igg ql (s)
17053-0,aby l. longbeachae 1 igg ql (s)
17053-0,l. longbeachae ql igg 1 (s)
70174-8,dicarboxytetradecenoylcarnitine (c14:1-dc) [moles/volume] in cerebral spinal fluid
70174-8,dicarboxytetradecenoylcarnitine (c14:1-dc) fluid in cerebral spinal [moles/volume]
70174-8,spinal fl dicarboxytetradecenoylcarnitine (c14:1-dc) [moles/volume] in cerebral spinal fluid
70174-8,dicarboxytetradecenoylcarn csf-scnc
70174-8,cerebrospinal fluid-scnc dicarboxytetadeeoylcar point in time
70174-8,quantitative dicarboxytetradecenoylcarn csf-scnc
70174-8,c14:1-dc (csf) [moles/vol]
70174-8,c14:1dc (csf) [moles/l]
70174-8,[moles/vol] cerebral spinal fluid (cerebrospinal fluid) c14:1-dc
101942-1,candida lusitaniae dna [presence] in specimen by naa with probe detection
101942-1,candida lusitaniae ql dna [ql] in specimen by naa with probe detection
101942-1,candida lusitaniae detection [presence] in specimen by naa with probe dna
101942-1,c lusitaniae dna spec ql naa+probe
101942-1,c lusitania dna spec ql naa+pobe
101942-1,c lusitaniae spc dna presence naa+probe
101942-1,c. lusitaniae dna naa+probe ql (specimen)
101942-1,transcription mediated amplification c. lusitaniae presence naa+probe dna (specimen)
101942-1,c. lusitaniae ql naa+probe dna (specimen)
16227-1,diazepam [mass/volume] in urine by confirmatory method
16227-1,diazepam[mas/volue] in urine by cnfirmatory method
16227-1,iazpam [massvoume] inurin by cofirmatry mehod
16227-1,diazepam ur cfm-mcnc
16227-1,cfm-mcnc ur diazepam
16227-1,diazepam cmmcnc cnfrm ur
16227-1,diazepam confirm (u) [mass/vol]
16227-1,diazepam confirm (u) quant [mass/vol]
16227-1,quant diazepam confirm (u) [mass/vol]
62690-3,deprecated phenx measure - intraocular pressure
62690-3,deprcated phenx point in time mesure - intaocularpressure
62690-3,deprecated phenx pessure intraocuar measure-
48719-9,coxiella burnetii phase 2 igg ab [presence] in serum by immunofluorescence
48719-9,coxiella burnetii coxiella burnetii phase ii phase 2 igg ab [presence] serum in by immunofluorescence
48719-9,coxiella buretii phase fa 2 igg ab ser i [prsence by immunofluorescence
48719-9,c burnet ph2 igg ser ql if
48719-9,cburnet er ig h2 ql f serum
48719-9,c burntp iggser ql if
48719-9,c. burnetii phase 2 igg if ql (s)
48719-9,c. burnetii phase 2 igg if presence (s)
48719-9,c. brnetii phae 2 igg q fev if ql s)
55816-3,"3,4-dihydroxyphenylacetate [moles/volume] in urine"
55816-3,"3,4-dihydroxyphenylacetate [moles/volume] iii in urine"
55816-3,"3,4-dihydroxyphenylacetate in [moles/volume] urine"
55816-3,"3,4-dioh-phenylacetate ur-scnc"
55816-3,"ur-scnc 3,4-dioh-phenylacetate"
55816-3,"ur-scnc 3,4-dioh-phenylacetate qnt"
55816-3,"3,4-dihydroxyphenylacetate (u) [moles/vol]"
55816-3,34-diydrxyphenylatate (u) [moles/vol]
55816-3,"(u) 3,4-dihydroxyphenylacetate [moles/vol]"
93461-2,4-methoxybutyrylfentanyl [mass/volume] in urine by confirmatory method
93461-2,4-methoxy-butyryl fentanyl 4-methoxybutyrylfentanyl [mass/volume] in urine by confirmatory method
93461-2,4-methoxybutrylfetnyl [mas/volume illicit in urine by confirmatory method
93461-2,4-methbutfentanyl ur cfm-mcnc
93461-2,ur 4-methbutfentanyl cfm-mcnc quan
93461-2,c24h32n2o2 4-methbutfentanyl ur cfm-mcnc
93461-2,4-methoxybutyrylfentanyl confirm (u) [mass/vol]
93461-2,4-methoxybutyrylfentanyl confirm [mass/vol] (u)
93461-2,4-methxyutyrylfenanyl coirm (u) quan mss/vol]
101230-1,zinc finger protein of the cerebellum 4 ab [presence] in cerebral spinal fluid by immunoblot
101230-1,zic fingerprotein of the cerebellm 4 ab ql] i cereral spinalfluidb antibodies mmunoblot
101230-1,zinc fingr proein f the cerebellum 4 ab [presence] in cerebra serology spinal fludbyimmunoblt
101230-1,zic4 ab csf ql ib
101230-1,zic4 qualitative ab csf ql ib
101230-1,zic4 ib csf antibodies ql ab
101230-1,zinc finger protein of the cerebellum 4 ab ib ql (csf)
101230-1,zinc finger protein of ab cerebellum 4 the ib ql wblot (csf)
101230-1,zinc finger protein of the cerebellum 4 a ib l (cerebrospinal fluid)
6591-2,yellow fever virus neutralizing antibody [units/volume] in serum by neutralization test
6591-2,yellow fever virus neutralizing antibody [units/volume] in ser by infectiousdisease neutralization test
6591-2,yelo fevr [unit/voume] neutralizing antibody virus in ser by eutralization est
6591-2,yfv nab ser nt-acnc
6591-2,yfv ser nab qnt nt-acnc
6591-2,yfv sernt-acnc nt nab
6591-2,yellow fever virus neut ab neut test qn (s)
6591-2,yellow fever virus neut ab neut aby test qn (s)
6591-2,yellow fever (s) neut ab arbitrary concentration neut test qn virus
32682-7,hemoglobin f/hemoglobin.total in blood by electrophoresis
32682-7,hemoglobin f/hemoglobin.total by bld in electrophoresis
32682-7,hmogobin f/hemogbin.total i bld b hbf elctrophoresis
32682-7,hgb f mfr bld elph
32682-7,hgb f electr mfr bld elph
32682-7,hgb f mfr blood elph wb
32682-7,hemoglobin f elph (bld) [mass fraction]
32682-7,hemoglobin f elph whole blood (bld) [mass fraction]
32682-7,hemoglobin f elph (blood) [mass percent fraction]
5816-4,urate crystals [presence] in synovial fluid by light microscopy
5816-4,urate crystals synovial in [ql] fluid by light synovial fluid microscopy
5816-4,crystals urate [presence] in synovial fluid by light microscopy
5816-4,urate cry snv ql micro
5816-4,urate cry snv ql micro
5816-4,presence cryst cry snv urate micro
5816-4,urate crystals lm ql (syn fld)
5816-4,urate crystls lm q joint fluid (syn fld)
5816-4,(syn crystals lm presence urate fld)
32241-2,glutamate [moles/volume] in vitreous fluid
32241-2,quant glutamate [moles/volume] in fluid vitreous
32241-2,in [moles/volume] glutamate vitreous fluid
32241-2,glutamate vitf-scnc
32241-2,vitreous fluid glutamate vitf-scnc
32241-2,vi-sc glutamate
32241-2,glutamate (vitr fld) [moles/vol]
32241-2,(vitr glutamate fld) substance concentration [moles/vol]
32241-2,(vitr glutamate fld) [molesvol]
88237-3,lcds v4.00 - functional abilities and goals - planned discharge [cms assessment]
88237-3,lcds v4.00 - functional abilities and goals - survey planned discharge [cms assessment]
88237-3,lcds v4.00 - functional abilities and goals disch - planned discharge [cms assessment]
3592-3,ephedrine [presence] in urine
3592-3,ephedrine [presence] i urn urine
3592-3,drugs of abuse ephedrine [presence] in urine
3592-3,ephedrin ur ql
3592-3,epherin urql
3592-3,ephedrn l ur
3592-3,ephedrine ql (u)
3592-3,(u) ql ephedrine
3592-3,ephedrine ql (u)
68949-7,ehrlichia chaffeensis ab [titer] in serum by immunofluorescence
68949-7,ehrlicha chafeensis ab [ter] n erum by fluoresent immunofloscence
68949-7,ehrlichia chaffeensis immunofluorescence [titer] in ser immunofluorescence by ab
68949-7,e chaffeensis ab titr ser if
68949-7,titr chaffeensis ab e serum if
68949-7,e chaffeensis ab ser titr if
68949-7,e. chaffeensis ab if (s) [titer]
68949-7,. chffeenis if a (s) [titer]
68949-7,e. chaffnsis ab if (s) [titer]
4067-5,triamterene [mass/time] in 24 hour urine
4067-5,urine [mass/time] in quant 24 hour triamterene
4067-5,hour [masstime] in 24 triamterene urine
4067-5,triamterene 24h ur-mrate
4067-5,triamterene ur-mrate 24h
4067-5,ur 24h triamterene ur-mrate
4067-5,triamterene (24h u) [mass/time]
4067-5,triamteree (24h u) [mass/tie]
4067-5,triamtrene (24h mass rate u) [mass/time]
35739-2,brucella sp igg and igm panel - serum
35739-2,brucella pigg and igm pael - serum
35739-2,andigm spigg brucella panel- serum
35739-2,brucella igg+igm pnl ser
35739-2,brucella ser infectiousdisease pnl igg+igm
35739-2,buella bruc pnl iggim ser
35739-2,brucella sp igg and igm panel (s)
35739-2,brull sp igg and igm pne (s)
35739-2,brucella species igm igg and sp pane s)
62456-9,hiv 2 p15 ab [presence] in serum by immunoblot
62456-9,hiv 2 [presence] ab p15 in serum by id immunoblot
62456-9,hiv 2 p15 ab [presence] in serum immune blot by immunoblot
62456-9,hiv2 p15 ab ser ql ib
62456-9,hiv p15 ser ab ql ql ib
62456-9,ib p15 ab ser ql hiv2
62456-9,hiv 2 p15 ab ib ql (s)
62456-9,2 hiv p15 ab ib ql (s) pt
62456-9,hiv 2 p15 b ib ql (s)
59568-6,orotate [moles/time] in 24 hour urine
59568-6,orate 1 day [molestime] in 2 hour urn
59568-6,24 [moles/time] i orotate hour urine
59568-6,orotate 24h ur-srate
59568-6,orotate ua 24h ur-sat
59568-6,orotae ua ur-srate 24h
59568-6,orotate (24h u) [moles/time]
59568-6,[moles/time] (24h u) orotate
59568-6,ortate quant (24h [moles/time] u)
13709-1,argininosuccinate/creatinine [mass ratio] in urine
13709-1,argininosuccinate/creatinine [mass ratio] creat in urine
13709-1,argninosuccinate/creatinine [mass ratio urin i
13709-1,argininosuccinate/creat ur
13709-1,ur quan argininosuccinate/creat
13709-1,asa argninosuccinatcreat ur
13709-1,argininosuccinate/creatinine (u) [mass ratio]
13709-1,ratio] (u [mass argininosucciate/creainie
13709-1,[mass (u) argininosuccinate/creatinine mass ratio ratio]
34635-3,citalopram [mass/volume] in serum or plasma
34635-3,citalopram [mass/volume] in ser or plasma
34635-3,or [mass/volume] in ser drugs citalopram plasma
34635-3,citalopram serpl-mcnc
34635-3,citalopram serpl-mcnc
34635-3,serpl-mcnc citalopra
34635-3,citalopram [mass/vol]
34635-3,[mass/vol] ser or plasma citalopram
34635-3,citalopram [mass/vol]
76688-1,alpha-1-acid glycoprotein/creatinine [mass ratio] in urine
76688-1,alpha-1-acid glycoprotein/creatinine [mass ratio] in urine
76688-1,apha-1-acid gycoprtei/ratinne ass urine in ratio ucr
76688-1,a1acid glycoprotein/creat ur
76688-1,ur glycoprotein/creat a1acid
76688-1,glycoprotei/creat a1acid
76688-1,alpha-1-acid glycoprotein/creatinine (u) [mass ratio]
76688-1,alph-1-acid glyoprotein/creatinie (u [msrao]
76688-1,alpha-1-acid glycoprotein/creatinine (u) ratio] [mass
77226-9,workload dimensions panel [nmmds]
77226-9,pan workload dimensions panel [nmmds]
77226-9,workload dimensions panel [nmmds] pnl
26896-1,taurine [units/volume] in serum or plasma
26896-1,taurine plasma in ser or [units/volume]
26896-1,taurine plasma in serum or quan [units/volume]
26896-1,taurine serpl-acnc
26896-1,serplas taurine erpl-acnc
26896-1,serpl-acnc taurine
26896-1,taurine qn
26896-1,q random taurine
26896-1,taurine qn
33338-5,zolpidem [presence] in urine
33338-5,presence] olpidem urne screen
33338-5,zolpdem [ql] in urine lioran
33338-5,zolpidem ur ql
33338-5,zolpidem ur ql
33338-5,ur ql zolpidem ql
33338-5,zolpidem ql (u)
33338-5,(u) ql zolpidem myslee
33338-5,qualitative zolpidem presence (u)
4084-0,trimipramine [presence] in urine
4084-0,urine [ql] in trimipramine
4084-0,drug/toxicology trimipamine presenc] in une
4084-0,trimipramine ur ql
4084-0,timipraine r ql
4084-0,trimipramine ur presence
4084-0,trimipramine ql (u)
4084-0,trimipramine (u) ql
4084-0,ql ua trimipramine (u)
74425-0,myelocytes.neutrophilic/leukocytes in blood by manual count
74425-0,myelocytes.neutrophilic/leukocytes manual blood blood by in count
74425-0,manual in loo by myelotes.neutrphilic/leukocytes count
74425-0,myelocytes.neut nfr bld manual
74425-0,myelocytes.neut nfr bld manual
74425-0,nfr myelocyte myelocytes.neut bld manual
74425-0,myelocytes.neutrophilic/leukocytes manual cnt (bld)
74425-0,myelocytes.neutrophilic/leukocytes (bld) cnt manual
74425-0,myelocyteneutrophilic/leukocyts cnt mnual (bld)
90842-6,pca-1 ab [units/volume] in cerebral spinal fluid by line blot
90842-6,pca-1 ab [units/volume] in cerebral spinal fl spinal fluid by line blot
90842-6,pca-1 ab line in cerebral spinal fluid by [units/volume] blot
90842-6,pca-1 ab csf line blot-acnc
90842-6,pca-1 ab csf blot-acnc line
90842-6,pca-1 autoantibodies cerebrospinal fluid ab lnblot-acc
90842-6,pca-1 ab line blot qn (csf)
90842-6,pca-1 ab line lt q (csf
90842-6,pca-1 anti-yo-associated paraneoplastic cerebellar degeneration ab line blot qn (csf)
99577-9,columbia behavior scale for dementia panel [cbs-8]
99577-9,columia behaviorscale for survey [cbs-8] panel dementia
99577-9,clumbiabeavior scale deetia survey for pnl[bs-8]
99268-5,diclazepam [mass/volume] in urine by confirmatory method
99268-5,diclazepam [mass/volume] in urine by confirmatory gcms method
99268-5,dilazepam [s/volume i rine mehod cofmtory by
99268-5,diclazepam ur cfm-mcnc
99268-5,quan ur diclazepam cfm-mcnc
99268-5,diclazepam drug/toxicology ur cfm-mcnc
99268-5,diclazepam confirm (u) [mass/vol]
99268-5,iclzepam [mass/vo (u cnfrm
99268-5,confirm diclazepam (u) [mass/vol]
6931-0,silver [mass/time] in 24 hour urine
6931-0,siver [mass/time] hor in24 urine
6931-0,siver[mass/time] in 4 our urine urn
6931-0,silver 24h ur-mrate
6931-0,silver ur-mrat mass rate 24h
6931-0,slver 24h ur-mrat
6931-0,silver (24h u) [mass/time]
6931-0,silver (24h 24hr u) [mass/time]
6931-0,silver [mass/ti] quan u) (24h
92648-5,gabapentin [presence] in urine by confirmatory method
92648-5,gabapentin method in urine by screen confirmatory [ql]
92648-5,method [presence] in urine by confirmatory gabapentin horizant
92648-5,gabapentin ur ql cfm
92648-5,u gaapetin ql cfm
92648-5,gabapentin ur qualitative l fm
92648-5,gabapentin confirm ql (u)
92648-5,gabapentin (u) ql confirm
92648-5,(u) confirm presence gaapeni
80387-4,"hiv 1+2 ab [presence] in serum, plasma or blood by rapid immunoassay"
80387-4,"hiv 1+2 ab [rence] i r plama serum, antibodies blood y rapi immunoassay"
80387-4,"hiv 1+2 b [prsence] by serum, plasma or blood in rapid imunssay"
80387-4,hiv1+2 ab serplbld ql ia.rapid
80387-4,hiv1+ ab i seplbd ia.rapid ql
80387-4,hiv1+2 ab serplbld ql ia.apd
80387-4,hiv 1+2 ab ia.rapid ql (s/p/bld)
80387-4,1+2 i b pr ia.rapid presence (/p/bld)
80387-4,iv 1+2 ab ia.rapidql(/p/blood)
22729-8,valine [moles/volume] in specimen
22729-8,to be specified in another part of the message valine [moles/volume] specimen in
22729-8,valine specimen in [moles/volume] spec
22729-8,valine spec-scnc
22729-8,valine spec-scnc
22729-8,spec-scnc vane
22729-8,valine (specimen) [moles/vol]
22729-8,substance concentration valine [moles/vol] (specimen)
22729-8,(specimen) valine [moles/vol] quant
85765-6,staphylococcus aureus dna [presence] by naa with non-probe detection in positive blood culture
85765-6,staphylococcus aureus dna [presence] non-probe naa with by detection in positive bld naa+probe culture
85765-6,stahylococcus aureus dna [ql y naa with non-pro detectionin poitive blood culture
85765-6,s aureus dna bld pos ql naa+non-probe
85765-6,s ql ql dna bld pos aureus naa+non-probe
85765-6,pos dna bld saurus presence na+non-probe
85765-6,s. aureus dna naa+non-probe ql (pos bld culture)
85765-6,s. aureus dna naa+non-probe ql (pos blood culture)
85765-6,s. aureus dn clture) ql (pos bld naa+non-probe
80539-0,morphine [mass/mass] in hair
80539-0,in [mass/mass] morphine hair
80539-0,morphine mas/mass hair in
80539-0,morphine hair-mcnt
80539-0,ir-mcnt mohne pt
80539-0,hair-mcnt morphine mass content
80539-0,morphine (hair) [mass/mass]
80539-0,morphine (hair) as/mss]
80539-0,morphine [mass/mass] (hair)
57464-0,cortisol [mass/volume] in serum or plasma --11th specimen
57464-0,cortisol [ass/ome] n serum or pasma --11th secimen
57464-0,cortisol seci in serum serplas or plasma-11th [ass/olume
57464-0,cortis sp11 serpl-mcnc
57464-0,hydrocortisone serpl-mcnc sp11 coris
57464-0,serum or plasma-mcc qnt p cortis
57464-0,cortisol 11th specimen [mass/vol]
57464-0,cortiol 11th specimen [mass/vol
57464-0,specimen 11th cortisol [mass/vol]
6952-6,tolbutamide [mass/volume] in specimen
6952-6,tolbutamide in [mass/volume] misc specimen
6952-6,tolbutamide quantitative [mass/volume] in specimen
6952-6,tolbutamide spec-mcnc
6952-6,spec-mcnc quantitative tolbutamide
6952-6,spec-mcnc tolbutamide
6952-6,tolbutamide (specimen) [mass/vol]
6952-6,novo-butamide tolbutamide (secien) mass/vol]
6952-6,tolbutamide (specimen) level [mass/vol]
32738-7,beta 1 globulin [mass/volume] in body fluid by electrophoresis
32738-7,beta bdy [mass/voue] n lobuli flud electrophresis
32738-7,beta 1 fluid [mass/vole]in body globulin by electrophoresi body fluid
32738-7,beta1 glob fld elph-mcnc
32738-7,elph-mcnc glob fld beta1
32738-7,beta1 glob ld elph-mcnc
32738-7,beta 1 globulin elph (body fld) [mass/vol]
32738-7,bta 1 globulin elph b/f (bdy l) [mass/vo]
32738-7,glbulin 1 beta elh(body fld) fluid [mass/vol]
32355-0,bacteria identified in specimen by respiratory culture
32355-0,bacteria by in specimen identified respiratory c&s culture
32355-0,bacteria in identified specimen by respiratory culture
32355-0,bacteria spec resp cult
32355-0,bacteria spec resp misc cult
32355-0,bacteria spec cult resp
32355-0,bacteria identified respiratory culture nom (specimen)
32355-0,bacteria identified respiraory culture nm(specimen) random
32355-0,bacteria c&s identified nom culture respiratory (specimen)
55912-0,arylsulfatase [enzymatic activity/volume] in dbs
55912-0,arylsulfatase[enzymatic ds ctivity/volume]
55912-0,arylsulfatase [enymic iviy/volum] catalytic concentration in dbs
55912-0,arylsulfatase dbs-ccnc
55912-0,dbs-ccnc aryulfatase filter paper
55912-0,dbs-ccnc arylsulftas
55912-0,arylsulfatase (dbs) [catalytic activity/vol]
55912-0,(dbs) arylsulfatase [caalytic activity/vol] quan
55912-0,arylsulfatase (dbs) [catalytic activity/vol]
59366-5,leptospira interrogans sv sejroe ab [titer] in serum by agglutination
59366-5,leptospira intrrogans by ejeab iter] microbiology in serum sv agglutination
59366-5,lepospira [titer] sv sejroe ab iterogans in ser by agglutination
59366-5,l inter sejroe ab titr ser aggl
59366-5,l inter ser ab tir sejroe agl agg
59366-5,ab inter sejroe l titr ser aggl
59366-5,l. interrogans sv sejroe ab aggl (s) [titer]
59366-5,l. iterrogans sv sjroe ab aggl [tier] (s
59366-5,[titer] interrogans sv sejroe ab aggl (s) l.
17237-9,magnesium [moles/mass] in hair
17237-9,n [moles/mas] magnesium har
17237-9,magnesium [moles/mas] point in time hair in
17237-9,magnesium hair-scnt
17237-9,magnesium hair-sct
17237-9,hair-scnt magnesium quant
17237-9,magnesium (hair) [moles/mass]
17237-9,substance content (hair)moles/ass] magnum
17237-9,magnesium point in time (hair) moles/mass]
41194-2,west nile virus ab [units/volume] in serum by immunoassay
41194-2,west antibodies nile [units/volum] virusa serum by immunossay
41194-2,virus nile west ab [units/volume] anti in serum by immunoassay
41194-2,wnv ab ser ia-acnc
41194-2,wnv ab er ia-acnc
41194-2,wnv ab ser ia-acnc
41194-2,west nile virus ab ia qn (s)
41194-2,west ia virus ab nile qn (s)
41194-2,wes iaa nile viru b ia q ()
86222-7,lipoprotein.alpha 3 [moles/volume] in serum
86222-7,ioproen.alpha 3 [moles/vlume inserum
86222-7,lipoprotein.alpha serum [moles/volume] in 3
86222-7,hdl alpha 3 ser-scnc
86222-7,dl random alph 3 serum-scn
86222-7,hdl alpha 3 serum ser-scnc
86222-7,lipoprotein.alpha 3 (s) [moles/vol]
86222-7,lpoprotein.alph 3 [molevol] (s) ser
86222-7,lipoprotein.alpha 3 [moles/vol] (s)
48152-3,sorbitol/creatinine [molar ratio] in urine
48152-3,crea ratio] [molar sorbitol/creatinine in urine
48152-3,ratio] [molar sobitol/retnine in urine
48152-3,sorbitol/creat ur-srto
48152-3,sorbitolcreatur-srto quantitative
48152-3,ur-srto orbtol/creat
48152-3,sorbitol/creatinine (u) [molar ratio]
48152-3,sorbitol/creatinine [molar (u) ratio]
48152-3,sorbitol/creatinine ratio] [molar (u)
29670-7,rickettsia honei ab [titer] in serum
29670-7,ab honei rickettsia [titer] in serum
29670-7,rickettsia honei ab [titer] in ser
29670-7,r honei ab titr ser
29670-7,r titr ab honei ser
29670-7,rhonei ser itr aby ab
29670-7,r. honei ab (s) [titer]
29670-7,r. honei ab (s) [titer]
29670-7,autoantibody r. honei (s) titer
60159-1,pergolide [mass/volume] in urine
60159-1,pergolide urine random in [mas/volume]
60159-1,pergolide [mass/volume] urine in
60159-1,pergolide ur-mcnc
60159-1,ergolide urn r-mcnc
60159-1,perglid ur-mcnc
60159-1,pergolide (u) [mass/vol]
60159-1,random (u) pergolide [mass/vol
60159-1,ergolid(u) qnt mass/vol]
35383-9,galactomannan ag [units/volume] in serum or plasma
35383-9,galactomanna in [units/olume] serum or plasma ag serum or plasma
35383-9,galactomannan serp ag [units/volume] in ser or plasma
35383-9,galactomannan ag serpl-acnc
35383-9,galactomannan serp-acnc ag
35383-9,galactomannan serpl-acnc g
35383-9,galactomannan ag qn
35383-9,galactomannan ag qn
35383-9,galactomannan qn ag
45996-6,mood and behavior patterns section
45996-6,mod andbehaor section patterns
45996-6,mood section behavior patterns and
12711-8,hemoglobin a region [presence] in blood by electrophoresis alkaline (ph 8.9)
12711-8,8.9) a region [presence] in blood by electrophoresis alkaline (ph hemoglobin
12711-8,hemoglobin random a regin [prsence] in bloodb electrophoresis akain (ph 8.)
12711-8,hgb a reg bld ql elph alk
12711-8,hgb a re d ql elph alk
12711-8,reg a hgb bld ql elec elph alk
12711-8,hemoglobin a region elph ph 8.9 ql (bld)
12711-8,hemoglobin a region elph ph random 8.9 ql (bld)
12711-8,hemoglobin a region elph ph 8.9 ql (blood)
43024-9,herpes virus 6 igg ab [titer] in cerebral spinal fluid
43024-9,in virus 6 igg ab [titer] herpes cerebral titered spinal fluid
43024-9,herpes virus igg 6 ab [titer] in cerebral spinal fluid
43024-9,hhv6 igg titr csf
43024-9,hh6 igg titr csf
43024-9,hhv6 titr igg csf
43024-9,hhv 6 igg (csf) [titer]
43024-9,hhv6 igg cs) cerebrospinal fl [titer
43024-9,hhv (csf) igg 6 [titer]
33870-7,bilirubin.total [presence] in specimen
33870-7,bilirubin.total billirubin [presence] in specimen
33870-7,bilirubin.total in [presence] specimen
33870-7,bilirub spec ql
33870-7,qual specql bilirub
33870-7,ilrub spec presence spec
33870-7,bilirubin ql (specimen)
33870-7,bilirubin (specimen) ql
33870-7,bilrubin ql (pecimn)
67762-5,"hedis 2012, 2013 codes to identify nephropathy screening tests (cdc-j)"
67762-5,"heis 2012, 201 coesto deniy nephopthy screenig (cdc-j tests panel"
67762-5,"eds 2012, 2013 codes to nehroathy identify screning tests (cdc-j)"
67762-5,hedis 2012-13 cdc-j
67762-5,heds 2012-13 random cdc-j
67762-5,hedis 2012-3cdc-
67762-5,"hedis 2012, 2013 codes to identify nephropathy screening tests (cdc-j)"
67762-5,"hedis tests 2013 odes to identify nephropathy creenng 21, (cd-j) hedis 2012-13 cdc-j"
67762-5,"hedis identify 2013 codes to 2012, nephropathy screening tests (cdc-j)"
14421-2,bilirubin.total [mass/volume] in pleural fluid
14421-2,bilirubin.total [mass/volume] tbil in pleural fluid
14421-2,bilirubin.total billirubin [mass/volum] in pleural fluid
14421-2,bilirub plr-mcnc
14421-2,mass concentration plr-mcnc bilirub
14421-2,plrmcnc bliub point in time
14421-2,bilirubin (pleur fld) [mass/vol]
14421-2,bilirubin [mass/vol] fld) (pleur
14421-2,bilirubin fld) mass concentration (pleur [mass/vol]
24015-0,influenza virus a+b ag [presence] in specimen
24015-0,virus nlunza a+b ag prece]in specmen
24015-0,influnza virusab ag [preence in spec specimen
24015-0,fluav+flubv ag spec ql
24015-0,fluav+lbv ag q spec
24015-0,fluavflub ag sec q fluv
24015-0,fluav+flubv ag ql (specimen)
24015-0,ql a fluav+flubv (specimen)
24015-0,"fluavluv ag ql a,b (scimen)"
89587-0,herpes simplex virus 2 dna [presence] in lower respiratory specimen by naa with probe detection
89587-0,herpes simplex virus 2 dna [presence] in lower respiratory specimen by naa with probe detection
89587-0,herpes simplex virus 2 dna [presence] by lower respiratory specimen in naa with probe detection
89587-0,hsv2 dna lower resp ql naa+probe
89587-0,hsv2 dnalower probe amp resp ql naa+probe
89587-0,hsv2dna lower resp naa+probe presence
89587-0,hsv 2 dna naa+probe ql (lower resp)
89587-0,dna 2 hsv naa+probe ql (lower resp)
89587-0,sv  dna naapob q (lowerrsp)
52928-9,molybdenum/creatinine [molar ratio] in urine
52928-9,molybdum/creatnin substance ratio [mor ratio] inurine
52928-9,rai] [molar olybdenum/cratinne i urne
52928-9,molybdenum/creat ur-srto
52928-9,olybdenum/crear-srto
52928-9,moybdenum/creat ur-rto
52928-9,molybdenum/creatinine (u) [molar ratio]
52928-9,pt olybenum/creatinine [molarratio] (u)
52928-9,molybdenum/creatiine (u) [molar ratio]
60478-5,sex of tick
60478-5,of sex tick
60478-5,ex of infectious disease tick
60478-5,sex of tick
60478-5,sex of tick
60478-5,ex typ o tick
60478-5,sex nom (tick)
60478-5,sex nom (tick) gender
60478-5,sex (tick) typ nom
47814-9,"deprecated 3,4-dihydroxyphenyllactate/creatinine [molar ratio] in urine"
47814-9,"deprecated 3,4-di-oh-phenyllactate 3,4-dihydroxyphenylctte/ceatinine molar in ratio] urine"
47814-9,"deprecated ua 3,4-dihydroxyphenyllactate/creatinine [molar ratio] in urine"
47814-9,"deprecated 3,4-di-oh-phenyllactate/creat ur-srto"
47814-9,"3,4-di-oh-phenyllactate deprecate 3,4-diohhylactatecreat ur-srto"
47814-9,"3,4-di-oh-pnylatate/creat deprcted ur-srto"
47814-9,"3,4-dihydroxyphenyllactate/creatinine (u) [molar ratio]"
47814-9,"3,4-dhydroxyphenylatate/creatinin (u) ucr [olar ratio]"
47814-9,"chemistry 3,4-dihydroxyphenyllactate/creatinine (u) [molaratio]"
82315-3,level 3 emergency medical services patient care report - recommended cda r1 and r2 sections
82315-3,level 3 emergency medical services patient care report - recommended cda r1 and r2 sections lv
82315-3,level 3 emergency medical services patient care report and recommended cda r1 - r2 sections
82315-3,l3 ems pt care rpt cda r1+r2 sec
82315-3,l3 ems pt sec rpt cda r1+r2 care
82315-3,l3 ems pt care rpt cda iii r1+r2 sec
51775-5,chromatin ab [units/volume] in serum or plasma
51775-5,in ab [units/volume] chromatin serum or plasma
51775-5,aby chromtin ab[units/volue] in ser o lasma
51775-5,chromatin ab serpl-acnc
51775-5,chromain b serpl-anc
51775-5,chromatin ab serpl-acnc
51775-5,chromatin ab qn
51775-5,ab chromatin qn random
51775-5,chromatin ab antby qn
5109-4,coxsackievirus b4 neutralizing antibody [titer] in serum by neutralization test
5109-4,neutralizing b4 coxsackievirus antibody [titer] in serum by neutralization test cv b4
5109-4,coxsackievirus serum neutralizing antibody [titer] in b4 by neutralization cav test
5109-4,cv b4 nab titr ser nt
5109-4,b4 titrser nab nt
5109-4,c b4nab nt sr nt titr
5109-4,coxsackievirus b4 neut ab neut test (s) [titer]
5109-4,coxsackievirus b4 neut ab neut test (s) [titer]
5109-4,coxsackievirus b4 neut ab titer neut test (s) [titer]
106583-8,candida auris dna [presence] in body fluid by naa with non-probe detection
106583-8,andida auris dna point in time [presen] i body flud by naa with nonprobe detectio
106583-8,n auris da [presence] candida bdy lid bynaa ith nn-probe detection
106583-8,c auris dna fld ql naa+non-probe
106583-8,c pcr auris dna fld ql naa+non-probe
106583-8,c amplif auris dnafld ql naa+no-probe
106583-8,c. auris dna naa+non-probe ql (body fld)
106583-8,c. auris dna naa+non-probe ql dna nucleic acid probe (body fld)
106583-8,c. auris deoxyribonucleic acid dna presence naa+non-probe (body fld)
44079-2,chlamydia trachomatis iga and igg and igm [interpretation] in serum
44079-2,chlamydia trachoatis iga infectiousdisease and igg andigm [iterpetation] in seru
44079-2,hamydia trachomats iga and igg interpretation d inserum [iterpretation] igm
44079-2,c trach iga+igg+igm ser-imp
44079-2,c trach igaigg+igm ser-mp
44079-2,trah c ia+igggm ser-imp
44079-2,c. trachomatis iga and igg and igm (s) [interp]
44079-2,c. trachomatis impressions iga and igg and igm (s) [interp]
44079-2,c.trachomatis serum ga and igg and igm (s) [interp]
62475-9,herpes simplex virus 2 dna [#/volume] (viral load) in tissue by naa with probe detection
62475-9,herpes (viral virus 2 dna [#/volume] simplex load) in tissue by naa with probe detection
62475-9,hsv herpes (viral virus 2 dna [#/volume] simplex load) in tissue by naa with probe detection
62475-9,hsv2 dna # tiss naa+probe
62475-9,tiss # transcription mediated amplification hsv2dn a+probe
62475-9,dna probe dna hsv2 # tiss nprobe
62475-9,hsv 2 dna naa+probe (tiss) [#/vol]
62475-9,(tiss) 2 dna aa+proe sv quan [#/ol
62475-9,hs2 lcr [/vol] naa+proe (tss na
3914-9,penicillin v [mass/volume] in serum or plasma
3914-9,[mass/volume] v quantitative penicillin in serum or plasma
3914-9,penicillin v[mass/volue] in serum rplasm plasma
3914-9,penicillin v serpl-mcnc
3914-9,peniillin v serpl-mcnc
3914-9,penicillin serpl-mcnc v
3914-9,penicillin v [mass/vol]
3914-9,penicillin [mass/vol serpl v
3914-9,serp penicllin ss/ol] v
73874-0,androstenetriol [moles/time] in 24 hour urine
73874-0,"androstenetriol 5 androstene, 3beta, 7beta, 17beta triol urine in 24 hour [moles/time]"
73874-0,androstenetriol [moles/time] hour 24 in urine
73874-0,aet 24h ur-srate
73874-0,ur-srate 24h 5-at aet
73874-0,urn et24h ur-srae
73874-0,androstenetriol (24h u) [moles/time]
73874-0,[moles/time] (24h u) androstenetriol
73874-0,androsteetriol (4h u) [moles/time]
47805-7,valine/amino acids.total in specimen
47805-7,valine/amino in acids.total specimen
47805-7,valine/amino percent acids.total in specimen
47805-7,valine sfr spec
47805-7,sfr valine quantitative spec
47805-7,vline f val spec
47805-7,valine/total aa (specimen) [molar fraction]
47805-7,valine/total aa [mola (speimen ation] percent
47805-7,valine/total aa (specimen) [molar fraction] miscellaneous
85094-1,escitalopram and norescitalopram panel - serum or plasma
85094-1,ecitalopram and pan noresitaoprm panel - serum or lasma
85094-1,escitalopram and serum panel - norescitalopram or plasma
85094-1,escitalopram + norescitalo pnl serpl
85094-1,escialoprm pl orescitalo erpl
85094-1,escitalopram+ norescitalo pnl srpl
85094-1,escitalopram and norescitalopram panel
85094-1,escitalopram norescitalopram and panel
85094-1,and escitalopram norescitalopram panel pnl
6466-7,microscopic observation [identifier] in duodenal fluid by wet preparation
6466-7,prep microscopic osevation [deniier]in duodena fid by wet preparation
6466-7,micoscpic obseratin [identiie] in dudenal prepartion by wet luid gastro
6466-7,wet prep duod fl
6466-7,wet prep duod fl
6466-7,wet prep fl duod
6466-7,microscopic observation wet prep nom (duod fld)
6466-7,microcopic osevto wet dudf prep nom (duod fld)
6466-7,observation microscopic wet prep nom (duod fld)
97291-9,noroxycodone [presence] in cord tissue by confirmatory method
97291-9,oroycodone presene] in cord tisse byonfirmtory ethod
97291-9,noroxycodone [ql] in cord tissue by confirmatory confirmation method
97291-9,noroxycodone tissco ql cfm
97291-9,cfm tissco cnfrm l noroxycodone
97291-9,noroxyodn presence tissco cfm
97291-9,noroxycodone confirm ql (umb cord tissue)
97291-9,cord confirm ql (umb noroxycodone tissue)
97291-9,noroxycodone confirm cord (umb ql tissue)
75880-5,14-3-3 eta ag [mass/volume] in serum by immunoassay
75880-5,meia 14-33 et a [mss/volume]in serm by immunoassay
75880-5,14-3-3 ag eta [mass/volume] in serum by immunoassay
75880-5,14-3-3 eta ag ser ia-mcnc
75880-5,4--3 ea ag ser enzyme immunoassay ia-mcc
75880-5,ag eta 14-3-3 serum ia-mcnc
75880-5,14-3-3 eta ag ia (s) [mass/vol]
75880-5,ag eta 14-3-3 ia (s) [mass/vol]
75880-5,eia 14-3-3 eta ag ia [mass/vol] (s)
74375-7,"2,2',3,5'-tetrachlorobiphenyl (pcb) [mass/volume] in serum or plasma by confirmatory method"
74375-7,"2,2',3,5'-tetrachlorobiphenyl (pcb) by in serum or plasma [mass/volume] confirmatory method"
74375-7,"2,2',3,5'-tetrachlorobiphenyl plasma [mass/volume] in serum or (pcb) by confirmatory method"
74375-7,"2,2',3,5'-pcb serpl cfm-mcnc"
74375-7,"cfm-mcnc serpl 2,2',3,5'-pcb"
74375-7,"2,2',3,5'-pcb cfm-mcnc serpl"
74375-7,"2,2',3,5'-tetrachlorobiphenyl (pcb) confirm [mass/vol]"
74375-7,"confirm (pcb) drugs 2,2',3,5'-tetrachlorobiphenyl [mass/vol]"
74375-7,"2,2',3,5'-tetrachlorobiphenyl (pcb) [mass/vol] confirm"
51419-0,sodium [moles/volume] corrected for glucose in serum or plasma
51419-0,sdium mole/voum] corecte fr glucs in erum r plas
51419-0,sodium [moles/volume] serum for glucose in corrected or plasma
51419-0,sodium glucose cor serpl-scnc
51419-0,sodium glucose cor serpl-scnc quantitative
51419-0,sodium glucose quant serpl-scnc cor
51419-0,sodium corrected for glucose [moles/vol]
51419-0,[moles/vol] rrected for glucose sodium
51419-0,for corrected sr sodium glucose [moles/vol]
101115-4,leukotriene e4/creatinine [mass ratio] in 24 hour urine
101115-4,leukotriene e4/creatinine [mass ratio] urn in 24 hour urine
101115-4,leukotriene e4/creatinine [mass 24hr ratio] in 24 hour urine
101115-4,lte4/creat 24h ur
101115-4,lte4/creat 24h ur
101115-4,lte4/creat24h ur
101115-4,leukotriene e4/creatinine (24h u) [mass ratio]
101115-4,mcrto lekotriene 4/creatinin (24h u) [mass ratio]
101115-4,eukoriene e4/creanine ratio] )[mass (2h
95183-0,clostridioides difficile toxin and bi-nap1-027 strain dna panel - stool by naa with probe detection
95183-0,clostridioides difficile toxin and bi-nap1-027 strain dna panel - stool by naa probe with target amplification with probe detection
95183-0,closridioidesdificile toxin and bi-na1-027 strain by panel - stool dna naa with prbe detecton
95183-0,c diff tox+bi-nap1-027 pnl stl naa+prb
95183-0,c diff pnl tox+bi-nap1-027 feces stl naa+prb
95183-0,c pnl tox+bi-nap1-027 diff stl naa+prb
95183-0,c. difficile toxin and bi-nap1-027 strain dna panel naa+probe (stl)
95183-0,c. difficile toxin dna bi-nap1-027 strain and panel naa+probe (stl)
95183-0,. difficile toxin and bi-nap-027 straindna c difficile panel na+probe (tl)
26963-9,methionine [moles/volume] in urine
26963-9,methionine in [moles/volume] urine
26963-9,methionine moles/volume] met in urine
26963-9,methionine ur-scnc
26963-9,quant ur-scnc methionine
26963-9,ur-scnc quantitative methioin
26963-9,methionine (u) [moles/vol]
26963-9,methionie () [moles/vol]
26963-9,methionine [moles/vol] (u) quan
93941-3,abo and rh group during infancy panel - blood
93941-3,abo and rh group during infancy random panel - blood
93941-3,abo and rh group during wb infancy panel - blood
93941-3,abo+rh gp pnl infant bld
93941-3,abo+rgp pn infantbld
93941-3,pnl abo+rh p pnl blood inant
93941-3,abo and rh group during infancy panel (bld)
93941-3,abo and rh group (blood) infancy panel during
93941-3,abo and rh abo+rh gp pnl infant group (bld) infancy panel during
53885-0,parvovirus b19 igg ab [units/volume] in body fluid
53885-0,parvvirus b19 i ab [units/volme] i boyfuid
53885-0,parvovirus ab igg b19 [units/volume] in body fluid
53885-0,b19v igg fld-acnc
53885-0,b19v ig fld-anc fl
53885-0,fld-acnc igg b19v
53885-0,parvovirus b19 igg qn (body fld)
53885-0,parvovirus igg b19 qn (body antibodies fld)
53885-0,parvovirus b19 ig qn (body fld) random
82726-1,natural killer cell cytotoxicity.12.5:1 effector to target cell ratio/positive control in blood mononuclear cells
82726-1,natural killer cell cttoxicity.12.5:1effector to targetcll ratio/psitive conrol nk ilod mononcler cells
82726-1,natural killer ratio/positive cytotoxicity.12.5:1 effector to target cell cell control nk in blood mononuclear cells
82726-1,nk cytotox.12.5:1 e:t/pos cntrl bld mc
82726-1,cytotox.12.5:1 rlacnc k e:t/pos cntrl blmc
82726-1,mc cytotox.12.5:1 e:t/pos cntrl bld nk
82726-1,nk cytotoxicity 12.5:1 e:t ratio/positive control (bld mc) [rel units/vol]
82726-1,12.5:1 cytotoxicity nk e:t ratio/positive control (blood mc) [rel units/vol]
82726-1,e:t cytotoxicity 12.5:1 nk quant ratio/positive control (blood mc) [rel units/vol]
90748-5,atomoxetine [mass/volume] in saliva (oral fluid) by confirmatory method
90748-5,in ms/vum] atomoxetine saliv (oralfluid) by confirmatory method
90748-5,atooxetine [mass/voume] in salva (oa fluid) by confirmatory mehod
90748-5,atomoxetine sal cfm-mcnc
90748-5,atomoxetine sal cfm-mcnc gcms
90748-5,cfm-mcnc sal atomoxetine
90748-5,atomoxetine confirm (sal) [mass/vol]
90748-5,[mass/vol] confirm (sal) atomoxetine quant
90748-5,atomoxetineconfirm strattera (sal)[as/vol]
63023-6,deprecated phenx measure - healthy food environments
63023-6,depecated henx measure panl - heth food enviroment
63023-6,deprecated food pnl measure - healthy phenx environments
94066-8,person-centered primary care measure [pcpcm]
94066-8,primry person-centered care mesure [pcpcm] pt
94066-8,person-centered care primary measure [pcpcm]
49773-5,galactitol [moles/volume] in serum or plasma
49773-5,galactitol [moles/volume] in plasma quant or serum
49773-5,substance concentration galactitol [moles/volume] in serum or plasma
49773-5,galactitol serpl-scnc
49773-5,galactilserpl-scnc
49773-5,sepl-scnc galactitl
49773-5,galactitol [moles/vol]
49773-5,galactitol [moles/vol]
49773-5,[moes/vol] galactitol
103612-8,n-desethyl sunitinib [mass/volume] in serum or plasma by lc/ms/ms --24 hours post dose
103612-8,quan n-desethyl sunitiib [mass/olume]i --24 or lasma lc/m/ms srum hors post dose
103612-8,n-desetyl sunitini[ass/voume] in seum or plasma b c/ms/ms drugs --24 hours post dose
103612-8,n-desethylsu 24h p serpl lc/ms/ms-mcnc
103612-8,n-desethysu 4h p serpl lc/ms/ms-mcnc
103612-8,n-desethylsu mass concentration 24h p serpl lc/ms/ms-mcnc
103612-8,n-desethyl sunitinib 24 hr post dose lc/ms/ms [mass/vol]
103612-8,n-deethyl sunitini quan 4 hr post dse lc/ms/ms [mass/vol]
103612-8,ndesethy sunitinib2 hr post dos lc/ms/ms [mass/vol]
50126-2,3-hydroxypalmitoylcarnitine (c16-oh) [moles/volume] in amniotic fluid
50126-2,[moles/volume]inamnioic (c16oh) 3-hydroxypamitoylcarnitine flud
50126-2,3-hydroxypalmitoylcarnitine substance concentration (c16-oh) fluid in amniotic [moles/volume]
50126-2,3oh-palmitoylcarn amn-scnc
50126-2,3oh-palmitoylcarn amn-scnc c16-oh
50126-2,3oh-palmitylarnamn-scnc amnio
50126-2,c16-oh (amn fld) [moles/vol]
50126-2,3oh-palmitoylcarn c16-oh [moles/l] fd (amn
50126-2,c16-oh [moles/vol] fld) (amn
73020-0,fluconazole induced neutrophil igg ab [presence] in serum or plasma by flow cytometry (fc)
73020-0,fluconazole induced neutrophil igg ab [presence] serum in or plasma by flow cytometry (fc)
73020-0,fluconazole inuced netrophil igg ab [presence] orplasma inserum by flw cytometry sr (fc)
73020-0,fluconazole (neut) igg serpl ql fc
73020-0,flucazole autoantibodies (neu) ig serp ql fc
73020-0,fluconazole serpl igg (neut) ql fc
73020-0,fluconazole induced neutrophil igg fc ql
73020-0,fluconazole induced pnm neutrophil igg fc ql
73020-0,l inducdneutrophi igg fc fluconazole
88950-1,deprecated mds v3.0 - rai v1.16.1 - swing bed pps (sp) item set [cms assessment]
88950-1,deprecated mds [cms - rai v1.16.1 - swing bed pps (sp) item set v3.0 point in time assessment]
88950-1,deprecated mds v3.0 - rai v1.16.1 - swing pnl bed pps (sp) item set [cms assessment]
79310-9,gamma butyrobetaine [moles/volume] in dbs
79310-9,gamma butyrobetaine [moles/volume] in dbs quantitative
79310-9,gamma butyrobetaine[moles/volume] in dbs
79310-9,g-butyrobetaine dbs-scnc
79310-9,dbs-scnc g-butyrobetaine filter paper
79310-9,g-butyrobetaine dbs-snc
79310-9,gamma butyrobetaine (dbs) [moles/vol]
79310-9,chemistry gamma butyrobetaine [moles/vol] (dbs)
79310-9,gamma butyrobetaine (dbs) [moles/vol]
50388-8,neisseria gonorrhoeae rrna [presence] in cervix by naa with probe detection
50388-8,neisseria gonorrhoeae rrna with in cervix by naa [presence] probe detection transcription mediated amplification
50388-8,neisseria rrna ribosomal rna gonorrhoeae [presence] in cervix by naa with probe detection
50388-8,n gonorrhoea rrna cvx ql naa+probe
50388-8,n obstetrics gonorrhoea rrna cvx ql aa+probe
50388-8,naa+probe gonorrhoea rrna cvx probe with ampification ql n
50388-8,n. gonorrhoeae rrna naa+probe ql (cvx)
50388-8,ngonorrhoeaerrn na+proe ql (cvx)
50388-8,naa+probe gonorrhoeae rrna n. ql (cvx)
40604-1,alpha-2-macroglobulin [presence] in urine by immunoelectrophoresis
40604-1,by [presence] in urine alpha-2-macroglobulin immunoelectrophoresis
40604-1,alpa-2-macrolobulin ql] macroglobn urine in immunoelectophoesis
40604-1,a2 macroglob ur ql iep
40604-1,ur macroglob a2 ql iep
40604-1,a2 macroglob ql ur iep
40604-1,alpha-2-macroglobulin iep ql (u)
40604-1,iep alpha-2-macroglobulin presence (u)
40604-1,alpha-2-macroglobuin iep (u) ql
107101-8,billing encounter information
107101-8,information encounter billing panl
107101-8,encounter billing information
107101-8,billing encounter information
107101-8,billng encounter iformation
107101-8,information enounter billing
4577-3,hemoglobin f - texas [presence] in blood by electrophoresis acid (ph 6.3)
4577-3,hemoglobin f - texas wb [presence] in blood by electrophoresis acid (ph 6.3)
4577-3,acid f - texa [presnce] n blood by electrophoesis hemolobin (ph 6.3) pr
4577-3,hgb f-texas bld ql elph acid
4577-3,f-texas hgb ordinal bld ql ephacid
4577-3,hgb ql f-texas bld ql elph acid
4577-3,hemoglobin f - texas elph ph 6.3 ql (bld)
4577-3,hemogloif - txs elph ph 6.  (l)
4577-3,hemoglobin f - wb texas elph ph 6.3 ql (bld)
54895-8,staff assessment for mental status [mdsv3]
54895-8,staff assessmen for [mdsv3] status menta
54895-8,staff assessment mental for status [mdsv3]
62305-8,fabry disease newborn screen interpretation
62305-8,fabry disease whole blood newborn screen interpretation
62305-8,fabry interpretation newborn screen disease
62305-8,fabry disease dbs-imp
62305-8,fabry disease dbs-imp
62305-8,fabry dbs-imp disease
62305-8,fabry disease (dbs) [interp]
62305-8,fabry (dbs) disease angiokeratoma corporis diffusum [interp]
62305-8,fabry disease (dbs) intep] impressions
47233-2,influenza virus a ab [presence] in serum --2nd specimen
47233-2,influenza virus a specimen [presence] in serum --2nd ab
47233-2,influenza virus a ab [presence] infectiousdisease in serum --2nd specimen
47233-2,fluav ab sp2 ser ql
47233-2,fluav a sp2 infectious disease serql
47233-2,antby fluav ab sp2 serum ql
47233-2,fluav ab spec 2 ql (s)
47233-2,fluav aby ab spec 2 ql (s)
47233-2,spec ab fluv 2 ql (s)
29797-8,highlands j virus neutralizing antibody [titer] in cerebral spinal fluid by neutralization test
29797-8,highlands j virus spinal antibody [titer] in cerebral neutralizing fluid vnt by neutralization test
29797-8,in j virus neutrlzing antibdy [titer] highlands ceral spinl fluid by cerebral spinal fluid neuraliton tes
29797-8,hjv nab titr csf nt
29797-8,hjv nab titr csf nt
29797-8,csf nab titr hjv nt
29797-8,highlands j virus neut ab neut test (csf) [titer]
29797-8,test j virus neut ab nab net highlands (csf) [iter]
29797-8,highlands j virus nt ab ne test (csf) [titr]
82182-7,escherichia coli k1 dna [presence] in cerebral spinal fluid by naa with non-probe detection
82182-7,eschrichia colik dna peence] in cereral spinal fluidby naawith non-probe eecion
82182-7,escherichia coli k1 dna with in cerebral spinal fluid by naa [presence] non-probe detection
82182-7,e coli k1 dna csf ql naa+non-probe
82182-7,e dna colik1 cs ql naa+non-probe lat
82182-7,e lat presence k1 nsf coi naanon-probe
82182-7,e. coli k1 dna naa+non-probe ql (csf)
82182-7,k1 coli e. pr dna naa+non-probe ql (cerebrospinal fluid)
82182-7,e. (csf) k1 dna naa+non-probe ql coli
81428-5,influenza virus a h7 eurasia rna [presence] in respiratory system specimen by naa with probe detection
81428-5,influenza virus a respiratory h7 eurasia rna [ql] in respiratory system specimen by naa with probe detection
81428-5,influenz irus a h7 eurasia rna [ql] tma in respirtory system pecimn by aa with proe detection
81428-5,fluav h7 euras rna resp ql naa+probe
81428-5,luav h euras rnaresp fluav h7 eurasia rna ql naarob
81428-5,fluav h7 resp rna euras ql naa+probe
81428-5,fluav h7 euras rna naa+probe ql (respiratory system specimen)
81428-5,fluav h7 euras probe with ampification rna naa+probe ql (respiratory system specimen)
81428-5,fluav h7 eurasrna naa+prob presence (respiatory point in time ytempeimen
14445-1,triglyceride [mass/volume] in amniotic fluid
14445-1,triglyceride level [mass/volume] in amniotic fluid
14445-1,triglycerides triglyceride [mass/volume] in amniotic fluid
14445-1,trigl amn-mcnc
14445-1,trigl amnmcnc mass concentration
14445-1,trigl amn-mcc point in time
14445-1,triglyceride (amn fld) [mass/vol]
14445-1,trigcride (mn fld[mass/vol] amniotic flu
14445-1,(amn triglyceride fld) [mass/vol]
80134-0,amphetamine [mass/mass] in hair by confirmatory method
80134-0,amphetamine [mass/mass] in hair by confirmatory method
80134-0,amphetamine hair in [mass/mass] by confirmatory method
80134-0,amphet hair cfm-mcnt
80134-0,cfm-mcnt hair amphet gcms
80134-0,pt amhet cf-mcnt hair
80134-0,amphetamine confirm (hair) [mass/mass]
80134-0,mphetamine cnfirm (hair) mass/mass]
80134-0,[mass/mass] confirm confirmation (hair) amphetamine
72974-9,phenobarbital induced neutrophil igg ab [presence] in serum or plasma by flow cytometry (fc)
72974-9,phenobarbital induced neutrophil igg ab [presence] in serum by plasma or flow neutrophils cytometry (fc)
72974-9,aby phnoarbital induced eutrophil igg b pesnce]i serum or plasmaby fow cytmetr (fc)
72974-9,phenobarb (neut) igg serpl ql fc
72974-9,phenbab (neut) igg serpl sepl qlfc
72974-9,phenobarb(net) ql serpl igg f
72974-9,phenobarbital induced neutrophil igg fc ql
72974-9,phenobarbital luminal induced igg neutrophil fc ql
72974-9,fc induced neutrophil igg phenobarbital ql
26497-8,mononuclear cells/leukocytes in synovial fluid
26497-8,mononuclear cells/leukocytes in synovial fluid
26497-8,mononulear cell/leukocytes synoval i fluid
26497-8,mononuc cells nfr snv
26497-8,leuk nfr cels mononuc snv
26497-8,number fraction monouc nfr cells snv
26497-8,mononuclear cells/leukocytes (syn fld)
26497-8,fld) cells/leukocytes number fraction (syn mononuclear
26497-8,mononuclear cls/ekote(yn fld)
22531-8,salmonella typhimurium ab [presence] in serum
22531-8,salmonella in ab [pesence] typhimurium serum
22531-8,typhimuium salmonella ab [presence] in serum
22531-8,s typhimur ab ser ql
22531-8,ab typhimur s ser ql
22531-8,s typhimur ab ql ser
22531-8,s. typhimurium ab ql (s)
22531-8,s. (s) ab ql typhimurium
22531-8,. typhimurium ab l (s)
10978-5,amitriptyline+nortriptyline [mass/volume] in urine
10978-5,amiriptyline+nortriptyline[mas/volume] in urin
10978-5,amitriptyin+nortrptyine [massvolum] in urine
10978-5,amitrip+nor ur-mcnc
10978-5,ur-mcnc amit amitrip+nor
10978-5,ur-mcnc amitrip+nr quantitative
10978-5,amitriptyline+nortriptyline (u) [mass/vol]
10978-5,[mass/vol] (u) amitriptyline+nortriptyline
10978-5,(u) amitriptyline+nortriptyline [mass/vol]
22248-9,cytomegalovirus igm ab [titer] in cerebral spinal fluid
22248-9,cytomegalovirus igm ab [titer] in cerebral spinal fluid antibodies
22248-9,cytomeglvirus cytomegalo virus im ab[tite] in cereral spinal fluid
22248-9,cmv igm titr csf
22248-9,cmvig titr antibody sf
22248-9,cmv igm itr cs
22248-9,cmv igm (csf) [titer]
22248-9,cmv igm aby (cerebrospinal fluid) [titer]
22248-9,igm cmv (cerebrospinal fluid)[titer]
2544-5,lactate dehydrogenase 4 [enzymatic activity/volume] in serum or plasma by chemical separation
2544-5,lactate by [enzymaic activy/volume] in serum or plma ydogenase chemicalsepration
2544-5,lactate dehydrenae 4 plasma atiity/olu] in l-lactate serum or [enzymatic by chmical sparation
2544-5,ldh4 serpl chem sepn-ccnc
2544-5,ldh4 chem serpl sep-ccnc
2544-5,ldh4 chm serpl quantitative sepn-ccc
2544-5,ldh 4 chemical separation [catalytic activity/vol]
2544-5,ldh chemical 4 separation [catalytic activity/vol] catalytic concentration
2544-5,cheical 4 lh sparation [cataytic activty/vol
70298-5,esrd mineral metabolism panel
70298-5,esrd mineral metabolism panel
70298-5,esrd minea metabolism panel pnl
16478-0,borrelia burgdorferi iga ab [presence] in serum by immunoassay
16478-0,borreia burgdorferi serum ab [ql] in ia by imunoasay
16478-0,borrelia burgdorferi iga ab [preence in serum y immunoasay
16478-0,b burgdor iga ser ql ia
16478-0,b burdor iga sr ql i
16478-0,ql burgdor iga lyme disease ser b ia
16478-0,b. burgdorferi iga ia ql (s)
16478-0,b. (s) iga ia ql burgdorferi
16478-0,b. burgdorferi iga ia antby ql (s)
99414-5,gamma globulin [mass/volume] in serum or plasma by immunofixation
99414-5,[massvoue] globuin gamma globul n seum o plama by immunofition
99414-5,immunoxation globulin [mass/volum] n sru or plas by gamma
99414-5,gamma glob serpl ife-mcnc
99414-5,gamma globserpl ife-mcnc
99414-5,gammaglob serl ife-mc
99414-5,gamma globulin immunofixation [mass/vol]
99414-5,globulin gamma immunofixation [mass/vol]
99414-5,gamma globulin immunofixation [mass/vol]
33834-3,lymphocytes plasmacytoid [#/volume] in blood by manual count
33834-3,hematology/cell counts lymphocytes in [#/voume] plasmacytoid blood by anual cont
33834-3,lympcytes plasmactod [#/voume] in blood by manua cunt
33834-3,plasmacoid lymphs # bld manual
33834-3,plasmacoid bld # lymphs manual
33834-3,plasmacoid blood # lymphs absolutes manual
33834-3,lymphocytes plasmacytoid manual cnt (bld) [#/vol]
33834-3,lymphoctesplmacyto manul cnt (bld) count/volume [#/vol]
33834-3,manual count/volume plasmacytoid lymphocytes cnt (blood) [#/vol]
14460-0,virus identified in urethra by culture
14460-0,virus identified in urethra by culture
14460-0,virus dnfied inurethra byculture
14460-0,virus urth cult
14460-0,cult urth virus
14460-0,virus rth cult
14460-0,virus identified cx nom (urethra)
14460-0,virus identified cx nom (urethra) id
14460-0,virus identified nom cx pt (urethra)
7814-7,bacillus anthracis ab [units/volume] in serum
7814-7,bacillus anthracis ab [units/volume] in serum
7814-7,bacill anthracis a [unitsvume] n antby serm
7814-7,b anthracis ab ser-acnc
7814-7,b athracis b sercnc
7814-7,anthracis b ab ser-acnc
7814-7,b. anthracis ab qn (s)
7814-7,b. anthracis ab qn (s)
7814-7,b. anthracis ab qn (s)
24341-0,gas and carbon monoxide panel - arterial blood
24341-0,gas and monoxide carbon panel - arterial blood
24341-0,monoxide and carbon gas panel - arterial blood
24341-0,gas + co pnl blda
24341-0,gas blda co art bld pnl +
24341-0,gas + co pnl random blda
24341-0,gas and carbon monoxide panel (blda)
24341-0,gas carbon and co-oximetry monoxide panel (blda)
24341-0,gas panel carbon monoxide and (blda)
103175-6,enterococcus faecalis+enterococcus faecium dna [presence] in wound by naa with probe detection
103175-6,enterococcus faecalis+enterococcus faecium dna [presence] in wound by naa detection probe with
103175-6,enterococcus faecalis+enterococcus faecium probe [presence] in wound by naa with dna detection
103175-6,e. fcalis+e. fcium dna wnd ql naa+probe
103175-6,e. fcalis+e. fcium dna wnd presence naa+probe
103175-6,e. fcalis+e.fcium dna qnaa+probe wnd
103175-6,enterococcus faecalis+enterococcus faecium dna naa+probe ql (wound)
103175-6,lat enterococcus faecalis+enterococcus faecium dna naa+probe ql (wound)
103175-6,enterococcus faecalis+enterococcus point in time faecium dna naa+probe ql (wound)
47545-9,5-hydroxyindoleacetate/creatinine [molar ratio] in 24 hour urine
47545-9,5-hydroxyindoleacetate/creatinie molarratio] 24 in hour crea urine
47545-9,5-hydroxyindoleacetate/creatinine [molar quant ratio] in 24 hour urine
47545-9,5oh-indoleacetate/creat 24h ur-srto
47545-9,5oh-indoleacetate/creat 24h ur-srto
47545-9,ur-srto 4 chemistry oh-indoleacetat/ceat
47545-9,5-hydroxyindoleacetate/creatinine (24h u) [molar ratio]
47545-9,[molr 5-hydroxyindoleacetic acid (24h u 5-hdrxyindoleacetate/creatinine rati]
47545-9,5-hydroxyindoleacetate/creatinine (24h u) [molar ratio]
99107-5,stimulants drug panel - urine by screen method
99107-5,stimulants drug panel - by urine screen method pnl
99107-5,stimulans dug screen - urineby panl drugs ethd
99107-5,stimulants drug panel ur scn
99107-5,stimulants drug panel ur scn
99107-5,ur drug panel scrn stimulants scn
99107-5,stimulants drug panel screen (u)
99107-5,stimulants drug panel screen (u)
99107-5,stimulans drug panelscree u)
73021-8,fexofenadine induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73021-8,fexofenadine induced neutrophil igm ab [presence] in serum flow plasma by or cytometry (fc)
73021-8,seum induced eutrohil igm a [preence] in feofnadine plasmabylw cytometry (fc)
73021-8,fexofenadine (neut) igm serpl ql fc
73021-8,feoenadine (neut) im ql serl fc
73021-8,fexfenadine (neutigm serpl ql fc
73021-8,fexofenadine induced neutrophil igm fc ql
73021-8,neutrophil induced fexofenadine igm pnm fc ql
73021-8,tilfur fexofenadine indud neutrophi igm fc presence
40803-9,methamphetamine [presence] in hair by screen method
40803-9,methamphetamine [presence] in hair scn by screen method
40803-9,methampetamie [presence] in hair byscrn ethod
40803-9,methamphet hair ql scn
40803-9,scn ql methamphehair
40803-9,methamphet drug/toxicology hair ql scn
40803-9,methamphetamine screen ql (hair)
40803-9,screen metamphetamine presence (air)
40803-9,screen methamphetamine ql (hair) scr
85980-1,streptococcus pneumoniae danish serotype 12f igg ab [mass/volume] in serum by immunoassay --1st specimen
85980-1,streptcoccus 12f danish seotype pneumoniae igg ab[mass/volue] n serum by iunoassay meia --1stspecimen
85980-1,stretococus pneumoniae daish serotype 12figg ab[mass/volume] n serum b immuoy --1st spen meia
85980-1,s pneum da 12f igg sp1 ser ia-mcnc
85980-1,s pneum dfig sp ser ia-mcnc
85980-1,s pneuda 12f igg sp1 se ia-mcnc
85980-1,s. pneumoniae danish type 12f igg spec 1 ia (s) [mass/vol]
85980-1,s. pneumoniae danish type 12f igg spec 1 ia (s) [mass/vol]
85980-1,s pneumoniae danish type 12 ia pe 1 igg (s) [ma/vol]
35448-0,hiv 1 p24 ab [presence] in saliva (oral fluid) by immunoblot
35448-0,hiv type i hv 1 24 ab[presence] in saliva oral luid by immunoblot
35448-0,(oral 1 p24 ab [presence] in saliva hiv fluid) by immunoblot
35448-0,hiv1 p24 ab sal ql ib
35448-0,presence p24 ab sal hiv1 ib
35448-0,hiv1 p24 ab ib presence sal
35448-0,hiv 1 p24 ab ib ql (sal)
35448-0,hiv (sal) microbiology p24 ab ib ql 1
35448-0,hiv 1 p24 ab ib ql autoantibody (sal)
2346-5,glucose [mass/volume] in pleural fluid
2346-5,pleural [mass/volume] in glucose flui
2346-5,lucose [mass/volume] i quan plural fluid
2346-5,glucose plr-mcnc
2346-5,plr-mcnc glucose quant
2346-5,glucose pleural fluid plr-mcnc
2346-5,glucose (pleur fld) [mass/vol]
2346-5,glucose (pleur fld [mass/vl]
2346-5,glucose (pleur fld) [mass/vol]
96487-4,neuronal intermediate filament igg ab [titer] in serum by immunofluorescence
96487-4,neuronal intermediate filament igg ab [titer] autoantibodies in ser by immunofluorescence
96487-4,neuronal intermediate filament ab igg [titer] in serum by immunofluorescence immunofluor
96487-4,nif igg titr ser if
96487-4,nif igg titr serum if
96487-4,nif igg titr s if
96487-4,neuronal intermediate filament igg if (s) [titer]
96487-4,neuronl intermediae fiament gg if (s) nif igg [titer]
96487-4,neronal filaent intermeiate igg if (s) [titer]
22098-8,avian paramyxovirus 1 ab [titer] in serum
22098-8,avian paramyxovirus 1 veterinary ab [titer] in serum
22098-8,avian paramyxovirus 1 ab [titer] in serum
22098-8,apmv1 ab titr ser
22098-8,apmv1 titr ab ser
22098-8,apmv1 ab titr serum anti
22098-8,avian paramyxovirus 1 ab (s) [titer]
22098-8,avian paramyxoviru1ab() [titer]
22098-8,avian paramyxovirus 1 ab (s) id [titer]
99072-1,kelch-like protein 11 igg ab [presence] in serum by cell binding immunofluorescent assay
99072-1,kelch-like protein ab igg 1 [prsence] n serm bycell biin immunofluorescent ssay
99072-1,kelch-like [ql] 11 igg ab protein in serum by cell binding immunofluorescent assay
99072-1,klhl11 igg ser ql cba ifa
99072-1,kl11 g ser presence cba ifa
99072-1,klhl11 igg ql ser cba ifa
99072-1,kelch-like protein 11 igg cell binding immunofluorescent assay ql (s)
99072-1,kelch-likprotein 1 ig cell bding immunofurescent assa ql (s)
99072-1,kelch-like protein 1 ig ell binding mmunofluoescent assay presence (s)
72317-1,rna polymerase iii rp11 igg ab [presence] in serum or plasma by immunoassay
72317-1,rna polymerase iii rp1 ig apreence] in serum or laa by immnoassay
72317-1,rna polymerase iii rp11 igg ab [presence] by serum or plas in immunoassay
72317-1,rnap iii rp11 igg serpl ql ia
72317-1,rnap iii rp11 igg serpl presence ia
72317-1,rnap iii pol3rk rp1igg serpl ql a
72317-1,rna polymerase iii rp11 igg ia ql
72317-1,rna polymerase rp11 iii ig ia presence
72317-1,rna polymerase iii rp11 igg pol iii ia presence
86837-2,"mds v3.0 - rai v1.14.1, v1.15.1, v1.16.1 - special treatments, procedures, and programs - nsd, ssd during assessment period [cms assessment]"
86837-2,"mds v3.0 during rai v1.14.1, v1.15.1, v1.16.1 - special treatments, procedures, and programs - txs nsd, ssd - assessment period [cms assessment]"
86837-2,"mds 3.0 - ri v.14.1, v1.15.1, v1.16. - special treatments procedures ad programs - nsd, ssd during asessmen period ms assessment]"
35257-5,natriuretic peptide b [mass or moles/volume] in serum or plasma
35257-5,natriuretic peptide b [mass heart disease or moles/volume] or serum in plasma
35257-5,natriurtic pete  [mass r moles/vou] in erum or plasma
35257-5,bnp serpl-mscnc
35257-5,serpl-mscnc brain natriuretic peptide bnp
35257-5,bnp serpl-mscnc
35257-5,natriuretic peptide b [mass or moles/vol]
35257-5,natriuretic peptide b [mass or moles/vol]
35257-5,natriuretic peptide b [mass or moles/vol]
43172-6,triiodothyronine (t3) ab [presence] in serum
43172-6,triiodothyronine (t3) ab in [presence] serum
43172-6,triodothronine (t3) ab [presence] in srum anti
43172-6,t3 ab ser ql
43172-6,t3 ser ab point in time ql
43172-6,t3 serology ab serum ql
43172-6,t3 ab ql (s)
43172-6,ab t3 ql pt (s)
43172-6,ql 3ab (s)
41480-5,bk virus dna [#/volume] (viral load) in urine by naa with probe detection
41480-5,b vrus dna [#/volume] (vral absolutes load) in rine by naa with probe detectin
41480-5,bk virus dna [#/volume] (viral load) in urine by naa with probe detection
41480-5,bkv dna # ur naa+probe
41480-5,bkv dna# probe with target amplification urnaa+probe
41480-5,dna b # ur naaprobe
41480-5,bk virus dna naa+probe (u) [#/vol]
41480-5,bk vius naa+probe dna (u)[vol] ct
41480-5,bk (u) dnanaa+probe deoxyribonucleic acid virus [#vol]
48917-9,"respiratory allergen panel, us - south atlantic states b - serum"
48917-9,"respiratory allergen states us - south atlantic point in time panel, b - serum"
48917-9,"repiratory alleren panel, u - south atantic pnl state b - ser"
48917-9,resp allergen s atl b pnl ser
48917-9,allergen resp s atl b pnl ser
48917-9,resp allerge s atl  pnl ser
48917-9,"respiratory allergen panel, us - south atlantic states b (s)"
48917-9,"us allergen panel, respiratory - south atlantic states b (s)"
48917-9,"respiratory allergen panel, us - south (s) states b atlantic"
50358-1,phenylacetate/creatinine [molar ratio] in 24 hour urine
50358-1,phelactae/creatinine hour rati]in 4 molar urine
50358-1,phenylacetate/creatinine [molar ratio] in 24 hour urine scrto
50358-1,phenylacetate/creat 24h ur-srto
50358-1,phenylacetate/creat 24hr ur-srto 24h
50358-1,phnylacetate/creat 24h ur-srto
50358-1,phenylacetate/creatinine (24h u) [molar ratio]
50358-1,phenylacetate/creatinine (24h u) [molar cr ratio]
50358-1,phenylacetate/creatinine (24h u) ur ratio] [molar
14584-7,adenosine monophosphate.cyclic [moles/time] in 24 hour urine
14584-7,adenosine monophosphate.cyclic [moles/time] 24 in hour urine camp
14584-7,aenosine monophoshate.cyclic 24 [moles/time]in hour urine
14584-7,camp 24h ur-srate
14584-7,camp ur-srate 24h
14584-7,camp 24h amp ur-srate
14584-7,adenosine monophosphate.cyclic (24h u) [moles/time]
14584-7,camp monophosphate.cyclic adenosine (24h u) [moles/time]
14584-7,adensine mnophoshate.cycli (2hu)[moles/time]
23601-8,mareks disease virus serotype [identifier] in tissue by organism specific culture
23601-8,mareks diseas virus serotyp [identifier] in tisue by orgnism specifi culture
23601-8,mareks disease diseases organism serotype [identifier] in tissue by virus specific culture
23601-8,gahv sertyp tiss cult
23601-8,gahv sertyp tiss cult
23601-8,gahv tiss sertyp cult
23601-8,mareks disease virus serotype org specific cx nom (tiss)
23601-8,"mareks serotype virus tissue, unspecified disease org specific cx nom (tiss)"
23601-8,mareks disease virus tissue serotype org specific cx nom (tiss)
24214-9,eastern equine encephalitis virus ab [titer] in serum by immunofluorescence --2nd specimen
24214-9,eastern equine encephalitis virusbtiter] in sumby immunofluorescence--2nd speime
24214-9,encehalitisvirus equine eastern ab [titer] inserum dilution factor (titer) by imunofluorescence--2nd specimen
24214-9,eeev ab sp2 titr ser if
24214-9,eeev immunofluor ab sp2 if ser titr
24214-9,eeev ab sp2 titr ser second if
24214-9,eeev ab spec 2 if (s) [titer]
24214-9,i ab spe eeev (s convalescent [tier]
24214-9,fluoresent eeev ab spec 2 if (s) [titer]
33400-3,neisseria meningitidis serogroup b+escherichia coli k1 ag [presence] in serum by latex agglutination
33400-3,neisseria meningitidis serogroup b+escherichia coli serum ag [presence] in k1 by latex agglutination
33400-3,neisseria meninitidis serogrup b+escherihia coli k1 ag meningococcus [prsence] i serum b latex aglutination
33400-3,n men sg b+e coli k1 ag ser ql la
33400-3,n men sg b+e infectiousdisease coli k1 ag ser ql la
33400-3,men s b+ecol k1 ag ordinal se qll
33400-3,n. meningitidis b+e. coli k1 ag la ql (s)
33400-3,n. meningtids b+e. coli (s) n men sg b+e coli k1 ag ql k1
33400-3,n.mningitdis b+e. colik1 ag la infectiousdisease ql ()
31936-8,pneumocystis jirovecii ag [presence] in nose
31936-8,pneumocysis jirovecii noe [presenc]in ag
31936-8,pneumocystisjiovecii nose [presence] in a qual
31936-8,p jirovecii ag nose ql
31936-8,jirvciig p os ql
31936-8,p jirovecii microbiology ag nose presence
31936-8,p. jirovecii ag ql (nose)
31936-8,p.iroecii g presence (nose)
31936-8,qualitative p. jirovecii ag ql (nse)
12343-0,thiazides [identifier] in urine
12343-0,identity or presence thiazides [identifier] urine in
12343-0,urine [identifier] in thiazides
12343-0,thiazides ur
12343-0,thiazides nominal ur
12343-0,tiziesr
12343-0,thiazides nom (u)
12343-0,nom hazies (u)
12343-0,thiazides nom (u) random
19339-1,amobarbital [presence] in urine by screen method
19339-1,creen [presnce] in urine by amobarbial method
19339-1,amobarbital screen [presence] in urine by screen method
19339-1,amobarbital ur ql scn
19339-1,ql r point in time mobrbita scn
19339-1,mobarbial ur pr scn l
19339-1,amobarbital screen ql (u)
19339-1,(u) screen presence amytal amobarbital
19339-1,amobarbital (u) presence potentialforabuse screen
88585-5,legionella sp identified in lower respiratory specimen by organism specific culture
88585-5,legionella sp specific in lower respiratory specimen by organism identified culture
88585-5,legionll sp id ientfid specific lower espiratory speimen by organism in culture
88585-5,legionella lower resp cult
88585-5,resp lwr legionella cult
88585-5,legionella lower cult resp
88585-5,legionella sp identified org specific cx nom (lower resp)
88585-5,org sp identified legionella specific cx nom (lower resp)
88585-5,legionela p ientified og specific cx nom (lowr resp)
70173-0,jc virus ab [presence] in serum or plasma by immunoassay
70173-0,jc immnoassay ab [resenen ser plasm by viru
70173-0,jc virus ab [presence] in ser or plasma by immunoassay
70173-0,jcpyv ab serpl ql ia
70173-0,serum or plas ab jcpyv serpl ql ia
70173-0,jcpyv ab screen serpl qla
70173-0,jc virus ab ia ql
70173-0,jc virus ab ia presence
70173-0,j virus ab i ql
3783-8,methapyrilene [presence] in urine
3783-8,in [presence methapyrilee rinofol urin
3783-8,methapyrilene in [presence] urine
3783-8,methapyrilene ur ql
3783-8,thapyrilen presence ur
3783-8,methapyrilene ur presence
3783-8,methapyrilene ql (u)
3783-8,ql methapyrilene (u)
3783-8,sleepwell methapyrilene (u) ql
47678-8,lactate dehydrogenase [enzymatic activity/volume] in 24 hour urine
47678-8,lctate ehydrogenase[nmac acivit/lume n 24 hour urine
47678-8,lactate dydrogase 24 actiityvolume] in [nzymatic hourure
47678-8,ldh 24h ur-ccnc
47678-8,lact ldh 24 ur-cnc
47678-8,ldh 24h lact ur-ccnc
47678-8,ldh (24h u) [catalytic activity/vol]
47678-8,2-hydroxy-propionate activity/vol] (24h u) [catalytic ldh
47678-8,[catalytic (24h u) ldh activity/vol]
94111-2,7-aminoflunitrazepam [presence] in urine by screen method
94111-2,point in time 7-aminoflunitazeam [ql] inurineby scren method
94111-2,7-aminoflunitrzepam[ql] in urine by screen method
94111-2,7aminoflunitrazepam ur ql scn
94111-2,7aminoflunitrazepam ordinal ur ql scn
94111-2,scn ur ql 7aminoflunitrazepam
94111-2,7-aminoflunitrazepam screen ql (u)
94111-2,ur 7-amnoflunitrazepm screen presence (u)
94111-2,ql screen screen 7-aminoflunitrazepam (u)
43206-2,tetrachloroethylene [mass/volume] in urine
43206-2,level tetrachloroethylene in [mass/volume] urine
43206-2,quan tetrachloroethylene urine in [mass/volume]
43206-2,ttce ur-mcnc
43206-2,ur-mcnc ttce
43206-2,ur-mcnc quantitative ttce
43206-2,tetrachloroethylene (u) [mass/vol]
43206-2,tetrahloroehylene [mas/vol (u)
43206-2,tetrachloroethylene (u) [ass/vol]
29377-9,narcotics and opioids [identifier] in gastric fluid
29377-9,narcotics in opioids [identifier] and gastric fluid
29377-9,arcotics and pioids [identfier in gastric fli
29377-9,narcotics gast
29377-9,gast narcotics
29377-9,gast narcotics
29377-9,narcotics and opioids nom (gast fld)
29377-9,identity or presence (gast and opioids nom narcotics fld)
29377-9,narcotics and identity or presence opioids nom (gast fld)
72412-0,bk virus subtype in urine by naa with probe detection
72412-0,bk microbiology virs dtection in urine by naa ith probe subtype
72412-0,detectio irs subtype in urie b naa with microbiology probe bk
72412-0,bkv subtyp ur naa+probe
72412-0,subtypur id bkv naa+pobe
72412-0,bkv sbtyp urnaa+probe
72412-0,bk virus subtype naa+probe nom (u)
72412-0,bk u) subtype na+pobe om virus
72412-0,bkvirs subtype na+prbe nom (u)
3792-9,methotrexate [mass/volume] in cerebral spinal fluid
3792-9,methotrexate [mass/volume] fluid cerebral spinal in
3792-9,methotrexate [mass/volume] mass concentration in cerebral spinal fluid
3792-9,mtx csf-mcnc
3792-9,mtx cerebral spinal fluid csf-mcnc
3792-9,methotrexat csf-mcnc mtx
3792-9,methotrexate (csf) [mass/vol]
3792-9,methotrexate [mass/vol] (cerebrospinal fluid) mass concentration
3792-9,methotrexate [mass/vol] (csf)
54635-8,resident mood interview (phq-9) [reported phq-9 cms]
54635-8,rident cms] interview (phq-9) [reporedph-9 mood
54635-8,resident phq intervew (ph-9) [reported mood cms]
41014-2,human coronavirus nl63 igg ab [presence] in serum
41014-2,huan cornavirus nl63 ig a [presence] aby in serum
41014-2,human coronavirus nl63 [presence] ab igg in ser autoantibody
41014-2,hcov nl63 igg ser ql
41014-2,hcov nl63 gser l anti
41014-2,hcov nl63 igg ser ql pr
41014-2,hcov nl63 igg ql (s)
41014-2,cov nl3 ig ql (s)
41014-2,hcov nl63 igg (s) presence
21209-2,coccidioides immitis ab [presence] in cerebral spinal fluid by immune diffusion (id)
21209-2,coccidioides immitis ab [presence] in cerebral fluid spinal by immune diffusion (id)
21209-2,cocciioidesimmits b [rsence in cereral spnl flud by immue dffusio (id)
21209-2,c immitis ab csf ql id
21209-2,ab immitis c cerebrospinal fluid ql id
21209-2,c immits abcsf infectious disease ql i
21209-2,c. immitis ab immune diff ql (csf)
21209-2,imune c. immitis ab immune diff q (cf)
21209-2,c. imitis ab immune diff ql cerebrospinal fluid)
16315-4,acid phosphatase [enzymatic activity/volume] in blood by tartrate inhibited
16315-4,acid phosphatase [enzymatic activity/volume] in blood by tartrate inhibited acid phosphatase.total
16315-4,acid tartrate [enzymtic actiity/volume]in blodby phosptae inhibited
16315-4,acp bld tart inhib-ccnc
16315-4,acp bld trt ihib-ccnc
16315-4,acp bld art inhib-ccnc
16315-4,acid phosphatase tartrate inhibited (bld) [catalytic activity/vol]
16315-4,acid phosphatase tartrate nhibited (bld) [catalyti activty/vl]
16315-4,acid phosphatase atrate inhibited (bl) [cataytic actiity/vol]
4420-6,quinine [mass] of dose
4420-6,quinine[mass] of quan de
4420-6,quiine [mass] of dose
4420-6,quinine dose
4420-6,dose random qinne
4420-6,quinine dose
4420-6,quinine (dose) [mass]
4420-6,quinine (dse) random [mass]
4420-6,qinine (ose) qnt mas]
3537-8,nordiazepam [mass/volume] in serum or plasma
3537-8,nordiazepam [mass/volume] plasma serum or in
3537-8,nordiazepam plasma in serum or [mass/volume]
3537-8,nordiazepam serpl-mcnc
3537-8,nordiazpam serl-cnc
3537-8,nordiazepam serum or plasma-mcnc
3537-8,nordiazepam [mass/vol]
3537-8,[mass/vol] nordiazepam
3537-8,[mass/vol] nordiazepam
8053-1,western equine encephalitis virus igm ab [units/volume] in serum
8053-1,quan western equine encephalitis virus igm ab [units/volume] in serum
8053-1,western equine [units/volume] virus igm ab encephalitis in serum
8053-1,weev igm ser-acnc
8053-1,sr-acc immune globulin m gm weev
8053-1,autoantibodies weev igm ser-cnc
8053-1,weev igm qn (s)
8053-1,weev igm qn (s)
8053-1,(s) weev igm qn weev
25087-8,3-methylglutaconate/creatinine [molar ratio] in urine
25087-8,3-methylglutaconate/creatinine 3me-glutaconate [molar ratio] in urine
25087-8,3-methylglutaconate/creatinine [molar ratio] in urine
25087-8,3me-glutaconate/creat ur-srto
25087-8,3e-gluaconate/reat ur-srto quantitative
25087-8,qnt ursrto 3me-glutaconat/cra
25087-8,3-methylglutaconate/creatinine (u) [molar ratio]
25087-8,3-methylglutaconate/creatinine (u) [molar ratio] scrto
25087-8,point in time 3-methylglutaconate/creatinine [molar (u) ratio]
51786-2,hiv 2 ab signal/cutoff in serum or plasma by immunoassay
51786-2,hiv 2 ab signal/cutoff in ser or plasma by immunoassay
51786-2,hi 2 antby ab in signl/cutoff serm or plaa b immunoaa
51786-2,hiv 2 ab s/co serpl ia
51786-2,hiv 2 ia plasma s/co serpl ab
51786-2,human immunodeficiency virus hiv ab erpl s/co ia
51786-2,hiv 2 ab signal/cutoff ia [rel units/vol]
51786-2,units/vol] 2 ab signal/cutoff ia [rel hiv
51786-2,hiv 2 ab sinal/utff aids ia[rel unit/vol]
20643-3,glutamine [moles/volume] in serum or plasma
20643-3,pasma [mles/volme] in srum or glutamie
20643-3,lutin molesvolume] i erum or plas
20643-3,glutamine serpl-scnc
20643-3,serpl-scnc quant glutamine
20643-3,serpl-scnc glutamine
20643-3,glutamine [moles/vol]
20643-3,[moles/vl] serpl gltamine
20643-3,chemistry glutamine[moles/vol]
49077-1,influenza virus b igg ab [mass/volume] in cerebral spinal fluid
49077-1,inluenza virus b iggab [massolue] inerl pinal fluid
49077-1,influenza virus b spinal influenza b ab [mass/volume] in cerebral igg fluid
49077-1,flubv igg csf-mcnc
49077-1,csf-mcnc autoantibody igg flubv
49077-1,csf-mcnc spinal fld igg flubv
49077-1,flubv igg (csf) [mass/vol]
49077-1,[mass/vol] igg (csf) flubv
49077-1,[mass/vol] igg (cerebrospinal fluid) flbv microbiology
1965-3,bile [presence] in stool
1965-3,bile stool in fecal [ql]
1965-3,bile ql [ql] in stool
1965-3,bile stl ql
1965-3,biletl ql stl
1965-3,stl bile ql
1965-3,bile ql (stl)
1965-3,tl) q screen ble
1965-3,(stl) q bie
33873-1,dopamine/creatinine [molar ratio] in urine collected for unspecified duration
33873-1,dopamine/creatinine [molar ratio] in urine collected for unspecified duration
33873-1,dopamine/creatinine [molar ratio] in urine collected for unspecified duration ucr
33873-1,dopamine/creat ?tm ur-srto
33873-1,?mur-srt doaminecreat qnt
33873-1,?mu-st doamine/creat
33873-1,dopamine/creatinine unsp time (u) [molar ratio]
33873-1,[molar unsp time (u) ucr dopamine/creatinine ratio]
33873-1,dopamine/creatinne unsp time (u) molarratio]
16983-9,hydralazine [presence] in urine
16983-9,hydlzine [presence] in rne
16983-9,rine [presence] in qualitative hydrlaine
16983-9,hydralazine ur ql
16983-9,hydralazine ql ur
16983-9,l hydralazineur apresoline
16983-9,hydralazine ql (u)
16983-9,hyaazin ql (u) pr
16983-9,hydralazie (u) pr ql
29807-5,anaplasma phagocytophilum igm ab [presence] in cerebral spinal fluid by immunoblot
29807-5,aaplama phagoytphilum im ab[resnce] in cererl spna by fluid immunoblot
29807-5,anaplasma phagoytophilumig ab [presencein crebral spina flui by immunoblot
29807-5,a phagocytoph igm csf ql ib
29807-5,a phagocytoph igm csf presence ib
29807-5,a phagocyph igm csf ql b
29807-5,a. phagocytophilum igm ib ql (csf)
29807-5,a. phagocytophilum ib igm presence (csf)
29807-5,phagocytophilum a. igm ib ql (csf)
29839-8,jamestown canyon virus igg ab [units/volume] in cerebral spinal fluid
29839-8,jamestown canyon virus igg ab [units/volume] in cerebral spinal fluid
29839-8,jamestown canyon virus immune globulin g igg fluid [units/volume] in cerebral spinal ab
29839-8,jcv igg csf-acnc
29839-8,igg jcv csf-acnc immunoglobulin g
29839-8,point in time jcv igg csf-acnc
29839-8,jamestown canyon virus igg qn (csf)
29839-8,jamestown virus canyon igg qn (csf)
29839-8,igg canyon virus jamestown qn (csf)
15468-2,equine infectious anemia virus ab [presence] in serum by immune diffusion (id)
15468-2,qine infectiosanmia iru ab [presece in srm byimmune diffusion(id)
15468-2,equine infectious anemia irus b b in seru [presece] imune iffson (id)
15468-2,eiav ab ser ql id
15468-2,eiav ab equin ser ql d
15468-2,eiav swamp fever ab serum ql id
15468-2,equine infectious anemia virus ab immune diff ql (s)
15468-2,quie swamp fever infectios anemia immuediff ab virus ql (s)
15468-2,equine infectious emia virus ab immune diff presence (
26903-5,canine distemper virus igg ab [titer] in cerebral spinal fluid by immunofluorescence
26903-5,canine distemper virus igg ab [titer] immunofluorescence cerebral spinal fluid by in
26903-5,canine distemper virus igg ab fluid in cerebral spinal [titer] by immunofluorescence neurology
26903-5,cdv igg titr csf if
26903-5,cdviggtitr if cerebrospinal fluid
26903-5,cerebrospinal fluid igg titr cdv immunoglobulin g if
26903-5,canine distemper virus igg if (csf) [titer]
26903-5,canne istemper virus igg if (csf) [tter]
26903-5,canin [titer virus trf ig if (csf) distepr
18263-4,cholesterol in hdl [mass/volume] in serum or plasma ultracentrifugate
18263-4,choleterol in hl [mass/vume] in serum or plasmaultracentifugate
18263-4,cholesterol in hdl [mass/volume] or ser in plasma ultracentrifugate
18263-4,hdlc serpl.ultracent-mcnc
18263-4,serpl.ultracent-mcnc hdlc choles
18263-4,serum or plasma.ultracent-mcnc hdlc heart disease
18263-4,cholesterol in hdl (s/p ultracentrifugate) [mass/vol]
18263-4,cholesterlin hdl(s/pultracentrifugate)[ms/vol]
18263-4,quantitative holesterol in ltracentrifugate) (s/p hdl mass/vo
54331-4,propionylcarnitine (c3) [moles/volume] in amniotic fluid
54331-4,propionlcaritine amiotic oesvolume] in amnio (c3) fluid
54331-4,ropionylarnitne (c) fluid in amitc [mles/olume]
54331-4,propionylcarn amn-scnc
54331-4,propionylcarn amn-scnc chemistry
54331-4,propionylcarn amncnc
54331-4,c3 (amn fld) [moles/vol]
54331-4,c3 (amn fld) [moles/vol]
54331-4,(amn c fld) [moles/vol amn fl
21307-4,glucose [mass/time] in 10 hour urine
21307-4,glucose [mass/time] in 10 hours 10 urine hour
21307-4,gluc glucose hour in 10 [mass/time] urine
21307-4,glucose 10h ur-mrate
21307-4,mass rate 10h gucose ur-mrae
21307-4,ur-mrat 10h gucose
21307-4,glucose (10h u) [mass/time]
21307-4,) (10h glucose [masstme]
21307-4,u) (10h glucose [mss/time]
29261-5,abnormal lymphocytes/leukocytes in blood by manual count
29261-5,lymphocytes/leukocytes abnormal in blood by manual count
29261-5,bnrmal lymhocytes/leukocytesiblood by anal count
29261-5,lymph abn nfr bld manual
29261-5,lymph abn nfr blood manul
29261-5,lymph abn nfr blood qnt manual
29261-5,abnormal lymphocytes/leukocytes manual cnt (bld)
29261-5,abnomal lymphocytes/eukocyes manual nt (ld)
29261-5,abnormal lymphocytes/leukocytes manual lymp cnt (bld)
78933-9,assisted circulation procedures performed panel
78933-9,procedures ircuaton asisted performed panel
78933-9,assisted peromed prcedures crcultion anel
78933-9,assist circ proc perf pnl
78933-9,assit circ roc perf pnl
78933-9,sistcirc pro perf pn
63434-5,coxsackievirus a ab [titer] in cerebral spinal fluid by complement fixation
63434-5,coxsackievirus a ab [titer] in cerebral spinal by fluid complement fixation
63434-5,cerebral a ab [titer] in coxsackievirus infectiousdisease spinal fluid by complement fixation
63434-5,cv a ab titr csf cf
63434-5,cv ab a titr csf cf
63434-5,cv csf ab titr a cf
63434-5,coxsackievirus a ab cf (csf) [titer]
63434-5,coxsacieviru spinal fl ab cf(csf) [titer]
63434-5,complement fixation coxsackievirus a cf ab (csf) [titer]
67568-6,circulating tumor cells.breast [#/volume] in blood
67568-6,in tumor cels.breast [#/volume] circulating blod
67568-6,cells.breast tumor circulating [#/volume] in blood
67568-6,ctc.breast # bld
67568-6,cc.breast# blood
67568-6,ctc.reast quantitative # bl
67568-6,circulating tumor cells.breast (bld) [#/vol]
67568-6,circulating tumo cells.breast (bld) [#/vo] tc
67568-6,(bld) tumor cells.breast circulating [#/vol]
80175-3,s-adenosylhomocysteine [moles/volume] in serum or plasma
80175-3,s-adnsylhomocysteine or in serm [mols/volume] plasma
80175-3,ser [moes/volume] in s-denosylhomocyste or plasma
80175-3,sah serpl-scnc
80175-3,serpl-scnc sah plsm
80175-3,sah serpl-scnc
80175-3,s-adenosylhomocysteine [moles/vol]
80175-3,plasma [moles/v] s-denosylhomocysteine
80175-3,[moles/vol] s-adenosylhomocysteine
16292-5,"1,4-dioxane [mass/volume] in urine"
16292-5,"1,4-dioxane urine in [mass/volume]"
16292-5,"1,4-dioxane urn in [mass/volume] urine"
16292-5,"1,4dioxane ur-mcnc"
16292-5,"4dioxane 1,4dioxane ur-mcnc"
16292-5,"1,4dioxane tetrahydro-p-dioxin ur-mcnc"
16292-5,"1,4-dioxane (u) [mass/vol]"
16292-5,"glycol ethylene ether [mss/vol] 1,4-dioaneu)"
16292-5,"1,4-dioxane [mass/vol] (u)"
60099-9,loxapine [mass/volume] in blood
60099-9,loxapine [mass/volume] in bld
60099-9,level oxapie [mass/volume] in blood
60099-9,loxapine bld-mcnc
60099-9,bld-mcnc drugs loxapine
60099-9,loxapine bld-mcnc drugs
60099-9,loxapine (bld) [mass/vol]
60099-9,loxine mas/vol] (bld)
60099-9,loaie [massvol] (bd) pt
32205-7,unidentified cells [#/volume] in synovial fluid by manual count
32205-7,nidetifed abs cells[#/vo] ynvia in luid bymanul count
32205-7,unidentified cells [#/volume] in synovial joint aspirate fluid by manual count
32205-7,unident cells # snv manual
32205-7,uientcells # snv manual
32205-7,snvmanual cells # nident
32205-7,unidentified cells manual cnt (syn fld) [#/vol]
32205-7,unidentified cells (syn t manual fld) [#vol]
32205-7,unietifie ll (syn cnt manual fl) [#/v]
35164-3,alpha linolenate (c18:3w3) [moles/volume] in serum or plasma
35164-3,alpha linolenate (c18:3w3) [moles/volume] serp in serum or plasma
35164-3,alpha linolenate [moles/volume] (c18:3w3) in serum or level plasma
35164-3,a-linolenate serpl-scnc
35164-3,serpl-scnc a-linolenate
35164-3,serpl-scnc qnt a-lnolenate
35164-3,alpha linolenate (c18:3w3) [moles/vol]
35164-3,plasma alpha linolenate [moles/vol] (c18:3w3)
35164-3,alpha linolenate [moles/vol] (c18:3w3)
89994-8,trypanosoma cruzi igg ab [presence] in serum or plasma from donor by rapid immunoassay
89994-8,trypanosoma cruzi igg ab [presence] by serum or plasma from donor in rapid immunoassay
89994-8,trypanosoma cruzi igg ab serum in [presence] or plasma infectious disease from donor by rapid immunoassay
89994-8,t cruzi igg serpl donr ql ia.rapid
89994-8,t cruz igg spl onr ql ia.rapid
89994-8,t crzi igg ql dor serpl ia.rapid
89994-8,t. cruzi igg ia.rapid ql (s/p donor)
89994-8,t. aby ruzi ig ia.rapql (/p donor)
89994-8,presence(s/p cruzi igg ia.rapid t. donor)
101586-6,cortisol [moles/volume] in serum or plasma by lc/ms/ms
101586-6,cortisol [moles/volume] in ser or plasma by quan lc/ms/ms
101586-6,by [moles/volume] in serum or plasma cortisol lc/ms/ms
101586-6,cortis serpl lc/ms/ms-scnc
101586-6,lc/ms/ms-scnc serpl cortis
101586-6,cots serpl lc/ms/-scnc
101586-6,cortisol lc/ms/ms [moles/vol]
101586-6,cortisollc/ms/ms pl [moles/vol]
101586-6,cortisol lc/ms/ms [moles/vol] serum or plasma
44998-3,chlamydia trachomatis ab [presence] in serum --1st specimen
44998-3,clamyda [presenc] ab trachomtis in ser --1st pecimen
44998-3,chlamydia trachomatis ab [presence] in ser --1st specimen
44998-3,c trach ab sp1 ser ql
44998-3,c trach lymphogranuloma venereum b p1 sr ql
44998-3,c trach ab sp er ql
44998-3,c. trachomatis ab spec 1 ql (s)
44998-3,trachomatis c. ab spec 1 ql (s) microbiology
44998-3,ctrahomatis (s) presence spec1
72577-0,protein.monoclonal/protein.total [pure mass fraction] in 24 hour urine by electrophoresis
72577-0,prtein.monoclnal/prtin.total [pur ass in raction] 2 ur urine by electrphores
72577-0,proteinmonoconal/prote.ttal [pure mass fractio] in 24 hour urine by electrophoresis
72577-0,m protein 24h mfr.df ur elph
72577-0,elph protein 24h mfr.df ur m
72577-0,m protein 24h mfr.df ur elph
72577-0,protein.monoclonal elph (24h u) [pure mass fraction]
72577-0,protein.monoclonal elph (24h kidney u) mass [pure fraction]
72577-0,potein.monoclnal elph monoclonal spike (24h puremass u) fracion]
22226-5,coxsackievirus b1 ab [titer] in serum
22226-5,coxsacievirs serum a [iter in b1
22226-5,coxsckievirus b1ab [titer] random in erm
22226-5,cv b1 ab titr ser
22226-5,ser b1 ab titr cv
22226-5,cv b1 ab titr serum
22226-5,coxsackievirus b1 ab (s) [titer]
22226-5,anti coxsackievirus [titer] ab (s) b1
22226-5,cxsackieirus b1 b titered (s) [titer]
55414-7,seizures per month
55414-7,seizures quantitative per month
55414-7,per seizures month
55414-7,seizures/month nrate
55414-7,seizures/month nrate
55414-7,siues/month nrate quant
101335-8,etizolam [presence] in urine by confirmatory method
101335-8,urine [prsece] in tizolam by cnfirmatory method
101335-8,method [presnce]in urine byconfirato etizola
101335-8,etizolam ur ql cfm
101335-8,ua etizolam ur ql cm
101335-8,ur etizolam ql cfm
101335-8,etizolam confirm ql (u)
101335-8,eizolam q(u) conirm
101335-8,etizolam confirm presence (u) etizolam
73268-5,midazolam induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73268-5,midazolam indcd platlet igm ab [presen] in seu or plamab flw plt cytometry (fc)
73268-5,midazolam induced orplsma igm b [presenc] in ser ltele by flow cytometry fc) ind plt igm
73268-5,midazolam ind plt igm serpl ql fc
73268-5,midazolam imserpl point in time plt ind ql fc
73268-5,midazoam ind plt igmserpl ordinal q fc
73268-5,midazolam induced platelet igm fc ql
73268-5,midazolam induced platelet antibody fc igm ql
73268-5,midazolam fc platelet igm induced ql
63475-8,bk virus dna [presence] in blood
63475-8,bk dna virus [prsnce] n bood
63475-8,bk viu point in time in dna[pesenc] lod
63475-8,bkv dna bld ql
63475-8,qual kvda bld ql
63475-8,bkv dna blood ql infectious disease
63475-8,bk virus dna ql (bld)
63475-8,bk qual virus dna presence (bld)
63475-8,bk vius na ql (bld) bkv
47118-5,maprotiline [moles/volume] in urine
47118-5,in [moles/olume] maprotil point in time urine
47118-5,in [moles/volue] apotiline urine
47118-5,maprotiline ur-scnc
47118-5,quant marotiline u-scnc
47118-5,maprilneur-scnc point in time
47118-5,maprotiline (u) [moles/vol]
47118-5,[moles/vol] (u) maprotiline urn
47118-5,[moles/vol] (u) maprotiline ludiomil
72745-3,norfentanyl [mass/volume] in saliva (oral fluid) by confirmatory method
72745-3,cfm norfentanyl [ass/volume]in salva(oral fluid) by confirmatoy mthod
72745-3,norfenanyl [mass/volu] in saliva mehod addiction fluid) bcnfirmatory (oral
72745-3,norfentanyl sal cfm-mcnc
72745-3,cfm norfentanyl cfm-mcnc sal
72745-3,cfm-mcnc sal norfentanyl
72745-3,norfentanyl confirm (sal) [mass/vol]
72745-3,confirm norfentanyl (sal) cnfrm [mass/vol]
72745-3,norfentanyl conirm (sal) [mass/vol]
87473-5,cobalt [mass/mass] in specimen
87473-5,drug/toxicology cobalt[mss/mass] in secimen
87473-5,[mass/mass] cobalt in specimen
87473-5,cobalt spec-mcnt
87473-5,cobalt qnt spec-mcnt
87473-5,spec-mcnt misc cobalt
87473-5,cobalt (specimen) [mass/mass]
87473-5,specmen)[masmas] cobalt
87473-5,cobalt spec (specimen) [mass/mass]
22725-6,ornithine [moles/volume] in specimen
22725-6,[moles/volume] ornithine in specimen
22725-6,ornithine [molsvolume] n specimen to be specified in another part of the message
22725-6,ornithine spec-scnc
22725-6,spec-scnc ornithine
22725-6,spec-scnc ornithine
22725-6,ornithine (specimen) [moles/vol]
22725-6,ornithine (specimen) [moles/vol]
22725-6,oritine quantitative (specimen) [moles/vol]
88159-9,microscopic observation [identifier] in aspirate by acid fast stain
88159-9,stain observation [identifier] in aspirate by acid fast microscopic
88159-9,microscopic observaton[idenifier] in asirate b acid fast stn acid fas si
88159-9,acid fast stn aspirate
88159-9,acid fast stn aspirate acid fast stn
88159-9,acid fast stn afb stain aspirate
88159-9,microscopic observation acid fast stain nom (asp)
88159-9,(asp) observation acid fast stain nom microscopic
88159-9,microscopic obervation acid stain ast identity or presence nom (asp)
106991-3,methyl-1-testosterone [presence] in urine by gas chromatography-mass spectrometry
106991-3,methyl-1-testosterone [presence] in urn urine by gas chromatography-mass spectrometry
106991-3,[ql] methyl-1-testoteron n urine by gas ql cromatoraphy-mass pectomty
106991-3,methyl-1-testosterone ur ql gc-ms
106991-3,methyl-1-testosterone ur ql gc-ms
106991-3,methyl--teststrone drug/toxicology u gc- ql
106991-3,methyl-1-testosterone gas chromatography-mass spectrometry ql (u)
106991-3,u) gachrmatography-massspectrometry ql methyl-1-testosterone
106991-3,metl-1-tesostroe as chratgraphy-mass (u) ql spectrometry
74795-6,total thyroxine binding capacity in serum or plasma
74795-6,bind total thyroxine binding capacity in ser or plasma
74795-6,total total tbc thyroxine binding capacity plasma serum or in
74795-6,total tbc serpl
74795-6,serpl tbc total
74795-6,total tc sep serpl
74795-6,total thyroxine binding capacity [relative ratio]
74795-6,total thyroxine binding capacity [relative ratio]
74795-6,total ratio] bindingcapacity [relative tt4 thyroxine
43017-3,histoplasma capsulatum mycelial phase ab [titer] in body fluid
43017-3,histopasma capsulatm mycelia hase fluid fl [titer]inbody ab
43017-3,bodies istplasma capsulatum myeial pase ab [tter] n ody fluid
43017-3,h capsul myc ab titr fld
43017-3,h capsul fld histo ab titr myc
43017-3,h capsul myc ab titr fld
43017-3,h. capsulatum mycelial phase ab (body fld) [titer]
43017-3,h capsulatum mycelial (body hase fld) histopl [titer]
43017-3,h. capsulatum mycelial phase a boy fld) [titer]
79226-7,aripiprazole [mass/volume] in body fluid
79226-7,aripiprazole [mass/volume] body in fluid
79226-7,[mass/volumein aiprazol odyfuid
79226-7,aripiprazole fld-mcnc
79226-7,aripiprazole fld-mcnc
79226-7,fld-mcnc aripiprazole bf
79226-7,aripiprazole (body fld) [mass/vol]
79226-7,[ma/ol] (body fld) aripipazole
79226-7,bf aripiprazole [mass/vol] fld) (body
14355-2,microscopic observation [identifier] in cervix by koh preparation
14355-2,microscopic observation [identifier] in koh by cervix preparation
14355-2,microscopic observation [identifier] in prep cervix by koh preparation
14355-2,koh prep cvx
14355-2,random kh prep cvx
14355-2,prep koh cvx
14355-2,microscopic observation koh prep nom (cvx)
14355-2,microsopic pt obrvation ko pep nom (cvx)
14355-2,microscoic obervation koh cervix cvx) om prep
4408-1,probenecid [mass] of dose
4408-1,dose [mass] of probenecid
4408-1,dose [mass] of probenecid
4408-1,probenecid dose
4408-1,dose med or substance probenecid oe
4408-1,dose probenecid drug doses
4408-1,probenecid (dose) [mass]
4408-1,probenecid (dose) mass]
4408-1,probenecid (dose) [mass]
53175-6,octanoylcarnitine (c8) [moles/volume] in dbs
53175-6,ctanoylcarnitine (c8) chemistry [mols/volume] i dbs
53175-6,in (c8) [moles/volume] octanoylcarnitine dbs
53175-6,octanoylcarn dbs-scnc
53175-6,quantitative oanocar dbs-scnc
53175-6,whole blood dbs-scnc octanoylcarn
53175-6,c8 (dbs) [moles/vol]
53175-6,c8 dbs) mles/vl]
53175-6,(dbs) dbs c8 [moles/vol]
13262-1,leishmania tropica igg ab [units/volume] in serum
13262-1,leishmaia [units/volum] ig ab tropica l tropicalis in serum
13262-1,leishmania microbiology tropica ab igg [units/volume] in ser
13262-1,l tropica igg ser-acnc
13262-1,l igg tropica ser-acnc
13262-1,igg tropica l ser-anc
13262-1,l. tropica igg qn (s)
13262-1,l. tropica (s) qn igg
13262-1,leishmaniasis l. trpica ig qn ()
18327-7,microscopic observation [identifier] in duodenal fluid by other stain
18327-7,microscopic observation [identifier] st in duodenal fluid by other stain
18327-7,microscopic observation [identifier] in duodenal fluid by other stain identity or presence
18327-7,other stn duod fl
18327-7,dud othrstn infectious disease fl
18327-7,fl tn do other
18327-7,microscopic observation other stain nom (duod fld)
18327-7,microscopic observation other stain nom (duod fld)
18327-7,microscopc fld other stain no (duod infectious disease obervation
88712-5,lipase [enzymatic activity/volume] in peritoneal dialysis fluid
88712-5,dialysis ativity/olume] in peritoeal lipase[enzymtic flid
88712-5,liase [zyatic activity/voume] in steapsin pritoneal ilyis fluid
88712-5,lipase diafp-ccnc
88712-5,peritoneal dialysis fluid lipasediaf-ccnc
88712-5,peritoneal dialysis fluid lipse diafp-ccnc
88712-5,lipase (perit dial fld) [catalytic activity/vol]
88712-5,(perit lipase dial fld) [catalytic activity/vol]
88712-5,lipase (perit tributyrase activity/vol] fld) [catalytic dial
3782-0,methapyrilene [mass/volume] in serum or plasma
3782-0,methapyrilene [mass/volume] or serum in plasma
3782-0,methapyilene [massvolume] inserum co-pyronil or plasma
3782-0,methapyrilene serpl-mcnc
3782-0,sr-mcnc methapyrilne plasma
3782-0,sr methapyrilene epl-mcnc
3782-0,methapyrilene [mass/vol]
3782-0,[mass/vol] tenalin methapyrilene
3782-0,[mass/vol] methapyrilene
104602-8,borrelia burgdorferi b31 igm ab [presence] in serum by line blot
104602-8,serum burgdorferi b31 igm ab [presence] in borrelia by line blot
104602-8,borrelia burgdorferi b31 igm ab [presence] in ser by line blot
104602-8,b. burgdorferi b31 igm ser ql line blot
104602-8,blot burgdorferi b31 igm ser ql line b.
104602-8,b. burgdorferi b31 igm sr ser ql line blot
104602-8,borrelia burgdorferi b31 igm line blot ql (s)
104602-8,blot brgorfer b31 igm ine borrelia ql s)
104602-8,borelia burgdorfei b1 igm line blot ql s) lyme disease
81377-4,"goals, preferences, and priorities regarding the appointment of healthcare agents narrative - reported"
81377-4,"goals,preferenes, andprioritie regarding he healthcar of appointment agens narrative - pt reported"
81377-4,"goals, preferences, adriorities regading the ppointment of elthcare agens narrative - reported"
81377-4,gpp healthcare agent reported
81377-4,gpp healthcare agent reported gpp healthcare agent
81377-4,gpp reported agent healthcare
59228-7,squamous cell carcinoma ag [mass/volume] in cerebral spinal fluid
59228-7,squamous in carcinoma ag qnt [mass/volume] cell cerebral spinal fluid
59228-7,cell squamous carcinoma ag [mass/volume] in cerebral spinal fluid
59228-7,scc ag csf-mcnc
59228-7,g scc csf-cnc
59228-7,cerebrospinal fluid-mcnc ag scc
59228-7,squamous cell carcinoma ag (csf) [mass/vol]
59228-7,squamou spinal fl cell carcinoma ag sf) [mass/vl]
59228-7,squamous cell carcinoma ag (csf) cerebral spinal fluid [mass/vol]
90219-7,promis pediatric cognitive function - frequency - version 1.0
90219-7,promis function cognitive pediatric - frequency - version 1.0
90219-7,promis pediatric cognitive function - 1.0 - version frequency
29810-9,highlands j virus neutralizing antibody [titer] in serum by neutralization test
29810-9,highlads j irus point in time neuralizingatibdy tr] i srum by est neutralization
29810-9,highlands j virus neutralizing antibody antby [titer] in serum by neutralization test
29810-9,hjv nab titr ser nt
29810-9,hv nab titr hjv se nt
29810-9,titr nab hjv ser nt
29810-9,highlands j virus neut ab neut test (s) [titer]
29810-9,hghland j virus neut ab neut test (s) [titer]
29810-9,hghlandsj virus (s b neu test neut [titer]
62985-7,deprecated phenx measure - grammatical impairments
62985-7,deprecated phex meaure - rammatical impairments panel.phenx
62985-7,deprected phenx point in time measure - grammatica imaiments
79497-4,3-hydroxybenzoate [moles/volume] in serum or plasma
79497-4,orpasma iii [mles/volume] in serum 3-hydrxybenzoae
79497-4,level 3-hydroxybenzoate [moles/volume] in serpl
79497-4,3oh-benzoate serpl-scnc
79497-4,3oh-nzoate iii serl-sc
79497-4,3oh-benzoate serpl-scnc serp
79497-4,3-hydroxybenzoate [moles/vol]
79497-4,3-hydrxybenzoate[oles/o]
79497-4,[mols/vol] 3hydroxybenzoae
13143-3,deprecated streptococcus pneumoniae 4 ab [units/volume] in serum --1st specimen
13143-3,deprecated streptococcus pneumoniae 4 ab [units/volume] microbiology in serum --1st specimen
13143-3,pneumoniae streptococcus deprecated 4 ab [units/volume] in ser --1st specimen
13143-3,deprecated s pneum4 ab sp1 ser-acnc
13143-3,absp s pneum4 deecated se-acnc
13143-3,ab s pneum4 deprecated antibody sp1 ser-acnc
13143-3,s. pneumoniae 4 ab spec 1 qn (s)
13143-3,spec pneumoniae 4 antibody ab s. 1 qn (s)
13143-3,sec peumoniae 4 ab s. 1 pre immunization qn (s)
79527-8,4-deoxythreonate/creatinine [molar ratio] in urine
79527-8,[molar 4-deoxythreonate/creatinine ratio] in urine
79527-8,4-deoxythreonate/creatinine [molar ur ratio] urine in
79527-8,4-deoxythreonate/creat ur-srto
79527-8,4-deoxythreonate/creat ur-srto
79527-8,"ur-srto 4-deoxythreonate/creat 2,3-dihydroxybutanoate"
79527-8,4-deoxythreonate/creatinine (u) [molar ratio]
79527-8,4-deoxythreonate/creatinine [molar (u) ratio]
79527-8,[molar (u) 4-deoxythreonate/creatinine ratio]
76347-4,dehydroepiandrosterone sulfate (dhea-s)/cortisol [molar ratio] in serum or plasma
76347-4,dehydroepiandrosterone sulfate (dhea-s)/cortisol [molar ratio] in ser or plasma
76347-4,dehydroepiandrosterone sulfate (dhea-s)/cortisol [molar ratio] in serum dheas or plasma
76347-4,dhea-s/cortis serpl-srto
76347-4,dhea-/corts serpl-srto plasma
76347-4,random dhe-s/cortis serpl-rt
76347-4,dhea-s/cortisol [molar ratio]
76347-4,[molarraio] he-s/cortsol
76347-4,[molar f dhea-s/cortisol ratio]
88602-8,adenovirus ag [presence] in nasopharynx by immunoassay
88602-8,adenovirug [presence] in nasophrynx by immunoassy
88602-8,adeoius in [presence] ag nasopharynx by mmunoassa
88602-8,hadv ag nph ql ia
88602-8,ia ag nph ql hadv enzyme immunoassay
88602-8,hadvag ia nphql
88602-8,adenovirus ag ia ql (nph)
88602-8,adenovirus ql ia ag (nph)
88602-8,adeoiu ag microbiology aql (nph)
51804-3,rickettsia conorii igg ab [units/volume] in serum by immunoassay
51804-3,rickettsia igg conorii ab [units/volume] in serum by immunoassay
51804-3,rickettsia conrii quan gg ab [unitsvolume] seum in bymmunoassa
51804-3,r conorii igg ser ia-acnc
51804-3,r quant conorii igg serum ia-acnc
51804-3,ser onorii igg qnt r ia-anc
51804-3,r. conorii igg ia qn (s)
51804-3,(s) conorii igg ia qn r.
51804-3,quant r. conorii igg ia (s) qn
13977-4,gamma globulin/protein.total in cerebral spinal fluid by electrophoresis
13977-4,globulin/protein.total gama in cerebralspial fluid by eletrophoresis
13977-4,gamma gobulin/protein.total in cerebral spinal flid by lectrophorsi
13977-4,gamma glob mfr csf elph
13977-4,gamma elph mfr csf glb
13977-4,gammaglb mfr csf elph
13977-4,gamma globulin elph (csf) [mass fraction]
13977-4,elp globulin gamma (cs) [mass fraction]
13977-4,fraction] globulin elph (csf) [mass gamma neuro
4478-4,complement c1q [mass/volume] in serum or plasma
4478-4,complement c1q in [mass/volume] seruor plasma
4478-4,complement cq [mass/volume] i erum or plasma
4478-4,c1q serpl-mcnc
4478-4,qnt c1q serpl-mcnc
4478-4,rpl-mc c1
4478-4,complement c1q [mass/vol]
4478-4,complement [mass/vol] c1q
4478-4,complemet point in time c1 [mss/vol]
16549-8,carbinoxamine [presence] in urine
16549-8,carbinoxamine pr [presence] urine in
16549-8,carbinoxamine in [presence] pr urine
16549-8,carbinoxamine ur ql
16549-8,ur carbinoxamine point in time ql
16549-8,carbinoxamine ur ql qual
16549-8,carbinoxamine ql (u)
16549-8,(u) ql carbinoxamine
16549-8,ql carbinoxamne (u)
23290-0,mycoplasma mycoides ss mycoides small colony ag [presence] in specimen by immune diffusion (id)
23290-0,mycoplasma mycoides imun ss mycides small clony [esence] in specimen by immune diffusion (d)
23290-0,mycoplasma mycoides ss mycoides small ag colony [presence] in specimen by immune diffusion (id)
23290-0,m myc my sc ag spec ql id
23290-0,m myc my presence id ag spec sc id
23290-0,m id my sc ag spec ql mycoplasm myc
23290-0,m. mycoides ss mycoides small colony ag immune diff ql (specimen)
23290-0,m. mycoidess mycoides sall colony ag mmun diffql (specimen)
23290-0,m. myoides ss mycoides sall colny a immun diff q (specime)
38926-2,macroprolactin [mass/volume] in serum or plasma
38926-2,in [mass/volume] macroprolactin serum or plasma
38926-2,macroprolactin [mass/volume] in serum or serum or plasma plasma
38926-2,macroprolactin serpl-mcnc
38926-2,serum or plasma-mcnc macroprolactin
38926-2,serpl-mcnc macrorolactin
38926-2,macroprolactin [mass/vol]
38926-2,quant [ms/ol] mcroprolactin
38926-2,serum or plasma [mass/vol] macroprolactin
15156-3,cancer ag 125 [units/volume] in body fluid by dilution
15156-3,caneag 125 [nits/lm] b/f in bdy fluid by dilution
15156-3,cancer ag 125 [units/volume] in body fluid by dilution obgyn
15156-3,cancer ag125 fld dil-acnc
15156-3,bod cancer dil-acnc fld ag125
15156-3,dil-cnc gynecology canceag125ld
15156-3,cancer ag 125 dilution qn (body fld)
15156-3,caner ag 125 dutio q (bod fld)
15156-3,cancer ag 125 dilution fld) (body qn
32546-4,glucose-6-phosphate dehydrogenase [enzymatic activity/mass] in red blood cells
32546-4,glcoe-6-hoshate eydrogenase [enymatic activit/mass] heme in redbood ces
32546-4,glucose--phoshe blo [enzymtic ativity/mass] in red dehydrogena cells
32546-4,g6pd rbc-ccnt
32546-4,rbc-ccnt g6pd
32546-4,g6p pi rbc-cct
32546-4,g6pd (rbc) [catalytic activity/mass]
32546-4,g6pd (rbc) [catalytic activity/mass]
32546-4,gpd (rbc) [cataytic acivty/mass]
43047-0,coxsackievirus a7 ab [titer] in body fluid
43047-0,ab 7 coxsckievis [titer] in body flui
43047-0,coxsackievirus a7 body [tite] in ab uid
43047-0,cv a7 ab titr fld
43047-0,ab a7 cv ttr fld
43047-0,cv a7 ab cv titr fld
43047-0,coxsackievirus a7 ab (body fld) [titer]
43047-0,coxsackievirus a7 ab (body bf fld) [titer]
43047-0,coxsackievirus fld) ab (body antibody a7 [titer]
74927-5,deprecated pipamperone [mass/volume] in serum or plasma --trough
74927-5,deprecate pipamprone [mass/volume] in erum or lasma --tough
74927-5,dprecated pipamperone in [mas/vlume serum or lasma--troug
74927-5,deprecated pipamperone trough serpl-mcnc
74927-5,deprecated serpl-mcnc drug/toxicology trough pipamperone
74927-5,deprecated pipamperonetrouh serpl-mcnc
74927-5,pipamperone trough [mass/vol]
74927-5,pipamperone [mass/vol] trough
74927-5,pipamperone [mass/vol] serp trough
50111-4,3-hydroxylinoleoylcarnitine (c18:2-oh) [moles/volume] in amniotic fluid
50111-4,3-hydoxylinleoylcarnitine (c18:2-o) [mols/volum] in amnitic fuid
50111-4,fli (c18:2-oh) [moles/volume]in amniotic 3-hydoxylinoleoylcarniine
50111-4,3oh-linoleoylcarn amn-scnc
50111-4,mn-scnc 3h-lnoleoylcarn
50111-4,amn-cnc oh-linoleoylcrn
50111-4,c18:2-oh (amn fld) [moles/vol]
50111-4,[moles/vol] iii (amn fld) c18:2oh
50111-4,c18:2-oh (amn c18:2-oh fld) [moles/vol]
94273-0,muscle specific receptor tyrosine kinase igg ab [moles/volume] in serum by immunoassay
94273-0,muscle secific receptor tyrosie inase igg ab [mles/vlume] in serumby imuoassay
94273-0,muscle specfic receptor tysinekinse gg ab [moles/volume] in srum  mmunoasa
94273-0,musk igg ser ia-scnc
94273-0,musk igg ia-scnc ser
94273-0,seriscnc gg mk
94273-0,muscle specific receptor tyrosine kinase igg ia (s) [moles/vol]
94273-0,muscle specific receptor tyrosine kinase igg ia (s) [moles/vol]
94273-0,musclspecific eceptr tyrosine s) igg ia kinase sr [moles/vl]
14175-4,protoporphyrin [mass/mass] in 24 hour stool
14175-4,protoporphyrn 24 in [as/mas] hour stool heme
14175-4,protoporhyrn [ass/mas] in stool hour 24
14175-4,protopor 24h stl-mcnt
14175-4,stl-mcnt 24h protopor
14175-4,stl-mcnt 24h protopor
14175-4,protoporphyrin (24h stl) [mass/mass]
14175-4,protoporphyrin (24h stl) protoporph [mass/mass]
14175-4,protoporphyrin [mass/mass] stl) (24h
8791-6,left ventricular stroke volume index by indicator dilution
8791-6,left ventricular stroke dilution index by indicator volume
8791-6,left ventricular stroke volume index by indicator dilution
8791-6,lv svi indicator dilution
8791-6,lv dilution indicator svi
8791-6,svi lv indicator dilution
49000-3,free hemoglobin [presence] in cerebral spinal fluid
49000-3,free hemoglobin [presence] fluid cerebral spinal in
49000-3,free hemolobin [presence]incereral sinal flud
49000-3,hgb free csf ql
49000-3,hb csf free ql qual
49000-3,hb fr ql freecs
49000-3,free hemoglobin ql (csf)
49000-3,free (csf) ql hemoglobin spinal fld
49000-3,free ql hemoglobin (cf)
39776-0,urea [moles/volume] in serum or plasma --post dialysis
39776-0,urea [moles/volume] ser or plasma in ser or plasma --post dialysis
39776-0,urea --post in serum or plasma [moles/volume] dialysis
39776-0,urea p dialysis serpl-scnc
39776-0,dialysis p urea serpl-scnc ser or plasma
39776-0,ure p diaysis quant erpl-snc
39776-0,urea post dialysis [moles/vol]
39776-0,urea post dialysis [moles/vol]
39776-0,urea [moles/vol] dialysis post
98182-9,thyroxine (t4) free [moles/volume] in cord blood
98182-9,thyroxe t4) cord [mole/olume] in free blood
98182-9,cord (t4) thyrx free [moles/volume] in thyroxine blood
98182-9,t4 free bldco-scnc
98182-9,t4 free bldco-scnc ft4
98182-9,t4 freet4 free bldco-scnc
98182-9,free t4 (bldco) [moles/vol]
98182-9,free (ldco) t4 chemistry [moles/vo]
98182-9,t4 free (bldco) [moles/vol]
23278-5,mycoplasma gallisepticum ag [presence] in specimen by neutralization test
23278-5,mycoplasma gallisepticum ag [presence] in specimen by neutralization test screen
23278-5,mycoplasma gallisepticum ag [presence] specimen in by neutralization test
23278-5,m gallisep ag spec ql nt
23278-5,m gallisep point in time ag spec ql nt
23278-5,m gallisep spec unspecified ag ql nt
23278-5,m. gallisepticum ag neut test ql (specimen)
23278-5,m. gallisepticum ag neut ql test (specimen)
23278-5,m. gallisepticum ag infectiousdisease neut test ql (specimen)
48952-6,histoplasma capsulatum ag [mass/volume] in urine
48952-6,histoplasma in ag [mass/volume] capsulatum urine
48952-6,hisoplasmacapslaum ag [massolume] point in time in urine
48952-6,h capsul ag ur-mcnc
48952-6,h point in time capsul ag ur-mcnc
48952-6,histoplasmos asul ag ur-mcnc
48952-6,h. capsulatum ag (u) [mass/vol]
48952-6,h. h farciminosum capsulatum ag (u) [mass/vol]
48952-6,h. level capulatum ag umas/vol]
49337-9,adenovirus dna [#/volume] (viral load) in bone marrow by naa with probe detection
49337-9,adenovirs dna naa viral qbr load) in bone marow by [#/volume] wth pobe detction
49337-9,adenovirus [#/voume] da (via loa) n boe marrow pt by a wit probedeectio
49337-9,hadv dna # mar naa+probe
49337-9,avdna #mar naa+prbe
49337-9,hadv quan dna # mar naa+probe
49337-9,adenovirus dna naa+probe (bm) [#/vol]
49337-9,adenovirus (bm) naa+probe dna [#/vol]
49337-9,marrow (bone) dna adnovirus naa+prbe(bm)[vol
73429-3,colchicine induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73429-3,circulating platelet ab colchicine induced or igm ab [presence] in serum platelet plasma by flow cytometry (fc)
73429-3,dynamic colcine induce plateet gm ab [presence] i ser rplasma byflow cytoetry (fc)
73429-3,colchicine ind plt igm serpl ql fc
73429-3,igm indplt colcicne serum or plasma ql fc
73429-3,colchicine ind plt igm fc ql condylon serpl
73429-3,colchicine induced platelet igm fc ql
73429-3,colchicine l platelet igmfc inuced
73429-3,qual colchicine induced platelet igm fc presence
76631-1,albumin [mass/volume] in blood by bromocresol purple (bcp) dye binding method
76631-1,(p) nephrology [mass/volume]in blod by bromresol urpl lbumi d binding meho
76631-1,binding [mass/olume] in level blood by bromocresol purple (bcp) dye albuin meod
76631-1,albumin bld bcp-mcnc
76631-1,albumin bld liver bcp-mcnc
76631-1,bcp-mcnc nephrology bld albumin
76631-1,albumin bcp dye (bld) [mass/vol]
76631-1,albmin level cp dye (bld) [mass/vol]
76631-1,bcp albumin random dye (bld) [mass/vol]
30393-3,deprecated nucleated erythrocytes/100 leukocytes [ratio] in blood
30393-3,deprecated nucleated erythrocytes/100 leukocytes bld [ratio] in bld
30393-3,deprecated nucleated eryhrocytes/100 leukocyte rati in blood
30393-3,deprecated nrbc/wbc bld-rto
30393-3,deprecaednrbc/wbc bl-to quan
30393-3,100wbc dpecated blood-rto nrb/bc
30393-3,nucleated rbc/100 wbc (bld) [ratio]
30393-3,nuceted (bld)[ratio] red blood cells rbc/100wbc
30393-3,nucleated [ratio] wbc (bld) rbc/100
31604-2,rickettsia rickettsii ab [presence] in serum
31604-2,id rickettsia ckettsiia serum in [presece]
31604-2,ser rickettii ab[presenc] in rickettsi
31604-2,r rickettsi ab ser ql
31604-2,r rickettsi ab ser aby ql
31604-2,infectious disease r ab rickettsi ser ql
31604-2,r. rickettsii ab ql (s)
31604-2,q rickettsii ab r. ()
31604-2,abql rickettii r. ()
53802-5,arbovirus igg ab [interpretation] in serum by immunofluorescence narrative
53802-5,arbovirus igg ab [interpretation] in ser by immunofluorescence narrative
53802-5,arbovrus ig ab [interpretation] in narative by immunofluoresence serum
53802-5,arbovirus igg ser if-imp
53802-5,arbovirus ser igg if-imp
53802-5,arboirus igg if-imp er antibody
53802-5,arbovirus igg if nar (s) [interp]
53802-5,arbovirus igg [interp] nar (s) if
53802-5,arbovirus igg if nar abs (s) [interp]
31179-5,lopinavir [mass/volume] in serum or plasma
31179-5,lopinavir quan [mas/volume] in serum orplasma
31179-5,plasma [mass/volume] in drug/toxicology ser or lopinavir
31179-5,lopinavir serpl-mcnc
31179-5,serpl-mcnc lopinair
31179-5,serpl-mcnc lpinavir
31179-5,lopinavir [mass/vol]
31179-5,mass concentration [mass/vol] lopinavir
31179-5,lopavir [mass/vol]
5182-1,hepatitis a virus igm ab [units/volume] in serum by radioimmunoassay (ria)
5182-1,hepatitis a in igm ab hepatitis type a [units/volume] virus serum by radioimmunoassay (ria)
5182-1,hepatitis a virus [units/volume] ab igm in serum by radioimmunoassay (ria)
5182-1,hav igm ser ria-acnc
5182-1,hav igm ria-anc er
5182-1,hav igm ser ria-cnc hepatitis
5182-1,hav igm ria qn (s)
5182-1,hv (s) ria qn quant im
5182-1,hav ria igm qn (s)
35217-9,triglyceride [mass or moles/volume] in serum or plasma
35217-9,tiglyceride mass or mles/vlume] n ser r plsa
35217-9,triglyceride [mass or or in trig serum moles/volume] plasma
35217-9,trigl serpl-mscnc
35217-9,quantitative trigl serpl-mscnc
35217-9,serl-mscnc trigl trig
35217-9,triglyceride [mass or moles/vol]
35217-9,[mass triglyceride or moles/vol]
35217-9,triglyceride or [mass serp moles/vol]
72719-8,borderline symptom list - 23 item [bsl-23]
72719-8,borderline symptom list - 23 [bsl-23] item
72719-8,borderle panl symptomit - 3 iem [bl-2]
8029-1,deprecated streptococcus pneumoniae 9 igg ab [units/volume] in serum by immunoassay
8029-1,decatdstreptococcus pneumoiae 9iggab [unitsvoume] in serum by immnoassay quant
8029-1,deprecated trepococcus pnemoiae9 igg ab [units/volue] i srum by immunoassay
8029-1,deprecated s pneum9 igg ser ia-acnc
8029-1,deprecated s pneum9 igg serum ia-acnc
8029-1,pneumococcal deprecated s pneum9 igg serum ia-acnc
8029-1,s. pneumoniae 9 igg ia qn (s)
8029-1,s. pneumoniae 9 igg qn ia (s)
8029-1,s. neumonia eia 9 igg q() a
83133-9,pregnanolone/creatinine [molar ratio] in urine
83133-9,pregnanolo/reatinine i ratio] [molar urine
83133-9,pregnanolone/creatinine [molar in ratio] urine
83133-9,pregnanolone/creat ur-srto
83133-9,r-srto regnanolone/creat
83133-9,pregnanolone/creat ur-srto
83133-9,pregnanolone/creatinine (u) [molar ratio]
83133-9,(u) pregnanoloe/creatinine [mlar ratio] esoteric
83133-9,pregnanolone/creainine(u) ratio] [mola
12241-6,osmotic fragility of red blood cells by diluted rbc
12241-6,osmotic fragility of percent red bld cells by diluted rbc
12241-6,motic fraility of red blood cells by diutedrbc
12241-6,of nfr rbc diluted
12241-6,o nfr rbcdiued
12241-6,of nfr rbc diluted
12241-6,osmotic fragility diluted rbc (rbc)
12241-6,osmotic of fragility diluted rbc (rbc)
12241-6,fragil osmotic (rbc) iluted rbc ragility
101296-2,mycoplasma pneumoniae dna [presence] in throat by naa with non-probe detection
101296-2,myoplasapnemoniae dna [presence] in throtby naa with non-pro detection
101296-2,mycplasma pneumonae dna [resence] in throatby naa with non-probe deection
101296-2,m pneumo dna throat ql naa+non-probe
101296-2,naa+nn-probe hroat ql pneumodna
101296-2,m pneumo dna ql throat naa+non-probe
101296-2,m. pneumoniae dna naa+non-probe ql (throat)
101296-2,m. pneumoiae na ql na+non-probe ql (throat)
101296-2,(throat) pneumoniae dna random naa+non-probe ql m.
62591-3,deprecated phenx measure - oral health - number of natural teeth
62591-3,deprecated phenx measure - oral - health number of natural teeth
62591-3,phenx deprecated measure - oral health - number of natural teeth
27077-7,enterococcus sp igm ab [units/volume] in serum
27077-7,enterococussp igmab arbitrary concentration serum in [unit/vole
27077-7,enterococcus sp in ab [units/volume] igm serum
27077-7,enterococ igm ser-acnc
27077-7,igm enterococ ser-acnc
27077-7,gm enterococ sr-acnc
27077-7,enterococcus sp igm qn (s)
27077-7,enterococcus sp (s) qn igm
27077-7,enterococcus sp species igm qn (s)
96918-8,fodrin alpha subunit iga ab [units/volume] in serum or plasma by immunoassay
96918-8,fodrin lpha subunit igaab[units/volume in serm or pama by imunassay
96918-8,fodrin alpha subunit iga ab [units/volume] in ser or plasma quant by immunoassay
96918-8,fodrin alpha iga serpl ia-acnc
96918-8,aph fodrin immunoglobulin a iga erpa-acn
96918-8,fodrin alpha serum or plasma plasma iga ia-acnc
96918-8,fodrin alpha subunit iga ia qn
96918-8,fodrin alpha abs subunit iga ia qn
96918-8,fodrin alpha subunit ia suds iga qn
105720-7,flubromazepam [presence] in urine by confirmatory method
105720-7,flubromazeam [presence] i rine by confiratory cnfr method
105720-7,flubromazepam cfm [presence] in urine by confirmatory method
105720-7,flubromazepam ur ql cfm
105720-7,cfm ur q flubromazepm cfm
105720-7,ur cfm ql flubromaepamur
105720-7,flubromazepam confirm ql (u)
105720-7,conirm fluromzepam ql(u) lc/ms/ms
105720-7,flubromazepam confirm ql (u) confirmatory
47790-1,threonine/amino acids.total in specimen
47790-1,random specimen acids.total in threonine/amino
47790-1,in quant acids.total threonine/amino specimn
47790-1,threonine sfr spec
47790-1,acid threonine sfr spec
47790-1,threoninsfr pec
47790-1,threonine/total aa (specimen) [molar fraction]
47790-1,treonin/ttal aa (specimen) [molarfrction]
47790-1,threonine/total fraction] (specimen) [molar aa
56926-9,hepatitis c virus c1 ab [presence] in serum by immunoblot
56926-9,hepatiti c virus c1 mmuoblot [presnce] n ser by a
56926-9,by c virus c1 ab [presence] in id ser hepatitis immunoblot
56926-9,hcv c1 ab ser ql ib
56926-9,hcv c1 ab ser hepatology ql ib
56926-9,hcv qualitative c1 ab ser ql ib
56926-9,hcv c1 ab ib ql (s)
56926-9,hcv c1 ql ib ab (s)
56926-9,hcv c1 ql ib ab (s)
18242-8,methyprylon [mass/time] in 24 hour urine
18242-8,methypryon [ass/time] urine 4 hour mrate in
18242-8,2 [masstime] in methypryln hour 24 hours urine
18242-8,methyprylon 24h ur-mrate
18242-8,ur-mrate 24h methyprylon quan
18242-8,mrate methyprylon ur-mrate 24h
18242-8,methyprylon (24h u) [mass/time]
18242-8,(24h methyprylon u) [mass/time]
18242-8,methyprylon (24h [mass/time] u)
22721-5,glutamate [moles/volume] in specimen
22721-5,glutamae [oleslume] speime in to be specified in another part of the message
22721-5,glutamate [moles/volume] in specimen
22721-5,glutamate spec-scnc
22721-5,substance concentration glutmte specscc
22721-5,glutamate quantitative spec-scnc
22721-5,glutamate (specimen) [moles/vol]
22721-5,glutamate [moles/vol] (specimen) substance concentration
22721-5,lutate [molvol] (specimen)
24083-8,galactosylceramidase [enzymatic activity/mass] in fibroblast
24083-8,galacosylceramidase [enzymatic in activity/mass fibroblast
24083-8,in fib [enzymatic activity/mass] galactosylceramidase fibroblast
24083-8,galc fib-ccnt
24083-8,quan galcfib-ccn
24083-8,fib-ccnt galc
24083-8,galactosylceramidase (fibroblast) [catalytic activity/mass]
24083-8,galactosylceramidse(fibrblast) fib [ctlytiactivty/mass]
24083-8,galactosylceramiase (ibrblast) [ctalyti activty/ms]
51708-6,intercellular substance ab [titer] in serum by immunofluorescence
51708-6,intercellular substance ab [titer] in ser by immunofluorescence
51708-6,intercellular substance ab [titer] ser in ser by immunofluorescence
51708-6,ics ab titr ser if
51708-6,ics b titr sr if
51708-6,ics ab if titrsr
51708-6,intercellular substance ab if (s) [titer]
51708-6,intercellular dilution factor (titer) substance b f(s)titer]
51708-6,intercelluar if subsanceab (s) [titer]
47799-2,valine [moles/volume] in dbs
47799-2,valine in [moles/volume] dbs filter paper
47799-2,valine filter paper [moles/volume] in dbs
47799-2,valine dbs-scnc
47799-2,valine dbs-scnc
47799-2,dbs-scnc valine
47799-2,valine (dbs) [moles/vol]
47799-2,dbs valn [moles/vol]
47799-2,[moles/vl] db vline qnt
1679-0,24r-hydroxycalcidiol [mass/volume] in serum or plasma
1679-0,24r-hydroxycalidiol [mass/volume] serum in hydroxy calcidiol r plasma
1679-0,24r-hydroxycalcidiol [mass/volume] in plas or serum
1679-0,24r-oh-calcidiol serpl-mcnc
1679-0,serpl-mcnc 24r-oh-calcidiol
1679-0,24r-oh-calcdilsrpl-mcnc hydroxy calcidiol
1679-0,24r-hydroxycalcidiol [mass/vol]
1679-0,[mas/vol] serp 24r-hyroxyclcidiol
1679-0,"24(r),25-dihydroxycholecalciferol 24r-hydroxycalcidiol [mass/vol]"
12455-2,histoplasma capsulatum yeast phase ab [presence] in cerebral spinal fluid
12455-2,histoplasma capsulatum yeast phase ab [ql] in cerebral spinal fluid
12455-2,histoplasma capsulatum yeast phase ab [presence] in fluid spinal cerebral
12455-2,h capsul yst ab csf ql
12455-2,h csql yst ab capul
12455-2,h capsul point in time yst ab csf ql
12455-2,h. capsulatum yeast phase ab ql (csf)
12455-2,h. capsulatum yeast phase ab presence (csf)
12455-2,h. caplatum yeast phase cerebral spinal fluid ab ql (cs)
20699-5,bluetongue virus ab [presence] in serum by complement fixation
20699-5,bluetongue virus in [ql] ab serum by complement fixation
20699-5,i orbivirus ab [ql bletonguevirus seum by compement fixatio
20699-5,btv ab ser ql cf
20699-5,btv ql ser cf
20699-5,btv ab serum se qlcf
20699-5,bluetongue virus ab cf ql (s)
20699-5,bluetogue viusab cf q (s)
20699-5,bluetongue id virus ab cf presence (s)
53892-6,ribosomal p igg ab [units/volume] in serum
53892-6,ribosomal p igg ab [units/volume] in serum
53892-6,ribosomal p igg ab [units/volume] in serum
53892-6,ribosomal p igg ser-acnc
53892-6,ribosomal p antby igg ser-acnc
53892-6,sr p ribosomal igg serum-acnc
53892-6,ribosomal p igg qn (s)
53892-6,ribosmal pig q (s
53892-6,ribosomal p igg qn(s
20575-7,hepatitis a virus ab [presence] in serum
20575-7,hepatitis a virus ab [presence] hepatitis in ser
20575-7,etitia [pesne ab virus in serum
20575-7,hav ab ser ql
20575-7,ab hav antibodies ser presence
20575-7,hav ab ser ql ql
20575-7,hav ab ql (s)
20575-7,(s) ab ql hav
20575-7,hav abql ()
57192-7,deprecated outcome and assessment information set (oasis) form - version c - follow-up
57192-7,deprecate outcome and assessmnt information set (asis)form - vrsion c - follow-up
57192-7,deprecated outcome and assessment information set (oasis) form - version c - random follow-up
58761-8,coxiella burnetii phase 2 igg ab [titer] in cerebral spinal fluid by immunofluorescence
58761-8,coxiella bunetii y 2 igg ab [titr] in cerebral microbiology spinal fuid hae immunofluoresence
58761-8,coxiella burnetii phase 2 cerebral ab [titer] in igg spinal fluid by immunofluorescence
58761-8,c burnet ph2 igg titr csf if
58761-8,c burnet ph2 igg titr cerebrospinal fluid if
58761-8,c burnet ph2 igg titr csf if
58761-8,c. burnetii phase 2 igg if (csf) [titer]
58761-8,c burnetii phase 2g (cerebrospinal fluid) i [titer]
58761-8,c. burnetii pase 2 iggif (csf) [titer]
95621-9,pain/agitation panel npass
95621-9,pass pnl pain/agitation
95621-9,neonat npass panel painagitation
95621-9,pain/agitat pnl npass
95621-9,pain/agitat npass panel.neonat pnl
95621-9,pnl pain/agitat pain/agitat pnl npass
40904-5,deprecated streptococcus pneumoniae 12 igg ab [mass/volume] in serum by immunoassay --1st specimen
40904-5,deprecated streptococcus mass concentration pneumoniae 12 igg ab [mass/volume] in serum by immunoassay --1st specimen
40904-5,deprecated streptococcus immunoassay 12 igg ab [mass/volume] in ser by pneumoniae --1st specimen
40904-5,deprecated s pneum12 igg sp1 ser ia-mcnc
40904-5,deprecated serum pneum12 igg sp1 s ia-mcnc
40904-5,depreatds pnem12 igg sp1 ser ia-mcnc
40904-5,s. pneumoniae 12 igg spec 1 ia (s) [mass/vol]
40904-5,s. pneumonae 12 igg spec 1ia acute specimen (s) [ass/vol
40904-5,s. pneumoniae 12 igg [mass/vol] 1 ia (s) spec
63009-5,phenx domain - social environments
63009-5,phenx environments - social domain
63009-5,phenx - panel.phenx domain social environments
63009-5,domain - social environments
63009-5,- random domain social environments
63009-5,- domain social environments
75651-0,tetrahydrocannabivarin [mass/volume] in urine
75651-0,in [mass/volume] tetrahydrocannabivarin urine
75651-0,urine drug/toxicology [mass/volume] in tetrahydrocannabivarin
75651-0,carboxythcv ur-mcnc
75651-0,carboxythcv r-mcnc mass concentration
75651-0,carboxythcv urn ur-mcnc
75651-0,tetrahydrocannabivarin (u) [mass/vol]
75651-0,(u) tetrahydrocannabivarin [as/vol]
75651-0,tetrahydrocannabivarin (u) [mass/vol] urn
92330-0,promis item bank - self-efficacy for managing emotions - version 1.0
92330-0,promis for bank - self-efficacy item managing emotions - version 1.0 random
92330-0,promis item bank - self-efficacy for managing pnl emotions - version 1.0
11275-5,large granular lymphocytes/leukocytes in blood by manual count
11275-5,large granular count in blood by manual lymphocytes/leukocytes
11275-5,large granular lymphocytes/eukocyte y blood in anual count
11275-5,lg gran lymphs nfr bld manual
11275-5,lg gran fr white bld cells ymh bldmnual
11275-5,lg manual lymphs nfr hematology/cell counts blood gran
11275-5,large granular lymphocytes/leukocytes manual cnt (bld)
11275-5,lagegranular ct(bld) manual lymphocytes/leukocytes
11275-5,large lymphocytes/leukocytes granular manual cnt (bld)
105094-7,candida sp rrna [presence] in vaginal fluid
105094-7,candida sp screen rra [presence] in vginal fluid
105094-7,candida qual sp rrna [presence] in vaginal fluid
105094-7,candida rrna vag ql
105094-7,candida rrna agql
105094-7,candida rrna va q
105094-7,candida sp rrna ql (vag fld)
105094-7,candida sprra (vag ql ld vaginal fluid
105094-7,candida sp rrna (vag ql fld)
43025-6,herpes virus 6 igm ab [titer] in cerebral spinal fluid
43025-6,herpes virus 6 igm ab [titer] in cerebral spinal fluid
43025-6,herpes virus fluid igm ab [iter] in erebrl sinal 6
43025-6,hhv6 igm titr csf
43025-6,hhv6 titr igm csf
43025-6,csf igm titr hhv6 human herpes virus
43025-6,hhv 6 igm (csf) [titer]
43025-6,hhv [titer] aby igm(csf) 6
43025-6,neurology (csf) 6igm hhv [titr]
3566-7,dimetamphetamine [mass/time] in 24 hour urine
3566-7,dimetamphetamine [mass/time] in hour 24 urine
3566-7,dietamphetamine quantitative [mass/tie]in 24 hour urine
3566-7,dimetamphet 24h ur-mrate
3566-7,dmeamphet ur-mrte 24hr 24h
3566-7,24h dimetamphet ur-mrate drug/toxicology
3566-7,dimetamphetamine (24h u) [mass/time]
3566-7,dimetamphetamine ) (24h [mass/tme]
3566-7,quant dimetamphetamine (24h u) [mass/time]
42488-7,aspergillus sp ab [titer] in pleural fluid by complement fixation
42488-7,fixatin sp ab [titr] in pleural uid by cmplement aspeillus
42488-7,aspergillus sp ab [titer] titre in pleural fluid by complement fixation
42488-7,aspergillus ab titr plr cf
42488-7,aspergillus ab titr plr cf titered
42488-7,aspergillus ab titr plr cf
42488-7,aspergillus sp ab cf (pleur fld) [titer]
42488-7,(pleur sp aby ab cf aspergillus fld) [titer]
42488-7,pulmonary fd) spab cf (ple aspergillus [titer]
43601-4,ganglioside gd1b igg ab [presence] in serum
43601-4,ganglioside gd1b igg ab [presence] in ser
43601-4,ganglioside gd1b igg ab [presence] screen in ser
43601-4,gd1b gangl igg ser ql
43601-4,gd1b autoantibodies gngligg ser ql
43601-4,pr gd1b igg gangl ser ql
43601-4,ganglioside gd1b igg ql (s)
43601-4,(s) gd1b igg ql ganglioside
43601-4,gangliosde gdb igg ql (s)
89258-8,wound undermining panel
89258-8,wound panel undermining
89258-8,wound random undermining panel
89258-8,wound undermining panel
89258-8,panel woundundemini
89258-8,point in time wound undermining panel
83070-3,25-hydroxyvitamin d3+25-hydroxyvitamin d2 [mass/volume] in serum or plasma by immunoassay
83070-3,2-hydrxvitamin d3+25hydroxyvitam d2 25(oh)d3+25(oh)d2 [m/volume] in serum orplasma by immunoassay
83070-3,25-hydroxyvitamin d3+25-hydroxyvitamin d2 [mass/volume] serum in or point in time plasma by immunoassay
83070-3,25(oh)d3+25(oh)d2 serpl ia-mcnc
83070-3,ercalcidiol 25(oh)d3+25(oh)d2 srpl ia-c
83070-3,imcnc sel 25(oh)d3+25(oh)d
83070-3,25-hydroxyvitamin d ia [mass/vol]
83070-3,25-hydrxyvitamind ia [ss/vol]
83070-3,d 5-hydroxyvitam 25-hydroxycholecalciferol ia [mass/vol]
5163-1,fasciola sp ab [units/volume] in serum
5163-1,fasciola sp abs ab [units/volume] in serum
5163-1,in sp ab [units/volume] fasciola ser quant
5163-1,fasciola ab ser-acnc
5163-1,fasciola ab ser-acnc
5163-1,fasciola ser-acnc ab
5163-1,fasciola sp ab qn (s)
5163-1,fasciola sp ab n(s)
5163-1,fasciola qs) b sp
54575-6,current number of unhealed (non-epithelialized) pressure injuries at each stage
54575-6,injuies ber of unhealed non-epithelialed) ressure urren at each stage
54575-6,current number of unhealed (non-epithelialized) pressure injuries each at stage
729-4,leukocytes other [#/volume] in blood by manual count
729-4,leukocytes other [#/volume] in bld leuk by manual count
729-4,leukocytes other [#/volume] in blood by count manual
729-4,wbc other # bld manual
729-4,wbc quant other bld # manual
729-4,wbc other # bld manual
729-4,wbc other manual cnt (bld) [#/vol]
729-4,wbc other cnt manual (bld) [#/vol]
729-4,manual other wbc cnt (blood) [#/vol]
70726-5,functional assessment of chronic illness therapy-fatigue questionnaire - version 4 (facit-f)
70726-5,functional assessment of chronic illness therapy-fatigue questionnaire version - 4 (facit-f)
70726-5,functionlassessmet of chronicillness theray-fatigue -version queonnaire 4 (facit-f)
14779-3,hexacarboxylate [moles/volume] in plasma
14779-3,hexacrboxylate [moles/volue] n quantitative plsm
14779-3,hexacarboxylate plasma in [molvolume
14779-3,hexacarboxylate plas-scnc
14779-3,plas-snc hexcaroxylate
14779-3,plsm hexacarboxyle pas-snc
14779-3,hexacarboxylate (p) [moles/vol]
14779-3,(p) hexacarbox hexacarboxylate [moles/vol]
14779-3,hexacarboxylate (p) quantitative [moles/vol]
90271-8,bacteria identified in pericardial fluid by aerobe culture
90271-8,bacteria identified in pericardial fluid by aerobe aerobe culture
90271-8,bactri dentifie inpericarial pt fluid by aerbe culture
90271-8,bacteria pcar aerobe cult
90271-8,bacteria pcar cult aerobe
90271-8,bacteriar aerobe cult
90271-8,bacteria identified aer cx nom (pericard fld)
90271-8,bacteria identified aer cx aerobe nom (pericard fld)
90271-8,bacteria identified aer cx nom (pericard infectious disease fld)
43141-1,synthetic glucocorticoid panel [mass/volume] - serum or plasma
43141-1,syntheic or panel [mass/volume] - seru quantitative glucocorticoid plasm
43141-1,synthetic glucocorticoid panel plasma [mass/volume] - serum or plasma
43141-1,syn glucocorticoid pnl serpl-mcnc
43141-1,plasma synglucocoticoid pnl serplmcc
43141-1,syn glucocorticoid pnl serum or plasma-mcnc
43141-1,synthetic glucocorticoid panel [mass/vol]
43141-1,panel glucocorticoid synthetic [mass/vol]
43141-1,glucocorticoid synthetic panel [mass/vol]
81382-4,statement of document creator narrative - reported
81382-4,statement of document creator narrative - reported
81382-4,statement docmentcreator of statement of doc creator narrative - reorted
81382-4,statement of doc creator reported
81382-4,statement of finding doc creator reported
81382-4,statement ofdoc ceator repoted
79636-7,aspartylglycosamine/creatinine [molar ratio] in urine
79636-7,aspartylglycosamine/creatinine [molar acetylglucosaminylasparagine ratio] in uine
79636-7,aspartyllycosamne/cratinne ratio] [molar inurine
79636-7,aspartylglycosamine/creat ur-srto
79636-7,aspartyllcosmine/creat ur-srto
79636-7,asparaginylglucosamine aspartyllycsamine/creat u-srt
79636-7,aspartylglycosamine/creatinine (u) [molar ratio]
79636-7,aspartyglycoine/creatnne (u)[moa ratio]
79636-7,aspartylglycosamine/creatinine (u) [mola atio]
26666-8,chlamydia trachomatis h ab [presence] in serum
26666-8,chamydia trachomatis ab infectious disease [presenc] inserum
26666-8,chlamydia h abs trachomatis ab [presece in serum
26666-8,c trach h ab ser ql
26666-8,c trach ql serum ab h ql
26666-8,c trac h ab er presence
26666-8,c. trachomatis h ab ql (s)
26666-8,c. ab h trachoma trachomatis ql (s)
26666-8,c. trachomatis h ab ql pr (s)
75541-3,parvovirus b19 dna [log units/volume] (viral load) in plasma from donor by naa with probe detection
75541-3,parvovirus probe dna [logunits/volue]viral load)iplasm frm ono by naa with b1 detection
75541-3,prvvrus b19 dna [log unis/volume] (viral by in plasfrom donor load) naa with probe etetion
75541-3,b19v dna plas donr naa+probe-log iu
75541-3,b19v dna donr plas naa+probe-log point in time iu
75541-3,b19v lcr dna plasma donr naaprobe-logiu
75541-3,parvovirus b19 dna naa+probe (p donor) [log units/vol]
75541-3,parvovirus b19 dna naa+prob (p don) ligation-activated transcription [log unit/vo]
75541-3,parvovirus b19 (p naa+probe dna donor) [log units/vol]
16796-5,echovirus ab [units/volume] in serum by complement fixation
16796-5,echovirus ab [units/volume] autoantibody in by serum complement fixation
16796-5,echovirus fixation [units/volume] in serum by complement ab
16796-5,ecv ab ser cf-acnc
16796-5,ecv ab ser cf-acnc antby
16796-5,ser ab ecv cf-acc
16796-5,echovirus ab cf qn (s)
16796-5,echovirus ab quan cf qn (s)
16796-5,echovius ab cf qn s)
6492-3,neisseria meningitidis ag [presence] in specimen by immunofluorescence
6492-3,niseria meningitidis ag meningococcal meningitis [ql] i specien by immunofluorescene
6492-3,neisseria [presence] ag meningitidis in specimen by immunofluorescence
6492-3,n men ag spec ql if
6492-3,men mening n ag spec ql if
6492-3,mn ag specql if
6492-3,n. meningitidis ag if ql (specimen)
6492-3,n. meningitidis ag if presence (specimen) antigens
6492-3,n. meningitidis (specimen) n meningitidis if ql ag
719-5,hemoglobin [mass/volume] in cerebral spinal fluid
719-5,fluid [ma/volume] haemoglobin in cerebral spinl emgobin
719-5,hemoglobin [mass/volume] quan in cerebral spinal fluid
719-5,hgb csf-mcnc
719-5,hgb csf-mcnc
719-5,hgb csf-mcnc
719-5,hemoglobin (csf) [mass/vol]
719-5,(cerebrospinal fluid) hemoglobin [mass/vol]
719-5,mass concentration hemoglobin (csf) [mass/vol]
23666-1,babesia sp ab [titer] in serum by complement fixation
23666-1,babesia sp ab [titer] infectious disease in serum by complement fixation
23666-1,esia pt sp ab titr] nsrum by complement ixation
23666-1,babesia ab titr ser cf
23666-1,babesia ab itr serum cf
23666-1,babsia titr point in time ab ser
23666-1,babesia sp ab cf (s) [titer]
23666-1,babesia sp ab cf ttr (s) [titer]
23666-1,babesa sp complement fixation f b (s) [titer]
97266-1,methylenedioxymethamphetamine [presence] in cord tissue by screen method
97266-1,methylenedioxymethamphetamine [presence] screen cord tissue by in method
97266-1,drug/toxicology mehlenedioxymethamphetamine [presence] tisue cord in b sceen mtho
97266-1,mdma tissco ql scn
97266-1,mdma tissco scn ql drug/toxicology
97266-1,mma qlscn tissco
97266-1,methylenedioxymethamphetamine screen ql (umb cord tissue)
97266-1,ql screen methylenedioxymethamphetamine (umb cord tissue)
97266-1,methylenedioxymethamphetamine screen presence (umb tissue) cord random
50282-3,3-hydroxytetradecanoylcarnitine (c14-oh) [moles/volume] in amniotic fluid
50282-3,[moles/volume] (c14-oh) 3oh-tdecanoylcarn 3-hydroxytetradecanoylcarnitine in amniotic fluid
50282-3,3-hydroxyetdecanoylarnin (c4-oh) [moes/volume] in amn amniotic lid
50282-3,3oh-tdecanoylcarn amn-scnc
50282-3,amn-scc chemistry 3oh-tecanoylcarn
50282-3,amn-scnc amniotic flu 3oh-tdecanoylcarn
50282-3,c14-oh (amn fld) [moles/vol]
50282-3,[moles/vol] (amn quan fld) 14-h
50282-3,[moles/vol] (amn fld) c14-oh
2405-9,heparan sulfate [presence] in urine
2405-9,hearan sulfate [prence] inrine
2405-9,heparan slfate rine [prsence]i
2405-9,heparan sulfate ur ql
2405-9,hepran ql sulfat ql ur
2405-9,hepara sulfate ql ur
2405-9,heparan sulfate ql (u)
2405-9,heparan sulfate ql ql (u)
2405-9,(u) sulfate ql heparan
95790-2,adrenal cortical carcinoma probability [likelihood] based on clinical and lab data
95790-2,adrenal probabilit[likelihood] crcinoma coticl based on clinicalanlab data
95790-2,adrenal cortical carcinoma probability [likelihood] based on clinical qnt and lab data
95790-2,acc prob from clin+lab data
95790-2,acc prob rom data point in time clin+ab
95790-2,acc prob from clin+labdta risk
12785-2,dihydrocodeine free [mass/volume] in serum or plasma
12785-2,in free [mass/volume] dihydrocodeine serum or plasma
12785-2,ihyrocdeine fee [mass/volume] in plasma serumor
12785-2,dhc free serpl-mcnc
12785-2,dhc serpl-mcnc fr fre
12785-2,dhc free pl-mcnc
12785-2,dihydrocodeine free [mass/vol]
12785-2,dihydrocodeie serpl free mass/vol]
12785-2,free dihydrocodeine [mass/vol]
60067-6,cobalt [mass/mass] in tissue
60067-6,in [mass/mass] cobalt tisue
60067-6,cobalt [mass/mass] in qnt tissue
60067-6,cobalt tiss-mcnt
60067-6,tiss-mcnt drug/toxicology cobalt
60067-6,"tiss-mcnt cobalt tissue, unspecified"
60067-6,cobalt (tiss) [mass/mass]
60067-6,obal(tss) [ass/ass] random
60067-6,(tiss) cobalt quantitative [mass/mass]
9776-6,norchlordiazepoxide [mass/volume] in serum or plasma
9776-6,norchordiazepxde [mass/volm] i srumorpsma serpl
9776-6,in [mass/volume] norchlordiazepoxide drugs serum or plasma
9776-6,norchlordiazep serpl-mcnc
9776-6,serp-mcnc norhlordiazep
9776-6,sepl-mcnc nchlordiazep
9776-6,norchlordiazepoxide [mass/vol]
9776-6,[mass/vol] norchlordiazepoxide
9776-6,[massvol] nrchlordiazepoxide
32805-4,variant lymphocytes/leukocytes in bronchial specimen by manual count
32805-4,variantlymphocyte/eukoytes in bronchial speimen by manual count
32805-4,brnchial lymphocytes/leukcytes in varint seimen wbcs by mnual ount
32805-4,variant lymphs nfr bronch manual
32805-4,variant lymphs nfr bronch manual
32805-4,ariant lymphs nfr manual brnch
32805-4,variant lymphocytes/leukocytes manual cnt (bronch spec)
32805-4,variant lymphoyte/leukocytes mnual cn (bronch spec)
32805-4,variant lymphs lymphocyte/lekoctesmanal cn (bronch spec
32781-7,legionella sp ag [presence] in urine
32781-7,antigens leioela sp ag [pesnce] nuine
32781-7,legionella sp [presence] ag in urine
32781-7,legionella ag ur ql
32781-7,ur ag legionella ql
32781-7,lginell ag ql ua ur
32781-7,legionella sp ag ql (u)
32781-7,legionella sp (u) ql ag
32781-7,legionella sp ql ag (u)
79564-1,mucopolysaccharidosis type i newborn screen interpretation
79564-1,mucopolysaccharidosis type screen newborn i interpretation
79564-1,mucoplsaccharidosis tye i newborn sceen intepretatio wb
79564-1,mps i dbs-imp
79564-1,i mps dbs-imp
79564-1,wb mps i dbs-imp
79564-1,mucopolysaccharidosis type i (dbs) [interp]
79564-1,muopolysccharosis type i (db) [intep]
79564-1,mucopolysaccharidosis type i (dbs) [interp]
73819-5,heparin induced platelet igg ab [presence] in serum or plasma by immunoassay
73819-5,heparin [presence] platelet igg ab induced in ser or plasma by immunoassay
73819-5,eparin induced laelet igg ab plsma in erum or [ql] by immunoassay
73819-5,pf4 heparin cmplx igg serpl ql ia
73819-5,pf4 heparin cmplx igg sr serpl ql ia
73819-5,cmplx heparin p4 i serpl heparin dependent antibodies qlia
73819-5,heparin induced platelet igg ia ql
73819-5,platelet induced heparin igg ia ql
73819-5,heparin nduced platelet gg ql a
98409-6,mold identified in isolate by naa with probe detection
98409-6,with identified in isolate by naa mold probe detection
98409-6,mold identiie in with b n ilte probe etection
98409-6,mold islt naa+probe
98409-6,isltnaa+probe mod
98409-6,naa+probe moldilt
98409-6,mold identified naa+probe nom (isol)
98409-6,mold identied (isol) nom naa+rob
98409-6,mold identfied nom naa+probe (isol)
83089-3,cortisol [mass/volume] in 24 hour urine by immunoassay
83089-3,cortisol [massvolume] i 24 hourure by immuoassay
83089-3,cortisol hour in 24 [mass/volume] urine by immunoassay
83089-3,cortis 24h ur ia-mcnc
83089-3,cortis 24h ua ur ia-mcn
83089-3,compound f cortis r 24h a-mcnc
83089-3,cortisol ia (24h u) [mass/vol]
83089-3,crtisl ia (24h u) mss/vol] elisa
83089-3,cortisol ia (24h u) [mass/vol]
55538-3,flupenthixol [moles/volume] in serum or plasma
55538-3,flupenthixol [moles/volume] serpl in ser or plasma
55538-3,flupenthixol or in serum [moles/volume] plas
55538-3,flupenthixol serpl-scnc
55538-3,flupenthixolserpl-snc quantitative
55538-3,flupenthiol serl-scnc
55538-3,flupenthixol [moles/vol]
55538-3,[moles/vol] flupenthixol
55538-3,[moles/vol] flupenthixol
34378-0,teicoplanin [mass/volume] in serum or plasma --peak
34378-0,teicoplanin [mass/volume] in quan ser or plasma --peak
34378-0,teicoplanin drugs [mass/volume] in srum or plasm --peak
34378-0,teicoplanin peak serpl-mcnc
34378-0,peak teicoplanin serpl-mcnc id
34378-0,serpl-mcnc peak teicoplanin
34378-0,teicoplanin peak [mass/vol]
34378-0,teicoplanin peak [mass/vol] drugs
34378-0,teicoplanin peak [mass/vol]
2119-6,choriogonadotropin [moles/volume] in serum or plasma
2119-6,choriogonadotropin [moles/volume] in ser or plasma
2119-6,ser [moles/volume] plsm in choriogonadotropin or plasma
2119-6,hcg serpl-scnc
2119-6,hcg serpl-scnc
2119-6,serpl-scnc cg hcg
2119-6,hcg [moles/vol]
2119-6,[moe/vl] human chorionic gonadotropin hcg
2119-6,quantitative hcg [moles/vol]
6367-7,clostridium tetani igg ab [units/volume] in serum by immunoassay
6367-7,clostridium tetani igg ab [units/volume] in serum immunoassay by
6367-7,clostridium tetani igg ab [units/volume] in serum by immunoassay
6367-7,c tetani igg ser ia-acnc
6367-7,c tetani igg ia-acnc ser
6367-7,c tetani igg serum ia-acnc
6367-7,c. tetani igg ia qn (s)
6367-7,c. tetani antibodies igg ia qn (s)
6367-7,c. c tetani tetani igg iaqn s)
31912-9,neisseria meningitidis ag [presence] in specimen
31912-9,neisseria meningitidis ag other [presence] in specimen
31912-9,neisseria meningitidis ag [pesenc] in secimen
31912-9,n men ag spec ql
31912-9,n m ag ec ql
31912-9,n men a spe l
31912-9,n. meningitidis ag ql (specimen)
31912-9,n.meningtidiagql qualitative (specimen)
31912-9,point in time n. meningitidis ag ql (specimen)
40497-0,yersinia pseudotuberculosis 1 ab [titer] in serum
40497-0,yersinia pseudotuberculosis 1 ab [titer] in dilution factor (titer) serum
40497-0,yersinia pseudotuberculosis ab 1 [titer] in autoantibodies serum
40497-0,y pseudotb 1 ab titr ser
40497-0,y autoantibodies ab 1 pseudotb titr ser
40497-0,ttr pseudotb ab y sr
40497-0,y. pseudotuberculosis 1 ab (s) [titer]
40497-0,1 pseudotuberculosis y. ab (s) [titer] antby
40497-0,y. pseudotuberculosis 1 (s) ab [titer]
74794-9,thyroid hormone binding ratio (thbr) in serum or plasma
74794-9,thyoid horone binding atio (thbr) in srumor plasa
74794-9,thyroid hormone binding ratio quantitative (thbr) in serum or plasma
74794-9,thbr serpl
74794-9,t-uptake thb serpl
74794-9,erpl thbr chemistry
74794-9,thyroid hormone binding ratio (thbr) [relative ratio]
74794-9,hormone thyroid bindig ratio (thbr) [relativeao]
74794-9,ratio] hormone binding ratio (thbr) [relative thyroid chemistry
27111-4,histidine [moles/volume] in amniotic fluid
27111-4,hisidine [moles/volume] in anotic fui point in time
27111-4,histidine [moles/volume] fluid amniotic in
27111-4,histidine amn-scnc
27111-4,quan istidine an-snc
27111-4,amn-scnc histidine
27111-4,histidine (amn fld) [moles/vol]
27111-4,amn fl histidine (amn fld) [moles/vol]
27111-4,hsidine (amn fld) moles/vol
23027-6,dermatophilus congolensis ab [presence] in serum by immunoassay
23027-6,dermathilus serumby ab [presence] in ongoleis immunoasay
23027-6,iaa dermatophilus by ab [resce] in seru congoensis immunasy
23027-6,d congo ab ser ql ia
23027-6,d abs ab cono erqia
23027-6,d congo ab serum ql ia
23027-6,d. congolensis ab ia ql (s)
23027-6,d. congolensis s) meia iaql ab
23027-6,d. elisa congolensis ab ia ql (s)
91545-4,myelin oligodendrocyte glycoprotein ab [presence] in serum by cell binding immunofluorescent assay
91545-4,myelin oligodendrocyte glycoprotein immunofluorescent [presence] in serum by cell binding ab assay
91545-4,myelin oligodendrocyte glycoprotein ab [presence] anti in serum by cell binding immunofluorescent assay
91545-4,mog ab ser ql cba ifa
91545-4,mog ab serum ql cba ifa
91545-4,mog ab ql ser cba ifa
91545-4,myelin oligodendrocyte glycoprotein ab cell binding immunofluorescent assay ql (s)
91545-4,myelin oligodendrocyte glycoprotein ab cell binding immunofluorescent assay ql (s)
91545-4,(s) ogodendroyt glycoproei ab ell bindng mmunfluorescent assay ql melin
24204-0,legionella pneumophila ab [titer] in serum by immunofluorescence --2nd specimen
24204-0,legiona neumophila b [ter] in serum by immunoflurescence --2ndspecimn
24204-0,leginella pneuophiaab[titer] in serumbyimmunofuorscnce --2nd specimen trf
24204-0,l pneumo ab sp2 titr ser if
24204-0,l pneumo ab if titr ser sp2
24204-0,id pneumo ab sp2 titr er f
24204-0,l. pneumophila ab spec 2 if (s) [titer]
24204-0,l. pneumophila ab spec 2 if (s) [titer]
24204-0,ab pneumophila . spe 2 pneumophilia if (s) [tte]
14413-9,aspartate aminotransferase [enzymatic activity/volume] in urine
14413-9,urine aminotransferase [enzymatic activity/volume] in aspartate
14413-9,aspartate aminotransferase [enzymatic activity/volume] in quant urine
14413-9,ast ur-ccnc
14413-9,ast ur-ccnc
14413-9,r-ccnc ast
14413-9,ast (u) [catalytic activity/vol]
14413-9,ast (u[catalytic activity/vol]
14413-9,()[catalyticactity/vol] as
10878-7,iodine.protein bound [mass/volume] in serum or plasma
10878-7,iodine.protein bound or in serum [mass/volume] plas
10878-7,plasma iodine.protein bond [mass/volume] in ser or plasma
10878-7,pb iodine serpl-mcnc
10878-7,pb serpl-mcnc iodine
10878-7,ser or plasma pb iodine serpl-mcnc
10878-7,iodine.protein bound [mass/vol]
10878-7,iodine.proten boud pb iodine [mass/vol]
10878-7,iodine.protein bound [mass/vol]
2899-3,purine nucleoside phosphorylase [enzymatic activity/mass] in tissue
2899-3,prne ucloside chemistry [nzmatic phosoryla activityms] in tissu
2899-3,purine phosphorylase nucleoside quan [enzymatic activity/mass] in tissue
2899-3,pnp tiss-ccnt
2899-3,pnp ss-ccnt
2899-3,tiss-ccnt pnp
2899-3,purine nucleoside phosphorylase (tiss) [catalytic activity/mass]
2899-3,purie nclosde (tis)talytic phophoryla actvity/mas]
2899-3,"tissue, unspecified purine nucleoside phosphorylase (tiss) [catalytic activity/mass]"
13956-8,mycobacterium tuberculosis dna [presence] in specimen by naa with probe detection
13956-8,mycobacterium tuberculosis dna myco [ql] in specimen by naa with probe detection
13956-8,id mycobacterium tuberculosis dna [presence] in specimen by naa with probe detection
13956-8,m tb dna spec ql naa+probe
13956-8,aa+probe tb dna spe presence misc m
13956-8,m dna tb spec presence presence naa+probe
13956-8,m. tuberculosis dna naa+probe ql (specimen)
13956-8,m. tuberculosis probe with target amplification naa+probe dna ql (specimen)
13956-8,m. tuberculosis dna ql screen naa+probe (specimen)
32040-8,respiratory syncytial virus ag [presence] in nose by immunofluorescence
32040-8,respiratory syncytial immunofluorescence virus ag [presnce] in nose by immuofluorescece
32040-8,respiratory syncytial in ag [presence] virus nose by immunofluorescence
32040-8,rsv ag nose ql if
32040-8,sv ag ose ql if ordinal
32040-8,if ag nose presence rsv
32040-8,rsv ag if ql (nose)
32040-8,rsv ql immune fluorescence i ag (nose)
32040-8,rsv (nose) if ql ag
3470-2,chlorphentermine [mass/volume] in urine
3470-2,urine i clorphntermine[mas/vlume]
3470-2,chlorphetermin inurine [mass/volume]
3470-2,chlorphentermin ur-mcnc
3470-2,ur-mcnc chlorphentermin
3470-2,ur-mcnc chlorhentermi
3470-2,chlorphentermine (u) [mass/vol]
3470-2,chlorphentermine (u) [mass/vol]
3470-2,mass/ol] chlorphentermin(u)
38379-4,mycobacterium tuberculosis complex dna [presence] in specimen by naa with probe detection
38379-4,mycobacterium tuberculosis complex dna [presence] in specimen qual by naa with probe detection
38379-4,mycobacterium tuberculosis complex dna [ql] with specimen by naa in probe detection
38379-4,m tb cmplx dna spec ql naa+probe
38379-4,m tb cmplx dna spec presence naa+probe
38379-4,mb cmlx dna spec ql naa+probe
38379-4,m. tuberculosis complex dna naa+probe ql (specimen)
38379-4,m tuberculsis complex dna naa+prob ql specimen)
38379-4,m. ql complexdna naa+rbe tubrclsis (specimen)
81713-0,deprecated actin smooth muscle ab [presence] in serum by immunoblot
81713-0,ab actin smooth muscle deprecated [presence] in serum by immunoblot
81713-0,epecated random [presence]in ab actinsmoothmule serum by immnoblot
81713-0,deprecated sma ab ser ql ib
81713-0,deprecate riba ql b ser sma ib
81713-0,deprecated ser ab west blt sma presence ib
81713-0,actin smooth muscle ab ib ql (s)
81713-0,actin smoot muscle ab ib l (s)
81713-0,actinsmooh muscle ab ib presence (s) serum
74770-9,reporter information [ahrq]
74770-9,reporter iormatio pt [ahrq]
74770-9,reporter information [ahrq]
2333-3,gastrin [mass/volume] in serum or plasma
2333-3,gastrin [mass/volume] in ser or plasma
2333-3,gastrin serum in plasma [mass/volume] or plasma
2333-3,gastrin serpl-mcnc
2333-3,gastrin serum or plasma-mcnc
2333-3,serpl-mcnc gastrin
2333-3,gastrin [mass/vol]
2333-3,[mass/vl] astrn serum
2333-3,plasma [mass/vol] gastrin
19152-8,specimen specific gravity acceptable [presence] in urine
19152-8,urn speimen specific gravity cceptable [presence] in urine
19152-8,specimen specific gravity acceptable [ql] in urine
19152-8,acceptible sp gr ur ql
19152-8,sp acceptible gr ur ql
19152-8,accepile sp gr ur ql
19152-8,specimen specific gravity acceptable ql (u)
19152-8,speim secfic gavity acetable l (u)
19152-8,specimen specifc gravity (u) ql ccptable
22123-4,borrelia burgdorferi iga ab [presence] in cerebral spinal fluid
22123-4,borrelia burgdorferi ia ab abs pesence] incerebral pin flid
22123-4,ab iga borreliaburgdorfri [presence i cerebral spial b burg fluid
22123-4,b burgdor iga csf ql
22123-4,bbugr qual ql igacsf
22123-4,ql burgdor iga cerebrospinal fluid b cerebral spinal fluid
22123-4,b. burgdorferi iga ql (csf)
22123-4,burgdorferi b. iga ql (csf)
22123-4,b. burgdorferi iga (csf) ql
74575-2,pyruvate dehydrogenase e1 [enzymatic activity/mass] in tissue
74575-2,pyruvate dehydrgenase e1 [enzymtic in actiity/as] issue pdh
74575-2,pyruvate tissue e1 [enzymatic activity/mass] in dehydrogenase
74575-2,pdh e1 tiss-ccnt
74575-2,pt pdh e1 tis-cct
74575-2,tiss-ccnt e1 catalytic content pdh
74575-2,pyruvate dehydrogenase e1 (tiss) [catalytic activity/mass]
74575-2,prvate (tiss)[catlytic dehrogasee1 acivty/mass
74575-2,(tiss) dehydrogenase e1 pt pyrvate [catalytic actiit/mass]
94868-7,ganglioside gd1b igg ab [presence] in serum by immunoassay
94868-7,ganglioside gd1b igg ab gd1b [presence] in ser by immunoassay
94868-7,ganglioside gd1b igg ab [ql] in serum elisa by immunoassay
94868-7,gd1b gangl igg ser ql ia
94868-7,g1bgag ql ser igg random ia
94868-7,ia ganl ig ser ql gd1b
94868-7,ganglioside gd1b igg ia ql (s)
94868-7,ganglioside gd1b igg ia ql (s)
94868-7,gangloside neurology d1b iggia (s) ql
96489-0,neuronal intermediate filament light chain igg ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
96489-0,neuonal intermediate ilament light in igg ab [presence] cerebalspinal fluid b cell nif binding immnofluorescent assay
96489-0,euronal intermediate flament light cha igg ab [prsenc] in cerbraspinalfluid by cell bdingimunoflorescent asa
96489-0,nif-l igg csf ql cba ifa
96489-0,nif-l igg point in time csf ql cba ifa
96489-0,nif-l igg csf ifa cba ql
96489-0,neuronal intermediate filament light chain igg cell binding immunofluorescent assay ql (csf)
96489-0,neuronal intermediate filament light chain spinal fluid igg cell binding immunofluorescent assay ql (csf)
96489-0,neuronal intermediate filament binding chain igg cell light immunofluorescent assay ql (csf)
46970-0,bk virus dna [presence] in cerebral spinal fluid by naa with probe detection
46970-0,bk virus dna [presence] in cerebral spinal fluid by naa with probe detection
46970-0,bk virus dna [ql] in cerebral spinal probe by naa with fluid detection
46970-0,bkv dna csf ql naa+probe
46970-0,ligase chain reaction bkv dna csf ql naa+probe
46970-0,bkv microbiology dna cf ql naa+rbe
46970-0,bk virus dna naa+probe ql (csf)
46970-0,bk virus dna naa+probe ql (cerebrospinal fluid)
46970-0,microbiology ql virus dna naa+probe bk (csf)
73376-6,fluconazole induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73376-6,fluconazole induced cytometry diflucan igg ab [presence] in serpl by flow platelet (fc)
73376-6,random luconazole serum plateet igg ab [presence] in induced or plasm by flow cytomety (fc)
73376-6,fluconazole ind plt igg serpl ql fc
73376-6,flucnol ind pl ql iggserpl fc
73376-6,plt ind fluconazole igg serpl pl ql fc
73376-6,fluconazole induced platelet igg fc ql
73376-6,fluconazole induced ind plt igg platelet igg fc ql
73376-6,induced fluconazole platelet igg fc ql
21395-9,monocytes+macrophages/leukocytes in synovial fluid by manual count
21395-9,moncytesacrophages/leukoytes i synovialfluid b manu count
21395-9,monocytes+macrophages/leukocytes in synovial fluid count manual by
21395-9,monos+macros nfr snv manual
21395-9,nfr quantitative monos+macros snv manual
21395-9,monos+macros nfr snv manual mono
21395-9,monocytes+macrophages/leukocytes manual cnt (syn fld)
21395-9,monocytes+macrophages/leukocytes manual (syn cnt fld)
21395-9,monocytes+macrophages/leukocytes manual cnt (syn fld)
3310-0,alphaprodine [mass/volume] in urine
3310-0,alphaprodine [mass/volume] in urine
3310-0,alphaprodine nisentil [mass/volume] in urine
3310-0,alphaprodine ur-mcnc
3310-0,ur-cnc aphaprodie
3310-0,ur-mcnc alphaprodine
3310-0,alphaprodine (u) [mass/vol]
3310-0,alhaprodine (u) [mass/vol] ua
3310-0,[mass/vol] (u) alphaprodine
104410-6,hepatitis a virus igg ab [titer] in serum by immunoassay --2nd specimen
104410-6,hepatitis a virus igg ab [titer] immunoassay serum by in --2nd specimen
104410-6,hepatitis a second virus igg ab [titer] in serum by immunoassay --2nd specimen
104410-6,hav igg sp2 titr ser ia
104410-6,ia igg sp2 titr ser hav
104410-6,itr igg sp2 hav ser a random
104410-6,hav igg spec 2 ia (s) [titer]
104410-6,2 igg spec hav ia (s) enzyme immunoassay [titer]
104410-6,hav antibodies iggspec i 2 (s) ter]
3835-6,deprecated n-ethylnicotinamide [mass/volume] in urine
3835-6,deprecated nethlicotnamide in [mass/volme] urie
3835-6,ua deprcatd n-ethlnicotinmide in [mas/volume] uine
3835-6,deprecated nen ur-mcnc
3835-6,nen deprcted ne ur-cnc
3835-6,deprecated ur-mcnc nen
3835-6,n-ethylnicotinamide (u) [mass/vol]
3835-6,n-ethylnicotinaide (u) [mass/vol
3835-6,[mass/vol] (u n-ethylnicotiamide
104871-9,histoplasma capsulatum+blastomyces dermatitidis ag [presence] in urine by immunoassay
104871-9,hstoplama casulatum+blastomyc dermatitidis g urine [presence]n by immunoassy
104871-9,apsltum+blomyes hitoplasma dermatitidis ag [presence] in random urine by immunoassay
104871-9,h capsul h+ b derma ag ur ql ia
104871-9,h capsul h+ b derma ag ur presence ia
104871-9,h b dermatitidis capsu h+ dera a ur ql ia
104871-9,histoplasma capsulatum+blastomyces dermatitidis ag ia ql (u)
104871-9,ia capsulatum+blastomyces dermatitidis ag histoplasma ql (u)
104871-9,histoplasma dermatitidis capsulatum+blastomyces ag ia ql (u)
63531-8,centromere ab [titer] in cerebral spinal fluid by immunofluorescence
63531-8,centromere fluid [titer] in cerebral spinal ab by immunofluorescence
63531-8,centromere random fluid [titer] in cerebral spinal ab by immunofluorescence
63531-8,centromere ab titr csf if
63531-8,centromere ab if cerebrospinal fluid titr spinal flu
63531-8,cetroer ab immunoflour titr cerebrospinal fluid if
63531-8,centromere ab if (csf) [titer]
63531-8,cntromere ab (csf) if [titer]
63531-8,fluorescent antibody cetromerea (csf) if [titer]
70850-3,burkholderia mallei [presence] in specimen by organism specific culture
70850-3,specific malle [presence] n specie by organism urkholderia cultue
70850-3,burkholderia mallei [presence] in culture by organism specific specimen
70850-3,b mallei spec ql cult
70850-3,b spec mallei ql cult
70850-3,b mallei spec cult pt ql
70850-3,b. mallei org specific cx ql (specimen)
70850-3,b. mallei org specifi screen cx q (specien)
70850-3,b. mallei org specific cx point in time ql (specimen)
97294-3,oxazepam [presence] in cord tissue by confirmatory method
97294-3,serax [presence] oxazepam in cord tissue by confirmatory method
97294-3,oxazepam in [presence] cd tissueby confrmatorymethod lc/ms/ms
97294-3,oxazepam tissco ql cfm
97294-3,oxazepam tissco random ql cfm
97294-3,oxazepam tissco presence cfm
97294-3,oxazepam confirm ql (umb cord tissue)
97294-3,oxazepam confirm lc/ms/ms qlumb cord tissue)
97294-3,ql confirm oxazepam (umb cord confirmation tissue)
41123-1,toxoplasma gondii hs ab [units/volume] in serum
41123-1,toxplasma [unis/volume] hs ab gonii in seum
41123-1,toxoplasma gondii hs ab [units/volume] toxo in serum
41123-1,t gondii hs ab ser-acnc
41123-1,t gondii hs ab serum-acnc sr
41123-1,godii t hs ab abs ser-cnc
41123-1,t. gondii hs ab qn (s)
41123-1,t. (s) hsab q gonii
41123-1,ab gondii hs t. pt qn (s)
82191-8,herpes simplex virus 2 dna [presence] in cerebral spinal fluid by naa with non-probe detection
82191-8,herpes simplex virus 2 dna [ql] in cerebral spinal fluid by naa with non-probe detection
82191-8,herpes simplex virus 2 dna [presence] in naa spinal fluid by cerebral with non-probe detection
82191-8,hsv2 dna csf ql naa+non-probe
82191-8,hsv2 naa+non-prbe csf spinal fluid ql da
82191-8,hsv2 csf dna ql naa+non-probe ligase chain reaction
82191-8,hsv 2 dna naa+non-probe ql (csf)
82191-8,sv 2 dna aa+on-probe ql (csf)
82191-8,dnanaa+non-prbe id hsv ql(cerebrospinal fluid)
61058-4,alpha-phenyl-2-piperidine acetate [presence] in urine
61058-4,alphaphenyl-2-piperidine pr acetate [presnce] in urine
61058-4,alpha-pheny-2-pperidine [presece] acetae in urine
61058-4,ppaa ur ql
61058-4,ppaa ur ql
61058-4,ql ur ppaa
61058-4,alpha-phenyl-2-piperidine acetate ql (u)
61058-4,point in time alpha-phenl--piperidieacetate l (u)
61058-4,lpha-phenyl-2-piperidine phenylpiperidine acetic acid acetate ql (u)
26729-4,ovary igg ab [titer] in serum by immunofluorescence
26729-4,ovary by b [titer in ser igg immunofuoresnce
26729-4,oary igg ab [titr imunfluorescence serum trf by in
26729-4,ovary igg titr ser if
26729-4,ovary titr igg ser if
26729-4,ovary igg titr titered serum if
26729-4,ovary igg if (s) [titer]
26729-4,ovry igg if (s) [titer]
26729-4,ovary gg if (s) immunofluor titer]
106916-0,basophils/cells in bronchoalveolar lavage
106916-0,in bsophils/cells broncoalveolar lavag cellularity
106916-0,basophils/cells in bronchoalveolar lavage
106916-0,basophils nfr bal
106916-0,nfr basophils bal
106916-0,basophils hematology/cell counts nfr bal
106916-0,basophils/cells (bal)
106916-0,(bal) basophils/cells
106916-0,(bal) basophils/cells
29725-9,leptospira interrogans sv bulgarica ab [presence] in serum by agglutination
29725-9,leptospira interans svbulgaricaab [presenc] serum in by aggltinton
29725-9,leptospira interrogans sv bulgarica antibody [ql] ab in serum by agglutination
29725-9,l inter bulgar ab ser ql aggl
29725-9,l inter bulgar ab ser ql aggl
29725-9,l interbulga ab ser ql ggl
29725-9,l. interrogans sv bulgarica ab aggl ql (s)
29725-9,l. interogans sv bulgarica ab aggl presence random (s
29725-9,ab interrogans sv bulgarica l. aggl ql (s)
31214-0,actinobacillus pleuropneumoniae serotype 5 ab [presence] in serum
31214-0,sertype contagious swine pleuropneumonia pleupneumonia actnobacillus 5 ab [presence] in serum
31214-0,antibodies actinobacillus pleuropneumoniae ab 5 serotype [ql] in serum
31214-0,a pleuropn 5 ab ser ql
31214-0,5 pleuropn a ab pr serum ql
31214-0,a pleuropn 5 a ser ql
31214-0,a. pleuropneumoniae type 5 ab ql (s)
31214-0,a. peuropneumoniaetype5 bql (s)
31214-0,a. pleuropneumoniae (s) 5 ab ql type
95913-0,coccidioides sp dna [presence] in tissue by naa with probe detection
95913-0,coccidioides spda [presece] in tissue by detetion withproe naa
95913-0,coccidioies sp dna tissu in [presenc] b naa wih prob deectio
95913-0,coccidioides dna tiss ql naa+probe
95913-0,dna coccidioides tiss ql naa+probe
95913-0,coccidioides dna naa+probe ql tiss
95913-0,coccidioides sp dna naa+probe ql (tiss)
95913-0,coccidioides sp dna naa+probe ql (tiss) lcr
95913-0,coccdoidessp dna amplif ql naa+probe (tiss)
70181-3,alpha aminobutyrate [moles/volume] in serum or plasma from fetus
70181-3,2-aminobutyric acid seum aminobutyrate [moles/volum]in alpha or plasm from feus
70181-3,plasm aminoutyrate [mole/volume] in ser or alph from fetus
70181-3,a-aminobutyr serpl fetus-scnc
70181-3,fetus-scnc serl a-amibutyr
70181-3,chemistry a-aminobutyr serum or plasma fetus-scnc
70181-3,alpha aminobutyrate (s/p fetus) [moles/vol]
70181-3,alpha fetus) (s/p aminobutyrate [moles/vol]
70181-3,[mols/vol] serpl miobutyrate (s/p fetus) alpha
88579-8,mycoplasma pneumoniae dna [presence] in lower respiratory specimen by naa with probe detection
88579-8,myoplasma pneumoniae dn presene] in lower respiratory specimen by naait prbe detection
88579-8,qualitative mycolama pneumoniae da [prsence] n lowe rspiratory speimen by naaith prbe detectio
88579-8,m pneumo dna lower resp ql naa+probe
88579-8,m lower low dna pneumo resp ql naa+probe
88579-8,m pneumo nucleic acid sequence based analysis dna lower resp ql naa+probe
88579-8,m. pneumoniae dna naa+probe ql (lower resp)
88579-8,m. pneumoniae dna (lower ql naa+probe resp)
88579-8,pneumoniae id m. dna naa+probe ql (lower resp)
22386-7,legionella pneumophila 3 igm ab [titer] in serum
22386-7,legionella pneumophila infectiousdisease 3 igm ab [titer] in ser
22386-7,legionella [titer] 3 igm ab pneumophila in serum
22386-7,l pneumo3 igm titr ser
22386-7,ser peumo3 pneum im titr l
22386-7,l pneumo3 igm titr ser
22386-7,l. pneumophila 3 igm (s) [titer]
22386-7,l peumophla 3 igm dilution factor (s) [titer]
22386-7,l. pneumophila 3 [titer] (s) igm
23238-9,mycobacterium avium ss avium serotype [identifier] in specimen
23238-9,mycobacterium avium ss avium serotype [identifier] specimen unspecified in
23238-9,mycobacterium aviumss vium serotype [identifi] in specimn
23238-9,m avium av sertyp spec
23238-9,m spec av sertyp avium
23238-9,mycobacterium avium m aviu av spec sertyp
23238-9,m. avium ss avium serotype nom (specimen)
23238-9,m. avm ss avium nom ssp serope (speimn)
23238-9,m. avium avium ss serotype nom (specimen) acid fast bacilli
88116-9,escherichia coli gene panel - specimen by naa with probe detection
88116-9,schrichia coli ge panl na specimen by - with proedetectio
88116-9,eshericha coli gene pnel pan - specimen by naa wth probedetection
88116-9,ec gene pnl spec naa+probe
88116-9,ec en pnl specnaa+probe
88116-9,spec gene pnl ec naa+probe
88116-9,e. coli gene panel naa+probe (specimen)
88116-9,e.coli gene anel na+probe amplif (pecimn)
88116-9,e.coligene naat naa+pobe panel (specien)
55887-4,3-hydroxyanthranilate [moles/volume] in serum or plasma
55887-4,in [molesvolume] 3hydrxanthanilat seum or pasm
55887-4,3-hydroxyanthralate[ols/volume] sr ineru or plas
55887-4,3oh-anthranilate serpl-scnc
55887-4,serpl-scnc 3oh-anthranilate
55887-4,epl-scnc 3oh-anthranilate
55887-4,3-hydroxyanthranilate [moles/vol]
55887-4,[moles/vol] 3-hydroxyanthranilate
55887-4,point in time 3-hydroxyanthranilate [moles/vol]
56902-0,amylase/creatinine [ratio] in 24 hour urine
56902-0,amylase/creatinine hour in 24 [ratio] urine
56902-0,amylase/creatinine [atio]in24 hour urin 24 hours
56902-0,amylase/creat 24h ur-rto
56902-0,chemistry amylase/creat ur-rto 24h
56902-0,24h amylase/creat ur-rto
56902-0,amylase/creatinine (24h u) [ratio]
56902-0,(24h amylase/creatinine u) [ratio]
56902-0,amylase/creatinine (24h [ratio] u)
62568-1,deprecated phenx measure - cancer - personal and family history
62568-1,deprecated phenx measure - cancer measure - cancer personal family hx - personal and family history
62568-1,cancer phenx measure - deprecated - personal and family history pan
59714-6,nitrous oxide [mass/volume] in blood
59714-6,itrus oxide drug/toxicology [mass/volme] in blood
59714-6,nitrous oxide [mass/voume] in bood
59714-6,n2o bld-mcnc
59714-6,bld-mcnc n2o
59714-6,n2o bd-mnc
59714-6,nitrous oxide (bld) [mass/vol]
59714-6,nitros [massvo] bld) oxide
59714-6,[mass/vol] drugs oxide (bld) nitrous
76592-5,staphylococcus aureus sau3ai gene [#/mass] in xxx.tissue by naa with probe detection
76592-5,staphlococcus aureus number content sa3a gne [#/mass] n xxx.isue by naa wih prbe dtection
76592-5,sthylococcus xxx.tissue sau3ai gene [#mss] in aurus b naa with proe detcton
76592-5,s aureus sau3ai xxx.tiss naa+probe
76592-5,s ures sau3a xxx.is microbiology naa+probe
76592-5,s aureu sau3axxx.tss naarobe
76592-5,s. aureus sau3ai gene naa+probe (unsp tissue) [#/mass]
76592-5,s. aureus sau3ai (unsp naa+probe gene tissue) [#/mass] probe with target amplification
76592-5,s eena+prob au3ai aureus (unsp tissue) strand displacement amplification [#/mas]
80146-4,tricyclic antidepressants [presence] in blood by screen method
80146-4,tricyclic antiepressants presece] scrn by blood in screen method
80146-4,trcyclic antdepressans [presence] method bood by sceen in
80146-4,tricyclics bld ql scn
80146-4,ql bld tricyclics scn
80146-4,tricylics sc bldql antidepressant
80146-4,tricyclic antidepressants screen ql (bld)
80146-4,tricyclcantidepresnt screen ql (blood)
80146-4,tricyclic scr antidepressants screen (bld) ql
16116-6,tetrahydrocortisone [mass/time] in 24 hour urine
16116-6,tetrahydrocortisone qnt [mass/time] in 24 hour urine
16116-6,tetrahydocortisone i24 [mas/te] hour urne
16116-6,thcortisone 24h ur-mrate
16116-6,thcortisone 24ur-mrate
16116-6,thcortisne 24h ur-mrate 1 day
16116-6,tetrahydrocortisone (24h u) [mass/time]
16116-6,drug/toxicology u) (24h tetrahydrocortisone [mass/time]
16116-6,tetrahydrocortisone 24hr (24h u) [mass/time]
93972-8,acetaminophen-cysteine adduct [moles/volume] in serum or plasma
93972-8,acetaminophen-cysteine adduct [moles/volume] in serum or plasma
93972-8,serum adduc [mole/volume] in aceaminophen-steie r lasma
93972-8,apap-cysteine serpl-scnc
93972-8,apap-cysteine serpl-scnc
93972-8,serpl-scnc apap-cysteine
93972-8,acetaminophen-cysteine adduct [moles/vol]
93972-8,acetaiophen-cysteine quant addut [mols/vol]
93972-8,acetaminophen-cysteine adduct [moles/vol] apap
34711-2,cholinesterase [presence] in serum or plasma
34711-2,cholinesterase [presence] plasma serum or in
34711-2,cholinesterase [presence] in serpl
34711-2,cholinesterase serpl ql
34711-2,cholinestase ql serpl benzoylcholinesterase
34711-2,cholinesterase serpl presence
34711-2,cholinesterase ql
34711-2,cholinesterase ql pseudocho
34711-2,ql cholinesterase
56620-8,elastase ab [units/volume] in serum by immunoassay
56620-8,elastase serum unitsvolume] ab by immnoassy
56620-8,antibodies elastase ab [units/volume] in serum by immunoassay
56620-8,elastase ab ser ia-acnc
56620-8,suds elastase ab serum ia-acnc
56620-8,elastase serum ab ia-acnc
56620-8,elastase ab ia qn (s)
56620-8,elastase ab ia qn arbitrary concentration (s)
56620-8,elstase ab ia qn ela (s)
32853-4,neuronal ab [units/volume] in serum by immunoassay
32853-4,neuronal ab units/volume] isrumbyimmunoassay
32853-4,in ab [units/volume] neuronal serum by immunoassay
32853-4,neuronal ab ser ia-acnc
32853-4,nuroal ab ser ia-acn
32853-4,neronl a serum ia-acnc
32853-4,neuronal ab ia qn (s)
32853-4,qn ab ia neuonal anti )
32853-4,neuronal ab ia iaa n (s)
3396-9,cocaine [mass/volume] in serum or plasma
3396-9,cocaine [mass/lume] in ser or serpl lasma
3396-9,ccaine mass/voue] plasma serum o in
3396-9,cocaine serpl-mcnc
3396-9,cocine serl-mcn
3396-9,cocane srp-mcnc
3396-9,cocaine [mass/vol]
3396-9,cocaie [mass/vol] qnt
3396-9,[mas/vol] ccaine
101406-7,sudan virus rna [presence] in blood by naa with probe detection
101406-7,sudan virus rna [ql] i lood by nawth probedeectin
101406-7,sudan virus rna probe amp [presence] bld in by naa with probe detection
101406-7,sudan virus rna bld ql naa+probe
101406-7,ql virus na blood sudan naa+probe
101406-7,virs sudan na ld qlnaa+probe
101406-7,sudan virus rna naa+probe ql (bld)
101406-7,udan whole blood virus rna naa+probe ql (bld)
101406-7,sudan virus rn naa+probe ql (bld)
97858-5,coccidioides sp ab [titer] in specimen by complement fixation
97858-5,coccdioide by [ier] in specimen random spab complement fixatin
97858-5,coccidioides sp ab [titer] in specimen by complement fixation
97858-5,coccidioides ab titr spec cf
97858-5,titr ab coccidioides spec cf
97858-5,cocidiodes ab aby titr spec cf
97858-5,coccidioides sp ab cf (specimen) [titer]
97858-5,coccdioids spa cf (speimen) [titer]
97858-5,coccidioids sp [tite] cf (specimen) a
9359-1,tacrine [mass/volume] in serum or plasma
9359-1,drug/toxicology tacrine plasma in serum or [mass/volume]
9359-1,tacrine serumor [ms/volume]i plasm
9359-1,tacrine serpl-mcnc
9359-1,tacrine serpl-mcnc
9359-1,tacrine drugs serpl-mcnc
9359-1,tacrine [mass/vol]
9359-1,[mass/vol] tacrine
9359-1,[mass/vol] serum tacri
103675-5,phosphorylated tau 181 [mass/volume] in plasma by immunoassay
103675-5,[mass/volume] tau18 hophorylted in plasma by quan immuoassay
103675-5,phosphorylated tau 181 [mass/volume] in plasma by plasma immunoassay
103675-5,p-tau181 plas ia-mcnc
103675-5,ia-mcnc plas p-tau181
103675-5,ptau1 plasma i-mcn
103675-5,phosphorylated tau 181 ia (p) [mass/vol]
103675-5,phosphorylate tau (p) ia 8 quan [mass/vl]
103675-5,phosphrylatedtu [mass/vol] ia (p) 81
86861-2,dengue virus 4 neutralizing antibody [titer] in specimen by neutralization test
86861-2,dengue virus 4 neutralizing test antibodies [titer] in specimen by neutralization antibody
86861-2,dengue virus 4 neutralizing antibody [titer] ser virus neutralization in specimen by neutralization test
86861-2,denv4 nab titr spec nt
86861-2,denv4 nab titr spec nt
86861-2,denv4 nab titr pc nt
86861-2,denv 4 neut ab neut test (specimen) [titer]
86861-2,antibody denv 4 ab neut neut test (specimen) [titer]
86861-2,neu 4 denv b nut st (specmen) [titer]
80545-7,posaconazole [mass/mass] in hair
80545-7,posaconazole qnt [mass/mass] hair in
80545-7,i [mass/mass] posaconazole hair
80545-7,posaconazole hair-mcnt
80545-7,posaconazole hair-mcnt
80545-7,random hair-mcnt posaconazole
80545-7,posaconazole (hair) [mass/mass]
80545-7,(hair) point in time posaconazole [mass/mass]
80545-7,posaconazole (hair) [mass/mass]
23230-6,mareks disease virus ag [presence] in feather by immune diffusion (id)
23230-6,diffuio diseas virus ag [presence] in feather by immune mareks id)
23230-6,maeks disease virus ag [presenc] in ether by immune vet dffuson (id)
23230-6,gahv ag feather ql id
23230-6,gahv ag feather veterinary ql id
23230-6,ag gahv feather qlid screen
23230-6,mareks disease virus ag immune diff ql (feather)
23230-6,infectious disease ql disease virus ag immune diff mareks (feather)
23230-6,marek dsease virus agimmunediff presence father)
7901-2,helicobacter pylori iga ab [units/volume] in serum
7901-2,helicobacter pylori ig seum [units/volume] in universallaborders ab
7901-2,helicobacter plori iga ab point in time [units/volume] n ser
7901-2,h pylori iga ser-acnc
7901-2,pylori h iga ser-acnc aby
7901-2,ser-acnc pylori iga quantitative h
7901-2,h. pylori iga qn (s)
7901-2,h. pylori iga qn (s) immunoglobulin a
7901-2,h. qn iga pylori (s)
26060-4,european tick borne encephalitis virus igm ab [units/volume] in serum by immunoassay
26060-4,europan tick brne encephalitis ab ig virus [units/volume]in ser byimmunoassa
26060-4,european ab borne encephalitis virus igm tick [units/volume] in serum quan by immunoassay
26060-4,tbev igm ser ia-acnc
26060-4,bev igm ser ia-acnc
26060-4,igm tbev ser ia-acnc
26060-4,european tick borne encephalitis virus igm ia qn (s)
26060-4,(s) tick borne encephalitis virus igm ia qn european
26060-4,european tick borne encephalits virus igm ia elisa qn(s)
79157-4,cold agglutinin [titer] in serum by 22 degree c incubation --1 hour post incubation
79157-4,cold agglutinin [titer] in serum by 22 degree c incubation --1 agglutination hour post incubation
79157-4,titre cold agglutinin [titer] in post by 22 degree c incubation --1 hour serum incubation
79157-4,ca 1h p inc titr ser 22 deg c inc
79157-4,a 1h p 22deg titr ser ic c inc
79157-4,ca 1h p inc titr ser 22 deg c inc
79157-4,cold agglutinin 1 hr post incubation 22 degree c incubation (s) [titer]
79157-4,cold agglutinin 1 hr post incubation 22 degree c incubation (s) [titer]
79157-4,cld agglutinin hr degree incubatio 22 post c incuation s) [titer]
31820-4,equine infectious anemia virus ag [presence] in specimen
31820-4,equine equin anemia infecious virus ag presnce] inecmen
31820-4,equine specimen anemia virusag [presence in to be specified in another part of the message infectiou
31820-4,eiav ag spec ql
31820-4,eiv ql agsec
31820-4,eiav miscellaneous spec ag ql
31820-4,equine infectious anemia virus ag ql (specimen)
31820-4,equine (specimen) anemia virus ag presence infectious
31820-4,equine inectious anemia virs ag ql(specimen)
38753-0,tetrachloroethane [mass/volume] in air
38753-0,tetrachlroethane ar i [mass/volume] drug/toxicology
38753-0,tetrachloroethane [mass/volume] air in
38753-0,tetrachloroethane air-mcnc
38753-0,air-mcnc tetrachloroethane
38753-0,"tetrachloroethane 1,1-dichloro-2,2-dichloroethane air-mcnc"
38753-0,tetrachloroethane (air) [mass/vol]
38753-0,(air) tetrachloroethane [mass/vol]
38753-0,[mass/vol] (air) tetrachoroethane
17741-0,trichlorophenoxyacetate [mass/volume] in serum or plasma
17741-0,trichlorophenoxyacetate plasma in serum or [mass/volume]
17741-0,trichlorophenoyacetat [mass/volume] o seum n plasma
17741-0,tcpa serpl-mcnc
17741-0,tcpserplmcnc tcpa
17741-0,tcpa serpl-mcnc
17741-0,trichlorophenoxyacetate [mass/vol]
17741-0,trichlorophenoxyacetate [mas/vol]
17741-0,[as/ol] tichloophenoxyacetate pt
17535-6,ribonucleoprotein extractable nuclear ab [presence] in serum by immunofluorescence
17535-6,ribonucleoprotein extractable serum ab [ql] in nuclear by immunofluorescence
17535-6,ribonucleoprotein extrctble nuclear ab [presec] in rum by imunoflorescence
17535-6,ena rnp ab ser ql if
17535-6,ab rnp ena ser ql if serum
17535-6,ena rnp ab ser fluorescent antibody ql if
17535-6,ribonucleoprotein extractable nuclear ab if ql (s)
17535-6,ql rbonucleopotin ql clear a if extractale (s)
17535-6,ribonuceprotein ena rnp extracablenucler a if presence (s)
9412-8,leucine [moles/volume] in cerebral spinal fluid
9412-8,leucine [moles/volume] in cerebral spinal substance concentration fluid
9412-8,leucine [moles/volume] cerebral in spinal fluid
9412-8,leucine csf-scnc
9412-8,lucine cs-scnc
9412-8,csf-scnc leucine
9412-8,leucine (csf) [moles/vol]
9412-8,[oles/vol] (csf) lucne
9412-8,(csf)[moles/vo] cerebral spinal fluid lucne
44485-1,herpes simplex virus 2 [presence] in vaginal fluid by organism specific culture
44485-1,herpes simpex vrus 2 presence] in vainal fluid pr by rganism specific culture
44485-1,herpessimplex virus 2 [presenceinvagial fluid vag fld orgnism specific cultre
44485-1,hsv2 vag ql cult
44485-1,hsv2 genital vaginal vag ql cult
44485-1,ql vag hsv2 cult
44485-1,hsv 2 org specific cx ql (vag fld)
44485-1,hsv 2 org specifi qual cx presence (vag fld)
44485-1,hsv 2 org specifc cx ql (vag fld) hsv
3980-0,probenecid [mass/volume] in urine
3980-0,probenecid drugs urine in [mass/volume]
3980-0,probenecid in [mass/volume] urine
3980-0,probenecid ur-mcnc
3980-0,ur-mcnc probenecid
3980-0,ur-mcnc probenecid
3980-0,probenecid (u) [mass/vol]
3980-0,drug/toxicology (u[mass/vol] probenecid
3980-0,probenecid (u) [mass/vol]
35208-8,estrone (e1) [mass or moles/volume] in serum or plasma
35208-8,estrone (e1) [mass moles/volume] or serum or plasma in serum or plasma
35208-8,estrone (e1) [mass or moles/volume] in seu or plas
35208-8,estrone serpl-mscnc
35208-8,ser or plasma estroneserpl-mscnc
35208-8,estrone serum or plasma-mscnc qnt
35208-8,e1 [mass or moles/vol]
35208-8,e1 [mass moles/vol] or
35208-8,e1 moles/vol] or [mass
62354-6,chromosome analysis.metaphase panel - amniotic fluid by fish
62354-6,chromosome analysis.metaphase panel - amniotic fluid by amn fish
62354-6,chromosome fish panel - amniotic fluid cytogenetics by analysis.metaphase
62354-6,chrom analy metaphase pnl amn fish
62354-6,fish analy metaphase pnl amn chom
62354-6,fish panel.hl7.cytogen analy metaphase pnl amn chrom
62354-6,chr analysis.metaphase panel fish (amn fld)
62354-6,chr anaysis.metaphase fld) fish (am panel
62354-6,chr fish panel analysis.metaphase (amn fld)
59693-2,hydroxytriazolam [mass/volume] in body fluid by confirmatory method
59693-2,hydrotrazola [mass/vlume] in bodyflid by confirmatory method
59693-2,hydroxytriazolam [mass/volume] in body fluid by confirmatory method
59693-2,oh-triazolam fld cfm-mcnc
59693-2,fld oh-triazolam cfm-mcnc
59693-2,confirmation oh-triazolam fld cfm-mcnc
59693-2,hydroxytriazolam confirm (body fld) [mass/vol]
59693-2,hydroxytriazolam confirm random (body fld) [mass/vol]
59693-2,hydroxytriazolam confirm fld) (body [mass/vol]
59754-2,titanium [mass/mass] in hair
59754-2,titanium drug/toxicology [mass/mass] hair in
59754-2,titanium [mass/mass] in hair
59754-2,titanium hair-mcnt
59754-2,hair-mcnt titanium
59754-2,ttanium hir-mcnt
59754-2,titanium (hair) [mass/mass]
59754-2,titanim (hair) [mas/mass]
59754-2,(hair) mass content titanium [mass/mass]
18200-6,blastomyces dermatitidis igm ab [presence] in serum
18200-6,ab dermiidis igm blastomyces [presence] serum
18200-6,blastomyces dermatitidis [presence] ab igm in serum
18200-6,b dermat igm ser ql
18200-6,ser dermat igm b ql
18200-6,b dermat ser igm ql
18200-6,b. dermatitidis igm ql (s)
18200-6,ql dermatitidis igm b. (s) aby
18200-6,b. dermattidis igm ql (s)
75080-2,n-acetyl-l-aspartate [moles/volume] in serum or plasma
75080-2,serplas n-acetyl--asparte plasm in ser or [oles/volume
75080-2,n-acetyl-laspartate [moles/volume] in serm or plasma
75080-2,n-ac-l-asp serpl-scnc
75080-2,serpl-scnc n-ac-l-asp serp
75080-2,serum or plasma-scnc -ac-l-asp
75080-2,n-acetyl-l-aspartate [moles/vol]
75080-2,[mol/vol] nacetyl-l-aspatate
75080-2,[moles/vol] n-acetyl-l-apartte
25731-1,plasmodium sp ab [titer] in serum by immunofluorescence
25731-1,in anti sp ab [titer] plasmodium serum by immunofluorescence
25731-1,plasmodium sp immunofluorescence ab [titer] in serum by immunofluorescence
25731-1,plasmodium ab titr ser if
25731-1,ab plasmodium titr ser if
25731-1,plasmodium if titr ser trf ab
25731-1,plasmodium sp ab if (s) [titer]
25731-1,lasmdum species sp (s) if a [titer]
25731-1,plsmodium sp a if (s) [titr]
14807-2,lead [moles/volume] in blood
14807-2,blood [moles/volum] drugs in lad
14807-2,lead [moles/volume] in bld
14807-2,lead bld-scnc
14807-2,lead blood-scnc quant
14807-2,bld-scnc whole blood lead
14807-2,lead (bld) [moles/vol]
14807-2,lead (ld) [molesvol]
14807-2,lead [mols/vol] (bld)
16176-0,bartonella quintana igg ab [units/volume] in cerebral spinal fluid
16176-0,bartonella quintana igg ab [units/volume] in cerebral spinal b quintana fluid
16176-0,bartonella quintana igg ab [units/volume] spinal cerebral in fluid
16176-0,b quintana igg csf-acnc
16176-0,igg quintana b cerebrospinal fluid-acnc
16176-0,b igg quintana csf-acnc
16176-0,b. quintana igg qn (csf)
16176-0,b. qunan igg qn (csf)
16176-0,b. uitna igg qn (csf)
44084-2,fatty acids pattern [interpretation] in serum or plasma
44084-2,fatty acids pattern [interpretation] in chemistry serum or plasma
44084-2,fatty acids pattern [interpretation] serum in or plasma
44084-2,fatty acids pattern serpl-imp
44084-2,fatty acids serpl-imp interpretation pattern
44084-2,serpl-imp acids pattern fatty
44084-2,fatty acids pattern [interp]
44084-2,fatty plas pattern[intep] acids
44084-2,pattrn fattyacids [interp]
88156-5,microscopic observation [identifier] in amniotic fluid by acid fast stain
88156-5,microscopic observation [identifier] in amniotic fluid by acid fast stain acd
88156-5,icroscopc obervation [dentifie] in amnioti luid identity or presence by acid fast stain
88156-5,acid fast stn amn
88156-5,acid faststn amn
88156-5,acid identity or presence fast stn amn
88156-5,microscopic observation acid fast stain nom (amn fld)
88156-5,microscopic observation cid fasttain nom (amn fld) nominal
88156-5,microscopic observation acid stain fast nom (amn fld)
6547-4,rotavirus identified in specimen by organism specific culture
6547-4,rotavirus specimen in identified by organism specific culture
6547-4,rotavirus identified specimen in by organism specific infectiousdisease culture
6547-4,rv spec cult
6547-4,rv cult miscellaneous spec
6547-4,rv cult spec
6547-4,rotavirus identified org specific cx nom (specimen)
6547-4,rotairus idntified org specifi cx nom id (specimen)
6547-4,rotavirus identified org specfc cx (specimn) nom
11208-6,atrial natriuretic factor [mass/volume] in plasma
11208-6,nariuretic fact atial actor [mass/volume] inplasma
11208-6,in natriuretic factor [mass/volume] atrial plasma
11208-6,anf plas-mcnc
11208-6,plas-mcn anf quantitative
11208-6,plas-mcnc anf
11208-6,atrial natriuretic factor (p) [mass/vol]
11208-6,atrial natriuretic factor (p) [mass/vol]
11208-6,trial natriuretic factor [massvl] (p) qnt
5847-9,herpes simplex virus 2 ag [presence] in genital specimen by immunofluorescence
5847-9,hrpes simplex virus ag [presence] in genital specimen byimmunfluescence
5847-9,herpes simplex virus 2 ag [presence] in immunofluorescence specimen by genital
5847-9,hsv2 ag genital ql if
5847-9,if gental immune fluorescence q hsv2ag
5847-9,ag hsv2 gnital ql if
5847-9,hsv 2 ag if ql (genital specimen)
5847-9,hsv antigen if ag 2 presence (genital specimen)
5847-9,hsv 2 infectious disease ag if ql (genital specimen)
43620-4,actinomyces israelii ab [presence] in serum
43620-4,actinomes isreli serum point in time [presence] in ab
43620-4,ab israelii actinomyces [presence] in serum
43620-4,a israelii ab ser ql
43620-4,a serum ab israelii ql
43620-4,a ser ab israelii sr ql
43620-4,a. israelii ab ql (s)
43620-4,a. israelii random a ql (s)
43620-4,israelii a. ab ql (s)
54040-1,hedis 2009 codes to identify ldlc screening (cdc-h)
54040-1,identifyldlc 2009 coesto eds screenng (cdch) panel.hedis
54040-1,hedis asympt 2009 codes to identify ldlc screening (cdc-h)
54040-1,hedis 2009 cdc-h
54040-1,cdch 009 panel hedis
54040-1,hedis 2009 asymptomatic cdc-h
54040-1,hedis 2009 codes to identify ldlc screening (cdc-h)
54040-1,(cdc-h) code to pnl dentiyldl screenng hedis2009
54040-1,hedis 2009 codes screening identify point in time ldlc to (cdc-h)
29586-5,immunoelectrophoresis panel - serum
29586-5,serum immunoelectrophoresis panel - serum
29586-5,immunoelectrophoresis panel - chemistry serum
29586-5,iep pnl ser
29586-5,iep pnl pn iep serum
29586-5,iep pnl serum
29586-5,immunoelectrophoresis panel (s)
29586-5,(s) panel immunoelectrophoresis
29586-5,immunoelectophoresispan (s) chemistry
38713-4,n-nitrosomorpholine [mass/volume] in air
38713-4,n-ntromorholin air in [mass/lume]
38713-4,n-nosomorpholine [ass/volume] in air
38713-4,nmor air-mcnc
38713-4,air-mcnc nmor
38713-4,nitrosomorpholine nmor air-mcnc
38713-4,n-nitrosomorpholine (air) [mass/vol]
38713-4,n-nitrosmorpholin pt ir) [massvl]
38713-4,[mass/vol] (air) quant n-nitrosomorpholine
44279-8,16-alpha hydroxypregnenolone/16-alpha hydroxydehydroepiandrosterone [mass ratio] in urine
44279-8,in hydroxypregnenolone/16-alpha hydroxydehydroepiandrosterone [mass chemistry ratio] 16-alpha urine
44279-8,16-aph hyroxypregnenolone/1-aph point in time hydroxydehydroepiandrosterone [mas ratio]i urine
44279-8,16a oh-preg/16a oh-dhea ur
44279-8,16a oh-preg/16a ur oh-dhea
44279-8,16a oh-preg/16a ur oh-dhea
44279-8,16-alpha hydroxypregnenolone/16-alpha hydroxydehydroepiandrosterone (u) [mass ratio]
44279-8,16-alpha hydroxypregnenolone/16-alpha (u) hydroxydehydroepiandrosterone [mass ratio] chemistry
44279-8,16-alpha ratio] hydroxydehydroepiandrosterone (u) [mass hydroxypregnenolone/16-alpha quantitative
2242-6,deprecated estradiol free [mass/volume] in serum or plasma
2242-6,serumor estradiol free[mass/vlume] n deprecated plas
2242-6,deprecated estradiol free [mass/volume] in estradiol free serum or plasma
2242-6,deprecated estradiol free serpl-mcnc
2242-6,deprecated estradiol serpl-mcnc free level
2242-6,erecated serum or plasma-mcc free esradiol
2242-6,free e2 [mass/vol]
2242-6,free e2 [mass/vol]
2242-6,free e2 [mass/vol] estradiol free
72806-3,jwh-073 carboxylated (synthetic cannabinoid metabolite) [mass/volume] in urine by confirmatory method
72806-3,jwh-073 arboxylate (synthetic cannainoid metaboi) [ms/voume] n urineby cnfirmatory metod
72806-3,jwh073 lc/ms/ms meabolit) (synthetic cannaino caboxyated mass/volume] i urine bycofrmaory method
72806-3,jwh-073 carboxylated ur cfm-mcnc
72806-3,conf jwh-073 cfm-mcnc ur carboxylated
72806-3,jwh-073 carboxylated ur cfm-mcnc
72806-3,jwh-073 carboxylated confirm (u) [mass/vol]
72806-3,jwh-073 confirm carboxylated synthetic cannabinoid () [ass/ol]
72806-3,jwh-073 carboxylated confirm (u) [mass/vol]
75113-1,alpha linolenate (c18:3w3) [entitic substance] in red blood cells
75113-1,alpha linolenate (c18:3w3) [entitic substance] in red blood cells
75113-1,alpha linolenate (c18:3w3 lood substance] in red [ntitic alpha linolenic acid cell
75113-1,a-linolenate entsub rbc
75113-1,a-linolenate entsub erythrocytes rbc
75113-1,rbc entsub a-linolenate
75113-1,alpha linolenate (c18:3w3) (rbc) [entitic substance]
75113-1,alpha linolenate (c18:3w3) (rbc) [entitic substance]
75113-1,alpha substance] (c18:3w3) (rbc) [entitic linolenate
23582-0,rabbit hemorrhagic disease virus ag [presence] in tissue by immune stain
23582-0,rabbit hemorrhagic disease virus ag [ql] in microbiology tissue by immune stain
23582-0,rabbit hemorrhagic disease ag virus [presence] in tissue by immune stain
23582-0,rhdv ag tiss ql imstn
23582-0,rhdv ag ts presence imstn
23582-0,rhdv tiss rabbit hemorrhagic disease ag presence imstn
23582-0,rabbit hemorrhagic disease virus ag immune stain ql (tiss)
23582-0,rabbit veterinary hemorrhagic disease virus ag immune stain ql (tiss)
23582-0,rabbit hemorrhagic disease virus ag immune stain ql ql (tiss)
25133-0,sarcosine/creatinine [molar ratio] in urine
25133-0,sarcosine/creatinine in ratio] [molar urine
25133-0,sarcosine/creatinine [molar substance concentration ratio ratio] in urine
25133-0,sarcosine/creat ur-srto
25133-0,ur-srto sarosine/creat sar
25133-0,u-srto sarcosinecreat
25133-0,sarcosine/creatinine (u) [molar ratio]
25133-0,(u) sarosine/cretinin [molar ratio]
25133-0,[molar (u) sarcosine/creatinine creat ratio]
3022-1,deprecated thyroxine free index in serum or plasma
3022-1,deprecated thyroxie free indexn ser or lasma
3022-1,deprcate thyroxine free index n ser or sr plasma
3022-1,deprecated fti serpl-mcnc
3022-1,dereated point in time fti erpl-mcnc
3022-1,serpl-mcnc fti deprecated
3022-1,free t4 index [mass/vol]
3022-1,free t4 index [mass/vol] t-4
3022-1,[massvol] t4 inde free
47559-0,alpha aminobutyrate [moles/volume] in dbs
47559-0,ala ainobutyrate [oles/volume] in db
47559-0,apa dbs [mole/volume]in amiobutyrate
47559-0,a-aminobutyr dbs-scnc
47559-0,a-ainobutyr dbs-sn
47559-0,a-aminobutyr dbs-scnc
47559-0,alpha aminobutyrate (dbs) [moles/vol]
47559-0,lpha [oles/vol] aminoutyrt(dbs)
47559-0,[moles/vol] aminobutyrate (dbs) alpha
9653-7,trichlormethiazide [mass/volume] in urine
9653-7,trichlormethiazide [mass/volume] in urine
9653-7,trichlormethiazide [mass/volume] level in urine
9653-7,tcm ur-mcnc
9653-7,tcm ur-mcn
9653-7,ur-mcnc tcm
9653-7,trichlormethiazide (u) [mass/vol]
9653-7,tichlormethazid(u) [mass/vol
9653-7,qnt trichlormethiazide (u) [mass/vol]
63480-8,pseudomonas aeruginosa.multidrug resistant isolate [presence] in specimen by organism specific culture
63480-8,pseudomonas aeruginosa.multidrug resistant isolate [ql] in specimen by organism c&s specific culture
63480-8,seudoonas aeruginosa.mulirug resistant isolat [pesence] in clture oranismspcifc speinby
63480-8,p aerug.mri spec ql cult
63480-8,p aerug.mri spec cult ql
63480-8,p ql spec aerug.mri ql cult
63480-8,p. aeruginosa.multidrug resistant isolate org specific cx ql (specimen)
63480-8,p. infectiousdisease erginosa.multidrug (specimen) islat og specfic cx ql resistant
63480-8,p.aeruginosa.multdrug resistant isolate or cx pcfic presence(spcimen)
34223-8,17-ketosteroids/creatinine [molar ratio] in urine
34223-8,17-ketosteroids/creatinine [molar point in time ratio] urine in
34223-8,in [molar ratio] 17-ketostroidsceatinine urin
34223-8,17ks/creat ur-srto
34223-8,ur 7ks/creatur-ro
34223-8,ur-srto 17ks/creat
34223-8,17-ketosteroids/creatinine (u) [molar ratio]
34223-8,17-ketosteroids/creatinine ratio] [molar (u)
34223-8,17-ketosteroids/creatinine [molar (u) ratio]
22313-1,hepatitis a virus igg ab [units/volume] in serum
22313-1,hepatitis a autoantibodies virus serum ab [units/volume] in igg
22313-1,hepatiis a vrus ig ab [nits/volume] in serum
22313-1,hav igg ser-acnc
22313-1,hav abs igg serum-acnc
22313-1,hav igg ser-acnc
22313-1,hav igg qn (s)
22313-1,infectiousdisease qn igg hav (s)
22313-1,hav igg qn (s)
29969-3,rubidium [mass/time] in 24 hour urine
29969-3,rubidium [mass/time]in 24 hour urine
29969-3,ur rubidium 24 in [mass/time] hour urine
29969-3,rubidium 24h ur-mrate
29969-3,ruidim rb ur-mrate 24h
29969-3,rubidium 24h ur-mrate
29969-3,rubidium (24h u) [mass/time]
29969-3,[mass/tme] (24h u) quantitative ruidiu
29969-3,rubidiu [mss/time] quantitative ) 24
16668-6,cortisol free [mass/time] in 72 hour urine
16668-6,[mas/time] fee cortisol in 72 hururine
16668-6,cortisol hur 72 hours [mas/time]in 72 fre urine
16668-6,cortis f 72h ur-mrate
16668-6,cortis ur-mrate 2h f f
16668-6,quant cortis f 72ur-mrate
16668-6,cortisol free (72 hour u) [mass/time]
16668-6,fr u) (2 hur cotisolfee [ass/tie
16668-6,coriol free 72 hou u) [mass/time
21035-1,11-deoxycortisol [mass/volume] in serum or plasma --morning specimen
21035-1,11-deoxycortisol [mass/volume] in plasma or serum --morning specimen
21035-1,11-doxycrtisl [ass/volume] in seru or plsma --morning secimen
21035-1,11dc am serpl-mcnc
21035-1,11dc cortexolone serpl-mcn am
21035-1,mass concentration 1dcamserpl-cnc
21035-1,11-deoxycortisol morning specimen [mass/vol]
21035-1,mornng 11-deoxycortisol specimen serpl [ass/vl]
21035-1,11-deoxycortisol morning specimen [mass/vol]
53277-0,urinalysis type of cast panel - urine by computer assisted method
53277-0,urinalysis type of cast panel by urine - computer assisted method
53277-0,urialyss type assistedmethod castanel urineby computer f
53277-0,ua casts pnl ur comp assist
53277-0,ua ur castpn com assis
53277-0,ua comp pnl ur casts artificial intelligence assist
53277-0,urinalysis type of cast panel computer assisted (u)
53277-0,urinalsis type urn cast of panel computer assitd ()
53277-0,assited type of cast pane cmuter urinaysis ()
105052-5,bacteria [presence] in urine sediment by microscopy
105052-5,bacteria [presence] in urine qualitative sediment by microscopy
105052-5,ur bceria [presene] sedmty inurine microscopy
105052-5,bacteria urns ql micro
105052-5,bacteria urns q mcro
105052-5,bacteria ql urns micro
105052-5,bacteria microscopy ql (urine sed)
105052-5,(urinesed) screen bacteiamicrocopyql
105052-5,bacteria (urine urn ql microscopy sed)
90236-1,keratan sulfate [moles/volume] in dbs
90236-1,dbs [moles/volumen keratansulfate
90236-1,keratosulfate keratan [moles/volume] sulfate in dbs
90236-1,keratan sulfate dbs-scnc
90236-1,eratan quantitative slfte db-scc
90236-1,dbs-scnc sulfate keratan
90236-1,keratan sulfate (dbs) [moles/vol]
90236-1,kertan ulfate level (dbs) [olesvol]
90236-1,sulfate keratan s) [moles/vol]
103148-3,steroid drug screening panel - serum or plasma by lc/ms/ms
103148-3,steroid drug screening plsm or - serum panel plasma by lc/ms/ms
103148-3,teroid drugscreenin anel - plasma o erum sr y lc/s/ms
103148-3,steroid drug screen pnl serpl lc/ms/ms
103148-3,steoid drug plasma serp pnl sreen lc//ms
103148-3,screen drug steroid pnl drugs serum or plasma lc/ms/ms
103148-3,steroid drug screening panel lc/ms/ms
103148-3,steroid pan screening drug panel lc/ms/ms
103148-3,steroid screening drug panel lc/ms/ms
62440-3,nucleated erythrocytes/leukocytes [ratio] in body fluid by automated count
62440-3,nucleated fl erythrocytes/leukocytes count in body fluid by automated [ratio]
62440-3,nucleated erythroytesleukocyte [rato] in fluid body flud by automated ount
62440-3,nrbc fld auto-rto
62440-3,nrbc fld auto-to
62440-3,nrbc fld auto-rto
62440-3,nucleated rbc/leukocytes auto (body fld) [ratio]
62440-3,nucleated rbc/leukocytes auto (body fld) [ratio] nuc
62440-3,nucleated rbc/leukocytes (body auto fld) [ratio] leukocyte
71251-3,additional concerns - faact-parent [facit]
71251-3,aditonal faact-parnt oncerns panl [fait]
71251-3,additional concerns - faact-parent [facit]
101274-9,mds v3.0 - rai v1.18.11 - medications during assessment period [cms assessment]
101274-9,mds - - rai v1.18.11 v3.0 medicationsduring assessment eriod [cms assessent]
101274-9,mds v.0 - rai essment] medicatons durigassessment period [cms panl v1.18.11
24429-3,parasite identified in blood
24429-3,in identified parasite blood
24429-3,parasteidentifid blood in parasites
24429-3,parasite bld
24429-3,nominal blood parasite
24429-3,arasite bld
24429-3,parasite identified nom (bld)
24429-3,parasite nom identified (bld)
24429-3,(bld) identified nom parasite
104689-5,egg white ige panel - serum
104689-5,egg white ige serum - panel
104689-5,eg white ige pnel - serum
104689-5,egg white ige pnl ser
104689-5,plser white ige gg
104689-5,egg white ige pnl serum
104689-5,egg white ige panel (s)
104689-5,white egg ige panel (s)
104689-5,egg white allergen panel ige ()
74904-4,dopamine [moles/volume] in cerebral spinal fluid
74904-4,fluid [moles/vlme] inceebrlspinal spinal fluid dopamine
74904-4,dopamine [moles/volume] cerebral in spinal fluid
74904-4,dopamine csf-scnc
74904-4,point in time dopamine cerebrospinal fluid-scnc
74904-4,quan csf-scc dopamine
74904-4,dopamine (csf) [moles/vol]
74904-4,dopamine (cerebrospinal fluid) [molesvol]
74904-4,dopamine (csf) olesl]
104560-8,phenx - housing instability due to affordability 281201
104560-8,phenx - housing instability pnl due to affordability 281201
104560-8,phenx - housing 281201 due to affordability instability
104560-8,housing due to afford
104560-8,dueto housng fford
104560-8,due housing to afford
73297-4,loratadine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73297-4,lataine induedplalet igg a [presence] inserum or plasma by fow cytometryfc
73297-4,loratadine indced plaelet igg plsm ab [preence]i erum r lamaby flow cytometry (fc)
73297-4,loratadine ind plt igg serpl ql fc
73297-4,ql ind plt igg serpl loratadine fc
73297-4,lotadine nd thrombocyte l igg serpl l c
73297-4,loratadine induced platelet igg fc ql
73297-4,platelet induced loratadine igg fc presence autoantibodies
73297-4,platelet induced loratadine igg fc ql
33396-3,neisseria meningitidis serogroups a+c+w135+y ag [presence] in serum
33396-3,neiseria meningtidi srogoups ac+w5+y ag [presence] in seum
33396-3,neisseri meningococcus enngitidisserogrup a+c13+y ag [pesen in serum
33396-3,n men sg a+c+w135+y ag ser ql
33396-3,n mesg a+c+w135+y serq ag
33396-3,microbiology a+c+w135+y mn sg n ag ser q
33396-3,n. meningitidis a+c+w135+y ag ql (s)
33396-3,n.meingtidi serum a+c+w135+y ag presence (s)
33396-3,ac+w135+y meningitidis n. gl (s
24051-5,acid alpha glucosidase [enzymatic activity/mass] in leukocytes
24051-5,acid alpha glucosidase [enzymatic leukocytes in activity/mass]
24051-5,acidalphaglucosidase leukcytes ctivi/mass] in [ezmaic
24051-5,acid a-glucosidase wbc-ccnt
24051-5,a-glucosidase acid wbc-ccnt
24051-5,acid a-glucosidase wbc-ccnt
24051-5,acid alpha glucosidase (wbc) [catalytic activity/mass]
24051-5,acid alpha glucosidase (wbc) activity/mass] [catalytic
24051-5,acid alpha glucosidase (wbc) [catalytic activity/mass] acid maltase
76067-8,abbreviated injury scale panel aaam
76067-8,abbreviaed injuryscale panel aam
76067-8,abbreviated injry scale panel aam
76067-8,ais panel aaam
76067-8,as panel aam
76067-8,ais panel aaam
54060-9,hedis 2009 tests used in early prenatal care - abo and rh (ppc-c)
54060-9,hedis 2009 used tests in early prenatal care - abo and rh (ppc-c)
54060-9,hedis 209 tests ued n early preata care r abo and - panel.hedis (ppcc)
54060-9,hedis 2009 ppc-c abo+rh
54060-9,hedis 2009 rh phenotyping ppc-c abo+r
54060-9,hedis 2009 ppc-c abo+rh pan
54060-9,hedis 2009 tests used in early prenatal care - abo and rh (ppc-c)
54060-9,hds 2009 ss used inearly prentl cae- pan abo and rh (ppc-c)
54060-9,hdis 2009 tests and in early prntal car -abo used rh (ppc-c
43807-7,urease [presence] in tissue --4 hours post incubation
43807-7,urease [presence] in tissue 4h p inc --4 hours post incubation
43807-7,urease [presence] post tissue qual --4 hours in incubation
43807-7,urease 4h p inc tiss ql
43807-7,4h urease p inc tiss ql
43807-7,urease 4h p inc tiss presence
43807-7,urease 4 hr post incubation ql (tiss)
43807-7,urease gi r pst incubaion ql (iss)
43807-7,urease4 hr post incubation presence tiss)
19180-9,choriogonadotropin.beta subunit free [units/volume] in serum or plasma
19180-9,choriogonotropin.beta subunit free units/volume] ser in or plasma
19180-9,or subunit free [units/volume] in serum choriogonadotropin.beta plasma
19180-9,b-hcg free serpl-acnc
19180-9,b-hc fre serpl-acnc
19180-9,b-cg free tumor marker erpl-acnc
19180-9,free beta hcg qn
19180-9,hcg fr beta free qn
19180-9,beta free hcg qn
39467-6,chloride [moles/volume] in peritoneal dialysis fluid
39467-6,chlorde [moles/volume] nertneal dialysis fluid
39467-6,peritoneal [moles/volume] in chloride dialysis fluid
39467-6,chloride diafp-scnc
39467-6,chloride diafp-scnc
39467-6,cl chlride diaf-scnc
39467-6,chloride (perit dial fld) [moles/vol]
39467-6,quant chloide (prit dial fld [moesvol]
39467-6,chloride (perit dial fld) [moles/vol] quantitative
4109-5,alfentanil [mass] of dose
4109-5,alfentanil [mass] dose of fanaxal
4109-5,of [mas] alfntanl dose
4109-5,alfentanil dose
4109-5,alfentanil dose
4109-5,dose alfentanil
4109-5,alfentanil (dose) [mass]
4109-5,(dose) alfentani [ms]
4109-5,alfntanil (dose) [mas]
90294-0,mmp-9 ab [units/volume] in serum or plasma by immunoassay
90294-0,point in time mmp-9 ab [units/volume] in serum or plasma by immunoassay
90294-0,mmp-9 ab in [units/volume] serum or plasma by immunoassay
90294-0,mmp-9 ab serpl ia-acnc
90294-0,mp-9 ab serpl ia-nc
90294-0,mp-9 ab srl aanc
90294-0,matrix metalloproteinases-9 ab ia qn
90294-0,matrix quan metalloproteinases-9 ab qn ia
90294-0,mmp-9 ab matr etlloproteinass-9 ab ia qn
86068-4,streptococcus pneumoniae danish serotype 23f igg ab [mass/volume] in serum --2nd specimen
86068-4,sttococus pnumoniae danish gg serotype23f b [mass/volume]in erum s pneum da type 2nd specimen
86068-4,igg pneumoniae anish serotype 23f stretococus ab [mss/vlume in serum immune globulin g --2nd secimen
86068-4,s pneum da 23f igg sp2 ser-mcnc
86068-4,s pnum da 23f igg p2 ser-mcnc
86068-4,s pnem da 23f ig p2 sermcnc
86068-4,s. pneumoniae danish type 23f igg spec 2 (s) [mass/vol]
86068-4,s. pneumoniae danish 2 23f igg spec type (s) [mass/vol]
86068-4,2f pneumniae danishtype s. igg spe 2 (s) pcv7 [mass/vol]
50338-3,cannabinoids [mass/volume] in dialysis fluid
50338-3,cannabinoids dialysis in [mass/volume] fluid
50338-3,cnnabinoids [mass/volue] in dialysis fuid
50338-3,cannabinoids dial fld-mcnc
50338-3,dialysis fluid canabinidsdial fld-mcnc
50338-3,fld-mcnc dial cannabinoids
50338-3,cannabinoids (dial fld) [mass/vol]
50338-3,anabioids dialfld) [massvol] level
50338-3,cannabinods dial quan fld) [mass/vol]
17698-2,tetraethyl lead [mass/volume] in blood
17698-2,ttraethyl plumbism [massvume lead in blood
17698-2,tetraethl lead mass concentration mass/volum] n bloo
17698-2,tetraethyl lead bld-mcnc
17698-2,pb tetaethl lad bld-mcnc
17698-2,tetraethyl lead blood-mcnc
17698-2,tetraethyl lead (bld) [mass/vol]
17698-2,tetraetylled (bld) [mass/vol] quantitative
17698-2,tetraethyl lad [mas/vol] (bl) quan
4368-7,oxedrine [mass] of dose
4368-7,oxedrine dose of [mass]
4368-7,f mass] oxedrine ose sympatol
4368-7,oxedrine dose
4368-7,dose oxedrine
4368-7,doe oxedrne
4368-7,oxedrine (dose) [mass]
4368-7,drugs of abuse oedrine (doe) [mas]
4368-7,oxedin [mas] ds) pt
57345-1,creatinine [mass/volume] in peritoneal dialysis fluid --overnight
57345-1,creatinine[ass/vlume] in peritonl dialysis fuid -overnight
57345-1,cretinie[mass/volume] i peritnal quant fluid dialysis --overnight
57345-1,creat overnight diafp-mcnc
57345-1,creat oernight diafp-mcnc
57345-1,overnight creat diafp-mcnc
57345-1,creatinine overnight (perit dial fld) [mass/vol]
57345-1,creatinine overnight (perit dial fld) [mass/vol]
57345-1,creatinine overnight (peit dia fld) [mass/vol
5578-0,antimony [mass/volume] in blood
5578-0,antmony [mas/voume] in blod
5578-0,inblood mass/volme] antmony
5578-0,antimony bld-mcnc
5578-0,animony bld-mcnc
5578-0,ntimony quan bld-mcnc
5578-0,antimony (bld) [mass/vol]
5578-0,antimony [mass/vol] (bld)
5578-0,antimony (bld) [mass/vol]
13321-5,human papilloma virus igg ab [presence] in serum
13321-5,human papilloma virus igg in [ql] antibodies ab serum
13321-5,human papilloma virus igg serum [presence] in hpv ab
13321-5,hpv igg ser ql
13321-5,igser hpv presence
13321-5,hpv igg ql se
13321-5,hpv igg ql (s)
13321-5,hpv ig presence (s)
13321-5,hpv immunoglobulin g igg presence(s)
29713-5,orientia tsutsugamushi gilliam ab [titer] in serum by immunofluorescence
29713-5,orientia tsutsugamushi gilliam ab immunofluorescence in serum by [titer]
29713-5,orientia by gilliam ab [titer] in serum tsutsugamushi immunofluorescence
29713-5,o tsut gill ab titr ser if
29713-5,o tsutsugamushi ser tsut gill ab titr o if
29713-5,o tsut gill ab ser titr if
29713-5,o. tsutsugamushi gilliam ab if (s) [titer]
29713-5,(s) tsuugamusi gilliam ab if o. [titer] ttr
29713-5,o. tsutsugamushi giliamab if (s) random [titr]
29389-4,acetaminophen [presence] in gastric fluid
29389-4,u209 acetaminophen [presence] in gastric fluid
29389-4,acetaminophen in [ql] gastric fluid
29389-4,apap gast ql
29389-4,appgast ql
29389-4,ql gast apap
29389-4,acetaminophen ql (gast fld)
29389-4,actaminophen presence gas fld)
29389-4,acetaminophen (gast presence point in time fld)
5145-8,echovirus 6 ab [titer] in serum by complement fixation
5145-8,echovirus 6 ab [titer] in serum titered by complement fixation
5145-8,echovirus ab 6 [titer] in serum by complement fixation
5145-8,ecv6 ab titr ser cf
5145-8,cf ab titr serum ecv6
5145-8,ser ecv6 cf ttr r a
5145-8,echovirus 6 ab cf (s) [titer]
5145-8,echviru abcf 6 ) [titer]
5145-8,ehvirus 6 ab cf (s [tter]
48797-5,organic acids panel - urine
48797-5,orgnic panel acids - point in time urine
48797-5,organic acids panel acd urine -
48797-5,organic acids pnl ur
48797-5,rganic ur acidspl
48797-5,acid organcacis pn ur
48797-5,organic acids panel (u)
48797-5,panel organiacid (u)
48797-5,oganic acis panel (u) point in time
45330-8,leptospira interrogans igg ab [titer] in serum by immunofluorescence
45330-8,antibody leptospira interrogans igg ab [titer] in serum by immunofluorescence
45330-8,leptospira interrogans igg ab [titer] ser in by immunofluorescence
45330-8,l inter igg titr ser if
45330-8,if inter igg titr ser l
45330-8,l intr igg titr serum if
45330-8,l. interrogans igg if (s) [titer]
45330-8,l. interrogans igg if (s) [titer]
45330-8,l. interrogans igg dilution factor (titer) if (s) [titer]
92297-1,promis item bank - smoking - negative psychosocial expectancies for all smokers - version 1.0
92297-1,promis item bank - smoking - negative psychosocial expectancies pnl for all smokers - version 1.0
92297-1,promis item bank - smoking - negative psychosocial expectancies for all smokers - version 1.0
90519-0,"mds v3.0 - rai v1.17.2 - special treatments, procedures, and programs - ipa during assessment period [cms assessment]"
90519-0,"mds v3.0 - rai v1.17.2 - special treatments, procedures, and programs - ipa during assessment period panel.survey.cms [cms assessment]"
90519-0,"d v3.0 - ra v1.17.2 - special reatments, pocedures, nd progams - ipa urngassesment period [cms ssessmen]"
49807-1,deprecated streptococcus pneumoniae 19 ab [units/volume] in serum by immunoassay --2nd specimen
49807-1,deprecated in pnemoniae 19 ab [unisvolume] strptococcus seru by immuoassy --2n specimen
49807-1,deprecated streptocccuspneumoniae 19 [unitsvolume] ab in serum by imunoassay --2nd pecimen
49807-1,deprecated s pneum19 ab sp2 ser ia-acnc
49807-1,pneumo deprecated s pneum19 ab sp2 serum ia-acnc
49807-1,deprecated s pneum19 sp2 ab ser ia-acnc
49807-1,s. pneumoniae 19 ab spec 2 ia qn (s)
49807-1,s. pneumoniae 19 ab spec ia 2 microbiology qn (s)
49807-1,s. pneumoniae 19 ab spec 2 qn ia (s) autoantibody
20821-5,escherichia coli k99 [presence] in stool by agglutination
20821-5,escherchacoli k99 [ql] soolby agglutination e coli
20821-5,escherichia coli k99 [ql] in ordinal agglutination by stool
20821-5,e coli k99 stl ql aggl
20821-5,ggl coli k99 sl presence e stl
20821-5,e o002 coli ql stl k99 aggl
20821-5,e. coli k99 aggl ql (stl)
20821-5,aggl coli k99 e. presence (stl)
20821-5,e. col k99 aggl ql (stl)
71883-3,methemoglobin/hemoglobin.total [pure mass fraction] in blood
71883-3,methemoglobin/hemoglobin.total [pure mass fraction] blood in
71883-3,methemogobin/hemoglobin.total [pure mass fraction  blood
71883-3,methgb mfr.df bld
71883-3,methgb ld whole blood mfr.df
71883-3,methgb bl mfrdf
71883-3,methemoglobin (bld) [pure mass fraction]
71883-3,methaemoglobin ethemogobin (bld) [pur mass raction]
71883-3,methemoglobin (bld) [pure totl mass fraction]
74602-4,3-hydroxytetradecanoylcarnitine (c14-oh) [enzymatic activity/mass] in fibroblast
74602-4,3-hydroyttradecanoylcarnitine (c14-h [enzymatic activity/mass] fibroblat in
74602-4,fibroblast (c14-oh) [enzymatic activity/mass] in 3-hydroxytetradecanoylcarnitine
74602-4,3oh-tdecanoylcarn fib-ccnt
74602-4,fib fib-ccnt 3oh-tdecanoylcarn
74602-4,oh-tdecanoylcarib-ccnt qnt
74602-4,c14-oh (fibroblast) [catalytic activity/mass]
74602-4,c14-oh actiity/mass] [catalytic (fibroblast)
74602-4,c14-oh (fibroblast) activity/mass] [catlytic
23210-8,listeria sp ab [presence] in serum
23210-8,lieria sp ab pesence] in srum
23210-8,ab[presencein point in time sp listeria serum
23210-8,listeria ab ser ql
23210-8,listeria antibodies ser ab ql
23210-8,listeria ab ser ql
23210-8,listeria sp ab ql (s)
23210-8,listeria p ab presence(s)
23210-8,listeriasp infectious disease abql (s)
12194-7,creatinine [mass/volume] in peritoneal fluid --12 hours post peritoneal dialysis
12194-7,peritoneal [mass/volume] in eritoneal flui--12hours post cetinine dilysi
12194-7,creatinine ascites [mass/volume] in peritoneal fluid --12 hours post peritoneal dialysis
12194-7,creat 12h p pd prt-mcnc
12194-7,creat pd p 12h prt-mcnc
12194-7,rea 12h p pd prtcnc
12194-7,creatinine 12 hr post pd (periton fld) [mass/vol]
12194-7,creatinine hr 12 post pd (periton renal fld) [mass/vol]
12194-7,creatinine 12 qnt (periton post pd hr fld) [mass/vol]
20472-7,eosinophils [presence] in specimen by wright stain
20472-7,eosinopils [presence] in simenby wright stain random
20472-7,eosinophils [ql] in specimen by wright stain
20472-7,eosinophil spec ql wright stn
20472-7,eosinophil spec l wght stn
20472-7,wright ql eosinophilspec tn
20472-7,eosinophils wright stain ql (specimen)
20472-7,eosinopil wright stain presence (specimen)
20472-7,eosiophils (specimen) stain ql st wriht
50392-0,3-keto n-valerate [moles/volume] in cerebral spinal fluid
50392-0,crebral nvalerte [mols/volume] in 3-keto chemistry spina fluid
50392-0,3-keto n-valerate [moles/volume] in cerebral spinal fl spinal fluid
50392-0,3-keto n-valerate csf-scnc
50392-0,3-eto n-valet csf-cn
50392-0,3kto n-vlera csf-scnc
50392-0,3-keto n-valerate (csf) [moles/vol]
50392-0,(cerebrospinal fluid) n-valerate 3-keto quantitative [moles/vol]
50392-0,3-keto [moles/vol] (csf) n-valerate
22502-9,measles virus igg ab [titer] in serum
22502-9,measles virus igg in [titer] ab ser
22502-9,virus measles igg ab [titer] in msls serum
22502-9,mev igg titr ser
22502-9,ev it igg se
22502-9,mev igg ser titr
22502-9,mev igg (s) [titer]
22502-9,igg mev (s) [titer]
22502-9,mev (s) igg [tter] microbiology
23563-0,vesicular stomatitis indiana virus ab [presence] in serum by immunoassay
23563-0,vesicular stomatitis indiana virus ab [presence] id serum in by immunoassay
23563-0,vescular vir indiana soatitis ab [pesence] iserum by immnoassay
23563-0,vsiv ab ser ql ia
23563-0,vsiv ql ser ab ia
23563-0,vsiv ql ser ab ia
23563-0,vesicular stomatitis indiana virus ab ia ql (s)
23563-0,ia stoatits idianaviru vsv-in ab vesicular ql (s
23563-0,vesiular indiaa tomatiis virus b enzyme immunoassay ia ql (s)
1818-4,alpha mannosidase [enzymatic activity/volume] in serum or plasma
1818-4,alpha mannosidase [nzymatic activity/volume] in serum r plasma
1818-4,alpha mannosidase [enzymatic actvity/volume] in serum r a-mannosidase plasma
1818-4,a-mannosidase serpl-ccnc
1818-4,a-mannosidase ser or plasma serpl-ccnc
1818-4,serpl-ccnc a-mannosidase
1818-4,alpha mannosidase [catalytic activity/vol]
1818-4,aph mannosiase [catalytic ctivity/v] serp
1818-4,alpha manosidase [catalyti activity/vol] alfa
2745-8,ph of capillary blood
2745-8,ph of blood capillary
2745-8,ph of capillary blood capillyblood
2745-8,ph bldc
2745-8,ph bdc
2745-8,bldc ph lung
2745-8,ph (bldc)
2745-8,pulmonology (ldc) ph
2745-8,ph (bld)
60171-6,silicon [mass/volume] in red blood cells
60171-6,silicon red in [mass/volume] blood cells
60171-6,silicon red in [mass/olum] bood clls
60171-6,silicon rbc-mcnc
60171-6,silicon rbc-mcnc
60171-6,rbc-mcnc slion mass concentration
60171-6,silicon (rbc) [mass/vol]
60171-6,silio (rbc) [mass/vl]
60171-6,slico (rbc) mas/vol]
17598-4,specific gravity of synovial fluid
17598-4,fluid gravity of synovial specific
17598-4,specific gravity of synovial fluid
17598-4,sp gr snv
17598-4,spgr nv
17598-4,spgrsnv
17598-4,specific gravity (syn fld)
17598-4,specific gravity joint aspirate (syn fld)
17598-4,speificgravity (syn fld)
95645-8,murray valley encephalitis virus neutralizing antibody [titer] in specimen by neutralization test
95645-8,murray valley encephalitis in neutralizing antibody [titer] virus specimen by neutralization test
95645-8,murray neutralization encephalitis virus neutralizing antibody [titer] in specimen by valley test
95645-8,mvev nab titr spec nt
95645-8,spec nab ti mvev nt
95645-8,ttr nab mvev spec nt
95645-8,mvev neut ab neut test (specimen) [titer]
95645-8,mvev neut neut ab test (specimen) [titer]
95645-8,mvev neut ab neut test (specimen) [titer]
91830-0,middle east respiratory syndrome coronavirus (mers-cov) rna [presence] in lower respiratory specimen by naa with probe detection
91830-0,middle as espirtorysyndrome coronavius (mers-cv) rna detecio in lower respirtory specimenby naawt poe [pesence]
91830-0,middle east respiratory syndrome coronavirus (mers-cov) rna [ql] in lower respiratory specimen by naa with probe detection
91830-0,mers-cov rna lower resp ql naa+probe
91830-0,mrscov rep lower na mers-cov rna q naa+probe
91830-0,mers-cov rna lower res corona virus presence na+prob
91830-0,mers-cov rna naa+probe ql (lower resp)
91830-0,mers-cov corona virus rna naa+probe ql (lower resp)
91830-0,hcov-emc/2012 merscov rna naa+pobe resp) lower ql
19424-1,dextromethamphetamine [presence] in urine by confirmatory method
19424-1,detroethamhetamine [presence] in by rine onfiratoy method
19424-1,confirmation dextromethamphetamine confirmatory in urine by [ql] method
19424-1,d-methamphet ur ql cfm
19424-1,qcfm d-mthamphetu
19424-1,d-methamphet drugs of abuse ur cfm ql
19424-1,dextromethamphetamine confirm ql (u)
19424-1,dextromethamphetamine (u) ql confirm
19424-1,dextromethamphetamine confirm ql (u) addiction
70624-2,functional assessment of cancer therapy for patients with neurotoxicity questionnaire - version 4 (fact-gog-ntx) [facit]
70624-2,functionlassessment of fact-gog-ntx - version 4 cancer therapyor patiets with neurotoxicity questionnaire - vesion 4 (factgog-nx) [fcit]
70624-2,funciona ssessmet of acertherapy for patents wit neurotoxicityqestionnaire - ersion4 (fac-og-nx) [facit]
32786-6,thyroperoxidase ab [titer] in serum or plasma
32786-6,thyroperoxidase ab [titer] in serum autoantibodies or plasma
32786-6,thyrperoxidase ab [titr] inserumr psma
32786-6,thyroperoxidase ab titr serpl
32786-6,thyroperoxidase ab serpl titr
32786-6,thyroperoxidase ab titr antibodies serpl
32786-6,tpo ab [titer]
32786-6,ab tpo [titer]
32786-6,ab tpo [titer]
44037-0,glucosylceramidase [presence] in blood
44037-0,glusylceradse [presence] in blood
44037-0,glucosylcridase [ql] ql in blood
44037-0,glucosylceramidase bld ql
44037-0,ordinal glucosylceramidae ql blood
44037-0,glucosylceamids bld ql
44037-0,glucosylceramidase ql (bld)
44037-0,glucosylceramidase (bld) ql
44037-0,ql glucosylceramidase bld)
24318-8,manual differential panel - blood
24318-8,manual differential panel -bld hematology/cell counts
24318-8,panel.hematology& cell counts manul pnel differenial -blood
24318-8,manual diff bld
24318-8,manualdiff blood wb
24318-8,diff manual bld
24318-8,manual differential panel (bld)
24318-8,manal dfferential pael bld)
24318-8,manual (bld) panel differential
53197-0,3-hydroxytetradecenoylcarnitine (c14:1-oh) [moles/volume] in dbs
53197-0,3-hydroxytetradecenoylcarnitine [moles/volume] (c14:1-oh) in dbs
53197-0,3-hydroxytetradecenoylcarnitine [moles/volume] (c14:1-oh) in dbs
53197-0,3oh-tdecenoylcarn dbs-scnc
53197-0,dbs 3oh-tdecenoylcarn dbs-scnc
53197-0,3oh-tdecenoylcarn dbs-scnc
53197-0,3-hydroxytetradecenoylcarnitine (c14:1-oh) (dbs) [moles/vol]
53197-0,3-hydroxytetradecenoylcarnitine (c14:1-oh) (dbs) [moles/vol]
53197-0,dried blood spot 3-hydroxytetradecenoylcarnitine (c14:1-oh) (dbs) [moles/vol]
29226-8,quinidine [mass/volume] in body fluid
29226-8,body [mass/volume] in qunidine bod fluid
29226-8,body [mass/volume] in quinidine fluid b/f
29226-8,quinidine fld-mcnc
29226-8,quinidine fld-mcnc
29226-8,fl-mcnc quiniine quant
29226-8,quinidine (body fld) [mass/vol]
29226-8,fluid quinidine (body fld) [mass/vol]
29226-8,(bdyfd) quinidine [mass/vol] random
26626-2,chlamydia trachomatis l2 ab [presence] in serum
26626-2,chlamydia trachmatis l2 ab [presence] in srum
26626-2,chlaydi trachomtis l2 infectiousdisease [presence] ab in ser
26626-2,c trach l2 ab ser ql
26626-2,c trach l2 ql serum ab
26626-2,c trach l2 ab serum ql
26626-2,c. trachomatis l2 ab ql (s)
26626-2,c. trachomatis l2 ql ab abs (s)
26626-2,c. trachomatis l2 ab microbiology presence (s)
2694-8,osmolality of 24 hour urine
2694-8,osmolaliy of 24 hour urie
2694-8,24 of osmolality hour urine nephrology
2694-8,osmolality 24h ur
2694-8,smolalty osmo 24 ur
2694-8,osmolality 24h ur
2694-8,osmolality (24h u) [osmolality]
2694-8,osmolality [osmolality] u) (24h
2694-8,osmolality [osmolality] u) (24h
18453-1,suberylcarnitine (c8-dc) [mass/volume] in serum or plasma
18453-1,suberylcarnitine (c8-dc) [mass/volume] in serum quan or plasma
18453-1,suberylcarnitine (c8-dc) plasma [mass/volume] in serum or plasma
18453-1,suberylcarn serpl-mcnc
18453-1,c8-dc serpl-mcnc uberycarn
18453-1,serpl-mcnc suberylcarn serpl
18453-1,c8-dc [mass/vol]
18453-1,[mass/vol] c-dc plasma
18453-1,c8-d mass/o] plsm
64120-9,fourth most predominant hemoglobin in dbs
64120-9,fourth most predominant hemoglobin findings in dbs
64120-9,fourh most peominnt hemogoin n dbs
64120-9,4th most predominant hb dbs
64120-9,predominant most 4th hb dbs
64120-9,predoinant mos 4th hb dbs finding
64120-9,fourth most predominant hemoglobin nom (dbs)
64120-9,fort ost blood predominanthemoglobi nom (ds)
64120-9,predominant most fourth hemoglobin nom (dbs)
57320-4,trypanosoma cruzi ab [presence] in serum or plasma by immunoassay
57320-4,trypanosoma cruzi ab [presence] plasma in ser or plasma by immunoassay
57320-4,trypanosoma cuzi ab [presene]in ser opasma b immuoassy
57320-4,t cruzi ab serpl ql ia
57320-4,microbiology t cruzi absepl ql ia
57320-4,t cruzi ab serpl ia q
57320-4,t. cruzi ab ia ql
57320-4,t. iaa cruzi ab i presence
57320-4,t. cruzi ab ia presence
31943-4,pneumocystis jirovecii ag [presence] in specimen
31943-4,pneumocyti jiovecii screen ag [presence inpecien
31943-4,pneumocystis jirovecii ag specimen in [presence]
31943-4,p jirovecii ag spec ql
31943-4,spec jirovecii ag p ql
31943-4,p ql ag spec jirovecii p carinii
31943-4,p. jirovecii ag ql (specimen)
31943-4,agql(specimn) jirvecii
31943-4,p. jirovecii ag l (specimen)
14015-2,thyroxine (t4).prealbumin bound/prealbumin [mass ratio] in serum or plasma
14015-2,thyroxine (t4).pralbuin boundprealbumin in ratio] serum [mass serum or plas
14015-2,thyroxin (t4).prelbumin serum bound/prealbumin[massratio] n srum or plasma
14015-2,t4 pa bnd/prealb serpl
14015-2,t4 bnd/prealb pa serpl
14015-2,pa t4 bnd/prealb serpl
14015-2,t4.prealbumin bound/prealbumin [mass ratio]
14015-2,bound/prealbumin t4.prealbumin ss rato]
14015-2,[mass 4.preabuminbound/realbumin ratio] serplas
59037-2,phosphate [mass/volume] in peritoneal dialysis fluid
59037-2,phsphate [mass/voume] n peritoneal dialysis flid
59037-2,phosphate fluid in peritoneal phosphate total dialysis [mass/volume]
59037-2,phosphate diafp-mcnc
59037-2,random diafp-mcnc phosphate
59037-2,phosphate po4 diafp-mcnc
59037-2,phosphate (perit dial fld) [mass/vol]
59037-2,phosphrous phosphte (perit fld) dial [mass/vol
59037-2,phosphate (perit dial fld) [mass/vol]
1666-7,17-hydroxycorticosteroids [mass/volume] in urine
1666-7,17-hydroxycorticosteroids [mass/volume] in quant urine
1666-7,urine [mss/volume] in 17-hydroxycorticosteroids qnt
1666-7,17ohcs ur-mcnc
1666-7,ur-mcnc 17ohcs
1666-7,ur-cnc quant 17ohcs
1666-7,17-hydroxycorticosteroids (u) [mass/vol]
1666-7,[mass/vol] (u) 17-hydroxycorticosteroids
1666-7,[mas/vol] (u) 17-hydroxycorticostroids
88681-2,herpes simplex virus ag [presence] in cornea or conjunctiva by immunofluorescence
88681-2,herps siplex vius ag or in cornea [presence] onjnctva byimunofluorescence
88681-2,heres simplexvirus ag [ql] i cornea or njunctiva by mfluorescenc
88681-2,hsv ag corn/cnjt ql if
88681-2,hsv a corn/cnj acif ql if
88681-2,hv a corn/cnjt  if
88681-2,hsv ag if ql (corn/cnjt)
88681-2,hsv trf ag if ql (corn/jt)
88681-2,if ag hsv ql (corn/cnjt)
100708-7,plasma cells/leukocytes in synovial fluid
100708-7,plasma cells/leukocytes synovial in fluid
100708-7,plasma cells/leukocytes in synovial fluid
100708-7,plasma cells nfr snv
100708-7,nfr joint fld cells plasma snv
100708-7,plasma cells nfr snv
100708-7,plasma cells/leukocytes (syn fld)
100708-7,leuc plas cells/leukocytes (syn fld)
100708-7,sf plasma cells/leukocytes (syn fld)
92077-7,promis parent proxy item bank - physical stress experiences - version 1.0
92077-7,promisparentpoxy item bank- physial stress xperience - verson 1.0
92077-7,promis parent proxy item bank - physical panl stress experiences - version 1.0
32365-9,torque teno virus dna [presence] in serum or plasma by naa with probe detection
32365-9,toque tenovirus dna [pesence] in serm or plasma by naa wth probe detection
32365-9,torqe eno virs da [resence]in seum or plasa by na wt probe detection
32365-9,ttv dna serpl ql naa+probe
32365-9,naa+probe dna serpl presence ttv
32365-9,tt ql daserl 3 self-sustaining sequence replication aa+pobe
32365-9,torque teno virus dna naa+probe ql
32365-9,torque dna probe teno virus dna naa+probe ql
32365-9,torque teno virus dna naa+probe presence
33413-6,lipoprotein.beta/total lipoprotein in pleural fluid
33413-6,liporotin.beta/totallipoprotein in pleural fluid
33413-6,lipoprotein.beta/total lipoprotein in pleural fluid
33413-6,ldl mfr plr
33413-6,ldl plr mfr
33413-6,thoracentesis fluid ldl mfr plr
33413-6,lipoprotein.beta/total lipoprotein (pleur fld) [mass fraction]
33413-6,lipoprotein.beta/total (pleurfld) lipoprotein quant [mass fracin]
33413-6,lipoprotein.beta/total lipoprotein (pleur fld) [mass fraction]
11075-9,norfentanyl [mass/volume] in urine
11075-9,norfentanyl [mas/volum] i urine
11075-9,norfentanyl potentialforabuse [mass/volume] in urine
11075-9,norfentanyl ur-mcnc
11075-9,addiction ur-mcnc norfentanyl
11075-9,ur-mcnc ur norfentanyl
11075-9,norfentanyl (u) [mass/vol]
11075-9,norfentanyl [mass/vol] (u)
11075-9,[mas/vol] norfentanyl(u) qnt
58906-9,nucleated cells [#/volume] in cerebral spinal fluid by manual count
58906-9,nucleatd cels [/volume] random incerebral spinal flui by anua count
58906-9,nucleated cel [#/volume] i cerebral spinal fluid by manual quantitative count
58906-9,nuc cell # csf manual
58906-9,nuc cell csf # manual
58906-9,quantitative cell nuc # csf manual
58906-9,nucleated cells manual cnt (csf) [#/vol]
58906-9,nucleated [#/vol] cnt (csf ellsmanual
58906-9,manual cells quan nucleated cnt (csf) [/vo]
74889-7,phosphate [moles/volume] in saliva (oral fluid)
74889-7,qnt phosphate [moles/volme] n saliva (oral flid)
74889-7,flid) [mols/voume] phosphrous aliva oral phospate
74889-7,phosphate sal-scnc
74889-7,phosphate phosphorous al-scnc
74889-7,phosphate level sal-scnc
74889-7,phosphate (sal) [moles/vol]
74889-7,phosphate (sal) [moles/vol] chemistry
74889-7,[moles/vol] (sal) phosphate
43248-4,epinephrine/creatinine [mass ratio] in 24 hour urine
43248-4,epinephrine/creatinie [mass ratio] in 24 hour urine
43248-4,epiephrine/reatnine cr [mass ratio] in 4hour urine
43248-4,epineph/creat 24h ur
43248-4,mcrto ur 24h epineph/creat
43248-4,epinphcreat 24h ucr r
43248-4,epinephrine/creatinine (24h u) [mass ratio]
43248-4,(24h epinephrine/creatinine u) [mass ratio]
43248-4,epinephrinecraiie (24h [mas u) ratio]
16803-9,echovirus 4 ab [units/volume] in serum by complement fixation
16803-9,echovirs 4 ab [units/volume] in serum by complement fixation
16803-9,echovirus complement ab [units/volume] in serum by 4 fixation
16803-9,ecv4 ab ser cf-acnc
16803-9,ecv4 ab ser cf-acnc
16803-9,ab ecv4 ser cf-acnc
16803-9,echovirus 4 ab cf qn (s)
16803-9,echovirus 4 qn cf ab (s) quan
16803-9,echovirus id 4 ab cf qn (s)
23329-6,ovine progressive pneumonia virus ab [presence] in serum
23329-6,ovine progressive pneumonia virus ab [presence] in ser
23329-6,ovine ab pneumonia virus progressive [presence] in serum
23329-6,oppv ab ser ql
23329-6,ser autoantibodies ab oppv ql
23329-6,oppv ab oppv ql ser
23329-6,ovine progressive pneumonia virus ab ql (s)
23329-6,vine progressive pneunia virusab q infectiousdisease (s)
23329-6,ovine progressive pneumonia virus ab presence (s)
56489-8,acidity.titratable [moles/time] in 24 hour urine
56489-8,acidity.titratable [moles/time] i 4 quantitative hour urine
56489-8,acidity.titratable [moles/time] hour 24 ur in urine
56489-8,titratable acidity 24h ur-srate
56489-8,tittable aidity ur-srate 24h ua
56489-8,titraabe acidity 24h r-srat
56489-8,acidity.titratable (24h u) [moles/time]
56489-8,aidit.titratable chemistry moles/time] u (24
56489-8,acidity.titratable (24h [moles/time] u)
72574-7,coproporphyrin/porphyrins.total [pure substance fraction] in 24 hour urine
72574-7,coproporphyrin/porphyrins.total [pure substance fraction] in 24 hour urine tot
72574-7,coproporphyrin/porphyrins.total [pure substance fraction] ur urine 24 hour in
72574-7,copro 24h sfr.df ur
72574-7,r fr.df urn copro24h
72574-7,totl copro 24h ur sfr.df
72574-7,coproporphyrin/total porphyrins (24h u) [pure substance fraction]
72574-7,coproporphyrin/total porphyrins (24h [pure u) substance fraction]
72574-7,coproporphyrins coproporphyrin/total porphyrins (24h u) [pure substance fraction]
43722-8,5-ethyl-5-phenylhydantoin [presence] in specimen
43722-8,[presence] 5-ethyl-5-phenylhydntoi in specimen
43722-8,[presnce] 5-ehy-5-phenhdantoin in specimn
43722-8,5-ethyl-5-phenylhydantoin spec ql
43722-8,spec 5-ethyl-5-phenylhydantoin ql
43722-8,random 5-ethyl--phenylhydantoin pe ql
43722-8,5-ethyl-5-phenylhydantoin ql (specimen)
43722-8,5-ethyl-5-phenylhydantoin ql (specimen) other
43722-8,5-ethyl-5-phenylhyaton qual presence (specie)
56736-2,purkinje cells ab [presence] in cerebral spinal fluid by immunoblot
56736-2,purkinje cells cellularity ab [ql] in cerebral spinal fluid by immunoblot
56736-2,purkinjecel ceeba [presence] n ab sinal flui by immunobot antibody
56736-2,purkinje cells ab csf ql ib
56736-2,cerebral spinal fluid purkinje cells ab csfl ib
56736-2,purkinje ib ab csf ql cells
56736-2,purkinje cells ab ib ql (csf)
56736-2,purkinje ab autoantibody clls ib ql (csf)
56736-2,ib ab pt purkinjecells ql (cf)
35218-7,osteocalcin [mass or moles/volume] in serum or plasma
35218-7,osteoalcin [mass ser mles/volume] in or o chemistry lama
35218-7,osteocalcin in or moles/volume] [mass serum or plasma
35218-7,osteocalcin serpl-mscnc
35218-7,serpl-mscnc osteocalcin
35218-7,serp-mcnc osteocacin
35218-7,osteocalcin [mass or moles/vol]
35218-7,osteocalcin [mass or moles/vol] quantitative
35218-7,les/vol] [ass o osteocalci
44043-8,basophils [presence] in pleural fluid by light microscopy
44043-8,basophils [ql] in pleural fluid by screen light microscopy
44043-8,basophil [resence] in pleural fluid by light mirsopy
44043-8,basophils plr ql micro
44043-8,bsohils lm plr ql micro
44043-8,thoracentesis fluid basphilsplr lmicro
44043-8,basophils lm ql (pleur fld)
44043-8,basophils lm presence thoracentesis fluid (pleur fld)
44043-8,basophils l lpleu fld)
27251-8,phenylpropanolamine [mass/volume] in vitreous fluid
27251-8,phenylpropanolamine [mass/volume] in vitreous fluid
27251-8,penlpropanolamine vitreous humour fuid vitreous [mas/olume]in
27251-8,ppa vitf-mcnc
27251-8,ppa vitreous fluid vitf-mcnc
27251-8,ppa vitf-mcnc
27251-8,phenylpropanolamine (vitr fld) [mass/vol]
27251-8,phenylpropanolamine (vitr fld) [mass/vol]
27251-8,vitreous fluid fld)[mas/vol] (vtr pheylroalamine
4398-4,phenylephrine [mass] of dose
4398-4,phenylephrine [mass] dose of
4398-4,f qnt phenylephinems] dose
4398-4,phenylephrine dose
4398-4,dose phenyleprin
4398-4,phenylehrine dose random
4398-4,phenylephrine (dose) [mass]
4398-4,(dose)[mass] phenylephrine
4398-4,phenylephrine [mass] (dose)
46259-8,morphine free [presence] in serum or plasma by screen method
46259-8,orphine free [presece] or ser in plasmab screen screen metod
46259-8,morphine free [presence] or serum in plas by screen method
46259-8,morphine free serpl ql scn
46259-8,morphine free serpl ql sc morphine sulfate
46259-8,qual morphine free serpl ql scn
46259-8,morphine free screen ql
46259-8,morphine free screen non-protein bound ql
46259-8,morphin ql ql freecren
600-7,bacteria identified in blood by culture
600-7,blood identified in bacteria by culture
600-7,b idetifed in blod bacteria ulture
600-7,bacteria bld cult
600-7,cult cult blood bacteria
600-7,bacteria cult nominal bld
600-7,bacteria identified cx nom (bld)
600-7,acteria idntifid bld c om (bld)
600-7,bacteria identified nom cx (bld) cult
47220-9,cholesterol in hdl 4+5 [mass/volume] in serum or plasma
47220-9,cholesteol in hdl 4+5 mass/volue] in ser or plasma
47220-9,4+5 in hdl cholesterol [mass/volume] in serum or plasma
47220-9,hdl4+5c serpl-mcnc
47220-9,ser hdl4+5cserpl-mcnc
47220-9,hdl4+5cerpl-mcnc hdl-c
47220-9,cholesterol in hdl 4+5 [mass/vol]
47220-9,choleseol in hdl 4+5 [mass/vo
47220-9,cholesterol in hdl [mass/vol] 4+5
33509-1,hemoglobin [mass/volume] in body fluid
33509-1,in [mass/volume] hemoglobin body fluid
33509-1,emogloin [mass/volme] n bdy luid
33509-1,hgb fld-mcnc
33509-1,quan fld-mcnc hgb
33509-1,mass concentration fld-mcnc hgb
33509-1,hemoglobin (body fld) [mass/vol]
33509-1,[mass/vol] (body fld) hemoglobin
33509-1,[mass/vol] (body ld) hemoglobin
49167-0,orientia tsutsugamushi karp igm ab [titer] in serum
49167-0,orienta tsutsgamushi karp in b[titer] igm ser
49167-0,orientia tsutsugamushi karp igm ab [titer] in aby ser
49167-0,o tsut karp igm titr ser
49167-0,o tsut rickettsia tsutsugamushi serotype karp karp serum titr igm
49167-0,o tsut karp igm titr ser
49167-0,o. tsutsugamushi karp igm (s) [titer]
49167-0,o.tsutsausi karp (s) im o tsut [titer]
49167-0,igm tsutsugamushi karp o. antby (s) [titer]
19549-5,mesoridazine cutoff [mass/volume] in urine for confirmatory method
19549-5,mesoridazine cutoff [mass/volume] in urine for confirmatory method
19549-5,mesoridazine cutoff [mass/volume] in urine confirmatory for method
19549-5,mesoridazine cto ur cfm-mcnc
19549-5,cfm-mcnc confirmation cto ur mesoridazine
19549-5,quantitative ur cto mesoridazine cfm-mcnc
19549-5,mesoridazine cutoff confirm (u) [mass/vol]
19549-5,mesoridazine (u) confirm cutoff [mass/vol]
19549-5,cfm [mass/vo] cuof confirm (u) mesoidaine
31065-6,polio virus 3 ab [titer] in body fluid by complement fixation
31065-6,fixation virus 3 ab [titer] in body fluid by complement polio
31065-6,polio virus 3 ab [titer] in body fixation by complement fluid
31065-6,pv3 ab titr fld cf
31065-6,cf ab titr ld pv3
31065-6,b pv3 ttr fld cf
31065-6,polio virus 3 ab cf (body fld) [titer]
31065-6,polio virus 3 ab fld) (body cf [titer]
31065-6,polio vius 3 ab cf (body fd)[titer] b/f
94646-7,sars-cov-2 (covid-19) rdrp gene [cycle threshold #] in respiratory system specimen by naa with probe detection
94646-7,sars-cov-2 (covid-19) in gene [cycle threshold #] rdrp respiratory system specimen by naa with probe detection
94646-7,sars-cov-2 (covid-19) naa gene [cycle threshold spec #] in respiratory system specimen by rdrp with probe detection
94646-7,sars-cov-2 rdrp ct resp qn naa+probe
94646-7,sars-co-2 rdr ct rsp q na+probe
94646-7,ct rdrp sars-cov-2 resp qn naa+probe
94646-7,sars-cov-2 (covid-19) rdrp gene naa+probe (respiratory system specimen) [threshnum]
94646-7,sars-cov-2 (covid-19) rdrp gene naa+probe (respiratory system specimen) [threshnum] sars coronavirus 1
94646-7,naa+probe (covid-19)dr gene sars-ov-2 (resiratory system amplified specimen) [thresnum]
90940-8,promis parent proxy short form - mobility 8a - version 2.0
90940-8,promis parent proxy short form - mobility 8a - version 2.0
90940-8,promis proxshortform parent oiity8a - version 2.0 promise
34312-9,glucose/creatinine [molar ratio] in urine
34312-9,glucoseur ratio] [molar glucose/creatinine in urine
34312-9,quan glucose/creatinine [molar ratio] urine in
34312-9,glucose/creat ur-srto
34312-9,ur-sro gluose/at
34312-9,quantitative glucose/creat ur-srto
34312-9,glucose/creatinine (u) [molar ratio]
34312-9,gluose/creatnne (u) ratio] [molar random
34312-9,glucose/creatinine [molar (u) ratio]
32095-2,methanol [moles/volume] in urine
32095-2,methanol [moles/volume] urine in
32095-2,methao [moles/volue]in qnt urine
32095-2,methanol ur-scnc
32095-2,methanol ur-scnc
32095-2,methanol u-cn methyl alcohol
32095-2,methanol (u) [moles/vol]
32095-2,methanol [moles/vol] (u)
32095-2,(u) methanol [moles/vol]
2998-3,thiamine [mass/volume] in blood
2998-3,thimine [mss/volum] bld in
2998-3,vitamin b-1 thaie [massvlume] i bld
2998-3,vit b1 bld-mcnc
2998-3,vit bld-mcnc b1
2998-3,vt b1 blood-mcnc quantitative
2998-3,thiamine (bld) [mass/vol]
2998-3,(bld) thiamine [mass/vol]
2998-3,vit b1 (bld) thiamie [massvol]
11100-5,tetrachloroethylene [mass/volume] in blood
11100-5,blood in tetachlooethylene[mass/volume] mass concentration
11100-5,[ma/volume] random tetrachlorethylene in blood
11100-5,ttce bld-mcnc
11100-5,bld-mcnc ttce level
11100-5,bld-mcnc ttce
11100-5,tetrachloroethylene (bld) [mass/vol]
11100-5,tetrachloroethylene (bld) [mass/vol]
11100-5,(blood) tetrachloroethylene [mass/vol]
11470-2,clostridium botulinum toxin [units/volume] in stool
11470-2,bounum clostridium toxin [unit/vlume] in tool
11470-2,lostridum otulinum quant toxin n [units/volume] stool
11470-2,c bot tox stl-acnc
11470-2,c stl-acnc tox ot
11470-2,c bot stl-acnc faeces tox
11470-2,c. botulinum toxin qn (stl)
11470-2,toxin botulinum c. qn qnt (stl)
11470-2,faeces c. botulinum (stl) qn toxin
66150-4,over the counter medications
66150-4,over counter the medications
66150-4,over the medications panel.phenx counter
66150-4,over the counter medications
66150-4,over the counter pan medications
66150-4,over the counter medications panel
56762-8,oligoclonal bands igg [presence] in serum or plasma
56762-8,oligoclonal bandsigg resence] in serum r plasma
56762-8,oligoclonlbands igg seum immune globulin g [presence] orplasma
56762-8,oligoclonal bands igg serpl ql
56762-8,oligoclonal bands igg serpl ql
56762-8,oligoclonal bands igg random serpl ql
56762-8,oligoclonal bands igg ql
56762-8,igg bands oligoclonal ql
56762-8,oligoclonal bands fraction igg presence
59010-9,fractional excretion of potassium [ratio] in urine and serum or plasma collected for unspecified duration
59010-9,fractional excretion potassium of [ratio] in urine and serum or plasma collected for unspecified duration
59010-9,fractional excretion of potassium [ratio] in urine and serpl collected for unspecified duration
59010-9,fract excret k ?tm ur+serpl-rto
59010-9,fract ur+serpl-rto k ?tm excret
59010-9,fract quan exetk ?tm ur+serl-rto
59010-9,fractional excretion of potassium unsp time (u+s/p) [ratio]
59010-9,quant frctional xcretionof potassium unsp time u+sp) [ratio]
59010-9,frationa exretion of serpl potassium unsp time (us/p) [rato]
85795-3,rubella virus e1 gene and genotype panel - specimen
85795-3,rubella virus point in time e1 gene and genotype panel - specimen
85795-3,rubellavrus e1 gne dgenotyp pael - specimen
85795-3,rubv e1 + genotype pnl spec
85795-3,rubv e1 + infectiousdisease geotype pnl spec
85795-3,genotpe + infectiousdisease rubve1 pnl spec
85795-3,rubella virus e1 gene and genotype panel (specimen)
85795-3,ubella vius e1 gene and genotye pal (specimen)
85795-3,rubella e1 virus gene and genotype panel (specimen)
24449-1,carnitine esters [moles/volume] in urine
24449-1,carnitine esters in [moles/volume] urine
24449-1,carnitine estrs in [moles/volume] urine chemistry
24449-1,carn esters ur-scnc
24449-1,carn ur-scnc random esters
24449-1,arnesters ur-scnc
24449-1,carnitine esters (u) [moles/vol]
24449-1,carnitine (u) esters [moles/vol]
24449-1,carniine esters (u) [moles/vol]
2180-8,cystine+cysteine [mass/volume] in serum or plasma
2180-8,plasa in ser r ystin+cystein[mass/voume]
2180-8,ystine+cysteine [mass/voume] qnt plasma serum or in
2180-8,cys+cysteine serpl-mcnc
2180-8,serpl-mcnc cys+cysteine dicysteine
2180-8,cys+csteine erpl-mcnc
2180-8,cystine+cysteine [mass/vol]
2180-8,[mass/vol] cystine+cysteine serplas
2180-8,serum cytine+cyteine [mass/vol]
8758-5,right ventricular cardiac index by spiral ct
8758-5,rightvenricula cardiac inde by ct spiral
8758-5,spiral ventricular cardiac index by right ct pt
8758-5,rv cardiac index spiral ct
8758-5,rv cardiac index spiral ct quant
8758-5,rv cardiac spiral point in time index ct
18488-7,calcium [mass/volume] in 24 hour urine
18488-7,[mass/volume] calcium in 24 hour urine qnt
18488-7,calcium [mass/volume] in chemistry 24 hour urine
18488-7,calcium 24h ur-mcnc
18488-7,clcium urmcnc 24h
18488-7,cal calcium 24h ur-mcnc
18488-7,calcium (24h u) [mass/vol]
18488-7,(24h calcium u) [mass/vol]
18488-7,calcium (24h u) level [mass/vol]
104368-6,chlamydophila psittaci ab [titer] in serum by immunoassay --2nd specimen
104368-6,chlamydophila psittaci ab [titer] in serum immunoassay smqn by --2nd specimen
104368-6,clamydophila psittaci ab [titer] --2ndspecimen ser b sp2 imuoassay i
104368-6,c psittaci ab sp2 titr ser ia
104368-6,c psittaci ab sp2 titr se ia
104368-6,c psitci ab sp2 titr serum i
104368-6,c. psittaci ab spec 2 ia (s) [titer]
104368-6,titered c. psittaci (s) spec 2 ia ab [titer]
104368-6,c. pittaci ab ia 2 spec (s) [titer]
85556-9,rothman index calculated
85556-9,rothman index clculated quantitative
85556-9,index rothman calculated
85556-9,ri score calc
85556-9,scor ri calc
85556-9,calc score ri
69563-5,candida glabrata dna [presence] in vaginal fluid by naa with probe detection
69563-5,ordinal canddaglbaa da [presence] in probe fluid y aa with vaginal deecton
69563-5,detection glabrata dna [ql] in vaginal fluid by naa with probe candida
69563-5,c glabrata dna vag ql naa+probe
69563-5,c glabrata vag dna ql naa+probe
69563-5,c glabata dna vag l naaprobe
69563-5,c. glabrata dna naa+probe ql (vag fld)
69563-5,c. (vag dna naa+probe presence glabrata fld)
69563-5,c. glabrata dna naa+probe fld) (vag ql
32346-9,uroporphyrin [moles/mass] in stool
32346-9,uroporphyrin stool in [moles/mass]
32346-9,uroporphyin [moles/ass in octacarboxyl porphyrin stool
32346-9,uropor stl-scnt
32346-9,stl-scnt rpo
32346-9,stl-scnt faecal ropor
32346-9,uroporphyrin (stl) [moles/mass]
32346-9,uroporphyrin qnt (stl) [moles/mass]
32346-9,uroporphyrin (stl) [moles/mass]
87991-6,acanthamoeba sp identified in contact lens by organism specific culture
87991-6,aanthamoea s identified in ontact lens organism by pecifc ultue
87991-6,acanthamoeba sp identified in organism lens by contact specific species culture
87991-6,acanthamoeba cont lens cult
87991-6,acanthamoeba cult lens cont
87991-6,acanthamoeba cont cult lens soil amoeba
87991-6,acanthamoeba sp identified org specific cx nom (contact lens)
87991-6,cont lens acanthamoeba sp cx org specific identified nom (contact lens)
87991-6,acanthamoeba sp identified org specific cx nom (contact cultures lens)
66441-7,beta hydroxybutyrate [moles/volume] in blood by test strip
66441-7,beta hydroxybutyrate [moes/olumein strip by tes blood
66441-7,bethydoxybutyrate [moles/volume n bood by tet strip
66441-7,b-oh-butyr bld strip-scnc
66441-7,dipstick bld b-oh-butyr strip-scnc
66441-7,bld b-oh-butyr trip-scnc 3-hydroxybutyrate
66441-7,beta hydroxybutyrate test strip (bld) [moles/vol]
66441-7,bta srip test hydroxybutyrate (bld) [moles/vol]
66441-7,beta hydroxybutyrate test [moles/vol] (bld) strip beta hydroxy butyrate
16926-8,haemophilus influenzae a ag [presence] in cerebral spinal fluid
16926-8,haemophilus influenzae a ag [presence] in cerebral spinal fluid qual
16926-8,aemohilu spinal fl inluenzae cerebral ag [resene] in a spinal fluid
16926-8,haem influ a ag csf ql
16926-8,hem infl a ag csf presence
16926-8,haem ag a influ csf ql
16926-8,h. influenzae a ag ql (csf)
16926-8,screen h. influenzae (csf) ag ql a
16926-8,ag influenzae a h. ql (csf)
18347-5,deprecated streptococcus pneumoniae 12 ab [units/volume] in serum --2nd specimen
18347-5,deprecated streptococcus pneumoniae 12 ab [units/volume] convalescent in serum --2nd specimen
18347-5,deprecated streptcoccus pneumonie 1 ab [unis/voume] in seum --2nd specen
18347-5,deprecated s pneum12 ab sp2 ser-acnc
18347-5,deprecated s ser-acnc ab sp2 ser pneum12
18347-5,deprecated s pneum12 ab sp2 s pneum12 ser-acnc
18347-5,s. pneumoniae 12 ab spec 2 qn (s)
18347-5,12 pneuonie . ab spe 2 qn s)
18347-5,s. 2 12 ab spec pneumoniae qn (s)
85682-3,haemophilus influenzae ccs gene [cycle threshold #] in specimen by naa with probe detection
85682-3,haemopilu influenzae cc id gene [cycle threshold ] in specimen by na wth probedetectin
85682-3,in influenzae ccs gene [cycle threshold #] haemophilus specimen by naa with probe detection
85682-3,h influen ccs ct spec qn naa+probe
85682-3,h inluen ctspec ccs qn na+probe
85682-3,other inluen ccs ct spec qn na+probe
85682-3,h. influenzae ccs gene naa+probe (specimen) [threshnum]
85682-3,(specimen) influenzae ccsen naa+probe h. thrshnu]
85682-3,(specimen) influenzae ccs gene spec naa+probe h. [threshnum]
47737-2,proline/amino acids.total in specimen
47737-2,pro proline/amino pecimen in acis.toal
47737-2,in acids.total proline/amino other specimen
47737-2,proline sfr spec
47737-2,spec qnt prolinesfr
47737-2,proline pe sfr
47737-2,proline/total aa (specimen) [molar fraction]
47737-2,proline/total aa (specimen) [molar fraction]
47737-2,prline/totaaa fraction] [molar (pecimen totl
48079-8,"3,6-epoxydodecanedioate/creatinine [molar ratio] in urine"
48079-8,"3,6-epoxydodecanedioate/creatinine [molar ratio] urine in"
48079-8,"3,6-epoxydodecanedioate/creatinine [molar ratio] in quant urine"
48079-8,"3,6-epoxydodecanedioate/creat ur-srto"
48079-8,36-eoxyodecanedioate/creatur-srto urn
48079-8,"ur-srto crea 3,6-poxydodeanedioate/cret"
48079-8,"3,6-epoxydodecanedioate/creatinine (u) [molar ratio]"
48079-8,6-epoxydodenedioate/creatinne urn (u [molar ratio]
48079-8,"3,6-epoxydodecanedioate/creatinine (u) [molar ucr ratio]"
20417-2,histoplasma capsulatum mycelial phase ab [titer] in serum
20417-2,phase capsulatum mycelial histoplasma ab [titer] in ser
20417-2,histoplasma capsulatum mycelial phase ab ser in [titer]
20417-2,h capsul myc ab titr ser
20417-2,h myc capsul ab titr serum
20417-2,h capsul myc ab titr ser
20417-2,h. capsulatum mycelial phase ab (s) [titer]
20417-2,h. capsulatum mycelia phseb () [tter]
20417-2,h. capsulatum mycelia phase ab (s)[tie]
95666-4,tahyna virus igg ab [presence] in specimen by immunoassay
95666-4,tahyna virus immunoassay in specn by iggb[presence]
95666-4,tahyna virs igg screen in [presece] ab secen by immnoasay
95666-4,tahv igg spec ql ia
95666-4,tahvigg sec qlia
95666-4,ia igg spec ql tahv meia
95666-4,tahyna virus igg ia ql (specimen)
95666-4,tahyna infectiousdisease vius iggia l (specimn)
95666-4,other tahyna virus igg ia presence (specimen)
42364-0,streptococcus pneumoniae 6 serotypes igg panel [mass/volume] - serum
42364-0,streptococcus pneumoniae 6 serotypes igg panel [mass/volume] - serum
42364-0,treptococus pneumoniae 6 panel ig serotypes massvolume] -serum
42364-0,s pneum 6 serotypes igg pnl ser-mcnc
42364-0,s pneu 6 serotypesigg plser-mcn
42364-0,igg pneum 6 serotypes s pnl ser-mcnc
42364-0,s. pneumoniae 6 types igg panel (s) [mass/vol]
42364-0,. pneumoniae6 types gg panl(s)[massvol]
42364-0,s. pneumoniae panel types igg 6 (s) [mass/vol]
47230-8,herpes simplex virus glycoprotein g igg ab [presence] in serum
47230-8,herpes simplex virus glycoprotein g igg ab [presence] ser in
47230-8,herpes simplexvrus glyoprotein g igg ab [presene] in serum
47230-8,hsv gp g igg ser ql
47230-8,microbiology serum gpg igg hsv ql
47230-8,hsv gp g igg srql
47230-8,hsv glycoprotein g igg ql (s)
47230-8,hsv glycopote screen g ig l (s
47230-8,hsv glycoprotei g iggl (s)
35691-5,xxx microorganism dna [presence] in specimen by naa with probe detection
35691-5,xxx microorganism dna [presenc] n specien by naa wit probe detetin
35691-5,xxx microorganim dna [presence] in pecimenby naawihprobe etection
35691-5,other microorg dna spec ql naa+probe
35691-5,other microorg dna presence spec naa+probe
35691-5,other microorg dna spec pcr ql aa+rbe
35691-5,unsp microorganism dna naa+probe ql (specimen)
35691-5,amplif microorganism uns dna na+proe q (specime)
35691-5,nsp ql dna naa+probe icrorganism (specime)
15034-2,bromide [moles/volume] in serum or plasma
15034-2,bromid n [moes/volum] seru plas
15034-2,romde [moles/volue in seumorplasma
15034-2,bromide serpl-scnc
15034-2,brme serl-cnc
15034-2,serpl-scnc bromide
15034-2,bromide [moles/vol]
15034-2,[moles/vol] bromide
15034-2,bromide moles/vol]
73078-8,warfarin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73078-8,warfarin induced platelet igg ab [presence] in ser pl cytometry plasma by flow or (fc)
73078-8,warfarin induced platelet igg ab [presence] in serum or plasma by flow cytometry coumarins (fc)
73078-8,warfarin ind plt igg serpl ql fc
73078-8,warfarin ind plt igg serum or plasma ql fc
73078-8,warfarin ind plt igg 4-hydroxycoumarin serpl ql fc
73078-8,warfarin induced platelet igg fc ql
73078-8,sofarin warfarin induced platelet igg fc ql
73078-8,ql warfarin iduced patelet ql f igg
34187-5,dna double strand ab [titer] in serum by immunofluorescence (if) crithidia luciliae
34187-5,dna ab strd doubl ds [titr in serum by immunofluoescence (if) crithidia luilie
34187-5,dna double strand ab autoantibody [titer] in serum by immunofluorescence (if) crithidia luciliae
34187-5,dsdna ab titr ser clif
34187-5,dsdna ab anticomplement immunofluorescence titr ser clif
34187-5,dsdna ab tir ser clif
34187-5,dna double strand ab if crithidia luciliae (s) [titer]
34187-5,dna double strand ab if crithidia luciliae (s) [titer]
34187-5,double dna strand ab if rithidia luiliae () [tter]
27427-4,streptococcus pneumoniae danish serotype 7f igg ab [mass/volume] in serum by immunoassay --2nd specimen
27427-4,in pneumoniae aby danish serotype 7f igg ab [mass/volume] streptococcus serum by immunoassay --2nd specimen
27427-4,streptococcuspneumoniae danishserotype 7 igg ab[mass/volume] in serum by immuoassay--2nd specmen
27427-4,s pneum da 7f igg sp2 ser ia-mcnc
27427-4,s pneum da 7f sp2 pcv13 igg serum ia-mcnc
27427-4,s id pneum da 7f igg sp2 ser ia-mcnc
27427-4,s. pneumoniae danish type 7f igg spec 2 ia (s) [mass/vol]
27427-4,type pneumoniae danish s. 7f igg spec 2ia (s) [ms/vol]
27427-4,s. pneumoniae (s) type 7f igg spec 2 ia danish [mass/vol]
22912-0,bovine herpesvirus 1 ag [presence] in tissue by immune stain
22912-0,in hrpesviru 1 ag [presence] bovin tissue by immune stain
22912-0,bovine herpesvirus 1 [ql] ag in tissue by immune stain
22912-0,bohv1 ag tiss ql imstn
22912-0,bohv1 imstn tiss ql vet ag
22912-0,bohv1 ag iss presence imstn
22912-0,bovine herpesvirus 1 ag immune stain ql (tiss)
22912-0,bvine hepesvirus 1 ag immue stain presence(tiss) presence
22912-0,1 bovineherpesvirus ag imune stin ql (tiss) immunohistochemical stain
813-6,leukocytes [#/volume] in synovial fluid by automated count
813-6,leuoytes [#/olue] cont synvial fluid by automated in
813-6,leukocytes [#/volume] in synovial random fluid automated by count
813-6,wbc # snv auto
813-6,# wbc synovial fluid snv auto
813-6,wbc auto snv #
813-6,wbc auto (syn fld) [#/vol]
813-6,cnt wbc ut (syn [#/vol] fld)
813-6,auto wbc fld) (syn auto [#/vol]
21113-6,bismuth [mass/volume] in 24 hour urine
21113-6,bismuth [mass/volume] in 24 urn hour urine
21113-6,bisuth [mss/volume] in 2 hour urne
21113-6,bismuth 24h ur-mcnc
21113-6,bisuth 24h ur-mcnc
21113-6,ur-mcnc 24h bismuth
21113-6,bismuth (24h u) [mass/vol]
21113-6,24 hours bismuth u) (24h [mass/vo]
21113-6,bismuth drugs (24h u) [mass/vol]
3315-9,alprenolol [presence] in urine
3315-9,alprenolol ur in [presence] urine
3315-9,alprenolol [presence] drug/toxicology in urine
3315-9,alprenolol ur ql
3315-9,alprenolol ur presence
3315-9,ur alprenolol ql
3315-9,alprenolol ql (u)
3315-9,alprenolol ql (u) qualitative
3315-9,qual alprnolol ql (u)
33872-3,cystine [moles/mass] in leukocytes
33872-3,cystine inleukocytes [oles/mss]
33872-3,cystine leukocytes in leukocytes [moles/mass]
33872-3,cystine wbc-scnt
33872-3,cystine bcscnt
33872-3,cystine wbc-scnt leukocytes
33872-3,cystine (wbc) [moles/mass]
33872-3,cystne(wbc)[moles/mass] quantitative
33872-3,quan (wbc) cystine [moles/mass]
4441-2,thiopental [mass] of dose
4441-2,thioental [mass] of quan dose
4441-2,drug doses of [mss] thiopentl dose
4441-2,thiopental dose
4441-2,dose thiopental
4441-2,thiopental dose pentothal
4441-2,thiopental (dose) [mass]
4441-2,thiopental (dose) [mass] dose med or substance
4441-2,(dose) thiopental pt [mass]
88904-8,influenza virus a ag [presence] in lower respiratory specimen by immunofluorescence
88904-8,ag time resolved fluorescence virus a influenza [ql] in lower respiratory specimen by immunofluorescence
88904-8,nfluenza virus a ag [presne] in low respiraory specimen by immunfluorescence
88904-8,fluav ag lower resp ql if
88904-8,qlif ag loer rep fuav
88904-8,fluavag resp lowe presence i immune fluorescence
88904-8,fluav ag if ql (lower resp)
88904-8,infectious disease fluav ag if ql (lower resp)
88904-8,fluav ag if ql (lower immune fluorescence resp)
61032-9,7-aminoflunitrazepam [presence] in serum or plasma
61032-9,7-anoflunitrazepa 7aminoflunitrazepam [presnce] in serm or plasma
61032-9,7-aminoflunitrazepam serp [presence] in ser or plasma
61032-9,7aminoflunitrazepam serpl ql
61032-9,serpl 7aminoflunitrazepam ql
61032-9,7aminoflunitrazepam serpl serplas ql
61032-9,7-aminoflunitrazepam ql
61032-9,ql 7-aminoflunitrazepam
61032-9,presence 7-aminoflunitrazepam
13460-1,deprecated cholesterol.in ldl/cholesterol.in hdl [mass ratio] in serum or plasma
13460-1,dereatedcholeserol.in ldlcholesteol.in dl [mass rati]in plasma serumor
13460-1,deprecated cholesterol.in ldl/cholesterol.in hdl [mass quantitative ratio] in ser or plasma
13460-1,deprecated ldlc/hdlc serpl-mrto
13460-1,dprecatedldc/hdlc serpl-mrto random
13460-1,serpl-mrto ldlc/hdlc deprecated
13460-1,cholesterol in ldl/cholesterol in hdl [mass conc ratio]
13460-1,cholestero hdl ldl/cholestrolin in [mass conc rati
13460-1,in in ldl/cholesterol cholesterol hdl [mass conc ratio]
20917-1,organophosphate pesticides [presence] in blood by screen method
20917-1,rganphosphate pestiides [rsence] in blood by screen method
20917-1,organophosphate pesticides [presence] in blood screen by method
20917-1,op pesticides bld ql scn
20917-1,bld pesticides pr op presence scn
20917-1,scn pesticides bld ql op
20917-1,organophosphate pesticides screen ql (bld)
20917-1,organophosphate pesticides screen ql (bd) scn
20917-1,organophosphate ql screen pesticides (bld)
14553-2,mumps virus ag [presence] in urine sediment by immunofluorescence
14553-2,mumps virus immunofluorescence [presence] in urine sediment by ag
14553-2,mumps ur virus ag [presence] in urine sediment by immunofluorescence
14553-2,muv ag urns ql if
14553-2,muv point in time ag urns ql if
14553-2,urns muv ag urns presence if
14553-2,muv ag if ql (urine sed)
14553-2,muv ag (urine immunofluor presence if sed)
14553-2,infectious disease (urine ag if ql muv sed)
3901-6,para hydroxyamphetamine [presence] in urine
3901-6,hydroxyamphetamine para [ql] in urine
3901-6,para para hydroxy amphetamine ydroxyphtm presence] in urin
3901-6,p-oh-amphet ur ql
3901-6,qual ur p-oh-amphet ql
3901-6,p-oh-ampet pr ur ql
3901-6,para hydroxyamphetamine ql (u)
3901-6,para hydroxyamphetamine drug/toxicology presence (u)
3901-6,para hydroxyamphetamine ur (u) presence
4059-2,tobramycin [mass/volume] in serum or plasma --trough
4059-2,tobramycin [ass/volume] quantitative in srumor plas --trough
4059-2,tobramycin in [masolume] serum o plasma drug/toxicology -trough
4059-2,tobramycin trough serpl-mcnc
4059-2,tobramycin trough serpl-mcnc serpl
4059-2,tobramycin trough serpl-mcnc
4059-2,tobramycin trough [mass/vol]
4059-2,tobramycin [mass/vol] trough
4059-2,trough tobramycin [mass/vol]
84908-3,cancer pathology panel - prostate cancer
84908-3,cancer pathology panel cancer prostate -
84908-3,cancer - panel pathology prostate cancer
84908-3,cancer path pnl prostate cancer
84908-3,cancer path other cancer prostate pnl
84908-3,cancr path prostatecncer pnl
84908-3,cancer pathology panel (prostate cancer)
84908-3,cancer pathology panel misc (prostate cancer)
84908-3,cancer (prostate panel pathology cancer)
18385-5,butalbital [presence] in urine by confirmatory method
18385-5,btlbital [resnce] in urineby ua confirmtory eto
18385-5,butalbitl [resence] in riny conirmaory urn methd
18385-5,butalbital ur ql cfm
18385-5,butalbital ur cfm ql
18385-5,butalbital ql ur cfm
18385-5,butalbital confirm ql (u)
18385-5,btalbital conf onfirm ql u)
18385-5,utalbitalonfirm ql (u) addiction
12505-4,cadmium [mass/volume] in red blood cells
12505-4,level cadmium [mass/volume] in red blood cells
12505-4,cadmium blood in quantitative red [mass/volume] cells
12505-4,cadmium rbc-mcnc
12505-4,rbc-mcnc cadmium
12505-4,rbc-mcnc quan cadmium
12505-4,cadmium (rbc) [mass/vol]
12505-4,erythrocytes [mass/vol] (rbc) cadmium
12505-4,admu rbc) mass/vol] red blood corpusles
57671-0,brucella melitensis igm ab [units/volume] in serum by immunoassay
57671-0,b melitensis brucella melitensis igm b [uitvlume]in serm by immuoasay
57671-0,melitensis brucella im ab [unit/volume]in ser by immunoassay
57671-0,b melitensis igm ser ia-acnc
57671-0,b eitensis ig serum ia-acnc
57671-0,id serum igm meltensis i-cn
57671-0,b. melitensis igm ia qn (s)
57671-0,abs b. melitensis iga qn (s)
57671-0,b. melitensis random igm ia qn (s)
45343-1,sex+stage of tick
45343-1,of sex+stage tick point in time
45343-1,tick of sex+stge
45343-1,sex+stage tick
45343-1,sex+stage tick identity or presence
45343-1,sx+tag tic
45343-1,sex and stage nom (tick)
45343-1,infectious disease (tick) and stage nom sex
45343-1,(tick) and stagenom sex
104712-5,human coronavirus nl63 rna [presence] in specimen by molecular genetics method
104712-5,human coronavirus in rna microbiology [presence] nl63 specimen by molecular genetics method
104712-5,human coronavirus nl63 rna [ql] in specimen by molecular genetics method
104712-5,hcov nl63 rna spec ql
104712-5,cv nl6 rnapecql random
104712-5,ql nl63 rna spec hcov
104712-5,hcov nl63 rna molgen ql (specimen)
104712-5,hcov nl63 rna molgen presence (specimen)
104712-5,hcov nl63 rna hcov nl63 molgen ql (specimen)
62648-1,phenx - causes and treatments of known infertility - female protocol 100202
62648-1,phenx - causs an treaments panl femae known infetility - of protocl 100202
62648-1,phenx - causes treatments and of known infertility - female protocol 100202
62648-1,cause treat infertility female proto
62648-1,treat cause infertility female proto
62648-1,cause tret femle infertlity prot
87210-1,care area assessment (caa) and care planning during assessment period [cms assessment]
87210-1,care area assessmet (caa) car and planningduring assessmnt perod [cms asesment]
87210-1,care area assessment (caa) and care planning during assessment period [cms panel.survey.cms assessment]
92890-3,hepatitis a and b and c virus immunity andor previous exposure panel - serum or plasma
92890-3,hepatitis a and b and c virus immunity andor previous pnl exposure panel - serum or plasma
92890-3,hepatitis a and b and c immunity virus andor previous exposure panel - serum or plasma
92890-3,hav+hbv+hcv immunity +or expos pnl serpl
92890-3,hv+hbv+hcv immunity+orexpos serum or plasma pnl serpl
92890-3,serpl immunity +or expos pnl hav+hbv+hcv
92890-3,hepatitis a and b and c virus immunity andor previous exposure panel
92890-3,hepatitis a and b and c virus immunity andor panel.microbiology previous exposure panel
92890-3,hpatitis an b c nd virus imunity andor hepatit previous expoue panel
49425-2,papova virus sv 40 dna [#/volume] (viral load) in specimen by naa with probe detection
49425-2,papova vrus sv 40 dna [#/volue] (viral lad) inspcimn by naa wit probe detecion
49425-2,papova virus sv 40 dna [#/volume] (viral load) in specimen by naa with probe detection
49425-2,sv40 dna # spec naa+probe
49425-2,sv40 dna naa+probe spec #
49425-2,sv40 naa+probe spec # dna naa+probe
49425-2,papova virus sv 40 dna naa+probe (specimen) [#/vol]
49425-2,papova naa+probe [#/vol] sv 40 dna naa+probe (specimen) virus
49425-2,papova virus (specimen) 40 dna naa+probe sv [#/vol]
24453-3,deprecated carnitine (c0) [molecules/mass] in tissue
24453-3,"deprecated tissue, unspecified carnitine in [molecules/mass] (c0) tissue"
24453-3,[molecules/mass] carnitine (c0) deprecated chemistry in tissue
24453-3,deprecated carnitine tiss
24453-3,deprecatecarnitne chemistry tis
24453-3,deprecated carnitine tiss chemistry
24453-3,carnitine (tiss) [moles/mass]
24453-3,carnitine (tiss) substance content [moles/mass]
24453-3,[moles/mass] (tiss) substance content carnitine
35648-5,c reactive protein [quintile] in serum or plasma by high sensitivity method
35648-5,c sensitivit [qintile in seum o plam by ih reactiveprotein method
35648-5,c ractivepoein [quinile] in seum or plasma by high sensitivty methd
35648-5,crp quint serpl qn hs
35648-5,crp quint serpl pr qn hs
35648-5,crp quint serp qn hs
35648-5,crp high sensitivity method [quintile]
35648-5,crp high sensitivity method hscrp [quintile]
35648-5,method high sensitivity crp serp [quintile]
56651-3,cadmium/creatinine [ratio] in urine
56651-3,cadmium/creatinine in ua [ratio] urine
56651-3,cadmium/creatinine urine in [ratio]
56651-3,cadmium/creat ur-rto
56651-3,cadmium/creat urn urto
56651-3,ur-rto cadmiu/crea
56651-3,cadmium/creatinine (u) [ratio]
56651-3,[ratio] (u) crea cadmium/creatinine
56651-3,cadmium/creatinine (u [raio]
27107-2,lysine [moles/volume] in amniotic fluid
27107-2,[moles/volume] lysine in amniotic fluid
27107-2,lysine [moes/volume]in amniotc flid
27107-2,lysine amn-scnc
27107-2,amn-scnc lysine
27107-2,amn-scnc substance concentration lysine
27107-2,lysine (amn fld) [moles/vol]
27107-2,lysine amn fl) [moles/vol]
27107-2,lysine (amn point in time ld) [moles/vol]
49352-8,epstein barr virus dna [#/volume] (viral load) in urine by naa with probe detection
49352-8,dna barr virus epstein [#/volume] (viral load) in urine by naa with probe detection
49352-8,epstein probe virus dna [#/volume] (viral load) in urine by naa with barr detection
49352-8,ebv dna # ur naa+probe
49352-8,absolutes ebv dna # ur naa+probe
49352-8,ur dna # ebv naa+probe
49352-8,ebv dna naa+probe (u) [#/vol]
49352-8,dna ebv naa+probe (u) [#/vol]
49352-8,ebv [#/vol] naa+probe (u) dna
104111-0,legionella pneumophila dna [presence] in upper respiratory specimen by naa with non-probe detection
104111-0,legonellapneumopila dna [presence] ql iuppe respiratory specimen by naa with non-probedetection
104111-0,lionela pneuopha dna [presence] in upper repirtry seime by nucleic acid sequence based analysis naaith non-robe dection
104111-0,l pneumo dna upper resp ql naa+non-probe
104111-0,naat lneumo dnupper resp presence naa+nn-robe
104111-0,tma l pneumo dna upper resp ql naa+non-probe
104111-0,l. pneumophila dna naa+non-probe ql (upper resp)
104111-0,l. pneumophila dna naa+non-probe resp) (upper ql
104111-0,pneuohila l. dna a+non-probeql (pper amplified resp
48630-8,creatinine [mass/volume] in peritoneal fluid --pre dialysis
48630-8,ascitic fluid ass/olume] ceatinine in peritonea fuid -pr dialysis
48630-8,creatinine dialysis in peritoneal fluid --pre [mass/volume]
48630-8,creat pre dial prt-mcnc
48630-8,dial pre creat prt-mcnc
48630-8,creat prt-mcn dial pre
48630-8,creatinine pre dialysis (periton fld) [mass/vol]
48630-8,creatinine pre dialysis (periton fld) [mass/vol]
48630-8,creatinine (periton dialysis pre fld) prt [masvol]
101112-1,mds v3.0 - rai v1.18.11 - swing bed pps (sp) item set during assessment period [cms assessment]
101112-1,md v3. - ra v.1.11 - assesment bed pps (sp iem set during sing periodcs ssessmnt]
101112-1,mds v3.0 - rai v1.18.11 - swing bed pps (sp) assessment set during item period [cms assessment]
96463-5,copper free/total copper in serum or plasma by calculation
96463-5,copper fre/total oper or seum in plama by callation
96463-5,copper free/total copper plasma ser or in by calculation
96463-5,copper free/total copper mfr serpl calc
96463-5,copper free/total copper serpl mfr serpl calc
96463-5,copper free/total copper serpl mfr calc
96463-5,copper free/total copper calc [mass fraction]
96463-5,copper [mass copper calc free/total fraction]
96463-5,copper freetoal coper ca [massfraction]
86102-1,streptococcus pneumoniae danish serotype 10a igg ab [mass/volume] in serum --2nd specimen
86102-1,streptococcus pneumoniae danish serotype 10a igg ab [mass/volume] in ser --2nd specimen
86102-1,streptococcus pneumoniae danish serotype 10a igg ab [mass/volume] in ser --2nd specimen
86102-1,s pneum da 10a igg sp2 ser-mcnc
86102-1,s pnema 10a ig sp2 r-mcn
86102-1,s pneumd10a igg sp se-mcnc
86102-1,s. pneumoniae danish type 10a igg spec 2 (s) [mass/vol]
86102-1,s. pneumoniae danish type 10a 2 spec igg (s) [mass/vol]
86102-1,s. nemoniae danish ype 10a igg spec 2 (s) [mas/vol]
2766-4,phenylalanine [mass/volume] in urine
2766-4,phenylaanin [massvolume] in urine
2766-4,in [mass/volme] phenylalanne urie
2766-4,phe ur-mcnc
2766-4,ua phe ur-mcnc
2766-4,ur-mcnc phe
2766-4,phenylalanine (u) [mass/vol]
2766-4,(u) random phenylalanine [mass/vol]
2766-4,phenylalanine () [mss/v]
83094-3,digoxin [moles/volume] in serum or plasma by immunoassay
83094-3,or [moles/volume] in serum digoxin plasma by immunoassay
83094-3,[moles/volume] digoxin in ser or plasma by immunoassay
83094-3,digoxin serpl ia-scnc
83094-3,digoxin quan serpl ia-scnc
83094-3,digoxin serum or plasma ia-scnc
83094-3,digoxin ia [moles/vol]
83094-3,serpl digoxin [moles/vol] ia
83094-3,[moles/vol] eia ia digoxin
71951-8,infant development inventory [idi]
71951-8,nfant development inventory [idi]
71951-8,ifant development inventry [id]
93758-1,erysipelothrix sp [presence] in tissue by immune stain
93758-1,erysipelothrix pt stain [presence] in tissue by immune sp
93758-1,in s [reenc] eysipelotri qual issue by immestain
93758-1,erysipelothrix sp tiss ql imstn
93758-1,eryipelothrix sp iss qmstn spp
93758-1,erysipelothrix tiss sp ql imstn
93758-1,erysipelothrix sp immune stain ql (tiss)
93758-1,ql sp immune stan erysipelthrix (tiss
93758-1,rysipethrix immnestinql sp (tiss)
74646-1,methamphetamine [presence] in saliva (oral fluid) by confirmatory method
74646-1,methamphetamin [presence] insaliva (ral flid) y confirmatry method
74646-1,fluid) [ql] in saliva (oral methamphetamine by confirmatory method
74646-1,methamphet sal ql cfm
74646-1,methamphet ql sal cfm drug/toxicology
74646-1,sal ethamphet cfm salql
74646-1,methamphetamine confirm ql (sal)
74646-1,conf methamphetamine confirm presence (sal)
74646-1,confirm methamphetamine ql (sal)
1979-4,biopterin [mass/volume] in 24 hour urine
1979-4,biopterin [mass/volume] hour 24 in urine
1979-4,biopterin mass/volume] in24hur urine
1979-4,biopterin 24h ur-mcnc
1979-4,24h biopterin ur-mcnc
1979-4,biopterin 24h r-cnc
1979-4,biopterin (24h u) [mass/vol]
1979-4,bopterin (24 u) [mass/vol]
1979-4,biopterin chemistry (24h u) [mass/vol]
22132-5,borrelia burgdorferi igm ab [presence] in cerebral spinal fluid
22132-5,borrelia burgdorferi igm ab [presence] in fluid spinal cerebral
22132-5,borrelia burgdorferi igm ab [ql] in fluid spinal cerebral
22132-5,b burgdor igm csf ql
22132-5,csfql burgdor igm b
22132-5,b burgdor igm cs lymes q
22132-5,b. burgdorferi igm ql (csf)
22132-5,b. ql igm burgdorferi (csf)
22132-5,b. burdorfer ig presence (csf)
40404-6,tripelennamine [presence] in gastric fluid
40404-6,tripeennamine in presene] gastricfluid
40404-6,tripelennamine [peence] gastric contents in gastic flid
40404-6,tripelennamine gast ql
40404-6,presence triplennaminegas gastric contents
40404-6,tripelnnmine gast ql
40404-6,tripelennamine ql (gast fld)
40404-6,(gast ql tripelennamine fld)
40404-6,ql tripelenamine (ast qualitative fld)
88515-2,natural killer cell cytotoxicity.3.75:1 effector to target cell ratio/positive control in blood mononuclear cells
88515-2,natural killer cell cytotoxicity.3.75:1 effector to target cell ratio/positive control in blood qnt mononuclear cells
88515-2,natural killer cell ytotoxiiy.3.51 efector o target cl ratio/positive cotrol in blood mononucearcells
88515-2,nk cytotox.3.75:1 e:t/pos cntrl bld mc
88515-2,nk pbmc cytotox.3.75:1 e:t/pos cntrl bld mc
88515-2,nk cytotox.3.75:1 e:t/pos cntrl bld mc pbmc
88515-2,nk cytotoxicity 3.75:1 e:t ratio/positive control (bld mc) [rel units/vol]
88515-2,nk whole blood cytotoxicity control e:t ratio/positive 3.75:1 (bld mc) [rel units/vol]
88515-2,nk cytotoxicity 3.75:1 e:t [rel control (bld mc) ratio/positive units/vol] quan
55959-1,ornithine/amino acids.total in serum or plasma
55959-1,ornithine/mino acid.total inserum r aa lasma
55959-1,ornithine/amino or in serum acids.total plasma
55959-1,ornithine sfr serpl
55959-1,ornithi sfr serum or plasma
55959-1,fr ornthine serl quantitative
55959-1,ornithine/total aa [molar fraction]
55959-1,ornithine/total aa [molar fraction] orn
55959-1,aamolar onithne/total fractio]
634-6,bacteria identified in specimen by aerobe culture
634-6,bacteria by in specimen identified aerobe culture
634-6,bacteia ientifed in specimen byaerobe culure
634-6,bacteria spec aerobe cult
634-6,bacter aerobe id spec cult
634-6,bacteria specaerobe cult
634-6,bacteria identified aer cx nom (specimen)
634-6,bcteria (specimen) aercx no aerobe identified
634-6,aer identified bacteria cx nom (specimen)
46445-3,patient-confidential section set naaccr v.11
46445-3,patient-confidential section set tumor registry(naaccr) naaccr v.11
46445-3,patient-confidential section set naaccr north american association of central cancer registries v.11
46445-3,patient-confidential section naaccr v.11
46445-3,ptint-cofidentil setinnaaccv.11
46445-3,aient-confidntial ection pnl naaccr v.1
94559-2,sars-cov-2 (covid-19) orf1ab region [presence] in respiratory system specimen by naa with probe detection
94559-2,sars-cov-2 (covid-19) orf1ab region probe with ampification [presence] in respiratory system specimen by naa with probe detection
94559-2,sars-cov-2 (covid-19) orf1ab detection [presence] in respiratory system specimen by naa with probe region
94559-2,sars-cov-2 orf1ab resp ql naa+probe
94559-2,sars-cov-2 orf1ab resp  naapoe
94559-2,sarscov-2 orf1ab resp amplification ql naa+probe
94559-2,sars-cov-2 (covid-19) orf1ab region naa+probe ql (respiratory system specimen)
94559-2,sars-cov-2 (covid-19) orf1ab region naa+probe (respiratory ql system specimen)
94559-2,sas-co-2 (covid-19 (respiraory regionaapobe q rf1ab system specimn)
43357-3,chlamydia trachomatis d+e+f+g+h+i+j+k igm ab [titer] in serum by immunofluorescence
43357-3,lmydia trachomats d+e+f+g+h+i+j+k igm ab [tter in serum acif b immunolucence
43357-3,igm trachomatis d+e+f+g+h+i+j+k chlamydia ab [titer] in ser by immunofluorescence
43357-3,c trach d+e+f+g+h+i+j+k igm titr ser if
43357-3,ttr c trach d+ef+g+h+i++k igm titr se if
43357-3,ser trach d+e+f+g+h+i+j+k igm titr c if
43357-3,c. trachomatis d+e+f+g+h+i+j+k igm if (s) [titer]
43357-3,infectiousdisease c. trachomatis d+e+f+g+h+i+j+k igm if (s) [titer]
43357-3,de++g+h+i+j+k trachomati c. g if immunofluorescence (s) [titer
29321-7,rickettsia typhi igg ab [presence] in body fluid
29321-7,igab typhi ricktti bod [pesence] inbody fluid
29321-7,"in thi igg ab presence] icetti body fluid, unsp bo luid"
29321-7,r typhi igg fld ql
29321-7,r typhi igg fld presence
29321-7,flu r yphi igfld ql
29321-7,r. typhi igg ql (body fld)
29321-7,r. typhi igg presence (body fld)
29321-7,r typhi igg typh ql (bod fld)
60113-8,deprecated oxypurinole
60113-8,xypuinl serp deprecated
60113-8,xypurinole deprecated
60113-8,deprecated oxypurinole
60113-8,deprecated oxypurinole qnt
60113-8,oxypurinol deprecated
60113-8,oxypurinol [mass/vol]
60113-8,[mass/vol] oxypurinol ser
60113-8,oxypurinol [mass/vol] drug/toxicology
38177-2,kappa light chains.free [mass/time] in 24 hour urine
38177-2,kappa immunoglob light hour [mass/time] in 24 chains.free urine
38177-2,ppa chain light chainsfree [mass/time] in 2 hur urie
38177-2,kappa lc free 24h ur-mrate
38177-2,lc kappa free 24hr-mrate
38177-2,kapa ree lc quan 24h ur-mrte
38177-2,immunoglobulin light chains.kappa.free (24h u) [mass/time]
38177-2,mmunoglolin light [mass/ime] u) chains.kapa.free(24h
38177-2,ligh immunoglbulin chains.kappa.free (24hu) [mass/time]
3833-1,moxalactam [mass/volume] in serum or plasma
3833-1,moxalactam or serum n serum [mass/olme] plas
3833-1,moxalatam plasma inserumor [mass/volume]
3833-1,moxalactam serpl-mcnc
3833-1,serpl oxalacamserl-mcc
3833-1,serpl-mcnc moxalactam
3833-1,moxalactam [mass/vol]
3833-1,moxalactam [mass/vol] quan
3833-1,ser or plasma moalactam[mass/vo]
103716-7,deprecated yersinia pestis dna [presence] in blood by naa with non-probe detection
103716-7,deprcted qbr yersiia pestisda by in bld [prence] na with non-probedetcton
103716-7,sda deprecated yersinia pestis dna [presence] in blood by naa with non-probe detection
103716-7,deprecated y pestis dna bld ql naa+non-probe
103716-7,pestis y deprecated dna bld ql naa+non-probe
103716-7,depecated y pstis dna bld q na+on-robe
103716-7,y. pestis dna naa+non-probe ql (bld)
103716-7,estisdna y. na+non-probe ql (bld)
103716-7,whole bld y.ptis dnanaa+non-probe ql (bld)
25989-5,threonine/creatinine [molar ratio] in 24 hour urine
25989-5,threoninecreatinine [mola ratio] substance concentration ratio in urine 24hour
25989-5,threoine/creatinine [molar rtio] ucr in 24 hour urine
25989-5,threonine/creat 24h ur-srto
25989-5,threonine/creat 24h urn ur-srto
25989-5,quantitative threonine/creat ur-srto 24h
25989-5,threonine/creatinine (24h u) [molar ratio]
25989-5,threonine/creatinine u) (24h [molar ratio]
25989-5,threonine/creatinine (24h [molar u) ratio] ur
62389-2,chromosome analysis master panel
62389-2,chromosome panel master point in time analysis
62389-2,chromosome panel master analysis
62389-2,chromosome analysis master panel
62389-2,master analysis chromosome pane
62389-2,chromosome karyotype master analysis panel
62389-2,chr analysis master panel (bld/tiss)
62389-2,chrnalysis panel master (bd/tis)
62389-2,chr analysis master panel (bld/tiss)
22340-4,herpes simplex virus ab [titer] in cerebral spinal fluid
22340-4,herpes simplex virus cerebral [titer] in point in time ab spinal fluid
22340-4,herpes simplex virus ab [titer] in spinal cerebral fluid id
22340-4,hsv ab titr csf
22340-4,hs btt abs csf
22340-4,hsv csf titr ab
22340-4,hsv ab (csf) [titer]
22340-4,hsv [titer] (csf) ab
22340-4,hsv (csf) ab [titer]
102084-1,b-cell lymphoblastic leukemia monitoring minimal residual disease detection in blood or marrow by flow cytometry (fc)
102084-1,b-cell blood lymphoblastic minimal monitoring leukemia residual disease detection in blood or marrow by flow cytometry (fc)
102084-1,b-cell lymphblstic leukemia moitorin minimal residal disease blod in detectin or marrow by flow cytometry fc)
102084-1,bcell lym lk monitor mrd det bld/mar fc
102084-1,bcell marrow (bone) et monitr md lymlk blood/mr fc
102084-1,bcell lym lk monitor mrd det bld/mar fc
102084-1,b-cell lymphoblastic leukemia monitoring minimal residual disease detection fc (bld/bm)
102084-1,b-cell lymphoblastic point in time leukemia monitoring minimal residual disease (bld/bm) fc detection
102084-1,b-cell lympholastic leukemia monitorinminimal residual disease etcion fc bld/mar (bld/bm
50265-8,2-dechloroethylifosfamide [mass/volume] in blood --pre dose ifosfamide
50265-8,2-dechloroethylifosamide --predose in ifex blood mass/olume] fosfamd
50265-8,2-dechloroethylifosfamide in [mass/volume] blood iff --pre dose ifosfamide
50265-8,2-dce-if pre iff bld-mcnc
50265-8,bld-mcnc pre iff 2-dce-if
50265-8,2-dce-if iff pre bld-mcnc mitoxana
50265-8,2-dechloroethylifosfamide pre dose ifosfamide (bld) [mass/vol]
50265-8,dose pre 2-dechloroethylifosfamide random ifosfamide (bld) [mass/vol]
50265-8,2-dechloroethylifosfamide pre dose drugs ifosfamide (bld) [mass/vol]
608-0,bacteria identified in ear by aerobe culture
608-0,bacteria identified in ear by identity or presence aerobe culture
608-0,bacteria identified identity or presence in ear by aerobe cultre
608-0,bacteria ear aerobe cult
608-0,bacteria bact ear aerobe cult
608-0,c&s bacteria ea aerobe cult
608-0,bacteria identified aer cx nom (ear)
608-0,acteria (ear) cx nom identifiedar
608-0,bacteria identifed aer (ear) nom cx
23541-6,venezuelan equine encephalitis virus ab [presence] in serum by complement fixation
23541-6,venezuelan equine encephalitis virus ab [presence] in serum random by complement fixation
23541-6,venezuelan equine encephalitis virus ab [presence] in ql serum by fixation complement
23541-6,veev ab ser ql cf
23541-6,veev ab r l cf equin
23541-6,veevab serum ql cf antibody
23541-6,veev ab cf ql (s)
23541-6,(s) equin bcf ql vev
23541-6,vev ab cf q 
86004-9,streptococcus pneumoniae danish serotype 14 ab [mass/volume] in serum --2nd specimen
86004-9,stretococcuspneumniae danish [mass/volume] ab seotype14 in serum --2nd specimen
86004-9,ser anih serotype 14ab [mass/olue] in streptocccuspneumoniae --2nd speimen
86004-9,s pneum da 14 ab sp2 ser-mcnc
86004-9,s pneum sp2 14 ab da serum-mcnc
86004-9,s neum pt da 14ab p2 ser-mcnc
86004-9,s. pneumoniae danish type 14 ab spec 2 (s) [mass/vol]
86004-9,s. pneumoniae danish pneumon type 14 ab spec 2 (s) [mass/vol]
86004-9,s. pneumoniae danish type (s) ab spec u.s. serotype 14 2 14 [mass/vol]
20962-7,serpulina hyodysenteria [presence] in spiral colon by organism specific culture
20962-7,serpulina hyodysenteria [presence] in spiral colon by organism specific sp colon culture
20962-7,serpuina hyoyseteri[prsence] in qualitative piral col by organim pecifi culture
20962-7,s hyodysenter sp colon ql cult
20962-7,colon hyodysenter sp s ql cult
20962-7,s olon s ydysentr l cult
20962-7,s. hyodysenteria org specific cx ql (spiral colon)
20962-7,s. hyodysenteria cx specific org presence ordinal (spiral colon)
20962-7,s. hyodysenteria org specific cx ql (spiral colon) lgi
77729-2,"oxymorphone [mass/volume] in serum, plasma or blood by confirmatory method"
77729-2,"oxymorphone [mass/volume] in serum, lc/ms/ms plas or confirmatory by blood method"
77729-2,oxyophone [mass/volume] in serum lasma or od byconfirmatory mthod
77729-2,oxymorphone serplbld cfm-mcnc
77729-2,serplbld oxymorphone cfm-mcnc
77729-2,cfm-mcnc serplbld oxymorphone
77729-2,oxymorphone confirm (s/p/bld) [mass/vol]
77729-2,(s/p/bld) confirm oxymorphone [mass/vol]
77729-2,oxymorphone (s/p/bld) confirm [mass/vol]
104731-5,clostridioides difficile toxin genes [presence] in stool by molecular genetics method
104731-5,clotridiodes diffiile toxin gees[presence] in sool by moleclar genticsmetod
104731-5,clostridioides difficile toxin genes [presence] in stool by molecular genetics method
104731-5,c diff tox gens stl ql
104731-5,c diff tox gens ordinal stl presence
104731-5,diff tox gens stl presence
104731-5,c. difficile toxin genes molgen ql (stl)
104731-5,c. difficile toin genes mlge screen q (stl)
104731-5,stl ql difficile toxin genes molgen c. (stl)
3743-2,mefenorex [mass/time] in 24 hour urine
3743-2,mefenorex [mass/time] 24 in hour urine
3743-2,24 hours mefenorex [mass/time] 24 in hour urine
3743-2,mefenorex 24h ur-mrate
3743-2,mefenorex 24h ur-mrate
3743-2,24h mass rate mefenorex ur-mrate
3743-2,mefenorex (24h u) [mass/time]
3743-2,mrate mefenor 24h u)[mass/time]
3743-2,mefenorex u) (24h [mass/time]
63217-4,cyclic citrullinated peptide igg ab [units/volume] in body fluid by immunoassay
63217-4,cyclic citrullinated peptide igg ab [units/volume] in body fluid by immunoassay
63217-4,citrullinated cyclic peptide igg ab [units/volume] in body fluid by immunoassay meia
63217-4,ccp igg fld ia-acnc
63217-4,ccp igg ia-acnc fld
63217-4,ccp fld igg i-acn ccp3
63217-4,cyclic citrullinated peptide igg ia qn (body fld)
63217-4,cyclic citrullinated peptide ia igg qn (body fld)
63217-4,eia qn ctrulinatd pptide igg ia clic (body fld)
48897-3,orientia tsutsugamushi gilliam igg ab [titer] in body fluid by immunofluorescence
48897-3,orienta tssuamushi gillam gg ab [tier]i ody oriental scrub typhus fluid by immunofluorescence
48897-3,orienia sutsugamush gilliam igg o tsutsugamushi ab [tite] in body fluid immuofluorescence
48897-3,o tsut gill igg titr fld if
48897-3,o tsut immunofluor gill fld titr igg if
48897-3,o tsut gill igg if fld titr
48897-3,o. tsutsugamushi gilliam igg if (body fld) [titer]
48897-3,gllia tsutsgamushi g if (ody fd) [titer]
48897-3,o. tsutsugamushi gilliam igg if (body fld) [titer]
31252-0,basement membrane ab [units/volume] in serum
31252-0,basement membrane ab [units/volume] in quant serum
31252-0,basement serum ab [units/volume] in membrane
31252-0,bm ab ser-acnc
31252-0,er-acnc ab arbitrary concentration bm
31252-0,ab autoantibody bm ser-acnc
31252-0,basement membrane ab qn (s)
31252-0,ab membrane basement qn (s) basem
31252-0,ab membrane basement qn (s) antibody
38293-7,"cis-1,2-dichloroethylene [mass/volume] in water"
38293-7,"cis-1,2-dichloroethylene i [mass/volume] in water"
38293-7,"in [mass/volume] cis-1,2-dichloroethylene water"
38293-7,"cis-1,2-dce wat-mcnc"
38293-7,"wat-mcnc cis-1,2-dce"
38293-7,"random ci-1,2-deat-mcnc"
38293-7,"cis-1,2-dichloroethylene (water) [mass/vol]"
38293-7,"cis-1,2-dichloroethylene [ass/vol] wate)"
38293-7,"[mass/vol] (water) cis-1,2-dichloroethylene random"
71649-8,lymphocytes/leukocytes [pure number fraction] in body fluid by manual count
71649-8,lymphocytes/leukocytes [pure number fraction] fluid body in by manual count
71649-8,lymphocyes/ukocytes body n [puenumefraction fluid fluid by manual count
71649-8,lymphocytes nfr.df fld manual
71649-8,leuc nfdf ymphocytes l manual
71649-8,lymphocytes nfr.df manual fld
71649-8,lymphocytes/leukocytes manual cnt (body fld) [pure # fraction]
71649-8,lymphocytes/lekocytes manuacnt (body fld) [pre # fraction]
71649-8,lypocytes/leukoytes manual cnt (body fld)[ure # facin]
25289-0,streptococcus pneumoniae danish serotype 18c igg ab [units/volume] in serum --2nd specimen
25289-0,streptocccus neumniae danishserotype 18c igg ab [units/olume] in serum --d pecmen
25289-0,stretococcs pneumoniae daish rotye 18c igg ab [units/volume] in serum -2n specimen
25289-0,s pneum da 18c igg sp2 ser-acnc
25289-0,da pneum s 18c igg aby sp2 ser-cnc
25289-0,immune globulin g s pnum da18c ig sp2 ser-acc
25289-0,s. pneumoniae danish type 18c igg spec 2 qn (s)
25289-0,qn pnuoniae danish type 18c igg sec 2 s. (s)
25289-0,s. pneumniae das type 18c igg spec spec qn ()
81216-4,progress note - recommended c-cda r2.0 and r2.1 sections
81216-4,proress note r2.0 c-a -recommended and r2.1 sectins
81216-4,progress note - recommended evaluation and management c-cda r2.0 sections r2.1 and
81216-4,prog note c-cda r2.0+2.1 sections
81216-4,prog note visit note c-cda r2.0+2.1 sections
81216-4,prog subsequent visit evaluation note c-cda r2.0+2.1 sections
13827-1,beryllium/creatinine [mass ratio] in urine
13827-1,berylliumreatnie [mas rtio] in uine
13827-1,erllium/ceatinie [mss ratio] urine i
13827-1,beryllium/creat ur
13827-1,berylium/crat quantitative ur
13827-1,beryllium/creat ur
13827-1,beryllium/creatinine (u) [mass ratio]
13827-1,beryllium/creatinine ua ratio] [mass (u)
13827-1,ratio] (u) random [mass beryllium/creatinine
5122-7,cytomegalovirus ab [units/volume] in serum or plasma by immunofluorescence
5122-7,cytomeglovirus imunofluorescence [units/volume] time resolved fluorescence n serum orplsa by ab
5122-7,cytomegalovirus or [units/volume] in serum ab plasma autoantibodies by immunofluorescence
5122-7,cmv ab serpl if-acnc
5122-7,cmv if-acnc serpl ab
5122-7,if-acnc ab serum or plasma cmv
5122-7,cmv ab if qn
5122-7,cmv if ab arbitrary concentration qn
5122-7,aby cmv ab if qn
1659-2,11-hydroxyandrosterone [mass/volume] in urine
1659-2,in [mass/volume] 11-hydroxyandrosterone mass concentration urine
1659-2,11-hydroxyandroseroe [mass/volume] in urie
1659-2,11oh-androst ur-mcnc
1659-2,11oh-androst ur-mcnc pt
1659-2,quant 11ohdrost u-cnc
1659-2,11-hydroxyandrosterone (u) [mass/vol]
1659-2,11-hydroxyandrosteone [ass/vol] (u)
1659-2,11-hydroxyandrosterone (u) pt [mass/vol]
1782-2,alkaline phosphatase.renal [enzymatic activity/volume] in serum or plasma
1782-2,orplasma phosphatae.rnal [enzymatic activity/volue in serum alkaline alp
1782-2,alkaline phosphatase.renal [enzymatic activity/volume] in serum plas or
1782-2,alp renal serpl-ccnc
1782-2,quant alp serpl-ccnc renal
1782-2,ap enl serpl-ccn
1782-2,alp renal [catalytic activity/vol]
1782-2,alp [catalytic renal ap activity/vol]
1782-2,alp renal [catalytic activity/vol]
95845-4,nucleated cells [#/volume] in sputum by manual count
95845-4,by cells [#/volume] in sputum nucleated manual count spt
95845-4,nucleated cells manual in sputum by [#/volume] count count/volume
95845-4,nuc cell # spt manual
95845-4,n cell # spt manul
95845-4,nuc cll # spt manual
95845-4,nucleated cells manual cnt (sput) [#/vol]
95845-4,nucleated cells (sput) nuc cnt manul [#/l]
95845-4,nucleated [#/vol] manual cnt (sput) cells
31763-6,chlamydia sp ag [presence] in conjunctival specimen
31763-6,chlamydia sp i [preene] ordinal ag conjunctival specimen
31763-6,chlamydia sp ag [presence] in ql conjunctival specimen
31763-6,chlamydia ag conjunct ql
31763-6,g clamydia conjunct ql
31763-6,ag chlamydia conjunct ql
31763-6,chlamydia sp ag ql (conj)
31763-6,chlamydia sp ag presence (conj)
31763-6,chlamydia (conj) ag ql sp id
15153-0,deprecated indirect bilirubin [mass/volume] in serum or plasma
15153-0,[mas/volume] bilirubin deprecatedindirect inserumorplasma
15153-0,deprecated indirect bilirubin in [mass/volume] serum or plasma
15153-0,deprecated bilirub indirect serpl-mcnc
15153-0,deprecated bilirub indirect serpl-mcnc chemistry
15153-0,deprecated indirect bilirub sr serpl-mcnc
15153-0,bilirubin.indirect differential light absorption [mass/vol]
15153-0,bili bilirubin.indirect differential absorption light [mass/vol]
15153-0,absorpon differentiallight bilirubin.inirect bilirubin primary [mas/vol]
53996-5,nuclear matrix ab pattern [presence] in serum by immunofluorescence
53996-5,nuclear matrix b patten [presnce] in seum by imunofluoresece
53996-5,nuclear matrix ab pattern [presence] in serum by immunofluorescence
53996-5,ana nuclear matrix ser ql if
53996-5,ana nuclear matrix ql ser if
53996-5,ana if matix ser presence nuclear
53996-5,nuclear matrix ab pattern if ql (s)
53996-5,if matrix screen ab pattern nuclear presence (s)
53996-5,nuclear matrix i pattern fa ab ql(s
49905-3,hiv 1 ab [presence] in specimen by rapid immunoassay
49905-3,hiv 1 ab by in specimen [presence] rapid immunoassay
49905-3,hiv 1 ab [presence] in specimen by rapid immunoassay random
49905-3,hiv1 ab spec ql ia.rapid
49905-3,ab hiv1 spec ql ia.rapid meia
49905-3,h1 ab spe presence ia.rapid
49905-3,hiv 1 ab ia.rapid ql (specimen)
49905-3,hiv 1 ab presence ia.rapid (specimen)
49905-3,hi 1 abia.rapid (secimen) presence
41876-4,rickettsia typhi and rickettsia spotted fever group igg and igm panel - serum
41876-4,sf igg+igm pnl rickettsa typhi and rickettsia spoted fever grop igg and gm anel - serum
41876-4,riktsia tyhi and ickettsia potted feve groupigg a igm pnel - serm
41876-4,r typhi and sf igg+igm pnl ser
41876-4,r typhiand sf igg+igm pnlser
41876-4,typhi r and sf igg+igm pnl ser
41876-4,r. typhi and r. spotted fever group igg and igm panel (s)
41876-4,r. typhi ad . pttd infectious disease feve group igg and igm panel (s
41876-4,r. typhi and r. spotted fever group igg (s) igm panel and
71778-5,rift valley fever virus ag [presence] in serum by immunoassay
71778-5,rift valle fevr vrus ag [ql]in serum by immunoassy
71778-5,rift valley fever ag virus meia [presence] in serum by immunoassay
71778-5,rvfv ag ser ql ia
71778-5,rvfv ag ql serum ia
71778-5,rvfv ag serum ia ql
71778-5,rift valley fever virus ag ia ql (s)
71778-5,rift virus fever valley antigen ag ia ql (s)
71778-5,rf aley fevervirus ia ag ql (s)
70239-9,testosterone [moles/volume] in serum or plasma by detection limit <= 3.47 pmol/l
70239-9,testosrone [moes/olume] in rum or plsma by detectionlimit <= .47 pmol/l
70239-9,testoterone [moles/volume] i serum or plsma by deeion limi <=347 = 3.47 pmol/l pmol/l
70239-9,testost serpl dl<= 3.47 pmol/l-scnc
70239-9,tesotserpl dl<= pmol/l-cnc 3.47
70239-9,testost serpl l= 3.47 pmol/l-scc
70239-9,testosterone dl <= 3.47 pmol/l [moles/vol]
70239-9,testosterone dl <= 3.47 [moles/vol] pmol/l
70239-9,left pmoll <=3.47 testosteroned oles/vl]
76141-1,reticulocyte corpuscular hemoglobin concentration mean [mass/volume] in blood
76141-1,reticulocyte corpuscular hemoglobin concentration qnt mean [mass/volume] in blood
76141-1,reticulocyte corpuscular hemoglobin concentration mean [mass/volume] in blood hb
76141-1,chcmr bld-mcnc
76141-1,bld-mcnc chcmr
76141-1,bld-mcnc chcmr
76141-1,reticulocyte corpuscular hemoglobin concentration mean (bld) [mass/vol]
76141-1,rculocyte copuscular hemoglobin concentato mean (bld) [mass/vol]
76141-1,reticulocyte corpuscular hemoglobin concentraton mean (blood) avg [mass/vol]
29568-3,west nile virus neutralizing antibody [titer] in serum by neutralization test
29568-3,west nile virus neutralizing antibody [titer] in serum by test neutralization
29568-3,westnile irus eutralizing antiboy tite] in serum by neutralization test
29568-3,wnv nab titr ser nt
29568-3,wnv nab nt serum titr neutralization
29568-3,wnv titr nab ser nt
29568-3,west nile virus neut ab neut test (s) [titer]
29568-3,neut nile virus west ab neut test (s) [titer]
29568-3,west le vu neut neut ab test (s) [tite]
48383-4,collagen.bovine type 1 ab [units/volume] in serum
48383-4,ab type 1 colagen.ovine [units/volume] in serum
48383-4,collagen.boine type 1ab in [units/volme] serum
48383-4,collagen.bovine1 ab ser-acnc
48383-4,ser-acnc ab collagen.bovine1 beef
48383-4,collagen.bovine1 ab serum-acnc
48383-4,collagen.bovine type 1 ab qn (s)
48383-4,quant collagen.bovine type ab 1 qn (s)
48383-4,collage.bovinetype 1 ab qn (s)
90250-2,vanillylmandelate and homovanillate panel - urine
90250-2,vanillylmandelate and homoanillte panl - rne
90250-2,vanillylmandelate panel mhma homovanillate and - urine
90250-2,vma + hma panel ur
90250-2,vma panel hma + ur
90250-2,vma random + hma panel ur
90250-2,vanillylmandelate and homovanillate panel (u)
90250-2,homovanillate and vanillylmandelate panel (u)
90250-2,vanillylmandelate and homovanillate panel (u)
50618-8,phosphatidylcholine.saturated/surfactant.total in amniotic fluid
50618-8,phosphatidylcholine.saturated/surfactant.total in fluid amniotic
50618-8,phosphatidylcholine.saturated/surfactant.total in amniotic fluid random
50618-8,pc satd mfr amn
50618-8,pc satmfr amn
50618-8,pc amn mfr amn fl satd
50618-8,phosphatidylcholine.saturated/total surfactant (amn fld) [mass fraction]
50618-8,phophatiylcholin.saturted/otal surfactant (amn fl) [ms action]
50618-8,phosphatidylcholine.saturated/total surfactant (amn fld) pt [mass fraction]
40807-0,phencyclidine [presence] in hair by screen method
40807-0,bycreen [prsenc] in hair qualitative phenyclidine methd
40807-0,in [presence] phencyclidine hair by screen method
40807-0,pcp hair ql scn
40807-0,pcp hair ql scn screen
40807-0,pcp q hir har scn
40807-0,phencyclidine screen ql (hair)
40807-0,potentialforabuse phencyclidine scren ql (hair)
40807-0,presence scren phencycliine (hair)
29719-2,orientia tsutsugamushi litchfield ab [titer] in serum by immunofluorescence
29719-2,orientia tsutsugamuh immunofluorscence [ter] in serum rickettsia tsutsugamuchi by itchfieldab
29719-2,immunfluorescence sutsugamshilitcheldab [titer] in seru by orienti
29719-2,o tsut litch ab titr ser if
29719-2,titr tsut litch ab o ser if
29719-2,o tut trf litch a titr se if
29719-2,o. tsutsugamushi litchfield ab if (s) [titer]
29719-2,o. [titer] abif (s) tsutsugamushlitchfied
29719-2,o. tsutsugamushi litchfield ab if (s) [titer]
16583-7,chlamydophila pneumoniae igm ab [titer] in cerebral spinal fluid by immunofluorescence
16583-7,chlamydophila pneumoniae igm ab [titer] in fluid spinal cerebral by immunofluorescence
16583-7,[titer] pneumoniae igm ab chlamydophila in cerebral spinal fluid titer by immunofluorescence
16583-7,c pneum igm titr csf if
16583-7,c pneum titr igm csf if
16583-7,c cerebrospinal fl pneum cerebrospinal fluid titr igm if
16583-7,c. pneumoniae igm if (csf) [titer]
16583-7,c. (csf) igm if pneumoniae [titer]
16583-7,c.pnumoniaeigm [iter] (cs) i c pneumoniae
23165-4,leptospira interrogans sv autumnalis ab [presence] in serum by agglutination
23165-4,leptospira interrogan sv autumnali a [presence] id in serum y aglutintion
23165-4,leptospira interrogans [presence] autumnalis ab sv in serum by agglutination
23165-4,l inter autum ab ser ql aggl
23165-4,ser inter autum ab l ql aggl
23165-4,interutum l b ser ql agl
23165-4,l. interrogans sv autumnalis ab aggl ql (s)
23165-4,qualitative l. inerrogans sv (s) ql utumnalisaaggl
23165-4,serum aggl nterrogans sv auumnalisab l. l (s)
32096-0,methaqualone [presence] in specimen
32096-0,methaquaone in [preence] specimen
32096-0,methaqualone specimen in [presence]
32096-0,methaqualone spec ql
32096-0,methaqualone ql spec
32096-0,methaqualonpec ql
32096-0,methaqualone ql (specimen)
32096-0,q mthaqalone (specimen) qualitative
32096-0,ql methaqualone (specimen)
70069-0,streptococcus intermedius dna [presence] in specimen by naa with probe detection
70069-0,strptococcus inermediu dna[preence] in specimen by naa with probe detctin
70069-0,dna ligase chain reaction intermedius streptococcus [presence] in specimen by naa with probe detection
70069-0,s intermedius dna spec ql naa+probe
70069-0,naa+prbe interedius dn spec ql s
70069-0,s intermedius spec dna presence naa+probe
70069-0,s. intermedius dna naa+probe ql (specimen)
70069-0,s. naat itermedius dna aa+probe q specimen)
70069-0,s. inermedus dna transcription mediated amplification naa+probe (specimen) ql
50780-6,cancer ag 19-9 [units/volume] in pericardial fluid
50780-6,cancer ag 19-9 [units/voume] in pericaial fluid tumor marker
50780-6,cancer ag 19-9 [units/volume] carbohydrate antigen in pericardial fluid
50780-6,cancer ag19-9 pcar-acnc
50780-6,cancer cancer ag19-9 ag199 pc-acnc
50780-6,cancer ag19-9 pericardial fluid pcar-acnc
50780-6,cancer ag 19-9 qn (pericard fld)
50780-6,ag19-9 cancer qn periad fld)
50780-6,ca cancer ag qn 19-9 (pericard fld)
27097-5,2-methylbutyrylglycine/creatinine [mass ratio] in urine
27097-5,2-methylbutyrylglycine/creatinine ratio] [mass in urine
27097-5,in [assraio] 2-methbutyrylglycine/creatinine urine
27097-5,2me-butyrylglycine/creat ur
27097-5,ur 2me-buyrylglycine/ceat
27097-5,quant 2me-butyrylglycine/reat ur
27097-5,2-methylbutyrylglycine/creatinine (u) [mass ratio]
27097-5,2-methylbutyrylglycine/creatinine (u) ratio] [mass
27097-5,2-methylbutyrlglyciecreatinie mass concentration ratio u) [mass ratio]
12702-7,antimony [presence] in serum or plasma
12702-7,antimony [presnce]n ser o pasma
12702-7,antimon [presence] i serum or plasa
12702-7,antimony serpl ql
12702-7,ql srpl antiony
12702-7,anioy serum or plasma serpl l
12702-7,antimony ql
12702-7,animony q
12702-7,ql antimony
66499-5,cholesterol in vldl.beta [mass/volume] in serum or plasma
66499-5,cholesterol [mass/volume] vldl.beta in in serum or plasma
66499-5,cholesterol in vldl.beta [mass/volume] in plasma or serum
66499-5,vldlc beta serpl-mcnc
66499-5,beta vldlc serpl-mcnc
66499-5,beta vldlc plasma serum or plasma-mcnc
66499-5,cholesterol in vldl.beta [mass/vol]
66499-5,cholesterol in vldl.beta [mass/vol]
66499-5,vldl.beta in sr cholesterol [mass/vol]
31450-0,la crosse virus igg ab [units/volume] in cerebral spinal fluid
31450-0,lacrosse virus igg ab [units/volume spinal cerebral in fluid
31450-0,la crosse irs igg ab neurology [uits/olume] in spinal cerebra fluid
31450-0,lacv igg csf-acnc
31450-0,csf-acnc igg lacv
31450-0,igg lacv cerebrospinal fluid-acnc
31450-0,la crosse virus igg qn (csf)
31450-0,la crosse virus igg qn (cerebrospinal fluid) spinal flu
31450-0,la crosse (cerebrospinal fluid) igg quantitative qn virus
91130-5,hantavirus rna [presence] in lower respiratory specimen by naa with probe detection
91130-5,hantavirus rna [presence] in lower 3sr sr respiratory specimen by naa with probe detection
91130-5,hantavirus rna [ql] in lower respiratory specimen by naa with probe detection
91130-5,hantavirus rna lower resp ql naa+probe
91130-5,antavirus ql random lowerrep rn na+probe
91130-5,ligase chain reaction hantavirus rna resp lower ql naa+probe
91130-5,hantavirus rna naa+probe ql (lower resp)
91130-5,probe with target amplification hantavirus na aa+prob presence (lower resp)
91130-5,hanta virus hantvirus rna naa+probe q (lower res)
104737-2,human metapneumovirus rna [presence] in specimen by molecular genetics method
104737-2,human metapneumovirus spec rna [prence] in specimen by molecular getics method
104737-2,ordinal human metapneumovirus rna [presence] by specimen in molecular genetics method
104737-2,hmpv rna spec ql
104737-2,hmpv presence spec rna
104737-2,hmpv unspecified rna spec ql
104737-2,hmpv rna molgen ql (specimen)
104737-2,miscellaneous hmpvra molge presence (specimn)
104737-2,rna hmpv molgen ql (specimen)
62462-7,influenza virus a+b rna [presence] in specimen by naa with probe detection
62462-7,influenza virus a+b rna [presence] in specimen by probe with target amplification naa with probe detection
62462-7,presence inflenza vius a+b rna[pesence] n pecimen ynaaithprobe detetion
62462-7,fluav+flubv rna spec ql naa+probe
62462-7,spec rna fluav+flubv ql qual naa+probe
62462-7,fluav+flubv rna spec ql naa+probe
62462-7,fluav+flubv rna naa+probe ql (specimen)
62462-7,flua+flubv rna ql naa+probeql(specimen)
62462-7,fluav+flub nasba na naa+prbe l (secimen)
60551-9,interferon.beta 1a ab [titer] in serum or plasma
60551-9,interferon.beta 1a ifn-b ab [titer] in serum or plasma
60551-9,interferon.beta 1a a[titer] pama seum or in
60551-9,inf-b1a ab titr serpl
60551-9,inf-b1aab titr serpl
60551-9,inf-b1a ab titr serpl
60551-9,interferon.beta 1a ab [titer]
60551-9,[titer] 1a ab point in time interferon.beta
60551-9,ab 1a interferon.beta autoantibody [titer]
40938-3,yersinia sp igg ab [units/volume] in serum by immunoassay
40938-3,in sp igg ab [unit/volume] yersinia ser by immunoassay
40938-3,igg sp yersinia ab [units/volume] arbitrary concentration in ser by immunoassay
40938-3,yersinia igg ser ia-acnc
40938-3,ersia i er aacnc arbitrary concentration
40938-3,yersinia igg ser ia-acnc random
40938-3,yersinia sp igg ia qn (s)
40938-3,(s) sp igg eia ia qn yersinia
40938-3,yersi sp igg a (s)
85745-8,streptococcus pneumoniae danish serotype 19f dna [cycle threshold #] in specimen by naa with probe detection
85745-8,streptcoccus pneumoniae danish dna 19f serotype [cycletreshol#] in specimen by naa with probe deectin
85745-8,streptococus pneumoniae danish seotype 19f dna [cycle thresold#]i speimenby detection with ro naa
85745-8,s pn da sero 19f dna ct spec qn naa+prb
85745-8,19f pn d sero s dn ct spec qn tma naa+prb
85745-8,s p dna 19f dasero ct spc qn naa+rb
85745-8,s. pneumoniae danish type 19f dna naa+probe (specimen) [threshnum]
85745-8,s. pneumoniae dnis type 19f dna naa+prob (specime [threhnum
85745-8,s pneum da 19f dna s. pneumoniae danish type 19f dna naa+probe (specimen) [threshnum]
3085-8,urate [mass/volume] in synovial fluid
3085-8,fluid [mass/volume] in synovial urate
3085-8,urate [mass/volume] in ua synovial fluid
3085-8,urate snv-mcnc
3085-8,snv-mcnc urate
3085-8,sn-cnc urate
3085-8,urate (syn fld) [mass/vol]
3085-8,urate [mass/vol] fld) (syn
3085-8,urate (syn [mass/vol] fld) random
74316-1,prrsv orf5 gene rna [presence] in specimen by naa with probe detection
74316-1,probe orf5 gene rna [presence] in specimen by naa with prrsv detection
74316-1,in orf5 gene na [presence] prrsv specien by aa with proe detection
74316-1,prrsv orf5 gene rna spec ql naa+probe
74316-1,pork prrsvorf5 gene rna spec ql naa+probe
74316-1,prrs or5 gene rnaspec qlnaapobe
74316-1,prrsv orf5 gene rna naa+probe ql (specimen)
74316-1,prrsv orf5 gene rna naa+probe ql (specimen) porcine reproductive and respiratory syndrome
74316-1,lelystad virus prrsv orf5 gene naa+probe rna ql (specimen)
16638-9,coccidioides immitis igg ab [units/volume] in cerebral spinal fluid
16638-9,coccdoides immiti c immitis ig ab units/volume] in cerebral spinalfluid
16638-9,coccidioides immitis igg ab cerebral in [units/volume] spinal fluid
16638-9,c immitis igg csf-acnc
16638-9,c quant immitis igg csf-acnc
16638-9,csf-acnc immitis igg c
16638-9,c. immitis igg qn (csf)
16638-9,c. immitis qn igg (csf) glenospora metaeuropea
16638-9,. imiis spinal flu (csf) qn igg
94098-1,dense fine speckled 70 protein igg ab [presence] in serum or plasma by immunoassay
94098-1,dense fine speckled 70 protein igg ab [presence] in serum prot or plasma by immunoassay
94098-1,dens fin specled 70 protein ig a immuoassay inserum or plsma y [prsence
94098-1,dfs70 igg serpl ql ia
94098-1,dfs70 ql serpl igg ia
94098-1,dfs70 igg abs serpl ql ia
94098-1,dense fine speckled 70 protein igg ia ql
94098-1,dene fie speckled 70 protein igg ia l
94098-1,dense protein speckled 70 fine igg ia ql serology
9528-1,histoplasma capsulatum iga ab [units/volume] in serum by immunoassay
9528-1,histoplasma iga capsulatum ab [units/volume] in serum by immunoassay
9528-1,[units/vlue capsuatum ga histoplasma farciminosum ab histplasma inserm byimmunoassay
9528-1,h capsul iga ser ia-acnc
9528-1,h capsul iga ser ia-acnc quan
9528-1,h apsliga seiaacnc
9528-1,h. capsulatum iga ia qn (s)
9528-1,h. capsulatum iga ia qn (s)
9528-1,(s) capsulatum iga ia qn h.
75653-6,manual differential comment [interpretation] in body fluid narrative
75653-6,manual differn differential body [interpretation] in comment fluid narrative
75653-6,manual differential comment [interpretation] in body fluid narrative
75653-6,manual dif comment fld-imp
75653-6,manua comm cmmentfldim dif
75653-6,manual fl-imp comment if
75653-6,manual differential comment nar (body fld) [interp]
75653-6,manual diferential commet na (body fld) [itep]
75653-6,impression manual differential comment nar (body fld) [interp]
82415-1,ha ab [presence] in serum by line blot
82415-1,ha ab [presence] autoantibodies in serum by line blot
82415-1,ha aby ab [presence] in seru by ine blot
82415-1,ha ab ser ql line blot
82415-1,ha ab ql ser line blot
82415-1,line ab ser presence ha blot
82415-1,ha ab line blot ql (s)
82415-1,ha ab ine blot q (s) autoantibodies
82415-1,ha qualitative blot lie ab presence(s)
31580-4,purkinje cells igg ab [units/volume] in serum
31580-4,purnjecells igg ab [units/volume] in srum
31580-4,purkinje cells igg in [units/volume] ab serum
31580-4,purkinje cells igg ser-acnc
31580-4,lls ukinje igg ser-acnc
31580-4,prkin ells sr-acnc igg
31580-4,purkinje cells igg qn (s)
31580-4,purinje cels igg qn (s)
31580-4,purkinje (s) igg qn cells
104429-6,measles virus igm ab [ratio] in serum by immunoassay
104429-6,measls virus igm antby ab [ratio] n srum by immassay
104429-6,aby measles ab igm vius [ratio] in erum by imunassy
104429-6,mev igm ser ia-rto
104429-6,a-ro ser meigm autoantibody
104429-6,mevigm sr a-to serum
104429-6,mev igm ia (s) [ratio]
104429-6,mevigm ia (s)[ratio]
104429-6,mev igm ia suds [ratio] (s)
13547-5,butriptyline [presence] in serum or plasma
13547-5,inserum [presence] butritylne o plas
13547-5,butiptyline [presence] in seum o asma
13547-5,butrip serpl ql
13547-5,drug/toxicology ql serpl butrip
13547-5,srpql butrip
13547-5,butriptyline ql
13547-5,ql butriptyline pr
13547-5,butriptyline serplas ql
42344-2,discharge diet (narrative)
42344-2,findings discharge diet(narativ
42344-2,(narrative) point in time diet discharge
13930-3,rheumatoid factor [titer] in synovial fluid by agglutination
13930-3,rheuatod fctor [iter] rf n aggutinatin synialfludy
13930-3,rheumatoid factor [titer] in synovial fluid by agglutination
13930-3,rheumatoid fact titr snv aggl
13930-3,rheumatid agg fact aggl trsnv
13930-3,rheumatoid fact titr snv aggl
13930-3,rheumatoid factor aggl (syn fld) [titer]
13930-3,rheumatoid factor (syn sf aggl fld) [titer]
13930-3,rheuatoid fctor aggl (syn fld) [titer] titre
8243-8,styrene [mass/volume] in blood
8243-8,styrene [mass/vlme] in blood qnt
8243-8,styrene [mass/volume] blood in
8243-8,styrene bld-mcnc
8243-8,bld-mcnc styrene
8243-8,ld-mcnc drug/toxicology styrne
8243-8,styrene (bld) [mass/vol]
8243-8,drugs [mass/vol] (bld) styrene
8243-8,[mass/vol] (bld) styrene
74318-7,prrsv north american strain rna [cycle threshold #] in specimen by naa with probe detection
74318-7,prrsv north american strain rna [cycle threshold #] in specimen by naa detection qbr probe with
74318-7,prrsvoth aa strain rna [cycle threshold#] in secmen by american with pob detection
74318-7,prrsv na strain rna ct spec qn naa+probe
74318-7,prrsv lcr na strain rna c spec n naa+probe
74318-7,prsv a qn rna ct spc srain naa+probe
74318-7,prrsv north american strain rna naa+probe (specimen) [threshnum]
74318-7,prsv north aerican strin rna naa+prob(specimen) tma [threshnum]
74318-7,prrsv sda north american strain rna naa+probe (specimen) [threshnum]
44537-9,htlv i dna [presence] in blood by naa with probe detection
44537-9,htlv i da presencein od b naa with rob detectio
44537-9,htlv i dna [presence] in bld detection naa with probe by
44537-9,htlv i dna bld ql naa+probe
44537-9,htlv i dna blood polymerase chain reaction ql naa+probe
44537-9,htlv i dna ql 3sr sr bld naa+probe
44537-9,htlv i dna naa+probe ql (bld)
44537-9,htlv idna naa+prbe ql bld)
44537-9,htv i dna a+rob ql(blood wb
82435-9,deprecated rna polymerase iii ab [units/volume] in serum by immunoblot
82435-9,deprecated rna polymerase iii ab in [units/volume] serum by immunoblot
82435-9,deprected rna lymease abs ii srum ab[unts/volume]in byimmunoblot
82435-9,deprecated rnap iii ab ser ib-acnc
82435-9,deprecated rnap iii ab immunoblot serum ib-acnc
82435-9,depreca rnap iiiaber ib-anc
82435-9,rna polymerase iii ab ib qn (s)
82435-9,rna polyerase ii a ib qn (s)
82435-9,rna plymerase iii a ib qn ()
10370-5,phencyclidine [mass/mass] in hair
10370-5,phencyclidine [mass/mas] in air
10370-5,phncycldine[mass/mass] in hair
10370-5,pcp hair-mcnt
10370-5,pcp hair-mcnt
10370-5,hair-mcnt pcp
10370-5,phencyclidine (hair) [mass/mass]
10370-5,[mass/mass] (hair) drug/toxicology phencyclidine
10370-5,phencyclidine (hair) [mass/mass]
15006-0,11-ketoetiocholanolone [moles/time] in 24 hour urine
15006-0,11-ketoetiocholanolone [moles/time] in 24 urine hour
15006-0,11-ketoetiocholanolone [moles/time] in 24 urine hour
15006-0,11ketoetioch 24h ur-srate
15006-0,11ketoeioch r-ste 4h
15006-0,11ketoetioch 24h ur-srate
15006-0,11-ketoetiocholanolone (24h u) [moles/time]
15006-0,11-ketoetiochlnolone (24h quant u)[moles/time]
15006-0,[moles/time] 11ketoetioch (24h u) 11-ketoetiochanolone
18477-0,lithium [moles/time] in 24 hour urine
18477-0,urie n 24 our lthim[moles/tme]
18477-0,lithium [moles/time] ur in 24 hour urine
18477-0,lithium 24h ur-srate
18477-0,ur-srate 24h lithium
18477-0,lithu 24h ur-srate qnt
18477-0,lithium (24h u) [moles/time]
18477-0,lithium u) (24h [moles/time]
18477-0,quan lithium [moles/time] u) (24h
97931-0,mayaro virus rna [presence] in specimen by naa with probe detection
97931-0,mayaro virs na detection in specimenby naa qual wit probe [presnce]
97931-0,mayaro virus rna [presence] in specimen by naa with probe detection mayv
97931-0,mayv rna spec ql naa+probe
97931-0,mayv ql spec rna naa+probe
97931-0,ayv naaobe spe l rna
97931-0,mayaro virus rna naa+probe ql (specimen)
97931-0,mayaro virs rna aa+robe ql (specime)
97931-0,mayaro l(specimen) rnanaa+proe amplified virus
63549-0,albumin in serum - albumin in peritoneal fluid [mass concentration difference]
63549-0,albumin - serum in albumin in peritoneal fluid [mass concentration difference]
63549-0,albumin in sum  albumin n peritoneal flu [mass cocentrtion difference]
63549-0,albumin ser-prt fld-mcdiff
63549-0,ser-prt albumin fld-mcdiff
63549-0,albumin ascites ser-prt fld-mcdiff
63549-0,albumin in serum - albumin in peritoneal fluid (periton fld+s/p) [mass conc diff]
63549-0,albumin in serum - albumin in peritoneal fluid (periton fld+s/p) [mass conc pl diff]
63549-0,alumin in - serum albumin in peritonel fluid (peritn fld+s/) [mas conc dff]
88211-8,rabies virus ag [presence] in cerebral spinal fluid by immunoassay
88211-8,rabis virus ag [presence] i cerbral pinalui by immuoasay
88211-8,rabies vrus ag [presene] i qualitative cebralspinal fluid by immuasay
88211-8,rabv ag csf ql ia
88211-8,sfqlia g rabv neurology
88211-8,ag rabv csf ql ia
88211-8,rabies virus ag ia ql (csf)
88211-8,rabies antigen virus ag ia ql (csf)
88211-8,rabies virus ia ag ql (csf
56054-0,deprecated phenx measure - arm span
56054-0,upper extremity deprecate phnx mesur - arm san
56054-0,depreated phenx pnl meaure arm span
22607-6,venezuelan equine encephalitis virus ab [titer] in serum
22607-6,venezuelan equine encephalitis virus ab [titer] in ser
22607-6,enezuean autoantibody equie encephaitis [titer] virusab in srum
22607-6,veev ab titr ser
22607-6,veev ab titr serum veev
22607-6,ttr veev ab titr serum
22607-6,veev ab (s) [titer]
22607-6,ab veev (s) [titer]
22607-6,vev ab (s) [titer]
62697-8,deprecated phenx measure - visual acuity
62697-8,deprecated panel.phenx phenx visual - measure acuity
62697-8,deprecated penx measur - viual acuity
6448-5,legionella pneumophila ag [presence] in urine by radioimmunoassay (ria)
6448-5,antigen numophila legionela g [presence inurine by radimunasay (ra)
6448-5,legionella pneumophila ag [ql] in urine by radioimmunoassay (ria)
6448-5,l pneumo ag ur ql ria
6448-5,l pneumo g ur ql ria
6448-5,l pneumo ag ur ql ria pr
6448-5,l. pneumophila ag ria ql (u)
6448-5,l. pneumophila ag ql ria (u)
6448-5,l. pneumphila a ia ql pneu (u
14399-0,creatinine [mass/volume] in pleural fluid
14399-0,in [mas/olume] creatnine leural flid
14399-0,creatinine [mass/volume] in pleural fluid
14399-0,creat plr-mcnc
14399-0,plr-mcnc creat cr
14399-0,plr-mcnc creat
14399-0,creatinine (pleur fld) [mass/vol]
14399-0,(pleur ceatinie fld) [mass/vol]
14399-0,creatinine fld) qnt (pleur [mass/vol]
44982-7,chlamydophila pneumoniae iga ab [presence] in serum
44982-7,chlamydophila pneumonae iga a [resence]in ser
44982-7,chlamydophila microbiology pnemoniae iga ab [pesence] in serum
44982-7,c pneum iga ser ql
44982-7,c pneum iga se ql pneumonia
44982-7,c serum iga pneum ql
44982-7,c. pneumoniae iga ql (s)
44982-7,c. umoniae igaql (s)
44982-7,c. pneumoniae iga ql (s)
48869-2,rickettsia sp dna [presence] in specimen by naa with probe detection
48869-2,ricketsia s dna [prsence] in speimen by qualitative naawith robe detection
48869-2,rickettsi s dna [preence] in specimen by ligation-activated transcription naa with probe detection
48869-2,rickettsia dna spec ql naa+probe
48869-2,rickettsia ql spec dna nasba naa+probe
48869-2,rikettsia naa+proe specql da
48869-2,rickettsia sp dna naa+probe ql (specimen)
48869-2,rickettsia sp dna naa+probe (specimen) ql
48869-2,rickettsia sp dna naa+probe presence (specimen) other
18293-1,deprecated hemoglobin.fetal/hemoglobin.total^post partum
18293-1,hemoglobin.fetal/hemoglobin.total^post deprecated partum kleihauer stain
18293-1,deprecated hemogobin.fetal/hemoglobi.ttal^postprtum pst
18293-1,deprecated hgb f p partum fr bld kb
18293-1,depecated hg fp partu qual fr l kb
18293-1,deprecate hgb f p whole blood partum fr bld kb
18293-1,hemoglobin.fetal post partum kleihauer-betke method ql (bld)
18293-1,hemolobin.ftl partum ost kleihauerbee mehod ql (bld)
18293-1,hemoglobin.fetal post partum kleihauer-betke p partum method ql (bld)
24420-2,haemophilus somnus ab [titer] in serum
24420-2,haemophilus somnus ab [titer] in serum
24420-2,aemophilus som ab [titer] in point in time seru
24420-2,h somnus ab titr ser
24420-2,h somnus ab titr dilution factor (titer) ser
24420-2,titr somnus ab h serum
24420-2,h. somnus ab (s) [titer]
24420-2,h. somnus ab [titer] (s)
24420-2,h. [titer] ab (s) somnus
95239-0,hepatitis d virus igm panel - serum
95239-0,hepatiti d virus igm pael - serum
95239-0,hepatitis panel virus igm liver d - ser
95239-0,hdv igm pnl ser
95239-0,ser igm pnl hdv
95239-0,hdv im point in time pnl ser
95239-0,hdv igm panel (s)
95239-0,dv igm panel (s) id
95239-0,hdv igm panel (s) delta hepatitis
67725-2,mycobacterium sp identified in isolate by hplc
67725-2,isolate sp ientified in cobacterium by hlc
67725-2,mycoacteium sp identified microbiology in isolat pc by
67725-2,mycobacterium islt hplc
67725-2,hplc islt species mycobacterium
67725-2,hplc islt isol mycobacterium
67725-2,mycobacterium sp identified hplc nom (isol)
67725-2,mycoacterium spidentifidhplc (isol) nm
67725-2,ycobacteriu p dentified (isol) nom plc
13791-9,phenylacetate/creatinine [mass ratio] in urine
13791-9,ratio] [mass phenylacetate/creatinine in urine
13791-9,phenylacetate/creatinine phenylacetic acid [mass ratio] in urine
13791-9,phenylacetate/creat ur
13791-9,ur phenylacetate/crat
13791-9,phenylacetate/creat phenylacetic acid ur
13791-9,phenylacetate/creatinine (u) [mass ratio]
13791-9,ratio] (u) urn [mass phenylacetate/creatinine
13791-9,(u) phenylacetate/creatinine mass concentration ratio [mass ratio]
53597-1,mannobioside igg ab [units/volume] in serum or plasma by immunoassay
53597-1,mannobioside igg ab [units/volume] in by or plasma serum immunoassay
53597-1,mannobioside ser ab [units/volume] random in igg or plasma by immunoassay
53597-1,mannobioside igg serpl ia-acnc
53597-1,serpl qnt igg mannobioside ia-acnc
53597-1,mannobiosde gg serpl ia-cnc
53597-1,mannobioside igg ia qn
53597-1,mnnobioside igg ia qn
53597-1,mannobioside immune globulin g igg ia qn
101289-7,sars-cov-2 (covid-19) rna [presence] in throat by naa with non-probe detection
101289-7,sars-cov-2 rna (covid-19) [presence] in throat by naa with non-probe detection
101289-7,sars-cov-2 (covid-19) rna [ql] in throat by naa with non-probe detection
101289-7,sars-cov-2 rna throat ql naa+non-probe
101289-7,sars-cov-2 rna throat presence naa+non-probe
101289-7,sars-cov-2 rna presence throat naa+non-probe presence
101289-7,sars-cov-2 (covid-19) rna naa+non-probe ql (throat)
101289-7,sars-cov-2 (covid-19) rna 3sr sr naa+non-probe ql (throat)
101289-7,sars-cv- rna (covid-19 naa+non-probe ql (hroat)
51406-7,immunoglobulin light chains.free [mass/time] in 24 hour urine
51406-7,immunoglobulin light chains.free [mass/time] in 24 hour urine
51406-7,immnoglbli immuno light chains.free [mas/te in 24 hour urine
51406-7,bj protein free 24h ur-mrate
51406-7,bjproein 24h free ur-mrate
51406-7,protein bj free 24h ur-mrate
51406-7,immunoglobulin light chains.free (24h u) [mass/time]
51406-7,bj protein immunoglobulin (24h chains.free light u) [mass/time]
51406-7,u) light chains.free (24h immunoglobulin [mass/time]
49926-9,glucose-6-phosphate dehydrogenase [enzymatic activity/mass] in red blood cells by who method
49926-9,who dehydrogenase [enzymatic activiymass] in phosphate total red blo ells by glucose-6-phospate method
49926-9,glucose-6-phophate acvity/mass [enzymatic dhydrogenae in red boo cellsby who metho
49926-9,g6pd rbc who method-ccnt
49926-9,rbc g6pd who method-ccnt
49926-9,g6pd method-ccnt who rbc
49926-9,g6pd who method (rbc) [catalytic activity/mass]
49926-9,g6pd who method (rbc) activity/mass] [catalytic
49926-9,g6pd who method (rbc) [catalyti activity/mass]
59341-8,stiripentol [mass/volume] in urine
59341-8,urine [mass/volume] in stiripentol
59341-8,stiripntol [mass/volume] inurne urn
59341-8,stiripentol ur-mcnc
59341-8,mass concentration siripntol u-mcnc
59341-8,stiripentol ur-mcnc
59341-8,stiripentol (u) [mass/vol]
59341-8,point in time stiripentol [mass/vol] (u)
59341-8,[mass/vol] (u) stiripentol
105269-5,fractional excretion of calcium [ratio] in urine and serum or plasma collected for unspecified duration
105269-5,fraciona excretion unspecified calcium [ratio]inurine an ser orplasma ua ollected fr of duratin
105269-5,fractional excretion f plasa [atio] in urine and serumor calcium collected forunspeified duaton
105269-5,fracti excret of ca ?tm ur+serpl-rto
105269-5,racti excret ?tm fca ur+serpl-rto
105269-5,frci excret of urerplrto ?tm chemistry c
105269-5,fractional excretion of calcium unsp time (u+s/p) [ratio]
105269-5,rto fractional excretion [ratio] calcium unsp time (u+s/p) of
105269-5,fractionl (u+s/p) of calcium unp time exretion quantitative [ratio]
38384-4,cocaine [presence] in gastric fluid
38384-4,cocaine fluid in gastric [presence]
38384-4,drug/toxicology cocaine [presence] in flid gsrc
38384-4,cocaine gast ql
38384-4,cocaine gast presence
38384-4,gast cocaine ql
38384-4,cocaine ql (gast fld)
38384-4,(gast ql potentialforabuse cocaine fld)
38384-4,cocain ql (gas illicit fld
88204-3,respiratory syncytial virus a rna [presence] in cornea or conjunctiva by naa with probe detection
88204-3,respiratory syncytial virus a rna [ql] in cornea or conjunctiva by naa dna probe with probe detection
88204-3,respiratory syncytial virus a rna in [presence] cornea or conjunctiva by naa with probe detection
88204-3,rsv a rna corn/cnjt ql naa+probe
88204-3,rsv naa+probe rna corn/cnjt ql a
88204-3,rsv a presence corn/cnjt amplification ra naa+probe
88204-3,rsv a rna naa+probe ql (corn/cnjt)
88204-3,(corn/cnjt) a rna naa+probe ql rsv
88204-3,naa+probe a rna rsv presence (corn/cnjt)
32077-0,glutethimide [presence] in specimen
32077-0,glutethimie [preence] in to be specified in another part of the message specmen
32077-0,gltethimide [presene] in spcmn
32077-0,glutethimide spec ql
32077-0,ql spec glutethmide
32077-0,ql spec glutethimide
32077-0,glutethimide ql (specimen)
32077-0,glutethimid ordinal presence (specimen)
32077-0,lutethimide presence (spcimen)
46949-4,fludrocortisone [mass/volume] in urine
46949-4,quan fludrocortisneassvolume]in urine
46949-4,fludrocortisone [mass/volume] in drug/toxicology urine
46949-4,fludrocortisone ur-mcnc
46949-4,ur-mcnc quantitative fludrocortisone
46949-4,ua fludrocortisone ur-mcnc
46949-4,fludrocortisone (u) [mass/vol]
46949-4,fludrocortisone [mass/vol] (u)
46949-4,fludrocortisone (u) [mass/vol]
94840-6,chloride [moles/volume] in urine from fetus
94840-6,chloride fetus in urine from [moles/volume]
94840-6,chloide [moles/vlume] qnt n urine fro fetus
94840-6,chloride ur fetus-scnc
94840-6,chloride ur substance concentration ftus-scnc
94840-6,choide ur fetus-scnc
94840-6,chloride (u fetus) [moles/vol]
94840-6,chloride ua (u fetus) [moles/vol]
94840-6,chloride [moles/vol] fetus) (u
74922-6,n-acetyl-l-aspartate [moles/volume] in cerebral spinal fluid
74922-6,n-aetyl-l-aspartat [moles/vlume] cerebral in spnal fluid
74922-6,n-acetyl-l-aspartat left [moesvolume] in cerebral sinal fluid
74922-6,n-ac-l-asp csf-scnc
74922-6,n-ac-l-as csf-scnc
74922-6,qnt n-ac-l-asp cerebrospinal fluid-scnc
74922-6,n-acetyl-l-aspartate (csf) [moles/vol]
74922-6,n-acetyll-aspartate [oles/vol] (s)
74922-6,n-acetyl-l-apartate (sf spinal fluid [moles/vol]
2789-6,phosphoethanolamine [mass/volume] in serum or plasma
2789-6,phosphoethnolamine quant mas/voume] in ser or plsa
2789-6,phosphethnolamine in [ass/volume] ser orplama
2789-6,petn serpl-mcnc
2789-6,quantitative petn serpl-cnc
2789-6,ptn serpl serpl-mcnc
2789-6,phosphoethanolamine [mass/vol]
2789-6,[mssvol phsphoethaolamine quantitative
2789-6,[mass/vol] mass concentration phosphoethanolamine
41217-1,yellow fever virus igg ab [presence] in serum
41217-1,yello fever virus ig in [presence ab serum
41217-1,yellow fever point in time virus in ab [presence] igg serum
41217-1,yfv igg ser ql
41217-1,ql igg sr yv
41217-1,yfv ser igg ql
41217-1,yellow fever virus igg ql (s)
41217-1,yellow fver s) ql virsig
41217-1,yellow fever virus igg presence (s)
104117-7,11-hydroxytestosterone [moles/volume] in serum or plasma by lc/ms/ms
104117-7,level 11-hydroxytestosterone by in ser or plasma [moles/volume] lc/ms/ms
104117-7,11-hydroxytestosterone [moles/volume] in by or plasma serum lc/ms/ms
104117-7,11oh-testost serpl lc/ms/ms-scnc
104117-7,lc/ms/ms-scnc erl 11oh-tetost
104117-7,serpl 11oh-testost lc/ms/ms-scnc
104117-7,11-hydroxytestosterone lc/ms/ms [moles/vol]
104117-7,level 11-hydroxytestosterone lc/ms/ms [moles/vol]
104117-7,11-hydroxytestosterone [moles/vol] lc/ms/ms
78814-1,cannabicyclohexanol cutoff [mass/volume] in urine for confirmatory method
78814-1,cannabicyclohexanol confimatory in urine for cutff[mss/volume] mthd gcms
78814-1,canabicycloheano urinefor i cutoff[mass/lme] conimatory ethod lc/ms/ms
78814-1,cannabicyclohexanol cto ur cfm-mcnc
78814-1,cm-mcc ur cannabicycloexanolcto
78814-1,canabiccohxanol quant cto ur cfm-mcn
78814-1,cannabicyclohexanol cutoff confirm (u) [mass/vol]
78814-1,(u) cutofconfirm cannabicloexanol mas/vl] ua
78814-1,cofirm cutoff cannabcyclohexol (u) point in time [a/vol]
31779-2,chlamydophila psittaci ag [presence] in genital specimen
31779-2,hlamydopil psittac [preence] ag antigen in genital specimn
31779-2,ag psitaci hlamydophila [resene] n enital specimen
31779-2,c psittaci ag genital ql
31779-2,psittacosis c psittaci ag genital ql
31779-2,c chlamydia psittaci psttaci l enital ag
31779-2,c. psittaci ag ql (genital specimen)
31779-2,c. psittaci ag ql (genital specimen)
31779-2,c. psittaci (genital ql ag specimen)
9360-9,bartonella quintana igg ab [titer] in serum
9360-9,baronella quintana ab anti igg [titer] nseru
9360-9,in quintana igg ab [titer] dilution factor (titer) bartonella ser
9360-9,b quintana igg titr ser
9360-9,b quintana igg titr ser
9360-9,b quintana ser titr igg
9360-9,b. quintana igg (s) [titer]
9360-9,dilution factor (titer) b. quintana (s) igg [titer]
9360-9,. quintn ig (s) titer]
77028-9,influenza virus a h1 2009 pandemic rna [presence] in nasopharynx by naa with probe detection
77028-9,influenza virs a h1 209 ligation-activated transcription pandemic rna [prsence] in nasoharynx by naa with probe detein
77028-9,influenza virus a h1 2009 pandemic na naa nasopharynx by [prsence]in with pobe deetio
77028-9,fluav h1 2009 pand rna nph ql naa+probe
77028-9,fluav h1 2009pand rna nphqlnaa+probe
77028-9,flua 1 2009 nph rna pand ql ordinal na+probe
77028-9,fluav h1 2009 pand rna naa+probe ql (nph)
77028-9,fluav h1 2009 pand naa+probe rna presence (nph)
77028-9,fluav h1 point in time 2009 pan rnanaa+robe (nph) ql
94388-6,neuronal nuclear type 2 igg ab [presence] in cerebral spinal fluid by line blot
94388-6,neurolnucear sinal 2 igg b [presence qualitative cerebral type flui by lne blot
94388-6,neuronal igg type 2 nuclear ab [presence] in cerebral spinal fluid by line blot
94388-6,hu2 igg csf ql line blot
94388-6,blot igg csf ql line hu2
94388-6,antibody ql igg csf hu2 line blot
94388-6,neuronal nuclear type 2 igg line blot ql (csf)
94388-6,neuronal nuclear type anti 2 igg line blot ql (cerebrospinal fluid)
94388-6,2 nuclear type neuronal igg line blot ql (csf) hu
78813-3,cannabicyclohexanol [mass/volume] in urine by confirmatory method
78813-3,cnnaicyclohexanol [mass/vume] confirmatory in urineby confirmatory method
78813-3,cannabicyclohexanol [mass/volume] in confirmation urine by method confirmatory
78813-3,cannabicyclohexanol ur cfm-mcnc
78813-3,ur cannabicyclohexanol cfm-mcnc
78813-3,cannabicyclohexanol cp 47 cfm-mcnc ur
78813-3,cannabicyclohexanol confirm (u) [mass/vol]
78813-3,cannabicyclohexanol [mass/vol] (u) confirm
78813-3,[mass/vol] confirm (u) cannabicyclohexanol
5006-2,haemophilus influenzae rrna [presence] in specimen by probe
5006-2,hamphilu nluenzae rrna [ql] n specimen by screen probe
5006-2,haemophilus influenzae rrna [presence] in qual specimen by probe
5006-2,haem influ rrna spec ql probe
5006-2,haem miscellaneous influ probe spec ql rrna
5006-2,haem influ spec rrna ql probe
5006-2,h. influenzae rrna probe ql (specimen)
5006-2,h. influenzae rrna probe (specimen) ql
5006-2,. inflenzae rrna prbe ql (specien)
17270-0,methylacrylate [mass/volume] in serum or plasma
17270-0,methlacrylate [mass/volum] plasa serum or in
17270-0,pl methylacrylae [mass/volume] in seum or plasma
17270-0,me-acrylate serpl-mcnc
17270-0,me-acrylate serp serpl-mcnc
17270-0,m-acrylateel-mcnc
17270-0,methylacrylate [mass/vol]
17270-0,[massvol] mtylacrylate
17270-0,methylacrylate [mass/vol]
49859-2,amphotericin b [mass/volume] in specimen
49859-2,amphotericin in [mass/volume] b specimen
49859-2,aphotericin b[mass/voume] in peime
49859-2,amphotericin b spec-mcnc
49859-2,spec-mcnc mphotericin
49859-2,quantitative amphotericin b spec-mcnc
49859-2,amphotericin b (specimen) [mass/vol]
49859-2,b amphotricin (specien) misc [mss/vol]
49859-2,amphotericin b (specimen) [mass/vol]
72907-9,hna genotype panel - serum or plasma
72907-9,hna - serp panel genotype serum or plasma
72907-9,hna genotype panel sr - serum or plas
72907-9,hna genotype pnl serpl
72907-9,hna enotype nl serpl
72907-9,hna genotype point in time pnl serpl
72907-9,hna genotype panel
72907-9,genotype hna panel
72907-9,hna panel genotype serpl
33904-4,neisseria gonorrhoeae rrna [presence] in conjunctival specimen by probe
33904-4,neisseria gonorrhoeae rra [esece]in specimen conunctival b poe
33904-4,neissera onorrhoeae rra[presene] probe conjuntival secimen by in
33904-4,n gonorrhoea rrna conjunct ql probe
33904-4,n gonorrhoea rrna conjunct probe ql
33904-4,n gonorrhoea dna nucleic acid probe rrna conjunct ql probe
33904-4,n. gonorrhoeae rrna probe ql (conj)
33904-4,n. gnorrhoeae ql(cnj) prbe rna
33904-4,n.gonrrhoeae rrna presence(cnj) pob
95930-4,pulmonary vasodilator test panel
95930-4,pulmonary vasodilatr test pnel
95930-4,pulmonary pan vasodilator test panel
95930-4,pulm vasodil pnl
95930-4,pum point in time vasdil pnl
95930-4,random lm vasodil pnl
48059-0,giardia lamblia+cryptosporidium sp ag [presence] in stool by immunoassay
48059-0,giardia lamblia+rptosporidium imunoassay in spp stool by spag[presence
48059-0,giardia microbiology lamblia+cryptosporidium sp ag [presence] in stool by immunoassay
48059-0,g lamblia+cryptosp ag stl ql ia
48059-0,g lamblia+cryptosp ag st q g duodenalis ia
48059-0,g ql a stl lamblicryptosp ia
48059-0,g. lamblia+cryptosporidium sp ag ia ql (stl)
48059-0,ia lamblia+cryptsporiium sp ag g. ql (stl)
48059-0,g. lamblia+cryptosporidium sp ag ia ql (stl) g lamblia
60257-3,bacteria identified in cornea by culture
60257-3,by identife incornea bacteria culure
60257-3,bacteria identified in cornea by culture
60257-3,bacteria crn cult
60257-3,bacteria crn cult
60257-3,cornea bacteria crn cult
60257-3,bacteria identified cx nom (cornea)
60257-3,bacteria identified nom cx (cornea)
60257-3,bacteria idetfied cornea) nom cx
3896-8,oxymesterone [mass/time] in 24 hour urine
3896-8,oxymestrone [mss/time] n 24hour urine
3896-8,oysterone [ass/time in 24 hur urine
3896-8,oxymesterone 24h ur-mrate
3896-8,oxymesterone 24h ur-mrate
3896-8,ur-mrate 24h oxymesterone
3896-8,oxymesterone (24h u) [mass/time]
3896-8,oxymeerone (24h u) [ass/ime]
3896-8,oxymsterone (24h mass/tim] u)
2312-7,galactose 1 phosphate [mass/volume] in red blood cells
2312-7,[mass/volume] 1 phosphate galactose in red phosphate total blood cells
2312-7,galactose 1 phosphate [mass/volume] in red blood cells phosphorus
2312-7,gal1po4 rbc-mcnc
2312-7,gal1po4 rc-mcc
2312-7,gal1po4 rbc-mcnc
2312-7,galactose 1 phosphate (rbc) [mass/vol]
2312-7,phosphate 1 galactose (rbc) [mass/vol] pi
2312-7,galactose 1 phosphate (rbc) phosphorous [mass/vol]
87395-0,west nile virus rna [cycle threshold #] in specimen by naa with probe detection
87395-0,west nile virus rna [cycle threshold #] in specimen by naa with infectiousdisease probe detection
87395-0,west nilvirus na[ycle treshold #] n pecimen by amplification naa wth rob detection
87395-0,wnv rna ct spec qn naa+probe
87395-0,wnv spec ct rna qn naa+probe
87395-0,wnv na ct qn spec naa+probe
87395-0,west nile virus rna naa+probe (specimen) [threshnum]
87395-0,west nile vrus na+proe rna ribonucleic acid (spcimen) [threshnum]
87395-0,west nile virus rna (specimen) naa+probe [threshnum]
35016-5,myelocytes [#/volume] in body fluid
35016-5,myelocytes [#/volume] in fluid body fluid
35016-5,myelocytes quantitative [#/volume] in d fid
35016-5,myelocytes # fld
35016-5,myelocytes fld #
35016-5,myelocytes # fld
35016-5,myelocytes (body fld) [#/vol]
35016-5,[#/vol] (body fld) myelocytes
35016-5,(body myelocytes fld) [#/vol]
79251-5,diazepam cutoff [mass/volume] in saliva (oral fluid) for confirmatory method
79251-5,diazepam cutoff[ma/volume] in saliv method luid) forconfirmatory (oral
79251-5,iazepam cuoff [mss/vlume] in aia (orl fluid) f confrmatory metho
79251-5,diazepam cto sal cfm-mcnc
79251-5,cto diazepam sal cfm-mcnc
79251-5,diazepam sal cto cfm-mcnc
79251-5,diazepam cutoff confirm (sal) [mass/vol]
79251-5,diazepam ctof cfir quan (sa) [mass/vol]
79251-5,diazepam cutoff confirm (sal) [mass/vol]
68939-8,enolase.neuron specific [mass/volume] in pleural fluid
68939-8,eolas.neuronspecific [mas/volume]in plural lid
68939-8,enolase.neuron specific [mass/volume] in pleural fluid pleural
68939-8,nse plr-mcnc
68939-8,plrmcnc nse enolase 2
68939-8,plr-mcnc eno2 nse
68939-8,enolase.neuron specific (pleur fld) [mass/vol]
68939-8,eoase.neuro specfic (pleu fld) eno2 [mass/vol]
68939-8,spec (leur scific enolase.neuron fld) [mass/ol
14865-0,parathyrin [interpretation] in serum or plasma
14865-0,parathyrin plasma in erum o [interpretation]
14865-0,parathyrin[inerpretatin] inserum o plasma plasa
14865-0,pth serpl-imp
14865-0,pth serum or plasma-imp nominal
14865-0,pth seplimp
14865-0,parathyrin [interp]
14865-0,[interp paathyrin
14865-0,parathyrin [interp]
38416-4,parasite identified in body fluid by inspection
38416-4,fluid identifed n bod parasite by inspection
38416-4,parasite identified in body infectiousdisease fluid by inspection
38416-4,parasite fld inspect
38416-4,parasite inspect fld infectious disease
38416-4,fld parasite body fluid insect
38416-4,parasite identified inspection nom (body fld)
38416-4,parasite identified inspection nom (body fld)
38416-4,parasite infectiousdisease identified inspection nom (body fld)
19463-9,ethylmorphine [presence] in urine by confirmatory method
19463-9,ethylmrphine [resence]n rie by confirmatorymethd
19463-9,uin [presnce]i ehylmorphe by confirmatorymetho
19463-9,emp ur ql cfm
19463-9,presence ur emp cfm
19463-9,emp ur ql cfm
19463-9,ethylmorphine confirm ql (u)
19463-9,ethylmorphie conf ql(u) confirm
19463-9,ethylmorphine ql confirm (u)
51739-1,codeine free [mass/volume] in urine
51739-1,codene free [mas/volume]in urine
51739-1,codeine codeine free free urine in [mass/volume]
51739-1,codeine free ur-mcnc
51739-1,odinefee ur-mcnc
51739-1,free codeine ur-mc
51739-1,codeine free (u) [mass/vol]
51739-1,codeine free (u) [mass/vol]
51739-1,codene free (u) [mass/vol]
8157-0,arsenic [mass/mass] in nail
8157-0,arsenic [mass/mass] in ungal nail nail
8157-0,arsenic [mass/mass] random in nail
8157-0,arsenic nail-mcnt
8157-0,nail-mcnt arsenic
8157-0,nail-mcnt arsenic
8157-0,arsenic (nail) [mass/mass]
8157-0,arsenic [mass/mass] (nail)
8157-0,arsenic (nail) [mass/mass]
50919-0,thorium [moles/mass] in tissue
50919-0,thorium tissue in [moles/mass]
50919-0,point in time thoium [moles/mass] in tissue
50919-0,thorium tiss-scnt
50919-0,tiss-scnt thorium
50919-0,tiss-scnt thorium
50919-0,thorium (tiss) [moles/mass]
50919-0,thorium (tiss) [moles/mass]
50919-0,thorium (tiss) [moles/mass]
7793-3,howell-jolly bodies [presence] in blood by light microscopy
7793-3,howl-jolly liht [presence in bod by bodies microscpy
7793-3,howell-jolly qualitative bodies [presence] in blood by light microscopy
7793-3,howell-jolly bod bld ql smear
7793-3,howell-jolly ql bld bod smear
7793-3,howell-jolly ql bld bod smear
7793-3,howell-jolly bodies lm ql (bld)
7793-3,howell-joly bodies lm presence(bld)
7793-3,howll-jolly ql lm bodies (blood)
43099-1,vanillylmandelate and creatinine panel - 24 hour urine
43099-1,vanilllmandelate and cr creatinine panel - 24 hor urine
43099-1,vanilylmandlate and hour panel- 24 creatinine urine
43099-1,vma + creat pnl 24h ur
43099-1,"vma + creat pnl 24h r 3-methyl,4-oh mandelic acid"
43099-1,creat universallaborders + vma pnl 24h ur
43099-1,vanillylmandelate and creatinine panel (24h u)
43099-1,vanillylmandelate and u) panel (24h creatinine
43099-1,vanillylmandelate and creatinine pane (4hu)
92814-3,borrelia afzelii+burgdorferi+garinii igg ab [presence] in serum by immunoassay
92814-3,borrla afelii+bugdorferi+garniiggab [presence] in serumby immunoassy
92814-3,borrelia afelii+burgrferi+garnii gg ab [presence] i serum by immunoasay
92814-3,b afz+burg+gari igg ser ql ia
92814-3,b ql az+bug+ari igg ser ql i
92814-3,b serum ig afz+burg+gar q sr ia
92814-3,b. afzelii+burgdorferi+garinii igg ia ql (s)
92814-3,b. afzelii+burgdorferi+garinii igg ql ia (s)
92814-3,b. afzelii+burgdorferi+garinii (s) immune globulin g ia ql igg
88901-4,adenovirus [presence] in stool by organism specific culture
88901-4,in [presence] adenovirus stool by organism specific culture
88901-4,adenovirus gastro by n stol [presence] ogansm specifc culture
88901-4,hadv stl ql cult
88901-4,hadv infectiousdisease stl cult presence
88901-4,qlclt stl hdv
88901-4,adenovirus org specific cx ql (stl)
88901-4,adenovirus org faecal ql(stl) cx secifc
88901-4,specific org bowel movement adenovirus cx presence (stl)
53325-7,urinalysis type of crystal panel - urine by computer assisted method
53325-7,urinalysis type by crystal panel - urine of computer assisted method
53325-7,urinlysis compute of crystal panel - urine by panel.urinalysis type asited method
53325-7,ua crystal pnl ur comp assist
53325-7,ua crystal assist ur comp pnl
53325-7,ua crystal pnl ur comp assist ur
53325-7,urinalysis type of crystal panel computer assisted (u)
53325-7,urinalysis type of pan crystal panel computer assisted (u)
53325-7,urinalysis type panel crystal of computer assisted (u)
17869-9,orotate/creatinine [molar ratio] in urine
17869-9,orotte/creatinine [moarrao in point in time uine
17869-9,orotate/creatinine urine ratio] in [molar
17869-9,orotate/creat ur-srto
17869-9,ur-srto substance concentration ratio orotate/creat
17869-9,ur-srto ortt/cret
17869-9,orotate/creatinine (u) [molar ratio]
17869-9,orotic acid orotate/creatinine (u) [molar ratio]
17869-9,orotate/creatinine (u) ratio] [molar
11477-7,microscopic observation [identifier] in sputum by acid fast stain
11477-7,microscopic observation [identifier] fast sputum by acid in stain
11477-7,micrcopi [identifier] bservation in sputum acifast stain
11477-7,acid fast stn spt
11477-7,aci spt stn fast afb stain
11477-7,acid fast id stn spt
11477-7,microscopic observation acid fast stain nom (sput)
11477-7,microscopi obsrvtio acd fast stain nm (sput)
11477-7,microscopic acid fast stn observation acid fast (sput) nom stain
101879-5,osmolality of arterial blood by calculated by sum of electrolytes
101879-5,osmolality of calc arterial blood by calculated by sum of electrolytes
101879-5,osmolality calculation by arterial blood by calculated of sum of electrolytes
101879-5,osmolality blda calc.sum of elec
101879-5,osmolality la calc.sum o abg elec
101879-5,art osmolalty blacalc.suo elec
101879-5,osmolality calculated by sum of electrolytes (blda) [osmolality]
101879-5,osmolality sum by calculated of electrolytes quantitative (blda) [osmolality]
101879-5,osmolality calculated by art blood sum of elctrolytes (blda) [osmolaity
18308-7,pneumocystis sp identified in lung tissue by immune stain
18308-7,pnuocystiss identified in lungtissue by mune imstn stai
18308-7,pneumocystis sp identified in lung tissue by immune stain
18308-7,pneumocystis lung tiss imstn
18308-7,imune pnumcystis istn lungiss
18308-7,tiss lung pneumocystis imstn
18308-7,pneumocystis sp identified immune stain nom (lung tissue)
18308-7,immune sp identified pneumocystis stain nom (lung tissue)
18308-7,pneumocystis sp identified immune stain tissue) (lung nom
53603-7,mumps virus rna [presence] in serum by naa with probe detection
53603-7,3sr sr mumps virus rna [presence] in serum by with naa probe detection
53603-7,mums viru rna [resnce] in serumby naa with probe detecion
53603-7,muv rna ser ql naa+probe
53603-7,muv rna serum naa+probe ql ser
53603-7,muv ra srql na+prbe
53603-7,muv rna naa+probe ql (s)
53603-7,mu rna naa+probe presence 3 self-sustaining sequence replication (s)
53603-7,presence lcr rna naa+probe muv (s)
14237-2,myelin basic protein iga ab [units/volume] in serum
14237-2,point in time yelin baic proten iga ab unitsvolume] n serum
14237-2,basi myli protein iga ab [unit/volume] in erum
14237-2,mbp iga ser-acnc
14237-2,mbp iga serum-acnc
14237-2,bp iga er-acnc quantitative
14237-2,myelin basic protein iga qn (s)
14237-2,myelin basi proten iga qn (s)
14237-2,myln basic proinga prot qn (s)
62344-7,chromosome analysis.metaphase panel - blood by fish
62344-7,chromosome nalysis.metaphase - panel blod by fish
62344-7,bld genetics anaysis.metaphase panel- cromosome by fish
62344-7,chrom analy metaphase pnl bld fish
62344-7,chrom analy metaphase pnl bld fish
62344-7,chrom analymetahasepnl bd fish
62344-7,chr analysis.metaphase panel fish (bld)
62344-7,(bld) analysis.metaphase panel blood fish chr
62344-7,hr chrom analy is panel analysis.metaphase (bld)
100138-7,schistosoma sp 18-19kd ab [presence] in serum by immunoblot
100138-7,schistosom sp18-kd ab [presenc] n ser by immunolo
100138-7,schistosoma by 18-19kd ab [presence] in ser sp immunoblot
100138-7,schist sp 18-19kd ab ser ql ib
100138-7,sp schit 1819kd ab serum ql ib
100138-7,schist sp ab 18-19kd ser presence ib
100138-7,schistosoma sp 18-19kd ab ib ql (s)
100138-7,ql p 18-19kd ab ib schistooma (s)
100138-7,schistosoma ab 18-19kd sp ib ql (s)
13122-7,deprecated sulfatide ab.igm in serum or plasma
13122-7,deprecated slatide ab.igmn erum oplasma
13122-7,deprecated sulfatide ab.igm in ser or plasma
13122-7,deprecated sulfatide igm serpl
13122-7,deprecated igm sulfatide serpl
13122-7,deprecated sulfatide serpl igm serpl
13122-7,sulfatide igm
13122-7,sulfatide igm aby
13122-7,slfatide igm
87648-2,malathion [mass/mass] in specimen
87648-2,malathion specimen in [mass/mass]
87648-2,malathion specimen in [mass/mass]
87648-2,malathion spec-mcnt
87648-2,spc-mcnt malation maldison
87648-2,maathin sp-mcnt
87648-2,malathion (specimen) [mass/mass]
87648-2,(specimn) malahon [mass/ms]
87648-2,malathion [mass/mass] (specimen)
2027-1,"carbon dioxide, total [moles/volume] in venous blood"
2027-1,"carbon dioxide, total co2 total [molesvoume] in venos blood"
2027-1,"carbon dioxide, total [moles/volume] in venous blood"
2027-1,co2 bldv-scnc
2027-1,bldv-scnc co2
2027-1,bldv-scnc co2 quantitative
2027-1,co2 (bldv) [moles/vol]
2027-1,c2 (bldv)[mles/vol] quantitative
2027-1,[moles/vol] (bldv) co2
5862-8,influenza virus a ag [presence] in specimen by immunoassay
5862-8,influenza virus a influenza a immunoassay [presence] in specimen by ag
5862-8,influenza ag a avian influenza virus [presenc] in specimen by immunoassy
5862-8,fluav ag spec ql ia
5862-8,eia ia a pec ql fluav
5862-8,fluav ag fluv spec presence ia
5862-8,fluav ag ia ql (specimen)
5862-8,fluav ag ia ql (specimen) ordinal
5862-8,fluav ag ia ql (specimen)
55312-3,yeast.pseudohyphae [presence] in vaginal fluid by koh preparation
55312-3,yeast.pseudohyphae [presence] in vaginal fluid by koh qualitative preparation
55312-3,preparation [presence] in vaginal fluid by koh yeast.pseudohyphae
55312-3,yeast pseudohyphae vag ql koh prep
55312-3,prep l koh id yeastpseudohyhaevag
55312-3,yeast pseudohyphae vag ql id koh prep
55312-3,yeast.pseudohyphae koh prep ql (vag fld)
55312-3,(vag koh prep ql yeast.pseudohyphae fld)
55312-3,yeast.pseudoyphaekoh prep ql (vag fld)
74501-8,patient safety event report - hospital - summary of initial report (sir) - version 1.2 [ahrq]
74501-8,patien safety even eport - hospital - ummary of inia report (sir)- verion 1.2 [ahr] pt safety event
74501-8,patient point in time report event report - hospital - summary of initial safety (sir) - version 1.2 [ahrq]
7854-3,dengue virus 1 ab [presence] in serum by immunoassay
7854-3,dengue virus 1 ab [presence] in by serum immunoassay
7854-3,denguevirus1 in [presene] ab serum by immunoass
7854-3,denv1 ab ser ql ia
7854-3,env1 ab q pr serum ia
7854-3,denv1 ab ia ql ser
7854-3,denv 1 ab ia ql (s)
7854-3,ab 1 denv ia ql (s) infectiousdisease
7854-3,denv antibody 1 ab ia ql (s)
39482-5,trimeprazine [moles/volume] in serum or plasma
39482-5,trimeprazine [moles/volume] in serpl
39482-5,trimeprazine in [moles/volume] serum or plasma
39482-5,trimeprazine serpl-scnc
39482-5,serpl-scnc trimeprazine
39482-5,serp-scnc trimerazine
39482-5,trimeprazine [moles/vol]
39482-5,[moles/vol] trimeprazine
39482-5,trimeprazine [moles/vol]
35725-1,chlamydia sp rrna [presence] in throat by probe
35725-1,throat p rrn [pesence] in chlamdia by probe chlamid
35725-1,chlamdia sp rrna presnce] in thoat by probe
35725-1,chlamydia rrna throat ql probe
35725-1,probe rrna throat presence chlamydia dna nucleic acid probe
35725-1,chlaydia ql throat rrna probe pr
35725-1,chlamydia sp rrna probe ql (throat)
35725-1,chlamydia sp rrna probe ql random (throat)
35725-1,chamydia probe sprrna ql (throat)
14452-7,virus identified in cervix by culture
14452-7,by identified in crvix viru identity or presence culture
14452-7,virus identified in cervix obgyn by culture
14452-7,virus cvx cult
14452-7,viru cvx lt
14452-7,virus cvx nominal cult
14452-7,virus identified cx nom (cvx)
14452-7,virus identified cx nom (cvx) infectiousdisease
14452-7,virus idntified cx (vx random nom
75143-8,deoxyuridine [moles/volume] in cerebral spinal fluid
75143-8,oxuridine [moles/voume] n cerebral spinal fluid
75143-8,deoxyuridine spinal flu [moles/volume] in cerebral spinal fluid
75143-8,deoxyuridine csf-scnc
75143-8,cerebrospinal fluid-scnc deoyuridine
75143-8,deoxyuridine cerebrospinal fluid-scnc spinal fl
75143-8,deoxyuridine (csf) [moles/vol]
75143-8,deoxyidine (csf) [mols/ol] quantitative
75143-8,du deoxyuriin(csf) [moles/o]
53028-7,cyclic citrullinated peptide ab [presence] in serum
53028-7,cyclic citrulnate eptide b [resence] nserum
53028-7,cyci cirulinated peptide ab rsenc] in ql serum
53028-7,ccp ab ser ql
53028-7,cc ab antibody ser ql
53028-7,ccp ab ser ql autoantibodies
53028-7,cyclic citrullinated peptide ab ql (s)
53028-7,cyclc citrllinted presence ab peptide (s)
53028-7,cyclic citrullinated peptide ql ab (s)
23692-7,canine distemper virus igg ab [titer] in serum
23692-7,canine distemper virus igg ab [titer] in serum
23692-7,serum aby distemper virus igg ab [titer] in canine
23692-7,cdv igg titr ser
23692-7,igg cdv titr ser
23692-7,antibodies dv igg tit ser
23692-7,canine distemper virus igg (s) [titer]
23692-7,canine ( ig dog disteperiru titer]
23692-7,canine distemper virus igg (s) [titer]
26979-5,flurazepam [mass/mass] in meconium
26979-5,flurazepam [mass/mass] in mec meconium
26979-5,flurazepam [mass/mass] inmecnium
26979-5,flurazepam mec-mcnt
26979-5,flurazepam mec-mcnt quant
26979-5,flurazepammec-mcnt random
26979-5,flurazepam (mec) [mass/mass]
26979-5,(mec) flurazepam [mass/mass]
26979-5,[mass/mass] random (mec) flurazepam
23524-2,trypanosoma evansi ab [units/volume] in serum by immunoassay
23524-2,rypanosomaevansiabuit/vou] in serum elfa by imunoasay
23524-2,trypanosoma evansi by [units/volume] in serum ab immunoassay
23524-2,t evansi ab ser ia-acnc
23524-2,derrengadera ser evansi ab t ia-acnc
23524-2,antby t evansi a ser iaanc
23524-2,t. evansi ab ia qn (s)
23524-2,t. ab evansi ia qn (s)
23524-2,qn evansi ab autoantibody ia t. (s)
31356-9,echovirus 4 ab [presence] in serum
31356-9,echovirus in ab [presence] 4 serum
31356-9,echovirus 4 ab [presenc] i sum qual
31356-9,ecv4 ab ser ql
31356-9,ecv b ser ql
31356-9,ab ecv4 ser ql
31356-9,echovirus 4 ab ql (s)
31356-9,echovrus 4 ab l(s
31356-9,echovirus  ab ql s)
8166-1,tetrahydrocannabinol [mass/volume] in meconium
8166-1,meconim [mass/volume] pt i ttrhydronnabinol
8166-1,tetrahdrcannabinol meconium [mass/volume]in
8166-1,thc mec-mcnc
8166-1,mec-mcnc thc
8166-1,thc mecmcnc
8166-1,tetrahydrocannabinol (mec) [mass/vol]
8166-1,tetrahydrocannabinol level (mec) [mass/vol]
8166-1,tetrahydrocannabinol [mass/vol] (mec)
99788-2,functional communication measure - cognition ages 6 or older panel [asha noms]
99788-2,functional communication measure-cognition ages noms] or oder panel [sha 6
99788-2,panl survey.slp measure - conition age 6 or older functionacomuncatin asha nos]
72750-3,oxycodone [mass/volume] in saliva (oral fluid) by confirmatory method
72750-3,fluid) [mass/volume] in saliva (oral oxycodone by confirmatory confirmatory method
72750-3,oxycodone [mass/volume] in saliva percodan (oral fluid) by confirmatory method
72750-3,oxycodone sal cfm-mcnc
72750-3,oxycoone al percodan cfm-mcnc
72750-3,mass concentration c-mcnc sal oxycodone
72750-3,oxycodone confirm (sal) [mass/vol]
72750-3,ocodo level confim (sal) [mass/vol]
72750-3,oxycodone confirm sal) [mass/vol] drugs of abuse
14325-5,bacteria identified in specimen by environmental culture
14325-5,environmental identified in specimen by bacteria culture
14325-5,acteria idenified in specimen by environmenal culture
14325-5,bacteria spec envir cult
14325-5,cult bateia spec envir cult
14325-5,spec bateria envircult cult
14325-5,bacteria identified environmental culture nom (specimen)
14325-5,bacteria culture environmental identified nom random (specimen)
14325-5,spec bacteria idetified environmeal culture (secimen) no
55958-3,oleoylcarnitine (c18:1) [moles/volume] in urine
55958-3,oleoylcarnitine urine [moles/volume] in (c18:1)
55958-3,quant oleoylcarnitine urine [moles/volume] in (c18:1)
55958-3,oleoylcarn ur-scnc
55958-3,ur-scnc random oleoylcarn
55958-3,ur-scnc oleoylcarn
55958-3,c18:1 (u) [moles/vol]
55958-3,c18:1 (u) chemistry [moles/vol]
55958-3,c18:1 (u) octadecenoyl carnitine [moles/ol]
4434-7,deprecated sulfonamide [mass] of dose
4434-7,deprecated sulfonamide quan [mass] of dose
4434-7,of sulfamide [mass] depecated quant dose
4434-7,deprecated sulfonamide dose
4434-7,dose point in time dprecatedsulfonamid
4434-7,sulfas dose sulfonamide deprecated
4434-7,sulfonamide (dose) [mass]
4434-7,sulonamide (dse) [ass
4434-7,(dose) sulfonamide [mass]
45059-3,ehrlichia chaffeensis igg and igm panel [titer] - unspecified time serum by immunofluorescence
45059-3,ehrlichia chaffeeni igg and igm panel[itr] - uspecifed tme serum y imufluorsence ttr
45059-3,ehrlichia chaffeensis igg and igm panel [titer] - unspecified time ser ser by immunofluorescence
45059-3,e chaff igg+igm pnl ?tm titr ser if
45059-3,e chff ir pnl ?tm igg+igm ser if
45059-3,e chafigg+gm pnl ?tm titr serif
45059-3,e. chaffeensis igg and igm panel unsp time if (s) [titer]
45059-3,e. chaffeensis igg panel igm and unsp time if (s) acif [titer]
45059-3,e. time smqn iggandim pnel unsp chafensi if (s)[tier]
9822-8,bacteria identified in dialysis fluid by culture
9822-8,bacteri identified in by fluid dalysis ulture
9822-8,id bacteria deified in ialysi fluid y culture
9822-8,bacteria dial fld cult
9822-8,dialfld microbiology bceri lt
9822-8,bacteria cult fld dial
9822-8,bacteria identified cx nom (dial fld)
9822-8,bacteia identife nominal cx nom (dial fld
9822-8,bacteria id identified cx nom (dial fld)
2350-7,glucose [mass/volume] in urine
2350-7,in [mass/volume] glucose quan urine
2350-7,glucose level [mass/volume]n urine
2350-7,glucose ur-mcnc
2350-7,ur-mcnc glucose quan
2350-7,glucose ur-mcnc level
2350-7,glucose (u) [mass/vol]
2350-7,glucose (u) [massvol
2350-7,glucose [mas/vol] universallaborders ()
683-3,genital mycoplasma identified in genital specimen by organism specific culture
683-3,genital mycoplasma identified in genital point in time specimen by organism specific culture
683-3,specfic mycoplama ientiiedingental spcime organis genital microbiology clure
683-3,genital mycoplasma genital cult
683-3,genital genital mycoplasma cult
683-3,spp genita mycolasmagental cult
683-3,genital mycoplasma identified org specific cx nom (genital specimen)
683-3,genital mycoplasma identified org specific (genital nom cx specimen)
683-3,genital mcoplasma identifiedorg specific cx om genital specimen)
94575-8,heavy metals panel - 24 hour urine
94575-8,heavy metas pne - 2 hour uine panel.drug & toxicology
94575-8,panel metals heavy - 24 hour urine
94575-8,heavy met pnl 24h ur
94575-8,heavy met pnl 24h ur
94575-8,heavy met 24h pnl ur
94575-8,heavy metals panel (24h u)
94575-8,heavy metals panel (24h u)
94575-8,heavy meals panel (24hu)
43607-1,microalbumin [mass/time] in 12 hour urine
43607-1,n microalbumin[masime] 12 hoururin
43607-1,micro albumin hour [mass/time] in 12 microalbumin urine
43607-1,microalbumin 12h ur-mrate
43607-1,12 hours -mae h microalbumin
43607-1,12h quantitative microalbmin ur-mrate
43607-1,albumin dl <= 20 mg/l (12h u) [mass/time]
43607-1,lbumin dl mass rate <= 20 mg/l(12h u) [ass/time]
43607-1,albmin u) qnt <= 20 gl12h dl masstime]
696-5,neisseria gonorrhoeae [presence] in throat by organism specific culture
696-5,neissei gonorrhoeae [presenc]in hroat by oranismspecific culture
696-5,neisseri onorrhoeae [presnce] in n gonorrhoea throa y organismspecific culure
696-5,n gonorrhoea throat ql cult
696-5,n gonorrhoea throat presence cult
696-5,n goorrhoea point in time throt ql cu
696-5,n. gonorrhoeae org specific cx ql (throat)
696-5,n. ql org specific cx gonorrhoeae (throat)
696-5,n. cultures ql org specific cx gonorrhoeae (throat)
49616-6,legionella sp dna [identifier] in specimen by naa with probe detection
49616-6,legonell sp na[ientfier] robe specimen by naa wth in amplified detectio
49616-6,legionella sp dna [identifier] in specimen by naa with probe detection
49616-6,legionella dna spec naa+probe
49616-6,dna probe legionella naa+probe spec dna
49616-6,probe with ampification pec dna leinella na+proe
49616-6,legionella sp dna naa+probe nom (specimen)
49616-6,leionella sp dnanarobe nom (spcimen)
49616-6,naa+probe spna leginella nom (secmen)
94264-9,brucella sp ab [titer] in cerebral spinal fluid by immunocapture agglutination
94264-9,brucella sp ab immunocapture in cerebral microbiology spinal fluid by [titer] agglutination
94264-9,bcella sp a [titer] inerebral spinal fluid by immunocaptue ggltination
94264-9,brucella ab titr csf capture aggl
94264-9,titr ab brucella cerebrospinal fluid capture aggl capture aggl
94264-9,brucella ab titr infectiousdisease csf capture aggl
94264-9,brucella sp ab immunocapture agglutination (csf) [titer]
94264-9,bruella p ab immunocapture aglutnaion (csf) [titer]
94264-9,brucella immunocapture ab sp aggltintion(csf [titer]
3318-3,amdinocillin [mass/volume] in serum or plasma
3318-3,amdincllin [mass/volume] in ser quantitative or plsma
3318-3,pivmecilliam amdinocillin in [mass/volume] serum or plasma
3318-3,amdinocillin serpl-mcnc
3318-3,mdinocillin serp-mcn
3318-3,drug/toxicology serpl-mcnc amdinocillin
3318-3,amdinocillin [mass/vol]
3318-3,[mass/vol] amdinocillin
3318-3,[mass/vol] amdinocilln
94709-3,epilepsy autoimmune ab panel - cerebral spinal fluid
94709-3,epiesy utoimune a panel -erebralpnal fluid
94709-3,epilepsy panel ab autoimmune - cerebral spinal fluid
94709-3,epilepsy autoimmune ab pnl csf
94709-3,autoimmune epilepsy ab pnl pnl csf
94709-3,pnl autoimmune ab spinal fld epilepsy csf
94709-3,epilepsy autoimmune ab panel (csf)
94709-3,autoimmne eilesy abpanel epilepsy autoimmune ab pnl (cs)
94709-3,panel.serology epilepsy panel ab autoimmune (csf)
95358-8,rabbit hemorrhagic disease virus rna panel - specimen by naa with probe detection
95358-8,rabbit hemorrhagic disease virus rna panel - specimen by naa tma with probe detection
95358-8,rabt hmorrhagicdiseasevrs na pae - specimen by nawitprobe detectio
95358-8,rhdv rna pnl spec naa+probe
95358-8,rna rhdv pnl spec naa+probe
95358-8,rhdv rna pnl spec naa+probe
95358-8,rabbit hemorrhagic disease virus rna panel naa+probe (specimen)
95358-8,rabihemorrhagicisase (secn) rna panel naprobe vius
95358-8,rabbit hemorrhaic disease vius rna (specien) naa+probe panel
90854-1,duke anxiety depression scale [duke-ad]
90854-1,duke [due-a] panel depressionscale aniet
90854-1,pnl duke sale eression aniety [duke-ad]
93771-4,calprotectin [mass/volume] in synovial fluid
93771-4,synovial fluid calrotctin [mass/volme] in synovial fluid
93771-4,calprotectin [mass/volume] fluid syovial quan in
93771-4,calprotectin snv-mcnc
93771-4,calrtecin joint aspirate nv-cc
93771-4,snv-mcnc calprotectin chemistry
93771-4,calprotectin (syn fld) [mass/vol]
93771-4,calprotectin fld) (syn [mass/vol]
93771-4,fld) (syn calprotectin [mass/vol]
75633-8,rheumatoid arthritis disease activity score calculated by vectrada
75633-8,rheumatoid disease arthritis activity score calculated by vectrada
75633-8,rheumatoid activity arthritisdseas scor calculated byvectrada
75633-8,ra das score calc vectrada
75633-8,ra calcvectra soe ra das das
75633-8,ra das score calc vectrada
75633-8,rheumatoid arthritis disease activity score calculated by vectrada [score]
75633-8,heumatoi plasma arthritis disase activity scre vectrada by clcuatd score
75633-8,rheuatd arthritis pl calculatedby atiitysce isease vectrada [scoe]
6371-9,cryptosporidium sp ag [presence] in stool by immunoassay
6371-9,cryposporidium p g [presence] in stool infectious disease by immunoaay
6371-9,cyptosoridium [presence] ag sp in sl by immunoassay
6371-9,cryptosp ag stl ql ia
6371-9,cryptosp a stl ql a
6371-9,cryptosp ag crypt ql stl ia
6371-9,cryptosporidium sp ag ia ql (stl)
6371-9,cryptosporidium ag sp fecal ia ql (stl)
6371-9,cryptosporidium sp ag ql qualitative ia (stl)
13242-3,sporothrix schenckii igm ab [units/volume] in serum
13242-3,sporothrix schenckii igm ab [units/volume] in ser
13242-3,sporothrix shenckii igm ab [units/volume] in serm
13242-3,s schenckii igm ser-acnc
13242-3,sr s schenckii igm ser-acnc
13242-3,anti s schenckii igm serum-acnc
13242-3,s. schenckii igm qn (s)
13242-3,s (s) qn schenckiiigm
13242-3,s. im schnckii anti qn (s)
95215-0,cbc w differential panel - stem cell product
95215-0,bc stemcell differentil pan panel - w product
95215-0,cbwdifferentia panel - stem cel prouct pnl
95215-0,cbc w diff pnl stem prod
95215-0,cbc  diff pnl stem prod
95215-0,cbcw iff point in time pnl pod stem
95215-0,cbc w differential panel (stem cell product)
95215-0,(stem w differn differential panel cbc cell product)
95215-0,cbc w differential panel (stem cell product) diff
32998-7,tissue transglutaminase igg ab [units/volume] in serum
32998-7,anti tissue ransglutaminase igg erum [uits/volume] in ab
32998-7,tissue transglutaminase in ab [units/volume] igg serum
32998-7,ttg igg ser-acnc
32998-7,ttg ser-acnc igg
32998-7,igg ttg ser-acnc
32998-7,ttg igg qn (s)
32998-7,igg ttg arbitrary concentration qn (s)
32998-7,tg (s) iggq
71872-6,hemoglobin a2/hemoglobin.total [pure mass fraction] in blood
71872-6,fraction] a2/hemoglobin.total [pure totl mass hemoglobin in blood
71872-6,hemogobin a/hmoglobintotal [puremasfration] blood in
71872-6,hgb a2 mfr.df bld
71872-6,hgb a2 hgb a2 mfr.df blood
71872-6,g fr.dfbld a2
71872-6,hemoglobin a2 (bld) [pure mass fraction]
71872-6,puremassfration] tot a2 (blood) eogloin
71872-6,[pure a2 (bld) qnt hemoglobin mass fraction]
89966-6,norquetiapine [mass/volume] in urine by confirmatory method
89966-6,noruetiapine [mass/olume] n confirmatory y urine method
89966-6,oqetiapine quant [mas/volme] in urineby confirmatory method
89966-6,norquetiapine ur cfm-mcnc
89966-6,norquetiapineur cfm-mn
89966-6,norquetiapine ucfm-mcnc
89966-6,norquetiapine confirm (u) [mass/vol]
89966-6,[mass/vol] confirm (u) norquetiapine
89966-6,norquetiapine confirm cnfrm (u) [mass/vol]
54037-7,hedis 2009 panel
54037-7,hedis 2009 panel random
54037-7,panel 2009 hedis
54037-7,hedis 2009 pnl
54037-7,209 hedis nl
54037-7,hedis pnl 2009
54037-7,hedis 2009 panel
54037-7,panel 2009 hedis
54037-7,hedis 2009 pan panel
60485-0,interferon gamma [mass/volume] in body fluid
60485-0,interferon in bodies [mass/volume] gamma body fluid
60485-0,inteferon gamma [mas/volume] in body fld
60485-0,ignf fld-mcnc
60485-0,fld-mcnc gnf
60485-0,fld-mcnc bf ignf
60485-0,interferon gamma (body fld) [mass/vol]
60485-0,interferon gamma (body fld) [mass/vol]
60485-0,gamma interferon (body fld) [mass/vol]
12972-6,urea nitrogen [mass/volume] in peritoneal dialysis fluid --1st specimen
12972-6,urea nitrogen [mass/volume] in point in time peritoneal dialysis fluid --1st specimen
12972-6,urea nitrogen [mass/volume] in peritoneal dialysis --1st fluid specimen
12972-6,urea nit sp1 diafp-mcnc
12972-6,urea nit s1 diafp-mcnc
12972-6,urea diafp-mcnc nitp1
12972-6,urea nitrogen spec 1 (perit dial fld) [mass/vol]
12972-6,first nitrogen urea sec 1 (perit dial fld) [mass/vo]
12972-6,uea nitrogen spec un dial (peit 1 fld) [mass/vol]
75212-1,malonylcarnitine (c3-dc)/decanoylcarnitine (c10) [molar ratio] in dbs
75212-1,malonylcarnitine (c3-dc)/decanoylcarnitine (c10) scrto [molar ratio] in dbs
75212-1,malonylcrnitine (c3-dc)/decnoylcarntine (c10) [mor ati indbs
75212-1,malonylcarn/c10 dbs-srto
75212-1,dbs-srto malonylcarn/c10 quant
75212-1,dbs-srto quan malonylcarn/c10
75212-1,c3-dc/decanoylcarnitine (c10) (dbs) [molar ratio]
75212-1,c3-dc/decanoylcarnitine (c10) substance ratio (dbs) [molar ratio]
75212-1,c10 c3-dc/decanoylcarnitine (c10) ratio] [molar (dbs)
23765-1,porcine adenovirus ag [presence] in tissue by immunofluorescence
23765-1,porcine adenovirus random ag [ql] in tissue by immunofluorescence
23765-1,immuofluoresene adenoirus ag [pesnce] i tissue porcine
23765-1,padv ag tiss ql if
23765-1,padv tiss ag presence if
23765-1,padv ag if ql tiss
23765-1,porcine adenovirus ag if ql (tiss)
23765-1,porcin adenovirus ag iql (tis
23765-1,ordinal porcine adenovirus if ag ql (tiss)
73206-5,phenytoin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73206-5,phenytoin induced platelet serm ab [prsence] in igg or plasma by flow cytometry (f)
73206-5,phenytoin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73206-5,phenytoin ind plt igg serpl ql fc
73206-5,phenytoin ind plt ig serpl presence fc
73206-5,penytoin ind pl igg srpl ql fc
73206-5,phenytoin induced platelet igg fc ql
73206-5,phenytoin fc platelet igg induced ql
73206-5,phenytoin induced platelet igg fc ql ordinal
53437-0,carnitine palmitoyltransferase 1 [enzymatic activity/mass] in fibroblast
53437-0,carnitine palmitoyltansferase activityss] [enzymatic 1 in broblast
53437-0,carnitine palmitoyltransferase 1 [enzymatic cpt activity/mass] in fibroblast
53437-0,cpt1 fib-ccnt
53437-0,ct1fib-ccnt carnitine acyltransferase i
53437-0,cpt1 carnitine acyltransferase i fb-ccnt
53437-0,carnitine palmitoyltransferase 1 (fibroblast) [catalytic activity/mass]
53437-0,fibr carnitine palmitoyltransferase 1 (fibroblast) [catalytic activity/mass]
53437-0,palmitoyltransferase carnitine 1 (fibroblast) [catalytic activity/mass]
42249-3,levetiracetam [presence] in urine by screen method
42249-3,levetirctam presence] n urine by screen metho
42249-3,levetiraceta ql] y uine ur in screen method
42249-3,levetiracetam ur ql scn
42249-3,ql u levetiraceam random scn
42249-3,ur levetiracetam presence drugs scn
42249-3,levetiracetam screen ql (u)
42249-3,lvetiractam sren keppra ql (u)
42249-3,ql screen levetiracetam (u) ordinal
23440-1,swine vesicular disease virus neutralizing antibody [presence] in serum by neutralization test
23440-1,swi vesicular dsease virus neutralizin antibody pesece in ser b neutrlizatin test
23440-1,swie vsicular [presence] virusnetralizing antibody disease neutralization in serum by neutralization est
23440-1,svd nab ser ql nt
23440-1,svd nab ser ql vet nt
23440-1,ser qual nab svd ql nt
23440-1,swine vesicular disease virus neut ab neut test ql (s)
23440-1,tes vesicular diseae virus nut ab eut swine ql s)
23440-1,swine vesicular disease virus neut ab neut test ql (s) veterinary
13490-8,lutropin/creatinine [mass ratio] in urine
13490-8,lutropin/creatinie [mass raio] in rine
13490-8,lutropin/creatinine [mass ratio] in urine lh
13490-8,lh/creat ur
13490-8,ur lh/crea
13490-8,lh/creat ur
13490-8,lutropin/creatinine (u) [mass ratio]
13490-8,lutropin/creatinine [mass (u) ratio]
13490-8,lutrpin/atinine (u)[mas atio]
26867-2,fentanyl [units/volume] in 24 hour urine
26867-2,potentialforabuse fetanyl [units/volume] n urine hour 24
26867-2,hour [units/volume] in 24 fentanyl urine
26867-2,fentanyl 24h ur-acnc
26867-2,qnt fentanyl ur-acnc 24h
26867-2,ur-acc 24h fentanyl
26867-2,fentanyl qn (24h u)
26867-2,fentanyl (24h qn u)
26867-2,fentanyl qn (24h u)
22342-0,herpes simplex virus igg ab [interpretation] in serum
22342-0,hees siplex virs igg ab [inerprtation] n serum
22342-0,herpes igg virus simplex ab [interpretation] in serum
22342-0,hsv igg ser-imp
22342-0,ser-imp hsvigg
22342-0,hsv igg random ser-imp
22342-0,hsv igg (s) [interp]
22342-0,hsv [intep] () igg antibody
22342-0,herp splx hsv (s) igg [interp]
22782-7,african swine fever virus ag [presence] in tissue by agglutination
22782-7,afcan swin fever vius ag [prsence] intisu by agglutiation
22782-7,african swin ever virus g [presence] in tissu bggltination
22782-7,asfv ag tiss ql aggl
22782-7,asfv agtiss agg antigens ql
22782-7,asfv ag tiss presence aggl id
22782-7,african swine fever virus ag aggl ql (tiss)
22782-7,africn swne fever viru a aggl ql (tiss)
22782-7,swin african fever vius g aggl ql id (tiss)
87207-7,care area assessment (caa) summary during assessment period [cms assessment]
87207-7,care are assessment(caa) summary during assessment [cms perod assessment]
87207-7,care area assessment (caa) summary during pnl assessment period [cms assessment]
23532-5,trypanosoma sp ab [presence] in serum by agglutination
23532-5,trypansma by a [presence] in species serum sp agglutination
23532-5,trypanosoma by ab ordinal [presence] in serum sp agglutination
23532-5,trypanos ab ser ql aggl
23532-5,ser ab trypanos presence aggl
23532-5,tpanos ab ser infectious disease ql aggl
23532-5,trypanosoma sp ab aggl ql (s)
23532-5,trypanosoma sp anti ab (s) ql aggl
23532-5,ab s trypanosoma aggl ql (s)
41025-8,ribonucleoprotein extractable nuclear ab [mass/volume] in serum
41025-8,ab extractable nuclear ribonucleoprotein [mass/volume] in ser
41025-8,ribnucleoprotein extracable sr nlea insru mas/volume ab
41025-8,ena rnp ab ser-mcnc
41025-8,ena sermcnc ab rnp
41025-8,ena rnp ab ser-mcn
41025-8,ribonucleoprotein extractable nuclear ab (s) [mass/vol]
41025-8,ribonucleopotein exractabl nuclar ab (s mass/vol] antby
41025-8,ribonucleoproten etracable nuclearab ena (s)[ass/vo]
105614-2,aspergillus sp dna [#/volume] in bronchoalveolar lavage by naa with probe detection
105614-2,aspergillus lavag dna [#/volume]in bronchoalvelar sp by na with probe detion
105614-2,aspergilus sp na [#/volume] in broncholveolr lag prbedetection naa with by
105614-2,aspergillus dna # bal naa+probe
105614-2,aspergilus dn # bal naa+probe
105614-2,naa+probe dna # bal aspergillus
105614-2,aspergillus sp dna naa+probe (bal) [#/vol]
105614-2,aserillus [#/vol] dnanaa+prbe qnt (bal) sp
105614-2,amplif aspergillus sp dna naa+probe (bal) [#/vol]
12195-4,creatinine renal clearance/1.73 sq m in 24 hour urine and serum or plasma
12195-4,cretininerenalcerance/1.73 sq m 24 our rine plasma nd ser or plasma
12195-4,creatinine renal clearance/1.73 sq m in 24 hour serpl urine and serum or plasma
12195-4,creat cl/1.73 sq m 24h ur+serpl-arvrat
12195-4,sqm creatc/1.73 24h u+serpl-arvrt clr
12195-4,creat 24h sq m cl/1.73 ur+serpl-arvrat
12195-4,creatinine renal clearance/1.73 sq m (24h u+s/p) [vol rate/area]
12195-4,ceatnine renal clearanc/1.73 s m kidney (24h u+s/ [vol rate/are]
12195-4,creatinine renl clearnce/1.3sq m (24h u+s/) vol rat/area]
57324-6,influenza virus a igg ab [units/volume] in serum by immunoassay --1st specimen
57324-6,influenza virus a igg ab antibodies [units/volume] in serum by immunoassay --1st specimen
57324-6,influenza virus a igg ab [units/volume] in ser by immunoassay --1st specimen
57324-6,fluav igg sp1 ser ia-acnc
57324-6,ser sp1 igg p1 luav i-acnc
57324-6,flua immune globulin g ig sp1 er ia-acnc
57324-6,fluav igg spec 1 ia qn (s)
57324-6,fluav igg 1 spec ia qn (s)
57324-6,fluav igg spec qn 1ia sr (s)
94539-4,hepatitis a virus igm and total panel - serum or plasma qualitative
94539-4,hepatitis a virus igm and total panel - serum or plas qualitative
94539-4,hepatitis a virus igm and total panel - or serum plasma qualitative
94539-4,hav igm + total pnl serpl
94539-4,hav pnl igm pnl total + serpl
94539-4,hav gm  total pl serl
94539-4,hav igm and total panel ql
94539-4,hav igm ql total panel and
94539-4,hav igm and total ql panel
93303-6,intensity of ideation [c-ssrs]
93303-6,c-ssrs] ofideatin intesity
93303-6,panel.survey.cssrs intensity of ideation [c-ssrs]
76583-4,klebsiella pneumoniae phoe gene [presence] in swab specimen by naa with probe detection
76583-4,klebsiella pneumoniae phoe gene amplified [presence] in swab specimen by naa with probe detection
76583-4,klebsiella pneumoniae phoe gene [presence] in probe with target amplification swab specimen by naa with probe detection
76583-4,kl pneum phoe swab ql naa+probe
76583-4,kl naa+probe phoesabql pneum
76583-4,kl pneum 3 self-sustaining sequence replication phoe naa+probe ql swab
76583-4,k. pneumoniae phoe gene naa+probe ql (swab specimen)
76583-4,k. pneumoniae gene phoe naa+probe ql (swab specimen)
76583-4,k. swab pneu phoegene na+probe ql pneumoniae specimen)
22493-1,rickettsia typhus group igg ab [titer] in serum
22493-1,group yphus rkettsia igg ab [titer] in typhus serum
22493-1,rickettsia typhus in igg ab [titer] group serum
22493-1,rick typhus igg titr ser
22493-1,random rick typhus igg titr ser
22493-1,rick typhuigg rick typhus ser titr
22493-1,r. typhus group igg (s) [titer]
22493-1,r. typhus group gg(s)[titer] dilution factor (titer)
22493-1,r. typhus roup igg (s) [titer]
55805-6,cyclosporine [mass/volume] in blood by lc/ms/ms
55805-6,cyclosporine [mass/volume] by bld in lc/ms/ms
55805-6,cyclosporine [mass/volume] in blood lc/ms/ms by
55805-6,cyclosporine bld lc/ms/ms-mcnc
55805-6,bldc/ms/ms-cnc yclosporine
55805-6,lc/ms/ms-mcnc bld cycosporine quantitative
55805-6,cyclosporine lc/ms/ms (bld) [mass/vol]
55805-6,lc/ms/ms cyclosporine (bld) [mass/vol]
55805-6,cyclosporine [mass/vol] (bld) lc/ms/ms
48822-1,tubular basement membrane igg ab [units/volume] in serum by immunoassay
48822-1,tubular by membrane igg ab [units/volume] in serum basement immunoassay
48822-1,tubular basemet mebrane igg ab [units/volume in erum by iunoasay
48822-1,tbm igg ser ia-acnc
48822-1,tb random gg serum ia-acnc
48822-1,igg tbm ser ia-acnc
48822-1,tubular basement membrane igg ia qn (s)
48822-1,tbulr baemenmembraeigg random ia qn (s)
48822-1,tubular basement membrane igg ia qn point in time (s)
97526-8,balamuthia mandrillaris ag [presence] in specimen by immunofluorescence
97526-8,balamuthia qualitative mandrillaris by [presence] in specimen ag immunofluorescence
97526-8,balamuthia mandrillaris ag immunofluorescence in specimen by [presence]
97526-8,b mandrillaris ag spec ql if
97526-8,b ql spec mndrillarisg fa if
97526-8,screen bmandrillaris pec ag qlif
97526-8,b. mandrillaris ag if ql (specimen)
97526-8,aif mandrillaris b. ql (speimen)
97526-8,b. madrillaris ag ql if (pecimen
9332-8,carbon tetrachloride [mass/volume] in blood
9332-8,carbon tetrachloride blood in [mass/volume]
9332-8,carbon tetrachloride [mass/volume] in blood
9332-8,carbon tet bld-mcnc
9332-8,bld-cnc tet carbn
9332-8,tet carbon bld-mcnc
9332-8,carbon tetrachloride (bld) [mass/vol]
9332-8,carbon [mass/vol] (blood) tetrachloride
9332-8,carbon (blood) terachloride [mass/l]
7926-9,influenza virus a phillipines ab [units/volume] in serum
7926-9,influenza virus a phillipines ab antibody [units/volume] in serum
7926-9,influenza virus a phillipines ab [units/volume] influ in serum
7926-9,fluav phill ab ser-acnc
7926-9,ab phill fluav ser-acnc
7926-9,fowl plague phill fluav ab seracnc
7926-9,fluav phill ab qn (s)
7926-9,(s) phill ab antibody qn fluav
7926-9,fluav phill ab (s) qn
32081-2,hydromorphone [presence] in specimen
32081-2,potentialforabuse hydromorphone [prsnein specin
32081-2,[presence] ordinal hydrmorphne in specimen
32081-2,hydromorphone spec ql
32081-2,hydromorphone ql spec
32081-2,ql spec spec hydromorphone
32081-2,hydromorphone ql (specimen)
32081-2,ql hydromorphone (specimen)
32081-2,hydromophone ql (specimen) dilaudid
41462-3,taenia solium larva ab [presence] in specimen by immunoblot
41462-3,taenia solium larva ab [ql] in specimen by immunoblot
41462-3,taenia solium larva ab [ql] in specimen by immunoblot
41462-3,t sol lar ab spec ql ib
41462-3,t sol lar ab spec id presence ib
41462-3,t sol ar b spec ql ib
41462-3,t. solium larva ab ib ql (specimen)
41462-3,t. (specimen) larva ab ib ql solium
41462-3,t. solium ql ab ib larva (specimen)
24010-1,haemophilus influenzae b ag [presence] in cerebral spinal fluid
24010-1,haemophilus cerebral b ag [ql] in influenzae cerebrospinal fl spinal fluid
24010-1,haemophilus influenzae antigens b ag [presence] in cerebral spinal fluid
24010-1,haem influ b ag csf ql
24010-1,ham influ b a spinal flu cerebrospinal fluid ql
24010-1,hem influ agcsf b neurology ql
24010-1,h. influenzae b ag ql (csf)
24010-1,b influenzae h. ag ql spinal flu (csf)
24010-1,h. ql influenzae b ag ql (csf)
4164-0,cefoxitin [mass] of dose
4164-0,cefoxitin of [mass] dose quant
4164-0,of [mass] cefoxitin dose
4164-0,cefoxitin dose
4164-0,mefoxin dose cefoxitin
4164-0,ceoxitin dse point in time
4164-0,cefoxitin (dose) [mass]
4164-0,random (dose)[mass] cfxiti
4164-0,cefoxitin [mass] (dose)
9386-4,nifedipine [mass/volume] in serum or plasma
9386-4,or [mass/volume] in serum nifedipine plasma
9386-4,in [mass/volume] nifedipine serum or plasma drug/toxicology
9386-4,nifedipine serpl-mcnc
9386-4,mass concentration nifedpine srpl-mnc
9386-4,niedipine serum or plasma-mcc
9386-4,nifedipine [mass/vol]
9386-4,ifedipine drug/toxicology [mass/vol
9386-4,mass/vol] ifedipine
43049-6,coxsackievirus a10 ab [titer] in body fluid
43049-6,coxsackievirus a10 ab [titer] in titer body fluid
43049-6,cosackiviru 10 in [tter] ab bod fluid
43049-6,cv a10 ab titr fld
43049-6,cv a10 ab fld titr
43049-6,cv a10 ab titr fld id
43049-6,coxsackievirus a10 ab (body fld) [titer]
43049-6,coxsackievirus a10 ab fld) (body [titer]
43049-6,coxsacievius a10 ab fld (body fl) titer]
55070-7,insurance billing
55070-7,pnl insurance biing
55070-7,insurncilling panel.survey.cms
47509-5,streptococcus pneumoniae danish serotype 33f igg ab [mass/volume] in serum --1st specimen
47509-5,pneumococcal pneumonia streptococcus pneumoniae danish serotype 33f igg ab [mass/volume] in ser --1st specimen
47509-5,streptococcus pneumoniae 33f serotype danish igg ab [mass/volume] in serum --1st specimen
47509-5,s pneum da 33f igg sp1 ser-mcnc
47509-5,s pneum da quant 33f igg sp1 ser-mcnc
47509-5,s peum da 33f i sp1 serum-mcnc
47509-5,s. pneumoniae danish type 33f igg spec 1 (s) [mass/vol]
47509-5,[mass/vol] pneumoniae danish type 33f igg spec 1 (s) s.
47509-5,s. danish pneumoniae type antibodies 33f igg spec 1 (s) [mass/vol]
1753-3,albumin [presence] in urine
1753-3,qualitative albmin [presece] in urine
1753-3,albumin urine [presnce]in
1753-3,albumin ur ql
1753-3,albumin ur ql random
1753-3,albumin ur presence
1753-3,albumin ql (u)
1753-3,ql albumin (u) ur
1753-3,ql alumi (u)
17431-8,pentobarbital [mass/volume] in gastric fluid
17431-8,in [mass/volume] drugs pentobarbital gastric fluid
17431-8,quant pentobarbital [mass/volume] in gastric fluid
17431-8,pentobarb gast-mcnc
17431-8,penobarb gasmcnc
17431-8,gast-mcnc pentobarb quan
17431-8,pentobarbital (gast fld) [mass/vol]
17431-8,pentobarbital (gastfld) [mass/vol]
17431-8,(gast pntoarial fld [mas/ol]
34997-7,promonocytes [#/volume] in body fluid
34997-7,promonocytes [#/volume] in bod body fluid
34997-7,in [#/volum] promonocyte body flud
34997-7,promonycytes # fld
34997-7,promonycytes # hematology/cell counts fld
34997-7,prmonycytes #fl quan
34997-7,promonocytes (body fld) [#/vol]
34997-7,romonocytes (body fld) [#/vol]
34997-7,absolute promonocytes fld) (body [#/vol]
86812-5,"mds v3.0 - rai v1.14.1, v1.15.1, v1.16.1 - identification information - nt, st during assessment period [cms assessment]"
86812-5,"mds v3.0 - pnl rai v1.14.1, v1.15.1, v1.16.1 - identification information - nt, st during assessment period [cms assessment]"
86812-5,"mds v3.0 - rai centers for medicare and medicaid assessment v1.14.1, v1.15.1, v1.16.1 - identification information - nt, st during assessment period [cms assessment]"
5057-5,blastomyces dermatitidis ab [titer] in serum by complement fixation
5057-5,by dermatitidis ab [titer] in serum blastomyces complement fixation
5057-5,[titer] dermatitidis ab blastomyces in serum by complement dilution factor (titer) fixation
5057-5,b dermat ab titr ser cf
5057-5,b er ab tit derat cf autoantibody
5057-5,b derat ab cf titr ser cf
5057-5,b. dermatitidis ab cf (s) [titer]
5057-5,(s) dermatitidis ab cf b. [titer]
5057-5,b. dermatitidis ab cf(s) [titer]
43703-8,cytomegalovirus [presence] in blood by shell vial culture
43703-8,cytomegalovirus [presence] vial point in time bld by shell in culture
43703-8,comegalovirs [presence] inblood byshell via culture
43703-8,cmv bld ql shell vial cult
43703-8,cm bld ql shel via cult
43703-8,cmv blood ql shell vial cult
43703-8,cmv shell vial culture ql (bld)
43703-8,cmv shell vial ulture q (bld) microbiology
43703-8,cmv (blood) vial culture screen ql shell
4518-7,complement factor d [mass/volume] in serum or plasma
4518-7,quantitative complement fator d serum in [ass/volme] o lasma
4518-7,complement fctor d [mass/volume] inserum or plsa
4518-7,comp fact d serpl-mcnc
4518-7,d fact comp fact d comp serum or plasma-mcnc
4518-7,d ac comp serplmcnc
4518-7,complement factor d [mass/vol]
4518-7,complemen factrd [mass/ol]
4518-7,complement factor d [mass/vol]
2413-3,hippuran renal clearance in 24 hour urine and serum or plasma
2413-3,hipuran renal clearance in pl 24 hour urie an srm or plsma
2413-3,hippuran renal clearance clearances in 24 hour plasma and serum or urine
2413-3,hippuran cl 24h ur+serpl-vrate
2413-3,ua 24h cl hippurn ur+serpl-vrate
2413-3,hippuran clearanc cl 24h ur+serpl-vrate
2413-3,hippuran renal clearance (24h u+s/p) [vol/time]
2413-3,hipuran real clearance (24h u+s/p [vol/ime]
2413-3,hipurn renal clearnce u+s/p) clr (24h [vol/tim
4242-4,ethambutol [mass] of dose
4242-4,of [mass] ethmbuto point in time dos
4242-4,[mass] ethambutol of dose
4242-4,ethambutol dose
4242-4,ethambutol dose
4242-4,ethambutol dose
4242-4,ethambutol (dose) [mass]
4242-4,ehambutol (dse)[mass] myambutol
4242-4,ethambutol dose med or substance [mass] (dose)
62905-5,deprecated phenx measure - personal and family history of psoriasis
62905-5,deprecated panel.phenx phex measure - of and family histor personal soriasis
62905-5,deprecatedphenx measure - pesonaland family history psoriasis of
33603-2,bactericidal permeability increasing protein igg ab [units/volume] in serum
33603-2,protein permeability increasing bactericidal igg ab [units/volume] in serum
33603-2,actercidal permability incresing protin igg ab [unit/vlume] in serum
33603-2,bpi igg ser-acnc
33603-2,se-acnc bpiigg
33603-2,bpi point in time igg serum-acnc
33603-2,bactericidal permeability increasing protein igg qn (s)
33603-2,bactericidal igg increasing protein permeability qn (s)
33603-2,batericidal permeability increasing protein qn qnt igg ()
45088-2,deprecated chlamydia trachomatis rrna [presence] in penis by dna probe
45088-2,depreated chlayda trachomtis ra [presence] in peni by dna probe
45088-2,deprecated chlamydia trachomatis rrna [presence] penis in by dna probe
45088-2,deprecated c trach rrna penis ql prb
45088-2,deprecated arbitrary concentration c trach rrna penis presence prb
45088-2,deprecated c trach prb penis ql rrna
45088-2,c. trachomatis rrna probe ql (penis)
45088-2,c. trachomati probeql ra (penis
45088-2,c. trachomatisrna probe ql (penis) random
31680-2,theileria annulata ab [units/volume] in serum
31680-2,theileria annulata ab serum in [units/volume]
31680-2,theileria annulata ab id [units/volume] in ser
31680-2,t annulata ab ser-acnc
31680-2,t annulata serum-acnc ab autoantibodies
31680-2, annulat ab serum-acnc
31680-2,t. annulata ab qn (s)
31680-2,(s) annulata ab qn t. arbitrary concentration
31680-2,t. autoantibodies annulata ab qn (s)
12532-8,meclizine [presence] in serum or plasma
12532-8,meclizine [presence] in serum or ordinal plasma
12532-8,meclzine [preence] pasm serum or in
12532-8,meclizine serpl ql
12532-8,serpl meclizine ql
12532-8,meclizine ql serpl plasma
12532-8,meclizine ql
12532-8,eclzine antivert presence
12532-8,ql meclizine
5168-0,gall canaliculi ab [units/volume] in serum
5168-0,antibodies gall canaliculi ab [units/volume] serum in
5168-0,[units/volume] canaliculi ab gall in serum
5168-0,gall canaliculi ab ser-acnc
5168-0,gll caaliculi ab ser-anc
5168-0,gall random ab canaliculi ser-acnc
5168-0,gall canaliculi ab qn (s)
5168-0,antibody gall canaliculi qn ab (s)
5168-0,gall canaliculi qnt ab qn (s)
34336-8,lysozyme/creatinine [ratio] in urine
34336-8,lysozyme/creatinine in [ratio] urine
34336-8,ucr [ratio] lysozyme/creatinine in urine
34336-8,lysozyme/creat ur-rto
34336-8,lysozyme/creat ur-rto k208
34336-8,ur-ro lyozyme/cret
34336-8,lysozyme/creatinine (u) [ratio]
34336-8,(u) lysozyme/creatinine [ratio]
34336-8,lsozyme/ceatinine(u) [ratio] lysozymes
35222-9,phosphate [mass or moles/volume] in urine
35222-9,phosphate or [mass moles/volume] in urine urn
35222-9,phosphate [mass or moles/volume] in quant urine
35222-9,phosphate ur-mscnc
35222-9,ur-mscnc phosphate
35222-9,phosphte phosphorous ur-scn
35222-9,phosphate (u) [mass or moles/vol]
35222-9,phosphate (u) [mass moles/vol] or
35222-9,quan phosphate or [mass (u) moles/vol]
47610-1,creatinine [moles/volume] in stool
47610-1,cratinine in [mole/volme] sool
47610-1,creatinine [moles/volume] in stool
47610-1,creat stl-scnc
47610-1,stl-scc creat
47610-1,sl-scn creat
47610-1,creatinine (stl) [moles/vol]
47610-1,(stl) creatinine [moles/vol]
47610-1,feces creatinine [moles/vol] (stl)
3831-5,morphine [mass/volume] in urine
3831-5,morphine [mass/volume] urine point in time in
3831-5,drug/toxicology urine [mass/volume] in morphine
3831-5,morphine ur-mcnc
3831-5,morphin ur-mcnc
3831-5,morphi ur-mcnc
3831-5,morphine (u) [mass/vol]
3831-5,morphn (u ur [mas/vol]
3831-5,morphine [mass/vol] (u)
26990-2,phentermine [mass/volume] in milk
26990-2,hentermine milk [masoum]n
26990-2,phentermine illicit [mass/volume] in milk
26990-2,phentermine mlk-mcnc
26990-2,phentermin mlkmcnc addiction
26990-2,phentermine mlk-mcnc
26990-2,phentermine (milk) [mass/vol]
26990-2,[mass/vol] (milk) phentermine
26990-2,hentermine (mik) [mass/vol]
16410-3,asparagine [presence] in urine
16410-3,asparagine urine in chemistry [presence]
16410-3,asparagine [presence] in urine ur
16410-3,asparagine ur ql
16410-3,asparagine ur ql
16410-3,asparagine ur presence
16410-3,asparagine ql (u)
16410-3,asparagine (u) presence
16410-3,q asparagine (u)
12177-2,amino acids/creatinine [ratio] in urine
12177-2,urine acids/creatinine [ratio] in amino
12177-2,amino acids/creatinine cr [ratio] in urine
12177-2,amino acids/creat ur-rto
12177-2,ur-rto quan ainoids/creat
12177-2,amino acids/creat ur-rto
12177-2,amino acids/creatinine (u) [ratio]
12177-2,(u) acids/creatinine amino [ratio]
12177-2,amino (u) acids/creatinine [ratio]
57410-3,actin.filamentous ab [units/volume] in serum or plasma by immunoassay
57410-3,actinfilamentous ab [units/volume]in plasma or seum y immunoassay
57410-3,actinfilamentou ab [unitvolume] in serumo plsma by immunoassay
57410-3,f-actin ab serpl ia-acnc
57410-3,f-actin srpl ab quan ia-cnc
57410-3,f-actin ab serpl serpl ia-acnc
57410-3,actin.filamentous ab ia qn
57410-3,actin.filmentous ab i qn
57410-3,actin.filamentous autoantibodies ab qn ia
1994-3,calcium.ionized [moles/volume] in blood
1994-3,cliu.ionized moles/volume] in bld
1994-3,calcium.ionzed [mole/volume] inblood
1994-3,ca-i bld-scnc
1994-3,ca-i ld-scnc
1994-3,quantitative ca-i bld-scnc
1994-3,calcium.ionized (bld) [moles/vol]
1994-3,clcium.ionized (bd) [ol/vol]
1994-3,calciumionied (bd) substance concentration [moles/vo]
14772-8,gold [moles/volume] in serum or plasma
14772-8,gold serum in [moles/volume] or plas
14772-8,gold in serp [moles/volume] serum or plasma
14772-8,gold serpl-scnc
14772-8,gold serpl-scnc
14772-8,gold serpl-scnc drug/toxicology
14772-8,gold [moles/vol]
14772-8,gold serum or plasma [moles/vol]
14772-8,serplas [moles/ol] gold
44090-9,escherichia coli o157:h7 [presence] in isolate by organism specific culture
44090-9,escherichia coli o157:h7 [presence] by isolate in organism specific culture
44090-9,escherichia in o157:h7 [ql] ordinal coli isolate by organism specific culture
44090-9,e coli o157h7 islt ql cult
44090-9,e coli o157h7 e coli ql islt cult
44090-9, coli o157h7islt ql cut
44090-9,e. coli o157:h7 org specific cx ql (isol)
44090-9,orgspeciic o157:h7 .oi cx presence (isol)
44090-9,e. ol o157:7 org specfi cx presence (iol)
2425-7,histidine ammonia lyase [enzymatic activity/volume] in serum
2425-7,histidine mmonia yase [enzymatic i ctivity/vume] serum quan
2425-7,histidineaonialyase [eymatic serum i ctiity/voume]
2425-7,hal ser-ccnc
2425-7,sr-ccnc amm hal
2425-7,haser-ccnc ammon
2425-7,histidine ammonia lyase (s) [catalytic activity/vol]
2425-7,histidine ammonia lyases) [catalytic tivity/vol]
2425-7,activity/vol] pt ammonia lyase (s) [catalytic histidine
88461-9,babesia microti and b. divergens+mo-1 and b. duncani 18s rrna gene panel - blood by naa with non-probe detection
88461-9,babeia mroti ad b. dvegens+mo-1 naa b.dunani s ra gene panel blood by and withon-probe detection
88461-9,abesia micoti and . divergens+o-1 and b. duncan 18s rrna by panel - blood gene a with non-probe detecion
88461-9,babesia sp 18s rrna pnl bld naa+non-pr
88461-9,babesia sp 18s rrna pnl blood qbr naa+non-pr
88461-9,pnl sp 18s rrna babesia blood naa+non-pr
88461-9,b. microti and b. divergens and b. duncani ssu rrna gene panel naa+non-probe (bld)
88461-9,b. microti and naat b. divergens and b. duncani ssu rrna gene panel naa+non-probe (bld)
88461-9,b. microti and b. divergens ssu b. duncani and rrna gene panel naa+non-probe probe amp (blood)
97844-5,blood pressure panel 24 hour mean
97844-5,blood pressure panel 24 hour mean
97844-5,blod pessure panel 24 average our mea
97844-5,bp pnl 24h mean
97844-5,avg bp 4h pnl mea
97844-5,bp cardiology nl 24h mean
24192-7,coxsackievirus b4 neutralizing antibody [titer] in serum by neutralization test --2nd specimen
24192-7,coxsacivrus nutralizing anibody microbiology [titer] n serum b neutraization test --2ndspeien
24192-7,coxackieirus antiby bneutraliing [titer]in ser byneuralization est--nd specimn
24192-7,cv b4 nab sp2 titr ser nt
24192-7,cv nab b4 sp2 titr ser nt
24192-7,cv b4 anti nab sp2 titr ser nt
24192-7,coxsackievirus b4 neut ab spec 2 neut test (s) [titer]
24192-7,coxsackievirus b4 neut neut spec 2 ab test (s) [titer]
24192-7,coxsackievirus b4 neut ab spec 2 neut test (s) [titer]
26450-7,eosinophils/leukocytes in blood
26450-7,eosinophils/leocytes in blood
26450-7,eosinophils/leukocytes in bld wb
26450-7,eosinophil nfr bld
26450-7,eosinophil n bl
26450-7,nfr eosinophil bld white blood cell
26450-7,eosinophils/leukocytes (bld)
26450-7,eosinophils/leukocytes (bld)
26450-7,eosinophils/leukocytes (blood)
26674-2,legionella longbeachae 1 ab [presence] in serum
26674-2,legiella longbeachae n ab ql [ql] 1 erum
26674-2,legionella longbeachae 1 ab [presence] in serum random
26674-2,l longbeachae1 ab ser ql
26674-2,l longbeachae1 ab antibody ser ql
26674-2,ab longbeachae1 l id ser ql
26674-2,l. longbeachae 1 ab ql (s)
26674-2,l longbeachae l. longbeachae 1 ab ql (s)
26674-2,l. lonbeachae1 legion ab ql (s)
17893-9,bacteria # 2 identified in sputum by aerobe culture
17893-9,bacteria # 2 identified in sputum by aerobe culture
17893-9,bacteria culture 2 identifie in nominal sputum by arobe #
17893-9,bacteria spt aerobe cult org #2
17893-9,bactriapt sputum org cult aerobe #2
17893-9,bacteria cult aerobe spt org #2
17893-9,bacteria identified # 2 aer cx nom (sput)
17893-9,acteria identified # 2 aer cx infectiousdisease nom (sput)
17893-9,bacteria infectiousdisease aer # 2 identified cx nom (sput)
49906-1,hydroxydecanedioate/creatinine [molar ratio] in 24 hour urine
49906-1,hydrxydecanedate/creatinin[moar rati] rine 24 hou in
49906-1,hydroxydecanedioate/creatinine [molar ratio] in 24 hour urine
49906-1,oh-decanedioate/creat 24h ur-srto
49906-1,ohdecanedioate/crea 4h u-srt
49906-1,oh-decanedioate/creat ur-srto 24h
49906-1,hydroxydecanedioate/creatinine (24h u) [molar ratio]
49906-1,hydroxydecandioate/retinine (24h ratio] [moar u)
49906-1,u) (24h hydroydecanedioate/reatinine [mola ratio]
38243-2,brucella abortus igg ab [presence] in serum
38243-2,rucella igg abortus ab[reenc]iserum
38243-2,brucella abortus immunoglobulin g [presence] ab igg in ser
38243-2,b abortus igg ser ql
38243-2,b abortus iggser l bovine brucellosis
38243-2,autoantibodies presence abortus igg se b
38243-2,b. abortus igg ql (s)
38243-2,b. abortus igg ql (s)
38243-2,b. antibody abortus igg (s) ql
69964-5,bicarbonate [moles/volume] standard in plasma
69964-5,bicarbonae [moles/volume] standard n lasma
69964-5,standard [moles/volume] bicarbonate plsm in plas
69964-5,hco3 std plas-scnc
69964-5,ho3std plas-scnc
69964-5,hco3 plas-scnc std
69964-5,hco3 standard (p) [moles/vol]
69964-5,qnt hco3 standrd (p [mls/vo]
69964-5,hco3 sadard (p) [moles/vol pl
72936-8,valproate induced neutrophil igg ab [presence] in serum or plasma by flow cytometry (fc)
72936-8,valproate iduced flo igg ab [presence] in serum orplasm by neutrophil cymetry (fc)
72936-8,valproateinduced igg neutroil ab[presence] in serum olasma byflw cytometry fc)
72936-8,valproate (neut) igg serpl ql fc
72936-8,valproate (neut) ql serpl igg fc
72936-8,valroae (neut) igg ql antby serl fc
72936-8,valproate induced neutrophil igg fc ql
72936-8,valproate fc neutrophil igg induced ql
72936-8,valproate ql neutrophil igg fc induced
2812-6,porphobilinogen deaminase [enzymatic activity/volume] in red blood cells
2812-6,[enzymatic deaminase porphobilinogen chemistry activity/volume] in red bld cells
2812-6,porphobilinogen deaminase [enzymatic activity/volume] in red blood cells
2812-6,pbg deaminase rbc-ccnc
2812-6,bg deainase bc-ccc
2812-6,pb quantitative deaminase rbc-ccnc
2812-6,porphobilinogen deaminase (rbc) [catalytic activity/vol]
2812-6,porhobilinogen [catalyicactvity/ol] quant deaminase(rb)
2812-6,porphobilinogen deaminase (rbc) [catalytic activity/vol] random
82866-5,allo-pregnanediolone [moles/time] in 24 hour urine
82866-5,allo-pregnanediolone hour in 24 [moles/time] urine pdl
82866-5,allo-pregnanedioone pdl 24 in moles/time] hour urine
82866-5,allo-pregnanediolone 24h ur-srate
82866-5,24h allo-pregnanediolone ur-srate
82866-5,allo-pregnanediolone 24h ur-srate
82866-5,allo-pregnanediolone (24h u) [moles/time]
82866-5,allo-pregnanediolone (24h [moles/time] u) qnt
82866-5,allo-pregnanediolone u) (24h [moles/time]
104400-7,european tick borne encephalitis virus rna [presence] in tissue postmortem by naa with probe detection
104400-7,european tick borne encephalitis virus rna [presence] in with postmortem by naa tissue probe detection
104400-7,probe tick borne encephalitis virus rna [presence] in tissue postmortem by naa with european detection
104400-7,tbev rna tissue postmortem ql naa+probe
104400-7,tbev tissue rna postmortem ql naa+probe
104400-7,tbev rna tissue postmtmql naa+pro
104400-7,european tick borne encephalitis virus rna naa+probe ql (tissue postmortem)
104400-7,european tick borne encephalitis virus rna naa+probe presence (tissue postmortem)
104400-7,european tick borne rna virus encephalitis naa+probe ql (tissue postmortem)
78963-6,mannose-6-phosphate isomerase [enzymatic activity/mass] in leukocytes
78963-6,mannose-6-phosphate isomerase in activity/mass] [enzymatic leukocytes
78963-6,maose-6phosphat omeras [enzymati activity/mass] in leukytes
78963-6,m6pi wbc-ccnt
78963-6,phosphate total m6pi wc-ccnt
78963-6,i phos m6pi wbc-ccnt
78963-6,mannose-6-phosphate isomerase (wbc) [catalytic activity/mass]
78963-6,activity/mass] somerae (wb) po4 [atlytic mannose-6-posphte
78963-6,mannose-6-phosphateisomerase(wbc) [catalyc random activity/ass]
101813-4,"2,6-dimethylaniline [mass/volume] in urine by confirmatory method"
101813-4,"2,6-dimethylaniline cfm [mass/volume] in method y confirmatory urine"
101813-4,"2,6-dimethylaniline gcms [mass/volume] urine in by confirmatory method"
101813-4,"2,6-dimethylaniline ur cfm-mcnc"
101813-4,"2,6-dimethylnilne drugs m-mcnc ur"
101813-4,26-diethylanilne urcfm-mcnc
101813-4,"2,6-dimethylaniline confirm (u) [mass/vol]"
101813-4,"2,6-dimhylailine confirm (u) [mass/vol] ua"
101813-4,"quant 2,6-dimethylaniline [mass/vol] (u) confirm"
63325-5,ribosomal igg ab [titer] in serum by immunoassay
63325-5,ribosomal igg ab dilution factor [titer] in ser by immunoassay
63325-5,ribosomal igg immunoassay [titer] in ser by ab
63325-5,ribosomal igg titr ser ia
63325-5,igg ribosomal titr ser ia
63325-5,ribosomal titr igg serum ia
63325-5,ribosomal igg ia (s) [titer]
63325-5,ribosomal igg abs ia (s) [titer]
63325-5,ribosomal igg (s) ia [titer]
23414-6,rinderpest virus ag [presence] in exudate by immunoelectrophoresis
23414-6,rinderpest virus ag [ql] in morbillivirus exudate by immunoelectrophoresis
23414-6,rndepest vius ag imuoelectrophoresis morbillivirus in xudate by [ql]
23414-6,rpv ag exudate ql iep
23414-6,rpv ag exudate presence iep
23414-6,rpv ag exudateqliep
23414-6,rinderpest virus ag iep ql (exud)
23414-6,rinderpest virus ag ip infectious disease (exud) l
23414-6,rinderpes virusag ql(exud) iep ie
28555-1,nicotine+cotinine [presence] in urine by confirmatory method
28555-1,nictine+cotinine[presence] n urine by confirmatry random method
28555-1,i nicotinecotnine[presenc urine by confirmator mthod
28555-1,nicotine+cotinine ur ql cfm
28555-1,notine+otinine ur lc/ms/ms l cfm
28555-1,nicotine+cotinine ur cfm ql
28555-1,nicotine+cotinine confirm ql (u)
28555-1,nicotine+cotinineconfirm l (u)
28555-1,ql confirm nicotine+cotinine (u)
2770-6,phenylpyruvate [mass/volume] in blood
2770-6,random [mas/vlume] peylpyruvate in blood
2770-6,phenylpyruvate [mas/vlume] in bld
2770-6,phenylpyruvate bld-mcnc
2770-6,ld-mnc mass concentration phenylpyruvate
2770-6,bldmcc phenpyruvte
2770-6,phenylpyruvate (bld) [mass/vol]
2770-6,phenylpyruvate (blood) [mass/vol]
2770-6,(bld) phenylpyruvate [mass/vol]
29353-0,17-ketosteroids.total neutral [mass/time] in 12 hour urine
29353-0,17-ketosteroids.total neutral [mass/time] in hour 12 urine
29353-0,17-ketosteroids.total neutral [mass/time] in 12 hour urine
29353-0,17ks neut 12h ur-mrate
29353-0,12h neut 17ks ur-mrat
29353-0,quant 17ks neut ur-mrate 12
29353-0,17-ketosteroids.total neutral (12h u) [mass/time]
29353-0,17-ketosterois.total neutral mass rate (12h u) [mass/time]
29353-0,12h neutral 17-ketoseroids.total u) qnt [mas/time]
59807-8,phosphatidylglycerol [moles/volume] in amniotic fluid
59807-8,amniotic [moles/volume] in phosphatidylglycerol fluid
59807-8,phosphatidylglycerol [moles/volume] amniotic in fluid
59807-8,pg amn-scnc
59807-8,amn-scnc pg amn fl
59807-8,mn-scnc p
59807-8,phosphatidylglycerol (amn fld) [moles/vol]
59807-8,phophatidylglycerol substance concentration fld)[moles/vl] (amn
59807-8,phosphatidylglycrol(amn fld) moles/vol] quan
40438-4,hiv 1 gp41 ab [presence] in serum or plasma by immunoassay
40438-4,hiv 1 gp41 ab [presence] in serum plsm or plasma by immunoassay
40438-4,hiv 1 gp41 ab [presence] in serum or plasma by sr immunoassay
40438-4,hiv1 gp41 ab serpl ql ia
40438-4,hiv1 gp41 a pl serplq ia
40438-4,gp41 hiv1 ab serum or plasma ql ia
40438-4,hiv 1 gp41 ab ia ql
40438-4,hiv 1 gp41 ab pr ia ql
40438-4,hiv 1 gp41 ab presence ia
43369-8,pla1 ab [presence] in platelet rich plasma
43369-8,ab pla1 [presence] antby in platelet rich plasma
43369-8,pla1 ab [presence] in pltelet rich plasma
43369-8,pla1 ab prp ql
43369-8,pla1 ql prp ab
43369-8,la1 ab ppql
43369-8,pla1 ab ql (prp)
43369-8,(prp) ab ql pla1
43369-8,pla1 ab (prp) ql
46999-9,bacterial vaginosis and vaginitis rrna panel - vaginal fluid by probe
46999-9,bacerial vnis and vaginitis rrna pnel - vaginal fluid by probe
46999-9,bacterial obgyn vaginosis and vaginitis rrna panel fluid vaginal - by probe
46999-9,vaginosis/itis rrna pnl vag probe
46999-9,vaginosis/itis rrna pnl probe vag
46999-9,vaginosis/itis rrna pnl vag probe
46999-9,bacterial vaginosis and vaginitis rrna panel probe (vag fld)
46999-9,bacterial vaginosis (vag vaginitis rrna panel probe and fld)
46999-9,bacterial vaginosis pnl and vaginitis rrna panel probe (vag fld)
38644-1,caprolactam [mass/volume] in air
38644-1,caprolactam level [mass/volume] in air
38644-1,point in time caprolactam[mass/olume] in ar
38644-1,caprolactam air-mcnc
38644-1,caprolactam air-mcnc
38644-1,carolactam random air-mcnc
38644-1,caprolactam (air) [mass/vol]
38644-1,quantitative caprolactam [mass/vol] (air)
38644-1,caprolactam 2-azacycloheptanone (air) [mass/vol]
32139-8,haemophilus influenzae ag [presence] in cerebral spinal fluid
32139-8,haeopilus influezae ag [presenc] cerebral in spial fli
32139-8,haemophilus influenzae qual ag [presence] in cerebral spinal fluid
32139-8,haem influ ag csf ql
32139-8,pr hem influ agcsf l
32139-8,haem cerebrospinal fluid ag influ spinal fluid ql
32139-8,h. influenzae ag ql (csf)
32139-8,h. influnzae aq (csf
32139-8,h.ifluenzae ag ql (csf
29902-4,chlorobenzene [mass/volume] in urine
29902-4,lorbenzene [mas/volume] point in time in uine
29902-4,chlorobenzne quantitative in [mass/voume] urine
29902-4,chlorobenz ur-mcnc
29902-4,ur-mcnc chlorobenz
29902-4,ur-mcnc chloroenz
29902-4,chlorobenzene (u) [mass/vol]
29902-4,chlorbenzn u [mass/vl
29902-4,mss/vl] () chlorobenzene
2774-8,phosphate [mass/volume] in blood
2774-8,phosphate [mass/volume] in blood phosphorous
2774-8,in quant [mass/volume] phosphate bld
2774-8,phosphate bld-mcnc
2774-8,bld-mcnc phosphae
2774-8,blood-mcnc phosphate
2774-8,phosphate (bld) [mass/vol]
2774-8,phosphate phos [mass/vol] (blood)
2774-8,[mass/vol] (blood) phosphate
73980-5,visit duration
73980-5,isi duration
73980-5,duration visit
73980-5,visit duration
73980-5,duration visit
73980-5,encounter duration visit duration
6776-9,estrone (e1) [mass/time] in 24 hour urine
6776-9,estrone (e1) [mass/time] in 24 hour urine
6776-9,estone ine [mass/tme] in 2 hor (e)
6776-9,estrone 24h ur-mrate
6776-9,ur-mrate 24h estrone
6776-9,ur-mrate 24h estrone quantitative
6776-9,e1 (24h u) [mass/time]
6776-9,(24h e1 qnt u) [mass/time]
6776-9,e1 (24h 24hr u) [mass/time]
59212-1,alloisoleucine [moles/volume] in urine
59212-1,alloisoleuine in quant [moles/volume] urine
59212-1,alloisoleucin [moles/volume] in urine
59212-1,alloisoleucine ur-scnc
59212-1,alloisoleucine ur-scnc
59212-1,alloisoleucine ur-scnc
59212-1,alloisoleucine (u) [moles/vol]
59212-1,ua [moles/ol] (u) alloisleuci
59212-1,alloisoleucin (u) [moles/vol] level
12877-7,borrelia burgdorferi 47kd ab [presence] in serum by immunoblot
12877-7,borrelia burgdorfer 47kd ab presnce] in srum by immunoblot lymes
12877-7,borrelia bgdoferi 47kd ab [presenc] in ser by imunblot
12877-7,b burgdor47kd ab ser ql ib
12877-7,b burgdor47kd ab ser presence ib
12877-7,b ugdor47kd ab serum id qlb
12877-7,b. burgdorferi 47kd ab ib ql (s)
12877-7,b. burgdorferi 47kd ab ib presence (s)
12877-7,b. burgdorferi 7kd microbiology (s) b ql ab
4515-3,deprecated complement factor b [mass/volume] in serum or plasma
4515-3,deprecaed complement factor b ass/volum] n serm plasma or
4515-3,deprecated complement factor b [mass/volume] in serpl
4515-3,deprecated comp fact b plas-mcnc
4515-3,deprecated comp act b pas-mcnc
4515-3,b comp fact deprecated plas-mcnc
4515-3,complement factor b (p) [mass/vol]
4515-3,comlement actor p b glycine rich beta glycoprotein [mass/vo]
4515-3,pt complement factor b (p) [mass/vol]
3411-6,bumetanide [mass/time] in 24 hour urine
3411-6,bumetnide[mass/time]in 24 huruine
3411-6,bumetanide [mass/time] in 24 hour urine
3411-6,bumetanide 24h ur-mrate
3411-6,urmrate bumetanide24h
3411-6,buetanie 24hur-mrat
3411-6,bumetanide (24h u) [mass/time]
3411-6,(24h bumetanide u) [mass/time]
3411-6,u)[mass/time] bumetanide(2h
40901-1,3-hydroxybenzoylecgonine [mass/mass] in meconium
40901-1,3-hydoxbenzoylecgonine meconium [mas/mass]in
40901-1,3-hydroxybenzoylecgonine 3-oh-be [mass/mass] in meconium
40901-1,3oh-bze mec-mcnt
40901-1,me-mcnt 3oh-be
40901-1,mec-mcnt iii 3oh-bze
40901-1,3-hydroxybenzoylecgonine (mec) [mass/mass]
40901-1,[mass/mass] (mec) 3-hydroxybenzoylecgonine
40901-1,(mec) 3-hydroxybenzoylecgonine [mass/mass]
59961-3,propoxyphene [moles/volume] in gastric fluid
59961-3,prpoxyphene [moesvolume] substance concentration in fluid gastric
59961-3,propoxyphene in quantitative [moles/volume] gastric fluid
59961-3,propoxyph gast-scnc
59961-3,gast-scnc potentialforabuse propoxyph
59961-3,gas-scn propoxyph
59961-3,propoxyphene (gast fld) [moles/vol]
59961-3,(gast propoxphen fld) [moles/vl]
59961-3,propoxphene (gas [moles/vol fld) gastric fluid
10244-2,oxygen content in left pulmonary artery
10244-2,in content oxygen left pulmonary artery
10244-2,oygen cotent o2ct in lef pulmonary artery
10244-2,o2 ct pa-l-scnc
10244-2,o2ct o2 ct pa-l-scnc
10244-2,o2 ctpal-scnc
10244-2,oxygen content (left pulmonary artery) [moles/vol]
10244-2,oxygen content l (left pulmonary artery) [moles/vol]
10244-2,oxygen contnt (let pulmnary atery pa [molesvl]
12292-9,dimethyltryptamine [presence] in urine
12292-9,dimethytryptamine[presence] pr in urie
12292-9,ordinal uine in dimethyltryptamine[presence]
12292-9,dimet-tryptamine ur ql
12292-9,ur qual dim-tryptamine ql
12292-9,dimet-tryptamine pr ur ql
12292-9,dimethyltryptamine ql (u)
12292-9,dimethyltryptamine (u) presence
12292-9,dimethyltryptamine ql (u)
105788-4,bacterial carbapenem resistance blaoxa-58 [cycle threshold #] in positive blood culture by naa with probe detection
105788-4,acterialarapenem resitane carbapenem res blaoxa-58 by [cycle threshold #]in poitive ood culture baoxa-58 naa with probe detction
105788-4,bacterial carbapenem resistance lcr blaoxa-58 positive threshold #] in [cycle blood culture by naa with probe detection
105788-4,carbpnm res blaoxa58 ct bld +qn naa prb
105788-4,arbpnm res blaoxa58 lat ct bld q na prb
105788-4,carbpnm res blaoxa58 ct blood +qn naa prb
105788-4,bacterial carbapenem resistance blaoxa-58 naa+probe (pos bld culture) [threshnum]
105788-4,baceal crbanem resstanceblaa-58 naa+pob (pos bl clture [hreshnu]
105788-4,bacterilarbapenem resstace blaoxa-8 naa+pobe (ps ld culture [threshnum]
92641-0,diphenhydramine [mass/volume] in urine by confirmatory method
92641-0,diphenhydramine [mass/volume] in urine by confirmatory method
92641-0,method [mass/volume] in urine by confirmatory diphenhydramine
92641-0,diphenhy ur cfm-mcnc
92641-0,diphnh urn fmcnc ur
92641-0,diphenhy cfm-mcnc ur
92641-0,diphenhydramine confirm (u) [mass/vol]
92641-0,quantitative (u) onfirm dpenhydramie [mass/vol]
92641-0,(u) confirm urn diphenhdrami [mas/vol]
6576-3,escherichia coli verotoxin 2 [presence] in stool
6576-3,escherichia coli verotoxin 2 qual [presence] in stool
6576-3,e coli vtn2 scherihia coli in 2 [resenc] vrotoxin stool
6576-3,e coli vtn2 stl ql
6576-3,e coli stl vtn2 infectiousdisease ql
6576-3,stl coli vtn2 e ql
6576-3,e. coli verotoxin 2 ql (stl)
6576-3,2 coli stl verotoxin e. presence (stl)
6576-3,e. coli verotxi 2 ql (stl)
2628-6,methylenetetrahydrofolate dehydrogenase nadp [enzymatic activity/volume] in serum
2628-6,metyleetetrahydoolate dehydrogenasenadp [ezymti ativity/volume] in erum
2628-6,methylenetetrahydrofolate dehydrogenase nadp dehydrog [enzymatic activity/volume] in serum
2628-6,mtd.nadp ser-ccnc
2628-6,serum-ccnc catalytic concentration mtd.nadp
2628-6,ser-ccnc mtd.nadp
2628-6,methylenetetrahydrofolate dehydrogenase nadp (s) [catalytic activity/vol]
2628-6,methylenetetrahydrofolate dehydrogenase nadp (s) [catalytic activity/vol]
2628-6,methylenetetrahydrofolate quant dehydrogenase nadp (s) [catalytic activity/vol]
23231-4,mareks disease virus dna [presence] in specimen by naa with probe detection
23231-4,mreksdisease virus dna [preence] i specimen by aa ith probe detection
23231-4,pr mareksdsease virusdna with n secime by naa [presence] probe detection
23231-4,gahv dna spec ql naa+probe
23231-4,gahv ql spec dna naa+probe tma
23231-4,spec gahvdna ql naaprobe
23231-4,mareks disease virus dna naa+probe ql (specimen)
23231-4,mareks disease ql dna naa+probe virus (specimen)
23231-4,mreks diseases disease virus dnanaa+rob ql (specimen)
91063-8,bacteria identified in platelets from blood product unit by aerobe culture
91063-8,bacteria identified by platelets from bld product unit in aerobe culture
91063-8,bacteria identified in platelets cultures from bld product unit by aerobe culture
91063-8,bacteria plts bpu aerobe cult
91063-8,bacteiaplts bpu aerob cult
91063-8,acteria erobecut bpu plts
91063-8,bacteria identified aer cx nom (plts bpu)
91063-8,bacteria identified aer cx bpu) (plts nom
91063-8,bacteria identified nom cx aer (plts bpu)
52975-0,respiratory syncytial virus ab [units/volume] in serum by complement fixation
52975-0,respiratory fixation virus ab [units/volume] in ser by complement syncytial
52975-0,respiratory ser virus ab [units/volume] in syncytial by complement fixation
52975-0,rsv ab ser cf-acnc
52975-0,infectious disease rsv ab ser cf-acnc
52975-0,aby f-acnc rsvabser
52975-0,rsv ab cf qn (s)
52975-0,rsv ab quan cf qn (s)
52975-0,rsv qnt ab cf qn (s)
93017-2,plasma cells with abnormal marker pattern [#] in bone marrow by flow cytometry (fc)
93017-2,plasma cells ith abnormamarker marow [#] in bone patten by lw cytometry(fc)
93017-2,plasma cells with abnorm abnormal marker pattern [#] in bone marrow by flow cytometry (fc)
93017-2,pc.abnormal mar fc
93017-2,fc mar pc.abnormal
93017-2,mar pc.abnormal fc
93017-2,plasma cells with abnormal marker pattern fc (bm) [#]
93017-2,plasma cells with fc marker pattern abnormal (bm) [#]
93017-2,plasma with cells abnormal marker pattern fc (bm) [#]
9790-7,methyl bromide [mass/volume] in serum or plasma
9790-7,ser bromide [mass/volume] in methyl ch3br or plasma
9790-7,in drug/toxicology bromide [mass/volume] methyl ser or plasma
9790-7,me- bromide serpl-mcnc
9790-7,me- bromide serpl-mcnc
9790-7,broie br me- serpl-cnc
9790-7,methyl bromide [mass/vol]
9790-7,brmide[mas/vol] mhl
9790-7,methyl bromide [mass/vol]
38348-9,herpes virus 6 dna [identifier] in specimen by naa with probe detection
38348-9,hepes virus  dna [identifier] in scimen  naa with probe deection
38348-9,hrpes in 6 ligation-activated transcription dna [identifier] virus specimen by naa wih probe detectin
38348-9,hhv6 dna spec naa+probe
38348-9,hhv6 probe with ampification dna spec naa+probe
38348-9,hhv6 dna spec naa+probe
38348-9,hhv 6 dna naa+probe nom (specimen)
38348-9,hhv 6 dna nom naa+probe (specimen)
38348-9,infectious disease hhv 6 dna naa+probe nom (specimen)
96413-0,pancreatic polypeptide [mass/volume] in serum or plasma --fasting
96413-0,pancreatic polypeptide [mass/volume] in ser serplas or plasma --fasting
96413-0,pancreatic polyeptid in [mss/olume] serpl ser or plasma --asting
96413-0,panc polypept p fast serpl-mcnc
96413-0,pan polypet fast serpl rpl-mcnc
96413-0,panc polypept fast p serpl-mcnc
96413-0,pancreatic polypeptide post fast [mass/vol]
96413-0,[mass/vol] polypeptide post fast pancreatic
96413-0,[mass/vol] polypeptide post fast pancreatic
38997-3,west nile virus igg ab [units/volume] in serum by immunoassay
38997-3,wst elfa nile viru igg ab [unitsvolume] bymmunoassay serum i
38997-3,west nile virus igg by [units/volume] in serum ab elfa immunoassay
38997-3,wnv igg ser ia-acnc
38997-3,igg wnv ser ia-acnc autoantibody
38997-3,wnv ser igg ia-acnc
38997-3,west nile virus igg ia qn (s)
38997-3,west qn virus igg ia nile (s)
38997-3,west nile vius q ia ig (s
29156-7,lutropin [units/volume] in 24 hour urine
29156-7,icsh lutropin [units/vlume] n 24 hour urie
29156-7,lutropin [units/volume] hour 24 in urine
29156-7,lh 24h ur-acnc
29156-7,ur-acnc 24h lh
29156-7,24h lutenizing hormone lh ur-acnc
29156-7,lutropin qn (24h u)
29156-7,lutropin (h qn u chemistry
29156-7,u) qn (24h lutropin 24hr
11223-5,deprecated phenolphthalein
11223-5,deprecatdphenolpthalein
11223-5,phenolphthalein deprecated
11223-5,deprecated phenolphthalein ur ql
11223-5,deprcated pheolphthalein phenolthalein ur ql
11223-5,ql ql phenolphthalein ur deprecated
11223-5,phenolphthalein ql (u)
11223-5,pheophthlei qlu)
11223-5,phenolphthalei l (u)
2159-2,creatinine [mass/volume] in amniotic fluid
2159-2,creatinine in [mass/volume] amniotic fluid
2159-2,creatinie [mass/volume] af in aniotic fuid
2159-2,creat amn-mcnc
2159-2,creat amn-mcnc amniotic fluid
2159-2,an-mcnc ceat
2159-2,creatinine (amn fld) [mass/vol]
2159-2,creatinine gyn (amn [mass/vol] fld)
2159-2,cretnne amn fld) [ms/vol]
94158-3,phenx - ethnicity protocol 010502
94158-3,penx - etnicity panel 1502 rotocol
94158-3,phnx - panl ethnicity rotocol 010502
94158-3,phenx - ethnicity protocol
94158-3,penx panel.phenx - etnicity protocl
94158-3,phen panl protocol ethniity -
16259-4,urate dihydrate crystals [presence] in stone by infrared spectroscopy
16259-4,urate dihydrate in [presenc] crystls stoe by infrred pecroscopy
16259-4,urate dihydrate crystals by in stone [presence] infrared spectroscopy
16259-4,urate dihyd cry stone ql ir
16259-4,stone urte dihyd cry stone ql ir
16259-4,urate dihyd cry stone presence ir
16259-4,urate dihydrate crystals infrared spectroscopy ql (stone)
16259-4,infrared hydrate crystals qualitative urate sectoscopy presence(stone)
16259-4,urate dihydrate crystals infrared crys spectroscopy ql (stone)
38585-6,acetone [mass/volume] in air
38585-6,air [mass/volume] in acetone
38585-6,acetone quant air in massolue]
38585-6,acetone air-mcnc
38585-6,air-mcnc acetone
38585-6,air-mcnc acetone
38585-6,acetone (air) [mass/vol]
38585-6,acetone ai [mass/vol]
38585-6,acetone [mass/vol] (air)
29649-1,rickettsia australis ab [presence] in serum by immunofluorescence
29649-1,rickettsia australis ab [presence] immunofluor in serum by immunofluorescence
29649-1,ordinal rickettsia immnofuoescence ab[presnce] i serumby astralis
29649-1,r australis ab ser ql if
29649-1,a astrai r ser ql if
29649-1,australis er ab antibodies ql f
29649-1,r. australis ab if ql (s)
29649-1,r. (s) ab if ql australis
29649-1,r. australis ab if l (s)
29531-1,diphenhydramine [presence] in specimen
29531-1,diphenhydramine pr in [presence] specimen
29531-1,[presence] diphenhydramine in specimen illicit
29531-1,diphenhy spec ql
29531-1,diphenhy ql spec
29531-1,iphenhy specql
29531-1,diphenhydramine ql (specimen)
29531-1,diphenhydramine ql addiction (specimen)
29531-1,diphenhydramine ql (specimen)
3677-2,hydrochlorothiazide [mass/volume] in urine
3677-2,hydrochlorothiazide [mass/volume] urine in
3677-2,hydrochlorothiazide [mass/volume] in urine
3677-2,htcz ur-mcnc
3677-2,ur-mcnc hcz
3677-2,htcz ur-mcnc
3677-2,hydrochlorothiazide (u) [mass/vol]
3677-2,hydrochlorothiazide ur (u) [mass/vol]
3677-2,[mass/vol] (u) hydrochlorothiazide
24342-8,gas and carbon monoxide panel - capillary blood
24342-8,blood - capillary gas - carbon monoxide panel and capillary blood
24342-8,gas and carbon monoxide panel - capillary bld
24342-8,gas + co pnl bldc
24342-8,as pulmonary + onl ldc
24342-8,gas + co pnl panel.chemistry bldc
24342-8,gas and carbon monoxide panel (bldc)
24342-8,carbon and gas monoxide panel (bldc)
24342-8,gas an caro monoxide pnel (bldc)
79898-3,objective refraction panel
79898-3,objective panel reracion
79898-3,objetive panel refactio visual
79898-3,obj refraction pnl
79898-3,obj pnl refraction
79898-3,oj optic globe refractionpnl
58458-1,mitochondria ab pattern [interpretation] in serum by immunofluorescence
58458-1,itochondria in pattern[interpretation] ab serum byimmunofluorescence
58458-1,mitochodria b pattern fa [interpretation] y inserum immunofluorescence
58458-1,mitochondria ab pattern ser if-imp
58458-1,mitochondria antby ab pattern ser if-imp
58458-1,mitohodria ab patter ser f-imp fluoresent
58458-1,mitochondria ab pattern if (s) [interp]
58458-1,ab mitochondria pattern if (s) [interp]
58458-1,ptterni ab mitochondia autoantibody (s) [intep]
95792-8,benign mass probability [likelihood] based on clinical and lab data
95792-8,beninmasspbality [likelihood] lab on clinica and point in time based data
95792-8,beinass prblit based [likelih] o pt cinical and ab data
95792-8,benign mass prob from clin+lab data
95792-8,benign prob mass from oncology clin+lab data
95792-8,benign mass prob from clin+lab data from clin+lab data
96978-2,noninvasive prenatal fetal aneuploidy and 22q11.2 deletion panel - plasma cell-free+wbc dna by dosage of chromosome-specific cfdna
96978-2,noninvaive prenatafetal aeuploidy an 22q11.2 deletion panl - plasma cel-ree+wbc da b dosage of chromosome-specific cfdna
96978-2,noinvasive prenatl cell-fre+wbcdna aneuploidy and 22q11.2 deletionpanel plas fetl by dosage of chromosome-specific cfdna
96978-2,nip aneu + 22q11.2 pnl wbc.dna+cfdna
96978-2,ip 2q11.2 aneu pnl wbc.da+cfdna
96978-2,ni + aneu plasma 2q11. pl wbc.dna+cfdna
96978-2,noninvasive prenatal fetal aneuploidy and 22q11.2 deletion panel dosage of chromosome-specific cfdna (plasma cell-free+wbc dna)
96978-2,nninvasive petfetal aneuploidyand2q11 deletion panl dosage of chroosme-speciic cfdna (plasma cell-freewc dn)
96978-2,noninvasive prenatal fetal aneuploidy and 22q11.2 deletion panel dosage pan of chromosome-specific dna) (plas cell-free+wbc cfdna
79464-4,phosphorylase [enzymatic activity/mass] in red blood cells
79464-4,phosphorylase [enzymatic activity/mass] red in bld cells
79464-4,phosphoryase blod activity/mss in quant ed [enzymatic cell
79464-4,phosphorylase rbc-ccnt
79464-4,red blood corpusles phosphorylase rbc-ccnt
79464-4,phosphorylase rbc-ccnt
79464-4,phosphorylase (rbc) [catalytic activity/mass]
79464-4,activity/mass] (rbc) [catalytic phosphorylase
79464-4,hosphorylase (rbc) [catalytic red blood cells actiity/mas]
25970-5,phenylalanine/creatinine [molar ratio] in 24 hour urine
25970-5,phenylaanie/creatinine[mola ratio] scrto in 24 our urine
25970-5,phenylalanine/creatinine [molar 24 in ratio] hour urine
25970-5,phe/creat 24h ur-srto
25970-5,phe/creat ur-srto 24h
25970-5,phe/reat r-srto 24h
25970-5,phenylalanine/creatinine (24h u) [molar ratio]
25970-5,phenyalanine/creatinine (24h u) quant [molar ratio]
25970-5,phenylalanine/creatinine [molar u) (24h ratio]
22902-1,bovine herpesvirus 1 ab [presence] in serum by immune diffusion (id)
22902-1,bovine herpesvir 1 ab ql] in serum byimmune diusion (id)
22902-1,bovine herpesvius 1a [resence] in ser by immun diffuson id)
22902-1,bohv1 ab ser ql id
22902-1,bohv1ab id imm ql ser
22902-1,bohv1 ab abs sr ql id
22902-1,bovine herpesvirus 1 ab immune diff ql (s)
22902-1,ql herpesvirus 1 ab immune di bovine (s)
22902-1,bovine herpesvirus 1 ab imune dif presence (s) beef
48650-6,hepatitis b virus dna [#/volume] (viral load) in serum or plasma by probe and target amplification method detection limit = 500 copies/ml
48650-6,hepatit b a na microbiology [#/volume]ial load) n ser or plasm by prbe vrus target amplification meto detectinimit= 500 copes/ml
48650-6,hepatitis b count viru dn[#/volume] (viral ad) in serum or plasma by probe and target amplification mehod detection limit = 500 copies/l
48650-6,hbv dna # serpl naa dl=500
48650-6,hbv absolute dna dl=500 serpl naa #
48650-6,hbv polymerase chain reaction dna # serpl naa dl=500
48650-6,hbv dna naa+probe dl = 500 copies/ml [#/vol]
48650-6,hbv quant dna narobe dl 500 copies/ml [#/vol]
48650-6,hbv dna dl naa+probe = 500 copies/ml [#/vol]
85589-0,irf-pai - physical therapy - week 2 [cms assessment]
85589-0,irfpai-physical thrap - week 2 [cm pnl assessment]
85589-0,irf-pai - pyscal theapy -week 2 [cm ssesment]
80963-2,salicylates free [mass/volume] in serum or plasma
80963-2,saliclates [ass/olume] free in serum or plasma
80963-2,salicylates free [mss/volume inserum plasma r plasma
80963-2,salicylates free serpl-mcnc
80963-2,salicylate salicylates serum or plasma-mcnc free
80963-2,salcylates quant free srplmnc
80963-2,salicylates free [mass/vol]
80963-2,2-hydroxybenzoate salicylates [mass/vol] free
80963-2,[mass/vol] free salicylates
74999-4,"5,10-methylenetetrahydrofolate reductase [enzymatic activity/mass] in leukocytes"
74999-4,"[enzymatic reductase 5,1-methylenetetrahydrofate activty/mas] in leukocyte"
74999-4,"5,10-methylenetetrahydrofolate reductase qnt [enzymatic activity/mass] in leukocytes"
74999-4,mthfr wbc-ccnt
74999-4,wbc-ccnt mthfr
74999-4,quant mthfr wbc-ccnt
74999-4,"5,10-methylenetetrahydrofolate reductase (wbc) [catalytic activity/mass]"
74999-4,"5,10-methylenetetrahydrofolate reductase activity/mass] [catalytic (wbc)"
74999-4,"5,0-mehylenetetrahydrofolate (wc)[catalytic reductase activiy/mass] fadh2"
55441-0,deprecated antithrombin ag in platelet poor plasma
55441-0,deprecated antithrombin ag in platelet poor plasma antithrombin iii
55441-0,deprecated antithrombin plasma in platelet poor ag
55441-0,deprecated at iii ag ppp
55441-0,deprecated at iii hematology ag ppp
55441-0,deprecated at iii ag ppp
55441-0,antithrombin ag (ppp)
55441-0,(pp ag antitrombin antigen
55441-0,antithrombin (ppp) ag
33964-8,sars coronavirus urbani rna [presence] in specimen by naa with probe detection
33964-8,sars coronavirus urbani detection [presence] in specimen by naa with probe rna
33964-8,sar coronavirus rbani rn [presence] in specimen y nawith probe detectin
33964-8,sars-cov urb rna spec ql naa+probe
33964-8,sars-cov urb rna spec presence naa+probe
33964-8,ss-cov ub rna spec naa+roe spec
33964-8,sars-cov urbani rna naa+probe ql (specimen)
33964-8,sars-cov ribonucleic acid urbani rna ql naprbe (specimen)
33964-8,sars-cov urb rna naa+probeql(specmen)
7852-7,cytomegalovirus igg ab [units/volume] in serum or plasma
7852-7,cytomegalovirus igg ab [units/volume] serum in or plasma cytomgal
7852-7,cytomegalovirus serum [unis/vlum] in iggab r plasma
7852-7,cmv igg serpl-acnc
7852-7,cvigg serum or plasma-acnc id
7852-7,serpl-acnc igg cmv
7852-7,cmv igg qn
7852-7,cv igg qn
7852-7,cmv igg qn
63328-9,rna polymerase iii ab [presence] in serum by immunoassay
63328-9,ab polymerase iii rna [presence] in ser by immunoassay ser
63328-9,rnalymrase iii ab [presence] in ser by immunassay
63328-9,rnap iii ab ser ql ia
63328-9,ql iii ab serum rnap ia
63328-9,rnap ii presence sr ab ia
63328-9,rna polymerase iii ab ia ql (s)
63328-9,rnapolymeras iii a ia presence (s)
63328-9,rn polymease iii ia b autoantibody ql (s)
53464-4,decadienoylcarnitine (c10:2) [moles/volume] in cerebral spinal fluid
53464-4,decadienoylcarnitine (c10:2) spinal fl [moles/volume] in cerebral spinal fluid
53464-4,decadienoylcarnitine (c10:2) [moles/volume] in spinal cerebral fluid level
53464-4,decadienoylcarn csf-scnc
53464-4,sf-scnc decdienoylcarn
53464-4,level decadienoylcarn csf-scnc
53464-4,c10:2 (csf) [moles/vol]
53464-4,c10:2 quantitative (cerebrospinal fluid) [moles/vol]
53464-4,c10:2 (csf) [moles/vol]
8756-9,right ventricular cardiac index by angiography biplane
8756-9,bdy surface rght cardiac ventricular index by angiogaphy bilane
8756-9,right ventricular index cardiac by angiography biplane
8756-9,rv cardiac index angio bp
8756-9,rv cariac inex angio b
8756-9,inx cardic rv angio hemodynamics bp
32027-5,monocytes+macrophages/leukocytes in pericardial fluid by manual count
32027-5,mnocyesmacrophage/leukocytes in fluid pricardial by manualcount
32027-5,monocytes+macrophages/leukocytes in pericardial fluid count manual by
32027-5,monos+macros nfr pcar manual
32027-5,monos+macros nfr pcar pt manual
32027-5,monos+macros nfr manual pcar
32027-5,monocytes+macrophages/leukocytes manual cnt (pericard fld)
32027-5,fld) manual cnt (periard onocyesmacrophages/leuocyts
32027-5,pt monocytes+macophages/leukocytes maual ct(pericard fld)
53946-0,escherichia coli shiga-like toxin identified in specimen
53946-0,escherichia coli shiga-like e coli sltec toxin in identified specimen
53946-0,escherichia coli shiga-like in identified identity or presence toxin specimen
53946-0,e coli sxt spec
53946-0,coli e sxtspec
53946-0,coli point in time e st sec
53946-0,e. coli shiga-like toxin identified nom (specimen)
53946-0,e coli sxt e. (specimen) shiga-like toxin identified nom coli
53946-0,nom coli shiga-lke toxin idetfied e. (specimen)
10231-9,right ventricular ejection fraction
10231-9,quan right ejection ventricular fraction
10231-9,fraction ventricular ejection right
10231-9,rv ef
10231-9,fractions ef rv
10231-9,rv 
28602-1,beta aminoisobutyrate/creatinine [ratio] in urine
28602-1,beta aminoisobutyrate/creatinine [ratio] in urine
28602-1,beta aminoisobutyrate/creatinine cr [ratio] urine in
28602-1,b-aib/creat ur-rto
28602-1,ur-t b-aib/creat
28602-1,ur-rto b-aib/creat
28602-1,beta aminoisobutyrate/creatinine (u) [ratio]
28602-1,beta aminoisobutyrate/creatinine [ratio] (u)
28602-1,beta aminoisobutyrate/creatinine b (u) [ratio]
23199-3,leptospira sp igg ab [presence] in serum by immunoassay
23199-3,lptpira meia serum igg ab [presnc] i sp b immunoassay
23199-3,[presence] sp igg ab leptospira in serum by immunoassay
23199-3,leptospira igg ser ql ia
23199-3,leptospira leptospirosis ser igg ql ia
23199-3,leptospra igse ql ia
23199-3,leptospira sp igg ia ql (s)
23199-3,leptospira sp igg ia ql spp (s)
23199-3,leptospira sp igg presence ia immunoglobulin g (s)
50938-0,vancomycin [moles/volume] in body fluid
50938-0,vancomycin [moles/volume] in body fluid
50938-0,vancomycin [moles/volume] in body body fluid fluid
50938-0,vancomycin fld-scnc
50938-0,vancomycin fld-scnc
50938-0,fld-scnc vancomycin
50938-0,vancomycin (body fld) [moles/vol]
50938-0,fld vcomycin (bodyfld)[mles/ol]
50938-0,[moles/vol] (body fld) vancomycin
53051-9,beta globulin+gamma globulin/protein.total in body fluid by electrophoresis
53051-9,bea globulin+gamma bodies globulin/proein.total in body fluid by electrohoresi
53051-9,bodies beta gobulin+gammaglobulinpoteintotal body in lui y lectrophoresis
53051-9,b+g-globulin mfr fld elph
53051-9,fld fr b+g-globuin elph
53051-9,fld mr b+-gloulin elp
53051-9,beta globulin+gamma globulin elph (body fld) [mass fraction]
53051-9,beta qnt glbulin+gmma globulin elph bod ld) [mass fractio]
53051-9,beta fraction] globulin elph fluid (body fld) [mass globulin+gamma
78779-6,alizapride [mass/volume] in blood
78779-6,alizaprde qnt [mas/volume] in bld
78779-6,alizapride [mass/volume] in bld
78779-6,alizapride bld-mcnc
78779-6,drugs bld-mcnc alizapride
78779-6,bld-mcnc alizapride
78779-6,alizapride (bld) [mass/vol]
78779-6,(bld) alizapride [mass/vol]
78779-6,(bld) drugs alizaprie [mass/vl]
40359-2,dextromethorphan [presence] in specimen
40359-2,dextromethorphan specimen in [presence]
40359-2,dextromehorphan other [presenc] in specimen
40359-2,d-methorphan spec ql
40359-2,ql spec d-mehorphn
40359-2,d-methorphan ql spec
40359-2,dextromethorphan ql (specimen)
40359-2,dextromethorphan spec presence (specimen)
40359-2,d-methorphan dextromethorphan (specimen) ql
13471-8,cadmium/creatinine [mass ratio] in urine
13471-8,[mass cadmiu/creatinne ratio] in uine
13471-8,cadmium/creatinine [mass in ratio] drug/toxicology urine
13471-8,cadmium/creat ur
13471-8,r cadium/creat
13471-8,qnt admiu/creat ur
13471-8,cadmium/creatinine (u) [mass ratio]
13471-8,camium/creatinine( [mass ratio] crea
13471-8,cadmium/creatinine [mass ua (u) ratio]
30399-0,deprecated hemoglobin distribution width [length] in blood
30399-0,deprecated hemoglobin istribution blood [length] in wdt
30399-0,deprecate heglobin distribuio with in [length bld
30399-0,deprecated hdw bld
30399-0,deprecated length hdw bld
30399-0,random hdw deprecated blood
30399-0,hemoglobin distribution width (bld) [length]
30399-0,hemoglobin distribution (bld) width [length]
30399-0,hemoglobin distribution width (bld) [length]
86700-2,rotavirus c rna [cycle threshold #] in specimen by naa with probe detection
86700-2,rotavirus with rna [cycle threshold #] in probe with ampification specimen by naa c probe detection
86700-2,rotavirus in rna [cycle threshold #] c specimen by naa with probe detection
86700-2,rvc rna ct spec qn naa+probe
86700-2,rvc rna qn spec ct naa+probe
86700-2,rvc rna naa+probe spec qn ct quantitative
86700-2,rotavirus c rna naa+probe (specimen) [threshnum]
86700-2,rotavirus c rna (specimen) naa+probe [threshnum]
86700-2,rotavirus cra aa+rob specimen) [threhnum]
13207-6,borrelia burgdorferi igm ab [presence] in synovial fluid by immunoblot
13207-6,borrela burgdorferiigm ab [ql] n synovia fuidby riba immunoblo
13207-6,borrela burgdoreri igm ab [preece] in synvial fluid by immunoblt
13207-6,b burgdor igm snv ql ib
13207-6,b burgdor igm point in time snv presence ib
13207-6,snv burgdor igm b ql ib
13207-6,b. burgdorferi igm ib ql (syn fld)
13207-6,. burgdorferi igm ib q fld (syn
13207-6,igm urgdorferi b. ib q (sn fld)
44458-8,brucella abortus igg+igm ab [units/volume] in serum
44458-8,brucella bortus igg+igm ab [units/volume] in antibodies erum
44458-8,bruela infectiousdisease aborus igg+igm ab [units/voume] in srum
44458-8,b abortus igg+igm ser-acnc
44458-8,abortus b igg+igm serum-acnc
44458-8,igg+igm abortus b ser-acnc
44458-8,b. abortus igg+igm qn (s)
44458-8,b. antibodies abortu igg+ig qn (s)
44458-8,b. abortus igg+igm qn (s)
73664-5,yersinia adhesion protein yada [presence] in isolate
73664-5,yersinia adhesio protein ada [ql] in isolate
73664-5,yersinia adhesion protein yada [presence] in isolate
73664-5,yersinia yada islt ql
73664-5,yersinia presence islt yada
73664-5,ordinal yersinia yada islt ql
73664-5,yersinia adhesion protein yada ql (isol)
73664-5,yersina prtei adeson yda q (isol)
73664-5,yersinia adhesion protein isol yada ql (isol)
74335-1,mica*016 igg ab [presence] in serum
74335-1,mica*016 igg ab [presence] in serum
74335-1,ig ica*016 b [presnce in seum
74335-1,mica*016 igg ser ql
74335-1,igg mica*016 ser ql
74335-1,mica*016 ql ser autoantibodies igg
74335-1,mica*016 igg ql (s)
74335-1,mica0 igg ser q (s)
74335-1,mia*16 g ql (s)
86339-9,streptococcus pneumoniae danish serotype 6a+6b igg ab [units/volume] in serum
86339-9,streptococcus ab danish serotype 6a+6b igg pneumoniae [units/volume] in serum
86339-9,streptococcus ab danish serotype 6a+6b antibody igg pneumoniae [units/volume] in serum
86339-9,s pneum da 6a+6b igg ab ser-acnc
86339-9,s pneum da 6a+6b igg pneumococ ser-acnc ab
86339-9,s pneum da 6a+6b igg ab ser-acnc
86339-9,s. pneumoniae danish type 6a+6b igg ab qn (s)
86339-9,. pneuoniae 6a+6b s pneumo type danish igg ab qn s
86339-9,s. pneumoniae danish ype 6a+6b pneumonia igg ab qn (s)
75812-8,antihistamines [interpretation] in serum or plasma or urine qualitative by screen method
75812-8,ntihitamine [interpetation] in serm or plasma or uine qualitativeby screen meth
75812-8,atihistaines [inerpretation] in serum orplsma orurne ualiative byscren metho
75812-8,antihistamines ser/plas/urn scn-imp
75812-8,impressions anthistaminesser/plas/urn scn-ip
75812-8,antihistamines scn-imp ser/plas/urn
75812-8,antihistamines screen ql (s/p/u) [interp]
75812-8,antihistamines screen qualitative ql (s/p/u) [interp]
75812-8,ntihistamnes scren ls/p/u) [interp] random
15031-8,angiotensin i [moles/volume] in plasma
15031-8,angiotensin i in [moles/volume] plasma
15031-8,angiotensin i [moles/volume] in plasma
15031-8,angiotensin i plas-scnc
15031-8,plas-scnc quantitative i angiotensin
15031-8,angiotensin plas-scnc i plasma
15031-8,angiotensin i (p) [moles/vol]
15031-8,angiotensin i (p) [moles/vol]
15031-8,agiotenini [moles/vol] (p)
51940-5,escherichia coli shiga-like toxin 1 [presence] in stool by immunoassay
51940-5,escherichia colshigalietoxin 1 [prsence in stool by immunoassy
51940-5,escherichia [presence] shiga-like toxin 1 coli in stool by immunoassay
51940-5,e coli sxt1 stl ql ia
51940-5,e coli sxt1 suds stl ql ia
51940-5,e coli o002 sxt1 stl presence ia
51940-5,e. coli shiga-like toxin 1 ia ql (stl)
51940-5,e. shiga-like coli toxin 1 ia ql (stl)
51940-5,ia coli shiga-like toxin 1 e. presence (stl)
80287-6,neurological assessment panel
80287-6,eurological panel assement panel.h&p
80287-6,neurological pan assessment panel
80287-6,neurological assessment pnl
80287-6,neurological assessment pnl p prime
80287-6,euroogicl neuro assessment pnl pnl assessment
26523-1,promyelocytes [#/volume] in blood
26523-1,promyelocts [#/volume] in blood
26523-1,pomyeloctes [#/volume] random in loo
26523-1,promyelocytes # bld
26523-1,blood # pomyelcyte
26523-1,promyelocytes # blood
26523-1,promyelocytes (bld) [#/vol]
26523-1,[#/vol] (bld) promyelocytes
26523-1,pomyelocyts (bd) [/vol]
97779-3,sodium [moles/volume] in dialysis fluid --1 hour specimen
97779-3,[molesvolume] soum in dialysis fluid --1 hospecme
97779-3,sodium point in time in [moles/volume] dialysis fluid --1 hour specimen
97779-3,sodium 1h spec dial fld-scnc
97779-3,sodium 1h spec dial fld-scnc dialysate
97779-3,sodu 1 spec na dial fld-scc
97779-3,sodium 1 hour specimen (dial fld) [moles/vol]
97779-3,sodium 1 hour specimen (dial fld) [moles/vol] renal
97779-3,sodium 1 hour [moles/vol] (dial fld) specimen 1 hour
12783-7,oligoclonal bands [interpretation] in serum or plasma
12783-7,oligoclonal in [interpretation] bands serum or plasma
12783-7,liocln bnds [interpretaton] in serm or plasma
12783-7,oligoclonal bands serpl-imp
12783-7,oligoloal band serl-imp sr
12783-7,bands oligoclonal serpl-imp
12783-7,oligoclonal bands [interp]
12783-7,bands oligoclonal random [interp]
12783-7,bands oligoclonal [interp] fractionated
23446-8,swine vesicular disease virus ag [presence] in specimen by complement fixation
23446-8,swine vesicular disease virus ag comp fixation [presence] in specimen by complement fixation
23446-8,swine vesicular complement virus ag [presence] in specimen by disease fixation
23446-8,svd ag spec ql cf
23446-8,sd ag spec ql ordinal cf
23446-8,svd ag cf presence spec id
23446-8,swine vesicular disease virus ag cf ql (specimen)
23446-8,swine microbiology vesicular disease virus ag cf ql (specimen)
23446-8,swine vesicular disease virus ag cf miscellaneous ql (specimen)
31277-7,burkholderia pseudomallei igm ab [units/volume] in specimen
31277-7,burholderi pseudmalei quantitative ig b [unts/volume] i specimen
31277-7,burkholderia pseudomallei igm ab [units/volume] specimen in
31277-7,b pseudomal igm spec-acnc
31277-7,b spec-acnc igm pseudomal
31277-7,miscellaneous pec-acnc igm bpseudomal
31277-7,b. pseudomallei igm qn (specimen)
31277-7,(specimen) pseudomallei igm qn b.
31277-7,b. pseudomallegm q (specimen)
106911-1,cd3+cd8+ (t8 suppressor) cells/lymphocytes in bronchoalveolar lavage by flow cytometry (fc)
106911-1,(t c3+c8+ suppressor) cells/lyhocytes in bronholveolar lavage b leu-2 flow ytometry (c)
106911-1,cd3+cd8+ bronchoalveolar suppressor) cells/lymphocytes in (t8 lavage by flow cytometry (fc)
106911-1,cd3+cd8+ cells/lymph nfr bal fc
106911-1,bronchial alveolar lavage c3+cd8+ fc nf bal els/ymh
106911-1,cd3+cd8+ nfr cells/lymph bal fc
106911-1,cd3+cd8+ (t8 suppressor) cells/lymphs fc (bal)
106911-1,cells/lymphs (t8 suppressor) cd3+cd8+ fc (bal)
106911-1,cd3+cd8+ (t8 suppressor/cytotoxic t cells suppressor) cells/lymphs fc (bal)
47354-6,deprecated streptococcus pneumoniae 5 igg ab [mass/volume] in serum by immunoassay --2nd specimen
47354-6,s pneumo deprecated streptococcus pneumoniae 5 igg ab [mass/volume] in serum by immunoassay --2nd specimen
47354-6,deprecated streptococcus pneumoniae 5 igg ab [mass/volume] strept in serum by immunoassay --2nd specimen
47354-6,deprecated s pneum5 igg sp2 ser ia-mcnc
47354-6,deprected s pneum5 igg sp2 seria-cnc
47354-6,precated s sp2 igg nem ser ia-mcnc
47354-6,s. pneumoniae 5 igg spec 2 ia (s) [mass/vol]
47354-6,s. [mass/vol] strep 5 igg spec 2 ia (s) pneumoniae
47354-6,s. peumoniae 5 igg sec2 ia (s) [mass/vol]
59325-1,salvinorin b [mass/volume] in blood
59325-1,salvinorin b [mass/volume] blood in
59325-1,salvinorin b [mass/volume] in bld
59325-1,salvinorin b bld-mcnc
59325-1,mass concentration savinon bld-cnc
59325-1,salvinorin level b bld-mcnc
59325-1,salvinorin b (bld) [mass/vol]
59325-1,salvinorin b (bld) quant [ass/vol]
59325-1,salvinorin [mass/vol] (blood) b
97559-9,acetylcholine receptor ganglionic neuronal igg+igm ab [moles/volume] in serum by immunoassay
97559-9,acetylcholine receptor ganglionic neuronal igg+igm immune globulin m ab [moles/volume] in serum by immunoassay
97559-9,acetylcholine igg+igm ganglionic neuronal receptor ab [moles/volume] in serum by immunoassay
97559-9,nachr igg+igm ser ia-scnc
97559-9,ser igg+igm nachr ia-scnc
97559-9,ser igg+igm nachr autoantibody ia-scnc
97559-9,acetylcholine receptor ganglionic neuronal igg+igm ia (s) [moles/vol]
97559-9,acetylcholine receptor ganglionic euronal igg+igm ia (s)[moles/vl]
97559-9,acetylcholine (s) ganglionic neuronal igg+igm ia receptor [moles/vol]
3556-8,dichlorphenamide [mass/volume] in urine
3556-8,dichlorphenamid [mass/volume] glauconide inuine
3556-8,dchlorphenamie [mas/volume in urine
3556-8,dichlorphenamide ur-mcnc
3556-8,dichlorphenamide ur-mcnc
3556-8,ur-cnc dichlorphenaide quan
3556-8,dichlorphenamide (u) [mass/vol]
3556-8,dichlorphenamide (u) [mass/vol]
3556-8,dichlorphenamide (u) [mass/vol] urn
73482-2,carisoprodol induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73482-2,carisoprodol induced platelet igm ab [presence] in serpl by flow cytometry (fc)
73482-2,carisoprodol induced platelet immunoglobulin m igm ab [presence] or ser in plasma by flow cytometry (fc)
73482-2,carisoprodol ind plt igm serpl ql fc
73482-2,plt ind carisoprodol igm serpl ql fc
73482-2,carisoprodol ind igm plt serpl ql fc
73482-2,carisoprodol induced platelet igm fc ql
73482-2,carisoprodol induced platelet igm fc serum ql
73482-2,carisoprool indued fc lateletigm l
88221-7,chlamydia trachomatis dna [presence] in throat by naa with probe detection
88221-7,chlamydia trachomatis by [presence] in throat dna naa with probe detection
88221-7,chlamydia lat trachomatis dna [presence] in throat by naa probe with detection
88221-7,c trach dna throat ql naa+probe
88221-7,c trach dna throat presence naa+probe infectious disease
88221-7, trach dnatroat l naa+rob
88221-7,c. trachomatis dna naa+probe ql (throat)
88221-7,c. naa+probe dna trachomatis ql (throat)
88221-7,ql microbiology trachomatis dna naa+probe c. (throat)
61417-2,imipramine/creatinine [mass ratio] in urine
61417-2,n [mass ratio] mcrto impramne/creatinine rine
61417-2,imipramine/creatinine [mass ratio] in urine
61417-2,imipramine/creat ur
61417-2,ur imipramine/creat
61417-2,miprmine/creat ur
61417-2,imipramine/creatinine (u) [mass ratio]
61417-2,imipramine/creatinine (u) [mass ratio] imipra
61417-2,imipramine/creatinine quant (u) [mass ratio]
13096-3,deprecated myelin associated glycoprotein ab.igm in serum
13096-3,derecated yelin assocatdglycoprotin ab.igm glycoprot in erum
13096-3,depectd seum associatedglycprotein gg a.im in myelin
13096-3,deprecated mag igm ser
13096-3,deprecated glycoproteins mag igm ser
13096-3,deprecated serology mag serum igm
13096-3,myelin associated glycoprotein igm (s)
13096-3,myelin associated glycoprotein igm (s) magm
13096-3,myelin glycoprot associated glycoprotein igm (s)
75679-1,deprecated klebsiella pneumoniae ygge gene [presence] by nucleic acid capture and probe detection in positive blood culture
75679-1,deprecated klebsiella pneumoniae ygge gene [presence] by nucleic acid capture and probe detection in positive bld culture
75679-1,deprecated positive pneumoniae ygge gene [presence] by nucleic acid capture and probe infectiousdisease detection in klebsiella blood culture
75679-1,deprecated k pneumoniae ygge bld pos ql prb mag
75679-1,microbiology deprecated k pneumoniae ygge bld pos presence prb mag
75679-1,deprecated k pneumoniae ygge bld pos pneumonia ql prb mag
75679-1,k. pneumoniae ygge gene nucleic acid capture and probe detection ql (pos bld culture)
75679-1,. pneumonae ygge gene nuleic acid capture and proe detctonql (pos ld cultue)
75679-1,k. pneumoniae acid gene nucleic ygge capture and probe detection ql (pos bld culture)
58022-5,prostanozol [presence] in urine
58022-5,protaozol in [presence urine
58022-5,proanzol [ql] urne in
58022-5,prostanozol ur ql
58022-5,ur prostanozol ql potentialforabuse
58022-5,prostanozol ur illicit presence
58022-5,prostanozol ql (u)
58022-5,(u) ql prostnozol
58022-5,ostanzol (u) pr presence
17526-5,retinyl esters [mass/volume] in serum or plasma
17526-5,serplas retinyl plasma [mass/volume] in serum or esters
17526-5,retinyl esters quan [mass/volume] in plasma or serum
17526-5,vit a ester serpl-mcnc
17526-5,v sr a ester serpl-mcnc
17526-5,erpl-mcnc a eter vit quantitative
17526-5,retinyl esters [mass/vol]
17526-5,rinl esters [ass/vol]
17526-5,pl etes[mass/vo] rtinyl
53835-5,"1,5-anhydroglucitol [mass/volume] in serum or plasma"
53835-5,"sr 1,5-anhydroglucitol [mass/volume] in serum plas or"
53835-5,"1,5-anhydroglucitol in [mass/volume] serum or random plasma"
53835-5,"1,5-anhydroglucitol serpl-mcnc"
53835-5,"1,5-anhydrogluctol serpl-mcnc"
53835-5,srpl-mcnc i 15-ahydroglucitol
53835-5,"1,5-anhydroglucitol [mass/vol]"
53835-5,"plsm 1,5-anhydroglucitol [mass/vol]"
53835-5,"1,5-anhydrogluiol ass/vl]"
51583-3,anulocytes [presence] in blood by light microscopy
51583-3,anulocytes [presence] in blood by light microscopy pr
51583-3,anulocytes [prsene] n blood by igh micoscopy random
51583-3,anulocytes bld ql smear
51583-3,smear ql anulocytesbldql
51583-3,smear bld ql anulocytes
51583-3,anulocytes lm ql (bld)
51583-3,anulocytes (bld) ql blood lm
51583-3,anulocytes wb ql lm (bld)
85363-0,21-hydroxylase ab [presence] in serum
85363-0,2-ydoxylas ab [presencein seru
85363-0,in anti ab [presence] 21-hydroxylase ser
85363-0,21hydroxylase ab ser ql
85363-0,21hyoxylase ab ser pr presence
85363-0,ser ab 21hydroxylase ql
85363-0,21-hydroxylase ab ql (s)
85363-0,21-ydroxylase ab point in time presence (s)
85363-0,random (s) ab ql 21-hydroxylase
47350-4,streptococcus pneumoniae danish serotype 33f igg ab [ratio] in serum --2nd specimen/1st specimen
47350-4,streptococcus pneumoniae danish serotype 33f --2nd ab [ratio] in serum igg specimen/1st specimen
47350-4,streptococcus pneumoniae danish in 33f igg ab [ratio] serotype serum --2nd specimen/1st specimen
47350-4,s pneum da 33f igg 2:1 ser-rto
47350-4,s pnem da 33f ig 2:1 ser-rto infectiousdisease
47350-4,s pneum 33f da ig 2:1 s pneum da 33f ab er-
47350-4,s. pneumoniae danish type 33f igg 2nd specimen/1st specimen (s) [ratio]
47350-4,s. pneumoniae danish type 33f igg spn 2nd specimen/1st specimen (s) [ratio]
47350-4,s. eumoniae anish type33f igg 2ndspeime/1stspeimen ([rati antibody
40719-7,hemoglobin [mass/volume] in cord blood
40719-7,hemolobin [mass/volum] in crd mass concentration blood
40719-7,hemoglobin [mass/volume] in cord blood cord blood
40719-7,hgb bldco-mcnc
40719-7,hgb bldco-mcnc level
40719-7,level bldco-mcnc hgb
40719-7,hemoglobin (bldco) [mass/vol]
40719-7,[mass/ol] (bldco) hemoglobin
40719-7,hemolobin (bdco) [mass/vol]
49820-4,3-hydroxyadipate/creatinine [molar ratio] in 24 hour urine
49820-4,3-hydroxyadipate/creatinine [molar ratio] 24 in hour urine
49820-4,3-hydroxyadiate/creatinine molratio] in 24 hor urine
49820-4,3oh-adipate/creat 24h ur-srto
49820-4,3haiatecret 24h ur-rto
49820-4,24h 3o-adipatecrat ur-srto substance concentration ratio
49820-4,3-hydroxyadipate/creatinine (24h u) [molar ratio]
49820-4,3-hydroxyadipatecreatinine (24h u) [molar ratio]
49820-4,3hydrxyaipate/creatinine (4h u) [mola ratio] creat
56154-8,protein.abnormal band/protein.total in serum or plasma by electrophoresis
56154-8,potin.abnormal band/proteintotal in ser or pasaby eectrohoresis
56154-8,protein.abnormal band/protein.total in plsm plas or serum by electrophoresis
56154-8,abn prot mfr serpl elph
56154-8,serpl pot mfr abn elp elph
56154-8,bands eph mfr serpl anprot
56154-8,protein.abnormal band elph [mass fraction]
56154-8,protein.abnormal band elph [mass fraction]
56154-8,fraction] band elph [mass protein.abnormal
14922-9,toxoplasma gondii iga+ige ab [units/volume] in serum by immunoassay
14922-9,oxoplsma gondii ga+igeab [unts/voume] in erum by immunoassa
14922-9,toxoplasma gondii iga+ige immunoassay [units/volume] in serum by ab
14922-9,t gondii iga+ige ser ia-acnc
14922-9,t ig+igesriacnc gonii
14922-9,t gondii er iga+ige i-acnc
14922-9,t. gondii iga+ige ia qn (s)
14922-9,t. gondii ia iga+ige qn (s)
14922-9,t.ondii ig+ige q ia (s)
51776-3,7-aminoclonazepam [mass/volume] in urine by confirmatory method
51776-3,7-aminoclonazepam method in urine by confirmatory [mass/volume]
51776-3,by [mass/volume] in urine 7-aminoclonazepam confirmatory quan method
51776-3,7aminoclonazepam ur cfm-mcnc
51776-3,7aminoclonazepam cfm-mcnc confirmatory ur
51776-3,ur 7minoclonazepam 7aminoclonazepam cfm-mcc
51776-3,7-aminoclonazepam confirm (u) [mass/vol]
51776-3,[mass/vol] confirm (u) 7-aminoclonazepam
51776-3,() 7-aminoclonazepamonfirm mass/vol]
45210-2,herpes simplex virus 2 igm ab [presence] in serum by immunofluorescence
45210-2,herpes simplex virus 2 igm ab [presence] in ser by immunofluorescence
45210-2,herpes simplex virus 2 point in time igm ab [presence] in serum immunofluorescence by
45210-2,hsv2 igm ser ql if
45210-2,hsv igm se ql if
45210-2,hsv2 serum igm ql if immune globulin m
45210-2,hsv 2 igm if ql (s)
45210-2,hsv 2 igm ql if (s)
45210-2,hsv 2 igm if ql (s)
18314-5,morphology [interpretation] in blood narrative
18314-5,blodnarratve [inerretation] in morhlog
18314-5,orpholoy [interpretation] inlood narrative
18314-5,morphology bld-imp
18314-5,morphology blood-imp
18314-5,blood-imp morphology
18314-5,morphology nar (bld) [interp]
18314-5,morphology narrative [interp] (bld) nar
18314-5,impressions morphology nar (bld) [interp]
73332-9,imipenem+cilastatin induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73332-9,imienem+ilastatin induced plasma igm ab[presence] in sem o plateet by fow cytometry imp (fc)
73332-9,imipenem+cilastatin induced platelet igm ab [presence] in serpl by screen flow cytometry (fc)
73332-9,imp+cs ind plt igm serpl ql fc
73332-9,mps ind lt igm serpl lfc serpl
73332-9,igm n plt imp+cs serplql fc plt
73332-9,imipenem+cilastatin induced platelet igm fc ql
73332-9,imipenem+ilastatn induce latelet fc igm presence
73332-9,imipenem+cilastatin induced platelet fc thrombocyte igm presence
90469-8,norfluvoxamine [mass/volume] in urine by confirmatory method
90469-8,norfluvoxamine [mass/volume] confirmatrymthod by inurine
90469-8,cnfirmatory [mas/volume] n urine by noluvoxamie method
90469-8,norfluvoxamine ur cfm-mcnc
90469-8,cfm-mcnc ur norfluvoxamine
90469-8,quan norfluvoxamine ur cfm-mcnc
90469-8,norfluvoxamine confirm (u) [mass/vol]
90469-8,norfluvxamine cfm confirm (u) [mass/vol]
90469-8,norfluvoxamine (u) confirm [mass/vol]
74604-0,3-hydroxymyristoleylcarnitine (c14:1-oh) [enzymatic activity/mass] in fibroblast
74604-0,3-hydroxymyistolelcarnitine point in time (c14:1-oh) [enzymatic activitymass] i ibroblast
74604-0,3-hydroxymyristoleylcarnitine [enzymatic (c14:1-oh) activity/mass] in fibroblast
74604-0,3oh-myristoleylcarn fib-ccnt
74604-0,3oh-mrisoleylcarn fib-ccnt
74604-0,3oh-myristoleylcarn fib-ccnt random
74604-0,3-hydroxymyristoleylcarnitine (c14:1-oh) (fibroblast) [catalytic activity/mass]
74604-0,activity/mass] (c14:1-oh) (fibroblast) [catalytic 3-hydroxymyristoleylcarnitine
74604-0,3-hydroxymyristoleylcarnitine (c14:1-oh) (fibroblast) [catalytic activity/mass]
589-2,legionella sp identified in bronchial specimen by organism specific culture
589-2,legionella sp in identified bronchial specimen by organism specific culture
589-2,legionela sp idntfied in brochial speimen byorganism pecific cultre
589-2,legionella bronch cult
589-2,legionell bronch cut
589-2,legonella cut respiratory bronch
589-2,legionella sp identified org specific cx nom (bronch spec)
589-2,leginela  identii org specific c nm (brnch spec)
589-2,legionella (bronch identified org specific cx nom sp spec)
81114-1,murray valley encephalitis virus igm ab [titer] in serum
81114-1,murray valley encephalitis virus igm ab [titer] in serum
81114-1,muray valley encephaliti ius serum b [tite] i im
81114-1,mvev igm titr ser
81114-1,mvev igm titr microbiology serum
81114-1,igmtitr mvev ser infectious disease
81114-1,mvev igm (s) [titer]
81114-1,[titer] igm smqn (s) mvev
81114-1,smqn mvev igm (s) [titer]
60472-8,complement c5.functional [units/volume] in serum or plasma
60472-8,comleent c5.funtional [nits/vlume sru in or plasma
60472-8,complement c5.functional point in time [units/volume] in eum or plasma
60472-8,c5.functional serpl-acnc
60472-8,c5functional serpl-acnc sr
60472-8,c5.functional serpl-acnc
60472-8,complement c5.functional qn
60472-8,serp complementc5.functinal qn
60472-8,complemen c5.funtional qn hematology/cell counts
55433-7,immature cells/leukocytes in blood
55433-7,immature quant cells/leukocytes in blood
55433-7,bld cells/leukocytes in immature
55433-7,immature cells nfr bld
55433-7,nfr cells immature wb bld
55433-7,immature bld nfr cells imm
55433-7,immature cells/leukocytes (bld)
55433-7,immature cells/leukocytes (blood)
55433-7,cells/leukocytes immature (bld)
16778-3,dinitrophenol [presence] in serum or plasma
16778-3,dinitrophenol [presence] in dinitrol or ser plasma
16778-3,pr dinitrophenol [presence] in serpl
16778-3,dinitrophenol serpl ql
16778-3,dintropheol epl l
16778-3,dinitrophenol serpl ql
16778-3,dinitrophenol ql
16778-3,dinitrophenol ql serplas
16778-3,dnitrophenl ql qual
57843-5,erythrocytes [#/volume] in peritoneal fluid by automated count
57843-5,erythrocytes [#/volume] by peritoneal fluid in automated count red bld cells
57843-5,erythrocyte [#volum] in peritneal fluid by automated count
57843-5,rbc # prt auto
57843-5,prt rbc auto
57843-5,red blood cell rbc # prt auto
57843-5,rbc auto (periton fld) [#/vol]
57843-5,rbc electr auto (periton ld [#/vol]
57843-5,rbc auto (periton fld) [#/vol]
60048-6,acetaminophen [mass/volume] in blood
60048-6,acetaminophen [mass/volume] in blood
60048-6,acetaminophen [mass/volume] in bld wb
60048-6,apap bld-mcnc
60048-6,bld-mcnc apap
60048-6,apap l-cnc
60048-6,acetaminophen (bld) [mass/vol]
60048-6,(bld) acetaminophen [ass/vol]
60048-6,drug/toxicology acetaminophen (bld) [mass/vol]
47866-9,phosphoribosylpyrophosphate synthetase [enzymatic activity/mass] in red blood cells
47866-9,phosphorosylpyrophosphateynthetase [enzymati red in quantitative ctivity/mas lod cells
47866-9,phosphoribosylpyrophosphate activity/mass] [enzymatic synthetase in red blood cells
47866-9,prps rbc-ccnt
47866-9,rbcccn rps
47866-9,pps rc-ccnt quan
47866-9,phosphoribosylpyrophosphate synthetase (rbc) [catalytic activity/mass]
47866-9,phosphoribosylpyrophosphate random synthetase (rbc) [catalytic activity/mass]
47866-9,phosphoribosylpyrophosphate synthetase [catalytic (rbc) activity/mass]
47695-2,lysine/amino acids.total in specimen
47695-2,miscellaneous lysine/amino acids.total in specimen
47695-2,lysne/amio acids.total in specimen
47695-2,lysine sfr spec
47695-2,fr lsin point in time sp
47695-2,chemistry sfr lysine spec
47695-2,lysine/total aa (specimen) [molar fraction]
47695-2,lysie/total aa (specimen) [olar faction]
47695-2,lysine/total [molar amino acid (specimen) aa fraction]
18253-5,serotonin [mass/time] in 24 hour urine
18253-5,sroonin [ass/time] in24 hor urie
18253-5,serotonin 24hr [mass/time] in 24 hour urine
18253-5,serotonin 24h ur-mrate
18253-5,serotonin ur-mrate 24h
18253-5,urate 24h 5-hydroxytryptophane seroton
18253-5,serotonin (24h u) [mass/time]
18253-5,u) (2 srotnin [mass/time]
18253-5,serotonin (24h 5-ht u) [mass/time]
88606-9,herpes simplex virus identified in lower respiratory specimen by organism specific culture
88606-9,herpes simplex virus identified in lower respiratory specimen by organism specific culture
88606-9,identiied simplex virus erpes in lower espiratory specimen byorganism scifi culture
88606-9,hsv lower resp cult
88606-9,sv lower ct rep identity or presence
88606-9,hsv resp ower cul
88606-9,hsv identified org specific cx nom (lower resp)
88606-9,low hs identifid or cx specfc nom lower rsp)
88606-9,hv identified rsp) spcific x nom (lower org
79543-5,hedis 2016-2019 value set - abo and rh
79543-5,hedis20162019 d typing valuset - abo and rh
79543-5,hedis 2016-2019 and set - abo value rh
79543-5,hedis 2016-19 abo and rh
79543-5,heis and ab 216-19 rh
79543-5,hedis 2016-19 pnl rh and abo
79543-5,hedis 2016-2019 value set - abo and rh
79543-5,hs 2016-2019 value set - random ad abo rh
79543-5,hedis 2016-2019 value set - abo and rh
38693-8,ethyl acrylate [mass/volume] in air
38693-8,ethyl acrylate qnt [massvolume]nair
38693-8,ethyl acrylate qnt [mass/volume] in air
38693-8,ethyl acrylate air-mcnc
38693-8,ethyl acrylate air-mcnc
38693-8,ethy acryate air-mcnc propenoate
38693-8,ethyl acrylate (air) [mass/vol]
38693-8,ethy acrylate ethyl 2-propenoate i) mass/vol]
38693-8,ethyl (air) acrylate [mass/vol]
25404-5,ethambutol [presence] in serum or plasma
25404-5,serum resence] plsm in ethambutol or plasma
25404-5,ethambutol [ql] in serum qual or plasma
25404-5,ethambutol serpl ql
25404-5,ethambutol serpl ql
25404-5,ql ql serpl ethambutol
25404-5,ethambutol ql
25404-5,ethmbutl ql
25404-5,ql ethambuto mycobutol
17523-2,reticulin igg ab [titer] in serum
17523-2,in igg ab [titer] reticulin reticuline serum
17523-2,reticulin igg ab in [titer serum
17523-2,reticulin igg titr ser
17523-2,reiclin igg titr ser
17523-2,reticulin serum igg ser titr
17523-2,reticulin igg (s) [titer]
17523-2,eiculin igg (s) [titer]
17523-2,reticuin titered igg(s [tite]
40939-1,yersinia sp igm ab [units/volume] in serum by immunoassay
40939-1,yersinia sp g ab [uits/olume] in meia seru by imuossay
40939-1,yrsiniasp igm ab [utsvolu in ser by immnoassay
40939-1,yersinia igm ser ia-acnc
40939-1,yersinaigm se ia-acnc
40939-1,yersinia ia-acnc ser igm
40939-1,yersinia sp igm ia qn (s)
40939-1,(s) spigmi qn spp ersina
40939-1,yersinia p igm iaqn (s)
72299-1,wound tunneling and undermining panel
72299-1,woun wnd tunnel+under pnl ane andunderming tunnelng
72299-1,wound tunneling an undermining anl
72299-1,wnd tunnel+under pnl
72299-1,pnl tunnel+uner wnd
72299-1,wnd tunl+under pnl
14048-3,elastase.pancreatic [mass/volume] in serum
14048-3,mass concentration elastase.pancreatic serum in [mass/volume]
14048-3,in [mass/volume] elastase.pancreatic ser
14048-3,elastase panc ser-mcnc
14048-3,elastase panc serum-mcnc
14048-3,elastse pnc sermcnc
14048-3,elastase.pancreatic (s) [mass/vol]
14048-3,elastase.pancreatic [mass/vol] (s)
14048-3,(s) random elastase.pancreatic [mass/vol]
86149-2,streptococcus pneumoniae danish serotype 8 igg ab [units/volume] in serum
86149-2,streptococcus pneumoniae danish serotype 8 igg ab [units/volume] in serum
86149-2,streptococcus serum danish serotype 8 igg ab [units/volume] in pneumoniae
86149-2,s pneum da 8 igg ser-acnc
86149-2,s pneum da pneumonia 8 igg ser-acnc
86149-2,s pneum da 8 ser-acnc igg
86149-2,s. pneumoniae danish type 8 igg qn (s)
86149-2,s. pneumoniae qn type 8 igg danish (s)
86149-2,pneumoniae s. danis tye 8 igg qn point in time (s)
62209-2,promis pediatric short form - peer relationships 8a - version 1.0
62209-2,promis pediatric - form - peer relationships 8a short version 1.0
62209-2,promis pediatic frm shor - peerrelationsips8a-ersion 0
22080-6,adenovirus ab [titer] in serum
22080-6,adenovirus ab [titer] in serum
22080-6,adenovirus [titr] ab in seum
22080-6,hadv ab titr ser
22080-6,ab hadv point in time titr ser
22080-6,hadv ab tir ser
22080-6,adenovirus ab (s) [titer]
22080-6,adenovirus ab (s) [titer] antibody
22080-6,adenovirus ab [tter] ()
86913-1,iron saturation goal serum or plasma
86913-1,iron satration or serm goal plama
86913-1,iron saturation quant goal serum or plasma
86913-1,iron satn goal mfr serpl
86913-1,iron satn goa mfr pl serum or plasma
86913-1,iron satn goal mfr serplas serpl
2682-3,ornithine carbamoyltransferase [enzymatic activity/volume] in amniotic fluid
2682-3,ornithine carbamoyltransferas [enzymatic aciit/olme oct n amniotic fluid
2682-3,ornithine carbamoyltransferase amniotic point in time activity/volume] in [enzymatic fluid
2682-3,oct amn-ccnc
2682-3,am-ccnc t
2682-3,oct catalytic concentration amn-ccnc
2682-3,ornithine carbamoyltransferase (amn fld) [catalytic activity/vol]
2682-3,orithine random crmyltansferase (amnld) [ctalyticativity/vol]
2682-3,[catalytic carbamoyltransferase (amn fld) ornithine activity/vol]
23525-9,deprecated trypanosoma evansi ab [presence] in serum
23525-9,deprecated trypanosoma evansi ab [presence] serum in
23525-9,[presence] trypanosoma evansi ab deprecated in ser autoantibody
23525-9,deprecated t evansi ab ser ql
23525-9,deprecated t ab evansi ser ql
23525-9,evansi t deprecated ab ser autoantibodies ql
23525-9,t. evansi ab ql (s)
23525-9,(s) evansi ab ql t.
23525-9,t. ql ab evansi (s)
94593-1,multiplex allergen panel - serum or plasma
94593-1,multiplex multiplex allergy array allergen panel - serum or plasma
94593-1,multiplex allergen pael - eum or pls
94593-1,multiplex allergy pnl serpl
94593-1,multiplex llergy pnl serl
94593-1,multiplex plasma allery sepl pnl
94593-1,multiplex allergen panel
94593-1,multiple allergen panel
94593-1,multiplex allergen panel
40566-2,neutrophils [#/volume] in body fluid by manual count
40566-2,trophils [#/volume] in by fluid ody manualcoun
40566-2,neutrophils [#/volume] in body fluid by manual count
40566-2,neutrophils # fld manual
40566-2,neutrophis # fld manual
40566-2,# neutrophils cnt fld manual
40566-2,neutrophils manual cnt (body fld) [#/vol]
40566-2,fld) manual cnt (body neutrophils [#/vol]
40566-2,neutrophils manual [#/vol] (body ct fld) cnt
20750-6,chicken anemia virus neutralizing antibody [presence] in serum by neutralization test
20750-6,chicken anemia virus antibody neutralizing [presence] in serum by neutralization test
20750-6,chicken anemia virus neutralizing antibody [presence] in ser by neutralization test
20750-6,cav nab ser ql nt
20750-6,ordinal cav nab ser ql nt
20750-6,cav q aby er nab nt
20750-6,chicken anemia virus neut ab neut test ql (s)
20750-6,anemia antby chicken virus nut ab neut test ql (s)
20750-6,chicken anema irus neut ab neut testq (s)
74169-4,cocaine [mass/volume] in saliva (oral fluid) by screen method
74169-4,cocaine [massvolume saliva (oal fluid) quantitative by screnmethod
74169-4,cocaine [mass/voume] in sava (oal fluid) by sceen mehod point in time
74169-4,cocaine sal scn-mcnc
74169-4,cocaine sal illicit scn-mcnc
74169-4,cocaine scn-mcnc level sal
74169-4,cocaine screen (sal) [mass/vol]
74169-4,cocaine screen addiction [ass/vol] (sal)
74169-4,[mass/vol] snow screen (sal) cocaine
2806-8,pipecolate [mass/volume] in serum or plasma
2806-8,pipecolate [mass/volume] in sr serum or plasma
2806-8,ipecolate [mass/volume] in serum serum or plasma or plasma
2806-8,pipecolate serpl-mcnc
2806-8,serpl-mcnc ipcolat mass concentration
2806-8,pipecolate serpl-mcnc
2806-8,pipecolate [mass/vol]
2806-8,[mass/vo] pipcoate
2806-8,chemistry pipcolate [mas/vol]
97922-9,california encephalitis virus rna [presence] in specimen by naa with probe detection
97922-9,california encephaitis lat virus rna [preence] in specimen bynaa with probe detection
97922-9,virus encephalitis california rna [presence] in specimen by naa with probe detection
97922-9,cev rna spec ql naa+probe
97922-9,cev polymerase chain reaction rna spec naa+probe ql
97922-9,ce na spec presence tma na+prbe
97922-9,cev rna naa+probe ql (specimen)
97922-9,cev rna naa+probe presence (specimen)
97922-9,ev rna na+probe ql(specmn)
31429-4,deprecated histoplasma capsulatum ab [units/volume] in serum
31429-4,depecaed hsoplasma capsulatum ab abs [unit/volume] n serm
31429-4,deprecaed histoplasma capsulatum units/volume] quantitative ab in serum
31429-4,deprecated histoplasma ab ser-acnc
31429-4,histo deprecated histoplasma serum-acnc ab
31429-4,deprecated histoplasma ab antibodies ser-acnc
31429-4,histoplasma sp ab qn (s)
31429-4,histopasma infectiousdisease sp a qn s)
31429-4,qn species sp ab histoplasma (s)
53838-9,arsenic.inorganic [mass/time] in 24 hour urine
53838-9,arsenic.inorganic [mass/time] hour 24 in urine drug/toxicology
53838-9,1 day [mass/time] arsenic.inorganic in 24 hour urine
53838-9,inorg arsenic 24h ur-mrate
53838-9,inrg rsenic ur-mrate 2h
53838-9,arsenc inorg 24h 24hr ur-mrate
53838-9,arsenic.inorganic (24h u) [mass/time]
53838-9,arsenic.inorganic [mass/time] u) (24h
53838-9,arseni.iorganic (24u) inorg arsenic [mss/tie]
22563-1,streptococcus pneumoniae igg ab [ratio] in serum --1st specimen/2nd specimen
22563-1,ab pneumoniae igg streptococcus [ratio] in serum --1st specimen/2nd sp1 specimen
22563-1,streptococcuspneumniae igg ab [ratio] pre immunization in --st serum specimenndspecimen
22563-1,s pneum igg 1:2 ser-rto
22563-1,s pneum abs igg 1:2 ser-rto
22563-1,ser-rto pne ig 1: s
22563-1,s. pneumoniae igg 1st specimen/2nd specimen (s) [ratio]
22563-1,s. peumoniae anti igg1st specen/nd specimen (s [raio]
22563-1,s. pneumoniae pneumococcus igg 1st specimen/2nd specimen (s) [ratio]
74591-9,suberylcarnitine (c8-dc) [enzymatic activity/mass] in fibroblast
74591-9,(c8-dc) subeylcarnine [enzymatic point in time activity/mas] in fibroblast
74591-9,suberylcarnitine (c-dc) [zymatic in actvity/mas] fibrobas
74591-9,suberylcarn fib-ccnt
74591-9,fib-ccnt sberylcrn c8dc
74591-9,fib-ccnt suberylcarn dicarboxylic carnitine
74591-9,c8-dc (fibroblast) [catalytic activity/mass]
74591-9,c8-dc (ibroblast) [catalytic activity/mass]
74591-9,[catalytic (fibroblast) c8-dc c8-dc acivity/mass]
20413-1,cannabinoids [mass/volume] in urine by confirmatory method
20413-1,cannabnoids [msvolume] in urin y confirmatory drug/toxicology mehd
20413-1,cannabinoids potentialforabuse [mass/volume] methd rineby cnfirmatory i
20413-1,cannabinoids ur cfm-mcnc
20413-1,cnfrm cfm-mcnc ur cannbnod
20413-1,cannbinoids cfm-mcnc r
20413-1,cannabinoids confirm (u) [mass/vol]
20413-1,cannabioids confirm (u) [mass/l]
20413-1,confirm cannabinods (u) [mass/vl] quant
71647-2,basophils/leukocytes [pure number fraction] in body fluid by manual count
71647-2,basophils/leukocytes [pure number fraction] in body fluid white blood cells by manual count
71647-2,basophils/leukocytes [ure number fractin] in body manual by flid coun
71647-2,basophils nfr.df fld manual
71647-2,white bld cell basopils fld nf.df manual
71647-2,fldmanua nfr.df basophils point in time
71647-2,basophils/leukocytes manual cnt (body fld) [pure # fraction]
71647-2,bodies basophils/leukocytes manual # (body fld) [pure cnt fraction]
71647-2,basophils/leukocytes manual cnt (body # [pure fld) fraction]
38572-4,benzidine [mass/volume] in air
38572-4,in [mass/volume] benzidine air
38572-4,benzidine [mass/volume] air in mass concentration
38572-4,benzidine air-mcnc
38572-4,benzidine para-diaminodiphenyl air-mcnc
38572-4,random bezidine air-mcc
38572-4,benzidine (air) [mass/vol]
38572-4,[mass/vol] level (air) benzidine
38572-4,benzidine (air) drug/toxicology [mass/vol]
30485-7,uracil [presence] in urine
30485-7,[resence] uracil in uine
30485-7,uracil [presence] in chemistry urine
30485-7,uracil ur ql
30485-7,uraci ordinal ur ql
30485-7,uracil ur ql
30485-7,uracil ql (u)
30485-7,ql() uraci ordinal
30485-7,uracil u) chemistry
29570-9,west nile virus neutralizing antibody [titer] in cerebral spinal fluid by neutralization test
29570-9,west nile virus neutralizing antibody [titer] neutralization cerebral spinal fluid by in test
29570-9,west nle virus nutraizing antibody [titer] in cerebral spalflud by dilution factor neutralization test
29570-9,wnv nab titr csf nt
29570-9,wnv dilution factor nab csf titr nt
29570-9,titr neutralization test nab wnv csf nt
29570-9,west nile virus neut ab neut test (csf) [titer]
29570-9,wst nie virus neut ab neurology neut tet (cs) [titer]
29570-9,west nile virus nut neut b test (sf[titer]
44000-8,choriogonadotropin [units/volume] in amniotic fluid
44000-8,fluid [units/volume] in amniotic fluid amniotic choriogonadotropin
44000-8,choriogonadotropin [units/volume] in amniotic quantitative fluid
44000-8,hcg amn-acnc
44000-8,choriogonadotropins total amn-acnc hcg
44000-8,amn-acnc hcg
44000-8,hcg qn (amn fld)
44000-8,hcg qn fld) (amn
44000-8,hcg fld) cg (amn qn
29981-8,tin/creatinine [mass ratio] in 24 hour urine
29981-8,tin/creatinine [mass in ratio] 24 hour urine
29981-8,ratio] [mass tin/creatinine in 24 hour urine
29981-8,tin/creat 24h ur
29981-8,ucr tin/creat 24h ur
29981-8,ur 4h tin/cret
29981-8,tin/creatinine (24h u) [mass ratio]
29981-8,ratio] quantitative (24h u) [mass tin/creatinine
29981-8,tin/creatinine (24h ur u) ratio] [mass
48945-0,chlordiazepoxide [mass/volume] in specimen
48945-0,hlordiazpoxide [mas/volume] specimen chlordiazep n
48945-0,specimen [mass/volume] in chlordiazepoxide
48945-0,chlordiazep spec-mcnc
48945-0,chlordiazep drug/toxicology spec-mcnc
48945-0,unspecified spec-mcnc chlordiazep
48945-0,chlordiazepoxide (specimen) [mass/vol]
48945-0,(specimen) chlordiazepoxide [mass/vol] point in time
48945-0,(spcimen) chlordiazepoxide chlordiaz [mas/ol]
31217-3,adenovirus ab [units/volume] in body fluid
31217-3,adenovirusab [units/voume] in fluid quantitative bdy
31217-3,adeovirus ab[unts/volume] i bd fluid
31217-3,hadv ab fld-acnc
31217-3,hadv ab fld-acnc aby
31217-3,ab hadv fl-anc
31217-3,adenovirus ab qn (body fld)
31217-3,adenovirus ab qn fld) (body
31217-3,adenovirus ab qn (body fld) autoantibodies
31888-1,mumps virus ag [presence] in cerebral spinal fluid
31888-1,mumps virus fluid [presence] ql in cerebral spinal ag
31888-1,ag virus mups spinal fl [resence in cerebral spina fluid
31888-1,muv ag csf ql
31888-1,uv ql spinal fl csf ag
31888-1,ag muv csf ql
31888-1,muv ag ql (csf)
31888-1,agql muv (csf) cerebral spinal fluid
31888-1,ag muv ql (csf)
1814-3,acid alpha glucosidase [enzymatic activity/volume] in semen
1814-3,acid alpha in [enzymaticativity/volue] gluosidase semen
1814-3,acd alpha glucosidase [enzymatic gaa actiity/volume] n semen
1814-3,acid a-glucosidase smn-ccnc
1814-3,a-glucosidase maltase-glucoamylase acid smn-ccnc
1814-3,acd a-glucosidae smn-ccnc
1814-3,acid alpha glucosidase (sem) [catalytic activity/vol]
1814-3,acid alpha glucosidase (sem) [catalytic activity/vol]
1814-3,acid alpha glucosidase (sem) glucosidosucrase activity/vol] [catalytic
48314-9,leishmania mexicana igg ab [titer] in serum by immunofluorescence
48314-9,lishmania mexicanagg b immunoflour [ite] n b seum mmunoflrescnce
48314-9,leishmaniamexicana gg ab [titer]in immnoflorescence b serum
48314-9,l mexicana igg titr ser if
48314-9,l mexicana titr igg ser if
48314-9,l autoantibody mexiana igg titser i
48314-9,l. mexicana igg if (s) [titer]
48314-9,l. mexicana (s) if igg [titer]
48314-9,l. leishmaniasis mexicana iggif() [titer]
3407-4,brompheniramine [presence] in serum or plasma
3407-4,brompheniramine [pesence]in seru or plasma
3407-4,bompheniramine serum in [ql] r sr plasma
3407-4,brompheniramine serpl ql
3407-4,ql serp bompeniramine
3407-4,brompheniramine serpl ql
3407-4,brompheniramine ql
3407-4,brompheniramine ql ql
3407-4,ql serum or plasma brompheniamine
85635-1,lcds v3.00 - active diagnoses [cms assessment]
85635-1,survey lcds v3.00 - active diagnoses [cms assessment]
85635-1,centers for medicare and medicaid assessment lcds v3.00 - active diagnoses [cms assessment]
64393-2,deprecated phenx measure - perceived stress
64393-2,derecated phenx measure - perceived stess
64393-2,deprecated measure phenx - perceived stress
9539-8,la crosse virus igg ab [titer] in cerebral spinal fluid by immunofluorescence
9539-8,lacrosse viu igg ab titer] in crebral spinal flui by immunofluorescence
9539-8,l roe virus igg ab titer]n cerebral spinal fluidby immunofluorescence trf
9539-8,lacv igg titr csf if
9539-8,lacv igg titr csf if
9539-8,lacv cerebrospinal fluid titr igg if
9539-8,la crosse virus igg if (csf) [titer]
9539-8,la crosse virus igg if (csf) titered [titer]
9539-8,(csf) crosse virus igg if la [titer]
35250-0,magnesium [mass or moles/volume] in urine
35250-0,magnesim o [mass moles/voume] in urine
35250-0,mgnesium [mass r ur moles/vlumein urine
35250-0,magnesium ur-mscnc
35250-0,ur-mscnc magnesium quantitative
35250-0,ur-mscnc magnesium
35250-0,magnesium (u) [mass or moles/vol]
35250-0,agneium(u) or [mass moles/vol]
35250-0,moles/vol] (u) [mass or magnesium
31230-6,aspergillus flavus ab [units/volume] in serum
31230-6,aspeglus flavus a [units/volume] in ser
31230-6,aspergillus flavus [units/volume] ab in a flavus ser
31230-6,a flavus ab ser-acnc
31230-6,a ser-acc ab lavus
31230-6,flavu anti ab seacnc
31230-6,a. flavus ab qn (s)
31230-6,a. antby flavus ab qn (s)
31230-6,a. flavus ab qn (s)
93187-3,bone age assessment - tanner-whitehouse (tw2) associated observations panel
93187-3,bone age assessment - imaging tanner-whitehouse (tw2) associated observations panel
93187-3,bone observations assessment - tanner-whitehouse (tw2) associated age panel
93187-3,bone age assess tw2 panel
93187-3,bone age assess tw2 panel
93187-3,bone panel assess tw2 age
33701-4,clostridium botulinum toxin a [presence] in specimen by mouse bioassay neutralization
33701-4,botulinum clostridium toxin a [presence] in specimen by mouse bioassay neutralization
33701-4,clostridium botulinum toxin a [presence] in specimen by mouse bioassay to be specified in another part of the message neutralization
33701-4,c bot tox a spec ql ma nt
33701-4,c bot spec tox a se qlma nt
33701-4,cbottox spec a ql a nt
33701-4,c. botulinum toxin a mouse bioassay neutralization ql (specimen)
33701-4,c. botulinum toxin a mouse bioassay qual neutralization presence (specimen)
33701-4,c. (specim) toxin a mouse boasayneutraizain presence botulinum
105654-8,finegoldia magna dna [presence] in specimen by naa with probe detection
105654-8,finegoldia magna dna probe in specimen by naa with [presence] detection
105654-8,fineodia mana dna[presnce] i speimen b naawth probe detectio
105654-8,f magna dna spec ql naa+probe
105654-8,f na+probe dna spec ql magna
105654-8,f probe with ampification magna dna naa+probe l sec
105654-8,f. magna dna naa+probe ql (specimen)
105654-8,f. magnadna na+pobe ql(specien)
105654-8,f. ql dna naa+probe magna (specimen)
22381-8,legionella pneumophila 1 igg ab [titer] in serum
22381-8,legionella pneumophila 1 igg ab [titer] in serum
22381-8,leginlla pneumophia 1 igg ab [titer] in serum
22381-8,l pneumo1 igg titr ser
22381-8,l ser igg titr pnemo1
22381-8,l pnemo1 igg pneu titr ser
22381-8,l. pneumophila 1 igg (s) [titer]
22381-8,l pneumopila 1 igg s) [ter]
22381-8,l.pneumophla 1 i igg (s) titer]
17625-5,deprecated streptococcus pneumoniae 23f ab [units/volume] in serum --2nd specimen
17625-5,deprecated --2n 23f quantitative ab [units/volume inseru streococcuspneumonae specimen
17625-5,deprecated streptococcus pneumoniae 23f aby ab [units/volume] in serum --2nd specimen
17625-5,deprecated s pneum23f ab sp2 ser-acnc
17625-5,deprecated ser-acnc quant ab sp2 pneum23f
17625-5,deprecated s ser-acnc ab s2 pneum23
17625-5,s. pneumoniae 23f ab spec 2 qn (s)
17625-5,23f pneumoniae s. ab spec 2 qn (s)
17625-5,pneumoniae 23f ab anti spec 2 qn (s)
80185-2,xanthopterin/creatinine [molar ratio] in urine
80185-2,xanthpteri/creatinine scrto molar ratio] in urine
80185-2,urine [molar ratio] in xanthopterin/creatiine
80185-2,xanthopterin/creat ur-srto
80185-2,cr xanthopterin/creat ur-srto
80185-2,xanthoptrin/creat ur-srto
80185-2,xanthopterin/creatinine (u) [molar ratio]
80185-2,xnhoptrin/creatinine(u) ratio] [olar
80185-2,xanthopterin/creatinine ksantopterin (u) [molar ratio]
35128-8,perforin [units/volume] in leukocytes
35128-8,perforin [units/volume] in leukocyts
35128-8,perforin ekocyt in units/volume] quantitative
35128-8,perforin wbc-acnc
35128-8,wbc-acnc erforin
35128-8,bc-acnc perfor
35128-8,perforin qn (wbc)
35128-8,qn perorn (w) wbcs
35128-8,erforin (wbc) qn
8097-8,striated muscle ab [titer] in serum
8097-8,ab muscle stited [iter] in serm
8097-8,ab muscle striated [titer] in serum
8097-8,stria mus ab titr ser
8097-8,sia ab mu titr ser ser
8097-8,mus stria ab titr titered ser
8097-8,striated muscle ab (s) [titer]
8097-8,a musce stria mus striate (s) [tite]
8097-8,striated [titer] b (s) muscle
91035-6,phencyclidine [presence] in tissue by screen method
91035-6,phenyclidine tissue [preencin tissue by sceen method
91035-6,phencclidine [pesence] in tissueby scren pt ethod
91035-6,pcp tiss ql scn
91035-6,pcp ql tiss scn scn
91035-6,pcp tiss scn q
91035-6,phencyclidine screen ql (tiss)
91035-6,ql qual sceen phencyclidine (tiss)
91035-6,phencyclidine screenql (tiss)
47275-3,s100 calcium binding protein b [mass/volume] in serum
47275-3,s100 b ining protin calcium [mas/vlume] in serm
47275-3,s100 protein binding calcium b [mass/volume] in ser
47275-3,s100 ca binding protein b ser-mcnc
47275-3,binding ca s100 protein b point in time ser-mcnc
47275-3,ca s100 binding quan protein b ser-mcnc
47275-3,s100 calcium binding protein b (s) [mass/vol]
47275-3,s100 calcium binding protein b (s) [mass/vol] prot
47275-3,s100 (s) binding protein chemistry b calcium [mass/vol]
74311-2,prrsv orf5 gene sequence [nucleotide sequence] in isolate by sequencing
74311-2,prrsv of5 gene sequence [nucleotide sequence] in isolateby equencing
74311-2,prrsv orf5 gene sequence [nucleotide sequence] by isolate in prrsv orf5 seq sequencing
74311-2,prrsv orf5 seq islt-seq
74311-2,seq prrorf5 islt-se
74311-2,prrsv nominal orf5 eq islt-seq
74311-2,prrsv orf5 gene sequence sequence nom (isol)
74311-2,prrsv orf5 (isol) sequence sequence nom mystery swine disease gene
74311-2,prrsv orf5 gene next generation sequencing sequence sequence nom (isol)
93839-9,histoplasma capsulatum igg ab [units/volume] in cerebral spinal fluid by immunoassay
93839-9,hitoplasm caslatum igg ab [unts/olume] pt in cerebra spinalfuid by immunosa
93839-9,histoplasma capsulatum igg ab [units/volume] in suds cerebral spinal fluid by immunoassay
93839-9,h capsul igg csf ia-acnc
93839-9,h capsul igg csf ia-acnc
93839-9,csf capsul igg h ia-acnc
93839-9,h. capsulatum igg ia qn (csf)
93839-9,(csf) capsulatum igg ia qn h.
93839-9,ia capsulatum igg h. qn eia (csf)
31395-7,filovirus ab [units/volume] in serum
31395-7,in quant ab units/volume] filovirus serum
31395-7,infectiousdisease filovrus ab [units/volume]i serum
31395-7,filovirus ab ser-acnc
31395-7,filovrus ab ser-acnc
31395-7,filovirus ab ser-acnc
31395-7,filovirus ab qn (s)
31395-7,filovirus ab qn (s)
31395-7,(s) ab qn filovirus
65363-4,glutathione [moles/volume] in blood
65363-4,[moles/volume] glutathione in bld
65363-4,inblood [moles/olume] glutathione
65363-4,glutathione bld-scnc
65363-4,bldcc gutathione
65363-4,bld-scnc quantitative glutathione
65363-4,glutathione (bld) [moles/vol]
65363-4,[moles/v] glutathine(blood)
65363-4,[moles/vol] (bld) glutathione
47355-3,deprecated streptococcus pneumoniae 5 igg ab [ratio] in serum --2nd specimen/1st specimen
47355-3,deprecated streptococcus acute specimen pneumoniae 5 igg ab [ratio] in serum --2nd specimen/1st specimen
47355-3,depecated streptoocs pneuoniae  igg ab [ratio in erum --2nd spcimn1st secimen
47355-3,deprecated s pneum5 igg 2:1 ser-rto
47355-3,2:1 s neum5 ig deprecaed ser-rto
47355-3,2:1 s pnm5ig deprecated serum-rto
47355-3,s. pneumoniae 5 igg 2nd specimen/1st specimen (s) [ratio]
47355-3,s. aby pneumonie 5 igg 2nd specime/1st specimen (s) [ratio]
47355-3,2nd pneumoniae 5 igg s. immunoglobulin g specimen/1st specimen (s) [ratio]
51817-5,coxsackievirus b igg ab [units/volume] in serum by immunoassay
51817-5,coxsackievrus b aby igg ab [units/volume] in erm by immunasa
51817-5,coxsackievirus b igg ab [units/volume] in serum by coxsackie immunoassay
51817-5,cv b igg ser ia-acnc
51817-5,e bgg cv ia-acn
51817-5,gg b cv seria-acnc
51817-5,coxsackievirus b igg ia qn (s)
51817-5,cxackeviu b igg iaqn coxsackie virus (s)
51817-5,coxsackievirus b iggia qn (s)
71881-7,methemoglobin/hemoglobin.total [pure mass fraction] in capillary blood
71881-7,methemoglobin/hemoglobin.total [pure capillary fraction] methgb in mass blood
71881-7,mehemoglobi/emoglobin.toal [pue mss raction] in capillary blood
71881-7,methgb mfr.df bldc
71881-7,methgb mfr.df bldc
71881-7,methgb bldc mfr.df
71881-7,methemoglobin (bldc) [pure mass fraction]
71881-7,methemoglobin (bldc) [pure mass fraction]
71881-7,ethemoglobin (ldc) pure mass fraction]
32582-9,phenylpropionylglycine [presence] in urine
32582-9,urine [pesence] random in phnylpropinylgyine
32582-9,phenylpropionylglycine [ql] in urine
32582-9,ppg ur ql
32582-9,ur ppg presence
32582-9,ordinal ppg ur ql
32582-9,phenylpropionylglycine ql (u)
32582-9,qual phenylpropionylglycine ql (u)
32582-9,urn phenylpropionylglycine (u) ql
82845-9,campylobacter jejuni iga and igg and igm panel - serum
82845-9,caplobater an qnt ia andigg jejuni igm panel - seru
82845-9,campylobacter immune globulin g jejuni iga and igg and igm panel - serum
82845-9,c jejuni iga+igg+igm pnl ser
82845-9, jejun ig+igg+igm pnl ser
82845-9,c jejuni immune globulin m ia+gg+igm serum pnl
82845-9,c. jejuni iga and igg and igm panel (s)
82845-9,c. jejuni iga and igg and igm panel (s) random
82845-9,igm jejuni iga and igg and c. panel (s)
58409-4,other cells/leukocytes in blood by automated count
58409-4,other boo in cels/leukocytes by autatedcount
58409-4,other cells/leukocytes hematology/cell counts in blood automated by count
58409-4,other cells nfr bld auto
58409-4,other auto nfr bld lkcs cells
58409-4,other cells auto blood nfr
58409-4,other cells/leukocytes auto (bld)
58409-4,other cels/leukocytes auto (bld
58409-4,other cells/leukocytes auto whole blood (bld)
100995-0,laceyella sacchari igg ab [presence] in serum
100995-0,ab[presence] sacchar igg laceella n serum
100995-0,laceyell sacchariigg ab microbiology [esence] in seum
100995-0,laceyella sacchari igg ser ql
100995-0,laceyella ql microbiology igg ser sacchari
100995-0,laceylla sacchar igg se ql
100995-0,laceyella sacchari igg ql (s)
100995-0,laceyella presence igg sacchari (s)
100995-0,laceyella sacchari ig presence immunoglobulin g (s)
96567-3,toxocara sp igg ab [presence] in ocular fluid by immunoassay
96567-3,oular sp i b [ql in toxcaa flid by imunoaay
96567-3,toocarasp igg b [presene] antibodies in ocular flid by mmunoasay
96567-3,toxocara igg ocflu ql ia
96567-3,toxocara pt ocflu igg ql ia
96567-3,toxocara ia ocflu ql igg
96567-3,toxocara sp igg ia ql (ocular fluid)
96567-3,ql sp igg ia toxocara (ocular fluid)
96567-3,toxocara spigg ia q (ocular flid)
7817-0,borrelia burgdorferi igg ab [units/volume] in serum
7817-0,borrelia burgdorferi igg ab [units/volume] in serum
7817-0,borrelia burgdorferi igg ab [units/volume] antby in ser
7817-0,b burgdor igg ser-acnc
7817-0,bburgdor iggsr-cnc antby
7817-0,igg bugdor microbiology ser-acc
7817-0,b. burgdorferi igg qn (s)
7817-0,b. burgdorferi igg qn antby (s)
7817-0,b. brgdorferi igg qn (s)
96400-7,retinol binding protein/creatinine [mass ratio] in 24 hour urine
96400-7,retinol urine protein/creatinine [mass mass ratio ratio] in 24 hour binding
96400-7,retinol binding protein/creatinine 24 ratio] in [mass rbp hour urine
96400-7,retinol bind prot/creat 24h ur
96400-7,rtinol bid prot/creat 2h r
96400-7,retinol bind prot/creat 24h ur
96400-7,retinol binding protein/creatinine (24h u) [mass ratio]
96400-7,[mass binding protein/creatinine (24h u) retinol ratio]
96400-7,retinol bining rotein/cretinine(24h u) [mass rati]
35702-0,acid hemolysis fraction in blood
35702-0,acid hemolysis fraction in bld
35702-0,acid hemolysis fraction in bld
35702-0,acid hemolysis nfr bld
35702-0,bld hemolysis nfr acid
35702-0,nfr hemolysis acid bld ham's acid
35702-0,acid hemolysis (bld)
35702-0,hemlyss(bld) acid
35702-0,hemolysis acid (bld)
73494-7,buspirone induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73494-7,buspirone nduced platelet im a [presence] i ser rplasma y immune globulin m fow cytometry (fc
73494-7,uspirone induce plateet gm b [presence] in ser or plama b flow cytometry (fc)
73494-7,buspirone ind plt igm serpl ql fc
73494-7,serum or plasma ind plt igm buspirone ql fc
73494-7,serpl ind plt im buspirone qlfc
73494-7,buspirone induced platelet igm fc ql
73494-7,buspirone iduced platelet igm fcql
73494-7,buspirone induced platelet igm fc ordinal ql
19283-1,benzodiazepines cutoff [mass/volume] in urine for screen method
19283-1,benzodiazepines cutoff for in uine [massvolu] sceen method
19283-1,benzodiazepines cutoff [mass/volume] in urine for screen method
19283-1,benzodiaz cto ur scn-mcnc
19283-1,enzodiaz sc-mcnc ctour
19283-1,quan benzodiaz ur cto scn-mcnc
19283-1,benzodiazepines cutoff screen (u) [mass/vol]
19283-1,cutoff benzodiazepines screen (u) drugs [mass/vol]
19283-1,benzodiazepies screen cutoff (u) [m/vol]
61031-1,7-aminoclonazepam [presence] in specimen
61031-1,7-aminoclonazepam specimen i [pesence]
61031-1,7-inoclnazepm [presence in secimen
61031-1,7aminoclonazepam spec ql
61031-1,7aminoclonazepam spec presence
61031-1,presence sec 7aminoclonazepam
61031-1,7-aminoclonazepam ql (specimen)
61031-1,7-aminoclonazepam presence (specimen)
61031-1,(specimen) ql 7-aminoclonazepam 7aminoclonazepam
2849-8,propionate (c3) [mass/volume] in serum
2849-8,mass concentration propionate (c3) ser in [mass/volume]
2849-8,propionate propioic acid in (c3)[mass/volume] erum
2849-8,propionate ser-mcnc
2849-8,opionate sermcnc
2849-8,quant ser-mcnc propionate
2849-8,propionate (c3) (s) [mass/vol]
2849-8,proionate (c3) (s)[mas/vol]
2849-8,random [mass/vol] c) s) propinate
3762-2,mesterolone [mass/volume] in urine
3762-2,mesteolone [mass/vlume] in urin
3762-2,mesterolone urine in [mass/volume] urn
3762-2,mesterolone ur-mcnc
3762-2,quantitative ur-mcnc mesterolone
3762-2,ur-mcnc mesterolone
3762-2,mesterolone (u) [mass/vol]
3762-2,esteolone [assvol] (u)
3762-2,drug/toxicology msterolone (u) [mass/vo]
22755-3,haemophilus influenzae b ab [mass/volume] in serum
22755-3,b ifluenzae haemohilus ab [mass/olume]n seum
22755-3,haemophilus haem influ b influenzae b ab [mass/volume] in serum
22755-3,haem influ b ab ser-mcnc
22755-3,haem influ b ab ser-mcnc autoantibodies
22755-3,haem influ ser-mcnc quant ab b
22755-3,h. influenzae b ab (s) [mass/vol]
22755-3,h. fueae a b (s) [massvol] sr
22755-3,quant .influenzae b ab (s) [massvol]
76073-6,fungus identified in nose by culture
76073-6,inns identifed fugus bculture cultures
76073-6,ngus innoseb identified culture
76073-6,fungus nose cult
76073-6,fungus nose cult nasal
76073-6,fungus nose cult
76073-6,fungus identified cx nom (nose)
76073-6,funus identified cx nom (nose)
76073-6,cultures funus cxnom(noe) identified
22482-4,rickettsia rickettsii igg ab [titer] in serum
22482-4,rickettsia rickettsii igg ab serum [titer] in serum
22482-4,rikettsia rickettsii igg b [tie] n seru
22482-4,r rickettsi igg titr ser
22482-4,ser rickettsi igg titr r
22482-4,r ig ricketti titr serum
22482-4,r. rickettsii igg (s) [titer]
22482-4,r. rickettsii igg (s) [titer]
22482-4,r. igg rickettsii (s) [titer]
23133-2,histoplasma farciminosum ab [presence] in serum by immunoassay
23133-2,histoplasma farciminosum ab by in serum [presence] immunoassay
23133-2,hsoplasmafarciminosum ab [presence] in serum h capsul farci by immnoassay
23133-2,h capsul farci ab ser ql ia
23133-2,h ql ai abser capsul ia
23133-2,h se frci ab capsul presence ia
23133-2,h. farciminosum ab ia ql (s)
23133-2,h. farciminosum (s) ia presence ab
23133-2,h capsul farci h. farciminosum ab ia ql (s)
59223-8,prostate specific ag [mass/volume] in peritoneal fluid
59223-8,rstat specifc ag flid n pertoneal [mass/volume]
59223-8,p-30 antigen prostate specific ag [mass/volume] in peritoneal fluid
59223-8,psa prt-mcnc
59223-8,prt-mcnc psa
59223-8,quant pa prt-mnc
59223-8,prostate specific ag (periton fld) [mass/vol]
59223-8,postate (perio a specific fld) [massvol]
59223-8,ag specific prostate (periton fld) [mass/vol]
5243-1,measles virus ab [titer] in serum by complement fixation
5243-1,mesles rusab tir] inserum by complement fixation
5243-1,measles virusab [titr] in serum by complementixatin titer
5243-1,mev ab titr ser cf
5243-1,mev cf autoantibody titr serum ab
5243-1,ab me titser cf
5243-1,mev ab cf (s) [titer]
5243-1,mev ab [titer] (s) cf
5243-1,mev (s) cf ab [titer]
105631-6,aerococcus viridans dna [presence] in specimen by naa with probe detection
105631-6,aerococcus viridans dna amplif [presence] in specimen by naa with probe detection
105631-6,probe viridans dna [presence] in specimen by naa with aerococcus detection
105631-6,aerococcus virid dna spec ql naa+probe
105631-6,aercoccus virid dna spec 3 self-sustaining sequence replication ql na+robe
105631-6,aerococcus virid dna spec presence naa+probe 3 self-sustaining sequence replication
105631-6,aerococcus viridans dna naa+probe ql (specimen)
105631-6,dna viridans aerococcus naa+probe ql (specimen)
105631-6,aeococusviridans na naa+robe ql specimen)
2810-0,porphobilinogen [mass/time] in 24 hour urine
2810-0,heme porphobilinogen [mass/time] in 24 hour urine
2810-0,porphobilinogen [mass/time] in hour 24 urine
2810-0,pbg 24h ur-mrate
2810-0,pbg 24h r-mrate
2810-0,pbg 24h ur-mrate
2810-0,porphobilinogen (24h u) [mass/time]
2810-0,[mass/time] (24h u) porphobilinogen
2810-0,porphobilingen(24h [masstie]
80515-0,kappa light chains.free [mass/volume] in serum by nephelometry
80515-0,light kappa chains.free [mass/volume] in quan serum bynephelometry
80515-0,nephelometry light fr chains.free [mass/volume] in ser by kappa
80515-0,kappa lc free ser neph-mcnc
80515-0,quant kappa lc free ser neph-mcc
80515-0,kappa lc free ser neph-mcnc
80515-0,immunoglobulin light chains.kappa.free nephelometry (s) [mass/vol]
80515-0,immunoglobulin light [mass/vol] nephelometry light scattering (s) chains.kappa.free
80515-0,mmglobulinlight chains.kapa.ree nephelometry light scattering (s) [mss/vol]
70902-2,additional concerns - fait-f [facit]
70902-2,additional concerns [facit] fait-f -
70902-2,functional assessment of chronic illness therapy ddtionalcocerns - fait-f [faci]
3586-5,doxylamine [presence] in urine
3586-5,urine [presence] in doxylamine
3586-5,urine [prencein ur doxylamine
3586-5,doxylamine ur ql
3586-5,ql ur doxylamine
3586-5,oymie ur ql
3586-5,doxylamine ql (u)
3586-5,oylamine q drug/toxicology u)
3586-5,dxylamine ql ()
1681-6,beta hydroxybutyrate dehydrogenase [enzymatic activity/volume] in blood
1681-6,hydroxybutyrate beta dehydrogenase [enzymatic activity/volume] in bld
1681-6,beta hydroxybtyrate dehydrogenase [nzymtic activityolume] n blood
1681-6,b-oh-butyr dehydrog bld-ccnc
1681-6,b-oh-butyr dehydrog bld-ccnc
1681-6,b-oh-butyr dehydrog b-oh-butyr bld-ccnc
1681-6,beta hydroxybutyrate dehydrogenase (bld) [catalytic activity/vol]
1681-6,beahydroxybutyrate deydrogenase (bl[catalytic activity/vo
1681-6,blood [atalytic hydoxybutrateehydrognase (bld) beta activity/vol]
76770-7,trace elements panel - hair
76770-7,trace elements panel - hair
76770-7,elemens pan trac panl - hair
76770-7,trace elements pnl hair
76770-7,trace elements hair pnl
76770-7,pnl elements trace ha
76770-7,trace elements panel (hair)
76770-7,trace elements pnl trace elements panel hir)
76770-7,tace elements panel (har)
97930-2,sindbis virus rna [presence] in specimen by naa with probe detection
97930-2,idbis virus rna presece detecio specien by aa with proe in
97930-2,sindbis nasba virus rna [presence] in specimen by naa with probe detection
97930-2,sinv rna spec ql naa+probe
97930-2,sinv rna qual spec ql naa+proe
97930-2,sinv rna spec pcr ql naa+probe
97930-2,sindbis virus rna naa+probe ql (specimen)
97930-2,naa+probe virus rna sindbis presence (specimen)
97930-2,sindbis virus rna naa+probe ql (specimen) infectious disease
17577-8,ganglioside gq1a igm ab [presence] in serum
17577-8,ganglioside gq1a serum ab [presence] in igm
17577-8,[presence] ql gq1a igm ab ganglioside in serum
17577-8,gq1a gangl igm ser ql
17577-8,gq1a igm gangl point in time ser ql
17577-8,gq1a gangl igm ser presence
17577-8,ganglioside gq1a igm ql (s)
17577-8,ganglioside gq1a igm ql (s) pr
17577-8,ganglioside gq1a ql ordinal igm (s)
12732-4,interleukin 12 [units/volume] in serum or plasma
12732-4,[units/volume] 1 intereukin quant in erum or pasma
12732-4,interleukin 12 [units/volume] pl in ser or plasma
12732-4,il12 serpl-acnc
12732-4,serum or plasma-acnc il12 point in time
12732-4,l12serpl-acnc
12732-4,interleukin 12 qn
12732-4,1 interleuki qn
12732-4,interleukin qn 12 pt
97260-4,lorazepam [presence] in cord tissue by screen method
97260-4,[presence] lorazepam in cord tissue pr by screen method
97260-4,lorazepam [presence] in screen tissue by cord method
97260-4,lorazepam tissco ql scn
97260-4,tissc pr orazepam ql scn
97260-4,lorazpam tissco ql scn
97260-4,lorazepam screen ql (umb cord tissue)
97260-4,lorazepam screen presence (umb tissue) cord
97260-4,presence screen lorazpam (umb co tissu)
57920-1,"carbon dioxide, total [moles/volume] in mixed venous blood by calculation"
57920-1,"carbon dioxide, total [moles/volume] in blood venous mixed by calculation"
57920-1,"carbon carbonic anhydride mixed toal [moles/volume] n dioxide, venous blood by calculation"
57920-1,co2 bldmv calc-scnc
57920-1,bdmv co2 calc-scnc
57920-1,co2 blmv calc-scn
57920-1,co2 calc (bldmv) [moles/vol]
57920-1,[moles/vol] calc (bldmv) co2
57920-1,co2 calc blood - mixed venous (bldmv) [moles/vol]
61060-0,temazepam [presence] in urine
61060-0,temazepam in [presence] urine
61060-0,[presece] temazepa in urine
61060-0,temazepam ur ql
61060-0,temazepam ur presence restoril
61060-0,temazepam ordinal ql ur
61060-0,temazepam ql (u)
61060-0,temazepam ql (u) qual
61060-0,(u) presence temazepam qual
3454-6,cephalothin [mass/volume] in serum or plasma
3454-6,cephalothin [mass/volume] in plasma ceporacin or ser
3454-6,cephalothin in drugs [mass/volume] ser or plasma
3454-6,cephalothin serpl-mcnc
3454-6,serum elothinserpl-mcnc
3454-6,serpl-mcnc quan cephalothin
3454-6,cephalothin [mass/vol]
3454-6,ephalothin[mas/vol] serum or plasma
3454-6,[mass/vol cephalothin keflin
91765-8,entamoeba sp dna [identifier] in aspirate by sequencing
91765-8,entoebaspdna [identifier]in asprate by squencing
91765-8,entamoeba sp sequencing [identifier] amoeba in aspirate by dna
91765-8,entamoeba dna aspirate seq
91765-8,entamoeba amoeba dna aspirate seq
91765-8,entamoeba dna seq aspirate
91765-8,entamoeba sp dna sequencing nom (asp)
91765-8,entamoeba sp dna sequencing aspirate nom (asp)
91765-8,entamoeba sp dna sequencing nom (asp)
62560-8,deprecated phenx measure - cumulative lifetime physical activity
62560-8,deprecated phenx measure - cumulative pnl lifetime physical activity
62560-8,deprecated phenx measure actvty -cumulativeifetime physical activity
77380-4,human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna [interpretation] in anorectal
77380-4,hman papilloma viru 16 an 18 an 31+33+35+39+45+51+52+56+8+5+66+8 dna [nterpretati] in anorectal interpretation
77380-4,and papilloma virus 16 human hpv 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna [interpretation] in anorectal
77380-4,hpv16+18+h risk 12 dna anorectl-imp
77380-4,norecl-imp risk 12d hpv16+18+h
77380-4,hpv168+h dnanoretl-imp 12 risk
77380-4,hpv 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (anorectal) [interp]
77380-4,hpv 16an 18ad impressions dna 31+33+35+39++51+52+5+58+59++68 (anotal) [inerp]
77380-4,hpv and 16 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (anorectal) [interp]
77744-1,htlv i and ii ab band pattern [interpretation] in serum or plasma
77744-1,bandptern[interetation] i adii a hlv in serm o plasma
77744-1,htlv i and htlv i+ii ab band pattern ii ab band pattern [interpretation] in serpl
77744-1,htlv i+ii ab patrn serpl-imp
77744-1,htlv i+ii serpl-imp patrn ab
77744-1,patrnserpl-imp ab hlv+i
77744-1,htlv i and ii ab band pattern [interp]
77744-1,htlv i [interp] ii ab band serp pattern and
77744-1,htlv i and ii antibody ab band pattern [interp]
86095-7,streptococcus pneumoniae danish serotype 3 ab [units/volume] in serum by immunoassay --2nd specimen
86095-7,streptococcus pneumoniae danish serotype 3 ab [units/volume] in ser by immunoassay --2nd specimen
86095-7,streptococcus serum pneumoniae danish serotype specimen ab [units/volume] in serum by immunoassay --2nd 3
86095-7,s pneum da 3 ab sp2 ser ia-acnc
86095-7,sneum da 3 ab sp2 ser aacnc
86095-7,s 3 da pneum ab sp2 serum ia-acnc
86095-7,s. pneumoniae danish type 3 ab spec 2 ia qn (s)
86095-7,(s) pnumonie danish type 3 a spc 2ia qn s.
86095-7,s. pneumoniaedaishtype 3 ab sec 2 ia qn (s
71797-5,protoporphyrin.zinc [moles/volume] in red blood cells
71797-5,blood [moles/volume]in red protporphyrin.zinc zpp cells
71797-5,rotoporhyzic zn [oles/volume]in blodcell red
71797-5,zpp rbc-scnc
71797-5,rbc-scnc substance concentration zpp
71797-5,rbc-scnc zpp dicarboxyl porphyrin
71797-5,protoporphyrin.zinc (rbc) [moles/vol]
71797-5,[moles/vol] (rbc) protoporphyrin.zinc
71797-5,pt (rbc) protoporphyrinzinc [moles/vol]
101145-1,ustekinumab [mass/volume] in serum or plasma by immunoassay --trough
101145-1,ustekinumab [mass/volume] in ser level or plasma by immunoassay --trough
101145-1,ustekinumab [mass/volume] in serum or plasma pl by immunoassay --trough
101145-1,ustekinumab trough serpl ia-mcnc
101145-1,utekinumab trough seria-cn
101145-1,ustekinumab trough ia-mcnc serum or plasma
101145-1,ustekinumab trough ia [mass/vol]
101145-1,ustkinmb trough ia iaa [mss/vol
101145-1,ustekinumab ia trough [mass/vol]
11250-8,phenylethylmalonate [mass/volume] in serum or plasma
11250-8,in [mass/volume] phenylethylmalonate serum or plasma
11250-8,phenylethylmalonate [mass/volume] in serum plasma or serplas
11250-8,phenylethylmalonate serpl-mcnc
11250-8,phenylethylmalonate serpl-mcnc quan
11250-8,level serplmcc enylethylmalnate
11250-8,phenylethylmalonate [mass/vol]
11250-8,[mass/vol] phenylethylmalonate
11250-8,[mass/vol] phenylethylmalonate
73331-1,ipratropium induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73331-1,ipatropium nuced platelet qual igg ab serum in [presence] or plasma by flow cytometry (fc
73331-1,iratopium indue flow iggab [resence] in erum o plma b platelet cytomery (fc)
73331-1,ipratropium ind plt igg serpl ql fc
73331-1,ipratropium ind plt igg serpl ql fc
73331-1,iratropi ind plt ig serpl qlfc
73331-1,ipratropium induced platelet igg fc ql
73331-1,ipratropium induced platelet igg ql fc
73331-1,ipratropium platelet circulating platelet ab induced igg fc presence
55808-0,11-deoxycorticosterone [moles/time] in 24 hour urine
55808-0,1-doxycoicosterne oles/tie] in 24 urn hur urine
55808-0,11-deoxycorticserone [mole/time] n 24 hour urin 21-hydroxyprogesterone
55808-0,11doc 24h ur-srate
55808-0,11doc ur-srate 24h 24hr
55808-0,11doc ur-srate 24h
55808-0,11-deoxycorticosterone (24h u) [moles/time]
55808-0,u)[moles/tim (24h 11deoycorticoterone
55808-0,u) (24h 11-deoxycorticosterone [moles/time] ua
88621-8,human coronavirus oc43 rna [presence] in cornea or conjunctiva by naa with probe detection
88621-8,humancoronavirus oc43 with [pesece icornea orconjunctiva b naa rn probe etectin
88621-8,human coronavirus oc43 rna [presence] in naa or conjunctiva by nucleic acid sequence based analysis cornea with probe detection
88621-8,hcov oc43 rna corn/cnjt ql naa+probe
88621-8,naa+probe oc43 rna corn/cnjt ql hcov
88621-8,hcov oc43 rna corn/cnjt naa+probe ql
88621-8,hcov oc43 rna naa+probe ql (corn/cnjt)
88621-8,hcov oc43 rna naa+probe ql (corn/cnjt) probe with ampification
88621-8,hcov oc43 hcov oc43 presence naa+probe rna (corn/cnjt)
5745-5,thallium [mass/volume] in urine
5745-5,level thallium [mass/volume] in urine
5745-5,thllim ua [mss/volume] inuine
5745-5,thallium ur-mcnc
5745-5,ur-mcnc thallium drugs
5745-5,ur-mcnc thllim
5745-5,thallium (u) [mass/vol]
5745-5,thallium u) [mass/vol]
5745-5,[mass/vol] point in time (u) thallium
5338-9,salmonella sp ab [titer] in serum by latex agglutination
5338-9,microbiology agglutination sp ab [titer] in ser by latex salmonella
5338-9,salmonella sp ab [titer] in serum by latex salmonel agglutination
5338-9,salmonella ab titr ser la
5338-9,salmonella ab titr serum la aby
5338-9,ab salmoella titr microbiology ser la
5338-9,salmonella sp ab la (s) [titer]
5338-9,salmonella sp ab la (s) [titer]
5338-9,(s) sp ab la salmonella [titer]
15383-3,leishmania donovani igm ab [titer] in serum
15383-3,leishmania donovani igm ab [titer] sr in serum
15383-3,[titer] donovani igm ab leishmania in serum
15383-3,l donovani igm titr ser
15383-3,l antibodies donovni igm titr se
15383-3,donovani l igm titr ser
15383-3,l. donovani igm (s) [titer]
15383-3,point in time donovani l. igm (s) [titer]
15383-3,(s) donovani igm l. [titer
14537-5,measles virus ag [presence] in eye by immunofluorescence
14537-5,measles virus ag [presence] by eye in immunofluorescence
14537-5,virus measles ag [presence] in eye by ifa immunofluorescence
14537-5,mev ag eye ql if
14537-5,mev if ordinal eye presence ag
14537-5,mev ag eye if trf presence
14537-5,mev ag if ql (eye)
14537-5,immunofluorescence mevag f ql (eye)
14537-5,mev (eye) if ql ag
55160-6,adenovirus igg and igm panel - serum
55160-6,adenvus ig and igm panel panel.microbiology - srum
55160-6,adenovirus igandigm pnel - serum
55160-6,hadv igg+igm pnl ser
55160-6,ser igg+igm universallaborders pnl hadv
55160-6,had serum pnl igg+igm
55160-6,adenovirus igg and igm panel (s)
55160-6,adenovirus igg and igm panel (s) point in time
55160-6,adenovirus igg and igm panel.microbiology (s) panel
104788-5,gardnerella vaginalis rrna [presence] in genital specimen by molecular genetics method
104788-5,gardnerella vaginalis molecular [presence] in genital specimen by rrna genetics method
104788-5,gardneella vaginalis rrna [presence] i enital specim y molecular gentcs methd
104788-5,g vaginalis rrna genital ql
104788-5,g rrnaenital vaginals presence presence
104788-5,g vaginalis ql genital rrna
104788-5,g. vaginalis rrna molgen ql (genital specimen)
104788-5,gen g. vagialis rrna molge ql (genitl specimen)
104788-5,g. vaginalis point in time rrna molgen (genital ql specimen)
13559-0,flecainide [presence] in serum or plasma
13559-0,flecainide [presene] plasm or inseru
13559-0,seum [presence] in fcainide or plas
13559-0,flecainide serpl ql
13559-0,ordinal ql serpl flecainide
13559-0,flecinide ql serl
13559-0,flecainide ql
13559-0,presence flecainide
13559-0,ql flecainide
90839-2,nmdar subunit 1 ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
90839-2,mdr subunit 1 ab [ql] in cerebral spinal fluid receptors by cell bning immunofuorescent asay
90839-2,fluid subunit 1 ab [ql] in cerebral spinal nmdar by cell binding immunofluorescent assay
90839-2,nmdar1 ab csf ql cba ifa
90839-2,nmdar1 ab cs ifa ba presence
90839-2,nmdar1 ab csf cba ql ifa
90839-2,nmdar subunit 1 ab cell binding immunofluorescent assay ql (csf)
90839-2,mar (csf) ab cel binding ql imuofluorescentassay ql subunit
90839-2,nmdasbunit 1 a cell bnding immunofluorescet assay ql (cf)
35722-8,chlamydia sp dna [presence] in serum by naa with probe detection
35722-8,chlamydia sp dna [ql] in serum by naa with probe detection
35722-8,chlamydia sp dna sr [presence] in detection by naa with probe serum
35722-8,chlamydia dna ser ql naa+probe
35722-8,chlamydia dna ser amplif presence naa+probe
35722-8,chlamydia naa+probe ser ql lcr dna
35722-8,chlamydia sp dna naa+probe ql (s)
35722-8,spdna chlamyda naa+probe tma q ()
35722-8,chlamydia sp dna 3sr sr naa+probe ql (s)
29630-1,3-methylglutarate [presence] in urine
29630-1,3-methylglutarate rne [resece]n
29630-1,3-methylglutarate in [presence] urine
29630-1,3me-glutarate ur ql
29630-1,3me-glutarate ur ql
29630-1,3me-glutarate ur presence pr
29630-1,3-methylglutarate ql (u)
29630-1,(u) ql 3-methylglutarate
29630-1,3-mthyllutarat point in time presence (u)
6483-2,mycoplasma pneumoniae rrna [presence] in specimen by probe
6483-2,by pnemoniae rrna[presence] spec in spcime mcoplasm probe
6483-2,mycoplasma pneumoniae rrna [presence] in specimen by probe
6483-2,m pneumo rrna spec ql probe
6483-2,to be specified in another part of the message m pneumo ql pe rrna prob
6483-2,m pneumo rrna spec ql probe m pneumoniae
6483-2,m. pneumoniae rrna probe ql (specimen)
6483-2,m. pemonae rrnprobe ql (spcimen)
6483-2,m. pneumoniae rrna probe presence ribosomal rna (specimen)
29714-3,orientia tsutsugamushi gilliam ab [presence] in serum by immunofluorescence
29714-3,orentia tutsamushi giliam ab prsence] in ser by immunoluoresence
29714-3,oienti tsutsugamushi gilliam ql ab[presence] in srm by immuofluorscence
29714-3,o tsut gill ab ser ql if
29714-3,o tsut gill ab ser presence if
29714-3,o acif tsutgill er ab ql f
29714-3,o. tsutsugamushi gilliam ab if ql (s)
29714-3,ab tsutugamushi gilliam o. sr if ql (s)
29714-3,o. ab gilliam tsutsugamushi if ql (s) acif
38297-8,di(2-ethylhexyl) phthalate [mass/volume] in water
38297-8,"d(2ehylhexyl) phthalate mass/volume]in wate 1,2-benzenedicarboxylic acid, bis(2-ethylhexyl) ester"
38297-8,di(2-ethylhxy) phthalate [mas/voume] i water
38297-8,dehp wat-mcnc
38297-8,wat-mcnc dehp
38297-8,wat-mcnc dehp bisoflex 81
38297-8,di(2-ethylhexyl) phthalate (water) [mass/vol]
38297-8,di(2-ethylhexyl) phthalate (water) [mass/vol]
38297-8,di-sec-octyl phthalate di(ethylhxyl) phthalate (water) [mass/v]
99015-0,citrobacter koseri dna [presence] in urine by naa with probe detection
99015-0,citrobacter koseri dna [presence] dna nucleic acid probe in urine by naa with probe detection
99015-0,citrbacter oseri dna [ql in urine by naa with 3 self-sustaining sequence replication pobe dtection
99015-0,c koseri dna ur ql naa+probe
99015-0,c koseri dn ur qlnaa+probe nasba
99015-0,c koseri aa+probe ur q dna
99015-0,citrobacter koseri dna naa+probe ql (u)
99015-0,naa+probe koseri dna citrobacter ql (u)
99015-0,naa+probe koseri dna citrobacter amplif ql (u)
15445-0,avian leukosis virus ag [titer] in serum by immunoassay
15445-0,avian leukosis virus ag immunoassay in serum by [titer]
15445-0,avian leukosis virus ag infectiousdisease [titer] in serum by immunoassay
15445-0,alv ag titr ser ia
15445-0,alv ag smqn tit serum ia
15445-0,alv ag titr ser ia
15445-0,avian leukosis virus ag ia (s) [titer]
15445-0,avian leukoss virus ag ia (s) [tter]
15445-0,avian meia leukosis [titer] ag ia (s) virus
74595-0,3-hydroxybutyrylcarnitine (c4-oh) [enzymatic activity/mass] in fibroblast
74595-0,3-hydroxybutyrylcarnitine (c4-oh) catalytic content [enzymatic activity/mass] in fibroblast
74595-0,3-hydroxybutyrylcarnitine (c4-oh) [enzymatic 3oh-butyrcarn activity/mass] in fibroblast
74595-0,3oh-butyrcarn fib-ccnt
74595-0,3oh-butyrcarn fib-ccnt chemistry
74595-0,c4oh fibccnt 3oh-btyrcarn
74595-0,c4-oh (fibroblast) [catalytic activity/mass]
74595-0,c4-oh (fibroblast) [catalytic activity/mass]
74595-0,c4-oh [catalytic (fibroblast) activity/mass]
90936-6,promis parent proxy short form - life satisfaction 4a - version 1.0
90936-6,promis parent proxy short form - life satisfaction 4a - version 1.0
90936-6,promis parent proxy short form - life satisfaction 4a - version 1.0
88683-8,bacteria identified in bronchoalveolar lavage by anaerobe culture
88683-8,bacteria identified in bronchoalveolar lavage by anaero culture anaerobe
88683-8,bacteria identified pulmonology in bronchoalveolar lavage by anaerobe culture
88683-8,bacteria bal anaerobe cult
88683-8,bacteria bal anaerobe cult infectiousdisease
88683-8,bal microbiology acteria anaeobe cult
88683-8,bacteria identified anaer cx nom (bal)
88683-8,acteraentifid nom x cult anaer (bal)
88683-8,anaerobe cult bactria ideified anae cxnom(bl)
23364-3,porcine enterovirus ag [presence] in specimen by immunofluorescence
23364-3,porcine enterovirus ag by in specimen [presence] immunofluorescence
23364-3,porcine enterovir agrsece] n specin by immunofluorescence
23364-3,pev ag spec ql if
23364-3,pev ag immune fluorescence spec ql if
23364-3,pev other ag spec ql if
23364-3,porcine enterovirus ag if ql (specimen)
23364-3,porcine enterovirus ag if presence (specimen)
23364-3,porcine enterovirus (specimen) if ql qual ag
10904-1,la crosse virus igg ab [titer] in serum by immunofluorescence
10904-1,l virus crosse igg ab [titer] in ser by immunoflorescence
10904-1,la crosse virus igg ab [titer] in by ser immunofluorescence
10904-1,lacv igg titr ser if
10904-1,lacv igg titr ser if
10904-1,acv igtitr sr if
10904-1,la crosse virus igg if (s) [titer]
10904-1,la [titer] virus igg if () cose
10904-1,a if virus igg crosse (s) [titer]
62973-3,phenx - gastroesophageal reflux disease (gerd) symptoms protocol 191101
62973-3,phenx - gastroesophageal gerd protocol disease (gerd) symptoms reflux 191101
62973-3,phenx - gastroesopageal reflux pnl disease (erd) symptoms protoco 191101
62973-3,gerd symptoms proto
62973-3,gerd symptom random proto
62973-3,gerd proto symptoms gerd
76346-6,microorganism identified in isolate by ms.maldi-tof
76346-6,microorganism identified isolate in by ms.maldi-tof identity or presence
76346-6,microorganism identiied isolateby in ms.maldi-to
76346-6,microorganism islt ms.maldi-tof
76346-6,ms.maldi-tof islt microorganism
76346-6,ms.maldi-tf ilt identity or presence icroorganis
76346-6,microorganism identified ms.maldi-tof nom (isol)
76346-6,microorganism identified ms.maldi-tof nom (isol)
76346-6,ms.maldi-tof identified microorganism nom (isol)
31572-1,prrsv ab [units/volume] in serum
31572-1,prrsv ab in [units/volume] serum
31572-1,prsv ab [units/voume in erum
31572-1,prrsv ab ser-acnc
31572-1,prrsv serum-acnc a aby
31572-1,porcine reproductive and respiratory syndrome b prrsv serum-acc
31572-1,prrsv ab qn (s)
31572-1,serum prrsv qn ab (s)
31572-1,prrsv ab (s) qn
42891-2,choriogonadotropin [units/volume] in body fluid
42891-2,choriogonadotropin bdy in [uits/volume] fluid
42891-2,choriogonadotropin [units/volume] in body flu
42891-2,hcg fld-acnc
42891-2,fluid fld-acnc hcg
42891-2,fld-acnc hcg
42891-2,hcg qn (body fld)
42891-2,(od fld qn cg fd)
42891-2,fld) qn (body hcg
19353-2,barbital [presence] in urine by screen method
19353-2,barbital [presence] in urineby screen method
19353-2,veronal barbital[presece] n urine by cren mthod
19353-2,barbital ur ql scn
19353-2,ur barbital ql scn
19353-2,barbital ur presence scn urn
19353-2,barbital screen ql (u)
19353-2,arbital screen sreen ql (u)
19353-2,barbial screen point in time ql (u)
2811-8,porphobilinogen [moles/volume] in urine
2811-8,prphobilinogen substance concentration [moles/volme] in urine
2811-8,in level [moles/volume] porphobilinogen urine
2811-8,pbg ur-scnc
2811-8,quantitative pbg ur-scnc
2811-8,ur-scnc pbg
2811-8,porphobilinogen (u) [moles/vol]
2811-8,[moles/vol] (u) porphobilinogen
2811-8,porpolnogen [mols/vo] (u)
73189-3,propoxyphene+acetaminophen induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73189-3,propoyphen+actainopen induced latelet o [resence] in c209 ser igab pls by flow cytometry (fc)
73189-3,propoxyphene+acetaminophen induced or igg ab [presence] in serum platelet plasma by flow cytometry (fc)
73189-3,propoxyph+apap ind plt igg serpl ql fc
73189-3,propoxyph+apap ind plt igg serpl cosalgesic ql fc
73189-3,popoxyph+aap ind pl ig serpl q fc
73189-3,propoxyphene+acetaminophen induced platelet igg fc ql
73189-3,propoxyphene+acetaminophen acetaminoph induced platelet igg fc ql
73189-3,popoyphene+acetaminophen induced platelet igg fc ql
81743-7,th-to ab [presence] in serum by line blot
81743-7,blot ab [presence] in serum by line th-to
81743-7,in ab [presence] th-to serum by line blot
81743-7,th-to ab ser ql line blot
81743-7,ser ab th-to presence antby line blot
81743-7,th-to line ser ql ab blot
81743-7,th-to ab line blot ql (s)
81743-7,th-o anti abine blot ql )
81743-7,th-to ab line blot presence (s)
85357-2,pedv prototype and s indel strain s gene panel - specimen by naa with probe detection
85357-2,pedv prototype and ligation-activated transcription s with strain s gene panel - specimen by naa indel probe detection
85357-2,pedv prototype - s indel strain s gene panel and specimen by naa with probe detection
85357-2,pedv pro+s indel s gene pnl spec naa+pr
85357-2,pedvpr+s indel s gen naapr pec pnl
85357-2,pedv pro+s indel gene s pnl spec naa+pr
85357-2,pedv prototype and s indel strain s gene panel naa+probe (specimen)
85357-2,pedv potoype and s indel srin s gene anel naa+probe (specimen)
85357-2,pedv prototype panel s indel strain s gene and naa+probe (specimen)
2582-5,lutropin.alpha subunit [moles/volume] in serum or plasma
2582-5,lutropn.alpa subuni [mole/vlume] inserum or substance concentration lasma
2582-5,[moes/volue]i subunt lutropin.alpha erumoplasma
2582-5,a-lh serpl-scnc
2582-5,serpl-scnc a-lh
2582-5,a-lh serpl-scnc
2582-5,lutropin.alpha subunit [moles/vol]
2582-5,lutropin.alpha [moles/vol] subunit
2582-5,lutropin.alpha leutinizing hormone subunit [moles/vol]
106919-4,neutrophils/cells in bronchoalveolar lavage
106919-4,lvage bronchalveolar netrohils/ellsin
106919-4,eutropis/cells random in bronchoalveolar lavage
106919-4,neutrophils nfr bal
106919-4,neutrophil neutophil nfr bal
106919-4,netrophil nfr bal point in time
106919-4,neutrophils/cells (bal)
106919-4,(bal) neutrophils/cells neut
106919-4,neutropils/ells (bal)
26965-4,isoleucine [moles/volume] in urine
26965-4,isoleucin urine in [moles/olume
26965-4,ile isoleucine [moles/volume] in urine
26965-4,isoleucine ur-scnc
26965-4,ur-scnc isoleucine
26965-4,isoleucine ur-scnc chemistry
26965-4,isoleucine (u) [moles/vol]
26965-4,(u) isoleucine [moles/vol]
26965-4,(u) isoleucie moleso] quantitative
42571-0,urea [mass or moles/volume] in serum or plasma
42571-0,urea or [mass moles/volume] in serpl
42571-0,serp urea mass or moles/volme] in serum or plasma
42571-0,urea serpl-mscnc
42571-0,urea erpl-msnc
42571-0,serpl-mscnc urea sr
42571-0,urea [mass or moles/vol]
42571-0,ra [masor moes/vol]
42571-0,quant moes/vol] [mass or urea
41438-3,cyclospora papionis dna [presence] in specimen by naa with probe detection
41438-3,cyclospora papionis dna [ql] in specimen by naa with probe detection
41438-3,cyclpora apionis dna [ql] in specimn byna ith prb detection qbr
41438-3,c papionis dna spec ql naa+probe
41438-3,specql papions dna c n+probe amplification
41438-3,presence papionis dna qbr spec c naa+probe
41438-3,c. papionis dna naa+probe ql (specimen)
41438-3,c papiois na aa+probe ql (spcimen)
41438-3,. papionis specimen naa+probe ql dna
50693-1,influenza virus a+b ab [titer] in serum by complement fixation
50693-1,infuenza irus a+b b[titer] nseru by cmplement fixaion
50693-1,influenza virus a+b ab [titer] in ser by complement fixation
50693-1,fluav+flubv ab titr ser cf
50693-1,ser ab titr fluav+flubv cf
50693-1,fluav+lubv ab titr ser cf bird flu
50693-1,fluav+flubv ab cf (s) [titer]
50693-1,fluav+flubv ab cf (s) [titer]
50693-1,fluv+flubv ab cf (s) [titr] autoantibody
60042-9,n-acetylprocainamide [mass/volume] in blood
60042-9,n-aetlprocainaie [ss/voume] drugs bloo in
60042-9,mass concentration n-acetylprocainamide n [mass/vlume] blood
60042-9,napa bld-mcnc
60042-9,quantitative bld-mcnc napa
60042-9,bld-mcnc napa
60042-9,n-acetylprocainamide (bld) [mass/vol]
60042-9,[mass/vol] (bld) n-acetylprocainamide
60042-9,n-acetylprocainamide (bld) [mass/vol] wb
55320-6,yeast [presence] in bronchial specimen by koh preparation
55320-6,yeast [presence] in bronchial specimen by potassium hydroxide preparation koh preparation
55320-6,yeast [ql] in bronchial potassium hydroxide preparation specimn bykoh preparation
55320-6,yeast bronch ql koh prep
55320-6,yeast koh ql infectious disease bronch prep
55320-6,yeast bnch ql koh prep
55320-6,yeast koh prep ql (bronch spec)
55320-6,yeast (bronch prep ql koh spec)
55320-6,prep yeast ko prep presence (broch spec
78816-6,carisoprodol+meprobamate [presence] in blood by confirmatory method
78816-6,carisoprodol+meprobamate [presence] in gcms blood by confirmatory method
78816-6,caisoprodol+meprobamate [ql ql in bod confirmatrymethod b
78816-6,carisoprodol+meprob bld ql cfm
78816-6,ql blood carisoprodol+meprob cfm
78816-6,carisoprodol+meprob bld ql cfm equanil
78816-6,carisoprodol+meprobamate confirm ql (bld)
78816-6,ql confrm carisoprodo+meprobamate (bld)
78816-6,conirmql carisoprodol+meprobamate (bl)
3605-3,ethacrynate [presence] in urine
3605-3,ethacrynate [presence] urine in
3605-3,[ql] ethacrynate in urine drugs
3605-3,ethacrynate ur ql
3605-3,ethacrynate ur random ql
3605-3,etacrynate ql ur
3605-3,ethacrynate ql (u)
3605-3,ethacrate ql screen (u
3605-3,ethacrnate (u) ql
79272-1,3-hydroxytrimethyl-l-lysine/trimethyllysine [molar ratio] in cerebral spinal fluid
79272-1,3-hydroxytrimethyl-l-lysine/trimethyllysine [molar ratio] in spinal cerebral fluid
79272-1,cerebal [molar ratio] in 3-hydoxtrimethyl-l-ysine/triethyllysine spnal flud
79272-1,3oh-trimethyl-l-lysine/tml csf-srto
79272-1,3oh-rimthyl-l-lsine/tmlcsf-rto left
79272-1,csf-srto 3oh-trimethyl-l-lysine/tml
79272-1,3-hydroxytrimethyl-l-lysine/trimethyllysine (csf) [molar ratio]
79272-1,3-hydroxytrimethyl-l-lysine/trimethyllysine (csf) [molar ratio]
79272-1,3-hydroxytrimethyl-l-lysine/trimethyllysine [molar (csf) ratio]
59238-6,prostate specific ag free/prostate specific ag.total in body fluid
59238-6,prostate specific ag free/prostate specific ag.total in body fluid
59238-6,ag specific prostate chemistry free/prostate specific ag.total in body fluid
59238-6,psa free mfr fld
59238-6,fld chemistry free mfr psa
59238-6,mfr ree psa fd
59238-6,free psa/total psa (body fld) [mass fraction]
59238-6,psa(od psa/toal ree fld) [massfraction]
59238-6,free psa/total psa (body fld) [mass fraction] non-protein bound
12245-7,porphobilinogen [presence] in 24 hour urine
12245-7,porphoblinogen [presene] in 24 hur urn
12245-7,porphobilinogenpresence n urine screen hour 24
12245-7,pbg 24h ur ql
12245-7,24h pbg r ql
12245-7,urn pbg 24h ur ql
12245-7,porphobilinogen ql (24h u)
12245-7,porphobilinogen u) chemistry 24h q
12245-7,porphobilinogen ql u) (24h
55873-4,palmitate (c16:0)/laurate (c12:0) [molar ratio] in serum or plasma
55873-4,palmitate (c16:0)/laurate or [molar ratio] in serum (c12:0) plasma
55873-4,lmtae seru (12:0) [molar ratio] in (c160)/laurate o plasma
55873-4,palmitate/laurate serpl-srto
55873-4,serpl-srto palmitate/laurate c16:0
55873-4,palmitate/laurate plasma serpl-srto
55873-4,palmitate (c16:0)/laurate (c12:0) [molar ratio]
55873-4,palmitate pl (c16:0)/laurate (c12:0) [molar ratio]
55873-4,palmate (c16:0)/laurate (c12:0) [molr ratio] quant
73134-9,sulindac induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73134-9,sulindac induced platelet igm ab [presence] in serum or plasma by cytometry flow (fc)
73134-9,sinda induced platelet igm ab [presence] o srum in plasma by serplas flow cytometry(fc)
73134-9,sulindac ind plt igm serpl ql fc
73134-9,sulindac ind plt igm serpl ql fc
73134-9,sulindc nd lt serum or plasma igm autoantibodies ql fc
73134-9,sulindac induced platelet igm fc ql
73134-9,nced sulindac platelet igm fc ql
73134-9,sulindac fc platelet igm induced presence
50133-8,3-hydroxystearoylcarnitine (c18-oh) [moles/volume] in amniotic fluid
50133-8,3-hyroxystearoylcarnitie (c18-o) les/vlume] in amniotic substance concentration lui
50133-8,3-hydroxystearoylcarnitine in [moles/volume] (c18-oh) amniotic fluid
50133-8,3oh-stearoylcarn amn-scnc
50133-8,3oh-stearoylcarn amn-scnc
50133-8,3oh-stearoylcarn amn-scnc
50133-8,c18-oh (amn fld) [moles/vol]
50133-8,fld) (amn random c18-oh [moles/vol]
50133-8,random c8-oh [oles/ol fld (amn
96524-4,rocio virus igm ab [presence] in specimen by immunoassay
96524-4,rocio virus igm ab by in specimen [presence] immunoassay
96524-4,ocio vrus gm ab [prece] spcimen in by immunoassay
96524-4,rocio virus igm spec ql ia
96524-4,rocio virus igm ia ql spec
96524-4,ocio virus igm spec presence i
96524-4,rocio virus igm ia ql (specimen)
96524-4,rocio virus igm ia ql elfa (specimen)
96524-4,to be specified in another part of the message virus rocio igm ia ql (specimen)
9454-0,herpes simplex virus ab [titer] in cerebral spinal fluid by complement fixation
9454-0,herpes simplex virus ab [titer] in cerebral spinal fluid by antibodies complement fixation
9454-0,herpes simplex virusab [tier]in cerebral spial fixation by complement fluid
9454-0,hsv ab titr csf cf
9454-0,hsv ab titr cerebrospinal fluid cf
9454-0,hsv ab titr csf cf
9454-0,hsv ab cf (csf) [titer]
9454-0,hsv ab [titer] (csf) cf
9454-0,hsv b c (cs) [titr]
42223-8,manganese/creatinine [molar ratio] in urine
42223-8,ur [mola manganse/creatinine rati] n urine
42223-8,in pt [molar ratio] manganese/creatinine urine
42223-8,manganese/creat ur-srto
42223-8,manganee/crea ur-srto
42223-8,manganese/creat ur-srto urn
42223-8,manganese/creatinine (u) [molar ratio]
42223-8,manganese/creatinine (u) ratio] [molar
42223-8,manganese/creatinine drugs (u) [molar ratio]
40639-7,lambda light chains [presence] in serum by immunofixation
40639-7,lambda immunofixation electrophoresis by chains [presence] in ser light immunofixation
40639-7,sr lambda light chains [presence] in ser by immunofixation
40639-7,lambda lc ser ql ife
40639-7,lambda lc serum ql ife
40639-7,immunoglob lmbda lc e q ie
40639-7,immunoglobulin light chains.lambda immunofixation ql (s)
40639-7,immunoglobulin ligh chains.lambda immunofixation ql (s)
40639-7,immnoglobulin light chains.lambda ifix immunfixationql (s)
9679-2,squamous cell carcinoma ag [mass/volume] in serum or plasma
9679-2,squamous cell carcinoma point in time ag [mass/volume] in serum or plasma
9679-2,squamous or carcinoma ag [mass/volume] in ser cell plasma
9679-2,scc ag serpl-mcnc
9679-2,serpl-mcnc ag scc
9679-2,serp-mcnc ag scc
9679-2,squamous cell carcinoma ag [mass/vol]
9679-2,[mss/vol] cell carcinomag sqmous
9679-2,[mass/vol] cell carcinoma ag squamous
89906-2,chronic respiratory questionnaire self-administered individualized format [crq-sai]
89906-2,chronic rspirtory questionnaire self-administered idivialized format [crq-sai]
89906-2,chronic respiratory questionnaire pnl self-administered individualized format [crq-sai]
94512-1,staphylococcus aureus and methicillin resistant staphylococcus aureus identified in isolate or specimen by molecular genetics method
94512-1,staphylococcus aureus and methicillin resistant staphylococcus aureus identified molecular isolate or specimen by in genetics method
94512-1,staphylococcus aureus and methicillin resistant staphylococcus specimen identified in isolate or aureus by molecular genetics method
94512-1,sa + mrsa islt/spm
94512-1,sa + mrsa islt/sp sa + mrsa
94512-1,id + sa mrsa islt/spm
94512-1,staphylococcus aureus and mrsa identified molgen nom (islt/spec)
94512-1,staphylococs aureu nom msa random identified mogen ad (ist/spe)
94512-1,aureus staphylococcus and mrsa infectiousdisease identified molgen nom (slt/spec)
26046-3,5-hydroxypropafenone [moles/volume] in serum or plasma
26046-3,in [moles/volume] quan 5-hydroxypropafenone serum or plasma
26046-3,5-hydroxypropafenone plasma in serum or [moles/volume]
26046-3,5oh-propafenone serpl-scnc
26046-3,serpl-scnc 5oh-propafenone
26046-3,5oh-propafenone serpl-scnc
26046-3,5-hydroxypropafenone [moles/vol]
26046-3,[moles/vol] 5-hydroxypropafenone
26046-3,5-hydroxypropafenone [moles/vol]
14433-7,albumin/globulin [mass ratio] in cerebral spinal fluid
14433-7,albumin/globulin [mas rati] ceebral globulins in spina fluid
14433-7,abui/gloulin [massratio] i cereral fluid spin
14433-7,albumin/glob csf
14433-7,csf albumin/glob
14433-7,albumin/gob csf
14433-7,albumin/globulin (csf) [mass ratio]
14433-7,(cerebrospinal fluid) mcrto albumin/globulin [mass ratio]
14433-7,(csf) albumin/globulin [mass ratio]
53934-6,lactate dehydrogenase in peritoneal fluid/lactate dehydrogenase in serum
53934-6,serplas lactate in dehydrogenase peritoneal fluid/lactate dehydrogenase in serum
53934-6,lcate dehydrogenase in perioel serum dehydrogenase in fluid/lactte
53934-6,ldh prt/serpl
53934-6,ldh prt/erpl
53934-6,ldh prt/serpl
53934-6,ldh in peritoneal fluid/lactate dehydrogenase in serum (periton fld+s/p) [relative ratio]
53934-6,ldh in peritoneal fluid/lactate dehydrogenase in serum (periton fld+s/p) [relative ratio]
53934-6,ldh [relative peritoneal fluid/lactate dehydrogenase in serum (periton fld+s/p) in ratio]
5884-2,virus identified in cerebral spinal fluid by culture
5884-2,virus identified in cerebrospinal fl cerebral spinal flud by culure
5884-2,virus spinal in cerebral identified fluid by culture
5884-2,virus csf cult
5884-2,c&s virus csf cult
5884-2,vius csf clt
5884-2,virus identified cx nom (csf)
5884-2,microbiology vir identified cx nm (csf
5884-2,identifed vius c nom(csf)
67763-3,"hedis 2012, 2013 codes to identify physiologic monitoring tests - blood urea nitrogen (bun) (mpm-a)"
67763-3,"hedis blood urea nitrogen 2012, 201 codes t idenfy phsiologicmonitoring tests - blood urea nitrogen (bun) (mpm-a)"
67763-3,hedis tets 21 codes to identify physioogic moioring 2012 - blood urea nitrogn nit (bun) (mpm-a)
67763-3,hedis 2012-13 mpm-a bun
67763-3,bun 2012-13 mpm-a hedis
67763-3,hedis 2012-13 n2 mpm-a bun
67763-3,"hedis 2012, 2013 codes to identify physiologic monitoring tests - blood urea nitrogen (bun) (mpm-a)"
67763-3,"hedis 2012, 2013 - to identify physiologic monitoring tests codes bld urea nitrogen (bun) (mpm-a)"
67763-3,"pnl ientify 2012, 2013 code to heds physiologic monoring test- blod uea itrogen (bun) (mpma)"
22620-9,yersinia enterocolitica igg ab [units/volume] in serum
22620-9,yersinia enterocolitica igg [uitsvolume] ab in ser
22620-9,yersinia enterocolitica [units/volume] ab igg in serum
22620-9,y enterocol igg ser-acnc
22620-9,enterocol y igg serum-acnc
22620-9,iggseracnc entrocol y enterocol y
22620-9,y. enterocolitica igg qn (s)
22620-9,y. enterocolitica igg qn autoantibodies (s)
22620-9,enterocolitica y. igg arbitrary concentration qn (s)
73186-9,propranolol induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73186-9,poranolol cytometr platelet igm ab [presene] in serum autoantibodies or plasmab flo inducd (fc
73186-9,propranolol induced ab igm platelet pr [presence] in ser or plasma by flow cytometry (fc)
73186-9,propranolol ind plt igm serpl ql fc
73186-9,propranolol serplas ind plt igm fc ql serpl
73186-9,propranolol fc plt igm serpl ql ind
73186-9,propranolol induced platelet igm fc ql
73186-9,ropraolol fc platelet igm induced platelet ab.free ql
73186-9,proranolol patelet indced igm c abs l
35223-7,progesterone [mass or moles/volume] in serum or plasma
35223-7,progesterone [mass or moles/volume] serum in or plasma
35223-7,proeserone[mass or moles/volme] in ser or lama progestin
35223-7,progest serpl-mscnc
35223-7,random progest serpl-mscnc
35223-7,progest serpl-mscnc
35223-7,progesterone [mass or moles/vol]
35223-7,progesterone or [mass moles/vol]
35223-7,progesterone [mass or serp moles/vol]
27304-5,lysine [moles/volume] in urine
27304-5,point in time urine mol/volume]in lysine
27304-5,lysine urine qnt in [moles/volume]
27304-5,lysine ur-scnc
27304-5,ur-scnc lysine quan
27304-5,ur-scnc lysine chemistry
27304-5,lysine (u) [moles/vol]
27304-5,(u)[moles/vl] lysine
27304-5,moles/vo] (u) lysine ua
51924-9,neutrophil cytoplasmic ab [titer] in serum by immunofluorescence
51924-9,neutrophil cytoplasmic ab [titer] by serum in immunofluorescence
51924-9,immunofluorescence cytoplasmic ab [titer] in serum by neutrophil
51924-9,anca ab titr ser if
51924-9,ancab itr ser if immunoflour
51924-9,anc ab tit serif serology
51924-9,neutrophil cytoplasmic ab if (s) [titer]
51924-9,neutrophil cytoplasmic anca ab if (s) [titer]
51924-9,fluorescent antibody eutrpil [iter] ab f (s) cytplasmic
2949-6,sodium [moles/volume] in dialysis fluid
2949-6,qnt dilysis dium[mols/voume]in luid
2949-6,sodiu [moe/volue] n flud ialyss diaf
2949-6,sodium dial fld-scnc
2949-6,fld-scnc qnt dial sodium
2949-6,dial sodium fld-scnc substance concentration
2949-6,sodium (dial fld) [moles/vol]
2949-6,odim (dialfld) [moles/vol] dialysis fluid
2949-6,sodium (dial fld) [oles/vl]
4033-7,deprecated spironolactone [mass/volume] in urine
4033-7,deprecated spironolactone [mass/lume] in urine
4033-7,deprecated spironolactone [mass/volume] in urine
4033-7,deprecated spironolactone ur-mcnc
4033-7,spironolactone aldactone deprecated ur-mcnc
4033-7,deprecated r-mcnc spironolctone
4033-7,spironolactone (u) [mass/vol]
4033-7,(u) spironolactone [mass/vol]
4033-7,novospiroton [mass/vol] (u) spironolactone
68386-2,glomerular basement membrane igg ab [presence] in serum by immunoassay
68386-2,glomerular basement membrane igg ab [presence] gbm in serum by immunoassay
68386-2,glomerular basement membrane igg ab [presence] anti serum in by immunoassay
68386-2,gbm igg ser ql ia
68386-2,gbm ql r igg ia
68386-2,gbm igg ser ql ia
68386-2,glomerular basement membrane igg ia ql (s)
68386-2,glomerular serum basement ql igg ia membrane (s)
68386-2,glmeular (s) embrane gg ia antby ql basemet
46253-1,bordetella pertussis filamentous hemagglutinin igg ab [units/volume] in serum by immunofluorescence
46253-1,bordtellaperussis filamentous hemagglutini imunofluorescen ab[units/volume] i ser by igg
46253-1,boretell pertui filamentos hemagglutinin id igg ab [univolume imunofuoresence serum y i
46253-1,b pert fha igg ser if-acnc
46253-1,b pert ser igg fha if-acnc
46253-1,b fha pert igg ser if-acnc
46253-1,b. pertussis filamentous hemagglutinin igg if qn (s)
46253-1,b. ertssisfilamtous hemagglutinin igg quantitative if qn (s)
46253-1,b. pertussis filamentous fluoresent hemagglutinin igg if qn (s)
59703-9,lorazepam [mass/volume] in serum or plasma by confirmatory method
59703-9,lorazepam [mass/volume] in confirmatory or plasma by serum method
59703-9,loraepam[mss/voume] serum confirmation in or plasma by firatory method
59703-9,lorazepam serpl cfm-mcnc
59703-9,loraepamsrpl cfm-mcnc
59703-9,lorazepam serum or plasma drugs cfm-mcnc
59703-9,lorazepam confirm [mass/vol]
59703-9,random lorazepam [mass/vol] confirm
59703-9,lorazepam confirm plas [mass/vol]
73792-4,infant activity during postductal oxygen saturation measurement
73792-4,measurement activity during postductal oxygen saturation infant
73792-4,inft easurement during postductal oxygen saturation activity
73792-4,infant active postductal patient
73792-4,infant active patient postductal
73792-4,h+p infant patient postductal active
73792-4,infant activity during postductal oxygen saturation measurement nom
73792-4,infant h&p.hx.lab activity during postductal oxygen saturation nom measurement
73792-4,infatactiity during oxyge postducta saturtion measurement no
78877-8,quetiapine [mass/volume] in urine by confirmatory method
78877-8,quetiapine [mass/volume] in urine qnt by confirmatory method
78877-8,quetiapine [mass/volume] in urine by quan confirmatory method
78877-8,quetiapine ur cfm-mcnc
78877-8,quetiapine cfm-mnc ur
78877-8,quetipine ur seroquel m-mcnc
78877-8,quetiapine confirm (u) [mass/vol]
78877-8,queiapine conirm (u) [ass/vol] conf
78877-8,quetiapine confirm (u) [mass/vol]
52915-6,aluminum [moles/volume] in urine
52915-6,[moles/voume] aluminum n quan urine
52915-6,aluminum [moles/volume urine in
52915-6,aluminum ur-scnc
52915-6,urscnc alminum
52915-6,ur-scnc aluminum
52915-6,aluminum (u) [moles/vol]
52915-6,aluminum (u) point in time [moles/vol]
52915-6,aluminum [moles/vl] (u)
88863-6,lung cancer antibody panel - serum or plasma by immunoassay
88863-6,lung by antibody panel - serum or plasma cancer immunoassay
88863-6,lung cancer antibody panel plas serum or - by immunoassay
88863-6,lung cancer antibody panel serpl ia
88863-6,lng caner antbody pael serpl ia
88863-6,lung cancer serpl panel antibody ia
88863-6,lung cancer antibody panel ia
88863-6,lung cacer anibody i panel
88863-6,lung cancer antibody panel ia panl
9600-8,taenia solium larva ab [presence] in serum by immunoblot
9600-8,taenia [presence] larva ab solium in serum by immunoblot
9600-8,taenia serum larva ab [presence] in solium by immunoblot
9600-8,t sol lar ab ser ql ib
9600-8,t sol lr bser ql ib blt
9600-8,t sol random lar ab ser ql ib
9600-8,t. solium larva ab ib ql (s)
9600-8,t. solium larva ib ab antby ql (s)
9600-8,t. solium (s) l larvaab
91536-3,promis pediatric item bank - depressive symptoms - version 2.0
91536-3,promis - item bank - depressive symptoms pediatric version 2.0
91536-3,romis pediaric item bank - depressiv symptoms sx 20 version -
9655-2,campylobacter jejuni ab [titer] in serum
9655-2,titered campylobacter jejuni ab [titer] in serum
9655-2,campylbater jejuniab [titer] i srum
9655-2,c jejuni ab titr ser
9655-2,c jejuni ab titr serum
9655-2,titr jejuni ttr ab c ser
9655-2,c. jejuni ab (s) [titer]
9655-2,(s) jejuni ab c. id [titer]
9655-2,c. [titer] ab (s) jejuni
1809-3,amylase.salivary [enzymatic activity/volume] in serum or plasma
1809-3,amylase.salivary [enzymatic activity/volume] in serpl
1809-3,amylase.salivary [enzymatic plasma in serum or activity/volume]
1809-3,amylase s serpl-ccnc
1809-3,qnt amylase s serpl-ccnc
1809-3,amylase s serpl-ccnc
1809-3,amylase.salivary [catalytic activity/vol]
1809-3,amylase.salivary calytic actviy/ol]
1809-3,plsm mylase.salvay[cataltiacivity/vl]
79162-4,chlordiazepoxide and norchlordiazepoxide panel - serum or plasma
79162-4,chlordizepxid and norclordiazepoxide panel - or serum plasma
79162-4,chlordiazepoxide and norchlordiazepoxide panel - desmethylchlordiazepoxide serum or plasma
79162-4,chlordiazepoxide and nor pnl serpl
79162-4,hordiazepxide and nor sepl pnl
79162-4,chlordiazepoxide and nor pnl serpl
79162-4,chlordiazepoxide and norchlordiazepoxide panel
79162-4,norchlordiazepoxide and chlordiazepoxide panel
79162-4,panl and norclodiazepoxie chlrdiaepoxid chlordiaze
71417-0,cms - psychiatric panel
71417-0,cms panel psychiatric -
71417-0,cs anl psychiatric -
6319-8,borrelia burgdorferi ab [units/volume] in body fluid by immunoassay
6319-8,borreli b/f burorferiab [units/oume] body in fluid y imunoay
6319-8,borrelia burgdorferi ab [units/volume] in body fluid by lyme disease immunoassay
6319-8,b burgdor ab fld ia-acnc
6319-8,b burgdor ab fld ia-acnc infectious disease
6319-8,b ia-acnc ab fld burgdor
6319-8,b. burgdorferi ab ia qn (body fld)
6319-8,b burgdrferi ab ia qn (bdy fld)
6319-8,b. burgdorfri ab ia qn (ody fld)
8073-9,insulin bovine ab [units/volume] in serum
8073-9,insulin ine ab [units/olue] in seum
8073-9,insulin bovine ab humulin [units/volume] in serum
8073-9,insulin bovine ab ser-acnc
8073-9,insulin bovine lente ab ser-acnc
8073-9,bovine insulin ab serum-acn
8073-9,insulin bovine ab qn (s)
8073-9,insulin bovine ab serum qn (s)
8073-9,qn(s point in time bvine b insulin
41636-2,ebola virus rna [presence] in specimen by naa with probe detection
41636-2,by virus rna [ql] in specimen ebola naa with probe detection
41636-2,ebola viru screen napresence in specimenby na wit robe detectio
41636-2,ebov rna spec ql naa+probe
41636-2,ligase chain reaction ebov rna spec presence naa+probe
41636-2,presence rna spec ebv n+probe
41636-2,ebola virus rna naa+probe ql (specimen)
41636-2,ebola (specimen) rna naa+probe ql virus ligation-activated transcription
41636-2,ebola (specimen) rna naa+probe ql virus
18243-6,mycoplasma pneumoniae igg ab [units/volume] in cerebral spinal fluid
18243-6,mycoplasm pneumoniae igg ab [units/olume] in cerebral spinal fluid
18243-6,mycoplasma pneumoniae igg ab [units/volume] in cerebral spinal myco fluid
18243-6,m pneumo igg csf-acnc
18243-6,m csf-acnc mycoplas igg pneumo
18243-6,m cerebrospinal fluid-acnc pnemoig
18243-6,m. pneumoniae igg qn (csf)
18243-6,m. pneumoniae antby igg qn (csf)
18243-6,m. pneumoniae igg qn (cerebrospinal fluid)
25499-5,adrenal cortex ab [titer] in serum by immunofluorescence
25499-5,adrenal cortex in [titer] ab serum by immunofluorescence
25499-5,arenl cortex ab [titer] b serum in immunofluorescnce
25499-5,adrenal cortex ab titr ser if
25499-5,adrenal cotex ab titr se if
25499-5,adenal cortex ab titr serum if
25499-5,adrenal cortex ab if (s) [titer]
25499-5,cortex adrenal dilution factor ab if (s) [titer]
25499-5,adrenal cortex (s) if ab [titer]
92589-1,promis short form - self-efficacy for managing symptoms 4a - version 1.0
92589-1,promis short form - slf-efficacy formanaging smptom 4 - version 1.0
92589-1,short promis form - self-efficacy for managing symptoms 4a - version 1.0
22263-8,ebola virus ab [titer] in serum
22263-8,ebola irus ab [titer] in serum
22263-8,ebola in ab [titer] virus ser
22263-8,ebov ab titr ser
22263-8,ser abitr ebov
22263-8,anti ebov ab titr serum
22263-8,ebola virus ab (s) [titer]
22263-8,ebola virus ab [titer] (s)
22263-8,ebola virus ab (s autoantibody [titer
60424-9,parainfluenza virus 4 ag [presence] in specimen
60424-9,parainfluenza virus 4 ag [presence] specimen infectious disease in
60424-9,4 virus prainfluenza ag[presece in specien
60424-9,hpiv4 ag spec ql
60424-9,hpiv4 misc ag spec ql
60424-9,presence ag spec hpiv4
60424-9,parainfluenza virus 4 ag ql (specimen)
60424-9,ordinal 4ag(specin) parainfluenzvirus
60424-9,parainfluenza virus (specimen) ag ql 4
70686-1,functional assessment of chronic illness therapy for patients with abdominal symptoms questionnaire - version 4 (facit-ad)
70686-1,functional assesment of chronic illnessheapy for patients facit with adomial symptosquestinnair - version 4(facitad)
70686-1,functional assessment of croni illness therapy for atiens with bdominalsymptos qustionnaire - vesion (facta)
42969-6,rickettsia rickettsii igm ab [presence] in serum
42969-6,[preence]in igm ab ricettsiaricettsii serum
42969-6,rickettsia rickettsi igm ab presence] in erum
42969-6,r rickettsi igm ser ql
42969-6,r rickettsii r rickettsi igm ser ql
42969-6,r ricketts igm ser ql
42969-6,r. rickettsii igm ql (s)
42969-6,r. rickettsii (s) ql igm
42969-6,. microbiology rckettii igmql s)
86575-8,measles virus rna [presence] in cerebral spinal fluid by naa with probe detection
86575-8,measlesvirus rna [presence]in cerebal y fuid pina naa with probe detection
86575-8,measles virus detection [presence] in cerebral spinal fluid by cerebrospinal fl naa with probe rna
86575-8,mev rna csf ql naa+probe
86575-8,mev rna cfql na+probe
86575-8,rna mev csf ql naa+probe
86575-8,mev rna naa+probe ql (csf)
86575-8,mev rna naa+prbe presence csf
86575-8,mev (csf) naa+pbel rna amplif
95569-0,tetrahydro-11-corticosterone [mass/time] in 24 hour urine
95569-0,tetrahydro-11-corticosterone [mass/time] in 24 hour urine
95569-0,tetrahydro-11-corticosterone [mass/time] hour 24 in urine
95569-0,th-11-corticosterone 24h ur-mrate
95569-0,th11-corticosterone 24 ur-mrate
95569-0,th-11-cortiosterone endocrinology 24h u-mrat
95569-0,tetrahydro-11-corticosterone (24h u) [mass/time]
95569-0,tetrahydro-11-corticosterone (24h u) [mass/time]
95569-0,tetahydro-11corticosteone (24h 24hr u) mass/tie]
20820-7,deprecated escherichia coli k99 [presence] in small intestine tissue by agglutination
20820-7,deprecated escherichia cli k99 [presence] in small itestinetissue y agglutination agglutnation
20820-7,k9 escheichia coli erecated [rsence] infectiousdisease in small intestine tisse by aglutintion
20820-7,deprecated e coli k99 tsmi ql aggl
20820-7,deprected e ggl k99 tsmiql arbitrary concentration coli
20820-7,deprecated coli k9smi o002 aggl ql
20820-7,e. coli k99 aggl ql (small intestine tissue)
20820-7,e. coli k99 aggl ql(mall testine isue)
20820-7,e. coli tissue) aggl ql (small intestine agglutination k99
34219-6,17-hydroxycorticosteroids/creatinine [molar ratio] in urine
34219-6,17-ydroycorticostroids/creainine [olar ratio] in urine
34219-6,quant 17-hydroxycorticosteroids/creatinine [molar ratio] in urine
34219-6,17ohcs/creat ur-srto
34219-6,ur-srto 17ohcs/creat
34219-6,17ohcs/crat 17-cs u-sro
34219-6,17-hydroxycorticosteroids/creatinine (u) [molar ratio]
34219-6,1-hydroxycorticoteroids/creatinine 17-hydroxy corticosteroids [molarrati]
34219-6,17-hydroxycorticosteroids/creatinine (u) ratio] random [molar
99073-9,kelch-like protein 11 igg ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
99073-9,kelch-like protein 11 igg ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
99073-9,kch-like protein 11 b gg [presence] in cerebralsial fluid by ell bindig immunoluorescent assy
99073-9,klhl11 igg csf ql cba ifa
99073-9,igg klhl11 cerebrospinal fluid ql cba ifa
99073-9,fa ig csfql ba klhl11 cerebral spinal fluid
99073-9,kelch-like protein 11 igg cell binding immunofluorescent assay ql (csf)
99073-9,kelc-like protein 11 igg cel bindin immnoflurescent assay presence immunoglobulin g (csf
99073-9,kelchlike rotei 11 igg cell bindingmmunofluoescent ssay ql (csf) random
8172-9,cannabinoids [presence] in serum or plasma by screen method
8172-9,cannabinoids [presence] in ser or plasma by screen method
8172-9,cannabinoids [presence] in serum or serum or plasma plasma by screen method
8172-9,cannabinoids serpl ql scn
8172-9,cannabinoids ql serpl scn
8172-9,cannabinoids serpl ql pl scn
8172-9,cannabinoids screen ql
8172-9,scr cannabinoids screen ql
8172-9,screen cannabinoids ql
4190-5,clobazam [mass] of dose
4190-5,clbazam[mass] of dose
4190-5,clobazam [mass] dose of
4190-5,clobazam dose
4190-5,dose clobazam urbadan
4190-5,dose clobazam
4190-5,clobazam (dose) [mass]
4190-5,cobzam [mass] clopax (dose
4190-5,clobazam (dose) [mass]
51201-2,palladium [mass/volume] in body fluid
51201-2,palladium [mas/volume] i body fluid
51201-2,palladium mss/volume] flui bod in
51201-2,palladium fld-mcnc
51201-2,fld-mcnc palladium
51201-2,fld-mcnc pallaum
51201-2,palladium (body fld) [mass/vol]
51201-2,palladium (body fld) [mass/vol] point in time
51201-2,fld) (body palladium [mass/vol]
58026-6,selenium [mass/volume] in nonbiological fluid
58026-6,selenium [mass/volume] quantitative in nonbiological fluid
58026-6,selenium [mass/vlume] mass concentration innonbiological flud
58026-6,selenium fld.nb-mcnc
58026-6,qnt selenium fld.nb-mcnc
58026-6,fld.nb-mcnc fld.nb selenium
58026-6,selenium (nonbiological fluid) [mass/vol]
58026-6,selenium [mass/vol] (onbiologicalfluid)
58026-6,selenium (nonbiological fluid) [mass/vol]
42953-0,snowshoe hare virus igm ab [titer] in serum
42953-0,snowsoehare in igm infectiousdisease ab [titer] virus serum
42953-0,soshehare virus igmb [titer] in serum
42953-0,sshv igm titr ser
42953-0,ser igm titr sshv
42953-0,sshv igm titr dilution factor ser
42953-0,snowshoe hare virus igm (s) [titer]
42953-0,snowshoe hare virus igm [titer] (s)
42953-0,snowshoe hare virus igm (s) [titer]
51657-5,hepatitis c virus ab [presence] in body fluid
51657-5,fld hepatitis c virus ab body in [presence] fluid
51657-5,hepatitis c ab virus [presence] in body fluid
51657-5,hcv ab fld ql
51657-5,hcv ab fld presence
51657-5,hcv ab fld ql hcv
51657-5,hcv ab ql (body fld)
51657-5,hc ab ql (bodyfld)
51657-5,hcv presence ab abs (body fld)
56537-4,tissue transglutaminase igg ab [units/volume] in serum by immunoassay
56537-4,tissue transglutaminase igg ab [units/volume] in ser by immunoassay
56537-4,tisue transglutamaseigg ab untsvlme] in ser by munoassay
56537-4,ttg igg ser ia-acnc
56537-4,autoantibody ttg igg ser ia-acnc
56537-4,ttgigg ser i-acnc
56537-4,ttg igg ia qn (s)
56537-4,ttg igg ia qn (s)
56537-4,(s) ig ia qn ttg
64119-1,third most predominant hemoglobin in dbs
64119-1,predominnt mst third hemoobin in ds
64119-1,thrd hematology/cell counts hemoglobinin pedomnnt ost dbs
64119-1,3rd most predominant hb dbs
64119-1,hb most predominant 3rd dbs
64119-1,db reominanthb rdmst
64119-1,third most predominant hemoglobin nom (dbs)
64119-1,om most prominant hemoglobin hird (dbs)
64119-1,third predominant most hemoglobin nom (dbs)
22661-3,coproporphyrin [moles/volume] in serum or plasma
22661-3,serplas coroorphin [mle/volume]i plsma or ser
22661-3,oproporphyrin [mole/volume] in erum or plasma
22661-3,copro serpl-scnc
22661-3,copro serpl serpl-scnc
22661-3,copro serpl-scnc substance concentration
22661-3,coproporphyrin [moles/vol]
22661-3,coproporphyrin hematology [moles/vol]
22661-3,chemistry [moles/vol] cproorphri
105667-0,morganella morganii dna [presence] in specimen by naa with probe detection
105667-0,morgnella specimen dna [ql] in moranii by naa with proe detection
105667-0,morganella morganii dna [presence] in with by naa specimen probe detection
105667-0,m. morganii dna spec ql naa+probe
105667-0,q morgani da 3sr sr spec m. naaprobe
105667-0,m.mrganii da spec presence naa+pob
105667-0,morganella morganii dna naa+probe ql (specimen)
105667-0,morganela morganiida naa+probe presence miscellaneous (specmen)
105667-0,morganii morganella dna naa+probe dna nucleic acid probe ql (specimen)
20936-1,pentachlorophenol [mass/mass] in tissue
20936-1,pentachlorophenol in [mass/mass] tissue
20936-1,[mass/mass] pentachlorophenol in tissue quan
20936-1,pentachlorophen tiss-mcnt
20936-1,tiss-mcnt qnt pentachlorophen
20936-1,iss-mcnt pcp pentachlorophn
20936-1,pentachlorophenol (tiss) [mass/mass]
20936-1,mas/mass] (tiss) pntachloophenol
20936-1,mass content pentachlorophenol (tiss) [mass/mass]
35044-7,variant lymphocytes [#/volume] in synovial fluid
35044-7,lymphocytes variant [#/volume] in qnt synovial fluid
35044-7,variant mphocytes [#/vlume] i synval luid joint flu
35044-7,variant lymphs # snv
35044-7,synov varint # lyphs snv
35044-7,rheumatology vaiant lymphs # snv
35044-7,variant lymphocytes (syn fld) [#/vol]
35044-7,syn fl variant lymphocytes (syn fld) [#/vol]
35044-7,variant lymphocytes syn (syn fld) [#/vol]
5001-3,enterococcus sp rrna [presence] in specimen by probe
5001-3,enterococcus sp dna probe rrna presece] secimen in by prbe
5001-3,enterococcus specimen rrna [presence] in sp by probe
5001-3,enterococ rrna spec ql probe
5001-3,entercoc rrna spec probe presence
5001-3,enterococ rrna presence spec probe ribosomal rna
5001-3,enterococcus sp rrna probe ql (specimen)
5001-3,enterococcus sp presence probe rrna (specimen)
5001-3,enterococcus qual probe rrna sp presence (specimen)
22571-4,teichoate ab [titer] in serum
22571-4,[titer] ab teichoate in serum
22571-4,teicoate serum ab [tier n seru
22571-4,teichoate ab titr ser
22571-4,teichoate ab aby titr ser
22571-4,teichoate aby ab titr ser
22571-4,teichoate ab (s) [titer]
22571-4,teichoate ab (s) [titer]
22571-4,ab antibodies teichoate (s) [titer]
77369-7,hiv 1 rna [presence] in semen by naa with probe detection
77369-7,hiv detection rna [presence] in semen by naa with smn probe 1
77369-7,with 1 rna [presence] in semen by naa hiv probe detection
77369-7,hiv1 rna smn ql naa+probe
77369-7,hiv1 rna smn ql screen naa+probe
77369-7,ql rnasmn hiv1 aa+pob ql
77369-7,hiv 1 rna naa+probe ql (sem)
77369-7,1 hiv rna naa+probe presence (sem)
77369-7,hiv type i hiv 1 rna na+robe ql (sem)
20666-4,echovirus ab [interpretation] in serum
20666-4,ab echovirus [interpretation] in serum
20666-4,echovirus ab in [interpretation] serum
20666-4,ecv ab ser-imp
20666-4,ecv ab autoantibody ser-imp
20666-4,ab cv er-imp
20666-4,echovirus ab (s) [interp]
20666-4,echovirus ab (s) [interp]
20666-4,infectiousdisease echovisab (s) [interp]
35052-0,leukocytes other [#/volume] in pleural fluid
35052-0,leura other [#olme]in leocyes fluid lung
35052-0,leukocytes other [#/volume] in pleural random fluid
35052-0,wbc other # plr
35052-0,wbc ther # plr
35052-0,wbc other # plr
35052-0,wbc other (pleur fld) [#/vol]
35052-0,[#/vol] other (pleur fld) leuc wbc
35052-0,wcother (pleur fld) [#vol
93727-6,insulin [moles/volume] in serum or plasma --post meal
93727-6,insulin [moles/volume] --post ser or plasma insul in meal
93727-6,insulin [moles/volume] in serum --post plasma or meal
93727-6,insulin p meal serpl-scnc
93727-6,insulin post pran measerpscnc p
93727-6,nsun pmeal serpl-scnc
93727-6,insulin post meal [moles/vol]
93727-6,insuli meal post [mole/vol
93727-6,insulin post quan meal [moles/vol]
55823-9,allo-tetrahydrodeoxycortisol [mass/volume] in 24 hour urine
55823-9,allo-teahodeoxycrtisol [mss/vole] in 24hr 24 hour re
55823-9,allo-tetrahydrodeoxycortisol [mass/volume] in quant 24 urine hour
55823-9,allo-th-dc 24h ur-mcnc
55823-9,allo-th-dc ur-mcnc 24h
55823-9,allo-th-dc ur-mcnc 24h
55823-9,allo-tetrahydrodeoxycortisol (24h u) [mass/vol]
55823-9,allo-tetrahydrodeoxycortisol [mass/vol] u) qnt (24h
55823-9,allo-tetrahydrodeoxycortisol (24h 1 day [mass/vol] u)
74813-7,nucleated cells [#/volume] in dialysis fluid by manual count
74813-7,uclated cells [/vole] in ialysis flid by manl count
74813-7,ulatecells[#/vlue] i dialysis luid by manual count
74813-7,nuc cell # dial fld manual
74813-7,nc el count/volume # dial fld manual
74813-7,nuc cell # dial fld anual
74813-7,nucleated cells manual cnt (dial fld) [#/vol]
74813-7,nucleated cells manual point in time cnt (dial fld) [#/vol]
74813-7,nucleated cells manual cnt # (dial fld) [#/vol]
17633-9,deprecated streptococcus pneumoniae 4 ab [units/volume] in serum --1st specimen
17633-9,deprecated streptococcus pneumococcus pneumoniae 4 ab [units/volume] in serum --1st specimen
17633-9,deprectd streptococcus pneumoae 4 ab nt/volume] in ser --1st specmen
17633-9,deprecated s pneum4 ab sp1 ser-acnc
17633-9,sp1 s pneum4ab deprecated ser-anc
17633-9,sp1 deprecated s ser-acnc ab sp1 pneum4
17633-9,s. pneumoniae 4 ab spec 1 qn (s)
17633-9,s. pneumoniae (s) ab spec 1 qn 4
17633-9,s. pneumoniae 4 ab spec 1 qn (s)
2520-5,lactate [moles/volume] in cerebral spinal fluid
2520-5,lactate [moles/volume] in cerebral spinal fluid
2520-5,lactate [moles/volume] in spinal cerebral fluid
2520-5,lactate csf-scnc
2520-5,cerebrospinal fluid-scnc lactate
2520-5,csf-scnc lactate
2520-5,lactate (csf) [moles/vol]
2520-5,[mole/vo] chemistry lactate(cerebrospinal fluid)
2520-5,lactat (csf) quantitative [moles/vol
41141-3,influenza virus a n2 ab [presence] in serum
41141-3,influenza virus a n2 ab [presence] abs in ser
41141-3,influenza virus serum n2 ab [ql] in antibody a
41141-3,fluav n2 ab ser ql
41141-3,fluav n2 ab er ql
41141-3,ab n2 fluav ser ql
41141-3,fluav n2 ab ql (s)
41141-3,ab fluavn2 l anti (s)
41141-3,fluav n2 ab (s) ql
19187-4,cancer ag 27-29 [units/volume] in pleural fluid
19187-4,ancer ag 2-29 [units/volum] in pleural fluid
19187-4,cancer ag quan 27-29 pleural in [units/volume] fluid
19187-4,cancer ag27-29 plr-acnc
19187-4,plr-acnc ag27-29 cancer
19187-4,cancer cancer ag27-29 ag27-9 plr-acnc
19187-4,cancer ag 27-29 qn (pleur fld)
19187-4,(pleur ag 27-29 qn carbohydrate antigen cancer fld)
19187-4,qn 7-29 cancera (leur fld)
21336-3,hiv 2 gp15 ab [presence] in serum by immunoblot
21336-3,hiv infectious disease 2 gp15 ab immunoblot in serum by [presence]
21336-3,hiv 2 gp15 ab [ql] in serum by antibodies immunoblot
21336-3,hiv2 gp15 ab ser ql ib
21336-3,hiv2 gp15 ab se ib q
21336-3,hiv2 ib b ser presence gp15 qualitative
21336-3,hiv 2 gp15 ab ib ql (s)
21336-3,hiv i g5 ab 2 ql (s)
21336-3,hiv ql g15 ab ib 2 (s)
51518-9,lactate dehydrogenase 4/lactate dehydrogenase.total in pleural fluid by electrophoresis
51518-9,lactate dehydrognse 4/lactate dehydrogenae.total tumor marker in pleural flud by electrophorsis
51518-9,lactate dehydrogenase pleural dehydrogenase.total in 4/lactate fluid by electrophoresis
51518-9,ldh4 cfr plr elph
51518-9,lh4 fr elph p
51518-9,ldh4 cfr pr elph
51518-9,ldh 4 elph (pleur fld) [catalytic fraction]
51518-9,fraction] elh (plur fld) [catlytic point in time ldh4
51518-9,4 ldh elph (pleur fld) [catlytic fraction]
4447-9,tolbutamide [mass] of dose
4447-9,tolbutmide[ass of dose
4447-9,tolbutamide quan [mass] ofdose
4447-9,tolbutamide dose
4447-9,qnt tolbutamid dse
4447-9,dose tolbutamide
4447-9,tolbutamide (dose) [mass]
4447-9,(doe) tolbutmid [ass]
4447-9,(doe)[mas] tolbutamide
62777-8,deprecated phenx measure - executive function
62777-8,deprecated phenx random measure - executive function
62777-8,deprecated phenx measure - fcn executive function
51903-3,chromium [mass/volume] in air
51903-3,chromium [mass/volume] in ir
51903-3,chromium air in drugs [mass/volume]
51903-3,cr air-mcnc
51903-3,air-mcnc cr
51903-3,cr air-mcnc qnt
51903-3,chromium (air) [mass/vol]
51903-3,chromium (air) [mass/vol]
51903-3,chromium (air) [mass/vol]
58413-6,nucleated erythrocytes/leukocytes [ratio] in blood by automated count
58413-6,nucleate erythroctes/leukocytes [tio]n blod coun automated b
58413-6,nuceated erytrocytes/eukocytes [raio] in bld by automated count red bld cell
58413-6,nrbc bld auto-rto
58413-6,l rbc elect auto-to
58413-6,bd nrbc aut-rto
58413-6,nucleated rbc/leukocytes auto (bld) [ratio]
58413-6,nucleated rb/leukocytes uto (bd) [ratio]
58413-6,ncleated rbc/leuocytes ato (bld) [ratio
60318-3,mexiletine [moles/volume] in specimen
60318-3,mexietne [moles/vlume] inspecimen
60318-3,mexiletine [moles/volume] specimen in
60318-3,mexiletine spec-scnc
60318-3,mexiletine spec-scnc
60318-3,eiletin spcscnc
60318-3,mexiletine (specimen) [moles/vol]
60318-3,[moles/vol] drug/toxicology (specimen) mexiletine
60318-3,mietie quant (specien) [oles/vol]
92148-6,promis item bank - dyspnea severity - version 1.0
92148-6,promis item 1.0 - dyspnea severity - version bank
92148-6,promis itm bank - dyspna severity - vron 0
31462-5,legionella pneumophila 4 igg ab [units/volume] in serum
31462-5,legionlla pnemophila 4 ab[unis/volum] immunoglobulin g igg in serum
31462-5,legionella pnemopila 4 gg ab [units/volume] in erum
31462-5,l pneumo4 igg ser-acnc
31462-5,l pneum4 igg ser-acnc
31462-5,pnumo4 eracnc igg autoantibody
31462-5,l. pneumophila 4 igg qn (s)
31462-5,l. pneumophila 4 igg qnt qn (s)
31462-5,. (s) 4 iggqn pneumphila
19402-7,clonazepam [mass/volume] in urine
19402-7,point in time clonazepam urine in [mass/volume]
19402-7,clonazepam [mass/volume] quantitative in urine
19402-7,clonazepam ur-mcnc
19402-7,clnazepam level ur-mnc
19402-7,ur-mcnc clonazepam
19402-7,clonazepam (u) [mass/vol]
19402-7,clonazepam (u) [mass/vol]
19402-7,clonazpam(u) mss/vol]
91131-3,rhinovirus rna [presence] in lower respiratory specimen by naa with probe detection
91131-3,rhinovirus rna [presence] in transcription mediated amplification lower specimen respiratory by naa with probe detection
91131-3,rhinovirus rna [ql] in lower respiratory specimen by naa detection probe with
91131-3,rhinovirus rna lower resp ql naa+probe
91131-3,pulmonary rhinovirus rnalower q esp naa+probe
91131-3,rhinovirus naa+probe rna lwer resp ql naa+probe
91131-3,rhinovirus rna naa+probe ql (lower resp)
91131-3,rhinovirus rna naa+probe ql lower id resp)
91131-3,rhinovirus rna naa+probe ql (lower resp) nucleic acid sequence based analysis
26797-1,alpha hydroxybutyrate [presence] in urine
26797-1,urine hydrybutyat [presenc] in lpha
26797-1,alpha hydroxybutyrate [presence] qualitative in urine
26797-1,a-oh-butyr ur ql
26797-1,ql pr ur a-oh-btyr
26797-1,a-oh-butyr ur ql
26797-1,alpha hydroxybutyrate ql (u)
26797-1,ydroxybutyrate alpha q (u)
26797-1,hydroxybutyrate alpha presence (u) alpha hydroxy butyrate
16171-1,cocaethylene [mass/mass] in hair
16171-1,cocaethlee [mass/mass] har in hair
16171-1,cocaethylne [mass/mass] inhair
16171-1,cocaethylene hair-mcnt
16171-1,drug/toxicology cocaethyene hair-mcnt
16171-1,hair-mcnt har coaetlene
16171-1,cocaethylene (hair) [mass/mass]
16171-1,ocaeylne [mass/mass] (hair)
16171-1,(hair) quant cocaethylene [mass/mass]
16969-8,histone h2a+h2b ab [units/volume] in serum by immunofluorescence
16969-8,histone h2a+h2b ab [units/volume] serum in h2a-h2b by immunofluorescence
16969-8,histone h2a+h2b ab [units/volume] antby ser in by immunofluorescence
16969-8,histone h2a+h2b ab ser if-acnc
16969-8,histone h2a+h2b ser ab if-acnc
16969-8,quan h2a+h2b histone ab ser if-acnc
16969-8,histone h2a+h2b ab if qn (s)
16969-8,histone h2a+h2b ab if qn (s)
16969-8,histoneh2+h2b ab f qn (s)
681-7,microscopic observation [identifier] in specimen by wright stain
681-7,microscopic observation specimen in [identifier] by wright stain
681-7,microscopic wright identifier] in specimen by osvaio stai
681-7,wright stn spec
681-7,wright stn spec
681-7,wright sec spec tn
681-7,microscopic observation wright stain nom (specimen)
681-7,microscopic observation wright nom stain (specimen)
681-7,microscopic universallaborders observation wright nom stain (specimen)
50151-0,5-hydroxytryptophan [moles/volume] in urine
50151-0,inurne [moles/volue] 5-hydroxytyptopha
50151-0,5-hydroxytryohan [molesvolume] quant in urie
50151-0,5oh-tryptophan ur-scnc
50151-0,random ur-scnc 5oh-tryptophan
50151-0,ur-cnc 5oh-trypohan
50151-0,5-hydroxytryptophan (u) [moles/vol]
50151-0,5-htp 5-hyroxytyptophan (u) [moles/vol]
50151-0,(u) 5-hydroxytryptophan [moles/vol] quant
100662-6,cortisol free and total panel - serum or plasma
100662-6,cotisol freeand toal panel serum or plasma panel.chemistry
100662-6,cortisofree total and panel- serum orplsma
100662-6,corto serpl
100662-6,serum or plasma corto
100662-6,totl serpl corto
100662-6,cortisol free and total panel
100662-6,cortisol and free total panel
100662-6,total free and cortisol panel
23171-2,leptospira interrogans sv bratislava ab [presence] in serum by agglutination
23171-2,leptosira interrogans s braisava ab presence] in serum baggutination
23171-2,leptospira interrogans sv bratislava ab by in serum [presence] agglutination point in time
23171-2,l inter brat ab ser ql aggl
23171-2,l interrat ab serum ql aggl
23171-2,l inter brat aggl serum ql ab
23171-2,l. interrogans sv bratislava ab aggl ql (s)
23171-2,l. interrogans sv bratislava ab aggl presence (s)
23171-2,l. interrogans sv b bratilva aggl presence(s)
58808-7,aspergillus sp ab [titer] in serum by hemagglutination
58808-7,by sp ab [titer] in ser aspergillus hemagglutination aspergillin
58808-7,microbiology asprgillus sp abtiter] in rum by hemagglutination
58808-7,aspergillus ab titr ser ha
58808-7,aspergillus microbiology ha titr serum ab
58808-7,spergills a tit ser ha
58808-7,aspergillus sp ab ha (s) [titer]
58808-7,aspergillus (s) random ab ha sp [titer]
58808-7,aspergillus sp a (s) [titer]
87656-5,carbofuran [mass/mass] in specimen
87656-5,carbofuran [mass/mass] in specimen
87656-5,carbouran in [mass/mass] specimen
87656-5,carbofuran spec-mcnt
87656-5,carbofurnspec-mcnt
87656-5,carbofurn secmnt
87656-5,carbofuran (specimen) [mass/mass]
87656-5,carbofuran (spemen) [ms/mass]
87656-5,carbofura (specien) [ass/mas]
18482-0,yeast [presence] in specimen by organism specific culture
18482-0,yeast cultures [presence] in specimen organism by specific culture
18482-0,yeast organism in specimen by [presence] specific culture
18482-0,yeast spec ql cult
18482-0,cult spec presence yeast screen
18482-0,cult spec ql yeast
18482-0,yeast org specific cx ql (specimen)
18482-0,org yeast specific cx ql (specimen)
18482-0,yeast cx specific org ql (specien)
35242-7,creatinine [mass or moles/volume] in dialysis fluid
35242-7,quant [mass creatinine or moles/volume] in dialysis fluid
35242-7,creatinine [mass renal or moles/volume] in dialysis fluid
35242-7,creat dial fld-mscnc
35242-7,creat dial level fld-mscnc
35242-7,creat dial fld-mscnc
35242-7,creatinine (dial fld) [mass or moles/vol]
35242-7,creatinine moles/vol] fld) [mass or (dial
35242-7,[mass fl) creainine(dial r moles/vol]
5761-2,zinc [mass/volume] in red blood cells
5761-2,zinc [mass/voume] in relod qnt cels
5761-2,[mass/volume] zinc in red bld cells
5761-2,zinc rbc-mcnc
5761-2,quant zinc rbc-mcnc
5761-2,zinc rbc-mcnc
5761-2,zinc (rbc) [mass/vol]
5761-2,zinc (rbc) [masl]
5761-2,zinc (rbc) [mass/vol]
54442-9,carnitine esters/carnitine.free (c0) [molar ratio] in urine
54442-9,carnitneses/crntine.free (c0 molar urine in ratio]
54442-9,carnitine esterscarntine.re (c0) [olar ratio] carnitine free in urine
54442-9,carn esters/c0 ur-srto
54442-9,esters/c0 carn non-protein bound ur-srto
54442-9,carn esters/c0 ur-srto
54442-9,carnitine esters/carnitine.free (c0) (u) [molar ratio]
54442-9,carnitne esters/caritnefree(c0) (u) moar c0 ratio]
54442-9,substance ratio u)[molar esters/carnitine.free (c0 canitie ratio]
4366-1,oxandrolone [mass] of dose
4366-1,mssofdos oxandrolone
4366-1,oxandrolone [mass] of dose qnt
4366-1,oxandrolone dose
4366-1,dose oxandrolone quantitative
4366-1,drug doses oxandrolone dose
4366-1,oxandrolone (dose) [mass]
4366-1,oxanolone [mss] (doe
4366-1,quant oxandrolone [mass] (dose)
84800-2,positive affect survey - self report - fixed length form - ages 18+ [nih toolbox]
84800-2,positive affectsurvy - self rport - fxed egth form pan - ges 18+[nih toolbox]
84800-2,positive affect survey len - self report - fixed length form - ages 18+ [nih toolbox]
1771-5,"aliphatic carboxylate, c14-c26.esters [mass/volume] in serum or plasma"
1771-5,"alihticcarboxylate, c14-c26.esters srm in [mass/volume] or plas"
1771-5,"aliphatic carboxylate, or [mass/volume] in serum c14-c26.esters plas"
1771-5,al carb c14-c26 ester serpl-mcnc
1771-5,al carb serpl-mcnc ester c14-c26 mass concentration
1771-5,sr a carb c14-c26 ester seplmcc
1771-5,"aliphatic carboxylate, c14-c26.esters [mass/vol]"
1771-5,"alihatic carbxylate, c14-c26.esters [mass/vol] point in time"
1771-5,"c14-c26.esters plasma carboxylate, aliphatic [mass/vol]"
22414-7,mumps virus ab [titer] in serum
22414-7,mumps virus in [titer] b ser
22414-7,ttr mumps irusab seru in [iter]
22414-7,muv ab titr ser
22414-7,muv titr ab ser
22414-7,muv ser titr ab
22414-7,muv ab (s) [titer]
22414-7,muv ab [titer] (s)
22414-7,ab serum muv (s) [titer]
53501-3,iron [moles/volume] in water
53501-3,[moles/vlume] iron in water
53501-3,[mols/olume] iron in substance concentration water
53501-3,iron wat-scnc
53501-3,wat-scnc iron
53501-3,wat-scnc iron
53501-3,iron (water) [moles/vol]
53501-3,[mols/vol] iron(wter)
53501-3,iron (water) [moles/vol]
27169-2,butyrate (c4) [mass/mass] in stool
27169-2,butyrate (c4) [mas/mass in stl stool
27169-2,butyrate (c4) [mass/mass] in stool stool = fecal
27169-2,butyrate stl-mcnt
27169-2,stl-mcnt butyrate
27169-2,stl-mcnt butyrate
27169-2,butyrate (c4) (stl) [mass/mass]
27169-2,(c4) butyrate (stl) [mass/mass]
27169-2,stl (c4) butyrate (stl) [mass/mass]
88225-8,neisseria gonorrhoeae dna [presence] in throat by naa with probe detection
88225-8,neisseriaonorrhoeae dna[ql] in hoatby naa with probe polymerase chain reaction detectin
88225-8,nisera gonorrheae dna[presnce]in throat dtect naa with probe by
88225-8,n gonorrhoea dna throat ql naa+probe
88225-8,n gonorrhoea dna naa+probe ql throat
88225-8,n gonorrhoea throat dna presence naa+probe
88225-8,n. gonorrhoeae dna naa+probe ql (throat)
88225-8,n. gonorrhoeae dna naa+probe ql (throat)
88225-8,naa+probe gonorrhoeae dna n. ql (throat)
73263-6,minoxidil induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73263-6,minoxidil induced platelet igg ab [presence] in ser or plasma by flow cytometry (fc)
73263-6,minoxidil r patelet igg a antibodies [presene]in srum induced pasma by flow cytomery (fc)
73263-6,minoxidil ind plt igg serpl ql fc
73263-6,serp indplt minxidil igg serplql fc
73263-6,minoxidil ind plt igg screen serpl ql fc
73263-6,minoxidil induced platelet igg fc ql
73263-6,minoxidil igg platelt nuced platelet ab.free fc q
73263-6,ql induced platelet igg fc minoxidil
13955-0,hepatitis c virus ab [presence] in serum or plasma by immunoassay
13955-0,epatitis c virus b [presence]in serum or plasma by enzyme immunoassay immunoassay
13955-0,hepatitis c [presence] ab virus in serum or plasma by immunoassay
13955-0,hcv ab serpl ql ia
13955-0,hcv serp ab serpl presence ia
13955-0,hcv hep c a serplql ia
13955-0,hcv ab ia ql
13955-0,hcv b ia ql
13955-0,hv ab universallaborders ia q
86591-5,toscana virus rna [presence] in serum by naa with probe detection
86591-5,oscanvius rna [prsence] in serum naa y with rob detection
86591-5,toscana virus na [prsence] in serum y na with prbe detection
86591-5,tosv rna ser ql naa+probe
86591-5,tosv naa+probe ser ql nucleic acid sequence based analysis rna
86591-5,tosv ra l serum na+probe
86591-5,toscana virus rna naa+probe ql (s)
86591-5,toscana virus rna na+prbe presence (s)
86591-5,toscana virus rna ql naa+probe (s)
41458-1,sars coronavirus rna [presence] in specimen by naa with probe detection
41458-1,sars coronavirus rna [presence] in severe acute respiratory syndrome specimen by naa with probe detection
41458-1,sars in rna [presence] coronavirus specimen by naa with probe detection
41458-1,sars-cov rna spec ql naa+probe
41458-1,sars-cov rna spec ql naa+probe
41458-1,sars-cov rna naa+probe ql spec
41458-1,sars-cov rna naa+probe ql (specimen)
41458-1,sars-cov rna naa+probe ql (specimen)
41458-1,sars-cov rna naa+probe presence (specimen)
21128-4,cadmium [mass/mass] in nail
21128-4,cadmim ail in [mass/mas]
21128-4,camium ail [mass/massin
21128-4,cadmium nail-mcnt
21128-4,nail-mcnt cadmium quant
21128-4,nail-mcnt cadmium
21128-4,cadmium (nail) [mass/mass]
21128-4,(nail) cadmium [mass/mass]
21128-4,cadmium (nail mas/mas] cd
35719-4,deprecated chlamydia sp dna [presence] in penis by probe and target amplification method
35719-4,deprecated chlamydia probe dna [presence] in penis by sp and target amplification method
35719-4,deprecated chlamydiasp na [ql] amplifiction eis by prob nd taret in method
35719-4,deprecated chlamydia dna penis ql pcr
35719-4,deprecated chlamyia dnapenis qlpcr
35719-4,deprecated chlamydia dna penis presence pcr
35719-4,chlamydia sp dna naa+probe ql (penis)
35719-4,chlamydia sp dn naa+probe ql (penis)
35719-4,chlamydia sp ql naa+probe dna (penis)
55430-3,walking distance unspecified time pedometer
55430-3,walking distance unspecified quan time pedometer
55430-3,walking distance time unspecified pedometer
55430-3,walk distance ?tm pedometer
55430-3,walk distance ?tm qnt pedometer
55430-3,alk ?tm distance edomeer
62668-9,phenx - menstrual history protocol 101101
62668-9,phnx - enstrual history prtocol01101
62668-9,phenx - menstrual 101101 protocol history
62668-9,menstrual hx proto
62668-9,menstual hx proto
62668-9,panl proto menstrualhx
14087-1,herpes simplex virus 1 igm ab [titer] in cerebral spinal fluid by immunofluorescence
14087-1,fluid simplex virus 1 igm ab [titer] in cerebral spinal herpes by immunofluorescence
14087-1,herpes simplex virus 1 igm ab cerebral in [titer] spinal fluid by immunofluorescence
14087-1,hsv1 igm titr csf if
14087-1,if igm herpes simplex virus 1 ab titr csf hsv1
14087-1,cfi spinal fluid ig titr hsv1
14087-1,hsv 1 igm if (csf) [titer]
14087-1,antby hsv ig i (cs)[titer]
14087-1,hsv igm 1 if (csf) [titer]
50384-7,"glomerular filtration rate [volume rate/area] in serum, plasma or blood by creatinine-based formula (schwartz)/1.73 sq m"
50384-7,"glomerular filtration rate [volume rate/area] in serum, plas or blood by creatinine-based formula (schwartz)/1.73 sq m"
50384-7,"glomerular filtration rat [volume rate/area] in ser, plasma or blood qnt bycininbased formua (schwarz)/1.73 sq"
50384-7,gfr serplbld schwartz-arvrat
50384-7,schwartz-arvrat serplbld quan gfr
50384-7,serplbd gf schwartz-arat
50384-7,gfr creatinine-based formula (schwartz)/1.73 sq m (s/p/bld) [vol rate/area]
50384-7,gfr creatinine-based formula (schwartz)/1.73 sq m (s/p/blood) [vol kidney rate/area]
50384-7,gfr creatinine-based formula (schwartz)/1.73 sq m (s/p/bld) plasma rate/area] [vol
5220-9,hiv 1 ab [units/volume] in serum or plasma by immunoassay
5220-9,i 1 ab o in srum [units/volume] plasma y immunoassay
5220-9,ab 1 hiv [units/volume] in serum or plasma by immunoassay
5220-9,hiv1 ab serpl ia-acnc
5220-9,hi1 ab quant sepl ia-acnc
5220-9,hiv1 ia-acnc serpl ab
5220-9,hiv 1 ab ia qn
5220-9,hiv 1 ia ab meia qn
5220-9,ab 1 hv ia qn
59254-3,acylcarnitine/acylcarnitine+carnitine free (c0) [molar ratio] in serum or plasma
59254-3,substance ratio acylcarnitine/acylcarnitinecrnitie fre (c0) in ratio] [mla erumor plas
59254-3,sum random free (c0) [molar atio]i aclcarnitine/acyarnitine+carnitine o plasma
59254-3,acylcarnitine/acyl+c0 serpl-srto
59254-3,serpl-srto acylcarnitine/acyl+c0
59254-3,acylcarnitine/acyl+c0 serpl-srto
59254-3,acylcarnitine/acylcarnitine+carnitine free (c0) [molar ratio]
59254-3,acylcaritine/acylcarnitin+cariine free c0) ratio] quantitative [molr
59254-3,quantitative acylcarnitineacylcarnitine+carnitine (c0) fre [moarratio]
62790-1,deprecated phenx measure - family history of diabetes
62790-1,deprecated phenx measure - family history pnl of diabetes
62790-1,deprecated phenx diabete - family panl hstory measue
42327-7,leukocytes [presence] in stool by methylene blue stain
42327-7,leukocytes [presence] insool by methylene bluestai
42327-7,stool [presence] in leukocytes by lkcs methylene blue stain
42327-7,wbc stl ql mb stn
42327-7,wbc stl ql mb stn
42327-7,wctlql mb stn faecal
42327-7,wbc methylene blue stain ql (stl)
42327-7,wbc mthylee bue tain ql (tl)
42327-7,wbc methlen ble stain ql (tl)
78831-5,hydroxybupropion [presence] in urine by confirmatory method
78831-5,in [presence] hydroxybupropion urine by confirmatory method
78831-5,hydroxybupropion [ql] method urine by confirmatory in
78831-5,oh-bupropion ur ql cfm
78831-5,ur oh-bupropion ql cfm
78831-5,oh-bupropion ur q cfm
78831-5,hydroxybupropion confirm ql (u)
78831-5,hydroxybupropion ql confirm ql (u)
78831-5,hydroxybupropion ql confirm (u) bupropion metabolite
10706-0,picornavirus [identifier] in stool by electron microscopy
10706-0,picornavirus [identifier] in stool by microscopy electron
10706-0,microsopy [identifer]in tool gi by electro ponavirus
10706-0,picornavirus stl em
10706-0,picornavirus gi stl em
10706-0,picornaviru point in time stl em
10706-0,picornavirus em nom (stl)
10706-0,picornavirus em identity or presence nom (stl)
10706-0,em picornavirus nom (stl)
22193-7,chlamydia trachomatis igm ab [titer] in serum
22193-7,chlamydia igmab trachomatis [titer]in serum
22193-7,chlayia antibody trachmatis igm b [titer] in seru
22193-7,c trach igm titr ser
22193-7,titr trach igm c serum
22193-7,c trach autoantibodies igm titr ser
22193-7,c. trachomatis igm (s) [titer]
22193-7,[titer] trachomatis igm (s) c. dilution factor (titer)
22193-7,gm rachomats c. (s)[titer]
38395-0,parainfluenza virus 1 ag [presence] in nasopharynx by immunofluorescence
38395-0,parainnza viu 1ag [presence] in parainfluenza type i imunofluorescnce by nasopharynx
38395-0,parainfena virus 1 ag [prsence] fluorescent antibody mmunofluorscnce by innasoarynx
38395-0,hpiv1 ag nph ql if
38395-0,hpiv1 presence nph ag para if
38395-0,hpiv1 ag immune fluorescence nph ql if
38395-0,parainfluenza virus 1 ag if ql (nph)
38395-0,arinluenza vrus 1 (nph) if l ag
38395-0,parainfluenza virus 1 ag ordinal if presence (nph)
43203-9,parainfluenza virus 1 ab [titer] in cerebral spinal fluid by complement fixation
43203-9,parainfluenza fixation ttr 1 ab [titer] in cerebral spinal fluid by complement virus
43203-9,parinfluena virus 1 ab [titer] in cerebral spinal aby lid by compleent fixation
43203-9,hpiv1 ab titr csf cf
43203-9,hpi1 abitr csf antby cf
43203-9,titr ab hpiv1 csf cf
43203-9,parainfluenza virus 1 ab cf (csf) [titer]
43203-9,[titer] virus1 ab cf (sf) paraifluenza
43203-9,parainfluenza cf 1 microbiology ab virus (csf) [titer]
47510-3,streptococcus pneumoniae danish serotype 33f igg ab [mass/volume] in serum --2nd specimen
47510-3,streptococcus pneumoniae danish eroype33f igg ab [mas/volume] in erm --2nd scimen
47510-3,streptococcus pneumoniae danish serotype 33f igg ab [mass/volume] in serum specimen --2nd
47510-3,s pneum da 33f igg sp2 ser-mcnc
47510-3,s pnum da 33f igg pser-mcc
47510-3,s pneumo pneum da 3igg sp2 ser-mcnc
47510-3,s. pneumoniae danish type 33f igg spec 2 (s) [mass/vol]
47510-3,s. pneumonae strep daish s)[mass/vol] 33f igg spe 2 type
47510-3,s. pneumoniae danish type 33f s pneum da type igg spec 2 (s) [mass/vol]
103618-5,hepatitis b virus rna [#/volume] (viral load) in serum or plasma by naa with probe detection
103618-5,hepatitis b virus rna [#/volume] (viral load) in nasba serum or plasma by naa with probe detection
103618-5,hepatiis b virus na r (viral lod i serum [#/voue] lasma amplification by naa with prbe tection
103618-5,hbv rna # serpl naa+probe
103618-5,rna hbv # serpl naa+probe
103618-5,hbv rna # serpl naa+probe
103618-5,hbv rna naa+probe [#/vol]
103618-5,n+prob[#/vl] rna probe with ampification hbv
103618-5,hepb ra hbv naa+probe [#/vol]
87407-3,golimumab ab [mass/volume] in serum or plasma by immunoassay
87407-3,serplas goimumab ab[massvome] in serum or immunoasay plasma
87407-3,plasm b[mass/vlume] in serm or golmumab by serum immnassay
87407-3,golimumab ab serpl ia-mcnc
87407-3,golimumab abs ab serpl ia-mcnc
87407-3,quan golimumab serum or plasma ab ia-mcnc
87407-3,golimumab ab ia [mass/vol]
87407-3,golimumab drug/toxicology ab ia [mass/vol]
87407-3,ia golmmb mas/vol]
97245-5,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) [presence] in cord tissue by confirmatory method"
97245-5,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) [presence] in cord tissue by confirmatory lc/ms/ms method"
97245-5,"2-ethylidene-1,5dimetyl-3,3-diphenylprolidine edd [presence] in mehod issue bycfirmtoy ord"
97245-5,eddp tissco ql cfm
97245-5,q tisso eddp cfm
97245-5,eddp tissco ql cfm
97245-5,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) confirm ql (umb cord tissue)"
97245-5,"2-ethylidene-1,5-dimethyl-3,3-iphenylyrolidine (eddp) conirm ql drug/toxicology (um cor tissue)"
97245-5,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine cord confirm ql (umb (eddp) tissue)"
92870-5,herpes simplex virus 1 dna [presence] in blood by naa with probe detection
92870-5,herpes iplex virus qual 1dna [preence] i bld by naa wit probe detecton
92870-5,virus simplx erp 1 da[presenc] in qualitative blood by naa with probe detection
92870-5,hsv1 dna bld ql naa+probe
92870-5,ql dn blood hsv1 naa+probe
92870-5,hsv1 dna ql bld naa+probe
92870-5,hsv 1 dna naa+probe ql (bld)
92870-5,hsv 1 dna na+probe ql (bl)
92870-5,hsv 1 (bld) naa+probe ql dna
93226-9,coccidioides sp ag [mass/volume] in serum or plasma by immunoassay
93226-9,coccidioies sp ag[ass/volume] in serpl y immunoassay
93226-9,coccidioides sp ag [mass/volume] in serum or enzyme immunoassay plasma by immunoassay
93226-9,coccidioides ag serpl ia-mcnc
93226-9,coccidioides ag serpl random ia-mcnc
93226-9,coccidioides ag ia-mcnc coccidiodes serum or plasma
93226-9,coccidioides sp ag ia [mass/vol]
93226-9,ia antigens sp ag coccidioides [mass/vol]
93226-9,ia sp ag coccidioides [mass/vol]
33643-8,limulus amebocyte lysate test [units/volume] in nonbiological fluid
33643-8,amebocyte limulus lysate test [units/volume] in nonbiological fluid
33643-8,liuls amecye lysate tes [unts/volume]in nonbiological fld
33643-8,lal test fld.nb-acnc
33643-8,lal test infectious disease ld.nb-acnc
33643-8,lal tetfld.nb-acc
33643-8,limulus amebocyte lysate test qn (nonbiological fluid)
33643-8,fluid) amebocyte lysate test qn (nonbiological limulus
33643-8,limulu amebocyte lysate test qn (nonbioloical fluid)
90920-0,lysophosphatidylcholine(20:0) [mass/volume] in dbs
90920-0,dbs [ass/volume] in lysophosphtidylcoline(20:0)
90920-0,in ysohsphatiylcoline(20:0)[mass/volume] filter paper dbs
90920-0,lysopc(20:0) dbs-mcnc
90920-0,sopc(20:0)dbs-cc
90920-0,dbs-mcnc lysopc(20:0)
90920-0,lysopc(20:0) (dbs) [mass/vol]
90920-0,lysopc(20:0) [mass/vol] (dbs)
90920-0,blood lysopc(20:0) [mass/vol] (dbs)
33285-8,cytomegalovirus igm ab [units/volume] in body fluid by immunoassay
33285-8,cytomegalovirus igm ab [units/volume] in body bod fluid by immunoassay
33285-8,ctomegaloirus igmb flid n body units/volume] by immunoassay
33285-8,cmv igm fld ia-acnc
33285-8,cmv igm fld ia-acnc
33285-8,cmv igm ia-acnc ld
33285-8,cmv igm ia qn (body fld)
33285-8,cmv igm iaqn body fld)
33285-8,cmv igm ia qn (body fld)
63300-8,nucleosome ab [presence] in serum by immunoassay
63300-8,nucleosoe ab [prsence] in srum b mmunoassa
63300-8,immunoassay ab [ql] in serum by enzyme immunoassay nucleosome
63300-8,nucleosome ab ser ql ia
63300-8,nucleosome ab ser presence ia enzyme immunoassay
63300-8,nuclosome ab ser ql qual ia
63300-8,nucleosome ab ia ql (s)
63300-8,nucleosome ab ia ql elfa (s)
63300-8,ia ab nucleosome ql (s)
38336-4,ethyl benzene [mass/volume] in water
38336-4,in benzene [mass/volume] ethyl point in time water
38336-4,ethyl enzene [mass/volume] in water quan
38336-4,ethyl benzene wat-mcnc
38336-4,ethyl benzene wat-mcnc
38336-4,ethyl wat-mcnc benzene
38336-4,ethyl benzene (water) [mass/vol]
38336-4,etyl bezene random (water[mass/vo]
38336-4,[mass/vol] benzene (wtr) eth quantitative
54477-5,dicarboxypalmitoylcarnitine (c16-dc) [moles/volume] in cerebral spinal fluid
54477-5,spinal (16-dc) [oles/volme] in ceebral spinal fl dicrboxypalmitoylcarntine flid
54477-5,cerebral spinal fluid dicarboxypalmitoylcarnitine (c16-dc) [moles/volume] in cerebral spinal fluid
54477-5,dicarboxypalmitoylcarn csf-scnc
54477-5,csf-cnc dicaroxypalmiolcarn
54477-5,csf-scnc dicarboxypalmitoylcarn
54477-5,c16-dc (csf) [moles/vol]
54477-5,16-dc (cerebrospinal fluid) [moles/vol]
54477-5,(csf) c16-dc level [moles/vol]
5314-0,rickettsia spotted fever group igm ab [units/volume] in serum by immunoassay
5314-0,rickettsia spotted fee grou ig ab [unisvume in sermby immunssay
5314-0,rickettsia spotted fever group igm ab [units/volume] in serum rickettsial by immunoassay
5314-0,rick sf igm ser ia-acnc
5314-0,rick sf igm ser ia-acnc
5314-0,eia igm sf rick ser ia-acnc
5314-0,r. spotted fever group igm ia qn (s)
5314-0,r. spotted fever group igm ia qn (s)
5314-0,r. spotted fever group ma qn immunoglobulin m (
9781-6,acanthamoeba sp identified in specimen by organism specific culture
9781-6,acanthamoeb sp idenified in spcimen specific organim by miscellaneous cultre
9781-6,acanthamoeba culture identified in specimen by organism specific sp
9781-6,acanthamoeba spec cult
9781-6,id acanhmeba pec cul
9781-6,acanthamoeba cult spec
9781-6,acanthamoeba sp identified org specific cx nom (specimen)
9781-6,canthamoeba sp identified rg specfic cx (secimen) om
9781-6,sp acanthamoeba identified org specific cx nom (specimen)
19526-3,lormetazepam cutoff [mass/volume] in urine for screen method
19526-3,lormetazepam cutoff [mass/volume] in urine for screen method drugs
19526-3,lormetazepam cutoff [mass/volume] in urine screen for method pt
19526-3,lormetazepam cto ur scn-mcnc
19526-3,lrmetazpam ctou pt scn-mcnc
19526-3,urn lormetazepm cto u c-mcnc
19526-3,lormetazepam cutoff screen (u) [mass/vol]
19526-3,lormetazepam screen cutoff (u) [mass/vol] mass concentration
19526-3,lormetazepam screen cutoff (u) [mass/vol]
31601-8,rickettsia spotted fever group igm ab [units/volume] in cerebral spinal fluid
31601-8,rickettsa spotted fever group igm b [unit/volum in crebal sinalfluid
31601-8,rickettsia spotted fever group cerebral ab [units/volume] in igm spinal fluid
31601-8,rick sf igm csf-acnc
31601-8,rick sf igm cerebrospinal fluid-acnc rickettsial
31601-8,rick sf gm csf-acnc
31601-8,r. spotted fever group igm qn (csf)
31601-8,r. spotted fever group igm qn (csf)
31601-8,r. spotted fever qn qnt igm group (csf)
97951-8,venezuelan equine encephalitis virus rna [presence] in specimen by naa with probe detection
97951-8,venezuelan equine encephalitis virus rna ligation-activated transcription [presence] in specimen by naa with probe detection
97951-8,venezean equin encephaliisvius rna [resence]in specimenby sda naa it probe detetion
97951-8,veev rna spec ql naa+probe
97951-8,vev presence screen spe rn na+probe
97951-8,ev rna na+probe ql spec
97951-8,veev rna naa+probe ql (specimen)
97951-8,rn veev naa+rob ql 3 self-sustaining sequence replication (pecien)
97951-8,dna probe veev rna naa+probe ql (specimen)
20648-2,isoleucine [moles/volume] in serum or plasma
20648-2,isoleucine [moles/volume] in ser or plasma
20648-2,isoeucine [oles/volum] in ser or plama
20648-2,isoleucine serpl-scnc
20648-2,quan serum or plasma-scn ioleucine
20648-2,serp-snc isoeucine
20648-2,isoleucine [moles/vol]
20648-2,[moles/vol] isoleucine
20648-2,[moles/vol] serpl isoleucine
49908-7,kappa light chains/lambda light chains [mass ratio] in 24 hour urine
49908-7,kappa light chains/lambda light chains [mass in ratio] 24 hour urine
49908-7,kappa light urine light chains [mass ratio] in 24 hour chains/lambda
49908-7,kappa lc/lambda 24h ur
49908-7,kappa lc/lambda 24h ur
49908-7,apa 24h lc/lambda ur
49908-7,immunoglobulin light chains.kappa/immunoglobulin light chains.lambda (24h u) [mass ratio]
49908-7,imunogloblin lht chains.kappa/imunogloulin hais.lambda liht (24h u [mass ratio]
49908-7,immunoglobulin light chains.kappa/immunoglobulin ratio] chains.lambda (24h u) [mass light
2044-6,carnitine [mass/volume] in semen
2044-6,carnitine [mass/volume] semen sem in
2044-6,caritine [mass/voume] in semen
2044-6,carnitine smn-mcnc
2044-6,s-mcn carnitine
2044-6,carnitine smn-mcn
2044-6,carnitine (sem) [mass/vol]
2044-6,carnitine quant (sem) [mas/vol]
2044-6,gu carnitine (sem) [mass/vol]
16344-4,alpha aminoisobutyrate [mass/volume] in amniotic fluid
16344-4,alpha aminoisobutyrate [mass/volume] in amniotic fluid
16344-4,alpha aminoisobutyrate [mass/volume] in amniotic fluid
16344-4,a-aib amn-mcnc
16344-4,a-aib amn-mcc
16344-4,a-aib amn-mcnc
16344-4,alpha aminoisobutyrate (amn fld) [mass/vol]
16344-4,alpa aminisobutyrate (amn fld) [mas/vol]
16344-4,alpha fld) (amn aminoisobutyrate [mass/vol] 2-aminoisobutyrate
25088-6,4-hydroxyphenylacetate/creatinine [molar ratio] in urine
25088-6,4-hdroxyphenlacetate/creatinine [mlar raio] iurine
25088-6,4-ydroxyphenyacetate/creatinie [molar 4oh-phenylacetate rati in urine
25088-6,4oh-phenylacetate/creat ur-srto
25088-6,4oh-phenylacetate/creat ur-srto urn
25088-6,ur-srto 4oh-phenylacetate/creat qnt
25088-6,4-hydroxyphenylacetate/creatinine (u) [molar ratio]
25088-6,4-hydroxyphenylacetate/creatinine [molar (u) ratio] substance ratio
25088-6,4-hydroxyphenycetate/creatinine (u) molar raio
14412-1,aspartate aminotransferase [enzymatic activity/volume] in gastric fluid
14412-1,activity/volume] aminotransferase [enzymatic aspartate in gastric fluid
14412-1,apartae asp aminotansferase[enzymati activty/volume] i gatric uid
14412-1,ast gast-ccnc
14412-1,gast-ccnc ast ast
14412-1,as gat-cn
14412-1,ast (gast fld) [catalytic activity/vol]
14412-1,ast (gast fld) activity/l] [cataltc
14412-1,ast (ast fld)[catalyti activiy/vol]
3946-1,phenmetrazine [mass/time] in 24 hour urine
3946-1,phenmetrzie [ass/tie] urine 24 hour in
3946-1,quantitative phenmetrazine [mass/time] urine 24 hour in
3946-1,phenmetrazine 24h ur-mrate
3946-1,ur-mrate 24h phenmetrazine
3946-1,24h phenmetrazine ur-mrate
3946-1,phenmetrazine (24h u) [mass/time]
3946-1,phenmetrazine (24h [mass/time] u)
3946-1,phenmetrain [mass/time] u) (24h
91801-1,parainfluenza virus 2 rna [presence] in upper respiratory specimen by naa with probe detection
91801-1,parainfluenza virus 2 rna [presence] qualitative in upper respiratory specimen by naa with probe detection
91801-1,parinfluenz virus 2 specimen [presene] in upper resiratoy rna by naa wih probe detection
91801-1,hpiv2 rna upper resp ql naa+probe
91801-1,hpiv2 rnauper ql resp naa+probe qual
91801-1,hpiv2 rna naa+probe resp presence upper
91801-1,parainfluenza virus 2 rna naa+probe ql (upper resp)
91801-1,resp) virus 2 rna naa+probe ql para (upper parainfluenza
91801-1,parainfluenza 2 virus rna naa+probe ql (upper resp)
105813-0,methicillin resistance mecc gene [cycle threshold #] in positive blood culture by naa with probe detection
105813-0,methicillin resistance mecc gene naa threshold #] in positive blood culture by [cycle with probe detection
105813-0,methiciln resstance mecc gen [cycle threshold #] in by blood culture strand displacement amplification positive naa with probe dtetion
105813-0,mrb mecc ct bld pos qn naa+probe
105813-0,mrb mecc t bl os q na+probe qnt
105813-0,mrb mecc ct bld qn pos naa+probe
105813-0,methicillin resistance mecc gene naa+probe (pos bld culture) [threshnum]
105813-0,methicillin resistance mecc gene naa+probe (pos blood culture) [threshnum]
105813-0,methicillin resistance culture) bact gene naa+probe (pos bld mecc [threshnum]
83110-7,progesterone [moles/volume] in serum or plasma by immunoassay
83110-7,prestrone quan [moles/volume]in serm or plasma by immunoassay
83110-7,in [moles/volume] progesterone serum or progestin plasma by immunoassay
83110-7,progest serpl ia-scnc
83110-7,ia-scnc serpl progest
83110-7,rogest serp a-cc
83110-7,progesterone ia [moles/vol]
83110-7,pogeseroneia[molesvol]
83110-7,prgesterone ia[moles/vol]
29993-3,eosinophils [presence] in sputum by wright stain
29993-3,sin [presence] insputum by wight eosinophils
29993-3,eosinophils [presence] in sputum stain wright by
29993-3,eosinophil spt ql wright stn
29993-3,stn sptqwright eosinohil
29993-3,eosinophil spt wright ql stn
29993-3,eosinophils wright stain ql (sput)
29993-3,eosinophils wright (sput) ql stain
29993-3,sinophilswright stain ql (sput
79612-8,l-homoarginine [moles/volume] in serum or plasma
79612-8,in [moles/volume] l-homoarginine ser or plasma
79612-8,l-homoarginine plasma in plsm serum or [moles/volume]
79612-8,l-homoarginine serpl-scnc
79612-8,serpl-scnc l-homoarginine
79612-8,serpl-scnc l-homoarginine
79612-8,l-homoarginine [moles/vol]
79612-8,[moles/vol] l-homoarginine
79612-8,l-homoarginine plasma [moles/vol]
78993-3,prolactin isoforms panel - serum or plasma
78993-3,prolactin isofoms lactotropin pnl ser - or lasma
78993-3,prolactin isoforms panel - serum plasma or
78993-3,prolactin isoforms pnl serpl
78993-3,random prolctin isofoms pnserp
78993-3,prolactin isoforms pnl prolacti pnl isoforms serpl
78993-3,prolactin isoforms panel
78993-3,prolactin isoforms panel pnl
78993-3,isoforms prolactin panel
13243-1,sporothrix schenckii iga ab [units/volume] in serum
13243-1,sporothrix antibodies schenckii in ab [units/volume] iga serum
13243-1,sporothrix schenckii autoantibodies iga in [units/volume] ab serum
13243-1,s schenckii iga ser-acnc
13243-1,s iga schenckii ser-acnc
13243-1,quant s schenckii iga serum-acnc
13243-1,s. schenckii iga qn (s)
13243-1,s. iga qnt schenckii qn (s)
13243-1,s scheckii igaqn ()
79514-6,n-acetyltyrosine [moles/volume] in serum or plasma
79514-6,n-acetyltyrosine [moles/volume] in serpl
79514-6,ser [mles/volue] i naetyltyrosin or quant plasma
79514-6,nat serpl-scnc
79514-6,serpl-scnc nat
79514-6,serpl-scnc nat
79514-6,n-acetyltyrosine [moles/vol]
79514-6,[moles/vol] n-aetyltyrsie
79514-6,[moles/vol] n-acetyltyrosine
3130-2,vitronectin [mass/volume] in plasma
3130-2,vitronectin [mass/volume] quan in plasma
3130-2,vitronectin quantitative in [mass/volume] plasma
3130-2,vitronectin plas-mcnc
3130-2,vitronectin pas-mcnc mass concentration
3130-2,vitronectin epibolin plas-mcnc
3130-2,vitronectin (p) [mass/vol]
3130-2,)[mass/vol] serum-spreading factor vitronectn
3130-2,s protein vitronectin (p) [mass/vol]
19689-9,deprecated psilocybin [mass/volume] in urine
19689-9,dpecated psilocybin[mass/volume] in urine
19689-9,deprecated psilocybin urine in [mass/volume]
19689-9,deprecated psilocybin ur-mcnc
19689-9,deprected pilcbin qnt ur-mc
19689-9,random deprecated psilocybin ur-mcnc
19689-9,psilocybin (u) [mass/vol]
19689-9,[mass/vol ur (u) psilocybin
19689-9,psilocybin [mass/vol] (u)
76134-6,sucrose [moles/time] in 5 hour urine --post xxx g sugar solution po
76134-6,sucro [moletime] p sug sol hur 5 in urine posxx g sugarsolutin o
76134-6,sucrose [moles/time] in 5 po urine --post xxx g quant sugar solution hour
76134-6,sucrose p sug sol 5h ur-srate
76134-6,sucroe p su sol hur-srate pst
76134-6,sucrose p sug sol h u-srate
76134-6,sucrose post unsp g sugar solution po (5 hour u) [moles/time]
76134-6,sucrose post unsp g (5 solution po sugar hour u) [moles/time]
76134-6,sucrose post unsp g sugar solution po substance rate (5 hour u) [moles/time]
44847-2,bacteria # 7 identified in urine by culture
44847-2,urn bateria 7 identfied i urin by clture
44847-2,bacteria ur # 7 identified in urine by culture
44847-2,bacteria ur cult org #7
44847-2,bacteria urcult or 7
44847-2,bacteria ur cult org id #7
44847-2,bacteria identified # 7 cx nom (u)
44847-2,nom identified # 7 cx bacteria (u)
44847-2,bacteria idenifie # 7 c nom point in time ()
101211-1,hantavirus sin nombre igg ab [presence] in serum or plasma by line blot
101211-1,hantairus sin nme igg ab [presence]n erum r plas byline blot
101211-1,abs hanavrs sinombre igg ab [pesece] in serumorplasma b line blot
101211-1,snv igg serpl ql line blot
101211-1,autoantibodies snv igg serum or plasma ql ine bot
101211-1,snv igg serpl ql lineblo
101211-1,hantavirus sin nombre igg line blot ql
101211-1,hantavirus blot serp ombre igg lin si ql
101211-1,hantavirus sin nombre igg line blot ql
4303-4,loxapine [mass] of dose
4303-4,loapine dose of [mass] quantitative
4303-4,loxapine [mass] of quantitative dose
4303-4,loxapine dose
4303-4,dose point in time loxapine
4303-4,loxapine dose
4303-4,loxapine (dose) [mass]
4303-4,loxapine [mass] (dose)
4303-4,(dose) loxapine [mass]
73536-5,alprazolam induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73536-5,alprazolam induced platelet igm ab [presence] in serpl by flow cytometry (fc)
73536-5,alpraolam inuced platelet cytoetry ab [presence] i serum or antibody pasma b flo igm (fc
73536-5,alpraz ind plt igm serpl ql fc
73536-5,alpaz ind plt m serpl l fc
73536-5,alpraz ind serpl igm plt presence fc
73536-5,alprazolam induced platelet igm fc ql
73536-5,alprazolam induced platelet igm serology fc presence
73536-5,alprazolam induced platelet igm fc antibodies ql
73460-8,celecoxib induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73460-8,celecoxib inducedlateet igm ab[presence] in srm o plasma by flow cytoet)
73460-8,celecoxib induced platelet igm ab [presence] cytometry serum or plas by flow in (fc)
73460-8,celecoxib ind plt igm serpl ql fc
73460-8,serpl nd pligm celcoxib ql c
73460-8,celecoxib plt ind igm serpl ql fc
73460-8,celecoxib induced platelet igm fc ql
73460-8,platelet iduced celecoxib gm fc platelt ql
73460-8,celecoxb inducd pltelet fc igm presence
70540-0,national comprehensive cancer network - colorectal symptom index questionnaire - 19 items (nccn - fcsi-19) [facit]
70540-0,national comprehensive cancer network - colorectal pnl symptom index questionnaire - 19 items (nccn fcsi-19) - [facit]
70540-0,national comprehensive (nccn network - colorectal symptom index questionnaire - 19 items cancer - fcsi-19) [facit]
66728-7,adenovirus dna [log #/volume] (viral load) in skin by naa with probe detection
66728-7,i dna [lg/volume] random (viral oad) denovirus ski by naa with probe dtecion
66728-7,adenovirus dna [log #/volume] probe load) in skin by naa with (viral detection
66728-7,hadv dna skin naa+probe-log#
66728-7,hadv dna naa+probe-log# skin
66728-7,hadv skinaa+probe-og# na
66728-7,adenovirus dna naa+probe (skin) [log #/vol]
66728-7,adenovirus (skin) amplification naa+probe dna [log #/vol]
66728-7,adenovirus #/vl aa+probe (skn) [log dna
47216-7,hepatitis b virus dna [#/volume] (viral load) in serum or plasma by probe and target amplification method detection limit = 200 copies/ml
47216-7,hepatitis serp b virus dna [#/volume] (viral load) in serum or plasma by = and target amplification method detection limit probe 200 copies/ml
47216-7,ptitis b 20 dna [#volume] (ira load) in ser or plasma by probe an target mplification method detectionlimt = virus copies/ml
47216-7,hbv dna # serpl naa dl=200
47216-7,hbv transcription mediated amplification dn # erpl naa dl=200
47216-7,hbv dna # serpl absolute naa dl=200
47216-7,hbv dna naa+probe dl = 200 copies/ml [#/vol]
47216-7,hbv 200 amplif naa+probe dl = dna copies/ml [#/vol]
47216-7,hv dna naaprobe quant dl = 200 copesml [#/vol]
60336-5,trimipramine [moles/volume] in specimen
60336-5,[moles/olume] trimipramine in other specimen
60336-5,trimipramine [moles/volume] specimen in
60336-5,trimipramine spec-scnc
60336-5,spec-scnc trimipramine
60336-5,trimipramine spec-scnc
60336-5,trimipramine (specimen) [moles/vol]
60336-5,rimipramine (specimen) substance concentration [oles/vol]
60336-5,triramine to be specified in another part of the message (specmen) [moles/vol]
22946-8,brucella sp ag [presence] in tissue from fetus by immunofluorescence
22946-8,brucella sp ag [presence] in fetus from tissue by immunofluorescence dfa
22946-8,brucella sp fetus [presence] in tissue from ag by immunofluorescence
22946-8,brucella ag tiss fetus ql if
22946-8,brucella fetusql tiss ag if
22946-8,ag brucella tiss fetus l if
22946-8,brucella sp ag if ql (tiss fetus)
22946-8,brucella time resolved fluorescence sp g ifql (tis fetus)
22946-8,random brcellasp ag if fets) (tiss ql
16551-4,"carbon dioxide, total [moles/volume] in capillary blood"
16551-4,"carbon dioxide, total [moles/volume] in finger stick capillary blood"
16551-4,"carbon blood total carbonic anhydride [moles/volume] in capillary dioxide,"
16551-4,co2 bldc-scnc
16551-4,co2 capillary bld bldc-scc
16551-4,ctco2 bldc-scnc co2
16551-4,co2 (bldc) [moles/vol]
16551-4,[moles/vol] (bldc) co2
16551-4,cap blood [moles/vol] bd) co2
51662-5,core respiratory allergens panel - serum
51662-5,core respratory allergens panel - ser
51662-5,core respiratory allergens panel serum -
51662-5,core resp allergen pnl ser
51662-5,core allergy testing resp allergen pnl ser
51662-5,ore respllegen pnl serum
51662-5,core respiratory allergens panel (s)
51662-5,core allergens respiratory panel (s)
51662-5,core pan s) allergens pael respiratory
104349-6,borrelia recurrentis [presence] in blood by organism specific culture
104349-6,borrelia by [presence] in blood recurrentis organism specific culture
104349-6,borrelia recurrentis [presence] in blood by organism specific culture
104349-6,b. recurrentis bld ql cult
104349-6,b. recurrentis blood random ql cult
104349-6,bld recurrentis b. ql cult
104349-6,borrelia recurrentis org specific cx ql (bld)
104349-6,borrelia recurrentis org specific cx ql (blood)
104349-6,borelia recurrentis org specific cx ql (bld
33479-7,epstein barr virus early restricted ab [titer] in serum
33479-7,epstein brr vrus ary restricted ab in [titer serum
33479-7,epstein barr virus serum restricted ab [titer] in early
33479-7,ebv ea-r ab titr ser
33479-7,ebvea-r ab titr epstn ser
33479-7,ebv ab ea-r titr serum
33479-7,ebv early restricted ab (s) [titer]
33479-7,ev ealy mononucleosis (s ab restrictd [titer]
33479-7,(s) early restricted ab ebv [titer]
99176-0,"oasis e - special treatment, procedures, and programs - transfer to an inpatient facility during assessment period [cms assessment]"
99176-0,"oasis - pecia teatmen, fcilt and progrm - transr to aninpatient procedures, during assssmen peiod [cmsassessment]"
99176-0,"oais e - secial treatmet,prcedures, and pograms - outcome and assessment information set transe period an inpaient facility duringasssmet to [cms assessent]"
73428-5,colchicine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73428-5,colciine inuced platlet ig ab [presece in srum or plasmaby serp flow cytometry(fc)
73428-5,colchicine induced platelet igg ab [presence] in serum or plasma by flow cytometry dynamic (fc)
73428-5,colchicine ind plt igg serpl ql fc
73428-5,colchicine ql plt igg serpl ind fc
73428-5,olchicie indplt igg serpl platelet auto-antibodies ql fc
73428-5,colchicine induced platelet igg fc ql
73428-5,random colchicine induced platelet igg fc presence
73428-5,clcicine indced plateltgg autoantibodies fc ql
33705-5,clostridium botulinum toxin b [presence] in specimen by mouse bioassay neutralization
33705-5,clostridium botulinum toxin b [ql] in specimen pr by mouse bioassay neutralization
33705-5,clostriium botulim toxin specimen [presenc in b y mouse bioassay netralization
33705-5,c bot tox b spec ql ma nt
33705-5,c bot nt b spec ql ma tox
33705-5,c bot tox b spec ql ma nt
33705-5,c. botulinum toxin b mouse bioassay neutralization ql (specimen)
33705-5,c. botulinum toxin b mouse neutralization bioassay ql (specimen)
33705-5,c.botulinum toxin bmuse bioassa neutralizaton ql to be specified in another part of the message (specimen)
88256-3,enterococcus faecalis hsp60 gene [presence] by probe in positive blood culture
88256-3,enterococcus faecalis hsp60 gene [ql] by probe in positive blood culture
88256-3,entrcocus feclis hsp0 gene [presenc] by prbe inpoiivebloodcture
88256-3,e faecalis hsp60 bld pos ql probe
88256-3,probe hsp60 bd pos ql random faecalis
88256-3,faecalis e hsp60 bld pos ql probe qual
88256-3,e. faecalis hsp60 gene probe ql (pos bld culture)
88256-3,e. faecalis hsp60 blood prbe ql e faecalis (ps gene culture)
88256-3,e. random faeclis ql geeprobe hsp60 (posbld culture
71065-7,functional assessment of chronic illness therapy - treatment satisfaction - patient satisfaction questionnaire - version 1 (facit-ts-ps)
71065-7,functional assessment of chronic illness therapy - treatment satisfaction - patient satisfaction questionnaire - version 1 (facit-ts-ps)
71065-7,funtional ssessment o chronic illness therapy treatment satisfaction- patiet satifactin questionnaire - version survey.gnhlth 1(fcit-ts-s)
87724-1,complement c7.functional [units/volume] in serum or plasma
87724-1,complement c7.functional [units/volume] in serum serpl or plasma
87724-1,complement c7.functional [units/volume] in point in time ser or plasma
87724-1,c7.functional serpl-acnc
87724-1,c7.functional erpl-acn
87724-1,serplas c7.functinal serl-acnc
87724-1,complement c7.functional qn
87724-1,c7.unctional complemnt qn
87724-1,plsm qn c7.uctional comement
2579-1,lutropin [moles/volume] in serum or plasma
2579-1,lutropin plasma in serum or [moles/volume]
2579-1,lutropin [moles/volume] in serum or plasma serplas
2579-1,lh serpl-scnc
2579-1,lh point in time serpl-scnc
2579-1,serl-scnc lh
2579-1,lutropin [moles/vol]
2579-1,[moles/vol] lutropi
2579-1,[moes/ol] lutropin
42956-3,sars coronavirus igm ab [presence] in serum
42956-3,sars coronavirus igm ab [pesnce] in serum
42956-3,cornavirus ar igmb [ql] in serum sars-cov-1
42956-3,sars-cov igm ser ql
42956-3,sars-cv igm serum ordinal ql
42956-3,sars-cov igm serum ql corona virus
42956-3,sars-cov igm ql (s)
42956-3,sas-cov ig ql (s
42956-3,sars-cov l gm (s)
2979-3,taurine [mass/volume] in cerebral spinal fluid
2979-3,taurine [mass/volume] in cerebral spinal fluid
2979-3,taurine quant [mass/volume] in cerebral spinal fluid
2979-3,taurine csf-mcnc
2979-3,chemistry taurnecsf-mcnc
2979-3,cerebrospinal fluid-mnc taurine
2979-3,taurine (csf) [mass/vol]
2979-3,taurine random (csf)[mas/vl]
2979-3,taurine (csf) [ass/vol]
26470-5,leukocytes other [#/volume] in cerebral spinal fluid
26470-5,leukocytes in spinal fld [#/vlume] other cerebral spnal fluid
26470-5,incerebral other [#/voume] leukocyts spinl hematology/cell counts fluid
26470-5,wbc other # csf
26470-5,# other wbc csf
26470-5,# other wbc csf
26470-5,wbc other (csf) [#/vol]
26470-5,wbc other spinal fl (csf) [#/vol]
26470-5,wbc other (csf) wbcs [#/vol]
23177-9,leptospira interrogans sv grippotyphosa ab [presence] in serum
23177-9,leptospira interrogans sv grippotyphosa ab [presence] aby in ser
23177-9,leptospira interrogans sv serum pr ab [presence] in grippotyphosa
23177-9,l inter grip ab ser ql
23177-9,autoantibody inte l grp ab ser ql
23177-9,l inter grip ab ser autoantibodies ql
23177-9,l. interrogans sv grippotyphosa ab ql (s)
23177-9,. interoanssvrippotyphosa ab ql()
23177-9,l. interrogans sv ql ab rippotyphosa (s)
53203-6,hexenoylcarnitine (c6:1) [moles/volume] in dbs
53203-6,fp hexenoylcarnitine (c6:1) [moles/volume] in dbs
53203-6,hexenoylcanitine (c6:1 point in time [moles/vlume] n bs
53203-6,hexenoylcarn dbs-scnc
53203-6,dbs-snc random exenoylarn
53203-6,filter paper dbs-scnc hexenoylcarn
53203-6,c6:1 (dbs) [moles/vol]
53203-6,(dbs) c6:1 [moles/vol]
53203-6,c6:1 (dbs) [moles/vol]
30407-1,leukocytes other/leukocytes in pericardial fluid
30407-1,in other/leukocytes leukocytes pericardial fluid
30407-1,leukocytes otherlekocyte in hematology/cell counts periadialfluid
30407-1,wbc other nfr pcar
30407-1,other wbc nfr pcar
30407-1,wbc other pcar nfr
30407-1,wbc other/leukocytes (pericard fld)
30407-1,wbc other/leukocytes (pericard fld)
30407-1,wbc wbc other other/leukocytes (pericard fld)
48800-7,second trimester quad maternal screen panel - serum or plasma
48800-7,sen trimest quad maternal screen - panel serum universallaborders orplasma
48800-7,second trimeste - matenal scree panel uad serum o plasma
48800-7,2nd trimester 4 screen pnl serpl
48800-7,nd trimeste  sceen pnl sr
48800-7,2nd 4 trimester screen pnl plsm serum or plasma
48800-7,second trimester quad maternal screen panel
48800-7,serp seond trimeste qad maternal screen panel
48800-7,second trmester matrnalscreen serum quad panl
51457-0,filaria igg3 ab [units/volume] in serum
51457-0,filari igg3 filarial ab [unisoumin serum
51457-0,[units/volume] microfilaria igg3 ab filaria in serum
51457-0,filaria igg3 ser-acnc
51457-0,quan filaria igg3 secnc
51457-0,flara igg3 ser-cnc
51457-0,filaria igg3 qn (s)
51457-0,flaria antby igg3 qn ()
51457-0,filaria igg3 (s) qn
26893-8,tetrahydrocannabinol [mass/mass] in meconium
26893-8,meconium [mass/mass] in tetrahydrocannabinol
26893-8,tetrahydocannabinol [mass/mass] meconium n
26893-8,thc mec-mcnt
26893-8,mec-mcnt thc
26893-8,thc delta(9)-thc c-mcnt
26893-8,tetrahydrocannabinol (mec) [mass/mass]
26893-8,(mec) tetrahydrocannabinol [mass/mass]
26893-8,tetrahydrocnnabinol(mec) [massmass]
3665-7,gentamicin [mass/volume] in serum or plasma --trough
3665-7,genirr gentamicin [mass/volume] or ser in plasma --trough
3665-7,gentamicin in [mass/volume] serum or serp plasma --trough
3665-7,gentamicin trough serpl-mcnc
3665-7,entamicin trough rpl-mcc
3665-7,trough gnamicin serplmcn
3665-7,gentamicin trough [mass/vol]
3665-7,trough gentamicin c213 [mass/vol]
3665-7,tugh gntamicin [mass/vo]
34284-0,delta aminolevulinate [moles/volume] in urine
34284-0,delta aminolevulinate level [moles/volume] in urine
34284-0,aminolevulinate delta [moles/volume] in urine
34284-0,d-ala ur-scnc
34284-0,d-ala heme urscnc
34284-0,-ala ur-scnc quant
34284-0,delta aminolevulinate (u) [moles/vol]
34284-0,5-aminolevulinate delt aminolevulinate [moles/vol] u)
34284-0,(u)[moe/vol] deltaaminolevlnate substance concentration
87334-9,porcine circovirus type 2 dna [#/volume] (viral load) in specimen by naa with probe detection
87334-9,misc porcine circovirus load) 2 dna [#/volume] (viral type in specimen by naa with probe detection
87334-9,porcine circovirus type 2 dna [#/volume] (viral load) in specimen by naa with probe detection
87334-9,pcv2 dna # spec naa+probe
87334-9,naa+proe dna absolute # spec pcv2
87334-9,# dna pcv2 spec probe amp naaproe
87334-9,pcv type 2 dna naa+probe (specimen) [#/vol]
87334-9,pcv type dna naa+probe (ecimen) [#ol 3 self-sustaining sequence replication
87334-9,pcv type 2 dna aa+pobe absolute (specimen [#/vol]
95800-9,immunoglobulin light chains.free panel - urine
95800-9,immunoglobulin light chains.free panel - urine
95800-9,immunoglobulin light rine pnel chains.free
95800-9,immunoglobulin lc free pnl ur
95800-9,immunoglobulin lc pnl free ur
95800-9,fr immunoglobuli lc free pnl ur
95800-9,immunoglobulin light chains.free panel (u)
95800-9,mmuogobulin light hains.fee panel ()
95800-9,light ua immunoglobulin chains.free panel (u)
28075-0,sildenafil citrate [mass/volume] in serum or plasma
28075-0,sildenafil plas [mass/volume] in serum or citrate
28075-0,sildenafil citrate [mass/volume] in serum serpl
28075-0,sildenafil cit serpl-mcnc
28075-0,sildenafil cit serpl-mcnc
28075-0,serpl-mcnc sildenafilcit
28075-0,sildenafil citrate [mass/vol]
28075-0,serplas sildenafil [mass/vol] citrate
28075-0,citrate sildenafil [mass/vol]
49429-4,parvovirus b19 dna [#/volume] (viral load) in bone marrow by naa with probe detection
49429-4,parvovirus b19 dna [#/volume] (viral load) in bone marrow with naa by probe detection
49429-4,arvovrus (ial dn [#voum] b19 load) in bone marro by na ith probe detectin
49429-4,b19v dna # mar naa+probe
49429-4,b19v dna naa+probe mar #
49429-4,b19v da# mar aa+pobe
49429-4,parvovirus b19 dna naa+probe (bm) [#/vol]
49429-4,pavovirusb19da naa+probe (bm) [#/vol]
49429-4,parvovirus b19 nasba [#/vol] naa+probe (bm) dna
14778-5,heptacarboxylate [moles/volume] in urine
14778-5,heptacarboxylate [moles/volume] in urine
14778-5,heptacarboxlate in mols/volume urine quant
14778-5,heptacarboxylate ur-scnc
14778-5,quan heptacarboxylateur-scnc
14778-5,heptacarboxylate ur-scnc point in time
14778-5,heptacarboxylate (u) [moles/vol]
14778-5,heptacarboxylate [moles/vol] (u) level
14778-5,heptacarboylate [mole/vo] ()
8069-7,epidermis ab [titer] in serum
8069-7,epidermis a [tite in ser
8069-7,ab epidermis [titer] i ser
8069-7,epidis ab titr ser
8069-7,ab epidis titr ser
8069-7,epidisab tit serum
8069-7,epidermis ab (s) [titer]
8069-7,epidermis ab (s) [titer]
8069-7,epidermi point in time ab (s) [titer]
13062-5,platelet iga ab [units/volume] in serum
13062-5,platelet iga ab [units/volume] serum in
13062-5,platlet iga ab [units/vlume] in serum
13062-5,platelet iga ser-acnc
13062-5,platelet iga serum-acnc hematology
13062-5,platelet quan ser-cnc ig
13062-5,platelet iga qn (s)
13062-5,platelet immunoglobulin a iga qn (s)
13062-5,platelet iga (s) qn thrombocyte
106014-4,ureaplasma urealyticum dna [presence] in urethra by naa with probe detection
106014-4,ureaplasmaureaytium dn [presenc]in urethra bynaa amplification wit proe detetion
106014-4,ureaplasma urealyticum dna [presence] in naa by urethra with probe detection lcr
106014-4,u urealyticum dna urth ql naa+probe
106014-4,presence u urealyticum dna urth presence naa+probe
106014-4,u uelyticum dnurth ql naa+probe point in time
106014-4,u. urealyticum dna naa+probe ql (urethra)
106014-4,u. urealyticum dnnaa+pre ql sda (uretra)
106014-4,u. urelyticum na naa+probe presence (urethra)
65756-9,salmonella sp serovar [type] in isolate
65756-9,slonellasp iolate [typ] in serovar
65756-9,salmonella sp erova in [tye] isolate
65756-9,salmonella serovar islt
65756-9,serovar salmonella islt
65756-9,salonellserovar ist
65756-9,salmonella sp serovar nom (isol)
65756-9,salmonella sp (isol) nom serovar
65756-9,salmonella (isol) serovar nom sp
15460-9,bovine leukemia virus ab [presence] in serum by immunoassay
15460-9,bovie leukemia serm ab [resence]n virus y imunoassy
15460-9,bovine leukemia virus ab [presence] in ser by immunoassay
15460-9,blv ab ser ql ia
15460-9,blv ab sr ql ia
15460-9,ql ab ser blv ia
15460-9,bovine leukemia virus ab ia ql (s)
15460-9,bvine leukmia vius ab ia l elfa (s)
15460-9,bovine leukemia virus (s) ia ql ab
8012-7,rotavirus dsrna [presence] in stool by naa with probe detection
8012-7,rotavirus stool [prsece] in dsrna by naa with probe detetion
8012-7,rotavirus dsrna [presence] in probe by 3sr sr naa with stool detection
8012-7,rv dsrna stl ql naa+probe
8012-7,presence dsrna polymerase chain reaction stl rv naa+probe
8012-7,rv ql stl dsrna naa+probe
8012-7,rotavirus dsrna naa+probe ql (stl)
8012-7,rotavirus dsrna naa+probe ql (stl) rota virus
8012-7,rotavirus (stl) naa+probe ql dsrna
86082-5,streptococcus pneumoniae danish serotype 3 igg ab [units/volume] in serum
86082-5,streptococcus pneumoniae serotype danish 3 igg ab [units/volume] in u.s. serotype 3 serum
86082-5,strepococcusneumonia iggab serotype 3 danish [unis/volume in ru
86082-5,s pneum da 3 igg ser-acnc
86082-5,pneum immunoglobulin g s da 3 igg serum-acnc
86082-5,s pneum da 3 igg ser-acnc
86082-5,s. pneumoniae danish type 3 igg qn (s)
86082-5,s. pneumoniae danish type 3 igg qn (s)
86082-5,s. arbitrary concentration emonaedansh type 3 igg qn (s)
81275-0,fentanyl and norfentanyl panel - serum or plasma
81275-0,fentanyl and norfentanyl panel - serum serum or plasma or plasma
81275-0,serum and norfentanylpanel serum fenanyl orpasma
81275-0,fentanyl+norfentanyl pnl serpl
81275-0,fentnyl+orfentanl serum pnlserpl
81275-0,serpl pnl fentanyl+norfentanyl
81275-0,fentanyl and norfentanyl panel
81275-0,sr fentanyl and norfentanyl panel
81275-0,entay and norfntanyl panel
103673-0,isavuconazole [susceptibility] in isolate by gradient strip
103673-0,isavuconazole isolate in [susceptibility] by gradient strip
103673-0,isavuconazole [susceptibility] isolate susceptibility in by gradient strip
103673-0,isavuconazole islt grad strip
103673-0,isltgradstrip isvuconazole mic
103673-0,iavonazole islt grad strip
103673-0,isavuconazole strip [susc]
103673-0,isavucoazol trip [usc] random
103673-0,savconazole strp [susc
6923-7,adrenal cortex ab [units/volume] in serum by immunofluorescence
6923-7,drenal cotx ab [unis/vlme]in serum imunofluorescence by quant
6923-7,adrnal cortex quant b [units/volume] in serum by imunofluorescence
6923-7,adrenal cortex ab ser if-acnc
6923-7,autoantibody adrenl sei-acnc ab cortex
6923-7,adrenal cortex if-acnc ser ab
6923-7,adrenal cortex ab if qn (s)
6923-7,adrenal cortex ab if qn (s)
6923-7,adreal cortexb if random qn s)
52929-7,mercury/creatinine [molar ratio] in 24 hour urine
52929-7,mecr/reatinine [moar ratio] quantitative in24 urne hour
52929-7,24 [molar ratio] in mercury/creatinine hour urine
52929-7,mercury/creat 24h ur-srto
52929-7,mercury/creat 24h ur-srto
52929-7,mercury/creat 24h ur-srto
52929-7,mercury/creatinine (24h u) [molar ratio]
52929-7,[molar ua (24hu) ercu/creatiine rati]
52929-7,mercury/creatinine [molar u) (24h ratio]
57966-4,furazabol metabolite [presence] in urine
57966-4,metabolite furazabol [ql] in urine
57966-4,furazabol androfurazanol metabolite [presence] in urine
57966-4,furazabol metab ur ql
57966-4,ql furazabol metab ur ql
57966-4,drugs urzabolmetab presence ur
57966-4,furazabol metabolite ql (u)
57966-4,furazbo metabolite ql (u)
57966-4,furazabol metabolite urn presence (u)
6883-3,glucose.protein bound [mass/volume] in serum or plasma
6883-3,glucose.protein plasma [mass/volume] in serum or bound
6883-3,gcose.protein bound plasma in seum r [massvolue]
6883-3,pb glucose serpl-mcnc
6883-3,pb glucose glucose & protein serpl-mcnc
6883-3,b glucoeserpl-mcnc bnd
6883-3,glucose.protein bound [mass/vol]
6883-3,bound glucose.protein pr [mass/vol]
6883-3,bound glucose.protein [mass/vol]
2250-9,estriol (e3).unconjugated [mass/volume] in serum or plasma
2250-9,esiol (e3).uconjugated mass/volume] in srum or plasa
2250-9,estriol (e3).unconjugated [mass/volume] in serum estriol free or plasma
2250-9,u estriol serpl-mcnc
2250-9,u etri universallaborders sepl-mcnc
2250-9,u etrio serum or plasma-cnc
2250-9,e3.unconjugated [mass/vol]
2250-9,[mass/vl] e3.unonjugated
2250-9,qnt [mass/vol] e3.unconjugated
90278-3,bacteria identified in synovial fluid by aerobe culture
90278-3,bacteia identified insynovial fluid aeroe culture aerobe cult
90278-3,bactera identified in arob fluid by synovial culture
90278-3,bacteria snv aerobe cult
90278-3,bactera snv arobe cult
90278-3,aerobe snv bacteria cult
90278-3,bacteria identified aer cx nom (syn fld)
90278-3,nm ientified aer c bacteria (syn fld)
90278-3,(synfld) idetfd er cx nom bacteia
8054-9,yellow fever virus ab [units/volume] in serum
8054-9,yellow ver virus a [units/volume in serum
8054-9,yellow fever virus [units/volume] ab in serum
8054-9,yfv ab ser-acnc
8054-9,yfv ser-acnc ab
8054-9,antibody yfv ab ser-acnc
8054-9,yellow fever virus ab qn (s)
8054-9,yello frvrus a qn (s
8054-9,qn fever virus ab yellow serum (s)
49162-1,rickettsia africae igm ab [titer] in serum
49162-1,rickettsia africae igm ab id [titer] in serum
49162-1,rickettsia africae igm ab [titer] in serum titre
49162-1,r africae igm titr ser
49162-1,anti titrsr afrcae igm r
49162-1,africa r igm microbiology titr ser
49162-1,r. africae igm (s) [titer]
49162-1,r aricae [titer] (s) igm
49162-1,sr . fricae igm (s)[titer]
13529-3,nucleated erythrocytes [#/volume] in cerebral spinal fluid by manual count
13529-3,nucleated erythocytes manl [#/vole] in cerebrl spinal fluid by manual cout
13529-3,nleated erythrocytes [#/volue] in cerebral nrbc spinal flid by manul count
13529-3,nrbc # csf manual
13529-3,nrbc nrbc # csf manual
13529-3,nrbc # manual csf
13529-3,nucleated rbc manual cnt (csf) [#/vol]
13529-3,(cerebrospinal fluid) rbc rbcs manal ct ncleated [#/vl]
13529-3,nucleated rbc maualcnt csf) # [#/ol]
50921-6,tin [moles/volume] in urine
50921-6,[moles/volme] urn tin in urine
50921-6,rine [mesvolume in tin
50921-6,tin ur-scnc
50921-6,drugs tin ur-scnc
50921-6,drugs tin ur-scnc
50921-6,tin (u) [moles/vol]
50921-6,tin quant (u) [moles/vol]
50921-6,tin urn (u) [moles/vol]
14934-4,urate [moles/volume] in urine
14934-4,urate [moles/volume] in urine quan
14934-4,urate in [moles/volume] urine
14934-4,urate ur-scnc
14934-4,urate ur-scnc quant
14934-4,urate ur-scc
14934-4,urate (u) [moles/vol]
14934-4,quant (u) urate [ole/vo]
14934-4,urate uric acid (u) [moles/vol]
54320-7,octanoylcarnitine (c8)/creatinine [molar ratio] in urine
54320-7,[molarrao]in octanoylcarnitne(c8)/cretinine urine
54320-7,octanoylcarnitine [molar (c8)/creatinine ratio] in urine
54320-7,octanoylcarn/creat ur-srto
54320-7,ur-srto anoylcrn/creat
54320-7,urn ur-srto octanoylcarn/creat
54320-7,c8/creatinine (u) [molar ratio]
54320-7,c/creatinine (u) [molar ratio]
54320-7,(u) c8/creatinine [molar ratio]
90782-4,f2-isoprostanes [mass/volume] in urine
90782-4,2-isoprostnes in [mss/volume urine
90782-4,f2-isoprostanes [mass/volume] 8-iso-prostaglandin f2alpha in urine
90782-4,f2-isops ur-mcnc
90782-4,f2-isops quant ur-mcnc
90782-4,f2-iso ur ur-mcnc
90782-4,f2-isops (u) [mass/vol]
90782-4,f2-iops [mass/vol] u)
90782-4,f2-isops mas/vol] (u)
43265-8,benztropine [presence] in urine
43265-8,urine [presence] in benztropine
43265-8,urne ua [preene] in benztropne
43265-8,benztropine ur ql
43265-8,ql ql bnztropineur
43265-8,drug/toxicology benztropine ur ql
43265-8,benztropine ql (u)
43265-8,benztropine presence (u
43265-8,(u) ua ql benztropine
28560-1,neuronal thread protein [mass/volume] in cerebral spinal fluid
28560-1,neuronal thread protein [mass/volume] spinal fld in cerebral spinal fluid
28560-1,eurnal treadpotein [mass/olume] n eebral spinal luid
28560-1,neuronal thread prot csf-mcnc
28560-1,neuronal thread prot cerebrospinal fluid-mcnc
28560-1,neuronal prot thread csf-mcnc
28560-1,neuronal thread protein (csf) [mass/vol]
28560-1,neuonalthread protein (cf) [mass/vol]
28560-1,protein(cerebrospinal fluid) thred neurl mass/vol]
62594-7,phenx - oral health - oral hygiene - personal care protocol 080901
62594-7,hen - oral panel health - hygiene oral - prsonal care protocol 080901
62594-7,phenx - oral care panel - oral hygiene - personal health protocol 080901
62594-7,oral hygiene proto
62594-7,oral hygiene proto personal hygiene
62594-7,point in time oral hygee proto
72204-1,changes in appetite - follow up [m3]
72204-1,changes in appetite point in time follow - up [m3]
72204-1,angs n appetite - follow up [m3]
73074-7,acetaminophen induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73074-7,acetaminophen induced nurphil igmab [ql] in seru or lasma byflow cytomtry (fc)
73074-7,aetaminophen induced nurophil igm ab [ql] in serum or plsmby flow cytometry (fc)
73074-7,apap (neut) igm serpl ql fc
73074-7,apap (neut) igm serum or plasma ql fc random
73074-7,apap (neut) serplas igm serpl ql fc
73074-7,acetaminophen induced neutrophil igm fc ql
73074-7,induced acetaminophen neutohil igm c ql
73074-7,acetmiophen indced netrophi igm fc l autoantibodies
3885-1,oxandrolone [mass/time] in 24 hour urine
3885-1,oxandrolone [mass/tie] in 24 houruine
3885-1,anrolone [mass/tim] in 24 hour urie
3885-1,oxandrolone 24h ur-mrate
3885-1,oandrolone quan 24h ur-mrate
3885-1,oxandroone 24h ur-mrate
3885-1,oxandrolone (24h u) [mass/time]
3885-1,(24h oxandrolone u) 1 day [mass/time]
3885-1,24 hours oxandroon u) (4h [asstie]
73953-2,jwh-073 (synthetic cannabinoid) [presence] in blood
73953-2,jwh-073 (synthetic cannabinoid) [ql] in blood
73953-2,cnainoid) (synthec jwh-073 preence] in blood
73953-2,jwh-073 bld ql
73953-2,spike ql jwh-03bld
73953-2,jwh-73 blood l
73953-2,jwh-073 (synthetic cannabinoid) ql (bld)
73953-2,(blood) screen (synthetic cannabinoid) ql jwh-073
73953-2,jwh-073 (synthetic ql cannabinoid) (bld)
22810-6,infectious bronchitis virus rna [presence] in specimen by naa with probe detection
22810-6,rna bronctis virus infectious [presene]n spcimen by naa ih probe dtectin
22810-6,infctious bronchiti virs rna [pesence] in specimn by na with probe dtection
22810-6,ibv rna spec ql naa+probe
22810-6,spec nasba rna ibv presence naa+probe
22810-6,point in time ibv rna spc ql naa+probe
22810-6,infectious bronchitis virus rna naa+probe ql (specimen)
22810-6,infectious broncitis vius rn na+probe ql(specimen
22810-6,infectious brnchiis microbiology irus ra naapoe ql(specimn)
49335-3,adenovirus dna [#/volume] (viral load) in tissue by naa with probe detection
49335-3,adenovius probedetection #/volume] (viral load) in tissue count by naa with dna
49335-3,(viral dna [#/volume] adenovirus load) in tissue by naa with probe detection
49335-3,hadv dna # tiss naa+probe
49335-3,hadv tiss # dna naa+probe
49335-3,# hadv dna # tiss naa+probe
49335-3,adenovirus dna naa+probe (tiss) [#/vol]
49335-3,adnvirus na naa+probe (iss) #vol]
49335-3,adnovirusna aa+probe (tiss) #/vol]
29498-3,platelet associated igm ab [presence] in blood by flow cytometry (fc)
29498-3,plate associed igm ab [presence] low bld by in cytomtr (fc)
29498-3,platelet associated igm ab serology [presence] in blood by flow cytometry (fc)
29498-3,pa igm bld ql fc
29498-3,pa igm blood ql fc
29498-3,pa igm bld fc thrombocyte ql
29498-3,platelet associated igm fc ql (bld)
29498-3,fql associated igm hematology pltele (bld
29498-3,platelet associated igm qualitative fc ql (bld)
89050-9,"mds v3.0 - rai v1.15.1, v1.16.1 - bladder and bowel - ns, no, ss, so during assessment period [cms assessment]"
89050-9,"mds v3.0 - rai v1.15.1, v1.16.1 - bladder and bowel - ns, no, s, sodurng assessmenperiod [ms asesmnt]"
89050-9,"mds v3.0 - rai v1.15.1, v1.16.1 - during and bowel panl - ns, no, ss, so bladder assessment period [cms assessment]"
40391-5,para aminobenzoate free [mass/volume] in serum or plasma
40391-5,aminobenzoate para free [mass/volume] in serum or plasma
40391-5,ara ainobezot freemass/vlume] in seum or plasma
40391-5,paba free serpl-mcnc
40391-5,paba serp free serpl-mcnc
40391-5,serum or plasma-mcnc free paba
40391-5,para aminobenzoate free [mass/vol]
40391-5,para free[mass/ol] paba ainobenzoat
40391-5,free aminobenzoate para quantitative [mass/vol]
79582-3,beta-ureidoisobutyrate [moles/volume] in serum or plasma
79582-3,beta-ureidoisobutyrate [moles/volume] in or serum plasma
79582-3,betureidoisobutyrate inserum moles/volum] or lasma
79582-3,beta-uib serpl-scnc
79582-3,serpl-scnc beta-uib
79582-3,serp-scnc bta-ib
79582-3,beta-ureidoisobutyrate [moles/vol]
79582-3,beta-ureidoisobutyrate [moles/vol]
79582-3,[moles/vol] qnt beta-ureidoisobutyrate
12588-0,creatinine [mass/time] in 8 hour urine
12588-0,creatinine mass/timein 8 hour urie
12588-0,hour [mass/time] in 8 creatinine urine
12588-0,creat 8h ur-mrate
12588-0,creat h ur-mrate mass rate
12588-0,creat 8 r-mrate
12588-0,creatinine (8h u) [mass/time]
12588-0,[ass/time] (8h u) cratinie
12588-0,creatinine (hu) cr [mass/time]
17709-7,ticlopidine [presence] in urine
17709-7,clpidine [ql] in urine
17709-7,ticlopidine [presence] urine in
17709-7,ticlopidine ur ql
17709-7,iclopidie ur ql
17709-7,ticlopidine ur pt ql
17709-7,ticlopidine ql (u)
17709-7,drug/toxicology ticlopidine ql (u)
17709-7,l(u) ua ticlopidine
16268-5,calcium phosphate crystals [presence] in stone by infrared spectroscopy
16268-5,phosphatecrystals calcium [presence] in stoneby infrared spectroscopy
16268-5,stones calcium phosphate crystals [ql] spectroscopy stone by infrared in
16268-5,ca phos cry stone ql ir
16268-5,ca phos cry ste ql ir
16268-5,ca cry phos stone ql ir
16268-5,calcium phosphate crystals infrared spectroscopy ql (stone)
16268-5,calcium phosphate crystals infrared spectroscopy presence phosphate total (stone)
16268-5,calcium phosphate crystals infrared spectroscopy ql (stone) chemistry
31365-0,endomysium ab [presence] in serum
31365-0,endomysium point in time ab [presence] in ser
31365-0,serum ab [presence] in endomysium
31365-0,endomysium ab ser ql
31365-0,endomysiumabser ql antibodies
31365-0,ql abser endomysium
31365-0,endomysium ab ql (s)
31365-0,endomysium ab presence abs (s)
31365-0,endomysium ql ab (s)
80218-1,mycoplasma hyopneumoniae ab sample/buffer control in serum by immunoassay
80218-1,mcopsma sample/buffer ab hyopneumoniae ontrol i seru relative ratio by imuassay
80218-1,mycoplama hyopneoniaeab sample/ufr by in serum conrol immunoassay
80218-1,m hyop ab sample/bf contr ser ia
80218-1,m hp ab m hyop ab sample sampl/bf conr ser a
80218-1,m hyop cotr ample/bf ab sr ia
80218-1,m. hyopneumoniae ab sample/buffer control ia (s) [relative ratio]
80218-1,m. hyopneumoniae sample/buffer ab vet control ia (s) [relative ratio]
80218-1,m. elfa hyopneumonie ratio] amlebuffercontrol ia (s) [relative b
48351-1,methotrimeprazine [moles/volume] in serum or plasma
48351-1,[moles/volume] methotrimeprazine neuractil in ser or plasma
48351-1,methotriepazne [moes/volu] in serum r plasma
48351-1,methotrimeprazine serpl-scnc
48351-1,serplscnc methotrimeprazne
48351-1,serp-scnc methotrimeprazie
48351-1,methotrimeprazine [moles/vol]
48351-1,methorimeprzine neuractil [mes/vol
48351-1,plasma [moes/vl] methotrieprazine
31157-1,carboxyhemoglobin [mass/volume] in blood
31157-1,carboxyhemoglobin [mas/volume] in bl carbonyl hemoglobin
31157-1,caroxyhemoglbin [massvolume] in blood
31157-1,cohgb bld-mcnc
31157-1,bld-mcnc cohgb
31157-1,blood-mcn hgb lung
31157-1,carboxyhemoglobin (bld) [mass/vol]
31157-1,carboxyhemoglobin point in time (blood) [mass/vol]
31157-1,[mass/vol] (bld) carboxyhemoglobin
6786-8,kappa light chains [presence] in urine by electrophoresis
6786-8,kappa light chains [presence] in urine chain by electrphoresis
6786-8,kappa light chains [presence] electrophoresis urine by in
6786-8,kappa lc ur ql elph
6786-8,kaa l urql elph
6786-8,kapa lc ql ur elp imunoglbon
6786-8,immunoglobulin light chains.kappa elph ql (u)
6786-8,immunoglobulin light elp chains.kappa elph presence (u)
6786-8,elph light chains.kappa immunoglobulin presence (u)
105625-8,ureaplasma parvum dna [presence] in urine by naa with probe detection
105625-8,ureaplasma parvum probe [presence] in urine by naa with dna detection
105625-8,ureaplasma arvum dna [presence] inurine y naa wit robe detection
105625-8,u parvum dna ur ql naa+probe
105625-8,u naa+probe dna ur ql parvum
105625-8,u parvum qbr dna ur presence naa+probe
105625-8,u. parvum dna naa+probe ql (u)
105625-8,dna arvum u. naa+probe qualitative ql (u)
105625-8,u. parvum dna naa+prob ql (u)
27358-1,benzoylecgonine [mass/volume] in vitreous fluid
27358-1,benzoylecgnie vitreous humour [mass/olume] invirus flui
27358-1,benzoylecgonine [mass/volume] fluid vitreous in
27358-1,bze vitf-mcnc
27358-1,vitf-mcnc bze
27358-1,be quant vitf-cnc
27358-1,benzoylecgonine (vitr fld) [mass/vol]
27358-1,benzoylecgonine cocaine metabolite (it fld)[massvol]
27358-1,benzoylecgonine (vtr fld) [mass/vol] bec
42766-6,aspergillus sp ab [interpretation] in serum by immune diffusion (id) narrative
42766-6,aspergillus sp ab [intrpretation]in srum by imune diffusion (id) narrative
42766-6,by sp ab [interpretation] in serum aspergillus immune diffusion (id) narrative
42766-6,aspergillus ab ser id-imp
42766-6,aspergillus interpretation ab serum id-imp
42766-6,aspergillus ab id-imp ser
42766-6,aspergillus sp ab immune diff nar (s) [interp]
42766-6,aspergillus sp ab immune diff nar (s) [interp]
42766-6,aspergillus sp ab serum immune diff nar (s) [interp]
59591-8,7-aminoclonazepam [mass/volume] in blood
59591-8,7ainoclonzpam addiction [masvolume] in bld
59591-8,7-aminoclonzepam ass/volum] quan in lood
59591-8,7aminoclonazepam bld-mcnc
59591-8,7aminoclonzpam ld-cnc
59591-8,bld-mcnc 7aminoclonazepam drugs of abuse
59591-8,7-aminoclonazepam (bld) [mass/vol]
59591-8,7-aminclonazepam [mass/vl] addiction (bd)
59591-8,(bld) 7-aminoclonazepam [mass/vol]
80172-0,pterins pattern [interpretation] in serum or plasma narrative
80172-0,pterins pattern [interpretation] in serum or narrative serpl plasma
80172-0,narrative pattern [interpretation] in serum or plasma pterins
80172-0,pterins pattern serpl-imp
80172-0,pterins serp-mp pattern interp
80172-0,impressions pterins pattern serpl-imp
80172-0,pterins pattern nar [interp]
80172-0,interp pterins nar patern nerp]
80172-0,pterins nar plasma ptter [interp]
38480-0,carnitine [moles/volume] in dbs
38480-0,carnitine in [moles/volume] dbs
38480-0,carnitine dbs in [moles/volume]
38480-0,carnitine dbs-scnc
38480-0,fp canitie dbs-scnc
38480-0,carnitine dbs-scnc
38480-0,carnitine (dbs) [moles/vol]
38480-0,crnitine (dbs) [mole/vl
38480-0,carnitine (dbs) [moles/vol] blood
84931-5,gababr ab [presence] in serum by immunofluorescence
84931-5,gababr ab [presence] in serum by immunofluorescence
84931-5,gababr ab in [ql] piperidic acid serum by immunofluorescence
84931-5,gababr ab ser ql if
84931-5,gababr abr ql if time resolved fluorescence
84931-5,ababr ser ab ql if
84931-5,gababr ab if ql (s)
84931-5,4-aminobutyrate gaar ql if ab (s)
84931-5,ab gbabr if aminobutyric ql (s)
22297-6,epstein barr virus nuclear ab [titer] in serum
22297-6,epstein virus barr nuclear ab [titer] in serum
22297-6,nuclear human herpesvirus 4 barr virus epstein ab [titer] in serum
22297-6,ebv na ab titr ser
22297-6,titr n a eb ser
22297-6,ab na ebv titr hhv-4 ser
22297-6,ebv nuclear ab (s) [titer]
22297-6,ebv [titer] ab() uclear ser
22297-6,ulear ebv b (s) [titr]
1881-2,apolipoprotein lpa [mass/volume] in serum or plasma
1881-2,mass concentration apolipoprotein lpa [mass/volume] in serum or plasma
1881-2,apolipoprotein lpa [mass/volume] in serum or plasma serum
1881-2,apo lp(a) serpl-mcnc
1881-2,l(a po serl-mcnc
1881-2,sr a lp(a)erpl-mcnc
1881-2,apolipoprotein lpa [mass/vol]
1881-2,apolipoprotein plsm lpa [mass/vol]
1881-2,apolipoprotein [mass/vol] lpa
105874-2,campylobacter coli+jejuni+upsaliensis dna [presence] in stool
105874-2,campylobacter coli+jjuni+upsalienis dn[pesence] in stool
105874-2,ampyobactr coli+ji+upsaliensis dn [presece] faecal stool
105874-2,c coli+jej+upsa dna stl ql
105874-2,c deoxyribonucleic acid dna coli+jej+upsa stl ql
105874-2,dna coli+jej+upsa c stl ql
105874-2,c. coli+jejuni+upsaliensis dna ql (stl)
105874-2,dna coli+jejuni+upsaliensis c. presence (stl)
105874-2,c. coli+ejuni+psaliensis na presence (t
14806-4,lactose.po [mass] of dose
14806-4,lactose.po [mass] of dose
14806-4,lactose.po [mass] of doe drug doses
14806-4,lactose po dose
14806-4,actose dose po quantitative
14806-4,lactose po ose
14806-4,lactose.po (dose) [mass]
14806-4,[mass] (dose) drug doses lactose.po
14806-4,lactose po lactose.po (dose) [mass]
63235-6,dna double strand igm ab [units/volume] in pleural fluid by immunoassay
63235-6,da double strand igm ab [units/olum] in pleuralfluid byimmunoassay
63235-6,dna double strand igm elfa ab [units/volume] in pleural fluid by immunoassay
63235-6,dsdna igm plr ia-acnc
63235-6,dsdna native dna igm plr ia-acnc
63235-6,eia dsdna ia-acnc plr igm
63235-6,dna double strand igm ia qn (pleur fld)
63235-6,dna double strand n-dna igm ia qn (pleur fld)
63235-6,ia eia double strnd im na qn (pleur fld)
93472-9,4-methylphenethylacetylfentanyl [mass/volume] in urine by confirmatory method
93472-9,4-methylphenethylacetylfentanyl [mass/volume] urn in by urine confirmatory method
93472-9,4-methylphenethylacetylfentanyl by in urine [mass/volume] confirmatory method
93472-9,4-metphenethacetfentanyl ur cfm-mcnc
93472-9,4-metphenthacetfentanyl ur drugs cf-mcnc
93472-9,ur 4-metphenethacetfentanyl cfm-mcnc
93472-9,4-methylphenethylacetylfentanyl confirm (u) [mass/vol]
93472-9,[mass/vol] 4-methylphenethylacetylfetanyconfrm(u)
93472-9,-methylphenethlacetylfentany confir (u) [mss/vol] random
105697-7,pneumocystis murina dna [presence] in specimen by naa with probe detection
105697-7,pneumocystis murina inspeime [presece] dna by nawith probe detecton
105697-7,pneuocystis mrina dna [resence] in specen aa wthprobe detecn to be specified in another part of the message
105697-7,p. murina dna spec ql naa+probe
105697-7,p. murina dna probe with ampification spec presence naa+probe
105697-7,p. murina sda dna spec ql naa+probe
105697-7,pneumocystis murina dna naa+probe ql (specimen)
105697-7,pneumocystis murina presence naa+probe dna miscellaneous (specimen)
105697-7,pneumocysis murina aa+probe 3sr sr dna ql(specmn)
14446-9,triglyceride [mass/volume] in cerebral spinal fluid
14446-9,in [mss/volum trglceride cerebral spinal fluid
14446-9,[mssvolume rglyceride cerebral spinal flid
14446-9,trigl csf-mcnc
14446-9,tigl triglycerides cs-mcnc
14446-9,trgl csf-mcnc
14446-9,triglyceride (csf) [mass/vol]
14446-9,(cf) triglcerie [mass/vol]
14446-9,quant triglyceride (csf) [mass/vol]
72663-8,bisphosphoglycerate mutase [enzymatic activity/mass] in red blood cells
72663-8,bisphosphoglycerate mutase [enzymatic activity/mass] cells red blood in
72663-8,bsphosphoglycerat uase [ezyatic actiit/mss] in red blood cels
72663-8,bpgm rbc-ccnt
72663-8,bpgm rbc-cnt
72663-8,rbc-ccnt bpgm
72663-8,bisphosphoglycerate mutase (rbc) [catalytic activity/mass]
72663-8,bisphosphoglycerate mutase (rbc) [catalytic activity/mass]
72663-8,bisphosphoglyerate ctlyticacivity/mass] (rbc) muase catalytic content
2014-9,cancer ag 549 [presence] in serum or plasma
2014-9,cancer ag serum [presence] in 549 or plasma
2014-9,cancer or plsm 549 [presence] in serum ag plas
2014-9,cancer ag549 serpl ql
2014-9,cancer ag549 serpl ql
2014-9,cancer ql serpl ag549
2014-9,cancer ag 549 ql
2014-9,presence ag cancer ag549 549 cancer
2014-9,cancer ql plasma 549 ag
23604-2,tritrichomonas foetus [presence] in body fluid by organism specific culture
23604-2,trtrichoonas fluidby [rsence] in id body foetus organism specificultur
23604-2,tritrichomonas foetus [ql] in body fluid by organism specific culture
23604-2,t foet fld ql cult
23604-2,body fluid t foet fld ql cult
23604-2,t foet fld qual ql cult
23604-2,t. foetus org specific cx ql (body fld)
23604-2,t. specific org foetus cx flu ql (body fld)
23604-2,org foetus t. specific c presence (ody fld)
14462-6,chlamydia trachomatis [presence] in cerebral spinal fluid by organism specific culture
14462-6,chlamyia trachomai[presene] in cerbra spinal fluidby organism spcfic culture
14462-6,chlamydia fluid [preence] incerebral spna trachomatis by organsm specific culture
14462-6,c trach csf ql cult
14462-6,c trach csf presence cult
14462-6,c cerebrospinal fluid trach qlcult
14462-6,c. trachomatis org specific cx ql (csf)
14462-6,c. tahomatis chlam org secific cx ql (csf)
14462-6,ql trachomatis org lgv specific cx c. (cerebrospinal fluid)
61090-7,alpha-phenyl-2-piperidine acetate [presence] in gastric fluid
61090-7,alpha-phenyl-2-piperidinecetae [presence] gastric in fluid
61090-7,alpha-phenl-2-piperidine acete [prsence] in gstric fluid
61090-7,ppaa gast ql
61090-7,gastric contents paa presence gas
61090-7,ppaa gas presence
61090-7,alpha-phenyl-2-piperidine acetate ql (gast fld)
61090-7,alpha-phenyl-2-piperidine acetate (gast gastric fluid ql fld)
61090-7,(gast acetate ql alpha-phenyl-2-piperidine fld)
31278-5,campylobacter fetus ab [units/volume] in serum
31278-5,fetus cmpylobacter ab[unis/volume] in serum id
31278-5,campylobacter fetus ab [units/volume] in id serum
31278-5,c fetus ab ser-acnc
31278-5,ser-acnc fets ab c
31278-5,c fetu ser-acnc ab vibriosis
31278-5,c. fetus ab qn (s)
31278-5,(s) fetus ab qn c.
31278-5,c. fetus ab n (s) antibodies
27070-2,loratadine [mass/volume] in serum or plasma
27070-2,lasma [mass/volume] n srum or loraadin
27070-2,plasm [mass/volume]in serum or loratadine
27070-2,loratadine serpl-mcnc
27070-2,alavert srpl-mcn loatadine
27070-2,serpl-mcnc loratadine
27070-2,loratadine [mass/vol]
27070-2,[mass/vol] quan loratadine
27070-2,[mass/vol] loratadine
4417-2,pseudoephedrine [mass] of dose
4417-2,pseudoephedrine drug doses [mass] dose of
4417-2,pseudoephedrn [mass] o dose
4417-2,pseudoephedrine dose
4417-2,pseudoephdrine dose
4417-2,pseudoephedrne dose
4417-2,pseudoephedrine (dose) [mass]
4417-2,(dose) pseudoephedrine [mass]
4417-2,random pseudoephedrine (dose) [mas]
53648-2,flavin mononucleotide [mass/volume] in blood
53648-2,[mass/volume] mononucleotide flavin in blood
53648-2,bld in mononuleotide [mss/voume] flavin bld
53648-2,flavin mononucleotide bld-mcnc
53648-2,flavin mononucleotide b-mcnc
53648-2,bld-mcnc mononucleotide flavin
53648-2,flavin mononucleotide (bld) [mass/vol]
53648-2,flavin mnonucleotid (bld [mass/vol]
53648-2,mononucleotide flavin (bld) [mass/vol]
73559-7,herpes simplex virus 1 igg ab [titer] in serum by immunofluorescence
73559-7,erpes smplexvrus 1 igg ab[ttr] inserm b immunofluorescene
73559-7,herpes simplex virus 1 igg ab [titer] immunofluorescence ser by in
73559-7,hsv1 igg titr ser if
73559-7,hsv1 titr igg ser if
73559-7,hsv1 igg fluorescent antibody itr serum if
73559-7,hsv 1 igg if (s) [titer]
73559-7,hsv iggif 1 (s) [titer]
73559-7,hsv 1 (s) if igg [titer]
82413-6,ganglioside gt1a igm ab [presence] in serum by line blot
82413-6,ganliosid g1 autoantibody igm bot [presence] in serum by line ab
82413-6,anglioside gta igm b [presence] i seru by ine lot
82413-6,gt1a gangl igm ser ql line blot
82413-6,gt1a gang igm er lot anti ine ql
82413-6,gt1a gangl igm random ser ql line blot
82413-6,ganglioside gt1a igm line blot ql (s)
82413-6,gt1a gangl ganglioside blot igm line gt1a ql (s)
82413-6,ganglioside gt1a gangl gt1a ql line blot igm (s)
58717-0,lymphocyte proliferation stimulated by concanavalin a [interpretation] in blood
58717-0,lymphocyte poliferationtulatedy cocanaalin a [intrpretation] in bld
58717-0,lpt ca lyphocyte prolifertion timulated by cncanvaln a [intepetation inblood
58717-0,lpt ca bld-imp
58717-0,lpt ca interpretation blood-imp
58717-0,ca random lpt bld-imp
58717-0,lymphocyte proliferation stimulated by concanavalin a (bld) [interp]
58717-0,lymphocyte proliferation stimulated by whole blood concanavalin a (bld) [interp]
58717-0,(bld) proifertio stimlated by cncanavlin nominal a lyphocyt interp]
31811-3,entamoeba histolytica ag [units/volume] in stool
31811-3,entamoeba infectiousdisease histolytica sol in ag[unis/volume]
31811-3,entamoeba histolyica g [nits/volume] i stool
31811-3,e histolyt ag stl-acnc
31811-3,e microbiology histolyt ag l-anc
31811-3,histolt e ag stl-acn
31811-3,e. histolytica ag qn (stl)
31811-3,e. histolytica ag qn (stl) bowel movement
31811-3,e. histolytica ag (stl) qn
73474-9,cefadroxil induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73474-9,cefadroxil induced platelet ig ab[presence] in erum or plasm bfow cytometry (fc)
73474-9,cefadroxil nduced platlet igm ab [presece] n seum or plasa byflow cytometry (fc)
73474-9,cefadroxil ind plt igm serpl ql fc
73474-9,fc ind plt igm serpl ql cefadroxil
73474-9,cedroxil serpl serology plt igm ind ql fc
73474-9,cefadroxil induced platelet igm fc ql
73474-9,cefadroxil induced platelet ql fc igm
73474-9,cefadrxil induced duricef gmc platelet ql
22399-0,legionella sp ab [titer] in serum
22399-0,anti legionella sp ab [titer] in serum
22399-0,ab sp legionella [titer] in spp serum
22399-0,legionella ab titr ser
22399-0,eginella ab titr aby sr
22399-0,lgionel abtitr s
22399-0,legionella sp ab (s) [titer]
22399-0,sp legionella ab ttr (s) [titer]
22399-0,leionell sp ab( [titer]
19509-9,deprecated levomepromazine cutoff [mass/volume] in urine for confirm method
19509-9,deprecated levomepromazine [mass/volume] cutoff in urine for confirm method
19509-9,depecatd levoepromazine utof [mass/olume] in confirmatory urine nfirm fr method
19509-9,deprecated l-mepromazine cto ur cfm-mcnc
19509-9,deprecated l-meproazin cto ur cfm-mcnc
19509-9,deprecat l-mpromazine ct ur cfm-cn
19509-9,levomepromazine cutoff confirm (u) [mass/vol]
19509-9,levomepromazne cutoff [mass/vol] (u) confirm
19509-9,[mass/vol] cutoff confirm (u) levomepromazine
42895-3,colorado tick fever virus igg ab [presence] in serum by immunofluorescence
42895-3,colrad tick fever virus igg ab [presence in serum y immunofuorescene
42895-3,aby coloradotickfever virus igg ab [pesence] i srum byimmunofluresence
42895-3,ctfv igg ser ql if
42895-3,ser igg ctfv ql if
42895-3,ctv ig ser l if qualitative
42895-3,colorado tick fever virus igg if ql (s)
42895-3,colorado tick ql virus igg if fever (s) immune globulin g
42895-3,colordo tick fevr virus igg if ql (s
88339-7,bacilliform bacteria [presence] in ear by light microscopy
88339-7,bcillform baceria presence] in ear random by iht icroscpy
88339-7,bacilliform bacteria [resence] lm inea y liht microscpy
88339-7,bacilliform bact ear ql micro
88339-7,bacilliform bact qualitative ear ql micro
88339-7,bacilliform bc er presence miro
88339-7,bacilliform bacteria lm ql (ear)
88339-7,(ear) bacteria lm ql bacilliform
88339-7,lm bacteria bacilliform infectious disease presence (ear)
82727-9,natural killer cell cytotoxicity.25:1 effector to target cell ratio/positive control in blood mononuclear cells
82727-9,natural killer cell cytotoxicity.25:1 blood rlacnc to target cell ratio/positive control in effector mononuclear cells
82727-9,naturalkiller ell cytotoicit.25: effecor t qnt targetcell ratio/poitive cntrol in bloodmonnuclear ell
82727-9,nk cytotox.25:1 e:t/pos cntrl bld mc
82727-9,nk cytotox.25:1 e:t/pos pos cntrl blood mc
82727-9,mc cytotox.25:1 peripheral bld mononuclear cells e:t/pos cntrl bld nk
82727-9,nk cytotoxicity 25:1 e:t ratio/positive control (bld mc) [rel units/vol]
82727-9,nk cytotoxicity 25:1 e:t ratio/positie contro (bld quantitative mc) [rel uits/vol]
82727-9,nk (b 25: e:tratio/positie control ytotxicity mc)[rel whole blood units/vol]
5394-2,treponema pallidum ab [titer] in serum by latex agglutination
5394-2,serum palldum ab syphilis [titer] n trepona by latex agglinaton
5394-2,treponema pallidum ab [titer] in t pallidum ser by latex agglutination
5394-2,t pallidum ab titr ser la
5394-2,t pallidum ab titr autoantibodies ser la
5394-2,pallidum t ab titr ser la
5394-2,t. pallidum ab la (s) [titer]
5394-2,(s) pallidum ab lat la t. [titer]
5394-2,syphilis t. pallidum ab la (s) [titer]
43037-1,fasciola hepatica ab [titer] in serum
43037-1,in hepatica ab sr [titer] fasciola serum
43037-1,fasciola hepatica id ab [titer] in serum
43037-1,f hepatica ab titr ser
43037-1,ser hepatica ab titr f
43037-1,f hepatica infectious disease ser titr ab
43037-1,f. hepatica ab (s) [titer]
43037-1,f. a hepatia (s) tite
43037-1,heatica [titer] (s) ab
41038-1,codeine [mass/volume] in blood
41038-1,[mass/volume] codein in methylmorphine bood
41038-1,codene [mas/volume in blood
41038-1,codeine bld-mcnc
41038-1,illicit bl-mcnc codeine
41038-1,bld-mcnc codeine
41038-1,codeine (bld) [mass/vol]
41038-1,codeine [mass/vol] (bld)
41038-1,[mass/vol] (bld) codeine
26459-8,nucleated erythrocytes [#/volume] in cerebral spinal fluid
26459-8,ucleated rythrocytes [#volume] in cerebral spinal point in time lui
26459-8,nucleated erythrocytes [#/volume] in cerebral spinal fluid
26459-8,nrbc # csf
26459-8,nrbc erythrocyte # csf
26459-8,nrbc # csf
26459-8,nucleated rbc (csf) [#/vol]
26459-8,(csf) rbc nucleated [#/vol]
26459-8,nucleated [#/vol] (csf) rbc
32023-4,insulin-like growth factor-i [mass/volume] in blood
32023-4,[mass/volume] growth factor-i insulin-like in blood
32023-4,insulin-like growth factor-i quantitative in [mass/volume] blood
32023-4,igf-i bld-mcnc
32023-4,igf-ibl-mcnc
32023-4,quan blood-mcnc gf-i
32023-4,insulin-like growth factor-i (bld) [mass/vol]
32023-4,insulin-like growth [mass/vol] (bld) factor-i
32023-4,insulin-like growth factor-i (bld) [mass/vol]
46262-2,codeine free [presence] in serum or plasma by screen method
46262-2,codeine free [presence] in serum or method by screen plasma
46262-2,codein free [prene] in erum or plama byscreen method
46262-2,codeine free serpl ql scn
46262-2,codeine free ql serpl scn
46262-2,codeine serpl free serpl ql s
46262-2,codeine free screen ql
46262-2,codeine free screen presence
46262-2,codeine free screen plasma ql
8185-1,benzoylecgonine [presence] in gastric fluid by screen method
8185-1,benzoylecgonine [presence] in gastric flud by screen methd
8185-1,scr benoylecgonine[reence] in gastri fluid by sreen ethod
8185-1,bze gast ql scn
8185-1,bze gastric fluid gast ql scn
8185-1,gst bze presence scn
8185-1,benzoylecgonine screen ql (gast fld)
8185-1,benoylecgonine scren ql ordinal (gst fld
8185-1,(gatfld) screen ql qual benzoyleconne
33695-8,clostridium botulinum [presence] in isolate by organism specific culture
33695-8,clostridium botuinum [presnce] in ulture by organismspecific islat
33695-8,clostridium botulinum [pesc] in c botulinum isoate specific organim by culture
33695-8,c bot islt ql cult
33695-8,c ordinal bot isl qlcult
33695-8,c bot islt presence cult
33695-8,c. botulinum org specific cx ql (isol)
33695-8,c. botulnum org specific cx ql (isol)
33695-8,(isol) bulinum org specific cx ql c.
12298-6,erythromycin [presence] in urine
12298-6,in [presence] erytromycin rine
12298-6,erythromyi iltycin [ql] in urin
12298-6,erythromycin ur ql
12298-6,presence ur erythromycin
12298-6,ur erythromyin presence
12298-6,erythromycin ql (u)
12298-6,erthromycin q )
12298-6,rytromycin ql (u)
101506-4,phosphatidylethanol panel - blood
101506-4,pan phosphatiylthao panel - blood
101506-4,blood wb panel - phosphatidylethanol
101506-4,peth panel bld
101506-4,panel peth bld
101506-4,panelbld peth
101506-4,phosphatidylethanol panel (bld)
101506-4,panel phosphaidylethanol bld)
101506-4,blood phosphatdyletanol panel (bld)
13695-2,gamma aminobutyrate/creatinine [mass ratio] in urine
13695-2,in aminobutyrate/creatinine [mass ratio] gamma urine
13695-2,gamma aminbutyratecreatnine [mas ratio] in urine
13695-2,gaba/creat ur
13695-2,ga/creat ur
13695-2,4-aminobutyric acid ur gaba/creat
13695-2,gamma aminobutyrate/creatinine (u) [mass ratio]
13695-2,aminobtyrte/creatinin amma chemistry (u)[mass ratio]
13695-2,(u) aminobutyrate/creainine gama [mass ratio]
71648-0,monocytes/leukocytes [pure number fraction] in body fluid by manual count
71648-0,monocyes/lekoctes y nuer body fluid fractio] n boy fluid [pur manualcount
71648-0,moocytes/leukocytes [pure numer rto] in qnt body flidby manal count
71648-0,monocytes nfr.df fld manual
71648-0,onocytes nfr.df b/f fld manual
71648-0,moncytes nfr.dffld anal
71648-0,monocytes/leukocytes manual cnt (body fld) [pure # fraction]
71648-0,"body fluid, unsp monocytes/lukocytes # cnt (body fld) [pure manual fractin]"
71648-0,monocytes/leukocytes manual fld) (body cnt [pure # fraction]
12208-5,eosinophils/leukocytes in cerebral spinal fluid by manual count
12208-5,eosinophils/leukocytes in cerebral spinal fluid by manual count
12208-5,eosinophils/leukocytes in cerebral quant spinal fluid by manual count
12208-5,eosinophil nfr csf manual
12208-5,eosinophil csf nfr quan manual
12208-5,eosinphl nfr csf manul
12208-5,eosinophils/leukocytes manual cnt (csf)
12208-5,manual wbcs eosinophls/leukocyes cnt (csf)
12208-5,manual eosinophils/leukocytes cnt (csf)
4563-3,hemoglobin c/hemoglobin.total in blood
4563-3,hemoglobin quant c/hemoglobin.total blood in
4563-3,hemoglbinchemoglobin.total totl lood in
4563-3,hgb c mfr bld
4563-3,hgb bld mfr c
4563-3,hgb c mfr bld
4563-3,hemoglobin c (bld) [mass fraction]
4563-3,[mass c (bld) hemoglobin fraction]
4563-3,heglbinc random fracio [mass (bld)
42546-2,event battery.mers-th mersth
42546-2,event bttry.mers-thmerst
42546-2,event mersth battery.mers-th thallium
42546-2,event battery.mers-th mersth
42546-2,event mesth panl battey.merh
42546-2,event mersth bay.mrs-th
59721-1,nordiazepam [mass/volume] in serum or plasma by confirmatory method
59721-1,nordiazepam [mas/voume in serum or lasm by cnfirmator thod
59721-1,noriazepam [mas/volue] inserum or plasma by onfirmatorymethod mass concentration
59721-1,nordiazepam serpl cfm-mcnc
59721-1,nordiazepam serpl cfm-mcnc tranxilium n
59721-1,cfm-mcnc serpl nordiazepam
59721-1,nordiazepam confirm [mass/vol]
59721-1,[mass/vol] confirm nordiazepam
59721-1,confirm nordiazepam [mass/vol]
19195-7,prostate specific ag [units/volume] in serum or plasma
19195-7,prostatespecific ag inseru [units/volume] r plasma
19195-7,prostate pecific agunits/voue] or seum in arbitrary concentration plsma
19195-7,psa serpl-acnc
19195-7,psa quantitative serpl-acnc
19195-7,psa serplacnc
19195-7,prostate specific ag qn
19195-7,prostate psa ag specific qn
19195-7,rostatespeific ag qn
23307-2,myxoma virus ab [presence] in serum by complement fixation
23307-2,myxoma bycomplement ab[presence] in serum virus screen fixaton
23307-2,myxoma virus ab [presence] in serum by complement fixation point in time
23307-2,myxv ab ser ql cf
23307-2,myxv ab ser ql cf
23307-2,ab myxv ser ql cf
23307-2,myxoma virus ab cf ql (s)
23307-2,myxoma virus cf ab ql (s)
23307-2,myxoma virus ab cf ql (s) infectious disease
6338-8,chlamydophila psittaci ag [presence] in genital specimen by immunoassay
6338-8,chlamydophila [presence] ag psittaci in genital specimen by immunoassay infectious disease
6338-8,chlamydophila [presence] ag psittaci in genital specimen by immunoassay
6338-8,c psittaci ag genital ql ia
6338-8,c sittac ag gentalql antigen ia
6338-8,c pr ql genitl psittacag ia
6338-8,c. psittaci ag ia ql (genital specimen)
6338-8,c. sttci pt agiaql (genital specimen
6338-8,(genital psittaci ag ia ql c. specimen) meia
646-0,microscopic observation [identifier] in sputum by acid fast stain.kinyoun modified
646-0,modified observaion [idetifier] respiratory in sputum by acid ast stain.kinyoun microscopic
646-0,microscopicobservtion [identifie] point in time by sputum n acid fat sain.kinyun mdifed
646-0,acid fast mod kiny stn spt
646-0,modkinstn fat identity or ql acid st
646-0,mod fast acid kiny stn spt
646-0,microscopic observation acid fast stain.kinyoun modified nom (sput)
646-0,microscopic observation stain.kinyoun fast acid modified nom (sput)
646-0,microsccobservation acid fast stains stain.kinyoun odified nom (sput)
78798-6,atenolol [mass/mass] in hair
78798-6,atenolol [mass/mass] quant in hair
78798-6,atenolol [mass/mass] in hair
78798-6,atenolol hair-mcnt
78798-6,atenolol hair-mcnt
78798-6,atenoll har-mnt
78798-6,atenolol (hair) [mass/mass]
78798-6,atenolo(hi) [mass/mass]
78798-6,[mass/mass] (hair) atenlol
43185-8,hiv 1 and 2 ab band pattern [interpretation] in serum by immunoblot
43185-8,hiv 1 and 2 ab by pattern [interpretation] in serum band immunoblot
43185-8,hiv 1 2 id ad ab band patter [interpretaion] in rumby immunoblot
43185-8,hiv 1 & 2 ab patrn ser ib-imp
43185-8,hiv 1 random & 2 ab patrn ser ib-imp
43185-8,hv1 & 2 ab patrn serum ib-imp riba
43185-8,hiv 1 and 2 ab band pattern ib (s) [interp]
43185-8,and 1 hiv 2 ab band pattern ib (s) [interp]
43185-8,hi 1 and 2 ab bad pattern ib (s) [interp]
17326-0,neisseria meningitidis serogroup a ag [presence] in cerebral spinal fluid by immunofluorescence
17326-0,esseria meingiidis serogroup aag[presence] in cerebral spinal flud byimmunofurescence
17326-0,neisseria meningitidis cerebral a ag [presence] in serogroup spinal fluid by immunofluorescence
17326-0,n men sg a ag csf ql if
17326-0,n men sg a ag csf ql if
17326-0,n men trf sg a ag csf ql if
17326-0,n. meningitidis a ag if ql (csf)
17326-0,n. meningitidis a ag if ql (cerebrospinal fluid)
17326-0,. menngitidi a ag if q (s
40740-3,osmotic fragility of red blood cells--incubated
40740-3,osmotic fragility of red erythrocytes blood cells--incubated
40740-3,osmoic cells--incubated of red lood fragility quantitative
40740-3,of incubated nfr rbc
40740-3,of rbc nfr incubted
40740-3,fragil icubatdnfr of rbc
40740-3,osmotic fragility incubated (rbc)
40740-3,osmotic (rbc) incubated fragility qnt
40740-3,omoti fragiliy incuated (rc)
88698-6,protein electrophoresis panel - body fluid
88698-6,protin elctrophoesis al lud ody -
88698-6,protein elctrophorsispanel  bodyfluid
88698-6,prot elph pnl fld elph
88698-6,prot lph pnl elph fld
88698-6,elph prot pnl fld elph panel.chemistry
88698-6,protein electrophoresis panel elph (body fld)
88698-6,"protein body fluid, unsp lectrophoresis nel elp (body fld"
88698-6,elph electrophoreispanel prote (bod fld) frac
28045-3,cortisol [presence] in saliva (oral fluid) --1st specimen
28045-3,oisol [presence] n saliva (orafluid)--stpecimn
28045-3,cortisol [presece] insaliva (oral fud) --1st specime
28045-3,cortis sp1 sal ql
28045-3,crtis p1 sal point in time ql
28045-3,screen cortis presence sal sp1
28045-3,cortisol spec 1 ql (sal)
28045-3,cortisol spec 1 17-hydroxycorticosterone ql (sal)
28045-3,cortisol spec 1 qual ql (sal)
4111-1,alprazolam [mass] of dose
4111-1,alprazolam of random [mass] dos
4111-1,alprazlam dse of qnt [mas]
4111-1,alpraz dose
4111-1,drug doses dose alprz
4111-1,dose alpraz
4111-1,alprazolam (dose) [mass]
4111-1,alpralam [mass] point in time (s)
4111-1,quantitative alprazolam (dose [mass]
13966-7,cystine [moles/time] in 24 hour urine
13966-7,cystine 1 day [mole/time] in2 hour urine
13966-7,hour [moles/time] urn in 24 cystine urine
13966-7,cystine 24h ur-srate
13966-7,cystine 24h ua ur-srate
13966-7,24h cystine qnt ur-srate
13966-7,cystine (24h u) [moles/time]
13966-7,cystine 2h u) [moles/time
13966-7,cystine u) (24h [moles/time]
19418-3,tetrahydrocannabinol cutoff [mass/volume] in urine for confirmatory method
19418-3,ttrahydocannabinl cutoff [mas/voumein urne quant forconfiratory method
19418-3,ttrahydrocannabinol cuof [mas/olu] inuriefor confirmatory gcms methd
19418-3,thc cto ur cfm-mcnc
19418-3,thc ur cto cfm-mcnc
19418-3,lc/ms/ms ctourcfm-mcnc t
19418-3,tetrahydrocannabinol cutoff confirm (u) [mass/vol]
19418-3,tetrahydrocannabnol cutoff onfirm (u) mas/vol]
19418-3,level terahydrocannabinol u)[mass/vol] confirm cutoff
2147-7,cortisol free [mass/time] in 24 hour urine
2147-7,cortisol quant free [mass/time] in 24 hour urine
2147-7,cortisolfree [mass/time] in 4 hour urine
2147-7,cortis f 24h ur-mrate
2147-7,cortis f 4 ur-mrate
2147-7,cortis f24h urmate
2147-7,cortisol free (24h u) [mass/time]
2147-7,cortio free (24 u) [mass/tme] 1 day
2147-7,cortisol u) (24h free [mass/time]
54593-9,assessment reference date - observation end date during assessment period [cms assessment]
54593-9,assessmetreferencedate - observation panel.survey.cms end deuing asessment period [cms assessment]
54593-9,assessment reference date - observation end date during assessment period [cms assessment]
34231-1,aldosterone/creatinine [molar ratio] in urine
34231-1,in [molar ratio] aldosterone/creatinine urine
34231-1,aldosterone/creatinine [molar ratio] in urine endocrine
34231-1,aldost/creat ur-srto
34231-1,quan ur-srto aldost/creat
34231-1,ur-to ldst/cret
34231-1,aldosterone/creatinine (u) [molar ratio]
34231-1,aldotrone/cratinie (u) [molar ratio]
34231-1,aldosterone/creatinine (u) [molar ratio] ua
79322-4,lysophosphatidylcholine(26:0) [moles/volume] in serum or plasma
79322-4,lysophosphatidylcholine(26:0) [moles/volume] in serum or plas
79322-4,lophosphatdylchoine(26:0) [moes/volume]in ser or plsa
79322-4,lysopc(26:0) serpl-scnc
79322-4,serpl-scnc quan lysopc(26:0)
79322-4,lysopc(26:0) serpl-scnc qnt
79322-4,lysopc(26:0) [moles/vol]
79322-4,lysopc26:0) [moles/vol]
79322-4,[moles/vol] lysopc(26:0)
86884-4,"mds v3.0 - rai v1.14.1, v1.15.1, v1.16.1 - activities of daily living (adl) assistance - support provided - nsd, nod, ssd, sod [cms assessment]"
86884-4,"mds v3.0 - rai v1.14.1, v1.15.1, v1.16.1 - activities of daily living (adl) assistance - support provided - nsd, nod, ssd, sod [cms assessment]"
86884-4,"md v3.0 - ai v1.1.1 v1.15.1, v1.16. -ctivities of daily liing(adl) assitan  suppot povided - nsd, nod, ss, sod [cm assesment]"
57333-7,calcium.ionized [mass/volume] adjusted to ph 7.4 in serum or plasma by ion-selective membrane electrode (ise)
57333-7,cacium.ionied [mass/ome adusted to ph7. in lasma or ser b ion-selective membre lctrode(ise)
57333-7,calcium.ionized [mass/volume] adjusted to ph 7.4 in membrane or plasma by ion-selective ser electrode (ise)
57333-7,ca-i adj ph7.4 serpl ise-mcnc
57333-7,ca-i pl adj ise-mcnc serpl ph7.4
57333-7,ca-i adj ph7.4 serpl ise-mcnc
57333-7,calcium.ionized adjusted to ph 7.4 ise [mass/vol]
57333-7,to adjusted calcium.ionized ph 7.4 ise [mass/vol]
57333-7,cal calcium.ionized adjusted to ph 7.4 ise [mass/vol]
32596-9,trifluoperazine [mass] of dose
32596-9,trifluoerazine [mss random of ose
32596-9,trifluoperazine of [mass] dose
32596-9,trifperazine dose
32596-9,trifperazine random dose
32596-9,stelazine trferazine ose
32596-9,trifluoperazine (dose) [mass]
32596-9,[mass] (dose) trifluoperazine novoflurazine
32596-9,trifluoperazne (doe) [ass]
54298-5,hexanoylcarnitine (c6) [moles/volume] in urine
54298-5,(c6) hexanoylcarnitine [moles/volume] in urine
54298-5,hexanoylcarnitine (c6) [moles/volume] in urine
54298-5,hexanoylcarn ur-scnc
54298-5,ur-scnc hexanoylcarn level
54298-5,ur-scnc hexanoylcarn
54298-5,c6 (u) [moles/vol]
54298-5,(u) c6 [moles/vol]
54298-5,c6 (u) [moles/vol]
43407-6,bacteria identified in wound deep by culture
43407-6,bacteria identified in by identity or ql deep wound culture
43407-6,bacteria identified in wound deep by culture
43407-6,bacteria deep wnd cult
43407-6,bacera id deep nd cult
43407-6,wnd deep bacteria cult
43407-6,bacteria identified cx nom (deep wound)
43407-6,idenifed bacteri cx nom (deep point in time wound)
43407-6,cx identified bacteria nom (deep wound) id
6958-3,western equine encephalitis virus igm ab [titer] in serum by immunofluorescence
6958-3,immunofluorescence equine encephlitis virus igm a [titer] in serum by westen
6958-3,western equine by virus igm ab [titer] in serum encephalitis immunofluorescence
6958-3,weev igm titr ser if
6958-3,weev ig titr ser if
6958-3,weev igm titr ser autoantibodies if
6958-3,weev igm if (s) [titer]
6958-3,weev igm f [tier] (s)
6958-3,igm weev if (s) [titer] pt
72935-0,valproate induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
72935-0,valproate induced cytometry igm ab[presence] in seru or plama byflow neutrophil (fc)
72935-0,valproate induced neutrophil igm ab [presence] by serum or plasma in flow cytometry (fc)
72935-0,valproate (neut) igm serpl ql fc
72935-0,alproat (neut) dynamic igmserpl ql fc
72935-0,valproate (neut) fc pnm serpl presence igm
72935-0,valproate induced neutrophil igm fc ql
72935-0,valproate ql neutrophil igm fc autoantibody induced
72935-0,valproate igmfql neutrophil induce pr
27903-4,coxsackievirus b2 ab [presence] in cerebral spinal fluid
27903-4,coxsackieviru b2 ab [ql] in cerebral sl fluid
27903-4,coxsackiviru b2 [prence] ab in coxsackie virus cerebra spinal fluid
27903-4,cv b2 ab csf ql
27903-4,cv ab b2 csf ql
27903-4,ql b2 ab cerebrospinal fluid spinal fld cv
27903-4,coxsackievirus b2 ab ql (csf)
27903-4,q b2 pr b oxsackieirus (sf)
27903-4,coxsackievirus ab b2 ql (csf)
72769-3,zolpidem phenyl-4-carboxylate/creatinine [mass ratio] in urine
72769-3,lpidem phenyl-4-caroxylate/creatinine [mass rto] in urie zoldem
72769-3,zolpidem inurine [mass raio] phey-4-carboylate/creatinne
72769-3,zolpidem phenyl-4-carb/creat ur
72769-3,zolpidem phenyl-4-carb/creat quant ur
72769-3,point in time zolpiem phenyl-4-carb/cratu
72769-3,zolpidem phenyl-4-carboxylate/creatinine (u) [mass ratio]
72769-3,zolpidem ivedal phenyl-4-carboxylate/creatinine (u) [mass ratio]
72769-3,zolpidem phenyl-4-carboxylate/creatinine (u) [mass ratio]
73022-6,fexofenadine induced neutrophil igg ab [presence] in serum or plasma by flow cytometry (fc)
73022-6,fxofeadie inuced neutrophil antibody igg ab [pesence]i seru or plsa by flow (fc) cytometry
73022-6,fexofeadine iued netrophil plasmayflow pl ab [presence]in srum or igg cytomtry (fc)
73022-6,fexofenadine (neut) igg serpl ql fc
73022-6,fxofenadine (neut) ig serp ql fc
73022-6,fexofenadine (neut) igg serpl ql random fc
73022-6,fexofenadine induced neutrophil igg fc ql
73022-6,fexofenadine induced neutrophil igg fc presence random
73022-6,serum or plasma fexofenadine fc neutrophil igg induced ql
21372-8,abnormal lymphocytes/leukocytes in cerebral spinal fluid by manual count
21372-8,abnormal lymphocytes/eukocyes ncrebal spnal flud by mnua cot
21372-8,abnormal lymphoyts/leukocyte in cerebra spinl fluid by manu count
21372-8,lymph abn nfr csf manual
21372-8,lymph abn nfr csf lymphocyte manual
21372-8,lymph abnnfr csfmaual
21372-8,abnormal lymphocytes/leukocytes manual cnt (csf)
21372-8,abnormal point in time lymphocytes/leukcytes manual cntcsf)
21372-8,abnormal lymphocytes/leukocytes cnt manual lymphocyte (csf)
64139-9,butalbital/creatinine [mass ratio] in urine
64139-9,butalbital/creatinine [mass rtio] in urine
64139-9,butalbital/creatinine urine ratio] in [mass
64139-9,butalbital/creat ur
64139-9,ur butalbital/creat
64139-9,butalbital/creat ur
64139-9,butalbital/creatinine (u) [mass ratio]
64139-9,butalbital/creatinine (u) random ratio] [mass
64139-9,ratio] (u) [mass butalbital/creatinine
74398-9,neutrophils [#/volume] in cord blood
74398-9,neutrophils [#/vle] qnt in cod blood
74398-9,neutrophis [#/vlme] inord pnm blood
74398-9,neutrophils # bldco
74398-9,neutrophils # bldco
74398-9,neutrophils number concentration # bldco
74398-9,neutrophils (bldco) [#/vol]
74398-9,(bldco) neutrophils [#/vol]
74398-9,neutrophils (bldco) [#/vol]
44753-2,sulfatide igm ab [presence] in serum
44753-2,sulfatide igm ab [presence] immunoglobulin m serum in
44753-2,sulfatide in ab [ql] igm serum antby
44753-2,sulfatide igm ser ql
44753-2,slatie imer q
44753-2,sulfatide ser random im ql
44753-2,sulfatide igm ql (s)
44753-2,presence igm sulfatide (s)
44753-2,sulfatide igm ql (s) antibodies
59628-8,clobazam [mass/volume] in body fluid
59628-8,clobazam [mass/volume] fluid body in
59628-8,clobazam in [mass/volume] body mass concentration fluid
59628-8,clobazam fld-mcnc
59628-8,fldcnc clbazam fl
59628-8,fld-mcnc clobazam
59628-8,clobazam (body fld) [mass/vol]
59628-8,clobazam [mass/vol] fld) (body
59628-8,clobazam fld) (body noiafren [mass/vol]
11582-4,wuchereria bancrofti ab [units/volume] in serum
11582-4,wuchereria serum ab [units/volume] random in bancrofti
11582-4,wuchereria bancrofti ab [units/volume] in infectiousdisease serum
11582-4,w bancr ab ser-acnc
11582-4,ab wbanr ser-ac
11582-4,w bancr quan ab ser-acnc
11582-4,w. bancrofti ab qn (s)
11582-4,ab bancrofti w. qn (s)
11582-4,(s) banrofi ab n w.
74315-3,prrsv rna [#/volume] (viral load) in specimen by naa with probe detection
74315-3,y rn [#/volume] (viral load)i porcine epidemic abortion & respiratory syndrome specimen prrsv naa with prob detcion
74315-3,prrsv amplified rna [#/volume] (viral load)in specimen by naa with proe etection
74315-3,prrsv rna # spec naa+probe
74315-3,prrsv # rna pec naa+probe
74315-3,# rna prrsv spec naa+probe
74315-3,prrsv rna naa+probe (specimen) [#/vol]
74315-3,(specimen) rna naa+probe prrsv [#/vol]
74315-3,prrsv ra naa+probe 3sr sr (specimen) [/vol]
86745-7,"mds v3.0 - rai v1.14.1, v1.15.1 - current number of unhealed pressure injuries at each stage during assessment period [cms assessment]"
86745-7,"mds v3.0 - rai v1.14.1, v1.15.1 - current number of unhealed pressure injuries at each stage during assessment period survey [cms assessment]"
86745-7,"mds v3.-rai v1.14.1, no v15.1 - current numbe of unheaed pressure injuries a each stage durng assessment period [cms asessment]"
11257-3,haemophilus influenzae b igg ab [mass/volume] in serum by immunoassay
11257-3,hemophilus iluenae b ig ab mss/volume]in seum by mmunoassay
11257-3,haemophilus influenzae b igg ab immunoassay in ser by [mass/volume]
11257-3,haem influ b igg ser ia-mcnc
11257-3,haem infu b igg ia-mcnc ser
11257-3,haem influ b igg ser ia-mcnc autoantibodies
11257-3,h. influenzae b igg ia (s) [mass/vol]
11257-3,h. inluenzae [mas/vol] iggia(s) b
11257-3,ia influenzae b igg h. (s) [mass/vol]
23351-0,peste des petits ruminants virus ab [presence] in serum
23351-0,peste des petits ruminants virus ab [ql] in serum
23351-0,peste des petis ab virus rumnants [ql] infectiousdisease in serum
23351-0,pprv ab ser ql
23351-0,pprv ab serum vet ql
23351-0,ab aby pprv e ql
23351-0,peste des petits ruminants virus ab ql (s)
23351-0,peste virus infectiousdisease petits ruminants des ab ql (s)
23351-0,peste des virus ruminants petits ab ql (s)
21495-7,rickettsia spotted fever group igm ab [titer] in cerebral spinal fluid by immunofluorescence
21495-7,in spotted fever group igm ab [titer] rickettsia cerebral spinal fluid by immunofluorescence
21495-7,rickettsia spotted point in time spinal group igm ab [titer] in cerebral fever fluid by immunofluorescence
21495-7,rick sf igm titr csf if
21495-7,rick igm sf titr csf if
21495-7,rick sf spinal fl igm tir csf if
21495-7,r. spotted fever group igm if (csf) [titer]
21495-7,r.spotted fever group igm trf if (csf) [titer]
21495-7,r. spotted fever if igm group (csf) titer [titer]
4154-1,carbromal [mass] of dose
4154-1,carbroma [ass] of se
4154-1,caromal[mass] ofdoe
4154-1,carbromal dose
4154-1,carbomaldose
4154-1,carbrmldose drug doses
4154-1,carbromal (dose) [mass]
4154-1,carbromal (de) [mass]
4154-1,abomal [mass] (dos
103841-3,zolpidem [presence] in meconium
103841-3,in [prence] zolpidem meconium
103841-3,zlpidem [ql] in meconium
103841-3,zolpidem mec ql
103841-3,zolpidem presence mec pr
103841-3,mc zolpiem
103841-3,zolpidem ql (mec)
103841-3,zopide ambien ql (mec)
103841-3,somidem (mec) ql zolpidem
74342-7,mica*006 igg ab [presence] in serum
74342-7,mica*006 igg ab [ql] in serum antibodies
74342-7,gg mica*00 b [presenc] serology in seum
74342-7,mica*006 igg ser ql
74342-7,mica*006 igg serum ql
74342-7,sr mica*006 ser igg ql
74342-7,mica*006 igg ql (s)
74342-7,ql autoantibodies igg mica*006 (s)
74342-7,mica*006 igg ql (s)
72611-7,diazepam [presence] in saliva (oral fluid)
72611-7,diazepam [presence] saliva ordinal in (oral fluid)
72611-7,diazepam [pesence] in saiva (oral valium flud)
72611-7,diazepam sal ql
72611-7,diazepam sal ql pr
72611-7,ql ordinal sal diazepam
72611-7,diazepam ql (sal)
72611-7,ql diazepam (sal)
72611-7,qualitative iazpam (l) l
5604-4,boron [mass/volume] in blood
5604-4,boron [massvolume] i blood
5604-4,bron blood in [assvolume random
5604-4,boron bld-mcnc
5604-4,boron quant bld-mcnc
5604-4,mass concentration blood-mcnc boron
5604-4,boron (bld) [mass/vol]
5604-4,boo [mass/vol] (ld)
5604-4,orn (blood [mss/vol] mass concentration
30388-3,erythrocytes [#/volume] in pericardial fluid
30388-3,eryhroces [#/volume] in pericardial luid
30388-3,erythrocytes [#/volume] in pericardial fluid
30388-3,rbc # pcar
30388-3,ct # rb pcr
30388-3,rbc cardiology # pcar
30388-3,rbc (pericard fld) [#/vol]
30388-3,rbc (pericard [#/vol] fld)
30388-3,fld) (pericard rbc [#/vol]
100909-1,cronobacter sakazakii [presence] by organism specific culture
100909-1,sakazakii cronobacte [ql] y organism specific microbiology culture
100909-1,cronoacter saazaki [presce]y organism specific culure
100909-1,c sakazakii ql cult
100909-1,enterobacter sakazakii cult sakazakii ql c
100909-1,sakazakii c ql cult
100909-1,cronobacter sakazakii org specific cx ql (envir)
100909-1,cronobacter sakaakii org speific cx presence (nvir)
100909-1,cronobacter sakazkii cx specific org ql (nvi)
46093-1,calcium.ionized [moles/volume] in dialysis fluid
46093-1,calcium.ionized [moles/volume] in dialysis fluid
46093-1,[moles/volume] calcium.ionized in dialysis chemistry fluid
46093-1,ca-i dial fld-scnc
46093-1,ca-idial fld-scnc
46093-1,dial ca-i fld-scnc cal
46093-1,calcium.ionized (dial fld) [moles/vol]
46093-1,random calcium.ionized (dial fld) [moles/vol]
46093-1,calcium.ionized (dial fld) [moles/vol] point in time
4035-2,spironolactone [mass/time] in 24 hour urine
4035-2,spironolactone [masstim] in mrate 24hour urin
4035-2,quantitative spironolactone [mass/time] in 24 hour urine
4035-2,spironolactone 24h ur-mrate
4035-2,ur-mrate 24h sironoactone 24 hours
4035-2,spironolactone 24h ur-mrate
4035-2,spironolactone (24h u) [mass/time]
4035-2,quant spironolacton u) (h [mass/time]
4035-2,[mass/time] 24h u) spironolactoe
35234-4,urea nitrogen [mass or moles/volume] in serum or plasma
35234-4,urea itroen [mass or plas moles/lume] in serumor plas
35234-4,urea nitrogen [mass or moles/volume] pl in serum or plasma
35234-4,bun serpl-mscnc
35234-4,serpl-mscnc qnt bun
35234-4,serpl-mscnc bun blood urea nitrogen
35234-4,urea nitrogen [mass or moles/vol]
35234-4,mas ureaitron or moles/vol]
35234-4,urea nitrogen moles/vol] or [mass
33575-2,chlamydia trachomatis i ab [titer] in serum by immunofluorescence
33575-2,chlamydia trachomatis i ab [titer] immunofluorescence serum by in
33575-2,y racomtis iab titer] in seum hlamydia immunofluorescece
33575-2,c trach i ab titr ser if
33575-2,c trach titr ab i ser if
33575-2,c trac i ab titr sr if infectious disease
33575-2,c. trachomatis i ab if (s) [titer]
33575-2,chlam trac c. trachomatis i ab [titer] (s) if
33575-2,i trachomatis c. ab if (s) [titer]
101915-7,troponin t.cardiac [mass/volume] in 6 hour serum or plasma
101915-7,troponin t.cardiac [mass/volume] in 6 hour srumor sr plasma
101915-7,troponin t.cardac [mas/volume] i 6 plas seum o mass concentration hour
101915-7,troponin t 6h serpl-mcnc
101915-7,t plasma troponin 6h serpl-mcnc
101915-7,6h t troponin serpl-mcnc pl
101915-7,troponin t.cardiac (6h) [mass/vol]
101915-7,troponin t.cardiac (6h) [mass/vol] serpl
101915-7,troponin (6h) t.cardiac [mass/vol] serplas
88135-9,varicella zoster virus [presence] in cornea or conjunctiva by organism specific culture
88135-9,varicella zoster virus [presence] in cornea or by conjunctiva organism specific culture
88135-9,chicken pox virus specific zoster virus [presence] in cornea or conjunctiva by organism varicella culture
88135-9,vzv corn/cnjt ql cult
88135-9,vzvcorn/cnjt presence cut chickenpox
88135-9,vzv ql corn/cnjt cult
88135-9,vzv org specific cx ql (corn/cnjt)
88135-9,vzvorg ql c pecifi (con/njt)
88135-9,vz org specic c q (corn/cnt)
53800-9,platelets panel - blood by automated count
53800-9,thrombocytes platelets bld - panel by automated count
53800-9,automated panel - blood by platelets count
53800-9,platelets pnl bld auto
53800-9,platelets auto plt blood pnl
53800-9,platelets nl bld auto
53800-9,platelets panel auto (bld)
53800-9,elect latelets panel auto (bl)
53800-9,platlets (bld) auto panel
26792-2,methylenedioxyamphetamine [mass/mass] in stool
26792-2,methyleneioxyamphetamine [mass/mass] n stool
26792-2,[mass/mass] methylenedioxyampetamine instoo
26792-2,mda stl-mcnt
26792-2,stl-mcnt mda
26792-2,stl-mcnt fecal mda
26792-2,methylenedioxyamphetamine (stl) [mass/mass]
26792-2,[mass/mass] (stl) methylenedioxyamphetamine
26792-2,methylenedioxyamphetamine (stl) [mass/mass]
95165-7,mycoplasma gallisepticum ab/positive control in serum by immunoassay
95165-7,mycoplasma gallisepticum b/posiiv control in seru by immunoassay
95165-7,mycoplasm galliepticm b/positivecontrolin serum y immunoasay
95165-7,m gallisep ab/pos cntrl ser ia
95165-7,m galiep ab/pos cnt mycoplsm serum ia
95165-7,antibody ab/po galise m cntrl er
95165-7,m. gallisepticum ab/positive control ia (s) [relative ratio]
95165-7,m. serum ratio] ab/positive control ia (s) [relative gallisepticum
95165-7,m gallisepticum m. gallisepticum ab/positive control ia (s) [relative ratio]
106785-9,contactin-associated protein 1 ab [presence] in serum by cell binding immunofluorescent assay
106785-9,contactin-asciated protein1 ab [preenc] in erum by cell iding imuoflrescetassa
106785-9,contactin-associated protein 1 ab [presence] in ser by cell binding immunofluorescent assay screen
106785-9,caspr1 ab ser ql cba ifa
106785-9,caspr1  serql ba if
106785-9,caspr1 ab sr presence cba if
106785-9,contactin-associated protein 1 ab cell binding immunofluorescent assay ql (s)
106785-9,contactin-associated protein 1 ab cell binding immunofluorescent assay ql (s)
106785-9,contactin-associated protein (s) ab cell binding immunofluorescent assay ql 1 autoantibodies
26981-1,phenylalanine [moles/volume] in amniotic fluid
26981-1,phenylalnine [mol/volume] qnt in mnioticfluid
26981-1,[moles/volume] henylalanine in chemistry amniotic fluid
26981-1,phe amn-scnc
26981-1,quan amn-scnc phe
26981-1,quan amn-scnc phe
26981-1,phenylalanine (amn fld) [moles/vol]
26981-1,phenylalanine (amn qnt fld) [moles/vol]
26981-1,phenylalanine fld) (amn [moles/vol]
101947-0,cytomegalovirus dna [presence] in respiratory system specimen by naa with probe detection
101947-0,eection dna[presence] in respiratory sym specmen by na with prob cytmegalovirus
101947-0,wit na [preence] in respiatory systemspecimen bynaa cytomegaloirus probe detection screen
101947-0,cmv dna resp ql naa+probe
101947-0,mv dnaresp presence naa+probe
101947-0,cmv cytomgal dna res presence naa+probe
101947-0,cmv dna naa+probe ql (respiratory system specimen)
101947-0,cmv specimen) naa+probe ql (respiratory system dna
101947-0,system naa+probe q qualitative (rspratory cmvdna secimen)
29348-0,alprazolam [mass/volume] in gastric fluid
29348-0,fluid [mass/volume] level in gastric alprazolam
29348-0,alprazolam [mas/volum] in astr flud quant
29348-0,alpraz gast-mcnc
29348-0,gast-mcnc alpraz
29348-0,gastric contents gast-mcnc lpaz
29348-0,alprazolam (gast fld) [mass/vol]
29348-0,alprazolam (gast [mass/vol] fd)
29348-0,[mass/vol] (gast fld) alprazolam
9431-8,isobutanol [mass/volume] in blood
9431-8,isobutanol [mass/volume] blood in
9431-8,isobutanol[mas/volume] in blod
9431-8,isobutanol bld-mcnc
9431-8,isobtano bld-mcnc
9431-8,isobutanolbld-mcnc
9431-8,isobutanol (bld) [mass/vol]
9431-8,isobutaol [mas/vol] (bd)
9431-8,(bld) isobutanol [mass/vol]
11234-2,propoxyphene [mass/mass] in hair
11234-2,prooxyphene [massmass] distalgesic in hr
11234-2,drugs propoxyphene [mss/mass] in air
11234-2,propoxyph hair-mcnt
11234-2,hair-mcnt propoxyph
11234-2,addiction propoxyph hair-mcnt
11234-2,propoxyphene (hair) [mass/mass]
11234-2,(hair) propoxyphene [mass/mass]
11234-2,popoxyphne (hair) [mass/mass] quantitative
71408-9,cms - eye panel
71408-9,cms - eye panel
71408-9,pael eye ms
76411-8,neutrophils [#] in body fluid by manual count
76411-8,neutrophils [#] in body fluid by manual count
76411-8,neutrophils [#] in body fluid by manual count
76411-8,neutrophils fld manual
76411-8,neutrophils manual fld
76411-8,neutophils fld manal
76411-8,neutrophils manual cnt (body fld) [#]
76411-8,hematology/cell counts neutrophils manual cnt fld) (body [#]
76411-8,neutrophil manua cnt (body fld)#]
32024-2,magnesium [mass/volume] in 24 hour urine
32024-2,magnesium [mass/volume] in 24 hou urine 24 hours
32024-2,24 [mss/volume] n magnsum our urine
32024-2,magnesium 24h ur-mcnc
32024-2,nephrology 24h magnesium ur-mcnc
32024-2,ur-mcnc 24h manesium
32024-2,magnesium (24h u) [mass/vol]
32024-2,u) magnesium(4 [mss/vol
32024-2,(24h agnesi renal [mass/vl]
5906-3,neutrophils [#/volume] in synovial fluid by automated count
5906-3,neutrophis fluid insynovial [#/volume] by auomated count
5906-3,neutrophils [#/voume] in synovial fluid by autoatd cunt
5906-3,neutrophils # snv auto
5906-3,synov # neutrohils snv auto
5906-3,neutrophils joint fld # snv auto
5906-3,neutrophils auto (syn fld) [#/vol]
5906-3,neutrophils auto [#/vol] fld) (syn joint aspirate
5906-3,auto neutrophils (syn cnt fld) [#/vol]
78781-2,alprazolam cutoff [mass/volume] in urine for confirmatory method
78781-2,alpraolamcutoff confirmatory inurine for [mass/voume] mehod
78781-2,alprazolam cutoff [mass/volume] in urine for confirmatory method
78781-2,alpraz cto ur cfm-mcnc
78781-2,alpraz random ur cto cfm-mcnc
78781-2,ur cto alpraz cfm-mcnc
78781-2,alprazolam cutoff confirm (u) [mass/vol]
78781-2,alprazol cutoff confrm (u) [masvol]
78781-2,alprazolam cutoff onfir [mass/vol] (u)
53878-5,deprecated neisseria gonorrhoeae rrna [presence] in penis by probe and target amplification method
53878-5,deprecated neisseria gonorrhoeae rrna id [presence] in penis by probe and target amplification method
53878-5,deprecated neisseria gonorrhoeae rrna [presence] in amplification by probe and target penis method pen
53878-5,deprecated n gonorrhoea rrna penis ql pc
53878-5,dprecaed n gonorrhoea n gonorrhoa presence penis rrna pc
53878-5,dpreated  gonorrhoea rrna pens ql pc
53878-5,n. gonorrhoeae rrna naa+probe ql (penis)
53878-5,n. naaprobeql rrn nrrhoea (penis)
53878-5,ngonorrhoa rr naa+pro ql (enis)
12334-9,para aminophenol [mass/volume] in urine
12334-9,para aminopheno urine in [mass/vlme] quantitative
12334-9,urine quant aminophenol [mass/volume] in para
12334-9,p-aminophenol ur-mcnc
12334-9,aminophnol ur-mcnc
12334-9,4-aminophenol p-aminophenol ur-mcnc
12334-9,para aminophenol (u) [mass/vol]
12334-9,aminophenol(u) para [mas/vl]
12334-9,para quantitative aminophenol (u) [mass/vol]
8193-5,benzoylecgonine [presence] in urine by samhsa screen method
8193-5,benzoylecgonine urine in [presence] by samhsa screen method
8193-5,benzoylecgonine [ql] in urine by samhsa screen method
8193-5,bze ur ql samhsa scn
8193-5,scn ur presence samhsa bze ordinal
8193-5,ua bze ur ql samhsa scn
8193-5,benzoylecgonine samhsa screen method ql (u)
8193-5,benzoylecgonine samhsa screen (u) ql method
8193-5,benzoylecgonine method screen samhsa ql (u)
50046-2,hemicystine [moles/volume] in serum or plasma
50046-2,serum or plasma hemicystine [moles/volume] in serum or plasma
50046-2,hmicystine moes/volume] in serumor plasma
50046-2,hemicystine serpl-scnc
50046-2,serpl-scnc hemicystine
50046-2,hmcystine erpl-scnc point in time
50046-2,hemicystine [moles/vol]
50046-2,[moe/vo] qnt hecytin
50046-2,[moles/vol] hemicystine
16234-7,amphetamine [mass/volume] in urine by confirmatory method
16234-7,onfirmatory [mass/voue] in rine by amphtamine method
16234-7,amphetamine [mass/volume] in urine speed by confirmatory method
16234-7,amphet ur cfm-mcnc
16234-7,addiction amphet ur cfm-mn
16234-7,amphet ur cnfr cfm-mcnc
16234-7,amphetamine confirm (u) [mass/vol]
16234-7,confirm amphetamine (u) [mass/vol]
16234-7,aphetamine confm u) potentialforabuse [mass/vol]
23784-2,toxoplasma gondii ab [titer] in serum by hemagglutination
23784-2,toxoplasma gondii random ab [titer] in serum by hemagglutination
23784-2,toxoplasma gondii ab [titer] in serum by hemagglutination
23784-2,t gondii ab titr ser ha
23784-2,t gondii ab smqn titr ha serum
23784-2,t gondii ab titr serum ha toxoplasmosis
23784-2,t. gondii ab ha (s) [titer]
23784-2,(s) gondii ab ha t. [titer]
23784-2,t. gondii ab ha (s) [titer]
91452-3,promis pediatric item bank - physical stress experiences - version 1.0
91452-3,promis pediatric item bank - pt physical 1.0 experiences - version stress
91452-3,promis pediatric item bank - physical stress experiences - version peds 1.0
56049-0,deprecated phenx measure - current age
56049-0,current phenx measure - deprecated age
56049-0,depreate phenx measure - curret ae
5408-0,yersinia enterocolitica o:8 ab [units/volume] in serum
5408-0,yersinia enteocolitica o:8 ab nts/volume] in seum anti
5408-0,inserm enterocolitic o8 ab units/volume] yersinia
5408-0,y entero o:8 ab ser-acnc
5408-0,entero y o:8 ab sr-acnc
5408-0,y entero o:8 ab ser-acnc quant
5408-0,y. enterocolitica o:8 ab qn (s)
5408-0,anti y. enterocolitica ab o:8 qn (s)
5408-0,y. enterocolitica o:8 infectious disease ab qn (s)
89321-4,buprenorphine-3-glucuronide [mass/volume] in serum or plasma by confirmatory method
89321-4,buprenorhie-3-glucuroide [mas/volum] in srumor lc/ms/ms plasm y confimatory meod
89321-4,plsm plasma [mass/volume] in serum or buprenorphine-3-glucuronide by confirmatory method
89321-4,b3g serpl cfm-mcnc
89321-4,drug/toxicology b3g serum or plasma cfm-mcn
89321-4,b3g serpl cfm-mcnc
89321-4,buprenorphine-3-glucuronide confirm [mass/vol]
89321-4,buprenorphine3-glucuronide cofir illicit [massvol]
89321-4,confirm buprenorphine-3-glucuronide ser [mass/vol]
100756-6,oligoclonal bands [interpretation] in cerebral spinal fluid by isoelectric focusing
100756-6,oligoclonal bands [interpretation] in cerebral spinal fluid by isoelectric focusing frac
100756-6,bands oligoclonal [interpretation] in cerebral spinal fluid by isoelectric focusing
100756-6,oligoclonal bands csf ief-imp
100756-6,oigoclonalbands cerebrospinal fluid ie-imp prot
100756-6,oigoclonal bands ef-mp spinal fld cerebrospinal fluid
100756-6,oligoclonal bands isoelectric focusing (csf) [interp]
100756-6,oligoclonal bands isoelectric focusing [interp] (csf)
100756-6,oligoclonal bands isoelectric [interp] (csf) focusing
47396-7,babesia microti dna [presence] in specimen by naa with probe detection
47396-7,babesia micrti dna [presence] in specimen by naa point in time wih pobe etection
47396-7,babesia microti dna [presence] in specimen by naa pcr with probe detection
47396-7,b microti dna spec ql naa+probe
47396-7,b microti dna scql naa+probe
47396-7,b microti dna spec naa+probe ql
47396-7,b. microti dna naa+probe ql (specimen)
47396-7,probe amp b. microti dna naa+probe ql (specimen)
47396-7,b. microti naa+probe dna ql (specimen)
29372-0,codeine [mass/volume] in gastric fluid
29372-0,cdeine [ass/volum in gstric fluid
29372-0,codeine [mass/volume] in fluid gastric
29372-0,codeine gast-mcnc
29372-0,drugs gast-mcnc codeine
29372-0,drug/toxicology codeine gast-mcnc
29372-0,codeine (gast fld) [mass/vol]
29372-0,codeine(gast [mas/vol] quantitative fd)
29372-0,codeine fld) (gast [mass/vol]
22513-6,saint louis encephalitis virus igm ab [titer] in cerebral spinal fluid
22513-6,saint louis encephalitis virus ig ab [titer] neebralspinl fluid
22513-6,saint encephalti loui virus gm ab [titer] in cerebrl spinal luid
22513-6,slev igm titr csf
22513-6,igm slev titr csf
22513-6,cerebrospinal fluid igm titr slev
22513-6,slev igm (csf) [titer]
22513-6,slev igm cerebral spinal fluid (cf) [titer]
22513-6,slev titer (cf) igm
55893-2,hypoxanthine phosphoribosyltransferase/adenine phosphoribosyltransferase [enzymatic activity ratio] in red blood cells
55893-2,hypoxanthie phosphoriboylransferase/adenne posphorioyltransferase [enzymatic activity ratio]in re blod cells
55893-2,hypoxanthine phosphoribosyltransferase/adenine phosphoribosyltransferase [enzymatic activity ratio] in red blood cells
55893-2,hprt/aprt rbc-crto
55893-2,rbc-crto hprt/aprt
55893-2,random rbc-crto hprt/aprt
55893-2,hypoxanthine phosphoribosyltransferase/adenine phosphoribosyltransferase (rbc) [catalytic ratio]
55893-2,hypoanthine raio] phosphoribosyltransferse (rbc) [caatic phsphoibosyltrnsferase/adenine
55893-2,hypoxanthine phosphoribosyltransferase/adenine phosphoribosyltransferase (rbc) [catalytic ratio]
44099-0,galactomannan ag [presence] in serum or plasma by immunoassay
44099-0,galactomannan ag [presence] in serum or random plas by immunoassay
44099-0,immuoassay agprsenc] in serum or plasma by galactomannan
44099-0,galactomannan ag serpl ql ia
44099-0,galactomannan ag serpl ql ia
44099-0,ag galactomannan ordinal serpl ql ia
44099-0,galactomannan ag ia ql
44099-0,iaa galactomannan ia ag q
44099-0,galactomannan ag ql ia
10715-1,schistosoma sp identified in urine sediment by light microscopy
10715-1,schtosom sp identified miroscopy urine sedient by light in
10715-1,schissom sp identifiedinurin sedimen by light nominal mcroscopy
10715-1,schistosoma urns micro
10715-1,schistosoma schistosomiasis micro urs
10715-1,schistosoma urns micro blood fluke
10715-1,schistosoma sp identified lm nom (urine sed)
10715-1,schistosoa sp identifie bilharziasis l nom (urine sed)
10715-1,schistosoma sp nom lm identified (urine sed)
4046-9,tetrahydrocortisone [mass/volume] in urine
4046-9,[mass/volume] ua tetrahydrocrtsone iurine
4046-9,[ass/olume tetrahydrocotisone in urin
4046-9,thcortisone ur-mcnc
4046-9,ur ur-mcnc thcortisone
4046-9,ur-mcnc tcortsone
4046-9,tetrahydrocortisone (u) [mass/vol]
4046-9,tetrahydrocortisone [mass/vol] ua (u)
4046-9,ua tetrahydrocortisone [mass/vol] (u)
45305-0,coproporphyrin 1 [moles/mass] in stool
45305-0,coproporphyrin 1 [moles/mass] bowel movement in stool
45305-0,coroporphyrin 1 heme [moles/mas] intol
45305-0,copro1 stl-scnt
45305-0,stl-scnt copro1
45305-0,stl-scnt copro1
45305-0,coproporphyrin 1 (stl) [moles/mass]
45305-0,quan 1 coproporphyrin (stl) [mols/mass]
45305-0,coproporpyri 1 coproporph (tl)[moles/mass]
85356-4,pedv prototype strain s gene [cycle threshold #] in specimen by naa with probe detection
85356-4,pedv prototype with s gene [cycle threshold #] in specimen by naa strain probe detection
85356-4,pedv prototype srain probe gene [ccle hreshold # in secien by transcription mediated amplification a ith s eection
85356-4,pedv proto s ct spec qn naa+probe
85356-4,pedv proto aa+probe ct se qn s
85356-4,pedv proto qn ct spec s naa+probe
85356-4,pedv prototype strain s gene naa+probe (specimen) [threshnum]
85356-4,pedv prototype strain s gene naa+probe (specimen) [threshnum]
85356-4,pedv prototype strain s gene naa+probe pedv proto s (specimen) [threshnum]
42182-6,gossypol bound [mass/volume] in specimen
42182-6,gosypolund miscellaneous [mass/volme] speme in
42182-6,gssypol i [mass/volume] oud specin
42182-6,gossypol bound spec-mcnc
42182-6,gossypol gossypol bound bound spec-mcnc
42182-6,gossypo spec-mnc bound
42182-6,gossypol bound (specimen) [mass/vol]
42182-6,gossypol bound (pecimen) [mass/vol]
42182-6,gossypol bound (specimen) [mass/vol]
74599-2,3-hydroxypalmitoleylcarnitine (c16:1-oh) [enzymatic activity/mass] in fibroblast
74599-2,3-hyroxypalmitoeylarnitine [enzymatic 3oh-palmitoleylcarn (c6:1-oh) activity/mass] n fibroblast
74599-2,3-hydroxyalmileylcanitie (c16:1-o) [zymatic activitymass] infiboblas
74599-2,3oh-palmitoleylcarn fib-ccnt
74599-2,fib-ccnt 3oh-palmitoleylcarn
74599-2,fib-ccnt 3oh-palmitoleylcarn
74599-2,c16:1-oh (fibroblast) [catalytic activity/mass]
74599-2,c16:1-oh c16:1-oh (fibroblast) [catalytic activity/mass]
74599-2,c161-oh 3-hydroxy palmitoleylcarnitine (fbroblast) [catlytc activity/mas]
49830-3,norcodeine [mass/volume] in serum or plasma
49830-3,norcodeine [mass/volume] in serpl
49830-3,pl orodeine [ass/volum] in lm erumor
49830-3,norcodeine serpl-mcnc
49830-3,serpl-mcnc norcodeine addiction
49830-3,norcodene serpl-mcnc addiction
49830-3,norcodeine [mass/vol]
49830-3,[massv] norcodine
49830-3,norcodeine addiction [mass/vol]
54580-6,deprecated minimum data set - version 3.0
54580-6,depreated version data set - mnimm 3.0
54580-6,deprecated minimum data set mdsv3 - version 3.0
6580-7,deprecated treponema identified
6580-7,deprecated treponema identified
6580-7,identified treponema deprecated
6580-7,deprecated treponema xxx cult
6580-7,deprecated cult to be specified in another part of the message xxx treponema
6580-7,cult treponema xxx deprecated
6580-7,treponema identified org specific cx nom (specimen)
6580-7,treponema identified spec nom specific cx org (specimen)
6580-7,specific identified org treponema cx nom (specimen)
5306-6,rickettsia sp ab [titer] in serum by complement fixation
5306-6,rickettsia serum ab [titer] in sp by complement fixation
5306-6,rckettsia sp b [titr] in srum ab complement ixation
5306-6,rickettsia ab titr ser cf
5306-6,serum dilution factor ab titr rickettsia cf
5306-6,ricettsia serum autoantibody tir ab cf
5306-6,rickettsia sp ab cf (s) [titer]
5306-6,rickettsia iter] ab cf (s) sp
5306-6,rickettsia sp ab cf (s) titered [titer]
32060-6,chloroquine [moles/volume] in serum or plasma
32060-6,chloroquine [moles/volume] in random serum or plasma
32060-6,chloroquine [moles/volume] drug/toxicology in serum or plasma
32060-6,chloroquine serpl-scnc
32060-6,srpl-scnc chloroqune
32060-6,clorochine chloroquine serum or plasma-scnc
32060-6,chloroquine [moles/vol]
32060-6,pl chloroquine [moles/vol]
32060-6,chloroquine level [moles/vol]
91768-2,ova and parasites identified in sputum by light microscopy
91768-2,ovaand parasites identified in sputumy lgt micrscopy
91768-2,ova sputum parasites identified in and by light microscopy
91768-2,o+p spt micro
91768-2,micro spt o+p
91768-2,spt micro +p ico
91768-2,ova and parasites identified lm nom (sput)
91768-2,ova and parasites identified lm (sput) nom parasite
91768-2,micro va ad (sput idntified lm nm parasites
2803-5,deprecated phytanate (c16:0(ch3)4) [mass/volume] in serum or plasma
2803-5,deprecated phytanate (c16:0(ch3)4) [mass/volume] in serum or plasma serplas
2803-5,deprecated phytanate (c16:0(ch3)4) [mass/volume] plasma serum or in
2803-5,deprecated phytanate serpl-mcnc
2803-5,serp-mcnc hytanate quan deprecated
2803-5,deprecated serpl-mcnc phytanate
2803-5,phytanate (c16:0(ch3)4) [mass/vol]
2803-5,c16:(ch3)4) hytanate [ass/vol]
2803-5,phytanate (c16:0(ch3)4) [mass/vol] quant
26458-0,erythrocytes [#/volume] in synovial fluid
26458-0,erythrocytes [#/volume] synovial in fluid
26458-0,[#/volume] erythrocytes in synovial fluid
26458-0,rbc # snv
26458-0,# rbc snv
26458-0,# absolute rbc snv
26458-0,rbc (syn fld) [#/vol]
26458-0,hematology/cell counts [#/vol] (syn fld) rbc
26458-0,absolute rbc (syn fld) [#/vol]
93403-4,citrobacter sp dna [presence] by naa with probe detection in positive blood culture
93403-4,ctrobactr p dna [ql]by naa wth pobe detetion inpiiveblood cultur
93403-4,citrobacte s dna probe da [preence] byna wih probdetection in positive ood cultue
93403-4,citrobac sp dna bld pos ql naa+probe
93403-4,citroba sp dna nasba bld pos ql aa+prob
93403-4,cirobac probe amp sp dna bl pos ql naa+probe
93403-4,citrobacter sp dna naa+probe ql (pos bld culture)
93403-4,bld sp dna naa+probe ql (pos citrobacter culture)
93403-4,citroact sp dna naa+probe ql (pos culure) bl
23316-3,nairobi sheep disease virus ab [presence] in serum
23316-3,nairobi sheep disease ab virus [ql] in serum
23316-3,qual nairobi sheep disase rus ab [psence] i srum
23316-3,nsdv ab ser ql
23316-3,nsdv ab ser q
23316-3,antibody nd serum ab
23316-3,nairobi sheep disease virus ab ql (s)
23316-3,anti nairobi sheep disease virus ab ql (s)
23316-3,nairobi sheep disease virus abs ab ql (s)
87439-6,zika virus iga+igg+igm ab [interpretation] in specimen qualitative by immunoassay
87439-6,zika vius iga+ig+igm anti ab interpettion] in secimen qualitative by immunoassay
87439-6,zika virus iga+igg+igm ab [interpretation] n specimen alitati by immunossay
87439-6,zikv iga+igg+igm spec ia-imp
87439-6,ia-imp iga+igigm immunoglobulin g spec zikv
87439-6,zikv iga+igg+igm ia-imp spec
87439-6,zikv iga+igg+igm ia ql (specimen) [interp]
87439-6,iga+igg+igm zikv unspecified ia presence (specime) [interp]
87439-6,zikv iga+igg+igm ia ql immunoglobulin m (specimen) [interp]
12375-2,clozapine+norclozapine [mass/volume] in serum or plasma
12375-2,lozapine+norclozapin[mas/volue in r serum plasma
12375-2,clozapine+norclozapine [mass/volume] plasma serum or in
12375-2,clozapine+nor serpl-mcnc
12375-2,quantitative clozapine+nor serum or plasma-mcnc
12375-2,clozapine+nor plsm serpl-mcnc
12375-2,clozapine+norclozapine [mass/vol]
12375-2,point in time clozapine+norclozapine [mass/vol]
12375-2,clozapine+norclozapine [mass/vol]
44301-0,asparagine/creatinine [mass ratio] in 24 hour urine
44301-0,[mass aparaine/cratinine atio in 2hour urine quantitative
44301-0,asparagin/creatiniemss rtio] in 4 hour urine
44301-0,asparagine/creat 24h ur
44301-0,aspaagineeat 24h ur 24 hours
44301-0,sparaine/crat 24h ur
44301-0,asparagine/creatinine (24h u) [mass ratio]
44301-0,(24u) asparagine/cratinine [mass mass concentration ratio rat]
44301-0,asparagine/creatinine chemistry (24h u) ratio] [mass
29525-3,aconitate/creatinine [molar ratio] in urine
29525-3,acoitate/crainne urine in [molarratio]
29525-3,aconitte/creatinine [ola rati]in ure cr
29525-3,aconitate/creat ur-srto
29525-3,urn ur-srto aconitate/creat
29525-3,aconitat/reat ur-srto aconitic acid
29525-3,aconitate/creatinine (u) [molar ratio]
29525-3,qnt ratio] (u) [molar aconitate/creatinine
29525-3,[mol aconitate/creatinine(u) ratio quan
99582-9,symptom and timing panel
99582-9,symptom and timing p prime panel
99582-9,and symptom timingpanel pt
99582-9,symptom and timing panel
99582-9,panel.h&p symptom and timing panel
99582-9,timing and random symptom panel
63336-2,scl-70 extractable nuclear ab [units/volume] in body fluid by immunoassay
63336-2,scl-70 xctble nuclear body [uis/volumein ab fluid by immunossay
63336-2,ab extractable fld nuclear scl-70 [units/volume] in body fluid by immunoassay
63336-2,ena scl70 ab fld ia-acnc
63336-2,ena abfld scl70 ia-acnc
63336-2,ena aby scl70 ab fld ia-acnc
63336-2,scl-70 extractable nuclear ab ia qn (body fld)
63336-2,sc-70 exractable nuclear abia q (body fld)
63336-2,scl-0 exractble nuclear abia qn (body fld)
14451-9,virus identified in eye by culture
14451-9,rus identiied in eyeb culture
14451-9,virus identified in eye by culture
14451-9,virus eye cult
14451-9,virus eye ult cultures
14451-9,cult eye viru
14451-9,virus identified cx nom (eye)
14451-9,infectious disease virusidentified cx nom eye)
14451-9,virs identiied cx o(eye)
18272-5,rna ab [units/volume] in serum
18272-5,rn ab [nts/volume] in ru
18272-5,rna ab serum in [units/volume]
18272-5,rna ab ser-acnc
18272-5,na ab ser-acn
18272-5,rna ab serum-cnc
18272-5,rna ab qn (s)
18272-5,qn ab rna (s)
18272-5,(s) ab qn antby rna
88149-0,microscopic observation [identifier] in nasopharynx by gram stain
88149-0,microscopic observation [identifier] in nasopharynx nominal by gram stain
88149-0,microscopic observaion [idenifier] nasoharynx by gram infectiousdisease stain
88149-0,gram stn nph
88149-0,gram stn nph gram stn
88149-0,nph st stn gram
88149-0,microscopic observation gram stain nom (nph)
88149-0,(nph) observationgram stainnm mcroscpic identity or presence
88149-0,microscopic observation point in time gram sta nom nph)
6460-0,bacteria identified in sputum by culture
6460-0,bacteria identified in sput by cultur
6460-0,uture identifiedin spum b batera
6460-0,bacteria spt cult
6460-0,bacteia id spt cut
6460-0,bacteria spt cult
6460-0,bacteria identified cx nom (sput)
6460-0,bacteria identified cx nom (sput)
6460-0,(sput) identified cx lung nom bacteria
16933-4,hepatitis b virus core ab [presence] in serum
16933-4,heatitis b point in time vius core ab [resnceinerum
16933-4,hepatitis ab virus core b [presence] in ser
16933-4,hbv core ab ser ql
16933-4,ser coreab hbv ql
16933-4,hbv core serum ab ql
16933-4,hbv core ab ql (s)
16933-4,ab core hbv ql (s) hbv
16933-4,hbv a hbv core presence (s)
62117-7,promis pediatric item bank - physical function - mobility - version 1.0
62117-7,promis pediatric versin ank - physical function - mobility - item 1.0
62117-7,version ite bak - physical unction -mobility promispeditrc 1.0 panel.survey.promis
33806-1,hiv 2 igg ab [presence] in serum by immunoblot
33806-1,hiv 2 igg ab [presenc] in rum by immunobot
33806-1,hiv igg ab [preence] aids in ser by immnoblt
33806-1,hiv 2 igg ser ql ib
33806-1,qlib igg serum anti iv2
33806-1,hiv 2 igg serum autoantibodies ql ib
33806-1,hiv 2 igg ib ql (s)
33806-1,2 id hv igg ib presence (s)
33806-1,ql hiv ql igg ib 2 (s)
101555-1,campylobacter upsaliensis dna [presence] in stool by naa with probe detection
101555-1,campylobacter upsaliensis dna [presence] in stool by naa with faeces probe detection
101555-1,campylobacter upsaliensis dna [presence] in naa+probe stool probe naa with by detection
101555-1,c upsaliensis dna stl ql naa+probe
101555-1,microbiology c upsaliensis dna stl ql naa+probe
101555-1,c upsaliensi dna tl dna probe lnaa+probe
101555-1,campylobacter upsaliensis dna naa+probe ql (stl)
101555-1,campylobacter upsaiensis 3sr sr dna ql naa+prob (stl)
101555-1,campylobacter upsalinsisdna naa+probe nasba ql (stl)
72498-9,tripeptidyl peptidase i [enzymatic activity/volume] in dbs
72498-9,tripeptidl petidase i [enzymati bs in ctivity/vlum]
72498-9,ripeptiyl [nzyatic i chemistry eptidase ctivit/volum]in dbs
72498-9,tripeptidyl peptidase i dbs-ccnc
72498-9,tripepidyl eptidase i b-ccn
72498-9,tripeptidyl qnt peptidase i dbs-ccnc
72498-9,tripeptidyl peptidase i (dbs) [catalytic activity/vol]
72498-9,[catalytic qnt peptidase i (dbs) tripeptidyl activity/vol]
72498-9,tripeptidyl peptidase i (dbs) [catalytic activity/vol]
80386-6,bladder tumor ag [presence] in urine by rapid immunoassay
80386-6,bladder tumor ag [ql] enzyme immunoassay in urine by rapid immunoassay
80386-6,by tumor ag [presence] in urine bladder rapid immunoassay
80386-6,bladder tumor ag ur ql ia.rapid
80386-6,ql tumor iaa ag ur bladder ia.rapid
80386-6,bladder tumor ag ur ql ia.rapid
80386-6,bladder tumor ag ia.rapid ql (u)
80386-6,bladder tumor ag ia.rapid ql qual (u)
80386-6,ladder agia.rapidql tmor (u)
5758-8,deprecated dimethylbenzene
5758-8,dimethylbenzene deprecated
5758-8,dimethylbenzene deprecated mass concentration
5758-8,deprecated dmb bld ql
5758-8,bld dmb deprecated ql
5758-8,xylene deprecated dmb bld presence
5758-8,dimethylbenzene ql (bld)
5758-8,ql bld dimethylbenzene (bld)
5758-8,ql dimethylbenzene (blood)
32233-9,carbamoyl phosphate synthetase [enzymatic activity/mass] in tissue
32233-9,carbamoyl phosphate quantitative in [enzyaicactiviymas] synhase tissue
32233-9,carbamoyl phosphate synthetase [enzymatic activity/mass] in tissue
32233-9,cps tiss-ccnt
32233-9,cpstissccnt chemistry
32233-9,ps tiss-cnt pi
32233-9,carbamoyl phosphate synthetase (tiss) [catalytic activity/mass]
32233-9,synthetas osphate arbamoyl pi (tiss [atalyti activity/ass]
32233-9,carbamoyl phos [catalytic synthetase (tiss) phosphate activity/mass]
94475-1,borrelia burgdorferi iga and igg and igm [interpretation] in cerebral spinal fluid
94475-1,borrelia burgdorer iga an gg and [intrpreaton] igm in cerebral spin fluid
94475-1,borrelia burgdorferi iga and spinal and igm [interpretation] in cerebral igg fluid
94475-1,b burgdor iga+igg+igm csf-imp
94475-1,b burgdor csf-imp iga+igg+igm
94475-1,b burgor iga+igg+igm csf-ip
94475-1,b. burgdorferi iga and igg and igm (csf) [interp]
94475-1,b. burgdorferi iga impression and [interp] and igm (csf) igg
94475-1,b. burgdorferi iga and immunoglobulin a igg and igm (csf) [interp]
17041-5,lactate dehydrogenase [presence] in urine
17041-5,lacttedehydrgenae in [rsece] urne
17041-5,[pesence]in dehydrogenase lacate rine
17041-5,ldh ur ql
17041-5,dh ql urql
17041-5,ldh ql ld ur
17041-5,ldh ql (u)
17041-5,ql ldh (u)
17041-5,pr (u) ldhq
4627-6,hemoglobin yoshizuka [presence] in blood
4627-6,point in time in yoshizukaprsence] hemoglobin blod
4627-6,emoglobin bood [preenc] in yoshizuka
4627-6,hgb yoshiz bld ql
4627-6,hgb shiz qualitative bld ql
4627-6,hgb bldql yoshiz
4627-6,hemoglobin yoshizuka ql (bld)
4627-6,ql yoshizuka hemoglobin (bld)
4627-6,hemoglobin ql yoshizuka ql (bld)
13448-6,calcium/osmolality [ratio] in serum or plasma
13448-6,calcium/osmolality [ratio] in serum or plasma serum or plasma
13448-6,calcium/osmolality in [ratio] qnt serum or plasma
13448-6,calcium/osmolality serpl-rto
13448-6,quan serpl-rto calcium/osmolalty
13448-6,serum or plasma-rto calcium/osmolality
13448-6,calcium/osmolality [ratio]
13448-6,calcium/osmolality serum or plasma [ratio]
13448-6,[ratio] quantitative calciu/osmlality
43153-6,blood coagulation device panel
43153-6,bloodcoagulatio device panel panel.devices
43153-6,bld coagulation device panel
43153-6,blood coagulation device pnl
43153-6,lood cagulation device pnl
43153-6,blood coagulation device panl pnl
17736-0,trichloroacetate [mass/volume] in blood
17736-0,triclorcette mss/volume] in bood
17736-0,trichoracetate[mass/volum] blood n
17736-0,tca bld-mcnc
17736-0,bld-mcnc tca
17736-0,quant tca bl-mcnc
17736-0,trichloroacetate (bld) [mass/vol]
17736-0,(bld) trichloroacetate [mass/vol]
17736-0,trichloroacetate (bl) [mass/vol]
35639-4,chlamydophila pneumoniae+chlamydophila psittaci dna [presence] in tissue by naa with probe detection
35639-4,chlamydophiapneumoniae+chlamydophila psitaci dna pesnce] in tisue detection aa screen with prbe by
35639-4,chlamydophila pneumonia+chlamydphlapsittaci amplification da prence]i tisue with naa by probedetetion
35639-4,c pn+psitt dna tiss ql naa+probe
35639-4,c tiss dna pn+psitt ql naa+probe
35639-4,c pn+psitt dna presence tiss naa+prbe
35639-4,c. pneumoniae+c. psittaci dna naa+probe ql (tiss)
35639-4,c. pneuniae+c. psittci dna na+robe (tis) ql
35639-4,c. pnemoniae+c. psittci dna naarobe (tiss) ql
69797-9,1-hydroxymidazolam [mass/volume] in serum or plasma
69797-9,1-hydroxymidzolam [mas/volume] in erum or point in time plas
69797-9,1-hydroxymidazolam [mass/volume] quan in serum or plasma
69797-9,1oh-midazolam serpl-mcnc
69797-9,serpl-mcnc 1oh-midazolam mass concentration
69797-9,1oh-midazolam qnt serpl-mcnc
69797-9,1-hydroxymidazolam [mass/vol]
69797-9,[mass/vol] 1-hydroxymidazolam
69797-9,[mss/ol] 1-hydroxymdazolm
71696-9,granulocytes/leukocytes in body fluid by automated count
71696-9,fluid in body granulocytes/leukoctes by automated ount
71696-9,grnlocytes/leukocytes in body flud byauoted count
71696-9,granulocytes nfr fld auto
71696-9,granulcyes fr auto lkcs fld
71696-9,grnulocytes nfr fld ato
71696-9,granulocytes/leukocytes auto (body fld)
71696-9,granulocytes/leukocytes auto fld) (body grans
71696-9,granuloctes/leukoyts fld) (body auo
60546-9,polio virus identified [type] in isolate by organism specific culture
60546-9,poliovirus polio vrus identified [typ in isolate by rgaism specific culure
60546-9,poio virus identified culture i isolate by orgnism specific [type]
60546-9,pv islt cult
60546-9,pv islt cult
60546-9,cult islt pv
60546-9,polio virus identified org specific cx nom (isol)
60546-9,polio identified virus org specific cx nom (isol)
60546-9,polio virus ientified rg cx specific nom (io)
34272-5,collagen crosslinked n-telopeptide/creatinine [ratio] in urine
34272-5,collagen crosslinke n-telopeptide/reainine [ratio] pt i urn
34272-5,collagen crosslinked n-telopeptide/creatinine [ratio] in urine
34272-5,collagen ntx/creat ur-rto
34272-5,ntx/creat collagen ur-rto
34272-5,collagen ur ntx/crat ur-rt
34272-5,collagen crosslinked n-telopeptide/creatinine (u) [ratio]
34272-5,collgen n-telopeptide/cetnine crsslinked n-telopeptide of type i collagen (u [ratio
34272-5,n-telopeptide/creatinine crosslinked collagen (u) [ratio]
43075-1,borrelia burgdorferi c6 ab [units/volume] in serum
43075-1,borrelia burgdorferi c6 in [units/volume] ab serum
43075-1,c6 burgdorferi borrelia ab [units/volume] in ser
43075-1,b burgdor c6 ab ser-acnc
43075-1,microbiology bugdor b c6abser-acnc
43075-1,arbitrary concentration b burdor ab c6 ser-acnc
43075-1,b. burgdorferi c6 ab qn (s)
43075-1,b. brgdorferic6 (s) qn b
43075-1,b. bugdorferi (s) quan ab qn c6
76598-2,klebsiella pneumoniae phoe gene [#/mass] in xxx.tissue by naa with probe detection
76598-2,klebsiella pneumoniae phoe gene [#/mass] in xxx.tissue probe naa with by detection
76598-2,klebsiella pneumoniae phoe gene [#/mass] in xxx.tissue by naa probe amp with probe detection
76598-2,kl pneum phoe xxx.tiss naa+probe
76598-2,phoe pneum kl xxx.tiss naa+probe kl pneum phoe
76598-2,klpnem phoexx.tiss to be specified in another part of the message naa+probe
76598-2,k. pneumoniae phoe gene naa+probe (unsp tissue) [#/mass]
76598-2,k. peumonae phoe enenaa+prbe (unsp tissue) [#/ass]
76598-2,k. gne phoe pneumonie naa+probe (unsp tissue) [#/mass]
8734-6,left ventricular cardiac output by spiral ct
8734-6,left ventricular cardiac output by spiral ct
8734-6,left ventricular cardacutputby spral ct
8734-6,lv output spiral ct
8734-6,lv output hrt spiral ct
8734-6,l output ventricular spiral ct
82972-1,"butabarbital [mass/volume] in serum, plasma or blood by confirmatory method"
82972-1,"butabarbital [mas/volume] cnirmatory seum, plasma or barbiturate blood by in method"
82972-1,"butabarbital [mass/volume] methd srum, plasma or bloodby confirmatry in"
82972-1,butabarbital serplbld cfm-mcnc
82972-1,cfm-mcnc serplbld butabarb butabarbital
82972-1,butabarbital serplbld fm-mcnc
82972-1,butabarbital confirm (s/p/bld) [mass/vol]
82972-1,butabaital confirm (s//bld [mass/vol] ser or plasma
82972-1,butabarbital confirm quan (s/p/blood) [mass/vol]
6604-3,influenza virus identified in specimen by organism specific culture
6604-3,inflenza viru idnified in specimen by organismspecific cultu
6604-3,influnza ius identified in pecimn by oanism scific culture
6604-3,fluv spec cult
6604-3,spec fluv cult
6604-3,infectious disease fluv cult pec
6604-3,fluv identified org specific cx nom (specimen)
6604-3,fluv identified infectiousdisease org (specimen) cx nom specific
6604-3,rgspecific identified fluv cx nom random (specimen)
72955-8,sertraline induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
72955-8,sertraline induced nutrophil igm ab [presece] in serm or plasa by flw cytometry (fc)
72955-8,sertraline induced neutrophil igm ab [presence] in serum or plasma by flow cytometry antibodies (fc)
72955-8,sertraline (neut) igm serpl ql fc
72955-8,sertraline fc igm antby serum or plasma ql (neut)
72955-8,sertraline net) igm serpl sr qlfc
72955-8,sertraline induced neutrophil igm fc ql
72955-8,ertralin inducd neutrophl ql fc igm pt
72955-8,srtrline iduced neutrphil igm neutr fc l
87349-7,senecavirus a vp1 gene [nucleotide sequence] in isolate by sequencing
87349-7,sequence] a vp1 gene sva [nucleotide senecavirus in isolate by sequencing
87349-7,senecavirus a vp1 next generation sequencing isolate [nucleotd sque] in gene bysequening
87349-7,sva vp1 gene islt-seq
87349-7,veterinary ilt-se vp1 gene sv
87349-7,sva sva vp1 gene islt-seq
87349-7,sva vp1 gene sequence nom (isol)
87349-7,v v1 gene sequence nom (sol)
87349-7,sva sequence gene vp1 nom (isol)
13130-0,motilin [units/volume] in serum or plasma
13130-0,motilin [unit/volume]in serm or point in time plama
13130-0,motilin [units/volume] in or ser plasma
13130-0,motilin serpl-acnc
13130-0,serpl-acnc pl motilin
13130-0,arbitrary concentration serpl-acnc motilin
13130-0,motilin qn
13130-0,qn motiin
13130-0,motilinq
43579-2,complement c3 [mass/volume] in pleural fluid
43579-2,fluid c3 [mass/volume] in pleural complement
43579-2,c3 complement [mass/volume] in pleural fluid
43579-2,c3 plr-mcnc
43579-2, plr-mc
43579-2,plr-mcnc c3
43579-2,complement c3 (pleur fld) [mass/vol]
43579-2,(pleur c3 complement fld) [mass/vol]
43579-2,olement c3 quant (pleur fld) [mass/ol]
17555-4,measles virus ab [units/volume] in serum --1st specimen
17555-4,measles virus ab autoantibodies [units/volume] in serum --1st specimen
17555-4,measles virus ab [units/volume] serum in autoantibody --1st specimen
17555-4,mev ab sp1 ser-acnc
17555-4,mev ab sp1 serum-acnc
17555-4,ab mev sp1 seranc
17555-4,mev ab spec 1 qn (s)
17555-4,mev ab spec 1 qn ()
17555-4,mv ab n pec1 (s)
32271-9,taurine [moles/volume] in body fluid
32271-9,taurine body in [moles/volume] fluid
32271-9,in [moles/volume] taurine quant body fluid
32271-9,taurine fld-scnc
32271-9,fld-scnc taurine tau
32271-9,fldscnc tarine
32271-9,taurine (body fld) [moles/vol]
32271-9,taurine (body fld) [moles/vol]
32271-9,substance concentration [moles/vol] (body fld) taurine
103638-3,4-hydroxy xylazine [mass/volume] in urine by confirmatory method
103638-3,4-hydroxy ylazine [mass/volume] i urie bconfirmory metho
103638-3,4-ydroy xylaine onfirmatory in urine by [ass/volume] method
103638-3,4oh-xylazine ur cfm-mcnc
103638-3,ur ur 4oh-xylazine cfm-mcnc
103638-3,cfm urcfm-mcc 4o-xlazine
103638-3,4-hydroxy xylazine confirm (u) [mass/vol]
103638-3,4-hydroxy confirm xylazine (u) [mass/vol]
103638-3,confirm xylazine 4-hydroxy (u) [mass/vol]
14202-6,chlamydia trachomatis c iga ab [titer] in serum by immunofluorescence
14202-6,chlamydia tracoati ab iga [titer] n serum by munofloresence
14202-6,chlamydia serum c iga ab [titer] in trachomatis by immunofluorescence immune globulin a
14202-6,c trach c iga titr ser if
14202-6,ser trach c iga titr c if
14202-6,ctrach aby c if titr ser iga
14202-6,c. trachomatis c iga if (s) [titer]
14202-6,trachomatis c. c iga if (s [tter]
14202-6,c.trachomatis c iga if (s) iter] immune fluorescence
96505-3,colorado tick fever virus igm ab [presence] in specimen by immunoassay
96505-3,colorado tick a virus igm ever [presence] in specimn by immunossay
96505-3,colorad tck secimn virus imab [prsece] in fever b immunoassay
96505-3,ctfv igm spec ql ia
96505-3,ctv pc igm ql i
96505-3,ctfv igm spec ql ia point in time
96505-3,colorado tick fever virus igm ia ql (specimen)
96505-3,colordo tck feve virs igmia ql (specmen)
96505-3,olorado tck fver virusigm ia ql (spcimen)
14530-0,rubella virus ag [presence] in vaginal fluid by immunofluorescence
14530-0,rubllavirus n [presene] g vaginal fluid vagina by immuofuorecence
14530-0,rublla viru ag fluoresent [presenc] in vaginl fid byimmunofluoresence
14530-0,rubv ag vag ql if
14530-0,rubv ql vag ag if
14530-0,rubv ag vag ql if
14530-0,rubella virus ag if ql (vag fld)
14530-0,fld) virus ag if ql (vag rubella
14530-0,virus rubla ag if ql (vag fld)
31135-7,cocaethylene [mass/volume] in bile fluid
31135-7,bile [mss/volume] in ocaetylen fluid
31135-7,[mass/volume] cocaethylene in quantitative bile fluid
31135-7,cocaethylene bifl-mcnc
31135-7,cocathylenebifl-mnc
31135-7,bifl-mcnc cocaethylene quant
31135-7,cocaethylene (bile) [mass/vol]
31135-7,random (bile) cocaethylene [mass/vol]
31135-7,mass/vol] random ccaethylne(bile)
50546-1,bacterial susceptibility panel by disk diffusion (kb)
50546-1,by uscepbility panel bacteal disk diffusion (kb
50546-1,diffusion susceptibility panel by disk bacterial (kb)
50546-1,bacterial susc pnl islt kb
50546-1,kb susc pnl islt bacterial
50546-1,susc bacterial pnl islt kb suscept
50546-1,bacterial susceptibility panel disk diffusion (kb) (isol)
50546-1,bactrial susceptibilty susceptiilty (isol) diskdffusio (kb panl
50546-1,bacterial susceptibility diffusion disk panel (kb) (isol)
3718-4,lithium [mass/mass] in hair
3718-4,lithium [mass/mas] i hi
3718-4,lithium [mass/mass] hair in
3718-4,lithium hair-mcnt
3718-4,hairmcnt drug/toxicology lithiu
3718-4,hair-mcnt lithium har
3718-4,lithium (hair) [mass/mass]
3718-4,lithium (hir) [massmass]
3718-4,[mas/mass] (hair lithium
7993-9,rhinovirus rna [presence] in specimen by naa with probe detection
7993-9,rhnovrus rna with in specimen by naa [resenc] probedetection
7993-9,detection ra [presenc]n specimenb naa wth prob rhinovirus
7993-9,rhinovirus rna spec ql naa+probe
7993-9,spec rna rhinovirus ql 3 self-sustaining sequence replication naa+probe
7993-9,rhinovirus rna id spec naa+probe ql
7993-9,rhinovirus rna naa+probe ql (specimen)
7993-9,hrv rhinovirus rna naa+probe (specimen) ql
7993-9,rhinovirus rnanaa+robe q (specimen)
47632-5,glycerol/creatinine [molar ratio] in urine
47632-5,urine [molar ratio] in glycerol/creatinine
47632-5,glycerol/creatinine in ratio] [mlar urie
47632-5,glycerol/creat ur-srto
47632-5,glycrol/creat ur-sro
47632-5,ur-srto glycerol/creat
47632-5,glycerol/creatinine (u) [molar ratio]
47632-5,glycerol/creatinine (u) [molar ratio]
47632-5,glycerol/creatinine (u) scrto ratio] [molar
14157-2,coproporphyrin [mass/volume] in serum or plasma
14157-2,coproporphyrin [mass/volume] in serp serum or plasma
14157-2,coproporphyrin sr [mass/volume] in seum plasma or
14157-2,copro serpl-mcnc
14157-2,serum or plas opro serpl-mcnc
14157-2,serp-mnc point in time copro
14157-2,coproporphyrin [mass/vol]
14157-2,coproporphyin ms/vol]
14157-2,[assvol] coproporphyrin serpl
81188-5,tumor site of stomach cancer
81188-5,tumor anatomy site of stomach cancer
81188-5,tumo ste stoach of clin cancer
81188-5,tumor site stomach cancer
81188-5,stomach site tumor cancer
81188-5,pt stomach uorite cacr
42978-7,polio virus 2 ab [titer] in body fluid
42978-7,polio virus bod 2 ab [titer] in body fluid
42978-7,polio ab 2 virus [titer] in body fluid
42978-7,pv2 ab titr fld
42978-7,fld titr body fluid pv2ab
42978-7,pv2 ab titr fl
42978-7,polio virus 2 ab (body fld) [titer]
42978-7,lio virus 2 ab [titer] fl) (bod
42978-7,polio virus fld) ab (body 2 [titer]
30513-6,pregnanetriolone/creatinine [mass ratio] in urine
30513-6,chemistry pregnanetrioone/creatinie [mass ratio] n urine
30513-6,pegnanetriolone/creatinine mass concentration ratio iurine ratio] [mas
30513-6,pregntrlone/creat ur
30513-6,ur pregntrlone/creat
30513-6,ur regntrone/creat
30513-6,pregnanetriolone/creatinine (u) [mass ratio]
30513-6,(u) pregnanetriolone/creatinine [mass ratio] pregnanetr
30513-6,(u pregnanetriolone/creatnie [mass ratio]
106918-6,lymphocytes/cells in bronchoalveolar lavage
106918-6,lavage in bronchoalveolar lymphocytes/cells
106918-6,lymphocytes/cells lymph in bronchoalveolar lavage
106918-6,lymphocytes nfr bal
106918-6,lymhocytes nfr bal
106918-6,al nfr cellularity lymphcytes
106918-6,lymphocytes/cells (bal)
106918-6,lymphs lymphocytes/cells (bal)
106918-6,lymphocytes/cells (bal)
4005-5,pseudoephedrine [mass/time] in 24 hour urine
4005-5,pseudoephedrine urine in 24 hour [mass/time]
4005-5,pseuoephedrine [mass/time] in 4 qnt hour urine
4005-5,pseudoephedrine 24h ur-mrate
4005-5,pseudoephedrine 24h ur-mrate urn
4005-5,pseudoephedrine ur-mrate 24h ur
4005-5,pseudoephedrine (24h u) [mass/time]
4005-5,mrate u) (24h pseudoehedrine [mass/time]
4005-5,pseudoepherine pseudoephed [mass/time] (24hu)
63291-9,neuronal nuclear type 2 ab [presence] in cerebral spinal fluid by immunoassay
63291-9,neuronal nuclear type serology 2 ab [presence] in cerebral spinal fluid by immunoassay
63291-9,neuronal nuclear typ 2 ab cerebral in [prence] pina fluid ii by immunassay
63291-9,hu2 ab csf ql ia
63291-9,hu2 b cerebrospinal fluid ql ia
63291-9,hu2 ab csf presence ia
63291-9,neuronal nuclear type 2 ab ia ql (csf)
63291-9,2 nuclear type neuronal ab ia ql (csf)
63291-9,neuronal nuclear type 2 ql ia ab (cerebrospinal fluid)
31761-0,canine parvovirus ag [presence] in stool
31761-0,n parvoviru ag[preence] canine stol
31761-0,[presence] parvovirus ag canine in stool bowel movement
31761-0,cpv ag stl ql
31761-0,cpv ag stl ql
31761-0,cpv parvo ag stl ql
31761-0,canine parvovirus ag ql (stl)
31761-0,qual canine parvvirs g (st ql
31761-0,aninepavovirus ag l (stl)
52937-0,barium/creatinine [molar ratio] in 24 hour urine
52937-0,barium/creatinine [molar ratio] in 24 hour urine cr
52937-0,in [molar ratio] baum/creatiine 4hur urine substance concentration ratio
52937-0,barium/creat 24h ur-srto
52937-0,barium/creat24h quant ur-srt
52937-0,brium/crea 24h quant ursrto
52937-0,barium/creatinine (24h u) [molar ratio]
52937-0,barium/creatinine (24h u) ratio] [molar
52937-0,rium/cretinine drug/toxicology (2h u) [molarrao]
33395-5,epstein barr virus capsid ab [presence] in serum
33395-5,epstein capsiab virus barr prsence in serum
33395-5,estein ar insem capsid ab [resence] vius
33395-5,ebv vca ab ser ql
33395-5,vca ebv ab serum ql
33395-5,hhv-4 serum vca ab ebv ql
33395-5,ebv capsid ab ql (s)
33395-5,ql capsid ab anti ebv (s)
33395-5,ebv capsid ql ab (s)
5664-8,heavy metals negative [identifier] in urine by screen method
5664-8,heavy metals negative [identifier] in method by screen urine
5664-8,heavyetal urine [idntifir scn in negative by screen mehod
5664-8,heavy metals neg ur scn
5664-8,hevy meal ng scn ur
5664-8,eavy ur metals neg ur scn
5664-8,heavy metals negative screen nom (u)
5664-8,creen metalsnegative heavy nom heavy met (u)
5664-8,heavy mels negative screen o neg (u)
99393-1,siderocytes panel - blood or marrow by prussian blue stain
99393-1,siderocytes panel - blood or marrow by prussian blue stain
99393-1,siderocytes st panel - blood or marrow by prussian blue stain
99393-1,siderocytes pnl bld/mar prus bl st
99393-1,mar prus bld/r siderocytespnl bl t
99393-1,bld/mar pnl sidercyes prsbl st mar
99393-1,siderocytes panel prussian blue stain (bld/bm)
99393-1,siderocytes panel prussian blue stain (bld/bm)
99393-1,siderocytes stain prussian blue panel (blood/bm)
34275-8,creatine/creatinine [molar ratio] in urine
34275-8,cretine/creatinne [molar atio] urne i
34275-8,cretinecreatinne[mlar in ur atio] urine
34275-8,creatine/creat ur-srto
34275-8,ur-srto creatine/creat
34275-8,scrto creatine/creat ur-srto
34275-8,creatine/creatinine (u) [molar ratio]
34275-8,substance concentration ratio ceatin/creatne (u) ratio] [olar
34275-8,creatine/creatinine (u) [molar ratio]
63301-6,parathyrin ab [presence] in serum by immunofluorescence
63301-6,[presence] ab parathyrin in serum by immunofluorescence
63301-6,parathormone paratyrin a [presenc] in eum y immunofluorescence
63301-6,pth ab ser ql if
63301-6,ser ab pt ql f
63301-6,pth if serum ql ql a
63301-6,parathyrin ab if ql (s)
63301-6,(s) ab if point in time ql parathyrin
63301-6,parathyrin ab if (s) presence
32116-6,theophylline [moles/volume] in serum or plasma --trough
32116-6,theophylline serum in [moles/volume] or plasma --trough
32116-6,theophylline [moles/volume] in plasma or serum --trough
32116-6,theophylline trough serpl-scnc
32116-6,troh theophylline quant serp-scnc
32116-6,level trougherl-scc hophyllne
32116-6,theophylline trough [moles/vol]
32116-6,[moles/vol] trough theophylline quan
32116-6,tough quan theophlin [moes/vo]
43833-3,quinine [presence] in specimen
43833-3,quinine in [presence] specimen
43833-3,quinine drug/toxicology in [presence] specimen
43833-3,quinine spec ql
43833-3,ql spec quinine
43833-3,quinine ql spec
43833-3,quinine ql (specimen)
43833-3,quinine q (speimen) other
43833-3,quinine presence misc (specimen)
34923-3,monoblasts/leukocytes in blood
34923-3,monoblasts/leukocytes blood in
34923-3,monoblsts/leukoytes in bld
34923-3,monoblasts nfr bld
34923-3,nfr monoblasts white blood cell bld
34923-3,monoblasts r bld
34923-3,monoblasts/leukocytes (bld)
34923-3,leuk monoblasts/leukocytes (bld)
34923-3,monoblasts/leukocyts (blood)
62750-5,phenx - attention-deficit - hyperactivity disorder symptoms protocol - adult 121501
62750-5,phenx attenton-deficit - hyperactivity disorder symtoms protocol panl adult 121501
62750-5,phenx - attentin-deficit - hyperactivit dsorder syptms sx protol - adult12150
62750-5,attention deficit hyperac adult proto
62750-5,attention deficit hyperac adult sx proto
62750-5,hyperac deficit attention adult proto
8783-3,right ventricular stroke volume by nuclear blood pool
8783-3,right ventricular stroke nuclear random by volume blood pool
8783-3,right ventricular stroke volume bld hrt nuclear by pool
8783-3,rv sv nuc bp
8783-3,rv nuc sv b pt
8783-3,rv nuc sv bp
88127-6,herpes simplex virus identified in cornea or conjunctiva by organism specific culture
88127-6,herpes simplex virus corneal identified in cornea or conjunctiva by organism specific culture
88127-6,herpes simplex virus identified in cornea or conjunctiva by organism specific identity or presence culture
88127-6,hsv corn/cnjt cult
88127-6,hv crn/cjt cult c&s
88127-6,hs corn/cnjt cult
88127-6,hsv identified org specific cx nom (corn/cnjt)
88127-6,hsv dentfied specific org cx nom (corn/cnjt) c&s
88127-6,hsv identified og cult specific cx nom (corn/cnjt)
34266-7,citrate [moles/volume] in urine
34266-7,citrate [moles/volume] urine in
34266-7,citrate quan [moles/volume] in urine
34266-7,citrate ur-scnc
34266-7,citrate u-cnc quant
34266-7,ur-scc substance concentration citate
34266-7,citrate (u) [moles/vol]
34266-7,citrate citric acid (u) [moles/vol]
34266-7,citrte (u) [mos/vol] substance concentration
2087-5,cholesterol in idl [mass/volume] in serum or plasma
2087-5,cholesterol in idl [mass/volume] in serum or plasma random
2087-5,cholesterol in idl [mass/volume] in beta vldl serpl
2087-5,idlc serpl-mcnc
2087-5,cholesterol total serpl-mcnc idlc
2087-5,cholesterol total idlc serum or plasma-cnc
2087-5,cholesterol in idl [mass/vol]
2087-5,in cholesterol idl [mass/vol] pl
2087-5,point in time hlesteol in idl[mass/vo]
39136-7,deprecated skin assessment panel
39136-7,deprecated skin assessment panel
39136-7,skin deprecated assessment panel
39136-7,deprecated skin assessment pnl
39136-7,deprecate pnl ssesmen skin
39136-7,deprecated skin assessment nl
12213-5,deprecated estradiol [mass/volume] in serum or plasma by ria
12213-5,deprecated estradiol quan [mass/volume] in serum or by plas ria
12213-5,plasma estradiol [mass/volume] in serum or deprecated by ria
12213-5,deprecated estradiol ser ria-mcnc
12213-5,erecated esradol ser ia-mcnc
12213-5,dprecated stadil ria-mcn ser
12213-5,e2 ria (s) [mass/vol]
12213-5,(s) sr ria e2 [mass/vol]
12213-5,e2 ria (s) [mass/vol]
100745-9,chloride [moles/volume] in mixed venous blood
100745-9,cloride [mles/voume] i mixd venus ld
100745-9,chloride [moles/volume] in quant venous mixed blood
100745-9,chloride bldmv-scnc
100745-9,chlorde bldm-snc
100745-9,blmv-scnc quantitative chloride
100745-9,chloride (bldmv) [moles/vol]
100745-9,chlorid [mevol] substance concentration bldm)
100745-9,chloride [moles/vol] (bldmv)
104446-0,rubella virus igm ab index [units/volume] in serum and csf
104446-0,rubelvirusgm a ndex [units/volume] erum in and cf
104446-0,rubella virus igm a indx in [units/volme] serum antibody andcsf
104446-0,rubv igm index ser+csf-acnc
104446-0,rubv congenital rubella syndrome igm index ser+csf-acnc
104446-0,ser+csf-acnc igm inex rubv
104446-0,rubella virus igm index qn (s+csf)
104446-0,virus pt rubela igm inex qn (s+csf)
104446-0,rubella vir qn(s+csf) inde igm congenital rubella syndrome
24349-3,drugs of abuse 5 panel - urine
24349-3,drugs of abuse 5 panel - urine
24349-3,drugs of urine 5 ua panel - abuse
24349-3,drugs of abuse 5 pnl ur
24349-3,drugs of abuse 5 ur pnl ur
24349-3,dugs of abue 5 panl nl ur
24349-3,drugs of abuse 5 panel (u)
24349-3,of dus abuse 5 panel (u)
24349-3,rugs pan of abuse 5 panel (u)
25450-8,isoleucine [moles/time] in 24 hour urine
25450-8,isoleucine chemistry [mles/tie] urine hour in
25450-8,isoleucine [moles/time] ur in 24 hour urine
25450-8,isoleucine 24h ur-srate
25450-8,isoleucin 24h ur ur-srate
25450-8,ua isoleucine 24h ur-srate
25450-8,isoleucine (24h u) [moles/time]
25450-8,isoeuine (24h u [moles/tie
25450-8,isoleucine [moles/time] u) (24h
85581-7,mycobacterium avium and mycobacterium intracellulare dna [identifier] in sputum or bronchial by naa with probe detection
85581-7,mycobacterium detecto and mycobacterium inracellulare da [identifier]in sputmr bronchia by naa wth prob avium
85581-7,mycobacterium avium and mycobacterium intracellulare dna [identifier] in sputum sputum or bronchial by with naa probe detection
85581-7,m avium+m intracel dna spt/bro naa+probe
85581-7,dna vium+m intracel tuberculosis m spt/bro naa+probe
85581-7,m avium+m intacedna na+proe spt/bro
85581-7,m. avium and m. intracellulare dna naa+probe nom (sput/bronchial)
85581-7,lung m. aium nd m. intrcellulare a+probe dna nom (sput/rnial)
85581-7,m. avium and ligase chain reaction m. itracelulare dna naa+probe nom (sput/rnchial)
38736-5,animal hair+epithelium [mass/volume] in air
38736-5,animl hair+epithelium [massvolume] i ar
38736-5,animal [mass/volume] hair+epithelium in air
38736-5,animal hair+epith air-mcnc
38736-5,air-mcnc hair+epith animal
38736-5,air-mcnc hair+epith animal
38736-5,animal hair+epithelium (air) [mass/vol]
38736-5,hair+epithelium animal (air) [mass/vol]
38736-5,mss/vol] haiepithelium (air) drug/toxicology anima
91644-5,tangible support [mos social support survey]
91644-5,tangible support [mos soialsupport survey]
91644-5,tangiblesupport [mos pnl urvey] support social
63445-1,sjogrens syndrome-a extractable nuclear 52kd ab [presence] in serum by immunoblot
63445-1,sjogrens syndrome-a extractable ab 52kd nuclear [presence] western blot in serum by immunoblot
63445-1,sjogrens syndrome-a sr extractable nuclear 52kd in [ql] ab serum by immunoblot
63445-1,ena ss-a 52kd ab ser ql ib
63445-1,ena ib 52kd ab ser ql ss-a
63445-1,en ss-a ss 52kd ab ser presence ib
63445-1,sjogrens syndrome-a extractable nuclear 52kd ab ib ql (s)
63445-1,sjogrens syndrome-a extractable nuclear (s) ab ib ql 52kd
63445-1,sjogrens syndromea extrctbe uclear 52kd ab ib ql(s)
55176-2,ed arrival and first assessment data at first encounter set deeds
55176-2,ed ed arrival & 1st assessment data arrival and first asesmnt data at firs encoter set deeds
55176-2,edarrivl and first assessmet daa pan t first eounter set des
55176-2,ed arrival and 1st assessment data deeds
55176-2,ed deeds and 1st assessment data arrival
55176-2,ed arrival and data elements for emergency department systems 1st assessment data deeds
11086-6,streptococcus pneumoniae ag [presence] in serum
11086-6,streptococcs nemoniaeag pneumococ serum in [presece]
11086-6,streptococcus pneumoniae ag in [presence] serum
11086-6,s pneum ag ser ql
11086-6,s pneum ag ser ql
11086-6,spn spneum a serum ql
11086-6,s. pneumoniae ag ql (s)
11086-6,s. strept pneumoniae ag ql (s)
11086-6,peumonaeag s. antigens ql (s)
60094-0,ketoprofen [mass/volume] in urine
60094-0,[mass/vlume] ktoprofn inurine
60094-0,ketoprofen [mas/volume] in quant urin
60094-0,ketoprofen ur-mcnc
60094-0,ur-mcnc ketoprofen oruvail
60094-0,ketoprofen umcnc ua
60094-0,ketoprofen (u) [mass/vol]
60094-0,ketprofen ()mass/vo
60094-0,ketoprofen (u) [mass/vol]
3664-0,gentamicin [mass/volume] in serum or plasma --random
3664-0,gentamicin plasma in serum or [mass/volume] --random
3664-0,quan gentamicin mss/voume serumor in plma --radom
3664-0,gentamicin rand serpl-mcnc
3664-0,serpl rand gentamcin serpl-mcnc
3664-0,serum or plasma gentamicin serpl-mcnc rand
3664-0,gentamicin random [mass/vol]
3664-0,ranom gntamicin [mss/vol]
3664-0,gentamicin random gent [mass/vol]
74085-2,isocoproporphyrin [moles/mass] in stool
74085-2,[moles/mass] isocoproporphyrin in stl stool
74085-2,faecal in [moles/ass] isocoproorphyri sool
74085-2,isocopropor stl-scnt
74085-2,bowel movement isocopropor stl-scnt
74085-2,isocoprpor stl-sct
74085-2,isocoproporphyrin (stl) [moles/mass]
74085-2,[moles/mass] (stl) isocoproporphyrin
74085-2,isocoropophyrin (sl) [moles/mass]
537-1,mycobacterium sp identified in peritoneal fluid by organism specific culture
537-1,mycobacterium sp specific in peritoneal fluid by organism identified culture
537-1,microbiology mycobacterium sp identified peritonealfluid by organsm secific cultue
537-1,mycobacterium prt cult
537-1,cult prt mycobacterium
537-1,prtcut mycobacteriu point in time
537-1,mycobacterium sp identified org specific cx nom (periton fld)
537-1,mycobacterium peritoneal fluid sp identifie og spcific cx nom(priton fl)
537-1,mcobacterium spidentfied (periton speific cx nom org fld)
4150-9,caffeine [mass] of dose
4150-9,ffeine[mass]f quan dose
4150-9,affeine [ma] of dose
4150-9,caffeine dose
4150-9,caffeine dose quantitative
4150-9,quant dose caffeine
4150-9,caffeine (dose) [mass]
4150-9,caffeine (dose) point in time [mass]
4150-9,caffeine quantitative [mass] (dose)
49262-9,fatty acids pattern [interpretation] in serum or plasma narrative
49262-9,acids faty pattern interpretation] in serum or plasma nrratie
49262-9,fatty plsm acids pattern [interpretation] in serum or plasma narrative
49262-9,fatty acids pattern serpl-imp
49262-9,pattern acids interp fat serpl-imp
49262-9,fatty acids pattern serum or plasma-imp
49262-9,fatty acids pattern nar [interp]
49262-9,fatty pattern acids nar [interp]
49262-9,fatty acidpattern nar [interp]
73313-9,levalbuterol induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73313-9,levalbuterol igg platelet induced ab [presence] in ser or plasma by flow cytometry (fc)
73313-9,lvalbuterolinduced plaelt igg ab [presence]in serum or plasma y flo ytometry (fc)
73313-9,levalbuterol ind plt igg serpl ql fc
73313-9,levalbuterol ind plt igg serpl presence fc
73313-9,serpl ind plt igg levalbuterol presence fc
73313-9,levalbuterol induced platelet igg fc ql
73313-9,igg induced platelet levalbuterol fc ql ind plt ab
73313-9,ind plt igg levalbterol induced pelet igg fc ql
3933-9,phenazocine [mass/time] in 24 hour urine
3933-9,urine [mass/time] in quant 24 hour phenazocine
3933-9,[mass/time] phenazocine in 24 hour urine ua
3933-9,phenazocine 24h ur-mrate
3933-9,phenazocine 24h ur-mrate ur
3933-9,pheazcin 24h ur-mrte
3933-9,phenazocine (24h u) [mass/time]
3933-9,phenaocine drugs (24h u mass/tie]
3933-9,phenazocine [mass/ime] u) (24h
45095-7,chlamydia trachomatis [presence] in genital specimen by organism specific culture
45095-7,urogenital genitalscimenbyrgnism trachomatis [presence] in chlamyia specificulture
45095-7,chlamydia trachomatis [presence] c&s in by specmen genta organism specific culture
45095-7,c trach genital ql cult
45095-7,l trchgenital c cult
45095-7,c trach genial ql cult
45095-7,c. trachomatis org specific cx ql (genital specimen)
45095-7,. tahoatis org spcific cx ql urogenital genital specimen)
45095-7,trachomatis c. trachoma org specific cx presence (genital specimen)
30143-2,legionella sp ab [presence] in serum --1st specimen
30143-2,legionella sp ab --1st in ser [presence] specimen
30143-2,legionella screen in ab [presence] sp ser --1st specimen
30143-2,legionella ab sp1 ser ql
30143-2,leginella ab sp1 ser pr ql
30143-2,ab legionella sp1 serum ql
30143-2,legionella sp ab spec 1 ql (s)
30143-2,egionlla sp ab spec 1ql sp1 (s)
30143-2,legionella sp spec ab microbiology 1 ql (s)
74377-3,baclofen [mass/volume] in unknown substance
74377-3,baclofen [mass/volume] in unknown substance quant
74377-3,baclofen unknown in [mass/volume] quant substance
74377-3,baclofen usub-mcnc
74377-3,baclofen usubmcnc
74377-3,uubmcnc bacofen
74377-3,baclofen (unknown substance) [mass/vol]
74377-3,[mass/vol] quantitative (unknown substance) baclofen
74377-3,baclofen (unknown substance) [mass/vol] lioresal
49165-4,orientia tsutsugamushi kato igg ab [titer] in serum
49165-4,serum titered tsutsuamushi kato igg ab [titer] i rientia
49165-4,orient tsutsugashi kato igg ab titer] in serum
49165-4,o tsut kato igg titr ser
49165-4,o titr kato igg tsut serum
49165-4,igg tsutato infectiousdisease o titr ser
49165-4,o. tsutsugamushi kato igg (s) [titer]
49165-4,o. tsutugamusi scrub typhus kato igg s) [titer]
49165-4,o. tsutsugamushi kato igg (s) [titer]
72343-7,monocytes/round cells in semen by manual count
72343-7,by cells in semen monocytes/round manual count
72343-7,monocys/roucels y random insemen manul cot
72343-7,monocytes/rnd cells nfr smn manual
72343-7,smn cells nfr rnd cells monocytes/rnd manual
72343-7,manual cells nfr smn monocytes/rnd
72343-7,monocytes/round cells manual cnt (sem)
72343-7,(sem) quan cells manual cnt monocytes/round
72343-7,monocytes/round cells anul cnt (em)
90492-0,mds v3.0 - rai v1.17.2 - type of assessment on existing record to be modified or inactivated during assessment period [cms assessment]
90492-0,mds v. - rai durig - type of assessent on exsting recod to be modifed orinactivted v.17.2 assessment eriod [cms asessment]
90492-0,mds 3.0 - rai 1.172 - type of assesment on existin pan record t be modified or inactivated duing assessment period [cs assessmnt]
23382-5,pseudorabies virus neutralizing antibody [presence] in serum by neutralization test
23382-5,pseudorabie virs netralizing antibody [preence] in ser by neutalization test
23382-5,by viru neutralizingantbody [preence] antby in ser pseudorabie neutraliation test
23382-5,prv nab ser ql nt
23382-5,prv nab ser ql nt
23382-5,prvabser screen q nt
23382-5,pseudorabies virus neut ab neut test ql (s)
23382-5,virus neutralization pseudorabies neut ab neut test ql (s)
23382-5,pseudorabies virus neut ab neut test veterinary ql (s)
35733-5,histoplasma capsulatum m ab [presence] in serum by immune diffusion (id)
35733-5,histoplma capsulatum ma[presence] in ser by immune diffion id)
35733-5,histoplasma capsulatum m (id) [presence] in ser by immune diffusion ab histoplasma farciminosum
35733-5,h capsul m ab ser ql id
35733-5,h cpsul m b ser q d
35733-5,h capsul m ab id antibody l se
35733-5,h. capsulatum m ab immune diff ql (s)
35733-5,ordinal h. capsatum m diffql immune ab (s)
35733-5,h. capsulatum m ab screen immune diff presence (s)
49904-6,histoplasma capsulatum m ab [presence] in cerebral spinal fluid
49904-6,histoplasma cpsulatu m ab [presenc] in cerbral spinalflid
49904-6,histoplasma capsulatum m fluid [presence] in cerebral spinal ab
49904-6,h capsul m ab csf ql
49904-6,h capsul m abcs ql
49904-6,infectious disease h capsul m ab cerebrospinal fluid ql
49904-6,h. capsulatum m ab ql (csf)
49904-6,(cerebrospinal fluid) capsulatum m ab ql h.
49904-6,h. capsulatum m ab ql (cerebrospinal fluid)
91856-5,human papilloma virus 16 dna [presence] in genital specimen by naa with probe detection
91856-5,human papilloma detection 16 dna [presence] in genital specimen by naa with probe virus
91856-5,huan papilloma in 16 dna [presenc vius genitlspcien bynaa with pobe dettion
91856-5,hpv16 dna genital ql naa+probe
91856-5,polymerase chain reaction hpv16 dna genital presence naa+probe
91856-5,hpv16dna genitl naa+probe presence dna probe
91856-5,hpv 16 dna naa+probe ql (genital specimen)
91856-5,hpv 16 dna naa+probe (genital ql specimen)
91856-5,hpv qual (genital dna naa+probe presence 16 specimn)
85735-9,congenital rubella case report panel
85735-9,congenital report case rubella panel
85735-9,pnl report rubella case congenital panel
85735-9,congenital rubella case report pnl
85735-9,rubella cngental case report pnl
85735-9,congenital rubella cse pan report nl
29259-9,monocytes abnormal/leukocytes in blood by manual count
29259-9,monocytes abnormal/leukocytes in bld wbc by manual count
29259-9,monoyte blood qnt in abnoml/leukoces y manual count
29259-9,abn monocytes nfr bld manual
29259-9,abn number fraction moncytesnfr bld mnual
29259-9,abn monocytes nfr bld manual
29259-9,monocytes abnormal/leukocytes manual cnt (bld)
29259-9,monocytes abnormal/leukocytes quant manual cnt (bld)
29259-9,monocytsanorml/leukoctes (bld) cn hematology/cell counts manual
22121-8,borrelia burgdorferi ab [units/volume] in serum
22121-8,borrelia udorferi ab [units/olum] in seum
22121-8,borrelia [untsvolume] ab bugdorfei in serum
22121-8,b burgdor ab ser-acnc
22121-8,qnt b ser-acnc ab burgdor
22121-8,ser-acnc burgdor ab autoantibody b
22121-8,b. burgdorferi ab qn (s)
22121-8,b. (s) abqn bugdorferi
22121-8,b. bugdorferi ab qn (s
30352-9,hemoglobin [mass/volume] in capillary blood
30352-9,hemoglobin cap bld [mass/volume] capillary in bld
30352-9,in [mass/volume] hemoglobin capillary blood
30352-9,hgb bldc-mcnc
30352-9,bldc-mcnc finger stick hgb
30352-9,hgb hgb bldc-mcnc
30352-9,hemoglobin (bldc) [mass/vol]
30352-9,hemoglobin bdc) [mass/vol
30352-9,molobin bldc [as/vol
101649-2,tau protein [mass/volume] in cerebral spinal fluid by immunoassay
101649-2,tau protei [mass/olue]in cerebrl spinal flud by immuoassay
101649-2,tau protein [mass/volume] cerebral in spinal fluid by immunoassay
101649-2,tau prot csf ia-mcnc
101649-2,prot tau sf ia-mcnc
101649-2,tau prot spinal fl cerebrospinal fluid ia-mcnc
101649-2,tau protein ia (csf) [mass/vol]
101649-2,spinal fl au mass/ol] ia (cerebrospinal fluid) protein
101649-2,tau protein level ia (cerebrospinal fluid) [mass/vol]
16197-6,codeine [presence] in urine by confirmatory method
16197-6,codeine [presence] in urine by confirmatory method
16197-6,codene [presenc] in urine by cnfirmatory method
16197-6,codeine ur ql cfm
16197-6,codeineur ql cfm
16197-6,ur codeine ql cfm
16197-6,codeine confirm ql (u)
16197-6,addiction (u) ofirm ql codeine
16197-6,codeine confirm (u) ql
50822-6,beryllium [moles/time] in 24 hour urine
50822-6,beryllium [moles/time] in 24 hour qnt urine
50822-6,substance rate beryllium oes/tie] in 24 hour ur
50822-6,beryllium 24h ur-srate
50822-6,ur-srat ua beryllum24h
50822-6,quan berylium ur-srae 24h
50822-6,beryllium (24h u) [moles/time]
50822-6,u) (24h beryllium [moles/time]
50822-6,beryllium (24h u) [moles/time]
51648-4,monocytoid cells/leukocytes in cerebral spinal fluid by manual count
51648-4,monocytoidcells/leukocytes in quantitative cerebral manualcont flud by spinal
51648-4,monocytoid fluid in cerebral spinal cells/leukocytes by manual count
51648-4,monocytoid cells nfr csf manual
51648-4,monocyid cell nfr quan cerebrospinal fluid manual
51648-4,monocytoid cells nfr csf mnual
51648-4,monocytoid cells/leukocytes manual cnt (csf)
51648-4,manual cells/leukocytes monocytoid cnt (csf)
51648-4,onocytoid cellsleukocytes manual manl cnt (cerebrospinal fluid)
31913-7,neisseria meningitidis serogroup b ag [presence] in specimen
31913-7,neisseria meningitidis serogroup b ag [presence] in specimen antigens
31913-7,neiseria mningtidi serogroup b  [presence] in specime
31913-7,n men sg b ag spec ql
31913-7,n me g b ag spec ql ql
31913-7,n qualitative men ag b sg spec ql
31913-7,n. meningitidis b ag ql (specimen)
31913-7,n. meningitidis ag b ql (specimen)
31913-7,n. meningitiis b ag l (specmen)
2920-7,deprecated retinal [mass/volume] in serum or plasma
2920-7,deprecated retinal [mass/volume] in serum or vit a aldehyde plasma
2920-7,deprecated etinal [mss/volume] in serum or plasma
2920-7,deprecated retinal serpl-mcnc
2920-7,serpl-cnc vit a1 aldehyde reinal erecated
2920-7,deprecated serpl-mcnc retinal serpl
2920-7,retinal [mass/vol]
2920-7,[mass/vol] retinal quantitative
2920-7,retinal [mass/vol]
3902-4,para hydroxyamphetamine [mass/volume] in urine
3902-4,para in [mass/volume] hydroxyamphetaine urine
3902-4,para [mass/volume] hydroxyaphetine in uine
3902-4,p-oh-amphet ur-mcnc
3902-4,ur-mcnc p-oh-amphet
3902-4,drug/toxicology p-oh-amphet ur-mcnc
3902-4,para hydroxyamphetamine (u) [mass/vol]
3902-4,para hydroxyamphetamine (u) [mass/vol]
3902-4,para hydroyampetamine [mas/vol] (u)
14362-8,microscopic observation [identifier] in throat by gram stain
14362-8,observation microscopic [identifier] in throat by point in time gram stain
14362-8,micoscpic observtion [identifier] in thrat by gram stain point in time
14362-8,gram stn throat
14362-8,throat gramsn
14362-8,gram gram stn st troat
14362-8,microscopic observation gram stain nom (throat)
14362-8,gram observaon microscopic stain nom (throat)
14362-8,microscopic observation (throat) stain nom gram
15060-7,enolase.neuron specific [mass/volume] in serum or plasma
15060-7,enolase.nuron speciic[mas/volume] in ser r plasma
15060-7,enolase.neuron specific [mass/volume] serum in or plasma
15060-7,nse serpl-mcnc
15060-7,nsesrplmcnc
15060-7,serpl-mcnc nse
15060-7,enolase.neuron specific [mass/vol]
15060-7,elase.neuronspecific spec [ass/vol]
15060-7,enolase.neuron phosphopyruvate dehydratase specific [mass/vol]
49374-2,hepatitis c virus rna [log #/volume] (viral load) in bone marrow by naa with probe detection
49374-2,hepatitis c virus rna [log with (viral load) in bone marrow log# by naa #/volume] probe detection
49374-2,hepatitis c virus id rna [log #/volume] (viral load) in bone marrow by naa detection probe with
49374-2,hcv rna mar naa+probe-log#
49374-2,hcv rna hcv mar naa+probe-log#
49374-2,mar rna hcv naa+probe-log#
49374-2,hcv rna naa+probe (bm) [log #/vol]
49374-2,hcv rna naa+probe (bm) infectious disease [log #/vol]
49374-2,(bm)[log rna naa+probe hcv #/vol]
51642-7,reticulocytes.high light scatter/reticulocytes.total in blood
51642-7,reticulocytes.high light scatter/reticulocytes.total in blood
51642-7,reticulocytes.high light pt scatter/reticulocytes.total in blood
51642-7,hl retics nfr
51642-7,hl retics nfr
51642-7,quan hl retics nfr
51642-7,reticulocytes.high light scatter/total reticulocytes (bld)
51642-7,reticulocytes light number fraction scatter/total reticulocytes.high (bld)
51642-7,retulcyes.hig light scatter/toal eiulocytes (bld)
85140-2,sadness survey - cat item bank - age 18+ [nih toolbox]
85140-2,sadess survey - cat item bank - age 18+ nih toolbox]
85140-2,sadess suvey - catitem panl bank - age 18+ [nih toolbox]
88463-5,"oasis e - skin conditions - soc, roc during assessment period [cms assessment]"
88463-5,"oasis e - skin panl conditions - soc, roc during assessment period [cms assessment]"
88463-5,"oasis e - panl skin conditions - soc, roc during assessment period [cms assessment]"
9829-3,beta globulin [mass/time] in 24 hour urine
9829-3,beta gloulin [mas/time]in ua 2 hou urine
9829-3,beta glbulin mas/time] in24 hour protein beta globulin uine
9829-3,b-globulin 24h ur-mrate
9829-3,b-globulin ur-mrate 24h
9829-3,b-globulin ur-mrate 24h
9829-3,beta globulin (24h u) [mass/time]
9829-3,beta [masstime] 24h u lbulin
9829-3,beta gloulin (24h u) [mass/time] globulins
74422-7,mumps virus igg ab [presence] in body fluid by immunoassay
74422-7,mmp virus igg body fluid ab[ql] inbody fluid by imunoassay
74422-7,fl mumps virus in ab [ql] igg body fluid by immunoassay
74422-7,muv igg fld ql ia
74422-7,muv ig flql i
74422-7,muv fld gg l ia
74422-7,muv igg ia ql (body fld)
74422-7,muv igg ia presence (bodyfl)
74422-7,muv igg ia ql (body fd
41130-6,mycobacterium avium ss paratuberculosis ab [units/volume] in serum
41130-6,mycobacterium avium ss paratuberculosis ab [units/volume] in serum
41130-6,mycbateriu aviu ss paauberulosis ab [unis/volme] in serum
41130-6,m avium paratb ab ser-acnc
41130-6,m avium paratb ser-acnc ab
41130-6,avium b arab se-acnc
41130-6,m. avium ss paratuberculosis ab qn (s)
41130-6,m. avim ss paratuerculis abqn (s)
41130-6,m avium ss paratuberculosis quan b qn (s
16691-8,cresols [identifier] in specimen
16691-8,in [identifier] cresols specimen
16691-8,cresol misc [idetifier] inspecimen
16691-8,cresols spec
16691-8,cresols pt spec
16691-8,spec cresols
16691-8,cresols nom (specimen)
16691-8,point in time nom cresols (specimen)
16691-8,(specimen drugs cresolsno
30132-5,coxsackievirus ab [presence] in serum --1st specimen
30132-5,coxsackievirus ab [presence] in serum --1st antby specimen
30132-5,oxackievirusa [presece] in serum --1st screen specime
30132-5,cv ab sp1 ser ql
30132-5,cv ab ql ser sp1
30132-5,cv ab sp1 serum pre immunization q
30132-5,coxsackievirus ab spec 1 ql (s)
30132-5,coxsackievirus 1 spec ab infectious disease ql (s)
30132-5,coxsackievirus ab pr spec 1 ql (s)
32345-1,uroporphyrin [moles/volume] in red blood cells
32345-1,uroporphyrin [moles/volume] in cells blood red
32345-1,quantitative uroporphyrin [moles/volume] in red blood cells
32345-1,uropor rbc-scnc
32345-1,octacarboxylporphyrin uropor rbc-scnc
32345-1,uroporrc-sc quant
32345-1,uroporphyrin (rbc) [moles/vol]
32345-1,urporphyrin [mles/vol] quan (rbc)
32345-1,[moles/vol] (rb) red bld cells uroporphyrin
2727-6,para nitrophenol [mass/volume] in urine
2727-6,ara [ass/volume] nitrophnol inurne
2727-6,pnp para ntrophenol [mass/olume] i urine
2727-6,p-nitrophenol ur-mcnc
2727-6,ur-mc p-nitrohenol
2727-6,p-nitropheno ur-mcnc p-nitrophenol
2727-6,para nitrophenol (u) [mass/vol]
2727-6,pra nitrophenl (u [mass/vol]
2727-6,para (u) drug/toxicology nitropenol [mass/vol]
16488-9,brucella abortus igg ab [units/volume] in serum by complement fixation
16488-9,brucella abortus igg ab fixation in serum by complement [units/volume]
16488-9,brucella igg aorus ab [units/vlume] in serum y qnt omlment fixaton
16488-9,b abortus igg ser cf-acnc
16488-9,b abortus igg ser cf-acnc infectious disease
16488-9,b abortus igg quant serum cf-acnc
16488-9,b. abortus igg cf qn (s)
16488-9,b. abus igg cf qn (s) contagious abortion
16488-9,igg abortus b bovine brucellosis cf qn (s)
16806-2,echovirus 6+18+30 ab [units/volume] in serum
16806-2,echorus n ab unts/voume] 6+18+30 serum
16806-2,echovirus 6+1830 ab [units/vlume] in infectiousdisease ser
16806-2,ecv6+18+30 ab ser-acnc
16806-2,ec618+30 qnt b serum-cnc
16806-2,ab ecv6+18+30 ser-acnc
16806-2,echovirus 6+18+30 ab qn (s)
16806-2,echovirus 6+18+30 ab qn antby (s)
16806-2,echovirs 618+30 ab (s) qn
6439-4,influenza virus a+b+c ag [presence] in throat by immunoassay
6439-4,influenza viru +bc [ql fluav+flubv ag in throat by iunossa
6439-4,influenza virus qual a+b+c ag [ql] in throat by immunoassay
6439-4,fluav+flubv+flucv ag throat ql ia
6439-4,influ fluav+flubv+fucv ag trotql ia
6439-4,throat ag fluav+flubv+flucv ql ia
6439-4,fluav+b+c ag ia ql (throat)
6439-4,fluav+b+c ag ia ql influ (throat)
6439-4,fluav+b+c ag ia ql(throat)
17031-6,jo-1 extractable nuclear ab [presence] in serum by immunofluorescence
17031-6,jo-1 extractable nuclear ab [presence] in immunofluorescence by serum ena
17031-6,jo- extratable nuclea ab [resence] in serum by immunoflrescnce
17031-6,ena jo1 ab ser ql if
17031-6,if jo1 ab serum ql ena
17031-6,ena jo1 ab ser ql if anti
17031-6,jo-1 extractable nuclear ab if ql (s)
17031-6,o-1 exractbl nuclara i ql i s
17031-6,if extractable nuclear ab jo-1 ql (s)
2467-9,igg subclass 2 [mass/volume] in serum
2467-9,quan igg subclass 2 ser in [mass/volume]
2467-9,igg subclass [mass/volume] 2 in ser immune globulin g
2467-9,igg2 ser-mcnc
2467-9,se-mcnc ig2
2467-9,serum-mcnc igg2
2467-9,igg subclass 2 (s) [mass/vol]
2467-9,igg subclass  (s) [mass/vol]
2467-9,igg 2 qnt subclass (s) [mass/vol]
5377-7,laceyella sacchari ab [units/volume] in serum
5377-7,sr seum saccri a [unit/volue] in laceyella
5377-7,aceyella sacchri aby ab [unitsvolme] in serum
5377-7,laceyella sacchari ab ser-acnc
5377-7,sacchari laceyela abse-anc
5377-7,laceyella ab sacchari serum-acnc
5377-7,laceyella sacchari ab qn (s)
5377-7,pt laceyella sachari a qn (s)
5377-7,laceyella sacchari ab qn (s)
57960-7,erythrocytes [morphology] in body fluid by light microscopy
57960-7,microscopy [orpholog] in bod body fid by lgh erytrocytes
57960-7,erythrocytes [mrphology] n bod fld by ligh microscopy
57960-7,rbc fld micro
57960-7,micro fld point in time rbc
57960-7,"fld rbc micro body fluid, unsp"
57960-7,rbc lm nom (body fld)
57960-7,nom rbclm (body fld)
57960-7,rbc lm nom (body fld)
9641-2,catecholamines/creatinine [mass ratio] in urine
9641-2,catecholamines/creatinin [mass rto]in epinephrine+norepinephrine+dopamine urine
9641-2,catecholamines/creatinine [mass rtio] in uine
9641-2,catechols/creat ur
9641-2,catecholamine ctechos/creatur
9641-2,ur catec catco/creat
9641-2,catecholamines/creatinine (u) [mass ratio]
9641-2,cateholamin/creatinine mass ua (u) atio]
9641-2,(u) catecholamines/creatinine [mass ratio]
50892-9,palladium [moles/mass] in hair
50892-9,pd hair palladium[oles/mass]in
50892-9,palladium in [moles/mass] hair
50892-9,palladium hair-scnt
50892-9,palladium pt hair-scnt
50892-9,hair-scnt quan palladium
50892-9,palladium (hair) [moles/mass]
50892-9,qnt palladium [moles/mass] (hair)
50892-9,[moles/mass] (har) alladim
57948-2,collagen crosslinked c-telopeptide [mass/volume] in 24 hour urine
57948-2,collagen crosslinked c-telopeptide [mass/volume] in 24 c-telopeptide of type i collagen hour urine
57948-2,collagen crosslinked c-telopeptide [mass/volume] in 24 urine hour
57948-2,collagen ctx 24h ur-mcnc
57948-2,qnt collagen ctx ur-mcnc 2h
57948-2,collagen ctx urn 24h ur-mcnc
57948-2,collagen crosslinked c-telopeptide (24h u) [mass/vol]
57948-2,(4 rosslinked urn c-telopepide collagen [mass/v]
57948-2,collagen mass concentration crosslinked c-telopeptide (24h u) [mass/vol]
7961-6,measles virus ab [units/volume] in serum
7961-6,measles abs virus ab [units/volume] in serum
7961-6,measles virus ab [units/volume] rubeola in serum
7961-6,mev ab ser-acnc
7961-6,ser-cnc quant b ev
7961-6,mev ab serum-acnc
7961-6,mev ab qn (s)
7961-6,(s) ab qn mev
7961-6,mev ab qn ()
106756-0,left ventricular end-diastolic frame [time] by mr
106756-0,left ventricular end-diastolic frame [time] by mr
106756-0,frame ventricular end-diastolic left [time] by mr
106756-0,lv end-diastolic frame time mr
106756-0,time end-diastolic frame lv quan mr
106756-0,lv end-diastolic frame time mr hrt
17674-3,sulfonamide [units/volume] in serum or plasma
17674-3,serur [units/volume] in serplas sulfonamide plas
17674-3,sulfonamide [units/volume] sulfa in ser or plasma
17674-3,sulfonamide serpl-acnc
17674-3,sulfonaideserl-acnc
17674-3,sulfonamide plasma sep-acnc
17674-3,sulfonamide qn
17674-3,sulfonamide qn
17674-3,sulfonamide pl qn
44721-9,histiocytes [presence] in blood by light microscopy
44721-9,micro hitcytes [presene] in bld by light microscopy
44721-9,histiocytes [presence] in blood by wb microscopy light
44721-9,histiocytes bld ql smear
44721-9,blood histiocytes ql smear histocytes
44721-9,mear bld ql histiocytes
44721-9,histiocytes lm ql (bld)
44721-9,histiocyteslmql (blood)
44721-9,hitiotes lm ql (bld)
14843-7,6-monoacetylmorphine (6-mam) [presence] in gastric fluid
14843-7,6-monoacetylmorphine fluid [presence] in gastric (6-mam)
14843-7,6monoacetylmophie 6am) gastrilui in [resne]
14843-7,6mam gast ql
14843-7,6mam gast ql 6mam
14843-7,6mam gast ql acetylmorphine
14843-7,6-monoacetylmorphine (6-mam) ql (gast fld)
14843-7,6-monoacetylmorphine addiction (6-mam) fld) (gast presence
14843-7,6-monoacetylmorphin (6-mam) 6-acetylmorphine fd) (gast q
69948-8,bordetella parapertussis igg ab [presence] in serum by immunoassay
69948-8,bordetella parapertussis igg ab [presence] in ser by immunoassay
69948-8,bordetell parpertussis igg ab [resence] abs in erum by munoassay
69948-8,b parapert igg ser ql ia
69948-8,b parapert igg serum ql ia
69948-8,b ser igg parapert ql ia
69948-8,b. parapertussis igg ia ql (s)
69948-8,b. parapetussis ig meia ia ql (s)
69948-8,b. parapertussis igg pr ia ql (s)
15012-8,aldosterone [moles/volume] in serum or plasma --upright
15012-8,aldosteroe mols/volum] qnt --uright srum or plasm in
15012-8,aldosterone [moles/volum] in serum or plasma -pright
15012-8,aldost upr serpl-scnc
15012-8,aldost upr serpl-scnc serpl
15012-8,aldost upr serpl-scnc
15012-8,aldosterone upright [moles/vol]
15012-8,aldosroneurht[molesvol]
15012-8,standing aldosterone [moles/vol] upright
68366-4,bacteria identified in blood product unit by culture
68366-4,bacteria identified in unit product blood by culture
68366-4,bacteria culture in bloo prduct unitby identified
68366-4,bacteria bpu cult
68366-4,cult infectious disease bpu bacteria
68366-4,cult bpu bacteria
68366-4,bacteria identified cx nom (bpu)
68366-4,(bpu) identified cx nom random bacteria
68366-4,bacteria identified (bpu) nom cx random
19352-4,aprobarbital cutoff [mass/volume] in urine for confirmatory method
19352-4,aprobarbital drugs cutoff [mass/volume] in urine for confirmatory method
19352-4,aprobarbital cutoff [mass/volume] in urine for confirmatory method
19352-4,aprobarbital cto ur cfm-mcnc
19352-4,aprobarbital conf cto ur cfm-mcnc
19352-4,aprobarbital cto cto ur cfm-mcnc
19352-4,aprobarbital cutoff confirm (u) [mass/vol]
19352-4,cfirm(u) aroarbitalcutoff [mass/vol
19352-4,aprobarbital drugs confirm cutoff (u) [mass/vol]
26900-1,chlordiazepoxide [mass/volume] in vitreous fluid
26900-1,vitreous quantitative [mass/volume] in chlordiazepoxide fluid
26900-1,chlordiazepoxide [mass/volume]in vireous luid
26900-1,chlordiazep vitf-mcnc
26900-1,mass concentration vitf-mcc chlordiazep
26900-1,chlordiazep vitf-mcnc
26900-1,chlordiazepoxide (vitr fld) [mass/vol]
26900-1,chlrdiazepoxide (vitr ld) random [mass/vol]
26900-1,chlordazepoxide (vitr fld) [massvol]
41843-4,lymphocytic choriomeningitis virus igg and igm panel [titer] - cerebral spinal fluid by immunofluorescence
41843-4,lyphocytic immunouorescence virus iandigm pane titer] - cerebrl fluoresent spinal fluid b chromeningitis
41843-4,fluid virus ig anigmanel [titer] - cerebra spinal ymphocyticchoriomeningits by immunofluorescnce
41843-4,lcmv igg+igm pnl titr csf if
41843-4,lcm igg+igm pnl fluoresent titr csf if
41843-4,mv igg+igm pnl titr immunoflour csf if
41843-4,lymphocytic choriomeningitis virus igg and igm panel if (csf) [titer]
41843-4,lymphocytic choriomenngitis vrs igg and igm panel i (csf) titer]
41843-4,lymphocytic choriomeningitis virus igg and igm panel if (csf) fa [titer]
22906-2,bovine herpesvirus 1 ag [presence] in specimen by immunoassay
22906-2,bovine herpesvirus 1 ag [resence] in specmn b immunoassay
22906-2,bovine hersvirus 1 a [ql] n pecimen byimmunoassay
22906-2,bohv1 ag spec ql ia
22906-2,other bov1 ag spec ql ia
22906-2,spec ag bohv1 bohv1 ql ia
22906-2,bovine herpesvirus 1 ag ia ql (specimen)
22906-2,boine herpesiru 1 ag ia (specien) ql
22906-2,bovine 1 herpesvirus ag bohv ia ql (specimen)
99408-7,matrix metallopeptidase 9 [mass/volume] in serum by immunoassay
99408-7,matrix metallopeptidase 9 iaa [mass/volume] in serum by immunoassay
99408-7,matrix elfa metallopeptidase 9 [mass/volume] in serum by immunoassay
99408-7,mmp9 ser ia-mcnc
99408-7,mmp9 ser ia-mcnc iaa
99408-7,a-mcnc serum mmp9
99408-7,matrix metallopeptidase 9 ia (s) [mass/vol]
99408-7,point in time matrix metallopeptidase [mass/vol] ia (s) 9
99408-7,ia metallopeptidase 9 enzyme immunoassay matrix (s) [mass/vol]
73057-2,acetylsalicylate induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73057-2,acetylsalicylate dynamic induced neutrophil igm ab [presence] in serum plasma or by flow cytometry (fc)
73057-2,acetylsalicylate induced neutrophil or ab [presence] in serum igm plasma by flow cytometry (fc)
73057-2,acetylsalicylate (neut) igm serpl ql fc
73057-2,serpl (neut) igm acetylsalicylate ql fc
73057-2,serpl (neut) abs igm acetylsalicylate ql fc
73057-2,acetylsalicylate induced neutrophil igm fc ql
73057-2,induced acetylsalicylate neutrophil aspirin igm fc ql
73057-2,cetylsalicylae iuedneutrophil igm fc presence
13913-9,adenovirus ab [titer] in serum by immunofluorescence
13913-9,anvirusab tie] in ser fluorescent antibody by immunofluoescence
13913-9,by ab titer] in ttr serum adenovrus immunofluorscene
13913-9,hadv ab titr ser if
13913-9,hav if titr sr b
13913-9,hadv ab if ser anti titr
13913-9,adenovirus ab if (s) [titer]
13913-9,ab adenovirus if (s) [titer]
13913-9,adenovirus if ab (s) id [titer]
11065-0,urea nitrogen [mass/volume] in serum or plasma --pre dialysis
11065-0,urea or [mass/volume] in serum nitrogen plas --pre dialysis
11065-0,urea nitrogen dialysis in level serum or plasma --pre [mass/volume]
11065-0,bun pre dial serpl-mcnc
11065-0,un pre chemistry dial srpl-cc
11065-0,bun pre plas dial serpl-mcnc
11065-0,urea nitrogen pre dialysis [mass/vol]
11065-0,urea nitrogen quantitative pre dialysis [mass/vol]
11065-0,dialys nrogen pre urea [mass/vl]
81107-5,leptospira interrogans sv shermani ab [titer] in serum by agglutination
81107-5,leptospira interoganssv shrmani ab [titer] i agglutination by ser
81107-5,interrogans leptospira sv shermani ab [titer]i serum byaglutination
81107-5,l inter sherm ab titr ser aggl
81107-5,l iter sherm ab titrser al
81107-5,l intr shrm ab tit ser agl antibodies
81107-5,l. interrogans sv shermani ab aggl (s) [titer]
81107-5,(s) interrogans sv shermani ab aggl l. [titer] smqn
81107-5,l. interrogans sv ab shermani aggl (s) [titer]
55394-1,protein and glucose panel - cerebral spinal fluid
55394-1,protein and luco pael - cerebral spina flud spinal fld
55394-1,protein and glucose panel - spinal cerebral fluid
55394-1,prot + glucose pnl csf
55394-1,+ quant prot lcosepnl csf
55394-1,prot + csf pnl glucose
55394-1,protein and glucose panel (csf)
55394-1,protein random and glucose (csf) panel
55394-1,pnel andglucose protin (csf) pan
77279-8,nursing staff retention panel [nmmds]
77279-8,nrsing [nmds] pan retentionpnel stff
77279-8,ursing staf retention pane [nmmds]
72446-8,3-hydroxysuberate [moles/volume] in serum or plasma
72446-8,3-hydroxysuberate [moles/volume] in serum or plas
72446-8,3-hydroxysuberate [moles/volume] in ser or plasma
72446-8,3ohsuberate serpl-scnc
72446-8,serpl-scn level 3osuberate
72446-8,3ohsubrat sepl-scnc
72446-8,3-hydroxysuberate [moles/vol]
72446-8,[moles/vol quantitative 3hydrxysubeate
72446-8,[moles/vol] 3-hydroxysuberate
46015-4,continence self-control categories set
46015-4,continece self-control panl caegoriesset
46015-4,continence self-cntrol catgories set
4587-2,hemoglobin h/hemoglobin.total in blood by electrophoresis
4587-2,quant hemoglbinh/hemoglobin.total inbl by electrohoresis
4587-2,ep in h/emoglobi.tota hemoglobin blood byelectrophorsis
4587-2,hgb h mfr bld elph
4587-2,hgb bl mf h lh
4587-2,hgb h mfr ld elp
4587-2,hemoglobin h elph (bld) [mass fraction]
4587-2,hemgobinh quantitative elph(bld) [mass fraction]
4587-2,hemoglbin (bld) elph h [mss frcion
56541-6,ganglioside gd1b igg ab [units/volume] in serum by immunoassay
56541-6,disialylganglioside ganglioside gd1b igg ab [units/volume] in serum by immunoassay
56541-6,ganglioside gd1b in ab [units/volume] igg ser by immunoassay
56541-6,gd1b gangl igg ser ia-acnc
56541-6,gd1b gangl igg ser serology ia-acnc
56541-6,gd1b gangl g ser ia-acc
56541-6,ganglioside gd1b igg ia qn (s)
56541-6,ganglioside gd1b disialolganglioside igg ia qn (s
56541-6,galiosid gd1b igg ia qn (s
76621-2,lysosomal acid lipase panel - fibroblast
76621-2,fib lysosomal acid lipase - pnel fibroblast
76621-2,lysosomal lipase acid panel - fibroblast
76621-2,lal panel fib
76621-2,panelfi lal
76621-2,panel lal fib
76621-2,lysosomal acid lipase panel (fibroblast)
76621-2,lysosomal acid (fibroblast) panel lipase
76621-2,lysosomal acd lipae panel (fibroblast) panl
1864-8,anserine [mass/volume] in cerebral spinal fluid
1864-8,anserine [mass/volume] spinal cerebral in spinal fld fluid
1864-8,inerbral anserine[mass/volume] spinalfuid spinal fld
1864-8,anserine csf-mcnc
1864-8,csf-mcnc anserine spinal flu
1864-8,csf-mcnc anserne point in time
1864-8,anserine (csf) [mass/vol]
1864-8,ansrine [mass/vl] (csf) chemistry
1864-8,mass concentration [mass/vol] (sf) anserie
31216-5,actinobacillus pleuropneumoniae ab [units/volume] in serum
31216-5,pleuropneumoniae actinobacillus antby ab [units/volume] in serum
31216-5,actinobacilus arbitrary concentration serm ab units/vlme] i leurpneumoiae
31216-5,a pleuropn ab ser-acnc
31216-5,a antibodies pleuopn ab seracnc
31216-5,a ab pleuropn ser-acnc
31216-5,a. pleuropneumoniae ab qn (s)
31216-5,a. pleuropneumoniae ab qn (s)
31216-5,a. pleuropneumoniae ab qn (s) antibodies
71150-7,pediatric - patients with brain cancer - parent_child questionnaire - version 1 (peds-fact-br - parent_child) [facit]
71150-7,pediatrc - paients wi brin cancer - parent_child questionnaire - versn 1(peds-fact-b  paent_chid) [fait]
71150-7,pediatric patients -version cner - arent_chil questionnaire withrai 1 (peds-act-br - prent_child) [facit]
4649-0,interferon [units/volume] in serum
4649-0,inserum [units/ume] interfro
4649-0,interferon [units/volume] point in time in serum
4649-0,ifn ser-acnc
4649-0,fn sr-acnc
4649-0,ifnser-acnc
4649-0,interferon qn (s)
4649-0,hematology/cell counts iterferon qn (s)
4649-0,(s) sr qn interfeon
60082-5,gold [mass/volume] in red blood cells
60082-5,gold random in [mass/volume] red blood cells
60082-5,old [massvolume] in random red bld cells
60082-5,gold rbc-mcnc
60082-5,rbc-mcnc gold
60082-5,gold rbc-mcnc
60082-5,gold (rbc) [mass/vol]
60082-5,[mass/vol] quantitative (rbc) gold
60082-5,gold [mass/vol] au (rbc)
97924-5,jamestown canyon virus rna [presence] in specimen by naa with probe detection
97924-5,by canyonvirus rna[presece] in naa+probe specime jmestown naa wtprobe dtection
97924-5,i cayonvirus screen rna [preence] jamestown pecime by naa ith probe detectin
97924-5,jcv rna spec ql naa+probe
97924-5,cv naa+probe ql rnaspe
97924-5,jcv rna spec q aa+probe
97924-5,jamestown canyon virus rna naa+probe ql (specimen)
97924-5,screen jamestown canyon virus rna naa+probe ql (specimen)
97924-5,jamestown 3sr sr canyon virus rna naa+probe ql (specimen)
75040-6,d-lactate [moles/volume] in cerebral spinal fluid
75040-6,d-lactate [moles/volume] cerebral in spinal fluid
75040-6,-lactate spnal cerebra [moles/volumein fluid
75040-6,d-lactate csf-scnc
75040-6,d-lactate csf-scc
75040-6,csfscnc d-lactate spinal fld
75040-6,d-lactate (csf) [moles/vol]
75040-6,moles/vl] (csf) dlactat
75040-6,d-lactate (cerebrospinal fluid) [moles/vol]
743-5,monocytes [#/volume] in blood by manual count
743-5,blood [#/volume] in monocytes by manual count
743-5,monocye [#/volume] in bloodbymanl count
743-5,monocytes # bld manual
743-5,monoctes # manual manl bld
743-5,monocytes # bld manual
743-5,monocytes manual cnt (bld) [#/vol]
743-5,monocyes cnt manual bld) [#/vol]
743-5,monocytesmanua cnt (bld) [#vol point in time
41757-6,fluticasone propionate [mass/volume] in serum or plasma
41757-6,fluticasone propionate [mass/volume] in cutivate ser or plasma
41757-6,fluticasone propionate [mass/volume] in serpl ser or plasma
41757-6,fluticasone prop serpl-mcnc
41757-6,prop fluticasone serpl-mcnc
41757-6,fluticasone prop serpl-mcnc propanoic acid
41757-6,fluticasone propionate [mass/vol]
41757-6,flutcasne popionate flonase [ass/vo]
41757-6,fluticasone [mass/vol] propionate
14586-2,aldosterone [moles/volume] in serum or plasma
14586-2,aldosterone in [mls/volume] sermor plasma
14586-2,alosterone [moles/volume i serum or level pasma
14586-2,aldost serpl-scnc
14586-2,serpl-scnc aldost
14586-2,ldo erpl-scnc
14586-2,aldosterone [moles/vol]
14586-2,sr losteron[mols/vol]
14586-2,plsm [moles/vol] aldosterone
14306-5,varicella zoster virus igg ab [units/volume] in serum by immunoassay --1st specimen
14306-5,varicella zoster virus igg ab [units/volume] in ser by immunoassay --1st specimen
14306-5,varicella zoster serum igg ab [units/volume] in virus by immunoassay --1st specimen
14306-5,vzv igg sp1 ser ia-acnc
14306-5,ser gg sp1 vzv ia-acc
14306-5,vzv igg sp1ser herpes zoster ia-acc
14306-5,vzv igg spec 1 ia qn (s)
14306-5,aby (s) igspec 1 ia qn vzv
14306-5,vzv igg spec 1 ia qn spec (s)
11537-8,surgical drains narrative
11537-8,narrative drains surgical
11537-8,surica drain narrative findings
11537-8,surgical drains
11537-8,drains surgical
11537-8,drains surgical report
40947-4,zinc [presence] in hair
40947-4,zinc in [ql] hair
40947-4,qual zic in [ql] hair
40947-4,zinc hair ql
40947-4,har zinc ql
40947-4,ql hair zinc ql
40947-4,zinc ql (hair)
40947-4,point in time zinc presence (hair)
40947-4,zic (hair) ql
44813-4,hepatitis c virus c22p ab [presence] in serum by immunoblot
44813-4,eptitis blt c virus c2p ser [presence in ab by mmunoblot
44813-4,by c virus c22p ab [presence] in ser hepatitis immunoblot
44813-4,hcv c22p ab ser ql ib
44813-4,sr hcv c2pab ser ql
44813-4,ser c22p ab hcv ql ib point in time
44813-4,hcv c22p ab ib ql (s)
44813-4,hcv ql ab ib c22p (s)
44813-4,hcv c22p ab ib ql pr (s)
95654-0,eastern equine encephalitis virus neutralizing antibody [titer] in specimen by neutralization test
95654-0,eastern equn et vius neutralizig antibody [titer] in specimen byneutralizatio ncephalitis
95654-0,eastern quine encephaliti virus netaliing atibody[ter] nspecimn by neutazation test
95654-0,eeev nab titr spec nt
95654-0,eeev nab nt id spec tit
95654-0,nab eeev titr spec dilution factor (titer) nt
95654-0,eeev neut ab neut test (specimen) [titer]
95654-0,eeev neut ab (specimen) test neut [titer]
95654-0,neutralization test [titer] neut ab neut test (specimen) eeev
47386-8,carboxy tetrahydrocannabinol [mass/volume] in serum or plasma by confirmatory method
47386-8,carboxy tetrhrocannbnol 11-nor-9-carboxy-delta-9-thc in [mas/volume] serum or plasm by cofiratory ethod
47386-8,carboxy tetrahydrocannabinol [mass/volume] in serum or plasma by confirmatory method
47386-8,carboxythc serpl cfm-mcnc
47386-8,carboxythc carboxytetrahydrocannabinol cfmmcc serpl
47386-8,11-nor-9-carboxy-thc carboxythc serpl cfm-mcnc
47386-8,carboxy tetrahydrocannabinol confirm [mass/vol]
47386-8,caroxy confrm tetrahydrocnnabinol [mas/vol]
47386-8,carboxy [mass/vol] confirm tetrahydrocannabinol
22186-1,chlamydia sp igm ab [titer] in serum
22186-1,chlamydia sp igm antibody ab [titer] in serum
22186-1,chlamydia sp igm [tier]in ab seum
22186-1,chlamydia igm titr ser
22186-1,igm chlamydia titr ser
22186-1,smqn chlamyda igm titr se
22186-1,chlamydia sp igm (s) [titer]
22186-1,sp chlamydia igm (s) [titer]
22186-1,(s)[tier] spim chlmyda
94481-9,human coronavirus nl63 rna [presence] in lower respiratory specimen by naa with non-probe detection
94481-9,[ql] coronavirus nl63 rna human in lower respiratory specimen by naa with non-probe detection
94481-9,[ql] coonairus nl63 rna human in lowr respiratory breathing secimenby aa with non-probedtection
94481-9,hcov nl63 rna low resp ql naa+non-probe
94481-9,hcovnl63 rna low naa+non-probe ql resp
94481-9,hcov ql nl63 rna low resp ql naa+non-probe
94481-9,hcov nl63 rna naa+non-probe ql (lower resp)
94481-9,hcov nl63 ra naa+non-probe q (loer nucleic acid sequence based analysis resp)
94481-9,hcov l6 rnanaanon-robe ql (owe resp)
29922-2,boron/creatinine [mass ratio] in 24 hour urine
29922-2,boron/creatinine [mass ratio] in 24 hour drugs urine
29922-2,boron/creatinine [mass ratio] in 24 hour urine
29922-2,boron/creat 24h ur
29922-2,boron/creat 24h ua ur
29922-2,boron/creat 24h ur ur
29922-2,boron/creatinine (24h u) [mass ratio]
29922-2,boron/reatnine(24h mcrto u)mas ratio]
29922-2,boron/creatinine u) (24h [mass ratio]
21040-1,deprecated alpha ketoglutarate/creatinine [mass ratio] in urine
21040-1,deprecated alpha [mass ketoglutarate/creatinine ratio] in urine
21040-1,deprecated alpha ketoglutarate/creatinine [mass ratio] in urine
21040-1,deprecated a-ketoglut/creat ur-mrto
21040-1,deprecated a-ketoglu/creat ur-mrt quantitative
21040-1,deprecated ur-mto a-ketoglut/crea
21040-1,alpha ketoglutarate/creatinine (u) [mass conc ratio]
21040-1,ur alpha ketoglutarate/creatinine (u) [mass conc ratio]
21040-1,alph ketoglutarate/creatinie (umass ratio] coc
88460-1,serotonin release 50 iu/ml heparin.low molecular weight [units/volume] in serum
88460-1,seroonin release point in time 50 ser molecularweight [units/volume] in iu/mlheparin.lo
88460-1,serotonin release serum iu/ml heparin.low molecular weight [units/volume] hepar in 50
88460-1,sra 50 iu/ml lmw heparin ser-acnc
88460-1,sra iu/ml 50 lmw heparin ser-acnc
88460-1,sra 50 heparin lmw iu/ml ser-acnc
88460-1,serotonin release 50 iu/ml heparin.low molecular weight qn (s)
88460-1,serotonin release 50 u/mlherin.lowmolecula wit n (s)
88460-1,serotonin release 50 iu/ml hparinlow (s) wight qn moleular
88498-1,oasis d - neuro and emotional and behavioral status - soc or roc during assessment period [cms assessment]
88498-1,oasis d - neuro and emotional pnl and behavioral status - soc or roc during assessment period [cms assessment]
88498-1,oasis d - neuro emotional behavioral status neuro and emotional and behavioral ttus - sc orroc dring assessment period [ms asesment]
8052-3,western equine encephalitis virus igg ab [units/volume] in serum
8052-3,western equine [units/volume] virus igg ab encephalitis in serum
8052-3,wstern euine encehalitis vrus gg ab infectious disease [units/vole] iseru
8052-3,weev igg ser-acnc
8052-3,weev igg serum-acnc
8052-3,weev infectious disease igg ser-acnc
8052-3,weev igg qn (s)
8052-3,igg weev qn (s)
8052-3,weev (s) qn igg
52764-8,extrinsic coagulation system with fibrinolysis inhibition thromboelastography panel - blood
52764-8,bld coagulation system with fibrinolysis inhibition thromboelastography panel - extrinsic
52764-8,extrinsic coagulation system with fibrinolysis inhibition thromboelastography panel - coag bld
52764-8,fibrinolysis inhib teg pnl bld
52764-8,fibrinolysis inhib pnl teg bld
52764-8,fibrinolysis inhib teg pnl blood
52764-8,extrinsic coagulation system with fibrinolysis inhibition thromboelastography panel (bld)
52764-8,extrinsic coagulation thromboelastography with fibrinolysis inhibition system panel (bld)
52764-8,extrinsic coagulation system with teg pnl fibrinolysis inhibition thromboelastography panel (bld)
78970-1,phosphomannomutase 1 [enzymatic activity/mass] in leukocytes
78970-1,leukocytes quantitative [enzymatic activity/mass] in hosphomannomutase
78970-1,phosphomannomutase 1 [enzymatic activity/mass] in pmm-1 leukocytes
78970-1,pmm1 wbc-ccnt
78970-1,pmm1 chemistry wbc-ccnt
78970-1,mm1 wbc-ccnt wbcs
78970-1,phosphomannomutase 1 (wbc) [catalytic activity/mass]
78970-1,1 phosphomannomutase (wbc) [catalytic activity/mass]
78970-1,phosphomannomutse (wbc pmm-1 [ctlytic activity/mass]
94757-2,sars-cov-2 (covid-19) n gene [presence] in respiratory system specimen by nucleic acid amplification using cdc primer-probe set n2
94757-2,srsv-2 cvid-19) n respatory [presene in ene system specimen by nucleic cid amplification centers for disease control and prevention using cc primer-probe set n2
94757-2,sars-cov-2 (covid-19) n gene preence] in resprator system specimen by nuceic acid amplification using cdc primer-probe set n2
94757-2,sars-cov-2 n gene resp ql naa n2
94757-2,sars-cov sarscov-2 n gene rep ql aa n2
94757-2,sars coronavirus 1 sars-cov-2 n gene resp presence naa n2
94757-2,sars-cov-2 (covid-19) n gene naa+probe cdc primer-probe set n2 ql (respiratory system specimen)
94757-2,sar-cov-2 (covid-19) systm naa+rbecc prmerproe set n2 ql (respiratory gene pecimen)
94757-2,sars-cov-2 (covid-19) n gene naa+probe cdc primer-probe set n2 presence (respiratory system specimen)
48903-9,rickettsia africae igg ab [titer] in body fluid by immunofluorescence
48903-9,ricettsa fluoresent africae igg ab [tite] in body fluid by immunofluorescence
48903-9,"rickettsia africae igg ab [titer] in body fluid by body fluid, unsp immunofluorescence"
48903-9,r africae igg titr fld if
48903-9,r africae igg titr fld anti if
48903-9,r ricket titr igg africae fld if
48903-9,r. africae igg if (body fld) [titer]
48903-9,r afrcae ld)[titer] if (body fluorescent antibody igg
48903-9,r. igg africae if (body fld) [titer] fa
88996-4,eicosapentaenoate (c20:5w3)/arachidonate (c20:4w6) [molar ratio] in serum or plasma
88996-4,eicosapentaenoate (20:5w)/arachidonate or [molar rati] inserum (c20:4w6) lasma
88996-4,eicosapentaenoate (c20:5w3)/arachidonate (c20:4w6) [molar plasma in serum or ratio]
88996-4,epa/aa serpl-srto
88996-4,point in time epa/aa serum or plasma-srto
88996-4,serpl-srto epa/a
88996-4,epa/arachidonate (c20:4w6) [molar ratio]
88996-4,rato] [mol pa/achidonate(c20:4w6) plsm
88996-4,ratio] (c20:4w6) [molar epa/arachidonate
94702-8,pca-1 ab [titer] in serum by immunofluorescence
94702-8,serum pca-1 ab [titer] in serum by immunofluorescence
94702-8,pca-1 ab [titer] in immunofluorescence by serum
94702-8,pca-1 ab titr ser if
94702-8,pca-1 ab titr ser paraneoplastic syndrome if
94702-8,pa-1 tir ab ser smqn if
94702-8,pca-1 ab if (s) [titer]
94702-8,(s) aif pca-1 [tier
94702-8,ab pca-1 if (s) [titer]
59809-4,lymphoma cells [presence] in blood
59809-4,lymphoma els [presence] in blood
59809-4,lymhoma cells [presence] bld in
59809-4,lymphoma cells bld ql
59809-4,ql cells bld lyphoma
59809-4,lymphoma cells ld presence
59809-4,lymphoma cells ql (bld)
59809-4,lympoma clls (blood) ql pr
59809-4,(bld) cells ql lymphoma
20544-3,mesoridazine [mass/volume] in urine by confirmatory method
20544-3,random mesoridazie [mass/volume] in uine by confiratymethod
20544-3,mesoridzine mas/volume] in rine by confirmaory method
20544-3,mesoridazine ur cfm-mcnc
20544-3,mesoridazine ur cfm-mcnc
20544-3,cfm-mcnc ur mesoridazine
20544-3,mesoridazine confirm (u) [mass/vol]
20544-3,[massvol] quantitative mesoridazinecnfirm(u)
20544-3,mesoridazine confirm (u) [mass/vol] cnfrm
69962-9,respiratory syncytial virus igm ab [presence] in serum by immunoassay
69962-9,microbiology respiratory syncytial virus by ab [ql] in serum igm immunoassay
69962-9,respiratory syncytial virus ab igm [ql] in serum enzyme immunoassay by immunoassay
69962-9,rsv igm ser ql ia
69962-9,rsv igm ql ser ia
69962-9,rsv a point in time serum ql igm
69962-9,rsv igm ia ql (s)
69962-9,rsv igm ia (s) ql
69962-9,rsv gm (s) ql ia
105414-7,interpretation of canine acute pain scale animal narrative
105414-7,interpretation of canine animal pain scale acute narrative
105414-7,scale of canine acute pain interpretation animal narrative
105414-7,canine acute pain scale imp animal
105414-7,im acute pain scale canine anmal
105414-7,random canine acute pain scale imp animal
30926-0,aluminum [mass/volume] in urine collected for unspecified duration
30926-0,alumium mass/volume] i urine colced for unspecifid duation
30926-0,aluminum[mass/volume] in urne collected for drugs uspecified duration
30926-0,aluminum ?tm ur-mcnc
30926-0,u-mcnc ?tm aluminum
30926-0,?tm aluminum ur-mcnc
30926-0,aluminum unsp time (u) [mass/vol]
30926-0,(u) unsp time aluminum [mass/vol]
30926-0,alumin time unsp (u)[mass/vol
97872-6,rabies virus ab panel - serum or plasma
97872-6,rabies virus ab panel - ser ser or plasma
97872-6,rbies virus ab pan - eru or plsma
97872-6,rabies ab pnl serpl
97872-6,serpl ab serum or plasma pnl rabies
97872-6,rabies plsm ab serpl pnl
97872-6,rabies virus ab panel
97872-6,panel virus ab rabies microbiology
97872-6,rabies viru rabv ab pane
90765-9,hedis 2019 value set - rh
90765-9,hedis 2019 value et pnl - rh
90765-9,hedis 2019 value set - rh
90765-9,hedis 2019 rh
90765-9,hedis rh 2019
90765-9,hedis 2019 rh hedis 2019 rh
90765-9,hedis 2019 value set - rh
90765-9,hedis value 2019 set - d typing rh
90765-9,hedis 2019 value set - rh
12336-4,hydralazine [presence] in serum or plasma
12336-4,hydralazine [resence] i serum or sr plasma
12336-4,r [resene] in seru hydalazin sr plasma
12336-4,hydralazine serpl ql
12336-4,hyralazne pl serp q
12336-4,hydralazine ql serpl
12336-4,hydralazine ql
12336-4,serplas ql hdralazne
12336-4,hydralazine ql drug/toxicology
32645-4,coxiella burnetii phase 1 igm ab [presence] in serum
32645-4,coxiella burnettii coxiella [presence] phase 1 igm ab burnetii in serum
32645-4,coxiella burnetii sr phase 1 igm ab [presence] in serum
32645-4,c burnet ph1 igm ser ql
32645-4,immunoglobulin m c rnetph1 igm ser ql
32645-4,burnet igm ph1 ser ql
32645-4,c. burnetii phase 1 igm ql (s)
32645-4,c. bretii phase 1 igm q (s)
32645-4,1 rnetii phase c. autoantibodies igm ql (s)
14674-6,corticotropin [moles/volume] in plasma
14674-6,quantitative cortcotopin pasma in [moles/vlume]
14674-6,corticotropin [moles/volume] in plas
14674-6,acth plas-scnc
14674-6,plas-scnc acth
14674-6,plas-scnc acth
14674-6,corticotropin (p) [moles/vol]
14674-6,[moles/vol] (p) corticotropin
14674-6,corticotopin (p) [moles/vol]
96077-3,hedis my 2020 value set - glucose tests
96077-3,hedis my 2020 value set - glucose tests glucoseur
96077-3,hedis my 2020 value set tests glucose -
96077-3,hedis my 2020 glucose tests
96077-3,hedis my 202 lucose tests
96077-3,hedis 2020 my glucose tests
96077-3,hedis my 2020 value set - glucose tests
96077-3,glu hedis - 2020 value set my glucose tests
96077-3,hedis m vlue gluc 202 st -gucosetests
22154-9,brucella canis igg ab [titer] in serum
22154-9,canis brucella ig ab [titer in ser
22154-9,brucella canis igg ab in [titer] serum
22154-9,b canis igg titr ser
22154-9,b igg canis titr ser
22154-9,b igg cais immune globulin g titrser
22154-9,br. canis igg (s) [titer]
22154-9,b cans igg serum (s) [titer]
22154-9,br. canis igg [titer] (s)
21064-1,acid alpha glucosidase [enzymatic activity/volume] in amniotic fluid
21064-1,acd lpha glucosiaseenzymatic activity/olume] in anitcfluid
21064-1,acid fluid glucosdse [enzymatic activity/oume] in amniotic alha
21064-1,acid a-glucosidase amn-ccnc
21064-1,acid alfa amn-ccnc a-glucosidase
21064-1,acid amn-ccnc a-glucosidase
21064-1,acid alpha glucosidase (amn fld) [catalytic activity/vol]
21064-1,acid glucosidase alpha acd (amn fld) [catalytic activity/vol]
21064-1,acid lpha glucosdas (am fld) [catalytic activity/vol]
5200-1,hepatitis d virus ab [units/volume] in serum by immunoassay
5200-1,hepatitis y ab [units/volum]in serum dvirus immunoassay
5200-1,hepatitis d vrus b [units/volme in delta hepatitis serm b immunoassay
5200-1,hdv ab ser ia-acnc
5200-1,hdv ab ia-acnc ser
5200-1,hdv ab antibodies se ia-acnc
5200-1,hdv ab ia qn (s)
5200-1,hdv (s) eia ia qn ab
5200-1,hv ab ia qn (s)
83145-3,grip strength test [nih toolbox]
83145-3,gri [nihtolbox] test strength
83145-3,grip strength test [nih toolbox]
83145-3,grip strength test nih
83145-3,strength grip test nih
83145-3,grip strength test nih
53079-0,dodecenoylcarnitine (c12:1) [moles/volume] in cerebral spinal fluid
53079-0,dodecenoylcarnitine (c12:1) [moles/volume] in cerebral spinal fluid cerebral spinal fluid
53079-0,dodenylcarnitine (c12:1) [mles/olm] spinalflud cerebal i
53079-0,dodecenoylcarn csf-scnc
53079-0,doecenoylcarn csf-scnc qnt
53079-0,dodecenoylcar cerebrospinal fluid-scn
53079-0,c12:1 (csf) [moles/vol]
53079-0,c12:1 (csf) [moles/vol]
53079-0,[moles/vol] (csf) c12:1
18310-3,deprecated hemoglobin.other/hemoglobin.total [interpretation] in blood
18310-3,dprcated hemolobin.othehemoglobin.otal [interpretation] in blod
18310-3,[interpretation] hemoglobin.other/hemoglobin.total deprecated in blood
18310-3,deprecated hgb other bld-imp
18310-3,deprecated interp hgb other bld-imp
18310-3,derecated ther hematology/cell counts blood-imp
18310-3,hemoglobin.other (bld) [interp]
18310-3,hemoglobin.other (bld) [interp] hgb
18310-3,[interp] (bld) hemoglobin.other
11601-2,echovirus 7 ab [units/volume] in serum
11601-2,echovirus in ab [units/volume] 7 serum
11601-2,echovirus 7 ab serum in [units/volume]
11601-2,ecv7 ab ser-acnc
11601-2,serum ecv7 bser-acnc
11601-2,ec7 serum-acnc ab
11601-2,echovirus 7 ab qn (s)
11601-2,echovirus 7 ab qn autoantibody (s)
11601-2,echovirus ab 7 qn (s)
38760-5,dibenzofuran [mass/volume] in air
38760-5,dibenzofuran [mass/volume] air in
38760-5,dibenzofuran [mass/volume] air in
38760-5,dibenzofuran air-mcnc
38760-5,dibezofuran air-mnc
38760-5,qnt dbenzofuran air-mcnc
38760-5,dibenzofuran (air) [mass/vol]
38760-5,(air)[mss/vol dibenofura qnt
38760-5,dibenzofuran [mass/vol] (air)
26955-5,aureobasidium pullulans igg ab [mass/volume] in serum
26955-5,aureoasidium in igg ab microbiology [massvoume] pllulans seru
26955-5,in pullulans igg ab [mass/volume] aureobasidium serum
26955-5,a pullulans igg ser-mcnc
26955-5,ser-mcnc ullulans antibodies ig a
26955-5,pullulas ig level sr-mcnc
26955-5,a. pullulans igg (s) [mass/vol]
26955-5,a. quantitative pululan igg (s) [mass/vol]
26955-5,a. pullulans ig (s) [mass/vo]
62653-1,phenx - difficulty in conceiving protocol 100401
62653-1,- henx difficulty in cnceiving protocl 0041
62653-1,phenx panel in difficulty - conceiving protocol 100401
62653-1,difficulty conceiving proto
62653-1,proto conceiving difficulty
62653-1,panel.phenx proto conceiving difficulty
54943-6,n-methyldiethanolamine [mass/volume] in urine
54943-6,n-methyldiethanolamine [mass/volume] urine point in time in
54943-6,urine [mass/volume] in n-methyldiethanolamine
54943-6,n-methyldiethanolamine ur-mcnc
54943-6,urcnc ua n-ethyldiethaolamin
54943-6,quant n-methldiethanolamine ur-cnc
54943-6,n-methyldiethanolamine (u) [mass/vol]
54943-6,n-methyldiethanolamine [mass/vol] (u)
54943-6,u n-methyldietanolamine [mass/vo]
94393-6,respiratory pathogens dna and rna panel - lower respiratory specimen by naa with probe detection
94393-6,respiratory pathogens dna specimen rna panel - lower respiratory and by naa with probe detection
94393-6,resiratory pthogensdna an rna anel - lowr resiator spcimen bynaa with probe dtection pcr
94393-6,resp path dna+rna pnl lower resp naa+prb
94393-6,resp path dna+rna pnl lower resp naa+prb resp pathogens
94393-6,resp path resp pnl lower dna+rna naa+prb
94393-6,respiratory pathogens dna and rna panel naa+probe (lower resp)
94393-6,respiratory pathogens dna panel rna and naa+probe (lower resp)
94393-6,spiratory pathogens (lower microbiology ra panel naaprobe dnaa resp)
101104-8,minimum data set (mds) - version 3.0 - resident assessment instrument (rai) version 1.18.11 during assessment period [cms assessment]
101104-8,minimum pnl data set (mds) - version 3.0 1.18.11 resident assessment instrument (rai) version - during assessment period [cms assessment]
101104-8,minimum pan data set (mds) - version 3.0 - resident assessment instrument (rai) version 1.18.11 during assessment period [cms assessment]
14711-6,epinephrine [moles/volume] in plasma
14711-6,epinephrine plasma in adrenaline [moles/volume]
14711-6,epinephrine [moles/volume] in quant plasma
14711-6,epineph plas-scnc
14711-6,plasma-scnc eineph
14711-6,plas-scnc epineph
14711-6,epinephrine (p) [moles/vol]
14711-6,epi epinephrine (p) [moles/vol]
14711-6,level epinphine (p) moes/vol]
97262-0,methylenedioxyamphetamine [presence] in cord tissue by screen method
97262-0,methlenedoxyamphetamine presece] in screenmetod tissue potentialforabuse by cord
97262-0,methylenedioxamphetaine [preence] in cord pr tissue by scree method
97262-0,mda tissco ql scn
97262-0,datissco ql scn ql
97262-0,mda scn ql tissco
97262-0,methylenedioxyamphetamine screen ql (umb cord tissue)
97262-0,mthylnedioxyamphetmie screen ql methylenedioxymethamphetamine metabolite tissue) ord (umb
97262-0,tissue) screen potentialforabuse presence (umb cord methylenedioxyamphetamine
98854-3,urothelial carcinoma probability score based on clinical and lab data
98854-3,urothelial carcinoma probability score clinical on based and lab data
98854-3,urothelial based probabiity sore carcinoa clincaland lab data
98854-3,urothelial ca prob score clin+lab data
98854-3,urotheliala prob score cin+lab data
98854-3,urothelial quantitative ca data score clin+lab prob
2130-3,citrulline [mass/volume] in serum or plasma
2130-3,ctrullie [mass/vlume] inserum o pasma
2130-3,cirulline [mass/volum] in sum o pasma
2130-3,citrulline serpl-mcnc
2130-3,citrulline serum or plasma-mcnc
2130-3,citrulline pt serpl-mcnc
2130-3,citrulline [mass/vol]
2130-3,citrulline [mass/ol] cit
2130-3,[mass/vol] plsm citrulline
96725-7,xanthoma cells [#/volume] in lower respiratory specimen by manual count
96725-7,xanthoma cells manl [#/volume] by lower respiratory specimen in manual count
96725-7,xanthoma by [#/volume] in lower quantitative respiratory specimen cells manual count
96725-7,xanthoma cells # lower resp manual
96725-7,xanthoma # cells lower resp manual
96725-7,xanthoma histiocyte cells # lower resp manual
96725-7,xanthoma cells manual cnt (lower resp) [#/vol]
96725-7,xanthma esp)#/vol] manal ct count/volume (owr cells
96725-7,xanthom cls maual ct (lower resp) [#/vol]
23081-3,equine herpesvirus 1 ag [presence] in tissue by immune stain
23081-3,equine erpesvirus 1 stin [peee] in tissu by immune ag
23081-3,equine herpesvirus 1 ag [presence] immune tissue by in stain
23081-3,ehv1 ag tiss ql imstn
23081-3,ehv1 ag tiss ql imstn i
23081-3,hv ag tiss presence mstn
23081-3,equine herpesvirus 1 ag immune stain ql (tiss)
23081-3,equine herpesvirus 1 ag immune stain ql immunostain (tiss)
23081-3,1 herpesvru equine ag immune tain ql(tiss
35141-1,purine nucleoside phosphorylase [enzymatic activity/volume] in cerebral spinal fluid
35141-1,purine nucleoside phosphorylase fluid activity/volume] in cerebral spinal [enzymatic
35141-1,prine nuleoside phosphryase [enzymati chemistry activity/volume] i cerebra spinal luid
35141-1,pnp csf-ccnc
35141-1,csf-cnc pnp
35141-1,cf-ccc pnp
35141-1,purine nucleoside phosphorylase (csf) [catalytic activity/vol]
35141-1,point in time phosphorylase nucleoside purine (csf) [catalytic activity/vol]
35141-1,purine posporyla nucleoside (csf) [catalyticactivityvol
8776-7,right ventricular stroke volume by angiography biplane
8776-7,right ventriular troke volume by angigraphy biplne
8776-7,right ventricular by volume stroke angiography biplane
8776-7,rv sv angio bp
8776-7,rv sv angio bp
8776-7,v rv angio bp volume
23953-3,aspergillus sp ab [titer] in cerebral spinal fluid by complement fixation
23953-3,asprgillus sp b [tier] in cerebral spinal fuid compfix by colemnt fxaton
23953-3,aspergillus cerebral ab [titer] in sp spinal fluid by complement fixation
23953-3,aspergillus ab titr csf cf
23953-3,aspergilus ab titr csf f
23953-3,aspergillus abtitr cscf anti
23953-3,aspergillus sp ab cf (csf) [titer]
23953-3,aspergllus sp a cf (cf) [titer]
23953-3,aspergilus sp ab cf (csf) [titer]
24226-3,coxsackievirus a10 ab [titer] in serum by complement fixation --1st specimen
24226-3,cf oxsacievirus a10 --1st tier] in seru by compleent fixtion ab specimen
24226-3,cackievirusa10 b [titer]inserum by spcimen fixatio -s complement
24226-3,cv a10 ab sp1 titr ser cf
24226-3,cv a10 ab sp1 cf ser titr
24226-3,cv a10 ab sp1 titr ser cf
24226-3,coxsackievirus a10 ab spec 1 cf (s) [titer]
24226-3,coxsacievirus a10 ab first pec 1 cf (s)[tie]
24226-3,cosackievius sr a10 absec [tite] cf(s) 1
93223-6,long-term care hospital (ltch) continuity assessment record and evaluation (care) data set (lcds) - version 5.00 during assessment period [cms assessment]
93223-6,lon-ter care during (ltc) continuty asssment recordand evaluatin (car) data set (lcds) - version 5.0 hosptal assessment perod [cmsassessme]
93223-6,long-term cre hospital ltc rsion assessment reord pan and ealuation (care)data set (lcds) - continuity 5.0 during assessnt peiod [cms assessment]
78837-2,jwh-018 pentanoate (synthetic cannabinoid metabolite) cutoff [mass/volume] in urine for confirmatory method
78837-2,jwh-018 pentanoate (synthetic cannabinoid metabolite) cutoff [mass/volume] in urine for level confirmatory method
78837-2,jwh-018 pentanoate (snthetic cannabinoid metabolie cuto mass/olume] nurine or confirmatory mehod
78837-2,jwh-018 pentanoate cto ur cfm-mcnc
78837-2,jwh-018 pentante cto r cfm-mcnc
78837-2,jwh-018 pentanoate cto ur cfm-mcnc
78837-2,jwh-018 pentanoate cutoff confirm (u) [mass/vol]
78837-2,jwh-018 pentanoate cutoff confirm [mass/vol] (u)
78837-2,am-678 jwh-018 entaote cutof onfim [mass/vol] ()
2415-8,histamine [mass/volume] in blood
2415-8,histamine [mass/volume] in blood qnt
2415-8,histamine [mass/volume] in blood
2415-8,histamine bld-mcnc
2415-8,histamine mass concentration bld-mcnc
2415-8,bld-mcnc histamine
2415-8,histamine (bld) [mass/vol]
2415-8,histamine [massvol] (blood) mass concentration
2415-8,histamine (blood) [mass/vol] mass concentration
20488-3,streptococcus agalactiae ag [presence] in cerebral spinal fluid
20488-3,trepcoccus strep b agalctiae g [preence] in cerebral spnl fluid
20488-3,ag agalactie streptococus [presence] n cerebra spinalfluid
20488-3,gp b strep ag csf ql
20488-3,gp ag strep b csf ql
20488-3,b gp strep ag csf ql
20488-3,s. agalactiae ag ql (csf)
20488-3,s. agalactiae ag (csf) ql
20488-3,ql s. ql ag agalactiae (csf)
39296-9,influenza virus a h1 ab [titer] in serum by hemagglutination inhibition
39296-9,infuenza vius a h1 ab [titer] heaglutinationinhibition serum by n
39296-9,influenza virus ah1 ab [titer] abs in by serum eaglutination inhibition
39296-9,fluav h1 ab titr ser hai
39296-9,fluav h a titr serum hai
39296-9,smqn fluavh1 b tir ser hai
39296-9,fluav h1 ab hai (s) [titer]
39296-9,fluav flua (s) hai hb titer]
39296-9,fluav h1 b (s) hai [titer]
22306-5,giardia lamblia igg ab [titer] in serum
22306-5,grdia point in time lamblia gg ab [titer] inserum
22306-5,giardia lamblia [titer] ab igg in serum
22306-5,g lamblia igg titr ser
22306-5,glamblia antibody ser iggtitr
22306-5,g lamblia igg titr ser
22306-5,g. lamblia igg (s) [titer]
22306-5,g. lamblia microbiology igg (s) [titer]
22306-5,g. (s) igg lamblia anti [titer]
23194-4,leptospira borgpetersenii sv sejroe ab [presence] in serum by agglutination
23194-4,infectious disease etospira bogpeterseni sejroe ab [presenc]inserm by agglutination
23194-4,leptospira borgpetersenii sv sejoe a [pesnce] random in by erum ggltinaton
23194-4,l borgp sej ab ser ql aggl
23194-4,aby l borgp sej ab ser presence aggl
23194-4,l borgp sejab se ql l borgp aggl
23194-4,l. borgpetersenii sv sejroe ab aggl ql (s)
23194-4,l borgpeterenii sv sejroe ab anti aggl ql s)
23194-4,l borgpeterseni qual sv sejro abaggl ql (s)
18442-4,3-hydroxybutyrylcarnitine (c4-oh) [mass/volume] in serum or plasma
18442-4,3-hydroxybutyrylcarnitine (c4-oh) [mass/volume] in ser or plasma
18442-4,3-hydroxybuyrylcarnitine(c4-h) [mass/volume plsma serum or pl n
18442-4,3oh-butyrcarn serpl-mcnc
18442-4,3-hydroxy butyrylcarnitine sermcnc 3oh-utyrcrn
18442-4,3oh-butyrcarn serpl-mcnc
18442-4,c4-oh [mass/vol]
18442-4,c4-oh[mass/vol]
18442-4,quantitative c4-oh [mass/vol]
97527-6,acanthamoeba sp ag [presence] in specimen by immunofluorescence
97527-6,acanthamoeba sp ag [presence] in specimen by immunofluorescence fluoresent
97527-6,acanthamoebasp ag [preence] in specien y imunofuorescence
97527-6,acanthamoeba ag spec ql if
97527-6,acanthamoeba ag spec presence if
97527-6,spec unspecified ag acanthamoeba ql if
97527-6,acanthamoeba sp ag if ql (specimen)
97527-6,acanthamebsp (specimen if l ag
97527-6,sp acanthamoeba ag spec if ql(specien)
82276-7,measured activity metabolic rate/predicted rmr [relative energy/time]
82276-7,quan measured actiitytablic rate/predicted rmr energy/ie] [relative
82276-7,measured actity metbolicrate/pedicted rmr [relaie enery/time]
82276-7,meas act metab rate/pred rmr
82276-7,ctmetab meas rate/pred 1 minute rmr
82276-7,meas act rate/pred metab activ rmr
23320-5,nairobi sheep disease virus ag [presence] in specimen by immunoassay
23320-5,nirobi sheep diseasvir ag prsenc]  specime by immunoassay
23320-5,nairobi sheep disease virus ag [ql] by specimen in immunoassay dis
23320-5,nsdv ag spec ql ia
23320-5,nsdv spc ag ql ia
23320-5,nsdv ag elfa ia pecl
23320-5,nairobi sheep disease virus ag ia ql (specimen)
23320-5,nairobi sheep disease nairovirus virus ag ia ql (specimen)
23320-5,nairobi sheep disease virus ag ia misc ql (specimen)
73390-7,esomeprazole induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73390-7,eomprazoleincd ig ltelet a [presence i serum or plas y flow cytometry (fc
73390-7,antibodies by induced platelet igm ab [presence] in serum or plasma esomeprazole flow cytometry (fc)
73390-7,esomeprazole ind plt igm serpl ql fc
73390-7,esomeprazole ind plt igmserpl ql fc thrombocyte
73390-7,esomeprazole ind plt igm serpl ql ind plt igm fc
73390-7,esomeprazole induced platelet igm fc ql
73390-7,plasma esomeprazole induced platelet igm fc ql
73390-7,platelet induced esomeprazole igm fc ql
62998-0,phenx - tinnitus protocol 201001
62998-0,201001 - tinnius protocl phen
62998-0,phenx pan 201001 tinnitus protocol -
62998-0,tinnitus proto
62998-0,tinnitus proto
62998-0,panl proto tinnitus
26945-6,triazolam [mass/mass] in hair
26945-6,triazolam [mass/mass] in hair drugs
26945-6,novo-triolam hair [massass] in triazolam
26945-6,triazolam hair-mcnt
26945-6,trazolam hairmcnt
26945-6,hair-mcnt triazoam
26945-6,triazolam (hair) [mass/mass]
26945-6,[mass/mass] (hair) quan triazolam
26945-6,apo-triazo (hair) triazolam [mass/mass]
75621-3,tnm pathologic staging after surgery panel cancer
75621-3,after pathologic staging tnm surgery panel cancer
75621-3,tnm pathologic surgery after staging panel random cancer
75621-3,tnm pathologic staging pnl cancer
75621-3,tnm pathologic staging cancer pnl
75621-3,tnm patholoic stging pnl cancer
47747-1,serine/amino acids.total in dbs
47747-1,serine/amio n acids.total dbs
47747-1,seieamino cids.tota n dbs
47747-1,serine sfr dbs
47747-1,sfr serine dbs
47747-1,acid serine dbs sfr
47747-1,serine/total aa (dbs) [molar fraction]
47747-1,quan serine/total aa [molar (dbs) fraction]
47747-1,tot serine/total aa (dbs) [molar fraction]
31510-1,mycoplasma capricolum ss capripneumonia ab [presence] in serum
31510-1,mycoplasma capricolum serum ab [presence] in sscapripnemonia
31510-1,in sscapripneuonia ab [presence mycoplasmacapricolum serum
31510-1,m cap caprip ab ser ql
31510-1,m cap caprip random ab ser ql
31510-1,caprip cap m ab serum ql
31510-1,m. capricolum ss capripneumonia ab ql (s)
31510-1,m. capriolum ss capripneumon myco ab ql (s)
31510-1,m. capricolum ss capripneumonia ab ql id (s)
47358-7,hepatitis b virus core ab [presence] in serum from donor by immunoassay
47358-7,hepatitis b virus core ab [ql] in serum from donor by screen immunoassay
47358-7,haitis b virus core a presence in erum from donor by immunoassay
47358-7,hbv core ab ser donr ql ia
47358-7,hbv ia a ser donr presence core
47358-7,hbv cre hbc ab ser donrl a
47358-7,hbv core ab ia ql (s donor)
47358-7,ql hbvcorebia (sdonor)
47358-7,hbv core ab ia ql (s donor)
27384-7,leptospira sp igm ab [units/volume] in cerebral spinal fluid by immunoassay
27384-7,leptspir sp igm ab [units/volume] i crebral spinal fluid by immunoassay
27384-7,elfa lptosira sp imab [units/volume] in cerbral spinal fluid by immuoassa
27384-7,leptospira igm csf ia-acnc
27384-7,letosira csf ig aacnc
27384-7,leptospira ia-acnc csf igm
27384-7,leptospira sp igm ia qn (csf)
27384-7,qn sp igm ia leptospira (csf)
27384-7,leptsprasp igm ia qn (csf)
94865-3,triglyceride [mass/volume] corrected for glycerol in serum
94865-3,triglyceride [mass/volume] corrected for heredity glycerol in serum
94865-3,tiglyceide[mas/volum] correced sum n orycerol sr
94865-3,trigl glycer cor ser-mcnc
94865-3,trigl lcr ser-mnc cr
94865-3,trigl ser-mcnc cor glycer
94865-3,triglyceride corrected for glycerol (s) [mass/vol]
94865-3,triglyceride orected [massvol] glycerol (s) fr
94865-3,triglycridecorected (s)mss/vol] glerol glycer cor for
24335-2,creatine kinase panel - serum or plasma
24335-2,anel kinas creatin - pnl serumor plasma
24335-2,pasm kinase panel - serum or creatine
24335-2,ck pnl serpl
24335-2,ck pnl serpl
24335-2,serl plasma pl
24335-2,ck panel
24335-2,panel ck
24335-2,ck panel ck
572-8,fungus identified in bone marrow by culture
572-8,fungus identified in bone marrow by culture bone marrow
572-8,fungus ientid in culture arrw by bone
572-8,fungus mar cult
572-8,cult mar fungus
572-8,cult mar nominal fungus
572-8,fungus identified cx nom (bm)
572-8,(bm) identified cx nom fungus
572-8,fungs cx identified nom (bm)
11229-2,3-o-methyldopa [mass/volume] in serum or plasma
11229-2,serum or plasma serum [mass/volume] in 3-o-methyldopa or plasm
11229-2,3-o-ethyldoa [mass/volume] aldomet in plasma or srum
11229-2,3-o-methyldopa serpl-mcnc
11229-2,3-o-methyldopa serpl-mcnc qnt
11229-2,serpl-mcnc 3-o-methyldopa 3-omd
11229-2,3-o-methyldopa [mass/vol]
11229-2,mas/vol] 3-o-methylop quan
11229-2,3-o-methyldopa [massvl] novomedopa
13139-1,deprecated streptococcus pneumoniae 1 ab [units/volume] in serum --1st specimen
13139-1,dprecated quantitative stretocccus pneumoie 1 ab [units/volume] inserum--1st speimen
13139-1,deprecated streptococcus pneumoniae 1 ab [units/volume] in infectious disease serum --1st specimen
13139-1,deprecated s pneum 1 ab sp1 ser-acnc
13139-1,sp1 s pneum1 a depecatd ser-acnc
13139-1,deprecated pnem ser-acc sp1 1ab
13139-1,s. pneumoniae 1 ab spec 1 qn (s)
13139-1,s. pneumoniae 1 ab spec 1 qn (s) pneum
13139-1,s. qn 1 ab spec 1 pneumoniae (s)
29233-4,coxsackievirus b4 ab [titer] in body fluid
29233-4,coxsackievirus b4 ab [titer] in body fluid
29233-4,body b4 ab [titr n coxsackieviru fui
29233-4,cv b4 ab titr fld
29233-4,cv b4 ab itr fld microbiology
29233-4,cv b fld tit a
29233-4,coxsackievirus b4 ab (body fld) [titer]
29233-4,coxsakievius b4 ab [titer] (bodyld)
29233-4,coxsackiviru 4 ab (body ld)[titer] aby
26672-6,ross river virus ab [presence] in serum
26672-6,rossriver virus ab [presce] in seru
26672-6,antibodies ros rver virus ab [presence]i serum
26672-6,rrv ab ser ql
26672-6,rrv ql ser ab
26672-6,rrv ql antby serum ab
26672-6,ross river virus ab ql (s)
26672-6,ross river virus ab ql (s) infectiousdisease
26672-6,ross (s) virus ab presence river
59581-9,coxsackievirus a7 igm ab [titer] in serum by immunofluorescence
59581-9,coxsackievirus a7 ab igm [titer] in serum by immunofluorescence
59581-9,coxsackievirus a7 igm ab [titer] serum in by immunofluorescence
59581-9,cv a7 igm titr ser if
59581-9,cv a7 igm coxsackie virus titr ser if
59581-9,cv a7 igm titr serum if
59581-9,coxsackievirus a7 igm if (s) [titer]
59581-9,[titer] a7 igm if (s) coxsackievirus
59581-9,coxsacivirs a7 [titer] if (s) igm
24248-7,polio virus 3 ab [titer] in serum --2nd specimen
24248-7,plio virus 3 ab [titer] serum in --2nd pecien
24248-7,polio virus 3 ab [titer] in microbiology serum --2nd specimen
24248-7,pv3 ab sp2 titr ser
24248-7,sr pv3 ab sp2 titr ser
24248-7,pv3 ab sp2 titr sr
24248-7,polio virus 3 ab spec 2 (s) [titer]
24248-7,polio virus [titer] ab spec 2 (s) 3
24248-7,polio virus (s) ab spec 2 3 [titer]
62923-8,phenx - emotional state - adult protocol 180501
62923-8,phenx - emotional state - adult protocol 180501
62923-8,phenx adult emotional pnl state - - protocol 180501
62923-8,emotional state - adult proto
62923-8,emotional state - adult proto
62923-8,- stae emotional adut proto
101180-8,2-methyl ap-237 [presence] in urine by confirmatory method
101180-8,2-methyl ap-237 [presence] urine in by confirmatory method
101180-8,2-methyl ap-237 [presece] in urine by coirmatory method
101180-8,2-methyl ap-237 ur ql cfm
101180-8,presence ap-237 ur 2-methyl cfm
101180-8,2-methyl cfm ur ql ap-237 drugs
101180-8,2-methyl ap-237 confirm ql (u)
101180-8,(u) ap-237 confirm ql 2-methyl point in time
101180-8,2-methyl ql confirm ap-237 (u)
74137-1,"norfentanyl [mass/volume] in serum, plasma or blood by confirmatory method"
74137-1,"norfentanyl confirmatory in serum, plasma or blood by [mass/volume] method"
74137-1,"norfentanyl [mass/volume] in serum, blood or plasma by confirmatory method"
74137-1,norfentanyl serplbld cfm-mcnc
74137-1,orentanyl serplbld serpl cfm-mcnc
74137-1,cfm-cc nofentanlserlbld serplbld
74137-1,norfentanyl confirm (s/p/bld) [mass/vol]
74137-1,[mass/vo] (/p/bd) norfentylconfirm
74137-1,norfentanl onfim (s/p/bld) [mass/vol]
58715-4,adulterants panel - urine
58715-4,adulterants panel - urine ur
58715-4,panel adulterants - urine
58715-4,adulterants pnl ur
58715-4,adulterants pnl ur
58715-4,adulterants pan nlur
58715-4,adulterants panel (u)
58715-4,(u) panel adulterants ur
58715-4,panel adulterants panel.chemistry (u)
62625-9,phenx - respiratory - personal - family hx of respiratory symptoms - diseases - adult protocol 090901
62625-9,phex - resiratory - peronal - famil hx of respiratoryymptoms- disease - adult protocol panl 09901
62625-9,phenx -respiratory - peronal- family x of resiatory symptom - ieaes - dult roocol 090901
62625-9,resp fam hx resp sympt adult proto
62625-9,sp fam hx res sympt adult proto
62625-9,resp sympt hx resp fam adult proto
43079-3,bluetongue virus 17 ab [titer] in serum
43079-3,reovirus bluetongue vrus17ab in [tite] serum
43079-3,buetongue vrus 17b titer] in erum
43079-3,btv17 ab titr ser
43079-3,titrser b btv17 titer
43079-3,tv17 tir ab er
43079-3,bluetongue virus 17 ab (s) [titer]
43079-3,bluetongue virus 17 ab (s) [titer]
43079-3,bluetongue autoantibody virus 17 ab (s) [titer]
43819-2,beta-2-microglobulin [presence] in urine
43819-2,urine in bea-2-microglobulin[pesence]
43819-2,[presence] beta-2-microglobulin in urine
43819-2,b2 microglob ur ql
43819-2,b2 ii ur microglob ql
43819-2,b2 microglob ur ql
43819-2,beta-2-microglobulin ql (u)
43819-2,ql beta-2-microglobli (u)
43819-2,(u) beta-2-mcrglobuinql
60178-1,tellurium [mass/mass] in hair
60178-1,tellurium [mass/mass] har in hair
60178-1,hair [mass/mass] in quant tellurium
60178-1,tellurium hair-mcnt
60178-1,tellurim mass content hair-mcnt
60178-1,ellrium te ar-mcnt
60178-1,tellurium (hair) [mass/mass]
60178-1,telluium (hair) [mas/mass] har
60178-1,telluriu (har) [mass/mass]
3747-3,meperidine [mass/volume] in urine
3747-3,meperidine addiction [mass/volume] in urine
3747-3,meperidine urine in [mass/volume]
3747-3,meperidine ur-mcnc
3747-3,meperidine umcnc pt
3747-3,meperdine ur-mcnc drugs of abuse
3747-3,meperidine (u) [mass/vol]
3747-3,meperidine illicit (u) [mass/vol]
3747-3,meperidine (u) [mass/vol] quant
31377-5,equine herpesvirus 1 ab [units/volume] in serum
31377-5,eqine herpirus random 1 ab [units/volume] in ser
31377-5,equine herpesvirus 1 ab [units/volume] in serum
31377-5,ehv1 ab ser-acnc
31377-5,ab ehv1 quantitative ser-acnc
31377-5,ehv1abser-acnc herpes virus
31377-5,equine herpesvirus 1 ab qn (s)
31377-5,equine herpesvirus abs 1 (s) qn ab
31377-5,quine herpesvirus 1 b n (s)
46171-5,deprecated borrelia burgdorferi 58kd igg ab [presence] in serum
46171-5,deprated borrelia burgdorferi 58kd infectiousdisease in [presence] iggab serum
46171-5,deprecated borlia burgorferi 58kd igg ab [presence] in serum
46171-5,deprecated b burgdor58kd igg ser ql
46171-5,deprecated burgdor58kd b b burgdor ggser ql
46171-5,deprecated ser burgdor58kd igg b ql
46171-5,b. burgdorferi 58kd igg ql (s)
46171-5,burgdorferi b. 58kd igg antby ql (s)
46171-5,b. burgdrferi 58kd igg ql (s)
5857-8,herpes simplex virus identified in isolate by immunofluorescence
5857-8,in simplex virus ientifi here isolat by mnofluorescence identity or presence
5857-8,herpe simplexirs immuofluorecence n solat by identity or presence identifie
5857-8,hsv islt if
5857-8,hsv if isl anticomplement immunofluorescence
5857-8,hsv if islt
5857-8,hsv identified if nom (isol)
5857-8,hsv identifiedif o herp splx (isol)
5857-8,hsv identified f nom isl)
27060-3,melatonin [presence] in saliva (oral fluid)
27060-3,melatonin [presence] in saliva (oral fluid)
27060-3,salia [prsence] in melatonin (oal fluid)
27060-3,melatonin sal ql
27060-3,melatonin al ql
27060-3,mltoni ql chemistry sal
27060-3,melatonin ql (sal)
27060-3,melatonin ordinal ql (sal)
27060-3,melatonin ql (sal)
93453-9,w-15 [mass/volume] in urine by confirmatory method
93453-9,-15 [mass/volume] in urine by confirmaory method
93453-9,w-15 [mass/volume] n urine byconimatory ethod
93453-9,w-15 ur cfm-mcnc
93453-9,w- cfm-mcnc ur
93453-9,cfm-mcnc ur w-15
93453-9,w-15 confirm (u) [mass/vol]
93453-9,point in time w-15 cfirm u) [mass/vol
93453-9,w-15 confirm (u) [mass/vol]
7819-6,brugia malayi ab [presence] in serum
7819-6,bruia b malayi [preence i seum
7819-6,brugia malayiab[presence in serum
7819-6,b malayi ab ser ql
7819-6,b malayi ab serum antibodies ql
7819-6, malayi ab serum ql
7819-6,b. malayi ab ql (s)
7819-6,malayi b. ab presence (s)
7819-6,b. ab malayi ql (s)
54149-0,homogenous nuclear ab pattern [presence] in serum by immunofluorescence
54149-0,homogeous nuclear ab pattern [presence] n ser by immunoflorcen screen
54149-0,near homogenous bpttern [presene]in serum anf by immunofluoescence
54149-0,ana homogen ser ql if
54149-0,ana homogen ser presence if
54149-0,immunoflour ana sel homoge if
54149-0,homogenous nuclear ab pattern if ql (s)
54149-0,homogenous nuclear ab pattern if ql (s)
54149-0,homogenous nuclear (s) pattern if ql ab
86842-2,"mds v3.0 - rai v1.14.1, v1.15.1, v1.16.1 - therapies - ns, nsd, ss, ssd during assessment period [cms assessment]"
86842-2,"mds v3.0 - rai v1.14.1, v1.15.1, v1.16.1 - ssd - ns, nsd, ss, therapies during assessment period [cms assessment]"
86842-2,"mds rai - v3.0 v1.14.1, v1.15.1, v1.16.1 - centers for medicare and medicaid assessment therapies - ns, nsd, ss, ssd during assessment period [cms assessment]"
95495-8,other substances used during the past 3 months [nida]
95495-8,other 3 used survey.nida during the past substances months [nida]
95495-8,other substances used during the past 3 months [nida]
11284-7,acuity assessment practitioner identification
11284-7,aciy asessmnt clin practitioner idetificaion
11284-7,acuity assessment identification practitioner
11284-7,acuity assessment pract id
11284-7,acuity assessment pract id
11284-7,acuity pract assesmet nominal id
22112-7,blastomyces dermatitidis ab [titer] in serum
22112-7,dermtitidi bastomyces ab b dermat titer n ser
22112-7,blastomyces dermatitidis ab [titer] in serum
22112-7,b dermat ab titr ser
22112-7,ttr bdermat ab titr serum
22112-7,b dermat ser titr ab
22112-7,b. dermatitidis ab (s) [titer]
22112-7,b. ab dermatitidis (s) [titer] anti
22112-7,infectious disease b.dermattidis ab (s) [iter]
2837-3,pregnenolone [mass/volume] in serum or plasma
2837-3,pregnenolone in [mass/volume] serum or plasma
2837-3,pregnenolone qnt [mass/volume] in serum or plasma
2837-3,preg serpl-mcnc
2837-3,serpl-mcnc preg
2837-3,peg serplmcnc
2837-3,pregnenolone [mass/vol]
2837-3,pregnenolone serp [mass/vol]
2837-3,pregnenolone [mass/vol] ser
99264-4,etizolam [mass/volume] in urine by confirmatory method
99264-4,etizolam [mass/volume] urine in by confirmatory method
99264-4,etizolam [mass/volume]inurineb cnfirmatory mthd
99264-4,etizolam ur cfm-mcnc
99264-4,etioam ur mmcnc
99264-4,etizolam cfm-mcnc ur
99264-4,etizolam confirm (u) [mass/vol]
99264-4,etizolam [mass/vol] (u) confirm
99264-4,etzolam conim ua ()[mass/vol
57761-9,heparin induced platelet ab [presence] in serum or plasma by immunoassay
57761-9,heparin induced platelet ab [presence] in ser or by plasma immunoassay
57761-9,ab induced platelet elfa heparin [presence] in ser or plasma by immunoassay
57761-9,pf4 heparin cmplx ab serpl ql ia
57761-9,ql heparin aby cmplx ab serpl pf4 ia
57761-9,pf4 heparin cmplx ab serum or plasma ql ia
57761-9,heparin induced platelet ab ia ql
57761-9,ql induced plele a ia hepari
57761-9,heparin inducedplatelet ab i ql heparin induced thromocytopenia
19294-8,cannabinoids confirm method [identifier] in urine
19294-8,cannabinoids urine method [identifier] in confirm
19294-8,in confir method [identifier] cannabinoids urine
19294-8,cannabinoids cfm meth ur
19294-8,cannabinoids cf meth u
19294-8,cannabinoids ur marijuana meth cfm
19294-8,cannabinoids confirm method nom (u)
19294-8,nom confirm method cannabinoids (u)
19294-8,cannabinoids confirm method nominal nom (u)
100123-9,chlamydophila pneumoniae iga ab [presence] in serum by immunoassay
100123-9,chlamyophla elisa pneumonae igab [preence] imunoasy ser by in
100123-9,chamydophila pneumoniae iga ab [presenceinseumby qualitative immunoassay
100123-9,c pneum iga ser ql ia
100123-9,c neumia serum ql ia
100123-9,c pneum iga se ql ia chlamydia
100123-9,c. pneumoniae iga ia ql (s)
100123-9,c. pneumoniae chlamydia ia iga ql (s)
100123-9,c. pneumoiae ia a pr q (s
50580-0,"maternal screen for fetal abnormalities such as open neural tube defects, trisomy 21 or trisomy 18 panel - serum or plasma"
50580-0,"maternal down syndrome screen for fetal abnormalities such as open neural tube defects, trisomy 21 or trisomy 18 panel - serum or plasma"
50580-0,"maternal screen for fetal abnormalities such as open neural tube defects, trisomy 21 or trisomy 18 panel - serpl"
50580-0,mat scn for fetal abnormalities serpl
50580-0,plsm ma scn for fetal abnormalies srl
50580-0,mat scn for plsm fetal abnormalitie serpl
50580-0,"maternal screen for fetal abnormalities such as open neural tube defects, trisomy 21 or trisomy 18 panel"
50580-0,"maternal screenfor fetal abnoralities opennural s such tue defects, trisomy arterial stenosis 2 or trisomy panel"
50580-0,"mateal screen for fetal anomalities edward syndrome such as open neural tue defects, trsomy 21 or triomy18 panel"
60443-9,hedis 2011 codes to identify colorectal cancer screening (col-a)
60443-9,hedis 21 codesto idenify coloectal cancer screening(col-a
60443-9,hedi 2011 codes o ientify colorectal cancer sreening (ola)
60443-9,hedis 2011 col-a
60443-9,hedis 2011 col-a
60443-9,2011 panel hedis col-a
60443-9,hedis 2011 codes to identify colorectal cancer screening (col-a)
60443-9,screening 2011 codes to identify colorectal cancer hedis (col-a)
60443-9,hedis 2011 codes to identify colorectal cancer screening (col-a)
32079-6,gold [moles/volume] in urine
32079-6,[moles/volume] gold substance concentration in urine
32079-6,[molesvolume] od in urine quantitative
32079-6,gold ur-scnc
32079-6,gold ur-scnc
32079-6,ur-scnc gold
32079-6,gold (u) [moles/vol]
32079-6,au gold [moles/vol] (u)
32079-6,point in time gold (u) [moles/vol]
18348-3,toxoplasma gondii igm ab [units/volume] in cerebral spinal fluid
18348-3,toxolasma gondii ig ab nits/vlume] cerebal in spinal fluid
18348-3,toxoplasma gondii igm ab [units/volume] in cerebral spinal infectious disease fluid
18348-3,t gondii igm csf-acnc
18348-3,csf-acnc gondii igm t
18348-3,csf-acnc gondii igm t
18348-3,t. gondii igm qn (csf)
18348-3,t. qn igm gondii (csf) autoantibodies
18348-3,. cerebral spinal fluid gondiiigm (cs qn
20747-2,carbamates [presence] in ingesta by screen method
20747-2,carbamates method in ingesta by screen [presence]
20747-2,carbamates [ql] in qual by ingesta screen method
20747-2,carbamates ingesta ql scn
20747-2,carbamates ingesta presence sc
20747-2,carbamates ingesta presence pr scn
20747-2,carbamates screen ql (ingesta)
20747-2,screen screen carbamates ql (ingesta)
20747-2,carbamate (ingesta) ordinal ql screen
22468-3,rickettsia (proteus ox19) ab [presence] in serum
22468-3,in (proteus ox19) ab [presence] rickettsia serum
22468-3,ab (protes ox19) rickettsia [pesence] in seru
22468-3,proteus ox19 ab ser ql
22468-3,prteusox19 ab screen serq
22468-3,proteus ox19 ql ser ab
22468-3,rickettsia (proteus ox19) ab ql (s)
22468-3,rickettsia ql ox19) ab (proteus (s)
22468-3,(proteus rickettsia ox19) ab ql (s)
67711-2,glutarylcarnitine (c5-dc)+3-hydroxyhexanoylcarnitine (c6-oh)/octanoylcarnitine (c8) [molar ratio] in dbs
67711-2,glutarylcarnitine (c5-dc)+3-hydroxyhexanoylcarnitine (c6-oh)/octanoylcarnitine (c8) [molar ratio] in dbs wb
67711-2,glutarylcarnitine quantitative (c5-dc)+3-hydroxyhexanoylcarnitine (c6-oh)/octanoylcarnitine (c8) [molar ratio] in dbs
67711-2,glut+3ohhexanoylcarn/c8 dbs-srto
67711-2,glut+3ohhexanoylcarn/c8 c6oh dbs-srto
67711-2,dbs-srto glut+3ohhexanoylcarn/c8
67711-2,c5-dc+c6-oh/octanoylcarnitine (c8) (dbs) [molar ratio]
67711-2,c5-dc+c6-oh/octanoylcarnitine (c8) (dbs) [molar ratio]
67711-2,[molar (c8) (dbs) substance ratio c5-dc+c6-oh/octanoylcarnitine ratio]
27926-5,hemoglobin.gastrointestinal [presence] in stool --8th specimen
27926-5,hemoglobin.gstrointestina point in time [presece]instool --8th specmn
27926-5,hemoglobin.gastrointestinal [presence] in stool pr --8th specimen
27926-5,hemoccult sp8 stl ql
27926-5,presence gastrocult p st heocclt
27926-5,ql sp8 stl hemoccult
27926-5,hemoglobin.gastrointestinal 8th specimen ql (stl)
27926-5,occult bld hemoglobin.gastrointestinal 8th specimen ql (stl)
27926-5,hemoglobin.gastrointestinal 8th specien ql (stl)
106607-5,streptococcus pneumoniae dna [presence] in body fluid by naa with non-probe detection
106607-5,trptcoccspneoniae dna [resence] in body deecton y na pneumococcal thnon-probe fuid
106607-5,streptococcus pneumoniae dna [presence] in body probe with target amplification fluid by naa with non-probe detection
106607-5,s pneum dna fld ql naa+non-probe
106607-5,s fld dna pneum presence amplification na+non-probe
106607-5,s pneum dna probe dna fld ql naa+non-probe
106607-5,s. pneumoniae dna naa+non-probe ql (body fld)
106607-5,naa+non-probe s. fld) aa+nonprobe ql (bdy peumoniaen
106607-5,spnemoniae dna naa+non-probe ql(body fld)
14627-4,bicarbonate [moles/volume] in venous blood
14627-4,bicarbonate [moles/volume] blood venus blood venos in
14627-4,bicarbonate in [moles/volume] bicarb venous blood
14627-4,hco3 bldv-scnc
14627-4,bld ven bldv-scnc hc3
14627-4,bldv-scnc h3
14627-4,hco3 (bldv) [moles/vol]
14627-4,hco3 (bldv) [moles/vol]
14627-4,hco3 (bldv) [moles/vol] quantitative
50610-5,alpha-1-fetoprotein [multiple of the median] adjusted for multiple gestations in serum or plasma
50610-5,alha-1feoprotein [mltiple mult gest adj fthe gestations adusted for multiple median] inserumor plasma
50610-5,ser or plasma alpha-1-fetoprotein [multiple of the in adjusted for multiple gestations median] ser or plasma
50610-5,afp mult gest adj mom serpl
50610-5,afp mom gest adj mult serpl
50610-5,afp mult gest serpl mom adj
50610-5,afp adjusted for multiple gestations [mom]
50610-5,mult gest adj afp adjusted for multiple gestations [mom]
50610-5,afp adjusted for mulple [mom] gestation
43190-8,myelin associated glycoprotein/sulfated glucuronic paragloboside igm ab [titer] in serum by immunoassay
43190-8,myelin sr asocited glycoprotei/sulfatedglucuronic paraloboside ig ab [iter] i seru by mmuoassay
43190-8,myelin associted goprotein/sulfate glucuroc paraglobside igm a titer]in ser by immnoassy
43190-8,mag/sgpg igm titr ser ia
43190-8,mag/sgpg meia gm eria titr
43190-8,iaa mg/pg igm ia titrsr
43190-8,myelin associated glycoprotein/sulfated glucuronic paragloboside igm ia (s) [titer]
43190-8,myelin mag associated lcoprotei/sulfaed glucurnic paagoboside ig ia (s) [iter]
43190-8,myein asociated (s) paragloboside igm ia titered glycoprotinsulfaedglucuronic [titer]
19450-6,dihydrocodeine cutoff [mass/volume] in urine for screen method
19450-6,level dihdrcodeine cuoff [massolume] methd uie for screen in
19450-6,dihydrocodeine cutoff [mass/volume] in urine method screen for cto
19450-6,dhc cto ur scn-mcnc
19450-6,dhc ur cto scn-mcnc
19450-6,co dhc ua ur scn-mcnc
19450-6,dihydrocodeine cutoff screen (u) [mass/vol]
19450-6,dihydrocodeine reen cutof (u) [mas/vo]
19450-6,screen dihydocodencutoff (u)mas/vol
3473-6,chlorpromazine [mass/volume] in urine
3473-6,chlorpromazine [mass/volume] quant in urine
3473-6,massvolume]i chlorpromazine urine
3473-6,chlorpromazine ur-mcnc
3473-6,ur-mcnc chlorpromazine random
3473-6,level chlorpromazine ur-mcnc
3473-6,chlorpromazine (u) [mass/vol]
3473-6,(u) chlorromazine [mass/o]
3473-6,[mass/vol] (u) chlorpromazine
44738-3,asialoganglioside gm1 igg ab [presence] in serum
44738-3,a m1ig asilaglioside [presen] autoantibodies in ser
44738-3,asialoganglioside gm1 in ab [presence] igg serum
44738-3,gm1 asialo igg ser ql
44738-3,gm1 serum igg asialo ql
44738-3,gm1 asialo igg ser ql
44738-3,asialoganglioside gm1 igg ql (s)
44738-3,asialoganglioside gm1 igg (s) ql sr
44738-3,asialoganglioside igg gm1 ql (s)
14653-0,clomipramine [moles/volume] in urine
14653-0,in [moles/volume] clomipramine urine
14653-0,clomipramine [moles/volume] in urine
14653-0,clomipramine ur-scnc
14653-0,ur-scnc clomipramine
14653-0,ur-scnc clomipramine
14653-0,clomipramine (u) [moles/vol]
14653-0,lomipramine drugs (u) [molesvol
14653-0,clomiramine (u) [molesvol]
2560-1,leucine [mass/volume] in serum or plasma
2560-1,plasma [mass/volume] in ser or quantitative leucine
2560-1,leucine [mass/volume] in serplas serum or plasma
2560-1,leucine serpl-mcnc
2560-1,plasma serpl-mcnc leucine
2560-1,sepl-mcnc qnt leuine
2560-1,leucine [mass/vol]
2560-1,serum leuine [mass/vol
2560-1,mass/ol] quant eucne
16132-3,hiv 1 p15+p18 ab [presence] in serum by immunoblot
16132-3,hiv 1 p15+p18 ab [ql] serum in by immunoblot western blot
16132-3,1 random hiv p15+p18 ab [resence]i serum b immunoblot
16132-3,hiv1 p15+p18 ab ser ql ib
16132-3,p15+p18 hiv1 ab ser ql ib
16132-3,hiv p15+p18 ab ib presence ser
16132-3,hiv 1 p15+p18 ab ib ql (s)
16132-3,hiv infectious disease 1 15+p18 ab ib l s)
16132-3,hiv 1p15+p18 screen ab b q (s)
77371-3,brassicasterol [moles/volume] in serum or plasma
77371-3,in point in time [moles/vlume] brassicasterol serum or plasma
77371-3,brassiastrol [les/volume] in serpl
77371-3,brassicasterol serpl-scnc
77371-3,point in time serpl-scnc assicasterol
77371-3,serpl-scnc serum brassicasterol
77371-3,brassicasterol [moles/vol]
77371-3,brassicastero [oles/vol]
77371-3,[moes/ol] sr brassicasterol
41456-5,deprecated respiratory syncytial virus rna [identifier] in unspecified specimen by probe & target amplification method
41456-5,eprecated resprtory syncytial vus rna [identifier] in unspecified specimen by probe & tatamplification method
41456-5,deprcated respiratory syncytia virus rna method in unsecfied secimenbyprobe & target ampliication [identifier]
41456-5,deprecated rsv gentyp xxx pcr
41456-5,gentyp rsv deprecated xxx pcr pcr
41456-5,deprecated xxx gentyp rsv pcr
41456-5,rsv genotype naa+probe (specimen)
41456-5,3 self-sustaining sequence replication rsv na+prbe genpe (seien)
41456-5,naa+probe genotype rs (specimen)
22754-6,deprecated dibucaine number in serum or plasma
22754-6,deprecated dibucaine number num in ser or plasma
22754-6,deprecated dibucaine or in serum number plas
22754-6,deprecated dibucaine number ser-acnc
22754-6,num ser-acnc dibucaine number deprecated
22754-6,derecated sr dibucaineumber se-acnc
22754-6,dibucaine number qn (s)
22754-6,dibucaie nmber qn (s)
22754-6,dibucaine number qn s)
22309-9,hantavirus puumala igm ab [titer] in serum
22309-9,hantavirus puumala [titer] ab igm smqn in ser
22309-9,serum puumala igm ab antibodies [titer] in hantavirus
22309-9,puuv igm titr ser
22309-9,puuv serum titr igm
22309-9,ser m ttr puuv
22309-9,hantavirus puumala igm (s) [titer]
22309-9,hantavirus puuala igm (s) [tier]
22309-9,hantavirus titered puumala igm (s) [titer]
45218-5,lymphocytic choriomeningitis virus igg ab [presence] in serum
45218-5,lymphocytic choriomeningitis virus igg ab [presence] qual in serum
45218-5,lymphocytic choriomeningitis virus igg ab [presence] in serum antibodies
45218-5,lcmv igg ser ql
45218-5,microbiology serum igg lcm q
45218-5,lcmv q e gg
45218-5,lymphocytic choriomeningitis virus igg ql (s)
45218-5,lyphocyic igg vrus choiomeningit l (s) infectiousdisease
45218-5,lymphocytic serum igg virus choriomeningitis ql (s)
38228-3,braden scale skin assessment panel
38228-3,panl bradescale skin assessment panel
38228-3,braden assessmnt skin scale panel
38228-3,braden scale skin assess pnl
38228-3,pnl scale skin skin assessment pnl assess braden
38228-3,integument braden scae skin assess p
2487-7,inter alpha trypsin inhibitor [mass/volume] in serum
2487-7,trypsininhibitor alha nter [mss/voume]in qnt seru
2487-7,inter alpha trypsin inhibior mass/volume] in srum
2487-7,inter a-trypsin inhib ser-mcnc
2487-7,ser-mcnc -trpsin inhib inter
2487-7,inhib a-trypsin inter ser-mcnc
2487-7,inter alpha trypsin inhibitor (s) [mass/vol]
2487-7,inter alpha trypsin inhibitor (s) [mass/vol]
2487-7,inter alpha trypsin [mass/vol] (s) inhibitor
89582-1,microscopic observation [identifier] in cervix by acid fast stain
89582-1,point in time miroscopic obrvtion [identiir] n cervi by acid fast tain
89582-1,microscopic in [identifier] observation cervix by acid fast stain
89582-1,acid fast stn cvx
89582-1,acid fast stn acid fast cvx stn
89582-1,stn fast acid cvx
89582-1,microscopic observation acid fast stain nom (cvx)
89582-1,irosopic observation acid infectiousdisease sai fast nom (cv)
89582-1,micrsopic observtin acid fst sain nom (cvx)
49154-8,rickettsia conorii igg ab [titer] in body fluid
49154-8,ig conor rickttsia ab [titer] in bodies bod fui
49154-8,ricketsiacnorii igg ab boyfluid [titer]in
49154-8,r conorii igg titr fld
49154-8,r fld titr cnorgg
49154-8,r cnorii ig ttr fld
49154-8,r. conorii igg (body fld) [titer]
49154-8,r. conorii igg (body smqn fld) [titer]
49154-8,(ody conoriiigg r fld) antibodies [titer]
95863-7,lcds v4.00 - bladder and bowel - planned discharge during assessment period [cms assessment]
95863-7,cds v400 - bladder and bowe - plnned pnl dicharge during asessment erid cms ssemet]
95863-7,assessment] v4.00 - bladder and bowel - planned discharge during assessment period [cms lcds
44369-7,hexokinase [presence] in plasma
44369-7,hexokinase in [presence] plama chemistry
44369-7,hexokinase plasma in [presence] plasma
44369-7,hexokinase plas ql
44369-7,chemistry hexokinase plas ql
44369-7,plas hexokinase ql
44369-7,hexokinase ql (p)
44369-7,ql hexokinase (p)
44369-7,hexokinase presence (p)
54310-8,linoleoylcarnitine (c18:2)/creatinine [molar ratio] in urine
54310-8,linoleoylcarntine (c18:2)/creatinine molar in ratio] urine
54310-8,linoleoylcaritine (c18:2)/creatinine molar ratio creat in urine
54310-8,linoleoylcarn/creat ur-srto
54310-8,linleoylcarn/creat ur-sto ii
54310-8,ur-sto linoleoycarn/creat
54310-8,c18:2/creatinine (u) [molar ratio]
54310-8,c18:2/creatinine c18:2 (u) [moar atio]
54310-8,c18:2/creatinin [oar scrto (u) ratio]
44299-6,arginine/creatinine [mass ratio] in 24 hour urine
44299-6,24 mass ratio] mass ratio n argininecreatinine oururine
44299-6,argininecreatinine [mass ratio n 24 hour urine
44299-6,arginine/creat 24h ur
44299-6,arginine/creat ur 24h
44299-6,arginine/creat 24h r 24hr
44299-6,arginine/creatinine (24h u) [mass ratio]
44299-6,creat inine/creatinine (2h u)[mass tio
44299-6,arginine/retinin urn (24h u) [ass ratio]
44423-2,herpes virus 7 dna [presence] in specimen by naa with probe detection
44423-2,herpes virus 3 self-sustaining sequence replication 7 with [presence] in specimen by naa dna probe detection
44423-2,herpes virus 7 dna human herpes virus type 7 naa in specimen by [presence] with probe detection
44423-2,hhv7 dna spec ql naa+probe
44423-2,naa+probe dna spec ql hhv7
44423-2,hhv7 dna naa+probe presence spec
44423-2,hhv 7 dna naa+probe ql (specimen)
44423-2,hhv 7 naa+probe dna ql (specimen)
44423-2,hhv 7 probe with target amplification dna naa+probe ql (specimen)
17941-6,bacteria # 6 identified in burn by culture
17941-6,baceria # 6 idntifid in id bur b culture
17941-6,bact bacteria # urn in idenified b ulture
17941-6,bacteria burn cult org #6
17941-6,bcri org cult bu #6
17941-6,infectious disease bacteria burn cult org #6
17941-6,bacteria identified # 6 cx nom (burn)
17941-6,6 identified # bacteria cx nom (burn)
17941-6,6 identified # bacteria cx nom (burn)
51589-0,dyserythropoiesis [presence] in blood by light microscopy
51589-0,dyserythropoiei [presence]in lood by lgh microsopy hematology/cell counts
51589-0,dyseryhropiesis [presence]in blood b ligh qualitative micrscopy
51589-0,dyserythropoiesis bld ql smear
51589-0,bld dyserythropoiesis ql smear
51589-0,dyserythropoiesis smear qualitative ql bld
51589-0,dyserythropoiesis lm ql (bld)
51589-0,dyserythrooiesis (blood) ql lm
51589-0,dyserythropoiesis lm (bld) ql
74365-8,palmitoyl protein thioesterase [enzymatic activity/mass] in fibroblast
74365-8,quantitative palmitoyl protein thioesterase [enzymatic activity/mass] in fibroblast
74365-8,palmitoyl protein hioestease [zyati actvity/mass] in fbrlast
74365-8,ppt fib-ccnt
74365-8,ppt chemistry fi-cnt
74365-8,ppt prot fib-ccnt
74365-8,palmitoyl protein thioesterase (fibroblast) [catalytic activity/mass]
74365-8,palmitoyl [catalytic thioesterase (fibroblast) protein activity/mass]
74365-8,palmitoyl protein thioesterase (fibroblast) [catalytic activity/mass]
49593-7,trichothecene iga ab [units/volume] in serum by immunoassay
49593-7,trichothecene iga ab [units/volume] in immunoassay by serum
49593-7,trichothecene iga ab in [units/volume] ser by immunoassay id
49593-7,trichothecene iga ser ia-acnc
49593-7,ser iga trichothecene pt ia-acnc
49593-7,trichotecene iga ser i-acnc
49593-7,trichothecene iga ia qn (s)
49593-7,trichothecene iga ia (s) qn
49593-7,trichothecene iga a n (s)
87651-6,"2,3,5-trimethylphenyl methylcarbamate [mass/mass] in specimen"
87651-6,",3,5-timethylphenyl methylcabmate [mass/ass] in veterinary specimen"
87651-6,"2,35-trimethylpenyl methylcarbamate [mass/mass] in pecimen"
87651-6,"2,3,5-trimethacarb spec-mcnt"
87651-6,"spe-mcnt 2,3,5timethacb"
87651-6,"pec-mcnt 2,3,5-trimthacarb"
87651-6,"2,3,5-trimethylphenyl methylcarbamate (specimen) [mass/mass]"
87651-6,",35trimethylphenl [mass/mass] (specime) methylcarbaate"
87651-6,"2,3,5-trimethylphenyl [mass/mass] (specimen) methylcarbamate"
47054-2,legionella pneumophila 10 igm ab [titer] in serum by immunofluorescence
47054-2,leinellapneumophila 10 igmab [titer in serum abs by imunoflurescence
47054-2,legionella by 10 igm ab [titer] in serum pneumophila immunofluorescence
47054-2,l pneumo 10 igm titr ser if
47054-2,10 pneumo trf l igm titr ser if
47054-2,l pneumo if igm titr titre ser 10
47054-2,l. pneumophila 10 igm if (s) [titer]
47054-2,l. pneumophila 10 igm if (s) [titer]
47054-2,l. pneumophila 10 igm if (s) [titer]
33799-8,dna double strand igg ab [units/volume] in serum or plasma by immunoassay
33799-8,[units/volume] quant double strand igg ab dna in ser or plasma by immunoassay
33799-8,immune globulin g dna dublestran ig ab [units/volme] in serumor plasma immunoassay
33799-8,dsdna igg serpl ia-acnc
33799-8,dsdna serpl enzyme immunoassay igg ia-acnc
33799-8,dsdn iggserp a-acnc
33799-8,dna double strand igg ia qn
33799-8,dna double strand igg ia qn
33799-8,dna igg strand double ia qn
59305-3,memantine [mass/mass] in tissue
59305-3,memantine [mass/mass] in quantitative tissue
59305-3,ematine [mass/mass] tsse in
59305-3,memantine tiss-mcnt
59305-3,tiss-cnt emanine
59305-3,quan tiss-mct meantine
59305-3,memantine (tiss) [mass/mass]
59305-3,(tiss) memantine [mass/mass]
59305-3,memantine point in time (tiss) [mass/mass]
101244-2,leucine-rich glioma-inactivated protein 1 ab [presence] in cerebral spinal fluid by immunofluorescence
101244-2,by glioma-inactivated protein 1 qual ab [ql] in cerebral spinal fluid leucine-rich immunofluorescence
101244-2,lucine-rich glioma-inactated protein 1 b [ql] in cerebral spinl fluid y imunofoescece
101244-2,lgi1 ab csf ql if
101244-2,lgi1 ab csf ql if fluorescent antibody
101244-2,lgi1 if csf ql abs ab
101244-2,leucine-rich glioma-inactivated protein 1 ab if ql (csf)
101244-2,leucine-rich glioma-inactivated protein 1 ab (csf) ql trf if
101244-2,glioma-inactivated leucine-rich protein 1 ab if ql (csf)
19545-3,mescaline cutoff [mass/volume] in urine for confirmatory method
19545-3,mesaline cutoff[assolme] in urine for cnfirmatory peyote method
19545-3,mescaline cutoff mass/voume] in drugs for urine confimatory method
19545-3,mescaline cto ur cfm-mcnc
19545-3,mescalin cnfr to ur cfm-mcc
19545-3,mescaline cfm-mcnc ur cto confirmation
19545-3,mescaline cutoff confirm (u) [mass/vol]
19545-3,mescaline (u) confirm cof [mas/vol]
19545-3,[masol] uoffconm (u) mescaline
12350-5,amphetamines [presence] in stool
12350-5,amphetamines [presence] in stool
12350-5,[resece] amphetamies instoo qual
12350-5,amphetamines stl ql
12350-5,amphtmines stl ql
12350-5,amphetamines stl illicit ql
12350-5,amphetamines ql (stl)
12350-5,ql amphetamines (stl) speed
12350-5,presence qualitative amphetamines (stl
49398-1,herpes virus 7 dna [#/volume] (viral load) in blood by naa with probe detection
49398-1,number concentration (count/vol) herpes virus 7 dna [#/volume] (viral load) in blood by naa with probe detection
49398-1,herpevr 7 dna [#/voume](viral load) in blood by naa detection probe th wb
49398-1,hhv7 dna # bld naa+probe
49398-1,hhv7 dna blood # naa+proe
49398-1,hhv7 dna # bld naa+probe
49398-1,hhv 7 dna naa+probe (bld) [#/vol]
49398-1,hhv 7 dna naa+probe bld) [#vol] transcription mediated amplification
49398-1,hhv 7 dna qnt naa+probe (bld) [#/vol]
48720-7,coxiella burnetii phase 1 igg ab [presence] in serum by immunofluorescence
48720-7,oxiela burneti phas 1 igg ab [presnce] in srumby imunofluorescence
48720-7,oxela burnetii pase 1 igg ab [ql]n serum by immunofluorescence
48720-7,c burnet ph1 igg ser ql if
48720-7,c ph1 burnet igg ser ql if
48720-7,c burnet ph1 igg ser if ql
48720-7,c. burnetii phase 1 igg if ql (s)
48720-7,. burneii phase 1 igg if ql (s)
48720-7,c. brnetii phas 1 igg () ifql
9325-2,tryptophan [moles/volume] in 24 hour urine
9325-2,tryptophan in [moles/volume] 24 hour urine
9325-2,24hr tryptophan [moles/vlume] in 24 hour urine
9325-2,tryptophan 24h ur-scnc
9325-2,trypophn 24h c244 u-scc
9325-2,1 day tryptophan ur-scnc 24h
9325-2,tryptophan (24h u) [moles/vol]
9325-2,tryptophan [moles/vol] u) (24h
9325-2,tryptophan c244 (24h u) [moles/vol]
79477-6,5-hydroxymethyl-2-furoate/creatinine [molar ratio] in urine
79477-6,5-hydroxymethyl-2-furoate/creatinine [molar furfural metabolite ratio] in urine
79477-6,5-hydroxymehyl-2-fuate/creatinine [molar rato]i urie
79477-6,5oh-methyl-2-furoate/creat ur-srto
79477-6,scrto 5oh-methyl-2-furoate/creat ur-srto
79477-6,ur-srto 5oh-methyl-2-furoate/creat
79477-6,5-hydroxymethyl-2-furoate/creatinine (u) [molar ratio]
79477-6,5-hroxyethyl-2-furoate/ceatinine(u) [lar ratio]
79477-6,furoic acid 5-hydroxymethyl-2-furoate/creatinine (u) [molar ratio]
15037-5,chymotrypsin [moles/mass] in stool
15037-5,cymotrypsin moles/mass] in stool
15037-5,chymotrypsin [moles/mass] stool in
15037-5,chymotryp stl-scnt
15037-5,stl-scnt chymotrypsine chymotryp
15037-5,chymotryp point in time tl-sct
15037-5,chymotrypsin (stl) [moles/mass]
15037-5,chytypin (stl [moes/mss]
15037-5,(stl) chymotryps substance content [moles/mas]
19287-2,cannabinoids tested for in urine by screen method nominal
19287-2,method tested for in ine by screen cannabinis nominal
19287-2,cannabinoidtested fo in urineb screen method nominal
19287-2,cannabinoids tested ur scn
19287-2,cannabinoids thc tested ur scn
19287-2,tested cannabinoids ur ur scn
19287-2,cannabinoids tested screen nom (u)
19287-2,cannabinoids scrennom(u) tested drugs
19287-2,scn tested cannabinoids screen nom (u)
89090-5,everyday cognition - study partner report form [ecog.partner]
89090-5,everday ogntion - studypartnr report pan orm [ecog.parter]
89090-5,everyday cognition - study partner report panel form [ecog.partner]
94427-2,dengue virus 1+2+3+4 3' utr rna [presence] in serum by naa with probe detection
94427-2,dengue infectiousdisease virus 1+2+3+4 3' utr rna [presence] in ser by naa with probe detection
94427-2,ordinal dengue virus 1+2+3+4 3' utr rna [presence] in ser by naa with probe detection
94427-2,denv 1+2+3+4 3' utr rna ser ql naa+probe
94427-2,naa+probe 3'utr na ii serq denv12+3+4
94427-2,naa+probe 1+23+4 3' utr denv 1+2+3+4 3' utr rna ser ql denv
94427-2,denv 1+2+3+4 3' utr rna naa+probe ql (s)
94427-2,denv utr 3' 1+2+3+4 rna naa+probe presence (s)
94427-2,denv+2+34 3' utr rna naa+probe denv ql(s)
63543-3,sjogrens syndrome-a extractable nuclear 52kd ab [presence] in body fluid
63543-3,sjogrens syndrome-a extractable nuclear 52kd ab [presence] in body fluid
63543-3,sjogrens syndrome-a anti extractable nuclear 52kd ab [presence] in body fluid
63543-3,ena ss-a 52kd ab fld ql
63543-3,ab ss-a 52kd ena fld ql
63543-3,ena ss-a 52kd ab fld ql
63543-3,sjogrens syndrome-a extractable nuclear 52kd ab ql (body fld)
63543-3,ro ab sjogrens syndrome-a extractable nuclear ab 52kd presence (body fld)
63543-3,sjogrens syndrome-a extractable nuclear antibodies 52kd ab ql (body fld)
89992-2,hydroxybupropion [presence] in urine by screen method
89992-2,hydroxybupopon [resence] in uie by 6-hydroxybupropion sreen method
89992-2,hydroxybupopion [prsene] method urne by bupropion metabolite screen in
89992-2,oh-bupropion ur ql scn
89992-2,oh-bupropion ur presence scn
89992-2,oh-bupropion ur ql scn
89992-2,hydroxybupropion screen ql (u)
89992-2,hydroxybupropion (u) ql screen
89992-2,(u) oh-bupropion screen ql hydroxybupopion
13738-0,estrogen/creatinine [mass ratio] in 24 hour urine
13738-0,estrogen/creatinine [mass ratio] in 24 ur hour urine
13738-0,esroencreatnine [mass ratio] in 24 hour urine
13738-0,estrogen/creat 24h ur
13738-0,estrogen/creat cr 24h ur
13738-0,ur 24h estrogen/creat
13738-0,estrogen/creatinine (24h u) [mass ratio]
13738-0,estrogen/creatinine (24h u) ratio] [mass
13738-0,estro/cetinine (24h [mass u) rtio]
34376-4,strongyloides sp igg ab [units/volume] in serum by immunoassay
34376-4,strongyloides infectiousdisease sp igg ab [units/volume] in serum by immunoassay
34376-4,strongyloides sp igg ab [units/volume] quan in serum by immunoassay
34376-4,strongyloides igg ser ia-acnc
34376-4,strongyloides igg ser ia-acnc
34376-4,trngyloides igg serum a-acc
34376-4,strongyloides sp igg ia qn (s)
34376-4,() elisa sp ig ia qn stronylides
34376-4,strongyloids spigg abs ia qn (s)
24360-0,hemoglobin and hematocrit panel - blood
24360-0,hemoglobin and hematocrit panel - quant blood
24360-0,hgb+hct pnl pael hematocrit emoglobinand - blood
24360-0,hgb+hct pnl bld
24360-0,hgb+hct pnl bld hematology/cell counts
24360-0,blood pnl hgb+hct
24360-0,hemoglobin and hematocrit panel (bld)
24360-0,hemogobi hematocrit nd panel universallaborders (bld)
24360-0,hemoglobin and (bld) panel hematocrit
22924-5,brucella abortus igg1 ab [presence] in serum
22924-5,brucella aborts igg1 b[prsence] anti inserum
22924-5,brucella abortusigg1 a[presnce] in seru
22924-5,b abortus igg1 ser ql
22924-5,b igg1 abortus ser ql
22924-5,b aotus igg1 ser ql
22924-5,b. abortus igg1 ab ql (s)
22924-5,b.abortus igg1 antby ab presence ()
22924-5,b. igg1 abortus ab ql (s)
88306-6,"deprecated mds v3.0 - rai v1.15.1 - medications - nsd, nd, ssd, sd during assessment period [cms assessment]"
88306-6,"deprecated mds v3.0 - [cms panl v1.15.1 - medications - nsd, nd, ssd, sd during assessment period rai assessment]"
88306-6,"deprecated mds v3.0 - rai v1.15.1- meications nsd, nd, ssd sd duing assssment period [ms ssesment] pnl"
38174-9,borrelia burgdorferi c6 ab [units/volume] in cerebral spinal fluid by immunoassay
38174-9,borrelia burgdorferi c6 ab [units/volume] c6 lyme peptide in cerebral spinal fluid by immunoassay
38174-9,borrelia urgdoferi c6 ab cerebralsinalfluid in [units/volume] b immunosay
38174-9,b burgdor c6 ab csf ia-acnc
38174-9,csf burgdor c6 ab b ia-acnc
38174-9,b burgdor c6 ia-acnc cs ab
38174-9,b. burgdorferi c6 ab ia qn (csf)
38174-9,b urgdorferic6 ab microbiology ia qn (csf)
38174-9,b. burgdorferi ia ab c6 qn (csf)
12437-0,tramadol [mass/volume] in serum or plasma
12437-0,traadol [mas/olume]i serum or lasma
12437-0,or [ass/volume] in plasma serm tramadl plasma
12437-0,tramadol serpl-mcnc
12437-0,tramadol serpl-mcnc serplas
12437-0,serpl-mcnc tramadol
12437-0,tramadol [mass/vol]
12437-0,[mass/vol] quantitative tramaol
12437-0,tramado [mass/vol]
3134-4,xylose [mass/volume] in blood
3134-4,xylose [mass/volme] bld in
3134-4,xylose [mass/volume] in bld
3134-4,xylose bld-mcnc
3134-4,xyloe bl-mcnc
3134-4,bld-mcnc yloe level
3134-4,xylose (bld) [mass/vol]
3134-4,xylose blood) [a/vol]
3134-4,chemistry [mass/vol] (blood) xylose
71618-3,macrophages/leukocytes [pure number fraction] in synovial fluid by manual count
71618-3,marophages/leukocytes joint fld [pure synovil fraction]in number fuid by manal count
71618-3,macrophages/leukocytes macrop [pure number fraction] in synovial fluid by manual count
71618-3,macrophages nfr.df snv manual
71618-3,manual nfr.df snv macrophages
71618-3,acrophages joint flu manul snv nr.df
71618-3,macrophages/leukocytes manual cnt (syn fld) [pure # fraction]
71618-3,hematology/cell counts macrophages/leukocyesmanual frction] (syn fld) [pure # cnt
71618-3,[pure#frction] mnual quan cnt (syn fd) macrphages/ukoctes
33271-8,microscopic observation [identifier] in blood by malaria thin smear
33271-8,microscopic thin [identifier] in blood by malaria observation smear
33271-8,microscopic wb observation smear in bld by malaria thin [identifier]
33271-8,malaria thin smear bld
33271-8,malaria thin bld smear
33271-8,malaria bld smear thin infectiousdisease
33271-8,microscopic observation malaria thin smear nom (bld)
33271-8,microscpic thin malaria observation smear no bld)
33271-8,microscopiobservation malaria thin smear nm (ld)
67563-7,legionella micdadei dna [presence] in specimen by naa with probe detection
67563-7,legionella micdadei 3 self-sustaining sequence replication dna [presence] in specimen by naa with probe detection
67563-7,legionella micdadei tma specimen [presence] in dna by naa with probe detection
67563-7,l micdadei dna spec ql naa+probe
67563-7,l micdadei dna spec presence naa+prbe
67563-7,l micdadei dna ql l micdadei spec naa+probe
67563-7,l. micdadei dna naa+probe ql (specimen)
67563-7,l. micdadei dna deoxyribonucleic acid naa+probe presence (specimen)
67563-7,l. micddei dna naa+proe l (scimn) polymerase chain reaction
78698-8,liver fibrosis score panel - serum or plasma calculated by hepascore
78698-8,liver plasma score panel - serum or fibrosis calculated by hepascore
78698-8,liver fibrosis score panel serum - or plasma calculated by hepascore
78698-8,liver fibr score pnl serpl hepascore
78698-8,liverfibr score pnl serpl hepascor sr
78698-8,pnl lie fibr score pnl serl hepascore
78698-8,liver fibrosis score panel calculated by hepascore
78698-8,liv sr fibrosis ore anel calculated byhepscore
78698-8,liver fibrosis score panel calculated by hepascore
93787-0,lymphocytic choriomeningitis virus igg+igm ab [presence] in cerebral spinal fluid
93787-0,lymphocytic choriomeningitis virus igg+igm ab [ql] in cerebral spinal fluid
93787-0,lymphocytic ab virus ig+ig hiomeningiti [presenc] ql in ceebral spinal fluid
93787-0,lcmv igg+igm csf ql
93787-0,lmv igg+igm csf ql
93787-0,igg+igm lcmv cerebrospinal fluid ql
93787-0,lymphocytic choriomeningitis virus igg+igm ql (csf)
93787-0,virus choriomeningitis lymphocytic igg+igm ql (csf)
93787-0,lymphocytc choriomeninitis vius igg+ig presence (cf)
54940-2,styrene [mass/volume] in serum or plasma
54940-2,styrene [mass/volume] in ser plasma quan or
54940-2,styrene or in serum [mass/volume] random plasma
54940-2,styrene serpl-mcnc
54940-2,serpl-mcnc styrene
54940-2,styrene drugs serpl-mcnc
54940-2,styrene [mass/vol]
54940-2,[mass/vol] styrene
54940-2,[ass/ol] styrene
29728-3,leptospira interrogans sv javanica ab [presence] in serum by agglutination
29728-3,leptospira in sv javanica ab [presence] interrogans infectiousdisease ser by agglutination
29728-3,leptospira interrogans sv javanica ab [presence] in serum by agglutination leptospirosis
29728-3,l inter javani ab ser ql aggl
29728-3,l terjvani ab ser ql aggl
29728-3,l ql javani ab ser inter aggl autoantibodies
29728-3,l. interrogans sv javanica ab aggl ql (s)
29728-3,presence interrogans id sv javanica ab aggl l. (s)
29728-3,. interrogans sv javanica  agg ql (s)
34562-9,cell count and differential panel - pleural fluid
34562-9,quantitative cell count and differential panel - pleural fluid
34562-9,cell count and differential panel - pleural fluid
34562-9,cell cnt + diff pnl plr
34562-9,cel cnt + diff pnlplr
34562-9,cell hematology/cell counts cnt + diff pnl pr
34562-9,cell count and differential panel (pleur fld)
34562-9,cell count (pleur qnt differential panel and fld)
34562-9,cell pleural count and differential panel (pleur fld)
88951-9,deprecated mds v3.0 - rai v1.16.1 - nursing home and swing bed omra (no and so) item set [cms assessment]
88951-9,deprcated mds v.0- ai v1.16.1 - nursing and hom swing bed mra (n and so) item set [cms assessmnt]
88951-9,precated mds v3.0  r v1.161 - nursing home and swing bedomra (no nd so) item set cms assessment]
86269-8,oasis c2 - elimination status - discharge from agency during assessment period [cms assessment]
86269-8,pan oasis c2 discharge elimination status - - from agency during assessment period [cms assessment]
86269-8,osis c2 - elimiati status - discharge fom ageny durig aesment perio [ms pan assessment
105974-0,norketamine [presence] in urine
105974-0,urine [presence] in norketamine
105974-0,norketamie urn [presence] in urn
105974-0,norketamine ur ql
105974-0,norketamine ur ql
105974-0,norketamine ketamine metabolite r ql
105974-0,norketamine ql (u)
105974-0,ql ur norketamine (u)
105974-0,norketamine (u) ql
35409-2,leishmania tropica igm ab [presence] in serum
35409-2,leishmania [presence] l tropica igm ab tropica in serum
35409-2,leishmnia tropia aby imab [presence inserum
35409-2,l tropica igm ser ql
35409-2,qual l tropica igm serum ql
35409-2,l tropica l tropicalis igm serum ql
35409-2,l. tropica igm ql (s)
35409-2,leishmaniosis l. tropica igm ql (s)
35409-2,l. tropica ql igm (s)
24171-1,polio virus 2 neutralizing antibody [titer] in serum by neutralization test --1st specimen
24171-1,polio neutralizaton eutrizing antiody [tite] n serum y virus2 est -1st specimn nab
24171-1,olovirs 2 neutralizing antibody [tite] test seru by neutralization conventional virus neutralization test in --st specmen
24171-1,pv2 nab sp1 titr ser nt
24171-1,titr nabs1 pv2 se nt
24171-1,pv2 nab point in time se titr sp1 nt
24171-1,polio virus 2 neut ab spec 1 neut test (s) [titer]
24171-1,poli irus 2 eut a spec 1 neut test ttr (s) [titer]
24171-1,pol ius2 ne ab spec 1 neuttest(s) [tte]
78819-0,clomipramine cutoff [mass/volume] in urine for confirmatory method
78819-0,clomipraminecutoff in [mas/volume] urine for confrmatory method quant
78819-0,confirmatory [mas/lume] in urinefor clomipramnecutof ethod
78819-0,clomipramine cto ur cfm-mcnc
78819-0,clomipramne cto r cfm-mnc
78819-0,clomipramine anofranil ur cto cfm-mcnc
78819-0,clomipramine cutoff confirm (u) [mass/vol]
78819-0,quantitative clomipramine utoff conirm (u) [mass/vol]
78819-0,clomipramine clomip cutoff confirm (u) [mass/vol]
15433-6,anaplasma marginale ab [presence] in serum by agglutination
15433-6,ab marginale anaplasma [presence] infectiousdisease in serum by agglutination
15433-6,anapasma marginale ab [presence] i sermby aglutination
15433-6,a marginale ab ser ql aggl
15433-6,a marginale vet aggl ser ql ab
15433-6,ql margnale ab ser a agl
15433-6,a. marginale ab aggl ql (s)
15433-6,a. marginale infectious disease ab aggl ql (s)
15433-6,a. marginale ab aggl presence (s)
106810-5,ige [units/volume] in cord blood by immunoassay
106810-5,ige immunoassay in cord blood by [units/volume] quantitative
106810-5,quan bld [units/volume] in cord ige by immunoassay
106810-5,ige bldco ia-acnc
106810-5,bldco qnt ige ia-acnc
106810-5,a-acc bldco ige chemistry
106810-5,ige ia qn (bldco)
106810-5,arbitrary concentration ige ia q (bldco)
106810-5,ige ia qn iaa (bldco)
63486-5,nut allergen panel - serum
63486-5,nut allergenpanel - srum
63486-5,panel allergen nut - serum
63486-5,nut allergen pnl ser
63486-5,nut pan allergen pnl serum
63486-5,ut allerg pnl ser
63486-5,nut allergen panel (s)
63486-5,panel allergen nut (s)
63486-5,nut panel allergen (s)
19565-1,methylenedioxyamphetamine [presence] in urine by screen method
19565-1,methylenedioxyamphetamine [ql] drugs of abuse in urine by screen method
19565-1,methylenedioxyamphetamine [presence] in urine by screen method
19565-1,mda ur ql scn
19565-1,scn ur ql mda
19565-1,scn ur ql mda
19565-1,methylenedioxyamphetamine screen ql (u)
19565-1,mda metylenediamphetamine screen qlu)
19565-1,methylenedioxyamphetamine screen ql (u) qual
57001-0,yersinia sp iga ab [units/volume] in serum by immunoassay
57001-0,ab sp iga yersinia [units/volume] in abs serum by immunoassay
57001-0,yersni sp iga bunits/volume] in serum by immunoassay
57001-0,yersinia iga ser ia-acnc
57001-0,ga immunoglobulin a yersinia ser ia-acnc
57001-0,yersiniaiga s ia-acnc
57001-0,yersinia sp iga ia qn (s)
57001-0,iga sp yersinia a antibody qns)
57001-0,yersinia sp (s) ia qn iga
23357-7,peste des petits ruminants virus ag [presence] in tissue by immune diffusion (id)
23357-7,peste des petits ruminants virus ag infectiousdisease [presence] in tissue by immune diffusion (id)
23357-7,ste des petits ruinnts vusag [ql] in tissue by immune diffusion id)
23357-7,pprv ag tiss ql id
23357-7,pprv ag id presence tiss
23357-7,pprv id tiss ql morbillivirus a
23357-7,peste des petits ruminants virus ag immune diff ql (tiss)
23357-7,peste qual des petits ruminants virus ag immune diff ql (tiss)
23357-7,ag des petits ruminants virus infectious disease peste immune diff presence (tiss)
61436-2,phenx - calcium intake - pediatric protocol 050201
61436-2,050201 - calcium intake - pediatric protocol phenx
61436-2,pen -calcim intake 00201 pdiatric protoc pnl -
61436-2,phenx calcium intake ped proto
61436-2,phenx pnl calium intke pedproo
61436-2,cal proto calcium intake ped phenx
62507-9,phenx - substance - age of first use protocol 031201
62507-9,phenx - substance - age 031201 first use protocol of
62507-9,phnx - substance -ae irst of panel.phenx use potoco 031201
62507-9,substance age first use proto
62507-9,first age substance use proto
62507-9,substance point in time age first use proto
2555-1,lecithin cholesterol acyltransferase [enzymatic activity/volume] in serum or plasma
2555-1,holeterol lecithn acylansferase [enzymaticacivity/volume] in serum chol or plasma
2555-1,lecithin cholesterol acyltransferase in point in time activity/volume] [enzymatic serum or plasma
2555-1,lcat serpl-ccnc
2555-1,serpl-ccnc lcat
2555-1,lcat c470 serpl-cnc
2555-1,lecithin cholesterol acyltransferase [catalytic activity/vol]
2555-1,phosphatidylcholine-sterol acyltransferase lecitin holesterol acytransfrase [atalytic atvity/vol]
2555-1,cholesterols lecithin cholsteol actiity/vol] [calytc acyltansferase
77621-1,natriuretic peptide.b prohormone n-terminal [mass/volume] in pleural fluid by immunoassay
77621-1,natriuretic peptide.b prohormone n-terminal [mass/volume] in pleural fluid by immunoassay
77621-1,natriuretic peptide.b prohormone n-terminal [mass/volume] pleural in fluid by immunoassay
77621-1,nt-probnp plr ia-mcnc
77621-1,plr nt-probnp ia-mnc
77621-1,ia-mcnc nt-probnplr
77621-1,natriuretic peptide.b prohormone n-terminal ia (pleur fld) [mass/vol]
77621-1,natriuretic peptide.b prohormone n-terminal ia (pleur fld) [mass/vol]
77621-1,natriuretic peptide.b ia n-terminal prohormone (pleur chemistry fld) [mass/vol]
22726-4,creatinine [moles/volume] in specimen
22726-4,cratinine [mles/volume] inspcimen
22726-4,ceatinine pecien in [molesolue]
22726-4,creat spec-scnc
22726-4,creat spec-scnc creat
22726-4,spec-scnc creat
22726-4,creatinine (specimen) [moles/vol]
22726-4,creatinine (specimen) [moles/vol]
22726-4,[moes/vol] creatinie(specime)
16971-4,histoplasma capsulatum iga ab [presence] in serum by immune diffusion (id)
16971-4,serum apsulatum iga ab [pesence] i histoplasa b histo immune difusion (id)
16971-4,histoplasma in iga ab [presence] capsulatum serum by immune pr diffusion (id)
16971-4,h capsul iga ser ql id
16971-4,ql capsul iga serum h id
16971-4,h capsul iga ser presence id histoplasmos
16971-4,h. capsulatum iga immune diff ql (s)
16971-4,h casulatu if immne ga presence s)
16971-4,h. capslatum (s) imm diff ql iga h capsul
54317-3,methylmalonylcarnitine (c4-dc) [moles/volume] in cerebral spinal fluid
54317-3,mehylmalolcaritne spinal flu (c4dc) [mles/voume] in cerebra spinl flui
54317-3,mthylmalonylcarnitin (c-dc)[moles/volume in cerebral spina fluid
54317-3,me-malonylcarn csf-scnc
54317-3,me-malonylcarn cerebrospinal fluid-scnc
54317-3,csf-scnc me-malonylcarn cerebral spinal fluid
54317-3,c4-dc (csf) [moles/vol]
54317-3,(csf)[mles/vol] dicarboxylic carnitine c4-dc
54317-3,(csf)[moles/vol] c4-dc
54146-6,mycobacterium tuberculosis igg ab [units/volume] in serum by immunoassay
54146-6,mycobacterium tuberculosis igg ab [units/volume] immunoassay serum by antibody in
54146-6,mycoacterim tuberculosis iggab [units/volume in serum myco by immunoassay
54146-6,m tb igg ser ia-acnc
54146-6,tb m igg ser ia-acnc
54146-6,m tb ser igg ia-acnc
54146-6,m. tuberculosis igg ia qn (s)
54146-6,. tubrculoss igia qn ()
54146-6,m. igg tuberculosis tuberculois iaq (s)
47133-4,trimipramine [moles/volume] in gastric fluid
47133-4,trimipramine gastric in [moles/volume] fluid
47133-4,trimipramine n mole/volume] asric fluid
47133-4,trimipramine gast-scnc
47133-4,qnt gast-scnc trimipramine
47133-4,trimipramine gastric contents gast-scnc
47133-4,trimipramine (gast fld) [moles/vol]
47133-4,trimiraine (gast moles/ol] fld) quan
47133-4,rimiprmine point in time (gast fld) [mles/vol]
93757-3,salmonella choleraesuis+infantis+typhimurium ab/positive control in specimen by immunoassay
93757-3,salmonella immunoassay ab/positive control in specimen by choleraesuis+infantis+typhimurium
93757-3,salmonella choleraesuis+infantis+yphmurium ab/positvecontrol antibodies in specimen immunoasa by
93757-3,s chol+inf+typhimur ab/pos cntrl spec ia
93757-3,shol+if+typhimur ab/pos cntrl sec ia
93757-3,s chol+inf+typhimur ab/pos cntrl spec ia
93757-3,s. choleraesuis+infantis+typhimurium ab/positive control ia (specimen) [relative ratio]
93757-3,antibodies s. choleraesis+infntis+tyhimuim ab/positive contol ia (specimen) [elte tio]
93757-3,s. choleraesuis+infantis+typhimurium s chol+inf+typhimur ab/positive control ia (specimen) [relative ratio]
29624-4,3-hydroxyglutarate [presence] in urine
29624-4,iii 3-hydroxyglutarate [presence] in urine
29624-4,i [presece] 3-hydoxylutrate urne
29624-4,3oh-glutarate ur ql
29624-4,3ohglutarate ur ql urn
29624-4,3oh-glutarate ur presence
29624-4,3-hydroxyglutarate ql (u)
29624-4,3-hydroxyglutarate presence ur (u)
29624-4,3-hdroxyglutarate ua (u) presence
35107-2,norclobazam [mass/volume] in serum or plasma
35107-2,norclobazam serum or plasma [mass/volume] in serum or plasma
35107-2,norclobazam or in serum [mass/volue] plasma
35107-2,norclobazam serpl-mcnc
35107-2,norclbzam serpl-cn
35107-2,norclobazam serpl-mcnc qnt
35107-2,norclobazam [mass/vol]
35107-2,norclobazam [mass/vol]
35107-2,norclobazm [mass/vo]
74864-0,iga.kappa [mass/volume] in serum or plasma
74864-0,iga.kapamas/volume] in quan sm or plasma
74864-0,iga.kappa [mass/volume] quant in serum or plasma
74864-0,iga kappa serpl-mcnc
74864-0,seplmcnc kapa plsm ig
74864-0,serpl-mcnc serpl kappa iga
74864-0,iga.kappa [mass/vol]
74864-0,assvol] iga.kappa
74864-0,[mass/vol] iga.kappa heavy chain
4125-1,amphetaminil [mass] of dose
4125-1,amphetaminil [mass] of dose
4125-1,drug doses amphetaminil [mass] of dose
4125-1,amphetaminil dose
4125-1,amphetaminildose
4125-1,amphetaminil addiction dose
4125-1,amphetaminil (dose) [mass]
4125-1,amphetaminil (dose) [mass]
4125-1,amphtaminil (dose) [mass addiction
25896-2,delta aminolevulinate [moles/volume] in 24 hour urine
25896-2,[oesvolme] minolevulinate delta in 24 hou urine
25896-2,delta aminolevulinate 4 in [mole/volume] hour substance concentration urin
25896-2,d-ala 24h ur-scnc
25896-2,d-aa ur 24h u-scnc
25896-2,24h d-ala ur-scnc
25896-2,delta aminolevulinate (24h u) [moles/vol]
25896-2,amnolev delta aminolevulinate (24h u) [moles/vol]
25896-2,(4h hematology aminlevulinate delt u) [moes/ol]
41142-1,influenza virus a n1 ab [presence] in serum
41142-1,influenza virus a n1 ab in [presence] serum
41142-1,influenza virus a n1 ab in [presence] serum
41142-1,fluav n1 ab ser ql
41142-1,ab n1 fluav ser ql
41142-1,antby ql n1 ab serum fluav
41142-1,fluav n1 ab ql (s)
41142-1,fluav n1ab presence (s)
41142-1,abs fluav (s) ab presence n1
4635-9,free hemoglobin [mass/volume] in serum
4635-9,free heoglbin [mass/vlume] in hematology/cell counts serum
4635-9,in [mass/volume] freehemogobin serum
4635-9,hgb free ser-mcnc
4635-9,hgb hb ser-mcnc free
4635-9,random hgb free ser-mcnc
4635-9,free hemoglobin (s) [mass/vol]
4635-9,free hemoglobin [ass/vol] quan s)
4635-9,hemoglobin free (s) [mass/vol]
4358-8,norfenefrine [mass] of dose
4358-8,mas] norfenerine of dose
4358-8,nrenefrine [mas] dose med or substance of do
4358-8,norfenefrine dose
4358-8,quantitative dose norfenefrine
4358-8,norenefrinedose
4358-8,norfenefrine (dose) [mass]
4358-8,norfenefrine [mass] (dose)
4358-8,nevadral retard [mass] norfenefrin(de)
95919-7,fungal pathogens panel - lower respiratory specimen by naa with probe detection
95919-7,fungal pathogens panel - lower fungal path panel respiratory specimen by naa with probe detection
95919-7,pobe pahoges panel probe with target amplification - lowe respiratry specmen by n with unga eection
95919-7,fungal path panel lower resp naa+probe
95919-7,naa+probe path panel lower resp fungal
95919-7,pt lower path panl ungal es naa+probe
95919-7,fungal pathogens panel naa+probe (lower resp)
95919-7,fungal pathogens panel naa+probe (lower resp)
95919-7,fungal pathogens naa+probe panel (lower resp)
17716-2,toxoplasma gondii ige ab [units/volume] in serum
17716-2,oxoplasma godii ige ab infectiousdisease [units/volume] n ser
17716-2,toxoplasma ie gondii ab [untsvolumein serum
17716-2,t gondii ige ser-acnc
17716-2,sr t gondii ige serum-acnc
17716-2,serum-acnc gondii ige t
17716-2,t. gondii ige qn (s)
17716-2,t. godii (s) n ige
17716-2,t. gondii ige qn (s)
40945-8,yersinia enterocolitica iga ab [presence] in serum
40945-8,yersinia enerocolitica iga ab [presence]i eum
40945-8,yersinia entercolitica iga ab[presece] in serum
40945-8,y enterocol iga ser ql
40945-8,iga enterocol anti y ser ql
40945-8,enterocol y iga antibodies ser presence
40945-8,y. enterocolitica iga ql (s)
40945-8,y. enterocoliica iaql ordinal (s)
40945-8,enterocolitca y. ig ql s)
31854-3,herpes simplex virus ag [presence] in skin
31854-3,hres smplex virs ag [presece] skin in
31854-3,herpes simlex virus ag skn [presence] in ski
31854-3,hsv ag skin ql
31854-3,hsv skin ag ql
31854-3,hsv ag skin presence
31854-3,hsv ag ql (skin)
31854-3,hsv ag ql (skin) herp splx
31854-3,ql a hsv (skin)
4271-3,gonadotropin releasing hormone [mass] of dose
4271-3,gonadotropin releasing hormone [mass] of dose quantitative
4271-3,gonoropi random releasing hormone [mas] dose o
4271-3,gnrh dose
4271-3,dose gnrh
4271-3,dose gnrh
4271-3,gonadotropin releasing hormone (dose) [mass]
4271-3,gonadtroin releaing hormone [as] (dose)
4271-3,gonadotopin (dose) reeasinghormone horm [ass]
51605-4,triglyceride [moles/volume] in synovial fluid
51605-4,triglyceride [moles/volume] quan in synovial fluid
51605-4,riglyceride n [moles/volume] synovial fluid
51605-4,trigl snv-scnc
51605-4,snv-scnc trigl
51605-4,tril snv-scc
51605-4,triglyceride (syn fld) [moles/vol]
51605-4,triglyceride (syn fld) [ms/ol
51605-4,triglyceride level (syn fld) [moles/vol]
5729-9,silicate [mass/volume] in serum or plasma
5729-9,ilicate n [ass/volume] serumor plasa
5729-9,ilicate [mass/volume] inserum or lasma
5729-9,silicate serpl-mcnc
5729-9,serpl-mcnc silcate point in time
5729-9,silicate serp-mcn
5729-9,silicate [mass/vol]
5729-9,silicate [mass/vol]
5729-9,[mass/vol] silicate
43074-4,borrelia burgdorferi c6 ab [units/volume] in cerebral spinal fluid
43074-4,borreli brgdorfi c6ab [untvolum in cerbral spina cerebral spinal fluid fluid
43074-4,borelia urgdorferi c6ab [unis/olume] in cerebral spinal flud
43074-4,b burgdor c6 ab csf-acnc
43074-4,csf-nc 6 ab burgdor b burg
43074-4,b burgdor c6 cerebrospinal fluid-acnc c6 lyme peptide ab
43074-4,b. burgdorferi c6 ab qn (csf)
43074-4,b. burgdorferi c6 ab qn (cerebrospinal fluid)
43074-4,b. antibodies burgdorferi c6 ab qn (csf)
26943-1,11-ketoandrosterone [mass/volume] in 24 hour urine
26943-1,11-ketoandrosterone [mass/volume] 24 in hour urine
26943-1,11-ketoandrosterone [mass/volue] hour 24 in rine
26943-1,11ketoandros 24h ur-mcnc
26943-1,11ketoandros 24h r-cn quan
26943-1,24h 1ketoandos urmcnc
26943-1,11-ketoandrosterone (24h u) [mass/vol]
26943-1,[mass/vol] (24h) 24hr 11-ketondrosterone
26943-1,11-ketoandrosterone (24h u) mass concentration [mass/vol]
30437-8,monocytes+macrophages/leukocytes in body fluid
30437-8,body in monocytes+macrophages/leukocytes fluid fluid
30437-8,fluid in body monocytes+macrophages/leukocytes
30437-8,monos+macros nfr fld
30437-8,monos+macros nr fld
30437-8,monosmacros nfr fld
30437-8,monocytes+macrophages/leukocytes (body fld)
30437-8,fl) random (body monocytes+acohages/leukoctes
30437-8,leuc monocytes+macrophages/leukocytes (body fld)
43184-1,6-monoacetylmorphine (6-mam) [presence] in serum or plasma by confirmatory method
43184-1,6-monoacetylmorphine (6-mam) [presence] in cnfr ser or plasma by confirmatory method
43184-1,6-monoacetylmorphie (6-mam) esence] n serm or plasma drugs by onfirmatory method
43184-1,6mam serpl ql cfm
43184-1,6mam serpl cfm ql
43184-1,6mm ql sepl cfm
43184-1,6-monoacetylmorphine (6-mam) confirm ql
43184-1,6-onoaceylmorphine (-ma) confirmation ql confirm
43184-1,6-monoacetylmorphine confirm (6-mam) ql
12482-6,ascorbate [mass/volume] in leukocytes
12482-6,ascrbate [mass/vlume] in leukoyts
12482-6,eukoytes [mass/volue]in ascorate
12482-6,vit c wbc-mcnc
12482-6,wbc-mcnc c vit
12482-6,vit vitamin c c wbc-mcnc
12482-6,ascorbate (wbc) [mass/vol]
12482-6,aorate (wbc) [mass/vol]
12482-6,ascorbate (wbc [mass/vol]
49264-5,folate+cyanocobalamin [interpretation] in serum or blood narrative
49264-5,foate+caocobalamn [ierpetati in serum rbloodnarrative
49264-5,folate+cyanocobalamin [interpretation] in serum or folic acid bld narrative
49264-5,folate+vit b12 serbld-imp
49264-5,chemistry flate+vit b12 serbld-ip
49264-5,vit m serbld-ip 12 folat+vi
49264-5,folate+cyanocobalamin nar (s/bld) [interp]
49264-5,folate+cyancobalamin nar (s/bld) [iterp]
49264-5,wb nar folate+cyanocobalamin sbl) [inter]
54906-3,norovirus genogroup ii rna [presence] in stool by naa with probe detection
54906-3,noovirus genogrup i rna [presence] intool b probe with naa detcton
54906-3,norovirus genogroup ii rna [resence] istol by na with prob detecton
54906-3,norovirus gii rna stl ql naa+probe
54906-3,na gii norovirs stl q naa+pobe ordinal
54906-3,norirus gi rnastl presence naa+probe
54906-3,norovirus genogroup ii rna naa+probe ql (stl)
54906-3,norovirus genogroup ii lcr rna naa+probe ql (stl)
54906-3,norovirus genogroup naa+probe ii rna naa+probe (stl) ql
44864-7,6-alpha hydroxytetrahydro-11-deoxycortisol/creatinine [mass ratio] in urine
44864-7,6-alpha ua hydroxytetrahydro-11-deoxycortisol/creatinine [mass ratio] in urine
44864-7,cortexolone masrtio] yroxytetrahydro-11-deoxycortisol/creatinine 6-alpa i urine
44864-7,6a-oh-ths/creat ur
44864-7,6a-oh-ths/creat ur
44864-7,6a-oh-hs/creat ur
44864-7,6-alpha hydroxytetrahydro-11-deoxycortisol/creatinine (u) [mass ratio]
44864-7,6-alpha hydroxyerahydro-1-deoxycortisolceatinine (u) 11dc mass ratio]
44864-7,6-alpha hydroxytetrahydro-11-deoxycortisol/creatinine [mass (u) ratio]
16901-1,gliadin iga ab [presence] in serum
16901-1,gliadin iga ab sr [presence] in serum
16901-1,seru iga ab [presene] in gliadin
16901-1,gliadin iga ser ql
16901-1,gliadin ql ser iga
16901-1,gliadin ig ser ql
16901-1,gliadin iga ql (s)
16901-1,giadi ga ql ()
16901-1,gliadin (s) ql iga
75762-5,methapyrilene [presence] in serum or plasma or urine by screen method
75762-5,methapyrilene or in serum [presence] plasma or urine by screen method
75762-5,methapyrilene [presence] in serum or plasma or urine by restryl screen method
75762-5,methapyrilene ser/plas/urn ql scn
75762-5,methapyilene ql ser/plasma/urn scn
75762-5,scn serum/plas/urn ql methapyrilene
75762-5,methapyrilene screen ql (s/p/u)
75762-5,methapyrilene screen ql scn (s/p/u)
75762-5,methapyrilene screenql (s/pu)
9476-3,hexanoylglycine [moles/volume] in urine
9476-3,urine [moles/volume] in hexanoylglycine
9476-3,hexanoyglycine in [moles/volume] urine
9476-3,hexanoylgly ur-scnc
9476-3,hexanoyl-glycine hexanol ur-scnc
9476-3,ur-scn hexanoylgly
9476-3,hexanoylglycine (u) [moles/vol]
9476-3,(u) hexanoylglycine [moles/vol]
9476-3,[moles/vol] (u) hexanoylglycine
26577-7,asparagine/creatinine [molar ratio] in urine
26577-7,asparagine/ceatinine [mor ratio] in urine creat
26577-7,asparagine/creatinine [molar ratio] in urine qnt
26577-7,asparagine/creat ur-srto
26577-7,ua asparagine/creat ur-srto
26577-7,ur-srto cr asparagine/creat
26577-7,asparagine/creatinine (u) [molar ratio]
26577-7,ratio] (u) [molar asparagine/creatinine
26577-7,(u) asparagine/creatinine [molar ratio] quant
2696-3,osmolality of specimen
2696-3,of osmolality specimen
2696-3,osmolalityof point in time specien
2696-3,osmolality spec
2696-3,spc osmolality
2696-3,osmolality spec random
2696-3,osmolality (specimen) [osmolality]
2696-3,osmolality [osmolality] (specimen)
2696-3,osmolaliy specimen) [smolality]
30054-1,tyrosine/creatinine [ratio] in urine
30054-1,yrsine/creatinin [ratio in urine
30054-1,tyrosine/creatinine [ratio] in uin
30054-1,tyrosine/creat ur-rto
30054-1,-ro tyrosie/creat
30054-1,ur-rto tyrosine/creat
30054-1,tyrosine/creatinine (u) [ratio]
30054-1,tyrosne/creatni [ratio] ()
30054-1,point in time ()[rat] tyrone/ratinine
93323-4,tauroursodeoxycholate [moles/volume] in serum or plasma
93323-4,tauroursodeoxycholate [moles/volume] in serum or plasma pl
93323-4,tauroursodeoxcoate moles/vlume] in seum r plasma
93323-4,tudca serpl-scnc
93323-4,pl serum or plasma-scnc tudca
93323-4,tudca serl-scnc
93323-4,tauroursodeoxycholate [moles/vol]
93323-4,substance concentration turoursodoxycholte [oles/vol]
93323-4,[moles/vol tauroursodexychlate quantitative
53729-0,deprecated borrelia burgdorferi 49736 ab.igg
53729-0,deprecated borrelia microbiology ab.igg 49736 burgdorferi
53729-0,deprecated borrelia 49736 burgdorferi ab.igg
53729-0,deprecated b burgdorferi 49736 igg
53729-0,drecated b urdrfer49736igg
53729-0,deprected serum or plasma b urgdrferi49736 ig
53729-0,b. burgdorferi 49736 igg qn
53729-0,b. 49736 burgdorferi igg qn
53729-0,b.burgdorferi 4976 igg qn
16357-6,deprecated amino beta guanidinopropionate [mass/volume] in cerebral spinal fluid
16357-6,depecated amino beta guandinoproponate [mass/voue] in cerebral spialfluid
16357-6,deprecated amino beta guanidinopropionic acid amino beta guanidinopropionate [mass/volume] in cerebral spinal fluid
16357-6,deprecated ab-gp csf-mcnc
16357-6,deprecated ab-g csf-mcc
16357-6,deprecated ab-gp ab-gp csf-mcnc
16357-6,amino beta guanidinopropionate (csf) [mass/vol]
16357-6,amino beta guaidinopropionate (csf) [assvol]
16357-6,[mass/vol] beta guanidinopropionate (cerebrospinal fluid) amino
59960-5,propoxyphene [moles/volume] in urine
59960-5,[moles/volume] propoxyphene in drug/toxicology urine
59960-5,d-propoxyphene in [moles/volue] propoxyphene urn
59960-5,propoxyph ur-scnc
59960-5,ur-scnc prooxyph
59960-5,ur-scnc drugs of abuse propoxyph
59960-5,propoxyphene (u) [moles/vol]
59960-5,cotonal-65 propoxyphene (u) [moles/vol]
59960-5,[mo/vol] illicit propoxyphene(u)
80098-7,glucosamine/creatinine [molar ratio] in urine
80098-7,glucosamine/creatinine [molar ratio] pt in urine
80098-7,urine [molarrati] in qnt glucosmine/cratinne
80098-7,glucosamine/creat ur-srto
80098-7,ur-srto glucosamine/creat
80098-7,glucosamin/reat ur-srto random
80098-7,glucosamine/creatinine (u) [molar ratio]
80098-7,[molar glucosamine/creatiine() ratio]
80098-7,glucosamine/creatinine (u) [molar ratio] quan
32194-3,monocytes+macrophages [presence] in pleural fluid by light microscopy
32194-3,monocytes+marphages [presence] macrophage in pleuralfud by light microscopy
32194-3,pleural [ql] in monocytes+macrophages fluid by light microscopy
32194-3,monos+macros plr ql micro
32194-3,miro monos+macrosplrql
32194-3,monos+macro plr ql mico
32194-3,monocytes+macrophages lm ql (pleur fld)
32194-3,monos monocytemacrphages lm presence (pleu fld)
32194-3,monocytes+macrophages ql lm (pleur fld)
101192-3,5f-mdmb-pica [presence] in urine by confirmatory method
101192-3,5f-mdmb-pica [presence] in urine method confirmatory by
101192-3,5f-dmb-pica [prsence] in urine by conirmatory method
101192-3,5f-mdmb-pica ur ql cfm
101192-3,5f-mdmb-picaur lcfm
101192-3,ur pr 5f-mdmb-pica ql cfm
101192-3,5f-mdmb-pica confirm ql (u)
101192-3,5fmmbpica confirm l (u
101192-3,fmm-pica confirm (u) ql cnfr
88499-9,oasis d - adl and iadls - soc or roc during assessment period [cms assessment]
88499-9,oasis pnl d - roc and iadls - soc or adl during assessment period [cms assessment]
88499-9,osis d- adl and iads - soc or ro dring ssessmnt period cmsassesment]
9730-3,pentacarboxylporphyrins [mass/time] in 24 hour urine
9730-3,pentacarboxylporphyrins chemistry [mass/time] in 24 hour urine
9730-3,pentacarboxylporphyrins [mass/time] urine 24 hour in
9730-3,penta-cp 24h ur-mrate
9730-3,penta-cp 2h pentacarboxyporhyrin ur-mrat
9730-3,ur-rate 24h pnta-cp
9730-3,pentacarboxylporphyrins (24h u) [mass/time]
9730-3,[mass/time] (24h u) pentacarboxlporphrin
9730-3,u) (4h pentacarbpophyrns [mass/tme]
4266-3,furosemide [mass] of dose
4266-3,[mass] frosemide ofdose
4266-3,furoseide [ass] of dose
4266-3,furosemide dose
4266-3,c210 dose furosemide
4266-3,dose furosemide
4266-3,furosemide (dose) [mass]
4266-3,lasix (dose) furosemide [mass]
4266-3,furosemide (dose) [mass]
76587-5,streptococcus pneumoniae nana gene [#/mass] in xxx.tissue by naa with probe detection
76587-5,strptococcus pneumoiae nna gene #/mass] i xxx.tissue ligation-activated transcription by naa with robe detectio
76587-5,streptococcus pneumoniae nana gene [#/mass] with xxx.tissue by naa in probe detection
76587-5,s pneum nana xxx.tiss naa+probe
76587-5,pneum s naxx.tiss naa+probe
76587-5,s pcr pneum nanaxxx.tiss naa+probe
76587-5,s. pneumoniae nana gene naa+probe (unsp tissue) [#/mass]
76587-5,s.pneumoiae naa+probe count/mass gene naa (unsp tissue [#/mass
76587-5,s. naa+probe nana gene pneumoniae (unsp tissue) [#/mass]
26485-3,monocytes/leukocytes in blood
26485-3,monocytes/leukocyts in white blood cell lood
26485-3,monocyts/leukocytes in blood
26485-3,monocytes nfr bld
26485-3,leuc bld nfr monocytes
26485-3,hematology/cell counts bld nfr onocytes
26485-3,monocytes/leukocytes (bld)
26485-3,blood monocytes/leukcys (bld)
26485-3,monos blood) moncytesekocytes
14897-3,deprecated protein [mass/volume] in plasma
14897-3,prtein deprecaed prot [ass/volume]in plasma
14897-3,deprecated protin in [mass/volue] plasma prot
14897-3,deprecated prot plas-mcnc
14897-3,deprectedprot plas-mcc
14897-3,deprecated prot plas-mcnc prot
14897-3,protein (p) [mass/vol]
14897-3,protein (p) [mass/vol]
14897-3,protein [mass/vol] (p)
99012-7,urinary tract pathogens panel - urine by naa with probe detection
99012-7,urinary tract pathogens panel - urine by naa with probe detection pnl
99012-7,uinary trct paogen panel - urineby naa with ur prbe detecton
99012-7,uti pathogens pnl ur naa+probe
99012-7,uti naa+probe pnl ur pathogens pcr
99012-7,pathogens uti pnl ur uti pathogens pnl naa+probe
99012-7,urinary tract pathogens panel naa+probe (u)
99012-7,urinarytract pathoens panelnaa+probe uropathogens (u)
99012-7,urinary tract panel pathogens naa+probe (u)
56990-5,toxoplasma gondii igg ab avidity [ratio] in serum by immunoassay
56990-5,toxoplasma by igg ab avidity [ratio] in ser gondii immunoassay
56990-5,quan toxoplasma gondii igg ab avidity [ratio] in serum by immunoassay
56990-5,t gondii igg avidity ser ia-rto
56990-5,t gondii igg avidity sr i-rto
56990-5,t g gondii avidity seria-rto
56990-5,t. gondii igg avidity ia (s) [ratio]
56990-5,autoantibody [ratio] gondii igg avidity ia (s) t.
56990-5,t. infectiousdisease gdii iggavidity [raio] ia(s)
38180-6,hepatitis c virus rna [log units/volume] (viral load) in serum or plasma by naa with probe detection
38180-6,hepatitis amplification c virus rna[log uitsvolume] viral load) n serum or plasma bynaa with probe detection
38180-6,hepatitis c virus ra lg units/volume] (viral lod in erum oplasma by na with probe detecton
38180-6,hcv rna serpl naa+probe-log iu
38180-6,hcvrna serum or plasma naa+pobe-log iu
38180-6,rn hcv serpl naa+probe-log iu quan
38180-6,hcv rna naa+probe [log units/vol]
38180-6,cv log iu rna units/o] [og naa+probe
38180-6,hcv [log naa+probe rna units/vol]
46947-8,budesonide [mass/volume] in urine
46947-8,[mass/volume] budesonide in urine
46947-8,budesonide urine quan in [mass/volume]
46947-8,budesonide ur-mcnc
46947-8,budesonide mass concentration ur-mcnc
46947-8,ur-mcnc budesonide mass concentration
46947-8,budesonide (u) [mass/vol]
46947-8,budesonide (u) [mass/vol] point in time
46947-8,[mass/vol] (u) budesonide
72174-6,rotavirus ag [presence] in stool by rapid immunoassay
72174-6,rotavirus ag [ql] in stool by rapid immunoassay
72174-6,random rotavirus ag [presence] in stool rapid by immunoassay
72174-6,rv ag stl ql ia.rapid
72174-6,rv ql stl ag ia.rapid antigen
72174-6,rv stl ag ql ia.rapid
72174-6,rotavirus ag ia.rapid ql (stl)
72174-6,rotavirus ag ia.rapid (stl) presence
72174-6,rotavirus ag ia.rapid ql (tl
51200-4,nickel [mass/volume] in body fluid
51200-4,nckel mass/vlume] i fluid body
51200-4,"[mass/volume] nickel in body fluid, unsp body fluid"
51200-4,nickel fld-mcnc
51200-4,fld-mcnc nickel
51200-4,ickel fl-mcnc quant
51200-4,nickel (body fld) [mass/vol]
51200-4,(body nickel drug/toxicology fld) [mass/vol]
51200-4,ikel [mass/vol] fld) (boy
59706-2,methylephedrine [mass/volume] in serum or plasma
59706-2,methlephedrin [mss/volume] serpl in serm or plasma
59706-2,methylephedrine level [mass/volume] plasma ser or in
59706-2,me-ephedrine serpl-mcnc
59706-2,me-ephedrine serum serum or plasma-mcnc
59706-2,erpl-mcnc ivilco me-phedrine
59706-2,methylephedrine [mass/vol]
59706-2,sr ethylephedrine mass/vol]
59706-2,methylephedrine [mass/vol]
71643-1,metamyelocytes/leukocytes [pure number fraction] in body fluid by manual count
71643-1,metamyelocytes/leukocytes [purenumber fraction] in boy fluid  manual ount
71643-1,mamyelocytes/leukocytes white blood cells pure manual fctio] i body flidb numer count
71643-1,metamyelocytes nfr.df fld manual
71643-1,meamelocytes nfrdf fl ana
71643-1,mtamyelocytes nfrdf ld manual
71643-1,metamyelocytes/leukocytes manual cnt (body fld) [pure # fraction]
71643-1,"metamyelocytes/leukocytes manual cnt (body fld) [pure # fraction] body fluid, unsp"
71643-1,metamelocytes/leukocyte mual (body cnt fd) [pure fractin]
63354-5,smith extractable nuclear ab [presence] in cerebral spinal fluid by immunoassay
63354-5,smith extractable nuclear ab [presence] in cerebral fluid suds spinal by immunoassay
63354-5,smith ncler xrctable b [prence]incerebal spinal fluid y immunoasay
63354-5,ena sm ab csf ql ia
63354-5,antibody ena sm ab csf ql ia
63354-5,screen ena sm ab csf ql ia
63354-5,smith extractable nuclear ab ia ql (csf)
63354-5,smith extractabe nuclear ab q ia neurology (csf)
63354-5,smith extractable nuclear ab ia ql (cerebrospinal fluid)
105871-8,giant platelets [presence] in blood
105871-8,giant platelets [ql] screen in blood
105871-8,giant platlets[pesence] n bld
105871-8,giant platelets bld ql
105871-8,giant bld platelets presence
105871-8,plateletsld giant hematology/cell counts ql
105871-8,giant platelets ql (bld)
105871-8,giant platelets ql (blood)
105871-8,giant platelets giant patelets presence (bd)
26460-6,nucleated erythrocytes [#/volume] in body fluid
26460-6,nucleated body [#/vlue] in erythrocyts nrbcs luid
26460-6,nucleated erythrocytes [#/volume] in body fluid
26460-6,nrbc # fld
26460-6,# fl nrbc fld
26460-6,nrbc # fld
26460-6,nucleated rbc (body fld) [#/vol]
26460-6,nucleated rbc [#/vol] (boyfld hematology/cell counts
26460-6,nucleted (ody rb absolutes fld) [#/vol]
70636-6,functional assessment of cancer therapy for patients with neurotoxicity questionnaire - 4 items - version 4 (fact-gog-ntx-4) [facit]
70636-6,functional assessment f cancerherapy for patiets witnerooxicity questionnaire - 4 tes - version 4 (ft-o-nx-4 [acit]
70636-6,functional assessment - cancer therapy for patients with neurotoxicity questionnaire - 4 items of version 4 (fact-gog-ntx-4) [facit]
88992-3,ustekinumab ab [mass/volume] in serum or plasma by immunoassay
88992-3,ustekinumab ab [mass/volume] in anti serum or plasma by immunoassay
88992-3,immunoassay ab [mass/volume] in serum or plasma by ustekinumab quantitative
88992-3,ustekinumab ab serpl ia-mcnc
88992-3,ustkinumabab serl ia-mcnc
88992-3,ab aby ustekinumab serpl ia-mcnc
88992-3,ustekinumab ab ia [mass/vol]
88992-3,usekinumab ia ab [mss/ol]
88992-3,usekinmab ab i [mass/vol] qnt
17363-3,nitrazepam [mass/volume] in serum or plasma by confirmatory method
17363-3,nitrazepam eatan n [s/vlume] in serpl by onfirmatory method
17363-3,nitrazepam [ss/vlume] in serum  plasma by confirmatoy method
17363-3,nitrazepam serpl cfm-mcnc
17363-3,nitrazepam serpl random cfm-mcnc
17363-3,mogadon nitrzeam serpl cfm-cnc
17363-3,nitrazepam confirm [mass/vol]
17363-3,nitrazepam [mass/vol] confirm
17363-3,[mass/vol] confirm nitrazepam
30482-4,suberylglycine [presence] in urine
30482-4,qualitative uberylglycine[prsece] inurine
30482-4,suberylglycine ur [ql] in urine
30482-4,suberylgly ur ql
30482-4,suberylgly ql ur
30482-4,u uberylgl ql
30482-4,suberylglycine ql (u)
30482-4,suberylglycine (u) presence
30482-4,qualitative suberylglycie (u) ql
57805-4,hedis 2010 tests used in early prenatal care - abo and rh (ppc-c)
57805-4,hedis 2010 tests used in early prenatal care - abo rh and (ppc-c)
57805-4,d typing hedis 2010 tests used in early prenatal care - abo and rh (ppc-c)
57805-4,hedis 2010 ppc-c abo+rh
57805-4,point in time hedis 2010 ppc-c abo+rh
57805-4,ab+rh panel ppc-c heis2010
57805-4,hedis 2010 tests used in early prenatal care - abo and rh (ppc-c)
57805-4,hed 210 tests used in early prenatalcae- aboand rh (pc-c)
57805-4,hedis 2010 tests used in early prenatal care - abo and rh random (ppc-c)
23490-6,deprecated transmissible gastroenteritis virus ab [presence] in serum
23490-6,deprecated transmissible gastroenteritis virus ab [presence] point in time in serum
23490-6,deprecated antibodies transmissible gastroenteritis virus ab [presence] in serum
23490-6,deprecated tgev ab ser ql
23490-6,tgev deprecated tgev ab ser ql
23490-6,deprecated tgev a sr q
23490-6,transmissible gastroenteritis virus ab ql (s)
23490-6,transmissible astroenteritis viru ab presence (s) antibody
23490-6,virus gastroenteritis transmissible ab ql (s)
13101-1,deprecated sulfate-3-glucuronyl paragloboside ab.igm in csf
13101-1,antby deprecated sulfate-3-glucuronyl paragloboside ab.igm in cerebrospinal fluid
13101-1,deprecated sulfate-3-glucuronyl paragloboside ab.igm in csf random
13101-1,deprecated sgpg igm csf
13101-1,sgpg deprecated igm csf
13101-1,deprecated sgpg igm cerebrospinal fluid
13101-1,sulfate-3-glucuronyl paragloboside igm (csf)
13101-1,sulfate-3-lucronylparagloboside igm (cs)
13101-1,sulfate-3-glucuronylaragloside igm (csf)
57009-3,mycoplasma pneumoniae igg ab [units/volume] in serum by immunoassay --2nd specimen
57009-3,mpasma pneumoniae ab igg [units/volume] in serum byimmunoasay --2nd pecimen
57009-3,mycoplasma pneumoniae igg ab [units/volume] in serum by immunoassay --2nd specimen
57009-3,m pneumo igg sp2 ser ia-acnc
57009-3,igg pneumo m sp2 ser ia-acnc
57009-3,sp2 pnem igg m er iaacnc
57009-3,m. pneumoniae igg spec 2 ia qn (s)
57009-3,m. peumoniaegg qn 2 ia pe (s)
57009-3,m. pneumoniae igg spec 2 ia (s) qn
99091-1,listeria monocytogenes dna [presence] in cerebral spinal fluid by naa with probe detection
99091-1,listeria monocytogenes dna [presence] in screen cerebral spinal fluid by naa with probe detection
99091-1,liseria monoytogenes dna [presence] n cerebrl pinal luid bynaa wih prbe deection
99091-1,l monocytog dna csf ql naa+probe
99091-1,l monocytog 3 self-sustaining sequence replication dna csf ql naa+probe
99091-1,ql monocytog dna csf l naa+probe
99091-1,l. monocytogenes dna naa+probe ql (csf)
99091-1,ql monocytogenes dna naa+probe l. (csf)
99091-1,l. oocytogenes dna naa+probe ql (csf)
16958-1,herpes simplex virus 2 igg ab [units/volume] in serum --2nd specimen
16958-1,herpes simplex virus igg 2 ab [units/volume] herp splx in serum --2nd specimen
16958-1,herpes simplex virus 2 igg ab [units/volume] in serum --2nd specimen hsv2
16958-1,hsv2 igg sp2 ser-acnc
16958-1,hsv2 igg ser-acnc sp2 sr
16958-1,sp2 igg hsv2 serum-acnc
16958-1,hsv 2 igg spec 2 qn (s)
16958-1,antibodies sv2 ig spec 2 qn (s)
16958-1,2 hsv igg spec 2 qn (s)
38429-7,ibuprofen [mass/volume] in serum or plasma --30 minutes post dose
38429-7,ibuprofen [mass/volume] in ser or plasma --30 minutes post dose
38429-7,plsm ibuprofen [massvolume] --30 eum or plasma in mites post dose
38429-7,ibuprofen 30m p serpl-mcnc
38429-7,p 30m ibuprofen c53 serpl-mcnc
38429-7,ibuprofn 30m p serplmcnc serplas
38429-7,ibuprofen 30 min post dose [mass/vol]
38429-7,30 ibuprofen minpost dos [mass/vol
38429-7,ibuprofen pl 30 min post dose [mass/vol]
54849-5,fall history on admission during assessment period [cms assessment]
54849-5,fall history on admission during assessment period [cms assessment]
54849-5,fllhsty oadmission during assesment] period [cm pan assessment
23655-4,aflatoxin [mass/mass] in tissue
23655-4,tissue [mass/mas] in aflatoxin
23655-4,[mass/mass] aflatoxin vet in tissue
23655-4,aflatoxin tiss-mcnt
23655-4,tiss-mcnt aflaoxin
23655-4,infectious disease tiss-cn aflatxin
23655-4,aflatoxin (tiss) [mass/mass]
23655-4,aflatoxin [mass/mass] (tiss)
23655-4,[mass/mass] (iss) afltoxin
23350-2,peste des petits ruminants virus ab [titer] in serum
23350-2,peste des petits antibody ruminants virus ab [titer] in ser
23350-2,ese des infectiousdisease petits umiant virus ab titer] in seru
23350-2,pprv ab titr ser
23350-2,pprv ab dilution factor titr ser
23350-2,pprv titered ser titr ab
23350-2,peste des petits ruminants virus ab (s) [titer]
23350-2,peste ab petits autoantibody ruminants virus des (s) [titer]
23350-2,peste des random petits [titer] virus ab (s) ruminants
41633-9,clostridium botulinum toxin b botb gene [presence] in specimen by naa with probe detection
41633-9,clostridium botulinum toxin b botb gene [presence] in specimen by naa with detection probe
41633-9,clostridium botulinum toxin probe botb gene [ql] in specimen by naa with b detection
41633-9,c botb gene spec ql naa+probe
41633-9,c botb gene spec presence naa+probe qual
41633-9,ql botb gene spec c naa+probe
41633-9,c. botulinum toxin b botb gene naa+probe ql (specimen)
41633-9,c. probe with ampification botulinum toxin gene botb b naa+probe ql (specimen)
41633-9,c. specimen) txinb botb bont gen aa+probe q botulinum
29614-5,phenmetrazine [mass/volume] in serum or plasma by confirmatory method
29614-5,cfm phenmetrazine [mass/volume] in serum or plasma by confirmatory method
29614-5,phenmetrazine [mass/volume] in serum lc/ms/ms or plasma by confirmatory method
29614-5,phenmetrazine serpl cfm-mcnc
29614-5,serpl phenetrazine fm-mcnc point in time
29614-5,phenmetraze gcms serpl cfm-mcnc
29614-5,phenmetrazine confirm [mass/vol]
29614-5,phnmetrazine potentialforabuse confirm [masvol]
29614-5,sr phenmrazine confirm [mas/vo]
104116-9,multiple sulfatase deficiency [enzymatic activity/volume] in dbs
104116-9,multipl in defiiency [enzyatic acivity/vume] sulfatase dbs
104116-9,multiple sulfatase deficiency in activity/volume] [enzymatic dbs
104116-9,multiple sulfatase deficiency dbs-ccnc
104116-9,multiple ulase defiienc qnt dbs-ccnc
104116-9,multiple qnt sulfatase dbs-ccnc deficiency
104116-9,multiple sulfatase deficiency (dbs) [catalytic activity/vol]
104116-9,multiple sulfatase (dbs) deficiency [catalytic activity/vol]
104116-9,blood multiple sulfatase deficiency (dbs) [catalytic activity/vol]
88861-0,hematopoietic stem cell transplantation risk panel ebmt
88861-0,hematopoietic cell stem transplantation risk panel ebmt
88861-0,hematopoietic stem risk transplantation cell panel ebmt
88861-0,hsct risk panel ebmt
88861-0,clin hsct risk panel ebmt
88861-0,hsct risk panel ebmt
6524-3,rabies virus neutralizing antibody [units/volume] in serum by neutralization test
6524-3,rabies virus in antibody [units/volume] neutralizing serum by neutralization test
6524-3,rabies virus nutralzing anibody [unts/volume] in serm by neutralizationtest
6524-3,rabv nab ser nt-acnc
6524-3,serum rabv nt-acnc ser nab
6524-3,rav nt-acnc r na
6524-3,rabies virus neut ab neut test qn (s)
6524-3,rabies autoantibody virus neut ab neut test qn (s)
6524-3,rabies virus neut ab arbitrary concentration neut test qn (s)
80980-6,frataxin [mass/volume] in dbs
80980-6,dbs [mass/volume] in frataxin
80980-6,frataxin [massvolume] in bs
80980-6,frataxin dbs-mcnc
80980-6,dbs-mcnc frataxin random
80980-6,blood dbs-mcnc frataxin
80980-6,frataxin (dbs) [mass/vol]
80980-6,(dbs) frataxin [mass/vol]
80980-6,frataxin qnt (dbs) mass/vol]
41997-8,heptacarboxylporphyrin [mass/volume] in 24 hour urine
41997-8,24 [mass/volume] in heptacarboxylporphyrin hour urine
41997-8,heptacarboxylporphyrin [mass/volume] in hour 24 urine
41997-8,hepta-cp 24h ur-mcnc
41997-8,hept-cp 24h heptacarboxyporphyrin ur-mcnc
41997-8,ur-mcc 4h 24 hours hepta-p
41997-8,heptacarboxylporphyrin (24h u) [mass/vol]
41997-8,1 day heptacarboxylporphyrin u) (24h [mass/vol]
41997-8,(24hu)[mas/ol] hptcarboxylporphyrin
49192-8,clostridium tetani toxoid igg ab [units/volume] in serum --2nd specimen
49192-8,clostridium tetani toxoid igg ab [units/volume] in serum --2nd specimen
49192-8,clostridium immunoglobulin g tetani ooid iggab [units/volume] in ser --2ndspecmen
49192-8,c tetani toxoid igg sp2 ser-acnc
49192-8,c tetani oxoid igg ser-acnc sp2
49192-8,c tetani toxoid igg spec sp2 ser-acnc
49192-8,c. tetani toxoid igg spec 2 qn (s)
49192-8,c. tetani toxoidigg sec 2 qn ()
49192-8,c. tetani toxod igg spc2qn (s)
81350-1,thoughts on pain management narrative - reported
81350-1,houghs on pain report managemnt narrative - eprted
81350-1,thoughts pain management narrative on pain management thoughts - reported
81350-1,thoughts pain management reported
81350-1,thouhts pain narrative managment reported
81350-1,mangemet pain thughts rpote
102036-1,abnormal prion protein [interpretation] in cerebral spinal fluid document by rt-quic
102036-1,anormal prion protein [ntrptaion] n cerebal pinal bovine spongiform encephalopathy flui dcument by rt-quic
102036-1,abnormal prion protein [interpretation] in cerebal spinal fluid ocument by rt-quic
102036-1,abn prion prot csf doc rt-quic-imp
102036-1,abn prion prot random csf doc rt-quic-imp
102036-1,ab rion prot csf doc rtuic-imp
102036-1,abnormal prion protein rt-quic doc (csf) [interp]
102036-1,abnomal prion doc rt-quic protein prot (cs) interp]
102036-1,anormal prion protein rt-quic doc(csf) impressions [interp]
27825-9,deprecated platelet associated ab [presence] in blood
27825-9,deprcated pltlet [presnce] ab assoiated in blod platelt
27825-9,deprecated platelet associated blood ab [presence] in blood
27825-9,deprecated pa ab bld ql
27825-9,deprecated pa ab ql bld
27825-9,deprecated pa b bld q
27825-9,platelet associated ab ql (bld)
27825-9,platee associated b ql (bld)
27825-9,ptelet ssocite ab platelets (blood) ql
16291-7,herpes simplex virus 1 [presence] in specimen by organism specific culture
16291-7,1[presence] simplex viru herpes n specime yorganism speificulture
16291-7,herpes simplex virus 1 [presence] in specimen by organism specific culture
16291-7,hsv1 spec ql cult
16291-7,hsv1 ordinal spec cult ql
16291-7,hsv1 spec ql other cut
16291-7,hsv 1 org specific cx ql (specimen)
16291-7,hsv 1 org specific ql screen cx (specimen)
16291-7,hsv 1 org specific cx ql unspecified (specimen)
99379-0,mercury [moles/volume] in milk
99379-0,mercury milk in [moles/volume]
99379-0,mercury milk in [moles/volume]
99379-0,mercury mlk-scnc
99379-0,ml-scc level mrcury
99379-0,lk-s mercury
99379-0,mercury (milk) [moles/vol]
99379-0,point in time (milk) mercury [moles/vol]
99379-0,mercury [moles/vol] (milk)
76618-8,mitochondrial respiratory chain enzymes [enzymatic activity/mass] in fibroblast by 1-14c-glutamate substrate
76618-8,mitochdrialreiraory fibroblast enzmes [enzymati actiity/mass] in chain y 1-14c-glutmae quan subsrate
76618-8,mitochondrial respiratory chain enzymes [enzymatic activity/mass] in fibroblast by 1-14c-glutamate substrate
76618-8,mito enzy fib 1-14c-glut substr-ccnt
76618-8,mito substr-ccnt fib 1-14c-glut enzy
76618-8,mito enzy fib sbstr-ccnt chains 1-14c-lut
76618-8,mitochondrial respiratory chain enzymes 1-14c-glutamate substrate (fibroblast) [catalytic activity/mass]
76618-8,mitohonrial respiratory chin random enzymes -14c-glutmae ubstate (fibroblas) [cataytic activity/ass]
76618-8,chain respiratory fibr mitocondrial enzyme 1-14cglutamate substrate(fiboblas)[catalyic ativity/mas]
1704-6,acetoacetate [presence] in serum or plasma
1704-6,acetoacetate [presence] in ser or plasma oxobutyrate
1704-6,[presence] acetoacetate in ser or plasma
1704-6,acetoacet serpl ql
1704-6,acetoacet ql serpl oxobutyrate
1704-6,acetoacet serpl ql
1704-6,acetoacetate ql
1704-6,ql acetoaetate
1704-6,ql acetoacetate plasma
59741-9,silver [mass/mass] in tissue
59741-9,silver quan tissue n [mass/mas]
59741-9,[mass/mass] quan silver in tissue
59741-9,silver tiss-mcnt
59741-9,tiss-mcnt siver
59741-9,tiss-mcnt silver
59741-9,silver (tiss) [mass/mass]
59741-9,(tiss) silver [mass/mass]
59741-9,ag silver (tiss) [mass/mass]
63350-3,sjogrens syndrome-b extractable nuclear ab [presence] in body fluid by immunoassay
63350-3,sjogrens sydroe-b exracalenlear ab [presence] in body luid by imunoasay
63350-3,sjogrens syndrome-b extractable nuclear ha ab ab [ql] in body fluid by immunoassay
63350-3,ena ss-b ab fld ql ia
63350-3,ena ql ab fd sjogren ss-b a
63350-3,ss-b en ab fl qlia
63350-3,sjogrens syndrome-b extractable nuclear ab ia ql (body fld)
63350-3,(body syndromeb extrctbluclear ab ia presence sjogrens fld)
63350-3,sjogrens syndrome-b extractable ab nuclear ia ql (body fld)
31863-4,influenza virus b ag [presence] in throat
31863-4,influenza virus b ag [ql] in fluv throat
31863-4,inflenza virus influ b inthrat [presence] a
31863-4,flubv ag throat ql
31863-4,thrat ag flub ql
31863-4,flubv throat ag ql
31863-4,flubv ag ql (throat)
31863-4,antigen flubv ql ag (throat)
31863-4,qualitative flubv ql ag (throat)
101985-0,candida parapsilosis dna [presence] in body fluid by probe.amp.tar
101985-0,dna parasilosis fld cani [prsce] in bod flid byprbe.amptar
101985-0,candida parapsilosis in [presence] dna body fluid by probe.amp.tar
101985-0,c parap dna fld ql probe.amp.tar
101985-0,c arap dna fld qprobe.amp.tar
101985-0,c parap ql fld dna probe.amp.tar
101985-0,c. parapsilosis dna naa+probe ql (body fld)
101985-0,ql parapsilsis dna naa+prbe c. (boy flu fld)
101985-0,c. ql dnanaa+pobe prasiosis body fld)
31696-8,vesicular stomatitis indiana virus ab [units/volume] in serum
31696-8,vesicular [units/volume] indiana virus ab stomatitis in aby serum
31696-8,esicular stomatitis indiana sr serum [units/volume] in virusab
31696-8,vsiv ab ser-acnc
31696-8,ab abs vsiv sr-acnc
31696-8,vsiv ab ser-acnc
31696-8,vesicular stomatitis indiana virus ab qn (s)
31696-8,vesicular virus indiana stomatitis ab qn (s)
31696-8,vesicular stomatitis virus indiana ab qn anti (s)
82853-3,prenanediolone+pregnanetriol/androsterone+etiocholanolone [molar ratio] in urine
82853-3,prenanediolone+pregnanetriol/androsterone+etiocholanolone [molar ratio] substance concentration ratio in urine
82853-3,panediolone+preanetriol/adrosteoe+etioholanolone [molar ratio] in urine pregntrl
82853-3,pdone+pt/an+et ur-srto
82853-3,ur-srto pdone+point in time/an+et esoteric
82853-3,ur-srto quant pone+pt/ane
82853-3,prenanediolone+pregnanetriol/androsterone+etiocholanolone (u) [molar ratio]
82853-3,pnanedioloe+pregnnetriol/anrosterone+tiocholanoone (u) [mlrraio]
82853-3,(u) prenanediolone+regnantriol/andrsterone+ioclanolone [molrrato]
76408-4,monocytes+macrophages [#] in body fluid by manual count
76408-4,monocytes+macrophages count in body fluid by manual [#] bodies
76408-4,monocytes+macrophages [#] in manual fluid by body count
76408-4,monos+macros fld manual
76408-4,manual fld monos+macros
76408-4,mno+macrosfld manual mono
76408-4,monocytes+macrophages manual cnt (body fld) [#]
76408-4,monocytesmacrophages cnt mnual cnt (body fld) [#
76408-4,monocytes+macrophages manual cnt (body [#] fld fld)
69754-0,bordetella pertussis+bordetella parapertussis filamentous hemagglutinin igg ab [presence] in serum by line blot
69754-0,bordeela by filametos hemagglutinin gg a [resenc] in serum peruis+bordetellaprartussis line blot
69754-0,bordetella pertussisboetell arapetssis lamentous hemaggutinin igg b [presncein serum by lin abs blot
69754-0,b pert+para.fha igg ser ql line blot
69754-0,b igg pertr.fha ser ql lineblo
69754-0,b pert+para.fha igg ser b parapertussis ql line blot
69754-0,b. pertussis+b. parapertussis filamentous hemagglutinin igg line blot ql (s)
69754-0,b. pertssis+b. parapertussis filamentous hemaggltinin igg infectiousdisease lne blot ql (s)
69754-0,b.pertussis+b.parapertusss filamentous ig hemagglutinin line blot ql (s
46221-8,glucose [moles/volume] in dialysis fluid --2 hour specimen
46221-8,[moles/volume] glucose in dialysis fluid --2 hour specimen
46221-8,--2 glu [molsvolume] n dialyis flid gucose hour spcimen
46221-8,glucose 2h spec dial fld-scnc
46221-8,dial 2h spec glucose fld-scnc random
46221-8,glucose 2h spc dial flsnc
46221-8,glucose 2 hour specimen (dial fld) [moles/vol]
46221-8,glucose 2 hour specimen (dial fld) [moles/vol] 2 hours
46221-8,glucose 2 quantitative hour specimn (dia fld) [les/vol]
102117-9,gastrointestinal stromal tumor multigene mutation panel - tissue by molecular genetics method
102117-9,gastrointestinal stromal tumor multigene random genetics panel - tissue by molecular mutation method
102117-9,gastrointestinal stromal tumor multigene mutation panel - tissue molecular by pnl genetics method
102117-9,gist multigene mut pnl tiss
102117-9,multiple-gene panel test multigene gist mut pnl tiss
102117-9,muigen gist mut molecular genetics nl tiss
102117-9,gist multigene mutation panel molgen (tiss)
102117-9,gist multigene point in time mutation panel molgen (tiss)
102117-9,molecular pathology mutation multigene gist panel molgen (tiss)
62626-7,phenx - respiratory - personal - family hx of respiratory symptoms - diseases - child protocol 090902
62626-7,phenx - respiratory - personal - family hx of panel respiratory symptoms - diseases child - protocol 090902
62626-7,phenx - espiratory -personal - amil hx of respiraory symptoms dseses - cildprotcol 090902
62626-7,resp fam hx resp sympt child proto
62626-7,rsp f x sp sympt child proto
62626-7,child fam hx rep smpt res proo
4176-4,chlormerodrin [mass] of dose
4176-4,chormerodrin dose of mass]
4176-4,[mass] chlormerodrin of dose med or substance dose
4176-4,chlormerodrin dose
4176-4,point in time chlrmerodrin dose
4176-4,chlormerodrin quan dose
4176-4,chlormerodrin (dose) [mass]
4176-4,chlormeorin (dos) neohydrin [mass]
4176-4,drug doses chlormerodrin [mass] (dose)
90414-4,b-cell phenotyping panel - blood
90414-4,- phenotyping panel b-cell pan blood
90414-4,- phenotyping panel b-cell blood
90414-4,b-cell phenotyping panel bld
90414-4,b-cell phenotypic phenotyping blood panel
90414-4,panl b-cell phenotypinganel blood
90414-4,b-cell phenotyping panel (bld)
90414-4,phenotyping b-cell pnel (bd)
90414-4,b-cell phenotyping panel (bld)
59727-8,oxazepam [mass/volume] in body fluid
59727-8,in [mass/volume] oxazepam body fluid
59727-8,oxazepam [mass/volume] in body fluid
59727-8,oxazepam fld-mcnc
59727-8,mass concentration fld-mcnc xapam
59727-8,ld-mcnc xazpam
59727-8,oxazepam (body fld) [mass/vol]
59727-8,oxazepam (body fld) [mass/vol]
59727-8,oxazepam (body bf fld) [mass/vol]
24084-6,galactosylceramidase [enzymatic activity/mass] in leukocytes
24084-6,galactosylceramidase [enzymatic in activity/mass] leukocytes
24084-6,galactosylceramidase [enzymatic leukocytes in activity/mass]
24084-6,galc wbc-ccnt
24084-6,quan galc wbc-ccn
24084-6,wbcs gacwbc-ccnt
24084-6,galactosylceramidase (wbc) [catalytic activity/mass]
24084-6,galc galactosylceramidase (wbc) [catalytic activity/mass]
24084-6,galactosylceramidase (wbc) activity/mass] [catalytic
38486-7,homocystine [presence] in dbs
38486-7,in [presence] homocystine dbs
38486-7,hmocysine [pesence in qualitative ds
38486-7,(hcys)2 dbs ql
38486-7,(hcys)2 dbs ql whole bld
38486-7,(hcys)2 dbs fp presence
38486-7,homocystine ql (dbs)
38486-7,homoystine ql (dbs)
38486-7,homocystine ql blood (dbs)
26710-4,leucine [moles/volume] in amniotic fluid
26710-4,leucine af [moles/volume] in amnioti fluid
26710-4,amnotic [moles/volme] in lecine random fid
26710-4,leucine amn-scnc
26710-4,amn-scnc leucine
26710-4,amn-scnc amn fl leucine
26710-4,leucine (amn fld) [moles/vol]
26710-4,leucine (amn fld) [moles/vol] point in time
26710-4,fld) (amn leucine [moles/vol]
34588-4,tick feeding duration
34588-4,feedinduration tic durat
34588-4,duration feding tick
34588-4,feeding ?tm tick-time
34588-4,tick-time ?tm feedig
34588-4,feedig ?m tik-time durat
34588-4,feeding duration unsp time (tick) [time]
34588-4,feeding duration unp time (tick) [ime]
34588-4,feeding unsp duration time (tick) [time]
105917-9,bacteria identified in bronchoalveolar lavage by culture
105917-9,bacteriaidentifed inbronchalveolar lavage by cultue
105917-9,in identfid ateria brnchoalveoar lavage by culture
105917-9,bacteria bal cult
105917-9,cult bal bacteria
105917-9,bal bacteria cult
105917-9,bacteria identified cx nom (bal)
105917-9,bacteria idetifid cxnm bronchial alveolar lavage (bal)
105917-9,bactei nominal cxnom identied bal)
62887-5,deprecated phenx measure - international travel history
62887-5,dereated phenx measure  itrnational trael history
62887-5,derecated phenx measure - interational travel history
23548-1,venezuelan equine encephalitis virus ag [presence] in specimen by neutralization test
23548-1,veneuean equin nepalitis virus ag [presence]i spcimen by nutraization tes
23548-1,venezuelan qune enphalitis virus ag presence in specime by neutralizatn test
23548-1,veev ag spec ql nt
23548-1,nt ag svn spec ql veev
23548-1,veev ag spe ql nt
23548-1,veev ag neut test ql (specimen)
23548-1,nt veev ql nut tes g (specimn)
23548-1,vev ag neuttestql miscellaneous (speimen)
55207-5,genetic analysis discrete result panel
55207-5,genetic random analysis result discrete panel
55207-5,genetic wb aalysis discet result panel
55207-5,genetic analysis discrete result pnl
55207-5,genetic analysis reslt isret nl
55207-5,esult nalyss panel.hl7.genetics disrete geneti pl
55207-5,genetic analysis discrete result panel molgen (bld/tiss)
55207-5,geneti analysisdirete reslt pel molge (ld/tis)
55207-5,entic result dicree anlysi pcr panel molgen (bld/tis
106594-5,streptococcus agalactiae dna [presence] in body fluid by naa with non-probe detection
106594-5,streptococcus agalactiae dna [presence] non-probe body fluid by naa with in detection
106594-5,streptococcus agalactiae dna [presence] in streptococci group b body fluid by naa with non-probe detection
106594-5,gp b strep dna fld ql naa+non-probe
106594-5,gp b/f b strp n fld ql aanon-probe
106594-5,gp b strep probe with target amplification dna fld ql naa+non-probe
106594-5,s. agalactiae dna naa+non-probe ql (body fld)
106594-5,s. agalactiae (body naa+non-probe amplif ql dna fld)
106594-5,s. dna screen agalactiae naa+non-probe ql (body fld)
25439-1,histamine [moles/time] in 24 hour urine
25439-1,histamine srate [moles/time] in 24 hor urine
25439-1,hstamine[moes/time] in 24 hour rine
25439-1,histamine 24h ur-srate
25439-1,istamine substance rate 24h ur-srate
25439-1,histamine 24h ur-srate
25439-1,histamine (24h u) [moles/time]
25439-1,(24hu)molestime] histamne
25439-1,histaine (24h [moles/ime] u)
15480-7,leptospira interrogans sv icterohaemorrhagiae ab [titer] in serum by agglutination
15480-7,lptopiraintrroans vicerohaemrrhagiae b [titer] in srum anti by aggluinin
15480-7,letospira interrgas autoantibodies sv serum in cteohaemorrhagiaeab[titer] by agglutintin
15480-7,l inter icter ab titr ser aggl
15480-7,l icter inter ab titr serum aggl
15480-7,l iter icter ggl titr ser ab
15480-7,l. interrogans sv icterohaemorrhagiae ab aggl (s) [titer]
15480-7,l. interrogans ab icterohaemorrhagiae sv aggl (s) [titer]
15480-7,l. interrogans sv icterohaemorrhagiae ab aggl (s) [titer]
17505-9,psilocybin/psilocin [mass ratio] in serum or plasma
17505-9,psilocybin/psilocin [mass mass concentration ratio ratio] in or serum plasma
17505-9,in [massrato psilocyin/psiloci seum or psma
17505-9,psilocybin/psilocin serpl
17505-9,psiocybin/silocinserl point in time
17505-9,serum or plasma psilocybin/psilocin
17505-9,psilocybin/psilocin [mass ratio]
17505-9,psilocybin/psilocin ratio] [mass ser or plasma
17505-9,psilocybin/psilocin [mass ratio]
42507-4,herpes simplex virus 1 igg ab [presence] in cerebral spinal fluid
42507-4,herpes siplex flui 1iggab [presence]n cererl spina vius
42507-4,herpes siple vus 1 igg b [resncein ceral spinal fluid
42507-4,hsv1 igg csf ql
42507-4,hsv1 igg cf presence
42507-4,hsv hsv1 igg csf presence
42507-4,hsv 1 igg ql (csf)
42507-4,1 autoantibodies hv ig ql csf)
42507-4,hsv igg 1 presence (csf)
54929-5,tissue transglutaminase ab [titer] in serum by immunofluorescence
54929-5,tissue antibody transglutaminase immunofluorescence [titer] in ser by ab
54929-5,tissue trnsglutaminase ab [titer] dilution factor (titer) in serum by immunofluorescece
54929-5,ttg ab titr ser if
54929-5,titre ser ab titr ttg if
54929-5,ttgab titr serif
54929-5,ttg ab if (s) [titer]
54929-5,ab abs ttg if (s) [titer]
54929-5,ttgab if(s) autoantibody [titer]
43823-4,aspergillus glaucus ab [presence] in serum by immune diffusion (id)
43823-4,aspergillus glaucus ab aspergillin [presence] in ser by immune diffusion (id)
43823-4,aspergillus glaucus ab [presence] in serum by immune diffusion (id)
43823-4,a glaucus ab ser ql id
43823-4,a glaucus ab imun ser q id
43823-4,presence glaucus imune ab ser a id
43823-4,a. glaucus ab immune diff ql (s)
43823-4,a. glaucus ab immune serum diff ql (s)
43823-4,a. glaucus ql immune aspergilus diff ab )
20401-6,speckled nuclear ab pattern [titer] in serum
20401-6,spcled nuclear ab smqn pattern [tite] i serm
20401-6,speckled nuclear ab random in [titer] pattern ser
20401-6,ana speckled titr ser
20401-6,ana dilution factor (titer) titr spekled ser
20401-6,spckled ana titr serum
20401-6,speckled nuclear ab pattern (s) [titer]
20401-6,spekednuear ab atern (s) [titer]
20401-6,speckled nuclear serum pattern ab (s) [titer]
9356-7,buspirone [mass/volume] in serum or plasma
9356-7,buspirone mass/volume] plasa ser or n
9356-7,plsm buspirone [mass/volume] in serpl
9356-7,buspirone serpl-mcnc
9356-7,serplas serpl-mcnc buspirone
9356-7,serpl-mcnc buspirone
9356-7,buspirone [mass/vol]
9356-7,busirone [mass/vol
9356-7,buspirone [mass/vol] random
14394-1,urea nitrogen [mass/volume] in pleural fluid
14394-1,urea nitrogen [mass/volume] in pleural fluid
14394-1,urea nitoge [mass/volume] in plurl fluid
14394-1,urea nit plr-mcnc
14394-1,thoracentesis fluid urea plr-mcnc nit
14394-1,plr-mcnc pleural fluid nit urea
14394-1,urea nitrogen (pleur fld) [mass/vol]
14394-1,ura [mass/vo] plerfld nitrogen
14394-1,urea quant nitrogen (pleur fld) [mass/vol]
55152-3,amiodarone and desethylamiodarone panel [mass/volume] - serum or plasma
55152-3,amiodarone an desetylamiodarne panel [mass/volume]- seru or plasma
55152-3,amiodarone and desethylamiodarone panel or - serum [mass/volume] plasma panel.drug & toxicology
55152-3,amiodarone + deseth pnl serpl-mcnc
55152-3,amiodarone + deseth pnl drugs serpl-mcnc
55152-3,amiodarone + mass concentration serpl-mcnc pnl deset
55152-3,amiodarone and desethylamiodarone panel [mass/vol]
55152-3,amiodarone and serum or plasma [mass/vol] panel desethylamiodarone
55152-3,[mas/vol] desethylamiodarone panl aiodaroneand quantitative
61177-2,paraneoplastic ab [presence] in serum by immunofluorescence
61177-2,pr b ab[pesence] seru paraneoplastic immunofluorescence
61177-2,paraneoplastic ab [presence] in by serum immunofluorescence
61177-2,paraneoplastic ab ser ql if
61177-2,raneopltic a rql i
61177-2,paraneoplastic ser ab ql if
61177-2,paraneoplastic ab if ql (s)
61177-2,paraneoplastic if ab trf ql (s)
61177-2,praneoplastic ab if ql (s)
59187-5,urea renal clearance/1.73 sq m in 24 hour urine and serum or plasma
59187-5,urea ur sq clearance/1.73 renal m in 24 hour urine and serpl
59187-5,urea renal clearance/1.73 sq m in hour 24 urine and serum or plasma
59187-5,urea cl/1.73 sq m 24h ur+serpl-arvrat
59187-5,urea cl/1.73 sq m 24h ur+serum or plasma-arvrat
59187-5,ureacl/1.73 sq m 24h u+serpl-rvrat serp
59187-5,urea renal clearance/1.73 sq m (24h u+s/p) [vol rate/area]
59187-5,urea renal clearance/1.73 sq m quan (24h u+s/p) [vol rate/area]
59187-5,uea clearance1.73 rena sq m (24h u+s/p) [v rate/area]
103166-5,adenovirus 1 and 2 beta dna [presence] in respiratory system specimen by naa with probe detection
103166-5,adenoviru 1 and 2 betadna [presence] in respiratory system specimen b na wit probe etectio
103166-5,adenovius 1 and 2 beta dna [ql] speimenby respiratory system in naawith probe detetion
103166-5,adnvirus 1+2 beta dna resp ql naa+probe
103166-5,adnvirus 1+2 beta dres ql na+pobe
103166-5,advirus 1+2 beta dna resp ql na+probe
103166-5,adenovirus 1 and 2 beta dna naa+probe ql (respiratory system specimen)
103166-5,adenovi 1and 2 beta dna naa+proe presence (respirtory system random specimen)
103166-5,adenovirus 1 and 2 beta dna naa+probe presence (respiratory system specimen)
30416-2,variant lymphocytes/leukocytes in cerebral spinal fluid
30416-2,vaiant spinal fluid lymphocytes/leukocytes n cerbrl spinal fluid
30416-2,ariant lymphocytes/leukocytesinerebral flui spinl
30416-2,variant lymphs nfr csf
30416-2,variant lymphs nfr csf
30416-2,spinal flu variant cerebrospinal fluid nfr lymphs
30416-2,variant lymphocytes/leukocytes (csf)
30416-2,varint (sf) neurology lyphocyts/leukocytes
30416-2,variant lymphocytes/leukocytes (csf) leuk
38393-5,legionella sp identified in pleural fluid by organism specific culture
38393-5,legionella infectiousdisease sp identified in pleural fluid by organism specific culture
38393-5,legionella culture identified in lung pleural fluid by organism specific sp
38393-5,legionella plr cult
38393-5,cult plr egioella infectiousdisease
38393-5,plr legionella cult spp
38393-5,legionella sp identified org specific cx nom (pleur fld)
38393-5,legionella sp identified species org specific cx nom (pleur fld)
38393-5,legionella sp identified org legion specific cx nom (pleur fld)
53865-2,galactomannan ag [units/volume] in cerebral spinal fluid
53865-2,galactomannan ag [units/volume] in cerebral cerebrospinal fl spinal fluid
53865-2,galactomannan arbitrary concentration ag units/volume] in cereral spinalfluid
53865-2,galactomannan ag csf-acnc
53865-2,gaactomannan ag cf-acnc neuro
53865-2,galactomannan ag cerebrospinal fluid-acnc
53865-2,galactomannan ag qn (csf)
53865-2,glactomnan ag q (csf
53865-2,galactann g qn (csf)
3749-9,mephenytoin [mass/volume] in serum or plasma
3749-9,mephenyton [mass/vlume]in erum or plasma
3749-9,mephentoin [mss/volume in serm orplasma
3749-9,mephenytoin serpl-mcnc
3749-9,pl mepheytoin serpl-cn
3749-9,serpl-mcnc mephenytoin
3749-9,mephenytoin [mass/vol]
3749-9,mephenyti[ass/vol]
3749-9,serp [ms/vol] mephenytoin
77395-2,human papilloma virus 18 dna [presence] in anorectal by naa with probe detection
77395-2,umanpapiloma virus 18 da [ql] in anorectal  naa with probe detection
77395-2,human qualitative papiloma virus 1 wth [preence] in anorctal byaa dna probe detectin
77395-2,hpv18 dna anorectl ql naa+probe
77395-2,hpv18 dna naa+probe ql anorectl
77395-2,hpv18 dna 3 self-sustaining sequence replication ql anorectl naa+probe
77395-2,hpv 18 dna naa+probe ql (anorectal)
77395-2,hpv dna 18 naa+probe presence (anorectal)
77395-2,nucleic acid sequence based analysis hpv 18 dna presence(anorctal) aa+robe
32284-2,bk virus dna [units/volume] (viral load) in serum or plasma by naa with probe detection
32284-2,bk virus nucleic acid sequence based analysis dna [units/volume] in load) (viral serpl by naa with probe detection
32284-2,bk virus dna [units/volume] (viral load) in serum or plasma with naa by probe detection
32284-2,bkv dna serpl naa+probe-acnc
32284-2,bkv dna erpl a+obe-acnc ligation-activated transcription
32284-2,serpl na bv na+probe-acnc
32284-2,bk virus dna naa+probe qn
32284-2,bk virus sr dna naa+pre qn
32284-2,bk probe amp irs dna naa+prbe qn
23839-4,deprecated cholinesterase [enzymatic activity/volume] in red blood cells
23839-4,deprecated red blood cells cholinesterase [enzymatic activity/volume] in red blood cells
23839-4,deprated cholinestease [enzymtic activity/volue]  red bloo cells
23839-4,deprecated cholinesterase rbc calc-acnc
23839-4,chemistry rbc cholinesterase deprecated calc-acnc
23839-4,rbc cholinesterase deprecated calc-acnc
23839-4,cholinesterase calc qn (rbc)
23839-4,cholinesterase qn calc (rbc)
23839-4,cholinesterase calc qn pseudocholinesterase (rbc)
5082-3,chlamydia sp ab [units/volume] in serum by immunoassay
5082-3,chlamydia sp ab [units/volume] in serum by immunoassay species
5082-3,chlamydia sp ab in [units/volume] serum by immunoassay
5082-3,chlamydia ab ser ia-acnc
5082-3,chlamydia ab serum ia-acnc
5082-3,chlamydia bser autoantibody ia-acnc
5082-3,chlamydia sp ab ia qn (s)
5082-3,chlamydia sp (s) ia qn ab
5082-3,chlamydia sp ab ia aby qn ()
60158-3,pergolide [mass/volume] in blood
60158-3,prgolide [mss/volume] in blod
60158-3,erolie [mass/volum] in blod
60158-3,pergolide bld-mcnc
60158-3,drugs bld-mcnc pergolide
60158-3,bld-mcc pergoide
60158-3,pergolide (bld) [mass/vol]
60158-3,(bld) pergolide [mass/vol] whole blood
60158-3,(bld) perolid [mass/vol]
82301-3,salmonella sp [presence] in stool by culture
82301-3,salmonella salmonel sp [ql] in stool by culture
82301-3,bowel movement salmella culture in stoo by sp[ql]
82301-3,salmonella stl ql cult
82301-3,salmonella stl cult ql
82301-3,screen cult stl ql salmonella
82301-3,salmonella sp cx ql (stl)
82301-3,(stl) sp cx presence salmonella
82301-3,salmonella sp cx ql (stl)
34617-1,other antibiotic [mass/volume] in specimen
34617-1,other antibiotic in [mass/volume] specimen
34617-1,antibiotic other [mass/volume] miscellaneous in specimen
34617-1,other antibiotic spec-mcnc
34617-1,other antibiotic spec-mcnc
34617-1,other antibiotic random spec-mcnc
34617-1,other antibiotic (specimen) [mass/vol]
34617-1,(specimen) antibiotic other [mass/vol]
34617-1,[mass/vol] antibiotic (specimen) other
53585-6,toxocara canis ige ab [units/volume] in serum
53585-6,toxocara canis in immunoglobulin e ab [units/volume] ige serum
53585-6,toxocara canis [units/volume] ab ige in serum
53585-6,t canis ige ser-acnc
53585-6,t ser-acnc ige canis
53585-6,t canis ige ser-acnc antibody
53585-6,t. canis ige qn (s)
53585-6,t. qn ie canis s)
53585-6,canis t. ige qn (s)
49005-2,calcium [moles/volume] in peritoneal dialysis fluid
49005-2,calcium [moles/volume] in nephrology peritoneal dialysis fluid
49005-2,calcum [mles/volum] in cal petea dialysis fld
49005-2,calcium diafp-scnc
49005-2,diaf-scnc calcium
49005-2,calcium nephrology diafp-scnc
49005-2,calcium (perit dial fld) [moles/vol]
49005-2,cacu diaf (peritdia f) [moles/vol]
49005-2,calcium (perit dial fld) [moles/vol]
100849-9,leukocytes [#/volume] in amniotic fluid by manual count
100849-9,leukocytes [#volume] in amitic fluid by manual count absolutes
100849-9,leukocytes [#/volume] in count fluid ct by manual amniotic
100849-9,wbc # amn manual
100849-9,wbc # amn aual
100849-9,amn # wbc manual amniotic flu
100849-9,wbc manual cnt (amn fld) [#/vol]
100849-9,wbc [#/vol cnt am leuk fld manal
100849-9,wbc mnual cnt (amn fld) [#/vl] abs
79686-2,5-hydroxymethyluracil [moles/volume] in cerebral spinal fluid
79686-2,in [moles/volume] 5-hydroxymethyluracil cerebral spinal fluid
79686-2,5-hydroxymethylurci [oles/volume] ncerebrl flid sinal point in time
79686-2,5oh-methyluracil csf-scnc
79686-2,5oh-methyluracil cerebrospinal fluid-scnc
79686-2,quant 5o-methyluracl sf-n
79686-2,5-hydroxymethyluracil (csf) [moles/vol]
79686-2,5-hydroxymethyluracil (csf) [moles/vol]
79686-2,spinal fluid 5-hydroxymethyluracil (cerebrospinal fluid) [moles/vol]
96599-6,neisseria gonorrhoeae dna [presence] in cervix by naa with probe detection
96599-6,nssri onorrhoeae da [eence] in dna nucleic acid probe cevix detection naa wih prbe by
96599-6,neisseria gonorhoeae dna [pesence]in cervix byna withprob detection
96599-6,n gonorrhoea dna cvx ql naa+probe
96599-6,n gonorrhoea dna v ql na+pobe
96599-6,n dnavx gonorhoea presence naa+pro
96599-6,n. gonorrhoeae dna naa+probe ql (cvx)
96599-6,n. dna gonorrhoee naa+probe q (cvx)
96599-6,n. gonorrhoeae dna ql naa+probe dna nucleic acid probe (cvx)
51508-0,lactate dehydrogenase 1/lactate dehydrogenase.total in pleural fluid by electrophoresis
51508-0,dehydrogenase lactate 1/lactate dehydrogenase.total in pleural fluid by electrophoresis
51508-0,pleural dehydrogenase 1/lactate dehydrogenase.total in lactate fluid by electrophoresis
51508-0,ldh1 cfr plr elph
51508-0,ldh1 plr cfr elph
51508-0,pleural fluid elph cfr plr ldh1
51508-0,ldh 1 elph (pleur fld) [catalytic fraction]
51508-0,ldh 1 eh (peur fld) [catalytic fraction]
51508-0,ldh [catalytic pleural elph (pleur fld) 1 fraction]
54354-6,beta 2 globulin [mass/volume] in urine by electrophoresis
54354-6,beta 2 globulin ep [mass/volume] in urine by electrophoresis
54354-6,bta2 globuln[mss/volume]in beta2 glob urne by electophoresis
54354-6,beta2 glob ur elph-mcnc
54354-6,beta2 glob electrophrs ur elph-mcnc
54354-6,glob beta2 ii eph-mcnc
54354-6,beta 2 globulin elph (u) [mass/vol]
54354-6,eph point in time 2 globulin beta (u) [mass/ol]
54354-6,beta level 2globlinelph (u) [mass/vol]
95023-8,fasi v1.0 - mobility [cms assessment]
95023-8,centers for medicare and medicaid assessment fasiv1.0 -mobility [cms asessment]
95023-8,survey fasi v1.0 - [cms mobility assessment]
62397-5,phenx - myocardial infarct protocol 040801
62397-5,phenx - protocol infarct myocardial 040801
62397-5,phenx - myocardial infarct 040801 protocol
62397-5,myocardial infarct proto
62397-5,mycardil inarct proto
62397-5,myocardial panel.phenx ifarct rot
1664-2,17-hydroxycorticosteroids [mass/volume] in amniotic fluid
1664-2,17-hydroxycorticosteroi [asvolume i amniotic fluid
1664-2,7hydroycoticosteroids [massvolume] n amniotic fluid
1664-2,17ohcs amn-mcnc
1664-2,amn-cnc 17hcs amn fl
1664-2,amn-mcnc 17ohcs
1664-2,17-hydroxycorticosteroids (amn fld) [mass/vol]
1664-2,17-cs (amn 17-hydroxycorticosteroids fld) [mass/vol]
1664-2,17-hydrxycoricoseroids (amn fd) [as/vol] amn
94708-5,encephalopathy autoimmune ab panel - cerebral spinal fluid
94708-5,spinalfluid autimmune ab panel - erebr spinal fld encephalopath
94708-5,encephlopathyautoimmune b panel - cerebral spinal fluid
94708-5,encephalopathy autoimmune ab pnl csf
94708-5,encephalopathy autoimmune ab pnl pnl csf
94708-5,encephalopathy random autoimmune ab pnl cerebrospinal fluid
94708-5,encephalopathy autoimmune ab panel (csf)
94708-5,encepalopathy autoimmune random ab pnel (csf)
94708-5,encephalopaty autimune ab panel (csf)
89533-4,scl-70 extractable nuclear ab [presence] in cerebral spinal fluid by line blot
89533-4,scl-70 extractable nuclear ab [ql] in cerebral spinal fluid by line neuro blot
89533-4,scl-70 extractable nuclear ab [presence] in cerebral spinal fluid dna-topoisomerase i by line blot
89533-4,ena scl70 ab csf ql line blot
89533-4,anf enscl7b cerebrospinal fluid lot lline
89533-4,ea lot ab anti-topo i csf qlline scl7
89533-4,scl-70 extractable nuclear ab line blot ql (csf)
89533-4,scl70exractable nuclear ab line blot (cerebrospinal fluid) ql
89533-4,scl-70 etractablenucear ab lie blot q (cerebrospinal fluid)
98008-6,deprecated neonatal infant pain scale panel
98008-6,deprecated neonatal infant scale pain panl panl
98008-6,panel neonatal infant pain scale deprecated pan
98008-6,deprecated nips
98008-6,nps depreated
98008-6,random nis deprecated
107242-0,tick borne encephalitis virus ab [interpretation] in serum or plasma
107242-0,tick borne encephalitis virus ab [interpretation] in or serum plasma
107242-0,tick borne ecphaitis vius [interpretation] a in serum or plasma
107242-0,tick borne encephalitis virus ab serpl-i
107242-0,tick borne encephalitis serpl-i ab virus
107242-0,tic borne encephlits iru ab serum or plasma-i
107242-0,tick borne encephalitis virus ab [interp]
107242-0,tick borne cephalitis vius a [interp]
107242-0,tick virus encephalitis borne ab[interp]
34637-9,5-methyltetrahydrofolate [mass/volume] in cerebral spinal fluid
34637-9,spinal fl 5-methylterhydroflate in [mass/volum] cerebral spinal fid
34637-9,5-methyletrahydrofolate [mass/volume] in cerebral spinal fluid
34637-9,5me-tetrahydrofolate csf-mcnc
34637-9,spinal fluid me-tetrahydrofolae cerebrospinal fluid-mcnc
34637-9,mass concentration cerebrospinal fluid-mcnc 5me-tetrahydrofolate
34637-9,5-methyltetrahydrofolate (csf) [mass/vol]
34637-9,(csf) 5-methyltetraydrofolae [mss/vol]
34637-9,[mass/vol] (csf) 5-methyltetrahydrofolate
1860-6,angiotensin ii [mass/volume] in plasma
1860-6,angotensin mass concentration in ii[mass/vlume plasma
1860-6,[mass/volume] ii angiotensin in plasma
1860-6,angiotensin ii plas-mcnc
1860-6,quan angiotensin ii plasma-mcnc
1860-6,plas-mcnc ii angiotensin
1860-6,angiotensin ii (p) [mass/vol]
1860-6,anionsin i(p) [massvol]
1860-6,agitensin i (p) [mas/vol]
2935-5,serine [presence] in serum or plasma
2935-5,seine [pesence] in or ql serum plasma
2935-5,serpl or [presence] in ser serine plasma
2935-5,serine serpl ql
2935-5,ql serpl serine
2935-5,serine screen serpl ql
2935-5,serine ql
2935-5,ql screen serine
2935-5,serine ql ql
93492-7,ampar2 igg ab [titer] in cerebral spinal fluid by immunofluorescence
93492-7,ampar2 igg ab [titer] in cerebral spinal fluid by immunofluorescence
93492-7,ampar2 igg ab [titer] in cerebral by fluid spinal immunofluorescence alfa
93492-7,ampar2 igg titr csf if
93492-7,csf ig titr amar2 serology i
93492-7,csf igg titr ampar2 if
93492-7,ampar2 igg if (csf) [titer]
93492-7,ampar2 igg [titer] (csf) if
93492-7,ampar2 if igg (csf) [titer]
17481-3,probenecid [units/volume] in urine
17481-3,pobenecid [units/volum] inurine
17481-3,probnecd [units/vlume]in urne
17481-3,probenecid ur-acnc
17481-3,proenecid ur-anc
17481-3,probenecid quantitative u-cnc
17481-3,probenecid qn (u)
17481-3,qn probenecid (u)
17481-3,probeneci qn(u)
94385-2,amphiphysin igg ab [presence] in serum by line blot
94385-2,amphiphysin igg line [presence] in serum by ab blot
94385-2,amphiphysin igg sr ab in [presence] serum by line blot
94385-2,amphiphysin igg ser ql line blot
94385-2,amphiphysin igg line ql ser blot
94385-2,srql igg amphiphyin line id blot
94385-2,amphiphysin igg line blot ql (s)
94385-2,screen amphiphysin igg line blot ql (s)
94385-2,apihysi igg line q blot (s)
20652-4,ornithine [moles/volume] in serum or plasma
20652-4,erm les/volum] in ornithine rplasma quant
20652-4,ornithine [moles/ume in ser r plasma
20652-4,ornithine serpl-scnc
20652-4,chemistry ornithine srpl-scnc
20652-4,serplscnc onithie
20652-4,ornithine [moles/vol]
20652-4,[moles/vl] rnithine
20652-4,ornithine [moles/ol]
40357-6,creatinine [moles/time] in 24 hour body fluid
40357-6,creatinine body in 24 hour [moles/time] fluid
40357-6,creatinine [moles/time] body 24 hour in fluid 24hr
40357-6,creat 24h fld-srate
40357-6,"fd-srate 24h body fluid, unsp creat"
40357-6,cat fl-rat 24h
40357-6,creatinine (24h body fld) [moles/time]
40357-6,creatinine (24h [moles/time] fld) body
40357-6,cratinine (24h [molstim] fld) boy
75973-8,ieee 11073 rosetta infant microenvironment panel infant microenvironment
75973-8,ieee 11073 rosetta infant microenvironment infant panel microenvironment
75973-8,rosetta 11073 ieee infant microenvironment panel infant panl microenvironment
75973-8,rosetta infant pnl inf microenvt
75973-8,rosetta miroenvt pl in infant
75973-8,pnlnf infan rostta miroenvt
3482-7,cimetidine [mass/volume] in serum or plasma
3482-7,serum [mass/volume] serp in cimetidine or plasma
3482-7,cimetidine [mass/volume] in tagj serum plasma or
3482-7,cimetidine serpl-mcnc
3482-7,drug/toxicology cimetidie erpl-mcn
3482-7,serpl-mcnc cimetidine
3482-7,cimetidine [mass/vol]
3482-7,drug/toxicology [mass/ol] cimetidine
3482-7,cimetiine[mass/vol]
33548-9,abnormal lymphocytes/leukocytes in body fluid by manual count
33548-9,abnormal lymphocytes/leukocytes in body fluid by manual count
33548-9,abnormal lymphocytes/leukocytes in body lymph abn fluid by manual count
33548-9,lymph abn nfr fld manual
33548-9,lymph abn nf fld manual
33548-9,lymphabn manual fd nfr
33548-9,abnormal lymphocytes/leukocytes manual cnt (body fld)
33548-9,abnomal lymphcyes/lukocytes nual cnt fluid (body fl
33548-9,abnormal fld) manual cnt (body lymphocytes/leukocytes
5092-2,clostridium tetani ab [units/volume] in serum
5092-2,antibodies tetaniab clostridi [uits/volume] in serm
5092-2,clostridium tetani ab [units/volume] sr in ser
5092-2,c tetani ab ser-acnc
5092-2,c tetaniabseracnc autoantibodies
5092-2,c tetani a ser-acc
5092-2,c. tetani ab qn (s)
5092-2,qn tetani ab c. (s)
5092-2,tetani c. ab qn (s)
32295-8,aluminum [moles/time] in 24 hour urine
32295-8,aluminum urine in 24 hour [les/tme
32295-8,aluminu [oles/tim] in 24 urine hur
32295-8,aluminum 24h ur-srate
32295-8,aluminum ur-srate 24h
32295-8,u-srate 24h aluminum
32295-8,aluminum (24h u) [moles/time]
32295-8,aluminum (24h u) [moles/time]
32295-8,u) (24h aluminum [moles/time]
88700-0,babesia microti igg and igm [interpretation] in serum
88700-0,bbesia immune globulin g microtigg an g [interpetn] i serum
88700-0,bbeiamirot infectious disease igg [intepretation] anim i serum
88700-0,b microti igg+igm ser-imp
88700-0,b microti infectious disease igg+igm serum-imp
88700-0,b microti ser-imp igg+igm
88700-0,b. microti igg and igm (s) [interp]
88700-0,b. micti igg and [interp] ) igm
88700-0,b. and igg autoantibody microti igm (s) [interp]
16976-3,hiv 1 ag [units/volume] in serum
16976-3,serum 1 quant ag [units/volume] in hiv
16976-3,hiv 1 ag serum in [units/volume]
16976-3,hiv1 ag ser-acnc
16976-3,hiv1 serum-acnc ag microbiology
16976-3,hiv1 ag human immunodeficiency virus serum-acnc
16976-3,hiv 1 ag qn (s)
16976-3,hiv 1 ag qn (s)
16976-3,hv ag 1 qn (s)
38350-5,herpes virus 6 dna [log #/volume] (viral load) in specimen by naa with probe detection
38350-5,hrpes vrus 6 dna [log #/volume] (vial load) in specmen y naa with probe detection
38350-5,with virus 6 dna [log #/volume] (viral load) in specimen by naa herpes probe detection
38350-5,hhv6 dna spec naa+probe-log#
38350-5,hhv6 spec dna naa+probe-log#
38350-5,hhv6 dna spec naat naa+probe-log#
38350-5,hhv 6 dna naa+probe (specimen) [log #/vol]
38350-5,hhv 6 dn naa+probe (specimen) [lg #vol]
38350-5,hhv (specimen) dna naa+probe 6 [log #/vol]
97239-8,n-desalkylflurazepam [presence] in cord tissue by confirmatory method
97239-8,n-desalkylflurazepam presence] in point in time crd tisse by confirmator method
97239-8,n-desalkylflurazepam [presence incod tissue by method confirmatory
97239-8,desalkylfluraz tissco ql cfm
97239-8,desalkylfluraz tissco conf ql cfm
97239-8,deslkylfluraz issco ql cf confirmatory
97239-8,n-desalkylflurazepam confirm ql (umb cord tissue)
97239-8,random n-desalkylflurazepam confirm ql umbcord tisue)
97239-8,(umb confirm ql n-deallfurazepam cord conf isue)
24450-9,carnitine esters [moles/mass] in tissue
24450-9,carnitine esters [moles/mass] in tissue
24450-9,carnitine quantitative esters tisu in mls/mass]
24450-9,carn esters tiss-scnt
24450-9,carn carn esters tiss-scnt esters
24450-9,esters carn tiss-scnt
24450-9,carnitine esters (tiss) [moles/mass]
24450-9,[moles/mass] quant esters (tiss) carnitine
24450-9,qnt carntine eters (tiss) [moles/mass]
30536-7,magnesium [mass/volume] in total parental nutrition
30536-7,[mass/voume] qnt magnesium in total parental ntrton
30536-7,totl [mas/volume] in magnesium panal nutrition
30536-7,magnesium tpn-mcnc
30536-7,tpn-mcnc magnesium random
30536-7,mg tpn-cnc magesium
30536-7,magnesium (total parental nutrition) [mass/vol]
30536-7,magnesium (total parental chemistry nutrition) [mass/vol]
30536-7,magnesium (total parental [mass/vol] quan nutrition)
25139-7,tryptophan/creatinine [molar ratio] in urine
25139-7,ratio] [molar tryptophan/creatinine in urine
25139-7,tryptphan/cratinine molar ratio] n uine
25139-7,tryptophan/creat ur-srto
25139-7,ur-srto tryptohan/ceat quan
25139-7,tryptohan/creat ur-srto
25139-7,tryptophan/creatinine (u) [molar ratio]
25139-7,rao] [molar tryptophancreatnneu) urn
25139-7,tryptophan/creatinine [molar (u) ratio] c244
77190-7,hepatitis b virus core and surface ab and surface ag panel - serum
77190-7,hepatitis b virus core and surface ab and surface ag - panel serum
77190-7,hepatitis b virus core and hbv core surface ab and surface ag panel - serum
77190-7,hbv core + surf ab + surf ag pnl ser
77190-7,hbv coe + surf b +surf ag pnl serum
77190-7,serum core + hep surf ab + surf ag pnl hbv
77190-7,hbv core and surface ab and surface ag panel (s)
77190-7,hbv and cor srae band surfac ag panl (s)
77190-7,hbv (s) and surface infectiousdisease ab and surface ag panel core
49204-1,bartonella henselae igm ab [titer] in body fluid
49204-1,bartonella henselae gm abtite] i body fluid
49204-1,bartonella body igm point in time ab [titer] in henselae fluid
49204-1,b henselae igm titr fld
49204-1,b henselaeigmtitr fl
49204-1,igm henselae b titr fld
49204-1,b. henselae igm (body fld) [titer]
49204-1,b. henselae (body id igm fld) [titer]
49204-1,b. henselae igm (body fld) [titer]
80162-1,bile alcohols [interpretation] in urine qualitative
80162-1,random qualitative alcohols [interpretation] in urine bile
80162-1,impressions bile lcools [intrpretatio]n rine qulittive
80162-1,bile alcohols ur-imp
80162-1,screen bile alcohols ur-imp
80162-1,ur bile alcohols ur-mp
80162-1,bile alcohols ql (u) [interp]
80162-1,bil () ql alcohol [interp]
80162-1,alcohols ble ql (u) [interp]
61397-6,enterococcus faecium dna [presence] in specimen by naa with probe detection
61397-6,enterococcus faecium dna [presence] in specimen naa by with probe detection
61397-6,enterococc faecium dna [presee] i secimen by naa with oe detection
61397-6,e faecium dna spec ql naa+probe
61397-6,e faecium dna spec ql naa+probe
61397-6,e faecium dna spec ql naa+probe 3sr sr
61397-6,e. faecium dna naa+probe ql (specimen)
61397-6,e. ql naa+poeq d faecum (specimen)
61397-6,e. faecium dna naa+probe ql (specimen) to be specified in another part of the message
73075-4,drug induced neutrophil ab [interpretation] in serum or plasma by flow cytometry (fc) narrative
73075-4,drug induced neutrophil ab [intepretaion] in serum narratv plaa impression bylwcytomety (fc) or
73075-4,drug induced neutrophil ab [interpretation] in serum or plasma by flow narrative (fc) plsm cytometry
73075-4,drug (neut) ab serpl fc-imp
73075-4,drug autoantibodies (neut) ab serpl fc-imp
73075-4,dru(nut) serplfc-imp ab neut
73075-4,drug induced neutrophil ab fc nar [interp]
73075-4,drug inuced nutrphil ab fc nar[interp] serology
73075-4,drug indued interpretation neutrophil ab fc nar [interp]
49799-0,treponema pallidum dna [presence] in cerebral spinal fluid by naa with probe detection
49799-0,treponema pallidum dna [presence] in cerebral spinal fluid by pr naa with probe detection
49799-0,treponema pallidum cerebral [presence] in dna spinal fluid by naa with probe detection
49799-0,t pallidum dna csf ql naa+probe
49799-0,t cerebrospinal fluid dna pallidum ql naa+probe
49799-0,t pallidumdna sf ligase chain reaction naa+poe
49799-0,t. pallidum dna naa+probe ql (csf)
49799-0,t. pallidum dna naa+probe ql (cerebrospinal fluid)
49799-0,t. strand displacement amplification pallidum dna naa+probe presence (csf)
55836-1,chitotriosidase [enzymatic activity/volume] in dbs
55836-1,chitotriosidase activity/volume] filter paper [enzymatic in dbs
55836-1,chitotrosiase [nzymati ativity/volum bs in
55836-1,chitotriosidase dbs-ccnc
55836-1,chttriosidedbs-ccnc pt
55836-1,dbs-ccnc chitotriosidase
55836-1,chitotriosidase (dbs) [catalytic activity/vol]
55836-1,chitotoidase (dbs)[cataytic ctiit/vol]
55836-1,hioriosidase quant (dbs) [catalytic activty/vol]
87366-1,actinobacillus pleuropneumoniae serotypes 1+9+11 ab/positive control in serum by immunoassay
87366-1,actibacillus pleropeumoniaseroypes 1+9+11 ab/psitive serum in contrl by immunoassay quantitative
87366-1,serotype pleuropnemoniae actinobacillus 1+911 ab/positie cotrol inseum by immunoassay
87366-1,a pleuropn 1+9+11 ab/pos cntrl ser ia
87366-1,ia pleuropn 1+9+11 ab/pos cntrl ser a
87366-1,pleuropn a 1911 a/oscnl ser ia
87366-1,a. pleuropneumoniae types 1+9+11 ab/positive control ia (s) [relative ratio]
87366-1,a. pleuropneumoniae types 1+9+11 ab/positive ratio] ia (s) [relative control
87366-1,. pleuropneumoniae types 1+9+11 ab/positive ontrl a (s) [relative antibody ratio]
32693-4,lactate [moles/volume] in blood
32693-4,lactate in [moles/volume] blood
32693-4,lacae bld in moes/vlume]
32693-4,lactate bld-scnc
32693-4,bld-scnc quantitative lactate
32693-4,blood-scnc lactate
32693-4,lactate (bld) [moles/vol]
32693-4,lactate [moles/vol] (bld)
32693-4,lactate (blood) [moles/vol
53931-2,histoplasma capsulatum ag [units/volume] in cerebral spinal fluid by immunoassay
53931-2,histoplasma capsulatum ag [units/volume] in cerebral spinal fluid h farciminosum by immunoassay
53931-2,histoplasma capsulatum ag [units/volume] cerebral in spinal fluid by immunoassay
53931-2,h capsul ag csf ia-acnc
53931-2,ag capsul h csf i-acnc
53931-2,h csf histoplasma farciminosum ag capsul ia-acnc
53931-2,h. capsulatum ag ia qn (csf)
53931-2,h. psulaum ia ag qn (csf)
53931-2,h. capslaum ag quant ia qn csf)
47534-3,2-hydroxyphenylacetate/creatinine [molar ratio] in urine
47534-3,2-yroxyenlacetat/creatinie [molar in ratio] uine
47534-3,-hydroxyphenylcetatereatinin [mol rato] urine i substance concentration ratio
47534-3,2oh-phenylacetate/creat ur-srto
47534-3,pt ur-srto oh-pheylacetate/creat
47534-3,2oh-henlacetatecretur-srto
47534-3,2-hydroxyphenylacetate/creatinine (u) [molar ratio]
47534-3,2-hydroxyphenylactate/ceatinin (u) [molaratio]
47534-3,2-hdroxphenylacetate/ratinine (u) [molar ratio]
19054-6,mycoplasma pneumoniae [presence] in specimen by organism specific culture
19054-6,mcplasm pneumoniae ql] in specime by mycoplas organism speific cutue
19054-6,mycoplasma pneumoniae [presence] in specimen by organism specific culture
19054-6,m pneumo spec ql cult
19054-6,pneumo spec cult ql
19054-6,m pneumo spec ql cult to be specified in another part of the message
19054-6,m. pneumoniae org specific cx ql (specimen)
19054-6,m. pneumoniaeorg specific cx ql (specimen
19054-6,m. random pneumoniae org pecific cx ql (specimen
23556-4,deprecated vesicular stomatitis virus ab [presence] in serum
23556-4,[presence] vesicular stomatitis random virus ab deprecated in serum
23556-4,deprecated vesicular vrus stomatiis ab [rsence in serm
23556-4,deprecated vsv ab ser ql
23556-4,deprecated vsv ab ql arbitrary concentration ser
23556-4,deprecated vsv ab serum ql
23556-4,vesicular stomatitis virus ab ql (s)
23556-4,vesicular (s) vir b presence aby stoatits
23556-4,vesicular stmatit serum ab viru l ()
29724-2,leptospira interrogans sv celledoni ab [presence] in serum by agglutination
29724-2,leptospira interrogans sv antby celledoni ab [ql] by serum in agglutination
29724-2,letospira interogans v celledoi a [presence]in serum by agglutination
29724-2,l inter celled ab ser ql aggl
29724-2,l infectiousdisease inter celled ab serum ql aggl
29724-2,l inter celled presence ser ab ggl
29724-2,l. interrogans sv celledoni ab aggl ql (s)
29724-2,l. intrrogns sv celledoni ab aggl presence ()
29724-2,l. interrogans sv celledoni ab aggl presence (s)
80182-9,s-adenosylmethionine/creatinine [molar ratio] in urine
80182-9,s-adenosylmethionine/creatinine in ratio] [molar urine
80182-9,s-adnosylmethionine/creatiin [molar in ratio] urine
80182-9,same/creat ur-srto
80182-9,same/reat u-srto
80182-9,sarat ur-sr
80182-9,s-adenosylmethionine/creatinine (u) [molar ratio]
80182-9,ua s-adenosylmethionine/creatinine (u) [molar ratio]
80182-9,ratio] (u) [molar s-adenosylmethionine/creatinine
13524-4,leukocytes other/leukocytes in body fluid by manual count
13524-4,leukctes other/lukocytes in body fluid b manual cont
13524-4,leukocytes other/leukocytes in manual fluid by body count
13524-4,wbc other nfr fld manual
13524-4,wbc fluid other nfr fld manual
13524-4,other white blood cells bc nfr fld mnual
13524-4,wbc other/leukocytes manual cnt (body fld)
13524-4,wbc white blood cells other/leukocytes manual fld) (body cnt
13524-4,manl wbc oth/leukocyts manual cnt (body fld
22079-8,actinomyces sp ab [titer] in serum
22079-8,p atinomces b [tier] in serum
22079-8,actinomyces s ab [iter] in serum
22079-8,actinomyces ab titr ser
22079-8,actinmyces ab tir er aby
22079-8,actinomyces ab titr er
22079-8,actinomyces sp ab (s) [titer]
22079-8,actinomyes s ab (s) [tite] actino
22079-8,actinomyces sp ab (s) [titer]
25503-4,phosphoserine [moles/time] in 24 hour urine
25503-4,phosphoserine [moles/time] in 24 hour urn urine
25503-4,in mole/time] phosphoserine 24hoururine
25503-4,phosphoserine 24h ur-srate
25503-4,urn phosphoserine 24 ur-srt
25503-4,24h phosphoserine ur-srate
25503-4,phosphoserine (24h u) [moles/time]
25503-4,u)[moles/time] phosphoserine24h
25503-4,(24h phosphoserine chemistry u)[mole/time]
13768-7,leucine/creatinine [mass ratio] in urine
13768-7,leucine/creatinine [mass ratio] in ur urine
13768-7,eucine/creatinne [mas ratio] in urine
13768-7,leucine/creat ur
13768-7,ur creat leucine/creat
13768-7,ur quant leucine/creat
13768-7,leucine/creatinine (u) [mass ratio]
13768-7,ratio] (u) [mass leucine/creatinine
13768-7,lecine/creatinine (u) [mas quantitative raio]
79224-2,baclofen [mass/volume] in body fluid
79224-2,bacloen [mas/olume] in body fluid body fluid
79224-2,baclofen[mas/voue in bod kemstro fluid
79224-2,baclofen fld-mcnc
79224-2,drugs fld-mcnc baclofen
79224-2,kemstro fld-mcnc baclofen
79224-2,baclofen (body fld) [mass/vol]
79224-2,balofen [mass/vol] (oyfld)
79224-2,fld)[mas/vol] (body aclofen
18374-9,riboflavin [mass/volume] in 24 hour urine
18374-9,[mas/volme] riboflavin 24 hour urine
18374-9,hur in 24 iboflavn[massvolme] urine
18374-9,vit b2 24h ur-mcnc
18374-9,quant vit b2 24h ur-mcnc
18374-9,vit b 24h u-mnc
18374-9,riboflavin (24h u) [mass/vol]
18374-9,(24h riboflavin u) [mass/vol] quant
18374-9,riboflavin u) (24h qnt [mass/vol]
47733-1,proline/amino acids.total in hair
47733-1,in id.tot proline/amino hair
47733-1,poline/aminocids.ttal in air pro
47733-1,proline sfr hair
47733-1,hair sfr proline
47733-1,hair sfr proline
47733-1,proline/total aa (hair) [molar fraction]
47733-1,proline/total aa (hair) [molar fraction]
47733-1,proline/total aa (hair) [molar har fraction]
56641-4,threonine/creatinine [ratio] in 24 hour urine
56641-4,threnne/creatine [ratio] in 24 urn hour urine
56641-4,threnine/creatnine chemistry [ratio] n 24 hour urine
56641-4,threonine/creat 24h ur-rto
56641-4,threonine/creat ur-rto 24h
56641-4,24 hours threonine/creat 24h ur-rto
56641-4,threonine/creatinine (24h u) [ratio]
56641-4,threonine/creatinine chemistry (24h u) [ratio]
56641-4,threonine/creatinine u) (24h [ratio]
19704-6,deprecated tetrahydrocannabinol cutoff [mass/volume] in urine for screen method
19704-6,dprected trahyrcannabinol cutff [msvolume]in urine for sren methd
19704-6,dprecated tetrydrocnnabiol cutoff [massvolume] in urine for method screen
19704-6,deprecated thc cto ur scn-mcnc
19704-6,deprecated thc ur cto scn-cc
19704-6,deprecated thc ur drugs cto scn-mcnc
19704-6,tetrahydrocannabinol cutoff screen (u) [mass/vol]
19704-6,ur tetahydrocnnabinolcuoff screen(u) [mss/vol]
19704-6,tetrahydrocannabinol cutoff [mass/vol] (u) screen nabilone
33650-3,cryoglobulin.iga [mass/volume] in serum
33650-3,cryglobulin.iga [mass/volume] in serm
33650-3,cryoglobulin.iga [mass/volume] serum in
33650-3,cryoglob iga ser-mcnc
33650-3,immunoglobulin a iga cryoglob ser-mcnc
33650-3,mass concentration cryogl iga ser-mcnc
33650-3,cryoglobulin.iga (s) [mass/vol]
33650-3,cryoglobulin.iga (s) [mass/vol]
33650-3,quantitative [mass/vol] (s) cryoglobulin.iga
49086-2,first trimester maternal screen with nuchal translucency panel
49086-2,first nuchal maternal screen with trimester translucency panel
49086-2,first timeste nuchal screen wih materal tasuceny panel
49086-2,1st trimester scn+nt pnl patient
49086-2,trimester 1st scn+nt pnl patient scrn
49086-2,1st pnl scn+nt trimester patient
49086-2,first trimester maternal screen with nuchal translucency panel
49086-2,rst trimester maternal screenwith 1st trimester scn+nt pnl nuchal trnslucencpanel
49086-2,first trimester maternal screen with nuchal pan translucency panel
1819-2,alpha mannosidase [enzymatic activity/mass] in tissue
1819-2,alpha in [enzymatc ctivity/mass] anosidase tissue
1819-2,tissue mannosidase [enzymatic activity/mass] in tissue alpha
1819-2,a-mannosidase tiss-ccnt
1819-2,chemistry tiss-ccnt a-mannosidase
1819-2,a-mannosidase tissccnt
1819-2,alpha mannosidase (tiss) [catalytic activity/mass]
1819-2,ala manosidase (tiss) [catlytic ctvity/mass]
1819-2,alpha qnt mannosidase activity/mass] [catalytic (tiss)
5611-9,cadmium [mass/volume] in urine
5611-9,urine in cadmium[mass/volume]
5611-9,cadmium urie in cd [mas/volume]
5611-9,cadmium ur-mcnc
5611-9,ur-mcc cadmum
5611-9,ur-mcnc cadmium ur
5611-9,cadmium (u) [mass/vol]
5611-9,(u) cadmium [mass/vol]
5611-9,cadmium (u) [mass/vol]
4394-3,phenothiazines [mass] of dose
4394-3,phenothiazines [mass] of dibenzothiazine dos
4394-3,phenothiazines [mass] of dose
4394-3,phenothiaz dose
4394-3,phenotiazdoe
4394-3,dose phenothiaz random
4394-3,phenothiazines (dose) [mass]
4394-3,dose med or substance phenothiazines (dose) [mass]
4394-3,(dse) penothiazines mass]
88577-2,legionella pneumophila dna [presence] in tissue by naa with probe detection
88577-2,legionella pneumophila dna [presence] tissue in tissue by naa with probe detection
88577-2,legionela pnumophla dna [presence] in tissue y naaith probe etection
88577-2,l pneumo dna tiss ql naa+probe
88577-2,l pneumo presence tiss dna presence naa+probe
88577-2,l naa+probe dna tiss ql pneumo
88577-2,l. pneumophila dna naa+probe ql (tiss)
88577-2,l. pneuophla dna (tiss) na+probeql
88577-2,l. dna pneumophila naa+probe ql (tiss)
105549-0,ku ab [units/volume] in serum
105549-0,ku ab serum in [units/volume]
105549-0,ku ab [units/volume] antibodies in serum
105549-0,ku ab ser-acnc
105549-0,k b serum-anc
105549-0,serum-acnc ab ku
105549-0,ku ab qn (s)
105549-0,ku qn ab serology (s)
105549-0,ab ku qn (s)
27174-2,inhibin [units/volume] in serum or plasma
27174-2,inhibin plasma in ser or [units/volume]
27174-2,ihibin point in time [unit/volume] iserum orplasma
27174-2,inhibin serpl-acnc
27174-2,serp-acnc inhibin
27174-2,serpl-acnc inhiin serplas
27174-2,inhibin qn
27174-2,qn inhibin pl
27174-2,qn inhibin pt
101523-9,bovine parainfluenza virus 3 neutralizing antibody [titer] in serum by neutralization test
101523-9,bovne byneuraliation viru neutralizing antibodies ntibodytiter] in serum paraifluenza test
101523-9,bovine anfluena virus 3 neutraliz antibody [titer] n erum by neutlization test
101523-9,bpiv3 nab titr ser nt
101523-9,titr nab dilution factor (titer) bpiv3 ser nt
101523-9,bpiv3ab dilution factor (titer) itr serum nt
101523-9,bovine parainfluenza virus 3 neut ab neut test (s) [titer]
101523-9,bovine parainfluenza virus 3 neut antby ab neut test (s) [titer]
101523-9,3 parainfluenza virus bovine neut ab neut test (s) [titer] vet
3499-1,clorprenaline [presence] in urine
3499-1,clorprenaline in [presence] urine drugs
3499-1,clorprenaline [presence] in urine
3499-1,clorprenaline ur ql
3499-1,clorprenaline ur ql
3499-1,clorprenaline ql ur
3499-1,clorprenaline ql (u)
3499-1,clorprenaline (u) ql
3499-1,clorrenalin presence (u)
24036-6,borrelia sp ag [presence] in specimen by immunofluorescence
24036-6,borrelia sp ag [ql] by specien in imunofluoreence
24036-6,borrliasp a [prence] in microbiology specimen by immunofluorescece
24036-6,borrelia ag spec ql if
24036-6,borrelia ag ql spec if
24036-6,rrelia agspecql immunofluorescence if
24036-6,borrelia sp ag if ql (specimen)
24036-6,borrelia sp ag if ql (specimen)
24036-6,borrelia s ag i fa ql (specime)
2224-4,enolase [enzymatic activity/volume] in serum
2224-4,enolase serum quan actiiy/olume] n [enzymatic
2224-4,enoase [ezymatic random ctivt/volue] in seru
2224-4,enolase ser-ccnc
2224-4,enolase sr-ccnc
2224-4,enolase catalytic concentration serum-ccnc
2224-4,enolase (s) [catalytic activity/vol]
2224-4,enolase [catalytic (s) activity/vol]
2224-4,nolase activity/vol] [calytic (s) serum
16439-2,benzene [presence] in blood
16439-2,blood [presence] in benzene ordinal
16439-2,benzene [presence] in bld
16439-2,benzene bld ql
16439-2,ql bd bnzene ql
16439-2,benzene bld ql blood
16439-2,benzene ql (bld)
16439-2,ql point in time benzene (bld)
16439-2,ql benzeneql (bd)
71850-2,deprecated oxygen saturation [pure mass fraction] in capillary blood by oximetry
71850-2,deprecated oxygen saturation random [pure mass fraction] in capillary bld by oximetry
71850-2,deprecated oxygen saturation [pure mass fraction] in capillary bld by satn oximetry
71850-2,deprecated sao2 df bldc oximetry
71850-2,d deprectedso2 bldc oximetry
71850-2,oxmetry so2 dfbldc dprecatd
71850-2,sao2% oximetry (bldc) [pure mass fraction]
71850-2,sao2% oximetry (bldc) fraction] mass [pure
71850-2,sao2% sao2 oximetry (bldc) [pure mass fraction]
31239-7,infectious bronchitis virus mass-41 ab [units/volume] in serum
31239-7,infectious arbitrary concentration bronchitis virus mass-41 ab [units/volume] in serum
31239-7,infectiousbochitis [unts/volume] mass-41 ab virs in ser
31239-7,ibv mass41 ab ser-acnc
31239-7,ab mas41 autoantibodies bv sracnc
31239-7,bv mass41 ab sr-acn quan
31239-7,infectious bronchitis virus mass-41 ab qn (s)
31239-7,infectious bronchitis virus antby mass-41 ab qn (s)
31239-7,inectious bronchitisvirus mss-1 ab qn (s) anti
23422-9,salmonella enteritidis igg ab [presence] in serum
23422-9,salmonella enteritidis igg ab in [presence] serum
23422-9,salmonella enteritidis igg [presence] ab in qual serum
23422-9,s enteritid igg ser ql
23422-9,s enteritid igg ser point in time ql
23422-9,ql enteritid infectious disease igg ser s
23422-9,s. enteritidis igg ql (s)
23422-9,s. (s) autoantibody igg enteritidis
23422-9,s. eneritidis ig ql s)
27948-9,herpes simplex virus 1+2 igg ab [units/volume] in serum by immunoassay
27948-9,herpes simplex virus 1+2 ser ab [units/volume] immune globulin g in igg by immunoassay
27948-9,herpes simplex virus 1+2 igg ab [units/volume] in serum by immunoassay elisa
27948-9,hsv1+2 igg ser ia-acnc
27948-9,sr igg hsv1+2 ia-cnc
27948-9,hsv1+2 igg quan ia-acnc er
27948-9,hsv 1+2 igg ia qn (s)
27948-9,hv 1+2 igg qn iaa ia (s)
27948-9,hsv 1+2 igg ia hsv1+2 qn (s)
62622-6,deprecated phenx measure - respiratory - peak expiratory flow rate - pefr
62622-6,deprecated phex measure- respiatory - peak expirtry dynamic flow rate - pefr
62622-6,deprecated - measure - respiratory phenx peak expiratory flow rate - pefr pt
95970-0,sars-cov-2 (covid-19) specific tcrb gene rearrangements [presence] in blood by sequencing
95970-0,sars-cov-2 (covid-19) specific tcrb gene rearrangements [presence] in bld by sequencing bld
95970-0,(covid-19)speciic sars-cov-2 tcrb gene rearrngements random [ql] in lod b sequencing
95970-0,sars-cov-2 tcrb bld ql seq
95970-0,seq bld ql sars-cov-2tcrb
95970-0,sars-cov-2 seq rearr bld ql tcrb
95970-0,sars-cov-2 (covid-19) specific tcrb gene rearrangements sequencing ql (bld)
95970-0,sarsco-2 (covid-19) pecfic tcb gene rarangements sequencingql (blood)
95970-0,sarscov-2 (covid19) specifc tcrb genererrangmens seqencing q (blood)
74319-5,mica*051 igg ab [presence] in serum
74319-5,mica*051 igg b [presence] i srum random
74319-5,qualitative mica*051 g inerum [prsence] ab
74319-5,mica*051 igg ser ql
74319-5,mica*051 igg anti ser ql
74319-5,mica*051 igg ql ser
74319-5,mica*051 igg ql (s)
74319-5,igg mica*051 ql s) random
74319-5,mica*051 igg ql (s)
61753-0,promis item bank - pain interference - version 1.0
61753-0,promis itembank - interferene- panel.survey.promis pn version 1.0
61753-0,promis item bank - pain panl interference - version 1.0
7943-4,lassa virus igg ab [titer] in serum by immunofluorescence
7943-4,lassa irus igg ab infectiousdisease [iter] by serm in immunouoescence
7943-4,lassa virus igg ab [titer] in ser by immunofluorescence
7943-4,lasv igg titr ser if
7943-4,ser iggtitr lasv ifa if
7943-4,las ttrser igg if
7943-4,lassa virus igg if (s) [titer]
7943-4,if virus igg lassa (s) [titer]
7943-4,if virus igg point in time lassa (s) [titer]
89342-0,babesia sp 18s rrna [presence] in blood by naa with probe detection
89342-0,babesia rrna sp18s [ql] inblodby naa wthproedetection
89342-0,babesa lat sp 1 rrn robe inbloodby naa with [presene] detecin
89342-0,babesia 18s rrna bld ql naa+probe
89342-0,baeia bl rrna 18s l naa+probe
89342-0,babesia 18s rrna bld ql lat naa+probe
89342-0,babesia sp 18s rrna naa+probe ql (bld)
89342-0,babesia sp 18s rrna naa+probe presence (bld)
89342-0,dna nucleic acid probe sp babesia 18srrnanaa+probe ql (blood)
43145-2,peak flow meter device panel
43145-2,pek flow random mete device panel
43145-2,eak low meter device panel
43145-2,peak flow meter device pnl
43145-2,flow peak meter pan devic pnl
43145-2,peak flow meter device pnl
24044-0,acetyl-coa:glucosamine acetyltransferase [enzymatic activity/mass] in leukocytes
24044-0,acety-oa:lucosame acetlranserase activity/ass] [enzyatic in leukocytes
24044-0,acetyl-coa:glucosamine acetyltransferase leukocytes activity/mass] in [enzymatic
24044-0,accoa:glucosamine at wbc-ccnt
24044-0,wbc-ccnt accoa:glucosamineat
24044-0,wbc-ct quant at accoa:lucosmine
24044-0,acetyl-coa:glucosamine acetyltransferase (wbc) [catalytic activity/mass]
24044-0,acetyl-coa:glucosamine activity/mass] (wbc) [catalytic acetyltransferase
24044-0,aetyl-coa:glucosamine activit/mass] (wbc) [catlytic cetyltranferas
44432-3,annexin v igm ab [units/volume] in serum or plasma
44432-3,annexin [units/volume] igm ab v in serum or annexin a5 plasma
44432-3,annexin plasma igm ab [units/volume] in serum or v
44432-3,annexin v igm serpl-acnc
44432-3,annexin pl v serum or plasma-acnc igm
44432-3,serpl-acnc v igm annexin
44432-3,annexin v igm qn
44432-3,qn aby v igm annexin
44432-3,sr v annexin imqn
87502-1,lcds v4.00 - mobility - admission performance during assessment period [cms assessment]
87502-1,lcds v4.00- mobility - admission erormace durin assessment period [cms pan assessmnt
87502-1,lcds v4.00 - mobility - admission performance centers for medicare and medicaid assessment during assessment period [cms assessment]
1872-1,apolipoprotein b-150 [mass/volume] in serum or plasma
1872-1,aplipoproten b-15 [mass/voume] i serum oplasma level
1872-1,apolipoprotein b-150 [mass/volume] in ser or plasma
1872-1,apo b150 serpl-mcnc
1872-1,apo serpl-mcnc b150
1872-1,serl-mcnc b150 apo
1872-1,apolipoprotein b-150 [mass/vol]
1872-1,apoipoprtein b-150 [massol]
1872-1,b-10 apolipoprot apolioprotein [as/vol]
58683-4,complement c5 [presence] in serum or plasma
58683-4,complement c5 [preence] inserum screen or plas
58683-4,coplement c5 [prsence] in ser or plasma ql
58683-4,c5 serpl ql
58683-4,c5 ql serum or plasma
58683-4,c5 sepl ql
58683-4,complement c5 ql
58683-4,c5ql complement
58683-4,complement presence qualitative c5
75128-9,uracil [moles/volume] in cerebral spinal fluid
75128-9,uracil [moles/volume] in chemistry cerebral spinal fluid
75128-9,urail cereral in [molevolume] spinal fluid
75128-9,uracil csf-scnc
75128-9,urail cf-cnc
75128-9,csf-scnc uracil
75128-9,uracil (csf) [moles/vol]
75128-9,quant uracil (cerebrospinal fluid) [moles/vol]
75128-9,point in time (csf) uacil [moles/vol]
90818-6,aquaporin 4 water channel igg ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
90818-6,auaporin 4ater channel igg ab [presene] in bining spinal fluid by cell ereral immunoflreet asa
90818-6,aquaporin 4 water channel igg ab [ql] in cerebral spinal fluid by cell antibody binding immunofluorescent assay
90818-6,aqp4 h2o channel igg csf ql cba ifa
90818-6,aqp4 h2o channe ig ql csf cba ia
90818-6,nmo aq4 csf chnnel igg h2o qlcbaifa
90818-6,aquaporin 4 water channel igg cell binding immunofluorescent assay ql (csf)
90818-6,aquaporin 4 igg channel water cell binding immunofluorescent assay ql (csf) autoantibody
90818-6,aquaporin 4 water channel igg cell binding immunofluorescent assay ql (csf)
26833-4,hippurate [presence] in urine
26833-4,qual hippurte [presenc]n urine
26833-4,[presence]in ipure qual urine
26833-4,hippurate ur ql
26833-4,presence hippurate
26833-4,hippurate ur ql
26833-4,hippurate ql (u)
26833-4,hippurate q benzyl alcohol metabolite ()
26833-4,hippurate ql hippuran (u)
101300-2,streptococcus pyogenes dna [presence] in throat by naa with non-probe detection
101300-2,streptococcu pyogenes dna presnce] nthroat by na with nn-robe deection
101300-2,streptococcs pyogenes dna [presece] i throa ith na by non-probe deection
101300-2,s pyo dna throat ql naa+non-probe
101300-2,s pyo dna throat upper respiratory ql naa+non-robe
101300-2,s dna pyo throat ql naa+non-probe
101300-2,s. pyogenes dna naa+non-probe ql (throat)
101300-2,s. pyogenes dna naa+non-robe gas presence(throat)
101300-2,s. pyogenes da na+non-robe ql throt)
53553-4,glucose mean value [moles/volume] in blood estimated from glycated hemoglobin
53553-4,gluose mean value mols/volume] in rom stimated blood gycated hmoglobin
53553-4,hemogloin mean alue [moles/voue in lood etmated fom lycated lucose
53553-4,est. average glucose bld ghb est-scnc
53553-4,est.verae glucos bld ghb estscnc
53553-4,est. average glucose ghb bld est-scnc
53553-4,average glucose estimated from glycated hemoglobin (bld) [moles/vol]
53553-4,average glucose estimated from glycated hemoglobin (bld) whole bld [moles/vol]
53553-4,average glucose estimated from lycatedhemoobin (bld)[molevo]
94250-8,borrelia burgdorferi oppa2 gene [presence] in specimen by naa with non-probe detection
94250-8,borrelia dna probe burgdoreri oppa2 gene [pesence] in detction by naa ith non-pobe specmen
94250-8,borrelia burgdorferi oppa2 gene [presence] in specimen by amplif naa with non-probe detection
94250-8,b burgdorferi oppa2 spec ql naa+non-prb
94250-8,b oppa2 lyme burgdorferi spec ql naa+non-prb
94250-8,b burgdorferi ql spec oppa2 naa+non-prb
94250-8,b. burgdorferi oppa2 gene naa+non-probe ql (specimen)
94250-8,pcr b. burgdorferi opa gene naa+non-pobe ql (specimen)
94250-8,b. burgdorferi oppa2 amplif genenaa+non-prb presence specimen)
67870-6,patient information - end stage renal disease form 2728
67870-6,patient ed - iformation stgerenal diseaseform 28
67870-6,patient informion dz - end stage renal disease form 278
53985-8,coarse speckled nuclear ab pattern [titer] in serum by immunofluorescence
53985-8,coarse speckled ana coarse speckled nuclear ab pattern [titer] in serum by immunofluorescence
53985-8,corse spekled immune fluorescence nuclear ab pattern [tter] in ser b immuofluorecence
53985-8,ana coarse speckled titr ser if
53985-8,acif speckled coarse ana titr serum if
53985-8,ana titrse peckled coarse if
53985-8,coarse speckled nuclear ab pattern if (s) [titer]
53985-8,coarse pckld nuclear ab pattern if s) [titer]
53985-8,oarse speckled nuclear ab pattern if s) [titer]
60083-3,hydroxybupropion [mass/volume] in blood
60083-3,hydroxybupropion in [mass/volume] bld
60083-3,hydroxybupropion in quant [mass/volume] blood
60083-3,oh-bupropion bld-mcnc
60083-3,bldmcnc oh-bupopion
60083-3,bldmcnc oh-bupropio
60083-3,hydroxybupropion (bld) [mass/vol]
60083-3,hydroxybupropion (bld) [mass/vol] 6-hydroxybupropion
60083-3,[mass/vol] (bld) hydroxybupropion
50408-4,protein.abnormal band/protein.total in urine by electrophoresis
50408-4,protein.abnral bd/prtin.total in electrophoresis by urine
50408-4,protein.abnormal band/protein.total in by urine electrophoresis
50408-4,abn prot mfr ur elph
50408-4,totl abn potmfr ur elph
50408-4,abn ur mfr prot elph
50408-4,protein.abnormal band elph (u) [mass fraction]
50408-4,fraction] ur bandelph (u) [mass protein.bnorma
50408-4,protein.abnormal fraction] elph (u) [mass band
55598-7,leukocytes.disintegrated/leukocytes in body fluid by manual count
55598-7,leukocytes.disintegrated/leukocytes in count fluid by manual body
55598-7,leukocytes.disintegrated/leukocytes in count fluid by manual body
55598-7,wbc.disintegrated nfr fld manual
55598-7,nfr wbc.disintegrated fld manual
55598-7,wbc.disintegrated nfr qnt manual fld
55598-7,wbc.disintegrated/leukocytes manual cnt (body fld)
55598-7,wb.disintegrated/leukcytes cnt mana (bo fld)
55598-7,(bdy wbcdisintegrated/leukoyteanlnt body fluid fld)
91338-4,promis parent proxy item bank - strength impact - version 1.0
91338-4,promis parent proxy item bank - strength impact - version panel.survey.promis 1.0
91338-4,prs parent proxy item panl bank - stregth impat - version 1.
18320-2,globulin [mass/volume] in urine by calculation
18320-2,globulin [mass/volume] in urine by calculation
18320-2,globulin [mass/volume] in urine by calculation globul
18320-2,globulin ur calc-mcnc
18320-2,ur globulin calc-cnc
18320-2,globulin calc-mcnc ur
18320-2,globulin calc (u) [mass/vol]
18320-2,globulin calc (u) [mass/vol]
18320-2,globulin (u) calc [mass/vol] globul
94845-5,sars-cov-2 (covid-19) rna [presence] in saliva (oral fluid) by naa with probe detection
94845-5,sars-cov-2 (covid-9) na [presence]in sliva (oral fluid) by naa with probe detecn
94845-5,sars-cov-2 (covid-19) rna [presence] in saliva (oral fluid) by naa with probe pr detection
94845-5,sars-cov-2 rna sal ql naa+probe
94845-5,sar-cv-2 infectious disease rna sa ql naa+ob
94845-5,ars-cov-2 dna nucleic acid probe rna sal ql naa+probe
94845-5,sars-cov-2 (covid-19) rna naa+probe ql (sal)
94845-5,sarscov-2 (covid-19) rna random naa+probe presence (sal)
94845-5,covid19 (sal) (coid-19) rn naa+probe ql ss-cov-2
88481-7,activity limitations panel [saq]
88481-7,activity limitations actvty panel [saq]
88481-7,ciity limitations pane [sa]
59065-3,chlamydophila psittaci [presence] in bronchial brush by organism specific culture
59065-3,chlamydophia psittaci [presece] in culture brush y organism specific bronchil
59065-3,bronchial psittaci [presence] in chlamydophila brush by organism specific culture
59065-3,c psittaci bro brush ql cult
59065-3,c psittaci bro brush presence point in time cult
59065-3,c&s psittci bro brush ql cult
59065-3,c. psittaci org specific cx ql (bronchial brush)
59065-3,c. psitaci org specific point in time cx ql (bronchial ush)
59065-3,c. infectious disease psittaci org specific cx ql (bronchial brush)
17622-2,deprecated streptocuccus pneumoniae 18 ab [units/volume] in serum --1st specimen
17622-2,depreated streptocucc s pneumo peumoniae 18 ab [units/olume] in serum --1st specimn
17622-2,depecated trptcucus pneumoniae 18ab [nis/volume] in -1st serum speimen
17622-2,deprecated s pneum18 ab sp1 ser-acnc
17622-2,s dprecated pneum18 ab p1 ser-acnc
17622-2,deprecated s pneum18 ab sp1 serum-acnc
17622-2,s. pneumoniae 18 ab spec 1 qn (s)
17622-2,s.pneumonia ab 18 spec 1 qn antby (s)
17622-2,autoantibody s. pneumoniae 18 ab spec 1 q (s)
100905-9,gram positive bacteria identified in isolate by organism specific culture
100905-9,gram positive bacteria identified in isolate by specific random organism culture
100905-9,gram microbiology positive bacteria identified in isolate by organism specific culture
100905-9,gp bact islt cult
100905-9,gp islt nominal bact cult
100905-9,cult bact islt gp
100905-9,gram positive bacteria identified org specific cx nom (isol)
100905-9,gram nominal positive bacteria identified org specific cx nom (isol)
100905-9,gram spec positive bacteria identified org specific cx nom (isol)
51189-9,4-hydroxybupivacaine [mass/volume] in serum or plasma
51189-9,4-hydroxybupivacaine [mass/volume] in ser plasma or plasma
51189-9,4-hydroxybupvacaine [mss/volume]in erum quan or plasma
51189-9,4oh-bupivacaine serpl-mcnc
51189-9,oh-buivacaine epl-mcn ser or plasma
51189-9,srpl-mn 4h-bpivacaine
51189-9,4-hydroxybupivacaine [mass/vol]
51189-9,4-hydroxybupivcain[masvol]
51189-9,4-hydroybupvaie[mass/vol]
43127-0,clomipramine and norclomipramine panel - serum or plasma
43127-0,pan andnrclomipramine comipramine - serumorplasma
43127-0,clomipramine and norlomipramine drugs panel - plasa or serum
43127-0,clomipramine+nor pnl serpl
43127-0,serpl pl clompramine+or
43127-0,clomipamine+nor sepl pnl drugs
43127-0,clomipramine and norclomipramine panel
43127-0,cloipramineand clom norcomipramine pael
43127-0,clomipramine panel norclomipramine desmethylclomipramine and
25232-0,nafcillin [mass/volume] in specimen
25232-0,nafcillin [mass/volume] specimen in quan
25232-0,nafcillin [mass/volume] in specimen
25232-0,nafcillin spec-mcnc
25232-0,sec-mcnc nafcillin other
25232-0,nafcillin spec-mcnc
25232-0,nafcillin (specimen) [mass/vol]
25232-0,nafcillin to be specified in another part of the message (pecimen) [mass/vol]
25232-0,[mass/vo] quantitative (specimen) nafcilin
53237-4,acrylylcarnitine (c3:1) [moles/volume] in dbs
53237-4,acrylylcarnine (c3:1) moles/volme] in db
53237-4,indbs [moles/volume] crylylcarntine(c3:1)
53237-4,acrylylcarn dbs-scnc
53237-4,wb dbs-scnc acrylylcarn
53237-4,ds-scnc acryylcarn fp
53237-4,c3:1 (dbs) [moles/vol]
53237-4,c:1 [moles/vol] (ds)
53237-4,c3:1 [moles/vol] (dbs)
77888-6,olanzapine [mass/volume] in urine by confirmatory method
77888-6,olanzapine [mass/volume] in urine by confirmatory method
77888-6,olanzapine [mass/volume] in urine by confirmatory method
77888-6,olanzapine ur cfm-mcnc
77888-6,olnzapine r cfmmcnc
77888-6,olanzapine ur ur cfm-mcnc
77888-6,olanzapine confirm (u) [mass/vol]
77888-6,olanzapine [mass/vol] confirmatory (u) confirm
77888-6,olanzapine confirm (u) level [mass/vol]
30039-2,anaplasma phagocytophilum dna [presence] in blood by naa with probe detection
30039-2,pcr analsma phaocohilumdna [presence] in blood b na with probe detecion
30039-2,anaplasma dna phaocytophum [esence] in blod dna probe bynaa with probe detection
30039-2,a phagocytoph dna bld ql naa+probe
30039-2,a blood dna ehrlichia equi phagocytoph ql naa+probe
30039-2,a pagocytoph dna transcription mediated amplification dql naa+oe
30039-2,a. phagocytophilum dna naa+probe ql (bld)
30039-2,a. phagocytophilum (bld) naa+probe ql dna
30039-2,a. phagocytophilum dna naa+probe ql (bld) blood
17300-5,mycoplasma hominis ab [titer] in serum by complement fixation
17300-5,serum hominis ab [titer] in myoplasa b complement fxatio
17300-5,mycoplas hmiis ab [titer] in serum by titer complemen iatio
17300-5,m hominis ab titr ser cf
17300-5,m hominis ser abtitr cf
17300-5,m hominis ab titr myco ser cf
17300-5,m. hominis ab cf (s) [titer]
17300-5,m. hominis ab cf (s) autoantibodies [titer]
17300-5,m. hoinis ab cf (s) [titer]
17232-0,lysozyme [enzymatic activity/volume] in tear
17232-0,n-acetylmuramide glycanhydrolase activity/volume] [enzymatic lysozyme in tear
17232-0,rk208 lysozyme [enzymatic activity/volume] in tear
17232-0,lysozyme tear-ccnc
17232-0,rk208 lysozymetea-ccnc
17232-0,tear-ccnc lysozyme
17232-0,lysozyme (tear) [catalytic activity/vol]
17232-0,lysozyme [catalytic (tear) activity/vol]
17232-0,lysozyme tears (tear) [catalytic activity/vol]
105963-3,zolpidem phenyl-4-carboxylate [mass/volume] in urine
105963-3,in phnyl-4-carboylate stilnox mass/volume] zopidm urine
105963-3,olpidem phenyl-4-carboxylae [mass/volume] urine in
105963-3,zolpidem phenyl-4-carb ur-mcnc
105963-3,zolpidem phenyl-4-carb ur-mcnc edluar
105963-3,zolpidem phenyl-4-carb ur-mcnc nytamel
105963-3,zolpidem phenyl-4-carboxylate (u) [mass/vol]
105963-3,damixan zlpidem [masl (u) henyl-4-carboxylate
105963-3,zolpidem phenyl4-carboxylate (u) [ass/vol]
22442-8,plasmodium malariae ab [titer] in serum
22442-8,plsmodium alaiae serum i ab[titer]
22442-8,serum point in time malariae ab [titer] in plasmodium
22442-8,p malariae ab titr ser
22442-8,p alariae b itr random serum
22442-8,p autoantibody alaiae ab titr ser
22442-8,p. malariae ab (s) [titer]
22442-8,p. malariae ab [titer] (s)
22442-8,p. malariae random ab (s) [titer]
20811-6,escherichia coli [presence] in specimen by culture fda method
20811-6,escherch random coli [presence] in specimen by clture da metho
20811-6,fda coli cult [presence] in specimen by culture escherichia method
20811-6,e coli spec ql cult fda
20811-6,e col pec ql cult qualitative fda
20811-6,e coli ec ql cult fda
20811-6,e. coli culture fda method ql (specimen)
20811-6,e. coli culture o002 fda method presence (specimen)
20811-6,e.cl culture da method presence (specimen)
26862-3,hydromorphone [mass/mass] in meconium
26862-3,in mas/mass] hydomorpone meconium
26862-3,hydromorphone [mass/mass] in meconium
26862-3,hydromorphone mec-mcnt
26862-3,hydromorphone illicit mec-mcnt
26862-3,hydromorphe mec-mcnt
26862-3,hydromorphone (mec) [mass/mass]
26862-3,[mass/mass] (mec) hydromorphone
26862-3,[mass/mass] quantitative hydromorphoneme)
7945-9,lassa virus igm ab [titer] in serum by immunofluorescence
7945-9,lassa virus igm ab [titer] in serum by immunofluorescence
7945-9,lassa virus igm microbiology ab [titer] in serum by immunofluorescence
7945-9,lasv igm titr ser if
7945-9,ser igmtit lasv if
7945-9,lasv igm titr serum i
7945-9,lassa virus igm if (s) [titer]
7945-9,assavirusigm (s)[titer] if
7945-9,lassa () igm if titer virus [ttr]
75063-8,glycerate [moles/volume] in serum or plasma
75063-8,glycerate oles/volume] in erum orlasma
75063-8,glycerate [moles/volume] in ser or quan plasma
75063-8,glycerate serpl-scnc
75063-8,point in time serpl-cnc glycerae
75063-8,serpl-scnc glycerate
75063-8,glycerate [moles/vol]
75063-8,[moles/vol] glycerate
75063-8,glceate[oles/vol]
43346-6,avian paramyxovirus 7 ab [titer] in serum
43346-6,avian pramyxovirus 7 ab [titer] in seu
43346-6,avian paramyxovirus [titer] ab 7 in serum
43346-6,apmv7 ab titr ser
43346-6,smqn ab apmv7 titr serum
43346-6,infectiousdisease apmv7 ab ser titr
43346-6,avian paramyxovirus 7 ab (s) [titer]
43346-6,avian 7 paramyxovirs titer ab (s)[titer]
43346-6,aianparayxovirus 7 ab apmv (s) [titer]
101783-9,fusarium oxysporum dna [presence] in specimen by naa with probe detection
101783-9,deoxyribonucleic acid fusariumysporum da [presenc] in speienby naa with probe dtectio
101783-9,fusarium oxysporum dna [presence] in specimen by ligation-activated transcription naa with probe detection
101783-9,f oxysporum dna spec ql naa+probe
101783-9,f oysporm dna spe q naa+proe
101783-9,f oxysporum dna ql spec naa+probe
101783-9,fusarium oxysporum dna naa+probe ql (specimen)
101783-9,fusarium oxysporuna naprobe qspecimen)
101783-9,fusarium oxysporum naa+probe dna ql (specimen)
6767-8,18-hydroxycorticosteroids [mass/volume] in serum
6767-8,18-oh-corticosteroids 18-hydroxycorticosteroids [mass/volume] in serum
6767-8,quantitative [mass/volme] 18-droxycortcosteroids in seru
6767-8,18oh-cs ser-mcnc
6767-8,18oh-cs serum-mcn
6767-8,ser-mcnc 18oh-cs
6767-8,18-hydroxycorticosteroids (s) [mass/vol]
6767-8,[massvol] quan 18-hydoxycorticostroidss)
6767-8,sr 18-hydroxycorticosteroids [mass/vol] (s)
38194-7,antidepressants [identifier] in gastric fluid
38194-7,antidepressants [identifier] in gastric fluid
38194-7,antidepressants [identifier] gastric point in time in fluid
38194-7,antidepressants gast
38194-7,antidepressants gast drugs of abuse
38194-7,gast antidepressants antidepres
38194-7,antidepressants nom (gast fld)
38194-7,antidepressants nom potentialforabuse (gast fld)
38194-7,antdepresans gast nom (gast fld)
7876-6,ehrlichia chaffeensis igm ab [presence] in serum
7876-6,ehlchia igm abs chaffensis ab [presece] i serum
7876-6,igm chffeensis ehrlichia ab [prsence] i ser antibody
7876-6,e chaffeensis igm ser ql
7876-6,e serum chaffeensisigm infectiousdisease l
7876-6,random e chaffeensis igm ser ql
7876-6,e. chaffeensis igm ql (s)
7876-6,e. serum chaffeensis igm ql (s)
7876-6,ig chaffeensis e ql (s) qual
105371-9,phenx - air quality index protocol 290101
105371-9,phex index quality panel.phenx -air protocol290101
105371-9,phenx - air index quality protocol 290101
105371-9,aqi proto 290101
105371-9,90101 aqiproto
105371-9,panel 29001 proto aqi
34176-8,tricyclic antidepressants [presence] in specimen
34176-8,specimen antideprssants [presence] in tricylic
34176-8,tricyclic antidepessnts in [presence] specin
34176-8,tricyclics spec ql
34176-8,other presence ticyclicsspec
34176-8,tricyclics drug/toxicology spec ql
34176-8,tricyclic antidepressants ql (specimen)
34176-8,tricyclicantidepressants ql (specimen
34176-8,antidepressants tricyclic ql (specimen) pr
54359-5,bicarbonate [moles/volume] in plasma --post dialysis
54359-5,ialysis n plasma --post bicarnate[mole/volume]
54359-5,bicar bicarboate moles/volume] n plasma --postdiaysis
54359-5,hco3 p dialysis plas-scnc
54359-5,plas-scnc pdialysis hco3
54359-5,dialysis p hco3 plas-scnc
54359-5,hco3 post dialysis (p) [moles/vol]
54359-5,hco3 dalysis post (p) [moles/vol]
54359-5,hco3 dialysis post (p) [moles/vol]
48080-6,"3,6-epoxyoctanedioate/creatinine [molar ratio] in urine"
48080-6,"3,6-epoxyoctanedioate/creatinine [molar ratio] in ur urine"
48080-6,"3,6-epoxyoctanedioate/creatinine in ratio] [molar urine"
48080-6,"3,6-epoxyoctanedioate/creat ur-srto"
48080-6,",6-poxyoctanedioate/cret r-srto"
48080-6,"ur-srto 3,-epoxyocanedioate/creat"
48080-6,"3,6-epoxyoctanedioate/creatinine (u) [molar ratio]"
48080-6,"(u) 3,6-epoxyoctanedioate/creatinine [molar ratio]"
48080-6,36-epoxyoctanedioatcrtinin (u) [molarratio]
32584-5,propionylglycine [presence] in urine
32584-5,[presence] propionylglycine in urine
32584-5,[presence] propionylglycine in urine
32584-5,propionylgly ur ql
32584-5,propionylgly ur presence
32584-5,pt ur ropionylly l
32584-5,propionylglycine ql (u)
32584-5,proonylglycine ql (u)
32584-5,(u) chemistry q proionyllycie
99409-5,acetaminophen-cysteine adduct [moles/volume] in serum or plasma by lc/ms/ms
99409-5,acetaminophen-cysteine adduct [moles/volume] in serplas ser or plasma by lc/ms/ms
99409-5,acetaminophen-cysteine adduct [moles/volume] in ser plasma or by lc/ms/ms
99409-5,apap-cysteine serpl lc/ms/ms-scnc
99409-5,serpl serplas apap-cysteine lc/ms/ms-scnc
99409-5,lc/ms/ms-scnc srpl appcystein
99409-5,acetaminophen-cysteine adduct lc/ms/ms [moles/vol]
99409-5,acetaminophen-cysteine adduct [moles/vol] lc/ms/ms
99409-5,acetaminophen-cysteine lc/ms/ms adduct [moles/vol]
58408-6,erythrocyte morphology panel - blood
58408-6,erythrocyte - panel morphology blood
58408-6,erythrocyte morphology panel - blood pnl
58408-6,rbc morphology pnl bld
58408-6,rbc pnl morphology bld
58408-6,rbc orphology l point in time bl
58408-6,rbc morphology panel (bld)
58408-6,rbc morphology panel (blood) hematology/cell counts
58408-6,rb pael mophlogy (bld)
9675-0,silicone iga ab [units/volume] in serum
9675-0,silicone iga ab [units/volume] in serum
9675-0,silicone iga ab [units/volume] in ser
9675-0,silicone iga ser-acnc
9675-0,siicoe ig ser-acnc
9675-0,silicone iga ser-acnc
9675-0,silicone iga qn (s)
9675-0,(s) iga qn antibody silicone
9675-0,(s igan ilicone autoantibodies
63279-4,mitochondria ab [presence] in cerebral spinal fluid by immunofluorescence
63279-4,mitochodria b [ql] in crebralspinal fluid byimmunofluesne
63279-4,mitochondri ab [ql] in erebral spnal flid by imunfluorecnc
63279-4,mitochondria ab csf ql if
63279-4,mitochondria aby ab cerebrospinal fluid ql if
63279-4,mitochondria ql ab csf ql if
63279-4,mitochondria ab if ql (csf)
63279-4,mitochondria ab ql if (cs)
63279-4,if ab itochondria (sf)
20844-7,avian infectious laryngotracheitis virus ag [presence] in lung tissue by immunofluorescence
20844-7,ia ifectious langtracetis vir a[resence] lug in tissue by immunofluorescece
20844-7,larygotracheitis nfectious avian virus ag [resen in ungissue by immunofluoscence
20844-7,ilt ag lung tiss ql if
20844-7,ilt ql lung tiss qual ag if
20844-7,ilt lung ag tiss ql if
20844-7,avian infectious laryngotracheitis virus ag if ql (lung tissue)
20844-7,avia infectios lrynorachiisvirus agif l(lun tisue)
20844-7,if lryngotacheitis virus ag aviannfetiu ql (lug tissue
97520-1,histoplasma capsulatum mycelial phase ab band pattern [identifier] in specimen by immune diffusion (id)
97520-1,hstoplasma capsulatum myclial hase ab an pater[identifier] in aby specien byimmne dffusion (id)
97520-1,histopasma cpsultum ycelial hase abband attern [identifier in specimenby immune diffusion (id
97520-1,h capsul myc ab patrn spec id
97520-1,h myc apsul ab infectious disease parnspec id
97520-1,spec capsul myc ab patrn h id
97520-1,h. capsulatum mycelial phase ab band pattern immune diff nom (specimen)
97520-1,h. capsulatum mycelial phase ab band pattern immune diff nom (specimen)
97520-1,ab capsulatum mycelial phase h. band pattern immune diff nom (specimen)
82990-3,3-hydroxy-3-methylglutaryl-coenzyme a reductase igg ab [presence] in serum or plasma by line blot
82990-3,3hyroxy-3-methylluaryl-coenzym a reductase igg  presence] i serum or asma by line blot
82990-3,3-hydroxy-3-methylglutaryl-coenzyme a reductase igg ab [presence] serum in or plasma by line blot
82990-3,hmgcr igg serpl ql line blot
82990-3,aby hmgcr ig spl line q blot
82990-3,hmgcr blot serpl ql line igg
82990-3,3-hydroxy-3-methylglutaryl-coenzyme a reductase igg line blot ql
82990-3,3-ydroxy-3-methylglutaryl-cenzme a redutase iggline ql antibodies blot
82990-3,3-hydroxy-3-methylglutaryl-coenzyme a reductase igg line sr blot ql
77378-8,human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna - specimen
77378-8,human papilloa virus 16and 18and 31+33+35+39+4+5+52+56+58+5+66+68 dna  specimen
77378-8,human papillmairus genital warts 16 and 18 and 31+3+35+39+45+5+52+5658+59+668 dna - secimen
77378-8,hpv16+18+h risk 12 dna pnl spec
77378-8,hpv16+18+h risk 12 dna spec pnl spec
77378-8,hpv16+18+h ris 12 dna misc pnl spec
77378-8,hpv 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna pnl (specimen)
77378-8,hpv 16 and 31+33+35+39+45+51+52+56+58+59+66+68 and 18 dna pnl (specimen)
77378-8,and 16 and 18 hpv 31+33+35+39+45+51+52+56+58+59+66+68 dna pnl (specimen)
73865-8,catecholamines 3 panel [moles/volume] - plasma
73865-8,catecolamines 3 panel [moles/volume] catecholamines 3 pnl - plama
73865-8,catecholamines 3panel [moles/volume] - pasma
73865-8,catecholamines 3 pnl plas-scnc
73865-8,catecholamines pnl 3 plas-scnc
73865-8,plasma-scnc 3 pnl catecholamines cate
73865-8,catecholamines 3 panel (p) [moles/vol]
73865-8,catecholamines 3 panel (p) [moles/vol]
73865-8,3 catec catechoamines panel(p) [mols/vol]
31530-9,neuronal ab [units/volume] in cerebral spinal fluid
31530-9,neronal a [units/vlu] i cerebral fluid pinal
31530-9,[units/volume] ab neuronal in cerebral spinal fluid
31530-9,neuronal ab csf-acnc
31530-9,neuronal csf-acnc b spinal flu
31530-9,cerebrospinal fluid-acnc neurology ab neuronal
31530-9,neuronal ab qn (csf)
31530-9,neuronal arbitrary concentration ab qn (csf)
31530-9,ab neuronal qn (csf)
5024-5,mycobacterium gordonae rrna [presence] in specimen by probe
5024-5,mycobacterium gordonae rrna [presence] specimen in by probe
5024-5,mycobacteriu gorae rrna [prsece] in ribosomal rna specin y prob
5024-5,m gordonae rrna spec ql probe
5024-5,m gordonae rrn spec qlrobe
5024-5,m l rrna pec gordonae afb obe
5024-5,m. gordonae rrna probe ql (specimen)
5024-5,(specimen) ordona rrn probe ql m. m gordonae
5024-5,m. robe rrna gordonae ql specimen)
61059-2,alpha-phenyl-2-piperidine acetate [presence] in specimen
61059-2,alpha-pheyl-2-iperidine actate[presence] in specimen
61059-2,[prsene] acetae alpha-phenyl-2-pipeidine in specimen ritalinic acid
61059-2,ppaa spec ql
61059-2,ql spec ppaa
61059-2,ethanoate ppaa sec q
61059-2,alpha-phenyl-2-piperidine acetate ql (specimen)
61059-2,alpha-phenyl-2-piperidine ql acetate (specimen)
61059-2,alpha-phenyl-2-piperidine ql acetate (specimen)
91874-8,mycoplasma genitalium dna [presence] in urethra by naa with probe detection
91874-8,mycoplasma genitalium dna [presence] mycoplasm in urethra by naa with probe detection
91874-8,mycplama with da [eence] urethra bynaa 3 self-sustaining sequence replication genitalium pobe etection
91874-8,m genitalium dna urth ql naa+probe
91874-8,m mycoplas genitalium dna urth ql naa+probe
91874-8,m genitalium dna ql urth naa+probe
91874-8,m. genitalium dna naa+probe ql (urethra)
91874-8,m. genitalium dna naa+proe ql (urethra)
91874-8,m. genialiumdna aa+prob ql (urethra
96568-1,toxocara sp igg ab [presence] in serum by immunoassay
96568-1,eia toxocara sp igg ab [presence] in ser by immunoassay
96568-1,[presence] sp igg ab toxocara in serum by immunoassay
96568-1,toxocara igg ser ql ia
96568-1,ql igg ser toxocara ia
96568-1,ser igg toxocara ql ia
96568-1,toxocara sp igg ia ql (s)
96568-1,toxocara sp igg ia ql (s)
96568-1,qual toxocara sp (s) ia ql igg
2303-6,fumarate [mass/volume] in urine
2303-6,fumarate [mass/volume] in urine
2303-6,fumarate urine in ua [mass/volume]
2303-6,fumarate ur-mcnc
2303-6,ur-mcnc urn fumarate
2303-6,quantitative ur-mcnc fumarate
2303-6,fumarate (u) [mass/vol]
2303-6,fumarate (u) point in time [mass/vol]
2303-6,[mass/vol] (u) chemistry fumarate
44523-9,histoplasma capsulatum igg ab [presence] in cerebral spinal fluid by immunoassay
44523-9,histoplasma capsulatum in ab [presence] igg cerebral spinal fluid by immunoassay
44523-9,histoplasma capsulatum igg fluid [presence] in cerebral spinal ab by immunoassay
44523-9,h capsul igg csf ql ia
44523-9,h ig capsu cs qlia
44523-9,h cerebrospinal fluid cerebral spinal fluid gg capsul ql ia
44523-9,h. capsulatum igg ia ql (csf)
44523-9,h. capsulatum igg ia ql (csf)
44523-9,h. capsulatum (csf) ia ql igg
73121-6,tetracycline induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73121-6,tetrcycline induced platelet ig ab [preece n seru or plasma y flow cometry anti (f
73121-6,tetracycline induced platelet igg ab [presence] in serum flow plasma by or cytometry (fc)
73121-6,tetracycline ind plt igg serpl ql fc
73121-6,tetracyclieid pl igg serum or plasma q fc
73121-6,tetracycline ind serpl igg platelets plt ql fc
73121-6,tetracycline induced platelet igg fc ql
73121-6,ql inuce pltelet igg fc autoantibodies tetrcycline
73121-6,tetracycline induced platelet ql fc igg
62542-6,deprecated phenx measure - alcohol - lifetime use
62542-6,deprecate phenx measure -coo -lifetime use
62542-6,panl deprecatephenx esur - alcohol- lifetimeuse
87832-2,fibroblast growth factor 21.intact [mass/volume] in serum or plasma
87832-2,fibroblast growth [mass/volume] 21.intact factor in serum or plasma
87832-2,fibroblas grwth fact 1.inact [mas/volum] in seum or pasma
87832-2,fgf-21.intact serpl-mcnc
87832-2,serp-mcn fgf-21.intact
87832-2,fgf-21.intac serpl-mcnc fact
87832-2,fibroblast growth factor 21.intact [mass/vol]
87832-2,fibroblast qnt growth factor 21.intact [mass/vol]
87832-2,firoblast groth factr 21.intact mass/vol
50060-3,fatty acids.very long chain c24:0 (tetracosanoate)/creatinine [molar ratio] in urine
50060-3,fty acs.very lng chain c24:0(teracosanoate/reatinine[molar raio nurine
50060-3,ftty acid.very log chan [olar c24:0(tetracosanoate)/creatinine rtio] chemistry in urine
50060-3,vlcfa c24:0/creat ur-srto
50060-3,c24:0/creat vlcfa ur-srto
50060-3,vlcfa c24:0/creat ur-srto vlc
50060-3,fatty acids.very long chain c24:0 (tetracosanoate)/creatinine (u) [molar ratio]
50060-3,c24:0 fatty chain long acids.very c24:0(tetracsanote)/reatiine (u) [moar rtio]
50060-3,fatty acids.very long chain c24:0 (tetracosanoate)/creatinine (u) [molar ratio]
101302-8,leptospira sp dna [presence] in blood by naa with non-probe detection
101302-8,leptospira sp dna [presence] in non-probe by naa with blood detection
101302-8,bld s dna presnce] in leptospir by na withnon-probe dtection
101302-8,leptospira dna bld ql naa+non-probe
101302-8,amplif leptospia dn bld l naa+non-pobe
101302-8,bld dna leptospira ql polymerase chain reaction naa+non-probe
101302-8,leptospira sp dna naa+non-probe ql (bld)
101302-8,leptospira sp dna tma naa+non-probe presence (bld)
101302-8,leptospira ligase chain reaction sp dna naa+non-probe ql (bld)
87218-4,rn asessment coordinator attestation of completion during assessment period [cms assessment]
87218-4,r asessment coordinato attstatio of coleton during ssessment pero [cms ssessme]
87218-4,rn asessment coordinator pan attestation period completion during assessment of [cms assessment]
95270-5,platelet and hla glycoprotein antibody panel - blood
95270-5,hla and platelet glycoprotein antibody panel - blood
95270-5,platelet antibody hla glycoprotein and panel glycoproteins - blood
95270-5,platelet + hla glycoprotein ab pnl bld
95270-5,lteet random ab ha glycprotein + plbld
95270-5,platelet + hla glycoprotein ab pnl bld
95270-5,platelet and hla glycoprotein antibody panel (bld)
95270-5,plelet whole bld and l glyoprotein antibody anel (bd)
95270-5,platelet glycoprotein hla and antibody panel (bld)
96892-5,covid-19 participant experience survey
96892-5,covid-19 experience participant survey
96892-5,expeencesurvey partiiant pnl covid-19
91771-6,influenza virus a subtype [identifier] in upper respiratory specimen by naa with probe detection
91771-6,influenza virus a subtype [identifier] upr rspirtory specime wit sda naa b prbe detection
91771-6,influenza virus a subtypedentifier] in upperrespiratory specimen b na with probe detection
91771-6,fluav subtyp upper resp naa+probe
91771-6,fluav subtyp upper resp naa+probe
91771-6,fluav subtyp upper probe with target amplification resp naa+probe
91771-6,fluav subtyp naa+probe nom (upper resp)
91771-6,fluav subtyp naa+proe m(upper esp)
91771-6,fluav (upper naa+probe nom subtyp resp)
33796-4,cotinine [moles/volume] in urine
33796-4,i cotnine[moles/volume] urine
33796-4,level cotinine [moles/volume] in urine
33796-4,cotinine ur-scnc
33796-4,quantitative r-scc cotinin
33796-4,ur-scnc cotinine
33796-4,cotinine (u) [moles/vol]
33796-4,(u) cotinine [moles/vol]
33796-4,quant (u) cotinine [moles/vol]
93744-1,htlv i and ii igg panel - cerebral spinal fluid
93744-1,htv i and igg ii htlv type 1+2 pael -cerebralspinal fluid
93744-1,hlv i htlv i+ii d i igg - panel cerebral spnal flid
93744-1,htlv i+ii igg pnl csf
93744-1,htlv i+ii igg pnl csf
93744-1,htlv pnl igg i+ii csf
93744-1,htlv i and ii igg panel (csf)
93744-1,human t-cell lymphotrophic virus panel i and ii igg htlv (csf)
93744-1,htlv i and ii spinal fld igg panel (csf)
73666-0,streptococcus.beta-hemolytic [type] in isolate by latex agglutination
73666-0,streptococcus.beta-emolyic agglutination in islae byatex [tye]
73666-0,streptococcus.beta-hemolytic [type] in agglutinton b ate isolate
73666-0,b-hem strep islt la
73666-0,la strep islt b-hem random
73666-0,b-hem strep islt la strept
73666-0,streptococcus.beta-hemolytic la nom (isol)
73666-0,streptococcus.beta-hemolytic la nom (isol)
73666-0,treptococus.beta-hemoyticlanom(iol) b-hem strep
12280-4,alanine [mass/volume] in amniotic fluid
12280-4,alanine [mass/volume] in fluid amniotic pt
12280-4,alanine amniotic amnio in [mass/volume] fluid
12280-4,alanine amn-mcnc
12280-4,alanine amn-mcnc
12280-4,alanine amn-mcnc
12280-4,alanine (amn fld) [mass/vol]
12280-4,alanine fld) (amn [mass/vol]
12280-4,(amn alanine fld) [mass/vol]
101158-4,flualprazolam [presence] in urine by confirmatory method
101158-4,flualprazolam [ql] in urine by confirmatory method
101158-4,flualprazolam [prence in rne by confirtory mhod
101158-4,flualprazolam ur ql cfm
101158-4,ur flualprazolam conf ql cfm
101158-4,ur flualprazolam q cfm
101158-4,flualprazolam confirm ql (u)
101158-4,screen flualprazolamonfirm ql (u)
101158-4,flualprazolam confirm presence (u)
52135-1,"t(9;22)(q34.1;q11)(abl1,bcr) transcript detection panel - blood or tissue by molecular genetics method"
52135-1,"transcript t(9;22)(q34.1;q11)(abl1,bcr) detection major breakpoints panel - bld or tissue by molecular genetics method"
52135-1,"panl t9;22)(q34.1;q11)(abl,bcr) transcript detectio panel - blood or tisse by molecula enetics method"
52135-1,"t(abl1,bcr) detect pnl bld/t"
52135-1,"bld/t detect pnl t(abl1,bcr)"
52135-1,"t(abl1,bcr) detect pnl blood/t"
52135-1,"t(9;22)(q34.1;q11)(abl1,bcr) transcript detection panel molgen (bld/tiss)"
52135-1,"t(9;22)(q34.1;q11)(abl1,bcr) transcript detection (bld/tiss) molgen panel"
52135-1,"jtk7 t(9;22)q34.1;q11)(abl1,bcr) transcript detection panel molgen (blood/tiss)"
31537-4,neuronal nuclear type 1 ab [units/volume] in cerebral spinal fluid
31537-4,in nuclear type 1 ab [units/volume] neuronal cerebral spinal fluid
31537-4,neuronal cerebral type 1 ab [units/volume] in nuclear spinal fluid
31537-4,hu1 ab csf-acnc
31537-4,hu1 ab cerebrospinal fluid-acnc
31537-4,spinal flu hu1 ab cerebrospinal fluid-acnc
31537-4,neuronal nuclear type 1 ab qn (csf)
31537-4,euonal nuclear ye 1 a qn (cerebrospinal fluid
31537-4,neuronl uclear (csf) 1 b q type
104702-6,rhinovirus+enterovirus rna [presence] in specimen by molecular genetics method
104702-6,rhinovirus+enterovirus rna resence] in peimn by spec moleclargenetic method
104702-6,rhinviu+enteovirus rna [presece] in mehod by olcular genetics specimn
104702-6,rv+ev rna spec ql
104702-6,rv+ev rna ql spec
104702-6,rna pcr rv+ev specql
104702-6,rhinovirus+enterovirus rna molgen ql (specimen)
104702-6,rhinovirus+enterovirus rna to be specified in another part of the message molgen ql (specimen)
104702-6,molgen rna rhinovirus+enterovirus ql (specimen)
20701-9,bluetongue virus ag [presence] in tissue by immunofluorescence
20701-9,bluetongue virus ag [presence] in tissue by immunofluorescence acif
20701-9,qualitative bluetongue virus ag [ql] immunofluorescence tissue by in
20701-9,btv ag tiss ql if
20701-9,btv if tiss q ordinal ag
20701-9,presence ag tiss btv if
20701-9,bluetongue virus ag if ql (tiss)
20701-9,bletngue virus agif presence (tiss)
20701-9,bluetongue virus ag ql(tis) if
44828-2,teriflunomide [mass/volume] in serum or plasma
44828-2,serp teriflunomide or in serum [mass/volume] plasma
44828-2,terflunomid mass/olum] in serum o plasma
44828-2,teriflunomide serpl-mcnc
44828-2,serpl-mcnc teriflunomide
44828-2,serpl-mcnc terifluomide
44828-2,teriflunomide [mass/vol]
44828-2,serum or plasma [mass/vol] teriflunomide
44828-2,sr teriflunomide [mass/vol]
23117-5,foot and mouth disease virus serotype [identifier] in serum by immunoassay
23117-5,foot and mouth diseasevirus sertype identiier] in srum byimmunoassay
23117-5,foot vet and mouth disease virus serotype [identifier] in ser by immunoassay
23117-5,fmdv sertyp ser ia
23117-5,ia sertyp ser serum fmdv
23117-5,fmdv sertyp ser ia
23117-5,foot and mouth disease virus serotype ia nom (s)
23117-5,foot virus isease admouth serotype ianom(s)
23117-5,foot and mouth dseae vrus ia serotpe nm (s)
5644-0,ethanol [presence] in urine
5644-0,ua ethanol [presence] in urine
5644-0,ethanol [presence] urine in
5644-0,ethanol ur ql
5644-0,ql hanolur
5644-0,ethanol screen ur ql
5644-0,ethanol ql (u)
5644-0,ql ethanol (u) urn
5644-0,ethanol (u) ql
40390-7,olanzapine [presence] in urine
40390-7,olanzapine [presence] in urine
40390-7,rine [presence] in olanzpne
40390-7,olanzapine ur ql
40390-7,olanzapine ur ql ql
40390-7,ur olanzapine ql
40390-7,olanzapine ql (u)
40390-7,ur olanzapine ql (u)
40390-7,oanzapin presence u)
50805-1,amitriptyline [moles/volume] in gastric fluid
50805-1,amitriptylene amitriptyline [moles/volume] in gastric fluid
50805-1,gastric in amitriptyline[moles/vlume] flid
50805-1,amitrip gast-scnc
50805-1,ast-scnc random amirip
50805-1,quan gas-scnc amitrip
50805-1,amitriptyline (gast fld) [moles/vol]
50805-1,amitriptylie d) (gast [mles/vol]
50805-1,amitriptline drugs fld) (gast [moles/ol]
53707-6,cv2 igg ab [presence] in cerebral spinal fluid by immunoblot
53707-6,cv2 igg ab [ql] in cerebral spinal fluid by immunoblot
53707-6,cv2 igg ab cerebral in [presence] spinal fluid by immunoblot
53707-6,cv2 igg csf ql ib
53707-6,wb cv2 igg csf ql ib
53707-6,ib igg csf ql cv2
53707-6,cv2 igg ib ql (csf)
53707-6,ql(csf) igg b v
53707-6,ulip cv2 (cerebrospinal fluid) ib ql igg
72821-2,creatinine [mass/time] by calculated in urine collected for unspecified duration
72821-2,reatinine [mas/tme] by calculated in urine collected or unspecified duration
72821-2,creatinine urine by calculated in [mass/time] collected for unspecified duration
72821-2,creat ?tm ur calc-mrate
72821-2,creat ?tm calc-mrate ur
72821-2,calc-mrate ?tm ur creat
72821-2,creatinine unsp time calc (u) [mass/time]
72821-2,creatnin unsp timecac mrate u) [mass/i]
72821-2,cratiin unp tm cac (u)[ms/time]
93020-6,polyclonal plasma cells/total plasma cells in bone marrow by flow cytometry (fc)
93020-6,cells/tota plasma point in time olyloal plasa cells in bone marrw y flo cytometry (fc)
93020-6,polyclonal plasma plasmacyte by plasma cellsin one marow cells/otal flow cytomery (fc)
93020-6,polyclonal pcs/total pcs nfr mar fc
93020-6,olyclonal pcsttal pc nfr ar fc
93020-6,polylonal pcs/tol mar pcs fc mar nfr
93020-6,polyclonal plasma cells/total plasma cells fc (bm)
93020-6,olyclonl plam plasmacytes cells/total plasa cels f (bm)
93020-6,polycloal cell plama plasmaells/totl fc bm) dynamic
62489-0,sulfate.inorganic [moles/time] in 24 hour urine
62489-0,sulfate.inorganic [moles/time] in 24 hour urine urn
62489-0,sufae.inorganic [oestime] in 24 hour urie
62489-0,inorg sulfate 24h ur-srate
62489-0,ur-srate sulfate 24h inorg
62489-0,24h sufate inorg ur-srate
62489-0,sulfate.inorganic (24h u) [moles/time]
62489-0,sulfat.inorganic substance rate (24h u) [moles/time]
62489-0,sulfae.inorganic (24hu) [moles/time]
15134-0,glutamate+glutamine+threonine [presence] in serum or plasma
15134-0,glutamate+lutamie+threonine in [presece] seru or plasma screen
15134-0,or [presece] pl i serum glutamate+ltamine+threonine plasma
15134-0,glu+gln+thr serpl ql
15134-0,g+gln+thr serl ql
15134-0,point in time glu+gln+thr ql serpl
15134-0,glutamate+glutamine+threonine ql
15134-0,presence glutmate+glutamin+treonine random
15134-0,ql glutamate+glutamine+threonine
96062-5,hedis my 2020 value set - bmi percentile
96062-5,hedis - 2020 value set my bmi percentile panel
96062-5,hedis my 2020 vale set - bmi pan perentil
96062-5,hedis my 2020 bmi prctl
96062-5,hedis prctl 2020 bmi my
96062-5,edis my2020 bm prctl
96062-5,hedis my 2020 value set - bmi percentile
96062-5,hedis my 020 value set bmi - rcentile
96062-5,my hedis 2020 value set - bm percentile
80548-1,sirolimus [mass/volume] in dbs
80548-1,sirolimus [as/volu] b in
80548-1,whole blood sirolimus [mass/volume] dbs in
80548-1,sirolimus dbs-mcnc
80548-1,srolmus dbs-mcnc
80548-1,quantitative irolimusdbs-mc
80548-1,sirolimus (dbs) [mass/vol]
80548-1,quant (dbs) irolimus [mas/vl]
80548-1,sirolimus(dbs) mass/vo]
43125-4,nicotine and metabolites panel [mass/volume] - urine
43125-4,niotin and metbolites panel [mass/vume] - urine
43125-4,icotie and metabolites panel [mass/volu] -urine
43125-4,nicotine+metab pnll ur-mcnc
43125-4,nicotine+metab ur-mcnc pnll
43125-4,nicotine+metab ur-mcnc pnll
43125-4,nicotine and metabolites panel (u) [mass/vol]
43125-4,icotine nd mtabolites (u) panel [mas/vol]
43125-4,nicoine [mass/vl] ur pael u) andmetabolites
38282-0,lymphocyte proliferation stimulated by 4.83 ug/ml tetanus toxoid [units/volume] in blood
38282-0,lymphcyte proifratio stmulatd by4.83 u/ml tetanus toxoid unitvolum] i blod
38282-0,lymphocyte proliferation stimulated whole blood by 4.83 ug/ml tetanus toxoid [units/volume] in blood
38282-0,lpt 4.83 ug/ml tt bld-acnc
38282-0,4.83u/ml lpt ttbd-acnc
38282-0,lpt 4.83 ug/ml stim tt bld-acnc
38282-0,lymphocyte proliferation stimulated by 4.83 ug/ml tetanus toxoid qn (bld)
38282-0,lymphocyte proliferation stimulated by 4.83 (blood) tetanus toxoid qn ug/ml
38282-0,lymphoyte qn simulaed by 4.83 ug/m tetanus oxoid prolieraton (bl)
49356-9,epstein barr virus dna [#/volume] (viral load) in tissue by naa with probe detection
49356-9,epstein barr by dna [#/volume] (viral load) in tissue virus absolutes naa with probe detection
49356-9,epstein barr virus dna [#/volume] (viral load) in tissue by viral load naa with probe detection
49356-9,ebv dna # tiss naa+probe
49356-9,evdna # tis naa+probe
49356-9,ebv dna # tiss naa+probe
49356-9,ebv dna naa+probe (tiss) [#/vol]
49356-9,bv dnanaa+pobe (tiss) [#vol]
49356-9,ebv dna naa+probe (tiss) lcr [#/vol]
44328-3,isocitrate [presence] in 24 hour urine
44328-3,iscitrte [pesence] i 24 hour urine
44328-3,pr isocitrate urine in24 hour [presece
44328-3,isocitrate 24h ur ql
44328-3,iocitrate ql 24h ur ql
44328-3,soctte 24h ur ql
44328-3,isocitrate ql (24h u)
44328-3,isocitrt u) (24h ql
44328-3,isocitrate ql screen (24h )
56686-9,hydroxyproline free/creatinine [ratio] in 24 hour urine
56686-9,hydroxyproline free/creatinine [ratio] 24 in hour urine
56686-9,uine fre/creatinine[raio] in 24 hou hydoxypoline hydrxyprln
56686-9,oh-proline free/creat 24h ur-rto
56686-9,oh-proline free/creat ur-rto 24h
56686-9,creat oh-proline free/creat 24h ur-rto
56686-9,hydroxyproline free/creatinine (24h u) [ratio]
56686-9,u) free/creatinine (24h qnt hydroxyproline [ratio]
56686-9,free/cetinine hydroxyproline (24 u) [ratio]
17749-3,tromethamine [mass/volume] in serum or plasma
17749-3,tromethamine [mass/volue] in ser orpasma
17749-3,or [mass/vlume] in srum tromethain plasma
17749-3,tromethamine serpl-mcnc
17749-3,serpl-mcnc tromethamine drugs
17749-3,tromethamineserpl-mnc
17749-3,tromethamine [mass/vol]
17749-3,tromehamine [msvol]
17749-3,tromethamine mass/vol]
41230-4,xanthine [presence] in specimen
41230-4,specimen [presence] in xanthine
41230-4,xanthine [ql] in specimen
41230-4,xanthine spec ql
41230-4,qual spec xanthine ql
41230-4,ql spec xanthine
41230-4,xanthine ql (specimen)
41230-4,xanthine ql (specimen)
41230-4,anthine spec qlspecimen)
31869-1,legionella pneumophila ag [presence] in sputum
31869-1,legionella neumphila g [presence] in spuu
31869-1,legionella [presence] ag pneumophila in sputum
31869-1,l pneumo ag spt ql
31869-1,point in time l ag pneumo spt ql
31869-1,l pneu pneumo presence spt ag
31869-1,l. pneumophila ag ql (sput)
31869-1,(sput) pneumophila ag ql l.
31869-1,l. pneumophila ag presence (sput)
47293-6,bacteria # 7 identified in genital specimen by aerobe culture
47293-6,bcteria #7 ientied id in genital specimen y aeobe culture
47293-6,genital # 7 idntified in bacteria speimenby aerbe clture
47293-6,bacteria genital aerobe cult org #7
47293-6,id bacteria #7 aerobe cult org genital
47293-6,bacteria genital #7 cult org aerobe
47293-6,bacteria identified # 7 aer cx nom (genital specimen)
47293-6,bacteria identified # 7 aer cx (genital nom specimen)
47293-6,bacteria identified # 7 id aer cx nom (genital specimen)
72364-3,lymphocytes/leukocytes in vitreous fluid by manual count
72364-3,ymphocytes/lukocytes in vitreous fluid white blood cell by manual coun
72364-3,lymhocytes/leukoctes by vitresflud in manual count lymp
72364-3,lymphocytes nfr vitf manual
72364-3,lymphocytes manual vitf nfr
72364-3,lymphocytes lympho nfr vitf manual
72364-3,lymphocytes/leukocytes manual cnt (vitr fld)
72364-3,lyphocyt/leukocytes manua cnt (ir hematology/cell counts fd)
72364-3,(vitr lymphs manual cnt lymphocytes/leukocytes fld)
72810-5,gabapentin [mass/volume] in urine by confirmatory method
72810-5,gabntin [mass/voume] in urieby confirmatory confimatoy method
72810-5,gabapentin in [mass/volume] qnt urine by confirmatory method
72810-5,gabapentin ur cfm-mcnc
72810-5,gabpentin ur cfm-mcnc
72810-5,gaapentn ur cfm-mcnc
72810-5,gabapentin confirm (u) [mass/vol]
72810-5,(u) confirm gabapentin [mass/vol]
72810-5,horizant gabpntin confirm (u [mas/vol
27436-5,n-desalkylflurazepam [mass/mass] in stool
27436-5,n-desalkylflurazepam [mass/mass] in stool
27436-5,-desalkyluaepam [masmass] stol
27436-5,desalkylfluraz stl-mcnt
27436-5,quantitative desalkylluraz tl-mcnt
27436-5,dslkylflraz stl-mcn stool = fecal
27436-5,n-desalkylflurazepam (stl) [mass/mass]
27436-5,n-desalkylflurazepam (stl) [mass/mass]
27436-5,[mass/mass] (stl) n-desalkylflurazepam
79486-7,"3,5-dihydroxybenzoate/creatinine [molar ratio] in urine"
79486-7,"3,5-dihydroxybenzoate/creatinine [molar ratio] in urine"
79486-7,"3,5-dihydroxybenzoate/creatinine [molar ratio] in urine"
79486-7,"3,5-dihydroxybenzoate/creat ur-srto"
79486-7,"ur-sto 3,5-dihyroxybenzoate/creat"
79486-7,"ucr 3,5-dihyroxybenzoate/creat ur-rto"
79486-7,"3,5-dihydroxybenzoate/creatinine (u) [molar ratio]"
79486-7,"3,5-dhroxybenzoate/creatinine (u) [molaratio]"
79486-7,"3,5-dihydroxybenzoate/creatinine (u) [molar ratio]"
72434-4,"4,5-dihydroxyhexanolactone [moles/volume] in serum or plasma"
72434-4,"serum 4,5-dihydroxyhexanolactone [mols/volm] in serum or plasm"
72434-4,"4,5-dihydroxyhexanolactone [moles/volume] in ser or plasma"
72434-4,"4,5-dioh-hexanolactone serpl-scnc"
72434-4,"4,5-dihydroxy-hexanoic acid lactone 4,5-dioh-hexanoactone serpl-scnc"
72434-4,"serpl-scnc 4,5-dioh-hexanolactone"
72434-4,"4,5-dihydroxyhexanolactone [moles/vol]"
72434-4,"quantitative 4,5-dihydroxyhexanolactone [moles/vol]"
72434-4,"[moles/vol] 4,5-dihydroxyhexanolactone"
62804-0,deprecated phenx measure - fasting serum insulin
62804-0,deprecated phenx - measure fasting serum insulin
62804-0,phenx deprecated measure - fasting serum insulin
27262-5,methaqualone [mass/mass] in meconium
27262-5,methaqualone meconium in [mass/mass]
27262-5,ethulon [mass/mass] drugs of abuse in menium
27262-5,methaqualone mec-mcnt
27262-5,methaqualone quantitative mecmcnt
27262-5,random methaqualone mec-mcnt
27262-5,methaqualone (mec) [mass/mass]
27262-5,methaqualoe (mec) [mass/mass]
27262-5,mehaqualon (me) [mass/mas] qnt
13466-8,lead/creatinine [mass ratio] in urine
13466-8,creat urine [mss ratio] in leadcreatinine
13466-8,[mass lead/creatinine ratio] in urine
13466-8,lead/creat ur
13466-8,ur lead/creat
13466-8,ua ur ledcret
13466-8,lead/creatinine (u) [mass ratio]
13466-8,[mass (u) cr lead/creatinine ratio]
13466-8,(u) lead/creatinine [mass ratio]
22374-3,deprecated la crosse virus igg ab [titer] in serum
22374-3,deprecated la crosse virus in ab [titer] dilution factor igg serum
22374-3,deprecated crosse aby la virus igg ab [titer] in ser
22374-3,deprecated lacv igg titr ser
22374-3,lacrosse virus lacv deprecated igg titr ser
22374-3,lacv deprecated ig tir ser titre
22374-3,la crosse virus igg (s) [titer]
22374-3,l rose vis igg (s titr]
22374-3,la (s) virus igg crosse [titer]
4114-5,amdinocillin [mass] of dose
4114-5,amdinocilin [mass] of dose
4114-5,amdinocillin [mass] of dose
4114-5,amdinocillin dose
4114-5,adinocilln dose dose med or substance
4114-5,dose amdinocillin
4114-5,amdinocillin (dose) [mass]
4114-5,mdinocillin (dose) mss]
4114-5,adinocillin [mass] (dose)
38730-8,"2,4,6-trichlorophenol [mass/volume] in air"
38730-8,"level 24,6-trichlrophenol [mass/volume] inair"
38730-8,"[mass/volume] 2,4,6-trichlorophenol in air 2,4,6-t"
38730-8,"2,4,6-tcp air-mcnc"
38730-8,"2,46-tcp air-mcnc"
38730-8,"2,4,6-tcp air-mcnc"
38730-8,"2,4,6-trichlorophenol (air) [mass/vol]"
38730-8,"2,4,6-trichlorophenol (air) ii [mass/vol]"
38730-8,"(air) 2,4,6-trichlorophenol [mass/vol]"
25084-5,2-oxoisocaproate/creatinine [molar ratio] in urine
25084-5,2-oxoiaproate/cretinine [molar atio] in cr rine
25084-5,2-oxoisocaprate/creanine [molar ratio] i urie
25084-5,2oxoisocaproate/creat ur-srto
25084-5,u-srto 2oxoiocaproat/creat
25084-5,2oxoisocaproate/creat ur-srto
25084-5,2-oxoisocaproate/creatinine (u) [molar ratio]
25084-5,2-oxoisocaproate/creatinine (u) [molar 2-oxoisocaproic acid ratio]
25084-5,[mor (u) 2oosocaprate/creatinine ratio] 2-keto-4-methylvalerate
49336-1,adenovirus dna [#/volume] (viral load) in bronchoalveolar lavage by naa with probe detection
49336-1,adenovirus dna [#/volue] (viral load) in bonchoaelar lage by n wit prbe dtection
49336-1,adenvrus da [#/volume] (vral load)  bronchoalveor lavageby aa with probe detecton
49336-1,hadv dna # bal naa+probe
49336-1,hadv dna # bal naa+probe ligation-activated transcription
49336-1,hadv dna count/volume # bal na+probe
49336-1,adenovirus dna naa+probe (bal) [#/vol]
49336-1,adenovirus dna (bal) naa+probe [#/vol]
49336-1,adenoviu [#/vol] naa+probe (bal) dna
73998-7,25h-nbome [presence] in urine by confirmatory method
73998-7,25-nbome by in urin [presnce] drug/toxicology confimatorymetd
73998-7,25h-nbome [presence] in urine by confirmatory method
73998-7,25h-nbome ur ql cfm
73998-7,25hnboe drug/toxicology ur q fm
73998-7,25h-nbome cfm qual ql ur
73998-7,25h-nbome confirm ql (u)
73998-7,25h-nbome cofirm ql (u)
73998-7,25h-nbome cnfirmql (u)
2292-1,formate [mass/volume] in serum or plasma
2292-1,formate in [mas/volum] serum or plasma qnt
2292-1,frmate [massvolum] in lsma r ser
2292-1,formate serpl-mcnc
2292-1,serpl-mcnc formate
2292-1,formate srpl-mcc
2292-1,formate [mass/vol]
2292-1,[mass/vol] formate
2292-1,forma [asvol
71145-7,pediatric - functional assessment of anorexia cachexia - parent_child questionnaire - version 1 (peds-faact - parent_child) [facit]
71145-7,pediatric - fnctinal assesent o anoreia achexi - parenchld quetionnaire - version 1 (peds-faat - pent_child [facit]
71145-7,ediatic pnl - untional - ofanorxia cahexia - parent_chld quesionnaire asessment ersion 1 pes-faact - parent_chd) fcit]
74682-6,trichloroethanol.free [mass/volume] in blood
74682-6,trichloroethanol.free [mass/volume] fr in blood
74682-6,[mass/volume] quantitative trichloroethanol.free in blood
74682-6,tcoh.free bld-mcnc
74682-6,bldmcnc tcoh.free tcoh.ree
74682-6,bld-mcn tcoh.fre
74682-6,trichloroethanol.free (bld) [mass/vol]
74682-6,(bld) trichloroethanol.free [mass/vol]
74682-6,(bld) trichloroethanol.free [mass/vol]
94359-7,glutamate decarboxylase 65 igg+igm ab [moles/volume] in cerebral spinal fluid by immunoassay
94359-7,glutaat decaboxylase 6 igg+igm ab pinal in cerebral [moles/voume fluiby mmunoassay
94359-7,glutamate decarboxylase 65 igg+igm ab [moles/volume] in cerebral spinal fluid by immunoassay
94359-7,gad65 igg+igm csf ia-scnc
94359-7,gad-65 gad65 igg+im i-cnc cerebrospinal fluid
94359-7,cerebrospinal fluid igg+igm gad65 ia-scnc eia
94359-7,glutamate decarboxylase 65 igg+igm ia (csf) [moles/vol]
94359-7,glutamate decarboxylase 65 igg+igm ia [moles/vol] (cerebrospinal fluid) spinal fl
94359-7,glutmate iaa dearboxylase 65 iggigmia (sf) [moles/vol]
94248-2,borrelia mayonii oppa2 gene [presence] in blood by naa with non-probe detection
94248-2,mayonii borrelia oppa2 gene [presence] in blood by naa with non-probe detection
94248-2,borelia amplif mayonii opa2 gene with in lood by naa [presnce] on-proe detectin
94248-2,b mayonii oppa2 bld ql naa+non-probe
94248-2,bmyonii bld ppa2 qlna+non-probe
94248-2,b myonii oppa2 bld ql naa+non-pobe
94248-2,b. mayonii oppa2 gene naa+non-probe ql (bld)
94248-2,b. mayonii ql oppa2 gene naa+non-probe ql (bld)
94248-2,b. naa+non-robe oppa2 gene mayonii presence (bld)
49424-5,papova virus sv 40 dna [#/volume] (viral load) in serum or plasma by naa with probe detection
49424-5,papova virus sv detctin /volume] (viralload) in serum or plasma b na with probe 40dna
49424-5,papova virus in 0 dna [volue] (viraload) sv ser or pasma b naa with probe detectio
49424-5,sv40 dna # serpl naa+probe
49424-5,sv-40 sv40 srp # a naa+probe
49424-5,sv40 dn serpl # na+robe
49424-5,papova virus sv 40 dna naa+probe [#/vol]
49424-5,papova 4 sv virus dna naa+proe [#/vo]
49424-5,papova quan vrus s 40 d naa+probe [#vol]
2500-7,iron binding capacity [mass/volume] in serum or plasma
2500-7,iron binding [mass/volume] capacity in ser or plasma
2500-7,iron binding capacity in [mass/volume] serum or plasma
2500-7,tibc serpl-mcnc
2500-7,serpl-mnc tibc
2500-7,serpl-mcnc tibc
2500-7,iron binding capacity [mass/vol]
2500-7,iron binding aacity [mas/vol]
2500-7,capacity binding iron [mass/vol]
30534-2,linoleoylcarnitine (c18:2) [moles/volume] in serum or plasma
30534-2,or (c18:2) [moles/volume] in ser linoleoylcarnitine plasma
30534-2,linoleoylcaritine (18:2)[moles/volume] in serumor plasma
30534-2,linoleoylcarn serpl-scnc
30534-2,serpl-scc linoleolcarn level
30534-2,linoleoylcarn erp-scnc
30534-2,c18:2 [moles/vol]
30534-2,c18:2 [moles/vol]
30534-2,c18:2[oles/o]
51612-0,sucrose [presence] in urine
51612-0,sose ql] i urine
51612-0,sucrose [preence] in point in time urine
51612-0,sucrose ur ql
51612-0,sucrose urql
51612-0,ucroseu pr presence
51612-0,sucrose ql (u)
51612-0,sucrose ql (u) ur
51612-0,sucrose ql ql (u)
73375-8,fluoxetine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73375-8,fluoxetine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc) anti
73375-8,fluoxetine induced platelet auto-antibodies platelet igg ab cytometry in serpl by flow [presence] (fc)
73375-8,fluoxetine ind plt igg serpl ql fc
73375-8,fluoxtine ind plt igg serpl ql fc
73375-8,fluoxetine ind plt igg fc ql serpl
73375-8,fluoxetine induced platelet igg fc ql
73375-8,pateleigg inuced luoxetne immune globulin g fcql
73375-8,fluoxetine induced platelet antibody igg fc ql
11592-3,aspergillus fumigatus 6 ab [presence] in serum
11592-3,aspergillus fumigatus 6 serum aspergil [presence] in ab
11592-3,id asprilus fumigatus 6 ab [presece] in serum
11592-3,a fumigatus6 ab ser ql
11592-3,a fumigaus6 farmers lung absel
11592-3,a fumigatus6 serum ab anti ql
11592-3,a. fumigatus 6 ab ql (s)
11592-3,a. 6ab fumigats ql (s)
11592-3,farmers lung a. fumigatus 6 ab presence (s)
11103-9,band form neutrophils/cells in bone marrow by manual count
11103-9,manual form nutrophils/cells in bne arrow by band count
11103-9,band form in bm neutrophils/cells bone marrow by manual count
11103-9,neuts band nfr mar manual
11103-9,minimal angle of resolution neuts band nfr mar manual
11103-9,band neuts nfr mar manual
11103-9,band form neutrophils/cells manual cnt (bm)
11103-9,and form anual neutrophils/cells cnt (bm)
11103-9,band orm netropils/cells pmn manual cnt (bm)
70890-9,additional concerns - fact-bmt [facit]
70890-9,additional - concerns fact-bmt survey.gnhlth [facit]
70890-9,addional concerns - cit functional assessment of chronic illness therapy fact-bmt
10672-4,helminth+arthropod identified in specimen
10672-4,maggot identifie helminth+arthopo in specimen
10672-4,fleas helminth+arthropod identified in specimen
10672-4,worm+insect spec
10672-4,worm+insect spec pt
10672-4,spec worm+insect
10672-4,helminth+arthropod identified nom (specimen)
10672-4,helmintharhrod identifed nom (spcmen)
10672-4,elminth+arthropod lice idenified nm(specien)
17392-2,osmium [mass/volume] in urine
17392-2,osmium [mass/volume] in urine
17392-2,in osmimass/vlume] urine
17392-2,osmium ur-mcnc
17392-2,ur-mcnc osmium
17392-2,osmiu u-mcnc
17392-2,osmium (u) [mass/vol]
17392-2,osmium (u) [mass/vol]
17392-2,osmium (u) [mass/vol]
6401-4,ehrlichia chaffeensis igg ab [presence] in serum by immunoassay
6401-4,ehrlichia haffensis igg serum [presnce in ab by immunossay
6401-4,ehrlichia chaffeensis igg in [presence] ab serum by immunoassay
6401-4,e chaffeensis igg ser ql ia
6401-4,chaffeensis e igg ser antibody q ia
6401-4,haffeensis e igg ser ql qual ia
6401-4,e. chaffeensis igg ia ql (s)
6401-4,e. (s) igg ia ql chaffeensis
6401-4,e. chaffeensis presence ia screen igg (s)
13155-7,deprecated streptococcus pneumoniae 14 ab [units/volume] in serum --1st specimen
13155-7,deprecaed streptococcus pemoniae14 ab [units/volume] in srum --1st specimen
13155-7,deprecated pneumoniae streptococcus 14 ser ab [units/volume] in ser --1st specimen
13155-7,deprecated s pneum14 ab sp1 ser-acnc
13155-7,ab infectious disease s pneum deprecated sp1 ser-anc
13155-7,spneu1 deprecated ab s1 ser-cnc
13155-7,s. pneumoniae 14 ab spec 1 qn (s)
13155-7,s.pneumoniae spec ab 14 1 qn () quantitative
13155-7,s. pneuonie 14 q spec 1 ab (s) antby
86152-6,streptococcus pneumoniae danish serotype 8 igg ab [mass/volume] in serum --1st specimen
86152-6,sreptococcus nemoniae danish serotpe 8 igg ab [mass/volue in ser -1st pcimen
86152-6,streptococcus pneumoniae danish serotype 8 igg ab [mass/volume] in serum --1st specimen
86152-6,s pneum da 8 igg sp1 ser-mcnc
86152-6,s pneum da sp1 igg 8 ser-mcnc
86152-6,s pneum da 8 igg ser-mcnc sp1
86152-6,s. pneumoniae danish type 8 igg spec 1 (s) [mass/vol]
86152-6,s. strep peumoniae danish tye 8 igg spe 1 s)mas/vol]
86152-6,s. s pneumo pneumoniae dnih tpe 8 g 1 spec (s) [mas/o]
55350-3,fenfluramine [presence] in urine
55350-3,fenfluramine in [ql] urine
55350-3,fenfluramine [ql] in pesos urine
55350-3,fenfluramine ur ql
55350-3,ql ur fenfluramine
55350-3,fenfluramine dima-fen ur presence
55350-3,fenfluramine ql (u)
55350-3,fenfluramine ql (u)
55350-3,fefuramine ql () ponderax
5744-8,thallium [mass/volume] in serum or plasma
5744-8,thallum r inseru [massvome] plasma quantitative
5744-8,thallium [mass/volume] plasma quantitative serum or in
5744-8,thallium serpl-mcnc
5744-8,thallium serpl-cnc mass concentration
5744-8,plasma serplmcnc thallium
5744-8,thallium [mass/vol]
5744-8,[mass/vol] serpl thallium
5744-8,thallium [mass/vol]
35191-6,bilirubin.direct [mass or moles/volume] in serum or plasma
35191-6,bilirbin.direct [mss o or in rum mole/volum] plasma
35191-6,bilirubin.diret in ormoles/volume] [mas ser or plasma
35191-6,bilirub direct serpl-mscnc
35191-6,associated bilirub serpl-mscnc direct
35191-6,dirtserpl-mscnc bilirub sr
35191-6,bilirubin.direct [mass or moles/vol]
35191-6,chemistry bilirubin.direct [mass or moles/vol]
35191-6,bilirubin.direct [mass moles/vol] or
20562-5,left ventricular stroke volume
20562-5,heart disease left vetriclar strok volume
20562-5,left ventricular toke olume heart disease
20562-5,lv sv
20562-5,quant lvsv
20562-5,lv sv lv
101422-4,human coronavirus oc43 rna [presence] in respiratory system specimen by naa with probe detection
101422-4,human coronavirus oc43 rna [presence] in respiratory system specimen corona virus by naa with probe detection
101422-4,human coronavirus oc43 rn presene] i rpiratory system pecmen by naawithprob detection
101422-4,hcov oc43 rna resp ql naa+probe
101422-4,o43 ligase chain reaction hcov rnaresp presence naa+robe
101422-4,hcov oc43 rnaresp ql aa+probe
101422-4,hcov oc43 rna naa+probe ql (respiratory system specimen)
101422-4,rna oc43 hco naa+probe ql (respiratory systm specimen)
101422-4,specimen) oc43 rna naa+probe ql (respiratory system hcov
14383-4,mononuclear cells/leukocytes in semen by manual count
14383-4,mononuclear cells/leukocytes in semen number fraction by manual count
14383-4,monoclercels/leukocyts in percent se by maual cont
14383-4,mononuc cells nfr smn manual
14383-4,mnouc cels gu nfr m nual
14383-4,cells ononu nr smnmanual
14383-4,mononuclear cells/leukocytes manual cnt (sem)
14383-4,monuclear cnt cells/leukoyesmanual sem)
14383-4,mononuclear cells/leukocyes mnual cnt (sem)
1371-4,bromsulphthalein [mass/volume] in serum or plasma
1371-4,bromsulhthlein plas inseum o [mass/volum]
1371-4,bromsulphthalein [mass/volume] plasma serum serum or in
1371-4,bromsulphthalein serpl-mcnc
1371-4,serplas bromsulphthalein serpl-mcnc
1371-4,serpl-mcnc bromsulphthalein
1371-4,bromsulphthalein [mass/vol]
1371-4,bomsulphhalein [mass/vol]
1371-4,plsm [mass/vol] bromsulphthalein
51616-1,hemoglobin a2+e/hemoglobin.total in blood
51616-1,hmoglobin 2+e/hemoglobin.ttal mass fraction blood in
51616-1,hmoglbin a2+e/hemolobin.tot in bood hb
51616-1,hgb a2+e mfr bld
51616-1,hgb a2+e mfr bld
51616-1,hgb a2+e mr wb bld
51616-1,hemoglobin a2+e (bld) [mass fraction]
51616-1,hemogobin a2+e bld) [mass fractio]
51616-1,hemoglobin a2+e (bld) [mass fraction]
44597-3,igg.monoclonal [presence] in serum by immunofixation
44597-3,igg.monoclonl [presence] n serum by immunofixation
44597-3,igg.onoclnal ordinal [presence] i serm by immunofixation
44597-3,m-igg ser ql ife
44597-3,m-gg ife screen presence ser
44597-3,m-igg ser pr ql ife
44597-3,igg.monoclonal immunofixation ql (s)
44597-3,igg.monoclonal immunofixation ql (s)
44597-3,immunoixatonql igg.monoconal (s)
46754-8,long chain hydroxy acyl dehydrogenase/trifunctional protein deficiencies newborn screen interpretation
46754-8,interpretation chain dehydrog hydroxy acyl dehydrogenase/trifunctional protein deficiencies newborn screen long
46754-8,long chain hydroxy acyl dehydrogenase/trifunctional protein deficiencies newborn screen interpretation
46754-8,lchadd/tfp dbs-imp
46754-8,dbs-imp lchadd/tfp interpretation
46754-8,dbs-imp lchadd/tfp
46754-8,long chain hydroxy acyl dehydrogenase/trifunctional protein deficiencies (dbs) [interp]
46754-8,long hain hydrox hdrxy acyl dehydrogenase/truntional protein deficiencies (bs) interp]
46754-8,long hydroxy chain acyl dehydrogenase/trifunctional protein deficiencies (dbs) [interp]
22201-8,chlamydia trachomatis g+f+k igg ab [titer] in serum
22201-8,chlamydia trachomatis g+f+k igg [titer] ab in serum
22201-8,chlamydia trachomatis g+f+k igg serum [titer] in ab
22201-8,c trach g+f+k igg titr ser
22201-8,c rach g+f+k ig titr se
22201-8,er g+f+ igg titr c trac cac
22201-8,c. trachomatis g+f+k igg (s) [titer]
22201-8,sr c. igg gf+k trhomat (s) [tter]
22201-8,c. trachomati gf+k igg () dilution factor (titer) [ter]
6613-4,haemophilus influenzae d ag [presence] in cerebral spinal fluid by immunofluorescence
6613-4,haemophilus inluenzae d a [presence]in by spinal flud cerebral immunofluorescence
6613-4,haemophilus influenzae d ag [presence] by cerebral spinal fluid in immunofluorescence
6613-4,haem influ d ag csf ql if
6613-4,haem inlu d ag q csf i
6613-4,hae influ agcsfql i
6613-4,h. influenzae d ag if ql (csf)
6613-4,ag inlena d h. if presence(cf)
6613-4,h. influenza d ag l if (sf)
49552-3,epinephrine+norepinephrine [mass/volume] in urine
49552-3,urine [mass/volume] in ur epinephrine+norepinephrine
49552-3,urie eppi [mass/vlum] in epinephrine+noreinehrine
49552-3,epineph+nor ur-mcnc
49552-3,ur-mcnc epneph+nor adrenaline
49552-3,epineph+nor ur-mcnc epi
49552-3,epinephrine+norepinephrine (u) [mass/vol]
49552-3,urn [mass/vol] einphrine+norepinephrine()
49552-3,[mass/vol] (u) epinephrine+norepinephrine
60481-9,hedis 2011-2013 codes to identify ldlc screening (cdc-h)
60481-9,asymptomatic 011-2013 hedis cods to identfy ldlcscreein(dch)
60481-9,identify 2011-2013 panel.hedis codes to hedis ldlc screening (cdc-h)
60481-9,hedis 2011-12 cdc-h
60481-9,hedis 2011-12 cdc-h
60481-9,hedis211-12cd-h
60481-9,hedis 2011-2013 codes to identify ldlc screening (cdc-h)
60481-9,hdis 011-2013codes t screening ldlc idetify (cdc-h)
60481-9,hedis 201-2013 ds to identifyldlcscrenin (cdc-h
32094-5,methanol [moles/volume] in specimen
32094-5,methanol [moles/volume] in specimen
32094-5,methanol [moes/volum in specime quant
32094-5,methanol spec-scnc
32094-5,meoh spec-scnc methnol
32094-5,spec-scnc methanol
32094-5,methanol (specimen) [moles/vol]
32094-5,methano (specimen) [oles/vol]
32094-5,substance concentration methanol (spcmen) [mols/vol]
93043-8,personal characteristics [prapare]
93043-8,personalharacteristics [praar]
93043-8,[prapar] random characteristics prsonal
100203-9,knee society score post-op panel [knee society score]
100203-9,knee society [knee post-op panel score society score]
100203-9,post-op society score knee panel [knee society score]
27033-0,proline [moles/volume] in amniotic fluid
27033-0,prolin [moes/volume] in amnioti flud
27033-0,proline [moles/volume] point in time in amniotic fluid
27033-0,proline amn-scnc
27033-0,proline mn-scnc amn
27033-0,am-scnc pro proline
27033-0,proline (amn fld) [moles/vol]
27033-0,(amn proline fld) [moles/vol]
27033-0,proline (amn [moles/vol] fld)
92947-1,streptococcus pyogenes dna [ncncrange] in bronchoalveolar lavage by naa with non-probe detection
92947-1,strpococcu pyogenes dna [ncnrange] in brnchoalveolr lavage ncncrng by naa with non-proe detecton
92947-1,streptococcus pogenes aa in brnchoalveolarlavage b dnancncrng with non-probe detection
92947-1,s pyo dna bal naa+non-prb-ncncrng
92947-1,s pyo group a strep dna bal naa+non-prb-ncncrng
92947-1,s pyo dna naa+non-prb-ncncrng bal
92947-1,s. pyogenes dna naa+non-probe (bal) [ncncrange]
92947-1,s. pyogenes group a strep dna naa+non-probe (bal) [ncncrange]
92947-1,s. pyogenes dna probe with ampification naaon-probe(bl) [ncnnge]
62958-4,deprecated phenx measure - colorectal procedures and outcomes
62958-4,eprecate phenx masure procedures -coloctal and outcomes
62958-4,deprecated phenx measure and colorectal point in time procedures - outcomes
33899-6,bilirubin.conjugated+indirect [moles/volume] in serum or plasma
33899-6,bilirubin.conjugated+idirect [moles/volume] in pasma serp or serum
33899-6,bilirubin.conjugated+indirect [moles/volume] in serpl
33899-6,bilirub conj+unconj serpl-scnc
33899-6,onj+unnjserpl-scnc bilirub serpl
33899-6,bilirub serpl-scnc conj+unconj
33899-6,bilirubin.conjugated+indirect [moles/vol]
33899-6,bilirubin.conjugated+indirect bilirubin glucuronides [moles/vol]
33899-6,[moles/vol] bilirubn.onjugated+indirect
44826-6,hepatitis d virus igm ab [units/volume] in serum by immunoassay
44826-6,hepatitis d virus igm ab [units/volume] in serum immunoassay by
44826-6,by d iru igm a[units/volume] in serum hepatitis immunoassy
44826-6,hdv igm ser ia-acnc
44826-6,ser igm hdv ia-acnc
44826-6,quant ia-acnc gm ser hdv
44826-6,hdv igm ia qn (s)
44826-6,qn igm ia hdv (s)
44826-6,hdv igm ia qn () sr
99096-0,mycoplasma pneumoniae dna [presence] in cerebral spinal fluid by naa with probe detection
99096-0,mycoplasma pneumoniae dna [ql] by cerebral spinal fluid in naa with probe detection
99096-0,mycoplasma pneumoniae myco dna [presence] in cerebral spinal fluid by naa with probe detection
99096-0,m pneumo dna csf ql naa+probe
99096-0,m pneumo dna csf naa+probe ql
99096-0,pneumo m dna m pneumo csf ql naa+probe
99096-0,m. pneumoniae dna naa+probe ql (csf)
99096-0,m. pneumoniae dna ql naa+probe (cerebrospinal fluid)
99096-0,m pneumonia naa+probe dna ql myco (csf)
80596-0,rhinovirus 5' utr rna [presence] in nasopharynx by naa with probe detection
80596-0,by 5' ut rna [presence]innasopharynx rhiovirs naawithprbe deection
80596-0,rhinovirus 5' utr rna [ql] in nasopharynx by naa with probe detection
80596-0,rhinovirus 5' utr rna nph ql naa+probe
80596-0,rhinovirus 5' utr rna naa+probe presence nph
80596-0,rinvirus 5' utr rna np l na+prob qbr
80596-0,rhinovirus 5' utr rna naa+probe ql (nph)
80596-0,utr 5' rhinovirus rna naa+probe presence (nph)
80596-0,rhinovirus 5' utr ql naa+probe rna (nph)
96322-3,klebsiella oxytoca dna [ncncrange] in lower respiratory specimen by naa with non-probe detection
96322-3,klebsiella oxtoca dna with in lower respirtory ecmen by naa ncnre] non-robedetecton
96322-3,klebsiella oxytca specien [ncncrange] in lower respiratory n by n with non-probe dtection ligase chain reaction
96322-3,k oxytoca dna l resp naa+non-prb-ncncrng
96322-3,k oxyc na amplified resp naa+nonprb-ncncrn
96322-3,k oytoa dna l resp naa+nonprbncncrng
96322-3,k. oxytoca dna naa+non-probe (lower resp) [ncncrange]
96322-3,k. oxytoca random dna naa+non-probe (lower resp) [ncncrange]
96322-3,k. oxytoca random d naa+nn-probe sp) (loer [ncncrange]
35634-5,secobarbital [mass/volume] in serum or plasma by screen method
35634-5,secoarbital [mass/olume] in scren orplasma by rm method
35634-5,secobarbital [mass/volume] in ser or plasma by screen method
35634-5,secobarbital serpl scn-mcnc
35634-5,plasma secobarbital serpl scn-mcnc
35634-5,ecobarbital serplscn-mcnc quan
35634-5,secobarbital screen [mass/vol]
35634-5,qnt secobarbital screen [mass/vol]
35634-5,secobarbital scren[mass/vol] addiction
53451-1,uracil arabinoside [mass/volume] in serum or plasma
53451-1,or arabinoside [mass/volume] in serum level uracil plasma
53451-1,uracilaabinoside serpl [mass/volum] serum in or plasa
53451-1,uracil arabinoside serpl-mcnc
53451-1,serum rcl rabinoside serum or plasma-mc
53451-1,uracil arabinoide serum or plasma-cnc
53451-1,uracil arabinoside [mass/vol]
53451-1,uracil arabinoside [mass/vol] plasma
53451-1,arabinoside uracil [mass/vol]
6523-5,rabies virus neutralizing antibody [units/volume] in cerebral spinal fluid by neutralization test
6523-5,rabies virus cerebral antibody [units/volume] in neutralizing spinal fld spinal fluid by neutralization test
6523-5,rabies virusneuralizng anibody [units/volume] in cerebral sinal fuid by neutraliaton test
6523-5,rabv nab csf nt-acnc
6523-5,rabv nt-n csf nab
6523-5,antby rabv nab csf nt-acnc
6523-5,rabies virus neut ab neut test qn (csf)
6523-5,rabies virus (cerebrospinal fluid) ab neut test qn neut point in time
6523-5,rabies virus neut ab neut test n (cerebrospinal fluid)
42181-8,myocardium ab [presence] in serum by immunofluorescence
42181-8,myocardium immunofluorescence [presence] in serum acif by ab
42181-8,myocardium ab [presence] in serum point in time by immunofluorescence
42181-8,myocardium ab ser ql if
42181-8,myocardium ab serum ql if
42181-8,myocardium ab ser fluoresent ql if
42181-8,myocardium ab if ql (s)
42181-8,myocardium ab (s) ifql
42181-8,ifa q ab if mocadium (s)
49377-5,hepatitis c virus rna [units/volume] (viral load) in cerebral spinal fluid by naa with probe detection
49377-5,heptits ligase chain reaction c virus with [unitsvolume] (viral lod)in cerebral spinalfluid by na rn probe detection
49377-5,hepatitis c virus rna [units/volume] (vira load)in cerebral spnal luid by naa hep wth pobe detection
49377-5,hcv rna csf naa+probe-acnc
49377-5,hv rna csfnaa+prb-acnc amplified
49377-5,hcv rna cerebrospinal fluid naa+probe-acnc amplification
49377-5,hcv rna naa+probe qn (csf)
49377-5,quantitative hcv rna naaroeqn (sf)
49377-5,hcv naa+probe rna qn (csf)
79152-5,acenocoumarol [mass/volume] in body fluid
79152-5,acenocoumarol fluid in body [mass/volume]
79152-5,acenocoumarol drugs [mass/volume] in body fluid
79152-5,acenocoumarol fld-mcnc
79152-5,acenocoumarol random fld-mcnc
79152-5,fld-mcnc acenocoumarol
79152-5,acenocoumarol (body fld) [mass/vol]
79152-5,aenocoumarol (body fl) [mass/v]
79152-5,acenocoumarol (body fld) [mass/vol]
74326-0,mica*036 igg ab [presence] in serum
74326-0,mica*03igg a[ql] in serum
74326-0,igg mica*036 ab ql [presence] in ser
74326-0,mica*036 igg ser ql
74326-0,mica*03 ig ser ql
74326-0,mica*036 ser igg serology ql
74326-0,mica*036 igg ql (s)
74326-0,mica*036gg ql () major histocompatibility complex class i chain-related antigen a
74326-0,mica*036 (s) ql igg
72133-2,montreal cognitive assessment [moca]
72133-2,montreal cognitive [moca] assessment
72133-2,montreal cognitive [moca] assessment point in time
13063-3,drug induced platelet ab [units/volume] in serum
13063-3,drug induced platelet ab [units/volume] autoantibody in ser
13063-3,drug inducd latelt ab[units/vlume] n serm
13063-3,drug ind plt ab ser-acnc
13063-3,drug ind ser-acnc ab plt aby
13063-3,drug ind plt antibodies ab serum-acnc
13063-3,drug induced platelet ab qn (s)
13063-3,(s) inuced antibodies platlet a qn drug
13063-3,dg inducedplatelt qn ab serology (s)
27417-5,candida sp iga ab [units/volume] in serum by immunoassay
27417-5,candida sp by ab [unt/volumein serum iga mmnoassay
27417-5,canida spiga ab [unitsvolme] in thrush serum y immunoassay
27417-5,candida iga ser ia-acnc
27417-5,candida iga quant ia-acnc ser
27417-5,cndida ia ser pt a-acnc
27417-5,candida sp iga ia qn (s)
27417-5,candida iga sp ia qn (s)
27417-5,candida sp iga ia qn (s) quantitative
105539-1,p-fluoro cyclopropyl fentanyl [mass/volume] in urine
105539-1,p-fluoro cyclopropyl fentanyl [mass/volume] duragesic in urine
105539-1,p-fluoro [mass/volume] fentanyl cyclopropyl actiq in urine
105539-1,p-fluoro cyclopropyl fentanyl ur-mcnc
105539-1,cycloprpl p-fluoro drugs fentyl ur-mcnc
105539-1,fentanyl cyclopropyl p-fluoro ur-mcnc
105539-1,p-fluoro cyclopropyl fentanyl (u) [mass/vol]
105539-1,p-fluoro cyclopropyl fentanyl (u) [mass/vol]
105539-1,p-fluoro cyclopropyl quan fentanyl (u) [mass/vol]
14848-6,neutrophils/leukocytes in pleural fluid by manual count
14848-6,neutrophils/leukocye by pleua fluid in manua count
14848-6,neutrophils/leukocytes in pleural pmn fluid by manual count
14848-6,neutrophils nfr plr manual
14848-6,nfr neutrophils plr manual
14848-6,neutropis fr neutr manua plr
14848-6,neutrophils/leukocytes manual cnt (pleur fld)
14848-6,cnt manual neutrohs/lekcytes neut (peur fld)
14848-6,neutrophils/leukocytes manual cnt random (pleur fld)
2073-5,chloride [moles/volume] in red blood cells
2073-5,chloide blodcells in red [mes/vlume]
2073-5,level chloride [moles/volum] in ed blodcells
2073-5,chloride rbc-scnc
2073-5,rbc-scnc chloride
2073-5,cl chlride rbc-snc
2073-5,chloride (rbc) [moles/vol]
2073-5,[moles/vol] (rb) chloide
2073-5,chloride(rc [moles/ol]
51385-3,plasma cells/leukocytes in cerebral spinal fluid by manual count
51385-3,plasmcells/leukcyts in cerbral sil fluid by white blood cells manual count
51385-3,plasma cells/leukocytes spinal cerebral in fluid by manual count
51385-3,plasma cells nfr csf manual
51385-3,plasma nfr cells cerebrospinal fluid cell manual
51385-3,nfr cells plasma csf manual quant
51385-3,plasma cells/leukocytes manual cnt (csf)
51385-3,plasma manual cells/leukocytes cnt (csf) number fraction
51385-3,plasma cells/leukocytes manual cnt (csf) quan
13618-4,tetrahydroaldosterone [mass/time] in 24 hour urine
13618-4,tetrahydroaldosterone in [mass/time] 24 hour urine
13618-4,tetrahydroaldosterone [mass/time] in 24 hour urine quant
13618-4,thaldost 24h ur-mrate
13618-4,ur-mrate mrate thaldost24h
13618-4,24h thaldost ur-mrate
13618-4,tetrahydroaldosterone (24h u) [mass/time]
13618-4,tetrahydroaldosterone mrate (24h [mass/time] u)
13618-4,chemistry tetrahydroaldosterone (24h u) [mass/time]
14556-5,mycobacterium tuberculosis dna [presence] in sputum by naa with probe detection
14556-5,mycobacterum tberculosi dna [presece in sda sputum probe naa with y detection
14556-5,mycobacterium tuberculosis dna [ql] in sputum by naa with probe detection
14556-5,m tb dna spt ql naa+probe
14556-5,naa+probe tb dna lung spt ql m
14556-5,mt ql spt dna naa+probe
14556-5,m. tuberculosis dna naa+probe ql (sput)
14556-5,m. tubeculosis na na+pobe l (ut)
14556-5,m. turculossdnaa+prob ql (sput
54468-4,cholesterol in hdl 2b/cholesterol in total hdl in serum or plasma by electrophoresis
54468-4,holesterolin hdl 2b/holesterol seumor total hdl in in high density lipoprotein cholesterols plsma by lectrphoris
54468-4,2b/cholesterol in hdl cholesterol in total hdl in serum or plasma by electrophoresis
54468-4,hdlc 2b mfr serpl elph
54468-4,mfr 2b hdlc serpl elph
54468-4,hdlc serpl mfr 2b elph
54468-4,cholesterol in hdl 2b/cholesterol in total hdl elph [mass fraction]
54468-4,coleserol choles in hl 2b/colesterol in total hdlelph [massfaction]
54468-4,cholesterol hdl in 2b/cholesterol in total hdl elph [mass fraction]
21595-4,varicella zoster virus igg ab [titer] in cerebral spinal fluid by immunofluorescence
21595-4,varicella oster spinal fld virus ig b [titer] cerebra in sinalfluid b immunoluorecence
21595-4,varicella zoster virus igg ab [titer] smqn in cerebral spinal fluid by immunofluorescence
21595-4,vzv igg titr csf if
21595-4,vv ig titr sf if
21595-4,vzv ig titr cerebrospinal fl cfif
21595-4,vzv igg if (csf) [titer]
21595-4,vzv i igg (cerebrospinal fluid) [titer] fluoresent
21595-4,vzv immune fluorescence igg if (csf) [titer]
34396-2,11-ketoetiocholanolone/creatinine [molar ratio] in urine
34396-2,11-ketoetiocolanolne/creatinine urne ato] i [molr
34396-2,11-ketoetiocholanolone/creatinine [molar ratio] in urine quantitative
34396-2,11ketoetioch/creat ur-srto
34396-2,ur-srto 11ketoetioch/creat
34396-2,ur-srto substance concentration ratio 11ketoetioch/creat
34396-2,11-ketoetiocholanolone/creatinine (u) [molar ratio]
34396-2,11-ketoetiocholanolone/creatinine quan (u) [molar ratio]
34396-2,11-ketoetiocholanolone/creatinine ratio] [molar point in time (u)
101680-7,neonatal aborh and ab antibody panel - blood from newborn
101680-7,neonatal aborh and antibody ab panel - blood from newborn
101680-7,neonatal aborh and blood bank ab - panel antibody blood from newborn
101680-7,nasr bld nb
101680-7,nb nasr nb bld
101680-7,blood nasr new born nb
101680-7,neonatal aborh and ab antibody panel (bld newborn)
101680-7,neonatal aor and ab ewborn) panl blood anibdy
101680-7,neonatal aborh and ab antibody panel (blood newborn)
95830-6,hematopoietic progenitor cell product characterization panel - blood product unit by flow cytometry (fc)
95830-6,hematopoietic progenitor cll produc charcterization ane - blood panel.bloodbank prductunitby flow cytometry(fc)
95830-6,hematopoietic progenitor cell product characterization panel (fc) blood product unit by flow cytometry -
95830-6,hpc product panel bpu fc
95830-6,hpc panel product bpu fc
95830-6,panel product hpc bpu fc
95830-6,hematopoietic progenitor cell product characterization panel fc (bpu)
95830-6,fc emaopoieic progenitor cell product characterization panel f (bpu)
95830-6,hematpoitic progenitor e rout characteriztion panel fc (bp)
15201-7,platelets large fragments [#/volume] in blood by manual count
15201-7,platelets # large fragments [#/volume] in blood by manual count
15201-7,manul lrge ragent platelt [#/volume] i bloodby platelets count
15201-7,platelets lg frg # bld manual
15201-7,plateletslgrg # maal bl fragment
15201-7,platelets lg frg # bld manual absolutes
15201-7,platelets large fragments manual cnt (bld) [#/vol]
15201-7,platelets large fragments manual cnt (bld) absolute [#/vol]
15201-7,framents large platelt mnual cnt (bld) platelet [#/vol]
86502-2,varicella zoster virus strain dna [type] in specimen by naa with probe detection
86502-2,varicella virus zoster strain dna [type] in specimen by naa with probe detection
86502-2,variell zster irus strain dna [type] in specmen by aa wit prb detection
86502-2,vzv strain dna spec naa+probe
86502-2,vzv strain spec dna naa+probe
86502-2,naa+probe strain dna spec vzv unspecified
86502-2,vzv strain dna naa+probe nom (specimen)
86502-2,deoxyribonucleic acid strain vzv dna naa+probe nom (specimen)
86502-2,v sran (specimen) nom vzv strain nana+proe
62588-9,phenx - oral health - fluoride use protocol 080601
62588-9,phenx - orl health - fluoride use protocol 08061 random
62588-9,oral phen health luorideuse protoco 080601 panel.phenx
62588-9,oral fluoride use proto
62588-9,olfluordeuse prt oral fluoride use proto
62588-9,oral fluoride use proto random
77755-7,6-monoacetylmorphine (6-mam) cutoff [mass/volume] in saliva (oral fluid) for confirmatory method
77755-7,6-monoacetylmorphine (6-mam) cutoff [mass/volume] in for (oral fluid) saliva confirmatory method
77755-7,6-monoaetylmorhne 6-ma) cutof [mas/volume] insaliva (oral fluid) forconfirmatory ethod
77755-7,6mam cto sal cfm-mcnc
77755-7,6-acetylmorphine 6am cto al fm-mcnc
77755-7,6 mam 6mam cto sal cfm-mcnc
77755-7,6-monoacetylmorphine (6-mam) cutoff confirm (sal) [mass/vol]
77755-7,6-mnoacetylorphine (6-mam cutoff onfir (sal) [masvol
77755-7,6-monoacetylmorphine (6-mam) cutoff confirm [mass/vol] (sal)
76464-7,american physical therapy association registry panel
76464-7,apta registry panel therapy physical american association rgiry panel
76464-7,ameian phyical associationregitry panl therapy pane
76464-7,apta registry panel
76464-7,apta registry pnl panel
76464-7,registry apta panel
88926-1,histoplasma capsulatum dna [presence] in tissue by naa with probe detection
88926-1,[presenc] apsulatum da histoplasma in tissue by naa wit prob detecion
88926-1,"histoplasma capsulatum tissue, unspecified dna [presence] in tissue by naa with probe detection"
88926-1,h capsul dna tiss ql naa+probe
88926-1,h capul dna tiss presence naa+probe
88926-1,h capsul dna tiss presence naa+probe
88926-1,h. capsulatum dna naa+probe ql (tiss)
88926-1,h. capsulatum dna naa+probe ql (tiss) histo
88926-1,id h. (tiss) dna naa+probe ql capsulatum
43828-3,benzodiazepines [presence] in specimen
43828-3,n benzodiazepies[preenc] specien
43828-3,benzodiazepines random [ql ispecimen
43828-3,benzodiaz spec ql
43828-3,spec benzodiaz spe ql
43828-3,benzodiaz ql spec
43828-3,benzodiazepines ql (specimen)
43828-3,benzodiazepines (specimen) pr ql
43828-3,(specimen) qualitative ql benzodiazepines
41029-0,listeria monocytogenes h1 ab [titer] in serum
41029-0,lsteri monocytogenes 1 ab [titer serum i
41029-0,listeria monocytogenes h1 ab [titer] serum in
41029-0,l monocytog.h1 ab titr ser
41029-0,l monocytog.h1 ab titr ser antibody
41029-0,l monocytog.h1 ab titr ser dilution factor (titer)
41029-0,l. monocytogenes h1 ab (s) [titer]
41029-0,moncygenes 1 ab sr (s) [tier]
41029-0,l. monocytogenes h1 ab (s) [titer]
79273-9,3-hydroxytrimethyl-l-lysine/trimethyllysine [molar ratio] in dbs
79273-9,3-hydroxytrimethyl-l-lysine/trimethyllysine substance concentration ratio [molar ratio] in dbs
79273-9,3-hydroxytrimethyl-l-lysine/trimethyllysine [molar ratio] in levo dbs
79273-9,3oh-trimethyl-l-lysine/tml dbs-srto
79273-9,3oh-trimethy-llysine/tl bs-sto
79273-9,dbs-srto 3oh-trimethyl-l-lysinetml
79273-9,3-hydroxytrimethyl-l-lysine/trimethyllysine (dbs) [molar ratio]
79273-9,atio] 3-hyroytrimethyl--lysine/trimethyllysine(dbs)[molar
79273-9,3-hydroxytrimethyl-l-lysinetrimehyllyie (db) [molar quantitative rtio
13729-9,deoxypyridinoline/creatinine [mass ratio] in urine
13729-9,deoxypyridnoline/creatinine [mass ratio] i urin
13729-9,free lysly-pyridinoline deoxypyridinoline/creatinine [mass ratio] in urine
13729-9,dpd/creat ur
13729-9,urn dpd/creat ur
13729-9,ur dpd/creat
13729-9,deoxypyridinoline/creatinine (u) [mass ratio]
13729-9,mass ratio (u) dexypyriinoline/creatinine [mass ratio]
13729-9,deoxypyridinoline/creatinine (u) [mass crea ratio]
26631-2,borrelia hermsii ab [presence] in serum
26631-2,presence] hermsii a borrelia in serum antby
26631-2,orreliahersii ser [resence] in antibody ab
26631-2,b hermsii ab ser ql
26631-2,b hermsii sr ab presence
26631-2,ql hermsii a er b
26631-2,b. hermsii ab ql (s)
26631-2,b. hrmsi ab ql (s)
26631-2,b. (s ab ql hermsii b hermsii
72619-0,norpropoxyphene [mass/volume] in saliva (oral fluid)
72619-0,norpropoxyphene (oral in saliva [mass/volume] fluid)
72619-0,norpropoxyphene [mass/volume] in oral fluid saliva (oral fluid)
72619-0,norpropoxyph sal-mcnc
72619-0,sal sal-mcnc norpropoxyph
72619-0,drugs norprpoph sal-mcnc
72619-0,norpropoxyphene (sal) [mass/vol]
72619-0,opropoxyphene (sal)[mass/vol]
72619-0,norproxphee [mass/vol] (sal)
101808-4,xylazine [mass/volume] in urine by confirmatory method
101808-4,xylzine i [mass/volume] uriney confirmator ethod
101808-4,xylazine in [mas/volume] urine by conimatorymethod
101808-4,xylazine ur cfm-mcnc
101808-4,xylazine cfm-mcnc ur
101808-4,ur xylazine ur c-mnc
101808-4,xylazine confirm (u) [mass/vol]
101808-4,xylazine [masvol] (u) confirm
101808-4,[mass/vol] confirm (u) xylazine
42530-6,smooth muscle ab [titer] in cerebral spinal fluid
42530-6,smooth muscleab [ite] in cerbral fluid spinal
42530-6,smooth musle ab cerebral n [titer] spial fluid
42530-6,smooth muscle ab titr csf
42530-6,smooth muscle ab titrcs
42530-6,cerebrospinal fluid muscle ab serology tir smooth
42530-6,smooth muscle ab (csf) [titer]
42530-6,(csf) uscle a smooth [tter spinal flu
42530-6,smooth muscle titer ab (cerebrospinal fluid) [titer]
26598-3,sarcosine [moles/volume] in cerebral spinal fluid
26598-3,sarcosine [moles/volume] in cerebral spinal fluid
26598-3,sarcosine in [moles/volume] spinal fl cerebral spinal fluid
26598-3,sarcosine csf-scnc
26598-3,chemistry csf-scnc sarcosine
26598-3,csf-scnc sarcosine spinal flu
26598-3,sarcosine (csf) [moles/vol]
26598-3,quan sarcosine (csf) [moles/vol]
26598-3,sarcosine [moles/vol] (csf)
76453-0,physical therapy initial visit panel
76453-0,physical panel initial visit therapy
76453-0,panel therapy initial visit apta physical
76453-0,pt init visit pnl
76453-0,pt visit init pnl
76453-0,pnl pt init pnl vst
34222-0,17-ketosteroids [moles/volume] in urine
34222-0,[moles/volume]in 17-ketotroids chemistry urine
34222-0,in [mles/volume] 17-eosteroids urine
34222-0,17ks ur-scnc
34222-0,ur-scnc 17ks
34222-0,urn u-scnc 17ks
34222-0,17-ketosteroids (u) [moles/vol]
34222-0,ketosteroid (u) 17-etosterids [moles/vol]
34222-0,17-ktosteods u) [moles/vol]
77379-6,human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna [interpretation] in cervix
77379-6,human papilloma virus 16 and 18 hpv16+18+hrisk12dna and 31+33+35+39+45+51+52+56+58+59+66+68 dna [interpretation] in cervix
77379-6,human pailloma irus 16 an 18 genital warts and31+33+3+39+4+51+52+56+58+5+6668 dna [iterpretaton] n cev
77379-6,hpv16+18+h risk 12 dna cvx-imp
77379-6,hpv16+18+h 12 risk dna cvx-imp
77379-6,hpv16+18+h risk 12 da cvx-imp hpv16+18
77379-6,hpv 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (cvx) [interp]
77379-6,and 16 hpv 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (cvx) [interp] infectiousdisease
77379-6,hpv 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 dna (cvx) [interp]
73405-3,doxazosin induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73405-3,doxazosin induced platelet igm ab [presence] in serum or plas by random flow cytometry (fc)
73405-3,doxazosin induced platelet in ab [presence] igm serum or plasma by flow cytometry circulating platelet ab (fc)
73405-3,doxazosin ind plt igm serpl ql fc
73405-3,doxazosin nd antibodies pt ig erplql fc
73405-3,doxazosin ind plt igm serpl l fc
73405-3,doxazosin induced platelet igm fc ql
73405-3,induced sr doxazosin platelet igm fc ql
73405-3,doxazosn induced thrombocyte ptelet ql fc igm
54015-3,azurocidin ab [presence] in serum
54015-3,[presenc] ab azurocidn inserum
54015-3,zurocidn ordinal ab[presnce] in serum
54015-3,azurocidin ab ser ql
54015-3,azurocidin ab er presence
54015-3,azuocdin abser ql
54015-3,azurocidin ab ql (s)
54015-3,(s) ab pr ql azurocidin
54015-3,azurocidin ab ql az (s)
19189-0,cancer ag 549 [units/volume] in serum or plasma
19189-0,cancer ag 549 [units/volume] ca in serum or plasma
19189-0,cancer ag 549 [units/volume] in serum or quan plasma
19189-0,cancer ag549 serpl-acnc
19189-0,ag549 cancer serl-acnc
19189-0,cancer serpl-acnc ag549
19189-0,cancer ag 549 qn
19189-0,59 g cancr qn
19189-0,cancer ag qn 549
59682-5,hydroxyethylflurazepam [mass/volume] in blood
59682-5,hydoxthyllurazeam [mass/volum] in blod drugs
59682-5,in [mass/volume] hydroxyethylflurazepam blood
59682-5,oh-ethylfluraz bld-mcnc
59682-5,oh-ethylfluraz bld-mcnc point in time
59682-5,bld-mcnc oh-ethylflraz flurazepam metabolite
59682-5,hydroxyethylflurazepam (bld) [mass/vol]
59682-5,hydroxyethylflurazpam wb blood [ass/o]
59682-5,hroxyethlflrazpam (blood) [mass/v]
105210-9,enterovirus rna [presence] in sputum by naa with probe detection
105210-9,enteroviru lower respiratory rna [pesenc] i sputum by na wth proe detectin
105210-9,enteroirus na [ql] in spuum nawith by prbedetecion
105210-9,ev rna spt ql naa+probe
105210-9,v rna ev spt presence na+probe
105210-9,ev rna spt presence naa+probe
105210-9,enterovirus rna naa+probe ql (sput)
105210-9,enteroviusrna na+pobe lower respiratory ql (sput)
105210-9,rna enterovirus naa+pobe ql(sput)
46191-3,histoplasma capsulatum igg ab [presence] in cerebral spinal fluid
46191-3,histoplasma capsulatum igg ab [ql] cerebral in spinal fluid
46191-3,pr histoplasmacapsulat igg ab [presence] spinal cerera in fluid
46191-3,h capsul igg csf ql
46191-3,h capsul igg ql pr csf
46191-3,h capsu ql histoplasmosis sf ig
46191-3,h. capsulatum igg ql (csf)
46191-3,h. igg capsulatum ql (csf)
46191-3,(csf) capsulatum igg ql h.
10578-3,glycerophosphocholine [moles/volume] in seminal plasma
10578-3,glycerophoshocholine plasma in seminal [molesvolue]
10578-3,glyceroposphocholine [moles/volume] in seminal plasma
10578-3,gpc semin plas-scnc
10578-3,gpc smin plas-scnc
10578-3,gpc semin plas-scnc
10578-3,glycerophosphocholine (seminal plasma) [moles/vol]
10578-3,glycerophosphocholine (seminal [moles/vol] plasma)
10578-3,(seminal glycerophosphocholine plasma) [moles/vol]
101770-6,trichophyton violaceum dna [presence] in specimen by naa with probe detection
101770-6,trichophyton violaceum dna [presence] in specimen by naa with probe detection
101770-6,trichophyton violaceum dna [presence] in amplification secimen by naa with probe detetion
101770-6,t. violaceum dna spec ql naa+probe
101770-6,t. violacm da t. violaceum dna spe ql na+prbe
101770-6,naa+robe vioaceum dna spec ql t. t. violaceum dna
101770-6,trichophyton violaceum dna naa+probe ql (specimen)
101770-6,tricophyton violacem dna naa+probe ql (secimen)
101770-6,trichophyon ilaceum dn t. violaceum naa+prbe presence (spcmn)
26795-5,alanine [presence] in 24 hour urine
26795-5,alanine resene]in 24 hour uine
26795-5,aanine peee] in24 1 day hour urine
26795-5,alanine 24h ur ql
26795-5,screen presence 24h ur alanine
26795-5,ql 24h ur alanine
26795-5,alanine ql (24h u)
26795-5,alanine u) (24h ordinal ql
26795-5,ql alanie (24h )
26035-6,serotonin [moles/volume] in plasma
26035-6,serotonin in enteramine [moles/volume] plas
26035-6,random serotonin [moles/vome] in plasma
26035-6,serotonin plas-scnc
26035-6,plas-scnc pl serotonin
26035-6,erotoinpls-scnc
26035-6,serotonin (p) [moles/vol]
26035-6,serotonin [moles/vol] (p) pl
26035-6,serotonin (p) [molesvl] substance concentration
47536-8,3-hydroxypropionate (3-oh-c3) [moles/volume] in plasma
47536-8,3-hydroxypropionate (3-h-c3 [moles/volue] in plama
47536-8,3-hydroxypropionate plas [moles/volume] in (3-oh-c3)
47536-8,3oh-propionate plas-scnc
47536-8,substance concentration las-scc 3o-propionate
47536-8,plasma-scnc 3o-propint 3oh-propionate
47536-8,3-hydroxypropionate (3-oh-c3) (p) [moles/vol]
47536-8,(3-oh-c3) 3-hydroxypropionate (p) [moles/vol]
47536-8,3-hydroxypopionate (p)[molesvol] pl 3-oh-c3
41015-9,human coronavirus oc43 igg ab [presence] in serum
41015-9,igg immune globulin g coronavirus oc43 human ab [presence] in ser
41015-9,human cornavirus oc43 igg ab [presnce] in seum
41015-9,hcov oc43 igg ser ql
41015-9,hcov oc43 ql serum igg
41015-9,hov oc43 ig ser ql
41015-9,hcov oc43 igg ql (s)
41015-9,hcov o43 igg ql pr (s)
41015-9,hcov oc43 igg ql ()
11048-6,glyceraldehyde 3 phosphate dehydrogenase [enzymatic activity/volume] in red blood cells
11048-6,glyceraldehyde 3 posphate ehydrogease [eymatc actiiy/volume] in red blood cels
11048-6,red 3 phosphate dehydrogenase [enzymatic activity/volume] in glyceraldehyde blood cells
11048-6,gapd rbc-ccnc
11048-6,gapd rbc-ccnc phosphorus
11048-6,rbc-ccnc gapd point in time
11048-6,glyceraldehyde 3 phosphate dehydrogenase (rbc) [catalytic activity/vol]
11048-6,phosphorous gyceraldehyde phosphae 3 dehydoenas (rbc) [cataltic activity/vol]
11048-6,glyceraldehyde 3 phosphate dehydrogenase (rbc) [catalytic activity/vol] red blood corpusles
22594-6,treponema pallidum igm ab [units/volume] in serum
22594-6,treponema pallidum igm ab [units/volume] i serum
22594-6,teonema in igm a [units/volue] immune globulin m pallidum erum
22594-6,t pallidum igm ser-acnc
22594-6,t ser-acnc igm pallidum
22594-6,t pallidum igm serum-acnc
22594-6,t. pallidum igm qn (s)
22594-6,pallidum t. igm qn (s)
22594-6,(s) pallidum igm qn t.
74807-9,transferrin receptor.soluble/log ferritin index [mass ratio] in serum or plasma
74807-9,transrrin eceptorsolube/lo ferritin index [as ratio] inserum or plasma
74807-9,transferrin receptor.soluble/log ferritin index [mass ratio] in serum or plasma quan
74807-9,stfr serpl
74807-9,serplas stfrerl
74807-9,stfr serpl quan
74807-9,transferrin receptor.soluble/log ferritin index [mass ratio]
74807-9,transferrin receptor.soluble/log ferritin index [mass ratio] rec
74807-9,transerrin receptor.soluble/log ertin index mass ratio] ser or plasma
49497-1,platelets [#/volume] in blood by estimate
49497-1,platelets [#/volume] in bld by estimate platelet
49497-1,platelets in [#/volume] blod thrombocytes estima
49497-1,platelet # bld est
49497-1,platelt est bld #
49497-1,# plateet thrombocyte bldt
49497-1,platelets estimate (bld) [#/vol]
49497-1,platelets (bld) estimate [#/vol]
49497-1,platelets estimate (blood) quan [#/vol]
57859-1,dextromethorphan [moles/volume] in specimen
57859-1,dexroethorphan quantitative [moles/olue] peimen in
57859-1,dextromethorphan [moles/volume] specimen in
57859-1,d-methorphan spec-scnc
57859-1,d-methorphan quantitative ec-scnc
57859-1,d-methorhan spec-cn
57859-1,dextromethorphan (specimen) [moles/vol]
57859-1,dextromethorphan (specimen) [moles/vol]
57859-1,(specimen) dextromethorphan [moles/vol]
12361-2,oxazepam [presence] in urine
12361-2,xazepam une diazepam metabolite in presne]
12361-2,i [resence] oxzpam urine
12361-2,oxazepam ur ql
12361-2,oazepm ur ordinal ql
12361-2,ur oxazepam ql
12361-2,oxazepam ql (u)
12361-2,oxazepam presence (u) ur
12361-2,oxzepm ql (u)
38645-8,captan [mass/volume] in air
38645-8,captan [mas/vlue] inair qnt
38645-8,captan quan [mass/volume] in air
38645-8,captan air-mcnc
38645-8,air-mcnc aptn
38645-8,qnt captan air-mcnc
38645-8,captan (air) [mass/vol]
38645-8,captan [mass/vol] drugs (air)
38645-8,captan (air) [mass/vol]
11476-9,microscopic observation [identifier] in gastric fluid by acid fast stain
11476-9,id microscopic oservation identifier] in gastr uid by acid fast stai
11476-9,microscopicobservation [idenifier] in gatric fuid bacd fast stin
11476-9,acid fast stn gast
11476-9,gastric fluid acid stn fast gast
11476-9,acid fast gast stn
11476-9,microscopic observation acid fast stain nom (gast fld)
11476-9,microscopic observation acid fast nom stain (gast fld)
11476-9,microscopic observation acid fast stain nom gastric contents (gast fld)
25992-9,lipase [enzymatic activity/volume] in 24 hour urine
25992-9,lipase lipase [enzymatic activity/volume] in 24 hour urine
25992-9,enzyatic ipase activty/olume] in 24 our urine
25992-9,lipase 24h ur-ccnc
25992-9,lipase 24 ur-ccnc 1 day
25992-9,lipase quant 24h ur-ccnc
25992-9,lipase (24h u) [catalytic activity/vol]
25992-9,lipae (24h u actvity/vol] [catalytic tributyrinase
25992-9,lipase (24h u) [catalytic activity/vol]
19702-0,deprecated tetrahydrocannabinol [presence] in urine by screen method
19702-0,deprecated ql tetrhydrocannabinol resence] screen urine by in metho
19702-0,deprecated tetrahydrocannabinol [presence] in drug/toxicology urine by screen method
19702-0,deprecated thc ur ql scn
19702-0,scn r ql screen deprecatethc
19702-0,deprecated rql thc scn
19702-0,tetrahydrocannabinol screen ql (u)
19702-0,tetrahydrocannabinol screen random (u) ql
19702-0,screen tetraydrocannabino ql (u)
70970-9,cryoglobulin [presence] in serum by hypotonic dilution
70970-9,[presence] cryoglobulin in serum by hypotonic dilution
70970-9,cryogobulin prsence] in serum by hypooni diluton
70970-9,cryoglob ser ql hypotonic dilution
70970-9,cryoglob ql ser sr hypotonic dilution
70970-9,cryoglob random serum ql dilution hypotonic
70970-9,cryoglobulin hypotonic dilution ql (s)
70970-9,cryoglobulins coglobulin hypotonic diution ql ()
70970-9,cryoglobulin presence dilution hypotonic (s)
104874-3,hematocrit [volume fraction] of blood by calculation --baseline
104874-3,hematocrit [vlu bld fractn] of bloo by calculato --baseline
104874-3,hematocrit fraction] [volume of blood by calculation calculation --baseline
104874-3,hct bs vfr bld calc
104874-3,hct bs calc bld vfr
104874-3,hct bs vfr bld calc
104874-3,hematocrit baseline calc (bld) [volume fraction]
104874-3,ematocri red bld corpuscle baseline alc (bld) [volume ractin]
104874-3,hematocrit basee cal (ld) volume fractin]
14624-1,barbiturates [presence] in gastric fluid
14624-1,barbiturats drugs [resence] in gastric fluid
14624-1,barbiturates [ql] in gastric fluid
14624-1,barbiturates gast ql
14624-1,ql gast barbiturates
14624-1,gast barbiturates ql
14624-1,barbiturates ql (gast fld)
14624-1,barbiturates drugs ql fld) (gast
14624-1,barbiturates ql (gast point in time fld)
2608-8,metanephrines [mass/volume] in urine
2608-8,urine [mass/volume] in metanephrines
2608-8,metanephrines [mass/lume in ine
2608-8,metanephs ur-mcnc
2608-8,metaneph ur-cnc
2608-8,ur-mcn metanephs
2608-8,metanephrines (u) [mass/vol]
2608-8,(u) metanephrines [mass/vol]
2608-8,[massvl] quantitative mtanehris(u)
101676-5,vim carbapenemase [presence] in isolate by rapid immunoassay
101676-5,vim carbapenemase qualitative [presnce] inisolte by raid immunoassay
101676-5,carbapenemase vim [presence] in isolate suds by rapid immunoassay
101676-5,vim carbapenemase islt ql ia.rapid
101676-5,carbapenemase vim islt presence ia.rapid
101676-5,vim carbapenemaseislt ql ia.rapd
101676-5,vim carbapenemase ia.rapid ql (isol)
101676-5,im l ia.rapd carbapenemase (iso) qual
101676-5,vim carbapenemase ia.rapid ql (isol) eia
43178-3,phentermine [presence] in hair by screen method
43178-3,phentermine [rsence] in ir by screen method
43178-3,hair [presence] in phentermine by screen drugs method
43178-3,phentermine hair ql scn
43178-3,phentermine scn hairql
43178-3,qualitative hair phentermine ql scn
43178-3,phentermine screen ql (hair)
43178-3,scree phentermine ql (hair)
43178-3,phenterminescreen ql random (hair)
59248-5,cholesterol esterase [enzymatic activity/mass] in tissue
59248-5,cholstrolesterase [enzymaticactivity/as] tissue in
59248-5,random choeserol sterase tissue in [nzymatcactivty/mass
59248-5,cholest est tiss-ccnt
59248-5,tis-ccn est choles
59248-5,cholest est cholest esttiss-ccnt
59248-5,cholesterol esterase (tiss) [catalytic activity/mass]
59248-5,cholesterol (tiss) esterase [catalytic activity/mass]
59248-5,cholesterol activity/mass] (tiss) [catalytic esterase
31272-8,bovine diarrhea virus ab [units/volume] in serum
31272-8,serm diarrhea viu beef b [uits/volume] in bvine
31272-8,bovinediarrha irus ab [unit/volume] in serum
31272-8,bvdv ab ser-acnc
31272-8,bvdv ab serum-acnc
31272-8,bvdv ab ser-acnc beef
31272-8,bovine diarrhea virus ab qn (s)
31272-8,bvine rrhea virus ab (s qn
31272-8,bovne diarrha virus ab qn arbitrary concentration (s)
80958-2,fractional excretion of magnesium [ratio] in urine and serum or plasma
80958-2,fractonal xcrtion f mansum atio] in urine and rum or plam
80958-2,fractional excretion serum magnesium [ratio] in urine and of or plasma
80958-2,fracti excret of mg ur+serpl-rto
80958-2,qnt fracti excret of mg ur+serpl-rto
80958-2,fracti excret magnes mg of ur+serpl-rto
80958-2,fractional excretion of magnesium (u+s/p) [ratio]
80958-2,of fractinalexcretion magnesium (u+s/p) [ratio
80958-2,(u+s/p)[ratio ecretion of magnesim fractional
45102-1,deprecated chlamydia sp identified in penis by organism specific culture
45102-1,deprecated chlamydia sp identified in penis by organism specific culture isolated
45102-1,deprecated lamdap ientified in penis infectious disease by specfi orgnism cture
45102-1,deprecated chlamydia penis cult
45102-1,deprecate spp chlamydia peniscult
45102-1,chlamyda derecated enisult species
45102-1,chlamydia sp identified org specific cx nom (penis)
45102-1,chlamydia sp identified or specifi infectious disease c nom (penis)
45102-1,chlamydia isolated sp identified org specific cx nom (penis)
88147-4,microscopic observation [identifier] in pericardial fluid by gram stain
88147-4,microcoic obserato [idntifier] ipricadial fluid by gra infectiousdisease stain
88147-4,cardiology microscopic observation [identifier] stain pericardial fluid by gram in
88147-4,gram stn pcar
88147-4,gram sn pcar
88147-4,gam point in time pc stn
88147-4,microscopic observation gram stain nom (pericard fld)
88147-4,microscopic observation gram nom stain (pericard fld)
88147-4,gram observation microscopic infectious disease stain nom (pericard fld)
18450-7,adipoylcarnitine (c6-dc) [mass/volume] in serum or plasma
18450-7,adipoylcarnitine (c6-dc) [mass/volume] plas serum plsm or in
18450-7,adipoylcarnitine (c6-dc) [mass/volume] in ser plasma or
18450-7,adipoylcarn serpl-mcnc
18450-7,adipoylcarn sr serpl-mcnc
18450-7,serpl-mcnc adipocar
18450-7,adipoylcarnitine (c6-dc) [mass/vol]
18450-7,c6dc adipoylcarnitine [mass/vol] (c6-dc)
18450-7,(c6-) adipolarnitine [ss/vl]
1910-9,asparagine [mass/time] in 24 hour urine
1910-9,sparagine [mas/tim] in 24 our urin
1910-9,asparagine [mass/time] in 24hr 24 hour urine
1910-9,asparagine 24h ur-mrate
1910-9,24h asparagine asn ur-mrate
1910-9,asparagine 24h ur-mrate
1910-9,asparagine (24h u) [mass/time]
1910-9,asparagine (24h [mass/time] u)
1910-9,asparagine (24h [mass/time] u)
73462-4,cefuroxime induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73462-4,cefuroxime induced flow igg ab [presence] in ser or plasma by platelet cytometry (fc)
73462-4,ceuroxime induced platele igga presece] inserum or plasma by flow cytomery (fc)
73462-4,cefuroxime ind plt igg serpl ql fc
73462-4,cefuroxime ind fc igg serpl ql plt
73462-4,cefuroxime ind plt fc serpl ql igg
73462-4,cefuroxime induced platelet igg fc ql
73462-4,cefuroxime igg thrombocyte platelet inucd fc presence
73462-4,cefuroie ig platelet induced fc ql antby
43223-7,sodium/creatinine [ratio] in urine
43223-7,in [ratio] sodium/ceatinine creat urine
43223-7,urine [ratio] in sodium/creatinine
43223-7,sodium/creat ur-rto
43223-7,ur-rto chemistry sodium/creat
43223-7,soium/creat u-rto chemistry
43223-7,sodium/creatinine (u) [ratio]
43223-7,(u) na+ sodium/creatinine [ratio]
43223-7,dium/creatnie (u)[ratio]
42572-8,11-deoxycortisol [mass/volume] in urine
42572-8,urine [mass/volume] in qnt 11-deoxycortisol
42572-8,[mass/voume] 1-deoxcotisol point in time n urine
42572-8,11dc ur-mcnc
42572-8,ur-mcnc 11dc
42572-8,level r-mcnc 11dc
42572-8,11-deoxycortisol (u) [mass/vol]
42572-8,11-deycortisol (u)[mass/vol] quan
42572-8,[mass/vol] (u) 11-deoxycortisol
14026-9,htlv i+ii p53 ab [presence] in serum by immunoblot
14026-9,htlv i+ii in ab [presence] p53 serum by abs immunoblot
14026-9,tlv i+ 53ab [resence] in sr serum by immunoblot
14026-9,htlv i+ii p53 ab ser ql ib
14026-9,htlv i+ii ql ab serum p53 ib ql
14026-9,htlv serum p53 ab i+ii ql ib
14026-9,htlv i+ii p53 ab ib ql (s)
14026-9,htlv screen i+ii p53 presence ib ab (s)
14026-9,ibql qualitative +ii p53 ab htlv (s)
60690-5,elicited items [timp]
60690-5,elicid items timp]
60690-5,[timp] eliiteditms
89577-1,troponin i.cardiac panel - serum or plasma by high sensitivity method
89577-1,trponini.cardiac - panel srum hs or plasma b hgh sesitivtymehod
89577-1,troponin i.cardiac panel - serum or plasma by high sensitivity method tni
89577-1,cardiac troponin i pnl serpl hs
89577-1,pan cardia tropoin i pnlserp h
89577-1,cardiac hs i pnl srpl troponin
89577-1,tropinin i.cardiac panel high sensitivity method
89577-1,tropinin i.cardiac panel high plsm sensitivity method
89577-1,method i.cardiac panel high sensitivity tropinin
99272-7,alpha-hydroxy flualprazolam [mass/volume] in urine by confirmatory method
99272-7,alpha-hydroxy flulprazolam[mass/volume] in urine  cnfirmatory method
99272-7,alpha-hydroxy method [mass/volume] in urine by confirmatory flualprazolam
99272-7,a-oh flualprazolam ur cfm-mcnc
99272-7,a-oh flualprazolam confirmatory ur cfm-mcnc
99272-7,flualprazolam a-oh u cfm-mcnc cfm
99272-7,alpha-hydroxy flualprazolam confirm (u) [mass/vol]
99272-7,alpha-hydroxy flualprazolam ur confirm (u) [mass/vol]
99272-7,alpha-hydroxy flulprazoa confirm(u) [mas/vol] confirmation
10246-7,oxygen content in right pulmonary artery
10246-7,oxyge o2 ct in content righ pulonaryart
10246-7,content oxygen in right pulmonary atery
10246-7,o2 ct pa-r-scnc
10246-7,ct o2 pa--scnc
10246-7,o2 pa-r-scnc ct
10246-7,oxygen content (right pulmonary artery) [moles/vol]
10246-7,(rig conten oxygn plmonary artery) moes/vol]
10246-7,content(ightpulmoary o2 oxygen artery) [moles/vo]
29343-1,rubella virus igg ab [units/volume] in body fluid
29343-1,rubellavirus in a [units/volume] igg body lui
29343-1,rubella igg virus ab [units/volume] in body fluid
29343-1,rubv igg fld-acnc
29343-1,rubv fld-acnc igg
29343-1,d-acnc igg rubv abs
29343-1,rubella virus igg qn (body fld)
29343-1,rubella virus igg qn (body infectious disease fld)
29343-1,rubella (body igg qn aby virus fld)
88010-4,tetradecenoylcarnitine (c14:1)/acetylcarnitine (c2) [molar ratio] in serum or plasma
88010-4,tetradecenoylcanitine (c4:1)/acetlcarnitine (c2 [mola rati] in ser or plasma
88010-4,tetrecenoycanitine (c141)/acetylcarnitine (c2) [molar rio] in serpl
88010-4,tdecenoylcarn/c2 serpl-srto
88010-4,tdecenoylcarn/c2 serpl-srto tdecenoylcarn
88010-4,serpl-srto tdecenoylcarn/c2 serplas
88010-4,c14:1/acetylcarnitine (c2) [molar ratio]
88010-4,(c2) c14:1/acetylcarnitine [molar ratio]
88010-4,(c2) c14:1/cetylcarniie [molar ratio]
9459-9,deprecated streptococcus pneumoniae 4 igg ab [units/volume] in serum by immunoassay
9459-9,deprecated streptococcus pneumoniae 4 igg meia ab [units/volume] in serum by immunoassay
9459-9,deprecated streptococcus pneumoniae 4 serum ab meia [units/volume] in igg by immunoassay
9459-9,deprecated s pneum4 igg ser ia-acnc
9459-9,depecated s pneum4igser pneumococcal i-acnc
9459-9,deprected s pneum4 gg er ia-acnc
9459-9,s. pneumoniae 4 igg ia qn (s)
9459-9,s. pneumonie 4 iggia qn (s)
9459-9,s. pnumoniae 4 pneumococ iggiq (s)
42371-5,neisseria meningitidis serogroup c ag [presence] in isolate by agglutination
42371-5,eisseria meniitidis serogroupc ag [resece] in islate by agglutintion
42371-5,srogroupc meningitidis nisera a [presence] n men serogroup in isolate y aglutinaion
42371-5,n men sg c ag islt ql aggl
42371-5,n aggl sg c n menigitidis ag islt ql men
42371-5,n men sg c ag islt presence aggl pr
42371-5,n. meningitidis c ag aggl ql (isol)
42371-5,n. meningitidis c ag aggl ql ql (iso)
42371-5,meningitidis n. rh bld group system c ag aggl ql (isol)
13629-1,interleukin 1 beta [mass/volume] in serum or plasma
13629-1,interleukin ser beta [mass/volume] il-1 in 1 or plasma
13629-1,itrleukin 1 beta [mass/volume] in serumo plas
13629-1,il1beta serpl-mcnc
13629-1,il1beta serpl-mcnc
13629-1,lymphocyte-stimulating hormone serpl-mcnc il1beta
13629-1,interleukin 1 beta [mass/vol]
13629-1,inerleukin 1 beta [mass/vo]
13629-1,interleukin 1 beta [mass/vol] il1
17267-6,methoxychlor [mass/volume] in urine
17267-6,methoxychlor [mass/volume] in urine
17267-6,methoxychlor [mass/volume] in urine
17267-6,methoxychlor ur-mcnc
17267-6,ur-mcnc methoxychlor
17267-6,methoxychlor u-mcc drugs
17267-6,methoxychlor (u) [mass/vol]
17267-6,methoxychlor quant (u) [mass/vol]
17267-6,methxychlr (u) [mass/vol random
74001-9,nbome [presence] in urine by screen method
74001-9,nbome [ql] inuriney sceen point in time mthod
74001-9,qualitative nbome screen in urine by [presence] method
74001-9,nbome ur ql scn
74001-9,nbome screen ur scn ql
74001-9,nbome ur presence scn
74001-9,nbome screen ql (u)
74001-9,nbomescreen pt ql (u)
74001-9,sreen nbome ql (u)
4648-2,deprecated homologous restriction factor
4648-2,deprecated homologous restriction random factor
4648-2,restriction homologous deprecated factor
4648-2,deprecated homologous restriction factor
4648-2,facto random hmoloousrestriction epcated
4648-2,dpreaed homologous esrictionfacto
4648-2,homologous restriction factor
4648-2,factor homoloousrstrictin
4648-2,factor restriction homologous hematology/cell counts
33016-7,methylenedioxyethylamphetamine [mass/volume] in serum or plasma
33016-7,sr plasma [mass/volume] in serum or methylenedioxyethylamphetamine
33016-7,illicit methylenedioxyethylamphetamine plas in serum or [mass/volume]
33016-7,mdea serpl-mcnc
33016-7,serpl-mcnc mdea
33016-7,mdea erpl-mcn
33016-7,methylenedioxyethylamphetamine [mass/vol]
33016-7,methylenedioxyethylamphetamine [mass/vol]
33016-7,methylenedioxyethylamphetamine [ass/ol]
38300-0,diquat [mass/volume] in water
38300-0,diquat in [mass/volume] water
38300-0,diquat [mass/volme] in quan ater
38300-0,diquat wat-mcnc
38300-0,"wat-mc diquat 6,7-dihydrodipyridol(1,2-a:2',1-c)pyrazinedium dibromide"
38300-0,at-mcnc diqt
38300-0,diquat (water) [mass/vol]
38300-0,diquat (water) [mass/vol]
38300-0,"diquat (water) [mass/vol] 1,1'-ethylene-2,2'-bipyridyllium dibromide"
61407-3,amitriptyline/creatinine [mass ratio] in urine
61407-3,in [mass ratio] amitriptyline/creatinine urine
61407-3,in [mass ratio] elatrol amitriptyline/creatinine urine
61407-3,amitrip/creat ur
61407-3,elatrol ur amitrip/creat
61407-3,ur point in time amitrip/creat
61407-3,amitriptyline/creatinine (u) [mass ratio]
61407-3,amitriptyline/creatinine (u) [mass mass concentration ratio ratio]
61407-3,amitriptyline/creatinine(u) ratio] [mass
13721-6,chloride/creatinine [mass ratio] in 24 hour urine
13721-6,chloride/creatinine [mass in ratio] 24 hour urine
13721-6,chloride/creatinine [mass ratio] in 24 creat hour urine
13721-6,chloride/creat 24h ur
13721-6,chloride/creat cl- 24h ur
13721-6,chloride/reat 24h u 24hr
13721-6,chloride/creatinine (24h u) [mass ratio]
13721-6,urn chloride/creatinine ratio] u) [mass (24h
13721-6,chloride/creatinne(4h u) [mass rto
7844-4,taenia solium larva iga ab [presence] in cerebral spinal fluid
7844-4,aenia cerebral larvaiga ab [ql] in solim anti spinal flui
7844-4,taenia solium larva iga ab cerebral in [ql] spinal fluid
7844-4,t sol lar iga csf ql
7844-4,t sol lar iga cerebrospinal fluid ql
7844-4,t sol lar ql aby cerebrospinal fluid iga
7844-4,t. solium larva iga ql (csf)
7844-4,t. solim (cerebrospinal fluid) igaq lra
7844-4,t. solium larva iga ql autoantibodies (csf)
14342-0,deprecated catecholamines/creatinine [mass ratio] in urine
14342-0,crea deprecated cateholamins/creatinine [ass ratio] in urine
14342-0,deprecated qnt ratio] [mass catecholamines/creatinine in urine
14342-0,deprecated catechol/creat ur-mrto
14342-0,ur-mrto catechol/creat deprecated
14342-0,depecatd catechol/creat ur-mrto pt
14342-0,catecholamines/creatinine (u) [mass conc ratio]
14342-0,catecholamines/creatinine ratio] [mass conc (u)
14342-0,(u) atecoamines/creainin [mass conc ratio]
92689-9,entamoeba histolytica dna [presence] in stool by naa with probe detection
92689-9,entamoebahsolyica dna [presence] n screen stool by naaithprobe detection
92689-9,entob histolytica dna [prene] in stol naa by with probe detetion naat
92689-9,e histolyt dna stl ql naa+probe
92689-9,histolyt e dna stl ql naa+probe
92689-9,e stl dna histolyt ql naa+probe
92689-9,e. histolytica dna naa+probe ql (stl)
92689-9,ql histolytica dna naa+prob e. stl)
92689-9,presence histolyticada naa+probe e. (stl)
73166-1,rifampin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73166-1,rifampin induced plsm platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73166-1,rifampin induced platelet circulating platelet ab igg ab [presence] in serpl by flow cytometry (fc)
73166-1,rifampin ind plt igg serpl ql fc
73166-1,rifampin igg plt ind serpl ql fc
73166-1,rimactane rifampin ind plt igg serpl ql fc
73166-1,rifampin induced platelet igg fc ql
73166-1,inuced rfampin plateletgg fc presence
73166-1,rifampin inuced platelt igg fc q
12550-0,papaverine [mass/volume] in serum or plasma
12550-0,papaverine[mss/olume] inserum or plasma
12550-0,papaverine in [mass/volume] ser or plasma
12550-0,papaverine serpl-mcnc
12550-0,serp-mn papaverine pavobid
12550-0,serpl-mcnc papaverin
12550-0,papaverine [mass/vol]
12550-0,[mass/vol] papaverine
12550-0,drugs [mass/vol] papaverine
49151-4,rickettsia parkeri igg ab [titer] in serum
49151-4,b parker ig rickettsia [titer] random in serum
49151-4,rickettsia parkeri igg ab [titer] in ser
49151-4,r parkeri igg titr ser
49151-4,igg parkeri r titr immune globulin g ser
49151-4,r titr igg parkeri ser
49151-4,r. parkeri igg (s) [titer]
49151-4,r. parkri [titr (s) ig
49151-4,r. igg parkeri (s) smqn [titer]
8231-3,phencyclidine [mass/volume] in meconium
8231-3,phencyclidine [mass/volume] in meconium
8231-3,pencyclidine [mass/olume] meconium in
8231-3,pcp mec-mcnc
8231-3,qnt mec-mcnc cp
8231-3,pcp mec-mcnc angel dust
8231-3,phencyclidine (mec) [mass/vol]
8231-3,addiction [mass/vol] phencycidne(mec)
8231-3,random phnyclidin (mec) [mass/vol]
74240-3,hedis 2014-2020 value set - cervical cytology
74240-3,hedi 2014-020 value set - crvical cytology
74240-3,point in time hedis 014-2020 ale set - cervicacyology
74240-3,hedis 2014-20 cerv cyto
74240-3,cyto 2014-20 random cerv hedis
74240-3,cyto heis201420cev
74240-3,hedis 2014-2020 value set - cervical cytology
74240-3,hedis 2014-2020 value hedis 2014-20 cerv cyto set - cervical cytology
74240-3,hedis 2014-2020 value set - cervical cytolog
47451-0,influenza virus a h2 ab [titer] in serum
47451-0,influenza virs ah ab [titer] in serum
47451-0,influenza virus a ttr h2 ab [titer] in serum
47451-0,fluav h2 ab titr ser
47451-0,fluav h2 titr sr ab serum
47451-0,fluav h ab ser titr
47451-0,fluav h2 ab (s) [titer]
47451-0,fluav h2 ab (s) [tter]
47451-0,fluav h2 ab (s) [titer]
29715-0,orientia tsutsugamushi karp ab [titer] in serum by immunofluorescence
29715-0,orientia by karp ab [titer] in serum tsutsugamushi immunofluorescence
29715-0,orentia tsutsugamushi kar ab [tter in serum by ttr immunofluorescnce
29715-0,o tsut karp ab titr ser if
29715-0,o tsut if immunofluor ab titr serum karp
29715-0,o tsut karpab itr serum if
29715-0,o. tsutsugamushi karp ab if (s) [titer]
29715-0,o. tsutsugamushi krp b if ()[titer]
29715-0,o. tsutsuaushi karpabif (s) rickettsia tsutsugamushi serotype karp [tter
1976-0,bilirubin.total [presence] in stool
1976-0,bilirubn.total[ql] instool
1976-0,bilirubin.total too billirubin [pesence]in
1976-0,bilirub stl ql
1976-0,stl bilirub ql
1976-0,blirubstl ql
1976-0,bilirubin ql (stl)
1976-0,ql bilirubin (stl) bowel movement
1976-0,qualitative (stl) ql bilirubin
53396-8,asparagine+ornithine/phenylalanine [molar ratio] in dbs
53396-8,[molrratio]in aspargneornitie/henylaanine s
53396-8,sparagieornitine/phenylalanine [molar rato] asn in dbs
53396-8,asn+orn/phe dbs-srto
53396-8,dbs-srto an+orn/phe dbs
53396-8,dbs-srto asn+orn/phe
53396-8,asparagine+ornithine/phenylalanine (dbs) [molar ratio]
53396-8,asparagine+ornithine/phenylalanine (dbs) ratio] [molar
53396-8,(dbs) asparagine+ornithine/phenylalanine [molar ratio]
30519-3,chenodeoxycholate [moles/volume] in serum or plasma
30519-3,cenodeoxyholate moles/olm] in serum or plasma
30519-3,chenodeoxycholate cdcae [moles/olume] or inser pasma
30519-3,cdcae serpl-scnc
30519-3,cdcae plsm serpl-scnc
30519-3,quan serum or plasma-scnc cdcae
30519-3,chenodeoxycholate [moles/vol]
30519-3,[moles/vol] chenodeoxycholate
30519-3,cdca chenodeoxycholate [moles/vol]
21056-7,alanine+cystine+histidine+homocysteine+leucine+phenylalanine+tyrosine [presence] in urine
21056-7,alanne+cystin+histidine+hoocyteine+leucine+phnyllanntyrosine in [ql] uine phe+tyr
21056-7,alanine+cystneistidine+homocysteine+leucne+phenylalanine+trosine [presene] n urine
21056-7,amino acids mixa ur ql
21056-7,mino acids mxa ur ql
21056-7,amino acids mixa ur ql
21056-7,alanine+cystine+histidine+homocysteine+leucine+phenylalanine+tyrosine ql (u)
21056-7,alanine+cystine+histidine+homocysteine+leucine+phenylalanine+tyrosine ql urn (u)
21056-7,alanine+cystine+histidine+homocysteine+leucie+phenyalanine+tyrosine l (u)
4337-2,morphine [mass] of dose
4337-2,morphine [ass] of dose
4337-2,morphine[mass] of dose
4337-2,morphine dose
4337-2,mrphie dose
4337-2,dose morphine
4337-2,morphine (dose) [mass]
4337-2,morpine dose med or substance (dose)[mass]
4337-2,morphine [mass] (dose)
50985-1,horowitz index in mixed venous blood
50985-1,horowitz index in mixed venous blood
50985-1,horowit random index n mixed venous blood
50985-1,horowitz index bldmv+ihg-rto
50985-1,index quantitative horowitz blmv+ig-rto
50985-1,horowitz index bldmv+ihg-rto
50985-1,horowitz index (bldmv+inhl gas) [ratio]
50985-1,horowitz index [ratio] gas) (bldmv+inhl
50985-1,horowt index (bldmv+inhl ga) quant [ratio]
43403-5,neisseria gonorrhoeae dna [presence] in specimen by probe with signal amplification
43403-5,neisseria gonorrhoeae dna [presence] in hybidization protection assay specimen amplification probe with signal by
43403-5,neissera gonorrhoeae dna presence] in probe by spcimen wth signalamplfiation
43403-5,n gonorrhoea dna spec ql probe+sig amp
43403-5,n onorhoea dna spc probe amp l probe+ig amp
43403-5,n gnorrhoea dnaspec l pbe+igamp
43403-5,n. gonorrhoeae dna probe+sig amp ql (specimen)
43403-5,gonorrhoeae n. dna probe+sig amp ql (specimen)
43403-5,. gonorrhoeae dna robe+sig amp ql (secimen)
59176-8,zopiclone [presence] in urine
59176-8,zpiclne urine in drug/toxicology [presence]
59176-8,urine [presence] i zopiclone
59176-8,zopiclone ur ql
59176-8,ur zopicone ql illicit
59176-8,zopiclone qualitative l ur
59176-8,zopiclone ql (u)
59176-8,zopiclon ql (u)
59176-8,zopiclone ql random (u)
95661-5,barmah forest virus igg ab [presence] in specimen by immunoassay
95661-5,igab[presence] orest virus mah inspecimen by immunoasay
95661-5,barmah orest irus igg ab presnce] in specien b immuassay
95661-5,bfv igg spec ql ia
95661-5,q igg screen spec bfv ia
95661-5,bvig qualitative spec presence
95661-5,barmah forest virus igg ia ql (specimen)
95661-5,barmah forest virus igg ia presence (specimen)
95661-5,barmah forest virus igg ia antibody ql (specime)
14418-8,calcium [moles/volume] in synovial fluid
14418-8,calcm [moles/volue] in synoval fluid
14418-8,calcium [oles/volume] in syoial synovial fluid fi
14418-8,calcium snv-scnc
14418-8,snv-scnc calcium
14418-8,sv-nc level caium
14418-8,calcium (syn fld) [moles/vol]
14418-8,calcium ca moles/vol] f) (yn
14418-8,calcium (syn fld) syn fl [moles/vol]
33344-3,leukotriene e4 [mass/volume] in urine
33344-3,leukotriene ur e4 [mass/volume] in urine
33344-3,leukotriene ur e4 in [mass/volum] une
33344-3,lte4 ur-mcnc
33344-3,ur-mcnc lte4
33344-3,point in time lte4ur-mcnc
33344-3,leukotriene e4 (u) [mass/vol]
33344-3,leukotriene (u) e4 quant [mass/vol]
33344-3,e4 leukotriene (u) [mass/vol] point in time
50202-1,iron [mass/volume] in serum or plasma --5th specimen
50202-1,[mass/volume] iron chemistry in ser or plasma --5th specimen
50202-1,iron [mass/volume] in serum o plasm serp --5th specmen
50202-1,iron sp5 serpl-mcnc
50202-1,serpl-mcnc serpl sp5 iron
50202-1,sp5 iron serpl-mcnc
50202-1,iron 5th specimen [mass/vol]
50202-1,[mass/ol] th specimen irn
50202-1,[mass/vol] 5th specimen iron
3037-9,deprecated prealbumin [enzymatic activity/volume] in serum or plasma
3037-9,deprcte transthyretin realbumi [enzymatic activiy/volume] in erm o plas
3037-9,dprecte prealumn [enzymatic activiy/volume] in sum r plasm
3037-9,deprecated prealb serpl-ccnc
3037-9,deprecated serpl-ccnc prealb sr
3037-9,deprecated transthyretin prealb serum or plasma-ccnc
3037-9,prealbumin [catalytic activity/vol]
3037-9,activity/vol [cataytic preabun
3037-9,activity/vol] [catalytic prealbumin
97923-7,sandfly fever naples virus rna [presence] in specimen by naa with probe detection
97923-7,sandfly fever naples polymerase chain reaction virus [presence] rna in specimen by naa with probe detection
97923-7,sandfly fever naples virus rna [presence] in specimen by naa with probe detection
97923-7,sfnv rna spec ql naa+probe
97923-7,sn raspec l lcr naa+probe
97923-7,sfnrnaspec ligation-activated transcription ql naa+probe
97923-7,sandfly fever naples virus rna naa+probe ql (specimen)
97923-7,sndfly fever transcription mediated amplification naples viru rn naa+probe ql (spcimen)
97923-7,safly qbr fevernaples virs rna na+probe presence (specimen)
31500-2,ganglioside gm1 igg+igm ab [units/volume] in serum
31500-2,gglosidgm1 serm b [unisvolme] in igg+igm
31500-2,ganglioside gm1 igg+igm antby ab [units/volume] in ser
31500-2,gm1 gangl igg+igm ser-acnc
31500-2,gm1 gangl igg+igm serum-acnc
31500-2,gangl gm1 serology igg+igm serum-acnc
31500-2,ganglioside gm1 igg+igm qn (s)
31500-2,quant ganglioside igg+igm gm1 qn (s)
31500-2,gangioside m1 igg+ig qn autoantibody (s)
628-8,bacteria identified in tissue by anaerobe culture
628-8,acteri idenifiedin tissue by anaerobe culture
628-8,baceria identified in tissue infectiousdisease anaerobculture by
628-8,bacteria tiss anaerobe cult
628-8,"cult tissue, unspecified tiss anaerobe bacteria"
628-8,anaerobe tiss bacteria cult
628-8,bacteria identified anaer cx nom (tiss)
628-8,bacteria identified anaer nom cx (tiss)
628-8,bacteria identified anaer nom cx (tiss)
68974-5,igg.intrathecally synthesized/igg.total in cerebral spinal fluid
68974-5,spinal syntheszed/igg.total in crerl igg.intathecally fuid
68974-5,igg.intrthecal ynthsied/igg.toal n cerral spinal fluid
68974-5,igg.it/igg.total mfr csf
68974-5,csf mfr igg.it/igg.total
68974-5,igg.it/igg.tol m cs
68974-5,igg.intrathecally synthesized/total igg (csf) [mass fraction]
68974-5,iggintrathecally synthesized/tota igg.it igg (cs) [ass fracton]
68974-5,spinal fld igg.intrathecally synthesized/total igg [mass (csf) fraction]
32190-1,microscopic observation [identifier] in cerebral spinal fluid
32190-1,microsopic oservation [identiier] in cereral spinal fuid
32190-1,microscopic observation [identifier] in infectiousdisease cerebral fluid spinal
32190-1,csf micro
32190-1,csf micro random
32190-1,sf micro spinal fluid
32190-1,microscopic observation nom (csf)
32190-1,micoscoic obsrvation (cs) nom
32190-1,microscopic obseration nom cerebrospinal fluid)
73888-0,tetrahydrocorticosterone [moles/time] in 24 hour urine
73888-0,tetrahdrocorticosterone [moes/tie] in 24 hoururine
73888-0,tetrahydrocorticosterone [mles/tie] n 24 hour urine
73888-0,thb 24h ur-srate
73888-0,ur-srate 24 hours 24h thb
73888-0,thb 24h ur-srate quant
73888-0,tetrahydrocorticosterone (24h u) [moles/time]
73888-0,[moles/time] (24h u) tetrahydrocorticosterone
73888-0,moles/time] quant (24h u) tetrahydroorticosteone
82403-7,deprecated ganglioside gd3 igg+igm ab [presence] in serum by immunoassay
82403-7,deprecated gliosie in igg+igm ab [presence] gd3 ser y immunoasa
82403-7,by ganglioside gd3 igg+igm ab [presence] wb in ser deprecated immunoassay
82403-7,deprecated gd3 gangl igg+igm ser ql ia
82403-7,pr depecatd g gangligg+igm qli ser
82403-7,deprecated gd3 gangl pr ser igg+igm ql ia
82403-7,ganglioside gd3 igg+igm ib ql (s)
82403-7,presence immunobl gd3 igg+igm ib ganglioside (s)
82403-7,ganglioie gd3igg+igm disialolganglioside ibl (s)
79379-4,hiv 1 rna+proviral dna [presence] in plasma by naa with probe detection
79379-4,hiv 1 rna+proiral dna[preence in plasmab with point in time naa prbe deteton
79379-4,hiv 1 rna+provira da [pesence] in plasma by deection with probe naa
79379-4,hiv 1 rna+proviral dna plas ql naa+probe
79379-4,hiv 1 rna+proviral dna plasma ql naa+probe
79379-4,hiv amplified 1 rna+proviral ql plas dna naa+probe
79379-4,hiv 1 rna+proviral dna naa+probe ql (p)
79379-4,hv 1 rnaproviral dna naa+probeql p)
79379-4,hiv 1 rna+proviral dna naa+probe ql (p)
72516-8,glucose [moles/volume] in blood by automated test strip
72516-8,glucose [moles/volume] in utomate by blood tes dip stick trip
72516-8,glucose [moles/volume] in blood auto by automated test strip
72516-8,glucose bld strip.auto-scnc
72516-8,glucos glu strp.auto-scnc ld
72516-8,bld glucose strip.auto-scnc
72516-8,glucose auto test strip (bld) [moles/vol]
72516-8,glucos auto moles/vol] auto stri (ld) test
72516-8,glucose auto test strip (bld) [moles/vol] whole blood
46062-6,treatments set
46062-6,set treatments txs
46062-6,set treatments
46440-4,edit overrides/conversion history/system admin section set naaccr v.11
46440-4,north american association of central cancer registries edit overrides/conversion history/system admin section set naaccr v.11
46440-4,dit verrdes/convsion histry/system adminsection setnaccr v.11
46440-4,edit ovrds/conv hx/sys admin naaccr v.11
46440-4,edit ovrds/conv hx/sys panl admin naaccr v.11
46440-4,edit ovrds/conv hx/sys panel admin naaccr v.11
58378-1,ethyl glucuronide [mass/volume] in urine by confirmatory method
58378-1,[mas/olume] glucuonide ethyl i glucouronide rine by confirmatry method
58378-1,gluuroni ethyl [mass/voume] in urine by confirmatoy mthod
58378-1,ethyl glucuronide ur cfm-mcnc
58378-1,confirmatory glucuronide ethyl ur cfm-mcnc
58378-1,ethyl lucuronie ur quantitative fm-mnc
58378-1,ethyl glucuronide confirm (u) [mass/vol]
58378-1,ethl glucuronide [mass/vol quan (u) confirm
58378-1,ethyl gcms glucuronide confirm (u) [mass/vol]
62857-8,micromegakaryocytes [#/volume] in blood by manual count
62857-8,micromegakaryocytes random [#/volume] in blood by manual count
62857-8,micromegakaryocytes [#/volume] quantitative in blood by manual count
62857-8,micromegakaryocytes # bld manual
62857-8,manual # blood micromegakaryocytes
62857-8,micromegakryocyte quantitative # manual bld
62857-8,micromegakaryocytes manual cnt (bld) [#/vol]
62857-8,micromegakaryocytes manual cnt # (bld) [#/vol]
62857-8,[#/vol] manual cnt (bld) micromegakaryocytes
60545-1,cryptosporidium sp dna [presence] in specimen by naa with probe detection
60545-1,cryptosporidium sp dna [presence] in specimen by naa with probe detection
60545-1,cryptosporidium sp dna [ql] in specimen by naa with probe detection
60545-1,cryptosp dna spec ql naa+probe
60545-1,cryptosp dna naat spec na+probe ql
60545-1,presence spec cryptospdna polymerase chain reaction na+pobe
60545-1,cryptosporidium sp dna naa+probe ql (specimen)
60545-1,crtosporiium sp da naa+proe ql (specien)
60545-1,cryptosporidium (specimen) dna naa+probe ql sp
44526-2,histoplasma capsulatum h ab [presence] in cerebral spinal fluid
44526-2,microbiology histoplasma capsulatum h ab [presence] in cerebral spinal fluid
44526-2,histoplasma in h ab [presence] capsulatum cerebral spinal fluid
44526-2,h capsul h ab csf ql
44526-2,h h capsul ab csf ql
44526-2,h capsul h ab antibodies cerebrospinal fluid ql
44526-2,h. capsulatum h ab ql (csf)
44526-2,. capsulatum h ab ql (csf)
44526-2,h. capsulatum h ab presence (csf)
602-3,bacteria identified in bone by aerobe culture
602-3,bacteria identified in bone by aerobe culture
602-3,bacteria identified in bone identity or presence by aerobe culture
602-3,bacteria bone aerobe cult
602-3,aerobe bone bacteria cult
602-3,c&s acteria bone aeob cult
602-3,bacteria identified aer cx nom (bone)
602-3,bacteria ientiied aerobe cult ae nom x (bone)
602-3,bacteria nom aer cx id identified (bone)
12890-0,borrelia burgdorferi 45kd ab [presence] in serum by immunoblot
12890-0,borrelia burgdorferi immunoblot 45kd ab [presence] in serum by immunoblot
12890-0,brrelia burgdoreri 45kd ab [prsence] sr inserum byimmunoblot
12890-0,b burgdor45kd ab ser ql ib
12890-0,ib burgdor45kd ab ser ql b
12890-0,b budrkd ab ser ql b
12890-0,b. burgdorferi 45kd ab ib ql (s)
12890-0,b. burgorferi burgdorf presence a ib 45k (s)
12890-0,burgdorferi b. 45kd ab ib ql (s)
73016-8,gabapentin induced neutrophil igg ab [presence] in serum or plasma by flow cytometry (fc)
73016-8,abapentin iduced neutophiig b [prsece] n serum or plasma cytomty flow by (fc)
73016-8,gabapentin induced neutrophil igg ab [presence] in serum by plasma or flow cytometry (fc)
73016-8,gabapentin (neut) igg serpl ql fc
73016-8,pr gabapenin (neut) serpl igg ql fc
73016-8,gabapentin neut) pnm fc seplq igg
73016-8,gabapentin induced neutrophil igg fc ql
73016-8,induced gabapentin neutrophil igg fc ql
73016-8,gabpentn iggfc neutrohil induced abs ql
51604-7,phosphate [moles/time] in 12 hour urine
51604-7,phosphate[moesime in pi 12 urine hour
51604-7,phosphate [moles/time] in 12 hour urn urine
51604-7,phosphate 12h ur-srate
51604-7,12h posphate ur-rate quant
51604-7,phophate phosphate total 12h ursrate
51604-7,phosphate (12h u) [moles/time]
51604-7,phoshate (2h u) [moles/time]
51604-7,u) (12h phosphate [moles/time]
14091-3,deprecated herpes simplex virus 2 igm ab [titer] in cerebral spinal fluid by immunofluorescence
14091-3,dpreced herpe smplex virus2 igmab [titer] in ceebral spina fluid by immunfluorecene
14091-3,deprcated erpes implexvirus  i ab [titer] i rebral spinal fluid by mmunofluorescenc
14091-3,deprecated hsv2 igm titr csf if
14091-3,deprecated titr igm hsv2 csf if
14091-3,time resolved fluorescence deprecate hs2 igm titr csf f
14091-3,hsv 2 igm if (csf) [titer]
14091-3,hsv 2 igm if (csf) [titer]
14091-3,[tier] 2 gm neurology if (csf) hsv
3496-7,clopenthixol [mass/volume] in serum or plasma
3496-7,cloenthixol [mas/volume] isrum plsma drug/toxicology or
3496-7,clopenhixol [mass/volume] qnt in serum or plama
3496-7,clopenthixol serpl-mcnc
3496-7,drugs clopenthixol serpl-mcnc
3496-7,clopenhixolserpl-mcnc drug/toxicology
3496-7,clopenthixol [mass/vol]
3496-7,clpentiol [mass/vol
3496-7,[mass/vol] clopenthixol
32281-8,carnitine free (c0)/carnitine.total in serum or plasma
32281-8,carnitine ree (c0)/arnitine.ttl n carnitine free erum or pasma
32281-8,arntneree (c0)/arnitine.total n serpl srumor plasma
32281-8,carnitine free sfr serpl
32281-8,carnitine fre sfr serpl
32281-8,carnitine free sfr serpl
32281-8,c0/total carnitine [molar fraction]
32281-8,carnitine c0/total [molar fraction]
32281-8,c0/total carnin [molar faction]
17943-2,bacteria # 3 identified in line specimen by iv line culture
17943-2,bacteia # 3 identified inlin secimen by iv line ulture
17943-2,bacteria # 3 identified in line infectiousdisease specimen by iv line culture
17943-2,bacteria line iv ln cult org #3
17943-2,bacteria line iv ln cult org #3
17943-2,bacteria line iv ln cult #3 org
17943-2,bacteria identified # 3 iv line culture nom (line specimen)
17943-2,bacteria identified # 3 iv line iv ln cult culture nom (line specimen)
17943-2,bacteria nom # 3 iline bact cutre identfied (inespecmn)
32593-6,eosinophils/leukocytes in specimen
32593-6,lkcs specimen in eosinophils/leukocytes
32593-6,specimen in eosinophils/leukocytes
32593-6,eosinophil nfr spec
32593-6,eosinophil nfr spec spec
32593-6,eosinophil spec qnt nfr
32593-6,eosinophils/leukocytes (specimen)
32593-6,(specimen) eosinophils/leukocytes
32593-6,(specimen) eosinophils/leukocytes
50901-8,porphyrins [moles/volume] in 24 hour urine
50901-8,porphyrins [moles/volume] urine 24 hour in
50901-8,porphyrins porph [moles/volume] urine 24 hour in
50901-8,porphyrins 24h ur-scnc
50901-8,porphyins 24h quant u-scnc
50901-8,porphyrins ur-scnc 24h
50901-8,porphyrins (24h u) [moles/vol]
50901-8,porphyrins (24h 1 day u) [moles/vol]
50901-8,prphyrins (24h u) [molsol]
101280-6,mds v3.0 - rai v1.18.11 - assessment administration during assessment period [cms assessment]
101280-6,mds v3.0 - rai v1.18.11- assessmnt ministration during assessmet perod [cms ssessmen]
101280-6,mds v3. -rai v1.18.11- assessmnt administration during assesment peiod cms assessment]
25726-1,oxcarbazepine [moles/volume] in serum or plasma
25726-1,oxcarbazeine [oles/volume] ser n orlasma
25726-1,oxcarbazepine [moles/volume] in serum or trileptal plasma
25726-1,oxcarbazepine serpl-scnc
25726-1,oxcarbazeine plsm serpl-scnc
25726-1,serpl-scnc oxcarbazepine
25726-1,oxcarbazepine [moles/vol]
25726-1,serp [moles/vol] oxcarbazepine
25726-1,oxcarbazepine [mles/vol]
25407-8,fasciola sp igg ab [units/volume] in serum by immunoassay
25407-8,fascola sp igga [unis/volume] in serum y immunoassay
25407-8,fasciola sp iggab [units/volme] in abs serum by mmunoassay
25407-8,fasciola igg ser ia-acnc
25407-8,fasciola immunoglobulin g ia-acnc ser igg
25407-8,fasciol i-acnc ggser
25407-8,fasciola sp igg ia qn (s)
25407-8,(s) sp igg ia qn fasciola
25407-8,fasciola sp igg ia qn random (s)
92809-3,influenza virus a h1 rna [presence] in upper respiratory specimen by naa with probe detection
92809-3,influenza polymerase chain reaction virus a h1 naa [presence] in upper respiratory specimen by rna with probe detection
92809-3,virus influenza a h1 rna [presence] in upper respiratory specimen by naa with probe detection
92809-3,fluav h1 rna upper resp ql naa+probe
92809-3,rsp 1 raupper fluav probe with ampification presence naa+probe
92809-3,fluav h1 rna upper naa+pre presence rsp
92809-3,fluav h1 rna naa+probe ql (upper resp)
92809-3,fluav h1 rna a+probe q (upper res)
92809-3,fluav h1 rna naa+probe ql qbr (upper resp)
16952-4,herpes simplex virus 1 dna [presence] in cerebral spinal fluid by naa with probe detection
16952-4,herpes simplex virus i 1 dna [presence] in cerebral spinal fluid by naa with probe detection
16952-4,herpes simplex virus 1 dna [presence] in cerebral spinal fluid by naa with probe detection
16952-4,hsv1 dna csf ql naa+probe
16952-4,hsv1 ql csf dna naa+probe
16952-4,hsv1 dna csf infectious disease ql naa+probe
16952-4,hsv 1 dna naa+probe ql (csf)
16952-4,hsv 1 dna naa+probe ql (csf) naa+probe
16952-4,hsv 1 dna spinal fl naa+probe presence (csf)
13584-8,tobramycin [mass/volume] in body fluid
13584-8,in [mass/voume] tobramycin body random fluid
13584-8,tobramycin mass/vlume] in body ld
13584-8,tobramycin fld-mcnc
13584-8,tobrmyin fld-mcnc
13584-8,aminoglycosides tobrmycin fld-mcnc
13584-8,tobramycin (body fld) [mass/vol]
13584-8,[mass/vl] (body fld tobramycin
13584-8,fld fld) tobramycin(body [mass/vol]
51701-1,ganglioside igg ab [presence] in serum by immunoblot
51701-1,serum igg ab[presence] i anglioside byimmunoblot
51701-1,gangliside igg ab [presece] in serum by mmoblo
51701-1,ganglioside igg ser ql ib
51701-1,ser igg ganglioside ql ib
51701-1,ganglioside riba igg ib ql ser
51701-1,ganglioside igg ib ql (s)
51701-1,ganglioside (s) ib ql igg
51701-1,ganglioside igg ib presence (s)
8152-1,amphetamines [presence] in urine by samhsa screen method
8152-1,amphetamines [presene] in urine by samhsa screen method
8152-1,amphetamines method in urine by samhsa screen [ql] potentialforabuse
8152-1,amphetamines ur ql samhsa scn
8152-1,ql amphetaminesur sas scn drugs of abuse
8152-1,amphetaines mhsasn l ur
8152-1,amphetamines samhsa screen method ql (u)
8152-1,amphetamines presence screen method samhsa (u)
8152-1,addiction amphetamines samhsa screen method ql (u)
89590-4,zika virus igg ab [titer] in serum by immunofluorescence
89590-4,zika virus igg ab [titer] in serum by immunofluorescence
89590-4,zika ttr virus ig ab[ier]in serum by iunouorescence
89590-4,zikv igg titr ser if
89590-4,zikv antby igg titr er if
89590-4,zikv igg titr ser antby if
89590-4,zikv igg if (s) [titer]
89590-4,if igg zikv (s) [titer] random
89590-4,zikv titer] if (s) igg fluorescent antibody
91899-5,anaplasma phagocytophilum and ehrlichia chaffeensis dna panel - blood
91899-5,anaplasma human granulocytic ehrlichiosis phagocytopilum ad ehrlicha caffeensis dna pael - blood
91899-5,anaplasma phagocytophilum and chaffeensis ehrlichia dna panel - blood
91899-5,a phagocyt + e chaff dna pnl bld
91899-5,a e + hagocyt chaf dna pl bld
91899-5,a phagocyt + chaff e dna pnl bld
91899-5,a. phagocytophilum and ehrlichia chaffeensis dna panel (bld)
91899-5,a phagoctophilum nd panel chaffeenss dna ehrlichia (bld)
91899-5,a. phagtohlmand erlichia chaffeensis panl dnapanel (blood)
31602-6,rickettsia typhus group igm ab [units/volume] in cerebral spinal fluid
31602-6,rickettsia typhus group igm ab [units/volume] in cerebralspinal fluid
31602-6,rickettsa typhus grop im ab uits/olue] in cerebral spinalfuid immunoglobulin m
31602-6,rick typhus igm csf-acnc
31602-6,rick csf-acnc igm typhus
31602-6,igm typhus rick csf-acnc
31602-6,r. typhus group igm qn (csf)
31602-6,r. typhus group igm qn (csf)
31602-6,r. neuro typhus roup (cerebrospinal fluid) qn gm
13312-4,iga igg ab [units/volume] in serum or plasma
13312-4,iga igg ab [units/volume] in serum or antby plasma
13312-4,iga igg serplas serum [units/volume] in ab or plasma
13312-4,iga igg serpl-acnc
13312-4,iga igg serpl-acnc
13312-4,autoantibodies igg iga sepl-acnc
13312-4,iga igg qn
13312-4,iga igg qn
13312-4,antby igg iga qn
2469-5,igg subclass 4 [mass/volume] in serum
2469-5,igg serum 4 [mass/volume] in quan subclass
2469-5,igg [massvolume] 4 subclas inerum
2469-5,igg4 ser-mcnc
2469-5,igg4 ser-nc subclasses
2469-5,ser-nc ig subclasses
2469-5,igg subclass 4 (s) [mass/vol]
2469-5,igg level subclass 4 (s) [mass/vol]
2469-5,igg subclass 4 (s) [mass/vol]
104354-6,borrelia recurrentis dna [presence] in cerebral spinal fluid by naa with probe detection
104354-6,borrelia recurrentis dna [presence] in with spinal fluid by naa cerebral probe detection
104354-6,borrelia n dna [resence] recurenti cerebal spinal fluid b aa with probe deection probe with ampification
104354-6,b. recurrentis dna csf ql naa+probe
104354-6,cerebrospinal fluid rerrents dna ql b. q na+prbe
104354-6,b. recurrentis dna csf presence naa+probe
104354-6,borrelia recurrentis dna naa+probe ql (csf)
104354-6,borrelia tma recurrentis naa+probe dna ql (csf)
104354-6,dna recurrentis borrelia naa+probe (cf) nucleic acid sequence based analysis
52958-6,methadone [moles/volume] in urine
52958-6,urine [moles/volume] in methadone
52958-6,methadone [moles/volume] in urine addiction
52958-6,methadone ur-scnc
52958-6,methadone ur-scnc quantitative
52958-6,ur-scnc quan methdone
52958-6,methadone (u) [moles/vol]
52958-6,(u) methadone [moles/vol]
52958-6,addiction [moles/vol] (u) methadone
74616-4,"1,1-dimethoxyoctadecane (dma 18:0)/octadecanoate (c18:0) [mass ratio] in fibroblast"
74616-4,"1,1-dimethoxyoctadcane(dm 80)/otadecanoae (c1:0) [mas ratio in fibroblast"
74616-4,"1,1-dimethoxyoctadecane (dma 18:0)/octadecanoate cetylacetic acid (c18:0) [mass ratio] in fibroblast"
74616-4,dma 18:0/c18:0 fib
74616-4,dma fib 18:0/c18:0
74616-4,dm cetylacetic acid 1:0/c18:0 ib
74616-4,"1,1-dimethoxyoctadecane (dma 18:0)/octadecanoate (c18:0) (fibroblast) [mass ratio]"
74616-4,"1,1-dimethoxyotadecane (dma 18:0)/ocadecanoate (fibrolast) (c18:0) [mass rato] mcrto"
74616-4,"(ibroblas) 18:)/octdecanoat (c1:0) 1,-dimethoyoctadecane(dma ass rato]"
35331-8,oxcarbazepine [mass/volume] in serum or plasma
35331-8,or [mss/volume] in ser xcarbazepine lasma
35331-8,or [mas/vlume in plasma seu oxcarbazepine plasm
35331-8,oxcarbazepine serpl-mcnc
35331-8,serpl-mcnc oxcarbazepine trileptal
35331-8,oxarbazepine serplmcnc
35331-8,oxcarbazepine [mass/vol]
35331-8,[mass/vol] oxcarbazepine trileptal
35331-8,oxcarbazepine drugs [mass/vol]
32009-3,cortisol free/creatinine [mass ratio] in 24 hour urine
32009-3,corisol [mass free/creainine non-protein bound ratio] in 24 hour urine
32009-3,cortiol [mass free/cretinine ratio] in24 mass concentration ratio hoururine
32009-3,cortis f/creat 24h ur
32009-3,f/creat cortis 24h ur
32009-3,cortis f/creat quantitative 24h ur
32009-3,cortisol free/creatinine (24h u) [mass ratio]
32009-3,hydrocortisone [mass free/cratinine(24h u) ortisol rio]
32009-3,cortisol fre/creatinine (4h [mss u) raio]
73465-7,ceftriaxone induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73465-7,cetriaxone inuced m ltelt ab [presenc] in sem or plasm by flow cytometry anti (fc)
73465-7,ceftriaxone induced platelet igm ab [presence] in ser or plasma by flow cytometry platelet auto-antibodies (fc)
73465-7,ceftriaxone ind plt igm serpl ql fc
73465-7,ceftriaxone ind plt serpl platelets igm ql fc
73465-7,ceftrixone indplt i serpl ql fc
73465-7,ceftriaxone induced platelet igm fc ql
73465-7,ceftriaxone inuced platelet igfc presence
73465-7,ceftriaxone ql platelet igm fc induced
17397-1,oxytriphylline [mass/volume] in serum or plasma
17397-1,oxytriphylline serum in [mass/volume] or plasma
17397-1,[mass/volume] oxytriphylline in ser or plasma
17397-1,oxytriphylline serpl-mcnc
17397-1,srplcc oxytriphyllin
17397-1,serum or plasma-mcnc oxytriphylline
17397-1,oxytriphylline [mass/vol]
17397-1,oxytrihylline drug/toxicology [mass/ol]
17397-1,[mass/vl] point in time oxytiphylline
3534-5,desipramine [mass/volume] in urine
3534-5,dsipramine [mass/volume] ur inurine
3534-5,desipramine [mass/volume] in urine
3534-5,desipramine ur-mcnc
3534-5,desipramine mass concentration ur-mn
3534-5,u-mnc dsipramine
3534-5,desipramine (u) [mass/vol]
3534-5,(u) desipramine qnt [mass/vol]
3534-5,desipramne u) [asvo
44002-4,choriogonadotropin [multiple of the median] adjusted in amniotic fluid
44002-4,choriogonadotropin [multiple of the choriogonadotropins total median] adjusted in amniotic fluid
44002-4,choriogonadotropin [multiple of the median] adjusted fluid amniotic in
44002-4,hcg adj mom amn
44002-4,amn adj mom hc
44002-4,adj hcg mom amn random
44002-4,hcg adjusted (amn fld) [mom]
44002-4,hcg adjusted (amn fld) [om]
44002-4,hcg [mom] (an fld) adjustd adj
45071-8,deprecated chlamydia trachomatis+neisseria gonorrhoeae rrna [presence] in penis by dna probe
45071-8,depecated chlamydia tachomatis+eiseri gonorrhoeae rrna [presence] probe penis by dna in
45071-8,deprecated probe trachomatis+neisseria gonorrhoeae rrna [presence] in penis by dna n gonorrhoea chlamydia
45071-8,deprecated c trach+gc rrna penis ql prb
45071-8,deprecated c rrna trach+gc penis presence prb
45071-8,deprecated lymphogranuloma venereum c tach+gc rrna ql penis pr
45071-8,c. trachomatis+n. gonorrhoeae rrna probe ql (penis)
45071-8,c.rachomatis+n. gonorrhoeae rrna proe ql qualitative (penis)
45071-8,c. trachomatis+n. dna nucleic acid probe gonorrhoeae rrna (penis) ql probe
25413-6,fluoride [moles/time] in 24 hour urine
25413-6,24 [moles/time] in fluoride hour urine
25413-6,24 [moles/time] in fluoride 1 day hour urine
25413-6,fluoride 24h ur-srate
25413-6,orid urn ur-srate 2h
25413-6,ur fluoride ur-srate 24h
25413-6,fluoride (24h u) [moles/time]
25413-6,fluorid (24h u) [mole/time] fl
25413-6,fluoride urn (24h [moles/time] u)
97286-9,norhydrocodone [presence] in cord tissue by screen method
97286-9,norhydrocodone [ql] in cord tissue screen by method
97286-9,method presence] in ord tisse y screen norhydrocodone
97286-9,norhydrocodone tissco ql scn
97286-9,scn scr tisc ql norhydrocoone
97286-9,q tissco nohydrocodone cn
97286-9,norhydrocodone screen ql (umb cord tissue)
97286-9,norhydrocodone screen presence (umb ordinal cord tissue)
97286-9,norhydcdone cor presence illicit (umb screen tssue
14887-4,primidone [moles/volume] in serum or plasma
14887-4,priidone [mols/volume] in or ser plama
14887-4,or [moles/volue]n serm primide drug/toxicology plasma
14887-4,primidone serpl-scnc
14887-4,serpl-scnc serp prmidone
14887-4,serum serpl-scnc primidone
14887-4,primidone [moles/vol]
14887-4,quan primidone [moles/vol]
14887-4,[moles/vol] primidone
31875-8,measles virus ag [presence] in cerebral spinal fluid
31875-8,measles neuro virus ag [presnce]n cereral spinal luid
31875-8,cerebral virus ag screen [ql] in measles spinal fluid
31875-8,mev ag csf ql
31875-8,mev mev ag csf ql
31875-8,antigen ql csf mevag
31875-8,mev ag ql (csf)
31875-8,ag mv presence (sf)
31875-8,mev ag (csf) ql
62459-3,coccidioides immitis igg ab [presence] in serum by immune diffusion (id)
62459-3,coccidioides immitis igg ab [presence] in serum by immune diffusion imm (id)
62459-3,cocidioids posadasia esteriformis immiti igg by in srum b[prsence] mune diffusion (id)
62459-3,c immitis igg ser ql id
62459-3,c esteriformis cimmitis igg serum ql id
62459-3,c immitis igg ql ser id
62459-3,c. immitis igg immune diff ql (s)
62459-3,c. immitis igg diff immun presence glenosporum louisianoideum s)
62459-3,immune immitis igg c. diff ql (s)
62212-6,promis item bank - pain behavior - version 1.0
62212-6,promis 1.0 bk - pain behavio - verson item
62212-6,promis item bank - pain behavior - version 1.0
22388-3,legionella pneumophila 4 igm ab [titer] in serum
22388-3,legonella in 4 igm ab [tier] pneuophila sum
22388-3,legonell peumophila4igm ab [titer] in serum
22388-3,l pneumo4 igm titr ser
22388-3,serum dilution factor (titer) pneumo4 igm titr l
22388-3,titr neumo4igm l ser pt
22388-3,l. pneumophila 4 igm (s) [titer]
22388-3,(s) pneumophila 4 igm l. [titer]
22388-3,l. pneumophila 4 sr igm (s) [titer]
91858-1,herpes simplex virus 2 dna [presence] in genital specimen by naa with probe detection
91858-1,herpes simplx virs 2 dna [presnce] ingeital specimen b naa with probe detection
91858-1,herpes probe with target amplification simplex virus 2 dna genital in [presence] specimen by naa with probe detection
91858-1,hsv2 dna genital ql naa+probe
91858-1,hsv2 naa+probe genital ql dna
91858-1,qlnaa+prb genitl hs2dna
91858-1,hsv 2 dna naa+probe ql (genital specimen)
91858-1,hsv dnana+probe ql (gnital urogenital spcimen)
91858-1,hsv 2 dna genital tract naa+probeql (genitl secimen)
92989-3,acinetobacter calcoaceticus-baumannii complex dna [ncncrange] in bronchoalveolar lavage by naa with non-probe detection
92989-3,acinetobacter calcoaceticus-baumannii complex dna [ncncrange] ligation-activated transcription in by lavage bronchoalveolar naa with non-probe detection
92989-3,acinetobacter calcoaceticus-baumannii complex dna [ncncrange] in with lavage ncncrng by naa bronchoalveolar non-probe detection
92989-3,acb cmplx dna bal naa+non-prb-ncncrng
92989-3,acb dna cmplx bal naa+non-prb-ncncrng
92989-3,accmplx dn balna+on-prb-ncncrng
92989-3,a. calcoaceticus-baumannii complex dna naa+non-probe (bal) [ncncrange]
92989-3,a.clcoceius-bauanii complex dn aa+non-probe (bal amplified [nccrange]
92989-3,a. calcoaeticus-bamannii complexdnana+nonproe (bal)[ncncrane]
29663-2,dengue virus igm ab [presence] in serum or plasma by immunoassay
29663-2,dengue virus igm serum [presence] in ab or plasma by immunoassay
29663-2,dengue irusigm b resence] in serum or pasma by autoantibodies immunoassay
29663-2,denv igm serpl ql ia
29663-2,denv igm erpl presence ia
29663-2,igm denv serpl ql autoantibody ia
29663-2,denv igm ia ql
29663-2,iiaql immunoglobulin m env
29663-2,denvim ia presence
30046-7,legionella pneumophila ab [units/volume] in serum by immunoassay
30046-7,legionella pnumophil ab serum [unis/volue] in serum by imunassay
30046-7,point in time legionella pneumophila ab [units/volume] in serum by immunoassay
30046-7,l pneumo ab ser ia-acnc
30046-7,autoantibody l pneumo ia-acnc ser ab
30046-7,l ia-acnc ab ser pneumo
30046-7,l. pneumophila ab ia qn (s)
30046-7,l. (s) ab ia qn pneumophila
30046-7,l. autoantibodies pneumophila ab qn ia s)
14815-5,lipoprotein.beta [moles/volume] in serum or plasma by calculation
14815-5,lipoprotein.beta [moles/volume] or serum in plasma by calculation
14815-5,calculation serpl [moles/volume] in serum or plasma by lipoprotein.beta
14815-5,ldl serpl calc-scnc
14815-5,ldl srpl ldl calc-scnc
14815-5,ldl level serpl clc-nc
14815-5,lipoprotein.beta calc [moles/vol]
14815-5,calc lipoprotin.bta serum [moles/vol]
14815-5,lporotei.bet calc sr moles/vol]
88784-4,function and daily living panel [hoos]
88784-4,function and [hoos] living panel daily
88784-4,functionand dailying panel [hos]
25235-3,cefazolin [mass/volume] in specimen
25235-3,cefazolin [mass/volume] in specimen drugs
25235-3,kefj cefazoin mas/volume] in specie
25235-3,cefazolin spec-mcnc
25235-3,spec-mcnc cefazolin
25235-3,cefamezin cefazoinspec-cnc
25235-3,cefazolin (specimen) [mass/vol]
25235-3,(specime) cefazoli [mass/ol]
25235-3,[mss/ol] (pecien) cefazolin cefamezin
87975-9,microscopic observation [identifier] in isolate by gram stain
87975-9,microscopic observation [identifier] id in isolate by gram stain
87975-9,microscopicobseration stain in isolate by gram [identier]
87975-9,gram stn islt
87975-9,stn gram tn ilt
87975-9,grm stn islt
87975-9,microscopic observation gram stain nom (isol)
87975-9,microscopic gram observation stain nom (isol)
87975-9,microscopic observation gram stain nom (isol)
19291-4,cannabinoids cutoff [mass/volume] in urine for screen method
19291-4,cannabinoids method [ms/volume in urine forscreen cutoff
19291-4,method cutoff [mass/volume] in quantitative urine for screen cannabinoids
19291-4,cannabinoids cto ur scn-mcnc
19291-4,cannabinoids cto ur scn-mcnc
19291-4,cannabinoids usn-mcnc ct
19291-4,cannabinoids cutoff screen (u) [mass/vol]
19291-4,cannbinids cutoff screen (u) [mass/vl]
19291-4,cutoffsceen delta-9-tetrahydrocannabinol canabinoids (u) [mass/vl]
8792-4,left ventricular stroke volume index by mr
8792-4,left ventricular stroke by index volume mr mitral regurgitation maximum velocity
8792-4,left ventricuar bsa stroke volume index by mr
8792-4,lv svi mr
8792-4,hrt ventr svimr lv
8792-4,lv svi mr l
97502-9,prion disease biomarker panel - cerebral spinal fluid
97502-9,prion isease biarker panel - ceebrl spinal flud
97502-9,prion disease fluid panel pt - cerebral spinal biomarker
97502-9,prion disease biomarker panel csf
97502-9,prion disease biomarker panel.chemistry panel csf
97502-9,prion disease biomarker panel cerebrospinal fluid
97502-9,prion disease biomarker panel (csf)
97502-9,spinal fluid prion disease biomarker panel (csf)
97502-9,(csf) disease biomarker panel prion
73549-8,acebutolol induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73549-8,aceutolol iduced platletigg ab [presence] in circulating platelet ab serm r plasma by flow ctometry (fc)
73549-8,acebutolol induced platelet igg ind plt igg ab [presence] in serum or plasma by flow cytometry (fc)
73549-8,acebutolol ind plt igg serpl ql fc
73549-8,plt aby acebutol igg serplql f
73549-8,acebutolol ind plt igg serpl antibodies ql fc
73549-8,acebutolol induced platelet igg fc ql
73549-8,acebutolol induced igg platelet fc presence
73549-8,acebutolol induced platelet presence presence fc igg
7855-0,dengue virus 1+2+3+4 rna [presence] in serum by naa with probe detection
7855-0,dengue virus rna 1+2+3+4 [presence] in ser by naa with probe detection
7855-0,dengevirus 1+2+3+4 rna [pesenc] in serum by naa with prob detection
7855-0,denv1+2+3+4 rna ser ql naa+probe
7855-0,env1+2+3+ rna se ql naa+probe
7855-0,denv1+2+3+4 rna qlnaa+probe ser
7855-0,denv 1+2+3+4 rna naa+probe ql (s)
7855-0,denv 1+2+3+4 rna naa+probe dna nucleic acid probe ql (s)
7855-0,denv 1+2+3+4 rna dna nucleic acid probe naa+probe ql (s
73006-9,levetiracetam induced neutrophil igg ab [presence] in serum or plasma by flow cytometry (fc)
73006-9,levetiracetam induced neutrophil igg ab [presence] serum in or plasma by flow cytometry (fc)
73006-9,levetiracetam induced neutrophil igg ab [presence] in serum (fc) plasma by flow cytometry or
73006-9,levetiracetam (neut) igg serpl ql fc
73006-9,levetiracetam (neut) igg neutr serpl ql fc
73006-9,levetiracetam (neut) igg serp presence fc autoantibodies
73006-9,levetiracetam induced neutrophil igg fc ql
73006-9,levetircetam neutropil antibody indud igg ql
73006-9,neutrophil (neut) igg induced levetiracetam igg fc ql
20810-8,deprecated ehrlichia equi ab [presence] in serum
20810-8,deprecated hrlihia equi ab[presence]in qual seru
20810-8,serum ehrlichia equi ab [presence] in deprecated
20810-8,deprecated a phagocytoph ab ser ql
20810-8,deprecated ql phagocytoph ab ser a
20810-8,deprecated a ab phagocytoph ser ql
20810-8,a. phagocytophilum ab ql (s)
20810-8,a.hagocyophilum ab ql (s)
20810-8,phagocytophilum a. ab ql (s)
15170-4,complement total hemolytic c50 [units/volume] in synovial fluid by immunoassay
15170-4,complement total hemolytic c50 [units/volume] in qnt synovial fluid by immunoassay
15170-4,cmlement complmt [unitsvlume]innvialfluid hemolyti50 tota byimmunassay
15170-4,comp c50 snv ia-acnc
15170-4,c50 comp snv ia-acnc
15170-4,comp c50 snv ia-acnc iaa
15170-4,complement total hemolytic c50 ia qn (syn fld)
15170-4,complement total hemolytic qn ia c50 (syn fld)
15170-4,complemet totl hemolytic c50 iaqn (syn elisa fld)
3532-9,desipramine [presence] in serum or plasma
3532-9,ql desipramine [presence] in serum or plasma
3532-9,desipramine [presence] in or ser serp plasma
3532-9,desipramine serpl ql
3532-9,srpl pl desipramine l
3532-9,desipramine ql desmethylimipramine serpl
3532-9,desipramine ql
3532-9,ql serp despramne
3532-9,ql desipramine serum or plasma
2093-3,cholesterol [mass/volume] in serum or plasma
2093-3,cholesterl [mss/oume or ser in plasma
2093-3,cholesterol [mass/volue] in serum or plas
2093-3,cholest serpl-mcnc
2093-3,sepl-mcn chlet quant
2093-3,serpl-mcnc cholest
2093-3,cholesterol [mass/vol]
2093-3,[mass/vo] coleserol
2093-3,cholesterol [mass/vol random
106552-3,campylobacter sp dna [presence] in stool by naa with probe detection
106552-3,campylobacter sp dna [presence] in stool by bowel movement naa with probe detection
106552-3,wit sp dna [presnce] in sool by na campylbacter probe detectin
106552-3,campylobacter dna stl ql naa+probe
106552-3,ql dna st cmpylobacte naa+probe
106552-3,camplobcter stl dna ql naa+prbe
106552-3,campylobacter sp dna naa+probe ql (stl)
106552-3,campylobcter p dna naa+probe 3 self-sustaining sequence replication ql (stl)
106552-3,campylobcter s random dna naa+probe q (st)
35139-5,interferon beta ab [titer] in serum or plasma
35139-5,interferon ser or plasma beta ab [titer] in ser or plasma
35139-5,interferon beta or [titer] in serum ab plasma
35139-5,ifn-b ab titr serpl
35139-5,ifnb serpl titr ab
35139-5,serpl ab titr if-b
35139-5,interferon beta ab [titer]
35139-5,be inteferon ab [tter]
35139-5,pl interfrobea [tite] ab
74451-6,other cells/leukocytes in blood from fetus
74451-6,other fetus in blood from cells/leukocytes
74451-6,other cells/leukocytes cell in blood from fetus
74451-6,other cells nfr bld fetus
74451-6,other cells nfr whole blood bld fetus
74451-6,otr bld fr ces fetus white blood cell
74451-6,other cells/leukocytes (bld fetus)
74451-6,celsleuoctes(bld other fetus)
74451-6,other cells/leukocytes (bld obstetrics fetus)
50148-6,gamma hydroxybutyrate [moles/volume] in amniotic fluid
50148-6,[moles/volume] hydroxybutyrate gamma in amniotic fluid
50148-6,hydroxbutyrate gam quantitative [moles/volume] i amniotic fluid
50148-6,g-oh-butyr amn-scnc
50148-6,g-oh-butyr amniotic flu amn-scnc
50148-6,amn-scnc g-oh-butyr
50148-6,gamma hydroxybutyrate (amn fld) [moles/vol]
50148-6,[moles/vol] hydroxybutyrate (amn fld) gamma
50148-6,level fld hdroxybutyrat(amn gama [mles/vol]
25265-0,oxacillin [mass/volume] in specimen
25265-0,oxacillin specimen in [mass/volume] c116
25265-0,oxacillin [mass/volume] in specimen
25265-0,oxacillin spec-mcnc
25265-0,spec-mcnc oxacillin
25265-0,spec-mcnc misc oxacillin
25265-0,oxacillin (specimen) [mass/vol]
25265-0,oxacillin [mass/vol] (specimen)
25265-0,[mas/vol] xacillin(pecimn)
73879-9,catecholamine metabolites and creatinine panel - urine
73879-9,catecholamine metb metabolites and creatinine panel - urine
73879-9,ur catecholamine metabolites and creatinine panel urine -
73879-9,catecholamines creat pnl ur
73879-9,catecholamines ur pnl creat
73879-9,catecholamines creat ur pnl
73879-9,catecholamine metabolites and creatinine panel (u)
73879-9,catechlamin mtabolites reatnine and panl (u)
73879-9,catecholamine metabolites and panel creatinine (u)
62890-9,phenx - medical history protocol 161301
62890-9,phenx - medical protocol history 161301
62890-9,phenx 161301 medical history protocol -
62890-9,medical history proto
62890-9,medical histor poto
62890-9,history medical pan proto
75630-4,interstitial collagenase [mass/volume] in serum or plasma
75630-4,interstitial collagenase [mass/volume] in ser or plasma
75630-4,irstitial collaenase [as/vlume] in erum or plas
75630-4,mmp-1 serpl-mcnc
75630-4,mmp-1 sepl-mcn
75630-4,mmp-1 sep-mcnc random
75630-4,interstitial collagenase [mass/vol]
75630-4,plas interstitial collagenase [mass/vol]
75630-4,inerstial [mass/vo] collagenase
59885-4,chlorpromazine [moles/volume] in gastric fluid
59885-4,gastric [moles/volume] in chlorpromazine fluid
59885-4,fluid [moles/volume] in gastric chlorpromazine
59885-4,chlorpromazine gast-scnc
59885-4,chlorpromazine quantitative gast-scnc
59885-4,gast-scnc chlorpromazine drugs
59885-4,chlorpromazine (gast fld) [moles/vol]
59885-4,chlorpromazine fld) (gst [ml/ol]
59885-4,chlorpromazine (gast fld) [moles/vol]
56648-9,phenylglyoxylate/creatinine [ratio] in 24 hour urine
56648-9,phenylglyoylate/creatinine [ratio uine 24 hour i
56648-9,phenylglyoxylate/creatinine [ratio] qnt in hour 24 urine
56648-9,phenylglyoxylate/creat 24h ur-rto
56648-9,ur-rto 24h phenylglyoxylate/creat
56648-9,phenylglyoxylate/creat cr 24h ur-rto
56648-9,phenylglyoxylate/creatinine (24h u) [ratio]
56648-9,[ratio] phga 24h u) penyglyoxylate/creatinine
56648-9,(24h phenylglyoxylate/creatinine u) [ratio]
16226-3,benzoylecgonine [mass/volume] in urine by confirmatory method
16226-3,benzoylecgonine [mass/volume] in urine confirmation method confirmatory by
16226-3,benzoylecgonine [mass/volume] confirmatory urine by in method
16226-3,bze ur cfm-mcnc
16226-3,urcfm-mnc bze pt
16226-3,bze ur cfm-mcnc
16226-3,benzoylecgonine confirm (u) [mass/vol]
16226-3,cnfr benzoylecgonine confirm (u) [mass/vol]
16226-3,benzoylecgonine [mass/vol] (u) confirm
14385-9,mononuclear cells/leukocytes in gastric fluid by manual count
14385-9,by cells/leukocytes in gastric fluid mononuclear manual count
14385-9,mononuclear cells/leukocytes by gastric fluid in manual count
14385-9,mononuc cells nfr gast manual
14385-9,mnonuc gast nf cells manual
14385-9,lkcs mnouc cells nfr gast mau
14385-9,mononuclear cells/leukocytes manual cnt (gast fld)
14385-9,mononuclear cells/leukocytes manual cnt (gast fld)
14385-9,ononuclear clls/leukocytes cnt manual (gast fld)
60474-4,reticulocytes [#/volume] in blood by automated count
60474-4,reticulocytes [#/volume] in blood by automated count
60474-4,in [#/volme reticulocytes blod by autmated cunt
60474-4,retics # auto
60474-4,retics # ct auto
60474-4,retic # auto
60474-4,reticulocytes auto (bld) [#/vol]
60474-4,reticulocytes auto [#/vol] (bld)
60474-4,reticulocytes [#/vol] (bld) auto
86559-2,human bocavirus dna [presence] in tissue by naa with probe detection
86559-2,human bocavirus dna detection in tissue by naa with probe [ql]
86559-2,human bocairus dna pesence] naaith random tisse by in proe etection
86559-2,hbov dna tiss ql naa+probe
86559-2,dna hbov tiss ql naa+probe
86559-2,ho dna tiss qlnaa+probe
86559-2,human bocavirus dna naa+probe ql (tiss)
86559-2,human bocavius dna l naa+probe (tiss)
86559-2,qbr human bocavirus dna naa+probe ql (tiss)
96257-1,copper free [mass/volume] in serum or plasma
96257-1,[mass/volume] ree cop in serum or plasm
96257-1,lasma free [mass/vlum] inerum or copper
96257-1,copper free serpl-mcnc
96257-1,copper free serpl-mcnc
96257-1,serpl-mcn copperfre
96257-1,copper free [mass/vol]
96257-1,free copper [mass/vol]
96257-1,[massvol] opperree
64387-4,deprecated phenx measure - balance
64387-4,deprecated bal phenx measure - balance
64387-4,deprecated measure phenx panl - balance
4498-2,complement c4 [mass/volume] in serum or plasma
4498-2,plasma comleent c4 [ass/volme] i eru or plsm
4498-2,serum c4 [mass/volume] in complement or plasma
4498-2,c4 serpl-mcnc
4498-2,sepl-mcnc c4
4498-2,c4 serpl-mcnc
4498-2,complement c4 [mass/vol]
4498-2,c4 complement [mass/vol]
4498-2,[ass/vol] c4 quant omplement
25469-8,meprobamate [moles/volume] in serum or plasma
25469-8,meprobamate [moles/volume] or sr ser in plasma
25469-8,mproamate oplasma ser [molesvolume]in serp
25469-8,meprobamate serpl-scnc
25469-8,meprobamteserpl-cn sr
25469-8,meprobmate serl-scnc
25469-8,meprobamate [moles/vol]
25469-8,meprobaatemles/vo] ser or plasma
25469-8,meprobamate [moles/vol]
23068-0,equine arteritis virus ab [presence] in serum by immune diffusion (id)
23068-0,eqine arteritis virusab [presene]in rum by imme diffusion (d
23068-0,equinearteritis difusion ab [pesence] insem by immune virus (id)
23068-0,eav ab ser ql id
23068-0,ab eav imm serum ql id
23068-0,eav ab serql id
23068-0,equine arteritis virus ab immune diff ql (s)
23068-0,equineateritis ab irus immune diff ql (s)
23068-0,ab arteritis virus equine immune diff presence (s)
106725-5,citizenship card person document
106725-5,ctizenship person cad documet
106725-5,citizenship finding card person document
106725-5,citizenship card person doc
106725-5,citizenship doc person card findings
106725-5,citizenship card doc person
73388-1,ezetimibe induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73388-1,ezetimibe induced platlet ig pl ab [prsence] in serum o plasma by flo cytometry (fc)
73388-1,[presence] induced platelet igm ab ezetimibe in ser or plasma by autoantibodies flow cytometry (fc)
73388-1,ezetimibe ind plt igm serpl ql fc
73388-1,ezetimibe fc plt igm serpl antibodies ql ind
73388-1,ezetimibe ind plt igm serum or plasma thrombocytes ql fc
73388-1,ezetimibe induced platelet igm fc ql
73388-1,ezetimibe induced platelet igm presence fc
73388-1,eetimibe iduedplteet igmfc ql serology
3685-5,hydroxymethoxyphenamine [mass/volume] in urine
3685-5,hydroxymethoxphenamin[mass/volume] inurine ur
3685-5,hydroxymethoxypeamie[mass/volum] in urine
3685-5,oh-methoxyphenamine ur-mcnc
3685-5,ur-cnc oh-metoxyphenamine
3685-5,ur-mcnc oh-ethoxyphenmie
3685-5,hydroxymethoxyphenamine (u) [mass/vol]
3685-5,(u) hydroxymethoxyphenamine quan [mass/vol]
3685-5,(u) hdroxymethoxyphenamin methoxyphenamine metabolite [mass/vol]
72615-8,nordiazepam [presence] in saliva (oral fluid)
72615-8,nordiazeam [presence] in salia (oral fluid)
72615-8,ordiazepm [esenc] in vegesan (ralfluid) salia
72615-8,nordiazepam sal ql
72615-8,sal nordiazepam ql
72615-8,qualitative nordiazepam sal ql
72615-8,nordiazepam ql (sal)
72615-8,madar nordiazpam q (sal)
72615-8,ql nordiaepam (sal)
55846-0,cryoglobulin.iga.monoclonal [presence] in serum
55846-0,cryoglobulin.iga.monoclonal [presence] serum in
55846-0,cryoglobulin.iga.monoclonal [presence] in ql serum
55846-0,cryoglob iga moncl ser ql
55846-0,cryoglob iga sr monc serql
55846-0,cryoglobulins iga cryoglb moncl ser q
55846-0,cryoglobulin.iga.monoclonal ql (s)
55846-0,qualitative cryolobulin.ia.mooonal ql (s)
55846-0,cryoglobulin.iga.monoclonal presence (s)
44820-9,leishmania brasilensis igm ab [titer] in serum by immunofluorescence
44820-9,leishmania basilnis igm ab [titer]n serum by trf imunofluorescence
44820-9,[titer] brasilensis igm ab leishmania in serum by immunofluorescence
44820-9,l braziliensis igm titr ser if
44820-9,l brazliensis igm titer titr ser if
44820-9,l braziliensis igm fluorescent antibody titr serum if
44820-9,l. brasilensis igm if (s) [titer]
44820-9,l.basilenis igm [titer] if(s) autoantibodies
44820-9,l. brasilensis antibody [titer] if (s) igm
48791-8,urea nitrogen peritoneal dialysis clearance/1.73 sq m
48791-8,urea square meter nitrogen peritoneal dialysis clearance/1.73 sq m
48791-8,urea diafp+serum or plasma nitrogen peritoneal dialysis clearance/1.73 sq m
48791-8,urea nit cl/1.73 sq m diafp+serpl-arvrat
48791-8,uea nitcl/1.73 quant diafp+serplarvra sqm
48791-8,urea it cl/.73 sq m diafp+serpl-avra peritoneal dialysis fluid
48791-8,urea nitrogen pd clearance/1.73 sq m (pd fluid+s/p) [vol rate/area]
48791-8,urea nitrogen m cearance/1.73 sq d (pd fluid+s/p) [vol rate/ara
48791-8,urea nirogen pdclearance/1.73 sq m (pd fluid+sp) serp [vol rat/rea]
94352-2,pca-tr igg ab [titer] in serum by immunofluorescence
94352-2,pca-t i paraneoplastic cerebellar degeneration ab [tite] in serum byimmnoflurescenc
94352-2,pc-tr immunoflour ab igg [titr] in srum byimmunoloresnce
94352-2,pca-tr igg titr ser if
94352-2,pca-tr igg ser titr if
94352-2,pca-tr titrser ig f
94352-2,pca-tr igg if (s) [titer]
94352-2,pca-tr igg [titer] (s) if
94352-2,pca-tr igg ifa if (s) [titer]
97305-7,temazepam [presence] in cord tissue by confirmatory method
97305-7,temaepam[resence] in cnfr metd tissue by confrmaory crd
97305-7,temazepam in [presence] conf ordtissue by confirmatory method
97305-7,temazepam tissco ql cfm
97305-7,cfm tissco presence temazepam
97305-7,tissco temazepam ql cfm
97305-7,temazepam confirm ql (umb cord tissue)
97305-7,temazepam confirm ql (umb ordinal cord tissue)
97305-7,temazepam cnfirm ql (umb tissue) cord
87306-7,clostridium perfringens cpe gene [presence] in isolate by naa with probe detection
87306-7,ordinal clostridim rfringen cp gene [presene in isoate by aa with probe detection
87306-7,clostridium perfringens cpe gene [presence] in isolate by naa with probe detection
87306-7,c perfringens cpe islt ql naa+probe
87306-7,c perfringenscpe naat islt ql +probe
87306-7,nasba c perfringens cpe islt ql naa+probe
87306-7,c. perfringens cpe gene naa+probe ql (isol)
87306-7,c. perfringens (isol) gene naa+probe ql cpe
87306-7,naa+probe perringens cpegene c. ql isol)
57706-4,congenital adrenal hyperplasia newborn screening comment-discussion
57706-4,congenial commet-iscuson random hyperplasia newborn screeing adenal
57706-4,congenital hyperplasia new born adrenal newborn screening comment-discussion
57706-4,cah nbs comment
57706-4,nbs cah filter paper comment
57706-4,cmmt comment nbs cah
57706-4,congenital adrenal hyperplasia newborn screening comment-discussion nar (dbs)
57706-4,congenital adrenal hyperplasia newborn screening com comment-discussion nar (dbs)
57706-4,congenital adrenal nar newborn screening comment-discussion hyperplasia (dbs)
91551-2,other cells/leukocytes in dialysis fluid by manual count
91551-2,other cel/leukocytes in dialysis flui by manual count
91551-2,other cells/leukocytes in dialysis quant fluid by manual count
91551-2,other cells nfr dial fld manual
91551-2,other fldmanual nfr dial cels
91551-2,oter fld dialysate nfrdial cels maual
91551-2,other cells/leukocytes manual cnt (dial fld)
91551-2,othe cels/leukocyte manual cnt (dial fld)
91551-2,other cells/leukocyts manual cnt (dial ld)
3583-2,doxepin+metabolites [mass/volume] in serum or plasma
3583-2,doxepin+metabolites serum [mass/volume] in serum or plasma
3583-2,insem doxpin+metabolites[mass/volue] or plasma
3583-2,doxepin+metab serpl-mcnc
3583-2,doxepin+metab serpl serp-mcc
3583-2,serpl-mcnc doxepin+metab
3583-2,doxepin+metabolites [mass/vol]
3583-2,doxepin+metabolites [mass/vol] doxpin
3583-2,[mass/vol] doxepin+metabolites plsm
23150-6,leishmania donovani ag [presence] in tissue by immune stain
23150-6,leishmania donovani by [presence] in tissue ag immune stain
23150-6,leishmnia donovani g presence] ihc in tissue byimmune stain
23150-6,l donovani ag tiss ql imstn
23150-6,l ql dnovani ag tis qlimstn
23150-6,ag ldonoani tis ql imn l donovani
23150-6,l. donovani ag immune stain ql (tiss)
23150-6,l. stain ag immune donovani presence (tiss)
23150-6,ag donovani l. immunestain presence(tiss infectiousdisease
68400-1,eosinophils [#/volume] in pleural fluid by manual count
68400-1,eosinophils [#/volume] in pleural fluid by absolute manual count
68400-1,eosinophils [#/volume] in pleural fluid by manual count
68400-1,eosinophil # plr manual
68400-1,plr # eosinophil manual manl
68400-1,eoinophil # plr manual
68400-1,eosinophils manual cnt (pleur fld) [#/vol]
68400-1,eosinophils manual cnt (pleur fld) [#/vol]
68400-1,eosnophil manual fld) (leur cnt [#/vol]
13401-5,hydroxyproline [mass/volume] in amniotic fluid
13401-5,hydroxyprolin [masolume] amnitic in fluid
13401-5,hydroxyproline mass/volume] in amniotic fui
13401-5,oh-proline amn-mcnc
13401-5,amn-mcnc oh-proline
13401-5,amn-mnc oh-oin af
13401-5,hydroxyproline (amn fld) [mass/vol]
13401-5,hydroxyproline hydroxylproline (amn fld) [mass/vol]
13401-5,qnt hydroxyproline (amn fld) [mass/vol]
56925-1,fractional excretion of phosphate [ratio] in 24 hour urine and serum or plasma
56925-1,fractonal xcretion hour hosphate [ratio] in 24 of urine and ser o plasma plsm
56925-1,fractinal excretion and phopate [ratio] in 24 hour urie phosphorous o serum or plasma
56925-1,fract excret po4 24h ur+serpl-rto
56925-1,fract phos excret po4 24h ur+serpl-rto
56925-1,fract 24h po4 ratios excret ur+serum or plasma-rto
56925-1,fractional excretion of phosphate (24h u+s/p) [ratio]
56925-1,fractonal excretion serum of phosphate (24 u+s/p) ratio]
56925-1,fractonalexcretion of phoshate (24h u+s/p) [atio]
59331-9,dinorsibutramine [mass/volume] in blood
59331-9,drug/toxicology dinorsibutramine [mass/volume] in blood
59331-9,inorsbutramine [mass/volume] in lood
59331-9,dinorsibutramine bld-mcnc
59331-9,bl-cnc dinorsbutramine quan
59331-9,whole blood bld-mcnc dinorsibutramine
59331-9,dinorsibutramine (bld) [mass/vol]
59331-9,dinorsibutramin (bld) [mass/vl] whole blood
59331-9,dinorsibutramine (blood) [mass/vol] mass concentration
59595-9,7-aminoclonazepam [mass/volume] in serum or plasma by confirmatory method
59595-9,7-aminoclonazepam point in time [mass/volume] in serum or plasma by confirmatory method
59595-9,method [mass/volume] in ser or plasma by lc/ms/ms confirmatory 7-aminoclonazepam
59595-9,7aminoclonazepam serpl cfm-mcnc
59595-9,7aminoclnazeam serpl cfmmcnc clonazepam metabolite
59595-9,lc/ms/ms 7aminoclonazepam serpl cfm-mcnc
59595-9,7-aminoclonazepam confirm [mass/vol]
59595-9,7-aminoclonazepam [mass/vol] confirm
59595-9,7-aminoclonazepam confirm [mass/vol] serum
49342-9,bk virus dna [#/volume] (viral load) in tissue by naa with probe detection
49342-9,bk virus dna [#/volume] (viral in naa+probe load) tissue by naa with probe detection
49342-9,bk virus da #/voum] count/volume (ial load) in tissue by naa wih rob detection
49342-9,bkv dna # tiss naa+probe
49342-9,bkv # dna tiss naa+probe
49342-9,bkv tss # dna naa+prbe
49342-9,bk virus dna naa+probe (tiss) [#/vol]
49342-9,b irus d naa+prbe (tiss [#/vol]
49342-9,bkirus na na+prob (tiss) [#/vol]
23828-7,bordetella pertussis filamentous hemagglutinin igg ab [units/volume] in serum
23828-7,bordetella serum filamentous hemagglutinin serum igg ab [units/volume] in pertussis
23828-7,erum hemglutinin gg ab [units/volume in bordetelapetussisfiaetous
23828-7,b pert fha igg ser-acnc
23828-7,infectious disease b pert fha igg ser-acnc
23828-7,b pert fha b pert fha igg ser-acnc
23828-7,b. pertussis filamentous hemagglutinin igg qn (s)
23828-7,filament hemagglutinin pertussis filamentous b. igg qn (s)
23828-7,b. hemagglutinn filamentous pertussis igg qn (s)
98497-1,visual acuity panel
98497-1,pnl acuity optic globe visual
98497-1,visal acuity pnl panel
98497-1,visual acuity pnl
98497-1,vsual vision pnl acity
98497-1,isual acutypnl
100855-6,cd3 cells/cells in blood mononuclear cells
100855-6,cd cells/cells i lod monuclear cells
100855-6,mononuclear cells/cellsn bood cd3 cells
100855-6,cd3 cells bld mc-nfr
100855-6,mc-nfr cells t3 bld cd3
100855-6,cd3 cells bld mc-fr
100855-6,cd3 cells/cells (bld mc)
100855-6,mc) cells/cells (bld cd3
100855-6,cd3 cells/ells (bl mc) point in time
17476-3,porphyrins [units/volume] in red blood cells
17476-3,[ui/volme]ired orpyrins bloodcells
17476-3,orphyrns [units/volume]in red boo cells
17476-3,porphyrins rbc-acnc
17476-3,rbc-acnc prphrins quantitative
17476-3,prphyrins rbcacnc
17476-3,porphyrins qn (rbc)
17476-3,n(rbc) porphyris point in time
17476-3,pophyins qn (rbc)
30557-3,smooth muscle igg ab [presence] in serum
30557-3,smooth mue igg prsenc ab in srum
30557-3,smooth musce igg b [rence] serum in ql
30557-3,smooth muscle igg ser ql
30557-3,smooth muscle igg ser ql
30557-3,smooth muscl muscle igg serum ql
30557-3,smooth muscle igg ql (s)
30557-3,smooth muscle igg ql musc (s)
30557-3,smooth muscle igg ql (s) sma
101976-9,voltage-gated calcium channel p/q type binding ab [mass/volume] in serum by immunoassay
101976-9,voltage-gated calcium channel p/q type binding ab [mass/volume] by serum in iaa immunoassay
101976-9,oltage-gated calciu channel p/qtyp binding a imunossa serum by [massvolume] abs
101976-9,vgcc-p/q bind ab ser ia-mcnc
101976-9,vgcc-pq iamc abser bind
101976-9,vgcc-p/q iaa ab bind ser ia-mcnc
101976-9,voltage-gated calcium channel p/q type binding ab ia (s) [mass/vol]
101976-9,voltage-gated calcium channel p/q type autoantibody binding ab ia (s) [mass/vol]
101976-9,voltage-gated channel calcium p/q type binding ab ia (s) [mass/vol]
44482-8,herpes simplex virus 1+2 igg ab [presence] in body fluid
44482-8,herpes simpe ab[presnce] 12 ig virus inboy fluid
44482-8,erpes igg virus 1+2 simple ab [presence] in bdy fluid
44482-8,hsv1+2 igg fld ql
44482-8,hsv+2 iggfld random l
44482-8,sv1+2 ig fl q
44482-8,hsv 1+2 igg ql (body fld)
44482-8,hsv 1+2 igg l (bodyl)
44482-8,fld) 1+2 igg ql (body hsv
3428-0,canrenone [presence] in urine
3428-0,urine canrenone[presence]in
3428-0,canrenone [prsence] in ql rine
3428-0,canrenone ur ql
3428-0,canrenoneur drugs l
3428-0,canrenone presence ur
3428-0,canrenone ql (u)
3428-0,arenoeql (u)
3428-0,canrenone ql (u)
6544-1,rickettsia sp identified in genital specimen by organism specific culture
6544-1,rickettsia p idntified in gnialspecimen by rganism specific culture spec
6544-1,rickettsia sp identified in genital specimen by organism specific culture
6544-1,rickettsia genital cult
6544-1,species cult genital rickettsia
6544-1,rikettsia genital cult
6544-1,rickettsia sp identified org specific cx nom (genital specimen)
6544-1,rickettsia sp identified org spp specific cx nom (genital specimen)
6544-1,rickettiasp identified cxnom specific org (genital spcimen) nominal
95206-9,hepatitis c virus ab panel - serum or plasma
95206-9,hepatitis c virus orpasma panel- ser ab
95206-9,hepatitis c virus ab panel - serum plasma or
95206-9,hcv ab pnl serpl
95206-9,ab cv hep plserpl
95206-9,hcv serpl pnl ab
95206-9,hcv ab panel
95206-9,hc ab panel
95206-9,ab panel.microbiology hcv panel
2071-9,chloride [moles/volume] in dialysis fluid
2071-9,chloride [moles/volume] dialysate in dialysis fluid
2071-9,chloride dialysis in [moles/volume] fluid
2071-9,chloride dial fld-scnc
2071-9,dial chloride fld-scnc
2071-9,chloride dial fld-scnc
2071-9,chloride (dial fld) [moles/vol]
2071-9,(dial chloride fld) [moles/vol] chemistry
2071-9,fld) (dial chloride [moles/vol]
25510-9,proline [moles/time] in 24 hour urine
25510-9,proline [moles/time] in 24 chemistry hour urine
25510-9,proline [moles/time] in 24 quant hour urine
25510-9,proline 24h ur-srate
25510-9,proline ur-srate 24h
25510-9,ursrate 24h proline substance rate
25510-9,proline (24h u) [moles/time]
25510-9,proline [moles/time] u) (24h
25510-9,proline qnt (24h u) [moles/time]
88956-8,deprecated minimum data set (mds) - version 3.0 - resident assessment instrument (rai) version 1.16.1 [cms assessment]
88956-8,deprecated mnmum pan dt set (mds) - ersion 3.0 - resident assesmnt instrument (ai)version 1.16.1 [ms assesment]
88956-8,deprecated minimum data set random (mds) - version 3.0 - version assessment instrument (rai) resident 1.16.1 [cms assessment]
73531-6,amlodipine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73531-6,amlodipine induced platelet serum ab [presence] in igg or plasma by flow cytometry pl (fc)
73531-6,amlodipine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc) antibody
73531-6,amlodipine ind plt igg serpl ql fc
73531-6,amlodipine serplas ind plt igg serpl ql fc
73531-6,amlodipine antibodies ind plt igg serpl ql fc
73531-6,amlodipine induced platelet igg fc ql
73531-6,amlodipine induced fc igg platelet ql
73531-6,amlodipine induced platelet igg fc ql
49310-6,nuclear ab pattern [interpretation] in serum narrative
49310-6,nuclear [interrtation] abpttrn i serum nartive
49310-6,serum ab pattern [interpretation] in nuclear narrative
49310-6,ana pat ser-imp
49310-6,ana ser-imp pat abs
49310-6,ana pt serum-mp
49310-6,nuclear ab pattern nar (s) [interp]
49310-6,nar ab pattern nuclear anf (s) [interp]
49310-6,nuclear ab na pattern nar (s) [interp]
31577-0,pseudorabies virus ab [units/volume] in serum
31577-0,pseudorabies ser ab [units/volume] in virus
31577-0,porbis virus ab [units/volum] insrum
31577-0,prv ab ser-acnc
31577-0,ser-acnc ab prv porcine herpes virus 1
31577-0,ser-acnc ab aujeszky's disease pr
31577-0,pseudorabies virus ab qn (s)
31577-0,(s) virus point in time a qn pseudoabies
31577-0,seuorabies virus s microbiology qn a
33677-6,francisella tularensis [presence] in isolate by organism specific culture
33677-6,specifc tularensis ql] in isolat by organism francisela culture point in time
33677-6,francisella tularensis [presence] in isolate by organism cultures specific culture
33677-6,f tular islt ql cult
33677-6,f uar islt ql ult
33677-6,presence tular islt f cult
33677-6,f. tularensis org specific cx ql (isol)
33677-6,f. tularensis org specific cx presence (isol) qual
33677-6,f. tularensis presence specific cx org (isol)
16123-2,cryptococcus sp ab [titer] in cerebral spinal fluid
16123-2,cryptococcus sp ab cerebral in [titer] spinal fluid
16123-2,fluid sp ab titered [titer] in cerebral spinal cryptococcus
16123-2,cryptoc ab titr csf
16123-2,cryptoc ab csf titr species
16123-2,cryptoc ab titr csf spinal flu
16123-2,cryptococcus sp ab (csf) [titer]
16123-2,cryptococcus sp ab [titer] (csf)
16123-2,autoantibodies cryptococcus sp ab (csf) [titer]
41218-9,xipamid [presence] in urine
41218-9,xipamid [presence] in aquaphoril urine
41218-9,xipamd [resence] inuine
41218-9,xipamid ur ql
41218-9,xipamid drug/toxicology ur ql
41218-9,ur xipamid ordinal ql
41218-9,xipamid ql (u)
41218-9,(u) xipamidql presence
41218-9,ql xipamid drug/toxicology (u)
4543-5,haptoglobin [mass/volume] in serum or plasma by electrophoresis
4543-5,haptoglobin [mass/volume] in serum or plasma quantitative by electrophoresis
4543-5,haptoglobin [mas/volume] in serumor plasma by eletophoresis
4543-5,haptoglob serpl elph-mcnc
4543-5,haptoglob elph-mcnc serpl
4543-5,haptoglbep elph-mcnc
4543-5,haptoglobin elph [mass/vol]
4543-5,elp hapoglobin [mss/vol]
4543-5,[mass/vol] elph haptoglobin
71689-4,mononuclear cells [#/volume] in body fluid by automated count
71689-4,mononuclear cells[#/volume] n body luid batomated count elec
71689-4,mononuclear cells mononuc [#/volume] in body fluid by automated count
71689-4,mononuc cells # fld auto
71689-4,mononuc auto # fld cells
71689-4,mononc cels ld # uto
71689-4,mononuclear cells auto (body fld) [#/vol]
71689-4,mononclear cels (body auto fl[#/vol]
71689-4,cells mononuclear auto (body fld) [#/vol]
63357-8,smooth muscle ab [presence] in cerebral spinal fluid by immunofluorescence
63357-8,smooth musceab[presence]in crebral spina fluid b mmunoluorescence
63357-8,moh mucle ab [ql] neuro in cerebral spnal fluid by immunofluorescence
63357-8,smooth muscle ab csf ql if
63357-8,smooth musle a ql cerebrospinal fluid if
63357-8,ql muscle ab csf smooth if
63357-8,smooth muscle ab if ql (csf)
63357-8,ab muscle smooth if ql (csf)
63357-8,smooth muscle ab ql if (csf)
20838-9,herbicide [presence] in gastric fluid by screen method
20838-9,herbiide [pesene] n b fluid gastric sceen methd
20838-9,herbicide [presence] scr in gastric fluid by screen method
20838-9,herbicide gast ql scn
20838-9,scn gast ql herbicide
20838-9,erbiide gatql scn gast
20838-9,herbicide screen ql (gast fld)
20838-9,herbcide presence screen (gast fld)
20838-9,herbicidescreen fl (gast ql
62731-5,"deprecated phenx measure - medications - pain relievers, statins, steroids"
62731-5,"deprecated phenx measure relievers, medications - pain - statins, steroids"
62731-5,"deprecated phenx relievers, - random medications - pain measure statins, steroids"
25957-2,methionine sulfoxide [moles/volume] in 24 hour urine
25957-2,[moles/volume] sulfoxide methionine in 24 hour urine
25957-2,methionine sulfoxide [moles/volume] in 24 hour urine
25957-2,mso 24h ur-scnc
25957-2,ur-scnc 24h quant mso
25957-2,u-sn 24h so
25957-2,methionine sulfoxide (24h u) [moles/vol]
25957-2,methionine sulfoxide (24h u) [moles/vol] substance concentration
25957-2,methionine sulfoxide (24h u) 1 day [moles/vol]
6880-9,cystathionine [mass/time] in 24 hour urine
6880-9,[mass/time] cystathionine in 24 hour urine
6880-9,cystathionine [mass/time] in 24 hour urine
6880-9,cystathionin 24h ur-mrate
6880-9,cystathionin ur-mrate 24h mrate
6880-9,cystathionin ur-mrate 24h
6880-9,cystathionine (24h u) [mass/time]
6880-9,[mass/time] (24h u) cystathionin quant
6880-9,cstathionine (24hu) [mss/tim] quantitative
62596-2,phenx - oral health - oral mucosal lesions protocol 081001
62596-2,phn -oral health - ora mucoal lesionsotocol 081001
62596-2,phenx -al heath - oralmuosal lesion protocol 8100
62596-2,oral mucosal lesions proto
62596-2,lesions mucosal oral proto panel.phenx
62596-2,oral pan mucosal lesions proto
25126-4,phenylpyruvate/creatinine [molar ratio] in urine
25126-4,phenylpyruvate/creainine [molarratio] in chemistry rine
25126-4,rtio] [molar phenylpyruvate/ceatine phenylpyruvic acid in urine
25126-4,phenylpyruvate/creat ur-srto
25126-4,ur-srto phnylyruvate/creat
25126-4,ur-srto phenylpyruvate/creat
25126-4,phenylpyruvate/creatinine (u) [molar ratio]
25126-4,phenylpyruvate/creatinine (u) [molar ratio] ur
25126-4,molarratio] (u) phenylyruvate/creatinine
22588-8,deprecated treponema pallidum ab [presence] in serum
22588-8,deecatedtreponema pallidum ab [presenc] n seum
22588-8,deprecated treponema pallidum ab [presence] in serum
22588-8,deprecated t pallidum ab serpl ql
22588-8,deprecated t alidum erpl ab presence
22588-8,pallidum t deprecated ab serpl ql
22588-8,t. pallidum ab ql
22588-8,sr . pallidum abl
22588-8,t. pallidum point in time ab ql
106975-6,dihydroboldenone [presence] in urine by gas chromatography-mass spectrometry
106975-6,dihydroboldnone [presene] n urine by gs chrmatogrphy-ass spectromtry
106975-6,dihydroboldenone [presence] by urine in gas chromatography-mass spectrometry
106975-6,dihydroboldenone ur ql gc-ms
106975-6,dihydrobolenone ql ur gc-s
106975-6,gc-ms ur diydroboldenn
106975-6,dihydroboldenone gas chromatography-mass spectrometry ql (u)
106975-6,dihydroboldenone gas spectrometry chromatography-mass ql (u)
106975-6,dihydroboldenone gas chromatography-mass spectrometry ur ql (u)
93502-3,nmdar subunit 1 igg ab [presence] in cerebral spinal fluid by cell binding immunofluorescent assay
93502-3,nmdar subunit 1 igg ab immunofluorescent in cerebral spinal fluid by cell binding [presence] assay
93502-3,nmdar cerebral 1 igg ab [ql] in subunit spinal fluid by cell binding immunofluorescent assay
93502-3,nmdar1 igg csf ql cba ifa
93502-3,nmdar1 igg csf spinal fl ql cba ifa
93502-3,ql igg cerebrospinal fluid nmdr1 cba ifa
93502-3,nmdar subunit 1 igg cell binding immunofluorescent assay ql (csf)
93502-3,immunofluorescent subunit 1 igg cell binding nmdar assay ql (csf)
93502-3,nmar subunit 1 ql cell biding immunofluorscent assay igg (cerebrospinal fluid)
18724-5,hla studies (set)
18724-5,ha studies (set)
18724-5,(set) sudies lab ha
3053-6,triiodothyronine (t3) [mass/volume] in serum or plasma
3053-6,triiodotyonine (t3) [mass/volume] in serum serpl
3053-6,[mass/volume] (t3) triiodothyronine in ser or plasma quan
3053-6,t3 serpl-mcnc
3053-6,serpl-mcnc t3
3053-6,serpl-mcnc t3
3053-6,t3 [mass/vol]
3053-6,[mass/vol] t3
3053-6,t3 [mass/vol]
38280-4,lymphocyte proliferation stimulated by 5.0 ug/ml candida albicans [units/volume] in blood
38280-4,lymphocyte prolfertion stmulted by5.0ug/ml candida lbicans [unis/volum] in blood m005
38280-4,lymphocyte proliferation in by 5.0 ug/ml candida albicans [units/volume] stimulated blood candidiasis
38280-4,lpt 5.0 ug/ml ca bld-acnc
38280-4,lpt 5.0 ug/ml ca bld-acnc
38280-4,pt 5.0 quantitative u/ml ca bld-acnc
38280-4,lymphocyte proliferation stimulated by 5.0 ug/ml candida albicans qn (bld)
38280-4,yphoyte roferatin stimulate y 5.0 quantitative u/l candidaalicans q (bld)
38280-4,lymphoe prolifeatin stimlatedby 5.0 andid ug/ml alicans d)
30316-4,alpha subunit free [mass/volume] in serum or plasma
30316-4,alpha subunit free [mass/volume] in serpl
30316-4,serplas alpa suun free [mass/volue] in serm or plasma
30316-4,alpha subunit free serpl-mcnc
30316-4,subnit alfa alpha freesep-mcnc
30316-4,free alpaubuit srpl-mcnc
30316-4,alpha subunit free [mass/vol]
30316-4,alpha subunit free [mass/vol]
30316-4,suunit apha free [mas/vol]
16210-7,diethylpropion [presence] in urine by confirmatory method
16210-7,diethylpropion [ql] in addiction urine by confirmatory method
16210-7,diethylpropion confirmatory in urine by [presence] method
16210-7,diethylpropion ur ql cfm
16210-7,ur cfm ur ql diethylpropion
16210-7,ql ur amphepramone diethylpropion cfm
16210-7,diethylpropion confirm ql (u)
16210-7,ql confirm diethylpropion (u) screen
16210-7,(u) confirm ql diethylpropion
551-2,brucella sp identified in blood by organism specific culture
551-2,brucella id sp identified in blood by organism specific culture
551-2,brucella sp identified in culture by organism specific blood
551-2,brucella bld cult
551-2,brucella c&s blood cult
551-2,brucela cul bld
551-2,brucella sp identified org specific cx nom (bld)
551-2,brucellasp denifiedorg specific cx om (bld)
551-2,brucella spenfied org specifi identity or presence cx nom (bl)
16448-3,cocaine [units/volume] in urine
16448-3,ccane [units/volume] in urine
16448-3,[unit/olume] ccaine in rine
16448-3,cocaine ur-acnc
16448-3,ur-acnc cocaine
16448-3,cocaie ur-acnc
16448-3,cocaine qn (u)
16448-3,qn cocaie (u)
16448-3,cocaine qn (u)
82134-8,respiratory pathogens dna and rna tested for in respiratory system specimen by naa with probe detection
82134-8,respirato respiratory dna andrna tested fori pathogens systemsecimen by naait probe etetion
82134-8,respiratory pathogens dna and rna tested specimen in respiratory system for by naa with probe detection
82134-8,resp path dna+rna tested resp naa+probe
82134-8,resp naa+probe dna+rna tested amplified resp path
82134-8,resp path naa+probe tested resp dna+rna nasba
82134-8,respiratory pathogens dna and rna tested naa+probe nom (respiratory system specimen)
82134-8,respirtory patogens dna and rna breathing ested aa+probe nom (resiratory system specime)
82134-8,respiratory pathogens dna and rna tested naa+probe nom system tma (respiratory specimen)
49298-3,protein fractions [interpretation] in serum or plasma narrative
49298-3,protein fractions random [interpretation] in or serum plasma narrative
49298-3,poteinractions [interretatin] in serum or plasma narratv
49298-3,prot pattern serpl-imp
49298-3,serp-ip pattern prot pr
49298-3,prot pattern serum or plasma-imp
49298-3,protein fractions nar [interp]
49298-3,potein fractions nar [nterp]
49298-3,protein [iterp nar fractins
63229-9,dna double strand igg ab [units/volume] in cerebral spinal fluid by immunoassay
63229-9,dna double sad suds igg ab i [unis/olume] ceebra spinalfluid by immnoassay
63229-9,dna double strand igg ab [units/volume] in aby cerebral spinal fluid by immunoassay
63229-9,dsdna igg csf ia-acnc
63229-9,iggcsf dsdna i-acn autoantibody
63229-9,dsdna igg csf ia-acnc immune globulin g
63229-9,dna double strand igg ia qn (csf)
63229-9,na eia double strnd gg ia qn (csf)
63229-9,dna double stranigg qn ia (sf)
76704-6,promis short form - satisfaction with participation in social roles 4a - version 1.0
76704-6,promis short fo  satisfction with partcipation in ocial roes 4a - vesion .0
76704-6,promis short form - satisfaction with participation in social 1.0 4a - version roles
33350-0,lysergate diethylamide [mass/volume] in urine by screen method
33350-0,lysergate diethylamide [mass/volume] in urine by screen method
33350-0,lysergate diethylamide [mass/volume] in urine by screen method
33350-0,lsd ur scn-mcnc
33350-0,ld scn-mcnc u
33350-0,scn-mcnc ur lsd
33350-0,lysergate diethylamide screen (u) [mass/vol]
33350-0,screen)[mass/ol ysergatedithylamide
33350-0,lyserge diehylmde potentialforabuse [massvol] (u) scren
74309-6,prrsv orf5 gene sequence homology to ingelvac mlv in isolate by sequencing
74309-6,prrsv seqencig genesequence homology swine to ingelvac mlv in isolate by orf5
74309-6,prrsv orf5 gene isolate homology tongelvc mlv in sequence by lelystad virus sequenig
74309-6,prrsv ingmlv hmlgy islt seq-nfr
74309-6,prrsv hmlgy ingmlv prrsv islt seq-nfr
74309-6,hmlgy ingmlv prrsv islt seqnf
74309-6,prrsv orf5 gene sequence homology to ingelvac mlv sequencing (isol)
74309-6,prrsv or5 microbiology seuencing sequence homology t igelvac mlv gen (isol
74309-6,prrsv sequence gene orf5 homology to ingelvac mlv sequencing (isol)
38343-0,chlorobenzene [mass/volume] in water
38343-0,chloobenzene [mass/lume] in ater
38343-0,water [mass/volume] n drugs chlorobenzee
38343-0,chlorobenz wat-mcnc
38343-0,benzene chloride wat-mcnc chlorobenz
38343-0,chlorobenz wat-mcnc quantitative
38343-0,chlorobenzene (water) [mass/vol]
38343-0,water) quantitative hlorobenene [mass/vol]
38343-0,chlorbenzene (watr) [mass/vol]
95714-2,varicella zoster virus igg ab [units/volume] in specimen by immunoassay
95714-2,varicella zoster virus igg ab [units/volume] in specimen by immunoassay
95714-2,varicella quantitative by irus ig ab [nits/volume] in spcien zoster immunoassy
95714-2,vzv igg spec ia-acnc
95714-2,vzv spec igg ia-acnc
95714-2,ia-acnc igg spec vzv
95714-2,vzv igg ia qn (specimen)
95714-2,vzvigg ia qnt (speimen) qn
95714-2,qn ig a elisa vz specimn)
20542-7,lysergate diethylamide [mass/volume] in urine by confirmatory method
20542-7,urine diethylamide [mass/volume] in level lysergate by confirmatory method
20542-7,quan lysergate dithylamide [mssvolum] in urine by confirmary metho
20542-7,lsd ur cfm-mcnc
20542-7,cfm-mcc lsdur
20542-7,cfm-mcnc ur lsd quantitative
20542-7,lysergate diethylamide confirm (u) [mass/vol]
20542-7,lysergate [mass/vol] confirm (u) diethylamide gcms
20542-7,lysergate diethylamide (u) confirm [mass/vol]
2552-8,lactose [mass/volume] in serum or plasma
2552-8,lacse[mss/vume] in serm or plasma
2552-8,lactose [mass/volume] or serum in plasma
2552-8,lactose serpl-mcnc
2552-8,serpl-mcnc quant lactose
2552-8,random serpl-mcnc lactose
2552-8,lactose [mass/vol]
2552-8,point in time lactose [mass/vol]
2552-8,mass/vl] lactose
34265-9,chloride/creatinine [molar ratio] in urine
34265-9,chlride/ceainine [lr atio] n rne
34265-9,chloride/creatinine [molar ratio] in urine
34265-9,chloride/creat ur-srto
34265-9,chlorie/creat u-srt
34265-9,ur-srto chloride/creat
34265-9,chloride/creatinine (u) [molar ratio]
34265-9,chloride/creatinine (u) ratio] [molar
34265-9,chloride/creatinine quantitative (u) ratio] [molar
86803-4,provider death registration - recommended cda r1 sections
86803-4,provider sects recommendcda r1 deathreisratio
86803-4,provider death registration - recommended sections r1 cda
86803-4,provider death reg cda r2.1 sec
86803-4,reg provider death reg cda r2.1 sec dath provider cda r2.1 sec
86803-4,provide eath reg cda r2.sec
99004-4,leptospira santarosai sv borincana ab [titer] in serum by agglutination
99004-4,leptospia [titer] sv borincana ab santarosai in serum b agglutination
99004-4,leptospira santarosai sv borincana ab [titer] serum in by agglutination
99004-4,l santarosai borincana ab titr ser aggl
99004-4,l santarosai aggl ab titr serum borincana
99004-4,l santarosai borincana ab titr serum aggl
99004-4,leptospira santarosai sv borincana ab aggl (s) [titer]
99004-4,leptospira satarosai s serum rincna ab [titer] (s) aggl
99004-4,leptospira anti santarosai sv borincana ab aggl (s) [titer]
55905-4,alpha cortol [mass/volume] in 24 hour urine
55905-4,alpha cortol [mass/volume] in 24 quantitative hour urine
55905-4,alpa cortol [mas/volume] n mass concentration 2 hour uri
55905-4,a-cortol 24h ur-mcnc
55905-4,ua a-corol24h ur-mcn
55905-4,ur-mcnc 24h a-cortol ua
55905-4,alpha cortol (24h u) [mass/vol]
55905-4,[mass/vol] cortol (24h u) alpha
55905-4,u) cortol (24h alpha [mass/vol]
68416-7,mesothelial cells [#/volume] in pleural fluid by manual count
68416-7,esothelial cells [#/volume] in pleural flud bymanual count
68416-7,mesothelial cells [#/volume] in pleural fluid by manual count mesothl cell
68416-7,mesothl cell # plr manual
68416-7,manual cell # plr mesothl
68416-7,mesothl # cell plr manal
68416-7,mesothelial cells manual cnt (pleur fld) [#/vol]
68416-7,mesothelial cells manual (pleur cnt fld) [#/vol]
68416-7,fld) cells mnual count cnt (pleur mesothelal [/vol]
23445-0,swine vesicular disease virus ag [presence] in skin by complement fixation
23445-0,swinevesicular diseae viru ag [prence] in ski y complement fixation
23445-0,swine vesicular disease virus ag cf [presence] in skin by complement fixation
23445-0,svd ag skin ql cf
23445-0,svd cf skin ql ag
23445-0,cf ql ag skin svd cf
23445-0,swine vesicular disease virus ag cf ql (skin)
23445-0,swine veicular diseae virus gcf presence (skn)
23445-0,swine iesevirus vesicular ag f ql (skin)
1995-0,calcium.ionized [moles/volume] in serum or plasma
1995-0,calcium.ionied [molesvolume] in serum universallaborders orplasma
1995-0,calcium.ionized [moles/volume] serum in or plasma
1995-0,ca-i serpl-scnc
1995-0,ca-i qnt serpl-scnc
1995-0,serpl-scnc ca-i
1995-0,calcium.ionized [moles/vol]
1995-0,[moles/vol] calcium.ionized
1995-0,[mole/vol] alcium.ionized
55560-7,orphenadrine [moles/volume] in serum or plasma
55560-7,orphenadrine [moles/volume] in ser or plasma
55560-7,orphenadrine [moles/volume] n ser myotrol o plsma
55560-7,orphenadrine serpl-scnc
55560-7,serl-scnc orphenadrine plasma
55560-7,serpl-cnc brocasipal orphenadrine
55560-7,orphenadrine [moles/vol]
55560-7,orpenadrne [mole/vol]
55560-7,orphenarine[moes/vol]
72201-7,influenza virus a matrix protein segment sequence identifier
72201-7,nflunza virus a matri poteinsegment dentifier sequence
72201-7,influenza virus a matrix protein segment sequence identifier
72201-7,fluav mp seg seqence id islt seq
72201-7,fluav id seg seqence mp islt seq
72201-7,fluav mp seqence random seg id islt seq
72201-7,fluav mp seg seqence id sequencing nom (isol) [id]
72201-7,fluav ngs (isol) seg seqence id sequencing nom mp [id]
72201-7,fluav mp seg id seqence sequencing nom (isol) [id]
57045-7,cardiac status
57045-7,status cardiac
57045-7,random cardiac status
62685-3,phenx - eye diseases - treatment in young children protocol 110401
62685-3,phenx - eye diseases - treatment 110401 panel.phenx young children protocol in
62685-3,phenx - eye diseses pnl - treatment in young childen protoco 1141
62685-3,eye diseases young children proto
62685-3,ey diseaes young children proto
62685-3,eye disesesyoung childre proto
62654-9,deprecated phenx measure - female reproductive organ surgical procedures
62654-9,deprecaed penmeaure  female reprodutive ogan sugical pocedures
62654-9,deprecated phenx measure - female reproductive surgical organ procedures
69355-6,parvovirus b19 dna [log #/volume] (viral load) in serum or plasma by naa with probe detection
69355-6,rvovus b1n [lo #/volume] (viraload) in serum r plasa by na with probe detection
69355-6,[log b19 dna parvovirus #/volume] (viral load) in serum fifth disease or plasma by naa with probe detection
69355-6,b19v dna serpl naa+probe-log#
69355-6,serpl dna b19v naa+probe-log#
69355-6,dna b1 serl naa+proe-log# pl
69355-6,parvovirus b19 dna naa+probe [log #/vol]
69355-6,parvovirus b19 naat dna naa+probe [log #/vol]
69355-6,parvovirus naa+probe dna ligase chain reaction b19 [log #/vol]
45314-2,coproporphyrin 3/coproporphyrin 1 [molar ratio] in urine
45314-2,1 3/coproporphyrin coproporphyrin [molar ratio] ur in urine
45314-2,tetracarboxyporphyrin cropohyrin 3/coproporphyrin 1 [molar raio] in urine
45314-2,copro3/copro1 ur-srto
45314-2,copro3/coro1 ur-srto
45314-2,ur-srto copro3pro1
45314-2,coproporphyrin 3/coproporphyrin 1 (u) [molar ratio]
45314-2,coproporphyrin 3/coproporphyrin 1 (u) [molar quant ratio]
45314-2,(u) 3/coproporphyrin 1 coproporphyrin [olr ratio] coproporphyrin iii
49394-0,herpes virus 7 dna [#/volume] (viral load) in urine by naa with probe detection
49394-0,herpes virus 7 dna [#/volume] (viral load) in urine by naa with probe count detection
49394-0,cnt herpes virus 7 dna [#/volume] (viral load) in urine by naa with probe detection
49394-0,hhv7 dna # ur naa+probe
49394-0,hhv7 dna ur # naprobe
49394-0,hhv7 naa+probe # ur dna
49394-0,hhv 7 dna naa+probe (u) [#/vol]
49394-0,hhv 7 dna quant naa+probe (u) [#/vol]
49394-0,aa+probe na hv (u) [vo]
62832-1,phenx - total physical activity - comprehensive - older adult protocol 150703
62832-1,phenx - total hysial acivity - cmprehensive - older adult protocol1073
62832-1,phenx 150703 total physical activity - comprehensive - older adult protocol -
62832-1,tot phys activity comp old adult proto
62832-1,tot phys acivi cop old adultpoto
62832-1,tot physactivity comp proto adult old
92813-5,borrelia afzelii+burgdorferi+garinii igg ab [presence] in cerebral spinal fluid by immunoassay
92813-5,[presence] afzelii+burgdorferi+garinii igg ab borrelia in cerebral spinal fluid by immunoassay
92813-5,borrelia ab igg afzelii+burgorferi+garnii random [prsence] in cerebral spinal fuid by immnoassay
92813-5,b afz+burg+gari igg csf ql ia
92813-5,afz+bur+gari igg cf ql ia anti
92813-5,ql afz+burg+gariigg csf b ia
92813-5,b. afzelii+burgdorferi+garinii igg ia ql (csf)
92813-5,anti bafzlii+burgdorfri+garinii igg ql ia (cerebrospinal fluid)
92813-5,presence afzelii+burgdorfrigarinii gg ia qual b. cf)
94549-3,isoheptacarboxylporphyrin [mass/time] in 24 hour stool
94549-3,[ass/time] soheptacarboxylporphyrin in 24 hour sool
94549-3,isohecarboxyporphyrin faeces [mass/time]in hour 2 stool
94549-3,isohepta-cp 24h stl-mrate
94549-3,isoheptacp 4h stl-mrae
94549-3,stl isohepta-cp 24h st-mrate
94549-3,isoheptacarboxylporphyrin (24h stl) [mass/time]
94549-3,(24hstl) bowel movement isoheptacoxylporphyrin [mass/tme]
94549-3,soheptacarboxyporpyrin (24h stl) [masstme]
94612-9,mycoplasma bovis ag [presence] in tissue by immune stain
94612-9,mcplasma bovis ag[ql in tsuey imune qualitative sin
94612-9,mycoplasma bovis ag [resence] in tissue by immune stn stain
94612-9,mp bovis ag tiss ql imstn
94612-9,mp bovis ag tiss screen ql imstn
94612-9,mp bovs imstn ag tiss presence imstn
94612-9,mp. bovis ag immune stain ql (tiss)
94612-9,mp. bovis ag immune stain stains presence (tiss)
94612-9,l ag immunestai mp.bois (tiss)
53018-8,sjogrens syndrome-a extractable nuclear 60kd ab [presence] in serum
53018-8,sjgrs syndrome-a etractle nuclear 60kab [presen] in serum
53018-8,sjogrens syndmea extractable 0kd nuclear ab [pesnce] in serm
53018-8,ena ss-a 60kd ab ser ql
53018-8,a ql 60kd ab ser ss-a ordinal
53018-8,ena ss-a abs 60kd ab ser ql
53018-8,sjogrens syndrome-a extractable nuclear 60kd ab ql (s)
53018-8,sjogrens nuclear extractable syndrome-a autoantibodies 60kd ab presence (s)
53018-8,sjogrenssyndrome- extractable nucler 60kd abq)
49605-9,hepatitis c virus rna [log units/volume] (viral load) in specimen by naa with probe detection
49605-9,hepatitis c virus quant rna [log units/volume] (viral load) probe specimen by naa with in detection
49605-9,hepatitis cvius ra [og units/volume] (virlld) i nasba specien by naa ith pobe deectio
49605-9,hcv rna spec naa+probe-log iu
49605-9,hcv rna amplification pecnaa+pobe-logiu
49605-9,cv rna qbr specnaaprob-log iu
49605-9,hcv rna naa+probe (specimen) [log units/vol]
49605-9,hep c hcvrna na+probe units/vol] [log (pecmen)
49605-9,hcv rna (specimen) naa+probe [log units/vol]
68364-9,pincer cells [presence] in blood by light microscopy
68364-9,pincer cells [presence] y blood in lgt microscpy ordinal
68364-9,pincer cells [presence] in by blood light microscopy
68364-9,pincer bld ql smear
68364-9,pincer ordinal bld ql smear
68364-9,pincer bld ql smear
68364-9,pincer cells lm ql (bld)
68364-9,pier ells lm ql (bd)
68364-9,lm cells pincer ql ql (bld)
97991-4,herpes virus 6 igg ab [units/volume] in serum by immunofluorescence
97991-4,herpes virus by igg ab [units/volume] in serum 6 immunofluorescence
97991-4,herpes virus 6 igg ab [units/volume] in serum by point in time immunofluorescence
97991-4,hhv6 igg ser if-acnc
97991-4,hhv6 gg ser if-acn
97991-4,igg human herpes virus hhv6 ser if-acnc
97991-4,hhv 6 igg if qn (s)
97991-4,hh 6 igg n if (s)
97991-4,hhv 6 igg qn if time resolved fluorescence (s)
53367-9,coccidioides sp igm ab [presence] in specimen
53367-9,coccidioids [prence] im ab sp in pecime
53367-9,coccidioides other sp igm ab [ql] in specimen
53367-9,coccidioides igm spec ql
53367-9,coccidioides igm point in time spec ql
53367-9,cocidioids igm spec ql
53367-9,coccidioides sp igm ql (specimen)
53367-9,(specimen) sp igm ql coccidioides
53367-9,(pecimen) sp igm presence coccdioides
106881-6,promis item bank v1.0 - emotional distress - anxiety - short form 8a
106881-6,promis - bank v1.0 item emotional distress - anxiety - short form point in time 8a
106881-6,promis ite survey.promis bnk - v.0 emoional distress anxiety- short for
22400-6,leptospira interrogans sv bratislava ab [titer] in serum
22400-6,leptospira interrogans random sv bratislava ab [titer] in serum
22400-6,leptospira interrogans sv bratislava ab [titer] in serum titer
22400-6,l inter brat ab titr ser
22400-6,iter brat serum ab titr ser
22400-6,l inter titr ab brat ser
22400-6,l. interrogans sv bratislava ab (s) [titer]
22400-6,l. interrogans sv bratislava ab [titer] (s)
22400-6,bratislavaab interogan sv veterinary l. (s) [titer
97290-1,noroxycodone [presence] in cord tissue by screen method
97290-1,noroxycodone [presence] in screen tissue by cord method
97290-1,noroxycodone by in cord tissue [presence] screen method
97290-1,noroxycodone tissco ql scn
97290-1,tissco noroxycodone ql scn
97290-1,scn tissco ql noroxycodone drug/toxicology
97290-1,noroxycodone screen ql (umb cord tissue)
97290-1,noyodone ql sceen (umb cord illicit tissue)
97290-1,noroxycodone screen ql (umb cord tissue) potentialforabuse
31212-4,actinobacillus pleuropneumoniae serotype 1 ab [presence] in serum
31212-4,actinbacilus actino serum serotype 1 ab [esence in pleuropneumonia
31212-4,qual actinobacillus pleuropneumoniae serotype 1 ab [presence] in serum
31212-4,a pleuropn 1 ab ser ql
31212-4,a pleuropn 1ab serum ql
31212-4,a ab 1 pleuropn serum ql
31212-4,a. pleuropneumoniae type 1 ab ql (s)
31212-4,a. pleuropneumoniae type ab 1 ql (s)
31212-4,a. pleuropneumoniae random ql 1 ab type (s)
91828-4,mycoplasma genitalium dna [presence] in lower respiratory specimen by naa with probe detection
91828-4,mycoplasma genitalium dna [presence] in lower respiratory specimen by strand displacement amplification naa with probe detection
91828-4,mycoplasma genitalium dna [presence] in lower respiratory specimen by amplif naa with probe detection
91828-4,m genitalium dna lower resp ql naa+probe
91828-4,m genitalium dna lower myco resp ql naa+probe
91828-4,m gnitaliumdna loweespql naa+probe
91828-4,m. genitalium dna naa+probe ql (lower resp)
91828-4,m. genitalium dna naa+probe ql probe amp (lower resp)
91828-4,m. dna genitalium naa+probe presence (lower resp)
76403-5,blasts [#] in body fluid by manual count
76403-5,blasts by in body fluid [#] manual count
76403-5,blsts [#] ody in fluid by manual blast count
76403-5,blasts fld manual
76403-5,flmanual point in time basts
76403-5,manual fld fluid blasts
76403-5,blasts manual cnt (body fld) [#]
76403-5,blasts manual cnt (body quant fld) [#]
76403-5,blasts manual bf cnt (body fld) [#]
92688-1,cryptosporidium parvum+hominis dna [presence] in stool by naa with probe detection
92688-1,cryptoporidium parvum+hominis da ordinal prsnce] in sol by naa with proe detction
92688-1,cryptosporidim parvum+homnis dna random in [ql] stool by naa with probe etection
92688-1,c parvum+hominis dna stl ql naa+probe
92688-1,qualitative cparvum+hominis stl dna presence naa+robe
92688-1,c parum+hominis dna stl ql naa+prbe
92688-1,c. parvum+hominis dna naa+probe ql (stl)
92688-1,ql parvum+hominis dna naa+probe c. microbiology (stl)
92688-1,probe with ampification c. parvum+hominis dna naa+probe presence (stl)
6477-4,mumps virus igg ab [titer] in serum by immunofluorescence
6477-4,mumps virus igg b serumby [tter] iunoluorescence
6477-4,mumps virus igg ab serum in [titer] by immunofluorescence
6477-4,muv igg titr ser if
6477-4,muv igg titr serum if
6477-4,muv igg tir ser if
6477-4,muv igg if (s) [titer]
6477-4,igg muv if (s) titer [titer]
6477-4,muv [titer] if infectious disease (s) igg
72753-7,hydrocodone [mass/volume] in saliva (oral fluid) by confirmatory method
72753-7,hydrocdone [mass/volume i saliva (ral fluid)by confirmtory methd
72753-7,hydrocodone [mass/volume] in saliva fluid) (oral by confirmatory method
72753-7,hydrocodone sal cfm-mcnc
72753-7,hydrcodone cfm-mcnc dihydrocodeinone sal
72753-7,cfm-mcnc sal hydrocodone
72753-7,hydrocodone confirm (sal) [mass/vol]
72753-7,hydrocodone confirm (sal) [mass/vol] random
72753-7,hydrocoone confirm mass/vol] (sal)
51697-1,cv2 ab [titer] in serum or plasma by immunofluorescence
51697-1,cv2 ab [titer i serum or by plasma immunofluorescence
51697-1,cv2 ab [titer] in serum or plas by immunofluorescence
51697-1,cv2 ab titr serpl if
51697-1,if serum ab titr serpl cv2
51697-1,serpl cv2 a titr serpl if
51697-1,cv2 ab if [titer]
51697-1,cv2 point in time ab [titer] if
51697-1,ab c2 if [titer] fa
42247-7,hemoglobin pattern [interpretation] in blood by hplc narrative
42247-7,hemoglobin pattern [interpretation] narrative blood by hplc in
42247-7,hemoglobin pattern [interpretation] in blood hplc impression by narrative
42247-7,hgb fract bld hplc-imp
42247-7,hg fract bd narrative hplc-imp
42247-7,hgb blood fract hplc-imp
42247-7,hemoglobin pattern hplc nar (bld) [interp]
42247-7,hemoglobin paternhplc wb [interp] (bld) nar
42247-7,(bld) pattern impression/interpretation of study hplc nar hemoglobin [interp]
14098-8,dimethylsulfoxide [mass/volume] in serum or plasma
14098-8,dimthylsulfoxde [mss/volum]in srum or quan plasma
14098-8,dimethylsulfoxide quant mass/volume] in eum plasma or
14098-8,dmso serpl-mcnc
14098-8,dmso plasma serpl-mcnc
14098-8,dmso plsm serpl-mcnc
14098-8,dimethylsulfoxide [mass/vol]
14098-8,[mass/vo] dimetylsulfoide
14098-8,dimethlsulfoxide quantitative [mass/vol]
74635-4,bacterial vaginosis dna panel - vaginal fluid by naa with probe detection
74635-4,bacteial vagiosis da pal - vginal luid byna wit proe detectin
74635-4,bacterial vaginosis dna panel fluid vaginal - by naa with probe detection
74635-4,bv dna pnl vag naa+probe
74635-4,bv dna pnl nucleic acid sequence based analysis vag naa+probe
74635-4,bv dna vag nl naa+probe lcr
74635-4,bacterial vaginosis dna panel naa+probe (vag fld)
74635-4,bacterial vaginosis (vag panel naa+probe dna fld)
74635-4,bacteril vaginsis dna panl naa+probe(vag fld
15384-1,leishmania mexicana igg ab [titer] in serum
15384-1,leishmaia meicana igg  [tite] in serm
15384-1,leishmania immune globulin g mexicana igg ab [titer] in ser
15384-1,l mexicana igg titr ser
15384-1,l mxica igg titr ser leishmaniasis
15384-1,igg mexicana l titr serum
15384-1,l. mexicana igg (s) [titer]
15384-1,l. mexican gg titer (s [titer]
15384-1,l. mexicana infectiousdisease igg (s) [titer]
106883-2,"hiv1+2 ab and treponema pallidum ab [presence] in serum, plasma or blood by rapid immunoassay"
106883-2,"or ab and treponema pallidum ab [presence] in serum, plasma hiv1+2 blood by rapid immunoassay"
106883-2,"hiv1+2 ab and treponema pallidum ab [presence] in serum, plasma or blood by rapid immunoassay"
106883-2,hiv1+2 t. pallidum ab spb ia
106883-2,ia t. palidum ab spb hiv1+2
106883-2,hiv1+2 t.pallidum ia pb ab
106883-2,hiv1+2 ab and treponema pallidum ab ia.rapid ql (s/p/bld)
106883-2,hiv1+2 ab and treponema (s/p/bld) ab ia.rapid ql antibody pallidum
106883-2,hiv1+ aand ab pallidum treonema ia.rapid s/p/bld)
10857-1,microsporidia identified in specimen by light microscopy
10857-1,microsporidia identified in specimen miscellaneous by light microscopy
10857-1,microsporidiaidentified in specimen y id light mcroscopy
10857-1,microsporid spec micro
10857-1,identity or presence microsporid pecmicro
10857-1,microsporid miscellaneous spec icro
10857-1,microsporidia identified lm nom (specimen)
10857-1,microsporidia identified to be specified in another part of the message lm nom (specimen)
10857-1,microsporidia identified lm random nom (specimen)
38729-0,"2,4,5-trichlorophenol [mass/volume] in air"
38729-0,"drug/toxicology ,4,5-trihlorophenol [mass/volume] inair"
38729-0,45-trichlorophenol [mass/volue] drug/toxicology iir
38729-0,"2,4,5-tcp air-mcnc"
38729-0,"air-cnc 2,4,5-tp"
38729-0,"quantitative 2,4,5-tcp air-mcnc"
38729-0,"2,4,5-trichlorophenol (air) [mass/vol]"
38729-0,"[mas/vol] (air) 2,4,5-trichlorophenol"
38729-0,"2,4,5-trichlorophenol (air) ii [mass/vol]"
689-0,deprecated neisseria gonorrhoeae [presence] in cervix by organism specific culture
689-0,deprecated neiseragonorrhoeae [presence]in by crvix organismspecific culture
689-0,qualitative by neisseria gonorrhoeae [presence] in cervix deprecated organism specific culture
689-0,deprecated n gonorrhoea cervix ql cult
689-0,n deprecated gonorrhoea cervix ql cult
689-0,deprecated point in time n gonorrhoea cervix presence cult
689-0,n. gonorrhoeae org specific cx ql (cvx)
689-0,n. gonorrhoeaeorg specific ql cx (cv)
689-0,n. gonorrhoeae org specific cx (cvx) ql
96080-7,hedis my 2020 value set - pregnancy test exclusion
96080-7,hedis my set vlue 2020 - pregnancy ts exclusion
96080-7,hedis my 2020 value - set pregnancy test exclusion
96080-7,hedis my 2020 preg test excl
96080-7,hedis excl 2020 preg test my
96080-7,panl hedi my 220 preg test excl
96080-7,hedis my 2020 value set - pregnancy test exclusion
96080-7,hedis my 2020 et value - pregnany test exclusion
96080-7,hedi pan y2020 valu set pregnancy test exclusion
93721-9,o-nortramadol [mass/mass] in meconium by confirmatory method
93721-9,o-nortramadol by in confirmation meconium [mass/mass] confirmatory method
93721-9,o-nortramadol [mass/mass] in meconium by confirmatory drug/toxicology method
93721-9,o-nortramadol mec cfm-mcnt
93721-9,o-nortramadol mec cfm-mcnt
93721-9,o-nortramadol mec cfm-mcnt cnfr
93721-9,o-nortramadol confirm (mec) [mass/mass]
93721-9,o-nortramadol [mass/mass] (mec) confirm
93721-9,o-nortramadol [mass/mass] (mec) confirm
60321-7,norclobazam [moles/volume] in specimen
60321-7,norclobazam specimen in [moles/volume]
60321-7,[moles/volume] norclobazam in quantitative specimen
60321-7,norclobazam spec-scnc
60321-7,spec-scnc norclobazam
60321-7,norclobazamspec-scnc point in time
60321-7,norclobazam (specimen) [moles/vol]
60321-7,moles/vo] (secimn) norlobaza
60321-7,(pecimen norclobazam mle/vol
33679-2,francisella tularensis dna [presence] in specimen by naa with probe detection
33679-2,by tularensis dna [presence] in specimen francisella naa with probe pr detection
33679-2,faisella specimen [presence] in tulrensisdna by naa with probe etectio
33679-2,f tular dna spec ql naa+probe
33679-2,f tular dna spec ql naa+probe
33679-2,f tular f tularensis spec dna ql naa+probe
33679-2,f. tularensis dna naa+probe ql (specimen)
33679-2,f. tularensis dna naa+probe (specimen) ql
33679-2,tularensis f. dna naa+probe ql (specimen)
48655-5,corynebacterium diphtheriae toxin ab [units/volume] in serum by immunoassay --2nd specimen
48655-5,corynbcterium c diphtheriae iphtheriae byimmunoassa b [uits/volume in erum toxn --2nd secimen
48655-5,by diphtheriae toxin ab [units/volume] in serum corynebacterium immunoassay --2nd specimen
48655-5,c diphtheriae tox ab sp2 ser ia-acnc
48655-5,c diphtheriae sp2 ab tox ser ia-acnc
48655-5,c diphtheriae tox serum sp2 ab ia-acnc
48655-5,c. diphtheriae toxin ab spec 2 ia qn (s)
48655-5,microbiology c. diphtheriae toxin ab spec 2 ia qn (s)
48655-5,c. diphtherieoin b pec2 ia qn(s)
62843-8,deprecated phenx measure - physical activity - self efficacy
62843-8,measure phenx deprecated - physical activity - self efficacy
62843-8,deprecated phenx measure - physical efficacy - self activity
71841-1,oxygen saturation [pure mass fraction] calculated from oxygen partial pressure in venous blood
71841-1,oxygen saturation [pure mass fraction] calculated from oxygen partial pressure in venous blood
71841-1,n saturion [pure mas fraction]calculaedfrom oxygn partia presure oxygen venous blood
71841-1,sao2 df bldv from po2
71841-1,sao2 po2 bldv from df
71841-1,po2 df bldv from sao2
71841-1,sao2% calculated from oxygen partial pressure (bldv) [pure mass fraction]
71841-1,sao2% oxygen from calculated partial pressure (bldv) [pure mass fraction]
71841-1,sao2% calculated from oxygen partial pressure (bldv) [pure mass fraction]
96906-3,"mds v3.0 - rai v1.17.2 - bladder and bowel - np, nq, sp during assessment period [cms assessment]"
96906-3,"mds v3.0 - rai assessment - bladder and bowel - np, nq, sp during v1.17.2 period [cms assessment]"
96906-3,"v1.17.2 v3.0 - rai mds - bladder and bowel - np, nq, sp during assessment period [cms assessment]"
25594-3,deprecated schistosoma sp igg ab [units/volume] in serum
25594-3,deprecate schstosoma ab sr igg sp unts/vlume]in ser
25594-3,derecated schistosoma spigg ab [its/volume] in anti serum
25594-3,deprecated schistosoma igg ser-acnc
25594-3,deprecated igg schistosoma ser-acnc
25594-3,igg schistosoma deprecated ser-acnc
25594-3,schistosoma sp igg qn (s)
25594-3,schistosoma sr (s) igg qn sp
25594-3,schistosoma igg quan n(s)
95559-1,evidence of adrenal cortical hormone excess [presence] in 24 hour urine
95559-1,vidence f adral cortial hrmone xcess [ql] in2 our urie
95559-1,evidence of adrenal cortical hormone excess [ql] in 24 24 hours hour urine
95559-1,adrenal hormone excess 24h ur ql
95559-1,adrenal hormone ql chemistry 24h ur excess
95559-1,adrenal hormone excess 24h ur ql ql
95559-1,evidence of adrenal cortical hormone excess ql (24h u)
95559-1,evidence of adrenal cortical hormone excess ql (24h u)
95559-1,hormoe of adrenal hormone excess areal cortcal evidence excessql24h u)
27337-5,amino beta guanidinopropionate [moles/volume] in cerebral spinal fluid
27337-5,amino beta guanidinopropionate [moles/volume] in cerebral spinal fluid
27337-5,amno spinal [oles/volume] n erebral betaguanidinopropionate fluid
27337-5,ab-gp csf-scnc
27337-5,b-p cerebrospinal fluid-scnc point in time
27337-5,csf-scnc b ab-gp
27337-5,amino beta guanidinopropionate (csf) [moles/vol]
27337-5,amino beta guanidinopropionate (csf) [moles/vol] quantitative
27337-5,amio beta guanidinopropionate (cerebrospinal fluid) [moles/vol]
1997-6,calcium [moles/volume] in cerebral spinal fluid
1997-6,calcium [moles/volume] in cerebral spinal fluid
1997-6,calcium [molsvolume] in cerebral sinalfluid
1997-6,calcium csf-scnc
1997-6,point in time calcium cerebrospinal fluid-scnc
1997-6,calcium cerebrospinal fluid-scnc
1997-6,calcium (csf) [moles/vol]
1997-6,(csf) cerebrospinal fl calcium [mols/vol]
1997-6,clium (csf) [moles/vol]
79640-9,saccharopine/creatinine [molar ratio] in urine
79640-9,saccharopine/creatinine [molar ratio] esoteric in urine
79640-9,urine rtio]in saccharopine/creainin[mla
79640-9,saccharopine/creat ur-srto
79640-9,ur-srto saccharopine/ceat
79640-9,ccharpin/creat ur-sto
79640-9,saccharopine/creatinine (u) [molar ratio]
79640-9,saccharopine/creatinine [molar (u) ratio]
79640-9,saccharopine/creatinine (u) cr [molar ratio]
88614-3,human coronavirus rna [presence] in aspirate by naa with probe detection
88614-3,hman cronavirus rna [presence] detction aspirate by na with probe in
88614-3,huan cornavirus transcription mediated amplification rna [presence] in spirate b na with prbe detetion
88614-3,hcov rna aspirate ql naa+probe
88614-3,hcov aspirate rna ql naa+probe
88614-3,ql rna aspirate hcov naa+probe
88614-3,hcov rna naa+probe ql (asp)
88614-3,ql ra naaprob hcov (sp) infectiousdisease
88614-3,pcr hcov ql naa+probe rna (asp)
6608-4,virus identified in isolate by culture
6608-4,virus identfied isol in isolate byculture
6608-4,id virus identified in byculture isolate
6608-4,virus islt cult
6608-4,vius slt cult
6608-4,infectiousdisease vrus islt cul
6608-4,virus identified cx nom (isol)
6608-4,virus identified cx nom (isol)
6608-4,virusdentfid c om isol)
93511-4,rickettsia rickettsii and coxiella burnetii phase 1 and coxiella burnetii phase 2 igg panel - serum
93511-4,ricket rickettsia rickettsii - coxiella burnetii phase 1 and coxiella burnetii phase 2 igg panel and serum
93511-4,rickettsia rickettsii and coxiea burneti phase 1 and coxill urneti phse 2 igg panel- serum
93511-4,r. rickettsii + c. burnetii 1 2 igg pnl
93511-4,r. rickettsii + c. burnetii 1 2 igg pnl q fev
93511-4,r. rickettsii igg c. burnetii 1 2 + pnl
93511-4,rickettsia rickettsii and coxiella burnetii phase 1 and 2 igg panel (s)
93511-4,rickettsia rickettsii and coxiella burnetii phase 1 pnl and igg 2 panel (s)
93511-4,rickettsia rickettsii and burnetii coxiella phase 1 and c burnet ph2 2 igg panel (s)
73840-1,11-dehydrotetrahydrocorticosterone [moles/time] in 24 hour urine
73840-1,11-ehydrotetrahydrocortcsterone [moles/time] in 24 hur urine
73840-1,[oles/time 11-dehyrotetraydrocorticosterone in 2 hour urine
73840-1,tha 24h ur-srate
73840-1,24h tha ur-srate
73840-1,24h th ur ursrae
73840-1,11-dehydrotetrahydrocorticosterone (24h u) [moles/time]
73840-1,11-dehydrotetrahydrocorticosterone (24h [moles/time] u)
73840-1,11-dehydrotetrahydrocorticosterone [moles/time] u) (24h
4461-0,warfarin [mass] of dose
4461-0,warfain [mss] ofdose
4461-0,wrfarin[mass] f ose
4461-0,warfarin dose
4461-0,warfarin dose
4461-0,dose warfarin
4461-0,warfarin (dose) [mass]
4461-0,(dse) wararin [mass]
4461-0,warfarin coumadin [mass] (dose)
55581-3,sulfasalazine [moles/volume] in serum or plasma
55581-3,sulfasalazine [moles/volume] in serum or quan plas
55581-3,sulfasalazine [moles/volume] in serpl
55581-3,sulfasalazine serpl-scnc
55581-3,ser-scc ulfaaazine plsm
55581-3,serpl-scnc sulfasalazine
55581-3,sulfasalazine [moles/vol]
55581-3,sulasalaie [moesvol
55581-3,[moles/vol] sulfasalazine substance concentration
69950-4,hemoglobin [mass/volume] in pericardial fluid
69950-4,pericrdial [mass/volume] in hemoglobin hgb fluid
69950-4,hemoglobin [mass/volume] in pericardial fluid
69950-4,hgb pcar-mcnc
69950-4,pcar-mcnc hgb
69950-4,pcar-mcnc hgb pcar
69950-4,hemoglobin (pericard fld) [mass/vol]
69950-4,hemoglobin fld) (pericard [mass/vol]
69950-4,quant hemoglobin fld)[mssvol] (pericard
11101-3,bacteria [#/area] in synovial fluid by microscopy high power field
11101-3,bacteria [#/area] in synovial fluid by field high power microscopy
11101-3,bacteria [#/area] in synovial fluid by microscopy high power field lm
11101-3,bacteria snv hpf-#/area
11101-3,bacteria snvhpf-#/area sf
11101-3,syn snv bacteria hpf-#/area
11101-3,bacteria lm.hpf (syn fld) [#/area]
11101-3,bcteria synov lmhpf (sy fld) [#/area]
11101-3,bacteria lm.hpf [#/area] fld) (syn
22203-4,clostridium tetani igg ab [units/volume] in serum
22203-4,clostridium tetani igg ab [units/volume] in serum
22203-4,clostridium tetani igg autoantibody ab [units/volume] serum in
22203-4,c tetani igg ser-acnc
22203-4,tetanus iggsr-acnc teani c
22203-4,c igg tetani ser-acnc
22203-4,c. tetani igg qn (s)
22203-4,c. tetani igg qn (s) infectiousdisease
22203-4,c. tetani igg qn quant (s)
35180-9,docosapentaenate (c22:5w3) [moles/volume] in serum or plasma
35180-9,docosapentaenae(c2:5w3) [molesvolue]in seru r pasm
35180-9,docosapenaenate serpl or mles/volme] in serum (c225w3 pasma
35180-9,dpa serpl-scnc
35180-9,plsm serpl-scnc dpa
35180-9,dpa serp-scn
35180-9,dpa [moles/vol]
35180-9,serum or plasma dpa [moles/vol]
35180-9,dpa c22:5w3 [moles/vol]
88916-2,leishmania sp dna [identifier] in tissue by naa with probe detection
88916-2,leishmania p dna intifier] n tissuey with naa probedetectin
88916-2,leishmania sp dna naa+probe [identifier] in tissue by naa with probe detection
88916-2,leishmania dna tiss naa+probe
88916-2,leishmania dna naa+probe tiss
88916-2,leishmania dna tiss naa+probe nucleic acid sequence based analysis
88916-2,leishmania sp dna naa+probe nom (tiss)
88916-2,leihmana sp dna nasba na+probe nom(tiss)
88916-2,leishmania sp dna nominal naa+prob nom(is)
90957-2,promis pediatric short form - pain interference 8a - version 2.0
90957-2,promis pediatric short form - pain interference 8a - version 2.0
90957-2,pan promis pediatric short form - pain interference 8a - version 2.0
73544-9,acyclovir induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73544-9,acyclovir induced platelet igg ab [presence] in serum platelt or plasma by flow cytometry (fc)
73544-9,cyclovir inced patelet igg ab [presence] in erum or plsma by flow platelets cyometry (fc)
73544-9,acyclovir ind plt igg serpl ql fc
73544-9,acyclovir ind plt immune globulin g gg serl ql fc
73544-9,acyclovi nd aciclovir plt igg serpl qlfc
73544-9,acyclovir induced platelet igg fc ql
73544-9,autoantibodies aylvirinduced platelet ig c ql
73544-9,acyclovir induced platelet igg fc ql
69863-9,process variables for assays phenx
69863-9,process variables for phenx assays
69863-9,process variables phenx assays for
69863-9,process variables assays phenx
69863-9,process variables assays phenx
69863-9,phenx variables assays pan process
102067-6,perfluoroheptane sulfonate [mass/volume] in serum or plasma
102067-6,[mass/volume] sulfonate perfluoroheptane in ser or plasma
102067-6,perluoroheptan sulonate [mass/volume] lasma or inserum
102067-6,pfhps serpl-mcnc
102067-6,pfhps serum serpl-mcnc
102067-6,serpl-mcnc drug/toxicology pfhps
102067-6,perfluoroheptane sulfonate [mass/vol]
102067-6,perfluoroepae sulnte[mass/vol]
102067-6,pefluooheptane sulfonate serum or plasma [massvol]
17632-1,deprecated streptococcus pneumoniae 4 igg ab [units/volume] in serum
17632-1,deprected tretococcus pnemoniae 4 ig ab aby [units/vume] in rum
17632-1,eprecaedstreptococus peumoniae 4ig ab units/vlume] n serum
17632-1,deprecated s pneum4 igg ser-acnc
17632-1,se-acnc pnem4 igg deprcads
17632-1,deprecated s point in time pneum4 igg ser-acnc
17632-1,s. pneumoniae 4 igg qn (s)
17632-1,infectious disease s. pneumniae qn igg (s)
17632-1,. (s) 4 gg infectious disease qn pneumoniae
59979-5,warfarin [moles/volume] in urine
59979-5,warfarin moles/voume] in urine
59979-5,warfarin oles/volue] urine i
59979-5,warfarin ur-scnc
59979-5,ur-scnc warfarin
59979-5,warfarin ur-scnc
59979-5,warfarin (u) [moles/vol]
59979-5,panwarfin warari (u) [molvol]
59979-5,warfarin [moles/vol] (u)
2915-7,renin [enzymatic activity/volume] in plasma
2915-7,renin [ezyatic actvit/volume] catalytic concentration n plasma
2915-7,renin plasma activity/volume] in [enzymatic
2915-7,renin plas-ccnc
2915-7,plas-ccnc renin
2915-7,universallaborders renin plas-ccnc
2915-7,renin (p) [catalytic activity/vol]
2915-7,ativty/vo] (p) [catlytic rnin
2915-7,renin (p) [catalytic acivity/ol] endocrine
52763-0,extrinsic coagulation system thromboelastography panel - blood
52763-0,extrinsic coagulation syste thoboelastograpy panel pnl lood
52763-0,exrinsiccoagulatin system throboelastogapy panel - blood
52763-0,extrinsic teg pnl bld
52763-0,blood teg pnl point in time extrinsic
52763-0,wb erinsc blood tegpnl
52763-0,extrinsic coagulation system thromboelastography panel (bld)
52763-0,coagulation extrinsic point in time system thmboelastography panel (bld
52763-0,wb thromboelastography coagulation system extrinsic panel (bld)
53650-8,methyl parathion [mass/volume] in gastric fluid
53650-8,methyl parathion in [mass/volume] gastric fluid
53650-8,drugs methyl parathion [mass/volume] in gastric fluid
53650-8,methyl parathion gast-mcnc
53650-8,parathion qnt ethyl gat-mcnc
53650-8,gast-mcnc parathion methyl
53650-8,methyl parathion (gast fld) [mass/vol]
53650-8,methyl gastric contents prthio (gast fl) [as/vo
53650-8,methyl parathion fld) (gast [mass/vol]
31371-8,epstein barr virus early igg ab [units/volume] in cerebral spinal fluid
31371-8,epstein barr virus early quantitative igg in [units/volume] ab cerebral spinal fluid
31371-8,in barr virus antibodies early igg ab [units/volume] epstein cerebral spinal fluid
31371-8,ebv ea igg csf-acnc
31371-8,ebv ea igg c-acnc
31371-8,ebv csf-acnc igg ea
31371-8,ebv early igg qn (csf)
31371-8,ebv earl igg qn (csf)
31371-8,ebv eligg autoantibodies qn (csf
80831-1,pepsin a panel - lower respiratory specimen
80831-1,peps a panl - lowerrespiratoryspecimen
80831-1,pepsin a anl -lowr repiratory specimen
80831-1,pepsin a pnl lower resp
80831-1,pepsin a pnl lower resp
80831-1,pepsin lower pnl resp
80831-1,pepsin a panel (lower resp)
80831-1,pepsin (lower panel a resp)
80831-1,pepsin a panl (lower resp)
71658-9,neutrophils/leukocytes [pure number fraction] in cerebral spinal fluid by manual count
71658-9,cerebral [pure number fraction] in neutrophils/leukocytes spinal fluid by manual count
71658-9,neuro neutrophils/leukocytes [pure number fraction] in cerebral spinal fluid by manual count
71658-9,neutrophils nfr.df csf manual
71658-9,neutrophls nfr.df csf maua
71658-9,neutrophil csf nr.df mnual
71658-9,neutrophils/leukocytes manual cnt (csf) [pure # fraction]
71658-9,neutrophils/leukocytes manual cnt fraction] [pure # quantitative (csf)
71658-9,neutophils/leukocyte manual ct (cerebrospinal fluid) [pure #fraction]
23084-7,equine herpesvirus 1 dna [presence] in tissue by naa with probe detection
23084-7,[ql] herpesvirus 1 dna equine in tissue by naa with probe detection
23084-7,equine herpesvirus 1 [pesence] dna in tissu by naa withprob detection
23084-7,ehv1 dna tiss ql naa+probe
23084-7,ehv1 lcr dna tiss naa+probe ql
23084-7,eh1 sda dna tiss presence naa+probe
23084-7,equine herpesvirus 1 dna naa+probe ql (tiss)
23084-7,equie hepesvirus 1 d (iss) l naa+probe
23084-7,equine herpesvirus 1 dna naa+probe ql (tiss) ehv1
23720-6,feline herpesvirus 1 ag [presence] in tissue by immunofluorescence
23720-6,feline herpeirus 1 ag tissue in [presence] by immuofluorescence
23720-6,felie herpesvius 1 ag [presence] in tissue byimmunofluorescence
23720-6,fehv1 ag tiss ql if
23720-6,"q agtiss fehv1 if tissue, unspecified"
23720-6,fehv1 ag tiss presence if ordinal
23720-6,feline herpesvirus 1 ag if ql (tiss)
23720-6,feline herpesvirus 1 ag if (tiss) presence
23720-6,feline herpiru ag 1 fluoresent if ql (tiss)
13467-6,selenium/creatinine [mass ratio] in urine
13467-6,selnium/creatinine mass raio] in uine
13467-6,selenium/creatinine [mass urine in ratio]
13467-6,selenium/creat ur
13467-6,selenium/creatr
13467-6,ur selenim/reat
13467-6,selenium/creatinine (u) [mass ratio]
13467-6,slenium/creatinine u) [ass rati]
13467-6,slenium/creaiine (u)[mass rati]
96104-5,wound stage foot university of texas diabetic wound classification system
96104-5,ound stage fot universiy of texa dabetic ound classificatin ystm
96104-5,wound stage foot university of texas diabetic qualitative wound classification system
96104-5,wound stage ft ut-dwcs
96104-5,wound ut-dcs ft stage
96104-5,wound age ft ut-dwcs
97752-0,herpes virus 6 dna [log #/volume] (viral load) in cerebral spinal fluid by naa with probe detection
97752-0,herpes virus dna 6 [log ligation-activated transcription #/volume] (viral load) in cerebral spinal fluid by naa with probe detection
97752-0,herpes virus 6 in [log #/volume] (viral load) dna cerebral spinal fluid by naa with probe detection
97752-0,hhv6 dna csf naa+probe-log#
97752-0,dna hhv6 csf naa+probe-log#
97752-0,pcr hv6dna csf naa+prob-log#
97752-0,hhv 6 dna naa+probe (csf) [log #/vol]
97752-0,ligase chain reaction hhv (cerebrospinal fluid) dna naa+probe 6 [log#/ol]
97752-0,hhv 6 na naa+probe (sf) [og #/vol]
101446-3,creatine kinase.mb [moles/volume] in serum or plasma by immunoassay
101446-3,creatine kinase.mb [moles/volume] in serum plasma or by immunoassay
101446-3,creatine kinase.b [oes/volume] in sum or by plaa immunoassay
101446-3,ck mb serpl ia-scnc
101446-3,mb serpl ck serpl ia-scnc
101446-3,serpl mb ck ia-scnc ck mb
101446-3,ck.mb ia [moles/vol]
101446-3,moles/vol] ia ck.mb substance concentration
101446-3,ck.mb ia [moles/vol] ck-mb
6619-1,acanthamoeba sp ab [presence] in cerebral spinal fluid by immunofluorescence
6619-1,acanthamoeba sp ab [presence] in cerebral spinal fluid by immunofluorescence
6619-1,acanthamoeba cerebral ab [presence] in sp spinal fluid by immunofluorescence
6619-1,acanthamoeba ab csf ql if
6619-1,fluorescent antibody canthamoebaab ql cs if
6619-1,acanthmeba antibodies ab csf ql if
6619-1,acanthamoeba sp ab if ql (csf)
6619-1,ql sp ab if acanthamoeba (csf)
6619-1,acanthamoeba sp ab spp if presence (csf)
53601-1,hiv 1 p24 ag [units/volume] in serum or plasma by immunoassay
53601-1,hiv 1 p24 ag or in serum [units/volume] plasma by immunoassay
53601-1,hiv 1 p24 ag [units/volume] or inserum sma by imunossay
53601-1,hiv1 p24 ag serpl ia-acnc
53601-1,hiv1 p24 ag serpl iaacnc quant
53601-1,hiv1 p4 ag serpl ia-acnc
53601-1,hiv 1 p24 ag ia qn
53601-1,hiv 1 p24 ag plsm i qn
53601-1,agia 1 p24 hi qn
91057-0,tropheryma whipplei dna [presence] in stool by naa with probe detection
91057-0,tropheryma whipplei by [presence] in stool dna naa with probe detection
91057-0,tropheryma whipplei dna [presence] in stool by naa with probe fecal detection
91057-0,t whipplei dna stl ql naa+probe
91057-0,naa+probe whipplei dna stl ql t
91057-0,t whiplei da tl ql na+probe
91057-0,t. whipplei dna naa+probe ql (stl)
91057-0,t. random naa+probe dna whipplei presence (stl)
91057-0,(stl) whipplei dna naa+probe stl presence t.
88847-9,microbiology cnamts panel - stool
88847-9,cnats microbiolgy pnel faeces - stool
88847-9,microbiology cnamts panel micro cnamts panel - stool
88847-9,micro cnamts panel stl
88847-9,pnl micro cnamts panel stl
88847-9,micro stool = fecal stl panel cnamts
88847-9,microbiology cnamts panel (stl)
88847-9,microbiolog cnamts panl panl (tl)
88847-9,roilogy faecal camtspanel (stl)
57974-8,hiv 1 ab [presence] in cerebral spinal fluid by immunoblot
57974-8,hiv 1 a [ql] in cerebral inal flui b immunoblot
57974-8,hiv 1 ab [presence] in spinal spinal fld cerebral fluid by immunoblot
57974-8,hiv1 ab csf ql ib
57974-8,hiv1 csf ab cerebrospinal fl ql ib
57974-8,hiv1 csf ab ql ib
57974-8,hiv 1 ab ib ql (csf)
57974-8,hiv 1 ab ib ql (csf)
57974-8,hiv1 ab l b (csf)
77169-1,cyclosporine [mass/volume] in blood --1 hour post dose
77169-1,cyclosporine [mass/volume] in blood hour --1 post dose
77169-1,in [mass/volume] cyclosporine blood --1 hor post dose
77169-1,cyclosporine 1h p bld-mcnc
77169-1,cyclosporine 1h bld-mcnc p
77169-1,cylosporine 1h p bld-mcnc
77169-1,cyclosporine 1 hr post dose (bld) [mass/vol]
77169-1,cyclosporine 1 hr quantitative post (bld) dose [mass/vol]
77169-1,cyclosporine 1 (bld) ptdose hr [mass/vol]
86157-5,streptococcus pneumoniae danish serotype 8 igg ab [ratio] in serum --2nd specimen/1st specimen
86157-5,trepococcuspneumoniae dn sertyp 8 igg ab[ratio] i serm --2nd seimen/1st pecimen
86157-5,random streptococcus pneumoniae danish serotype 8 igg ab [ratio] in serum --2nd specimen/1st specimen
86157-5,s pneum da 8 igg 2:1 ser-rto
86157-5,s pneum da 8 ig 2: se-rto
86157-5,s pneum da 8 ratios igg 2:1 ser-rto
86157-5,s. pneumoniae danish type 8 igg 2nd specimen/1st specimen (s) [ratio]
86157-5,s. pneuonia danish tye8 g 2nd secmen/1t pecien (s ratio] autoantibodies
86157-5,2nd pneumoniae danish type 8 igg s. specimen/1st specimen (s) [ratio]
13265-4,leptospira sp igm ab [titer] in serum
13265-4,leptospira sp infectious disease im ab in [titer] serum
13265-4,dilution factor (titer) leptospira ab spim [titer]in srum
13265-4,leptospira igm titr ser
13265-4,titr dilution factor igm leptospira ser
13265-4,letospira im ttr ser
13265-4,leptospira sp igm (s) [titer]
13265-4,leptospira [titer] igm (s) sp
13265-4,letopir p igm s) [tite]
31941-8,pneumocystis jirovecii ag [presence] in throat
31941-8,pneumocystis jirovecii ag [ql] throat in
31941-8,pneumocystis jirovecii ag [ql] in pcp throat
31941-8,p jirovecii ag throat ql
31941-8,p jirovecii ag ql throat upper respiratory
31941-8,p ql ag throat pneumocystis carinii jirovecii
31941-8,p. jirovecii ag ql (throat)
31941-8,random p. jirovecii ag ql (throat)
31941-8,p. (throat) ag presence jirovecii
71107-7,functional assessment of multiple sclerosis questionnaire - version 4 (fams) [facit]
71107-7,functional random assessment of multiple sclerosis questionnaire - version 4 (fams) [facit]
71107-7,functional assessment of multiple sclerosis questionnaire - version 4 (fams) [facit]
75355-8,other cells/leukocytes in synovial fluid by manual count
75355-8,other cells/leukocytes manual synovial fluid by in count
75355-8,othercels/ukocytes in synovial fluid by manua joint flu ont
75355-8,other cells nfr snv manual
75355-8,other cells nfr snv joint fluid manual
75355-8,othercells manual snv nfr
75355-8,other cells/leukocytes manual cnt (syn fld)
75355-8,other white bld cells cells/leukocytes manual cnt (syn fld)
75355-8,cellsleuocyte other manual cntsynld)
47459-3,legionella pneumophila 10 igg ab [titer] in serum
47459-3,legionella ttr pneumophila 10 igg ab [titer] in serum
47459-3,legionella pneumophila serum 10 igg ab [titer] in serum
47459-3,l pneumo 10 igg titr ser
47459-3,pneumo l 10 igg titr ttr ser
47459-3,l pneumo 10 igg titr abs ser
47459-3,l. pneumophila 10 igg (s) [titer]
47459-3,l. pmopila 10 igg (s) [iter]
47459-3,l. pneumophila 10 (s) igg [titer]
88260-5,gram negative blood culture panel by probe in positive blood culture
88260-5,gram negative blood culture panel by probe in dna probe positive blood culture
88260-5,gam bld pos negatieblod culture panel by probein positive blood cultur
88260-5,gn bld culture pnl bld pos probe
88260-5,gn bld cultrepnl probe pos bl
88260-5,gn pos culture pnl bld bld probe
88260-5,gram negative blood culture panel probe (pos bld culture)
88260-5,ram ngatie whole blood bld culture anel probe (pos blood culture)
88260-5,panel.microbiology gram negative blood culture panel probe (pos bld culture)
63035-0,deprecated phenx measure - neighborhood concentrated disadvantage
63035-0,deprecaed penx neigorhod - measure cncentrated disadvantage
63035-0,deprecated measure phenx - panel.phenx neighborhood concentrated disadvantage
101799-5,2-oxo-3-hydroxy-lysergate diethylamide/creatinine [mass ratio] in urine by confirmatory method
101799-5,2-xo--hydroxy-lysegate diethylamide/creatinine [mass ratio] i urineby coniratry mthod
101799-5,2-oxo-3-hydroxy-lysergate diethylamide/creatinine [mass ratio] in urine by confirmatory method
101799-5,2-oxo-3-oh-lds/creat ur cfm
101799-5,cfm ur 2-oxo-3-oh-lds/creat cfm
101799-5,2-oxo-3-oh-lds/creat quantitative r cf
101799-5,2-oxo-3-hydroxy-lysergate diethylamide/creatinine confirm (u) [mass ratio]
101799-5,2-oxo-3-hydroxy-lysergate diethylamide/creatinine confirm creat (u) ratio] [mass
101799-5,2-oxo-3-hydroxy-lysergate drug/toxicology diethylamide/creatinine confirm [mass (u) ratio]
12837-1,prostaglandin e1 [mass/volume] in 24 hour urine
12837-1,prtaglandi e1[mass/volume in 24hou urine
12837-1,prostaglandin e1 [mass/volume] urine 24 hour in
12837-1,prostaglandin e1 24h ur-mcnc
12837-1,2h e1 prostaglandin urmcnc urology
12837-1,prostaglandin e1 pg ur-mcnc 2h
12837-1,prostaglandin e1 (24h u) [mass/vol]
12837-1,prostaglandin e1 (24h u) [mass/vol]
12837-1,[mass/vol] e1 (24h u) prostaglandin
62570-7,deprecated phenx measure - personal perception and knowledge of smoking-related cancer risk
62570-7,deprecated phenx measure - personal perception and knowledge of smoking-related cancer risk
62570-7,pnl deprecaed enx and - personal percepion masure nowledge of smoing-relaed cacer rik
32863-3,osmotic fragility [interpretation] of red blood cells--fresh
32863-3,smotic fragility impression/interpretation of study [interrtatio of red bld cellsfresh
32863-3,omotic fragility [interpretation]of rd ells-fresh blood
32863-3,of fresh rbc-imp
32863-3,fsh of bc-imp red bld cells
32863-3,fresrbc-imp f
32863-3,osmotic fragility fresh (rbc) [interp]
32863-3,osmotic nominal fragility resh(rbc) [interp]
32863-3,osmotic fragility fresh [interp] (rbc)
26476-2,lymphocytes [#/volume] in body fluid
26476-2,lymphocytes [#/volume] in quan fluid body
26476-2,ymphocytes [#/volume flu body in bod
26476-2,lymphocytes # fld
26476-2,ct # lymphoces ld
26476-2,lymphocytes fld #
26476-2,lymphocytes (body fld) [#/vol]
26476-2,fld) (body lymphocytes [#/vol]
26476-2,lymphocytes (body fld) [#/vol]
23528-3,trypanosoma evansi ag [presence] in blood by immunoassay
23528-3,suds trypanosoma evansi ag in [presen bood by imunoassa
23528-3,typanosoma evansi g [presence] in blood by immunoassay
23528-3,t evansi ag bld ql ia
23528-3,t evansi ag ia ql bld
23528-3,evansi trypanosomosis ag bl ql ia
23528-3,t. evansi ag ia ql (bld)
23528-3,t. (bld) ag ia ql evansi
23528-3,t. evansi ag (bld) ql ia
89588-8,herpes simplex virus 2 ag [presence] in cerebral spinal fluid by immunofluorescence
89588-8,herpes simex vru 2 ag fluid i cerebal spinal [presece] by immunofluorescence hsv
89588-8,hres simplex virus in ag [presence] random 2 cerebral spinal fluid by imunofluorescence
89588-8,hsv2 ag csf ql if
89588-8,hv2 a cerebrospinal fluid ordinal ql if
89588-8,csf ql hsv2ag ql if
89588-8,hsv 2 ag if ql (csf)
89588-8,hs ql if 2a (csf)
89588-8,hsv 2 ag if ql id (csf)
4550-0,hemoglobin a2 [moles/volume] in blood by chromatography column
4550-0,hemoglobn a2 [oevolume] in bloo by chromatogapy blood column
4550-0,blood [ols/vlume] a2 hemoglobin n blood by hromatography clumn
4550-0,hgb a2 bld column chrom-scnc
4550-0,chrom-scnc abld column hgb
4550-0,hb haemoglobin a2 bld column chrom-scnc
4550-0,hemoglobin a2 chromatography column (bld) [moles/vol]
4550-0,random hemoglobin a2 chromatography [moles/vol] (bld) column
4550-0,hemoglobin a2 chromatography column (blood) [moles/vol] quan
46031-1,indicators of fluid status set
46031-1,idicatrs of fuid fld sttusset
46031-1,fld diaors offluid statu et
25869-9,beta alanine/creatinine [molar ratio] in 24 hour urine
25869-9,beta alanin/creatinine 24 hours [mlar ratio] in 24 hou urine
25869-9,bet alnine/creatinine [molar ratio in2 hoururine
25869-9,b-alanine/creat 24h ur-srto
25869-9,b-alanine/creat 24h chemistry ur-srto
25869-9,ur-srto 24h b-alanine/creat
25869-9,beta alanine/creatinine (24h u) [molar ratio]
25869-9,beta alanine/creatinine (24h [molar u) ratio]
25869-9,beta alanine/creatinine 24h u) 1 day [molar ratio]
2807-6,pipecolate [mass/volume] in urine
2807-6,[mass/volume] pipecolate in urine pipecolic acid
2807-6,ppcolat[mass/voume] in urie
2807-6,pipecolate ur-mcnc
2807-6,ur-mcnc pipecolate
2807-6,ur-mcnc pipecolate
2807-6,pipecolate (u) [mass/vol]
2807-6,quan pipecolate (u) [mass/vol]
2807-6,mass concentration ppecolte (u)mas/vol]
26508-2,band form neutrophils/leukocytes in blood
26508-2,in form neutrophils/leukocytes band blood
26508-2,bad form in neutrophils/leukocytes blod
26508-2,neuts band nfr bld
26508-2,percent neuts nfbld ban
26508-2,nus quantitative band nfr bld
26508-2,band form neutrophils/leukocytes (bld)
26508-2,band form neutrophils/leukocytes (bld) hematology/cell counts
26508-2,band white bld cells form neutrophils/leukocytes (bld)
73146-3,sotalol induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73146-3,sotalol inducd platlet i ab beta-cardone [resence] in erum (fc) plasmabyflow cytmetry or
73146-3,sotalol induced platelet igg ab [presence] in serum by plasma or flow cytometry (fc)
73146-3,sotalol ind plt igg serpl ql fc
73146-3,sotalol ind platelt fc igg serpl ql plt
73146-3,sotalol ind plt ig serpl qlfc
73146-3,sotalol induced platelet igg fc ql
73146-3,sotalol ql platelet igg fc induced
73146-3,sotalol induced platelet igg fc betudes ql
9581-0,western equine encephalitis virus ab [titer] in serum by immunofluorescence
9581-0,western eque encephalitis virus a titer] in serum by immunofluorescence
9581-0,autoantibody wesern eque encephalitis virus immunofluorecence [tite] in serm by ab
9581-0,weev ab titr ser if
9581-0,w a titr sr titre if
9581-0,eev ab weev titr ser if
9581-0,weev ab if (s) [titer]
9581-0,weev  i(s) [tit
9581-0,eev a if (s) tite]
100970-3,portable medical order completion information
100970-3,medical portable order portable med order completion info completion information
100970-3,portable medical order clin completion information
100970-3,portable med order completion info
100970-3,portabl med order ompletion info
100970-3,porble omplton order med info
100970-3,portable medical order completion information
100970-3,clin portable medical order completion information
100970-3,portable completion order medical clin information
72650-5,glucose in serum - glucose in pericard fld [molar concentration difference]
72650-5,glucose in serum - glucosein pericard fld [molar oncentration glucose ser - peric fld difference]
72650-5,glucose in ser - glucose in pericard fld [molar concentration difference]
72650-5,glucose ser - peric fld-scdiff
72650-5,quantitative gluose ser - peric fldscdif
72650-5,lcoe serum - prc ld-scdiff
72650-5,glucose in serum - glucose in pericard fld (pericard fld+s/p) [molar conc diff]
72650-5,glucose i mlar -glucose i priardfld pericard sr fld+s/p) serm condiff]
72650-5,glucose in serum - glucose in diff] fld (pericard fld+s/p) [molar conc cardio pericard
2100-6,cholylglycine [mass/volume] in serum
2100-6,cholylglycine [mass/volume] in serum
2100-6,ser [as/volume] in glycocholate choylgycie
2100-6,cholylglycine ser-mcnc
2100-6,sermcnc cholylglcine
2100-6,cholylglycine cg ser-mcnc
2100-6,cholylglycine (s) [mass/vol]
2100-6,colylglycine (s) [mass/vol]
2100-6,[mass/vol] (s) cholylglycine
54570-7,oral/dental status
54570-7,status oral/dental
54570-7,status oral/dental
52531-1,provider city
52531-1,nominal rvider ity
52531-1,provider nominal city
52531-1,provider city
52531-1,city provider
52531-1,random cit provider
74996-0,alkaline phosphatase.bone [z-score] in serum or plasma
74996-0,alkaline phosphatasebone[zscoe in ru opasma
74996-0,alkaline phosphatase.bone [z-score] or serum in plasma
74996-0,alp bone z-score serpl
74996-0,alp bone b-alp z-score serpl
74996-0,z-scoeerpl bone alp alp
74996-0,alp bone [z-score]
74996-0,alp sr bone [z-score]
74996-0,pt alp bone [zscore]
586-8,streptococcus agalactiae [presence] in specimen by organism specific culture
586-8,streptococcus agalactiae [presence] id in specimen by organism specific culture
586-8,streptococcus agalactiae [ql] in specimen by organism specific culture
586-8,gp b strep spec ql cult
586-8,gp ql strep spec b cult screen
586-8,gp b ql spec strep cult
586-8,s. agalactiae org specific cx ql (specimen)
586-8,microbiology s. agalactiae org (specimen) cx ql specific
586-8,s. agalactiae org q c specific (specimen)
22507-8,saint louis encephalitis virus ab [presence] in cerebral spinal fluid
22507-8,ab louis encephalitis infectiousdisease virus saint [presence] in cerebral spinal fluid
22507-8,sain louis encephalitis virus [presence] ab in cerebral spinal fluid
22507-8,slev ab csf ql
22507-8,slv ab ql csf
22507-8,slev ab cerebrospinal fluid ql
22507-8,slev ab ql (csf)
22507-8,slev (cerebrospinal fluid) ql ab
22507-8,(csf) ab ql slev
74093-6,gliquidone [mass/volume] in serum or plasma
74093-6,in [mass/volume] serum or plasma gliquidone serum or plasma
74093-6,sr gliqudone [mas/volume]in seru or pasma
74093-6,gliquidone serpl-mcnc
74093-6,gliquidne serl-cnc mass concentration
74093-6,drug/toxicology serl-mnc luione
74093-6,gliquidone [mass/vol]
74093-6,[mass/vol] gliquidone
74093-6,quantitative gliquidone [mass/vol]
22917-9,bovine leukemia virus ag [presence] in specimen
22917-9,bovne eukemia virus ag [prsence] qual in specimen
22917-9,bovine leukemia antigens virus ag [presence] in specimen
22917-9,blv ag spec ql
22917-9,spec blvag retrovirus ql
22917-9,antigen ag blv spec ql
22917-9,bovine leukemia virus ag ql (specimen)
22917-9,bovine leukemia virus screen ag ql (specimen)
22917-9,bovne leukemia (speimen) g presence virus
31658-8,streptococcus pyogenes enzyme ab [units/volume] in serum
31658-8,streptococcus pyogenes ab enzyme steptococcus group a [units/volume] in serum
31658-8,strepococcus pyogenes zyme serum [units/volue] in ab
31658-8,s pyog.enz ab ser-acnc
31658-8,s ab pyogenz ser-acnc id
31658-8,s pyog.en ranc ab
31658-8,s. pyogenes enzyme ab qn (s)
31658-8,ab pyogens ezyme s. qn (s)
31658-8,s. pyogenes enzymab arbitrary concentration qn (s)
104113-6,heparan-n-sulfatase [enzymatic activity/volume] in dbs
104113-6,hearan-nsulfatase [nzymatic dbs pt in activity/volume]
104113-6,dbs [enzymatic activity/volume] fp in heparan-n-sulfatase
104113-6,heparan-n-sulfatase dbs-ccnc
104113-6,dbs-ccnc heparan-n-sulfatase
104113-6,quan dbs-cnc eparan-n-slfatse
104113-6,heparan-n-sulfatase (dbs) [catalytic activity/vol]
104113-6,qnt [catalytic (dbs) heparan-n-sulfatase activity/vol]
104113-6,[catalytic (dbs) heparan-n-sulfatase activity/vol]
13017-9,deprecated tetrachloroethylene [mass/volume] in blood
13017-9,deprecated [mass/vlme tetracloroethylene inboo drugs
13017-9,blood tetrachloroethylene [mass/volume] in deprecated
13017-9,deprecated perchloroethylene bld-mcnc
13017-9,perchloroethylene deprecated bld-mcnc
13017-9,perchloroethylene deprecated blood-mcnc point in time
13017-9,perchloroethylene (bld) [mass/vol]
13017-9,(bld)[mas/vol] mass concentration perclorohylene
13017-9,[mass/vol] (ld) perchloroethylene point in time
35127-0,hemoglobin a2.prime/hemoglobin.total in blood
35127-0,hemoglobin a2.prime/hemoglobin.total blood in
35127-0,blood a2.prime/hemoglobin.total in hemoglobin
35127-0,hgb a2.prime mfr bld
35127-0,hematology/cell counts hgb a2.prime mfr blood
35127-0,a2.prime hgb mfr bld haemoglobin
35127-0,hemoglobin a2.prime (bld) [mass fraction]
35127-0,[mass random a2.prime (bld) hemoglobin fraction]
35127-0,hemoglobina2.prime bld) mass fraction]
30330-5,deprecated disialylganglioside gd1b igm ab [titer] in serum
30330-5,deprecated quan disialylgngliosid gd1b ig ab [tite] in serum
30330-5,deprecated [titer] gd1b igm ab disialylganglioside in serum
30330-5,deprecated gd1b disialyl igm titr ser
30330-5,igm gd1b disialyl deprecated titr ser
30330-5,deprecated ser gd1b disialyl igm titr ser
30330-5,disialylganglioside gd1b igm (s) [titer]
30330-5,[titer] gd1b igm (s) disialylganglioside
30330-5,disialgngliside [titr] (s) gd1bigm
29899-2,gamma globulin [presence] in 24 hour urine
29899-2,i globulin [presen] 1 day gamm 24 hour urne
29899-2,gamma globulin [presence] hour 24 in urine
29899-2,gamma glob 24h ur ql
29899-2,gamma glob 24h chemistry ur presence
29899-2,gamma glob 24h ur ql
29899-2,gamma globulin ql (24h u)
29899-2,gamma presence globulin (24h u)
29899-2,gamma 1 day u) (24h globulin
20446-1,herpes simplex virus igg ab [interpretation] in serum by immunoassay
20446-1,herpes simplevirus igg ab [iterpreaion] in erum ser byimmunasay
20446-1,herpes simplex virus in ab [interpretation] igg serum by immunoassay
20446-1,hsv igg ser ia-imp
20446-1,hsv ig ser ia-imp
20446-1,igg hsv ser iaimp
20446-1,hsv igg ia (s) [interp]
20446-1,hsv igg ia(s) [interp]
20446-1,hs igg ia (s) [interp]
47369-4,calcitonin [mass/volume] in body fluid
47369-4,calcitonin [mass/volume] body in quant fluid
47369-4,calcitonin [mass/volume] in body bodies fluid
47369-4,calcit fld-mcnc
47369-4,bf fd-mcnc calcit
47369-4,alcit fld-mcn
47369-4,calcitonin (body fld) [mass/vol]
47369-4,calcinin bdy fd) quantitative [mass/o]
47369-4,fld) (body calcitonin mass/vol]
52981-8,herpes simplex virus igg ab [units/volume] in serum by immunoassay
52981-8,herpes ab virusig smplex [units/volum] in ser by mmunassay
52981-8,herpes herp splx simplex virus igg ab [units/volume] in serum by immunoassay
52981-8,hsv igg ser ia-acnc
52981-8,hsv serum igg i-acnc
52981-8,hsv ser igg ia-acnc
52981-8,hsv igg ia qn (s)
52981-8,hsv qn ia igg antby (s)
52981-8,hsv igg a qn (s elisa
17005-0,iga subclass 1 [mass/volume] in cerebral spinal fluid
17005-0,iga subclass 1 [mass/volume] in fluid spinal cerebral
17005-0,1 subclass iga [mass/volume] in cerebral spinal fluid
17005-0,iga1 csf-mcnc
17005-0,iga1 cerebrospinal fluid-mnc
17005-0,csf-mcnc iga1
17005-0,iga subclass 1 (csf) [mass/vol]
17005-0,iga subclass (csf) 1 [mass/vol]
17005-0,iga [mass/vol] 1 (csf) subclass
80118-3,abacavir [mass/volume] in cord blood
80118-3,abacvir[mass/volume] i cord blood
80118-3,abcavir [mass/vlume] in cor blod
80118-3,abacavir bldco-mcnc
80118-3,qnt abacavir bldco-mcnc
80118-3,bldco-mcnc abacavir
80118-3,abacavir (bldco) [mass/vol]
80118-3,abacavir (bldco) [mass/vol]
80118-3,(bldco) cord (umbilical) blood abacavir [mass/vol]
31959-0,rubella virus ag [presence] in nose
31959-0,rubella irusag [preenc n congenital rubella syndrome nos
31959-0,ubella vrus ag in [prese] nose
31959-0,rubv ag nose ql
31959-0,nose ag rubv ql
31959-0,rubv ag nose microbiology presence
31959-0,rubella virus ag ql (nose)
31959-0,rubla vir ag (ose) ql
31959-0,rubella vrus ql ag nose)
27021-5,neisseria gonorrhoeae ab [titer] in cerebral spinal fluid by complement fixation
27021-5,nesseria smqn gonorrhoeae ab [titer n cerebral spinal flid by complement fxaton
27021-5,neisseri gonorrhoeae ab [titer in cerebral spinal fluid by n gonorrhoeae mplement fixation
27021-5,n gonorrhoea ab titr csf cf
27021-5,n gonorrhea ttr ab infectiousdisease cerebrospinal fluid cf
27021-5,n gonorrhoea ab titr csf cf
27021-5,n. gonorrhoeae ab cf (csf) [titer]
27021-5,n. gonorrhoeae ab cf [titer] (csf)
27021-5,n. [titer] ab cf (csf) autoantibody gonorrhoeae
88697-8,electrolytes and osmolality panel - stool
88697-8,electrolytes and osmolality panel quan - stool
88697-8,- and osmolality panel electrolytes too
88697-8,electrolytes & osmolality panel stl
88697-8,eletrlytes  osolality pane stl
88697-8,elctrlytes & osmolality pnel stl pan
88697-8,electrolytes and osmolality panel (stl)
88697-8,(sl) pnl ad osmoaliy pane electrolytes
88697-8,pt (stl) and osmolality panel electrolytes
13780-2,n-acetyltyrosine/creatinine [mass ratio] in urine
13780-2,[mass n-acetyltyrosine/creatinine chemistry ratio] in urine
13780-2,n-acetylyrosine/creatinine[mass rtio] n urine
13780-2,nat/creat ur
13780-2,at/creat r
13780-2,nat/cret creat ur
13780-2,n-acetyltyrosine/creatinine (u) [mass ratio]
13780-2,n-acetltyrosine/cratinine (u [mass ratio]
13780-2,[mass n-actyltyrosine/creatinne(u) rati quant
12379-4,halazepam [mass/volume] in serum or plasma
12379-4,halazepam [mass/volume] in serum or plasma
12379-4,serpl halazepam [mass/volume] plasma serum or in
12379-4,halazepam serpl-mcnc
12379-4,halazepam serpl-mcnc
12379-4,serpl-mcnc halazepam serum
12379-4,halazepam [mass/vol]
12379-4,[mass/vol] halazepam paxipam
12379-4,[mass/vol] halazepam
54217-5,public health notifiable condition
54217-5,public random health notifiable condition
54217-5,public health notifiable condition
54217-5,ph notifiable condition
54217-5,ph condition notifiable miscellaneous
54217-5,notifiablecondition point in time ph
82889-7,meta methylhippurate+ortho methylhippurate+para methylhippurate [moles/volume] in urine
82889-7,eta moles/volume] methylhippurate+para methylhippurate metylppurat+ortho in urine
82889-7,meta [moles/volume] methylhippurate+para methylhippurate methylhippurate+ortho in urine
82889-7,m+o+p-methylhippurate ur-scnc
82889-7,m+o+p-methylhippurate p-methylhippurate ur-scnc
82889-7,m+o+-methylhipuate urscnc
82889-7,meta methylhippurate+ortho methylhippurate+para methylhippurate (u) [moles/vol]
82889-7,meta methylhippurate+ortho methylhippurate+para (u) methylhippurate [moles/vol]
82889-7,mta mthylippurtertho methylhippurate+aramethylhippurate (u) [mols/vo]
14148-1,18-hydroxycortisol [mass/time] in 24 hour urine
14148-1,18-hydroxycorisl [ass/time in hour 24 urine
14148-1,in [mass/tme] 18-hydoxycorisl 24 hour urine 24hr
14148-1,18oh-cortis 24h ur-mrate
14148-1,18oh-cortis ur-mrate 24h
14148-1,24h 18oh-cortis ur-mrate
14148-1,18-hydroxycortisol (24h u) [mass/time]
14148-1,18-hydroxycortisol 1 day [mass/time] u) (24h
14148-1,18-hydroxycortisol quantitative (24h [mass/time] u)
58707-1,ephedrine+pseudoephedrine [mass/volume] in urine by confirmatory method
58707-1,ephedrine+pseudoephedrine mss/voume] in urine by confirmtory method
58707-1,in quan [mas/voume] ephdrie+pseudoepedrie urine by confirmatory method
58707-1,ephedrin+pseudo ur cfm-mcnc
58707-1,ephedin+peudour cfmmcnc confirmatory
58707-1,urn ephedrin+pseudo ur cfm-mcnc
58707-1,ephedrine+pseudoephedrine confirm (u) [mass/vol]
58707-1,[mss/ol] (u) ephedrine+pseudephedineconfir qnt
58707-1,ephedrine+pseudoephedrine [mass/vol] (u) confirm
93208-7,lcds v5.00 - health conditions - admission during assessment period [cms assessment]
93208-7,dsv5.00 -healh coditions -admssion during sessment peio [cms assessmet]
93208-7,lcdsv5.0 - health coditions - amisso during assessmentperio [cms assssment]
45270-6,acute leukemia panel - specimen by flow cytometry (fc)
45270-6,acte eukemia panl - specimen by flow cytometry(fc)
45270-6,acute leukemia panel - specimen by flow cytometry (fc)
45270-6,acute leukemia pnl spec fc
45270-6,fc leukemiapnl pec ace
45270-6,acut leukemia spec pnl fc
45270-6,acute leukemia panel fc (specimen)
45270-6,acue universallaborders leukemia panl fc (specimen)
45270-6,random acute fc panel leukemia (specimen)
43010-8,hiv 1+2 ab [presence] in specimen
43010-8,hiv 1+2 ab specimen in [presence] qualitative
43010-8,hiv 1+2 ab [resnce qual in secin
43010-8,hiv1+2 ab spec ql
43010-8,hiv1+2 ab spec ql screen
43010-8,ab hiv1+2 spec ql
43010-8,hiv 1+2 ab ql (specimen)
43010-8,hiv (specimen) ab ql 1+2 hiv type 1
43010-8,hiv ab 1+2 ql (speimen)
76046-2,ieee 11073 rosetta body measurement panel
76046-2,eee1107 retta body point in time measurementpnel
76046-2,ee 1103 rosetta measuremen body panel
76046-2,rosetta body meas pnl
76046-2,body rosetta meas pnl
76046-2,roseta body mas nl
82925-9,pm-scl-100 igg ab [presence] in serum by line blot
82925-9,pm-scl-100igg ab bot sermby lin [presenen
82925-9,pm-scl-100 igg ab [presence] in serum blot line by
82925-9,pm/scl-100 igg ser ql line blot
82925-9,pm/scl-100igg er presence line presence blot
82925-9,pm/scl-100 ser igg presence line blot
82925-9,pm-scl-100 igg line blot ql (s)
82925-9,pm-scl-100 polymyositis igg (s) blot ql line
82925-9,ql pm-scl-10igg line blot ql (s)
12487-5,butalbital [presence] in gastric fluid
12487-5,btalbital [pesence] in fluid gastric
12487-5,in qual [presence] butalbital gastric fluid
12487-5,butalbital gast ql
12487-5,butalbital gast qualitative ql
12487-5,butalbitl ql gast random
12487-5,butalbital ql (gast fld)
12487-5,butalbital presence (gat fld) qualitative
12487-5,pr butalbital (gast ql fld)
31781-8,classical swine fever virus ag [presence] in specimen
31781-8,classical swinefever ag virus point in time [resence]in specimn
31781-8,classical swie fever viru ag [prsenc] i specmen
31781-8,csfv ag spec ql
31781-8,csfv ql spec ag
31781-8,csfv ag spec presence
31781-8,classical swine fever virus ag ql (specimen)
31781-8,classcal swine ve vius random ag ql (specimen)
31781-8,casial ag fever microbiology virs swine ql (specimen
21382-7,manganese [mass/volume] in 24 hour urine
21382-7,manganese [mass/volume] in quan 24 hour urine
21382-7,[mass/volume] manganese in 24 hour urine
21382-7,manganese 24h ur-mcnc
21382-7,manganese 24h 24hr ur-mcnc
21382-7,manganese 24h ur-mcnc mn
21382-7,manganese (24h u) [mass/vol]
21382-7,manganese (24h u) mass concentration [mass/vol]
21382-7,manganese 4h 24hr u) [mass/vol]
56730-5,smith extractable nuclear ab [presence] in serum by immunoblot
56730-5,smith extractable qualitative nuclear by [presence] in serum ab immunoblot
56730-5,smit i nclear a [preence extractale ser by immunoblot
56730-5,ena sm ab ser ql ib
56730-5,ql b ser enas point in time ib
56730-5,ena sm ab serum antibody ql ib
56730-5,smith extractable nuclear ab ib ql (s)
56730-5,smith extractable nuclear ab ib ql (s) immunobl
56730-5,smith extractable nuclear ql ib ab (s)
10678-1,herpes simplex virus 1+2 ag [presence] in tissue by immune stain
10678-1,herpes simplex virus stain ag [presence] in tissue by immune 1+2
10678-1,epessimpex virs1+2 g [presnce] n issueby immue stain
10678-1,hsv1+2 ag tiss ql imstn
10678-1,hsv1+2 ordinal tiss ag ql mstn
10678-1,hsv1+2 ag herpes simplex virus type 1+2 tiss ql imstn
10678-1,hsv 1+2 ag immune stain ql (tiss)
10678-1,tis) 1+2ag immunestain ql sv
10678-1,hsv 1+2 ag immune stain ql (tiss)
30044-2,dirofilaria immitis ab [titer] in serum
30044-2,dirofilaria immitis ab [titer] in random eru
30044-2,imitisab dirofilara [tier] in ser
30044-2,d immitis ab titr ser
30044-2,d immitis ab ser titr
30044-2,anti d immitis ab titr ser
30044-2,d. immitis ab (s) [titer]
30044-2,d. sr immitis ab(s) [titer
30044-2,d immitis [titer] immitis ab (s) d.
9398-9,reticulin ab [titer] in serum
9398-9,reticuli b[titr]in serum
9398-9,[titer] ab gastro reticulin in srum
9398-9,reticulin ab titr ser
9398-9,reticuli anti ab itr ser
9398-9,reticulin ab abs titrser
9398-9,reticulin ab (s) [titer]
9398-9,reticulin titer ab () [titr]
9398-9,reticulin ab (s) [tite]
77881-1,risperidone cutoff [mass/volume] in urine for confirmatory method
77881-1,urine cutoff [mass/volume] in risperidone for confirmatory method cfm
77881-1,risperidone cutoff method in urine for confirmatory [mass/volume]
77881-1,risperidone cto ur cfm-mcnc
77881-1,risperidone cto ur cfm-mcnc
77881-1,risperidone cfm-mcnc ur cnfrm cto
77881-1,risperidone cutoff confirm (u) [mass/vol]
77881-1,risperidone (u) confirm cutoff [mass/vol]
77881-1,quant risperidone cutoff confirm [mass/vol] (u)
54569-9,percent intake by artificial route
54569-9,percent intake by route artificial
54569-9,by intake percent artificial route
74609-9,sebacylcarnitine (c10-dc) [enzymatic activity/mass] in fibroblast
74609-9,sebaclcaritine (c10-dc) [ezmati activty/mass] in firoblst
74609-9,sebacylcarnitine (c10-dc) [enzymatic activity/mass] in random fibroblast
74609-9,sebacylcarn fib-ccnt
74609-9,quantitative fib-ccnt sebacylcarn
74609-9,catalytic content fib-ccn sebacylcn
74609-9,c10-dc (fibroblast) [catalytic activity/mass]
74609-9,c10-dc (fibroblast) [catalytic catalytic content activity/mass]
74609-9,c10-dc (fibroblast) [catalytic activity/mass]
18769-0,microbial susceptibility tests set
18769-0,ast microbial susceptibili tts set
18769-0,susceptibility microbial tests ast set
31417-9,herpes virus 7 igm ab [units/volume] in serum
31417-9,herpesviru 7 in ab [unis/volume] igm seum antibody
31417-9,quantitative heres viru 7 igm ab [uis/volume] n serum
31417-9,hhv7 igm ser-acnc
31417-9,ser hhv7 igm se-acnc
31417-9,hh7 igm ser-acnc
31417-9,hhv 7 igm qn (s)
31417-9,hhv 7 qn human herpes virus igm (s)
31417-9,7 hhv igm qn (s) quan
80284-3,pulse intensity assessment panel
80284-3,useintensity ssesment panel.h&p panel
80284-3,pulse intensity assessment panel
80284-3,pulse intensity assessment pnl
80284-3,puseintensity assessment pnl
80284-3,pule pnl ssessment intensiy
23160-5,leishmania sp identified in tissue by immunofluorescence
23160-5,eshmania p ideified in tissue by immunofluorecenc
23160-5,leishmania sp identified in tissue visceral leishmaniasis by immunofluorescence
23160-5,leishmania tiss if
23160-5,leishmana i tiss
23160-5,immunofluor tissf leishmnia
23160-5,leishmania sp identified if nom (tiss)
23160-5,leishmaniap (tiss) nom identifieif
23160-5,leishmnisp i identifid nom tiss)
16360-0,amitriptyline [mass/volume] in serum or plasma --peak
16360-0,amitriptyle serplas [mass/volume] in r serm plama --eak
16360-0,amitriptyline[mass/volue] in ser or plasm --eak
16360-0,amitrip peak serpl-mcnc
16360-0,amitrip random peak serpl-mcnc
16360-0,amitrip peak serpl-mcnc endep
16360-0,amitriptyline peak [mass/vol]
16360-0,amitriptyline [mass/vol] drugs peak
16360-0,amitriptyline peak [mass/vol]
48639-9,urea nitrogen [mass/volume] in peripheral blood --post dialysis
48639-9,urea nitrogen peripheral in [mass/volume] quan blood --post dialysis
48639-9,urea nitrogen [mass/volme] in pripheral blood --pos dialysis
48639-9,bun p dialysis bldp-mcnc
48639-9,un diasibdp-mcnc p
48639-9,mass concentration bun ldp-mcn dialysis p
48639-9,urea nitrogen post dialysis (bldp) [mass/vol]
48639-9,urea nitrogen [mass/vol] dialysis (bldp) post
48639-9,ue dialyis post nitrogen (bldp) [as/vl]
74939-0,vigabatrin [mass/volume] in serum or plasma --trough
74939-0,vigabarn [mss/volume] serum in orplasma --trouh
74939-0,vigabatrin [mass/volume] in serpl --trough
74939-0,vigabatrin trough serpl-mcnc
74939-0,trough vigabatrin serpl-mcnc
74939-0,troughserpl-mcc vgabatrin quant
74939-0,vigabatrin trough [mass/vol]
74939-0,trough vigbatrin [mass/vol]
74939-0,vigabatrin [mass/vol] trough
22982-3,capripox virus ab [presence] in serum
22982-3,serum irs ab [presenein capripox
22982-3,capripox virus ql ab [presence] in serum
22982-3,capripox ab ser ql
22982-3,aby capripox ab serum ql
22982-3,capripox ab ser presence
22982-3,capripox virus ab ql (s)
22982-3,caprox virusb presence screen (s)
22982-3,capripox virus ab presence (s)
58445-8,manual differential comment [interpretation] in blood narrative
58445-8,manual differential comment [interpretation] in blood com narrative
58445-8,manual differential comment narrative in blood [interpretation]
58445-8,manual dif comment bld-imp
58445-8,comment dif manual bld-imp
58445-8,manual dif bld-imp comment
58445-8,manual differential comment nar (bld) [interp]
58445-8,manua dfferential comment impression nar (bld)[nterp]
58445-8,(bld) differential comment nar manual [interp]
8798-1,right ventricular stroke volume index by spiral ct
8798-1,right ventricular stroke volume index computed tomography y srl ct
8798-1,right index oke volum ventricular by spial t
8798-1,rv svi spiral ct
8798-1,svi rv spiral ct
8798-1,spiral si rv ct
2220-2,elastase.pancreatic free [enzymatic activity/volume] in serum
2220-2,elastase.panreaticfree [enzymatic activity/volume] in quantitative serum
2220-2,elstase.pancreatc free [nzymatic activity/volume] i serum
2220-2,elastase panc free ser-ccnc
2220-2,elastase panc free serum-ccnc
2220-2,elastase pac sr-ccnc free
2220-2,elastase.pancreatic free (s) [catalytic activity/vol]
2220-2,lastase.pancreatic free (s) random [catalyic activi/vol]
2220-2,(s) free elastase.pancreatic [catalytic activity/vol]
56659-6,para aminophenol/creatinine [ratio] in urine
56659-6,para aminophenol/creinine ua [ratio] in urine
56659-6,para aminopheol/creatinine [ratio] in urine
56659-6,p-aminophenol/creat ur-rto
56659-6,p-aminophenol/creat ur-rto quant
56659-6,p-amnophenol/creat ur-rto
56659-6,para aminophenol/creatinine (u) [ratio]
56659-6,para [ratio] (u) aminophenol/creatinine
56659-6,para aminophenol/creatinine rto (u) [ratio]
89773-6,improvement plan [cdc emergency operations centers]
89773-6,improvement [cdc plan emergency operations centers] cdc eoc
89773-6,pnl improvement [cdc plan emergency operations centers]
12531-0,deprecated cholesterol [mass/volume] in body fluid
12531-0,deprecated cholesterol [mass/volume] in flu body fluid
12531-0,deprecated luid in flu bod cholstero[mass/olume
12531-0,deprecated cholest fld-mcnc
12531-0,deprecated chlest fld-mcnc
12531-0,cholest deprecated fld-mcnc
12531-0,cholesterol (body fld) [mass/vol]
12531-0,(boyfld) cholesterol bodies [mss/vo]
12531-0,cholesterol (body chemistry fld) [mass/vol]
12301-8,procaine [presence] in urine
12301-8,procaine [presence] in ordinal urine
12301-8,procaine [presence] in drugs urine
12301-8,procaine ur ql
12301-8,procaine ql ur
12301-8,procaine urn ur ql
12301-8,procaine ql (u)
12301-8,procaine ur ql (u)
12301-8,procaine ordinal q (u)
40761-9,coxsackievirus a ab [titer] in serum --2nd specimen
40761-9,coxsackievirus a [titer] ab in ser --2nd specimen
40761-9,coxsackievirus ab a [titer] in serum --2nd specimen
40761-9,cv a ab sp2 titr ser
40761-9,a cv ab sp2 titr ser
40761-9,cv a ab ser titr sp2
40761-9,coxsackievirus a ab spec 2 (s) [titer]
40761-9,coxsackievirus a [titer] spec 2 (s) ab
40761-9,coxsakievius spec b sec 2 (s)[titr]
44474-5,herpes simplex virus 1 ag [presence] in throat
44474-5,herpes simplex virus 1 ag [ql] in throat
44474-5,hrpes simplex rus 1 antigens g [presnce] in throt
44474-5,hsv1 ag throat ql
44474-5,hsv1 ag presence troat
44474-5,infectiousdisease hsv1 ag throat ql
44474-5,hsv 1 ag ql (throat)
44474-5,ag 1 hsv q (throat)
44474-5,(throat) 1 agql hsv
2466-1,igg subclass 1 [mass/volume] in serum
2466-1,iggsubclass qnt serum in [mass/volue]
2466-1,igg subclass in [mass/volume] 1 serum level
2466-1,igg1 ser-mcnc
2466-1,ig1 immunoglobulin g subclass 1 ser-mcnc
2466-1,igg ser-mcnc igg1
2466-1,igg subclass 1 (s) [mass/vol]
2466-1,igg igg 1 sbclass 1 (s) [massvol]
2466-1,subclass igg 1 (s) [mass/vol]
18265-9,acetaminophen [presence] in body fluid
18265-9,[presence] acetaminophen in body fluid
18265-9,flui [presece] in acetamidophenol body acetaminophen
18265-9,apap fld ql
18265-9,apap ql fld
18265-9,apap bodies ql fld
18265-9,acetaminophen ql (body fld)
18265-9,acetaminophen presence fld) (body
18265-9,acetaminophen ql apap (body fld)
2885-2,protein [mass/volume] in serum or plasma
2885-2,protein [mass/volume] plasma ser or in
2885-2,in [ass/olume] plasma protein seum or plasma
2885-2,prot serpl-mcnc
2885-2,rot sepl-mcnc
2885-2,serpl-mcnc prot
2885-2,protein [mass/vol]
2885-2,[mass/vol] protein
2885-2,[ass/vol] protein level
23353-6,deprecated peste des petits ruminants virus ab [presence] in serum
23353-6,deprecated peste des petits ruminants virus serum [presence] in ab
23353-6,deprecatedpeste des peit ruminants vius ab [presence] autoantibodies in serum
23353-6,deprecated pprv ab ser ql
23353-6,deprete pprv abser ql
23353-6,deprecated pt pprv ser ab ql
23353-6,peste des petits ruminants virus ab ql (s)
23353-6,pestedes petts ruminans virus ab ql )
23353-6,peste des petits ruminants virus ab presence (s)
22347-9,histoplasma capsulatum ab [titer] in serum
22347-9,histoplasma capsulatum ab [titer] in ser
22347-9,histopasma microbiology capsulatum ab [titr] in eum
22347-9,h capsul ab titr ser
22347-9,h capsul antby ab titr ser
22347-9,h capul titre ab titr ser
22347-9,h. capsulatum ab (s) [titer]
22347-9,(s) capsulatum ab h. [titer]
22347-9,smqn h capulatum ab (s) [titer]
40917-7,streptococcus pneumoniae danish serotype 19a igg ab [mass/volume] in serum by immunoassay --2nd specimen
40917-7,streptococcus pneumoniae --2nd antby serotype 19a igg ab [mass/volume] in ser by immunoassay danish specimen
40917-7,streptococcus pneumoniae danish serotype 19a igg ab [mass/volume] in enzyme immunoassay serum by immunoassay --2nd specimen
40917-7,s pneum da 19a igg sp2 ser ia-mcnc
40917-7,s pneum da 19a igg sp2 ser ia-mcnc s pneum da 19a igg
40917-7,s pneum autoantibodies da igg 19a sp2 ser ia-mcnc
40917-7,s. pneumoniae danish type 19a igg spec 2 ia (s) [mass/vol]
40917-7,s. igg danish type 19a pneumoniae spec 2 pneumon ia (s) [mass/vol]
40917-7,9a pneumonie daish type s. spn igg spec ia (s) [mass/vl]
23444-3,swine vesicular disease virus ag [presence] in specimen by immunoassay
23444-3,swine vesicular dseasevirus a by in pecimn [presence] qualitative immunoassay
23444-3,swine vesicular disease virus ag [presence] immunoassay specimen by in
23444-3,svd ag spec ql ia
23444-3,ag svd spec ql ia
23444-3,vd ag speql 
23444-3,swine vesicular disease virus ag ia ql (specimen)
23444-3,swin vsicular diseae irus ag ia presence (specime)
23444-3,picornavirus snevesicular sease virusa a ql (specimen)
655-1,microscopic observation [identifier] in specimen by acid fast stain.kinyoun modified
655-1,micrscopic observatin identifir] in specmen by acd fat stain.kinyoun modiied
655-1,microscopi obseratio [identifier] in specimen by acid fast stain.kiyoun odified
655-1,acid fast mod kiny stn spec
655-1,acid fast mod kiny stn spec
655-1,id fast sn modkiny spec st
655-1,microscopic observation acid fast stain.kinyoun modified nom (specimen)
655-1,mioscoic observaion ac fast stain.kinoun modfied id nom (specimen)
655-1,microscopic observation modified fast stain.kinyoun acid nom (specimen)
1789-7,deprecated alpha aminobutyrate [mass/volume] in serum
1789-7,deprecated alpha aminobutyrate [mass/volume] quantitative in serum
1789-7,deprcated alpha aminobutyrate 2-aminobutyrate [ass/volume] in srum
1789-7,deprecated a-aminobutyr ser-mcnc
1789-7,deprecated a-aminobutyr serum ser-mcnc
1789-7,a-aminobutyr deprecated ser-mcnc
1789-7,alpha aminobutyrate (s) [mass/vol]
1789-7,alpha aminobutyrate [mass/vol] ()
1789-7,aminobutyrate alpha (s) 2-aminobutyric acid [mass/vol]
56994-7,tyrosine/creatinine [ratio] in 24 hour urine
56994-7,trosine/creatiine [rato]in 24our 1 day urine
56994-7,24 [ratio] in tyrosine/creatinine hour urine
56994-7,tyrosine/creat 24h ur-rto
56994-7,1 day tyrosine/creat 24h ur-rto
56994-7,24h ucr tyrosine/creat ur-rto
56994-7,tyrosine/creatinine (24h u) [ratio]
56994-7,tyrosine/creatinine (24h u) [ratio]
56994-7,tyrosine/creatinine tyr (24h u) [ratio]
25343-5,fasciola sp igg ab [units/volume] in serum
25343-5,fasciola sp igg abunits/volue]inser
25343-5,fasciola sp antibodies igg ab [units/volume] in serum
25343-5,fasciola igg ser-acnc
25343-5,igg fasciola serum-acnc
25343-5,fasciola igg quant ser-acnc
25343-5,fasciola sp igg qn (s)
25343-5,fasciola sp igg qn arbitrary concentration (s)
25343-5,fasciola sp (s) immunoglobulin g qn igg
97236-4,codeine free [presence] in cord tissue by screen method
97236-4,odein free [prsnce] i ord tisue b creen method
97236-4,codeine free [presence] in tissue cord by screen method
97236-4,codeine free tissco ql scn
97236-4,codeine q scn tissco free scn
97236-4,codeieree ssco ql scn
97236-4,codeine free screen ql (umb cord tissue)
97236-4,codine fre scren presence umb crd tissue)
97236-4,coene cor screen ql (um free issue)
42973-8,powassan virus igg ab [titer] in specimen
42973-8,powassanvirus igg specimen [titer]n ab
42973-8,[titer] virus igg ab powassan in specimen
42973-8,powv igg titr spec
42973-8,powv igg titr titre spec
42973-8,powv igg titr random spec
42973-8,powassan virus igg (specimen) [titer]
42973-8,powssan other virus igg specmen) [titer]
42973-8,powassan virus (specimen) dilution factor (titer) igg [titer]
17013-4,influenza virus a+b ab [units/volume] in serum by immunofluorescence
17013-4,by virus a+b ab [units/volume] in serum influenza immunofluorescence
17013-4,influenza virus a+b acif ab [units/volume] in ser by immunofluorescence
17013-4,fluav+flubv ab ser if-acnc
17013-4,fluav+flubv ab ser if-acnc trf
17013-4,fluav+lubv ab se ifacnc
17013-4,fluav+flubv ab if qn (s)
17013-4,qn(s) if flua+flubvab infectious disease
17013-4,fluav+flbv abif immune fluorescence qn (s)
74373-2,clonidine [mass/volume] in unknown substance
74373-2,clonidie [ass/volme] inunknownsubstanc
74373-2,clonidine [mass/volume] in unknown substance
74373-2,clonidine usub-mcnc
74373-2,usub-mcnc clonidine
74373-2,usub-mcnc clonidine drug/toxicology
74373-2,clonidine (unknown substance) [mass/vol]
74373-2,mass concentration clndine [mass/vo] sutance) (unknown
74373-2,clonidine (unknown substance) [mass/vol]
70011-2,enterovirus igg ab [presence] in serum or plasma by immunoassay
70011-2,enterovirus igg ab [presence] enzyme immunoassay in ser or plasma by immunoassay
70011-2,enterovirus igg ab [presence] in serum or plasma immunoassay qualitative by
70011-2,ev igg serpl ql ia
70011-2,ev ql serpl igg ia
70011-2,ev igg serpl ql ia
70011-2,enterovirus igg ia ql
70011-2,nteovru igg ia presence
70011-2,ia immunoglobulin g igg enterovrus presence
86696-2,rotavirus b rna [nucleotide sequence] in isolate by sequencing
86696-2,rotvirus id brna ilat sequence] in nucleotde b sequencin
86696-2,rv rotavirus b in ueotde seuence] rna islate by squncing
86696-2,rvb rna islt-seq
86696-2,rvb ra high-throughput sequencing islt-se
86696-2,islt-seq rna rvb
86696-2,rotavirus b rna sequence nom (isol)
86696-2,nom na seuence rtavirus (isol) isol
86696-2,rotairus nom(isol) rna sequence rotaviurs b
1833-3,alpha-1-fetoprotein [mass/volume] in cerebral spinal fluid
1833-3,alpha-1-fetoprotein afp fluid in cerebral spinal [mass/volume]
1833-3,alpa-1-fetproein [mass/volue i cerebral spina alphafetoprotein fluid
1833-3,afp csf-mcnc
1833-3,chemistry afp csf-mcnc
1833-3,afp cs-mcn spinal fluid
1833-3,afp (csf) [mass/vol]
1833-3,[mass/vol] (csf) afp
1833-3,afp (csf) [mass/vl]
55951-8,octenoylcarnitine (c8:1)/creatinine [molar ratio] in urine
55951-8,ocenoycarnitne (c8:1/creatinine [molr ratio] in urine
55951-8,otenolcarniti (c8:1)/creaiine [molar atio] inurine
55951-8,octenoylcarn/creat ur-srto
55951-8,octenoylcarn/creat ua ur-srto
55951-8,ur-srto octenoylcarn/creat
55951-8,c8:1/creatinine (u) [molar ratio]
55951-8,c81/creatinin (u) [molarratio]
55951-8,i ratio] (u) [molar c8:1/creatinine
47008-8,platelet associated igg ab [presence] in serum by immunoassay
47008-8,platelt associated [preence] ab igg in erumby immunoassay
47008-8,patelet associated igg ab[preence] n seum by immunoassay
47008-8,pa igg ser ql ia
47008-8,pa igg ser presence random ia
47008-8,pa igg ser antby ia presence
47008-8,platelet associated igg ia ql (s)
47008-8,platlet igg asociated ia presence s)
47008-8,platelet antibody associated igg ia presence (s)
27322-7,threonine [moles/volume] in urine
27322-7,[moles/volume] threonine in urine
27322-7,urine [moles/volume] in threonine quan
27322-7,threonine ur-scnc
27322-7,ur-scnc threine
27322-7,threonine ur-scnc
27322-7,threonine (u) [moles/vol]
27322-7,threonine (u) [moles/vol]
27322-7,(u) threonine [moles/vol]
82926-7,phospholipase a2 receptor igg ab [presence] in serum by line blot
82926-7,phospholipse a2 rcepor igg ab [resence] in serm b line blot
82926-7,phospholipase a2 receptor igg ab [presence] in ser by line blot
82926-7,pla2r igg ser ql line blot
82926-7,pla2r igg serum q lne blot
82926-7,antibodies pla2r iggser lie q blot
82926-7,phospholipase a2 receptor igg line blot ql (s)
82926-7,lineblot a2 receptor igg phosholipae presence s)
82926-7,"() a2 receptr iggline lot ql napi m 1 phospholipase a2, bee phopholipse"
103542-7,tubular reabsorption of phosphorus/glomerular filtration rate [mass/volume] in urine and serum or plasma
103542-7,tubular reabsorption quantitative of phosphorus/glomerular filtration rate [mass/volume] in urine and serum or plasma
103542-7,tubuar reabsorption of phsphorus/glmerlailtration urinead [ms/volume gfr in re serum or plasma
103542-7,tmp/gfr ur+serpl-mcnc
103542-7,ur+serpl-mcnc pl tmp/gfr
103542-7,tmp/gfr quantitative ur+serpl-mcnc
103542-7,tubular reabsorption of phosphorus/glomerular filtration rate (u+s/p) [mass/vol]
103542-7,tubular reabsorption of phoshous/glmeular filrtion rate (u+s/p)[mass/vol]
103542-7,urn tubular reabsorption of phosphorus/glomerular filtration rate (u+s/p) [mass/vol]
58402-9,tapentadol [mass/volume] in urine by confirmatory method
58402-9,tapentadol confirmatory in urine by [mass/volume] method
58402-9,tapentadol [mass/volume] in urine by confirmatory method drugs of abuse
58402-9,tapentadol ur cfm-mcnc
58402-9,quan tapentadol ur cfm-mcnc
58402-9,cfm-mcnc ur tapenta
58402-9,tapentadol confirm (u) [mass/vol]
58402-9,[mass/vol] confirm (u) tapentadol
58402-9,tapentadol [mass/vol] (u) confirm
5197-9,hepatitis b virus surface ag [presence] in serum by radioimmunoassay (ria)
5197-9,hepatitis b virus surface ag [presence] in ser by radioimmunoassay (ria)
5197-9,b hepatitis virus surface ag [presence] in screen serum by radioimmunoassay (ria)
5197-9,hbv surface ag ser ql ria
5197-9,hbv surface ag serum ql ria
5197-9,hbv surface ria ser ql ag
5197-9,hbv surface ag ria ql (s)
5197-9,hbv surface ag ria surf ql (s)
5197-9,hbv surface ag hbs ria ql ()
38658-1,acetate [mass/volume] in air
38658-1,acetae in [ass/volume] air mass concentration
38658-1,acetate [mass/volume] air in
38658-1,acetate air-mcnc
38658-1,quan ai-mcnc acetae
38658-1,air-mcnc acetate
38658-1,acetate (air) [mass/vol]
38658-1,(air) acetate [mass/vol] drug/toxicology
38658-1,acetate (air) [mass/vol]
17401-1,human papilloma virus 18 ag [presence] in specimen
17401-1,han paploma virus 18 ag [presnce i spcimen
17401-1,human papilloma virus [presence g 18 in speimen
17401-1,hpv18 ag spec ql
17401-1,hpv18 ag ql spec
17401-1,hpv18 ag spec presence
17401-1,hpv 18 ag ql (specimen)
17401-1,hpv ql ag 18 (specimen)
17401-1,qual hpv 18 ag ql (specimen)
30010-3,borrelia burgdorferi 93kd igg ab [presence] in synovial fluid by immunoblot
30010-3,borrelia burgdrferi 93kd g a[presnce]i synoia fluid by imunoblot
30010-3,borrelia burgdorferi 93kd fluid ab [ql] in synovial igg microbiology by immunoblot
30010-3,b burgdor93kd igg snv ql ib
30010-3,b igg burgdor93kd snv ql ib
30010-3,antibodies b burgdor93kd igg snv ql ib
30010-3,b. burgdorferi 93kd igg ib ql (syn fld)
30010-3,burgdorferi b. 93kd igg ib ql (syn fld)
30010-3, burgdorferi 9kd igg ib ql (sn fld)
53612-8,urate [mass/volume] in body fluid
53612-8,in [mas/lume] urate ody flid
53612-8,fluid [mass/volume] in level body urate
53612-8,urate fld-mcnc
53612-8,urate fld-mcnc
53612-8,fld-mcnc urate
53612-8,urate (body fld) [mass/vol]
53612-8,urate b/f (body fld) [mass/vol]
53612-8,urate (body [mass/vol] fld)
19710-3,tramadol [presence] in urine by screen method
19710-3,tramadol presence]n urine by screen metho
19710-3,urne resece]n tamado by scren metho
19710-3,tramadol ur ql scn
19710-3,ur pr trmadol ql scn
19710-3,tramadol urql scn
19710-3,tramadol screen ql (u)
19710-3,screen tramadol ql scn (u)
19710-3,tramadol screen ql (u)
17732-9,trichinella spiralis ab [presence] in serum by latex agglutination
17732-9,trichinella spiralis ab [presence] in latex by ser agglutination
17732-9,trichinella spiralis ab [presence] in serum agglutination latex by
17732-9,t spiralis ab ser ql la
17732-9,t spiralis ab ql ser la
17732-9,t spiralis lat ab ser ql la
17732-9,t. spiralis ab la ql (s)
17732-9,t. spias ab a t spiralis ql (s)
17732-9,t. spiralis ab laql ()
33513-3,specific gravity of specimen
33513-3,pecific to be specified in another part of the message gravity of pecimen
33513-3,specimn gravity of specific
33513-3,sp gr spec
33513-3,sp spec gr random
33513-3,sp gr spec
33513-3,specific gravity (specimen)
33513-3,specific (specimen) gravity miscellaneous
33513-3,specific gravity (specimen)
13568-1,n-desalkylflurazepam [presence] in serum or plasma
13568-1,n-desalkylflurazepam ql [presence] plas serum or in
13568-1,plasma [presence] in serum or n-desalkylflurazepam
13568-1,desalkylfluraz serpl ql
13568-1,deslkylfluraz ql drugs sepl
13568-1,desalkylfluraz ql serpl flurazepam metabolite
13568-1,n-desalkylflurazepam ql
13568-1,ql n-desallflurazepam
13568-1,plsm n-desalkylflurazepam ql
107179-4,mycobacterium sp identified in drain by organism specific culture
107179-4,mycobacterium sp identified in drain by organism specific culture species
107179-4,mycbacterium sp idntified in cultures drain by orgnism spcific cultre
107179-4,mycobacterium drain cult
107179-4,nominal ycobacteriu drain cult
107179-4,mycobact mycobacerium drain cult
107179-4,mycobacterium sp identified org specific cx nom (drain)
107179-4,mcobacerium sp idntifie org microbiology specifc cx nom (rain)
107179-4,sp mycobacterium identified or specific cx nom microbiology (drin)
12843-9,protein [mass/volume] in peritoneal dialysis fluid
12843-9,protein level in [mass/volum] peitonea dialyis luid
12843-9,protein [mass/volume] peritoneal in dialysis quant fluid
12843-9,prot diafp-mcnc
12843-9,pr diafp-mcnc prot
12843-9,diafp-mcnc prot
12843-9,protein (perit dial fld) [mass/vol]
12843-9,protein (perit dial fld) dialysate [mass/vol]
12843-9,protein (perit dial point in time fld) [mass/vol]
59199-0,deoxyadenosine/creatinine [molar ratio] in urine
59199-0,cr eoyadenosine/creatinine [molar ratio] in urine
59199-0,substance ratio deoxyadenosine/creatinine [molar ratio] in urine
59199-0,deoxyadenosine/creat ur-srto
59199-0,deoxyadenosine/creat u-srto random
59199-0,eoxyadenosine/eat ur-srto
59199-0,deoxyadenosine/creatinine (u) [molar ratio]
59199-0,(u) deoxyadenosine/creatinine [molar ratio]
59199-0,doxadenosne/cretinine (u) [molar ratio]
11254-0,chlamydophila pneumoniae ab [titer] in serum
11254-0,in pneumoniae ab [titer] chlamydophila serum antibody
11254-0,anti chlamdpilapneumoniae in [tter] ab seum
11254-0,c pneum ab titr ser
11254-0,c smqn tr ab pneum serum
11254-0,c ab pneum tirser anti
11254-0,c. pneumoniae ab (s) [titer]
11254-0,c. pneumonia ab c pneumoniae (s) [titer]
11254-0,[titer] cpn a(s) c.pnemoniae
66137-1,metamyelocytes [#/volume] in blood from fetus by manual count
66137-1,metmylocytes[#/vlume] in bld from fetus # by manual count
66137-1,mtamyelocytes [/volume] fro blood in fetusbymanua count
66137-1,metamyelocytes # bld fetus manual
66137-1,metyloytes  blood etusanual
66137-1,metamyelocytes metamyelocyte% # fetus blood manual
66137-1,metamyelocytes manual cnt (bld fetus) [#/vol]
66137-1,metamyelocytes number concentration (count/vol) manual cnt fetus) (bld [#/vol]
66137-1,metamyelocytes maual [#/vol] (blood fetu) cnt
98120-9,intercellular adhesion molecule 1 [mass/volume] in serum or plasma
98120-9,or adhesion molecule 1 [mass/volume] in serum intercellular qnt plasma
98120-9,intercellular adhesion molecule 1 [mass/volume] in plasma serpl
98120-9,icam-1 serpl-mcnc
98120-9,rplmcnc icam-1
98120-9,serum or plasma-mcnc cam-1
98120-9,intercellular adhesion molecule 1 [mass/vol]
98120-9,intercellular adhesion [mass/vol 1 molcle
98120-9,intercellular adhesion molecule 1 [mass/vol]
15387-4,leishmania tropica igm ab [titer] in serum
15387-4,leishmania [titer] igm ab tropica in ser
15387-4,leishmania tropica ab igm [titer] in ser
15387-4,l tropica igm titr ser
15387-4,l troica igm titrser abs
15387-4,l tropica igm titr ser autoantibody
15387-4,l. tropica igm (s) [titer]
15387-4,l. tropica igm (s) [titer] titre
15387-4,l. tropica igm (s) infectiousdisease [titer]
16215-6,mephobarbital [mass/volume] in serum or plasma by confirmatory method
16215-6,mephobarbital [mass/volume] in serum or pl plasma by confirmatory method
16215-6,mephobarbitl in [massvolume] serum r pasma by confrmatory metho
16215-6,mephobarbital serpl cfm-mcnc
16215-6,serpl mephobarbital serpl cfm-mcnc
16215-6,mephobarbital cfm-mcnc serpl
16215-6,mephobarbital confirm [mass/vol]
16215-6,[mass/vol] confirm mephobarbital
16215-6,mebaral confirm mephobarbital [mass/vol]
3706-9,labetalol [mass/volume] in urine
3706-9,labetalol lolum [mass/volume] in urine
3706-9,labelol [massvlume] n uri
3706-9,labetalol ur-mcnc
3706-9,labetalol alfabetal ur-mcnc
3706-9,ur-mcnc abtalol
3706-9,labetalol (u) [mass/vol]
3706-9,labetalol (u) [mass/vol] ur
3706-9,(u) labetalol [mass/vol]
3579-0,doxepin [mass/volume] in serum or plasma
3579-0,doxepin orplasm in serum [ma/lume]
3579-0,[as/volume] doxepi in serum serp or plasma
3579-0,doxepin serpl-mcnc
3579-0,doxepi qnt srpl-cnc
3579-0,serpl doxepin serpl-mcnc
3579-0,doxepin [mass/vol]
3579-0,adapin doxepn[mass/vol]
3579-0,mass concentration [mass/vol doxepin
88582-2,bordetella sp identified in nasopharynx by organism specific culture
88582-2,bordetella sp denfied in nasopharyn  organsm specific cultur
88582-2,bordetella sp identified in nasopharynx specific organism by culture
88582-2,bordetella nph cult
88582-2,id bordetella nph cult
88582-2,bordtella nominal nph cult
88582-2,bordetella sp identified org specific cx nom (nph)
88582-2,bordetella s idntied org spcific id cx (nph) nom
88582-2,bordtella sp speificcx org identifid om spp (nph)
49182-9,coxiella burnetii phase 2 igm ab [titer] in body fluid
49182-9,autoantibody coxiella burnetii phase 2 igm ab [titer] in body fluid
49182-9,coxiella buretii phase 2 igm ab [tie in body fluid
49182-9,c burnet ph2 igm titr fld
49182-9,cburnet infectiousdisease ph2 fld ir igm
49182-9,c burnet ph2 titr igm fld
49182-9,c. burnetii phase 2 igm (body fld) [titer]
49182-9,2 burnetii phase c. igm (bod fl) [titer]
49182-9,c. phase burnetii 2 igm (body fld) [titer
86325-8,bordetella pertussis+parapertussis ptxs1 gene [cycle threshold #] in specimen by naa with probe detection
86325-8,bordetella pertusis+parapertusi txs1 gene [cycle threshld#] n specimen by naa with probdetection
86325-8,bordetella pertussis+parapertussis dna nucleic acid probe ptxs1 gene [cycle threshold #] in specimen by naa with probe detection
86325-8,b pert+parap ptxs1 ct spec qn naa+probe
86325-8,b pert+parap ptxs1 ct spec qn naa+probe
86325-8,b prtparp ptx1 ctspec dna nucleic acid probe qn naa+prob
86325-8,b. pertussis+parapertussis ptxs1 gene naa+probe (specimen) [threshnum]
86325-8,(specimen) pertussis+parapertussis pertussis ptxs1 gene naa+probe b. [threshnum]
86325-8,b. perussis+parapertussi ptxs1 [threshnum] naa+roe (secimen) gen
100824-2,additional portable medical orders or instructions
100824-2,additional portable medical orders or instructions
100824-2,additional portable instructions orders or medical
100824-2,add portable medical orders instructions
100824-2,add findings portble medical order instructons
100824-2,insructios potablemedcal orders add
100824-2,additional portable medical orders or instructions
100824-2,random additional portable medical orders or instructions
100824-2,portable additional medical orders or instructions
56744-6,pl-7 ab [presence] in serum by immunoblot
56744-6,l-7 serumby [presene] in ql ab immunolot
56744-6,pl7 ab [reence] in aby serum by immunoblot
56744-6,pl7 ab ser ql ib
56744-6,p7 ab ser autoantibody ib l
56744-6,ql ab se pl7 ib
56744-6,pl-7 ab ib ql (s)
56744-6,pl-7 ab ib ql west blt (s)
56744-6,pl-7 immune blot abibql (s)
9733-7,porphyrins [mass/time] in 24 hour stool
9733-7,porphyrins in [mass/time] 24 hour heme stool
9733-7,porpyrins [mass/time] in 24 hou stool
9733-7,porphyrins 24h stl-mrate
9733-7,prhyrns 24 stl-mrate
9733-7,mrate porphyrins 24h stl-mrate
9733-7,porphyrins (24h stl) [mass/time]
9733-7,pophyrns (24h tl [mass/time
9733-7,porphyrins24h stl) [mass/ime] quan
13349-6,leukocytes [#/volume] in stool by manual count
13349-6,leocytes [#/volume] in stool anal by count
13349-6,leukocytes [#/volume] count stool by manual in
13349-6,wbc # stl manual
13349-6,white blood cells wb # sl manal
13349-6,stl # wbc manua
13349-6,wbc manual cnt (stl) [#/vol]
13349-6,wbc [#/vol] cnt (stl) manual
13349-6,wbcmanualcnt [#/vol] (stl)
73688-4,danazol [presence] in urine by screen method
73688-4,danazol [presence] method urine by screen in
73688-4,danzo presence by qual urine in screen metho
73688-4,danazol ur ql scn
73688-4,danazol ur presence scn
73688-4,danazol r presence drug/toxicology scn
73688-4,danazol screen ql (u)
73688-4,(u) screen ql danazol
73688-4,urn danazol scree ql(u)
82279-1,rmr panel
82279-1,pane ee rr
82279-1,panel rmr rmr pnl
82279-1,rmr pnl
82279-1,qnt rmr pnl
82279-1,pnl rmr
59642-9,clonazepam [mass/mass] in tissue by confirmatory method
59642-9,clonazepam [mass/mass] in tissue by conf confirmatory method
59642-9,clonazepam [mass/mass] in tissue by confirmatory method
59642-9,clonazepam tiss cfm-mcnt
59642-9,klonopin cfm-mcnt tiss clonazepam
59642-9,clonazepam cfm-mcnt tiss
59642-9,clonazepam confirm (tiss) [mass/mass]
59642-9,clonazepam confirm (tiss) quant [mass/mass]
59642-9,clonazepam random confirm (tiss) [mass/mass]
14019-4,htlv i+ii gp46 ab [presence] in serum or plasma by immunoblot
14019-4,htlv i+ii gp46 ab presenc] inserum or pr plasmaby immunobot
14019-4,htlv i+ii gp46 ab [presence] in ser or plasma by immunoblot
14019-4,htlv i+ii gp46 ab serpl ql ib
14019-4,htlv ql gp46 ab serpl i+ii ib
14019-4,tlv serl g46 riba ab i+ii qlib
14019-4,htlv i+ii gp46 ab ib ql
14019-4,tlv i+ii gp46 b ib ql
14019-4,i+ii htl riba gp4 ab ib ql
49081-3,beta-2-microglobulin [mass/volume] in dialysis fluid
49081-3,beta-2-microglobulin [mass/volume] in dialysis fluid
49081-3,beta-2-microglobulin mass/volume] in dialysis fluid
49081-3,b2 microglob dial fld-mcnc
49081-3,b2 kidney micoglob dial fldmcnc
49081-3,b miroglob ld-mcnc dl
49081-3,beta-2-microglobulin (dial fld) [mass/vol]
49081-3,beta-2-microglobulin (dial fld) [mas/vol]
49081-3,beta-2-microglobulin (dial [mass/vol] fld)
50301-1,adipoylcarnitine+methylglutarylcarnitine (c6-dc) [moles/volume] in urine
50301-1,ur urine (c6-c [ols/volume] in adpoylcarnitine+mthylglutarylcarnitin
50301-1,iurie [moles/olue] aipoylarnitine+methylglutarylcarnitine(c6-dc)
50301-1,adipoyl+meglutarylcarn ur-scnc
50301-1,adipoyl+meglutarylcarn quan ur-scnc
50301-1,ur-scnc adipoyl+meglutarylcarn
50301-1,adipoylcarnitine+methylglutarylcarnitine (c6-dc) (u) [moles/vol]
50301-1,(6-dc) qnt adipolcarnitine+methylgluarlcnine (u) [mole/vol]
50301-1,adipoylcarnitine+methylglutarylcarnitine [moles/vol] (u) (c6-dc) chemistry
31430-2,hiv 1 igg ab [presence] in cerebral spinal fluid
31430-2,hiv 1 igg ab [ql] in cerebral spinal fluid
31430-2,hiv1 hiv 1 igg ab [presence] in cerebral spinal fluid
31430-2,hiv1 igg csf ql
31430-2,c hiv1igg ql
31430-2,hiv1 igg cs q
31430-2,hiv 1 igg ql (csf)
31430-2,hiv1 ig (csf) ql
31430-2,igg microbiology hiv ql csf)
32111-7,secobarbital [presence] in specimen
32111-7,sobarbita [resnce] in specimen
32111-7,secobarbita [presnce in secimen
32111-7,secobarbital spec ql
32111-7,ql spec secobarbital
32111-7,spec secobarial q
32111-7,secobarbital ql (specimen)
32111-7,secobarbital ql secimen) to be specified in another part of the message
32111-7,secobarbital (specimen) ql
93242-6,11-ketotestosterone [mass/volume] in serum or plasma
93242-6,11kettestosterone mass/volume]in serp plasma r ser
93242-6,11-ketotesostene mass/lume] i or seru plasma
93242-6,11ketotestost serpl-mcnc
93242-6,serpl-mcnc 11kotesost serplas
93242-6,11ketotestost serpl-mcnc
93242-6,11-ketotestosterone [mass/vol]
93242-6,[mass/vol] 11-ketotestoterne
93242-6,[mass/vol] 11-ketotestosterone
72265-2,influenza virus b iga ab [units/volume] in serum by immunoassay
72265-2,ifluenzavirus b iga ab serum in [uit/vlume] by immunoasa
72265-2,iga virus b influenza ab [units/volume] in serum by immunoassay
72265-2,flubv iga ser ia-acnc
72265-2,flubv iga ser ia-acnc
72265-2,flubv ser iga infectiousdisease ia-acnc
72265-2,flubv iga ia qn (s)
72265-2,flubv (s) ia qn infectious disease iga
72265-2,flubv (s) ia qn iga
76659-2,antipsychotics drug panel - urine by screen method
76659-2,antipsychotics - panel drug urine by screen method
76659-2,ntipsyhocs dru metod - urine b screen panel
76659-2,antipsychotics pnl ur scn
76659-2,scn antipsychotics pnl pnl ur antipsychotics
76659-2,antipsychotics pnl ur sn
76659-2,antipsychotics drug panel screen (u)
76659-2,antipsychotics (u) panel screen drug
76659-2,ua antipsychotics drug panel screen (u)
79231-7,amoxapine [mass/volume] in body fluid
79231-7,body quantitative [mass/volume] in amoxapine fluid
79231-7,amoxapine [mass/volume] in body fluid
79231-7,amoxapine fld-mcnc
79231-7,fl-mcc amoxapine
79231-7,amoxapine fld-mcnc
79231-7,amoxapine (body fld) [mass/vol]
79231-7,aoxapine (body mass/vol] fld)
79231-7,amoxapine (body [ma/vol] fld) qnt
8079-6,myelin iga ab [units/volume] in serum
8079-6,quan melin g ab [ts/volum] insru
8079-6,myelin iga ab [units/volume] in ser
8079-6,myelin iga ser-acnc
8079-6,se-acnc ga myelin
8079-6,antibody iga myelin serum-acnc
8079-6,myelin iga qn (s)
8079-6,myelin iga (s) qn
8079-6,qn sr iga myelin s)
55834-6,cathepsin s [mass/volume] in serum or plasma
55834-6,cathesin pl s [mass/volume] plama serum or in
55834-6,cathepsin s [mass/volume] in or serum plasma
55834-6,cathepsin s serpl-mcnc
55834-6,cathepsin s serum or plasma-mcnc
55834-6,serpl-mcnc s serpl cathepsin
55834-6,cathepsin s [mass/vol]
55834-6,cathpsin sr [mss/vol] s
55834-6,point in time [ms/vol] s cathepsi
20621-9,albumin/creatinine [presence] in urine by test strip
20621-9,albumin/creatinine strip in uine ql by est [presence
20621-9,albumin/creatinine [ql] in urine by test strip renal
20621-9,albumin/creat ur ql strip
20621-9,albumin/creat ql ur strip
20621-9,screen albumincreat urql strip
20621-9,albumin/creatinine test strip ql (u)
20621-9,albumin/ceatinine tes strip ql (u) chemistry
20621-9,kidney ql tet trip albumin/creinine (u)
34363-2,pregnanetriolone [moles/volume] in urine
34363-2,[moles/volume] pregnanetriolone in urine chemistry
34363-2,pregnanetriolone pregnanetr in [moles/volume] urine
34363-2,pregntrlone ur-scnc
34363-2,ur-scnc pregntrlone point in time
34363-2,pregntrlone ua ur-scnc
34363-2,pregnanetriolone (u) [moles/vol]
34363-2,[moles/vol] pt (u) pregnanetriolone
34363-2,(u) pregnanetriolone [moles/vol]
53109-5,docosenoate (c22:1)/creatinine [molar ratio] in urine
53109-5,docosenoate c22:1)/creatiine urine ro in scrto moar
53109-5,docosenoate (c22:1)/creatinine [molar urine in ratio]
53109-5,docosenoate/creat ur-srto
53109-5,ur-srto docosenoate/creat
53109-5,docosenoate/creat ur-srto quant
53109-5,docosenoate (c22:1)/creatinine (u) [molar ratio]
53109-5,docosenoate (c22:1)/creatinine (u) [molar ratio]
53109-5,docosenoate (c22:1)/creatinine [molar (u) ratio]
8078-8,mycoplasma pneumoniae igm ab [units/volume] in serum
8078-8,mycplama pnmoniae gm ab [uits/voume in serum aby
8078-8,mycoplasma pneumoniae igm in [units/volume] ab serum
8078-8,m pneumo igm ser-acnc
8078-8,mycoplas m pneumoigm ser-acnc
8078-8,m infectiousdisease pneumoim serum-cnc
8078-8,m. pneumoniae igm qn (s)
8078-8,qn pneumoniae igm m. (s)
8078-8,quant m. igm pneumoniae qn (s)
94613-7,bovine respiratory syncytial virus ag [presence] in tissue by immune stain
94613-7,bovine [presence] syncytial virus ag respiratory in tissue by immune stain
94613-7,bovine resiratory synytia stains virus ag presence] in tissue by immune stain
94613-7,brsv ag tiss ql imstn
94613-7,imstn ag iss ql brsv
94613-7,brsv ag pr tiss ql imstn
94613-7,bovine respiratory syncytial virus ag immune stain ql (tiss)
94613-7,bovn resiatory (tiss virus agimune sain ql syncytial
94613-7,bovine respiratory syncytial virus immunohistochemical stain ag immune stain ql (tiss)
10860-5,varicella zoster virus [presence] in specimen by organism specific culture
10860-5,varicella zoster virs[presnce] i speimen by organism specifc culture
10860-5,varicella zostr vius speific in specimen byorganism [presence] cultue
10860-5,vzv spec ql cult
10860-5,vzv spec cult misc presence
10860-5,vzv spec hhv-3 ql cult
10860-5,vzv org specific cx ql (specimen)
10860-5,vzv org spefic c infectiousdisease ql (specimen)
10860-5,vzv org (secimen) cx presence pecific
59349-1,endoxifen [mass/volume] in serum or plasma
59349-1,endoxifen [mass/volume] in serum or plas
59349-1,ndoxifen [mass/volume in serum or plasma
59349-1,endoxifen serpl-mcnc
59349-1,serpl-mcnc endoxifen
59349-1,serpl-mcnc random endoxifen
59349-1,endoxifen [mass/vol]
59349-1,[massvol endoxifen
59349-1,drugs endoxifen [mass/vol]
55405-5,heart failure tracking panel
55405-5,heart failure tracking panel
55405-5,panl failuretracking ert
55405-5,heart failure tracking pnl
55405-5,pnl point in time failure tracking heart
55405-5,heart failure tracking pnl
74937-4,deprecated chlorprothixene [mass/volume] in serum or plasma --trough
74937-4,depreaed chloprothixene [mass/volume] in serum or plasa --tough
74937-4,deprecated chlorprothixene [mass/volume] serpl in ser or plasma --trough
74937-4,deprecated chlorprothixene trough serpl-
74937-4,drug/toxicology deprecated chlorprothixene rough serpl-
74937-4,depecated chlorprothixene trough serpl-
74937-4,chlorprothixene trough [mass/vol]
74937-4,chlorprothixene trough [mass/vol]
74937-4,trouh chlrprothiene [mass/vol]
32552-2,pyruvate kinase [enzymatic activity/mass] in red blood cells
32552-2,pyruvate kinase [enzymatic activity/mass] in red blood cells
32552-2,pyvae knse [enzmatic red activty/mass]in blood cells
32552-2,pk rbc-ccnt
32552-2,pk rbc-ccnt qnt
32552-2,rbc-ccnt pk
32552-2,pyruvate kinase (rbc) [catalytic activity/mass]
32552-2,activity/ms] kinse(rbc) [catalytic yruvae
32552-2,pyruvate kinase [catalytic (rbc) activity/mass]
45084-1,chlamydia trachomatis dna [presence] in vaginal fluid by naa with probe detection
45084-1,chlamyi tracomatis dna [ql] in vagnal flu by naa id with prbedetection
45084-1,chlamydia trchomatis dna presence] i vaginal fluid by naa ith proe obstetrics etection
45084-1,c trach dna vag ql naa+probe
45084-1, trach dn vag presence naa+probe
45084-1,c trach a vag ql naa+probe
45084-1,c. trachomatis dna naa+probe ql (vag fld)
45084-1,c. trachomatis dna (vag ql naa+probe fld)
45084-1,. presence dna naa+probe trachomatis (vag fld)
47284-5,platelets [#/volume] in cord blood
47284-5,in [#olume] latelts crd bld
47284-5,plateets[#/vlume]in number concentration ord blood
47284-5,platelet # bldco
47284-5,# platlet absolute bldco
47284-5,platelet hematology/cell counts # bldco
47284-5,platelets (bldco) [#/vol]
47284-5,[#vol] (bldco) ptelets
47284-5,(bldco) latelets [#/ol] number concentration
10667-4,fungus identified in specimen by animal inoculation
10667-4,fungus identified fungal specimen in by animal inoculation
10667-4,fungus in identified specimen by animal inoculation
10667-4,fungus spec anim inoc
10667-4,spec fungus spc anim inoc
10667-4,fungus spec anim anim inoc inoc
10667-4,fungus identified animal inoculation nom (specimen)
10667-4,fungus identity or presence identified animal inoculaion nom (speimen)
10667-4,fungu identfid anial inoculation nm (specimen)
88915-4,filaria dna [presence] in tissue by naa with probe detection
88915-4,detction na [presence]in tissue by naa with probe filria
88915-4,filaria dna [presence] in tissue nasba by naa with probe detection
88915-4,filaria dna tiss ql naa+probe
88915-4,ql da tiss filaria naa+probe
88915-4,naa+probe filaria dna tiss naa+probe ql
88915-4,filaria dna naa+probe ql (tiss)
88915-4,qual filaria dna naa+probe (tiss) presence
88915-4,dna fiara naa+proe presence (tiss) ordinal
96826-3,cardiovascular [score] sofa
96826-3,quan cardiovascular [score] sofa
96826-3,cardiosula sofa scale core]
96826-3,cardio score sofa
96826-3,score cardo sofa
96826-3,sofa score cardio
59725-2,oxazepam [mass/volume] in blood
59725-2,bloo [ass/voume] in oxazepam mass concentration
59725-2,oxazepam [as/volume bld in
59725-2,oxazepam bld-mcnc
59725-2,oxazepam wb bld-mcnc
59725-2,bld-mcnc oxazepam drugs
59725-2,oxazepam (bld) [mass/vol]
59725-2,oxaepam (bld [mass/vol]
59725-2,alepam [mass/vol] (bld) oxazepam
16689-2,creatinine [mass/time] in 48 hour urine
16689-2,hour [mass/time] in 48 creatinine urine
16689-2,urine in 48 hour ratinn[mass/time]
16689-2,creat 48h ur-mrate
16689-2,crat 8h urmrate
16689-2,48h creat ur-mrate
16689-2,creatinine (48 hour u) [mass/time]
16689-2,creatinine (48 quantitative hour u) [mass/time]
16689-2,mass rate creatinine u) hour (48 [mass/time]
91848-2,mycoplasma hominis dna [presence] in genital specimen by naa with probe detection
91848-2,mycolasmahominis dna [presence]in genital specimn by aa with proe dtectio
91848-2,mycoplasma hominis dna [ql] in genital specimen by naa with probe detection
91848-2,m hominis dna genital ql naa+probe
91848-2,m homni genitl dna q naa+pre m hominis
91848-2,hoinis da genia ql naa+robe
91848-2,m. hominis dna naa+probe ql (genital specimen)
91848-2,m.homin dna naa+probe presence ordinal (genital specmen)
91848-2,m. (genital dna naa+probe ql hominis specimen)
94511-3,sars-cov-2 (covid-19) orf1ab region [cycle threshold #] in specimen by naa with probe detection
94511-3,sars-cov-2 (covid-19) orf1a region [cye thresold #] in specmen prbedtection aa wth by
94511-3,rs-cov-2 (covd-19) of1ab region [ccle threhold ] n speimen amplified bynaa with probe detection
94511-3,sars-cov-2 orf1ab ct spec qn naa+probe
94511-3,sars-cov-2 orf1ab qn spe ct naaprobe
94511-3,sars-cv-2orf1ab ct spe id q aa+pobe
94511-3,sars-cov-2 (covid-19) orf1ab region naa+probe (specimen) [threshnum]
94511-3,[threshum] (covid-19) or1ab region naa+probe (secimen) sas-co-2
94511-3,sars-cov-2 (covid-19 orf1b egion naa+pbe transcription mediated amplification (secimen) thrshnum]
6289-3,lysozyme [moles/volume] in serum or plasma
6289-3,lysozyme or in quan serum [moles/lue] lasma
6289-3,lysozyme [moles/volume] plasma ser plsm or in
6289-3,lysozyme serpl-scnc
6289-3,serpl-scnc ysoye
6289-3,serpl-scnc lysozyme
6289-3,lysozyme [moles/vol]
6289-3,[moles/vol] lysozyme
6289-3,[moles/l] lysozyme
47297-7,corynebacterium diphtheriae toxin ab [units/volume] in serum by immunoassay --1st specimen
47297-7,corynebacterium diphtheriae in ab [units/volume] toxin serum by immunoassay --1st specimen
47297-7,corynebacterium [units/volume] toxin ab diphtheriae in serum by immunoassay --1st c diphtheriae tox specimen
47297-7,c diphtheriae tox ab sp1 ser ia-acnc
47297-7,diphtheriae c tox ab sp1 serum ser ia-acnc
47297-7,c random diphtheriae ser ab sp1 tox ia-acnc
47297-7,c. diphtheriae toxin ab spec 1 ia qn (s)
47297-7,c. diphtheriae toxn b pec i id qn (s)
47297-7,c. diphtheri spec spec ab toxi 1 ia qn (s)
60133-6,parathion [mass/volume] in body fluid
60133-6,[mass/oume] prahon in bod fluid
60133-6,fluid [mass/volume] in bod body parathion
60133-6,parathion fld-mcnc
60133-6,fld-mcnc parathion
60133-6,thiophos fld-mcnc parathion
60133-6,parathion (body fld) [mass/vol]
60133-6,"parathion(body fld)[mass/vol] body fluid, unsp"
60133-6,parahion(body mass concentration fld)[mas/vol]
43900-0,blastomyces dermatitidis ab [presence] in cerebral spinal fluid by complement fixation
43900-0,blastomyces dermatitidis ab [ql] in by spinal fluid cerebral complement fixation
43900-0,blastomyces by ab [presence] in cerebral spinal fluid dermatitidis complement fixation
43900-0,b dermat ab csf ql cf
43900-0,blastomycosis b demat ab csfql cf
43900-0,b dermat ab csf ql cf pr
43900-0,b. dermatitidis ab cf ql (csf)
43900-0,b. dermatitidis ab neurology cf ql(csf)
43900-0,b. dermatitidis blasto ab cf ql (csf)
50915-8,strontium [moles/time] in 24 hour urine
50915-8,strontium [moles/time] in 24 hour urine
50915-8,strontium [moles/time] in 24 hour urine drug/toxicology
50915-8,strontium 24h ur-srate
50915-8,sr strontium 24h ur-srate
50915-8,ur-srate strontium24
50915-8,strontium (24h u) [moles/time]
50915-8,stronium (24h u) [moles/time]
50915-8,u) (24h strontium [moles/time]
57389-9,urea [mass/volume] in 12 hour urine
57389-9,ure [mas/volume in 12 ua hour urine
57389-9,urea [mass/volum] in 12 hou urie
57389-9,urea 12h ur-mcnc
57389-9,urea 12hr ur-cnc 12h
57389-9,ue12hu-mcnc
57389-9,urea (12h u) [mass/vol]
57389-9,urea u) ur (12h [mass/vol]
57389-9,urea [mass/vol] u) (12h
5283-7,polio virus 2 neutralizing antibody [titer] in serum by neutralization test
5283-7,polio serum virus serum neutralizing antibody [titer] in 2 by neutralization test
5283-7,plio virus 2 neutralizng antibody [iter] in serum b neutralizaton test
5283-7,pv2 nab titr ser nt
5283-7,titr n polio virus type ii pv2 ser nt
5283-7,pv2 nab nt sr titr
5283-7,polio virus 2 neut ab neut test (s) [titer]
5283-7,polio virus 2 id neut ab neut test (s) [titer]
5283-7,polio virus 2 neut ab neut sr tst (s [titer]
57046-5,elimination status
57046-5,status elimination
57046-5,eliminaion status
60276-3,oxycodone+oxymorphone cutoff [mass/volume] in urine for screen method
60276-3,uine cuoff[mass/volume]in xcone+oxymorphone forscreen mehod
60276-3,oycdone+oxymorphone cutoff [mass/volue] in screen or urine scr metod
60276-3,oxycodone+oxymorphone cto ur scn-mcnc
60276-3,xycodoneoxymorpone scn-cnc ctou
60276-3,oxdone+oxymopone scn-mcnc ur cto
60276-3,oxycodone+oxymorphone cutoff screen (u) [mass/vol]
60276-3,oxyoone+oxymorhone cutoff cto screen (u) [ass/v]
60276-3,oxycdon+oxmorphone cutoff sceen (u) ass/vol
23831-1,bordetella pertussis.pertussis toxin igg ab [units/volume] in serum
23831-1,[units/volume] pt pertussis.pertussis toxin igg ab bordetella in serum
23831-1,ab pertussis.pertussis toxin igg bordetella [units/volume] in serum
23831-1,b pert.pt igg ser-acnc
23831-1,b er-acnc infectiousdisease igg pt.pt
23831-1,b pert.pt ser-acnc igg
23831-1,b. pertussis.pertussis toxin igg qn (s)
23831-1,quantitative . pertusss.pertussis toxin igg (s) qn
23831-1,b. pertusis.petuss quant oxiigg qn (s)
6384-2,dengue virus ag [presence] in serum by immunofluorescence
6384-2,dengu viru sr ag [presece] i serum by mmuoflorescence
6384-2,dengue virus immunofluorescence [presence] in serum by ag
6384-2,denv ag ser ql if
6384-2,denv ordinal ag i ql ser
6384-2,ser ag denv presence if
6384-2,denv ag if ql (s)
6384-2,denv qualitative ag if presence (s)
6384-2,denv ag if ql (s) immunoflour
48326-3,glipizide [presence] in serum or plasma
48326-3,glipizide or in serum [presence] plasma
48326-3,glipizide [presence] in ser or plasma ordinal
48326-3,glipizide serpl ql
48326-3,serplql glucotrol glipizide
48326-3,glipizide ql serpl
48326-3,glipizide ql
48326-3,glipizid serp ql
48326-3,ql glipizide
45308-4,heptacarboxylate [moles/mass] in stool
45308-4,heptacarboxylate [moles/mas] in stool quant
45308-4,heptaaboxlate [molesmass]in stool
45308-4,heptacarboxylate stl-scnt
45308-4,heptacaboxylate stl-cnt
45308-4,stlscnt eptacboxylate
45308-4,heptacarboxylate (stl) [moles/mass]
45308-4,hptacrboxylate (tl) [mole/mass]
45308-4,feces heptacarboxylate (stl) [moles/mass]
80143-1,atazanavir [mass/volume] in cord blood
80143-1,ataanavir [mss/volume] in cord blood
80143-1,atazanavir [mass/volume] blood cord drug/toxicology in
80143-1,atazanavir bldco-mcnc
80143-1,atazanavi bldco-mcnc
80143-1,ldo-mcnc atazanavir blood - (umbilical) cord
80143-1,atazanavir (bldco) [mass/vol]
80143-1,point in time (bldco) aazanavir [mass/vol]
80143-1,atazanavir (bldco) [mass/vol]
47438-7,fowl adenovirus ab [presence] in serum
47438-7,wl adnoviru ab i [presence] in erum
47438-7,fow [ql] ab adenovius n erm
47438-7,fadv1 ab ser ql
47438-7,fad1ab ser ql
47438-7,fadv1 ql ser ab
47438-7,fowl adenovirus ab ql (s)
47438-7,antibody adenovirus fowl ab ql (s)
47438-7,ql adenovirus ab fowl (s)
11022-1,barbiturates [mass/volume] in meconium
11022-1,brbiturates [mass/vlume] mconium drugs of abuse
11022-1,barbs barburtes [ass/volume in mconium
11022-1,barbiturates mec-mcnc
11022-1,barbiturates mec-mcnc
11022-1,babituratsmec-cnc
11022-1,barbiturates (mec) [mass/vol]
11022-1,barbiturates (mec) [mass/vol]
11022-1,bbiturats barbiturate [m/vol] (mec)
7947-5,legionella pneumophila ab [presence] in serum
7947-5,legionella pneumophila ab [presence] in ser
7947-5,legionella pneumophila aby ab [presence] in ser
7947-5,l pneumo ab ser ql
7947-5,l pneumo ab ser ql
7947-5,l pneumo ab ser ql l pneumonphila
7947-5,l. pneumophila ab ql (s)
7947-5,l. pneumophila ab presence (s)
7947-5,l. (s) ab antby ql pneumophila
78440-5,risperidone trough and 9-hydroxyrisperidone panel - serum or plasma
78440-5,risperidone trough and 9-hydroxyrisperidone plasma - serum or panel
78440-5,risperidone trough and 9-hydroxyrisperidone panel - ser or plasma
78440-5,risp trgh + 9oh-ris pnl serpl
78440-5,ristrgh + pnl 9oh-ris serpl risperidone metabolite
78440-5,risp trgh + 9oh-ris pnl serpl
78440-5,risperidone trough and 9-hydroxyrisperidone panel
78440-5,rispeidone rough and 9-hdroxyisperidoeanel
78440-5,panel troughand 9-hydroxyrisperidne risperidone
27280-7,tripelennamine [mass/volume] in urine
27280-7,tripelennamine urine in [mass/volume]
27280-7,[mass/voum] tipelennamine iurine
27280-7,tripelennamine ur-mcnc
27280-7,tripelennamine point in time ur-mcnc
27280-7,ur-mcnc quan tripelennamine
27280-7,tripelennamine (u) [mass/vol]
27280-7,urn tripelennamine () [mass/vol]
27280-7,tripelennamine (u) [mass/vol]
42673-4,calcium hydrogen phosphate dihydrate [saturation fraction] in 24 hour urine
42673-4,alcium hyrogen dihydrate phosphate [aturationfration] in ua 4hour urine
42673-4,calciumhydrge phospate diydrate saturtion fraction] in 24 hour urin
42673-4,ca h2 phos dihyd 24h satfr ur
42673-4,ca h2 phos dihyd ur nephrology satfr 24h
42673-4,ca h2 satfr dihyd 24h phos ur
42673-4,calcium hydrogen phosphate dihydrate (24h u) [saturation fraction]
42673-4,alcum hyrogn phosphte dihydrate (24h [saturation u fraction]
42673-4,cacium u) chpd phosphate dihydrte (24h hdrogen [saturatio fraction]
58355-9,plasma cells immature [#/volume] in blood
58355-9,whole bld plasma cells immature [#/volume] in bld
58355-9,cnt plasma cells immature [#/volume] in blood
58355-9,imm plasma cells # bld
58355-9,imm cells plasma # bld
58355-9,imm ld cells # plasma
58355-9,plasma cells immature (bld) [#/vol]
58355-9,(bld)[#/vol] cellimmatue plama
58355-9,pasma cels immatre (blood) [#/vol]
55911-2,arginine [moles/mass] in hair
55911-2,arginine [moles/mass] in hair qnt
55911-2,hair [moles/mass] in arginine
55911-2,arginine hair-scnt
55911-2,arginine hair-scnt
55911-2,hair-scnt arginine quantitative
55911-2,arginine (hair) [moles/mass]
55911-2,arginine (hair) [moles/mass]
55911-2,(hair) arginine arg [oles/mass]
40416-0,caffeine [presence] in gastric fluid
40416-0,caffeine fluid in gastric [presence] random
40416-0,caffeine [presnce] in gastic flui
40416-0,caffeine gast ql
40416-0,caffeine gast l
40416-0,caffeine gast drugs ql
40416-0,caffeine ql (gast fld)
40416-0,caffeine ordinal ql (gast fld)
40416-0,caffeine ql (gast fld) drug/toxicology
14423-8,bilirubin.total [mass/volume] in synovial fluid
14423-8,bilirubin.total bilirubins [mass/volume] synovial in fluid
14423-8,snv bilruin.tota [mss/volume]in synovial flid
14423-8,bilirub snv-mcnc
14423-8,snv-mcnc bilirub
14423-8,bilirub sn-mcnc qnt
14423-8,bilirubin (syn fld) [mass/vol]
14423-8,bilirubin (syn syn fld) [mass/vol]
14423-8,(syn biirbn fld) [mass/vol]
73356-8,haloperidol induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73356-8,haloperidol induced platelet igg ab [presence] plasma serum or in antibodies by flow cytometry (fc)
73356-8,haloperidol induced plateletigg ab [presence] plasma serm or n by flow cytoetry (fc)
73356-8,haloperidol ind plt igg serpl ql fc
73356-8,aloperidol sep pltigg ind plasma qlc
73356-8,ql ind plt igg serpl haloperidol fc
73356-8,haloperidol induced platelet igg fc ql
73356-8,serenace haloperidolinducd platelet c igg l
73356-8,igg induce ltelet hlperid ordinal fc ql
13167-2,streptococcus pneumoniae danish serotype 7f ab [units/volume] in serum
13167-2,[units/volume] pnumoniae danish srotype autoantibody 7f ab streptooccus i serum
13167-2,streptococc pneumoniae ans srotype 7fab [unts/volume] n ser
13167-2,s pneum da 7f ab ser-acnc
13167-2,s pnum da 7f a ser-acnc
13167-2,s pneum strept da 7f ab ser-acnc
13167-2,s. pneumoniae danish type 7f ab qn (s)
13167-2,ab pneumoniae danish sr type 7f s. qn (s)
13167-2,ype pneumoniae danih s. 7f b qn (s)
62869-3,phenx - assay for hepatitis c protocol 160301
62869-3,phenx - hepatitis for assay c protocol 160301
62869-3,phenx - assay 160301 hepatitis c protocol for
62869-3,assay for hepatitis c proto
62869-3,say for poto c hepatitis
62869-3,proto for hepatitis c assay
87509-6,long-term care hospital (ltch) continuity assessment record and evaluation (care) data set (lcds) - admission - version 4.00 during assessment period [cms assessment]
87509-6,long-trm ar hospita (th) continuiy report period assessment eord and vauation (care)aa set (lcds) -admssio - version 4.00 dring assessment perod [cms sessment]
87509-6,long-term care hospital (ltch) assessment assessment record and evaluation (care) data set (lcds) - admission - version 4.00 during continuity period [cms assessment]
62888-3,phenx - international travel history protocol 161201
62888-3,phenx - international travel history protocol 161201
62888-3,penx - intenational travel hisoy potocol 1612
62888-3,international travel hx proto
62888-3,international travel random hx proto
62888-3,random travel international hx proto
70856-0,rabies virus ab [units/volume] in cerebral spinal fluid by immunoassay
70856-0,rabiesvius ab [units/volume] in cerebral sinal by fluid immunossa
70856-0,raies virus by iaa [units/voume] in cererlspina fluid ab immunossay
70856-0,rabv ab csf ia-acnc
70856-0,rabv quant ab csf ia-acnc
70856-0,rabv ab i-acnc csf
70856-0,rabies virus ab ia qn (csf)
70856-0,rabies virus ab ia qn (cerebrospinal fluid)
70856-0,rabies qn ab ia virus (csf)
54241-5,influenza virus b ag [presence] in isolate
54241-5,isol infuenza ag b viu presence] in soae
54241-5,influenza virus b ag [reence] in isolate qualitative
54241-5,flubv ag islt ql
54241-5,flubv ag ql islt
54241-5,flubv islt ag ql
54241-5,flubv ag ql (isol)
54241-5,flubv ag presence(isol
54241-5,ag lubv ql (iso)
44528-8,histoplasma capsulatum m ab [presence] in serum
44528-8,capsulatum histoplasma m ab [presence] in serum
44528-8,[presence] capsulatum m ab histoplasma in serum
44528-8,h capsul m ab ser ql
44528-8,h ab m capsul autoantibodies ser ql
44528-8,h ser m ab capsul ql
44528-8,h. capsulatum m ab ql (s)
44528-8,h. capsulatum m ql ab (s)
44528-8,h. capsultum universallaborders ql(s) a m
55835-3,vegetable fibers [presence] in stool by light microscopy
55835-3,vegetable [prsece] fiers i stol blight microscopy
55835-3,vegetable fibers [presence] in light by stool microscopy
55835-3,vegetable fibers stl ql micro
55835-3,vegetable ql stl fibers micro
55835-3,vegetable fibers stl ql micro micros
55835-3,vegetable fibers lm ql (stl)
55835-3,vegetale fierslm ql (stl)
55835-3,presence fibers lm vegetable (stl)
101261-6,mds v3.0 - rai v1.18.11 - mood during assessment period [cms assessment]
101261-6,centers for medicare and medicaid assessment mds v.0 -ai v1.18.11 - mood uring [cms perio asessent assessment]
101261-6,mds during - rai v1.18.11 - mood v3.0 assessment period [cms assessment]
73269-3,midazolam induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73269-3,midazolam induced or igg ab [ql] in serum platelet plasma by flow cytometry (fc)
73269-3,midazolam induced platelet igg ab [presence] in serum plasma or by flow cytometry (fc)
73269-3,midazolam ind plt igg serpl ql fc
73269-3,miazola indplt pr igg serpl ql fc
73269-3,serpl ind plt igg midazolam ql fc
73269-3,midazolam induced platelet igg fc ql
73269-3,platelet induced midazolam igg serpl fc ql
73269-3,midazola nduced platelet fc igg ql
40528-2,opiates [presence] in hair
40528-2,opiate oates [presence] in hair
40528-2,opiates [ql] in hair
40528-2,opiates hair ql
40528-2,hair opiates addiction presence
40528-2,opiates pr hair ql
40528-2,opiates ql (hair)
40528-2,opiate oiate ql(hair)
40528-2,opates potentialforabuse presence (hair)
15367-6,ganciclovir [mass/volume] in serum or plasma
15367-6,ganciclovir [mass/volume] in serum sr plasma or
15367-6,ganciclvir or in serum [mass/voume] psma
15367-6,ganciclovir serpl-mcnc
15367-6,serum ganciclovir serpl-mcnc
15367-6,serpl-mcnc ganciclovir
15367-6,ganciclovir [mass/vol]
15367-6,ganciclovir [mass/vol]
15367-6,ganciclovir [mass/vol] quan
31085-4,methaqualone [mass/volume] in bile fluid
31085-4,bile [mass/volume] in methaqualone fluid
31085-4,methaqualone [mass/volume] in bile fluid
31085-4,methaqualone bifl-mcnc
31085-4,bifl-mcnc level methaqualone
31085-4,bifl-mcnc level methaqualone
31085-4,methaqualone (bile) [mass/vol]
31085-4,drugs methaqualoe (bile) [mas/vl]
31085-4,methaqualone (bile) quan [mass/vol]
45967-7,facility provider numbers set
45967-7,facility provider numbers set
45967-7,facility provider set numbers
96591-3,glomerular filtration rate [volume rate/area] in dbs by based on 1.73 sq m among black population
96591-3,glomerlar filtratin rae quant [volume rate/r in dbs bysed on 7 sq m among lackpopultion
96591-3,glomerlarfiltration rate[volumerate/area] in dbs by basd on1.73 sq m amg blackpoulation
96591-3,gfr dbs based on 1.73 sq m among bla
96591-3,fp gfr dbs based on 1.73 sq m among bla
96591-3,dbs gfr bsd on 1.73 sq m among bla
96591-3,gfr based on 1.73 sq m among black population (dbs) [vol rate/area]
96591-3,gfr based on 1.73 sq m gfr among black population (dbs) [vol rate/area]
96591-3,gfr based quan n1.73q m among back populaton b [vol ate/area]
56660-4,methyl formamide/creatinine [ratio] in urine
56660-4,methyl formamide/creatinine [ratio] in urine
56660-4,methyl in [ratio] formamide/creatinine urine
56660-4,mehyl formamide/creat ur-rto
56660-4,formamide/creat mehyl ur-rto
56660-4,mehyl formamide/creat ur-rto
56660-4,methyl formamide/creatinine (u) [ratio]
56660-4,methyl quant formamide/creatinine (u) [ratio]
56660-4,methyl formamde/reatine [ratio] u)
73184-4,pseudoephedrine induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73184-4,peudoephdrne flow platlet igm ab ind plt ab [prsence]in serum or plasma by induced cytometry(fc)
73184-4,pseudoephedrie inuce platelet gm ab fow i srum or pasma by [ql] cytmetry f)
73184-4,pseudoephedrine ind plt igm serpl ql fc
73184-4,pseudoephedrine ind plt igm presence ind plt igm serpl fc
73184-4,ind pseudoephedrine plt igm serpl ql circulating platelet ab fc
73184-4,pseudoephedrine induced platelet igm fc ql
73184-4,peudoephedrine igm platelet indced c ql
73184-4,pseudoehedine induced plaelet igm ql fc cenafed
51671-6,brucella sp ab [titer] in serum by tube agglutination
51671-6,brucella sp ab microbiology [titer] in serum tube by agglutination
51671-6,brucella sp ab [titer] in by serum tube agglutination
51671-6,brucella ab titr ser tube aggl
51671-6,tube aggl brucella ab titr aggl tube ser
51671-6,brucella ab titr setube aggl
51671-6,brucella sp ab tube agglutination (s) [titer]
51671-6,brucellasp ab tue gglutinaion(s) [titer]
51671-6,brucella tube ab sp agglutination (s) spp [titer]
58796-4,glomerular basement membrane igg ab [presence] in serum by immunofluorescence
58796-4,gomerlarbasment membane i ab resence] in erum byimmunolurecence immunofluorescence
58796-4,glomera bsemnt acif membrane igg ab [presence] in seru by immnoflurescence
58796-4,gbm igg ser ql if
58796-4,gbmigg ser l f
58796-4,antby gbm igg serum ql if
58796-4,glomerular basement membrane igg if ql (s)
58796-4,glomerular basement membrne immunoglobulin g igg if (s) ql
58796-4,glmerular aement membraneig i ql (s)
53385-1,snowshoe hare virus ab [presence] in specimen
53385-1,snowshoe ab irus hare [presence] in specimen
53385-1,snowshoe hare virus b [presenc] in specien
53385-1,sshv ab spec ql
53385-1,sshv spec ab ql
53385-1,sshv ab spec presence
53385-1,snowshoe hare virus ab ql (specimen)
53385-1,snowshoe id hare virus ab ql (specimen)
53385-1,snowshoe hae virus (specimen) ql ab
100742-6,lactate dehydrogenase.macromolecular [presence] in serum or plasma
100742-6,lactate dehydrogenase.macromolecular [presence] in ser or plasma
100742-6,lactatedehydrogenae.macomlecuar lma n serm or [ql]
100742-6,ldh macro serpl ql
100742-6,ldh acro serpl ldh macro ql
100742-6,mro ldh serpl ql
100742-6,lactate dehydrogenase.macromolecular ql
100742-6,lactate dehydrogenase.macromolecular presence
100742-6,chemistry dehydrogenase.macromolecular lactate presence
69765-6,rubella virus igm ab [presence] in body fluid by immunoassay
69765-6,rubella virus immunoassay ab [presence] in body fluid by igm antibodies
69765-6,ubela irus igm i anti [resnce] ab body fluid by immunoassay
69765-6,rubv igm fld ql ia
69765-6,rbv igm fld presence ia
69765-6,ldql igm rubv ia
69765-6,rubella virus igm ia ql (body fld)
69765-6,rubella vrs congenital rubella syndrome gm ia ql(ody fld)
69765-6,(bdy virus igm ia ql rubella ld) immune globulin m
50801-0,aluminum [moles/mass] in hair
50801-0,aluminum [moles/mass] hair in
50801-0,alumnum [moles/mass] qnt in hir
50801-0,aluminum hair-scnt
50801-0,quan aluminum hir-scnt
50801-0,aluminum aluminium hair-scnt
50801-0,aluminum (hair) [moles/mass]
50801-0,aluminum [moles/mas] air)
50801-0,(hair) aluminum [moles/mass]
25429-2,glutamate [moles/time] in 24 hour urine
25429-2,glutamate [moles/time] in 24 hour urine
25429-2,glutamate [moles/time] in glu 24 hour urine
25429-2,glutamate 24h ur-srate
25429-2,glutamate quantitative ur-rt 24h
25429-2,2h glutamate ur-rate ua
25429-2,glutamate (24h u) [moles/time]
25429-2,(24h glutamate u) [moles/time]
25429-2,glutamate [moles/time] u) (24h
91552-0,"mds v3.0 - rai v1.17.1, 1.17.2 - swing bed discharge (sd) item set during assessment period [cms assessment]"
91552-0,"mds v3.0 - rai v1.17.1, 1.17.2 assessment swing bed discharge (sd) item set during - period [cms assessment]"
91552-0,"mds v3.0 - rai v1.17.1, 1.17.2 - swing bed discharge (sd) item panel set during assessment period [cms assessment]"
78882-8,sertraline cutoff [mass/volume] in urine for confirmatory method
78882-8,ertraline cff conf [mass/volume] i urine for confiaorymethod
78882-8,sertraline cutoff [mass/volume] in urine cfm for confirmatory method
78882-8,sertraline cto ur cfm-mcnc
78882-8,cfm-mcnc cto ur sertraline drug/toxicology
78882-8,sertraline cto qnt ur cfm-mcnc
78882-8,sertraline cutoff confirm (u) [mass/vol]
78882-8,ertaline mass/vol cfirm (u) cutoff
78882-8,sertaline ctoffconfirm drug/toxicology (u)[mass/vol]
10753-2,fat.microscopic observation [identifier] in stool by sudan iv stain
10753-2,fat.microscopic observation bowel movement [identifier] in stool by sudan iv stain
10753-2,fat.microscopic feces obervation[identifer] in sool by suan ivstain
10753-2,fat stl sudan iv stn
10753-2,fa stl random v udan stn
10753-2,fat stains stn sudan iv stl
10753-2,fat.microscopic observation sudan iv stain nom (stl)
10753-2,fa.microscopi observatin sudan iv stain nom (tl)
10753-2,fat.microscopic observation faecal sudan iv stain nom (stl)
50285-6,3-dechloroethylifosfamide [mass/volume] in blood --1 day post dose ifosfamide
50285-6,3-dechloroethylifosfamide [mass/volume] in blood --1 day post dose ifosfamide
50285-6,3d-ifo postdose [as/vlum]inblood --1 d 3-dechloroethyliosfamide ifosfami
50285-6,3d-ifosfamide 1d p iff bld-mcnc
50285-6,3d-ifsfamide bld-mcnc if d
50285-6,3d-ifosfamide 1d p whole blood iff bdmcnc
50285-6,3-dechloroethylifosfamide 1 day post dose ifosfamide (bld) [mass/vol]
50285-6,3-dechlooethylifosfamide1 day pst dose ifosfamide blood bld) [mass/vol]
50285-6,post 1 day 3-dechloroethylifosfamide dose ifosfamide wb (blood) [mass/vol]
33707-1,yersinia pestis ab [titer] in serum
33707-1,yersiia pstis abtitr] in serum
33707-1,ab pestis yersina point in time [tier] in seru
33707-1,y pestis ab titr ser
33707-1,y serum ab titr pstis id
33707-1,ab pestis y itr e
33707-1,y. pestis ab (s) [titer]
33707-1,y. (s)[titer ab pestis pasturella pestis
33707-1,y. pestis ab point in time (s) [titer]
78699-6,liver fibrosis score panel - serum or plasma calculated by fibrometer
78699-6,liver calculated serpl scor panel -serumor plasma fbrosis yfibrometer
78699-6,calculated fibros scoe panel -serum or lasma liver by fibrometer
78699-6,liver fibr score pnl serpl fibrometer
78699-6,liver pnlserl scre ir fibrometer
78699-6,liver ibr scorepnl serum or plasma brometer
78699-6,liver fibrosis score panel calculated by fibrometer
78699-6,panl alculaed fibros score panel iv by fibrometer
78699-6,score fibrosis liver panel calculated by fibrometer
33968-9,sars coronavirus urbani ab [presence] in serum by immunoassay
33968-9,sr anti coronavrus urbani ab[ql] n serum byimmunoasy
33968-9,sars coronavirus by ab [presence] in serum urbani immunoassay
33968-9,sars-cov urb ab ser ql ia
33968-9,rb sas-cov serum ab ser qlia
33968-9,sars-cov urb sars-cov ab serum ql ia
33968-9,sars-cov urbani ab ia ql (s)
33968-9,presence urbani ab microbiology ia sars-cov (s)
33968-9,urbani antibody sars-cov ab ia ql (s)
5214-2,deprecated heterophile ab [presence] in serum by latex agglutination
5214-2,deprecated latex ab [presence] in ser by heterophile agglutination
5214-2,deprecated heterophile ab latex in serum by [presence] agglutination
5214-2,deprecated heteroph ab ser ql la
5214-2,deprecate hetroph ab la ql serum
5214-2,derecated heteroph ab ser l la
5214-2,heterophile ab la ql (s)
5214-2,heterophile ab la monospot presence (s)
5214-2,heterophile mono screen ab (s) ql la
59337-6,dinorsibutramine [mass/volume] in urine
59337-6,in [mass/volume] dinorsibutramine drugs urine
59337-6,point in time urine [mass/voume] in dinorsibutramie
59337-6,dinorsibutramine ur-mcnc
59337-6,ur-mcnc dinorsibutramine
59337-6,diorsibutramne ur-mcnc
59337-6,dinorsibutramine (u) [mass/vol]
59337-6,(u) dinorsibutramine [mass/vol]
59337-6,diorsibutramine (u [assol] ua
87581-5,aflatoxin g2 [mass/mass] in specimen
87581-5,g2 aflatoxin [mass/mass] in specimen
87581-5,aflatoxin g2 in [mass/mass] specimen
87581-5,aflatoxin g2 spec-mcnt
87581-5,g2 aflatoxin spec-mcnt quantitative
87581-5,aflatoxin g2 spec-mcnt
87581-5,aflatoxin g2 (specimen) [mass/mass]
87581-5,aflatoxin g2 (specimen) aflatoxicosis [mass/mass]
87581-5,[mass/mas] g2 (specimen) aflatoin
45062-7,c reactive protein [mass/volume] in cerebral spinal fluid
45062-7,c in protein [mass/volume] reactive neuro cerebral spinal fluid
45062-7,c reactive potin [massvolume] in cerebral spinl flui
45062-7,crp csf-mcnc
45062-7,csf-mcnc crp quantitative
45062-7,crp cerebrospinal fluid-mcnc
45062-7,crp (csf) [mass/vol]
45062-7,(cerebrospinal fluid) crp [mass/vol]
45062-7,(cs) crp [mass/ol]
91895-3,bacterial strain [type] in isolate by sequencing
91895-3,bacterial strai typ] in islt isolate bysequencin
91895-3,bacterial isolate [type] in strain by sequencing
91895-3,bacterial strain islt seq
91895-3,ist bacterial subtyping sran bactera seq
91895-3,bacterial typ islt strain se
91895-3,bacterial strain sequencing nom (isol)
91895-3,bacterial strain sequencing nom (isol)
91895-3,ngs (isol) sequncingnom bcterilstran
96407-2,pancreatic polypeptide [mass/volume] in serum or plasma --30m post sham feeding
96407-2,shm plypeptid [mass/volume] inserum or plasma --0m 30m p sham feed post pancreatic eeding
96407-2,pancreati poypetide[mas/volme] serum or plasma --30mpost shm eeding
96407-2,panc polypept 30m p sham feed serpl-mcnc
96407-2,pst panc polypept 30m p sham feed serpl-mcnc
96407-2,panc polypept 30m p sham feed serpl-mcnc
96407-2,pancreatic polypeptide 30m post sham feeding [mass/vol]
96407-2,pancreatic polypete 30m pstsham feedng [mass/vol]
96407-2,pancreatic olypeptide 30m quant post shm feeding mass/vol]
23964-0,brucella abortus igm ab [titer] in cerebral spinal fluid
23964-0,brucella abortus ab igm [titer] in cerebral antby spinal fluid
23964-0,brucella abortus igm ab [titer] in cerebral pinal fuid
23964-0,b abortus igm titr csf
23964-0,b abortus igm itr cs abort
23964-0,csf igm ttr titr babortus
23964-0,b. abortus igm (csf) [titer]
23964-0,b. abs (csf) igm abortus [titer]
23964-0,b.abortus igm (csf) iter]
14156-4,coproporphyrin [mass/mass] in 24 hour stool
14156-4,coproporphyrin [mass/mass] hour 24 in stool
14156-4,coproporphyrin 24 in [mass/mass] hour stool
14156-4,copro 24h stl-mcnt
14156-4,24h copro mass content stl-mcnt
14156-4,copro stl-mcnt 24h tetracarboxyl porphyrin
14156-4,coproporphyrin (24h stl) [mass/mass]
14156-4,coproporphyrin (24h stl) [mass/mass]
14156-4,coproporphyrin (24h chemistry stl) [mass/mass]
14041-8,choriogonadotropin.beta subunit [units/volume] in cerebral spinal fluid
14041-8,chorogonadotropin.eta sinal unts/volume n cerbral subunt flui
14041-8,chorgonadotropin.beta subunit [units/voume] in spinal fld cerebralpinal fuid
14041-8,b-hcg csf-acnc
14041-8,random csf-acnc b-hcg
14041-8,b-hcg cfacnc cg
14041-8,hcg.beta subunit qn (csf)
14041-8,subunit hcg.beta qn (csf)
14041-8,hcg.beta subunit qn chorionic gonadotropin (csf)
25600-8,rotavirus igm ab [units/volume] in serum
25600-8,rtavirus igm ab [unts/olume] in serum
25600-8,rotavirus im ab unisvolume] n serum
25600-8,rv igm ser-acnc
25600-8,v igm sr se-acnc
25600-8,rv igm ser-acnc
25600-8,rotavirus igm qn (s)
25600-8,rotavirus rotaviral igm qn (s)
25600-8,rtavirus im qn ()
55232-3,genetic analysis summary panel
55232-3,genetic anlyissummary pnel
55232-3,analysis genetic summary pnl panel
55232-3,genetic analysis summary pnl
55232-3,genetic analysis summary pnl
55232-3,gnetic nalsis ummarypnl whole blood
55232-3,genetic analysis summary panel molgen (bld/tiss)
55232-3,point in time genetc analyss sumary pael mlgen (bld/tiss)
55232-3,genetic analysis sumay panel molgen (blood/ss)
88190-4,crimean-congo hemorrhagic fever virus igm ab [presence] in serum by immunoassay
88190-4,crimean-cog hemorrhaic feve virus ig ab [presence] nerm by immunoassay
88190-4,virsig hemrrhagic fevr rimean-ongo b [prsence] in serum by ordinal munoassay
88190-4,crimean-cngo vr igm ser ql ia
88190-4,crimean-cngo q ig ser vr ia point in time
88190-4,crimean-cng vr igm ia q se elisa
88190-4,crimean-congo hemorrhagic fever virus igm ia ql (s)
88190-4,crimean-congo hemorrhagic fever virus igm ia ql iaa (s)
88190-4,crimean-congo hemorrhagic fever virus (s) ia ql suds igm
2759-9,phenols [mass/volume] in urine
2759-9,phenols mass/volume] quantitative in urne
2759-9,[mass/volume phenols in urine
2759-9,phenols ur-mcnc
2759-9,ur-mcnc phenols qnt
2759-9,phenols ur-mcnc
2759-9,phenols (u) [mass/vol]
2759-9,phenolsu) [as/vol]
2759-9,pt phenols (u) [mass/vol]
14397-4,urea nitrogen [mass/volume] in gastric fluid
14397-4,fluid n nitrogen [mass/volume] in gastric urea
14397-4,urea nitrogen [mass/volume] in gastric fluid
14397-4,urea nit gast-mcnc
14397-4,nit urea gast-mcnc
14397-4,rea nitgat-mcnc
14397-4,urea nitrogen (gast fld) [mass/vol]
14397-4,ure [mas/vol] (gastfld) level nitrogen
14397-4,(gast nitrogen urea fld [mass/vl]
97051-7,interferon beta [mass/volume] in serum or plasma
97051-7,serum beta [mass/volume] in interferon or plasma
97051-7,intefo beta [mass/volume] inserum or plasma
97051-7,ifn-b serpl-mcnc
97051-7,ifn-b plasma serpl-mcnc
97051-7,betaferon ifn-b serpl-mcnc
97051-7,interferon beta [mass/vol]
97051-7,beta interfron [mass/vol]
97051-7,beta ifn-b interferon [as/vol]
51595-7,glucose [presence] in stool
51595-7,glucose [presene] istool screen
51595-7,glcose [presenc in stool
51595-7,glucose stl ql
51595-7,stl glcose random ql
51595-7,stl glucose ql
51595-7,glucose ql (stl)
51595-7,gluoe ql (st)
51595-7,luose presence(stl) presence
29583-2,differential panel - pleural fluid
29583-2,anel- diferntial pan pleural fluid
29583-2,hematology/cell counts differntial panel - peuralflud
29583-2,diff pnl plr
29583-2,pleural fluid pnl diff plr
29583-2,diff panl pnl plr
29583-2,differential panel (pleur fld)
29583-2,diff pnl panel differential (plr fld)
29583-2,panel differential (pleur differl fld)
2960-3,somatostatin [presence] in plasma
2960-3,[presence] somatostatin in plasma
2960-3,in [presence] somatostatin plasma
2960-3,somatostat plas ql
2960-3,somatosta pla ql
2960-3,smatot plas q
2960-3,somatostatin ql (p)
2960-3,somatostatin qual ql (p)
2960-3,somatostatin (p) ql
78861-2,morphine [z-score] in urine
78861-2,morphine ur [z-srein rine
78861-2,z value in [z-score] morpine urine
78861-2,morphine z-score ur
78861-2,morhine -score z value ur
78861-2,morphine z-score addiction ur
78861-2,morphine (u) [z-score]
78861-2,[z-score] (u) morphine
78861-2,morphine drug/toxicology (u) [z-score]
48802-3,alpha-1-fetoprotein panel - serum or plasma
48802-3,aha--fetoprotein panel - serum or lasma
48802-3,alpha-1-fetoprotein panel - serum a1 or plasma
48802-3,afp pnl serpl
48802-3,serpl pnl afp
48802-3,serpl pnl afp
48802-3,afp panel
48802-3,ap panel
48802-3,feto panl ap
63343-8,sjogrens syndrome-a extractable nuclear 60kd ab [presence] in body fluid by immunoassay
63343-8,suds sjogrens sydrm-a xtractabl [presnce] 60kd ab nulear in bodyflui by immnoassay
63343-8,sjogrens sydrome-a extracale nuclear 60kd a [ql] in body fluid by immunoassay
63343-8,ena ss-a 60kd ab fld ql ia
63343-8,ena ss-a 60kd ab fld bod presence ia
63343-8,ena ia 60kd ab fld ql ss-a
63343-8,sjogrens syndrome-a extractable nuclear 60kd ab ia ql (body fld)
63343-8,sjogrens syndrome-a body fluid extratabl uclear 60kd a fld) (body iaql
63343-8,sjogrens ena ss-a syndrome-a extractable nuclear ab 60kd ia presence (body fld)
1728-5,adenosine monophosphate.cyclic/creatinine [mass ratio] in serum or plasma
1728-5,adenosine plasma [mass ratio] in serum or monophosphate.cyclic/creatinine
1728-5,adenosine onoposphate.cyclic/eatinine [massrtio] or sum i plasa
1728-5,camp/creat serpl
1728-5,sepl amp/creat
1728-5,serpl camp/creat creat
1728-5,adenosine monophosphate.cyclic/creatinine [mass ratio]
1728-5,ratio] qnt [mass adeosinemonohospha.cylic/creaiin
1728-5,adenosine onophosphat.cyclic/reatinine [massrati]
60043-7,acepromazine [mass/volume] in blood
60043-7,acepromazine [mass/volume] atravet in blood
60043-7,acepromazine [mass/volume] in bld
60043-7,acepromazine bld-mcnc
60043-7,bmcnc atravet acepromazin
60043-7,acepromine blood-mcnc drug/toxicology
60043-7,acepromazine (bld) [mass/vol]
60043-7,acepromazine [mass/vol] (bld)
60043-7,(bld) acepromazine [mass/vol]
104473-4,yersinia pseudotuberculosis 2 ab [presence] in stool
104473-4,yersinia pseudotuberculosis anti 2 ab in [presence] stool
104473-4,yersini antby psudotubrculosis2 stool in a[ql]
104473-4,y pseudotb 2 ab stl ql
104473-4,y pseudotb ql ab stl 2
104473-4,ab pseudotb 2 y feces stl presence
104473-4,y. pseudotuberculosis 2 ab ql (stl)
104473-4,y. ql 2 a psedotuberclosis (stl)
104473-4,y pseudouberculosis 2 ql ab stl)
74388-0,normirtazapine [mass/volume] in body fluid
74388-0,[as/olum] normirtazpine in body flud
74388-0,rmirtzine [mass/volume] in body flid
74388-0,normirtazapine fld-mcnc
74388-0,fld-mcnc normirtazpine
74388-0,body fluid ormirtazaine fld-mcnc
74388-0,normirtazapine (body fld) [mass/vol]
74388-0,normirtazapie (body fd)[massvol]
74388-0,nrirtazapine body fluid body fld) [mass/vol]
34171-9,histoplasma capsulatum ag [units/volume] in specimen
34171-9,histoplasma specimen ag [nitsvolume] in capsulatu other
34171-9,histoplasma capsulatum ag [units/volume] in specimen unspecified
34171-9,h capsul ag spec-acnc
34171-9,h capsul pec-acnc ag
34171-9,ag capsul h spec-acnc quant
34171-9,h. capsulatum ag qn (specimen)
34171-9,g capsulatum point in time h. qn (seimen)
34171-9,h. specimen) a qn id capslatum
85805-0,influenza virus a h7 ag [titer] in isolate by hemagglutination inhibition
85805-0,influenza [titer] a h7 ag virus in solate y hemaglutinatioinhibiio
85805-0,influenza virus [titer] h7 ag a in isolate by hemagglutination inhibition
85805-0,fluav h7 ag titr islt hai
85805-0,fluav islt g titr h7 hi
85805-0,fuav h7 ag ir ist hai
85805-0,fluav h7 ag hai (isol) [titer]
85805-0,influ fluav h7 ag hai [titer] (isol)
85805-0,fluav (isol) ag hai h7 [titer]
105772-8,haemophilus influenzae dna [cycle threshold #] in positive blood culture by naa with probe detection
105772-8,haemophilus influenzae dna [cycle threshold #] in positive blood culture by naa with probe detection
105772-8,haemphilus ifluenzae dna [cycl threshold #] in psitive bood culture by naaithprobe detection
105772-8,haem influ dna ct bld pos qn naa+probe
105772-8,haem dnat influ bld pos qnnaa+prob
105772-8,qn infl dnac blood nucleic acid sequence based analysis pos hm na+probe
105772-8,h. influenzae dna naa+probe (pos bld culture) [threshnum]
105772-8,h. influnzae dna naaprob (posbd cuture) [threshnum] transcription mediated amplification
105772-8,h. influenzae dna sda naa+robe (po bld cultre) [thesnum]
31894-9,mumps virus ag [presence] in serum
31894-9,[ql] virus ag antigens mumps in serum
31894-9,mumps virs muv gpresence] in ser
31894-9,muv ag ser ql
31894-9,mv sr ag ql
31894-9,muv qualitative ag ql serum
31894-9,muv ag ql (s)
31894-9,muv ql ag (s)
31894-9,muag ql (s)
61083-2,methylenedioxymethamphetamine [presence] in gastric fluid
61083-2,ethylendixymethaphetamne[presence in gatric fluid pr
61083-2,mthylenedioxyethaphetamine fluid n astric [presec] qual
61083-2,mdma gast ql
61083-2,illicit mdma gast ql
61083-2,ql gast mdma
61083-2,methylenedioxymethamphetamine ql (gast fld)
61083-2,methylenedioxymethamphetamine presence (gast fld)
61083-2,methylenedioxymethamphetamine ql (gast fld) drugs
33943-2,chlamydophila pneumoniae+chlamydophila psittaci dna [presence] in cerebral spinal fluid by naa with probe detection
33943-2,chlamydophla neumoniae+chlamyohila psittacidna [prsence] in cereral spinal fluid bynaa with probe polymerase chain reaction detection
33943-2,chlamydophil pneumonia+chlamydophila probe amp sitai dna [ql] by cerebral spialfluid i naath poe dtection
33943-2,c pn+psitt dna csf ql naa+probe
33943-2,c pn+psitt dna cerebrospinal fluid ql naa+probe
33943-2,c csf dna pn+psitt ql naapobe
33943-2,c. pneumoniae+c. psittaci dna naa+probe ql (csf)
33943-2,c. peumoniac. psttaci dna naa+probe ql (cerebrospinal fluid)
33943-2,c pneumoniae+c. psittacina ql naa+probe (csf)
96448-6,sars-cov-2 (covid-19) n gene [presence] in saliva (oral fluid) by nucleic acid amplification using cdc primer-probe set n1
96448-6,sars-co-2 coid-19) cdc [presence] in saliva (oral flud) by nueic acid amplificatio usig gene primer-proe set n
96448-6,sars-cov-2 (covid-19) n gene [presence] in saliva (oral fluid) dna nucleic acid probe by nucleic acid amplification using cdc primer-probe set n1
96448-6,sars-cov-2 n gene sal ql naa n1
96448-6,sars-cov-2 n gene sal sda ql naa n1
96448-6,ar-co-2 n gen sa nucleic acid sequence based analysis ql naa n1
96448-6,sars-cov-2 (covid-19) n gene naa+probe cdc primer-probe set n1 ql (sal)
96448-6,sars-co-2 (cvid-19) n dcprimer-probe naa+prbe gne set n1 (sal)
96448-6,sars-cov-2 (covid-19) n gene naa+probe cdc primer-probe set probe with target amplification n1 ql (sal)
80168-8,pterins panel - cerebral spinal fluid
80168-8,pterins panel - cerebral spinal fluid
80168-8,pterns anel spinal fl fluid spinal crebal
80168-8,pterins pnl csf
80168-8,cs pterinspl
80168-8,pterins pnl pan csf
80168-8,pterins panel (csf)
80168-8,(csf) panel pterins
80168-8,random panel pterins (cerebrospinal fluid)
609-8,bacteria identified in eye by aerobe culture
609-8,bacteri ientifiedin eye by are culture
609-8,bacteri identifed ey in by aerobe ulture
609-8,bacteria eye aerobe cult
609-8,cult eye aerobe bacteria
609-8,eye bacteria microbiology aerobe cult
609-8,bacteria identified aer cx nom (eye)
609-8,bacteria identified aer cx nom (eye)
609-8,bacteria identifie aer optic globe cx om (eye)
80598-6,respiratory syncytial virus b f gene [presence] in nasopharynx by naa with probe detection
80598-6,respiratory syncytial virus b f gene [presence] in nasopharynx by detection with naat probe naa
80598-6,respiratory syncytial virus naa f gene [presence] in nasopharynx by qualitative b with probe detection
80598-6,rsv b f gene nph ql naa+probe
80598-6,rsv b pcr f gene nph naa+probe presence
80598-6,rsv b f gene nph dna probe ql naa+prob
80598-6,rsv b f gene naa+probe ql (nph)
80598-6,naa+probe b f gene rsv ql (nph)
80598-6,rsv b ligase chain reaction f gene naa+probe ql nh)
28586-6,4-hydroxyphenyllactate/creatinine [ratio] in urine
28586-6,urine [ratio] in quan 4-ydroxyphenylactatecatinine
28586-6,4-hydroxyphenyllactate/creatinin [ratio] in urne
28586-6,4oh-phenyllactate/creat ur-rto
28586-6,4oh-phenyllactate/creat ur-rto
28586-6,ur-rto 4oh-phenyllactate/creat
28586-6,4-hydroxyphenyllactate/creatinine (u) [ratio]
28586-6,[ratio] (u) 4-hydroxyphenyllactate/creatinine
28586-6,4-hydroxyphenyllactate/creatinine crea [ratio] (u)
7951-7,legionella pneumophila 4 ab [titer] in serum by immunofluorescence
7951-7,egioella 4 neumophia ab tier] in seum immunofluorescnce
7951-7,infectious disease legionella pneuophila 4ab [tter]in serum by immunofluorescence
7951-7,l pneumo4 ab titr ser if
7951-7,lpneumo4 serum titr ab if
7951-7,l titer titr ab pneumo4 serum if
7951-7,l. pneumophila 4 ab if (s) [titer]
7951-7,. point in time peumphil 4 abif(s) [tter]
7951-7,peuoila 4 pneumophilia if ab (s) [titer]
66721-2,adenovirus dna [#/volume] (viral load) in body fluid by naa with probe detection
66721-2,flu adenovirus dna [#/volume] (viral load) in body fluid detection naa with probe by
66721-2,adenovius dna #/volum] (viral oad) i bo flud by naa with prob dtection
66721-2,hadv dna # fld naa+probe
66721-2,hadv naa+probe # fld dna
66721-2,hadv dna flu # fld naa+probe
66721-2,adenovirus dna naa+probe (body fld) [#/vol]
66721-2,adenovirus dna naa+probe (body [#/vol] fld) cnt
66721-2,adenovirus dna fld) (body naa+probe [#/vol]
97853-6,anticomplementary activity [titer] in specimen by complement fixation
97853-6,anticoplemenary [titer] activity in anticompl act specimen ycomplement ixation
97853-6,anticomplementary activity [titer] by specimen in complement fixation
97853-6,anticompl act titr spec cf
97853-6,anticompl ct f spec titr
97853-6,misc spec act titr anticompl cf
97853-6,anticomplementary activity cf (specimen) [titer]
97853-6,(specimen) acivity cf nicomplmentary [tter]
97853-6,anticomplementary activity actvty cf (specimen) [titer]
43335-9,fowl adenovirus ab [presence] in serum by immune diffusion (id)
43335-9,immune adenovirus ab [presence] in ser by fowl diffusion (id)
43335-9,aby fowl [presence] ab adenovirus in ser by immune diffusion (id)
43335-9,fadv1 ab ser ql id
43335-9,fadv1 ab serum ql id
43335-9,fadv1 vet ab serum ql id
43335-9,fowl adenovirus ab immune diff ql (s)
43335-9,fowl adenovirus abimme sr diff ql s)
43335-9,fowl adenovrus ab imune diff ql (s)
21042-7,3-hydroxydodecanoate (3-oh-c12:0)/creatinine [mass ratio] in urine
21042-7,3-hydroyddcanoat n [mass rato] (3-o-12:0)/reatnin urine
21042-7,3-hydroxydodecanoate (3-oh-c12:0)/creainin [as quantitative ratio] in ne
21042-7,3oh-dodecanoate/creat ur
21042-7,ur 3oh-dodecanoate/creat
21042-7,ur 3oh-dodecanoate/creat 3oh-dodecanoate
21042-7,3-hydroxydodecanoate (3-oh-c12:0)/creatinine (u) [mass ratio]
21042-7,(u) (3-oh-c12:0)/creatinine 3-hydroxydodecanoate [mass crea ratio]
21042-7,3-hydroxyodcanoate (3-o-c2:)/creatinine(u) [mass rato]
21000-5,deprecated erythrocyte distribution width [entitic volume] by automated count
21000-5,deprecated erythrocyte distribution width [entitic by volume] automated count
21000-5,deprecatederytrocyte distrbution width [entitic count by auomated olume]
21000-5,deprecated rdw rbc auto
21000-5,rdw auto rdw rbc deprecated
21000-5,rbcato dprcterd
21000-5,erythrocyte auto (rbc) [distwidth]
21000-5,(rbc) auto rcmi erythrocyte [distwidth
21000-5,erythrocyte [distwidth] (rbc) quan auto
55925-2,igm [mass/volume] in serum by electrophoresis
55925-2,igm [mass/volume in eu by elect electophoresis
55925-2,igm quan [mass/volume] in serum by electrophoresis
55925-2,igm ser elph-mcnc
55925-2,igm elph-mcnc ser elp
55925-2,ser igm elph-mcnc
55925-2,igm elph (s) [mass/vol]
55925-2,igm elph (s) [mass/vol] chemistry
55925-2,igm (s) elph [mass/vol]
80718-0,lymphocyte tcr gamma delta and alpha beta subsets panel - blood
80718-0,lymphocyte tcr gamma delta and alpha beta subsets panel - bld
80718-0,lymphocyte tcr gamma delta and alpha beta subsets panel - bld
80718-0,lymph tcr gam delt + alpha beta sub pnl
80718-0,lymph tcr gam alpha + delt beta sub pnl
80718-0,lymph alpha dlt tcrgam betasub nl
80718-0,lymphocyte tcr gamma delta and alpha beta subsets panel (bld)
80718-0,lyphocyte tcr gammdlta an lh beta (bld) panel subsets
80718-0,pnel tcr gama delt and quantitative alpha beta subsets ymphocte (bld)
60267-2,influenza virus c rna [presence] in isolate by naa with probe detection
60267-2,influenza virus c rna [ql] in isolate by naa with probe detection
60267-2,influenza point in time virus c rna [presence] in isolate by naa with probe detection
60267-2,flucv rna islt ql naa+probe
60267-2,flucv rna islt ql naa+probe
60267-2,naa+probe rna islt ql flucv
60267-2,flucv rna naa+probe ql (isol)
60267-2,flucv rnanaa+probe presence (isol)
60267-2,flucv naa+probe rna naa+probe ql (isol)
86603-8,periodontal attachment - recommended cda r1 set
86603-8,periodontal attachment recommended - cda r1 set
86603-8,perioontal atahmnt perio attach cda r1 set - recomended cda r1set
86603-8,perio attach cda r1 set
86603-8,panel perio r1 cda attach set
86603-8,perio attach cda rset
88786-9,symptoms panel [hoos]
88786-9,panel symptoms pnl [hoos]
88786-9,panel symptom [hoos
19560-2,methaqualone cutoff [mass/volume] in urine for confirmatory method
19560-2,mehaqualnectoff [mass/volume] in urin fr urn confirator methd
19560-2,methaqulonecutoff [mass/volume] in rine for confrmatory method
19560-2,methaqualone cto ur cfm-mcnc
19560-2,methaqualone ur cto cfm-mcnc
19560-2,methaqualoe ct ur cfm-mcnc
19560-2,methaqualone cutoff confirm (u) [mass/vol]
19560-2,ethaqualonecutoff onfirm confirmatory u) [mss/vol]
19560-2,methaqualon cutoff confrm (u) [mass/vl]
94469-4,f2 gene.c.20210g>a and c.1691g>a panel - blood or tissue by molecular genetics method
94469-4,f2 gene.c.20210g>a and c.1691g>a panel - blood or tissue by molecular genetics method
94469-4,f2gene.c.20210g>a c.1691g> panel - blood method issue by molecular genetic or
94469-4,f2 20210g>a + f5 1691g>a pnl bld/t
94469-4,f2 20210g>a f 1691g>a pnl prothrombin precursor bld/t
94469-4,f2 + 2210a f5 1691gapn bld/t
94469-4,f2 gene.c.20210g>a and c.1691g>a panel molgen (bld/tiss)
94469-4,"f2 gene.c.20210g>a and c.1691g>a panel molgen (blood/tiss) tissue, unspecified"
94469-4,ene.c.20210g>a f2 and .1691g>a panel molgen bldtiss)
24114-1,epstein barr virus capsid igg ab [presence] in serum by immunoassay
24114-1,estein barr byimmunossay capsid igg ab presene] i serum virus
24114-1,epstein br igg capsid viru aby ab presence in serm by immnoassay
24114-1,ebv vca igg ser ql ia
24114-1,ebv vca ia ser ql igg
24114-1,ebv vca igg vca serum ql i
24114-1,ebv capsid igg ia ql (s)
24114-1,ebv immunoglobulin g capsid igg ia ql (s)
24114-1,ebv capsid (s) ia ql igg
3766-3,metandienone [mass/time] in 24 hour urine
3766-3,in [mass/time] metandienone averbol 24 hour urine
3766-3,metandienone [mas/tme]n 24 hour metaboline urine
3766-3,metandienone 24h ur-mrate
3766-3,drugs metandienone ur-mrate 24h
3766-3,1 day ur-mrate 24h metandienone
3766-3,metandienone (24h u) [mass/time]
3766-3,(24h mtanenone u) [mass/time]
3766-3,metandienone (24h u) [mass/time]
31182-9,7-aminonitrazepam [mass/volume] in serum or plasma
31182-9,in serpl [mass/volume] 7-aminontrazepam sem or plasm
31182-9,7-aminonitrazepam serum in [mass/volume] or plasma
31182-9,7aminonitrazepam serpl-mcnc
31182-9,7aminonirazepam serpl-mn
31182-9,serpl-mcnc 7amonitrazepam
31182-9,7-aminonitrazepam [mass/vol]
31182-9,serpl [mass/vol] 7-aminonitrazepam
31182-9,[mass/vol] 7-minnitrazpam
80210-8,beryllium [mass/volume] in body fluid
80210-8,beryllium [mass/volume] in body fluid
80210-8,beryllium [mass/volume] in body b/f fluid
80210-8,beryllium fld-mcnc
80210-8,bodies fld-mcnc beryllium
80210-8,bellum fl-mcnc berylliosis
80210-8,beryllium (body fld) [mass/vol]
80210-8,beryllu fluid (body fld) [mas/vol]
80210-8,beryllium (body fld) [mass/vol]
81680-1,preoperative verification process panel
81680-1,preoperative verification panel process
81680-1,preoperative random vrification processpanel
81680-1,preop verif process pnl
81680-1,preop verif process nl
81680-1,rop verif pl process
51001-6,iodide [mass/volume] in urine
51001-6,drugs iodide [mass/volume] in urine
51001-6,iodide urine in [mass/volume]
51001-6,iodide ur-mcnc
51001-6,drugs iodide ur-mcnc
51001-6,iodide quan r-cnc
51001-6,iodide (u) [mass/vol]
51001-6,[mass/vol] (u) odde ur
51001-6,iodide (u) [mass/vol]
73255-2,moxifloxacin induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73255-2,moxifloxacin induced platelet igm ab [presence] autoantibody in serum or plas by flow cytometry (fc)
73255-2,moxifloxacin induced platelet igm ab [presence] in serpl by flow cytometry (fc)
73255-2,moxifloxacin ind plt igm serpl ql fc
73255-2,moxifloxain ind plt igm serp ql serum or plasma f
73255-2,moxifloxacn in pt igm ordinal sepl ql c
73255-2,moxifloxacin induced platelet igm fc ql
73255-2,platelet induced serum moxiloxacn igm fc presence
73255-2,moxifloxacin induced platelet thrombocytes igm fc ql
90979-6,vortioxetine [mass/volume] in serum or plasma
90979-6,in [mass/olme] ortioxetne serum or plasma
90979-6,vortioxetine [mass/volum] in plasm or serum
90979-6,vortioxetine serpl-mcnc
90979-6,vortioxetine serpl-mcnc
90979-6,serpl-mcnc vortioxetine quan
90979-6,vortioxetine [mass/vol]
90979-6,serplas [mass/vo] vortioxetine
90979-6,[mass/vol] vortioxetine
4186-3,ciprofloxacin [mass] of dose
4186-3,of [mass] ciprofloxacin dose
4186-3,cprofoxacn [mas]of dose
4186-3,ciprofloxacin dose
4186-3,ciprofloxacin dse ciloxan
4186-3,dose ciprofloxacin
4186-3,ciprofloxacin (dose) [mass]
4186-3,cipofloxacn (dose) [mas]
4186-3,ciprofloxacin (dose) [mass]
49301-5,protein fractions [interpretation] in 24 hour urine by electrophoresis narrative
49301-5,protei racios [inerretation] in 24 or urne upep by electrophoresis narrative
49301-5,protein fractions[interpretation] 24 hours in 24hour narrativ by ectrophoreis urine
49301-5,prot pattern 24h ur elph-imp
49301-5,prot pattern 24h urlph-im
49301-5,ua prot pattrn 24h ur elp-imp
49301-5,protein fractions elph nar (24h u) [interp]
49301-5,proein fractions eph nar 24h electrophhrs [interp] u)
49301-5,prten frationselph u) (24h nar [inter]
57782-5,cbc w ordered manual differential panel - blood
57782-5,pnl cbc w panel manual differential ordered - blood
57782-5,cbcw rdeed manual blood pnel - panl dferentil
57782-5,cbc w ordered manual diff bld
57782-5,cbc w diff manual ordered blood
57782-5,panl cbc ordered w manual diff blood
57782-5,cbc w ordered manual differential panel (bld)
57782-5,cbc manual wrdered differental panel (ld)
57782-5,cbc w rdered manual differntia panel (bld)
103668-0,gabapentin [presence] in cord tissue by screen method
103668-0,gabapentin [presence] tissue cord in by screen method
103668-0,gabapentin [ql] in cord method by screen tissue
103668-0,gabapentin tissco ql scn
103668-0,gabapentin scn ql tissco
103668-0,gabapenin cn presence drugs tissco
103668-0,gabapentin screen ql (umb cord tissue)
103668-0,gabapentin creen ql (umb cord horizant tisue)
103668-0,gabapentin screen ordinal ql (umb cord tissue)
44894-4,malignant cells/cells in cerebral spinal fluid by manual count
44894-4,malignant cells/cells in cerebral spinal fluid by manual count
44894-4,ceebral cels/cels i malignant spinal fluid b manualount cellularity
44894-4,malignant cells nfr csf manual
44894-4,fr cell malignant qnt csf manual
44894-4,malignant cells quant nfr csf manual
44894-4,malignant cells/cells manual cnt (csf)
44894-4,manual spinal fld cells/cells malignant cnt (cerebrospinal fluid)
44894-4,malignantcellsellsmanual (cerebrospinal fluid) nt
34713-8,clostridioides difficile toxin a+b [presence] in stool
34713-8,difficile clostridioides toxin a+b [presence] in stool
34713-8,toxin difficile lostridiodes a+b[presenc] in sool
34713-8,c diff tox a+b stl ql
34713-8,c a+b tox diff stl ql
34713-8,c diff tox a+b stl ql
34713-8,c. difficile toxin a+b ql (stl)
34713-8,c. dificile oxin universallaborders ab ql (sl)
34713-8,c. a+b toxin difficile c diff tox a+b ql (stl)
55784-3,leukocytes [#/volume] corrected for nucleated erythrocytes in bone marrow
55784-3,lkoctes [#/volume] corrected for nucleatederythrocyes n bone arrow
55784-3,leukocyte[#/voume] coreced bonemarrow nuclee rythocytes marrow (bone) in fo
55784-3,wbc nrbc cor # mar
55784-3,wbc nrbc cor # mar
55784-3,wbc nrbc cor # # mar
55784-3,wbc corrected for nucl rbc (bm) [#/vol]
55784-3,wbc corced for count nucl [#/ol] (b) rbc
55784-3,wbc corrected or nucl rbc (m)[#/vol]
21312-4,gold [mass/volume] in body fluid
21312-4,gold drug/toxicology [mass/volume] in body fluid
21312-4,"body [mass/volume] body fluid, unsp in gold flud"
21312-4,gold fld-mcnc
21312-4,fld-mnc b/f gold
21312-4,fld-mcnc gold drugs
21312-4,gold (body fld) [mass/vol]
21312-4,(ody bf old fld)[mass/vo]
21312-4,gold (body fld) body fluid [mass/vol]
6345-3,chlamydia sp ag [presence] in genital specimen by immunoassay
6345-3,chlamydia p ag[prsence] immunoassy genital pecien b in
6345-3,chlamydia immunoassay species ag [presence] in genital specimen by sp
6345-3,chlamydia ag genital ql ia
6345-3,chlamyda a gnita presence ia
6345-3,chlamydia genital ag ql ia
6345-3,chlamydia sp ag ia ql (genital specimen)
6345-3,ordinal clamydiasp agia q (genital secimen)
6345-3,chlamydia sp ag ordinal ia ql (genital specimen)
70664-8,parathyrin.intact intraoperative percent change in serum or plasma
70664-8,percentchae parahyrin.intactintraoertiv in srum plsm or plasma
70664-8,parathyrin.intact serum percent change in intraoperative or plasma
70664-8,pth-intact io % dif serpl
70664-8,pt-intact io % point in time dif serpl
70664-8,pth-intact io dif % sepl serum or plasma
70664-8,parathyrin.intact intraoperative percent change [mass conc % diff]
70664-8,diff] intraoperative percent change [mass conc % parathyrin.intact
70664-8,serum or plasma parathyrin.intact intraoperative percent change [mass conc % diff]
101443-0,soluble urokinase plasminogen activator receptor [mass/volume] in plasma
101443-0,soluble urokinase plasminogen activator in random [mass/volume] receptor plasma
101443-0,soluble activator plasmingen roknase receptor [mass/volme] inpasm
101443-0,supar plas-mcnc
101443-0,quantitative plas-mcnc supar
101443-0,supar plasma-mcnc
101443-0,soluble urokinase plasminogen activator receptor (p) [mass/vol]
101443-0,soluble uroinaeplasminogen activator receptr (p) [mass/vol]
101443-0,slue urokiase plasminogen activator rcptor () [mass/vol]
3463-7,chloroquine [mass/volume] in serum or plasma
3463-7,aralen chloroquine [mass/volume] serum in or plasma
3463-7,ser [mass/volume] in chloroquine or plasma
3463-7,chloroquine serpl-mcnc
3463-7,chlorqne aralen pl-mcnc
3463-7,serpl-mcnc chloroquine
3463-7,chloroquine [mass/vol]
3463-7,[mass/vol] malaquin chloroquine
3463-7,[mass/vol] chloroquine
14847-8,neutrophils/leukocytes in pericardial fluid by manual count
14847-8,flid n pericrial neutrophil/leukoces by mnual cont
14847-8,fluid in periardia eurphil/leukocyte maual count
14847-8,neutrophils nfr pcar manual
14847-8,pcar nfr neutrophils manual
14847-8,neutrophils nfr cardiology car manual
14847-8,neutrophils/leukocytes manual cnt (pericard fld)
14847-8,leuc manual neutrophils/leukocytes cnt (pericard fld)
14847-8,neuphils/leukocye manal cnt pricardfld) hematology/cell counts
24199-2,coxsackievirus b6 neutralizing antibody [titer] in serum by neutralization test --1st specimen
24199-2,cosackievirus b6 neutralizing antibody [tite] nsrumb nuralizationtest --1s specimen random
24199-2,coxsackievirus b6 neutralizing antibody [titer] in serum by neutralization test --1st specimen autoantibodies
24199-2,cv b6 nab sp1 titr ser nt
24199-2,nab b6 cv s1 titr ser nt dilution factor
24199-2,b6 virus neutralization test cv nab sp1 titr ser nt
24199-2,coxsackievirus b6 neut ab spec 1 neut test (s) [titer]
24199-2,coxsackievirus b6 neut ab spec1 antibody neut test (s) [tter]
24199-2,cosackievirus b6 sp1 spec ab neu 1 neut tet (s) [titer]
6962-5,yersinia enterocolitica o:9 ab [titer] in serum
6962-5,yersinia enterocolitica [titer] ab o:9 in serum
6962-5,ersinia eneocotica o:9 in titer] ab seru
6962-5,y entero o:9 ab titr ser
6962-5,y ab o:9 entero titr serum
6962-5,y titr o:9 ab entero ser
6962-5,y. enterocolitica o:9 ab (s) [titer]
6962-5,(s) enterocolitica o:9 ab antibodies y. [titer]
6962-5,y. ab o:9 enterocolitica antibodies (s) [titer]
4383-6,pentazocine [mass] of dose
4383-6,pentazocine quan [mass] dos of
4383-6,pentazocine [mass] quantitative of dose
4383-6,pentazocine dose
4383-6,pntazocine oe
4383-6,qnt dose pentazocine
4383-6,pentazocine (dose) [mass]
4383-6,pentazocine [mass] (dose)
4383-6,(dose) pentazocine addiction [mass]
55876-7,homocitrulline [moles/volume] in serum or plasma
55876-7,homocitrulline homocit serum in [moles/volume] or plas
55876-7,homocitrulline plasma [moes/olume]i plasm or srum
55876-7,homocitrulline serpl-scnc
55876-7,quantitative serpl-scnc homocitrulline
55876-7,serpl-scnc homocitrullie
55876-7,homocitrulline [moles/vol]
55876-7,[moles/vol] homocitrulline quantitative
55876-7,homocitrullne [moes/vo]
94067-6,color me healthy - children's symptom assessment app
94067-6,color me healthy point in time - children's symptom assessment app
94067-6,color me healthy - children's symptom assessment panel.h&p app
94067-6,color me healthy panel
94067-6,colorme pael sx helthy
94067-6,olor e healthy pae
50313-6,cyclospora sp identified in stool by safranin stain
50313-6,cyclospora sp identified in y too safraninstai
50313-6,cyclospora sp safranin in stool nominal by identified stain
50313-6,cyclospora stl safranin stn
50313-6,cyclopora stl stn safrni
50313-6,cclospora species sl sarni stn
50313-6,cyclospora sp identified safranin stain nom (stl)
50313-6,yclospora p idenifid st sfranistin nom (stl)
50313-6,cyclospora sp identified cyclosporiasis safranin stain nom (stl)
89244-8,karnofsky performance status panel
89244-8,karnofsky performance panel status
89244-8,panel karnofskyperformancestatus
89244-8,kps panel
89244-8,panel.clinical kps panel
89244-8,panel perform status kps
6502-9,neisseria meningitidis serogroup y ab [titer] in specimen by immunofluorescence
6502-9,neisseria meningitidi [titer] y ab serogroup in pecmen by immunofluoresence
6502-9,nissera meningitidis y serogrou a [tter in pecimen anti b immunofluorescenc
6502-9,n men sg y ab titr spec if
6502-9,y dilution factor men sg n ab titr spec if
6502-9,n men sg y ab titr spec if
6502-9,n. meningitidis y ab if (specimen) [titer]
6502-9,ab eningitiis y n. if specimen) [titer]
6502-9,n. meningitidis y ab if fluoresent (specimen) [titer]
9385-6,levodopa [mass/volume] in serum or plasma
9385-6,srum [mass/volume] in levodpa or plasa
9385-6,levodoa mas/volume] in seum orlasma quan
9385-6,l-dopa serpl-mcnc
9385-6,serpl-mcnc drug/toxicology -dop
9385-6,serpl-mcnc l-dopa
9385-6,levodopa [mass/vol]
9385-6,[mass/vol] sr levodopa
9385-6,levodopa [mass/vol]
77752-4,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) cutoff [mass/volume] in urine for screen method"
77752-4,"2-ethylidene-1,5-dimethyl-3,3-dihenylpyrroldine (edd)cutof [mas/volume] in urine or screen mehod"
77752-4,"ua 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) cutoff [mass/volume] screen urine for in method"
77752-4,eddp cto ur scn-mcnc
77752-4,edp ur cto iii nmcnc
77752-4,eddp cto scn-mcnc ur
77752-4,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) cutoff screen (u) [mass/vol]"
77752-4,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) cutoff drug/toxicology screen (u) [mass/vol]"
77752-4,"2-ehylidene-1,5dimethyl-3,3-diphenylpyrrolidine (dp cutoff creen (u) [mass/vol]"
81745-2,personal advance care plan r1.0 - recommended cda sections
81745-2,personal advance r1.0 plan care - recommended pan cda sections
81745-2,peroal adanc care pa r.0 - ecmmended da sections
81745-2,pers adv care plan r1.0 - rec cda sec
81745-2,pers adv care plan r1.0 - rec cda sec panel.doc
81745-2,es adv are p r1.0 - rec cda se
48790-0,creatinine [mass/time] in unspecified time peritoneal dialysis fluid
48790-0,peritoneal [mass/time] in unspecified time creatinine ?tm dialysis fluid
48790-0,creatinine[mass/tie] in unspecfied tmeeriton ialysis flud
48790-0,creat ?tm diafp-mrate
48790-0,cret ?tmdiafp-mrae ?tm
48790-0,?tm creat diafp-mrate
48790-0,creatinine unsp time (perit dial fld) [mass/time]
48790-0,creatinine mass rate unsp dial (perit time fld) [mass/time]
48790-0,[mass/time] unsp time (perit dial fd) reatinine
79508-8,4-hydroxymandelate [moles/volume] in serum or plasma
79508-8,4-hydroxymandelate [moles/volume] in plasma or serum
79508-8,4-hydroxymandelate serumr in [mo/volume] lama
79508-8,4ohmandelate serpl-scnc
79508-8,selscnc substance concentration 4ohmandelate
79508-8,4ohmandelate sr serpl-scnc
79508-8,4-hydroxymandelate [moles/vol]
79508-8,4-hydroxymandelate [moles/vol]
79508-8,[moe/ol] substance concentration -hydroxymadelte
93387-9,proteus mirabilis dna [presence] by naa with probe detection in positive blood culture
93387-9,with naa+probe mirabili dna [presenc by naa proteus probe detection in posiive bloodclure
93387-9,proteus mirabilis dna [presence] by naa with probe detection in qbr positive blood culture
93387-9,p mirabilis dna bld pos ql naa+probe
93387-9,p mirabilis dna blood pos ql naa+pobe 3 self-sustaining sequence replication
93387-9,p iabiis dnabld pos ql naa+pobe
93387-9,p. mirabilis dna naa+probe ql (pos bld culture)
93387-9,dna mirailis p. naa+probeql (posbld culture)
93387-9,p. mirabilis da naa+probe ql (pos bld culture)
13926-1,glutamate decarboxylase 65 ab [units/volume] in serum
13926-1,glutamatedecrboxylase insulin-dependent diabetes mellitus 65 ab [uits/volume]in serm
13926-1,glutae dearboylase 65 a [units/volume] in gada srum
13926-1,gad65 ab ser-acnc
13926-1,ga65 ab seracn
13926-1,gad65 ab serum-acnc
13926-1,glutamate decarboxylase 65 ab qn (s)
13926-1,gutamate a 5 earboxylse endocrine qn()
13926-1,glutamate decarboxylase ab 65 qn (s)
26468-9,leukocytes [#/volume] in peritoneal fluid
26468-9,leukocytes [#/volume] in peritoneal fluid
26468-9,fluid [#/volume] in peritoneal leukocytes
26468-9,wbc # prt
26468-9,prt absolutes # wbc
26468-9,white blood cell wbc# rt
26468-9,wbc (periton fld) [#/vol]
26468-9,wbc (periton fld) [#/vol]
26468-9,fld) wbc (periton wbc [#/vol]
55432-9,immature cells [#/volume] in blood
55432-9,immature bld [#/volume] bld in cells
55432-9,immature in [#/volume] cells blood
55432-9,immature cells # bld
55432-9,ct imature cells # ld
55432-9,mmaure cells# bl
55432-9,immature cells (bld) [#/vol]
55432-9,absolutes immate ells (bl) [#vl]
55432-9,wb cls(bl) immature [#/o]
8800-5,right ventricular stroke volume index by fick method
8800-5,rightventiular stroke olume indx by ick method quantitative
8800-5,rght ventricular stroe volue index b fick mehd
8800-5,rv svi fick
8800-5,vi rv fic
8800-5,svi surf r fick
45057-7,cardiolipin iga and igg and igm panel - serum
45057-7,cardioipin and iga iggand igm pael - serum
45057-7,cardiolipin iga and aca igg and igm panel - serum
45057-7,cardiolipin iga+igg+igm pnl ser
45057-7,r pl point in time cardilpinga+igg+gm
45057-7,cardiolipn iga+igg+igm er pnl
45057-7,cardiolipin iga and igg and igm panel (s)
45057-7,cardiolipin iga+igg+igm pnl cadiolipin iga and igg and igm pane (s)
45057-7,igm iga and igg and random cardiolipin panel (s)
89304-0,norhydrocodone [presence] in urine by screen method
89304-0,norhydrcodone [ql] n urie by screen metho
89304-0,in [presence] norhydrocodone urine by screen method
89304-0,norhydrocodone ur ql scn
89304-0,scn ur presence qual norhyroodone
89304-0,nrydroodne ur ql scn
89304-0,norhydrocodone screen ql (u)
89304-0,(u) point in time screen ql norhydrocodone
89304-0,(u) scren norhydrocodone
73123-2,terazosin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73123-2,terazosin indd platelet igg ab autoantibodies [prsenc]in serum or lasma by flow cytometr (fc
73123-2,terzosin in platelt igab [presenc platelet auto-antibodies induced serumor plasma by flow cytomety (fc)
73123-2,terazosin ind plt igg serpl ql fc
73123-2,ind immune globulin g terazosin plt igg serpl ql fc
73123-2,terazosin plt ind igg serum or plasma autoantibodies ql fc
73123-2,terazosin induced platelet igg fc ql
73123-2,terazosin induced platelet l fc igg
73123-2,erzosin plateletiggfc induced q
74506-7,16-alpha hydroxypregnenolone [moles/time] in 24 hour urine
74506-7,16-alpha hydroxypregnenolone [moles/time] in 24 quantitative hour urin
74506-7,16-alpha hyroxypregnenolone [moles/tme] n rine ua hour 24
74506-7,16a oh-preg 24h ur-srate
74506-7,16a 24h oh-prg qnt ur-sate
74506-7,16a 24h 24hr oh-preg ur-srate
74506-7,16-alpha hydroxypregnenolone (24h u) [moles/time]
74506-7,16-lpha hydroxyrgnenlone (24h qnt ) [molestime]
74506-7,[oles/time] hydroxypregnenolone4h u) urn 16-aph
71644-9,blasts/leukocytes [pure number fraction] in body fluid by manual count
71644-9,point in time blasts/leukocytes [pure number fraction] in body fluid by manual count
71644-9,blasts/leukocytes [pure number number fraction body in fraction] fluid by manual count
71644-9,blasts nfr.df fld manual
71644-9,fld nfr.df basts maal
71644-9,lkcs blasts nfr.df fld manual
71644-9,blasts/leukocytes manual cnt (body fld) [pure # fraction]
71644-9,blasts/leukocytes fl # cnt (body fld) [pure manual fraction]
71644-9,blasts/leukocytes manual cnt (body fld) [pure # fraction]
42990-2,mycoplasma pneumoniae igm ab [titer] in pleural fluid
42990-2,mycoplasm pneumoiae autoantibodies igmab [titrin pleural luid
42990-2,flid peumoniae gm ab [titer] in pleural coplasma
42990-2,m pneumo igm titr plr
42990-2,m pneumo igmtitr plr
42990-2,m pneum titr igm plr
42990-2,m. pneumoniae igm (pleur fld) [titer]
42990-2,m. pneumoniae fld) (pleur microbiology igm [titer]
42990-2,m. pneumoniae pleural fluid igm (leur [titer ld)
94256-5,magnesium [mass/volume] in sweat
94256-5,[mass/volume] magnesium in sweat
94256-5,magnesium in [mass/volume] sweat
94256-5,magnesium sweat-mcnc
94256-5,mgnesium quant seat-mcnc
94256-5,mg sweat-mcnc magnesium
94256-5,magnesium (sweat) [mass/vol]
94256-5,magnesium (swea) [mass/vol]
94256-5,magnesium quantitative (sweat)[ms/vol]
23791-7,vesicular stomatitis new jersey virus neutralizing antibody [titer] in serum by neutralization test
23791-7,escular svn stomatis new jersey virus neutralizing antibody in [titr] erm byneutrlization est
23791-7,vesicular infectiousdisease jersey new stomatitis virus neutralizing antibody [titer] in serum by neutralization test
23791-7,vsnjv nab titr ser nt
23791-7,vsnv nab titr sr nt
23791-7,vsnjnab itr ser t
23791-7,vesicular stomatitis new jersey virus neut ab neut test (s) [titer]
23791-7,vesicular stomatitis new jersey irus net ab neuttst (s) [titer]
23791-7,ttr vesicular stomatitis new jersey (s) neut ab neut test virus [titer]
94629-3,mycobacterium avium ss paratuberculosis dna [cycle threshold #] in specimen by naa with probe detection
94629-3,naawith aviumss paratuerculoss na[cyle threhol #] 3 self-sustaining sequence replication in specimen by mycobacterium pobe deection
94629-3,mycobacteriu aium ss paratuberculosis dna [cclethreshold #] robe specimen by naa with i infectious disease detecton
94629-3,m avium paratb dna ct spec qn naa+probe
94629-3,m avium paratb dna ct naa+probe qn spec
94629-3,qn aviuparatb dnac spec m na+proe
94629-3,m. avium ss paratuberculosis dna naa+probe (specimen) [threshnum]
94629-3,m. avim ss paratuberculosis nasba dna naa+roe (specmen) [thresnu]
94629-3,m. avium ss paratuberculosis dna dna probe naa+probe (specimen) [threshnum]
13681-2,beta aminoisobutyrate/creatinine [mass ratio] in urine
13681-2,betaminoisobutyratecreatinine [mass cr ratio] in ur
13681-2,beta aminoisobutyrate/creatnine crea [mass atio] in urine
13681-2,b-aib/creat ur
13681-2,b-aib/crat ur
13681-2,-ib/creat ur
13681-2,beta aminoisobutyrate/creatinine (u) [mass ratio]
13681-2,beta [mass (u) aminoisobutyrate/creatinine ratio]
13681-2,bet aminoisobutyate/creatinine () b [mss raio]
25384-9,coxiella burnetii igg ab [titer] in serum by immunofluorescence
25384-9,ciela burnetii igg ab [titer] serum in serum by immunfluoescence
25384-9,coxiela burnetii igg ab [titer] inerum by imunoluorescence
25384-9,c burnet igg titr ser if
25384-9,c burnet e iggtitr id if
25384-9,ser burnet igg aby titr c if
25384-9,c. burnetii igg if (s) [titer]
25384-9,c. burntii (s if ig [titer]
25384-9,(s)[titer] burnetii igg if c. titer
58121-5,prior functioning adl/iadl during assessment period [cms assessment]
58121-5,prior functioning adl/iadl during assessment period activities of daily living [cms assessment]
58121-5,prir functioning adl/iadldurin assessment peod [cms assesment]
73562-1,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) [mass/mass] in meconium by confirmatory method"
73562-1,"2-etylidee-1,5-imthyl-3,3-dphenylpyrrolidie (edp) [massmass in meconiumby cnfirmatory method"
73562-1,"-ethyidne-15-dimthyl3,3-diphenylpyrrolidin cnfrm (eddp) method i meonum byconimatory [mass/mass]"
73562-1,eddp mec cfm-mcnt
73562-1,cfm-mcnt mec eddp
73562-1,cfm-mct mec edp
73562-1,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) confirm (mec) [mass/mass]"
73562-1,"point in time [ass/ass] (mec) 2-eyliden-1,5-dimethyl-3,3-diphenypyrrolidine(eddp)confirm"
73562-1,"2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (eddp) confirm (mec) drugs [mass/mass]"
72436-9,phenylpyruvate [moles/volume] in serum or plasma
72436-9,phenylpyruvate [moles/volume] in plasma or ser
72436-9,phenylpyuvate [moles/volume]n seum or plas
72436-9,phenylpyruvate serpl-scnc
72436-9,phenylpyruvate random serpl-scnc
72436-9,phenylpyruvate srplscnc plas
72436-9,phenylpyruvate [moles/vol]
72436-9,substance concentration phenylpyruvate [moles/vol]
72436-9,[moles/vol] phenylpyruvate
10877-9,carnitine free (c0) [mass/volume] in urine
10877-9,ua carnitine free (c0) [mass/olue] in urine
10877-9,c0 carnitine free (c0) in [mass/volume] urine
10877-9,carnitine free ur-mcnc
10877-9,level ur-mnc fre crnitine
10877-9,carnitine free ur-mcnc quan
10877-9,c0 (u) [mass/vol]
10877-9,[massol] () c0
10877-9,0 () [mas/vl]
12536-9,butyl nitrate [presence] in blood
12536-9,butyl blood [presence] in nitrate
12536-9,butyl nitrate [presence] blood in
12536-9,butyl nitrate bld ql
12536-9,butyl nitate bld 
12536-9,nitrate butyl bld presence
12536-9,butyl nitrate ql (bld)
12536-9,butyl nitrate ql (blood)
12536-9,butyl nitrate bld) wb ql
69033-9,buprenorphine and norbuprenorphine panel - urine
69033-9,buprenorphine - norbuprenorphine panel and finobrin urine
69033-9,buprnorpine ndorbuprenorphine urne - panel
69033-9,buprenorphine+nor pnl ur
69033-9,buprenorphine+nor pnl ur
69033-9,ur pnl bupreophinnor
69033-9,buprenorphine and norbuprenorphine panel (u)
69033-9,buprenorphine and norbuprenorphine (u) panel
69033-9,and buprenorphine norbuprenorphine panel (u)
43573-5,borrelia burgdorferi igm ab [units/volume] in cerebral spinal fluid by immunoblot
43573-5,borrelia burgdorferi ab igm [units/volume] in cerebral spinal fluid by immunoblot quantitative
43573-5,borrelia burgdorferi igm ab [units/volume] in spinal cerebral fluid by immunoblot
43573-5,b burgdor igm csf ib-acnc
43573-5,b infectiousdisease igm burgdor csf ib-acnc
43573-5,b burgdor igm cerebrospinal fluid ib-acnc
43573-5,b. burgdorferi igm ib qn (csf)
43573-5,ib burgdorferi igm b. qn (csf)
43573-5,b. bb burgdorferi igm ib qn (csf)
73433-5,clonidine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73433-5,serp clonidine induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73433-5,cloniine induced abs platelet g ab [preence] in sum or plasma by flow cytometry (fc)
73433-5,clonidine ind plt igg serpl ql fc
73433-5,loidine ind plt igg serpl ql fc
73433-5,fc ind serum or plasma plt ig serpl ql clondine
73433-5,clonidine induced platelet igg fc ql
73433-5,clonidine fc platelet igg induced ql
73433-5,clonidine induced platelet igg fc ql
86890-1,"mds v3.0 - rai v1.17.2 - other health conditions - nd, sd during assessment period [cms assessment]"
86890-1,"mds v3.0 - ra v1.17.2  other health conditions - nd,s during assessment period cm asesment"
86890-1,"mds v3.0 - riv1.17.2 - pan othe halh condition- nd, sddurinassessment assessment] cm perio"
56136-5,ldl 1 [moles/volume] in serum or plasma
56136-5,dl1[moles/volme] in serum or plasma
56136-5,ldl 1 [moles/volume] in plasma or serum level
56136-5,ldl1 serpl-scnc
56136-5,pl ldl1serpl-scc
56136-5,plsm ldl1erpl-scn
56136-5,ldl 1 [moles/vol]
56136-5,ldl 1 point in time [moles/vol]
56136-5,1[moles/vol] serum or plasma ldl
105338-8,endomysium igg ab [presence] in serum by immunofluorescence
105338-8,endomyum igg ab [presence]in erumy immuoflurescence
105338-8,endomysium igg ab [presence] in serum by immunofluorescence
105338-8,endomysium igg ser ql if
105338-8,ql igg s nomyium aby if
105338-8,f iggser l endomysium
105338-8,endomysium igg if ql (s)
105338-8,endomysium igg if ql (s)
105338-8,if acif endomysiumig ql (s)
14390-9,amylase [enzymatic activity/volume] in dialysis fluid
14390-9,amylase [enzymatic activty/volume] in dialysis fli
14390-9,amylase [enzymatic fluid in dialysis activity/volume]
14390-9,amylase dial fld-ccnc
14390-9,amylase diastase dial ld-cnc
14390-9,amylase dial fld-ccnc alpha amylase
14390-9,amylase (dial fld) [catalytic activity/vol]
14390-9,amylase (dial fld) [catalytic activity/vol]
14390-9,amylase (dial ld) [atalytic ativity/vl] amyl
61424-8,noroxycodone [presence] in urine by confirmatory method
61424-8,noroxycodone [presence in urine confirmaory y mehod
61424-8,noroxcodone [presence] in urne drugs by confirmaory mehod
61424-8,noroxycodone ur ql cfm
61424-8,cf uql noroxycodone
61424-8,nroycodone ur cfm ql
61424-8,noroxycodone confirm ql (u)
61424-8,nooxycodone drugs confirm l u)
61424-8,noroxycodone random confirm ql (u)
5407-2,yersinia enterocolitica o:3 ab [units/volume] in serum
5407-2,yersinia enterocolitica o:3 ab [units/volume] in ser
5407-2,yersinia enterocolitica o:3 ab [units/volume] serum in
5407-2,y entero o:3 ab ser-acnc
5407-2,y entero o:3 ab ser-acnc
5407-2,y antby entero o:3 ab ser-acnc
5407-2,y. enterocolitica o:3 ab qn (s)
5407-2,qn entroctica o:3 ab y. (s) abs
5407-2, nterocolitica :3 ab qn (s)
5392-6,treponema pallidum ab [units/volume] in serum by immobilization
5392-6,treponema immobilization ab [units/volume] in serum by pallidum
5392-6,treponema pallidum by [units/volume] in serum antibody ab immobilization
5392-6,t pallidum ab ser immob-acnc
5392-6,tpllidum se ab immob-acnc qnt
5392-6,ab palum t serum immob-acnc
5392-6,t. pallidum ab immobilization qn (s)
5392-6,t. pallidum ab immobilization qn (s) sr
5392-6,(s) pallidum ab immobilization qn t.
76492-8,amphetamine+methamphetamine [presence] in urine by screen method
76492-8,amphetamin+methampetamine methd in rne by screen [presenc]
76492-8,pr amphetamine+methamphetamine screen in urine by [presence] method
76492-8,amphet+methamphet ur ql scn
76492-8,ampet+mehamphtur speed ql cn
76492-8,ql ur mphet+methamphet scn
76492-8,amphetamine+methamphetamine screen ql (u)
76492-8,amphetamine+methamphetamine (u) ql screen
76492-8,amphetamine+methamphetamine screen ql (u)
29726-7,leptospira interrogans sv cynopteri ab [presence] in serum by agglutination
29726-7,leptopira interogas sv cynopteri ab agglutination [pesence] i serm by agglutnation
29726-7,leptospira autoantibodies sv interrogans cynopteri ab [presence] in serum by agglutination
29726-7,l inter cynop ab ser ql aggl
29726-7,l nter cynp ab ser l inter ql aggl
29726-7,l anti inter cynop ab ser ql aggl
29726-7,l. interrogans sv cynopteri ab aggl ql (s)
29726-7,l. interrogans cynopteri sv ab aggl qual ql (s)
29726-7,l. interrogans sv cynopteri ab presence aggl (s)
73340-2,hydromorphone induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73340-2,hydromorphone induced platelet igm ab serum in [presence] or plas by flow cytometry (fc)
73340-2,hydromorphoneinduced latlet igm abpreence] in plasma or serum by flo cytmetry fc)
73340-2,hydromorphone ind plt igm serpl ql fc
73340-2,hydromrphone in plt igm serpl ql fc
73340-2,hydromorphone ind plt igm serpl q fc
73340-2,hydromorphone induced platelet igm fc ql
73340-2,hydromorphone fc platelet igm induced ql
73340-2,hydromorphone nducd fc igm platelet ql
21377-7,magnesium [mass/volume] in blood
21377-7,inbloo [mass/volume magnesium
21377-7,magnsum [mass/olume] od in
21377-7,magnesium bld-mcnc
21377-7,bld-mcnc magnesium
21377-7,bd-mcnc manesium
21377-7,magnesium (bld) [mass/vol]
21377-7,magesium (bd) [ass/vol]
21377-7,[mass/vl] (bld) agnesium
94611-1,pasteurella multocida toxin toxa gene [presence] in specimen by naa with probe detection
94611-1,paseurella multocida toxin tox gee [ql] i specimn b aa wih probedetecton
94611-1,pasteurella multocida toxin toxa gene [ql] in specimen by naa with probe detection
94611-1,p multoc tox toxa spec ql naa+probe
94611-1,naa+probe multoc tox amplified toxa spec presence p
94611-1,spcql multc tox toxa p naa+probe
94611-1,p. multocida toxin toxa gene naa+probe ql (specimen)
94611-1,(specimen) multocida toxin toxa gene naa+probe ql p.
94611-1,p. (pecien) tox toxa ene narobe l mutocida
4581-5,hemoglobin g - coushatta [presence] in blood by electrophoresis acid (ph 6.3)
4581-5,hemoglobin g - coushatta [presence] in blood (ph electrophoresis acid by 6.3)
4581-5,blodby - cushatta [presence] in heoglobin electrophoresis acid (ph elph 6.3)
4581-5,hgb g-coush bld ql elph acid
4581-5,hgb g-coush blood elph ql acid
4581-5,g-coush hgb bld presence elph random acid
4581-5,hemoglobin g - coushatta elph ph 6.3 ql (bld)
4581-5,l - cushtta elp ordinal ph 6.3 hemolobin (l)
4581-5,hemglobing - oushattaelp bld ph 6.3 ql (ld
85928-0,oasis c2 - medications - soc or roc during assessment period [cms assessment]
85928-0,oasi 2 - medcation report period - soc or o during sessment perid [cms ssessmen]
85928-0,oasis c2 - medications - soc or roc during assessment period [cms assessment]
101910-8,protein monoclonal panel 24hr urine
101910-8,protei monoclonalpanel m-band 4hrurne
101910-8,protein monoclonal panel 24hr urine
101910-8,protein mono pnl 24 hr ur
101910-8,para protein protein mono pnl 24 hr ur
101910-8,protein 24 pnl panel.chemistry mono hr ur
101910-8,protein monoclonal panel 24hr (24h u)
101910-8,protein 24hr panel m-band mnoclonal (24h u)
101910-8,proten 24 hours monoclonal pnel 24hr (24h u)
17433-4,ph of specimen
17433-4,to be specified in another part of the message of ph specimen
17433-4,phof spcmen
17433-4,ph spec
17433-4,ph other ec
17433-4,to be specified in another part of the message spec ph
17433-4,ph (specimen)
17433-4,ph speimen) log molar concentration
17433-4,(specimen) ph
87705-0,sedentary activity 24 hour
87705-0,sedentary clin activity 24 hour
87705-0,sedentary hour 24 activity
87705-0,sedentary activity 24h nrate
87705-0,sedentary nrate 24h activity
87705-0,activity sedentary 24h nrate
70217-5,thyroxine (t4) free [moles/volume] in serum or plasma by dialysis
70217-5,thyroxine (t4) free [moles/volume] serum in or plasma by dialysis
70217-5,thyroxine [moles/volume] free (t4) in serum or plasma serum or plasma by dialysis
70217-5,t4 free serpl dialy-scnc
70217-5,free t4 serpl dialy-scnc
70217-5,t4 fre serum or plasma dial-scnc non-protein bound
70217-5,free t4 dialysis [moles/vol]
70217-5,[moles/vol] t4 dialysis free
70217-5,ree t4 dalyss [moes/vo]
86069-2,streptococcus pneumoniae danish serotype 23f igg ab [units/volume] in serum --2nd specimen
86069-2,streptococcus pneumoniae danish 23f serotype igg ab [units/volume] in antibodies serum --2nd specimen
86069-2,streptococcus neumonie danish seotype 23f igg ab serum microbiology in [units/vlume] --2nd specimn
86069-2,s pneum da 23f igg sp2 ser-acnc
86069-2,s pneum da 23f ser-acnc sp2 igg
86069-2,s pneum 23f da igg sp2 ser-acnc
86069-2,s. pneumoniae danish type 23f igg spec 2 qn (s)
86069-2,s.pneumoiae danishtype 23f igg sp 2qn (s)
86069-2,s. pnumoiae danish tye spec post immunization igg 23f 2 qn (s)
97917-9,oropouche virus rna [presence] in specimen by naa with probe detection
97917-9,oopuch vius rna [presen] pecime by na with probe etection
97917-9,oropouche virus rna [resence] inspecimen by naa ithprobe detection
97917-9,oropouche virus rna spec ql naa+probe
97917-9,oropouche virusrna pc ql naa+robe
97917-9,orpuchvirus rna spec ql amplif naa+probe
97917-9,oropouche virus rna naa+probe ql (specimen)
97917-9,ropouche viru rna naa+probe ql (pecimen)
97917-9,oropouche virus naa+probe rna ql (specimen)
77758-1,7-hydroxyquetiapine cutoff [mass/volume] in urine for confirmatory method
77758-1,7-hydroxyquetiapine urine [mass/volume] in cutoff for confirmatory method
77758-1,[mass/volume] cutoff 7-hydroxyquetiapine in urine for confirmatory method
77758-1,7oh-quetiapine cto ur cfm-mcnc
77758-1,7oh-quetiapine ur cto cfcnc
77758-1,rcfm-mcnc cto 7oh-uetiaine
77758-1,7-hydroxyquetiapine cutoff confirm (u) [mass/vol]
77758-1,7-hydroxyquetiapine cutoff (u) confirm [mass/vol]
77758-1,quan 7-hydroxyqtiapne cuff confi (u) [mass/vl
89744-7,response plan [cdc emergency operations centers]
89744-7,response plan [cdc operations emergency centers]
89744-7,response plan [cdc emergency operations point in time centers]
14097-0,antimony [mass/time] in 24 hour urine
14097-0,antimon[mass/ime] in 24 hor urn rin
14097-0,antimony [mass/time] in 24 hour urine
14097-0,antimony 24h ur-mrate
14097-0,niony quant 24h ur-mrate
14097-0,24h antimony ur-mrate
14097-0,antimony (24h u) [mass/time]
14097-0,antimony (24h [mass/time] u)
14097-0,antimony (24h u[mass/tie]
3941-2,phendimetrazine [mass/time] in 24 hour urine
3941-2,phendimetrazine [mass/time] urine quan 24 hour in
3941-2,[mass/time] phendimetrazine in24 hour rine
3941-2,phendimetrazine 24h ur-mrate
3941-2,24h phendimetrazine ur-mrate
3941-2,phendimetrazine 24h ur-mrate
3941-2,phendimetrazine (24h u) [mass/time]
3941-2,phendimetrazine u) (24h [mass/time]
3941-2,(24h phendimetrazine u) [mass/time]
27278-1,phosphoethanolamine [moles/volume] in amniotic fluid
27278-1,phosphoethanolamine [moles/volume] in fluid amniotic
27278-1,posphoethanolamine [moles/volume] in amniotic fluid
27278-1,petn amn-scnc
27278-1,amn-scnc petn
27278-1,amn-scnc petn amn
27278-1,phosphoethanolamine (amn fld) [moles/vol]
27278-1,phosphoethanolamine [moles/vol] fld) (amn
27278-1,quantitative phosphoethanolamine (amn fld) [moles/vol]
22792-6,aleutian disease virus ab [presence] in serum by counterimmunoelectrophoresis (cie)
22792-6,aleutian ab autoantibodies virus disease [presence] in serum by counterimmunoelectrophoresis (cie)
22792-6,alian disease viru ab [presence] in srum by counterimmunoelectrophoresi (cie)
22792-6,adv ab ser ql cie
22792-6,cie ab ser ql adv screen
22792-6,qlcie autoantibodies ab ser dv
22792-6,aleutian disease virus ab cie ql (s)
22792-6,alutian disease virus cieql(s) b
22792-6,aleuta disease ab virus ie ql(s)
42501-7,glutamate decarboxylase 65 ab [units/volume] in cerebral spinal fluid
42501-7,in decarboxylase 65 ab [units/volume] glutamate cerebral autoimmune myelopathy spinal fluid
42501-7,glutamate decarboxylase 65 ab [units/volume] spinal cerebral in fluid
42501-7,gad65 ab csf-acnc
42501-7,ab ad5 spinal flu csf-acnc
42501-7,gad65 ab csf-acnc arbitrary concentration
42501-7,glutamate decarboxylase 65 ab qn (csf)
42501-7,glutamate (csf) 65 ab qn decarboxylase
42501-7,glutamate decarboxylase 65 ab qn glu (csf)
89670-4,promis cancer item bank - emotional distress - depression - version 1.0
89670-4,promis cancer item panel bank - emotional distress version depression - - 1.0
89670-4,promis random canceritem bank - eotioal ditress - deression -version 1.0
34147-9,treponema pallidum igg+igm ab [presence] in serum
34147-9,tepnea palldum igg+igm bprsence] in seu
34147-9,allidm trepnema gigm ab [presene] in seum
34147-9,t pallidum igg+igm ser ql
34147-9,t pallidum ser igg+igm presence
34147-9,t ser l igg+igm ser pallidu
34147-9,t. pallidum igg+igm ql (s)
34147-9,t. (s) ql pallidumigg+igm immunoglobulin m
34147-9,t. pallidum igg+igm ql pr (s)
37993-3,dna double strand ab [mass/volume] in serum by radioimmunoassay (ria)
37993-3,strand double dna qnt ab [mass/volume] in serum by radioimmunoassay (ria)
37993-3,dna double strand ab [mass/volume] in serum by radioimmunoassay (ria) serum
37993-3,dsdna ab ser ria-mcnc
37993-3,dsdna ab serum ria-mcnc dsdna
37993-3,ab dsdna ser ria-mcnc
37993-3,dna double strand ab ria (s) [mass/vol]
37993-3,dna double (s) ab ria strand [mass/vol]
37993-3,ria double strand ab dna ) quantitative mass/vol]
50100-7,beta hydroxybutyrate/acetoacetate [molar ratio] in cerebral spinal fluid
50100-7,ba hdrxytyrate/acetoacetate [olar ratio] in cerebal spnal fluid
50100-7,bea ydoxybutyrte/acetoacetat [moar ratio] in cerebral spinal fluid
50100-7,b-oh-butyr/acetoacet csf-srto
50100-7,csf-srto b-oh-butyr/acetoacet
50100-7,boh-butyactocetcsf-rto
50100-7,beta hydroxybutyrate/acetoacetate (csf) [molar ratio]
50100-7,bta hydroxbutyrate/ctoaetate(sf) [molarraio]
50100-7,beta hydroxybutyte/aetoacetate (csf) molar ratio]
32177-8,granulocytes/leukocytes in vaginal fluid
32177-8,granulocytes/leukocytes in gran vaginal fluid
32177-8,vaginal in granulocytes/leukocytes fluid
32177-8,granulocytes nfr vag
32177-8,nfr granucytes vag leukocyte
32177-8,vag fld granulocytesnfrvag
32177-8,granulocytes/leukocytes (vag fld)
32177-8,granuloctes/leucytes (va point in time fld)
32177-8,lkcs granulocytes/leukocytes (vag fld)
54486-6,glucose [mass/volume] in water
54486-6,in [mas/volme] gucose ater
54486-6,glucose in [mass/volume] water
54486-6,glucose wat-mcnc
54486-6,qnt glucosewt-mcnc
54486-6,wat-mcnc glucose
54486-6,glucose (water) [mass/vol]
54486-6,gucose (water)[mas/vol]
54486-6,gluose (water) point in time mass/vol]
104879-2,hematocrit [volume fraction] of blood --2.5 hours post dose glucose
104879-2,hematocrit [volume fraction] of blood hours --2.5 post dose glucose
104879-2,heatocrit [volumefraction] of bood --.5 hours postdose gucose
104879-2,hct 2.5h p glc vfr bld
104879-2,hct glc p 2.5h vfr bld
104879-2,hc 2.5h  glc fr blood
104879-2,hematocrit 2.5 hr post dose glucose (bld) [volume fraction]
104879-2,hematocrit 2.5 hr post (bld) glucose dose [volume fraction]
104879-2,hematocrit 2.5 hr post dos glcose glucoseur (bld) [volue fraction]
19687-3,psilocybin [presence] in urine by confirmatory method
19687-3,psilocybin cnfr urine n [rsence] by confirmatoy method
19687-3,psilocybin [presence] in urine by confirmatory method
19687-3,psilocybin ur ql cfm
19687-3,psilocybin ur ql cfm ur
19687-3,cfm ur presence psilocybin
19687-3,psilocybin confirm ql (u)
19687-3,psilocybin confirm ql (u) gcms
19687-3,qual psilocybin confirm ql (u)
3487-6,clobazam [mass/volume] in serum or plasma
3487-6,clobazam [mass/volue] serpl in serpl
3487-6,clobazam [mass/volume] ser in or ser or plasma plasma
3487-6,clobazam serpl-mcnc
3487-6,serpl-mcnc clobazam
3487-6,lobazam serpl-mcnc serpl
3487-6,clobazam [mass/vol]
3487-6,[mass/vol] clobazam
3487-6,[mass/vol] clobazam urbadan
58246-0,deprecated phenx measure - peripheral arterial disease
58246-0,epectephnx measure panl artrl eriphera - diseae
58246-0,deprecated phenx measure dz - peripheral arterial disease
47428-8,aspergillus niger h ab [presence] in serum
47428-8,aspergilus infectiousdisease niger h ab [presnce] in serum
47428-8,aspergillus niger h a [presence] in ser
47428-8,a niger h ab ser ql
47428-8,a niger ser ab h ql
47428-8,a niger aspergillin h ab ser ql
47428-8,a. niger h ab ql (s)
47428-8,ab nigr presence h a. presence (s)
47428-8,a. niger h ab presence (s)
59689-0,hydroxyethylflurazepam [mass/mass] in tissue by confirmatory method
59689-0,"tissuebyconfirmatory tissue, unspecified [massmass] in drxyethylurzepam metod"
59689-0,hydroxyethylflurazepam [mass/mass] method tissue by confirmatory in
59689-0,oh-ethylfluraz tiss cfm-mcnt
59689-0,cnfrm oh-etylfluaz cfm-mcnt tss
59689-0,oh-ethylfluraz tiss confirmation cfm-mcnt
59689-0,hydroxyethylflurazepam confirm (tiss) [mass/mass]
59689-0,hdroyetylflurazeam (tis) confirm mass/ass]
59689-0,hydroxyethylflurazepam confirm (iss) [mass/as]
11236-7,gemfibrozil [mass/volume] in serum or plasma
11236-7,[mass/volume] gemfibrozil in serum or drug/toxicology plasma
11236-7,[mass/volume] gemfibrozil in ser or plasma
11236-7,gemfibrozil serpl-mcnc
11236-7,serpl-mcnc lopid gemfibrozil
11236-7,serpl-mnc gemfibrozi random
11236-7,gemfibrozil [mass/vol]
11236-7,[mas/vl] gemfibrozil
11236-7,mass/vol] gemfibrozil drug/toxicology
14032-7,ciprofloxacin [mass/volume] in serum or plasma --trough
14032-7,ciprfloxacin [mass/volume] n serum or c81 lasma --troug
14032-7,ciprofloxacin [mass/volume] in plasma or serum --trough
14032-7,ciprofloxacin trough serpl-mcnc
14032-7,ciprofloxacin trough level serum or plasma-mcnc
14032-7,c81 ciprofloxacin trough serpl-mcnc
14032-7,ciprofloxacin trough [mass/vol]
14032-7,ciprofloxin trough ciprofloxacin [mass/vol]
14032-7,touh ciprofloxaci [mas/vol]
54105-2,hemoglobin pattern in dbs by isoelectric focusing
54105-2,hemoglobin pattern in dbs by isoelectric focusing
54105-2,hemoglobin focusing in dbs by whole blood isoelectric pattern
54105-2,hgb fract dbs ief
54105-2,hgb fract hgb dbs ief
54105-2,hgb ct dbsief
54105-2,hemoglobin pattern isoelectric focusing nom (dbs)
54105-2,hemoglobin pattern isoelectric focusing nom finding (dbs)
54105-2,hemoglobi pattern isoelectric pt focusing om (dbs)
43852-3,influenza virus b iga ab [presence] in serum
43852-3,inflenzavirus b iga ab [presence] in sem
43852-3,infenza virus b iga [presnce] ab in ser
43852-3,flubv iga ser ql
43852-3,ql igser luv
43852-3,iga abs l s ql
43852-3,flubv iga ql (s)
43852-3,abs flubviga ql (s)
43852-3,(s iga ql flubv
20685-4,anaplasma marginale ab [presence] in serum by card agglutination
20685-4,anaplasma marginale ab [presence] card serum by in agglutination
20685-4,anaplasa marginae ab [presnce inserum y card agluinatn
20685-4,a marginale ab ser ql card aggl
20685-4,a marginale ab serum l qualitative card aggl
20685-4,antibodies a arginale ab se qlcard aggl
20685-4,a. marginale ab aggl.card ql (s)
20685-4,a. mrginale ab aggl.card presence (s)
20685-4,. anti marinaeab (s) agglcrdql
62659-8,deprecated phenx measure - hormonal therapy
62659-8,deprecated phenx measure - hormonal pnl therapy
62659-8,deprecated phenx measue - hormonaltherapy random
26063-8,european tick borne encephalitis virus igm ab [units/volume] in serum
26063-8,european tick borne encephalitis virus igm ab tbev ab [units/volume] in ser
26063-8,european tick encephalitis borne virus igm ab [units/volume] in serum
26063-8,tbev igm ser-acnc
26063-8,abs ser-acnc tbevigm
26063-8,tbevig antibody ser-acnc
26063-8,european tick borne encephalitis virus igm qn (s)
26063-8,european aby tick borne encephalitis virus igm qn (s)
26063-8,eurpean tick gm encepalis irus bone qn immune globulin m (s)
40688-4,megakaryocytes [presence] in bone marrow by microscopy
40688-4,[presence] megakaryocytes in bone marrow by microscopy
40688-4,megakaryocytes [presec] by bone marrow in microscopy
40688-4,megakaryocytes mar ql micro
40688-4,megakaryocytes micro ql ordinal mar
40688-4,megakaryocytes mar micro ql
40688-4,megakaryocytes microscopy ql (bm)
40688-4,(bm) random microscopy presence megakaryocytes
40688-4,(bm) microscp presence megkaryocytes
26680-9,aspartate [moles/volume] in urine
26680-9,parat urine in ur [moles/volme]
26680-9,aspartate [moles/volume] in urine
26680-9,aspartate ur-scnc
26680-9,aspartate ur-scnc
26680-9,substance concentration aspartate ur-scnc
26680-9,aspartate (u) [moles/vol]
26680-9,aspartate [moles/vol] qnt (u)
26680-9,(u) aspatate point in time [moles/vol]
31642-2,deprecated streptococcus pneumoniae 3 igg ab [units/volume] in serum --2nd specimen
31642-2,deprecated abs streptococcus pneumoniae 3 igg ab [units/volume] in serum --2nd specimen
31642-2,deprecated ab pneumoniae 3 igg streptococcus [units/volume] in ser --2nd specimen
31642-2,deprecated s pneum3 igg sp2 ser-acnc
31642-2,deprecated s sp2 igg pneum3 ser-acnc
31642-2,drecated s pneum3 igg p2 er-acnc
31642-2,s. pneumoniae 3 igg spec 2 qn (s)
31642-2,s. pneumoniae 3 igg spec (s) qn strept 2
31642-2,2 pneumoniae 3 aby igg spec s. qn (s)
82506-7,oligosaccharides pattern [interpretation] in fibroblast by screen method narrative
82506-7,oligosaccharides pattern [interpretation] scr in fibroblast by narrative method screen
82506-7,oligosaccharides pattern [interpretation] in fibroblast by screen method narrative
82506-7,oligosaccharide pattern fib scn-imp
82506-7,oligosaccharide pattrn ib scn-imp
82506-7,oligosaccharide scn pattern fib scn-imp
82506-7,oligosaccharides pattern screen nar (fibroblast) [interp]
82506-7,oligosaccharides pattern screen nar (fibroblast) impression/interpretation of study [interp]
82506-7,oigosaccharies patern screen narrative nar (fibroblast) [interp]
105810-6,bacterial macrolide resistance erma gene [cycle threshold #] in positive blood culture by naa with probe detection
105810-6,bacterial macrolide resistance erma gene [cycle threshold #] in positive bld culture by naa with probe detection quan
105810-6,bacterial macrolide resistance erma gene [cycle threshold #] ligation-activated transcription in positive bld culture naa by with probe detection
105810-6,bac macrolide res erma ct bld +
105810-6,bac macrolderes ligation-activated transcription erma ct bd +
105810-6,bac acrolide rs rmact bld +
105810-6,bacterial macrolide resistance erma gene naa+probe (pos bld culture) [threshnum]
105810-6,dna nucleic acid probe bacterial marlide reistane ermagene naa+proe (pos bld cultur) [threshnum]
105810-6,bactera acrolie resistance ema gene naa+robe(pos [theshnum] cultur) ld quant
49375-9,hepatitis c virus rna [log #/volume] (viral load) in tissue by naa with probe detection
49375-9,hepatitis c virus rna [log #/volume] (viral load) in tissue by naa with probe detection
49375-9,hepatitis c virus rna [log (viral #/volume] load) in tissue by naa with probe detection
49375-9,hcv rna tiss naa+probe-log#
49375-9,rna hepatis hcv tiss naa+probe-log#
49375-9,naa+probe-l# rna tiss hc
49375-9,hcv rna naa+probe (tiss) [log #/vol]
49375-9,(tiss) rna naa+probe hcv [log #/vol] quantitative
49375-9,hcv rna naa+probe strand displacement amplification [log (tiss) #/vol]
21545-9,sulfatide igg ab [titer] in cerebral spinal fluid
21545-9,fluid igg ab [titer]in cerebral spinal slfati
21545-9,sulfatide igg ab [titer] in autoantibodies fluid spinal cerebral
21545-9,sulfatide igg titr csf
21545-9,csf igg titr sulfatide
21545-9,sulfatide igg titr cerebrospinal fluid spinal fl
21545-9,sulfatide igg (csf) [titer]
21545-9,(csf) suatideigg titer
21545-9,sulfatide igg [titer] (csf)
49158-9,rickettsia akari igg ab [titer] in body fluid
49158-9,rickettsia akari igg ab [titer] in body fluid
49158-9,rickettsia fluid igg ab [tier]in ricket body akari
49158-9,r akari igg titr fld
49158-9,r akari fld titr igg
49158-9,r akari igg titr fld
49158-9,r. akari igg (body fld) [titer]
49158-9,fld) akari igg (body r. [titer]
49158-9,r. immunoglobulin g akari igg fld) (body [titer]
16429-3,barbiturates [presence] in urine by confirmatory method
16429-3,barbiturates potentialforabuse [presence] in urine confirmatory by method
16429-3,method [presence] i urine by addiction cnfirmatry babitrate
16429-3,barbiturates ur ql cfm
16429-3,barbiturates ur cnfr presence cfm
16429-3,barbiturates ua ur ql cfm
16429-3,barbiturates confirm ql (u)
16429-3,barbiturates confir ql ordinal (u)
16429-3,barbiturates ql confirm (u)
92959-6,pseudomonas aeruginosa dna [ncncrange] in sputum by naa with non-probe detection
92959-6,pseudomonas aeruginosa naa [ncncrange] in sputum by dna with lat non-probe detection
92959-6,pseudoonas aeruginosa dna [cncrane] 3sr sr naa spuum by in with non-pobe detection
92959-6,p aeruginosa dna spt naa+non-prb-ncncrng
92959-6,p naa+non-prb-ncncrng dna smqn spt aeruginosa
92959-6,p naa+non-prb-ncncrng sputum dna spt aeruginosa
92959-6,p. aeruginosa dna naa+non-probe (sput) [ncncrange]
92959-6,p aeruginosa [ncnrange sda naa+non-pbe(sput) da
92959-6,p. aeruginosa dna probe dna naa+non-probe (sput) [ncncrange]
20546-8,methylenedioxyamphetamine cutoff [mass/volume] in urine for confirmatory method
20546-8,methyenedioxyampheamine ctff [mass/olum]in urine fo conirmatry methd
20546-8,methylenedioxyamphetamine cutoff [mass/volume] for urine in confirmatory method
20546-8,mda cto ur cfm-mcnc
20546-8,quant mda cto cfm-mcnc ur
20546-8,quantitative mda cto u cf-mnc
20546-8,methylenedioxyamphetamine cutoff confirm (u) [mass/vol]
20546-8,methylenedioxyamphetamine [mass/vol] confirm (u) cutoff mda
20546-8,confrm(u) ua cutof methyleneoxamhetamine [mas/vol]
96764-6,sars-cov-2 (covid-19) e gene [cycle threshold #] in respiratory system specimen by naa with probe detection
96764-6,sarscov-2 e (ovid-19) gen cycle thesold # in respirtoryystem specimen by aa with probe etection
96764-6,sarscov-2 2019 novel coronavirus (covi-19)e gene[cycle threshold #] in rspiratorysystem specmen by naa with prob detction
96764-6,sars-cov-2 e gene ct resp qn naa+probe
96764-6,sars-cov-2 e gene ct resp qn naa+probe
96764-6,sars-cov-2 e gene ct lcr resp qn naa+probe
96764-6,sars-cov-2 (covid-19) e gene naa+probe (respiratory system specimen) [threshnum]
96764-6,sacov (cvd-19) egene naa+robe (respirary sytem [heshnum] specimen)
96764-6,ystm (covid-19 egene na+probe (repraory sars-cov-2 specn) [threshnum]
17437-5,phenolphthalein [mass/volume] in urine
17437-5,phenolphthalein urine in [mass/volume]
17437-5,phenolphthalin in [mass/volume] rine
17437-5,phenolphthalein ur-mcnc
17437-5,phenolphthalein ur-mcnc
17437-5,ur-mcnc phenolpthalin
17437-5,phenolphthalein (u) [mass/vol]
17437-5,[mss/ol] level (u) phenolphthalen
17437-5,phnophthaein level (u) [mass/vo]
35096-7,ob ultrasound panel
35096-7,ultrasound ob panel pan
35096-7,ob ultrasound panel
35096-7,ob us pnl
35096-7,s ob pnl
35096-7,b us pnl gynecology
8738-7,left ventricular cardiac output by mr
8738-7,left ventricular by output cardiac mr
8738-7,left cardiac ventricular output by mr
8738-7,lv output mr
8738-7,output quantitative lv mr
8738-7,lv hrt ventr mr output
32698-3,magnesium ionized [mass/volume] in serum or plasma
32698-3,plasma magesiuionized [mass/volume in plsm r serum
32698-3,magnesium ionized [mass/volume] in serum or plasma plasma
32698-3,mg ionized serpl-mcnc
32698-3,g serplmcnc nized
32698-3,mg ioized serpl-mcnc serplas
32698-3,magnesium ionized [mass/vol]
32698-3,magnesium ionized [mass/vol]
32698-3,magnesium [mass/vol] qnt ionized
93692-2,nonalcoholic steatohepatitis score in serum or plasma
93692-2,nonalcoholic steatohepatitis score in serum or plasma
93692-2,score steatohepatitis nonalcoholic in serpl
93692-2,nash score serpl
93692-2,nash scoe srpl
93692-2,serpl score nash
93692-2,nash score [score]
93692-2,nash score serpl [score]
93692-2,nash score [score]
82354-2,human papilloma virus 16 and 18+45 e6+e7 mrna [identifier] in cervix by naa with probe detection
82354-2,human papilloma virus1 and 18+45 e6+7mrna [identifer] n cervix by naa with robe detection
82354-2,human papillomavirus 16 ad 18+456+e7 mrna [idenifier] in naa by cervi it hpv 16 & 18+45 pobedetction
82354-2,hpv16+18+45 e6+e7mrna cvx naa+probe
82354-2,hpv16+18+45 e6+e7mrna cvx naa+probe dna probe
82354-2,hpv16+18+45 cvx e6+e7mrna naa+probe
82354-2,hpv 16 and 18+45 e6+e7 mrna naa+probe nom (cvx)
82354-2,hpv 16 and 18+45 e6e7 mrn aa+probe nom (cvx)
82354-2,hpv 16 and 18+45 e6+e7 mrna (cvx) nom naa+probe
49526-7,influenza virus a h5 rna [presence] in isolate by naa with probe detection
49526-7,influenza virus a in 3 self-sustaining sequence replication rna [presence] h5 isolate by naa with probe detection
49526-7,influenza virus a h5 rna [presence] pt in isolate by naa with probe detection
49526-7,fluav h5 rna islt ql naa+probe
49526-7,fluv h5 na islt ql naa+pobe
49526-7,flav h5 rna isltql na+robe
49526-7,fluav h5 rna naa+probe ql (isol)
49526-7,fluav h5 rna naa+probe presence (isol)
49526-7,fluav h5 probe amp rna naa+probe ql (isol)
52960-2,clonidine [presence] in urine
52960-2,lonidine [presnce] in urine
52960-2,clonidine urine catapres in [presence]
52960-2,clonidine ur ql
52960-2,cndine ur presence
52960-2,clonidine presence ur screen
52960-2,clonidine ql (u)
52960-2,(u) ql clonidine
52960-2,clonidine (u) presence
55929-4,isoleucine [moles/mass] in hair
55929-4,isoleucine [moles/mass] in hair
55929-4,isoleucine in [moles/mass] hair
55929-4,isoleucine hair-scnt
55929-4,chemistry isoleucine hair-scnt
55929-4,isoleucine hair-scnt
55929-4,isoleucine (hair) [moles/mass]
55929-4,isoleucine chemistry (hair)[mles/mas]
55929-4,isoleuine mols/mass] (air)
5359-5,somatotropin ab [units/volume] in serum or plasma by radioimmunoassay (ria)
5359-5,somatotropin ab [units/volume] in serpl by radioimmunoassay (ria)
5359-5,somatotropin ab [units/volume] in ser or plasma by radioimmunoassay (ria)
5359-5,gh ab serpl ria-acnc
5359-5,radioimmunoassay gh ab serpl ria-acnc
5359-5,aby gh serpl ab ria-acnc
5359-5,somatotropin ab ria qn
5359-5,ria b soatotropn qn serpl
5359-5,somatotropin ab ria qn
55402-2,west nile virus igg and igm panel - serum
55402-2,west nile vrus igg ad igm pael - serm
55402-2,west nile point in time virus igg and igm panel - serum
55402-2,wnv igg+igm pnl ser
55402-2,wnv igg+igm ser pnl
55402-2,wnv igg+igm pnl ser
55402-2,west nile virus igg and igm panel (s)
55402-2,west wnv nile virus igg and igm panel (s)
55402-2,wes nile vrus iggand im panel (s)
58359-1,buprenorphine+norbuprenorphine [presence] in urine by screen method
58359-1,buprenex brenophine+nrbuprnorpine [presence] in by urine screen method
58359-1,buprenorphine+norbuprenorphine by in urine [presence] screen method
58359-1,buprenorphine+nor ur ql scn
58359-1,subutex ql ur buprenorphine+nor scn
58359-1,buprenorphine+nor scn presence ur
58359-1,buprenorphine+norbuprenorphine screen ql (u)
58359-1,scn buprenorphine+norbuprenorphine screen ql (u)
58359-1,buprenorphine+norbuprenorphine screen presence scn (u)
24263-6,coxsackievirus b4 ab [titer] in serum --1st specimen
24263-6,coxsackievirus b4 coxsackie ab [titer] in serum --1st specimen
24263-6,coxsackievirus b4 ab [tter] ttr n serm --1st specimen
24263-6,cv b4 ab sp1 titr ser
24263-6,cv b4absp1 ser ti
24263-6,cv id b ab sp1 titr ser
24263-6,coxsackievirus b4 ab spec 1 (s) [titer]
24263-6,random (s) b4 ab spec 1 coxsackievirus [titer]
24263-6,coxsackievirus b4 (s) spec 1 ab [titer]
8160-4,beryllium [mass/volume] in saliva (oral fluid)
8160-4,beryllium [mass/volume] in saliva (oral drug/toxicology fluid)
8160-4,saliva [mass/volume] in beryllium (oral fluid)
8160-4,beryllium sal-mcnc
8160-4,sl-mcnc beryllium
8160-4,beryllium sal-mcnc
8160-4,beryllium (sal) [mass/vol]
8160-4,mass/vol] beryllium(sa) qnt
8160-4,beryllium (sal) [mass/vol] berylliosis
72818-8,am-2201 4-hydroxypentyl (synthetic cannabinoid metabolite)/creatinine [mass ratio] in urine
72818-8,atio] 4-hydroxypentyl (sythetic canabinoid metabolite)/creainine [mas am-2201 in urin
72818-8,a-2201 etalite)/ceinin (yntetccannabinoid 4-hydroxypeny [mass atio] in urne qnt
72818-8,am-2201 4oh-pentyl/creat ur
72818-8,crea 4oh-pentyl/creat a-201 ur
72818-8,am-201 ur 4oh-entyl/crat
72818-8,am-2201 4-hydroxypentyl/creatinine (u) [mass ratio]
72818-8,quan m-2201 4-hydroxypentyl/ceatinine u) [mss raio]
72818-8,am-2201 4-hydroxypentyl/creatinine (u) [mass ratio]
87634-2,aldicarb [mass/mass] in specimen
87634-2,aldicarb [mass/mass] in specimen
87634-2,in [mas/mass alicarb spcien
87634-2,aldicarb spec-mcnt
87634-2,unspecified spec-mcnt aldicarb
87634-2,aldicarbspec-mc
87634-2,aldicarb (specimen) [mass/mass]
87634-2,adicarb mass/mass] (specie)
87634-2,aldicarb (specimen) [mass/mass] unspecified
69849-8,2-hydroxyisocaproate [moles/volume] in serum or plasma
69849-8,plasma [moles/volume] in serum or 2-hydroxyisocaproate
69849-8,serp -hdroxyisocarote [moles/volume] in serum orplasma
69849-8,2oh-isocaproate serpl-scnc
69849-8,serpl-scnc plsm 2oh-isocaprate
69849-8,serpl-scnc 2oh-isocaproate
69849-8,2-hydroxyisocaproate [moles/vol]
69849-8,[moles/vol] 2-hydroxyisocaproate
69849-8,2-hydroxyisocapoate pl [moles/vol]
56771-9,eosinophils/leukocytes in bronchial specimen by flow cytometry (fc)
56771-9,number fraction eosinophils/leukocytes in bronchial specimen by flow cytometry (fc)
56771-9,eosinophils/leukocytes in bronchial specimen by flow (fc) cytometry
56771-9,eosinophil nfr bronch fc
56771-9,eosinophil bronch nfr fc
56771-9,quantitative eosinophil nfr bronch fc
56771-9,eosinophils/leukocytes fc (bronch spec)
56771-9,eosinophils/leukocytes fc eosinophil (bronch spec)
56771-9,eosinophils/leukocytes fc (bronch qnt spec)
95233-3,microalbumin/creatinine qualitative in urine by test strip
95233-3,microalbumin/creatinine qual dip stick in urine by test strip
95233-3,strip qualitative in urine crea by test microalbumin/creatinine
95233-3,microalbumin/creat ur ql test str
95233-3,microalbumin/creat ur test presence str
95233-3,str urql test microalumin/crat screen
95233-3,albumin/creatinine test strip detection limit <= 20 mg/l ql (u)
95233-3,albumin/creatinine (u) strip detection limit <= 20 mg/l ql test
95233-3,albumi/creatinine test stri detection m/l <= 20 limit presence (u)
101364-8,francisella tularensis dna [presence] in blood by naa with non-probe detection
101364-8,francisella tularensis dna [presence] qual in blood by naa with non-probe detection
101364-8,franisell ularensis dna [presence] in bld by na with nn-probe deection
101364-8,f tular dna bld ql naa+non-probe
101364-8,f probe amp ldl dna ular naa+n-probe
101364-8, tulardna blood ql aa+npobe
101364-8,f. tularensis dna naa+non-probe ql (bld)
101364-8,f. tularensis dna naa+non-probe ql (bld)
101364-8,tularenis f. na naa+non-probe ql (bd)
33280-9,amphetamine+methamphetamine [mass/volume] in urine by screen method
33280-9,mhetamin+methaphtamine [mss/volume]in urine by creen metod
33280-9,amphetami+methamphetamine[mass/vole] in urine by screen method
33280-9,amphet+methamphet ur scn-mcnc
33280-9,amphet+methamphet amphet+methampht scn-mcnc r
33280-9,amphet amphet+methamphet ur scn-mcnc
33280-9,amphetamine+methamphetamine screen (u) [mass/vol]
33280-9,mphetamine+methampetamine scee (u) [mass/vol]
33280-9,amphetamine+methamphetamine screen (u) [mass/vol] quant
62628-3,phenx - respiratory - pulse oximetry - exercise protocol 091001
62628-3,phenx - respiratory - pulse oximetry - exercise protocol 091001
62628-3,plse rspiratory - phenx oximetry-exercise proool 091001
62628-3,resp pulse ox exercise proto
62628-3,resp pulse ox exercise panl proto
62628-3,rsp random pulse ox eercise proto
23016-9,coxiella burnetii [presence] in placenta by light microscopy
23016-9,coxiella burnetii [presence] in screen placenta microscopy light by
23016-9,microscopy burnetii [presence] in placenta by light coxiella
23016-9,c burnet placenta ql micro
23016-9,burnet c placenta ql micro
23016-9,c unet pacena l micro
23016-9,c. burnetii lm ql (placenta)
23016-9,c. bunetilm l (acet
23016-9,c. ql lm burnti (lacenta)
29804-2,powassan virus igg ab [presence] in cerebral spinal fluid by immunofluorescence
29804-2,virus powassan igg ab [presence] in cerebral spinal fluid by immunofluorescence
29804-2,powassan virus igg ab [presence] in cerebral spinal immunoflour fluid by immunofluorescence
29804-2,powv igg csf ql if
29804-2,powv igg cf ql if
29804-2,ifa powv igg csf presence if
29804-2,powassan virus igg if ql (csf)
29804-2,powasan point in time virus if igg ql (cerebrospinal fluid)
29804-2,powassan random virus igg if ql (cs)
66147-0,granulocytes/leukocytes in pleural fluid from fetus by manual count
66147-0,granulocytes/leukocytes in pleural fluid from fetus by manual count
66147-0,granulocyes/leukcytes gran in pleuralfluid fom fetus by manual coun
66147-0,granulocytes nfr plr fetus manual
66147-0,granulocytes nfr plr fetus hematology/cell counts manual
66147-0,fetus nfr plr granulocyte manual
66147-0,granulocytes/leukocytes manual cnt (pleur fld fetus)
66147-0,granulocytes/leukocytes manual (pleur cnt fld fetus)
66147-0,granulocytes/leukocytes manual fetus) (pleur fld cnt
76791-3,promis item bank - instrumental support - version 2.0
76791-3,item promis bank - instrumental support - pnl version 2.0
76791-3,promis item bank - instrumental support - version 2.0
29764-8,iron [moles/volume] in body fluid
29764-8,body moles/volum]in iro fluid
29764-8,iron [moes/volume] in body fluid
29764-8,iron fld-scnc
29764-8,fscnc body fluid ron
29764-8,iron fld fd-cnc
29764-8,iron (body fld) [moles/vol]
29764-8,iron fe body fld [oles/vl]
29764-8,[moles/vol] (body fld) iron
625-4,bacteria identified in stool by culture
625-4,bacteria identified ool in by cutur
625-4,by identified in stool bacteria culture
625-4,bacteria stl cult
625-4,bacteria cult stl
625-4,stl stool = fecal bacteria cult
625-4,bacteria identified cx nom (stl)
625-4,baceria intfied cx (stl) nom
625-4,bacteria identified cx nom cultures (stl)
73333-7,imipenem+cilastatin induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73333-7,imipenm+cilastatin induced platelet ig low [pesence n serum imp+cs or plasaby ab cytomer (f)
73333-7,imipenem+cilastatin induced platelet igg ab [presence] in serum or flow by plasma cytometry ind plt igg (fc)
73333-7,imp+cs ind plt igg serpl ql fc
73333-7,fc ind plt igg serpl ql imp+cs
73333-7,imp+cs ind plt fc serpl ql igg
73333-7,imipenem+cilastatin induced platelet igg fc ql
73333-7,iipenem+cilastatin induced platele igg fc ql
73333-7,fc iipeem+cilasain iduced plateletigg fc ql
88198-7,middle east respiratory syndrome coronavirus (mers-cov) rna [presence] in cornea or conjunctiva by naa with probe detection
88198-7,middle east respiratory syndrome coronavirus (mers-cov) rna [presence] in cornea or mers-cov rna conjunctiva by naa with probe detection
88198-7,middle ea 3sr sr respiratory syndome coronairu (mes-cov) rna [presence]in crnea or conjutiva b naa withrobe deection
88198-7,mers-cov rna corn/cnjt ql naa+probe
88198-7,ers-cv na presence corn/cnjt presence naa+proe
88198-7,amplified mers-cov rna corn/cnjt ql naa+probe
88198-7,mers-cov rna naa+probe ql (corn/cnjt)
88198-7,mers-cov ra naaprobe ql (corn/cnt
88198-7,ql rna naa+probe mers-cov (corn/cnjt)
33956-4,cyclosporine.polyclonal [mass/volume] in blood
33956-4,[massvlume]in cylosporine.polyclnal gengraf blood
33956-4,in quant [mass/volume] cyclosprine.polycnal blod
33956-4,cyclosporine polycl bld-mcnc
33956-4,mass concentration cyclosporine polycl bld-mcnc
33956-4,gengraf cyclosporinepolycl bld-mcnc
33956-4,cyclosporine.polyclonal (bld) [mass/vol]
33956-4,(bld) cyclosporie.plylonal ma/vol] whole blood
33956-4,ycloprine.olyclnal(ld)[massvol]
74445-8,porphyrin fractions panel [moles/mass] - stool
74445-8,porphyrin fractions [moles/mass] panel fractionation - stool
74445-8,porphyrin fractions panel stool - [moles/mass] stool = fecal
74445-8,porphyrin fract pnl stl-scnt
74445-8,fct porphyrin nl stlsnt
74445-8,porphyrin fract pnl stl-scnt pan
74445-8,porphyrin fractions panel (stl) [moles/mass]
74445-8,(stl) fractions panel fract porphyrin [moles/mass]
74445-8,porphyrin [moles/mass] panel (stl) chemistry fractions
54009-6,lysosome ab [presence] in serum by immunofluorescence
54009-6,ab soome [presence] in ser by immunofluorescence
54009-6,lysosom ab [resence] n serumby immunoflorescence
54009-6,lysosome ab ser ql if
54009-6,lysosome ab autoantibodies serum ql if
54009-6,ysosome ab serum ql if
54009-6,lysosome ab if ql (s)
54009-6,lysosome ab (s) ql if immunofluor
54009-6,if ab lysosome presence (s)
3775-4,methadone [mass/time] in 24 hour urine
3775-4,ethadone [mas/time in 24 hour dolophine urie
3775-4,methadone [mass/time] urine 24 hour in
3775-4,methadone 24h ur-mrate
3775-4,illicit ur-mrat 24h methdone
3775-4,ethdone 24h ur-mate
3775-4,methadone (24h u) [mass/time]
3775-4,methadone drug/toxicology (24h u) [mass/time]
3775-4,u) ur 24h methadone [mass/time]
56983-0,somatotropin [mass/volume] in serum or plasma --1 hour post resting
56983-0,somatotropin [mass/volume] in ser or plasma --1 hour post endocrine resting
56983-0,somatotropin [mass/volume] in serpl --1 hour post resting
56983-0,gh 1h p resting serpl-mcnc
56983-0,gh 1h p restng sepl-mcc
56983-0,resting mass concentration 1h p gh serpl-cnc
56983-0,somatotropin 1 hr post resting [mass/vol]
56983-0,somatotopin pl 1 hr postresting [mass/vol]
56983-0,saotropin 1 hr resti post [mass/vol]
17635-4,streptococcus pneumoniae danish serotype 18c igg ab [units/volume] in serum
17635-4,streptococcus pneumoniae danish serotype 18iggb [unis/volume in serum
17635-4,sreptooccus pnumniae ish in 18c spn ig ab [units/oume] serotype serum
17635-4,s pneum da 18c igg ser-acnc
17635-4,sr-acnc da 18 ig spneum
17635-4,spneum 18c da igg ser-acnc
17635-4,s. pneumoniae danish type 18c igg qn (s)
17635-4,pneumoniae s. danish type 18c igg qn (s)
17635-4,.pneumoniae danish type 8c ig qn (s)
76072-8,enterovirus d68 rna [presence] in specimen by naa with probe detection
76072-8,entervirus d68 rna [presence] inspcimen b naa with probe deection
76072-8,enterovius d68 naa [presence] ispeimen by a ithprobe etection
76072-8,ev d68 rna spec ql naa+probe
76072-8,ev d68 rna spec nucleic acid sequence based analysis presence naa+probe
76072-8,d68 ev rna spec ql naa+probe naa+probe
76072-8,enterovirus d68 rna naa+probe ql (specimen)
76072-8,enterovirus amplif d68 rna naa+probe ql (specimen)
76072-8,naa+probe enterovirus d68 ql naa+probe rna (specimen)
25729-5,parvovirus b19 igg ab [titer] in serum by immunofluorescence
25729-5,parvovirus b19 igg immunofluoresence in serum by ab[titer]
25729-5,parvovirus b19 igg ab [titer] in ser by immunofluorescence
25729-5,b19v igg titr ser if
25729-5,antibody b19 igg if titrser
25729-5,b19v igg antibodies titr ser if
25729-5,parvovirus b19 igg if (s) [titer]
25729-5,parvovirus b19 igg [titer] (s) if
25729-5,prvoirus b19 igg if s) [titer]
96366-0,naltrexone [presence] in saliva (oral fluid) by confirmatory method
96366-0,naltrexone[presenc i saliva (oral fluid) b confirmatory method
96366-0,potentialforabuse naltrexone saliva in [presence] (oral fluid) by confirmatory method
96366-0,naltrexone sal ql cfm
96366-0,nltexone sa ql fm
96366-0,naltrexone sal cfm ql
96366-0,naltrexone confirm ql (sal)
96366-0,naltrexone confirm presence (sal) conf
96366-0,naltrexone confirm presence vivitrol (sal)
1720-2,adenine phosphoribosyltransferase [enzymatic activity/volume] in red blood cells
1720-2,aenine phosphorbosyltransfese [enzymati activity/volum in red lood cels
1720-2,adenine phosphoribosyltransferase [enzymatic activity/volume] in red blood cells point in time
1720-2,aprt rbc-ccnc
1720-2,rbc-ccnc aprt
1720-2,aprt rbc-ccnc
1720-2,adenine phosphoribosyltransferase (rbc) [catalytic activity/vol]
1720-2,enine erythrocytes osphoriboyltransferae(rbc) activity/vo] catalytic
1720-2,adenine phosphoribosyltransferase (rbc) [catalytic activity/vol]
99270-1,8-aminoclonazolam [mass/volume] in urine by confirmatory method
99270-1,8-aminoclonazolam [mass/volume] in urine by confirmatory method
99270-1,8-aminoclonazolam [mass/volume] in method by confirmatory urine
99270-1,8-aminoclonazolam ur cfm-mcnc
99270-1,8-aminoclonazolam ur cfm-mcnc
99270-1,8-ainoclonazolam cnfr urcfm-mnc
99270-1,8-aminoclonazolam confirm (u) [mass/vol]
99270-1,(u) confirm 8-aminoclonazolam [mass/vol] lc/ms/ms
99270-1,[mass/vol] confirm (u) 8-aminoclonazolam
79638-3,beta alanine and beta aminoisobutyrate and gamma aminobutyrate pattern [interpretation] in serum or plasma narrative
79638-3,beta alanine amiobutrate bea amnoisobutyrate and gamm nd pattern [iterpretaton] in erum or plasma narrative point in time
79638-3,beta pattern and beta aminoisobutyrate and gamma aminobutyrate alanine [interpretation] in serum or plasma narrative
79638-3,b-alanine + b-aib + gaba patt serpl-imp
79638-3,b-alanine + b-aib + gaba patt srplimp
79638-3,b-alanine + -aib + gaa patt serpl-imp
79638-3,beta alanine and beta aminoisobutyrate and gamma aminobutyrate pattern nar [interp]
79638-3,beta alanine an eta aminoiobutate interp and gamma aminobtyrate pattrnnar [interp]
79638-3,amnobuyrate lnineand betaaminoisobutratean gama bea ptternnar [nterp]
6306-5,adenovirus 40+41 ag [presence] in stool by immunoassay
6306-5,adenovirus 40+1[prsene] insto screen by immunoasay
6306-5,adenovirus 40+41 ag [presence] in stool by immunoassay
6306-5,adv 40+41 ag stl ql ia
6306-5,40+41 adv qual ag stl ql ia
6306-5,adv 4+41ag sl qa
6306-5,adenovirus 40+41 ag ia ql (stl)
6306-5,adenovirus 40+41 ag ia fecal ql (stl)
6306-5,enovirus antigens a 40+ ia ql (stl)
81230-5,referring physician phone number
81230-5,phone physician referring number
81230-5,physician num referring phone number
81230-5,referring md phone #
81230-5,mdhone referrin
81230-5,referring md phone no #
33047-2,tranquilizers [presence] in urine by screen method
33047-2,tranquilizers qual method in urie byscreen [presnce]
33047-2,method [presence] in urine by screen tranquilizers
33047-2,tranquilizers ur ql scn
33047-2,tranquilizers ur ql scn drugs
33047-2,tranquilizers scn ql ur
33047-2,tranquilizers screen ql (u)
33047-2,pr screenql(u) ranquilizers
33047-2,tranquilizers screen (u) ql
24073-9,beta-n-acetylhexosaminidase.b [enzymatic activity/mass] in leukocytes
24073-9,beta-n-acetylhexosaminidase.b leukocytes activity/mass] in [enzymatic
24073-9,beta-n-acetylhexosaminidase.b activity/mass] [enzymatic in wbcs leukocytes
24073-9,hexosaminidase b wbc-ccnt
24073-9,wbc-ccnt b hexosaminidase
24073-9,hexosainidase b wc-ccnt
24073-9,beta-n-acetylhexosaminidase.b (wbc) [catalytic activity/mass]
24073-9,b-nah beta-n-acetylhexosaminidase.b (wbc) activity/mass] [catalytic
24073-9,(wbc) beta-n-acetylheoamiidase.b [catalytic activity/mass]
72721-4,base excess.100% oxygenated [moles/volume] standard in arterial blood by calculation
72721-4,base excess.100% oxygenated [moles/volume] standard in arterial blood by calculation
72721-4,be excess.10 oxygenated [moles/volme] standad in arterial calculation chemistry by lood
72721-4,base ex.oxy std blda calc-scnc
72721-4,ex.oxy base std blda calc-scnc
72721-4,ex.oxy base std blda calc-scnc
72721-4,base excess.100% oxygenated standard calc (blda) [moles/vol]
72721-4,base exces.0%oxygenated cac stadard bda) [moles/vol]
72721-4,qnt base excess.100% oxygenated standard calc (blda) [moles/vol]
35577-6,hypersensitivity pneumonitis panel - serum
35577-6,hypersensitivity panel pneumonitis - serum
35577-6,hypersensitivity pneumonitis panel - ser
35577-6,hp pnl ser
35577-6,hp pnl ser
35577-6,p nl ser
35577-6,hypersensitivity pneumonitis panel (s)
35577-6,(s) pneumonitis panel hypersensitivity
35577-6,hypersensitivity panel pneumonitis (s) allergens
52510-5,respiratory status
52510-5,status respiratory panel
52510-5,status respiratory
38528-6,protein.abnormal band [mass/time] in 24 hour urine
38528-6,protein.abnormal urine [mass/time] in pr 24 hour band
38528-6,protein.abnormal band [mass/time] in 24 hour urine
38528-6,abn prot 24h ur-mrate
38528-6,24h urn prot abn ur-mrate
38528-6,bn prot 24h ur-mrae
38528-6,protein.abnormal band (24h u) [mass/time]
38528-6,proin.abnormal abn u (24h band [mass/tim]
38528-6,band protein.abnormal (24h u) [mass/time]
90780-8,infliximab ab [units/volume] in serum by immunoassay
90780-8,infliximab suds b [unitsvle] in seum by imunosay
90780-8,infliximab ab immunoassay in serum by [units/volume]
90780-8,infliximab ab ser ia-acnc
90780-8,inliximab meia ab ia-acnc s
90780-8,inflixiab ab aby er ia-cnc
90780-8,infliximab ab ia qn (s)
90780-8,infliximab (s) ia qn abs ab
90780-8,infliximab ab ia qn (s)
59571-0,triglyceride [moles/time] in 24 hour urine
59571-0,triglyceride [moles/time] in 24 hour urine quan
59571-0,tiglycride [mols/time] in24 quantitative hour urne
59571-0,trigl 24h ur-srate
59571-0,trigl ur-srate 4h
59571-0,tigl 24h ur-sate
59571-0,triglyceride (24h u) [moles/time]
59571-0,triglyceride (24h u) [moles/time]
59571-0,trigyceride (24h [molstie] u)
41871-5,voltage-gated potassium channel ab [moles/volume] in serum
41871-5,voltge-gated potassium channel ab serum [moes/volume]in
41871-5,voltae-ated potssiu in ab [moles/volume] channel serum
41871-5,vgkc ab ser-scnc
41871-5,vgkcbsersc random
41871-5,ser-scnc ab vgkc
41871-5,voltage-gated potassium channel ab (s) [moles/vol]
41871-5,voltage-gatepotassim channel ab (s) [moles/vol]
41871-5,voltage-gated potassium ab substance concentration channel (s) [moles/vol]
14435-2,albumin/globulin [mass ratio] in peritoneal fluid
14435-2,albmin/globulin flui in peritneal globulins [massratio]
14435-2,protein.albumin albumin/globulin [mass ratio] peritoneal in fluid
14435-2,albumin/glob prt
14435-2,prt albumin/lob
14435-2,albuminglob pt
14435-2,albumin/globulin (periton fld) [mass ratio]
14435-2,albumin/globulin (periton fld) ratio] [mass
14435-2,albumin/globulin (peon glob fld [mass ratio]
94381-1,"2,3-dinor 11 beta-prostaglandin f2 alpha/creatinine [mass ratio] in 24 hour urine"
94381-1,"2,3-dnor 11 beta-prostaglandinf2 alpha/creatininemass rto] in hour 4 urine"
94381-1,"2,-dinor 11 beta-prostaglandin [mass alphareatinine 2 ratio] in 24 hor urine 24 hours"
94381-1,"2,3-dinor 11b-pg f2a/creat 24h ur"
94381-1,"ua 2,3-dinor 11b-pg f2a/creat 24h ur"
94381-1,"2,3-dinor 11b-pg f2a/creat 24h mass concentration ratio ur"
94381-1,"2,3-dinor 11 beta-prostaglandin f2 alpha/creatinine (24h u) [mass ratio]"
94381-1,"2,3-dinor 11 beta-prostaglandin crea f2 alpha/creatinine (24h ratio] [mass u)"
94381-1,"2,3-dinor 11 beta-prostaglandin f2 alpha/creatinine (24h u) [mass ratio]"
105920-3,campylobacter sp dna [identifier] in stool by naa with probe detection
105920-3,camylobactr spdna [identier] in with by naa stool pre tecio
105920-3,campylobacter sp dna detection in stool by naa with probe [identifier]
105920-3,campylobacter dna stl naa+probe
105920-3,campylobacter campy dna naa+probe stl
105920-3,campylobacter dna stl polymerase chain reaction naa+probe
105920-3,campylobacter sp dna naa+probe nom (stl)
105920-3,campylobacter sp dna naa+robe no (stl)
105920-3,campylobacter sp dna naa+probe (stl) nom
48910-4,rickettsia prowazekii igm ab [titer] in body fluid by immunofluorescence
48910-4,fluid prowazekii igm ab titre [titer] in body rickettsia by immunofluorescence
48910-4,ricettsia proazekii igm ab[titer]in body fluid by immunofloesee
48910-4,r prowazek igm titr fld if
48910-4,r prowazek igm titr fld if
48910-4,prowazek igm r prowazek titr fl if
48910-4,r. prowazekii igm if (body fld) [titer]
48910-4,r. prowazekii (body if igm fld) [titer]
48910-4,r. prowazekii igm if (body fld) [titer]
50383-9,deprecated glomerular filtration rate/1.73 sq m.predicted in 24 hour by creatinine-based formula (schwartz)
50383-9,deprecated creatinine-based filtration rate/1.73 sq m.predicted in 24 hour by glomerular formula (schwartz)
50383-9,deprecated glomerular filtration rate/1.73 sq m.predicted in 24 hour by creatinine-based formula (schwartz)
50383-9,deprecated gfr predicted serpl schwartz
50383-9,quantitative serpl gfr predicted deprecated schwartz
50383-9,dpeate gfr chemistry predicted srpl chwartz
50383-9,gfr.predicted schwartz [vol/time]
50383-9,[vol/time] schwartz gfr.predicted vrate
50383-9,schwartz gfr.prediced chemistry [vol/tme]
47199-5,methionine [mass] of dose
47199-5,methionine random [mass] dose of
47199-5,methionine dose of [mass]
47199-5,methionine dose
47199-5,dose methionine
47199-5,dse methione
47199-5,methionine (dose) [mass]
47199-5,methionine (dose) drug doses [mass]
47199-5,(doe) methionine [mass]
30398-2,hematocrit [volume fraction] of cerebral spinal fluid by calculation
30398-2,hematocrit [volume fraction] calculation cerebral spinal fluid by of
30398-2,hematocrit [volume fraction] fluid cerebral spinal of by calculation
30398-2,hct vfr csf calc
30398-2,csf vfr hct calc
30398-2,hct quantitative cerebrospinal fluid vf calc
30398-2,hematocrit calc (csf) [volume fraction]
30398-2,neuro hematocrit calc (csf) [volume fraction]
30398-2,hematocrit calc (csf) spinal flu [volume fraction]
38710-0,nitrobenzene [mass/volume] in air
38710-0,nitrobenene [mass/vlume] pt in air
38710-0,nirobenzene [ass/voume] level in ir
38710-0,nitrobenzene air-mcnc
38710-0,ntobenzene air-cc
38710-0,itrobenzenr-cnc
38710-0,nitrobenzene (air) [mass/vol]
38710-0,nitrobezen mass concentration (air)[mass/vol]
38710-0,itrobenene (ar mass concentration [mass/vol]
11559-2,fractional oxyhemoglobin in blood
11559-2,fractionaloyhmogloin n oxyhgb % bood
11559-2,inblood oxyhemobin frctional
11559-2,oxyhgb mfr bld
11559-2,oxyhgb bld mfr
11559-2,oxyhb mf blood
11559-2,oxyhemoglobin (bld) [mass fraction]
11559-2,[mass (bld) oxyhemoglobin fraction]
11559-2,oxyhemoglobin (bld) [mass fraction]
33397-1,neisseria meningitidis serogroups a+c+w135+y ag [presence] in serum by latex agglutination
33397-1,neisseria mnnitidis serogrops a+c+w135+y ag in presence] ser by latex glutination
33397-1,by meningitidis serogroups a+c+w135+ a [presenc] in erum neisera latex aggltinatin
33397-1,n men sg a+c+w135+y ag ser ql la
33397-1,la men sg +c+w15+y ag serum ql n
33397-1,n men meningid sg a+c+w135+y ag serum ql la
33397-1,n. meningitidis a+c+w135+y ag la ql (s)
33397-1,n. meningitidis a+c+w135+y ag la ql (s) acyw135
33397-1,n. meningitidis ag a+c+w135+y la ql (s)
1914-1,aspartate [mass/volume] in urine
1914-1,in apatate[mass/volme] rine quant
1914-1,asprtate [ma/volum in quan uine
1914-1,aspartate ur-mcnc
1914-1,ur-mcnc aspartate
1914-1,asparate ur ur-mcnc
1914-1,aspartate (u) [mass/vol]
1914-1,level aspartate (u) [mass/vol]
1914-1,aspartate (u) [mass/vol] urn
21266-2,ethion [mass/volume] in urine
21266-2,etion [mass/volume]  urine
21266-2,urine [mass/volume] in ethion
21266-2,ethion ur-mcnc
21266-2,ehion ur-mcnc
21266-2,drug/toxicology r-mcn et
21266-2,ethion (u) [mass/vol]
21266-2,ethion [mass/vo drug/toxicology (u)
21266-2,ur [ass/vol ethion(u)
23367-6,prrsv ab [presence] in serum by complement fixation
23367-6,fixation [presence] in seum by compemen prrsvab
23367-6,prrsv ab [ql] in serum by complement fixation
23367-6,prrsv ab ser ql cf
23367-6,prrsv ab seuchenhafter spatabort der schweine serum ql cf
23367-6,comp fixation cf ab ser ql prrsv
23367-6,prrsv ab cf ql (s)
23367-6,rr ) cf ql ab
23367-6,prrsv ab cf infectiousdisease presence (s)
48824-7,"respiratory allergen panel, us - north atlantic states a - serum"
48824-7,"respiratory states panel, us - north atlantic allergen a - serum"
48824-7,"respiratory allergn pa, us - northtlant states seru - a"
48824-7,resp allergen n atl a pnl ser
48824-7,resp allergen n atl serum pnl a
48824-7,resp allergen n atl random a pnl ser
48824-7,"respiratory allergen panel, us - north atlantic states a (s)"
48824-7,"serum respiratory allergen anel, us - northatnic tte a (s)"
48824-7,"respratory llergen panel, us random -north atlanticstates (s) a"
38992-4,amylase [units/volume] in 24 hour urine
38992-4,amylase 24 quan in [units/volume] hour urine
38992-4,mlase units/volme] in 24 ur urine
38992-4,amylase 24h ur-acnc
38992-4,amylase ur-acnc 24h
38992-4,amylase ur-acnc 24h
38992-4,amylase qn (24h u)
38992-4,amylase u) quantitative (24h qn
38992-4,amylase qn u) (24h
52824-0,la crosse virus igm ab [presence] in serum by immunoassay
52824-0,la crosse irus igm ab infectiousdisease [presence] immnoasy serm by in
52824-0,la serum virus igm ab [presence] in crosse by immunoassay
52824-0,lacv igm ser ql ia
52824-0,lacv igm ser ql ia antby
52824-0,iaa lacv igm ql ser ia
52824-0,la crosse virus igm ia ql (s)
52824-0,la viru rosse igm ia ql (s)
52824-0,la crosse virus (s) ia ql igm
86632-7,function and daily living panel [koosjr]
86632-7,function [koosjr] daily living panel and
86632-7,function and pan daily living panel [koosjr]
55547-4,labetalol [moles/volume] in serum or plasma
55547-4,[moles/volume] labetalol in serum or plasma
55547-4,labetalol lasm in ser o [moles/volume]
55547-4,labetalol serpl-scnc
55547-4,labetalol ipolab serpl-scnc
55547-4,labetalolserpl-scc
55547-4,labetalol [moles/vol]
55547-4,[moles/vol] labetalol
55547-4,labetlol [moles/vol]
2221-0,elastase.pancreatic [enzymatic activity/volume] in serum
2221-0,lstasepacreatic enzymatic actiy/volume]in ser
2221-0,elastase.pancreatic ctivty/volume] ezymatic n ser
2221-0,elastase panc ser-ccnc
2221-0,elastse pancreatc pac ser-ccn
2221-0,elastase panc serum-ccnc
2221-0,elastase.pancreatic (s) [catalytic activity/vol]
2221-0,elastase.pancreatic (s) quan [catalytic activity/vol]
2221-0,elastase.pancreatic activity/vol] [catalytic (s)
14217-4,htlv i p19 ab [presence] in serum
14217-4,htlv i p19 [presence] ab in serum
14217-4,p19 i htlv ab [presence] in ser
14217-4,htlv i p19 ab ser ql
14217-4,htlv i ab p19 ser ql
14217-4,htlv i p19 ab ser ql autoantibody
14217-4,htlv i p19 ab ql (s)
14217-4,htlv i ql ab p19 (s)
14217-4,htlv i p19 point in time ab (s) ql
2158-4,creatine kinase.total/creatine kinase.mb [enzymatic activity ratio] in serum or plasma
2158-4,creatine kinase.total/creatine kinase.mb [enzymatic activity ratio] in serum serplas or plasma
2158-4,cretine kinase.total/creatine kinas.mb [enzymatic activity ratio] in seum or plasm catalytic ratio
2158-4,ck/ck mb serpl-crto
2158-4,serpl-crto mb ck/ck quan
2158-4,serpl-crto mb sr ck/ck
2158-4,ck.total/creatine kinase.mb [catalytic ratio]
2158-4,rto] [catalytic ck.total/creatinekinase.mb
2158-4,ck.total/creatine kinase.mb ratio] [catalytic
88504-6,oasis d - data items collected at inpatient facility admission or agency discharge only - transfer during assessment period [cms assessment]
88504-6,inpatient d - data items collected at oasis facility admission or agency discharge only - transfer during assessment period [cms assessment]
88504-6,oasis d - data items collecte  inpatient facility dmissin or agenc dischrge only - ranfe duing asessment period [cm assssmen]
23854-3,dioxin [mass/volume] in serum or plasma
23854-3,dioxin [mass/volum] n serum serum o plasa
23854-3,"dioxin [mass/volume] 2,3,7,8-tetrachlorodibenzo-p-dioxin in serum or plasma"
23854-3,dioxin serpl-mcnc
23854-3,dioxin serum or plasma-mcnc
23854-3,serpl-mcnc dioxin serp
23854-3,dioxin [mass/vol]
23854-3,serum [masvol] doxn
23854-3,quantitative dioxin [mass/vol]
19563-6,methylenediamine cutoff [mass/volume] in urine for screen method
19563-6,methylenediamine cutoff [mass/volume] in urine for screen method
19563-6,for cutoff [mass/volume] in urine methylenediamine screen method
19563-6,me-enediam cto ur scn-mcnc
19563-6,me-enedim scr to ur cn-cnc
19563-6,me-endia cto ur scnmnc scr
19563-6,methylenediamine cutoff screen (u) [mass/vol]
19563-6,methylenediamine cutoff [mass/vol] (u) screen
19563-6,methylenediamine ua cutoff screen [mass/vol] (u)
18845-8,reference beat type (narrative) by ekg
18845-8,referene beat type (narrtve) by eg
18845-8,reference (narrative) type beat by ekg
102057-7,sphingolipid panel - serum
102057-7,phigolipd panl - seru panl
102057-7,serum singolipidpanel-
102057-7,sphingolipid pnl ser
102057-7,sphigolipidpnl panl serum
102057-7,ser pnl pan sphingolipid
102057-7,sphingolipid panel (s)
102057-7,panel sphingolipid (s)
102057-7,sphigolip panel (s
73187-7,propranolol induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73187-7,propranolol induce platelet [preene] b ig in erum or pasma by fl cytetry(c)
73187-7,propranolol induced platelet igg ab [presence] in serpl by flow cytometry (fc)
73187-7,propranolol ind plt igg serpl ql fc
73187-7,propranolol ind plt serpl igg ql fc
73187-7,q indplt gg srpl propranlol fc
73187-7,propranolol induced platelet igg fc ql
73187-7,propranolol induced platelet fc igg ql
73187-7,indce propranolol latelet gg fc ql
43186-6,acylcarnitine/carnitine.free (c0) [molar ratio] in urine
43186-6,acylcarnitine/carnitine.free (c0) [molar ratio] in urine
43186-6,acylcarnitine/carnitine.free (c0) [molar in ratio] urine
43186-6,acylcarnitine/c0 ur-srto
43186-6,r-srto acylcarnitine/c0
43186-6,ur-srto cylcarnitine/c0 scrto
43186-6,acylcarnitine/carnitine.free (c0) (u) [molar ratio]
43186-6,acylcarnitine/carnitine.free [molar (u) (c0) quantitative ratio]
43186-6,acylcarnitine/carnitie.free c0) ratio] [molar u)
13123-5,deprecated sulfate-3-glucuronyl paragloboside ab in serum
13123-5,deprecated sulfate-3-glucuronyl paragloboside ab in ser
13123-5,deprecated random sulfate-3-glucuronyl paragloboside ab in serum
13123-5,deprecated sgpg ab ser
13123-5,deprecated sgpg ab ser so4
13123-5,deprecated sgpg so4-2 ab ser
13123-5,sulfate-3-glucuronyl paragloboside ab (s)
13123-5,sulfate3glucuronyl aragooside point in time (s) ab
13123-5,sulfate-3-glucuronyl paragloboside ab (s) so4-2
56968-1,plasmodium sp ab [presence] in serum by immunofluorescence
56968-1,immunofluorescence sp ab [presence] in serum by screen plasmodium
56968-1,plasmodium sp [presence] ab in serum by immunofluorescence
56968-1,plasmodium ab ser ql if
56968-1,plasmodium if ser ql ab
56968-1,plasmodium if antibody ql abser
56968-1,plasmodium sp ab if ql (s)
56968-1,plasmodium sp (s) if ql ab autoantibodies
56968-1,pasmodium spabi l pr (s)
72899-8,isoleucine+leucine [moles/volume] in serum or plasma
72899-8,isoleucine+leucine [moles/volume] ile+leu in serum or plasma
72899-8,isolucin+leucine [moles/volume inserum plasma or
72899-8,ile+leu serpl-scnc
72899-8,serpl-scnc ile+leu ser or plasma
72899-8,serpl-scnc ile+le
72899-8,isoleucine+leucine [moles/vol]
72899-8,ile+leu [moles/vol] isoleucine+leucine
72899-8,[moles/vol] isoleucine+leucine
30449-3,neutrophils.hypersegmented [#/volume] in blood
30449-3,utropils.hpesegmented [#/voume]n blood
30449-3,neutrphils.hyersegmened #/volume] in bood
30449-3,neuts hyperseg # bld
30449-3,number concentration (count/vol) neuts hyperseg bld #
30449-3,hyperseg neuts # bld
30449-3,neutrophils.hypersegmented (bld) [#/vol]
30449-3,ntrophil.ypersegmentd (bld) [#/vol]
30449-3,hyperseg [#/vol] (bld) neutrophils.hypersegmented
29771-3,hemoglobin.gastrointestinal.lower [presence] in stool by immunoassay
29771-3,hemoglobin.gastrointestinal.lower [presence] immunoassay stool by in
29771-3,immunoassay [presence] in stool by chemistry hemoglobin.gastrointestinal.lower
29771-3,hemoccult stl ql ia
29771-3,stl bowel movement hemoccult ql ia
29771-3,hemoccul bowel movement ia ql st
29771-3,lower gi hemoglobin ia ql (stl)
29771-3,lower gi hemoglobin ia presence (stl)
29771-3,hemoglobin gi lower hemocult ia ql (stl)
87784-5,naproxen/creatinine [mass ratio] in urine by confirmatory method
87784-5,[mass naproxen/creatinine ratio] in urine by confirmatory method
87784-5,naproxen/creatinine [mass ratio] in gcms urine by confirmatory method
87784-5,naproxen/creat ur cfm
87784-5,naproxen/ceat ur cf
87784-5,naproxen/creat ur cfm cr
87784-5,naproxen/creatinine confirm (u) [mass ratio]
87784-5,lc/ms/ms naproxen/creatinine confirm (u) [mass ratio]
87784-5,naproxen/creatinine confirm mass ratio (u) [mass ratio]
71776-9,gamma interferon background [units/volume] in blood by immunoassay
71776-9,gama bld interferon background [units/olue]in bld by immunoassay
71776-9,gamma interferon background [unitsvolume in blood by immuoassay
71776-9,gamma interferon background bld ia-acnc
71776-9,interferon gamma background bld ia-acnc random
71776-9,gamma bld background interferon ia-acnc
71776-9,gamma interferon background ia qn (bld)
71776-9,gamma interferon background respiratory (blood) qn ia
71776-9,gamma interferon (bld) ia qn iaa background
74313-8,prrsv ab/positive control in specimen by immunoassay
74313-8,prrsv ab/positiveconrol in mmunoassa by specimen
74313-8,prrsv ab/positive cntrol i qnt pecimnby mmunassa
74313-8,prrsv ab/pos cntrl spec ia
74313-8,ia ab/poscntrl spec prr
74313-8,ia seuchenhafter spatabort der schweine ab/poscntrlspec prrsv
74313-8,prrsv ab/positive control ia (specimen) [relative ratio]
74313-8,rrsv ab/positive cntrol ia specimen) [relaivertio]
74313-8,prrsvab/positiv contro ia (specimen ratio] [relaiv
711-2,eosinophils [#/volume] in blood by automated count
711-2,eosinophils [#/volume] in bld by automated count
711-2,eosinophils [#/volume] in blood by automated count
711-2,eosinophil # bld auto
711-2,eosinophi # blood ao
711-2,eosinophil # auto blood
711-2,eosinophils auto (bld) [#/vol]
711-2,eosinophils count aut (bld) [#vol]
711-2,eosinophils auto [#/vol] (bld)
2003-2,deprecated calcium
2003-2,deprecate alium qual
2003-2,calcium deprecated
2003-2,deprecated calcium ur ql
2003-2,deprecatd calcium ur ql qual
2003-2,eprecatd clcium ur l
2003-2,calcium ql (u)
2003-2,calcium ql ql (u)
2003-2,calcium presence (u)
35678-2,sodium [moles/volume] in urine collected for unspecified duration
35678-2,sodium [moles/volume] in urine collected for unspecified duration universallaborders
35678-2,na sodium [moles/volume] in duration collected for unspecified urine
35678-2,sodium ?tm ur-scnc
35678-2,universallaborders sodium ?tm u-scnc
35678-2,sodium ur-scnc quan ?tm
35678-2,sodium unsp time (u) [moles/vol]
35678-2,sodium qnt unsp time (u) [moles/vol]
35678-2,sodum unsp time () urn [mols/vo]
62302-5,lysosomal storage disorders suspected [identifier] in dbs
62302-5,lysosomal storagedisordes in [ienifier] supected dbs
62302-5,lysosomal storage [identifier] suspected disorders in dbs
62302-5,lsd suspected dbs
62302-5,suspected lsd dbs dbs
62302-5,lsd suspectd dbs
62302-5,lysosomal storage disorders suspected nom (dbs)
62302-5,disorders storage lysosomal suspected nom (dbs) lsd suspected
62302-5,lysosomal storage disorders suspected nom (dbs)
17935-8,bacteria # 2 identified in blood by anaerobe culture
17935-8,bacteria random # 2 identified in blood by anaerobe culture
17935-8,bacteria # random 2 identifed i blood by anaeobe culture
17935-8,bacteria bld anaerobe cult org #2
17935-8,2 bld cult anaerobe cult org bacteria
17935-8,bacteria bld anerob cult org #2 microbiology
17935-8,bacteria identified # 2 anaer cx nom (bld)
17935-8,cx identified # 2 anaer bacteria nom (bld)
17935-8,bacteria identified # 2 aaer cxnom (bld)
40621-5,carcinoembryonic ag [mass/volume] in pericardial fluid
40621-5,carcinembryonic ag [mass/olume quantitative in eriardial fluid
40621-5,carcinoembryonic ag pericardial in [mass/volume] fluid
40621-5,cea pcar-mcnc
40621-5,cea pcar-mnc
40621-5,pcar-mcnc random cea
40621-5,carcinoembryonic ag (pericard fld) [mass/vol]
40621-5,[mass/vol] ag antigen (pericard fld) carcinoembryonic
40621-5,carcinoembryonic ag (pericard quan fld) [mass/vol]
11094-0,dichlorodiphenyltrichloroethane [mass/volume] in serum or plasma
11094-0,dicordipenyltrichloroetne [mas/volume] in erm or random plasma
11094-0,dichlorodiphenyltrichlorethane[mas/volume] ddt in serm r plas
11094-0,ddt serpl-mcnc
11094-0,d serplmcnc serplas
11094-0,quan serpl-mcnc ddt
11094-0,dichlorodiphenyltrichloroethane [mass/vol]
11094-0,drug/toxicology [mass/vol] dichlorodiphenyltrichloroethane
11094-0,[mass/vol] dichlorodiphenyltrichloroethane
97065-7,medical history for preventive vaccination against covid-19 (coronavirus disease 2019) - with mrna vaccine
97065-7,edical history for preventiv vaccinatinagintcovd-19 (cronaviru disease 2019) - with 2019 novel coronavirus mrna vaccie
97065-7,medicl sars-cov-2 istry for preventv vaccination against covid-19coronavirus dsease 201) - with rna vacin
97065-7,hx for covid -19 vaccine
97065-7,vaccine for covid -19 hx
97065-7,hx for cvid -19 vacine
60037-9,1-naphthol [mass/volume] in body fluid
60037-9,1naphthol inbody [massvoume] flud bod
60037-9,1-naphthol [mas/volume] inbdy fluid
60037-9,1naphthol fld-mcnc
60037-9,fld-mcnc 1naphthol
60037-9,1naphthol fl-mcc point in time
60037-9,1-naphthol (body fld) [mass/vol]
60037-9,1-naphthol quantitative (ody fld) [mass/vl]
60037-9,1-naphthol fld) (body [mass/vol]
32844-3,epstein barr virus capsid igg ab [units/volume] in serum --2nd specimen
32844-3,ab barr virus capsid igg epstein [unit/volume]i serum vca --2nd secimen
32844-3,epstein barr virus capsid igg ab [units/volume] in serum --2nd specimen
32844-3,ebv vca igg sp2 ser-acnc
32844-3,ebv vca ser-acnc sp2 igg
32844-3,autoantibodies igg vca ebv sp2 ser-acnc
32844-3,ebv capsid igg spec 2 qn (s)
32844-3,capsid ebv igg hhv-4 spec 2 qn (s)
32844-3,ebvcapsi gg spec2 qn (s
44294-7,albumin/globulin [mass ratio] in 24 hour urine by electrophoresis
44294-7,alumin/globulin [mass atio] in 24 hour urine by electrohoresis
44294-7,albumin/globulin [mass ratio] in 24 glb hour urine by electrophoresis
44294-7,albumin/glob 24h ur elph
44294-7,albumin/glob urelph urn 2h
44294-7,albumin/glob ur 24h elph
44294-7,albumin/globulin elph (24h u) [mass ratio]
44294-7,albin/lobuin elph (24hu) elect [mas ratio]
44294-7,albuminglbuln renal elph [mss u) (2h ratio]
55900-5,immunoglobulin light chains.free [presence] in urine by immunofixation
55900-5,immunoglobulin light ua chains.free by in urine [presence] immunofixation
55900-5,immunoglobuli lightchain.free [presenc] in urie by imufxation non-protein bound
55900-5,bj protein free ur ql ife
55900-5,bj protein free ur ql hematology ife
55900-5,protein bj free flc ur presence ife
55900-5,immunoglobulin light chains.free immunofixation ql (u)
55900-5,immunoglobulin light immuno chains.free immunofixation ql (u)
55900-5,immunoglbuin lght heme chains.fre mmuofixation ql (u
62480-9,adenovirus dna [presence] in bronchoalveolar lavage by naa with probe detection
62480-9,adenovirus dna [presence] qbr in bronchoalveolar lavage by naa with probe detection
62480-9,denovirus dna [presec] in bronchoalvlar avg by naa with probe detecton
62480-9,hadv dna bal ql naa+probe
62480-9,hadv dna bal presence screen naa+probe
62480-9,bal dna hadv ql naa+probe
62480-9,adenovirus dna naa+probe ql (bal)
62480-9,adenovirus dna naaprobe ql (al)
62480-9,adenvrus na random bl) presence naa+prob
26930-8,secobarbital [mass/mass] in hair
26930-8,secobarbital [mass/mass] in hair
26930-8,secobarbital [mass/mass] hair in
26930-8,secobarbital hair-mcnt
26930-8,secoarbital hair-mcnt drug/toxicology
26930-8,barbiturate hair-mcnt secobarbital
26930-8,secobarbital (hair) [mass/mass]
26930-8,secobarbital [ass/mass] hair)
26930-8,secobarbital (hair) drugs of abuse [mass/mass]
23436-9,salmonella pullorum rrna [presence] in specimen by probe
23436-9,salmonella in rrna [ql] pullorum specimen by probe
23436-9,salmonella [presence] rna ullorum ql in pecimenby probe
23436-9,s pullorum rrna spec ql probe
23436-9,s pulloum rrna speqlprobe
23436-9,s probe rrnaspeql pulorum
23436-9,s. pullorum rrna probe ql (specimen)
23436-9,s. prbe rna pullorum ql (spcime)
23436-9,s. pullorum rrna probe ql (specimen)
91039-8,methadone+metabolite [presence] in body fluid by screen method
91039-8,methadone+metabolite method in body fluid by screen [presence]
91039-8,methadone+metablite [presene] in body fluid by screen method
91039-8,methadone+metab fld ql scn
91039-8,fld methadone+metab ql scn
91039-8,methadone+metab ql fld scn
91039-8,methadone+metabolite screen ql (body fld)
91039-8,body fluid methadoe+metabolite sree bdy ql fld)
91039-8,methadone+metabolite screen (body ql potentialforabuse fld)
2802-7,phosphoserine [mass/volume] in urine
2802-7,hosphoserie [mass/vlume]inurne qnt
2802-7,phosphoserine [mass/volume] in urine
2802-7,phosphoserine ur-mcnc
2802-7,ua ur-mcnc phosphoserine
2802-7,ur-mcnc phosphoserine
2802-7,phosphoserine (u) [mass/vol]
2802-7,phosposerine [ass/vol] (
2802-7,[massol] (u) phosphoserine
61400-8,proteus mirabilis dna [presence] in specimen by naa with probe detection
61400-8,proteus mirabilis dna [presence] in specimen polymerase chain reaction by naa with probe detection
61400-8,proteus mirabili dna presnce] b inspecimen naa ith pobe deecion
61400-8,p mirabilis dna spec ql naa+probe
61400-8,naa+probe da strand displacement amplification specql mirai
61400-8,p mirabilis pcr dna spec ql naa+probe
61400-8,p. mirabilis dna naa+probe ql (specimen)
61400-8,p. mirabilis dna naa+probe infectiousdisease presence (specimen)
61400-8,p. mrbils dna naaprobe ql (specimn)
96557-4,hiv 1 and 2 rna panel - serum or plasma by naa with probe detection
96557-4,hiv 1 and 2 rna panel - serum or plasma by naa with probe detection
96557-4,hiv 1 and hiv 1 + 2 rna 2 ra pae- serum or plasmaby aa wth probe etection
96557-4,hiv 1 + 2 rna pnl serpl naa+probe
96557-4,hiv 1 + 2 rna pnl serpl naa+probe
96557-4,hi 1 + 2 rna naaprobe serpl nl pl
96557-4,hiv 1 and 2 rna panel naa+probe
96557-4,hiv rna and 2 1 panel panel.microbiology naa+probe
96557-4,hiv 1 and 2 rna panel naa+probe
95027-9,fasi v1.0 - motorized wheelchair/scooter - usual performance during assessment period [cms assessment]
95027-9,[cms v1.0 - motorized pnl wheelchair/scooter - usual performance during assessment period fasi assessment]
95027-9,fasi v1.0 pan - mooized wheechair/scooter - usual prfrmne during asesmntpriod[cms assessment]
25587-7,chromogranin a [moles/volume] in serum or plasma
25587-7,chroogrnin a [moles/volume] in sum sr or plama
25587-7,cromogrnin a [mole/volume]in serum or pasma
25587-7,cga serpl-scnc
25587-7,serpl-scnc plasma cga
25587-7,a chemistry serp-scnc
25587-7,chromogranin a [moles/vol]
25587-7,chromogranin serum a [moles/vol]
25587-7,chromogranin a [moles/vol]
76480-3,albumin [moles/volume] in cerebral spinal fluid
76480-3,albumin [ols/volme] spinal cerbral n fluid
76480-3,albumin in [moles/volume] cerebral spinal fluid
76480-3,albumin csf-scnc
76480-3,alumincsf-scnc spinal fluid
76480-3,cerebrospinal fluid-scnc albumin
76480-3,albumin (csf) [moles/vol]
76480-3,(csf) albumin [moles/vol]
76480-3,[moles/vol] (csf) albumin cerebral spinal fluid
25893-9,cysteine/creatinine [molar ratio] in 24 hour urine
25893-9,cysteine/creatinine [molar urine in 24 hour ratio]
25893-9,cysteine/creatinne [molar ratio] quant n 24 hour rin
25893-9,cysteine/creat 24h ur-srto
25893-9,ur-srto 24h cysteincrea
25893-9,cysteine/creat ur-srto 24h
25893-9,cysteine/creatinine (24h u) [molar ratio]
25893-9,(24h cysteine/creatinine u) [molar ratio]
25893-9,cysteine/creatinine (24h u) cys [molar ratio]
54366-0,calcium.ionized [moles/volume] adjusted to ph 7.4 in cord blood
54366-0,calcium.ionized blood adjusted to ph pt 7.4 in cord [moles/volume]
54366-0,calcium.ionzed blood toph 7.in cord [mole/volume]ajusted
54366-0,ca-i adj ph7.4 bldco-scnc
54366-0,cai adj ph7.4 bldcscnc
54366-0,adj ca-i ph7.4 cord (umbilical) bld bldcoscnc
54366-0,calcium.ionized adjusted to ph 7.4 (bldco) [moles/vol]
54366-0,ion calcium.ionized adjusted to ph 7.4 (bldco) [moles/vol]
54366-0,calcium.ionized adjusted [moles/vol] ph 7.4 (bldco) to
3961-0,deprecated phenylbutazone [mass/volume] in serum or plasma
3961-0,deprecated phenylbutazone serum or in serum [mass/volume] plas
3961-0,deprecated phenylbutazone [mass/volume] in serum plasma or
3961-0,deprecated phenylbutazone ser-mcnc
3961-0,deprecated ser-mcnc phenylbutazone
3961-0,deprecated spondyril serum-mcnc phenylbutazone
3961-0,phenylbutazone (s) [mass/vol]
3961-0,phenylbtazon (s) massvol]
3961-0,phenylbutazone (s) [mass/vol] spondyril
23188-6,leptospira interrogans ab [presence] in serum by agglutination
23188-6,leptopira interrogns ab [resence] in seu byagglutination
23188-6,leptospira inerrgan l interrogans ab[presence n serum y agglutinaton
23188-6,l inter ab ser ql aggl
23188-6,l intr aggl ser ql ab
23188-6,l inter ab ser screen presence aggl
23188-6,l. interrogans ab aggl ql (s)
23188-6,l. aggl ab infectious disease interrogans presence (s)
23188-6,l. nterrons serum ab gl l (s
80161-3,"5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/creatinine [ratio] in urine"
80161-3,"5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/creatinine urine in point in time [ratio]"
80161-3,"chemistry 5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/creatinine [ratio] in urine"
80161-3,"5b-choles-3a,7a,12a,24,25-pent/creat ur"
80161-3,"5b-choles-3a,a,a,4,-pnt/creat ur iii"
80161-3,"5b-choles-3a,7a,12a,24,25-pent/creat ur quantitative"
80161-3,"5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/creatinine (u) [ratio]"
80161-3,"5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/creatinine (u) [ratio] quan"
80161-3,"(u) 5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/creatinine [ratio] qnt"
51815-9,leptospira sp igg ab [units/volume] in serum by immunoassay
51815-9,leptospira sp igg ab [units/volume] in serum by immunoassay
51815-9,lptopira sp igg ab [unt/volue] in elisa srum by immunoassay
51815-9,leptospira igg ser ia-acnc
51815-9,leptospira serum igg ia-acnc
51815-9,eia leptospira igg serum ia-acnc
51815-9,leptospira sp igg ia qn (s)
51815-9,leospira sp iggiaqn() antibody
51815-9,leptspira sp random gg (s) qn ia
43405-0,chlamydia trachomatis and neisseria gonorrhoeae dna [identifier] in specimen by probe with signal amplification
43405-0,chlamydia trachomatis and neisseria gonorrhoeae dna [identifier] in point in time specimen by probe with signal amplification
43405-0,chlamydia trachomatis and neisseria gonorrhoeae dna [identifier] in specimen by probe with signal amplification
43405-0,c trach+gc dna spec probe+sig amp
43405-0,c trac+gc dna spec probe+sig am
43405-0,dna ctrch+gc spec probe+ig amp
43405-0,c. trachomatis and n. gonorrhoeae dna probe+sig amp nom (specimen)
43405-0,hybrid capture nucleic acid hybridization c. trachomatis and n. gonorrhoeaedna probe+si amp nom(specimen)
43405-0,c. trachomatis and n. gonorrhoeae dna probe+sig amp nom (specimen)
56642-2,serine/creatinine [ratio] in 24 hour urine
56642-2,seine/creatinne ratio] 24hr in uri
56642-2,urn erine/creatinine[rato] in 24 hour urin
56642-2,serine/creat 24h ur-rto
56642-2,r-rto 24h serin/cra
56642-2,srine/reat 24hurrto 1 day
56642-2,serine/creatinine (24h u) [ratio]
56642-2,[ratio] (24hu) serie/reatinine
56642-2,quantitative [ratio] ) serine/creatinine(24h
57683-5,plasmodium falciparum igm ab [presence] in serum by immunoassay
57683-5,plasmodium elisa falciparum igm ab by in ser [presence] immunoassay
57683-5,plasmodium falciparum igmab [presence in ser b immunoasa
57683-5,p falciparum igm ser ql ia
57683-5,p igm falciparum ser ql autoantibody ia
57683-5,fciarum ia elfa r ql gm
57683-5,p. falciparum igm ia ql (s)
57683-5,. falciparum igm i ql elfa (s)
57683-5,p. falciparum screen igm ia ql (s)
53398-4,arginine/phenylalanine [molar ratio] in dbs
53398-4,arginine/pheyalaine fp [molar ratio] in dbs
53398-4,ratio scrto [molar arginne/phenylalanine in dbs
53398-4,arginine/phe dbs-srto
53398-4,db-srto arginine/phe
53398-4,dbs dbs-srto arginine/phe
53398-4,arginine/phenylalanine (dbs) [molar ratio]
53398-4,arginine/phenylalanine(dbs)[olar ratio]
53398-4,arginine/phenylalanine(dbs) [moar rato]
63390-9,extractable nuclear ab [presence] in serum by immune diffusion (id)
63390-9,extractable nucler ab [presence] in serumbyimmune diffusion (d)
63390-9,immune nuclear ab presence] in imun serm by extrtale diffusion (id)
63390-9,ena ab ser ql id
63390-9,ena abs ql ser ab id
63390-9,ena ab ser serum ql id
63390-9,extractable nuclear ab immune diff ql (s)
63390-9,extractable immunodiff nuclear a dff immune ql (s)
63390-9,extractable nuclear ab immune diff ql (s)
44918-1,dopamine/creatinine [molar ratio] in 24 hour urine
44918-1,dopamine/creatinine [molar urine in 24 hour ratio]
44918-1,dopamine/creatinine [molar ratio] in 24 hour urine
44918-1,dopamine/creat 24h ur-srto
44918-1,ur-srto 24h dopamine/creat
44918-1,dopamine/reat ur-srto 24
44918-1,dopamine/creatinine (24h u) [molar ratio]
44918-1,u) (24h dopamine/creatinine ur [molar ratio]
44918-1,dopamine/creatinine [molar u) (24h ratio]
29354-8,reovirus ab [titer] in cerebral spinal fluid
29354-8,reovirus spinal [titer] in cerebral ab fluid
29354-8,[titer] b reirus n cerebral spinal flui
29354-8,reovirus ab titr csf
29354-8,reovirus ab cerebrospinal fluid titr
29354-8,revirus ab csf ttr dilution factor
29354-8,reovirus ab (csf) [titer]
29354-8,reovirus (csf) ab [titer]
29354-8,(csf) ab reovirus [titer]
90541-4,mobility - interim performance during assessment period [cms assessment]
90541-4,mility survey nterm peromance during assessment period [cs assessment]
90541-4,mobility [cms interim performance during assessment period - assessment]
42722-9,ompc ab [presence] in serum
42722-9,ompc ab [presence] antibodies in serum
42722-9,pc ab [presnce] inserum screen
42722-9,ompc ab ser ql
42722-9,ompc ab antby ser ql
42722-9,serum ab ompc ql
42722-9,ompc ab ql (s)
42722-9,mpc ql ab (s) abs
42722-9,om ab ql (s)
99153-9,outcome and assessment information set (oasis) form - version e - follow up during assessment period [cms assessment]
99153-9,utcome ad ssessme inormation centers for medicare and medicaid assessment set (oasis) frm - ersion e - follow up drng asessnt period [cm assment]
99153-9,utcome and assesment information st (oasis) form - vesion e - folow up during assessment period [cms assessme]
60163-3,phenolphthalein [mass/volume] in serum or plasma
60163-3,pheolphthalein [masvolume] serpl plasm erum or i
60163-3,phenolphthain [mass/volume] serumor i plasma
60163-3,phenolphthalein serpl-mcnc
60163-3,phenolphthalein serpl-mcnc
60163-3,serpl-mcnc phenolphthalein
60163-3,phenolphthalein [mass/vol]
60163-3,serp phenolphthalein [mass/vol]
60163-3,[mass/vol] phenolphthalein
40708-0,polio virus igg ab [titer] in serum --2nd specimen
40708-0,polio virus serum ab[tier] in igg -2ndsecimen
40708-0,in virus igg ab [titer] polio ser --2nd specimen
40708-0,pv igg sp2 titr ser
40708-0,titre pv igg sp2 se itr
40708-0,pv igg sp2 titr serum
40708-0,polio virus igg spec 2 (s) [titer]
40708-0,polio virus igg spec 2 (s) [titer]
40708-0,polio virus igg spec (s) 2 [titer] dilution factor (titer)
49483-1,hiv 1 [interpretation] in serum or plasma by immunoassay narrative
49483-1,iv 1 [nterpetation inseru or plasma impressions by muoassaynarratie
49483-1,hiv 1 [interpretation] in ser or plasma by immunoassay narrative
49483-1,hiv1 serpl ia-imp
49483-1,hiv1 serum or plasma a-imp
49483-1,infectious disease hiv1 serpl ia-imp
49483-1,hiv 1 ia nar [interp]
49483-1,hiv 1 eia ia nar [interp]
49483-1,v 1 ia nar meia [itep]
47600-2,ceruloplasmin [moles/volume] in serum or plasma
47600-2,eruloplasmin [moles/v] or erum chemistry in plsma
47600-2,cerulopasmn [oes/olume] in serum or serpl plama
47600-2,ceruloplasmin serpl-scnc
47600-2,serpl-scnc ceruloplasmin
47600-2,erulolasmin serplscnc
47600-2,ceruloplasmin [moles/vol]
47600-2,[moles/vol] ceruloplasmin
47600-2,ceruloplasmin[moles/ol] pl
35671-7,galactomannan ag [units/volume] in specimen
35671-7,galactomannan ag [nits/vlume] in infectious disease pecimen
35671-7,galactomannan in [units/volume] ag specimen
35671-7,galactomannan ag spec-acnc
35671-7,alactomannan infectious disease gspec-acnc
35671-7,antigens gaactomannan ag spc-acn
35671-7,galactomannan ag qn (specimen)
35671-7,(specime) ag alactonnan
35671-7,ag galactomannan qn (specimen)
15092-0,pregnanetriol [moles/volume] in urine
15092-0,pregnanetriol in [moles/volume] urine
15092-0,random [moles/olume] pregnantrio in urine
15092-0,pregntrl ur-scnc
15092-0,ur-scnc pregntrl quan
15092-0,pregntrl ur-scnc
15092-0,pregnanetriol (u) [moles/vol]
15092-0,pregnaneriol moles/o] ur (u
15092-0,[moles/vol] (u) pregnanetriol
95030-3,fasi v1.0 - instrumental activities of daily living - most dependent performance [cms assessment]
95030-3,fasi - v.0 instrumental activitis of daily livi - most dependent performance[cms assesment]
95030-3,fasi v1.0 livig instrumental activitiesof daily - - ost dependen performance [cm assessment]
23656-2,ammonia [mass/volume] in specimen
23656-2,nephrology ammonia [mass/volume] in specimen
23656-2,in [mass/volume] ammonia specimen
23656-2,ammonia spec-mcnc
23656-2,spec-mcnc chemistry ammonia
23656-2,ammonia spec-mcnc
23656-2,ammonia (specimen) [mass/vol]
23656-2,quan ammonia (specimen) [mass/vol]
23656-2,ammonia (spcimen) [masvol
87979-1,fungus identified in pleural fluid by culture
87979-1,fungus identified in pleural by fluid culture
87979-1,fungus identified in pleural fluid by culture
87979-1,fungus plr cult
87979-1,fungus thoracentesis fluid plr cult
87979-1,fungus infectious disease plr cult
87979-1,fungus identified cx nom (pleur fld)
87979-1,fungus identified cx nom (pleur fld)
87979-1,fungus identifed cx fungi (pleurfld) no
106734-7,"troponin t.cardiac [mass/volume] in serum, plasma or blood by rapid immunoassay"
106734-7,"troponin t.cardiac [mass/volume] in serum, plasma or bld by rapid immunoassay mass concentration"
106734-7,"point in time troponin t.cardiac [mass/volume] in serum, plasma or bld by rapid immunoassay"
106734-7,troponin t serplbld ia.rapid-mcnc
106734-7,tropnin t srplbld ia.rapid-cnc blood
106734-7,troponin t serplbld ia.rapid-mcnc
106734-7,troponin t.cardiac ia.rapid (s/p/bld) [mass/vol]
106734-7,troponin t.cardiac plasbld [mass/vol] (s/p/bld) ia.rapid
106734-7,troponin t.cardiac ia.rapid point in time (s/p/blood) [mass/vol]
105886-6,candida albicans dna [presence] in vaginal fluid
105886-6,candida albicans dna [presence] in vaginal fluid candidiasis
105886-6,fluid albcans da [presenc]invagial candida
105886-6,c albicans dna vag ql
105886-6,ql dn va albicans
105886-6,pr c albicans dna vag ql
105886-6,c. albicans dna ql (vag fld)
105886-6,c. albicans dna ql deoxyribonucleic acid (vag fld)
105886-6,c. albicans dna ql (vag fld)
97283-6,nordiazepam [presence] in cord tissue by confirmatory method
97283-6,nordiazepam [ql] in cord tissue praxadium by confirmatory method
97283-6,nordiazepam [ql] in cord tissue by confirmatory method
97283-6,nordiazepam tissco ql cfm
97283-6,nordiazepam nordaz tisscoql cfm
97283-6,nodiaepam madar iscoql cfm
97283-6,nordiazepam confirm ql (umb cord tissue)
97283-6,nordiazepam confirm cfm ql (umb cord tissue)
97283-6,nordiazeam confirm issue) (ubcord presence
13710-9,asparagine/creatinine [mass ratio] in urine
13710-9,asparagine/creatinine [mass in ratio] urine ur
13710-9,asparagine/creatinine mass concentration ratio in ratio] [mass urine
13710-9,asparagine/creat ur
13710-9,asparagine/creat ur
13710-9,ur asparagine/creat ua
13710-9,asparagine/creatinine (u) [mass ratio]
13710-9,asparagin/creainie(u) rati] [mass
13710-9,asparagine/creatinine (u) [mass ratio]
63289-3,myelin associated glycoprotein ab [units/volume] in body fluid by immunoassay
63289-3,myelin pt associated glycoprotein ab [units/volume] in body fluid by immunoassay
63289-3,myelin associated glycoprotein ab [units/volume] in fluid body fluid by immunoassay
63289-3,mag ab fld ia-acnc
63289-3,mag ab fld i-acnc
63289-3,bfd mag ia-acnc antby
63289-3,myelin associated glycoprotein ab ia qn (body fld)
63289-3,myelin glycoprotein associated ab ia qn (body fld)
63289-3,myelin associated fld) ab ia qn (body glycoprotein
18279-0,deprecated hemoglobin f [presence] in stool by apt-downey method
18279-0,feces deprecated heogloin f [presnce] in tool b at-downeymethod
18279-0,derated hemoglobin f [presence] in tol by apt-downeymhd
18279-0,deprecated hgb f stl ql apt-downey
18279-0,deprecated hgb f stl ql apt-downey
18279-0,qual deprea f hgb sl ql apt-oney
18279-0,hemoglobin f apt-downey method ql (stl)
18279-0,apt-dowey f hmoglobin mtod ql (stl)
18279-0,hemoglobin hgb f apt-downey method ql (stl)
50273-2,3-hydroxymyristoleylcarnitine (c14:1-oh) [moles/volume] in urine
50273-2,[moles/olume] (c4:1-oh) 3-hyroxymyristollcarnitne in chemistry urine
50273-2,3-hydroxymyristoleylcarnitine [moles/volume] (c14:1-oh) in urine
50273-2,3oh-myristoleylcarn ur-scnc
50273-2,ur-scnc 3oh-myristoleylcarn
50273-2,3oh-myristoleylcarn ur-scnc
50273-2,3-hydroxymyristoleylcarnitine (c14:1-oh) (u) [moles/vol]
50273-2,3-hydroxymyrtoleylcrnitine (c14:1-oh) quantitative (u) [moles/vol
50273-2,3-hydroxymyristoleylcarnitine (c14:1-oh) 9-cis-tetradecenylhydroxyl carnitine (u) [moles/vol]
78849-7,jwh-210 5-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [mass/volume] in urine for confirmatory method
78849-7,jwh-20 5-ydroxyptyl (synthetic cnnbinoid meabolite) utoff [mass/volume] in urine fr confimatory metho random
78849-7,jh-2105-hydroxyentyl (sythetic canabinoid confirmatory mtablite) cuoff[mssvlum] in ine for onirmaory method
78849-7,jwh-210 5-hydroxypentyl cto ur cfm-mcnc
78849-7,jwh-210 cfm-mcnc cto ur 5-hydroxypentyl
78849-7,jwh-210 5-hydrxypntyl cto ur cfm-mcnc
78849-7,jwh-210 5-hydroxypentyl cutoff confirm (u) [mass/vol]
78849-7,confim 5-hydroxypntyl cutoff jw-210 u) [mas/l]
78849-7,jwh-210 -hydrxypetyl cutoff cofirm (u) cfm [mass/vol]
22212-5,coxsackievirus a10 ab [titer] in cerebral spinal fluid
22212-5,coxsackievirus a10 ab [titer] in ceebra spnal abs flud
22212-5,coxsckeirusa0ab [titer]in cerebal pin fluid
22212-5,cv a10 ab titr csf
22212-5,c a1 random ttr c
22212-5,cv coxsackie a10 ab titr csf
22212-5,coxsackievirus a10 ab (csf) [titer]
22212-5,coxsackievirus (cerebrospinal fluid) ab a10 [titer]
22212-5,coxackeviru a10 ab (csf) [tit]
14339-6,igg/protein.total in cerebral spinal fluid
14339-6,cerebral in gg/potein.total spina fluid
14339-6,immunoglobulin g igg/protein.total in cerebral spinal fluid
14339-6,igg mfr csf
14339-6,igg mfr cerebrospinal fluid
14339-6,cerebrospinal fluid mfr cerebrospinal fl igg
14339-6,igg (csf) [mass fraction]
14339-6,igg (csf) [massfraction]
14339-6,ig (csf) fracion] [mass
31692-7,trypanosoma equiperdum ab [units/volume] in serum
31692-7,trypanosoma in ab [units/volume] equiperdum ser
31692-7,trypanosoma equiperdum ab [units/volume] in ser
31692-7,t equiperdum ab ser-acnc
31692-7,t ab equiperdum ser-acnc
31692-7,t equiperdum ser-acnc ab
31692-7,t. equiperdum ab qn (s)
31692-7,aby t. equiperdum ab qn (s)
31692-7,t equiperdum t. equiperdum ab qn (s)
94366-2,streptococcus pyogenes dna [presence] in lower respiratory specimen by naa with probe detection
94366-2,treptococus pyogenes dna [ql] n lower resprator specimen lcr by naa withprobe dtection
94366-2,streptococcus naa dna [presence] in lower polymerase chain reaction respiratory specimen by pyogenes with probe detection
94366-2,s pyo dna lower resp ql naa+probe
94366-2,s pyo dna lower resp ql naa+probe naa+probe
94366-2,s pyo ql lower resp dna naa+probe
94366-2,s. pyogenes dna naa+probe ql (lower resp)
94366-2,pyogenes s. random dna naa+probe ql(loweresp)
94366-2,s. dna pyogees naa+probeq (lowe resp
21402-3,mumps virus igm ab [titer] in cerebral spinal fluid by immunofluorescence
21402-3,mumps virus igm ab [titer] in cerebral immunofluorescence fluid by spinal
21402-3,mumps virus igm ab [titer] immunofluorescence cerebral spinal fluid by titre in
21402-3,muv igm titr csf if
21402-3,aby muv igmitr if csf
21402-3,muv igm if csf titr
21402-3,muv igm if (csf) [titer]
21402-3,muv igm if (csf) [titer] dilution factor (titer)
21402-3,muv igm if [titer] spinal fld (csf)
24193-5,coxsackievirus b5 ab [titer] in serum by complement fixation --1st specimen
24193-5,coxsacieirs compement [tier] in serum by b5b fixation --1st sr specimn
24193-5,coxsackievirus serum ab [titer] in b5 by complement fixation --1st specimen
24193-5,cv b5 ab sp1 titr ser cf
24193-5,cv b5 cf sp1 titr ser ab
24193-5,compfix cv b5 sp ab tirser cf
24193-5,coxsackievirus b5 ab spec 1 cf (s) [titer]
24193-5,coxsackievirus b5 ab spec 1 cf [titer] cv b5 (s)
24193-5,coxsackievirus b5 spec ab 1 cf (s) [titer]
24427-7,mycobacterium avium ss paratuberculosis [presence] in specimen by organism specific culture
24427-7,mycobacterium avium ss paratuberculosis [presence] specific specimen by organism in culture
24427-7,mycobacteium avium ss paratuerculosis [presece] inpcimen by aism spcific culure
24427-7,m avium paratb spec ql cult
24427-7,m avium paratb pec q clt acid fast bacillus
24427-7,m avium paratb spec presence cult
24427-7,m. avium ss paratuberculosis org specific cx ql (specimen)
24427-7,avium m. ss paratuberculosis org specific cx ql mycobact (specimen)
24427-7,m. rg ss paratuberculosis aium specfic ssp cx ql specimen)
3900-8,oxyphenbutazone [mass/volume] in serum or plasma
3900-8,oxyphenbutazone [mass/volume] in ser or plasma
3900-8,xyphenbuazone [mass/volume] in ser ser or plasma or asma
3900-8,oxyphenbutazone serpl-mcnc
3900-8,serpl-mnc xphebutazone pl
3900-8,serpl oxyphenbtazne serpl-mcnc
3900-8,oxyphenbutazone [mass/vol]
3900-8,[mass/vol] oxyphenbutazone sr
3900-8,californit massvol oxyphenutazone
101245-9,leucine-rich glioma-inactivated protein 1 ab [presence] in serum or plasma by immunofluorescence
101245-9,leucine-rich glioma-inactivated protein 1 by [presence] in ser or plasma ab immunofluorescence
101245-9,leucine-rihgliominactivaed protein  ab [preence]in um or plasma by immunofuoresence
101245-9,lgi1 ab serpl ql if
101245-9,lgi1 ab serology if ql serpl
101245-9,lgi1 ab spl lgi1 ab ql if
101245-9,leucine-rich glioma-inactivated protein 1 ab if ql
101245-9,leucine-rich glioma-inactivated 1 protein ab if presence
101245-9,leucine-rich glioma-inactivated protein 1 ab if ql
29857-0,anaplasma phagocytophilum igm ab [presence] in serum
29857-0,anaplasma phagocytophilum igm ab in infectious disease [presence] serum
29857-0,igm phagcytoplum analasma b[pesence] ehrlichia phagocytophila in serum
29857-0,a phagocytoph igm ser ql
29857-0,phagocytoph a igm se ql
29857-0,a phagocytoph igm ser e equi ql
29857-0,a. phagocytophilum igm ql (s)
29857-0,igm phagoctophilum a. presence qual (s)
29857-0,igm phagocytophilum a. presence autoantibodies (s)
21122-7,borrelia hermsii igm ab [titer] in serum by immunofluorescence
21122-7,immunfuorescenc hrmsii igmab [titer] in serum by borrelia
21122-7,borrelia antby hermsii igm ab [titer] in serum by immunofluorescence
21122-7,b hermsii igm titr ser if
21122-7,b hermsii igm titr ser if
21122-7,random b herm gm itrser if
21122-7,b. hermsii igm if (s) [titer]
21122-7,b. hermsii s) if gm [titer]
21122-7,b. igm hermsii if (s) [titer]
59159-4,microalbumin/creatinine [ratio] in 24 hour urine
59159-4,microalbumin/creatinine [ratio] in nephrology 24 hour urine
59159-4,microalbumin/creatinine [ratio] in 24 hour urine crea
59159-4,microalbumin/creat 24h ur-rto
59159-4,microalbumin/creat ur-rto 24h
59159-4,rto microalbumin/creat ur-rto 24h
59159-4,albumin/creatinine dl <= 20 mg/l (24h u) [ratio]
59159-4,albumin/creatinine dl <= 20 mg/l (4h ratio] u
59159-4,albumin/creatinine dl <= mg/l 20 (24h u) [ratio]
24097-8,n-acetylglucosamine-6-sulfatase [enzymatic activity/mass] in fibroblast
24097-8,n-acetylglucosamine-6-sulfatase fibroblast activity/mass] in [enzymatic
24097-8,n-acetylglucosamine-6-sulfatase fibroblast activity/mass] in [enzymatic
24097-8,nag6sulfatase fib-ccnt
24097-8,nag6sfatase fib-ccnt
24097-8,fib-cnt nag6sufatase mps iii d
24097-8,n-acetylglucosamine-6-sulfatase (fibroblast) [catalytic activity/mass]
24097-8,n-acetylglucosamine-6-sulfatase [catalytic (fibroblast) activity/mass] mps iii d
24097-8,n-cetylgucosamie-6-sulfatase fibroblat) point in time activity/mass [catalic
62847-9,phenx - cardiorespiratory fitness - non-exercise protocol 151401
62847-9,penx - cardiorespiratory 1101 non-exercise protocol fitness
62847-9,non-exercise - cardiorespiratory panel fitness - phenx protocol 151401
62847-9,cardioresp non-exercise proto
62847-9,roto on-exercise cariresp
62847-9,proto non-exercise cardioresp
56996-2,urea/creatinine [mass ratio] in 24 hour urine
56996-2,urea/creatinine [mass ratio] in 4 hour rine
56996-2,hour [mass ratio] in 24 urea/creatinine urine
56996-2,urea/creat 24h ur
56996-2,urecreat 24h ur
56996-2,urea/creat cr 24h ur
56996-2,urea/creatinine (24h u) [mass ratio]
56996-2,quantitative (24h urea/creatiine u) mas ratio]
56996-2,urea/creatinine ratio] u) [mass quantitative (24h
47613-5,decanoate (c10:0)/creatinine [molar ratio] in urine
47613-5,decanoate c1:0/creatinine [molarratio] n urine
47613-5,decanoate (c10:0)/creatinine [molar ratio] in random urine
47613-5,decanoate/creat ur-srto
47613-5,ur-rto decanoate/creat substance ratio
47613-5,ur-srto decanoate/creat
47613-5,decanoate (c10:0)/creatinine (u) [molar ratio]
47613-5,point in time decanoate [molar (c1:0)/creatnine(u) ratio]
47613-5,decanoate (c10:0)/creatinine ur (u) [molar ratio]
78351-4,tetradecadienoate (c14:2) [entitic substance] in red blood cells
78351-4,tetradecadienoate (c14:2) random [entitic blood in red substance] cells
78351-4,tetradecadienoate (c14:2) [entitic substance] in red blood cells chemistry
78351-4,tdecadienoate entsub rbc
78351-4,etsub point in time tdecadienoate rbc
78351-4,entitic substance etsbrbc tecadienoate
78351-4,tetradecadienoate (c14:2) (rbc) [entitic substance]
78351-4,tetradecadienoate tdecadienoate (rbc) (c14:2) [entitic substance]
78351-4,tetradecadienate (c142) [entitic (rbc) substance]
79487-5,lactyl lactate/creatinine [molar ratio] in urine
79487-5,[mola latte/creatinine chemistry lactyl raio inurine
79487-5,lactyllactate/creatini [moar raio] in urine
79487-5,lactyl lactate/creat ur-srto
79487-5,lactyl ur-rto lactate/creat point in time
79487-5,lactyl latate/creatur-srto lactic acid
79487-5,lactyl lactate/creatinine (u) [molar ratio]
79487-5,lactyl actate/cretinine u)[olar rati]
79487-5,[molar lactate/creatinine (u) lactyl ratio]
50922-4,tin [moles/mass] in hair
50922-4,tin [moles/mass] in hair drugs
50922-4,tin [moles/mass] in hair
50922-4,tin hair-scnt
50922-4,tin drug/toxicology hair-scnt
50922-4,hair-cnt tin har
50922-4,tin (hair) [moles/mass]
50922-4,tin [moles/mass] (hair)
50922-4,in quantitative (hair)[moles/mass]
75043-0,pyridoxine [moles/volume] in cerebral spinal fluid
75043-0,pyridxine cerebrl [mle/volume]in spinal fluid
75043-0,pyridxine [molevolue] in erebral spnal fluid spinal fluid
75043-0,vit b6 csf-scnc
75043-0,b6 quan vit cerebrospinal fluid-snc
75043-0,vit chemistry 6 cs-scnc
75043-0,pyridoxine (csf) [moles/vol]
75043-0,(csf)olsvol] pyridoxol pyridoxie
75043-0,[moes/vl] pyridoxol pridoxinecsf)
60258-1,bacteria identified in bone marrow by culture
60258-1,bacteia identfied in bone marrow random by cultur
60258-1,bacteria identified marrow bone nominal in by culture
60258-1,bacteria mar cult
60258-1,cult mar beria
60258-1,mar bacteria cult
60258-1,bacteria identified cx nom (bm)
60258-1,cx identified bacteria nom (bm)
60258-1,identified bacteria c&s cx nom (bm)
6913-8,chlamydophila pneumoniae igg ab [titer] in serum by immunofluorescence
6913-8,ab pneumoniae igg chlamydophila [titer] in serum by immunofluorescence
6913-8,chlmydophilpneumniae igg ab [titer] in serum b immunofluorscence
6913-8,c pneum igg titr ser if
6913-8,c titr igg pneum ser infectiousdisease if
6913-8,c anticomplement immunofluorescence if igg titr ser pneum
6913-8,c. pneumoniae igg if (s) [titer]
6913-8,c. pneumoniae (s) if igg [titer] trf
6913-8,c. pneumoniae igg if (s) [titer] immunoglobulin g
5084-9,chlamydia sp ab [titer] in serum by immunofluorescence
5084-9,serum hlamyia sp [ttr] ab in serum byiunofluoescec
5084-9,chlamydia sp ab [titer] in serum by immunofluorescence
5084-9,chlamydia ab titr ser if
5084-9,chlamdi abitr if ser
5084-9,chlamydia ab titr anti ser if
5084-9,chlamydia sp ab if (s) [titer]
5084-9,chlamydia sp ab if (s) [titer]
5084-9,chlamydia sp ab if (s) id [tter]
22928-6,brucella canis ab [presence] in serum
22928-6,brucella canis ab prsence] in ser
22928-6,peence]in cais a infectious disease brucela serum
22928-6,b canis ab ser ql
22928-6,b ser ab canis ql
22928-6,ql autoantibodies canis ab sr b
22928-6,br. canis ab ql (s)
22928-6,canis br. ab presence(s)
22928-6,ql canis ab br. (s)
32662-9,afipia felis igg ab [presence] in serum
32662-9,afipia eis ig ab [ql] in serum
32662-9,afipia felis igg ab [esence] in ser ordinal
32662-9,a felis igg ser ql
32662-9,a point in time felis igg serum ql
32662-9,l felsigg serum a
32662-9,a. felis igg ql (s)
32662-9,a. feis gg l ( antby
32662-9,feisigql a. (s)
78773-9,abacavir [mass/volume] in serum or plasma
78773-9,abacavir [mass/volume] in ser or plasma sr
78773-9,abacavir [mass/volume] n serum sr or plasma
78773-9,abacavir serpl-mcnc
78773-9,serplmcnc bavir
78773-9,abacavir serpl-cnc ser
78773-9,abacavir [mass/vol]
78773-9,[mass/vol] abacavir
78773-9,quant aaair[mass/vol]
9364-1,bordetella pertussis igm ab [units/volume] in serum
9364-1,bodetellpertusis antibody igm ab [unit/vole] in serum
9364-1,bordetella pertussis igm [units/volume] ab in serum
9364-1,b pert igm ser-acnc
9364-1,igmser-acnc pert b quantitative
9364-1,arbitrary concentration bpert igm ser-acnc
9364-1,b. pertussis igm qn (s)
9364-1,b. qn pertussisigm ()
9364-1,b. pertussis igm autoantibodies qn(s)
27058-7,beta alanine [moles/volume] in amniotic fluid
27058-7,beta alanine [moles/volume] amniotic random in fluid
27058-7,random beta alanine [moles/volume] fluid amniotic in
27058-7,b-alanine amn-scnc
27058-7,b-alanine amn-scnc
27058-7,b-lanine amn-scnc
27058-7,beta alanine (amn fld) [moles/vol]
27058-7,lanine bta (amn fl) [moes/ol] level
27058-7,beta alanine fld) (amn [moles/vol]
80310-6,pupil assessment panel
80310-6,pupil panl panel assessment
80310-6,pupil assessmen p prime panel
80310-6,pupil assessment pnl
80310-6,pupil assesnt pnl
80310-6,pupl assessment pnl
106915-2,alveolar macrophages/cells in bronchoalveolar lavage
106915-2,alveolar macrophages/cell in bronchoalveolarlaage
106915-2,qnt alveola macrophaes/cellsin bronchoalveolar lavage
106915-2,alv macro nfr bal
106915-2,alv macro macrphg nfr bl
106915-2,alv macro percent bal nfr
106915-2,alveolar macrophages/cells (bal)
106915-2,alveolar macrophages/cells (bal)
106915-2,alveolar qnt (bal) macrophages/cells
93470-3,furanylfentanyl [mass/volume] in urine by confirmatory method
93470-3,furanylfentanl [mass/volume] in conf urine ycofirmatoy metho
93470-3,furnlfentanyl drug/toxicology [mass/vlume] in rineby cofirmatory meod
93470-3,furanylfentanyl ur cfm-mcnc
93470-3,furanylfentayl r cfm-mcnc
93470-3,furanlfetanyl ur cfm-mcnc
93470-3,furanylfentanyl confirm (u) [mass/vol]
93470-3,furanylfentanyl confirm (u) [mass/vol]
93470-3,[mass/vol] confirm (u) random furanylfentanyl
104543-4,7-aminoclonazepam [mass/volume] in serum by lc/ms/ms
104543-4,7-aminoclonazepam qnt [mass/volume] in lc/ms/ms by serum
104543-4,lc/ms/ms [mass/volume] in serum by 7-aminoclonazepam
104543-4,7aminoclonazepam ser lc/ms/ms-mcnc
104543-4,7aminoclonazepamser lcm/ms-mcnc
104543-4,7aminoclonazpam lc/m/ms-mcnc ser random
104543-4,7-aminoclonazepam lc/ms/ms (s) [mass/vol]
104543-4,(s) lc/ms/ms 7-aminoclonazepam [mass/vol]
104543-4,lc/ms/ms 7-aminoclonazepam (s) random [mass/vol]
63262-0,glomerular basement membrane ab [presence] in serum by immunoassay
63262-0,glmerularasentmembrane ab [preece] in by erum iaa mmunoassay
63262-0,glomerular basement membrane ab [presence] in serum by immunoassay
63262-0,gbm ab ser ql ia
63262-0,gbm ab er ql elfa ia
63262-0,gbm ab serum ql ia
63262-0,glomerular basement membrane ab ia ql (s)
63262-0,glomerular ser basement membrane ab ia ql (s)
63262-0,glomerular basement membrane ab ia presence (s) abs
98110-0,chemokine (c-c motif) ligand 7 [mass/volume] in serum or plasma
98110-0,chmokine (c-c 7 ligand motf) [mass/volume] insermor plasma serum
98110-0,chmokine nc28 plasma otif igand [mass/olue] in seru or (c-c
98110-0,ccl7 serpl-mcnc
98110-0,serp serpl-mcnc ccl7
98110-0,serpcnc ccl7 random
98110-0,chemokine (c-c motif) ligand 7 [mass/vol]
98110-0,[mass/vol] (c-c c-c motif chemokine 7 motif) ligand 7 chemokine
98110-0,chemokine (c-c motif) ligand 7 [mass/vol]
2492-7,iodine [mass/time] in 24 hour urine
2492-7,iodine [mass/time] in 24 hour 24 hours urine
2492-7,iodine [mass/time] in 24 hou urine
2492-7,iodine 24h ur-mrate
2492-7,iodine ur-mrate 24h
2492-7,24h iodine ur-mrat
2492-7,iodine (24h u) [mass/time]
2492-7,qnt (24h iodine u) [mass/time]
2492-7,iodine (24h u)[ass/time] i
12341-4,mazindol [presence] in serum or plasma
12341-4,mazindol [presene] in sem orplasa
12341-4,mazindol [presence] serum in or plasma
12341-4,mazindol serpl ql
12341-4,drug/toxicology mazindol srpl ql
12341-4,ql serpl mazindol
12341-4,mazindol ql
12341-4,mazindol presence
12341-4,mazindol presence
15355-1,estrone sulfate [mass/volume] in serum or plasma
15355-1,quantitative estrone sulfate [mass/volume] in serum or plasma
15355-1,estrone quant sulfate [mass/volume] in serum or plas
15355-1,estrone sulfate serpl-mcnc
15355-1,sulfate estrone serpl-mcnc e1s
15355-1,estrone sulfate sr serpl-mcnc
15355-1,estrone sulfate [mass/vol]
15355-1,[mass/vol] sulfate estrone
15355-1,estrone quantitative sulfate [mass/vol]
12446-1,halogenated organic molecules [identifier] in urine
12446-1,halonted organic molecles ua [identifier] in urine
12446-1,alogenaed organic molecule [identifie] in urine
12446-1,halog hc ur
12446-1,halog hc ur ua
12446-1,random halog hc ur
12446-1,halogenated organic molecules nom (u)
12446-1,haloenated mlecules organic nom (u)
12446-1,halogenated organic mlecles identity or presence nom (u)
12883-5,borrelia burgdorferi 18kd ab [presence] in body fluid by immunoblot
12883-5,borreliabugdorferi 18kdab [presece] in body flud by mmunoblot
12883-5,borrelia burgdorferi 18kd body [presence] in ab fluid by immunoblot
12883-5,b burgdor18kd ab fld ql ib
12883-5,b burgdor18kd ld ab ql b
12883-5,b brgdor18d bodies ib abfldql
12883-5,b. burgdorferi 18kd ab ib ql (body fld)
12883-5,b. burgdorfei microbiology 18kd presence ib ab (ody fd)
12883-5,b. wb ab 18kd burgdorferi ib ql (bodyfld
62196-1,promis short form - satisfaction with participation in social roles 7a - version 1.0
62196-1,promis short form - satisfaction with participation in social roles panel 7a - version 1.0
62196-1,promis hort form - satisfaction with participation in social roles 7a - ersion 10
61088-1,oxazepam [presence] in gastric fluid
61088-1,fluid presence] in gastric oxazepam
61088-1,oxaepam flui gastri [presence]
61088-1,oxazepam gast ql
61088-1,oxazpam ql gastric fluid gst
61088-1,ql gastric contents oxaepmgst
61088-1,oxazepam ql (gast fld)
61088-1,oxazepam (gast ql fld)
61088-1,oxazepam ql fld) (gast
23337-9,ovine progressive pneumonia virus dna [presence] in specimen by naa with probe detection
23337-9,ovne proressive with virus dna presence] in spmen bynaa 3 self-sustaining sequence replication peumona prob detection
23337-9,ovine proessve neumoni virus dna presece] i specimn by naa wthprobe detection
23337-9,oppv dna spec ql naa+probe
23337-9,oppv presence daspc naaprobe
23337-9,oppv spec dna ql naa+probe
23337-9,ovine progressive pneumonia virus dna naa+probe ql (specimen)
23337-9,ovine virus pneumonia amplif progressive dna aa+probe l (pecen)
23337-9,pneumonia rogessve oine virus dna naa+probe dna nucleic acid probe ql (specimen)
4382-8,penicillin v potassium [mass] of dose
4382-8,penicillin v potasu of [mass] dose wycillin
4382-8,penicilin possiu [mass] f oe
4382-8,penicillin v potassium dose
4382-8,penicillin v dose med or substance potassium dose
4382-8,penicillin point in time v potassium dose
4382-8,penicillin v potassium (dose) [mass]
4382-8,penicillin v potassium (dose) [mass]
4382-8,penicillin v potassium [mass] (dose)
86843-0,resident mood interview (phq-9) - symptom presence in the last 2 weeks [cms assessment]
86843-0,reident ood panel intervew (hq-9) - syptompresenc in theast 2 weeks [cms assessmet]
86843-0,2 weeks thelast mooditervew (phq-9)- smpt pesence n resident weeks [cs assessment]
91827-6,mycoplasma hominis dna [presence] in lower respiratory specimen by naa with probe detection
91827-6,lower hominis dna [presence] in mycoplas respiratory secmen by na with mycoplas robe detection
91827-6,mycoplasma [presence] dna hominis in lower respiratory specimen by naa with probe detection
91827-6,m hominis dna lower resp ql naa+probe
91827-6,m resp dna lower hominis ql naa+probe
91827-6,m hoinis amplified dna loerresp ql na+probe
91827-6,m. hominis dna naa+probe ql (lower resp)
91827-6,(lower probe with target amplification hominis dna naa+probe ql m. resp)
91827-6,(lowerrsp) ominis dna naa+probe presence m.
29730-9,leptospira interrogans sv shermani ab [presence] in serum by agglutination
29730-9,leptospir interrogs sv [preence] ab shermani in srum by agglutination
29730-9,[presence] ierroganssv shermni b leptspira inserum byagglutiatin
29730-9,l inter sherm ab ser ql aggl
29730-9,l inter microbiology shermbsr l aggl
29730-9,ser serum inter sherm ab l ql aggl
29730-9,l. interrogans sv shermani ab aggl ql (s)
29730-9,. herni s interrogns ab agl ql s) autoantibody
29730-9,l. interrogan sv shermani ab aggl presence (s)
106061-5,enteric bacteria panel - stool by naa with probe detection
106061-5,naat enteric bacteria panel - stool by naa with probe detection
106061-5,enteric bacteria panel - stool by probe with bact naa detection
106061-5,enteric bacteria pnl stl naa+probe
106061-5,naa+probe bacteria pl lcr tl enteric
106061-5,amplification enteric bacteria stl pnl naa+probe
106061-5,enteric bacteria panel naa+probe (stl)
106061-5,enteric bacteria panel naa+probe (stl)
106061-5,entric sda bcteia panel naa+probe (stl)
60128-6,paramethadione [mass/volume] in urine
60128-6,parametadione [mass/olume] uine in
60128-6,in [mass/volume] paramethadione urine
60128-6,pmo ur-mcnc
60128-6,ur-mcnc pmo
60128-6,ur-mc pmo quant
60128-6,paramethadione (u) [mass/vol]
60128-6,paramethadione (u) [mass/vol] point in time
60128-6,paramethadine (u) ua [mass/vol]
10675-7,hepatitis b virus surface ag [presence] in tissue by orcein stain
10675-7,b hepatiti virus surfaceg [ql i tissue hepatis by orcein stain
10675-7,hepatis b virus [prsence] g surfae n tissu by orcein sain
10675-7,hbv surface ag tiss ql orcein stn
10675-7,hbv stn ag tiss orcein surface
10675-7,hbvsurface ag tis ql orcein stn
10675-7,hbv surface ag orcein stain ql (tiss)
10675-7,hb surface ql orcein tain ag (tiss)
10675-7,hbv surface ag orcein (tiss) ql stain
1939-8,beta fructofuranosidase [enzymatic activity/volume] in serum
1939-8,beta ser point in time [enzymatic activity/volume] in fructofuranosidase
1939-8,beta fructofuanosidase [zymati activity/volume] in serum b-fructofuranosidase
1939-8,b-fructofuranosidase ser-ccnc
1939-8,b-fructofuranosidase serum ser-ccnc
1939-8,beta fructosidase ser-ccnc b-fructofuranosidase
1939-8,beta fructofuranosidase (s) [catalytic activity/vol]
1939-8,beta fructofuranosidase (s) [catalytic activity/vol] catalytic concentration
1939-8,beta fructofuranosidase serum (s) [catalytic activity/vol]
23144-9,japanese encephalitis virus neutralizing antibody [titer] in serum by neutralization test
23144-9,serum encephalitis virus neutralizing antibody [titer] ttr in japanese by neutralization test
23144-9,jpanese encephaliis virusneutralizing antibod [titr] i ser by neutralization test
23144-9,jev nab titr ser nt
23144-9,jev ttr nab ser
23144-9,ser nab titr jev nt
23144-9,jev neut ab neut test (s) [titer]
23144-9,[titer] neut ab neut test (s) jev
23144-9,jev neut ab neut test (s) [tir]
16310-5,acetone [presence] in body fluid
16310-5,inbody [presence] acetone fluid
16310-5,fluid [presence] in body acetone
16310-5,acetone fld ql
16310-5,acetone fld ql
16310-5,flu acetone fld ql
16310-5,acetone ql (body fld)
16310-5,(body presence acetone fld)
16310-5,actone q (bodyfld)
88709-1,albumin/globulin [mass ratio] in body fluid by electrophoresis
88709-1,albumin/globulin [mass ratio] in fluid body by electrophoresis
88709-1,albumin/globulin ody rati] in [mass lid by electrophori
88709-1,albumin/glob fld elph
88709-1,fl albmi/lob elph
88709-1,lph ld mcrto lbumin/gob
88709-1,albumin/globulin elph (body fld) [mass ratio]
88709-1,body fluid albumin/globulin elph (body fld) [mass ratio]
88709-1,albumin/globulin elph (body fld) [mass rati]
59260-0,hemoglobin [moles/volume] in blood
59260-0,i [molesvolum] hemoglobin bloo
59260-0,hemoglobin [moles/volume] in bld substance concentration
59260-0,hgb bld-scnc
59260-0,hb qnt bld-scnc
59260-0,bld-scnc hgb
59260-0,hemoglobin (bld) [moles/vol]
59260-0,[moles/vo] (bld) heoglobin quant
59260-0,[moles/vol] wb (ld) hemoglobin
652-8,microscopic observation [identifier] in urine by acid fast stain.ziehl-neelsen
652-8,microscpic fast [identifier] in urneby acid observation ain.ziehl-neelsen
652-8,microscopic observation acid in urine by [identifier] fast stain.ziehl-neelsen urn
652-8,zn stn ur
652-8,ur stn zn
652-8,acd stn zn ur
652-8,microscopic observation acid fast stain.ziehl-neelsen nom (u)
652-8,nom observation acid infectiousdisease fast stain.ziehl-neelsen microscopic (u)
652-8,microscpi observation om stain.ziehl-eelen acidfast (u)
82268-4,met by population rmr panel
82268-4,mt by oplation rmr pel
82268-4,met by populatin mr panel
82268-4,met by pop rmr pnl
82268-4,by met pop rmr pnl
82268-4,met basal metabolic rate rm pop by pnl
47824-8,deprecated 5-hydroxycaproate/creatinine [molar ratio] in urine
47824-8,depreated 5-hydroxycaproae/creatinine [molar atio] in urine
47824-8,deprecated ua 5-hydroxycaproate/creatinine [molar ratio] urine in
47824-8,deprecated 5oh-caproate/creat ur-srto
47824-8,point in time ur-srto 5oh-caproate/creat deprecated
47824-8,5oh-caproate/creat deprecated ur ur-srto
47824-8,5-hydroxycaproate/creatinine (u) [molar ratio]
47824-8,-hydroxycaproate/cretinine (u) rati] [olar
47824-8,5-hydroxycaproate/creatinine ratio] [molar (u)
54450-2,cyp2c9 and vkorc1 panel - blood or tissue by molecular genetics method
54450-2,cyp2c9 and vkorc1 panel - by or tissue blood molecular genetics method
54450-2,yp2c9andvkorc1 pane-blood or tisue by pnl molecular gnecs mto
54450-2,cyp2c9 + vkorc1 pnl bld/t
54450-2,tissue vkorc1 + cyp2c9 pnl bld/t
54450-2,cyp2c9 vkorc1 + pnl bld/t
54450-2,cyp2c9 and vkorc1 panel molgen (bld/tiss)
54450-2,cyp2c9 and vkorc1 panel molgen (blood/tiss) molpath.pharmg
54450-2,molgen and pnl vkorc1 panel cyp2c9 (d/tiss)
63363-6,thyrotropin receptor ab [units/volume] in blood from fetus
63363-6,thyrotropin receptor ab [units/volume] in bld from fetus
63363-6,thyrotropn receptr ab [units/volume] in blofrom fetu
63363-6,tsh recep ab bld fetus-acnc
63363-6,tsh recep ab fetus-acnc bld
63363-6,tsh recep fetus-acnc bld ab
63363-6,tsh receptor ab qn (bld fetus)
63363-6,tsh receptor ab qn (bld fetus) bld
63363-6,tsh receptor ab qn (bld fetus) blood
82200-7,vibrio cholerae+parahaemolyticus+vulnificus dna [presence] in stool by naa with non-probe detection
82200-7,detection cholerae+parahaemolyticu+vulnificus dna[prsence] in stol by naa wth no-probe vibrio
82200-7,vibrio cholerae+parahaemolyticus+vulnificus [presence] dna in stool by naa with non-probe detection
82200-7,v chol+para+vul dna stl ql naa+non-probe
82200-7,v chol+para+vul dna stl naa+non-probe presence
82200-7,v chol+para+vul ql stl dna naa+non-probe
82200-7,v. cholerae+parahaemolyticus+vulnificus dna naa+non-probe ql (stl)
82200-7,v. dna cholerae+parahaemolyticus+vulnificus naa+non-probe ql (stl)
82200-7,dnanaa+non-probe coleae+paraaemolyticus+vunificu v ql (stl)
3853-9,nicotine [mass/volume] in serum or plasma
3853-9,nicotine [mas/volue] i ser or plasma ser
3853-9,nicotine [mass/volume] in ser plasma or
3853-9,nicotine serpl-mcnc
3853-9,nicotine epl-mcnc
3853-9,ncotineserpl-mcc
3853-9,nicotine [mass/vol]
3853-9,[mass/vol pl nicotne
3853-9,[mass/vol] sr nicotine
2950-4,sodium [moles/volume] in body fluid
2950-4,sodum [moles/volume] in body fluid
2950-4,body [moles/volume] in sodium fluid
2950-4,sodium fld-scnc
2950-4,bf sodium fld-snc
2950-4,fld-scnc sodium qnt
2950-4,sodium (body fld) [moles/vol]
2950-4,[moles/vol] (bdy fld) odi na+
2950-4,sodium (body [moles/vol] fld)
39137-5,oral assessment panel
39137-5,panl ora sesment anel
39137-5,oral assssment panel
39137-5,oral assessment pnl
39137-5,oral p prime pn assessmet
39137-5,ora pt pnl assesment
72823-8,staphylococcus aureus enterotoxin c sec gene [presence] in specimen by naa with probe detection
72823-8,staphylococcus naa enterotoxin c sec gene [ql] in specimen by polymerase chain reaction aureus with probe detection
72823-8,staphylococcus naat aureus enterotoxin c sec gene [presence] in specimen by naa with probe detection
72823-8,s aureus etx c gene spec ql naa+probe
72823-8, aureus etx c genespec ql naa+probe
72823-8,s aureusetx c gene sc presence aa+probe 3 self-sustaining sequence replication
72823-8,s. aureus enterotoxin c sec gene naa+probe ql (specimen)
72823-8,presence aureus enterotxin c ec gene na+probe s. (ecimen)
72823-8,s. (specimen) enterotoxin c sec gene naa+probe ql aureus
70017-9,parainfluenza virus 1+2+3+4 igm ab [presence] in serum by immunoassay
70017-9,parainfluenza virus 1+2+3+4 igm ab [presence] by serum in immunoassay
70017-9,painfluenza virus1+2+3+4 igm  presece] in serumy imunoassa
70017-9,hpiv 1+2+3+4 igm ser ql ia
70017-9,hpiv ql igm ser 1+2+3+4 ia
70017-9,hiv 1+2+34 igm srql ia
70017-9,parainfluenza virus 1+2+3+4 igm ia ql (s)
70017-9,autoantibodies ql 1+2+3+4 gm ia parinfluenzavirus (s)
70017-9,hpiv1 arainfluenza vrus 1+2+4 im iaql (s)
76405-0,metamyelocytes [#] in body fluid by manual count
76405-0,metmyelocytes [] in quantitative body flud by mnual ount
76405-0,in [#] metamyelocytes body flui maual cont
76405-0,metamyelocytes fld manual
76405-0,manual fld b/f metamyelocytes
76405-0,metamyeloctes fld manal fluid
76405-0,metamyelocytes manual cnt (body fld) [#]
76405-0,cnt metamelocytesmanual (bod fld) [] count
76405-0,metamyelocyte cnt manual (ody fld) meta [#]
57674-4,coxiella burnetii igm ab [presence] in serum by immunofluorescence --2nd specimen
57674-4,coxiella burnetii igm ab ser in [presence] by immunofluorescence --2nd specimen
57674-4,cxiella burnetii id igmab [ql] in sum by imunofluoresence --2nd secimen
57674-4,c burnet igm sp2 ser ql if
57674-4,c burnet igm sp2 ser presence if
57674-4,acif c uet gm sp2 ser if
57674-4,c. burnetii igm spec 2 if ql (s)
57674-4,c. urneti igm spec 2 if ql (s)
57674-4,c. burnetii gm spc 2 qualitative ifql (s)
44713-6,collagen crosslinked n-telopeptide/creatinine [molar ratio] in specimen by immunoassay
44713-6,collagn cosslinked -telopeptide/creainieolarraio] in specimen by immunossay
44713-6,n-telopeptide of type i collagen collagen crosslinked n-telopeptide/creatinine [molar ratio] in specimen by immunoassay
44713-6,collagen ntx/creat spec ia-srto
44713-6,colgen ntx/reatspec a-srto point in time
44713-6,collgen ntx/crea spec isrto
44713-6,collagen crosslinked n-telopeptide/creatinine ia (specimen) [molar ratio]
44713-6,ia crosslinked n-telopeptide/creatinine collagen (specimen) [molar ratio]
44713-6,collagn crssliked n-telopeptidecreatinine random (specmen) a [mlar atio]
104439-5,polio virus 3 ab [titer] in serum by immunoassay --1st specimen
104439-5,polio virus 3 ab enzyme immunoassay [titer] in serum by immunoassay --1st specimen
104439-5,poo virus 3a [iter] in specime by meia imunoassay --1st sum
104439-5,pv3 ab sp1 titr ser ia
104439-5,titr sp1 ab sp1 pv3 ser ia
104439-5,pv3 ab sp1 tr sr meia ia
104439-5,polio virus 3 ab spec 1 ia (s) [titer]
104439-5,polio virus 3 ab spec 1 ia (s) sr [titer]
104439-5,polio virus 3 ab spec 1 ia (s) [titer]
16193-5,pentobarbital [presence] in urine by confirmatory method
16193-5,pentobarbital [prsence] in urine by cofirmatory method
16193-5,confirmatory [ql] in urine by pentobarbital method
16193-5,pentobarb ur ql cfm
16193-5,pentobarb ur presence cfm
16193-5,pentobarb gcms ur ql cfm
16193-5,pentobarbital confirm ql (u)
16193-5,pentobarbital presence confirm (u)
16193-5,pentobarbital confirm presence (u) lc/ms/ms
23741-2,francisella tularensis ab [titer] in serum by complement fixation
23741-2,microbiology francisella by ab [titer] in serum tularensis complement fixation
23741-2,francisella f tular fixation ab [titer] in serum by complemet tularnsi
23741-2,f tular ab titr ser cf
23741-2,f tular ab cf ser tir infectious disease
23741-2,f tuar cf ser titr titered
23741-2,f. tularensis ab cf (s) [titer]
23741-2,f tularensi [iter] cf (s) ab
23741-2,. (s) ab cf tularensis [titr]
17504-2,psilocybin [presence] in urine
17504-2,sloybin [presence] in uine screen
17504-2,psilocybi [presence] in urie drug/toxicology
17504-2,psilocybin ur ql
17504-2,presence psilocybnurql
17504-2,psilocybin ur ql
17504-2,psilocybin ql (u)
17504-2,presence psilcybin (u)
17504-2,ql screen psilocybin (u)
17817-8,gamma globulin/protein.total by electrophoresis in urine collected for unspecified duration
17817-8,gamma tp globulin/protein.total by electrophoresis in urine collected for unspecified duration
17817-8,unspecified globulin/protein.total by electrophoresis electrophrs in urine collected for gamma duration
17817-8,gamma glob ?tm mfr ur elph
17817-8,gamma elect glob ?tm mfr ur elph
17817-8,pr gamma glob?tm elph ur mfr
17817-8,gamma globulin unsp time elph (u) [mass fraction]
17817-8,gamma globulin unsp time elph quant [mass (u) fraction]
17817-8,gamma globulin [mass time elph(u) unsp fration]
77340-8,alpha 1 globulin [mass/volume] by electrophoresis in urine collected for unspecified duration
77340-8,alpha unspecified globulin [mass/volume] by electrophoresis in urine collected for 1 duration ep
77340-8,alpha 1 globulin ur [mass/volume] by electrophoresis in urine collected for unspecified duration
77340-8,alpha1 glob ?tm ur elph-mcnc
77340-8,alpha glob elph-mcnc ?tmur
77340-8,alpha1 glob ?tm ur elph-mcnc
77340-8,alpha 1 globulin unsp time elph (u) [mass/vol]
77340-8,alpha 1 gobulin unsp time elp (u [mass/vol]
77340-8,globulin alpa unp me lph (u) [mss/vol] electr
78786-1,amitriptyline [mass/volume] in blood
78786-1,in amitriptylinemass/volume] bod
78786-1,amitriptyline in [ass/volume] quant lood
78786-1,amitrip bld-mcnc
78786-1,bld-mcnc drug/toxicology amitrip
78786-1,amitrip bl-mcn
78786-1,amitriptyline (bld) [mass/vol]
78786-1,amitriptyline [mass/vol] (bld)
78786-1,[mass/vol] (bld) level amitriptyline
17798-0,amikacin [mass/volume] in cerebral spinal fluid
17798-0,mkain fluid in cerebral spnal [ms/volume
17798-0,amiacin [mass/voume] ceebrl level in sinal flid
17798-0,amikacin csf-mcnc
17798-0,csfmcnc amikacin
17798-0,amacin csf-mcnc
17798-0,amikacin (csf) [mass/vol]
17798-0,amikacin qnt [mass/vol] (csf)
17798-0,amikacin (cerebrospinal fluid) [mass/vol]
17841-8,amylase [enzymatic activity/time] in 12 hour urine
17841-8,mylase [enzymatic in activity/time] diastase 12 our urin
17841-8,amyla [nzymic activiy/time]n 12 k87 hour rine
17841-8,amylase 12h ur-crate
17841-8,12h urn amylas ur-crate
17841-8,1hur-crate amylase amyl
17841-8,amylase (12h u) [catalytic activity/time]
17841-8,amylase activity/time] ams [catalyti (12hu)
17841-8,amylase (12h u) crate [cataltc activiy/time]
53828-0,cyclosporine [mass/volume] in blood --trough
53828-0,cyclosprine in [mass/volume] blood --trough pre
53828-0,cyclosporine [mas/volume] blood i -trouh
53828-0,cyclosporine trough bld-mcnc
53828-0,touh cyclosporine blcnc
53828-0,cyclosporine bld d-mcnc trough
53828-0,cyclosporine trough (bld) [mass/vol]
53828-0,cyclosporine (bld) trough [mass/vol]
53828-0,(bld) trough cyclosporine [mass/vol]
1858-0,angiotensin i [mass/volume] in plasma
1858-0,angiotensin [mass/volume] i in plasma
1858-0,angiotensi lasa [mass/vume]in i
1858-0,angiotensin i plas-mcnc
1858-0,i aniotensin plas-cnc level
1858-0,quan plas-mcnc i agotensin
1858-0,angiotensin i (p) [mass/vol]
1858-0,(p) angitensni mss/vol]
1858-0,angiotensin i (p) plasma [mass/vol]
23697-6,canine herpesvirus neutralizing antibody [presence] in serum by neutralization test
23697-6,canine herpesvirus neutralizing antibody [ql] in serum by neutralization test
23697-6,caine herpesvus nutralizing ntibody [pesene] inserum by utralization test
23697-6,cahv nab ser ql nt
23697-6,nt e ql cahvab
23697-6,ql nab ser ser virus neutralization cahv nt
23697-6,canine herpesvirus neut ab neut test ql (s)
23697-6,canine sr herpesvirus neut b ettest l (s
23697-6,canineherpesvirus neut ab neut test ql (s)
78537-8,urea nitrogen [moles/volume] in peritoneal dialysis fluid --4 hour dwell specimen
78537-8,urea nitrogen [moles/volume] in peritoneal dialysis fluid --4 hour dwell specimen dialysis fluid
78537-8,ureaitrogn [mole/volume] in peritoneal dialsis fluid --4 hou dwell substance concentration specimen
78537-8,urea nit 4h dwell spec diafp-scnc
78537-8,urea nit diafp-scnc dwell spec 4h
78537-8,dwell nit 4h urea spec diafp-scnc spec
78537-8,urea nitrogen 4 hour dwell specimen (perit dial fld) [moles/vol]
78537-8,urea nitroge  our dwell secimen (perit dialfld) [moles/vol]
78537-8,fld) nitrogen 4 hour dwell specimen (perit dial urea [moles/vol]
72798-2,methylenedioxypyrovalerone/creatinine [mass ratio] in urine
72798-2,methylenedioxypyrovalerone/creatinine [mass quant urine in ratio]
72798-2,methylenedioxypyrovalerone/creatinine ratio] [mass in mcrto urine
72798-2,mdpv/creat ur
72798-2,drugs ur mdpv/creat
72798-2,ur mdpv/cret
72798-2,methylenedioxypyrovalerone/creatinine (u) [mass ratio]
72798-2,methyenedioxypyrovalrone/ceatinie u[mass ratio]
72798-2,mehyeneioxyyrovalerone/creatinine(u)[mass ratio]
63533-4,centromere protein b ab [presence] in cerebral spinal fluid by immunoassay
63533-4,centromere protein b ab [ql] in immunoassay spinal fluid by cerebral
63533-4,centromere protein b b [pesence] in crebral sinalfluid by mmunoassay
63533-4,centromere b ab csf ql ia
63533-4,ntmere bab csf qlia
63533-4,ia b ab csf ql centromere
63533-4,centromere protein b ab ia ql (csf)
63533-4,centomere protein b ab ia presence csf)
63533-4,centromere protein b  ia ql cs)
34453-1,jamestown canyon virus rna [presence] in cerebral spinal fluid by naa with probe detection
34453-1,point in time jamestown canyon virus rna presence] in cerbal spinal probe by naa ith fluid detectin
34453-1,jamestown canyon virus rna ligase chain reaction [presence] in cerebral spinal fluid by naa with probe detection
34453-1,jcv rna csf ql naa+probe
34453-1,jcv naa+probe csf ql rna
34453-1,jcv random rna csf naa+probe ql
34453-1,jamestown canyon virus rna naa+probe ql (csf)
34453-1,jamestown canyon ligation-activated transcription virus ql naa+probe rna (cerebrospinal fluid)
34453-1,jamestown canyon virus rna naa+probe (csf) ql
17926-7,bacteria # 2 identified in wound deep by anaerobe culture
17926-7,bacteria # 2 dentified byanaerob woud deep i culture
17926-7,bacteria # 2 identified in anaerobe wound deep by anaerobe culture
17926-7,bacteria deep wnd anaerobe cult org #2
17926-7,cult deep wnd anaerobe bacteria rg anaerobe #2
17926-7,bacteria wnd deep anaerobe cult org #2
17926-7,bacteria identified # 2 anaer cx nom (deep wound)
17926-7,bacteria identified anaer infectious disease 2 # cx nom (deep wound)
17926-7,bacteria identified # anaer 2 cx nom (deep wound)
63323-0,ribosomal ab [titer] in cerebral spinal fluid by immunofluorescence
63323-0,rbosoml spinal [titer] incerebral ab luiby immuofluorescence
63323-0,ribosoml ab [titer] inceebral spinal flui by fluoresent immuofluorescence
63323-0,ribosomal ab titr csf if
63323-0,rbosoml a titr csf if neurology
63323-0,ribosmal cerebrospinal fluid spinal fl itr ab if
63323-0,ribosomal ab if (csf) [titer]
63323-0,ribosomal ab if (cerebrospinal fluid) [titer] spinal fl
63323-0,ribosomal ab (csf) if [titer]
59892-0,cotinine [moles/volume] in gastric fluid
59892-0,cotinine [moles/volme] in gastric flid
59892-0,fluid [moles/volume] in gastric cotinine
59892-0,cotinine gast-scnc
59892-0,gast-snc cotinine gast
59892-0,substance concentration gast-scnc cotinine
59892-0,cotinine (gast fld) [moles/vol]
59892-0,(gast gastric contents coinine fld) [mole/vol]
59892-0,cotinine [moles/vol] fld) substance concentration (gast
3303-5,acetazolamide [mass/time] in 24 hour urine
3303-5,cetzolamide [ass/ime] urine 24 hour in
3303-5,acetazolmide drugs [masstime] hoururine 24 i
3303-5,acetazolamide 24h ur-mrate
3303-5,aceazolamide 24 ur-mrate
3303-5,ur-mrate 24h acetazolamide
3303-5,acetazolamide (24h u) [mass/time]
3303-5,(24h acetazlamide u) [mass/time]
3303-5,(4h acetazlamide 24hr u) [masstie]
49207-4,bartonella elizabethae igm ab [titer] in serum
49207-4,bartonella point in time elizabethae igm ab [titer] serum in
49207-4,bartonella eliabethae aby igm ab [titer] in srm
49207-4,b elizabethae igm titr ser
49207-4,immune globulin m b elizabethaeigm tr ser
49207-4,b titr igm lizabetha sr
49207-4,b. elizabethae igm (s) [titer]
49207-4,b. elizabethae [titer] (s) igm
49207-4,elizabethae b. aby igm (s) [titer]
4115-2,amikacin [mass] of dose
4115-2,mikaci [mas] of dose
4115-2,amikacin [mass] of quan dose
4115-2,amikacin dose
4115-2,dose amikain
4115-2,dose amikacin
4115-2,amikacin (dose) [mass]
4115-2,amikacin (dose) [mass]
4115-2,amikacin (dose) quan [mass]
17734-5,trichinella spiralis igg ab [units/volume] in serum
17734-5,serum spirals igg a [units/volme] in trchinella
17734-5,trichinell spirlis ig b [units/volum i srum
17734-5,t spiralis igg ser-acnc
17734-5,quant spiralis t igg serum-acnc
17734-5,t igg spiralis quantitative ser-acnc
17734-5,t. spiralis igg qn (s)
17734-5,t. spiralis (s) qn igg
17734-5,t. spiralis igg qn (s
53153-3,alloisoleucine+isoleucine+leucine+hydroxyproline/phenylalanine [molar ratio] in dbs
53153-3,alloisleuie+isoleucine+eucine+ydroxyproine/phenyllanine [molr ratio dbs in
53153-3,alloisoleucine+isoleucine+leucine+hydroxyproline/phenylalanine [molar ratio] in dbs dbs
53153-3,aile+ile+leu+hyp/phe dbs-srto
53153-3,dbs-srto aile+ile+leu+hyp/phe
53153-3,scrto dbs-srto aile+ile+leu+hyp/phe
53153-3,alloisoleucine+isoleucine+leucine+hydroxyproline/phenylalanine (dbs) [molar ratio]
53153-3,(dbs) lloisolucin+isolucine+leucie+ydroxproine/phenylalanine [moar point in time ratio]
53153-3,quantitative (dbs) alloisleucneisoleucine+lucine+droxyprolne/pheylalanine [molar ratio]
98019-3,promegakaryocytes/cells in bone marrow by manual count
98019-3,promegakaryotes/cells maua bne maro b in cont quant
98019-3,promegakaryocytes/cells in bone marrow by manual count
98019-3,promegakaryocytes nfr mar manual
98019-3,promegakarcyte manual mar manl nr
98019-3,promegakaryytesnfr ar manual
98019-3,promegakaryocytes/cells manual cnt (bm)
98019-3,cnt manual promegakaryocytes/cells (bm) number fraction
98019-3,promegkarocyte/cels manual cnt(bm)
35486-0,fonofos [mass/volume] in serum or plasma
35486-0,fonofos serum drugs in [mass/volume] or plasma
35486-0,or [mass/volume] in serum fonofos plasma
35486-0,fonofos serpl-mcnc
35486-0,serpl-mcnc fonofos
35486-0,dyphonate fonofos serpl-mcnc
35486-0,fonofos [mass/vol]
35486-0,[mass/vol] fonofos
35486-0,fonofos [mass/ol] drug/toxicology
96506-1,oropouche virus igg ab [presence] in specimen by immunoassay
96506-1,virus oropouche igg ab [presence] in specimen by immunoassay
96506-1,oropouche virus by ab [presence] in specimen igg immunoassay
96506-1,oropouche virus igg spec ql ia
96506-1,oropouche spec iaa igg virus ql ia
96506-1,spec spec virus igg oropouche ql ia
96506-1,oropouche virus igg ia ql (specimen)
96506-1,meia oropouche virus igg ia presence (specimen)
96506-1,oropouche igg virus ia ql (specimen)
43354-0,avian metapneumovirus c ab [titer] in serum
43354-0,avianmetapneumovirus c a avian pneumovirus [titer] in serum
43354-0,avian metapneumovirus c ab dilution factor [titer] in serum
43354-0,ampv c ab titr ser
43354-0,ampv c autoantibody ab titr ser
43354-0,ampv titr ab trtvc ser
43354-0,avian metapneumovirus c ab (s) [titer]
43354-0,[titer] metapneumovis c ab (s) avian infectious disease
43354-0,smqn avian metapneumvus c a (s) [titer]
52931-3,lead/creatinine [molar ratio] in 24 hour urine
52931-3,led/creatinine[molar ratio]n quantitative hur 24 urine
52931-3,lead/creatinine [molar urine in 24 hour ratio]
52931-3,lead/creat 24h ur-srto
52931-3,lead/creat ur-srto 24h
52931-3,lead/creat 24h ur-srto plumbism
52931-3,lead/creatinine (24h u) [molar ratio]
52931-3,lead/creatinine (24h u) [molar ratio]
52931-3,plumbism u) 24h ead/cratinine [molar atio]
43055-3,clostridioides difficile toxin ab [titer] in serum
43055-3,clostriiides dificile toxin ab [tite] in serum
43055-3,serum difficile toxin ab titer] n clstridioides microbiology
43055-3,c diff tox ab titr ser
43055-3,c diff tox ab titr serum
43055-3,c diff to ab titr ser
43055-3,c. difficile toxin ab (s) [titer]
43055-3,c. dffi toxin (s)[titer] ab
43055-3,c. difficile dilution factor (titer) toxin ab (s) [titer]
99174-5,outcome and assessment information set (oasis) form - version e - transfer to an inpatient facility during assessment period [cms assessment]
99174-5,outcome and assessment report period information set version form - (oasis) e - transfer to an inpatient facility during assessment period [cms assessment]
99174-5,otcome an ssessmen information set (oasis form - verson e -transfer t an inpatiet facility dung assessent erod [cm assessment
79228-3,amlodipine [mass/volume] in body fluid
79228-3,amldipine [mass/vlme] fluid inbod
79228-3,amlodipine [mass/volume] in level fluid body
79228-3,amlodipine fld-mcnc
79228-3,ld-mcnc amlodipne
79228-3,fld-mcnc amlodipine
79228-3,amlodipine (body fld) [mass/vol]
79228-3,b/f (body amlodipine fld) [mass/vol]
79228-3,amlodipine (body fld) point in time [mass/vol]
27195-7,hydroxylysine [moles/volume] in amniotic fluid
27195-7,hroxylysie oh-lysine [moles/volume] in mniotic fluid
27195-7,hydroxylysine fluid in amniotic [moles/volume]
27195-7,oh-lysine amn-scnc
27195-7,amn-scc oh-lsine
27195-7,amn-cn qnt oh-lysie
27195-7,hydroxylysine (amn fld) [moles/vol]
27195-7,hydroxylysine [moles/vol] fld) (amn
27195-7,[moles/vol] (amn fld) hydroxylysine
4335-6,minocycline [mass] of dose
4335-6,minocycline o [mass dose
4335-6,minocycline of [mass] dose
4335-6,minocycline dose
4335-6,minoclin doe
4335-6,de miocycline klinomysin
4335-6,minocycline (dose) [mass]
4335-6,inocyline (dse)[mass
4335-6,dentomycin [mass] (dose) minocycline
29867-9,"3-hydroxy,3-methylglutarate [presence] in urine"
29867-9,"3hydroxy,3-methylglutarate [pesene] urine in"
29867-9,"3-hydroxy,3-methylglutarate in [presence] urine"
29867-9,3oh3me-glutarate ur ql
29867-9,3oh3me-glutarae ur q
29867-9,ql r screen 3oh3me-glutarate
29867-9,"3-hydroxy,3-methylglutarate ql (u)"
29867-9,"3-hydroxy,3-methylglutarate (u) presence"
29867-9,"(u) presence 3-hydroxy,3-methylglutarate"
101549-4,schmid fall risk assessment
101549-4,schmid fall panl risk assessment
101549-4,schmid pnl fall risk assessment
101549-4,schmid fall risk
101549-4,risk fall schmid random
101549-4,schmid panl fall risk
19346-6,amphetamine [mass/volume] in urine
19346-6,amphetmine urine in [mas/volume]
19346-6,mphetain drugs inurine [mass/volue]
19346-6,amphet ur-mcnc
19346-6,amphet ur-mcnc
19346-6,ur-mcnc amphet
19346-6,amphetamine (u) [mass/vol]
19346-6,ampetmine (u) ur [mass/vol]
19346-6,amphetamine (u) [mass/vol]
5285-2,polio virus 3 neutralizing antibody [titer] in serum by neutralization test
5285-2,polio virus dilution factor 3 neutralizing antibody in [titer] serum by neutralization test
5285-2,polio virus 3 neutralizing test [titer] in serum by neutralization antibody
5285-2,pv3 nab titr ser nt
5285-2,pv3 nab nt ser titr
5285-2,pv nab antby tir ser nt
5285-2,polio virus 3 neut ab neut test (s) [titer]
5285-2,polio virus test neut ab neut 3 (s) [titer]
5285-2,polio vrus a neut 3 neut test (s) [titer]
34994-4,smear morphology panel - blood
34994-4,smear wb morphology blood - panel
34994-4,smear morphology panel - bld smear morphology pnl
34994-4,smear morphology pnl bld
34994-4,smear point in time morphology pnl bld
34994-4,pnl morphology smear hematology/cell counts bld
34994-4,smear morphology panel (bld)
34994-4,smear panel morphology (bld)
34994-4,panl smear morphology panel (bld)
96466-8,"inositol 1,4,5-trisphosphate receptor type 1 igg ab [presence] in serum by cell binding immunofluorescent assay"
96466-8,"inositol1,4,5-trisphosphate receptor ab 1 igg tye [presece] in serum by cell binding immnoflorescent ay"
96466-8,"inositol 1,4,5-trsphospat reeptor assay 1 igg ab[presence] in autoantibody srum by cell binding immunolurescent type"
96466-8,ip3r 1 igg ser ql cba ifa
96466-8,ip3r 1 igg serum ql cba ifa
96466-8,sr ip3r 1 igg serum ql cba ifa
96466-8,"inositol 1,4,5-trisphosphate receptor type 1 igg cell binding immunofluorescent assay ql (s)"
96466-8,"inositol ,4,-trisphohte cetor type igg cell bindng imunfluorescent asay l (s)"
96466-8,"inositol 1,4,5-trisphosphate receptor type 1 igg cell binding immunofluorescent assay presence (s)"
11076-7,hepatitis c virus 5-1-1 ab [presence] in serum by immunoblot
11076-7,5-1-1ab c virus hepatitis [presence in ser by imunoblt
11076-7,hepatitis c virus 5-1-1 ab [presence] in immunoblot by serum
11076-7,hcv5-1-1 ab ser ql ib
11076-7,western blot hcv5-1-1 ab ser ql ib
11076-7,hcv5-1-1 ab ib ql ser
11076-7,hcv 5-1-1 ab ib ql (s)
11076-7,hcv5-1-1 a ib (s) ql
11076-7,hcv 5-1-1 autoantibodies ab ib ql (s)
8191-9,cocaine [presence] in serum or plasma by screen method
8191-9,cocaine [prsence in serum orplasma by sceen ethod
8191-9,cocaine [presece] in screen or plasma by seru ethod
8191-9,cocaine serpl ql scn
8191-9,cocane serpl l scn
8191-9,serpl scrn cocaine ql scn
8191-9,cocaine screen ql
8191-9,crack cocaine screen ql
8191-9,screen cocaine presence pr
6551-6,streptococcus agalactiae ag [presence] in throat by immunofluorescence
6551-6,streptococcus agalactiae ag by in throat [presence] immunofluorescence
6551-6,streptoccs throat ag [presee] in agalactiae universallaborders y immunoluorscene
6551-6,gp b strep ag throat ql if
6551-6,fluorescent antibody gp presence strep ag throat b if
6551-6,if microbiology strep agthroatql gpb
6551-6,s. agalactiae ag if ql (throat)
6551-6,s. agalactiae if ag presence (throat)
6551-6,s. agalactiae (throat) antigens if ql ag
88055-9,liver fibrosis score in serum or plasma by calculated by elf
88055-9,sermr fibrois score in liver plasma by calcuaed by elf
88055-9,liver fibrosis sorein sermorlasa by alculaed qnt by elf
88055-9,liver fibr score serpl calc.elf
88055-9,fbr lier scoe erpl calc.elf serum or plasma
88055-9,alc.elf fibr scoe erpl livr
88055-9,liver fibrosis score calculated by elf [score]
88055-9,liver fibrosis calculated score by elf [score]
88055-9,liver fibrosis score calculated by serp elf [score]
31549-9,parainfluenza virus 1 igm ab [units/volume] in serum
31549-9,painfluenza virus 1 igm ab [nits/olume] in serum
31549-9,parainfluenza [units/volume] 1 igm ab virus in serum
31549-9,hpiv1 igm ser-acnc
31549-9,ser-acnc igm hpiv1
31549-9,parainfluenza type 1 hpi1 gm ser-an
31549-9,parainfluenza virus 1 igm qn (s)
31549-9,prainfluenza virus qns) igm 1
31549-9,parainfluenza virus 1 igm qn (s)
80385-8,choriogonadotropin [presence] in serum by rapid immunoassay
80385-8,choroonadotropin [presece] n ser  rpid munassay
80385-8,horiogonadotoin[preence] rapidmmunoassay b inserum
80385-8,hcg ser ql ia.rapid
80385-8,cg ia.rapid serum ql hcg
80385-8,enzyme immunoassay hcg s q ia.rapd
80385-8,hcg ia.rapid ql (s)
80385-8,ql meia ia.rapid hcg (s)
80385-8,hcg (s) ql ia.rapid
49189-4,corynebacterium diphtheriae toxin igg ab [units/volume] in serum
49189-4,corynebacterium diphtheriae toxin igg ab [units/volume] in ser
49189-4,corynebacterium diphtheriae antby toxin igg [units/volume] ab in serum
49189-4,c diphtheriae tox igg ser-acnc
49189-4,diphtheriae c tox igg ser-acnc
49189-4,tox diphtheriae point in time c igg ser-acnc
49189-4,c. diphtheriae toxin igg qn (s)
49189-4,c. diphtheriae toxin qn igg (s)
49189-4,igg infectiousdisease diphtheiaetxin c. qn(s)
46449-5,text-diagnosis section set naaccr v.11
46449-5,text-diagosis naacr set tumor registry(naaccr) secton v11
46449-5,text-diagnosis section set pan naaccr v.11
46449-5,text-dx section naaccr v.11
46449-5,text-dx v.11 naccr ection
46449-5,text-dx naccr section v.1
98487-2,alzheimer's disease risk [score] in cerebral spinal fluid by calculation
98487-2,alzheimer's disease fluid [score] in cerebral spinal risk by calculation
98487-2,zheime's diease risk[scoe] in cerebral spinal fluid b calculaio
98487-2,alzheimer's risk score csf calc
98487-2,alzheimer's score spinal fl risk cerebrospinal fluid calc
98487-2,score azeier'srisk sf calc
98487-2,alzheimer's disease risk calc (csf) [score]
98487-2,alzheimer's chemistry (cerebrospinal fluid) risk calc disease [score]
98487-2,aleimer's diseae ik (sf[score] calc cerebrospinal fl
16601-7,chlamydia trachomatis rrna [presence] in urine by probe
16601-7,c trac chlamydia trachomaisrrna[prsenc] bprobe urine in
16601-7,chlamydi infectious disease trachomati by in urine rrna[presnce] probe
16601-7,c trach rrna ur ql probe
16601-7,c trach rrna ur ql probe
16601-7,c trac trach c rrna ur ql probe
16601-7,c. trachomatis rrna probe ql (u)
16601-7,probe trachomatis rrna c. ql (u)
16601-7,. racomatis rrna probe ql (u)
13570-7,norclomipramine [presence] in serum or plasma
13570-7,[presnce]inserum serum or plasma nrclomipramine or plasa
13570-7,norclomipramie lasma in serum or [presence]
13570-7,norclomipramine serpl ql
13570-7,l sepl norclomipramine
13570-7,serpl norclomipramine ql screen
13570-7,norclomipramine ql
13570-7,presence norclipraine
13570-7,ql nocoiramine
104603-6,borrelia burgdorferi b31 igg ab [presence] in serum by line blot
104603-6,orelia burgdorferi gg 3 ab[presence] ql inserum by ine blot
104603-6,burgdorferi borrelia b31 igg ab [presence] in serum by line blot
104603-6,b. burgdorferi b31 igg ser ql line blot
104603-6,b. random burgdorferi b31 ser igg ql line blot
104603-6,serum b3 ig burgdorferi qlline antibody blot
104603-6,borrelia burgdorferi b31 igg line blot ql (s)
104603-6,borrei burgdorferi b31 igg line blot l (s)
104603-6,borrelia antby urgdorfe b31 ggine ql bot (s)
40775-9,histoplasma capsulatum igm ab [titer] in serum --1st specimen
40775-9,histoplasma capsulatum igm ab [titer] in serum serum --1st specimen
40775-9,histoplasma capsulatum igm ab [titer] --1st autoantibodies serum in specimen
40775-9,h capsul igm sp1 titr ser
40775-9,h histopl capsul ser sp1 titr igm
40775-9,ser capsul igm sp1 titr h
40775-9,h. capsulatum igm spec 1 (s) [titer]
40775-9,h.apsulatum igm spc 1 (s) [tr]
40775-9,h. apsulatum point in time igm spec 1 (s) [titer]
25266-8,oxytetracycline [mass/volume] in specimen
25266-8,in qnt [mss/volume] oxtetacycline secimen
25266-8,oxytetracycline [mass/volume] in specimen
25266-8,oxytetracycline spec-mcnc
25266-8,spec-mcnc oxytetracycline clinimycin
25266-8,berkmycen spec-mcnc oxytetracycline
25266-8,oxytetracycline (specimen) [mass/vol]
25266-8,oxytetrcyline [mass/vol] point in time (specimen)
25266-8,oxytetracylin (specimen) ass/vol] quant
49553-1,kappa light chains.free/lambda light chains.free [mass ratio] in 24 hour urine
49553-1,kappa light chain.free/lbda light chansfree [massratio] n 24 hourure
49553-1,chain.free lig chai.free/lmbda light kapp [mass ratio in 2 hour urie
49553-1,kappa lc free/lambda free 24h ur
49553-1,free/lambda lc kappa free 24h ur
49553-1,aa l fre/lambda fee 24h ur
49553-1,immunoglobulin light chains.kappa.free/immunoglobulin light chains.lambda.free (24h u) [mass ratio]
49553-1,immunoglobuin light chains.kappa.free/imnoglobn lit cains.ambdafee (24h u) [mass rati]
49553-1,immunoglobulin light chains.kappa.free/immunoglobulin light chains.lambda.free (24h u) [mass hematology ratio]
73238-8,nizatidine induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73238-8,nizatidine inducd platelet igm ab [presenc] in erum plasma by flow cytmety (fc)
73238-8,niatidine inducedplatelet igm ab [presnce] in ser or lasma b fc) cytmetry low pr
73238-8,nizatidine ind plt igm serpl ql fc
73238-8,nizatidine aby ind plt igm serpl ql f
73238-8,nizatidine ind plt serpl igm ql fc
73238-8,nizatidine induced platelet igm fc ql
73238-8,nizatidine antby induced platelet igm fc ql
73238-8,nizatidine induced platelet fc igm ql dynamic
74246-0,hedis 2014 value set - hba1c tests
74246-0,pan hedis 2014 tests set - hba1c value
74246-0,hedis 214 point in time - set value hba1c tests
74246-0,hedis 2014 hba1c
74246-0,hedis hba1c 2014
74246-0,hedis2014 hba1c
74246-0,hedis 2014 value set - hba1c tests
74246-0,hedis 201 vlu set ha1c tests pan
74246-0,hedis 2014 value set pnl - hba1c tests
96036-9,"wound, ischemia, and foot infection classification system panel lower extremity wifi"
96036-9,"wond,ihemia, and foot infectio extremitwifi stem panel lower classification"
96036-9,"wound, ischemi, an foot infection clssification system panel lower extremty wifi"
96036-9,wifi pnl le wifi
96036-9,wifi le pnl wifi
96036-9,ifi nl le ifi
87744-9,carbaryl [mass/mass] in specimen
87744-9,carbaryl [mass/mass] in spemen
87744-9,carbayl [mss/mas] in speime unspecified
87744-9,carbaryl spec-mcnt
87744-9,sec-mct carbaryl
87744-9,spe-mct carbryl
87744-9,carbaryl (specimen) [mass/mass]
87744-9,carbaryl (specimen) [mass/mass]
87744-9,[mass/mass] (specimen) carbaryl
17679-2,taurine [presence] in cerebral spinal fluid
17679-2,spinal fl taurine [presence] in fluid spinal cerebral
17679-2,aurine [pesence] fluid cerebral spinl n
17679-2,taurine csf ql
17679-2,taurine qual ql csf
17679-2,ql csf taurine
17679-2,taurine ql (csf)
17679-2,(csf) q taurine
17679-2,point in time taurine ql(csf)
92866-3,herpes simplex virus 1 and 2 dna panel - serum or plasma by naa with probe detection
92866-3,hrpes simlex virs 1 and 2 dna panel-serum or plasma by pcr naa with robe detection
92866-3,heres siplex virus 1 ad 2 dna panl - srum o wt bynaa plas robe deetion
92866-3,hsv 1+2 dna pnl serpl naa+probe
92866-3,hsv 1+2 dna pnl serpl naa+probe
92866-3,hsv dna transcription mediated amplification 1+2 pnl serpl naa+probe
92866-3,hsv 1 and 2 dna panel naa+probe
92866-3,hsv 1 and 2 panl dna a+probe transcription mediated amplification
92866-3,hsv 1 and dna anel naa+probe qbr
101761-5,trichophyton concentricum dna [presence] in specimen by naa with probe detection
101761-5,trichophyton concentricum dna [presence] in specimen with naa by pr probe detection
101761-5,richphyton conentricum dna[rence] detectio specimenby na with probe in
101761-5,t. concentricum dna spec ql naa+probe
101761-5,concentricum t. dna spec ql naa+probe
101761-5,concentricum t dnaspec ql naa+probe
101761-5,trichophyton concentricum dna naa+probe ql (specimen)
101761-5,trichophyton concetricu ql naa+prob dna spcime)
101761-5,trichophyton concentricum dna naa+probe ql (specimen)
12880-1,borrelia burgdorferi 58kd ab [presence] in body fluid by immunoblot
12880-1,orrlia budorferi 58kd ab [prsence] in body fluid by immunoblo presence
12880-1,borrelia burgdorferi 58kd ab [presence in body fluid by unoblt
12880-1,b burgdor58kd ab fld ql ib
12880-1,b burgdor58kd ab ql fld ib
12880-1,b burgdor58kdab ib ql fld
12880-1,b. burgdorferi 58kd ab ib ql (body fld)
12880-1,b. burgdorferi 58kd ab ib presence (body fld)
12880-1,fl b. burdoreri58kd ab ib ql(ody fl)
55569-8,phentermine [moles/volume] in serum or plasma
55569-8,phentermine [moles/volume] in plasma or ser
55569-8,phenmine [mole/vum] substance concentration in serum or pasma
55569-8,phentermine serpl-scnc
55569-8,phentermine serpl-scnc plasma
55569-8,phentermine point in time serpl-scnc
55569-8,phentermine [moles/vol]
55569-8,pentermine sr [mols/vol
55569-8,phentermine [moles/vol] level
5238-1,leishmania sp ab [units/volume] in serum
5238-1,leishmania sp quant ab [units/volume] in serum
5238-1,leishmania in ab [units/volume] sp serum
5238-1,leishmania ab ser-acnc
5238-1,lishmniaabsr-cnc quan
5238-1,leishmania serum-acnc ab
5238-1,leishmania sp ab qn (s)
5238-1,ab sp leishmaia qn random (s)
5238-1,sr lesmaniasp b q (s)
62405-6,phenx - birth weight protocol 020201
62405-6,birth henx- weightprotocol020201
62405-6,birth - phenx weightprtocol020201
62405-6,phenx - birth weight protocol
62405-6,panel.phenx phenx - birth weight protocol
62405-6,phenx - birth prtoo eight
6433-7,htlv i igg ab [presence] in serum by immunoassay
6433-7,suds htv i igg ab [preence] in seru munassa by
6433-7,igg i htlv ab [presence] in ser by immunoassay
6433-7,htlv i igg ser ql ia
6433-7,htlv i igg serum ql ia
6433-7,htlv i igg ia ql ser autoantibodies
6433-7,htlv i igg ia ql (s)
6433-7,htlv i igg ia ql (s) anti
6433-7,i htlv igg ia ql (s)
9503-4,deprecated chloral hydrate [presence] in urine
9503-4,deprecatedchlral ordinal hydate [preen] n urine
9503-4,deprecated chloral hydrate elix-node [presence] in urine
9503-4,deprecated chloral hydrate ur ql
9503-4,deprecated chlorahdrae urql trichloroethanol
9503-4,deprecated chloral hydrate q ur
9503-4,chloral hydrate ql (u)
9503-4,hloral hydrate q (u)
9503-4,chloral hydrae presence u)
98703-2,motor nerve conduction panel nerve
98703-2,motor nerve panel conduction nerve
98703-2,motor nrve onducionpane neve
98703-2,motor nc pnl nerve
98703-2,motor nc neuro pnl nerve
98703-2,motor pnl nc nerve
93879-5,n-palmitoylsphingosine/n-lignoceroylsphingosine [molar ratio] in plasma
93879-5,[molar n-palmitoylsphingosine/n-lignoceroylsphingosine ratio] in plasma
93879-5,n-palmitoylsphingosine/n-lignoceroylsphingosine plasma ratio] in [molar
93879-5,c16 ceramide/c24 ceramide plas-srto
93879-5,c16 ceramide/c24 plas-srto ceramide
93879-5,cermide/c24 quan c16 ceramide plas-sto
93879-5,c16 ceramide/c24 ceramide (p) [molar ratio]
93879-5,pl c16 ceramide/c24 ceramide (p) [molar ratio]
93879-5,c16 cemide/c24ceramide (p) [molar ratio]
88714-1,dehydroaripiprazole [mass/volume] in serum or plasma by confirmatory method
88714-1,dehydroaripiprazole [mass/volume] in ser or plasma by confirmatory method
88714-1,dehydroaripiprazole [mass/volume] in ser or plasma by confirmatory method
88714-1,dehydroaripiprazole serpl cfm-mcnc
88714-1,dehydroaripiprazole ser serpl cfm-mcnc
88714-1,cfm-mcnc serpl dehydoaipiprazole
88714-1,dehydroaripiprazole confirm [mass/vol]
88714-1,confirm[mass/vol] dehydroarprazoe
88714-1,confirm dehydroaripiprazole [mass/vol] serum
107221-4,calciferol binding protein [mass/volume] in serum or plasma
107221-4,calciferol bindin proten [mass/volume] in srm orasma
107221-4,vitamin d2 alcifol binding potein [mass/volue] in serum or plasma
107221-4,vit d binding protein serpl-mcnc
107221-4,binding d vit protein serpl-mcnc
107221-4,sr vit protein binding d serpl-mcnc
107221-4,calciferol binding protein [mass/vol]
107221-4,calciferol binding protein [mass/vol] plsm
107221-4,calciferol protein binding [mass/vol]
61063-4,carboxy tetrahydrocannabinol [presence] in specimen
61063-4,tetrahydrocannabinol carboxy [ql] in specimen
61063-4,carboxy in [presenc] tetraydrocannabiol specimen
61063-4,carboxythc spec ql
61063-4,carboxythc ql spec
61063-4,ql spec caoxythc marijuana
61063-4,carboxy tetrahydrocannabinol ql (specimen)
61063-4,specimen 11-nor-delta-9-thc-9-cooh etrahyrocannabino ql crboxy
61063-4,(specimen) tetrahydrocannabinol presence carboxy
86711-9,porcine deltacoronavirus ag [presence] in tissue by immune stain
86711-9,porcine deltacoronavirus ag [ql] in tissue by immune stain
86711-9,poinedelacoraviruag [presence] in tissue by stain immue
86711-9,pdcov ag tiss ql imstn
86711-9,dcov ag tiss pdcov presence imstn
86711-9,imm pdcov ag tss ql imtn
86711-9,porcine deltacoronavirus ag immune stain ql (tiss)
86711-9,detacoronavirusag orcie mmune stainql (tiss) qual
86711-9,porcine deltacroairus ag imun stain presence (tiss)
23398-1,rift valley fever virus ab [titer] in serum by hemagglutination inhibition
23398-1,rif valley fever virus ab [titer]in serm by hemaglutinton inibiton
23398-1,rift hemagglutination fever virus ab [titer] in serum quantitative by valley inhibition
23398-1,rvfv ab titr ser hai
23398-1,titr ab rvfv serum hai
23398-1,ab rvfv titr ser hai
23398-1,rift valley fever virus ab hai (s) [titer]
23398-1,rift valley fever (s) ab hai virus [titer]
23398-1,rift valley fever irus ab hai (s) dilution factor [titer]
95716-7,17 alpha-hydroxylase ab [titer] in serum by immunofluorescence
95716-7,17 serum ab [titer] in alpha-hydroxylase by immunofluorescence fluoresent
95716-7,17 alpha-hydroxylase by [titer] in serum ab immunofluorescence
95716-7,17a-hydroxylase ab titr ser if
95716-7,17a-hydroxlas ab titr  if
95716-7,se dilution factor titr 7ahydroxylaseab if
95716-7,17 alpha-hydroxylase ab if (s) [titer]
95716-7,17 (s) ab if alpha-hydroxylase [titer] fluoresent
95716-7,7 alpha-hydoylas if() serology ab [tter]
90812-9,ampar1 ab [titer] in cerebral spinal fluid by cell binding immunofluorescent assay
90812-9,ampar1 ab [titer] in cerebral spinal fluid by recptr cell binding immunofluorescent assay
90812-9,in ab [titer] ampar1 cerebral spinal fluid by cell binding immunofluorescent assay
90812-9,ampar1 ab titr csf cba ifa
90812-9,ampar1 cba titr cerebrospinal fluid ab ifa
90812-9,ampar1 ab csf titr cba ifa
90812-9,ampar1 ab cell binding immunofluorescent assay (csf) [titer]
90812-9,ampar1 ab cell binding dilution factor immunofluorescent (csf) assay [titer]
90812-9,ampar1 ab cell binding recept immunofluorescent assay (csf) [titer]
97184-6,ravulizumab [mass/volume] in serum
97184-6,ravulizumab [mass/oume] drug/toxicology in erum
97184-6,ravulizumab quan [mass/volume] in serum
97184-6,ravulizumab ser-mcnc
97184-6,ser-mcnc avuizuma
97184-6,ser-mcnc ravulizumab point in time
97184-6,ravulizumab (s) [mass/vol]
97184-6,level avulizuma (s) [mass/vol]
97184-6,ravulizumab (s) [mass/vol] quantitative
70571-5,functional assessment of chronic illness therapy - bone treatment convenience and satisfaction questionnaire - version 1 (facit-ts-btcsq)
70571-5,functional assessment of chronic therapy illness - bone treatment convenience and satisfaction questionnaire - version 1 (facit-ts-btcsq)
70571-5,- asesentof chronic llness therap -bone treatmen conveninc ad satifactin qustionnaire survey.gnhlth functiona version 1 (faci-ts-btcsq)
7952-5,legionella pneumophila 5 ab [titer] in serum by immunofluorescence
7952-5,leginella pneumophila 5 ab [tier] in erm byimmunfluoresence
7952-5,legionella pneumophila 5 [titer] ab in serum by immunofluorescence
7952-5,l pneumo5 ab titr ser if
7952-5,l pneumo5 if titr er ab
7952-5,l pneumo5 ab titr serum if
7952-5,l. pneumophila 5 ab if (s) [titer]
7952-5,l. pneumophila 5 ab if (s) [titer]
7952-5,l. ab id 5 pneumophila if (s) [titer]
5140-9,echovirus 3 neutralizing antibody [titer] in serum by neutralization test
5140-9,echovirus 3 neutralizing antibody echovirus type 3 [titer] in serum by neutralization test
5140-9,echovirus test neutralizing antibody [titer] in serum by neutralization 3
5140-9,ecv3 nab titr ser nt
5140-9,ecv3 nab titr ser nt
5140-9,abttr ec3 er nt antibody
5140-9,echovirus 3 neut ab neut test (s) [titer]
5140-9,echovirus 3 neut ab neut test titre (s) [titer]
5140-9,echovirus 3 neut (s) neut test ab [titer]
53986-6,coarse speckled nuclear ab pattern [presence] in serum by immunofluorescence
53986-6,oarse speckled nuclr ab fluorescent antibody pattern presece] in seuby immunoflurescence
53986-6,coarse speked nuclear ab attern [preence]in serm by iunofluorescnce
53986-6,ana coarse speckled ser ql if
53986-6,serum coarse speckled ana ql if
53986-6,ana coarse specle sr lif
53986-6,coarse speckled nuclear ab pattern if ql (s)
53986-6,coarse speckled ql ab pattern if nuclear (s)
53986-6,coarse speckled nuclear ab point in time pattern presence if (s)
26661-9,trichinella sp ab [presence] in serum
26661-9,trichinella sp ab in [presence] serum
26661-9,tichina ab sp [presece] n infectiousdisease ser
26661-9,trichinella ab ser ql
26661-9,ql ab ser trichinella
26661-9,bserql trichinela
26661-9,trichinella sp ab ql (s)
26661-9,abs ql ab riciellasp (s)
26661-9,id richiella ql(s) ab sp
53457-8,gamma 3 globulin.abnormal band/protein.total in serum or plasma by electrophoresis
53457-8,gamma 3 globulin.abnormal band/protein.total in serum or plas by electrophoresis
53457-8,gamma or globulin.abnormal band/protein.total in serum 3 plasma by electrophoresis
53457-8,gamma 3 glob abnormal mfr serpl elph
53457-8,gamma 3 glob abnormal mfr serpl elph
53457-8,fr glob abnormal electro gmma3 serp elph
53457-8,gamma 3 globulin.abnormal band elph [mass fraction]
53457-8,gamma 3 globulinanrmal band elph[mass frction]
53457-8,ftion] glb globulin.abnormal a elph [mass gmma3
29409-0,desipramine [mass/volume] in gastric fluid
29409-0,desipramine [mas/volume] fluid inasti
29409-0,desipramine in [mass/volume] gastric fluid point in time
29409-0,desipramine gast-mcnc
29409-0,gast-mcnc norpramin desipramine
29409-0,desipraminegast-mcnc qnt
29409-0,desipramine (gast fld) [mass/vol]
29409-0,desipamine (gast mass concentration ld mass/o]
29409-0,drugs fd) (gast dsiprmne [mass/v]
46050-1,skin treatments set
46050-1,set panel treatments skn
46050-1,skin set treatments
69031-3,enterocyte iga ab [presence] in serum
69031-3,immune globulin a enterocyt iga ab[pesence]in serum
69031-3,terocye gab serum [presence]in
69031-3,enterocyte iga ser ql
69031-3,enterocyte ql igasr
69031-3,etercyte ordinal iga ser q
69031-3,enterocyte iga ql (s)
69031-3,enterocyte iga ql serology (s)
69031-3,enterocyte iga ql s)
43909-1,bordetella pertussis ag [presence] in nasopharynx
43909-1,bordetella pertussis ag [presence] qualitative in nasopharynx
43909-1,bordetella pertussis ag ordinal nasopharynx in [presence]
43909-1,b pert ag nph ql
43909-1,b pert nph ag ql
43909-1,b presence a nph pert
43909-1,b. pertussis ag ql (nph)
43909-1,b. pertussis ql ag (nph)
43909-1,b. (nph) agql screen ertussis
71084-8,technical quality [facit]
71084-8,point in time [facit] quality technical
71084-8,technical [facit] quality
43250-0,xanthine derivatives [presence] in urine
43250-0,xanthine derivatives pr [presence] in urine
43250-0,xanthine derivatives [presence] urine in
43250-0,xanthine deriv ur ql
43250-0,xanthine point in time ql ur deriv
43250-0,anhine deriv ur random presence
43250-0,xanthine derivatives ql (u)
43250-0,derivatives xanthine presence (u)
43250-0,xanthine derivatives ql (u)
23104-3,equine influenza virus a2 ag [titer] in specimen by hemagglutination inhibition
23104-3,influenza equine virus a2 ag [titer] in specimen by hemagglutination inhibition
23104-3,equine influenza infectiousdisease virus a2 ag [titer] in specimen by hemagglutination inhibition
23104-3,eiv a2 ag titr spec hai
23104-3,eiva2 ag titrspec hai
23104-3,eiv a2 ag titr sec hai
23104-3,equine influenza virus a2 ag hai (specimen) [titer]
23104-3,equine influenza virusa2 smqn ag hai (specimen [titer]
23104-3,equine inluenza vir a2 ag hai (specimen) [titer] influ
106012-8,overall social vulnerability index reporting period
106012-8,overall social vulnerabilty index reporting period
106012-8,overall socia vulnerability index reporting perid
106012-8,overall svi rptperiod prctl
106012-8,overall prtl rptperiod svi
106012-8,prctl svi rptperiod overall
70539-2,functional assessment of cancer therapy - colorectal symptom index questionnaire - 9 items (fcsi-9) [facit]
70539-2,functional assessment of cancer therapy - colorectal symptom (fcsi-9) questionnaire - 9 items index [facit]
70539-2,functional aessmnt of symptm therapy - colorectal cner index questionnaire - 9 itms cs-9) [facit]
56921-0,entamoeba histolytica ab [presence] in serum by immunofluorescence
56921-0,entamoba ql]in b histolytc seubmunofluorescence id
56921-0,infectious disease entamoeba histolytica ab [presence] in serum by immunofluorescence
56921-0,e histolyt ab ser ql if
56921-0,if b immunofluor ser ql ehistolyt
56921-0,ab histolyt e serum ql if amoeba
56921-0,e. histolytica ab if ql (s)
56921-0,autoantibody e. histolytica ab if (s presence
56921-0,e. histolytica ab if (s) ql
44616-1,deprecated pulse oximetry panel
44616-1,deprecated pulse oximetry quant panel
44616-1,eprecated oximetrypnel puse
44616-1,deprecated pulse oximetry pnl
44616-1,oximery plse deecated qnt pl
44616-1,dprecated pulse oxmety pnl
21361-1,laxatives present [identifier] in stool by screen method
21361-1,laxatives present [identifr] in stool by screen method
21361-1,mthod preset [idntife] in stool drugs byscree laxatives
21361-1,laxatives present stl scn
21361-1,present laxatives stl scrn scn
21361-1,lxativs presenstl scn
21361-1,laxatives present screen nom (stl)
21361-1,screen present random laxatives nom (stl)
21361-1,laxatives screen present nom (stl)
22179-6,chlamydophila psittaci igg ab [titer] in cerebral spinal fluid
22179-6,spinal psittaci igg ab [titer] in cerebral chlamydophila fluid
22179-6,chlamydophl psittaci igg ab [tier in cerebral spinal fluid
22179-6,c psittaci igg titr csf
22179-6,c psittaci csf titr igg
22179-6,titre c psittac igg titr c
22179-6,c. psittaci igg (csf) [titer]
22179-6,c. psittaci igg [titer] (csf)
22179-6,psittaci c. igg (csf) [tter]
45324-1,ethyl glucuronide [mass/volume] in urine
45324-1,ethyl [mass/volume] glucuronide in urine
45324-1,ethyl urine [mass/volume] in glucuronide
45324-1,ethyl glucuronide ur-mcnc
45324-1,ethyl pt glcuronide u-mcn
45324-1,ethyl urmcn guronide
45324-1,ethyl glucuronide (u) [mass/vol]
45324-1,(u) glucuronide ethyl [mass/vol]
45324-1,ethyl glucuronide() mass/vol]
16218-0,nalbuphine [presence] in urine by confirmatory method
16218-0,[presene] random nlbuphine i urine by confirmatry metod
16218-0,nabuphine [ql]in urine screen confirmatory method
16218-0,nalbuphine ur ql cfm
16218-0,nalbuphne r ql cfm
16218-0,q ur drugs of abuse nalbupine cfm
16218-0,nalbuphine confirm ql (u)
16218-0,(u) cofirm ql nalbphie
16218-0,(u) confirm ql naluphine qual
19129-6,deprecated microscopic observation [identifier] in tissue by biopsy culture
19129-6,deprecated [identifier] observation microscopic in tissue by biopsy culture
19129-6,in microscopic observation [identifier] deprecated tissue by biopsy culture
19129-6,deprecated biopsy culture smear tiss
19129-6,depecated random biopsy culture smeartiss
19129-6,depecated biopsy culturesmea tiss
19129-6,microscopic observation biopsy cx nom (tiss)
19129-6,mcroscopic observtion bipsy cx nom (tis)
19129-6,biopsy observation microscopic cx nom (tiss) c&s
12359-6,benzodiazepines [presence] in stool
12359-6,benzodiazepines[presence] in stool
12359-6,bowel movement benzodiazepines [presence] n sool
12359-6,benzodiaz stl ql
12359-6,ql ql stl benzodiaz
12359-6,stl benzodiaz ql
12359-6,benzodiazepines ql (stl)
12359-6,bzodiazepine presence stl
12359-6,benzodiazepines ql benzodiaz (tl)
71869-2,hemoglobin c/hemoglobin.total [pure mass fraction] in blood by hplc
71869-2,hemoglobin c/hemoglobin.total [pure mass fraction] by blood in hplc
71869-2,hemoglobin c/hemoglobin.total [pure mass hplc in hgb blood by fraction]
71869-2,hgb c mfr.df bld hplc
71869-2,mfr.df c hgb blood hplc
71869-2,hgb bld mfr.df hplc totl
71869-2,hemoglobin c hplc (bld) [pure mass fraction]
71869-2,hemoglobin c hplc (bld) [pure mass fraction]
71869-2,hemoglobin c hplc bld) [pure mass fraton]
18729-4,urinalysis studies (set)
18729-4,attach.lab studies(set) urinalysis
18729-4,(set) studies urinalysis
9791-5,organochlorine pesticides [type] in serum or plasma
9791-5,organochlorine pesticides plasma in serum or [type]
9791-5,organchlorine pesicides [type] r serum plasma in plasa
9791-5,oc pesticides serpl
9791-5,oc drug/toxicology serpl pesticides
9791-5,oc psticide serpl
9791-5,organochlorine pesticides nom
9791-5,orgohlrine nom pesticides serum or plasma
9791-5,organochlorine plasma nom pesticides
27196-5,hydromorphone free [mass/volume] in vitreous fluid
27196-5,hydromorhone free [masvolume] n vitreous hydromorphinone fuid
27196-5,hydorhone free [mass/volume] in vitrous fluid
27196-5,hydromorphone free vitf-mcnc
27196-5,hydromorphone free vitf vitf-mcnc
27196-5,freevitf-mcnc random hydromorphone
27196-5,hydromorphone free (vitr fld) [mass/vol]
27196-5,hydromorhone fld)[as/vol] ree(vitr level
27196-5,hdromorphone free vtr fld) [massvo non-protein bound
80190-2,catheterization and angiography procedure details panel
80190-2,cardiology atheteriatn and angioraphy procedure deails panel
80190-2,cteterization nd angography procedue deails panel
80190-2,cath+angio proc det pnl
80190-2,cth+agio det proc pnl
80190-2,poc cath+angio cardio det pnl
16633-0,cocaine [presence] in blood
16633-0,cocaine [presence] in blood
16633-0,cocaine [presence] bld potentialforabuse in
16633-0,cocaine bld ql
16633-0,cocae bll
16633-0,cocaine bl l
16633-0,cocaine ql (bld)
16633-0,ql cocaine screen (bld)
16633-0,cocaine ordinal ql (bld)
79405-7,"1,4-alpha glucan branching enzyme [enzymatic activity/mass] in fibroblast"
79405-7,"1,4-alpha glucan branching enzyme [enzymatic activity/mass] in fibroblast"
79405-7,"1,4-alpha glucan branching enzyme [enzymatic activity/mass] in fibroblast"
79405-7,glgb fib-ccnt
79405-7,fib-cnt glgb
79405-7,fib-ccnt glgb
79405-7,"1,4-alpha glucan branching enzyme (fibroblast) [catalytic activity/mass]"
79405-7,"1,4-alpha glucan alpha-1,4-glucan branching enzyme branching enzyme (fibroblast) [catalytic activity/mass]"
79405-7,"1,4-alpha glucan branching enzyme [catalytic (fibroblast) activity/mass] catalytic content"
53092-3,collagen crosslinked c-telopeptide [moles/volume] in serum or plasma
53092-3,collagen crosslinked plasma [moles/volume] in serum or c-telopeptide
53092-3,rosslinked cllagen c-telpeptide [mols/vlum] i serum orplama ctx
53092-3,collagen ctx serpl-scnc
53092-3,collagen serpl-scnc ctx
53092-3,collagen ctx level serpl-scnc
53092-3,collagen crosslinked c-telopeptide [moles/vol]
53092-3,collgen crosslinked ctelopeptide [mles/vol]
53092-3,[moles/v] plas coslinked c-elopetide collagen
20930-4,paraquat [mass/mass] in tissue
20930-4,tissue [mass/mass] in paraquat
20930-4,paraquat [mass/mass] in tissue
20930-4,paraquat tiss-mcnt
20930-4,tiss-mcnt quan paraquat
20930-4,tiss-mn paraquat
20930-4,paraquat (tiss) [mass/mass]
20930-4,"mass/mass] (tis paraquat tissue, unspecified"
20930-4,[mass/mass] drugs (tiss) paraquat
101219-4,legionella sp dna [presence] in specimen by naa with probe detection
101219-4,legionella probe amp sp dna [ql] in specimen by naa with probe detection
101219-4,naa sp dna [presence] naat in specimen by legionella with probe detection
101219-4,legionella dna spec ql naa+probe
101219-4,presence dna spec legionella microbiology naa+probe
101219-4,naa+probe dna deoxyribonucleic acid spec ql legionella
101219-4,legionella sp dna naa+probe ql (specimen)
101219-4,legionela s dna naa+obe amplification ql (spcime)
101219-4,dna polymerase chain reaction sp legionella naa+probe ql (specimen)
8089-5,platelet associated igg ab [units/volume] in blood
8089-5,platelet associated igg antibody ab [units/volume] in blood
8089-5,lateet associtd ig ab[units/volume] bld in
8089-5,pa igg bld-acnc
8089-5,heme a bl-acnc igg
8089-5,pa platelet auto-antibodies igg bd-acn
8089-5,platelet associated igg qn (bld)
8089-5,igg associated platelet qn (bld)
8089-5,(bld) associated igg qn platelet
43321-9,avian metapneumovirus b ab [titer] in serum by immunoassay
43321-9,avianmetapneumoirus b ab su in [titr] byimunasay
43321-9,avian metapneumovirus b ab [titer] in ser by immunoassay
43321-9,ampv b ab titr ser ia
43321-9,titr b ab ampv ser i
43321-9,mpv b titr b ser ia
43321-9,avian metapneumovirus b ab ia (s) [titer]
43321-9,avian meapneumrus b ab titer] s) ia
43321-9,avian b metapneumovirus ab ia (s) [titer]
93974-4,iohexol [mass/volume] in serum or plasma
93974-4,iohexol [mass/volume] or serum in plasma
93974-4,iohexol[massvolume] in or serum plsm lasma
93974-4,iohexol serpl-mcnc
93974-4,serpl-mcnc iohexol
93974-4,serpl-mcnc ihexol
93974-4,iohexol [mass/vol]
93974-4,[mass/vol] iohexol serpl
93974-4,[mass/vol] iohexol
24405-3,aeromonas salmonicida [presence] in specimen
24405-3,id aeromonas [presence] salmonicida in specimen
24405-3,aermonas salmonicida [presence in spcimen
24405-3,a salmonicida spec ql
24405-3,a salmnicid sec ql
24405-3,infectiousdisease salmonicia a spcql
24405-3,a. salmonicida ql (specimen)
24405-3,salmonicida a. ql (specmen
24405-3,a. ulcer disease salmonicida ql (specimen)
4534-4,cyanmethemoglobin/hemoglobin.total in blood
4534-4,in hb yanmethemoglobin/hemoglin.otal blood
4534-4,cyamethemgloin/hemoglobn.toal in bloo
4534-4,cyanmethgb mfr bld
4534-4,cyanmthgb mfr bld
4534-4,mfr cyanmethgb bld
4534-4,cyanmethemoglobin (bld) [mass fraction]
4534-4,(ld) cyametemoglobi [mass fraction]
4534-4,whole blood cyanethmglob (bd) ractin] [mas
2921-5,retinoate [mass/volume] in serum or plasma
2921-5,retinoate or in serum [mass/volume] plasma
2921-5,retinotmass/volme]in sem or pasma
2921-5,retinoate serpl-mcnc
2921-5,retioateserpl-mcnc
2921-5,serpl-mcnc retinoate
2921-5,retinoate [mass/vol]
2921-5,[mass/vo] rtinate
2921-5,[mas/vo] etinoat
91392-1,total score ort
91392-1,ort score total
91392-1,ort score tot total
91392-1,total score ort
91392-1,score total ort
91392-1,core tota or
11116-1,normoblasts orthochromic/cells in bone marrow by manual count
11116-1,ormoblasts orthohromic/cells quant in bone maroby manual cunt
11116-1,normoblasts orthochromic/cels in bone marrow by manual cunt
11116-1,ortho normoblasts nfr mar manual
11116-1,rtho point in time norobasts nfr mar maual
11116-1,ortho normoblasts mar nfr manual
11116-1,normoblasts orthochromic/cells manual cnt (bm)
11116-1,cnt orthochromic/cells manual cell normoblasts (bm)
11116-1,(bm) orhochromic/cells manl cnt normoblass
89324-8,insulin intact [units/volume] in serum by lc/ms/ms
89324-8,inslinintact [units/volme] in serum by quant c/mss
89324-8,[units/volume] point in time intact insulin in serum by lc/ms/ms
89324-8,insulin intact ser lc/ms/ms-acnc
89324-8,intact insulin ser lc/ms/ms-acnc
89324-8,insulin intact serlc/ms/ms-acnc
89324-8,insulin intact lc/ms/ms qn (s)
89324-8,inulin intact lc/m/ms (s) qn
89324-8,insulin intact (s) qn lc/ms/ms
25997-8,urate [moles/volume] in 24 hour urine
25997-8,urine quantitative [moles/volume] in 24 hour urate
25997-8,urate [moles/volume] kidney in 24 hour urine
25997-8,urate 24h ur-scnc
25997-8,urate 24h ur-scnc
25997-8,rate ua 24h ur-scn
25997-8,urate (24h u) [moles/vol]
25997-8,urae (24h u) [moles/vol]
25997-8,urte (24h substance concentration u moles/vol]
53281-2,urinalysis type of cast panel [#/volume] - urine by computer assisted method
53281-2,urinalysis type of cast metod [#/volume] - urine by cmputer asssted panel
53281-2,urinalysis type of cast panel [#/volume] - urine by computer assisted method
53281-2,ua casts pnl # ur comp assist
53281-2,ua casts pnl comp ur # assist
53281-2,ua casts pnl # ur comp assist
53281-2,urinalysis type of cast panel computer assisted (u) [#/vol]
53281-2,urinalysis type of cast assisted computer panel (u) [#/vol]
53281-2,urinalysis type panel cast of computer assisted (u) [#/vol]
26625-4,coccidioides sp ab [presence] in serum
26625-4,sp coccidioides ab [ql] antibodies in serum
26625-4,[preence s b serum cocidioides inserum
26625-4,coccidioides ab ser ql
26625-4,coccidioides ab pr ser ql
26625-4,ql ab ser coccidioides
26625-4,coccidioides sp ab ql (s)
26625-4,coccidiodes ab sp coccidioides ql (s)
26625-4,cocciioies sp ab q (s
101149-3,borrelia burgdorferi igm ab index [units/volume] in serum and csf
101149-3,borrelia burgdorferi igm ab index [units/volume] spinal fl csf serum and in
101149-3,borrelia bugdorferi igm ab inex [unis/volum] and serm n csf
101149-3,b burgdor igm index ser+csf-acnc
101149-3,burgdo b igm index sr+cs-acn
101149-3,b ai igm burgdor index ser+cerebrospinal fluid-acnc
101149-3,b. burgdorferi igm index qn (s+csf)
101149-3,b. antibody burgorfer gm indexqn (s+csf)
101149-3,lymes b. ugdorferi igm ndex qn (s+csf)
69561-9,thyrotropin [units/volume] in cord blood
69561-9,thyrotropin [units/volume] in cord bld cord bld
69561-9,blood [units/volume] in cord thyrotropin
69561-9,tsh bldco-acnc
69561-9,bldco-acnc tsh
69561-9,bldc-acnc tsh
69561-9,tsh qn (bldco)
69561-9,qn(bldco tsh
69561-9,qnt ts qn (bldco)
58757-6,parvovirus b19 igg ab [units/volume] in cerebral spinal fluid by immunoassay
58757-6,parvovirus b19 igg ab [units/volume] in cerebral spinal fluid by immunoassay
58757-6,parvovirus b19 igg fluid [units/volume] in cerebral spinal ab by immunoassay
58757-6,b19v igg csf ia-acnc
58757-6,b19v igg csf ia-acnc
58757-6,19v cs igg i-anc
58757-6,parvovirus b19 igg ia qn (csf)
58757-6,qn b19 igg ia spinal fl parvovirus (csf)
58757-6,parvovirus n(csf) igg ia b9
19496-9,hydroxyethylflurazepam cutoff [mass/volume] in urine for confirmatory method
19496-9,hydrxyethylflurazepam cutoff [as/volume] in for urine confirmatory method
19496-9,hydroxyethylflurazepam for [mass/volume] in urine cutoff confirmatory method
19496-9,oh-ethylfluraz cto ur cfm-mcnc
19496-9,h-ethylfluraz cto ur cfmmcnc
19496-9,oh-ethylfluraz level ur cto cfm-mcnc
19496-9,hydroxyethylflurazepam cutoff confirm (u) [mass/vol]
19496-9,hydroxyethylflurazepam point in time cutoff confirm (u) [mass/vol]
19496-9,hydroxyethyflrazepam cutof conirm (u) [masvol]
41228-8,xanthine [presence] in serum
41228-8,xanthie chemistry [ql] srum in
41228-8,xanthine [presence] in ser
41228-8,xanthine ser ql
41228-8,xanthine ql ser
41228-8,xnthine serql
41228-8,xanthine ql (s)
41228-8,xanthine ql (s)
41228-8,ql(s) xanthine chemistry
99710-6,venous lumen volume dialysis catheter
99710-6,venous lumen volume dalysis caeter
99710-6,venous lumen volume dialysis clin catheter
99710-6,venous lumen vol dialysis catheter
99710-6,venous catheter ol dialysis umen
99710-6,clin cathete lumen voldialysis venous
20509-6,hemoglobin [mass/volume] in blood by calculation
20509-6,emoin[mass/volume] i lood by calculation
20509-6,hemoglobin blood in [mass/volume] by calculation
20509-6,hgb bld calc-mcnc
20509-6,hgb calculation bld calc-mcnc
20509-6,calc-mc hgbbld
20509-6,hemoglobin calc (bld) [mass/vol]
20509-6,hemoglobin calc (bld) [mass/vol]
20509-6,hemogobi calc(blood) [mass/vo]
4650-8,interleukin 1 [units/volume] in serum or plasma
4650-8,interleuin [units/volum] serum serplas in or plasma
4650-8,in 1 [units/volume] interleukin serum or plasma
4650-8,il1 serpl-acnc
4650-8,il1 serpl-acnc serplas
4650-8,l1 serpl-cnc arbitrary concentration
4650-8,interleukin 1 qn
4650-8,interleukin 1 qn
4650-8,qnt interleukin n 1
1752-5,albumin [mass/volume] in synovial fluid
1752-5,fluid in ynovia albumin[mss/volume] qnt
1752-5,albumin [mass/volume] in synovial fluid rheumatology
1752-5,albumin snv-mcnc
1752-5,albumin snv-mcnc
1752-5,lbumin snv-mcnc
1752-5,albumin (syn fld) [mass/vol]
1752-5,albumin [mass/vol] fld) (syn
1752-5,albumin (syn [mass/vol] fld)
22455-0,pseudorabies virus herdcheck gene deletion ab [presence] in serum
22455-0,pseudorabies virus herdcheck gene ab deletion [presence] in serum
22455-0,pseudorabies virus herdcheck gene serum ab [presence] in deletion
22455-0,prv herdcheck ab ser ql
22455-0,pr herdcheck ab ser ql
22455-0,prv ql ab serum autoantibodies herdcheck
22455-0,pseudorabies virus herdcheck gene del ab ql (s)
22455-0,pseudorabies herdcheck virus gene del ab ql (s)
22455-0,gene virus herdceck pseudorabies del ab ql (s)
56745-3,pl-12 ab [presence] in serum by immunoblot
56745-3,in ab [ql] pl-12 serum by immunoblot
56745-3,ser ab pl-12 [presence] in serumby immunoblot
56745-3,pl12 ab ser ql ib
56745-3,ib ab ser immunoblot ql pl12
56745-3,l12 ab serum ib ql
56745-3,pl-12 ab ib ql (s)
56745-3,pl-1 ib ab presence ()
56745-3,presence(s ab ib pl12
74843-4,baylisascaris sp igg ab [presence] in cerebral spinal fluid by immunoassay
74843-4,ylisascaris s igg ab fluid n cebral pinal [ql] by immnoassay
74843-4,baylisascaris s igg ab [pesnce] inceebral spnal antby fuid by immunoay
74843-4,baylis sp igg csf ql ia
74843-4,baylis sp igg csf infectiousdisease ql ia
74843-4,baylis sp igg csf presence ia
74843-4,baylisascaris sp igg ia ql (csf)
74843-4,baylisascaris ql igg ia sp (csf)
74843-4,baylisascaris sp igg ia (cerebrospinal fluid) ql
79460-2,galactose 1 phosphate uridyl transferase [enzymatic activity/substance] in red blood cells
79460-2,phosphorous bld phophae rdyltransferase [enzymatic activty/ubstance] in red galactose1 cells
79460-2,galactose gal-1-po4 1 phosphate uridyl transferase [enzymatic activity/substance] in red blood cells
79460-2,gal1put csub rbc
79460-2,gal1put csub gal-1-put rbc
79460-2,csub gal1put po4 rbc
79460-2,galactose 1 phosphate uridyl transferase (rbc) [catalytic activity/moles]
79460-2,galactose qnt 1 phosphate uridyl transferase (rbc) [catalytic activity/moles]
79460-2,glactose 1 hosphat uriyltranserase (bc) catalytic ativit/moles]
5009-6,hepatitis b virus dna [presence] in specimen by naa with probe detection
5009-6,hepatitis b by dna [presence] in specimen virus naa with probe detection
5009-6,[ql] b virus dna hepatitis i specien by naa ith prob tection
5009-6,hbv dna spec ql naa+probe
5009-6,naa+proe dna spec hep b ql hv
5009-6,hbv ql dna sec naa+probe ql
5009-6,hbv dna naa+probe ql (specimen)
5009-6,naa+probe dna hbv ql (specimen) naat
5009-6,hbv dna presence naa+probe (specimen)
62498-1,phenx - tobacco - 30d quantity and frequency - adult protocol 030802
62498-1,phenx - tobacco - 30d quantity and frequency - adult protocol 030802
62498-1,pnx - tobacco  30quanty and rqency -ault protocol 030802
62498-1,tobacco 30d quant freq adult proto
62498-1,tobacc30 quant panl freq adult proto
62498-1,random tobacco 30d quant freq adult proto
13886-7,lactate dehydrogenase 1/lactate dehydrogenase.total in urine by electrophoresis
13886-7,lactte dehdroese 1lactate dehydroenasettal in urine y elecrohoresis
13886-7,1/lactaedehydroenase.total dhydrogenase dehydrog lactate in rine by electophoresi
13886-7,ldh1 cfr ur elph
13886-7,ldh1 ur cfr elph
13886-7,ldh1 cfr ld-1 ur elph
13886-7,ldh 1 elph (u) [catalytic fraction]
13886-7,ldh 1 elph 2-hydroxy-propionate (u) [catalytic fraction]
13886-7,ldh ld-1 1 [catalytic () elph fraction]
73517-5,atenolol induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73517-5,atenolol duced platelet igm ab [pesnce]in seru r pasm by flow ytometry (fc)
73517-5,atnolol induced platelet igm ab [presence] in seum or pasma byflow cytometry(fc)
73517-5,atenolol ind plt igm serpl ql fc
73517-5,atenolol ind fc igm serpl ql plt
73517-5,aenool screen ind plt gm seplql c
73517-5,atenolol induced platelet igm fc ql
73517-5,fc induced platelet igm atenolol ql
73517-5,atenolol platelet indd point in time ig fc l
44273-1,classical swine fever virus rna [units/volume] (viral load) in specimen by naa with probe detection
44273-1,classical swine fever virus rna [units/volume] (viral load) in naa by specimen with probe detection
44273-1,strand displacement amplification classical wine fever virus rna[units/vlume] (viral load) in specmen by naa with proe etection
44273-1,csfv rna spec naa+probe-acnc
44273-1,csfv rna spec naa+probe-acnc qbr
44273-1,veterinary csfv rna spec na+probe-anc
44273-1,classical swine fever virus rna naa+probe qn (specimen)
44273-1,clasicalwinefever virus rn naa+probqn (seimn)
44273-1,classical swine lcr feve (specimn rna na+proe qn iru
5176-3,helicobacter pylori igg ab [units/volume] in serum by immunoassay
5176-3,helicobacter pyori gg ab quan unis/voume] in serum by immuoassa
5176-3,helicobacter pylori by ab [units/volume] in serum igg immunoassay
5176-3,h pylori igg ser ia-acnc
5176-3,h pylori igg serum ia-acnc
5176-3,h ia-acnc igg ser pylori
5176-3,h. pylori igg ia qn (s)
5176-3,h. (s) sr igg ia qn pylori
5176-3,qn pylori igg ia h. (s)
767-4,neutrophils.hypersegmented/leukocytes in blood by manual count
767-4,neutrophils.hypersegmentd/leukocyes in manual by bld count
767-4,neutrophils.hypersegmented/leukocytes in blood by manual count
767-4,neuts hyperseg nfr bld manual
767-4,neuts yperseg manual bl fr lkcs
767-4,neutshypersg manual bl neuts hyperseg nfr
767-4,neutrophils.hypersegmented/leukocytes manual cnt (bld)
767-4,neutrophils.hypersegmented/leukocytes cnt manual (blood)
767-4,anual white bld cell nutrophils.hypersgmented/leukocytes nt (ld)
103202-8,deprecated sars-cov-2 (covid-19) rna in respiratory specimen by naa with probe detection
103202-8,depreated sars-ov-2 (covid-9) rna i rspiratoy specien by naa with probe detection
103202-8,deprecated probe (covid-19) rna in respiratory specimen by naa with sars-cov-2 detection
103202-8,deprecated sars-cov-2 rna resp naa+probe
103202-8,panl dprecatd rsp rna sarscov-2 naa+roe
103202-8,deprecated sars-cov-2 rna resp sars-cov-1 naa+probe
103202-8,sars-cov-2 (covid-19) rna naa+probe (resp)
103202-8,sars-cov-2 (resp) rnanaa+obe 3 self-sustaining sequence replication (covid-9)
103202-8,rna (covid-19) sars-cov-2 naa+probe (resp)
81116-6,hepatitis c virus core ab+ag [presence] in serum
81116-6,hepatitis c virus core [presence] ab+ag in serum
81116-6,hepatitis c virus in ab+ag [presence] core serum
81116-6,hcv core ab+ag ser ql
81116-6,core hcv abag sr ql
81116-6,hcv core ab+ag serum ql
81116-6,hcv core ab+ag ql (s)
81116-6,hcv core ab+ag ql microbiology (s)
81116-6,core hcv ab+ag ql (s)
45214-4,isoleucine+leucine [moles/volume] in dbs
45214-4,substance concentration [moles/voumen isolecie+leucine dbs
45214-4,dbs [moles/volume] in isoleucine+leucine
45214-4,ile+leu dbs-scnc
45214-4,dbs-scnc ile+leu
45214-4,dbs-scn quan il+leu
45214-4,isoleucine+leucine (dbs) [moles/vol]
45214-4,[moles/vol] (dbs) isoleucine+leucine
45214-4,ile [oles/vol] (bs) isoleucie+leucine
42570-2,sodium [mass or moles/volume] in serum or plasma
42570-2,serum or plasma sodiu [mass or moles/volum]in or erum plsma
42570-2,sodium [mass or moles/volume] in level serpl
42570-2,sodium serpl-mscnc
42570-2,serpl-mscnc sodium
42570-2,serpl-mscnc sodium
42570-2,sodium [mass or moles/vol]
42570-2,sr mles/vl] [mass or sodium
42570-2,sodium or [mass moles/vol]
74859-0,ethanol [mass/volume] in blood estimated from serum or plasma level
74859-0,serum [mass/volume] in blood estimated from ethanol or plasma level
74859-0,etanol [mass/olue] n blood estimated from serum r plama level
74859-0,bld ethanol est from serpl-mcnc
74859-0,etoh serpl-mcnc ethanol est from bld
74859-0,bld est ethanol from serpl-mcnc
74859-0,ethanol estimated from serum or plasma level (bld) [mass/vol]
74859-0,ethanol estimated from serum plasma or level (bld) [mass/vol]
74859-0,random ethanol stimate frm level plas serumor (bld) [mass/ol
70635-8,functional assessment of cancer therapy for patients with neurotoxicity questionnaire - 13 items - version 4 (fact-gog-ntx 13) [facit]
70635-8,functional assessment ofcacer herapy for patents ith neurotoxiity questionnaire  1 item version 4 (ac-gog-x13) [fact]
70635-8,functional assessment of cancer therapy 13 patients with neurotoxicity questionnaire - for items - version 4 (fact-gog-ntx 13) [facit]
97170-5,adalimumab [mass/volume] in serum or plasma --trough
97170-5,adalimumab [mass/volume] in quantitative serum or plasma --trough
97170-5,adalimumab [ms/volume] in serum o plasma --trugh humira
97170-5,adalimumab trough serpl-mcnc
97170-5,adalimumab trough humira serpl-mcnc
97170-5,serpl-mcnc trough adalimumab drugs
97170-5,adalimumab trough [mass/vol]
97170-5,trough adalimumab [mass/vol]
97170-5,adalimumab level trough [massvol]
73520-9,argatroban induced platelet igg ab [presence] in serum or plasma by flow cytometry (fc)
73520-9,argatroban induced platelet flow ab [presence] in ser or plasma by igg cytometry (fc)
73520-9,argatroban ser induced platelet igg ab [presence] in ser or plasma by flow cytometry (fc)
73520-9,argatroban ind plt igg serpl ql fc
73520-9,argatroban ind plt igg serpl ql fc
73520-9,platelet auto-antibodies argatroban ind plt serpl igg ql fc
73520-9,argatroban induced platelet igg fc ql
73520-9,antibodies gg induced platelet argaroban f presence
73520-9,argatroban igg platelet induced fc ql
79471-9,"1,4-cyclohexanediol/creatinine [molar ratio] in urine"
79471-9,"in [mlarratio] ,4-cyclhexeol/cretinine uine"
79471-9,"1,-cyclohexandil/creatinine[olar urin in atio]"
79471-9,"1,4-cyclohexanediol/creat ur-srto"
79471-9,"ur-srto 1,4-cyclohexanediol/creat"
79471-9,"1,4-cycohexnediolcreat ur-srto"
79471-9,"1,4-cyclohexanediol/creatinine (u) [molar ratio]"
79471-9,"1,4-cylheaneilceainine (u) [molr ratio]"
79471-9,"1,4-cylohexaediolretinine (u) [molar rato]"
54383-5,cytochrome c oxidase [enzymatic activity/mass] in fibroblast
54383-5,activity/mass]in quan c xidase [ezymatic cytchrme fibroblast
54383-5,cytochrome c oxidase [enzymatic activity/mass] in fibroblast
54383-5,cyc oxidase fib-ccnt
54383-5,fibr cyc oxidase fib-ccnt
54383-5,quan cyc oidase fibccnt
54383-5,cytochrome c oxidase (fibroblast) [catalytic activity/mass]
54383-5,ctochre actvity/mass] oxidase (fibroblast [catalyti c
54383-5,cytochrome fib c [catalytic (fibroblast) oxidase activity/mass]
74537-2,neisseria meningitidis serogroup c dna [presence] in specimen by naa with probe detection
74537-2,neisseriameingitidis serogrop dna [presenc] i specimen by misc naa with probedtection
74537-2,neisseri meingitidis eroroup with dn [prsenc] n spcimen b naa c prbe meningococcal meningitis detecton
74537-2,n men sg c dna spec ql naa+probe
74537-2,pcr n men sg c dna spec presence naa+probe
74537-2,n men sg c dna spec polymerase chain reaction ql naa+probe
74537-2,n. meningitidis c dna naa+probe ql (specimen)
74537-2,n meningitidis c dna naa+probe ql specimen)
74537-2,n. eningitidis c dna na+probql speimen)
88573-1,onchocerca sp igg2 ab [presence] in serum by immunoassay
88573-1,nchocerca spigg ab [presnce] in serum by immunoassay
88573-1,onchocerca ser igg2 ab [presence] in sp by immunoassay
88573-1,onchocerca igg2 ser ql ia
88573-1,filariasis ochceca ql igg2ser ia
88573-1,ig2 infectiousdisease onhcrca ser ql i
88573-1,onchocerca sp igg2 ia ql (s)
88573-1,onchocerca sp igg2 ia (s) ql
88573-1,onchocercasp igg2 i l )
48111-9,glutathione.reduced [moles/mass] in red blood cells
48111-9,glutathione.reduced cells in red blood [moles/mass]
48111-9,glutathione.reduced [moles/mass] in cells blood red
48111-9,gsh rbc-scnt
48111-9,rbc-scnt substance content sh
48111-9,gsh chemistry rbc-scnt
48111-9,glutathione.reduced (rbc) [moles/mass]
48111-9,quan glutathione.reduced [moles/mass] (rbc)
48111-9,[moles/mass] (rbc) quan glutathione.reduced
36923-1,epstein barr virus dna [#/volume] (viral load) in blood by naa with probe detection
36923-1,eptein barr virus dna transcription mediated amplification [#/volume] (viral lod) iblood b na wih probe detection
36923-1,epseinarr virs dna #/volume] (vrl load) in blod by naa with probe detction
36923-1,ebv dna # bld naa+probe
36923-1,ebv dn # bld naa+probe
36923-1,bv dna # ld naa+prob
36923-1,ebv dna naa+probe (bld) [#/vol]
36923-1,ebv dna (bld) naa+proe [#vol]
36923-1,ebv absolute dna naa+probe (bld) [#/vol]
96371-0,tapentadol [presence] in saliva (oral fluid) by confirmatory method
96371-0,apentadol [resence] in (oralfluid) saliv by confimatory methd cnfr
96371-0,tapentadol [ql] cnfr in saliva (oral fluid) by confirmatory method
96371-0,tapentadol sal ql cfm
96371-0,cfm sal ql random tapentadol
96371-0,cfm qual sal ql tapentadol
96371-0,tapentadol confirm ql (sal)
96371-0,random tapentadol confirmql sa)
96371-0,qual tapentadol confirm presence (sal)
79593-0,allocystathionine/creatinine [molar ratio] in urine
79593-0,allocystathionine/creatinine in ratio] [molar urine
79593-0,allocystathionine/crinne [olarratio] in urine ua
79593-0,allocystathionine/creat ur-srto
79593-0,ur-srto allocystathionine/creat
79593-0,allcysathonine/creat ua ur-srt
79593-0,allocystathionine/creatinine (u) [molar ratio]
79593-0,[molarrtio] allocysathioine/creatinine(u)
79593-0,ratio] (u)[mola allocystathionine/creatnin
1794-7,amylase [enzymatic activity/volume] in duodenal fluid
1794-7,amylase [enzymatic activity/volume] in duodenal fluid
1794-7,amylase [enzymatic quan activity/volume] n duodenal fuid
1794-7,amylase duod fl-ccnc
1794-7,amylase uod fl-ccnc
1794-7,amylase duod fl-ccnc random
1794-7,amylase (duod fld) [catalytic activity/vol]
1794-7,amylase diastase (duod fld) catalytic activity/vol]
1794-7,amylase(duod fld) [catalytic actiity/vol]
3674-9,heptaminol [mass/time] in 24 hour urine
3674-9,heptaminol [mass/time] in 24 hour urine
3674-9,24 [ss/tie n heptamio hou urine
3674-9,heptaminol 24h ur-mrate
3674-9,hepamol 24h ur-ma
3674-9,heptaminol 24h ur-mrate urn
3674-9,heptaminol (24h u) [mass/time]
3674-9,heptaminol [mass/time] u) (24h qnt
3674-9,heptaminol u) (24h [mass/time]
56629-9,myelin ab [titer] in serum by immunofluorescence
56629-9,myelin ab tier] serology in serum byimmunofuorescece
56629-9,myelin ab antibodies [titer in seum b immunofluoescece
56629-9,myelin ab titr ser if
56629-9,myelin ser titr ab if
56629-9,ab yein titr ser if
56629-9,myelin ab if (s) [titer]
56629-9,[tier] ab if abs (s) myelin
56629-9,immune fluorescence myeln ab if (s) ter]
82410-2,ganglioside gq1b igg+igm ab [presence] in serum by line blot
82410-2,pr nglioide gq1bigg+igm ab[presence] in serbylne blot
82410-2,ganglioside gq1b igg+igm ab [ql] in serum by line blot
82410-2,gq1b gangl igg+igm ser ql line blot
82410-2,gq1b gangl blot ser ql line igg+igm
82410-2,gq1b gangl igg+igm ser tetrasialylganglioside ql line blot
82410-2,ganglioside gq1b igg+igm line blot ql (s)
82410-2,ganglioside sr igg+igm gq1b line blot ql (s)
82410-2,ganglioside gq1b igg+igm line blot presence (s) autoantibodies
86161-7,streptococcus pneumoniae danish serotype 8 ab [units/volume] in serum --2nd specimen
86161-7,streptococcus pneumoniae danish serotype spec 8 ab [units/volume] in serum --2nd specimen
86161-7,stretococs pneumoniae danis serotye8 ab [units/volum] in serum--2nd spcmen s pneumoniae
86161-7,s pneum da 8 ab sp2 ser-acnc
86161-7,peu s a 8absp2ser-acnc
86161-7,peum s a8absp2 ser-acnc
86161-7,s. pneumoniae danish type 8 ab spec 2 qn (s)
86161-7,s. ab danish type 8 pneumoniae spec 2 qn (s)
86161-7,s. pneumonae das type 8ab spec qn 2 (s)
14585-4,albumin/creatinine [molar ratio] in urine
14585-4,albmi/creatinine urn in [molarratio] urine
14585-4,albumin/creatiine [mola rato] urne
14585-4,albumin/creat ur-srto
14585-4,ur-srto albumin/creat ucr
14585-4,ur-srto albumin/creat cr
14585-4,albumin/creatinine (u) [molar ratio]
14585-4,albumin/creatinine (u) [molar ratio]
14585-4,[molar (u) albumin/creatinine nephrology ratio]
9381-5,pyridinoline [mass/time] in 2 hour urine
9381-5,pyridinoline 2 n masst] hour urine
9381-5,pyrdinoline [mass/ime] in 2 hour urine
9381-5,pyd 2h ur-mrate
9381-5,pyd  ur-mrate
9381-5,pyd 2h ur-mate 120 minutes
9381-5,pyridinoline (2h u) [mass/time]
9381-5,2h pyriinoline u) [mas/time] mrate
9381-5,pyridinoine [mass/time] u) (2h quant
43581-8,complement c4 [mass/volume] in peritoneal fluid
43581-8,[massvolume]in comlmentc4 comp pritoneal fluid
43581-8,complement c4 [mass/volume] beta 1 e-globulin in peritoneal fluid
43581-8,c4 prt-mcnc
43581-8,c4 prtmcnc quan
43581-8,prt-mcnc c4
43581-8,complement c4 (periton fld) [mass/vol]
43581-8,compleent fl)[mss/vol] c4(perion peritoneal fluid
43581-8,fld periton complement [mss/vol] quantitative
4167-3,ceftizoxime [mass] of dose
4167-3,ceftizxime [mass] of dose
4167-3,ceftizoxime [mass] of ceftrix dose
4167-3,ceftizoxime dose
4167-3,dose quant ceftizoxime
4167-3,drug doses ose ceftizoxime
4167-3,ceftizoxime (dose) [mass]
4167-3,ceftizoxime (dos) eposelin [mass]
4167-3,[mass] (dose) ceftizoxime
27356-5,phencyclidine [mass/volume] in vitreous fluid
27356-5,point in time phencyclidine [mass/volume] in vitreous fluid
27356-5,hencylidne flui in vitreous [mssvolum] drugs of abuse
27356-5,pcp vitf-mcnc
27356-5,vit-mcnc pcp level
27356-5,vitf-mcnc pcp
27356-5,phencyclidine (vitr fld) [mass/vol]
27356-5,phencyidin (vit fl) [ass/vo]
27356-5,[ass/vol] (vitr fd) phencycidine
69842-3,alpha hydroxybutyrate [moles/volume] in cerebral spinal fluid
69842-3,alpha spinal flu hydrxybutyrate [moles/volume] i ceebral spinl fluid
69842-3,alha ydroxybutyrate [molesvol]in spinal cerebral fluid
69842-3,a-oh-butyr csf-scnc
69842-3,-oh-butyrcsf-scnc
69842-3,a-oh-butyrcsf-scnc cerebral spinal fluid
69842-3,alpha hydroxybutyrate (csf) [moles/vol]
69842-3,hydroxybutyrate lpha (cerebrospinal fluid) [moles/vol]
69842-3,alpha hydroxybutyrate (cerebrospinal fluid)moles/vol]
48873-4,ehrlichia sp identified in specimen by organism specific culture
48873-4,culture sp identified in specimen by organism specific ehrlichia
48873-4,hrlichia sp identified i specimen by orgais specific cultur
48873-4,ehrlichia spec cult
48873-4,cult spec ehrlichia
48873-4,ehrlichia spec cult nominal
48873-4,ehrlichia sp identified org specific cx nom (specimen)
48873-4,ehrlichia identified sp org species specific cx nom (specimen)
48873-4,specific sp identified org ehrlichia cx infectious disease nom (specimen)
86197-1,pentylone [mass/volume] in urine by confirmatory method
86197-1,pentylon [mss/volume] in urne b cofirmatory method
86197-1,pentylone [mass/volume] confirmatory in urine by confirmatory method
86197-1,pentylone ur cfm-mcnc
86197-1,ur drugs pentylone cfm-mcnc
86197-1,pentylone ur drug/toxicology cfm-mcnc
86197-1,pentylone confirm (u) [mass/vol]
86197-1,petyloe [mass/ol] cnfrm u) confirm
86197-1,pentyone (u) onfirm [ass/vol]
88550-9,scedosporium apiospermum dna [presence] in lower respiratory specimen by naa with probe detection
88550-9,scedosporimapiopermum dna [ql] i lower spiratory specimen by naa with prbe qualitative detection
88550-9,by apiospermum dna [presence] in lower respiratory specimen scedosporium naa with probe detection
88550-9,s apiospermum dna low resp ql naa+probe
88550-9,s aiosperu infectiousdisease dna low resp q na+probe
88550-9,presence apiospermum dna low resp s naa+probe amplif
88550-9,s. apiospermum dna naa+probe ql (lower resp)
88550-9,s. apiospermum dna naa+probe ql (lower resp) pcr
88550-9,. rsp) dna naa+prbel (lower apiospermum
38312-5,tetrachloroethylene [mass/volume] in water
38312-5,tetrachloroethylene in [mass/volume] water
38312-5,tetrachloroethylene [mass/volume] in water
38312-5,ttce wat-mcnc
38312-5,wat-mcnc drug/toxicology ttce
38312-5,tce watcnc
38312-5,tetrachloroethylene (water) [mass/vol]
38312-5,tetrahlooethylene (water) [mass/vol]
38312-5,tetrchloroehylene quan (water) [mass/vol]
73435-0,clonazepam induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73435-0,clonazepam induced platelet igm ab [presence] in serum or plasma by flow serpl cytometry (fc)
73435-0,clonazeam indced latelet igm ab [ql in erum r plsm by flow qual cytoetry c)
73435-0,clonazepam ind plt igm serpl ql fc
73435-0,clonazepam fc igm serpl ql indplt
73435-0,platelt igm in plt clonazepa sepl qlf
73435-0,clonazepam induced platelet igm fc ql
73435-0,clonazepam induced platelet igm fc presence
73435-0,lonazpam induced platelet igm c ql
68383-9,microscopic observation [identifier] in body fluid by koh preparation
68383-9,mcroscopi obsrvation identfer] inbody id fluid by koh prearation
68383-9,micrscopc ervation [identifier in bod fluidby koh preparation b/f
68383-9,koh prep fld
68383-9,koh prep fld
68383-9,koprep d
68383-9,microscopic observation koh prep nom (body fld)
68383-9,kh obervation icroscopic pre nom (body fld
68383-9,microscopic obseration koh infectious disease prep nom (body fld)
3882-8,oxacillin [mass/volume] in serum or plasma
3882-8,oxacillin [mass/volume] serum in or serum plasma
3882-8,oxacillin [mass/volume] in serum or serum plasma
3882-8,oxacillin serpl-mcnc
3882-8,point in time serpl-mcnc oxacillin
3882-8,oxacilln serl-cnc
3882-8,oxacillin [mass/vol]
3882-8,drug/toxicology oxaciln [ass/vol]
3882-8,quant [mass/vol] oxacillin
25968-9,pentacarboxylporphyrins [moles/volume] in 24 hour urine
25968-9,in [moles/volume] substance concentration pentacarboxylporphyrins 24 hour urine
25968-9,hour [moles/volme] in 24 pentacarbxylporphyrins rine
25968-9,penta-cp 24h ur-scnc
25968-9,24h penta-cp ur-scnc
25968-9,pnta-cp urscnc 24h
25968-9,pentacarboxylporphyrins (24h u) [moles/vol]
25968-9,penacarboxylporphrins [moles/vol] pentacarboxyporhyrin u) (24h
25968-9,pentacarboxylporphyrins qnt (24h u) [moles/vol]
59301-2,desloratadine [mass/volume] in urine
59301-2,mass concentration urin [mass/voume]in dslratadie
59301-2,desloratadine quant [mass/volume] in urine
59301-2,desloratadine ur-mcnc
59301-2,ur-mcnc desloratadine
59301-2,ur-mcnc urn desloratadine
59301-2,desloratadine (u) [mass/vol]
59301-2,(u) ur desloratadine [mass/vol]
59301-2,desloatadine (u) [mas/vol]
103629-2,monkeypox virus igg ab [titer] in serum by immunoassay
103629-2,monkeypox virus igg ab [titer] by serum anti in immunoassay
103629-2,monkeypox virusigg ab [titer] in serum by immunoaay mvpx
103629-2,mvpx igg titr ser ia
103629-2,mvpx serum titr igg ia meia
103629-2,mvpx igg titr ser immune globulin g ia
103629-2,monkeypox virus igg ia (s) [titer]
103629-2,monkeypox virus igg ia(s) [titer] anti
103629-2,vrus monkeypox igg ia (s point in time iter]
87463-6,nickel [mass/mass] in specimen
87463-6,ie [mas/mass] specien in
87463-6,nickel [mas/mass] in specimen
87463-6,nickel spec-mcnt
87463-6,nickel spec-mct
87463-6,ickel spec-mnt drug/toxicology
87463-6,nickel (specimen) [mass/mass]
87463-6,nickel (specimen) point in time [mass/mass]
87463-6,nickel (specimen) [mass/mass]
35056-1,histiocytes [#/volume] in cerebral spinal fluid
35056-1,histocytes [#/volue] in cerebral spinal fld
35056-1,histiocytes [#/volume] in fluid spinal cerebral
35056-1,histiocytes # csf
35056-1,cerebrospinal fluid # histiocytes
35056-1,histocytes csf point in time
35056-1,histiocytes (csf) [#/vol]
35056-1,histiocytes [#/vol] (csf)
35056-1,(csf) histiocytes [#/vol]
88183-9,mycobacterium sp identified in isolate by sequencing
88183-9,mycobacterium sp identified in isolate by sequencing
88183-9,cobcterium isoateby microbiology identified n sp sequencing
88183-9,mycobacterium islt seq
88183-9,mycobacterium islt seq
88183-9,islt mycobacterium seq
88183-9,mycobacterium sp identified sequencing nom (isol)
88183-9,mycobacteriu sp detified equencing nom (isol)
88183-9,mycobacterium sp identified sequencing nom acid fast (isol)
14888-2,procainamide [moles/volume] in serum or plasma
14888-2,procainamide [mlesvolume] in serum o drugs pla
14888-2,procainamide [mes/olume] n ser or plasma drugs
14888-2,procainamide serpl-scnc
14888-2,pocainamide serpl-cnc quan
14888-2,serpl-scnc procainamide drugs
14888-2,procainamide [moles/vol]
14888-2,[moles/vol] procainamide
14888-2,[moles/vol] prcainamide
29747-3,tocopherols [moles/volume] in serum or plasma
29747-3,tocopherols plsm [moles/volume] in ser or plasma
29747-3,tocopherols [moles/volume] in serum or plasma serum
29747-3,tocopherols serpl-scnc
29747-3,tocopherols serpl-scnc
29747-3,serpl-scnc serpl tocopherols
29747-3,tocopherols [moles/vol]
29747-3,[moles/vol] tocopherols
29747-3,[moles/vol] qnt tocopherols
38434-7,ibuprofen [mass/volume] in serum or plasma --3 hours post dose
38434-7,ibuprofen [mass/volume] in serum or plas --3 hours post dose
38434-7,ibuprofen [mass/volue] qnt in erum oplasma --3 hours pot doe
38434-7,ibuprofen 3h p serpl-mcnc
38434-7,ibuprofen 3h p serpl-mcnc
38434-7,ibuprofe quantitative p serpl-mcnc
38434-7,ibuprofen 3 hr post dose [mass/vol]
38434-7,ibuprofen 3 hr post [mass/vol] dose
38434-7,iburofen 3 hr mass concentration pst dose [mass/vol]
48701-7,luteinizing releasing hormone [mass] of dose
48701-7,luteinizig dose homone[mass]of releaing
48701-7,[mass] point in time releasing hormone luteinizing of dose
48701-7,luteinizing releasing horm dose
48701-7,luteinizing dose horm releasing
48701-7,lueinizing relsing horm ose random
48701-7,luteinizing releasing hormone (dose) [mass]
48701-7,luteinizing quan [as] eleasinghormonedose)
48701-7,luteinizing releasing [mass] (dose) hormone random
76654-3,beryllium [mass/mass] in hair
76654-3,beyllium in be [mass/mass] hai
76654-3,hair in beryllium[mass/mas]
76654-3,beryllium hair-mcnt
76654-3,brylliu hair-mcnt
76654-3,hair-mcnt beryllium
76654-3,beryllium (hair) [mass/mass]
76654-3,har (hir) beryllium [ass/mass]
76654-3,quant beryllium (hair) [mass/mass]
53220-0,dicarboxystearoylcarnitine (c18-dc) [moles/volume] in dbs
53220-0,in (c18-dc) [moles/volume] dicarboxystearoylcarnitine chemistry dbs
53220-0,in (c18-dc) [moles/volume] dicarboxystearoylcarnitine dbs
53220-0,dicarboxystearoylcarn dbs-scnc
53220-0,dicarboxylic carnitine dbs-scnc dicarboxystearoylcarn
53220-0,dbsscnc random dicarboxystearylan
53220-0,dicarboxystearoylcarnitine (c18-dc) (dbs) [moles/vol]
53220-0,(db) (c18-dc) dicarboxysteoylcarnitine qnt [mols/vol]
53220-0,dcarboxeroylcarnitin quant c8-dc) (db) [moles/vol]
50204-7,iron [mass/volume] in serum or plasma --7th specimen
50204-7,iron level [mass/volume] in serum --7th plasma or specimen
50204-7,in [mass/volume] iron serum or plasma --7th specimen
50204-7,iron sp7 serpl-mcnc
50204-7,iron sp serl-mcnc
50204-7,iron sp7 serpl-mcnc
50204-7,iron 7th specimen [mass/vol]
50204-7,iron specimen 7th [mass/vol]
50204-7,iron mass concentration pecimen[mass/vo] 7h
86950-3,thymus igg ab [titer] in serum or plasma by immunofluorescence
86950-3,thymus ig a [tir] in seru rpasma by immunoflorescence
86950-3,or igg ab [titer] in serum or plasma serum thymus plasma by immunofluorescence
86950-3,thymus igg titr serpl if
86950-3,hymus igg serpl titr if point in time
86950-3,thymusiggitr fluoresent serpl if
86950-3,thymus igg if [titer]
86950-3,[titer] igif fluorescent antibody hymus
86950-3,thymus igg if antby [ter]
16353-5,amino beta guanidinopropionate [presence] in urine
16353-5,amino betaguanidinopropionate[presence] ua i urine
16353-5,amino betaguandinopropionate [presen] in urine amino beta guanidinopropionic acid
16353-5,ab-gp ur ql
16353-5,ql ur ab-gp
16353-5,random ab-gp l ur
16353-5,amino beta guanidinopropionate ql (u)
16353-5,amino beta guanidinopropionate ql (u) urn
16353-5,amio bea b ganiinopropionate q (u)
35418-3,herpes simplex virus identified in bronchial specimen by organism specific culture
35418-3,hees simplexvrus identified in organism by bronchiaspecimn secifc culture
35418-3,herpes simplex nominal virus identified in bronchial specimen by organism specific culture
35418-3,hsv bronch cult
35418-3,hsv cult bronch
35418-3,hsv cult brnh id
35418-3,hsv identified org specific cx nom (bronch spec)
35418-3,specific id identified org hsv cx nom (bronch spec)
35418-3,hsv identified infectiousdisease org specific cx nom (bronch spec)
5299-3,rheumatoid factor [titer] in serum by latex agglutination
5299-3,rheumatoid random factor [titer] in serum by latex agglutination
5299-3,rheumatoid factor [titer] serum in by latex agglutination
5299-3,rheumatoid fact titr ser la
5299-3,heumatoid act titr se la
5299-3,fact rheumatoid titr ser fact la
5299-3,rheumatoid factor la (s) [titer]
5299-3,rheumatoid factor la rheumatology (s) [titer]
5299-3,serology rheumatoid factor la (s) [titer]
73842-7,tetrahydrodeoxycortisol [moles/volume] in 24 hour urine
73842-7,erahdrooxyortisol [moles/volume] in 24 hour urine
73842-7,tetrahydrodeoxycortisol [moles/volume] in 24 hour urine quant
73842-7,th-dc 24h ur-scnc
73842-7,h-d 4hur-scnc quant
73842-7,4h hdc ur-scc
73842-7,tetrahydrodeoxycortisol (24h u) [moles/vol]
73842-7,[moles/vol] (24h u) tetrahydrodeoxycortisol
73842-7,tetrahydrodeoxycortisol 24 hours (24h u) [moles/vol]
81527-4,promis short form - cognitive function - abilities subset 8a - version 2.0
81527-4,promis short form - cognitive function - abilities subset 8a cognitive status - version 2.0
81527-4,2.0 short form - cognitive function panel - abilities subset 8a - version promis
3114-6,uroporphyrinogen decarboxylase [enzymatic activity/volume] in plasma
3114-6,uroporphyrinogen decarboxylase [enzymatic activity/volume] in plas
3114-6,in decarboxylase [enzymatic uro activity/volume] uroporphyrinogen plasma
3114-6,uro-d plas-ccnc
3114-6,plasma-ccnc catalytic concentration uro-d
3114-6,uro-dplas-ccnc
3114-6,uroporphyrinogen decarboxylase (p) [catalytic activity/vol]
3114-6,uroporphyrinogen (p) decarboxylase [catalytic activity/vol]
3114-6,uroporphyrinogen decarboxylase activity/vol] qnt [catlytic (p)
5088-0,chlamydia trachomatis ab [titer] in serum by immunofluorescence
5088-0,clamydia trachomatis autoantibody ab [titer] inseruby immunfluorescence
5088-0,chlamydi trachomais ab [titr] n serum by immunofluorescence
5088-0,c trach ab titr ser if
5088-0,trf c trach ab titr ser if
5088-0,ifa tach a titr se f
5088-0,c. trachomatis ab if (s) [titer]
5088-0,c. trachomats if a (s) [titer] titre
5088-0,trachomatis c. ab if (s) aby [titer]
60119-5,palladium [mass/volume] in serum or plasma
60119-5,plladium [mas/volume] in serm or plasm
60119-5,quan palladium [mass/volume] in serum or plasma
60119-5,palladium serpl-mcnc
60119-5,quan serum or plasma-mcnc palladium
60119-5,palladium point in time serpl-mcnc
60119-5,palladium [mass/vol]
60119-5,[mass/vol] paladium
60119-5,plladium [mass/ol]
15033-4,ascorbate [moles/time] in 24 hour urine
15033-4,ascorbate [moles/time] in 24 hour urine
15033-4,24 [oles/time] n ur ascorbte hour uine
15033-4,vit c 24h ur-srate
15033-4,vit c 24h ur-sat
15033-4,vit c 24 r-rae
15033-4,ascorbate (24h u) [moles/time]
15033-4,ascorbte [mle/time] u) (24h
15033-4,(24h ascorbate u) vitamin c [moles/time]
33859-0,somatotropin/creatinine [ratio] in 12 hour urine
33859-0,rto somattropn/creatinie ratio in 1 hur urine
33859-0,hour [ratio] in 12 somatotropin/creatinine urine
33859-0,gh/creat 12h ur-rto
33859-0,gh/creat urrt 12h
33859-0,12h gh/creat ur-rto
33859-0,somatotropin/creatinine (12h u) [ratio]
33859-0,somatotroin/reatinine (12h gh u) [rtio]
33859-0,somatotropin/creatiine (12h quant u) [ratio]
85626-0,kidney failure 2-year and 5-year risk panel by kfre
85626-0,kidney failre -yar and 5-year riskpanel b kfre
85626-0,kidney failure 2-year and panel risk 5-year by kfre
85626-0,kidney fail 2y + 5y risk kfre.dyn pnl
85626-0,kidney fail risk + 5y 2y kfre.dyn pnl
85626-0,idney fail 2y + y isk kfre.dyn pnl
85626-0,kidney failure 2-year and 5-year risk panel kfre
85626-0,kidney pnl failure 2-year and panel risk 5-year kfre
85626-0,kidney falue 2-year 5-year and rs pane kfre
27203-9,follitropin [units/volume] in 24 hour urine
27203-9,follitropin [units/volume] in 24 urine hour
27203-9,follitropin [units/volume] in urine hour 24
27203-9,fsh 24h ur-acnc
27203-9,24h h ur-acnc
27203-9,fsh urn 24h ur-acnc
27203-9,follitropin qn (24h u)
27203-9,follitropin fsh ) 24h qn
27203-9,follitropin u) (24h qn
18406-9,arsenic trioxide [mass/volume] in urine
18406-9,arsenic trioxide [mass/volume] in urine
18406-9,arsenic urine [mass/volume] in trioxide
18406-9,arsenic trioxide ur-mcnc
18406-9,ur-cnc trioxid aseni urn
18406-9,areic u-mcnc trioxide
18406-9,arsenic trioxide (u) [mass/vol]
18406-9,arsenc () trioide [mass/vol]
18406-9,arsenic (u) trioxide [mass/vol]
10879-5,isovalerylglycine [mass/volume] in urine
10879-5,n [ass/volume isvlerylglycie urine
10879-5,isovalerylglycine [mass/volume] in urine
10879-5,isovalerylgly ur-mcnc
10879-5,urmcnc isovaerygly
10879-5,isovalerylgly ur-mcnc
10879-5,isovalerylglycine (u) [mass/vol]
10879-5,[mass/vol] (u) isovalerylglycine
10879-5,[mass/vol] (u) isovalerylglycine
11528-7,deprecated radiology unspecified site and modality study
11528-7,radiology deprecated unspecified site and modality study
11528-7,attach deprecated radiology modality site and unspecified study
11528-7,deprecated
11528-7,study report deprecated
11528-7,attach deprecated
100110-6,leishmania sp 14kd igg ab [presence] in serum by immunoblot
100110-6,leishmania sp 14kd in ab [presence] igg ser by immunoblot
100110-6,immunoblot sp 14kd igg ab spp [presence] in serum by leishmania
100110-6,leishmania sp 14kd igg ser ql ib
100110-6,leismaia sp se igg 14kd presence ib
100110-6,leishmaiasp abs l er 14kigg ib
100110-6,leishmania sp 14kd igg ib ql (s)
100110-6,wblot leishmania sp 14kd igg ib ql (s)
100110-6,leishmania sp autoantibody 14kd igg ib ql (s)
17055-5,legionella longbeachae 2 igg ab [presence] in serum
17055-5,legionella longbeachae 2 igg ab [presence] in ser
17055-5,legionela n 2igab pr presence] longbechae serum
17055-5,l longbeachae2 igg ser ql
17055-5, lonbechae2 ig ser presence
17055-5,l longbeachae2 antby igg ser presence
17055-5,l. longbeachae 2 igg ql (s)
17055-5,l. longbeachae 2 igg ql (s) point in time
17055-5,l. ql 2 sr igg longbeachae (s)
56981-4,somatotropin [mass/volume] in serum or plasma --30 minutes post resting
56981-4,smaropin [mss/olume] in serum or plasm -30 minutes pst restin
56981-4,somatotropin [massvolume] in post or plas --30 minutes growth hormone serm resting
56981-4,gh 30m p resting serpl-mcnc
56981-4,gh 30m p serpl-mcnc chemistry resting
56981-4,gh 30m p resting serpl-mcnc
56981-4,somatotropin 30 min post resting [mass/vol]
56981-4,somatotropin 30min post resting [ss/vol]
56981-4,somatotropin resting pst min post 30 [mass/vol]
14427-9,globulin [mass/volume] in pleural fluid
14427-9,glob% in [mass/volume] globulin pleural fluid
14427-9,globulin [mass/volume] in pleural fluid
14427-9,globulin plr-mcnc
14427-9,globulin prcnc level
14427-9,plr-mcnc globulin
14427-9,globulin (pleur fld) [mass/vol]
14427-9,globulin (pleur fld) [mass/vol]
14427-9,globulin(leur [mass/vol] fld)
2104-8,choriomammotropin [mass/volume] in serum
2104-8,horiomammotrpin [mass/vlume] in seum chemistry
2104-8,[mass/volume] choriomammotropin in serum
2104-8,choriomammotropin ser-mcnc
2104-8,criomammoropin er-mcnc
2104-8,r-mcnc choriomammtopin hpl
2104-8,choriomammotropin (s) [mass/vol]
2104-8,choriomammotropin (s) [mass/vol] cs
2104-8,[mass/vol] (s) choriomammotropin
40521-7,monocytes/leukocytes in pleural fluid by manual count
40521-7,monoctes/leukocs bymnual leura pleural fluid in count
40521-7,monocytes/leukocytes in by fluid pleural manual count
40521-7,monocytes nfr plr manual
40521-7,monocyes manual plr nfr
40521-7,monocyesn plr nual quantitative
40521-7,monocytes/leukocytes manual cnt (pleur fld)
40521-7,manual monocytes/leukocytes leuk cnt (pleur fld)
40521-7,monocytes/leukocytes fld) cnt (pleur manual
25415-1,folate [moles/volume] in blood
25415-1,folate blood in [moles/volume]
25415-1,folate [moles/volume] in blood vitamin m
25415-1,folate bld-scnc
25415-1,bld-scnc folat folate
25415-1,folate bld-scnc
25415-1,folate (bld) [moles/vol]
25415-1,(blood) quan folte [mole/vol]
25415-1,[mle/vol] (bld) folate
59162-8,potassium [moles/volume] in 24 hour stool
59162-8,potassium faeces [moles/volume] in 24 stool hour
59162-8,potassium in [moles/volume] 24 substance concentration hour stool
59162-8,potassium 24h stl-scnc
59162-8,potassium stl-scnc 24h fecal
59162-8,24h potassium stl-snc
59162-8,potassium (24h stl) [moles/vol]
59162-8,chemistry potassium (24h stl) [moles/vol]
59162-8,potassium (24h stl s) [moles/vol]
26006-7,borrelia burgdorferi ab [presence] in serum by hemagglutination
26006-7,borrelia burgdorferi ab [ql] in serum by hemagglutination
26006-7,borrelia burgdorferi ab [presence] in hemagglutination by qualitative ser
26006-7,b burgdor ab ser ql ha
26006-7,b burgdor ha serql ab
26006-7,b burgdorferi b burgdor ab ser ql ha
26006-7,b. burgdorferi ab ha ql (s)
26006-7,b. burdoferi ab (s) ql ha
26006-7,b. burgdorferi ab ha ql ql (s)
3629-3,fenetylline [mass/time] in 24 hour urine
3629-3,or [mass/time] n fenethylline 24 fnelline urie
3629-3,[mass/time] fenetylline in quantitative 24 hour urine
3629-3,fenetylline 24h ur-mrate
3629-3,ur-mrate 24h feneyllin
3629-3,fenetylline 24h ur-mrate
3629-3,fenetylline (24h u) [mass/time]
3629-3,fentylline 24u ua [mass/time]
3629-3,(2hu) eetylie 24 hours [mass/time]
27416-7,scl-70 extractable nuclear ab [units/volume] in serum
27416-7,scl-70 extractabe clear ab[units/voe] serum anf in
27416-7,scl-70 extractable arbitrary concentration nuclear b [nits/volume] in seru
27416-7,ena scl70 ab ser-acnc
27416-7,ena ser-acnc ab scl70
27416-7,se-acnc sl70 ab na
27416-7,scl-70 extractable nuclear ab qn (s)
27416-7,cl-70 extractable nuclear ab qn (s)
27416-7,scl-70 extractable nuclear ab qn (s
62816-4,deprecated phenx measure - integrated fitness
62816-4,deprecated pan - measure phenx integrated fitness
62816-4,deprecated phenx measure - integrated fitness
49349-4,cytomegalovirus dna [#/volume] (viral load) in bronchoalveolar lavage by naa with probe detection
49349-4,cytomgavirus dna[#/volme] (viral load) inbonchoalveolar lavage b na wit probe detectio
49349-4,naa dna [#/volume] (viral load) in strand displacement amplification bronchoalveolar lavage by cytomegalovirus with probe detection
49349-4,cmv dna # bal naa+probe
49349-4,cmv dna # bal naa+probe amplified
49349-4,cmv # dna bal naa+probe
49349-4,cmv dna naa+probe (bal) [#/vol]
49349-4,cmv (bal) naa+probe dna [#/vol]
49349-4,cmv dna [#/vol] (bal) naa+probe
34447-3,cache valley virus rna [presence] in blood by naa with probe detection
34447-3,cae valley viusra [ql] in blod by naa with probe etein
34447-3,cahe valley virus rna [preence i bood by a wth id pe detection
34447-3,cvv rna bld ql naa+probe
34447-3,cvv ql blood rna naa+probe microbiology
34447-3,vv rna bldql naa+probe naat
34447-3,cache valley virus rna naa+probe ql (bld)
34447-3,naa+probe valley virus rna cache ql (bld)
34447-3,cche valleyvius orthobunyaviruses rna ql aa+probe (bd)
83079-4,beta-2-microglobulin [units/volume] in urine by immunoassay
83079-4,beta-2-microglobulin ua [units/volume] in urine by immunoassay
83079-4,qnt beta-2-microglobulin [units/volume] urine in by immunoassay
83079-4,b2 microglob ur ia-acnc
83079-4,b2micrlob ia-acnc ur b2-m
83079-4,b2 ia-acnc r microglb
83079-4,beta-2-microglobulin ia qn (u)
83079-4,beta-2-microglobulinia q (u
83079-4,i t-2-microglobuln qn (u) iaa
100705-3,mycoplasma genitalium rrna [presence] in anorectal by naa with probe detection
100705-3,mycoplasma genitalium rrna [presence] in ligase chain reaction anorectal by naa with probe detection
100705-3,myoplasmagitlium rrna [presnce] in anorectal naa with mycoplsm probe detecion
100705-3,m genitalium rrna anorectl ql naa+probe
100705-3,ql genitalium rrna anorectl m naa+probe
100705-3,m genitaliu rrna anorectl ql naa+pobe
100705-3,m. genitalium rrna naa+probe ql (anorectal)
100705-3,m. lat genitalium rrna naa+probe ql (anorectal)
100705-3,m.genitalim strand displacement amplification rrn presence naa+probe (nrectal)
97645-6,parainfluenza virus 1+2+3+4 rna [presence] in specimen by naa with probe detection
97645-6,parainfluenza virus 1+2+3+4 rna [presence] in naa by specimen with probe detection
97645-6,arainflez virus 1+2+3+4 rna [preence] inspecimen b naa with pobe detection
97645-6,hpiv 1+2+3+4 rna spec ql naa+probe
97645-6,hpiv 1++34 ql rnaspec n+probe
97645-6,hpiv +2+3+4 rna specql na+probe
97645-6,parainfluenza virus 1+2+3+4 rna naa+probe ql (specimen)
97645-6,virus parainflenza +2+4rna ordinal na+pobeql (spcimen)
97645-6,(specimen) virus 1+2+3+4 rna naa+probe ql parainfluenza pcr
59164-4,alkaline phosphatase [enzymatic activity/volume] in dialysis fluid
59164-4,[enzymati phosphatase alkaline activity/olume] in diaysis fluid
59164-4,diaf alkaline phosphatase [enzymatic activity/volume] in dialysis fluid
59164-4,alp dial fld-ccnc
59164-4,chemistry dial alp fld-ccnc
59164-4,dial alp fld-ccnc
59164-4,alp (dial fld) [catalytic activity/vol]
59164-4,alp(ial [catatic ld) activty/vo]
59164-4,alp dial fld) [catalyic chemistry activity/vol]
99723-9,medication added to peritoneal dialysis fluid [volume]
99723-9,medication added to peritoneal dialysis fluid qnt [volume]
99723-9,medication added to peritoneal dialysis fluid [volume]
99723-9,med add to peri dialysis fld vol
99723-9,add med to peri qnt dialysis fld vol
99723-9,med add to peri dialysis fld vol quan
27930-7,neutrophils/leukocytes in bronchial specimen
27930-7,neutrophils/leukocytes in bronchial specimen
27930-7,neutrophils/leukocytes lung specimen bronchial in
27930-7,neutrophils nfr bronch
27930-7,netrophils broch percent nr
27930-7,neutrophilsfr bronch
27930-7,neutrophils/leukocytes (bronch spec)
27930-7,neutrophils/leukocytes spec) (bronch
27930-7,neutrophils/leukocytes (bronch spec
31173-8,mevinphos [mass/volume] in blood
31173-8,mevinphos[mass/volume in blood
31173-8,mevinphos apavinphos blood in [mass/volume]
31173-8,mevinphos bld-mcnc
31173-8,level bld-mcnc mevinphos
31173-8,quantitative blood-mcnc mevinphos
31173-8,mevinphos (bld) [mass/vol]
31173-8,[mass/vol] (bld) mevinphos
31173-8,[mss/vol] (bld) mevinphos
76541-2,indication icd code [identifier]
76541-2,indication icd random [identifier] code
76541-2,[identifir] ic cde indication
76541-2,indication icd code
76541-2,indication code icd
76541-2,indication icd code
101233-5,glutamate decarboxylase 65 ab [presence] in serum by immunoblot
101233-5,glutamate decarboxylase by ab [presence] in ser 65 immunoblot
101233-5,glutamate decarbxyase abs 65 ab [peece] i srum by immunobo
101233-5,gad65 ab ser ql ib
101233-5,ab gad65 serum ql ib
101233-5,gad65 ab ib ql ser
101233-5,glutamate decarboxylase 65 ab ib ql (s)
101233-5,glutamate decarboxylase 65 ql ib ab (s)
101233-5,glutamate decarboxylase 65 ab west blt ib ql (s)
49901-2,heptacarboxylporphyrin iii [mass/time] in 24 hour stool
49901-2,heptacarboxylporphyrin iii [mass/time] in 24 hour stool
49901-2,24 iii [mass/time] in heptacarboxylporphyrin mrate hour stool
49901-2,hepta-cp3 24h stl-mrate
49901-2,hepta-cp3 stl-mrate 24h
49901-2,24h chemistry hepta-cp sl-mte
49901-2,heptacarboxylporphyrin iii (24h stl) [mass/time]
49901-2,heptacarboxylporphyrin iii (24h [mass/time] stl)
49901-2,stl)[mass/time] hetacarbxylorphyriniii(2h
93458-8,ah-8533 [mass/volume] in urine by confirmatory method
93458-8,ah-8533ass/olume] in urin method bycnirmatory
93458-8,ah-8533 [mass/vlume] in urine by method conf confirmatry
93458-8,ah-8533 ur cfm-mcnc
93458-8,ur ah-8533 cfm-mcnc
93458-8,quan a-533ur cfm-mnc
93458-8,ah-8533 confirm (u) [mass/vol]
93458-8,ah-533confirm (u) [mass/vol]
93458-8,conf ah-8533 [massvol] (u) confrm
20895-9,mycoplasma gallisepticum ag [presence] in tissue by immune stain
20895-9,mycolasma gallisepicum [ql] ag in tissue by immunestain
20895-9,gallisepticum mycoplasma ag [presence] in tissue by immune stain
20895-9,m gallisep ag tiss ql imstn
20895-9,gallisep m ag tiss ql imstn
20895-9,m gallisep ag imstn ql tiss mycoplasmosis
20895-9,m. gallisepticum ag immune stain ql (tiss)
20895-9,m l ag immune stain galisepticu (tiss)
20895-9,m. galispicum ag mycoplas immune (tiss) l stai
50812-7,arsenic [moles/volume] in red blood cells
50812-7,arsenic [molesvoume] in red bld clls
50812-7,arsenic [moles/volume] in red blood cells
50812-7,arsenic rbc-scnc
50812-7,pt rbc-scc arsenic
50812-7,drugs arsenic rbc-scnc
50812-7,arsenic (rbc) [moles/vol]
50812-7,[moles/vol] (rbc) arsenic
50812-7,point in time arsenic (rbc) [moles/ol]
71889-0,carboxyhemoglobin/hemoglobin.total [pure mass fraction] in arterial blood
71889-0,carboxyhemoglobin/hemoglobin.total [pure mass pulmonology fraction] in bld arterial
71889-0,[pure carboxyhemoglobin/hemoglobin.total mass fraction] in arterial art blood
71889-0,cohgb mfr.df blda
71889-0,carbonyl hemoglobin cogb bl mfr.df
71889-0,gb mfr.df bla
71889-0,carboxyhemoglobin (blda) [pure mass fraction]
71889-0,carboxyhemoglobin (blda) mass carboxyhemoglob [pure fraction]
71889-0,carboxyheglobin (blda) [pure mass fractin quantitative
35655-0,butyrylcarnitine (c4) [moles/volume] in serum or plasma
35655-0,butyrylcarnitine (4) [molesvolume] in seru or plasm
35655-0,butyrylcarnitine (c4) [moles/volume] in serpl
35655-0,butyrylcarn serpl-scnc
35655-0,serpl-scnc butyrylcarn
35655-0,butyrylcan serpl-scnc
35655-0,butyrylcarnitine (c4) [moles/vol]
35655-0,point in time butyrylcarnitine (c4) [moles/vol]
35655-0,butyrylcarnitine (c4) [moles/vol]
4163-2,cefotetan [mass] of dose
4163-2,cefotetan [ass of doe random
4163-2,doe of cefoetan[mass]
4163-2,cefotetan dose
4163-2,dose cefotetan
4163-2,cefotetan dose
4163-2,cefotetan (dose) [mass]
4163-2,drug doses [mass] cefotetan(dose)
4163-2,(dose) cefotetan quantitative [mass]
5623-4,chromium [mass/volume] in urine
5623-4,chromim [mass/volume] in urine cr
5623-4,chromium urine in [mass/volume]
5623-4,cr ur-mcnc
5623-4,ur-mcnc cr quantitative
5623-4,cr drugs u-mcnc
5623-4,chromium (u) [mass/vol]
5623-4,drug/toxicology (u) chromium [mass/vol]
5623-4,chromium [mass/vol] drugs (u)
94334-0,enterocytozoon bieneusi 18s rrna gene [presence] in specimen by naa with non-probe detection
94334-0,enterocytozoon bieneusi in rrna ordinal gene [presence] 18s specimen by naa with non-probe detection
94334-0,enterocytozoon [presence] 18s rrna gene bieneusi in specimen by naa with non-probe detection ligation-activated transcription
94334-0,e bieneusi 18s rrna spec ql naa+non-prb
94334-0,e bieneusi 18srrnaspec qnaa+non-rb
94334-0,e bieneusi 18s naa+non-prb spec ql probe with ampification rrna
94334-0,e. bieneusi 18s rrna gene naa+non-probe ql (specimen)
94334-0,e. bieneusi 18s gene rrna naa+non-probe ql (specimen)
94334-0,e. bieneusi 18s rrna presence naa+non-probe gene (specimen)
59244-4,arylsulfatase c [enzymatic activity/mass] in leukocytes
59244-4,arlsatase n [ezymaic activity/mass] c leukocys
59244-4,[ezymati arylsulfaase activity/mass] pt in leukocytes
59244-4,arylsulfatase c wbc-ccnt
59244-4,wbc-ccnt c arylsulfatase
59244-4,arylsulaase c random wbc-cnt
59244-4,arylsulfatase c (wbc) [catalytic activity/mass]
59244-4,arylsulfatase c (wbc) [catalytic activity/mass]
59244-4,arlsulfatase quan c [ctalyticactiity/mass] (wc)
53713-4,pca-1 ab [titer] in cerebral spinal fluid
53713-4,pca-1 ab [titer] in cerebral spinal fluid
53713-4,pca-1 ab [tie] in crebral spinal fluid
53713-4,pca-1 ab titr csf
53713-4,ab pca-1 titr csf
53713-4,pca-1 titr ab csf titered
53713-4,pca-1 ab (csf) [titer]
53713-4,pca-1 (csf) a [titer]
53713-4,[titer] ab (csf) pca-1
26061-2,european tick borne encephalitis virus ab [titer] in serum
26061-2,europen tick boeencephlitis virs b [titer] in serm
26061-2,european tick encephalitis borne virus ab [titer] in serum
26061-2,tbev ab titr ser
26061-2,antby titr ab tbev ser
26061-2,bev ab ser titr
26061-2,european tick borne encephalitis virus ab (s) [titer]
26061-2,antibodies european tick borne encephalitis virus ab (s) [titer]
26061-2,european tic borne encephalitisvirus ab (s) [titer]
29838-0,jamestown canyon virus igm ab [presence] in cerebral spinal fluid
29838-0,jaeton cayo virus m b [presence] in cerebral spial luid
29838-0,jamestown viru canyon igm a [psnce] in autoantibodies cerebral spinal flud
29838-0,jcv igm csf ql
29838-0,jcv igm autoantibodies csf ql
29838-0,jcv csf gm antby q
29838-0,jamestown canyon virus igm ql (csf)
29838-0,jamestown ql virus igm canyon (csf)
29838-0,(csf) spinal fld canyon virus igm ql jamestown
60316-7,methaqualone [moles/volume] in specimen
60316-7,in [moles/volume] methaqualone specimen
60316-7,methaqualone [moles/volume] in specimen substance concentration
60316-7,methaqualone spec-scnc
60316-7,unspecified spec-scnc methaqualne
60316-7,spec-scnc methaqualone
60316-7,methaqualone (specimen) [moles/vol]
60316-7,quantitative (specimn)[moles/vol] methaqualone
60316-7,[moles/vol] (specimen) methaqualone miscellaneous
78858-8,methcathinone [mass/volume] in urine by confirmatory method
78858-8,ethcathinone [mas/volume] in urine by confirmatry method
78858-8,methcathinone [mass/volume] in urine confirmatory by method
78858-8,methcathinone ur cfm-mcnc
78858-8,ucf-mcnc mehcthino quantitative
78858-8,methcathinone cfm-mcnc ur urn
78858-8,methcathinone confirm (u) [mass/vol]
78858-8,methcthion confirm (u [mass/vol]
78858-8,(u) confirm methcathinone [mass/vol]
12314-1,clorazepate [presence] in urine
12314-1,drugs clozepte [presenc] in urie
12314-1,[presence] clorazepate in urine
12314-1,clorazepate ur ql
12314-1,clorazepate presence ur
12314-1,corazpate ql random ur
12314-1,clorazepate ql (u)
12314-1,(u) ql clorazepate
12314-1,presence clorazepate (u)
101834-0,dexamethasone [moles/volume] in serum or plasma
101834-0,dexamethasone [moles/volume] in serum or plasma hexadrol
101834-0,dexamethasone plasma in erum or dexameth [moles/volume]
101834-0,dexamethasone serpl-scnc
101834-0,serpl-scnc dexamethasone
101834-0,dexamethasone dexameth serpl-scnc
101834-0,dexamethasone [moles/vol]
101834-0,[moles/vol] dexamethasone
101834-0,ser dexamethasone [moles/vol]
2675-7,deprecated ornithine [mass/volume] in serum or plasma
2675-7,ornithine deprecated [mass/volume] in serpl
2675-7,deprecated ornithine[mass/volume] erum in or plas
2675-7,deprecated ornithine plas-mcnc
2675-7,plasma deprecated ornithine plas-mcnc
2675-7,deprecated ornithine plas-mcnc quan
2675-7,ornithine (p) [mass/vol]
2675-7,(p)[mas/vol] ornihne plas
2675-7,(p) ornithine quantitative [mass/vol]
32335-2,pipecolate [moles/volume] in urine
32335-2,pipecolate [moles/volume] urine in pipa
32335-2,pipecolate ur [mlesvoume] urie in
32335-2,pipecolate ur-scnc
32335-2,ur-snc urn pipcolate
32335-2,u-cn piecolate ur
32335-2,pipecolate (u) [moles/vol]
32335-2,pipecolate ur (u) [moles/vol]
32335-2,pipecolate (u) quantitative [moles/vol]
43576-8,acylcarnitine/carnitine.free (c0) [ratio] in urine
43576-8,aylcarnitinecrnitine.free (0) atio] in urine
43576-8,acylcarnitie/carnitine.free(c0) [ratio] quant in urie
43576-8,acylcarnitine/c0 ur-rto
43576-8,acylcarnitine/c0 ur-rto ur
43576-8,ur-rto acylcarnne
43576-8,acylcarnitine/carnitine.free (c0) (u) [ratio]
43576-8,acylcarnitiecarnitine.free [ratio] u) (c0)
43576-8,acylcarnitine/carnitine.free (c0) (u) [ratio]
88191-2,crimean-congo hemorrhagic fever virus igg ab [presence] in serum by immunoassay
88191-2,crimean-congo ab fever virus igg hemorrhagic immunoglobulin g [presence] in ser by immunoassay
88191-2,crimean-congo hemorrhagic fever virus igg ab [presence] in serum by immunoassay
88191-2,crimean-cngo vr igg ser ql ia
88191-2,criean-cngo eia vr igg ser presence ia
88191-2,rimean-cngo iggsr vr ql antibody ia
88191-2,crimean-congo hemorrhagic fever virus igg ia ql (s)
88191-2,infectious disease ia hemorrhagic fever virus igg crimean-congo ql (s)
88191-2,igg anti hemorrhagic fever virs crimeancogo i presence ()
26603-1,asparagine [moles/volume] in cerebral spinal fluid
26603-1,aparagine [moles/volume] in cerebral spina fuid
26603-1,[moles/volume] asparagine in cereralspinal fluid
26603-1,asparagine csf-scnc
26603-1,csf-scnc aargine spinal fl
26603-1,csf-scnc substance concentration asparagine
26603-1,asparagine (csf) [moles/vol]
26603-1,asparaine (cs [moles/vol]
26603-1,[moles/vol] quant asparagine(cerebrospinal fluid)
15497-1,pseudorabies virus ab [presence] in serum by immunoassay
15497-1,[presence] virus ab pseudorabies in serum by immunoassay
15497-1,pseudorabie virs immunassay [resece] in ser by ab
15497-1,prv ab ser ql ia
15497-1,prv ql ser ab ia
15497-1,prv ab ql ser ia
15497-1,pseudorabies virus ab ia ql (s)
15497-1,pseuorabies ordinal virus ab ia ql (s
15497-1,pseudorabies virus elfa ab ia presence (s)
3932-1,phenazocine [mass/volume] in urine
3932-1,phenazocine in [mass/volume] urine
3932-1,[mass/volume] phenazocine in urine
3932-1,phenazocine ur-mcnc
3932-1,penazocine ur-mcnc qnt
3932-1,ur-mcnc drugs phenzocine
3932-1,phenazocine (u) [mass/vol]
3932-1,phenazocin (u) quan [mass/vol]
3932-1,mass/vol] (u phenzocine quant
40914-4,streptococcus pneumoniae danish serotype 18c igg ab [mass/volume] in serum by immunoassay --1st specimen
40914-4,18c pneumoniae danish serotype streptococcus igg ab [mass/volume] in serum by immunoassay --1st specimen
40914-4,streptococcus pneumoniae danish serotype 18c igg ab [mass/volume] in mass concentration serum by immunoassay --1st specimen
40914-4,s pneum da 18c igg sp1 ser ia-mcnc
40914-4,pneum da 18c igg s1 iamcnc serum
40914-4,s pneum a18cgg sp1 se ia-mcnc
40914-4,s. pneumoniae danish type 18c igg spec 1 ia (s) [mass/vol]
40914-4,. pneumoniae danis ye 18c igg spc 1 i (s) [mass/vol]
40914-4,s. pneumoniae danish type 18c s pneum da 18c ab igg spec 1 ia (s) [mass/vol]
72411-2,monocytes+macrophages [#] in cerebral spinal fluid by manual count
72411-2,moocytes+acrophage[#] in cerbral spnal flid by cerebral spinal fluid manl count
72411-2,mono monocytes+macrophages [#] in cerebral spinal fluid by manual count
72411-2,monos+macros csf manual
72411-2,monos+macros c anual
72411-2,monos+macros csf monos+macros maal
72411-2,monocytes+macrophages manual cnt (csf) [#]
72411-2,monocytes+macrophages manual cnt (csf) [#]
72411-2,moocytes+macrohages ct(csf)[#] manual
54059-1,hedis 2009 tests used in early prenatal care (ppc-c)
54059-1,hedis 209 ests used inealy prenata care (pc-c
54059-1,pnl hedis 2009 tests used in early prenatal care (ppc-c)
54059-1,hedis 2009 ppc-c
54059-1,hedis ppc-c 2009
54059-1,ppc-c 2009 edi hedis 2009 ppc-c
54059-1,hedis 2009 tests used in early prenatal care (ppc-c)
54059-1,hedis 2009 tests used in early prenatal care (ppc-c)
54059-1,hedis 2009 tests used pnl in early prenatal care (ppc-c)
9489-6,arsenic [mass/volume] in body fluid
9489-6,in [mass/volume] arsenic body fluid
9489-6,arsei level [mass/volme] in flud body
9489-6,arsenic fld-mcnc
9489-6,fld arsenic fld-mcnc
9489-6,fld-mcnc arsenic
9489-6,arsenic (body fld) [mass/vol]
9489-6,arsenic (body fld) [mass/vol
9489-6,arsenic (body [mass/vol] point in time fld)
6411-3,giardia lamblia igg ab [titer] in serum by immunofluorescence
6411-3,giardia lamblia igg ab titered [titer] in serum by immunofluorescence
6411-3,giardi lmblia ab gg titer]in seruby immunofluorecence
6411-3,g lamblia igg titr ser if
6411-3,igg lambia g titr se if
6411-3,g lamblia igg titr immunoglobulin g ser if
6411-3,g. lamblia igg if (s) [titer]
6411-3,g lmblia igg if (s) [tite]
6411-3,infectious disease . lamblia igg if (s) [iter]
99765-0,interleukin 12 [mass/volume] in cerebral spinal fluid
99765-0,cerebral 12 [mass/volume] in interleukin spinal fluid
99765-0,mass concentration interleukin 12 [mass/volume] in cerebral spinal fluid
99765-0,il12 csf-mcnc
99765-0,csf-mcnc il12
99765-0,csf-mcnc il12
99765-0,interleukin 12 (csf) [mass/vol]
99765-0,interleukin [mass/vol] (csf) 12
99765-0,interlukin 12 (csf) [mass/vol] spinal flu
89654-8,parainfluenza virus identified in upper respiratory specimen by organism specific culture
89654-8,para speimen virs identified in uppe respratoy parainfluenza by oganism specifcculture
89654-8,parainfluenza virus identified hpiv in upper respiratory specimen by organism specific culture
89654-8,hpiv upper resp cult
89654-8,upper infectious disease hpiv resp cult
89654-8,hpiv upper resp upper resp cult
89654-8,parainfluenza virus identified org specific cx nom (upper resp)
89654-8,paraifluenzavirus identity or presence identified org specific cx o (upper res)
89654-8,aainluenza virs idntified org specific cx nom (upper resp)
50748-3,alpha-2-macroglobulin/creatinine [mass ratio] in urine
50748-3,alpha-2-macogobulin/ceatinine ua raio] mass in urine
50748-3,ratio] [mass alpha-2-macroglobulin/creatinine in urine
50748-3,a2 macroglob/creat ur
50748-3,quan macroglob/creat a ur
50748-3,macroglob/creat a2 ur
50748-3,alpha-2-macroglobulin/creatinine (u) [mass ratio]
50748-3,alpha-2-macroloblin/creainine(u) ratio] [mas
50748-3,amg alpha-2-macroglobulin/creatinine [mass (u) ratio]
12983-3,volatiles and gases [identifier] in urine
12983-3,volatiles and gses [dentfier] urine in nominal
12983-3,volails and volatile [idetfier] gases inurie
12983-3,volatiles ur
12983-3,ur ur volaties
12983-3,identity or ql volatiles ur
12983-3,volatiles and gases nom (u)
12983-3,nom and gases identity or presence volatiles (u)
12983-3,nom and gases volatiles potentialforabuse (u)
79332-3,l-2-hydroxyglutarate [moles/volume] in dbs
79332-3,l-2-hydroxyglutarate [moles/volume] in dbs
79332-3,l-2hydroxyglutarate [moles/volume] in dbs
79332-3,l2hg dbs-scnc
79332-3,dbs-scnc lhg quan
79332-3,dbs-scnc l2hg
79332-3,l-2-hydroxyglutarate (dbs) [moles/vol]
79332-3,l-2-hydroxyglutarate (dbs) [moles/vol] l2hg
79332-3,l-2-ydroxyglutarate quant (dbs) [moles/vol]
35407-6,leishmania mexicana igm ab [presence] in serum
35407-6,mexicana leishmania igm ab [presence] in ser
35407-6,leishmania mexicana igm ab [presence] in leishmaniasis serum
35407-6,l mexicana igm ser ql
35407-6,l ser igm mexicana presence
35407-6,ser mexica igm l l autoantibody
35407-6,l. mexicana igm ql (s)
35407-6,l. mexicana (s) ql igm
35407-6,l. exicana gmq (s) l mexicana
47550-9,adenosine deaminase [entitic catalytic activity] in leukocytes
47550-9,adenosine deaminase [entitic activity] catalytic in leukocytes
47550-9,adenosine deaminase [entitic catalytic activity] in entitic catalytic activity leukocytes
47550-9,adenosine deaminase wbc qn
47550-9,adenosine deaminase wbc qn
47550-9,adenosine qn wbc deaminase
47550-9,adenosine deaminase (wbc) [entitic catalytic activity]
47550-9,catalytic deaminase (wbc) [entitic adenosine activity]
47550-9,adenosine deaminase (wbc) [entitic point in time catalytic activity]
65808-8,nortapentadol [mass/volume] in urine
65808-8,nortapentadol [mass/volume] in random urine
65808-8,dmt nortapentadol [mass/volume] in urine
65808-8,nortapentadol ur-mcnc
65808-8,ur-mcnc nortapentadol
65808-8,ur-mcnc nortapentadol
65808-8,nortapentadol (u) [mass/vol]
65808-8,nortapentadol (u) fentanyl metabolite [mass/vol
65808-8,(u) notapentdo [mass/vol]
13027-8,ethyl acetate [mass/volume] in serum or plasma
13027-8,ethyl acetate seum in [mas/olume] o plasma acetic acid ethyl ester
13027-8,ethyl acetate [massvolume] in serum plasma or
13027-8,ethyl acetate serpl-mcnc
13027-8,etyl actate etoac serplmcnc
13027-8,random aetate ethyl serl-mnc
13027-8,ethyl acetate [mass/vol]
13027-8,acetic acid ethyl ester etyl acetate [ass/ol]
13027-8,ethyl acetae [mass/vol]
57848-4,maltose [presence] in urine
57848-4,maltose in [presence] urine
57848-4,[presence] malose in urine
57848-4,maltose ur ql
57848-4,maltose presence ur
57848-4,ur maltose ql
57848-4,maltose ql (u)
57848-4,maltose urn presence (u)
57848-4,q maltse (u
55456-8,deprecated hemoglobin s in blood
55456-8,inblood hemoglobin deprcated
55456-8,s hgb s hmogobin deprecaed inblood
55456-8,deprecated hgb s bld
55456-8,deprecated random hgb bld s
55456-8,hgb s deprecated s hgb bld
55456-8,hemoglobin s (bld)
55456-8,(blood) s molobin
55456-8,hemoglobin s blood (bld)
18490-3,chlamydia trachomatis g+f+k iga ab [titer] in serum by immunofluorescence
18490-3,chlmydia trachoatis by iga ab [titer] i antibodies ser g immunofluorescence
18490-3,chlamydia trachomatis g+f+k iga ab [titer] in serum immunofluorescence by
18490-3,c trach g+f+k iga titr ser if
18490-3,titr g+f+k iga rach ser if
18490-3,c trach g+f+kia titr ser if
18490-3,c. trachomatis g+f+k iga if (s) [titer]
18490-3,c. g++k immunofluorescence rcomatis iga if (s) [iter]
18490-3,c. g+f+kiga trahomati if (s [titer
100132-0,schistosoma sp 9kd ab [presence] in serum by immunoblot
100132-0,immunoblot sp 9kd ab [ql] in serum by schistosoma
100132-0,scisosma sp 9kdab [presence]in ser by immunolot
100132-0,schistosoma sp 9kd ab ser ql ib
100132-0,immunoblot schistosoma sp 9kd a ser ql b
100132-0,scistosoma sp 9kd west blot ser ql
100132-0,schistosoma sp 9kd ab ib ql (s)
100132-0,schistosoma sp 9kd ql ib ab (s)
100132-0,wb chisosoma ql(s) 9kd a ib sp
13745-5,glutaconate/creatinine [mass ratio] in urine
13745-5,lutonate/creatinie [mass ratio] in urine
13745-5,glutaconate/creatinine in ratio] [mass urine
13745-5,glutaconate/creat ur
13745-5,gutaconae/cret ur
13745-5,ur glutaconate/creat
13745-5,glutaconate/creatinine (u) [mass ratio]
13745-5,glutaconate/creatinine crea (u) ratio] [mass
13745-5,glutaconate/reatinine (u) rtio] [mss
12808-2,uroporphyrin [mass/time] in urine
12808-2,[mass/time] uroporphyrin in urine
12808-2,uroporphyrin [mass/time] in hematology urine
12808-2,uropor ur-mrate
12808-2,urn uropor ur-mrate
12808-2,ur-rate uropor
12808-2,uroporphyrin (u) [mass/time]
12808-2,[mass/tie] u) uroporphyin
12808-2,uroporphyrin (u) [mass/time]
73673-6,yersinia enterocolitica serotype [type] in isolate by agglutination
73673-6,yersinia enterocoicaserotype [type] in isolate b agglutination
73673-6,infectious disease esiia nterocoliica serotype [te] in islate by aglutination
73673-6,y enterocol sertyp islt aggl
73673-6,y nteroco sertyp id islt agl
73673-6,y sertyp enterco islt microbiology aggl
73673-6,y. enterocolitica serotype aggl nom (isol)
73673-6,y. nteocliiaserotype agg agg nom(isol
73673-6,y. enterocolitica nom aggl serotype (isol)
53276-2,urinalysis type of non-squamous epithelial cells panel [#/area] - urine by computer assisted method
53276-2,non-squamous type quantitative of urinalysis epithelial cells panel [#/area] - urine by computer assisted method
53276-2,urinalysis type of non-squamous epithelial cells by [#/area] - urine panel computer assisted method
53276-2,ua epith pnl #/area ur comp assist
53276-2,pnl epith ua #/area ur comp assist
53276-2,epith ua pnl #/area ur comp assist
53276-2,urinalysis type of non-squamous epithelial cells panel computer assisted (u) [#/area]
53276-2,urinalysis type of non-squamous epithelial (u) panel computer assisted cells [#/area]
53276-2,urinalysis type of non-squamous epithelial cells panel computer pan assisted (u) [#/area]
43392-0,ldl 1 [mass/volume] in serum or plasma
43392-0,ldl 1 plasma in serum or [mass/volume]
43392-0,ldl 1 [mass/volume]in erm r pasma
43392-0,ldl1 serpl-mcnc
43392-0,serum or plasma-mcnc ldl1
43392-0,serpl-mcnc l1 ldl1
43392-0,ldl 1 [mass/vol]
43392-0,dl [mass/ol chemistry 1
43392-0,[mass/vol] 1 ldl
32804-7,neutrophils/leukocytes in bronchial specimen by manual count
32804-7,leuc in neutrophils/leukocytes bronchial specimen by manual count
32804-7,neutrhilsleukocytes inbronchial specimen by manual count
32804-7,neutrophils nfr bronch manual
32804-7,netopil manua quantitative brnch nfr
32804-7,neutrophils nfr bronch manual
32804-7,neutrophils/leukocytes manual cnt (bronch spec)
32804-7,quant neutrophils/leukocytes manual cnt (bronch spec)
32804-7,neutrophils/leukocytes neut manual cnt (bronch spec)
69769-8,dicarboxyoleylcarnitine (c18:1-dc)/creatinine [molar ratio] in urine
69769-8,dicaboxyoleylcrnitine (c18:1-dc/creatinne [mola atio] in urine
69769-8,dicarboxyoleylcarnitine ratio] quantitative [molar (c18:1-dc)/creatinine in urine
69769-8,dicarboxyoleylcarn/creat ur-srto
69769-8,i ur-srto dicarboxyoleyarn/ceat
69769-8,ucr dcarboxyoleylcarn/creat ur-srto
69769-8,c18:1-dc/creatinine (u) [molar ratio]
69769-8,[molar c18:-dc/reatinine raio
69769-8,c18:1-dc/creatinine (u) ratio] [molar
23359-3,peste des petits ruminants virus rna [presence] in tissue by naa with probe detection
23359-3,peste des petits detecion a presenc] in tissu by naa with prob ruminatsvirus
23359-3,estedes petits ruminansvius rna pesece] i naa tissue with proe detectin
23359-3,pprv rna tiss ql naa+probe
23359-3,pprvna tis aa+probe presence
23359-3,rna pprv tiss ql naa+proe
23359-3,peste des petits ruminants virus rna naa+probe ql (tiss)
23359-3,(tiss) des petits ruminants virus rna naa+probe presence peste
23359-3,pest des petit ruminants virus na naa+probe ql (tiss)
57936-7,cholesterol in hdl 2a [mass/volume] in serum or plasma
57936-7,cholesterol in hdl serplas 2a [mass/volume] or serum in plasma
57936-7,cholesterol or hdl 2a [mass/volume] in serum in plasma serp
57936-7,hdlc 2a serpl-mcnc
57936-7,hdlc tchhdl 2a serpl-mcnc
57936-7,hdlc hdlc a serpl-mcnc
57936-7,cholesterol in hdl 2a [mass/vol]
57936-7,cholesterol 2a hdl in [mass/vol]
57936-7,serum chlesterol in hdl 2a [mass/vol]
2316-8,galactosylgalactosylglucosylceramidase [enzymatic activity/mass] in tissue
2316-8,galactsylgalacosylglucosyleramidase [enzymaticactivity/mass] tisue in
2316-8,qnt enzyatic galactoylgalatosylglucoslceamidase ativiy/mass] in tissue
2316-8,galgalglucceramidase tiss-ccnt
2316-8,galgalglucceamidase tisscct catalytic content
2316-8,"tiss-ccnt glgalgluceramidase udp-galnac:beta-1,3-n-acetylgalactosaminyltransferase 1"
2316-8,galactosylgalactosylglucosylceramidase (tiss) [catalytic activity/mass]
2316-8,[catalytic (tiss) galactosylgalactosylglucosylceramidase activity/mass]
2316-8,galactosylgalactosylglucosylceramidase [catalytic (tiss) activity/mass]
61105-3,prochlorperazine [moles/volume] in gastric fluid
61105-3,prochlorperzine [moles/volume] in gstric fuid
61105-3,buccastem prochlorperazine [moles/volume] in gastric fluid
61105-3,prochlorperazine gast-scnc
61105-3,prochlorperazine gast-scnc
61105-3,gast-scnc prochlorperazine stemzine
61105-3,prochlorperazine (gast fld) [moles/vol]
61105-3,pt prchloperine(gast fl)[mole/vol]
61105-3,prohlorperazine (gast fl) mole/vo]
79584-9,beta alanine and beta aminoisobutyrate and gamma aminobutyrate panel - urine
79584-9,beta alanine and beta aminobutyrate and gamma aminoisobutyrate panel - urine
79584-9,bta alnie and eta ainoisobutrate and gammaanobutyrae nel - urin
79584-9,b-alanine + b-aib + gaba pnl ur
79584-9,b-alanie b-alanine b-aib + gaba pnl r
79584-9,b-alanie+ b-aib + gab pnl r
79584-9,beta alanine and beta aminoisobutyrate and gamma aminobutyrate panel (u)
79584-9,beta b alanine nd beta aminoisobutyrae and pnel minbutyrae gamma (u)
79584-9,bta alanne and betaaminoisobutyrate and gamma aminobutyrate panel (u)
75234-5,o-desmethylvenlafaxine [presence] in urine
75234-5,ur o-desmethylvenlafaxine [presence] in urine
75234-5,o-desmethylenlafaxine uine in [presence]
75234-5,odv ur ql
75234-5,odv ql ur
75234-5,venlafaxine metabolite odv ql r
75234-5,o-desmethylvenlafaxine ql (u)
75234-5,o-desmethylvenlafaxine (u) ql
75234-5,o-desmethylvenlafaxine (u) ql
43057-9,chlamydophila psittaci igm ab [titer] in cerebral spinal fluid
43057-9,chlamydophila psittaci igm ab [titer] in cerebral spinal fluid c psittaci
43057-9,chlamydophila immunoglobulin m psitaci igm ab [titer] incerebra spinl fluid
43057-9,c psittaci igm titr csf
43057-9,cerebrospinal fluid titered gm titr psitaci
43057-9,c csf titre igm titr psittaci
43057-9,c. psittaci igm (csf) [titer]
43057-9,igm psittaci c. (csf) [titer]
43057-9,c. igm psittaci (csf) [titer]
79134-3,abacavir [mass/volume] in cerebral spinal fluid
79134-3,abacavi [mass/vlume spinal fld i cerebral spial fluid
79134-3,fluid [mass/volume] in cerebral spinal abacavir
79134-3,abacavir csf-mcnc
79134-3,csf-mcnc abacavir
79134-3,csf-mcnc abacavir
79134-3,abacavir (csf) [mass/vol]
79134-3,[mass/vol] (cs) abacavir
79134-3,abcvi drugs (csf) [mass/vol]
44327-5,iron [presence] in body fluid
44327-5,fluid [presence] in body flu iron
44327-5,iron [presence] in ordinal body fluid
44327-5,iron fld ql
44327-5,chemistry ld iron ql
44327-5,b/f iron fld ql
44327-5,iron ql (body fld)
44327-5,b/f iron presence (body fld)
44327-5,iron ql body fl)
19423-3,dextromethamphetamine [presence] in urine by screen method
19423-3,urine [presence] in dextromethamphetamine by screen method
19423-3,dextrometamphetamine presence] in urne by screen mehod
19423-3,d-methamphet ur ql scn
19423-3,d-methamphet ur scn ql
19423-3,d-methamphet ur scn ql
19423-3,dextromethamphetamine screen ql (u)
19423-3,u) screen d-methamphet ql dexromethamphetamine
19423-3,dextromthamphetamie (u) ql qual screen
51584-1,immature granulocytes [#/volume] in blood
51584-1,count immature granulocytes [#/volume] in bld
51584-1,immature granulocytes [#/volume] in blood
51584-1,imm granulocytes # bld
51584-1,bld granulocytes # imm
51584-1,granulocytes imm quantitative # bld
51584-1,immature granulocytes (bld) [#/vol]
51584-1,[#/vol] granulocytes (blood) immature
51584-1,immat [#/vol] granulocytes (ld) imature
44280-6,17-hydroxypregnenolone/creatinine [mass ratio] in urine
44280-6,urine [asratio] in 17-hydrxyprgneoloe/creatnine
44280-6,17-hydroxypregnenolone/creatinine ratio] [mass in urine
44280-6,17oh-preg/creat ur
44280-6,ur point in time 17oh-preg/creat
44280-6,ua ur 17oh-preg/creat
44280-6,17-hydroxypregnenolone/creatinine (u) [mass ratio]
44280-6,17-hydroxypregnenolone/creatinine (u) [mass ratio]
44280-6,17-hydroxypregnenolone/creatinine (u) [mass creat ratio]
83254-3,self-care - discharge performance [cms assessment]
83254-3,self-care ssesment] dchare perforance[cms -
83254-3,self-care - discharge performance [cms assessment]
77178-2,boron [mass/mass] in hair
77178-2,in point in time [mass/mass] boron hair
77178-2,boron mas/mass] in b hair
77178-2,boron hair-mcnt
77178-2,boon quantitative hair-mcnt
77178-2,hair-mcnt boron har
77178-2,boron (hair) [mass/mass]
77178-2,boron (hair) [mass/mass] mass content
77178-2,[mass/mass] (hair) boron
22884-1,border disease virus rna [presence] in tissue by naa with probe detection
22884-1,border disease virus rna 3sr sr [ql] in tissue by naa with probe detection
22884-1,nucleic acid sequence based analysis border proeetection virurna [resence] tissueby naa with disease
22884-1,border dv rna tiss ql naa+probe
22884-1,border dv l qual tiss a naa+pro
22884-1,order tiss rna v q na+probe
22884-1,border disease virus rna naa+probe ql (tiss)
22884-1,boderdisease virus rna naaprobe presence(tss)
22884-1,border disase random virus rna presence naa+probe (tis)
13962-6,beta glucuronidase [enzymatic activity/volume] in serum or plasma
13962-6,beta glucuronidase [enzymatic or in serum activity/volume] plasma sly disease
13962-6,beta plasma [enzymatic activity/volume] in ser or glucuronidase
13962-6,b-glucuronidase serpl-ccnc
13962-6,plsm b-glucuronidase serpl-ccnc
13962-6,pt b-glucuronidase serpl-ccnc
13962-6,beta glucuronidase [catalytic activity/vol]
13962-6,beta [catalytic glucuronidase activity/vol]
13962-6,beta [catalytic glucuronidase activity/vol]
8836-9,systemic vascular resistance index by indicator dilution
8836-9,systemic vascuar iluion by indicaor resstancenex
8836-9,systemic vascular bodies resistance index by indicator dilution
8836-9,sv ri indicator dilution
8836-9,r sv indicatr dilution hemodynamics
8836-9,sv ri idicator ilution
23758-6,neospora caninum ab [titer] in serum
23758-6,neospora caninum ab in [titer] serum
23758-6,neospora caninum ab [titer] in serum
23758-6,n caninum ab titr ser
23758-6,n titr ab dilution factor caninum ser
23758-6,n caninum titered ab ser titr
23758-6,n. caninum ab (s) [titer]
23758-6,n.aninum [titer] (s) autoantibody ab
23758-6,ab infectiousdisease caninum n. (s) [titer
11215-1,delta aminolevulinate [mass/volume] in urine
11215-1,delta aminolevulinate 5-aminolevulinate [mass/volume] in urine
11215-1,delta mass concentration aminolevulinate [mass/volume] in urine
11215-1,d-ala ur-mcnc
11215-1,ur-mcnc d-ala
11215-1,d-ala heme ur-mcnc
11215-1,delta aminolevulinate (u) [mass/vol]
11215-1,deta (u) minolevuline [mass/vol]
11215-1,aminolevulinic acid aminolevulnate delta (u) [mas/vol]
62538-4,phenx - environmental exposures - ultraviolet light exposure protocol 061301
62538-4,- phenx environmental exposures - ultraviolet light exposure protocol 061301
62538-4,phenx - environmetal eposure - ultravolet lighexoue protocol 061301
62538-4,environ exp uv light proto
62538-4,uv light exposure environ exp uv light proto
62538-4,environep uv light prot
26723-7,varicella zoster virus ab [titer] in cerebral spinal fluid by immunofluorescence
26723-7,varicella zoster virus in [titer] ab cerebral spinal fluid by immunofluorescence
26723-7,varicella zoster virus ab [titer] in cerebral spinal fluid by immunofluorescence
26723-7,vzv ab titr csf if
26723-7,vz dilution factor (titer) ab itr csf if
26723-7,vz csf titr ab if
26723-7,vzv ab if (csf) [titer]
26723-7,vzv ab if (csf) [titer]
26723-7,[titr] a neurology if (cs) vz
23207-4,leptospira subtype [identifier] in specimen
23207-4,leptospira subype [dentiier] n spp specime
23207-4,specimen subtype [identifier] misc in leptospira
23207-4,leptospira subtyp spec
23207-4,spec subtyp leptospira
23207-4,leptospira misc subtyp spec
23207-4,leptospira sp subtype nom (specimen)
23207-4,nom sp subtype leptospira (specimen)
23207-4,unspecified lepospira sp ubtpe nom specimen)
23830-3,bordetella pertussis.pertussis toxin iga ab [units/volume] in serum
23830-3,bordetlla prussis.pertussis ser iga ab [unts/olume] n toxin
23830-3,bordetella pertussis.pertussis toxin iga ab [units/volume] whooping cough in serum
23830-3,b pert.pt iga ser-acnc
23830-3,seracc pert.pt i b
23830-3,b pert.pt iga quantitative serum-acnc
23830-3,b. pertussis.pertussis toxin iga qn (s)
23830-3,b. pertussis.pertussis toxin (s) qn iga
23830-3,random b. petussis.pertussis toxn iga qn (s)
10986-8,doxycycline [mass/volume] in serum or plasma
10986-8,plsma [mass/volume] n seum mass concentration or doxcycline
10986-8,ser mss/olue] in doxycyclie or plasma
10986-8,doxycycline serpl-mcnc
10986-8,doxycyclin serum or plasma-mcnc
10986-8,serpl-mcnc c216 doxycycline
10986-8,doxycycline [mass/vol]
10986-8,[massvl] doxyycline serplas
10986-8,point in time doxycycline [mass/vol]
47473-4,legionella pneumophila 9 igg ab [titer] in serum
47473-4,legionella pneumophila 9 igg ab [titer] in anti serum
47473-4,legionella [titer] 9 igg ab pneumophila in serum
47473-4,l pneumo9 igg titr ser
47473-4,l pneumo9 igg legion titr ser
47473-4,l pneumo9 titr igg ser abs
47473-4,l. pneumophila 9 igg (s) [titer]
47473-4,l. pneumophila 9 (s) igg [titer]
47473-4,l. pneumophila 9 igg (s) [titer]
49110-0,mycoplasma sp identified in urine by organism specific culture
49110-0,ycoplasma sp identified in by urie oganism specific culture
49110-0,mycoplasma sp spp identified in urine by organism specific culture
49110-0,mycoplasma ur cult
49110-0,mycolasma u clt
49110-0,mycoplsm mycoplasma ur ult
49110-0,mycoplasma sp identified org specific cx nom (u)
49110-0,mycoplasma sp identified org specific cx nom (u)
49110-0,mycopasma sp identified og pecific cx nom (u)
15131-6,isoleucine+leucine [presence] in serum or plasma
15131-6,isolucne+eucine [presence] in serum pl or plasma
15131-6,isoleucine+leucine [presence] sr serum in or plas
15131-6,ile+leu serpl ql
15131-6,ile+leu ql serum or plasma
15131-6,ile+leu ql serpl
15131-6,isoleucine+leucine ql
15131-6,ser isoleucine+leucine ql
15131-6,ioleucin+leucin presence
88575-6,onchocerca sp igg4 ab [presence] in serum by immunoassay
88575-6,sp onchocerca igg4 ab [presence] in serum id by immunoassay
88575-6,onchcerca sp igg ab[presence] in serum by immunoassay
88575-6,onchocerca igg4 ser ql ia
88575-6,ochocerca igg4 serum qlia antby
88575-6,onchocerca ql ser igg4 ia
88575-6,onchocerca sp igg4 ia ql (s)
88575-6,enzyme immunoassay onchocerca sp igg4 ia ql (s)
88575-6,nchecasp igg4 ia pr (s) l
75655-1,mononuclear cells [#] in cerebral spinal fluid by manual count
75655-1,count cells [#] in cerebral spinal fluid mononuc cells by manual mononuclear
75655-1,ononucler mononuc cells cells [] in cerebral spinal fluid by manualcount
75655-1,mononuc cells csf manual
75655-1,csf cells mononuc manual manl
75655-1,cells mononuc cerebrospinal fluid manual qnt
75655-1,mononuclear cells manual cnt (csf) [#]
75655-1,mononulear clls manal cnt (cerebrospinal fluid) cnt [#]
75655-1,mononuclear cels mnual cnt(sf [#]
42234-5,alpha subunit free [units/volume] in serum or plasma
42234-5,alpha subunit free [units/volume] in serpl
42234-5,alpa subu free [unit/volume]in quan serum or plasma
42234-5,alpha subunit free serpl-acnc
42234-5,fee subunit alpha serpl-acnc
42234-5,alpha ree sbunt serpl-acnc
42234-5,alpha subunit free qn
42234-5,subuit alpha free qn
42234-5,alha free sbunit qn arbitrary concentration
95148-3,hepatitis b virus surface ag and hepatitis b virus e ab and ag panel - serum or plasma
95148-3,hpatitis b virus surfac ag ad hepatitis hbe b virs e ab and ag panel - ser or plasma
95148-3,eptitis b virus surfac a nd hepatiti b rus e a and a panel  ru or plama
95148-3,hbv surf ag + hbv e ab + ag pnl serpl
95148-3,hbv surf ag hepatis a hbv e ab + + pn serpl
95148-3,hbv urf ag + hbve ab ag + pnl serpl
95148-3,hbv surface ag and hbv e ab and ag panel
95148-3,pnl hbv surface ag and e hbv ab and ag panel
95148-3,bv surface ag and hbv e ab a ag panl
97609-2,anaerococcus prevotii+vaginalis dna [presence] in synovial fluid by naa with non-probe detection
97609-2,qualitative anaroocus prevotiivaginalis dna [presence] n synovial fluid by naawthnon-probe detection
97609-2,anaerococcus [ql] dna prevotii+vaginalis in synovial fluid by qual naa with non-probe detection
97609-2,a prev+vag dna snv ql naa+non-probe
97609-2,snv prev+vagdna a l naa+non-pobe
97609-2, pev+vag dna snv presence na+on-robe
97609-2,a. prevotii+vaginalis dna naa+non-probe ql (syn fld)
97609-2,a. prvoti+vaginalis pr dnanaa+nn-probe presence (syn fld)
97609-2,a. prevotii+vaginalis dna naa+non-probe (syn presence probe with target amplification fld)
94838-0,enterovirus rna [presence] in amniotic fluid by naa with probe detection
94838-0,enerovirus rna amn [prsence]in amnitic fluid bynaa with probe etection
94838-0,with microbiology rna [presence] in amnotic fluid by naa etrovirus pobe detetion
94838-0,ev rna amn ql naa+probe
94838-0,ev naa+probe amn ql rna
94838-0,ev rna naa+probe ligation-activated transcription ql amn
94838-0,enterovirus rna naa+probe ql (amn fld)
94838-0,eneovius rna naa+pob ql (amn fld)
94838-0,fld) rna naa+probe ql (amn enterovirus
13151-6,deprecated streptococcus pneumoniae 9 ab [units/volume] in serum --1st specimen
13151-6,deprecated streptococcus pneumoniae specimen ab [units/volume] in serum --1st 9
13151-6,deprecated streptococcus pneumoniae 9 in [units/volume] ab serum --1st specimen
13151-6,deprecated s pneum9 ab sp1 ser-acnc
13151-6,ab s peum depecated s1ser-acnc
13151-6,deprecate s neum9 ab p1 er-acnc
13151-6,s. pneumoniae 9 ab spec 1 qn (s)
13151-6,s. pneumoniae 9 ab spec (s) qn 1
13151-6,s. 1 9 ab spec id pnumoni qn (s)
35134-6,thyrotropin ab [presence] in serum
35134-6,thyrotropin ab serm in [preence]
35134-6,thyrotropin [presence] ab in thyroid stimulating hormone serum
35134-6,tsh ab ser ql
35134-6,tsh ab serum ql
35134-6,tsh ab ser ql
35134-6,tsh ab ql (s)
35134-6,th ab presence qual ()
35134-6,ab tsh ql (s)
48114-3,hexadecanedioate/creatinine [molar ratio] in urine
48114-3,creat hexadecanedioat/creatinine [molarrti] in rine
48114-3,hexadecanedioate/creatinine [molar ratio] in urine
48114-3,hexadecanedioate/creat ur-srto
48114-3,hexadecanedioate/creat ur-srto
48114-3,ur-srto hexadecanedioate/creat
48114-3,hexadecanedioate/creatinine (u) [molar ratio]
48114-3,hedecnedote/creatinine () [molar ratio] scrto
48114-3,hexadecanedioate/creatinine (u) substance ratio [molar ratio]
47505-3,deprecated streptococcus pneumoniae 6 igg ab [mass/volume] in serum
47505-3,deprecated infectious disease streptococus pneumoniae 6 g b [mass/volume] in seum
47505-3,deprecated streptococcus pneumoniae6 [ss/volume] ab igg inserm
47505-3,deprecated s pneum6 igg ser-mcnc
47505-3,deprecated s igg pneum6 ser-mcnc
47505-3,depecated pneum igg ser-mcc pneumococcal
47505-3,s. pneumoniae 6 igg (s) [mass/vol]
47505-3,s. [mass/vol] 6 igg (s) pneumoniae
47505-3,igg pneumoniae 6 s. (s) [mass/vol]
54518-6,preferences for customary routine and activities
54518-6,o preferences customary rouine and activities
54518-6,preferences for customary routine and activities
13102-9,deprecated disialylganglioside gd1b ab in serum
13102-9,deprecated diialylnlioside g1b bn ser
13102-9,ab sr dsalygangliosidgd1b dpecated in serum
13102-9,deprecated gd1b disialyl ab ser
13102-9,deprecated gd1b disialyl ab ser
13102-9,gd1b deprecated autoantibodies disialyl ab ser
13102-9,disialylganglioside gd1b ab (s)
13102-9,disialylganosie gd1b (s) ab
13102-9,diialylganlioide serology d1b ab ()
7925-1,influenza virus a mississippi ab [units/volume] in serum
7925-1,influenza virus a mississippi ab [units/volume] in serum
7925-1,influenza serum a mississippi ab [units/volume] in virus
7925-1,fluav miss ab ser-acnc
7925-1,fluav ab miss fluav serum-acnc
7925-1,fluav miss ab seracn
7925-1,fluav miss ab qn (s)
7925-1,fluavmiss antibody ab qn (s
7925-1,fluav miss abqn (s)
92306-0,promis item bank - smoking - nicotine dependence for all smokers - version v1.0
92306-0,promis item for - smoking - nicotine dependence bank all smokers - version v1.0
92306-0,promis item bank - smoking - nicotine dependence for all smokers - version v1.0
9638-8,toluene [mass/volume] in urine
9638-8,toluene level [mass/volume] in urine
9638-8,toluene [mass/volume] in urine
9638-8,toluene ur-mcnc
9638-8,pt ur-mcnc toluene
9638-8,tolueneur-mcnc quantitative
9638-8,toluene (u) [mass/vol]
9638-8,()massvl] tlune
9638-8,oluene potentialforabuse (u)ass/vol]
104830-5,basement membrane iga ab [titer] in serum by immunofluorescence
104830-5,basement ab iga membrane [titer]in ser by mmunofluorescece antby
104830-5,basementmembrae iga ab [titer] seru in by immunofluorescnce
104830-5,bm iga titr ser if
104830-5,bm ia titr serology serum if
104830-5,bm titr iga ser if
104830-5,basement membrane iga if (s) [titer]
104830-5,autoantibodies basement (s) igai membrane [ttr]
104830-5,basemnt membrae iga if (s) [tite ser
48399-0,herpes simplex virus 1 glycoprotein g igg ab [units/volume] in cerebral spinal fluid
48399-0,herpes simplex virus 1 glycoprotein g microbiology igg ab [units/volume] in cerebral spinal fluid
48399-0,herpes simplex virus 1glycoprotein g igg ab [uits/volume] in cerebal spinal flid
48399-0,hsv1 gg igg csf-acnc
48399-0,hsv1 gg igg csf-acnc neuro
48399-0,arbitrary concentration hsv gg igg cerebrospinal fluid-acnc
48399-0,hsv 1 glycoprotein g igg qn (csf)
48399-0,aby hsv1 glycoproteing ig q (csf)
48399-0,hsv 1 lyorotein g igg q (csf)
61151-7,albumin [mass/volume] in serum or plasma by bromocresol green (bcg) dye binding method
61151-7,albuin[ass/volume]in plasma ser or (bcg) b bromcesol green plasma dye indig method
61151-7,albumin serum in [mass/volume] or plasma by bromocresol green (bcg) dye binding method
61151-7,albumin serpl bcg-mcnc
61151-7,albumin bcg-mcnc serpl
61151-7,bcg-mcnc serpl quantitative albumin
61151-7,albumin bcg dye [mass/vol]
61151-7,bcg albumin dye [mass/vol]
61151-7,albumin bcg dye [massvol] liver
46002-2,psychosocial well-being section
46002-2,well-being psychosocial section
46002-2,psychosocial well-bng secion
54300-9,homocysteine [moles/volume] in amniotic fluid
54300-9,in [moles/volume] homocysteine amniotic fluid
54300-9,homoysteine[mole/volume] in amnioc flud
54300-9,hcys amn-scnc
54300-9,amn-scnc hcys
54300-9,homocyst(e)ine amn-scnc hcys
54300-9,homocysteine (amn fld) [moles/vol]
54300-9,[moles/vol] (amn fld) homocysteine
54300-9,homocysteine heredity (amn fld) [moles/vol]
63042-6,17-hydroxyprogesterone/creatinine [mass ratio] in urine
63042-6,17-hydroxyprogestro/cetinine mss ratio] in urine 17-ohp
63042-6,1-hydroxyprogesterne/creatinine[assratio] in urine creat
63042-6,17ohp/creat ur
63042-6,17ohp/creat ur mcrto
63042-6,ur 17ohp/creat
63042-6,17-hydroxyprogesterone/creatinine (u) [mass ratio]
63042-6,17-hydrxprogestern/cretnine (u) [mass rtio]
63042-6,17-hydroxyprogesterone/creatinine (u) [mass ratio]
5625-9,cobalt [mass/volume] in blood
5625-9,cobalt [massvolume]in blood
5625-9,[mass/volume] quant cobalt in bld
5625-9,cobalt bld-mcnc
5625-9,cobalt bld-mcnc
5625-9,bld-mcnc quantitative cobalt
5625-9,cobalt (bld) [mass/vol]
5625-9,(bld) cobalt [mass/vol]
5625-9,(bld)[mass/vol] cobalt whole blood
41420-1,leishmania tropica ab [titer] in serum by immunofluorescence
41420-1,leishmania tropica ab [titer] titre in ser by immunofluorescence
41420-1,leishmania infectiousdisease tropica by [titer] in serum ab immunofluorescence
41420-1,l tropica ab titr ser if
41420-1,l troica a tit ser if
41420-1,if tropica ab titr sr l
41420-1,l. tropica ab if (s) [titer]
41420-1,l. tropica ab if (s) [titer] anticomplement immunofluorescence
41420-1,l. tropica microbiology ab if (s) [titer]
23227-2,mareks disease virus neutralizing antibody [presence] in serum by neutralization test
23227-2,mreks diseas vru neutralizing antibod [presenc] in serm byneutralzation est microbiology
23227-2,mareks disease virus veterinary neutralizing antibody [ql] in serum by neutralization test
23227-2,gahv nab ser ql nt
23227-2,ghv nab ser ql n
23227-2,gahv nab serum ql nt herpesvirus
23227-2,mareks disease virus neut ab neut test ql (s)
23227-2,mareks disease virus (s) ab neut test ql neut
23227-2,mareks presence eut ab neut test iseasevirus (s)
49858-4,peptide yy [mass/volume] in serum or plasma
49858-4,peti yy [mas/voue] in serum pas or
49858-4,peptide yy [mass/volume] in serum or plasma mass concentration
49858-4,peptide yy serpl-mcnc
49858-4,y pepide erp-mcnc
49858-4,pptide yy srpl-cn
49858-4,peptide yy [mass/vol]
49858-4,[mass/vol] yy peptide quan
49858-4,peptide [mass/vol] yy
94137-7,hedis 2020 value sets
94137-7,2020 hedis value sets
94137-7,hedis 2020 value panel sets
94137-7,hedis 2020 value sets
94137-7,panel hedis 2020 sets value
94137-7,hedis sets vae 2020 pnl
94137-7,hedis 2020 value sets
94137-7,hedis2020 panel.hedis sets vlue
94137-7,hedis 2020 sets value
94504-8,sars-cov-2 (covid-19) ab panel - serum or plasma by immunoassay
94504-8,sars-cov-2 (covid-19) ab panel - ser or plasma by immunoassay
94504-8,sar-ov- (ovid-19) ab pane wuhan coronavirus - or serum plas by immunoasay
94504-8,sars-cov-2 ab pnl serpl ia
94504-8,ab sars-cov-2 pnl serum or plasma ia sars coronavirus 1
94504-8,sars-cov-2 ab serpl pnl ia
94504-8,sars-cov-2 (covid-19) ab panel ia
94504-8,ab (covid-19) sars-cov-2 panel ia
94504-8,sars-cv-2 (coid-19) ab panel ia
79458-6,beta-n-acetylhexosaminidase [enzymatic activity/volume] in dbs
79458-6,activityolume] [enzmati beta-n-acetlhexosamnidae in dbs
79458-6,activity/volume] [enzymatic beta-n-acetylhexosaminidase in dbs
79458-6,b-nah dbs-ccnc
79458-6,b-nah dbs-ccnc
79458-6,s-cnc b-nah
79458-6,beta-n-acetylhexosaminidase (dbs) [catalytic activity/vol]
79458-6,beta-n-acetylhexosaminidase [catalytic (dbs) activity/vol]
79458-6,bta-n-acetylhexosamiidase dbs)[catlytic activity/vl]
74688-3,sodium [moles/volume] in serum or plasma --post dialysis
74688-3,sdium [molevolue] in serumor plasma plasma --post dialysis
74688-3,sodium dialysis inserum or plasma -pst [moles/volume] quant
74688-3,sodium p dialysis serpl-scnc
74688-3,sodium serpl-scnc na dialysis p
74688-3,pdialysis sdium dialy serpl-scnc
74688-3,sodium post dialysis [moles/vol]
74688-3,sodium ost dialysis molesvol] random
74688-3,soium ps dilysi random mos/vol]
99779-1,neisseria gonorrhoeae rrna [presence] in conjunctival specimen by naa with probe detection
99779-1,neisseriagonorrhoeae rra [resence] specmen conjunctival in by polymerase chain reaction naa with probe detecton
99779-1,neisseria by random rrna [presence] in conjunctival specimen gonorrhoeae naa with probe detection
99779-1,n gonorrhoea rrna conjunct ql naa+probe
99779-1,ligation-activated transcription n onorrhoea rrna conjunct presence naa+probe
99779-1,n onorrhoa conjut rrna ql naa+probe
99779-1,n. gonorrhoeae rrna naa+probe ql (conj)
99779-1,n. norhoee rrna naa+probe ql (con) gono
99779-1,n. onorrhoeae rrna naaprobe l (conj)
3444-7,cefonicid [mass/volume] in serum or plasma
3444-7,cefonicid [mass/voume] in serp ser r lsma
3444-7,cefoncid [mass/volume in oplasma drug/toxicology serum
3444-7,cefonocid serpl-mcnc
3444-7,serplas sepl-mcnc cefonocid
3444-7,serp serpl-mcnc cefonocid
3444-7,cefonicid [mass/vol]
3444-7,[mass/vol] cefonicid
3444-7,point in time [mass/vol] cefonicid
17579-4,ganglioside gq1b igg ab [presence] in serum
17579-4,ganglioside g1b igg ab [presene]in seru
17579-4,ganglosidgq1bgg ab [pesence] in srum
17579-4,gq1b gangl igg ser ql
17579-4,gq1b ql gangl igg serum ql
17579-4,gq1b gangl ser igg ql
17579-4,ganglioside gq1b igg ql (s)
17579-4,ganglioside gq1b (s) ql igg
17579-4,gq1b ganglioside igg ql (s)
2988-4,testosterone [mass/volume] in urine
2988-4,testosterone [massvolume]in urine point in time
2988-4,in [mass/volume] testosterone urine
2988-4,testost ur-mcnc
2988-4,quan ur-mcnc tetost
2988-4,ur-mcnc testost testost
2988-4,testosterone (u) [mass/vol]
2988-4,tstostrne testo (u) [mass/vol]
2988-4,(u) testosteroe mass concentration [mass/vol]
4535-1,cytotoxic percent reactive ab [presence] in serum by quick method
4535-1,cytotoxic percent reactive ab [presence] in ser by quick method autoantibody
4535-1,cytotoxic percent sr reactive serum [presence] in ab by quick method
4535-1,ctox pct react ab ser ql qck
4535-1,ctox point in time pct react ab ser ql qck
4535-1,ser pct reat anti ab ctox ql qck
4535-1,cytotoxic percent reactive ab quick method ql (s)
4535-1,cytotoxic ql reactive ab quick method percent (s)
4535-1,cytotoxic pecent reactive ab uick method ctox pct react qls)
12629-2,glucose [mass/volume] in 24 hour peritoneal dialysis fluid
12629-2,lucose [ms/volme] in 24 hour peritneal dialysis flui
12629-2,glucose hour in 24 [mass/volume] peritoneal dialysis fluid
12629-2,glucose 24h diafp-mcnc
12629-2,glucose diafp-mcnc 24h
12629-2,24h glucose diafp-mcnc
12629-2,glucose (24h perit dial fld) [mass/vol]
12629-2,dial (24h perit glucose fld) [mass/vol]
12629-2,glucose (24h perit gluc [mass/vol] fld) dial
23756-0,neospora caninum ab [units/volume] in serum by immunoassay
23756-0,neospora caninum ab [unts/volume] in serum by immunoassay
23756-0,neopora caninum ab [unt/volu] in serum by immunoassay
23756-0,n caninum ab ser ia-acnc
23756-0,n caninum ia-acnc ser autoantibodies ab
23756-0,n ia-acnc abser cninum
23756-0,n. caninum ab ia qn (s)
23756-0,n. suds cninum qn ia a (s)
23756-0,n. caninum ab ia qn (s)
31818-8,equine herpesvirus 1+4 ag [presence] in body fluid
31818-8,equine +4ag herpesvrus [presence] in bod fluid
31818-8,eqine herpesvirus 1+4 ag [preene] i by flui
31818-8,ehv1+4 ag fld ql
31818-8,ehv1+4 ql fld ag antigen
31818-8,ev1+ ag fld l
31818-8,equine herpesvirus 1+4 ag ql (body fld)
31818-8,ql herpesvirus 1+4 ag equine (body fld)
31818-8,ql herpesvirus 1+4 ag equine ordinal (body fld)
62573-1,phenx - pre-existing cancer conditions protocol 070801
62573-1,pan phenx - pre-existing cancer conditions protocol 070801
62573-1,phenx - pre-existing cancer conditions protocol panel 070801
62573-1,pre-existing cancer conditions proto
62573-1,pre-existing proto conditions cancer
62573-1,pre-existing cancer conditions proto
101161-8,p-fluorofentanyl/creatinine [mass ratio] in urine by confirmatory method
101161-8,p-fluorofentanyl/creatinine in ratio] [mass urine by confirmatory method
101161-8,p-fluoofentanyl/cretinine rineb ratio] in [a onirmatory method
101161-8,4-fluorofentanyl/creat ur cfm
101161-8,4-florfentnylcra ur cm
101161-8,ur cr 4-fluorofentanyl/creat cfm
101161-8,4-fluorofentanyl/creatinine confirm (u) [mass ratio]
101161-8,4-fluorofentnylcreatinine ti] (u)[mss cofrm
101161-8,4-fluorofentanyl/creatinine (u) confirm [mass ratio]
53462-8,eicosanoylcarnitine (c20) [moles/volume] in dbs
53462-8,eiosaylcarnitine (c0) [mole/volume] in dbs
53462-8,eicosanoylcarnitine dbs [moles/volume] in (c20)
53462-8,eicosanoylcarn dbs-scnc
53462-8,dbs-scnc eicosanoylcarn
53462-8,eicosanoylarn dbs-snc whole blood
53462-8,c20 (dbs) [moles/vol]
53462-8,[moles/vol] (dbs) c20
53462-8,c20 [moles/vol] (dbs)
86244-1,deprecated outcome and assessment information set (oasis) form - version c2 - follow-up - recertification or other follow-up [cms assessment]
86244-1,depeaed outcome and assessment 2 set (oass) rm - vrsion informaion - follow-up - recrtiication r ter othr fl-up [cm ssessment]
86244-1,deprecated outcome and assessment assessment] set (oasis) form - version c2 - follow-up - recertification or other follow-up [cms information
6428-7,histoplasma capsulatum ag [units/volume] in serum by immunoassay
6428-7,hitpasma by ag [units/volume] i serum capslaum immunassay
6428-7,ser capsulatum a antigen [unis/volume] in hioplasma y munoassay
6428-7,h capsul ag ser ia-acnc
6428-7,capsul microbiology h ag ser ia-acnc
6428-7,h caps ag ser iaanc
6428-7,h. capsulatum ag ia qn (s)
6428-7,capsulatum h. ag ia qn (s)
6428-7,h. ia ag capsultum n (s)
74469-8,glucose-6-phosphate dehydrogenase/pyruvate kinase [ratio] in blood
74469-8,glucos-6-phosphate dehdrogense/pyruvae kinase ood in [ratio]
74469-8,glucose-6-phosphate dehydrogenase/pyruvate blood [ratio] in kinase
74469-8,g6pd/pk bld-rto
74469-8,bld-rto blood g6pd/pk
74469-8,bld-rto g6pd/pk
74469-8,g6pd/pyruvate kinase (bld) [ratio]
74469-8,(b) kinase g6pd/pyruvate ratio]
74469-8,gluc (bl) kiase g6pd/pyruvate [ratio
32185-1,itraconazole [mass/volume] in serum or plasma --trough
32185-1,itrconazole [mas/volume] in or serum lama -tough
32185-1,itraconazole [mass/volume] serum in or plasma --trough
32185-1,itraconaz trough serpl-mcnc
32185-1,itracoaz trough pre serpl-mcnc
32185-1,infectiousdisease itraconz trough sep-mcnc
32185-1,itraconazole trough [mass/vol]
32185-1,[massvol] sr trough itraconazole
32185-1,[mass/vol] trough serp itraconazole
4195-4,clonidine [mass] of dose
4195-4,clonidine [mass] dose of quant
4195-4,of [mass] clonidie dose
4195-4,clonidine dose
4195-4,clondine qnt dose
4195-4,coidine dose
4195-4,clonidine (dose) [mass]
4195-4,conidine (dose) [mass]
4195-4,clnidine (dose) potentialforabuse [mass]
49069-8,epstein barr virus ab [titer] in serum
49069-8,[titr]n barr virus ab estein eum
49069-8,epstein barr virus ab [titer] in ser
49069-8,ebv ab titr ser
49069-8,ebv ab titr ser
49069-8,ebv b antibody titrser
49069-8,ebv ab (s) [titer]
49069-8,ter] ab (s) bv dilution factor
49069-8,[titer abs) ebv
85906-6,home health patient tracking sheet - resumption of care during assessment period [cms assessment]
85906-6,home health patient tracking sheet - [cms of care during assessment period resumption assessment]
85906-6,cre health patient trackinsheet -reumpion of home during assesmnt period [cmsassessment]
32334-5,pipecolate [moles/volume] in serum or plasma
32334-5,pipecolate [moles/volume] plas serum plas or in
32334-5,in [moles/volume] pipecolate serum or plasma
32334-5,pipecolate serpl-scnc
32334-5,pipecolteserpl-snc pipecolic acid
32334-5,srpl-scnc pipecolate
32334-5,pipecolate [moles/vol]
32334-5,[moles/vol] pipecolate
32334-5,pipecolate [moles/vol]
61197-0,oxycodone+oxymorphone [presence] in urine by confirmatory method
61197-0,xycodone+oxymrphone [ql] n urine by confrmatory method
61197-0,opana oxycodone+oxymorphone [presence] in urine by confirmatory method
61197-0,oxycodone+oxymorphone ur ql cfm
61197-0,oxycodone+oxymorphone ur cfm ql
61197-0,ql ur oxycode+oymophone cfm
61197-0,oxycodone+oxymorphone confirm ql (u)
61197-0,oxycodone+xymorphone confirm numorphone q (u)
61197-0,oxycodone+oxymorphone confirm (u) percodan presence
75215-4,ornithine/citrulline [molar ratio] in dbs
75215-4,ornithine/citrulline [molar ratio] in dbs
75215-4,ratio] [molar ornithine/citrulline in dbs
75215-4,ornithine/cit dbs-srto
75215-4,ornithine/cit dbs-srto
75215-4,dbs-srto ornithine/cit
75215-4,ornithine/citrulline (dbs) [molar ratio]
75215-4,ornithine/citrulline (dbs) [molar fp ratio]
75215-4,qnt ornihine/citruie (dbs)oar ratio
80642-2,floxacillin free [mass/volume] in serum or plasma
80642-2,serp floxacillin free [mass/volume] in ser plasma or
80642-2,floxacillin ree plsma in serum or [mass/volme]
80642-2,floxacillin free serpl-mcnc
80642-2,point in time floxacillin free serpl-mcnc
80642-2,floxacillin free serp-mcnc serum
80642-2,floxacillin free [mass/vol]
80642-2,[mas/vl] fre flopen floxacillin
80642-2,free floxacillin [mass/vol]
23155-5,leishmania sp ab [presence] in serum by immunoelectrophoresis
23155-5,leishmaniasp b[presence] i sru immunoeectrophoresis by autoantibody
23155-5,leishmania sp ab [presence] in serum immunoelectrophoresis by
23155-5,leishmania ab ser ql iep
23155-5,lehmania ab ser ql iep
23155-5,leshmania ab presence se presence iep
23155-5,leishmania sp ab iep ql (s)
23155-5,iep leishmaniaspab ql (s)
23155-5,leishmania sp ab iep ql (s)
105924-5,bacteria identified in surgical wound by culture
105924-5,bacteria in identified surgical wound by culture
105924-5,bacteria in ientifed urgiclwound by cuture
105924-5,bacteria surgical wound cult
105924-5,bacteria surgical cult surg wound
105924-5,cult surgical wound bacteria
105924-5,bacteria identified cx nom (surgical wound)
105924-5,bacteria ideiied x nom (surgical cultures wound)
105924-5,identity or presence baceria identfied cx nom (sgicl ound)
41040-7,palmitoylcarnitine (c16) [moles/volume] in blood
41040-7,palmitoylcarnitine (c16) in [moles/volume] blood
41040-7,palitoycarnine (c16)[mole/volume] in bld
41040-7,palmitoylcarn bld-scnc
41040-7,hexadecanoylcarnitine palmitoylcarn bld-scnc
41040-7,palmitoylcarn bl-snc
41040-7,c16 (bld) [moles/vol]
41040-7,quan c16 (blood) [moles/vo]
41040-7,c16 (bld) [moles/vol]
57976-3,hiv 2 gp140 ab [presence] in serum by immunoblot
57976-3,hiv 2 gp140 ab [presence] in serum immunoblot wb by
57976-3,hiv 2 g14 ab [resence n serum by immunoblot
57976-3,hiv 2 gp140 ab ser ql ib
57976-3,hiv 2 gp140 ab west blt serum ql ib
57976-3,hiv 2 gp140 ab serum ql ib
57976-3,hiv 2 gp140 ab ib ql (s)
57976-3,hi 2 p140 ab ibql (s)
57976-3,hi g140 ab qualitative ib ql ()
107282-6,infusion start date and time
107282-6,infusion start and date drugs time
107282-6,infusion start date and im
107282-6,infs start d/t
107282-6,d/t start in started
107282-6,infs d/t start
107282-6,infusion start date and time
107282-6,infusion start date time and
107282-6,infusion start date and drug/toxicology time
75140-4,allantoine [moles/volume] in cerebral spinal fluid
75140-4,in [moles/volume] allantoine cerebral spinal fluid
75140-4,alntoi [moles/vole] in cerebal spinal cerebrospinal fl fluid
75140-4,allantoine csf-scnc
75140-4,allatoine -snc
75140-4,allantoine -scnc
75140-4,allantoine (csf) [moles/vol]
75140-4,chemistry allantoine (cerebrospinal fluid) [moles/vol]
75140-4,[moles/vol] (csf) allantoine
62306-6,fabry disease newborn screening comment-discussion
62306-6,newborn nbs comment disease fabry screening comment-discussion
62306-6,newborn disease fabry screening comment-discussion
62306-6,fabry disease nbs comment
62306-6,fabry disease comment chemistry nbs
62306-6,comment disease nbs fabry
62306-6,fabry disease newborn screening comment-discussion nar (dbs)
62306-6,fabry disease newborn screening comment-discussion (dbs) cmnt nar
62306-6,fabry disease newborn chemistry screening comment-discussion nar (dbs)
51515-5,lactate dehydrogenase 3/lactate dehydrogenase.total in peritoneal fluid by electrophoresis
51515-5,lacttededrogenase 3/lactate dehydrogense.tota in fluid peritoneal by ectophoresis
51515-5,lactate dehydrogenase 3/lactate dehydrogenase.total in electrophoresis fluid by peritoneal
51515-5,ldh3 cfr prt elph
51515-5,ldh3cfr prt elph
51515-5,elp cf prt ldh3
51515-5,ldh 3 elph (periton fld) [catalytic fraction]
51515-5,(periton 3 elph lactic acid ldh fld) [catalytic fraction]
51515-5,ldh 3 elph (periton fld) [catalytic fraction]
63478-2,platelet glycoprotein ib/ix ab [presence] in blood by immunoassay
63478-2,platelet glycoroein heme [prsence] ab ib/ix in bodby immunassay
63478-2,platelet glycoprotein ib/ix ab [presence] blood in blood by immunoassay
63478-2,plat gp ib/ix ab bld ql ia
63478-2,plat gp qlia abbd ib/ix
63478-2,plt gp ib/ix ab bld presence ia
63478-2,platelet glycoprotein ib/ix ab ia ql (bld)
63478-2,platelet ib/ix glycoprotein ab aql (bld)
63478-2,i/ix glycoproten paelet b ia ql (bld)
1721-0,adenosine triphosphate [mass/volume] in blood
1721-0,adenosine wb triphosphate [ass/lume] in blood
1721-0,denosine triphopate wb [mass/volume] in blod
1721-0,atp bld-mcnc
1721-0,bld-mcnc atp
1721-0,atp bld-mcnc point in time
1721-0,adenosine triphosphate (bld) [mass/vol]
1721-0,adenosine triphosphate (bld) [mass/vol] level
1721-0,[mass/vol] triphosphate (bld) adenosine
92972-9,klebsiella oxytoca dna [ncncrange] in sputum by naa with non-probe detection
92972-9,klebsiella ncncrng oxytoca dna [ncncrange] in non-probe by naa with sputum detection
92972-9,kebsiella oxytoca dna [cnrange] in deection by naa wih on-prob sutum
92972-9,k oxytoca dna spt naa+non-prb-ncncrng
92972-9,k oxytoca dna nasba spt naa+non-prb-ncncrng
92972-9,3 self-sustaining sequence replication k oxytoca dna spt naa+non-prb-ncncrng
92972-9,k. oxytoca dna naa+non-probe (sput) [ncncrange]
92972-9,k. oxtoca dna ncncrnge] (sput) n+non-probe
92972-9,k. oxytoca naa+non-probe dna (sput) [ncncrange] sda
27972-9,histidine [units/volume] in serum or plasma
27972-9,histidin [nits/volume] in or ser plsma
27972-9,histidine [units/volume] in serum or histidinemia plasma
27972-9,histidine serpl-acnc
27972-9,his serpl-acnc histidine
27972-9,serpl serpl-acnc histidine
27972-9,histidine qn
27972-9,point in time qn histidine
27972-9,serpl histidine qn
4247-3,ethylmorphine [mass] of dose
4247-3,f ethylmrphine[mss] dos
4247-3,ethylmorphin [mass] drug doses of dose
4247-3,emp dose
4247-3,emp dose
4247-3,p point in time dose
4247-3,ethylmorphine (dose) [mass]
4247-3,ethylmorpin (dose) [mass]
4247-3,dionina ethylmorphine (doe) [ma]
5101-1,coxsackievirus a7 neutralizing antibody [titer] in serum by neutralization test
5101-1,coxsackieviru a7 eutralizing aibody [tite] serum in byeutralizaion test
5101-1,in a7 neutralizing antibody [titer] coxsackievirus serum by neutralization test autoantibody
5101-1,cv a7 nab titr ser nt
5101-1,cv titr nab a7 ser nt
5101-1,a7 cv nab autoantibodies titr serum nt
5101-1,coxsackievirus a7 neut ab neut test (s) [titer]
5101-1,svn a neut coxsackieviusa neut test (s) [titer]
5101-1,coxsckievirus a7 virus neutralization test (s) abneut test neut [tter]
73361-8,glipizide induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73361-8,glipizide induced platelet igm ab [presence] in serum or plasma (fc) aby flow cytometry by
73361-8,gipizie nducd platelet igm a [prsence] in erum orplasma b flow ytoetr(fc)
73361-8,glipizide ind plt igm serpl ql fc
73361-8,serpl ind plt igm glipizide ql fc
73361-8,glipizide ind plt igm serpl ql fc
73361-8,glipizide induced platelet igm fc ql
73361-8,glipizide induced plateet fc igm ql
73361-8,glipizide platelet induced serplas igm fc ql
19309-4,thiazides cutoff [mass/volume] in urine for confirmatory method
19309-4,hiazides cto [mas/volue in onfirmatoy for urin mehod
19309-4,thiazids cutoff [mass/volume] confirmatory urine or n method
19309-4,thiazides cto ur cfm-mcnc
19309-4,cfm-mcnc ur tiazidescto
19309-4,cto thizides cto ur cm-mcnc
19309-4,thiazides cutoff confirm (u) [mass/vol]
19309-4,thiazide cutoff confirm level (u) [mass/vol]
19309-4,thiazides cutoff point in time confirm u) [mass/vol]
75861-5,hedis 2015-2020 value set - ldl-c tests
75861-5,hedi 2015-220 random vlue se - ll-c tests
75861-5,hedis 2015-2020 value - set ldl-c tests pan
75861-5,hedis 2015-20 ldl-c
75861-5,hedis 2015-20 panl ldl-c
75861-5,2015-20 hedis ldl-c
75861-5,hedis 2015-2020 value set - ldl-c tests
75861-5,hedis tests value set - ldl-c 2015-2020
75861-5,2015-2020 hedis value set - ldl-c tests
88785-1,stiffness panel [hoos]
88785-1,stiffness [hoos] panel
88785-1,survey.gnhlth stiffness panel [hoos]
55812-2,18-hydroxycortisol [moles/volume] in 24 hour urine
55812-2,uine in 24 hu 8-hydrxyortisol[moles/volme]
55812-2,18-ydroxycortisol [moes/volume] in24 hur rne
55812-2,18oh-cortis 24h ur-scnc
55812-2,18oh-cortis 24h ur ur-scnc
55812-2,24hr urnc 24 18oh-crtis
55812-2,18-hydroxycortisol (24h u) [moles/vol]
55812-2,18-hydroxycortisol substance concentration (24h u) [moles/vol]
55812-2,18-hydroxycortisol (24h u)[mols/vol]
48834-6,"respiratory allergen panel, us - rocky mountain states a - serum"
48834-6,"eiator serm panel, - rocky mountain states rocky mountain states a- allrgen"
48834-6,"respiratory rocky pnl panel, us - allergen mountain states a - serum"
48834-6,resp allergen rockies a pnl ser
48834-6,rockies allergen resp a pnl se zone 11
48834-6,resp allergen rockies pnl a ser
48834-6,"respiratory allergen panel, us - rocky mountain states a (s)"
48834-6,"tates allrgn pane, u - rocky mountain resrtory alrgen a ()"
48834-6,"respiratory allergen rocky mountain states panel, us - rocky mountain states a (s)"
16345-1,alpha aminobutyrate [presence] in urine
16345-1,alpha aminobutyrate [ql] in ua urine
16345-1,alpha [presene] aminobtyrate iuine
16345-1,a-aminobutyr ur ql
16345-1,a-aminobutyr ur ql
16345-1,a-aminobutyr ur ordinal ql
16345-1,alpha aminobutyrate ql (u)
16345-1,ala aminobutyre ql (u)
16345-1,alpha amiobutrate l (u)
47277-9,erythrocyte [distwidth] in red blood cells from cord blood
47277-9,erythrocytdistwidth] in rd blood cells fomcor blood
47277-9,cells [distwidth] point in time in red blood erythrocyte from cord blood
47277-9,rdw rbc bldco
47277-9,bldco b rdw
47277-9,rbc quantitative rdw bldco
47277-9,erythrocyte (rbc bldco) [distwidth]
47277-9,quant erytrocyte (rbc bldco) [distwidth]
47277-9,erythocyte (rbc [istwidh] bldco)
59948-0,oxcarbazepine [moles/volume] in gastric fluid
59948-0,oxcarazepine [moles/volume] in quan gastri fluid
59948-0,drug/toxicology oxcarbazepine [moles/volume] in gastric fluid
59948-0,oxcarbazepine gast-scnc
59948-0,gatscnc oxcarbazepine
59948-0,st-scnc oxcarbazepie substance concentration
59948-0,oxcarbazepine (gast fld) [moles/vol]
59948-0,oxcarbazepine (gast [moles/vol] fld)
59948-0,(gas quantitative ocrbazepne ld) [moles/vo]
38728-2,2-aminotoluene [mass/volume] in air
38728-2,2-aminotoluene [mass/volume] o-methylbenzenamine in air
38728-2,2-methyl-1-aminobenzene 2-aminotoluene [mass/volume] in air
38728-2,2-aminotoluene air-mcnc
38728-2,2-methyl-1-aminobenzene 2-aminotoluene air-mcnc
38728-2,2aminotolune ar-mcn
38728-2,2-aminotoluene (air) [mass/vol]
38728-2,quant 2-aminotoluene (air) [mass/vol]
38728-2,2-aminotoluene 1-methyl-2-aminobenzene (air) [mass/vol]
24094-5,n-acetylgalactosamine-4-sulfatase [enzymatic activity/mass] in leukocytes
24094-5,n-acetylgalactosamine-4-sulfatase [enzymatic wbcs activity/mass] in leukocytes
24094-5,n-acetylgalactosamine-4-sulfatase [enzymatic rhasb activity/mass] in leukocytes
24094-5,arylsulfatase b wbc-ccnt
24094-5,arlsulfaase b aryl sulfatase b wc-ccnt
24094-5,arlsulftase wbc-ccnt b
24094-5,n-acetylgalactosamine-4-sulfatase (wbc) [catalytic activity/mass]
24094-5,-cetylgalactoamine-4-ulfats caytic (wbc) activity/mass]
24094-5,nacetlgalactosamine-4-slfatase (wbc) activity/mas] ctalytic galnac6s sulfatase
14630-8,bilirubin.indirect [moles/volume] in serum or plasma
14630-8,bilirubin.indirect [moles/volume] or serum in plasma
14630-8,bilirubin.indirect [moles/volume] in serpl
14630-8,bilirub indirect serpl-scnc
14630-8,bilirub indirect bu serpl-scnc
14630-8,bilirub indirect serum or plasma-scnc bilirubins
14630-8,bilirubin.indirect [moles/vol]
14630-8,moes/ol bilirubin.indrect
14630-8,liver moles/vol] biliruin.indirect
73374-1,fluoxetine induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73374-1,fluoxetine induced platelet igm in [presence] ab serum or plasma by flow cytometry (fc)
73374-1,fluoxetine induced platelet igm ab [presence] in serum or plasma pr by flow cytometry (fc)
73374-1,fluoxetine ind plt igm serpl ql fc
73374-1,fluoxetine ind plt igm serpl fc ql
73374-1,fluoxine ind pt presence igm serl presence fc
73374-1,fluoxetine induced platelet igm fc ql
73374-1,fluoxetine platelet plt induced igm fc ql
73374-1,fluoxetine igm platelet ndced fc ql
16878-1,francisella tularensis igm ab [units/volume] in serum
16878-1,in tularnsisig ab [units/voum] francisella serm
16878-1,f tularensis franisela b[units/volume] igm tularensis in serum
16878-1,f tular igm ser-acnc
16878-1,f tular serum-acnc igm
16878-1,ser-acnc microbiology tular igm f
16878-1,f. tularensis igm qn (s)
16878-1,f. tularensis igm quan qn (s)
16878-1,f. tlarensis igm (s) microbiology
41158-7,canine herpesvirus ab [presence] in serum
41158-7,[presence] hrpesvirus b cnine nserum
41158-7,in herpesirus ab [ql] canin serum
41158-7,cahv ab ser ql
41158-7,cahv ab ql serum antby
41158-7,cahv ql ser ab
41158-7,canine herpesvirus ab ql (s)
41158-7,canine herpevirs (s) ql a
41158-7,anine hepsirus ab presence(s)
87754-8,terbufos [mass/mass] in specimen
87754-8,specimen [mass/mass] in terbufos
87754-8,erbufos [massmass n specime mass content
87754-8,terbufos spec-mcnt
87754-8,specmcnt vet terufos
87754-8,spc-mcnt terbufos
87754-8,terbufos (specimen) [mass/mass]
87754-8,spec [mass/mas] (secimen) terbufos
87754-8,terbufos [mass/mass] (specimen) spec
97506-0,glucose management indicator
97506-0,glucose indicator management
97506-0,glucose managemet glucoseur indiator
97506-0,glucose management indicator
97506-0,glucose management percent indicator
97506-0,indicator endocrinology glucosemanagment
97506-0,glucose management indicator calc (reporting period interstitial fluid)
97506-0,glucose management quant indicatorcal (reporting rio intersitial fluid)
97506-0,gucose management indicator alc period (reporti inersitialflud)
85102-2,mood disorder questionnaire [mdq]
85102-2,mood questionaire diorder [mq]
85102-2,questionaire dsrder mood survey [mdq]
32048-1,amitriptyline+nortriptyline [presence] in specimen
32048-1,amitriptyline+nortiptlie [presece] in specimen ordinal
32048-1,amitriptyline+nortriptylne [presence] specimen in
32048-1,amitrip+nor spec ql
32048-1,amitrip+nor presence spec
32048-1,amtrip+nor ql spec
32048-1,amitriptyline+nortriptyline ql (specimen)
32048-1,ql amitriptyline+nortriptyline (specimen)
32048-1,specimen) trepiline q amitriptylie+nortriptylne
16499-6,butorphanol [mass/volume] in urine by confirmatory method
16499-6,buorphanol [mss/volue] in illicit urine by cofirmtor method
16499-6,metho in urine by confirmatoy butrphanol[massvlume]
16499-6,butorphanol ur cfm-mcnc
16499-6,utophanol ur cfm-mc confirmation
16499-6,buophanol ur addiction cfm-mcnc
16499-6,butorphanol confirm (u) [mass/vol]
16499-6,[mass/vol] confirm (u) utorhnol
16499-6,cofirm butorphnol (u) [mass/vol]
75378-0,"hepatitis b virus core ab [presence] in serum, plasma or blood by rapid immunoassay"
75378-0,"heatits b virus cre ab[prsence] in serm, orlood asma y rapd immunoassay"
75378-0,"epatitis b viuscor ab [presence] in serum, plasma or whole bld serum, plasmaor bloo by rapid munassay"
75378-0,hbv core ab serplbld ql ia.rapid
75378-0,hbv core abs ab ql serpbd ia.rapid
75378-0,hbv core ql serplbld ab ia.rapid
75378-0,hbv core ab ia.rapid ql (s/p/bld)
75378-0,hbv ab core ia.rapid ql (s/p/bld)
75378-0,hbv core b ia.rapid l (s/p/ld) serpl
105712-4,"n,n-dimethylpentylone/creatinine [mass ratio] in urine by confirmatory method"
105712-4,"n,n-dimethylpentylone/creatinine [mass ratio] in urine quantitative by confirmatory method"
105712-4,",-dimethylpentylone/creatinine [mass metd in uine by coniraory aio] quant"
105712-4,"n,n-dimethylpentylone/creat ur cfm"
105712-4,"cfm ucr u n,n-imethylentylone/reat"
105712-4,"urcfm n,n-dimethylpentylone/ceat ur"
105712-4,"n,n-dimethylpentylone/creatinine confirm (u) [mass ratio]"
105712-4,"(u) confirm n,n-dimethylpentylone/creatinine [mass ratio]"
105712-4,"n,n-dimethylpentylone/creainne confirm (u) [mass ratio]"
34984-5,unidentified cells/leukocytes in synovial fluid
34984-5,nidentifid joint flu cells/ekocytes in snvi fluid
34984-5,in cells/leukocytes unidentified synovial fluid wbcs
34984-5,unident cells nfr snv
34984-5,unident cells nfr snv
34984-5,cells unident nfr snv
34984-5,unidentified cells/leukocytes (syn fld)
34984-5,unidentified cells/leukocytes (syn qnt fld)
34984-5,unidentified elleukoes (syn ld)
86256-5,patient history and diagnoses - transfer or discharge from agency during assessment period [cms assessment]
86256-5,patient history and diagnoses - transfer or during from agency discharge assessment period [cms assessment]
86256-5,patiethistory and dignoses - trasfer or hx discharg fom agncy period assesen dig [cms assessment]
87391-9,porcine teschovirus rna [cycle threshold #] in specimen by naa with probe detection
87391-9,pocine teshoviru rna[cycle strand displacement amplification b #]in pecimen thresold naa with prbedetction
87391-9,porcine teschoirus rna naa treshld #] in pecien y [ycle with probe detectin
87391-9,ptv rna ct spec qn naa+probe
87391-9,ptv rna qn spec ct naa+probe lcr
87391-9,to be specified in another part of the message ptv rna ct spec qn naa+probe
87391-9,porcine teschovirus rna naa+probe (specimen) [threshnum]
87391-9,porcne teschovius rna naa+prbe (specimen) [thrsnum]
87391-9,naa+probe teschovirus rna porcine (specimen) [threshnum] quantitative
46431-3,alpha 1 antitrypsin [mass/mass] in 72 hour stool
46431-3,alpha 1 antitypsin 72 hours [mass/mass] i 72 hour stool
46431-3,alpha hour antitrypsin [mass/mass] in 72 1 stool
46431-3,a1at 72h stl-mcnt
46431-3,stl-mcnt 72h a1at faeces
46431-3,72h a1at stl-mcnt
46431-3,alpha 1 antitrypsin (72 hour stl) [mass/mass]
46431-3,apha 1 antitrypin (72 hr stl) [mass/mass]
46431-3,alpa alpha-1-protease inhibitor 1 antirypsin (72 hour st) [mass/mas]
23315-5,nairobi sheep disease virus ab [presence] in serum by immunofluorescence
23315-5,nairobi sheep disease virus ab [presence] in ser by immunofluorescence
23315-5,nairbi sheep dsease virus ser [prencen a b immunofuorescece
23315-5,nsdv ab ser ql if
23315-5,ab immune fluorescence dv sr ql f
23315-5,nsdv ab ser ql if
23315-5,nairobi sheep disease virus ab if ql (s)
23315-5,naiobi she diseevirus abif ql (s)
23315-5,naobi sheep disease vius ab if ql (s)
88960-0,mds v3.0 - rai v1.17.2 - skin conditions during assessment period [cms assessment]
88960-0,mds v3.0 v1.17.2 rai - - skin conditions during assessment period [cms assessment]
88960-0,mds v3.0 perod ra v1.17.2 - in panl cndtion durng assssment - [cms assesent
58991-1,urea [mass/time] in 18 hour urine
58991-1,urea [mass/time] in hour 18 urine
58991-1,rea 18hou in [mass/tie urine
58991-1,urea 18h ur-mrate
58991-1,1h urea u-mte
58991-1,urea 18h ur-mae
58991-1,urea (18h u) [mass/time]
58991-1,urea (18h [mass/time] u)
58991-1,urea (18h u) [mass/time] mass rate
31716-4,african swine fever virus ag [presence] in specimen
31716-4,african swine fever virus ag specimen in [ql]
31716-4,afrcan ag fever virus swe [presence] in specien
31716-4,asfv ag spec ql
31716-4,asfv ag spec ql
31716-4,asfv ag spec presence
31716-4,african swine fever virus ag ql (specimen)
31716-4,african swine fever virus (specimen) ql ag
31716-4,infectiousdisease african swine fever virus ag ql (specimen)
85998-3,streptococcus pneumoniae danish serotype 14 igg ab [mass/volume] in serum by immunoassay --2nd specimen
85998-3,streptococcus pneumoniae danish serotype 14 igg ab [mass/volume] in ser by immunoassay --2nd specimen
85998-3,stretococus neumoniae danish sroype 14igg ab [massvlume] in serum bimmunoassay --2nd specmen
85998-3,s pneum da 14 igg sp2 ser ia-mcnc
85998-3,pt s igg da 14 pneum sp2 ser ia-mcnc
85998-3,s pneum da ia-mcnc aby igg sp2 serum 14
85998-3,s. pneumoniae danish type 14 igg spec 2 ia (s) [mass/vol]
85998-3,s. type14 daish pneumoiae igg spec infectious disease 2 a(s) [mss/vo]
85998-3,ia pneumoniae danish type 14 igg spec 2 s. (s) [mass/vol]
94601-2,listeria monocytogenes ag [presence] in tissue by immune stain
94601-2,steriamoncytogenes ag [presece] in imune by tissue stin
94601-2,listeria monocytogenes ag [presence] immune tissue by in stain
94601-2,l monocytog ag tiss ql imstn
94601-2,ag monocytog l tiss ql imstn
94601-2,l monocytog ag tiss presence imstn
94601-2,l. monocytogenes ag immune stain ql (tiss)
94601-2,l. l monocytog moncytogenes ql immne stan ag iss)
94601-2,l. monocytogenes ag immune stain ql (tiss)
31495-5,lymphocytic choriomeningitis virus igm ab [units/volume] in serum
31495-5,serum choriomeningitis antibodies virus igm ab [units/volume] in lymphocytic
31495-5,lymphocytic choriomeningitis sr virus igm ab [units/volume] in serum
31495-5,lcmv igm ser-acnc
31495-5,lcmv serum-acnc igm
31495-5,lcmv quan igm ser-acnc
31495-5,lymphocytic choriomeningitis virus igm qn (s)
31495-5,infectious disease lymphoctic choriomeningitis igmqn(s) virus
31495-5,lymphocytic igm virus choriomeningitis qn (s)
62953-5,phenx - assessment of functional gastrointestinal disorders - child protocol 190103
62953-5,henx ssessment of functionalgastrointestinal dordrs- potocol chl 190103
62953-5,penx- assessment disorr functional gastrintestinal of - child protocol 19003
62953-5,assess func gi disorders child proto
62953-5,asess funcgi disorderschld gi proto
62953-5,proto func gi disorders pnl child assess
82969-7,"pentobarbital [mass/volume] in serum, plasma or blood by confirmatory method"
82969-7,"peobarbital[mass/olume]i seum, plas r confirmatry addiction b blood mthod"
82969-7,"pentobrital [mas/volume] serp n srum, psma orlood by onfirmaoy method"
82969-7,pentobarb serplbld cfm-mcnc
82969-7,serlbd penobarb cf-mcnc
82969-7,pentobar cfm-mcnc serplbld
82969-7,pentobarbital confirm (s/p/bld) [mass/vol]
82969-7,serum or plasma pentobarbital confirm (s/p/bld) [mass/vol]
82969-7,pentobarbital confirm (s/p/bld) [mass/vol]
58433-4,crystals panel - urine sediment
58433-4,urine sediment crystals panel - urine sediment
58433-4,- panel crystals urine sediment
58433-4,crystals pnl urns
58433-4,crystal nl urns
58433-4,rystal pnl pan urns
58433-4,crystals panel (urine sed)
58433-4,crystls nel (urine sed)
58433-4,(urine pael crystals sed)
94574-1,heavy metals panel - nail
94574-1,heavy metals panel - heavy met pnl nail
94574-1,heavy metals heavy met panel - nail
94574-1,heavy met pnl nail
94574-1,heavymet pnl nil
94574-1,heavy pnl met nail drugs
94574-1,heavy metals panel (nail)
94574-1,heavy panel metals (nai)
94574-1,eavy etas panel ungal nail (nil)
94677-2,"glomerular filtration rate [volume rate/area] in serum, plasma or blood by creatinine and cystatin c-based formula (ckd-epi)/1.73 sq m"
94677-2,"glomerular filtration rate [volume rate/area] in serum, plasma or plasma bld by creatinine and cystatin m formula (ckd-epi)/1.73 sq c-based"
94677-2,"gloerular fltrationate [oume rate/area] i serum, plas o blood by creatinine d cystatin c-based formula (ckd-epi)/1.73 sq m"
94677-2,gfr/bsa.pred serplbld creat+cyst ckd-epi
94677-2,gfr/bsa.pred serplbld creat+cyst ckd-epi
94677-2,gfr/bared erplbld serplbld cret+ct ckd-epi
94677-2,gfr creatinine and cystatin c-based formula (ckd-epi)/1.73 sq m (s/p/bld) [vol rate/area]
94677-2,(ckdei)/1.7 creinine and cystatin c-bae formula gr sq m (s//bld) [vol rat/area]
94677-2,gr creatinine quan ad cstain-based s (ckd-epi)/.7 forula m (s/p/bld) [ol rate/area]
35317-7,thermoactinomyces vulgaris 1 ab [presence] in serum by immune diffusion (id)
35317-7,thermoactiomycesvulgaris 1 serum [pesence] in ab by immune diffusion (id)
35317-7,thermoactinomyces vulgaris 1 ab [presence] in serum (id) immune diffusion by
35317-7,t vulgaris1 ab ser ql id
35317-7,t vulgari1 ab serum qual ql id
35317-7,id t vulgaris1 ser ab ql id
35317-7,t. vulgaris 1 ab immune diff ql (s)
35317-7,t. vulgaris1 abimmune diff ql (s)
35317-7,t. vlgas 1 b immune dif ql (s)
75148-7,orotidine [moles/volume] in cerebral spinal fluid
75148-7,orotidine [molesvolume] in cerebral spinal fluid
75148-7,otdine [moles/volue]in spinl cerebral flui
75148-7,orotidine csf-scnc
75148-7,orotidine csf-scnc substance concentration
75148-7,csf-scnc orotidine
75148-7,orotidine (csf) [moles/vol]
75148-7,orotidine (cerebrospinal fluid) [moles/vol]
75148-7,[moles/vol] (csf) orotidine
69027-1,morphine [mass/mass] in meconium by confirmatory method
69027-1,morphine method in meconum byconfrmatory [mas/mass]
69027-1,morphine meconium in [mass/mass] by confirmatory method
69027-1,morphine mec cfm-mcnt
69027-1,omph morphine meccfm-mnt
69027-1,morhinec cfm-mcnt
69027-1,morphine confirm (mec) [mass/mass]
69027-1,morhineconfirm (mec) [mssmass] addiction
69027-1,confirmation morphine [mass/mass] (mec) confirm
19126-2,bacteria identified in bone marrow by aerobe culture
19126-2,bactr ientifiedi bonemarrow c&s byarobe cuture
19126-2,in identified bacteria bone marrow by aerobe culture
19126-2,bacteria mar aerobe cult
19126-2,bacteria mar arbe ult
19126-2,bactria mar aerobe cut cult
19126-2,bacteria identified aer cx nom (bm)
19126-2,bacteria identified aer cx nom (bm) bact
19126-2,idetified batera aer bact c nom (m)
50545-3,bacterial susceptibility panel by minimum inhibitory concentration (mic)
50545-3,inhibitorycncentration susceptibility panel y minimm batia pnl (mi)
50545-3,bacterial suscptbili ane b mnimu inhitry cncentation panel.antibiotic susceptibilities (ic)
50545-3,bacterial susc pnl islt mic
50545-3,bacterial susc pnl random mic islt
50545-3,bacterial susc pnl islt mic
50545-3,bacterial susceptibility panel mic (isol)
50545-3,bacteril susceptibility pael mic point in time (isol)
50545-3,bacteial susceptibilities sscepibility panl mc (isol)
50821-8,beryllium [moles/volume] in urine
50821-8,urine [moles/volume] in beryllium
50821-8,in [moles/volume] beryllium quan urine
50821-8,beryllium ur-scnc
50821-8,drug/toxicology ur-scc beryllium
50821-8,beryllium ur-scnc
50821-8,beryllium (u) [moles/vol]
50821-8,moles/vol] (u) beryllium
50821-8,eryllium qnt (u) moles/vol]
25409-4,filaria ab [titer] in serum by immunofluorescence
25409-4,fiaria ab [tter] in serum by immunofluorescence
25409-4,filaria ab [titer] in immunofluorescence by serum
25409-4,filaria ab titr ser if
25409-4,filaia ab autoantibody titrer if
25409-4,filaria ab ser titr antby if
25409-4,filaria ab if (s) [titer]
25409-4,iaria if ab (s) [titer]
25409-4,fiaia ab (s) immune fluorescence if [titer]
53498-2,anthranilate [moles/volume] in urine
53498-2,urine [moles/volume] in anthranilate
53498-2,anthranilate [moles/volume] anthranilic acid in urine
53498-2,anthranilate ur-scnc
53498-2,ur-scnc anthranilate
53498-2,ur-scnc anthanile ua
53498-2,anthranilate (u) [moles/vol]
53498-2,() anthranilate quant [mols/vl]
53498-2,[moles/vol] anthrailate(u)
85921-5,oasis c2 - respiratory status - soc or roc during assessment period [cms assessment]
85921-5,oasis c2 - respiratory survey status - soc or roc during assessment period [cms assessment]
85921-5,oasis c2 - respiratory status - soc pnl or roc during assessment period [cms assessment]
49345-2,bk virus dna [#/volume] (viral load) in blood by naa with probe detection
49345-2,bk virus dna [#/volume] by load) in blood (viral naa with probe detection
49345-2,k load dna [#/volume] (viral virus in bld by naa wih prbe etection
49345-2,bkv dna # bld naa+probe
49345-2,bld dna # bkv naa+probe
49345-2,# dna bkv bld naa+probe
49345-2,bk virus dna naa+probe (bld) [#/vol]
49345-2,bk (bld) blood na+probe virusdna [#/vol]
49345-2,count bk virus naa+probe dna (bld) [#/vol]
7985-5,polio virus 1 ab [units/volume] in serum
7985-5,polio virus ab 1 [units/volume] in serum
7985-5,polio virus in ab [uits/volume] 1 srum
7985-5,pv1 ab ser-acnc
7985-5,ab pv1 ser-anc
7985-5,poliovirus abser-acnc pv1
7985-5,polio virus 1 ab qn (s)
7985-5,polio virus 1 qn ab (s)
7985-5,polio virus quan 1 ab qn (s)
59235-2,prostate specific ag free/prostate specific ag.total in cerebral spinal fluid
59235-2,prostate spcific ag free/prostate speciic ag.total in cerbral spinal quant fluid
59235-2,cerebral specific ag free/prostate specific ag.total in prostate spinal fluid
59235-2,psa free mfr csf
59235-2,psa fr mfr free csf
59235-2,mfr free psa csf
59235-2,free psa/total psa (csf) [mass fraction]
59235-2,fre psa/toal psa(csf) [mass fration]
59235-2,fraction] psa/total psa (csf) chemistry [mass free
76022-3,8(9)-cholestenol [moles/volume] in serum or plasma
76022-3,[mole/vlume] 8(9-cholsenol serpl in serpl
76022-3,in [moles/volume] 8(9)-cholestenol serum or plasma
76022-3,8(9)-cholestenol serpl-scnc
76022-3,quantitative srplscnc 8(9)-cholestnol
76022-3,89)-chostenol serpl-scnc
76022-3,8(9)-cholestenol [moles/vol]
76022-3,pt [moles/vol] 8(9)-cholestenol
76022-3,()coleteno mole/vol]
26964-7,cystathionine [moles/volume] in urine
26964-7,cystathionine [moles/volume] in urine urn
26964-7,cysathionine [mles/volu] urine in
26964-7,cystathionin ur-scnc
26964-7,ur-scnc chemistry cystathionin
26964-7,quan ur-snc cystathioin
26964-7,cystathionine (u) [moles/vol]
26964-7,cystathionine (u) [moles/vol]
26964-7,(u) cystathionie [oles/vol
4361-2,nortriptyline [mass] of dose
4361-2,[mass] nortriptyline of dose
4361-2,nortriptyline [mass] of dose
4361-2,nortrip dose
4361-2,dose aventyl ortrip
4361-2,dose nrtrip
4361-2,nortriptyline (dose) [mass]
4361-2,[mass] (dose) ortriptyline
4361-2,nortriptyline (dose) [mass] amitriptyline metabolite
8060-6,adrenal cortex ab [units/volume] in serum
8060-6,real cortx b [nt/volm] in serum
8060-6,adrenal cortex ab arbitrary concentration [units/volume] in serum
8060-6,adrenal cortex ab ser-acnc
8060-6,adrenal cortex ab serum-acnc
8060-6,adrenal ab cortex random sracnc
8060-6,adrenal cortex ab qn (s)
8060-6,adrnal cotex ab qn ()
8060-6,adrenal ab cortex qn (s)
31649-7,deprecated streptococcus pneumoniae 6 ab [units/volume] in serum --2nd specimen
31649-7,deprecated streptococcus [units/volume] 6 ab pneumoniae pneumococcal in serum --2nd specimen
31649-7,dprecatd streptococus in 6 ab [units/volume] pneumoniae serum --2nd specimen
31649-7,deprecated s pneum6 ab sp2 ser-acnc
31649-7,deprecated s ab pneum6 sp2 ser-acnc
31649-7,deprecated s point in time ab pneum6 sp2 ser-acnc
31649-7,s. pneumoniae 6 ab spec 2 qn (s)
31649-7,s. pneumone 6 ab spec sp2 2 qn(s
31649-7,s. strep pneumoniae 6 ab spec 2 qn (s)
9494-6,blastomyces dermatitidis igg ab [units/volume] in serum
9494-6,blastomyces dermatiidis igg ab [uitsvolume]inseru
9494-6,blastomyces dermatitidis gg b serm in [units/volume]
9494-6,b dermat igg ser-acnc
9494-6,b anti dermat igg serum-acnc
9494-6,b drmatg se-anc
9494-6,b. dermatitidis igg qn (s)
9494-6,b. ermatitidis igg qn ()
9494-6,b.dermatitdi ig qn antibodies (s)
47677-0,isoleucine/amino acids.total in specimen
47677-0,amino acid isoleucinami aids.totalin spcimen
47677-0,isoleucine/mino specimn amino acid in acids.total
47677-0,isoleucine sfr spec
47677-0,isoleucisfr spec
47677-0,isoleucine percent sfr spec
47677-0,isoleucine/total aa (specimen) [molar fraction]
47677-0,isoleucine/total acid aa fraction] [molar (specimen)
47677-0,oleucine/ttal aa (specimen) [molar frction
20624-3,creatinine [mass/volume] in 24 hour urine
20624-3,creatinine [mass/volume] in 24 hour urine
20624-3,creatinine [mass/volume] in 24 hour urine
20624-3,creat 24h ur-mcnc
20624-3,creat creat 24h ur-mcnc
20624-3,creat2h urmcnc
20624-3,creatinine (24h u) [mass/vol]
20624-3,creatinine (24h [mass/vol] u)
20624-3,creatinine u) (24h [mass/vol]
23309-8,myxoma virus ab [presence] in serum by immunofluorescence
23309-8,virusab[preene] yxoma in ser by immunoflurescence
23309-8,myxoma virus ab [presne] n erum by imunoluorescence
23309-8,myxv ab ser ql if
23309-8,myxv ab ser presence if
23309-8,myxv if ser ql ab
23309-8,myxoma virus ab if ql (s)
23309-8,myxoma virus if a ql sr (s)
23309-8,myxoma if ab virus ql point in time (s)
42954-8,sindbis virus ab [titer] in serum
42954-8,sindbis virus anti ab [titer] in serum
42954-8,sindbis virus ab abs [titer] in serum
42954-8,sinv ab titr ser
42954-8,sinv ab ser titr
42954-8,ser ab titr sn
42954-8,sindbis virus ab (s) [titer]
42954-8,sindbis virus ab antby (s) [titer]
42954-8,a virus sindbis dilution factor ()[titer]
20735-7,brucella sp identified in milk by organism specific culture
20735-7,brucella sp identified organism milk by in specific culture
20735-7,bucela p identified in milk by organism specic cultur
20735-7,brucella mlk cult
20735-7,brcella mlk cul
20735-7,brucella mlk point in time cult
20735-7,brucella sp identified org specific cx nom (milk)
20735-7,rucella sp idenified org specificcx om (mil)
20735-7,rcella sp identified or speific cx nom(ilk)
31824-6,escherichia coli k1 ag [presence] in cerebral spinal fluid
31824-6,escherichia coli k1 ag [presence] in cerebral spinal fluid
31824-6,escherichi col k1 g [presenc] in cerebral spinal fluid
31824-6,e coli k1 ag csf ql
31824-6,e cerebrospinal fluid k1 ag coli ql
31824-6,e cli k1 agcsf ql antigens
31824-6,e. coli k1 ag ql (csf)
31824-6,e. coli k1 antigens ag ql (cerebrospinal fluid)
31824-6,coli e. 1 ag ql(csf)
46730-8,bacterial vaginosis whiff test [presence] in vaginal fluid
46730-8,pr presence] vaginosis whiff test bacterial i vaginal fluid
46730-8,bacterial vaginosis test whiff [ql] in vaginal fluid gyn
46730-8,bv whiff test vag ql
46730-8,bv point in time whif test vag presence
46730-8,bv test wiff vag presence
46730-8,bacterial vaginosis whiff test ql (vag fld)
46730-8,bacterial vaginosis test whiff ql (vag fld)
46730-8,bacterial vanosi whif test ql (vag fld)
62429-6,eastern equine encephalitis virus igm ab [presence] in body fluid by immunofluorescence
62429-6,eastern equine encephalitis virus igm ab [ql] in body fluid by immunofluorescence
62429-6,estern equineencephalitis vrus igm ab [presence]n boy fluid y infectiousdisease immunoflresen
62429-6,eeev igm fld ql if
62429-6,if bf igm fl ql eeev
62429-6,eeev igm fld time resolved fluorescence ql if
62429-6,eeev igm if ql (body fld)
62429-6,autoantibody eev igm i ql(body fl)
62429-6,eevigmif presence (bdyfld)
24188-5,coxsackievirus b3 neutralizing antibody [titer] in serum by neutralization test --2nd specimen
24188-5,coxsackievirus b3neutalizing antibody [titer] in secimen by neutralization test -2nd seru
24188-5,coxsackievirus b3 neutralizing [titer] antibody in serum by neutralization cvnt test --2nd specimen
24188-5,cv b3 nab sp2 titr ser nt
24188-5,cv b3 nab sp2 nt ser titr
24188-5,nab b3 cv sp2 titr ser nt
24188-5,coxsackievirus b3 neut ab spec 2 neut test (s) [titer]
24188-5,coxsackievirus dilution factor (titer) b3 neut ab spec 2 test neut (s) [titer]
24188-5,coxsackievirus b3 neut ab (s) 2 neut test spec [titer] abs
93749-0,mumps virus n gene [cycle threshold #] in specimen by naa with probe detection
93749-0,mumps virus gene [cycle threshold # inspecmen by probe amp naawit proe detection
93749-0,mmps viru naa gene [yclethreshol #] in secimen by n wit probe detection
93749-0,muv n gene ct spec qn naa+probe
93749-0,mu n genect spec qn na+proe
93749-0,muv n gene ct qn spec naa+probe
93749-0,muv n gene naa+probe (specimen) [threshnum]
93749-0,muv ngene na+probe amplified (specien) [threshnum]
93749-0,muv n gene naa+probe (specimen) [threshnum] probe with ampification
8848-4,coronary sinus oxygen saturation
8848-4,oxygen sinus coonay saturation
8848-4,sinus coronary oxygen saturation
8848-4,sao2 % cs
8848-4,cs % sao2
8848-4,sao2 % cs random
23968-1,dengue virus igm ab [units/volume] in serum
23968-1,engue virus ig ab [unit/volume] in seru point in time
23968-1,dengue virus igm ab [units/volume] in serum
23968-1,denv igm ser-acnc
23968-1,denv denv ser-acnc igm
23968-1,denv immunoglobulin m igm ser-acnc
23968-1,denv igm qn (s)
23968-1,denv antibody (s) qn igm
23968-1,antibody denv (s) qn igm
67761-7,"hedis 2012, 2013 codes to identify hba1c tests (cdc-d)"
67761-7,"hedis (cdc-d) 2013 codes to identify hba1c tests 2012,"
67761-7,"hedis 2012, panel.hedis 2013 codes to identify hba1c tests (cdc-d)"
67761-7,hedis 2012-13 cdc-d
67761-7,cdc-d 2012-13 hedis
67761-7,hedis 2012-13 cdc-d
67761-7,"hedis 2012, 2013 codes to identify hba1c tests (cdc-d)"
67761-7,"hedis 2012, 2013 pan codes to identify (cdc-d) tests hba1c"
67761-7,"panl hedis 2012, 2013 codes to (cdc-d) hba1c tests identify"
104547-5,monocyte and dendritic cell panel - blood by flow cytometry (fc)
104547-5,mnocyte ad panel- cell dendrtc bloodby flow point in time ctomry (fc)
104547-5,onoyte and denritic cell pael - blood by flw blood cytomet (fc)
104547-5,monocyte and dendritic cell pnl bld fc
104547-5,mnocyte dedritic and cell pnl blood f
104547-5,monocyte pnl dendritic cell and blood fc
104547-5,monocyte and dendritic cell panel fc (bld)
104547-5,hematology/cell counts monocyte and dendritic cell panel fc (blood)
104547-5,monocyte and panel cell dendritic fc (bld)
94732-5,duloxetine [presence] in saliva (oral fluid) by confirmatory method
94732-5,duloxetine method in saliva (oral oral fluid fluid) by confirmatory [ql]
94732-5,duloxetine [presence] in fluid) (oral saliva by confirmatory method
94732-5,duloxetine sal ql cfm
94732-5,duletine sal cfm ql qual
94732-5,duloxetine sal ql ql cfm
94732-5,duloxetine confirm ql (sal)
94732-5,duloxetine ql confirm (sal)
94732-5,duoxetine lc/ms/ms (sal) presence confirm
43213-8,polychlorinated biphenyl (pcb) [mass/volume] in blood
43213-8,polychlorinated [mass/volume] (pcb) qnt biphenyl in bld
43213-8,polychlorinated biphenyl (pcb) biphenyls [mass/volume] in blood
43213-8,pcb bld-mcnc
43213-8,pcb blood-mcnc
43213-8,bld-mcnc pc
43213-8,polychlorinated biphenyl (pcb) (bld) [mass/vol]
43213-8,(pcb)(blood)[ma/vol] polychlorinatedpnl
43213-8,polychlorinated biphenyl (bld) (pcb) [mass/vol]
14745-4,glucose [moles/volume] in body fluid
14745-4,glucose [moles/volume] in random body fluid
14745-4,glucose [moles/volume] in body fluid level
14745-4,glucose fld-scnc
14745-4,glucose fld-scnc substance concentration
14745-4,bod glucose fld-scnc
14745-4,glucose (body fld) [moles/vol]
14745-4,glucose (body fld) [moles/vol]
14745-4,glucose fld) (body [moles/vol]
18331-9,neutrophil cytoplasmic igm ab [units/volume] in serum
18331-9,neutrophil cytopasmic igm ab [unitsvolume] in serum
18331-9,neutrophil cytopasic ig ab [units/volme]i erum
18331-9,anca igm ser-acnc
18331-9,aca igm ser-acnc
18331-9,anca igm ser-anc random
18331-9,neutrophil cytoplasmic igm qn (s)
18331-9,neutrophil cytoplasmic igm qn (s) sr
18331-9,neutr neutrophil qn i cyplasmic ()
13801-6,protein/creatinine [mass ratio] in 24 hour urine
13801-6,ratio] [mass protein/creatinine in 24 hour urine
13801-6,protein/creainine [mass hor in 4 ratio] urne
13801-6,prot/creat 24h ur
13801-6,quant prot/creat ur 24h
13801-6,prot/creat ur 2h
13801-6,protein/creatinine (24h u) [mass ratio]
13801-6,protein/creatinine (24h mass concentration ratio u) [mass ratio]
13801-6,protein/creatinine (24h u) [mss ratio]
49341-1,adenovirus dna [#/volume] (viral load) in blood by naa with probe detection
49341-1,adenovirus dna [#/volume] (viral load) detection blood by naa with probe in
49341-1,adeovirus bloodby oad in [#/volume](viral naawith probe infectious disease detection
49341-1,hadv dna # bld naa+probe
49341-1,hadv dna naa+probe blood #
49341-1,ct #bld dn hadv naa+probe
49341-1,adenovirus dna naa+probe (bld) [#/vol]
49341-1,adenovirus dna [#/vol] (bld) naa+probe
49341-1,adeno virus dna adenovirus naa+probe (bld) [#/vol]
26934-0,lorazepam [mass/mass] in meconium
26934-0,orazepam [mss/mass in mcnum
26934-0,meconium [mass/mass] drug/toxicology in lorazepam
26934-0,lorazepam mec-mcnt
26934-0,loraepam mec-mcnt mec
26934-0,lorazepam mec mec-mcnt
26934-0,lorazepam (mec) [mass/mass]
26934-0,lorazepam(mec[mas/mass]
26934-0,[mass/mass] (mec) lorazepam
44384-6,hydrochlorothiazide [presence] in 24 hour urine
44384-6,hyrochorothizide n [preence] 24 hor urin
44384-6,hydrochlorothiazide [presence] in 24 hour urine
44384-6,htcz 24h ur ql
44384-6,htcz 24h ur htcz presence
44384-6,1 day htcz 24 ur q
44384-6,hydrochlorothiazide ql (24h u)
44384-6,(24h ql hydrochlorothiazide u) pr
44384-6,ql(24h hydrchlrothazide u
26807-8,glycine [presence] in 24 hour urine
26807-8,glcine [presnce] in 24 24 hours urine hour
26807-8,urine [presence] in 24 hour glycine
26807-8,glycine 24h ur ql
26807-8,glycine24ur ql
26807-8,glycine 24h ur presence
26807-8,glycine ql (24h u)
26807-8,glcine (24h ql pr )
26807-8,ordinal ) 24h gycineql
25980-4,serine/creatinine [molar ratio] in 24 hour urine
25980-4,serine/creatinine [molar rtio] in 24 hour urine
25980-4,serine/creatinie [molar rti]in2 our urne
25980-4,serine/creat 24h ur-srto
25980-4,24h serine/creat ur-srto
25980-4,serine/creat ur-srto 24h
25980-4,serine/creatinine (24h u) [molar ratio]
25980-4,u) (24h serinecreatinne molaatio]
25980-4,serine/ceainine 24h u) tio] [olar 1 day
6959-1,yersinia enterocolitica o:3 ab [titer] in serum
6959-1,yersinia enterocolitica ab o:3 [titer] in serum
6959-1,yersinia entercolitica o:3 seru [titer] in ab
6959-1,y entero o:3 ab titr ser
6959-1,ser eneroo:3 ab abs titr y
6959-1,smqn y entero o:3 ab titr ser
6959-1,y. enterocolitica o:3 ab (s) [titer]
6959-1,y. enterocolitica o:3 ab (s) dilution factor (titer) [titer]
6959-1,y antby enterocolitica [tite] ab (s) o3
53448-7,cycloguanil [mass/volume] in serum or plasma
53448-7,cyclogunl [mass/volume] in serpl
53448-7,cyclguanil [mass/voume] in seru o plasma
53448-7,cycloguanil serpl-mcnc
53448-7,serpl-mcnc cycloguanil quantitative
53448-7,serum or plasma-mcnc cycloguanil quant
53448-7,cycloguanil [mass/vol]
53448-7,cclouanil mass/vol]
53448-7,cloguanil [mas/vol]
46444-6,other-confidential section set naaccr v.11
46444-6,v.11 section set naaccr other-confidential
46444-6,other-confidential section set naaccr v.11
46444-6,other-confidential sec naaccr v.11
46444-6,aaccr sec otherconfientil v.11
46444-6,v.1 sec random naaccr other-cnfdential
22765-2,adult fly identified in specimen
22765-2,in fly identified adult specimen
22765-2,adlt id flyidenifiedi specimen
22765-2,adult fly spec
22765-2,adut spec misc fly
22765-2,adut fl infectiousdisease spec
22765-2,adult fly identified nom (specimen)
22765-2,adult fly nom dentfied (pecimen) infectious disease
22765-2,adult fly identified nom (specimen)
29924-8,scandium [mass/time] in 24 hour urine
29924-8,hourie [mass/tim] 24hr in 24 scandium
29924-8,scandium hour in 24 [mass/time] urine
29924-8,scandium 24h ur-mrate
29924-8,ur-rae 24h scandium drug/toxicology
29924-8,ur-mrate 24h scandium
29924-8,scandium (24h u) [mass/time]
29924-8,scanium (4h u) [mas/time
29924-8,[mass/time] (24h u) scandium
75353-3,other cells/leukocytes in body fluid by manual count
75353-3,ther manual i random bdy fluid by cells/leukocytes coun
75353-3,other cells/lekoctes n body flud by othr manual count
75353-3,other cells nfr fld manual
75353-3,other cells nfr fld manual
75353-3,other cells nfr fld manual
75353-3,other cells/leukocytes manual cnt (body fld)
75353-3,other cells/leukocytes manual cnt (body fld)
75353-3,other fld) manual cnt (body cells/leukocytes
30218-2,coxsackievirus a7 ab [presence] in serum
30218-2,cosackievirus a7 b [presence] in ser
30218-2,cxsakievus a7 ab [presence] in serum
30218-2,cv a7 ab ser ql
30218-2,cv a7 abser ql
30218-2,cv ql pr ab serum a
30218-2,coxsackievirus a7 ab ql (s)
30218-2,coxsackievirus a7 ab ql (s)
30218-2,aby coxsackievirus a7 (s) ql ab
97301-6,phenobarbital [presence] in cord tissue by confirmatory method
97301-6,phenobarbital [presence] in confirmatory tissue lc/ms/ms by cord method
97301-6,henobarbital [preence] incord tissu by conirmatory method
97301-6,phenobarb tissco ql cfm
97301-6,phenobarb tissco lc/ms/ms ql cfm
97301-6,ordinal phenobarb cfm tisscoql
97301-6,phenobarbital confirm ql (umb cord tissue)
97301-6,nirvonal phnbabital confirm ql (umb cord tissue)
97301-6,cnfr phenobarbital confirm ql (umb cord tissue)
10501-5,lutropin [units/volume] in serum or plasma
10501-5,lutropin [utsvolume] in pl sermr pama
10501-5,lutropin [units/volume] or ser in plasma
10501-5,lh serpl-acnc
10501-5,serpl-acnc icsh lh
10501-5,serpl-anc universallaborders lh
10501-5,lutropin qn
10501-5,universallaborders qn lutropin
10501-5,qn lutropin
2112-1,choriogonadotropin.beta subunit [presence] in urine
2112-1,choriogonadotropin.beta subunit [presce] inurine
2112-1,choriogonadotropin.beta [ql] subunit in urine
2112-1,b-hcg ur ql
2112-1,b-hcg ur l
2112-1,ql ur b-g
2112-1,hcg.beta subunit ql (u)
2112-1,hcg.beta subunit (u) screen ql
2112-1,hcg.beta suunit presence (u)
50800-2,acetone [moles/volume] in body fluid
50800-2,acetone [moles/volume] in body ketone bodies fluid
50800-2,fl [moles/voume] i bdy acetone
50800-2,acetone fld-scnc
50800-2,fld-scnc acetone
50800-2,fl-cnc acetone
50800-2,acetone (body fld) [moles/vol]
50800-2,acetone drug/toxicology (body fld) [moles/vol]
50800-2,(body acetone fld) bod [moles/vol]
13408-0,ornithine [mass/volume] in amniotic fluid
13408-0,inamniotc [mass/volume] nihine quantitative fluid
13408-0,rnithine pt as/olume]in amniotic fluid
13408-0,ornithine amn-mcnc
13408-0,amn-mcnc ornithine
13408-0,orithine amnmcnc
13408-0,ornithine (amn fld) [mass/vol]
13408-0,amniotic flu (amn ornithine fld) [mass/vol]
13408-0,ornithine (amn fld) amn [mass/vol
56484-9,uroporphyrin [mass/mass] in stool
56484-9,in heme mss/ass] uroporphyrin stol
56484-9,urophorph uroporphyrin mas/mass in sool
56484-9,uropor stl-mcnt
56484-9,tl-mct uropr
56484-9,uropor stl-mcnt
56484-9,uroporphyrin (stl) [mass/mass]
56484-9,[mass/mass] (stl) uroporphyrin
56484-9,urpophyrin chemistry stl) [mass/mss]
22680-3,mercury/creatinine [molar ratio] in urine
22680-3,mrcur/ceatinine molar ratio] in rin
22680-3,mercury/creatinine [molar in ratio] quan urine
22680-3,mercury/creat ur-srto
22680-3,quantitative ur-srto mercury/creat
22680-3,mercury/creatur-srto
22680-3,mercury/creatinine (u) [molar ratio]
22680-3,ratio] (u) [molar mercury/creatinine
22680-3,hg mcury/cratiine ratio] molar (u)
43162-7,monochloramine [mass/volume] in water
43162-7,monochloramine [assvolume] in water
43162-7,monochloramine [mass/volume] water random in
43162-7,monochloramine wat-mcnc
43162-7,mnochamine wat-mcnc
43162-7,monochloramine drug/toxicology wat-mcnc
43162-7,monochloramine (water) [mass/vol]
43162-7,[mass/vol] drug/toxicology (watr) monochloramine
43162-7,monochloramine massvol] (water)
63537-5,muscle specific receptor tyrosine kinase igg ab [mass/volume] in serum by immunoassay
63537-5,muscle specific receptor tyrosine kinase igg ab immunoassay in serum by [mass/volume]
63537-5,muscle specific receptor serum tyrosine kinase igg ab [mass/volume] in serum by immunoassay
63537-5,musk igg ser ia-mcnc
63537-5,musk ia-mcnc rec ser igg
63537-5,musk igg ser ia-mcnc
63537-5,muscle specific receptor tyrosine kinase igg ia (s) [mass/vol]
63537-5,muscle specific receptor [mass/vol] kinase igg ia (s) tyrosine
63537-5,musclescific recetr tyroseknase gg [mass/vol] (s) ia
43179-1,asialoganglioside gm1 igm ab [titer] in serum by immunoassay
43179-1,asiloganglioside eum igm ab [titer] n gm1 elisa by munoasay
43179-1,asialoganglioside ab igm meia gm1 [titer] in serum by immunoassay
43179-1,gm1 asialo igm titr ser ia
43179-1,gm1 dilution factor (titer) asialo igm titr ser ia
43179-1,ia asialo igm titr ser gm1
43179-1,asialoganglioside gm1 igm ia (s) [titer]
43179-1,(s gm igm ia aialogagliosde elisa titer]
43179-1,asialoganglioside gm1 igm ia (s) [titer]
6376-8,cytomegalovirus ag [presence] in serum or plasma by immunoassay
6376-8,cytomegalovirus ag [presence] in serpl by immunoassay
6376-8,[presence] ag cytomegalovirus in serum serpl or plasma by immunoassay
6376-8,cmv ag serpl ql ia
6376-8,cmv a ia srpql infectiousdisease
6376-8,cmv ag id serpl presence ia
6376-8,cmv ag ia ql
6376-8,ag cmv ia ql
6376-8,cmv ag ia ql
102061-9,"4,8-dioxa-3h-perfluorononanoate [mass/volume] in serum or plasma by lc/ms/ms"
102061-9,"4,8-dioxa-3h-perluoronoanoate [as/volum] inserum or plasa by lc/ms/ms"
102061-9,"4,8-diox-3h-perluorononnoate lc/s/m i serumor plamaby [mass/volume]"
102061-9,adona serpl lc/ms/ms-mcnc
102061-9,adona lc/ms/ms-mcnc serpl
102061-9,adona lc/ms/ms-mcnc serpl
102061-9,"4,8-dioxa-3h-perfluorononanoate lc/ms/ms [mass/vol]"
102061-9,"4,-doxa-3h-perfluoronnanot serpl c/ms/ms [mass/vol]"
102061-9,"4,8-dioxa-3h-perflornonanoat lc/ms/ms [mass/vol]"
16566-2,cefazolin [mass/volume] in urine
16566-2,cefazolin in [mass/volume] urine
16566-2,[mass/volume] cefazolin in level urine
16566-2,cefazolin ur-mcnc
16566-2,-mcnc cefazolin level
16566-2,ur-mcnc cefazolin
16566-2,cefazolin (u) [mass/vol]
16566-2,(u) drugs cefzoin [mass/vo]
16566-2,(u) cefazolin [mass/vol] ur
88921-2,echinococcus granulosus ab [titer] in serum by complement fixation
88921-2,echinococcus in ab [titer] granulosus serum by antibodies complement fixation
88921-2,echinococcus granulosus ab [titer] by ser in complement fixation
88921-2,e granulosus ab titr ser cf
88921-2,titr ab egranulosus er cf
88921-2,e granulosus ab titr cf autoantibodies ser
88921-2,e. granulosus ab cf (s) [titer]
88921-2,e. graulosus cf b complement fixation s)[titer]
88921-2,e. (s) ab cf granulosus id [titer]
46208-5,deprecated nursing notes
46208-5,deprecated findings nursing notes
46208-5,deprecated notes nursing document
46208-5,deprecated
46208-5,attach.clinrpt deprecated
46208-5,deprecated finding
41476-3,rickettsia rickettsii igg ab [presence] in serum by immunoassay
41476-3,iggab rickettsii ricketsa r rickettsi [prsence] inserum b immnoassy
41476-3,eum rickettsii igg b [presene]in rickttsia b immunoassa
41476-3,r rickettsi igg ser ql ia
41476-3,r rickettsi igg serql a
41476-3,ig ricketsi serum q ricket ia
41476-3,r. rickettsii igg ia ql (s)
41476-3,r. rickettsii igg (s) ql ia
41476-3,r. ql igg ia rickettsii (s)
42484-6,protein.monoclonal/protein.total in 24 hour urine by electrophoresis
42484-6,protein.monoclonal/protein.total in urine hour 24 by electrophoresis
42484-6,protein.monoclonal/protein.total hour 24 in urine by electrophoresis
42484-6,m protein 24h mfr ur elph
42484-6,m protein 24h mfr elph ur
42484-6,m protein24h mfr quantitative ur elph
42484-6,protein.monoclonal elph (24h u) [mass fraction]
42484-6,prtein.mooclonal elph (4h) [mass qnt fractin]
42484-6,protein.mooclonal pr elph u) (24h [mass fraction]
101924-9,transforming growth factor beta 1 [mass/volume] in urine by immunoassay
101924-9,elisa transforming growth factor beta 1 [mass/volume] in urine by immunoassay
101924-9,transforming growth factor beta 1 [mass/volume] in urine by immunoassay
101924-9,tgf-beta-1 ur ia-mcnc
101924-9,tg-beta-1 r ia-mcnc
101924-9,tgf-beta-1 elfa ia-mcnc ur
101924-9,transforming growth factor beta 1 ia (u) [mass/vol]
101924-9,transforming growth factor beta 1 ia (u) [mass/vol]
101924-9,transorming growth factor eta ia (u) i [ass/vol]
26796-3,oxalate [presence] in urine
26796-3,urine [ql] in oxalate
26796-3,oxalate [presence] urine in
26796-3,oxalate ur ql
26796-3,ua oxalate presence u
26796-3,oxalate ethanedioate ur ql
26796-3,oxalate ql (u)
26796-3,oxalate (u) ql
26796-3,oxalate (u) ql
91068-7,enterovirus rna [presence] in stool by naa with probe detection
91068-7,detection rna [presence] in stool by naa with probe enterovirus
91068-7,3sr sr entervirusrna etection in stool by naa wit pobe [presence
91068-7,ev rna stl ql naa+probe
91068-7,ev infectious disease rna stl ql naa+probe
91068-7,stl rna ev ql naa+probe
91068-7,enterovirus rna naa+probe ql (stl)
91068-7,enterovirus rna naa+probe random ql (stl)
91068-7,eteroirus rna aa+robe  (stl)
5376-9,thermoactinomyces candidus ab [units/volume] in serum
5376-9,thermoactinomyces candidus ab [units/volume] in ser
5376-9,thermoactinomyces arbitrary concentration candidus ab [units/volume] serum in
5376-9,t candidus ab ser-acnc
5376-9,t candidus ab serum-acnc
5376-9,t candidus ab ser-acn
5376-9,t. candidus ab qn (s)
5376-9,t. ab andids qn point in time (s)
5376-9,ab candius id t. qn()
104724-0,streptococcus agalactiae dna [presence] in specimen by molecular genetics method
104724-0,in agalactiae dna [presence] streptococcus specimen by molecular genetics spec method
104724-0,streptococcus agalactiae dna [presence] in specimen by molecular genetics molecular genetics method
104724-0,gp b strep dna spec ql
104724-0,gp b strep strep dna presence spec
104724-0,strep gb strepdnaspec ql
104724-0,s. agalactiae dna molgen ql (specimen)
104724-0,s. aaactiae na molgen ql (ecimen)
104724-0,s. agalactiae dna molgen presence (specimen)
3744-0,meperidine [presence] in serum or plasma
3744-0,meperide [presece] in srum or pasma
3744-0,alodan [presence meperidine inserum or plasma
3744-0,meperidine serpl ql
3744-0,eperiine serpl ql serpl
3744-0,l eperidinesepl
3744-0,meperidine ql
3744-0,ql meperid
3744-0,meeridine ql
59189-1,methyl ethyl ketone/creatinine [molar ratio] in urine
59189-1,ethyl methyl ketone methyl ethyl ktoe/creatinine [oar ratio] urine in
59189-1,quantitative [molar ketne/creatinine ethylethyl rato] in rine
59189-1,mek/creat ur-srto
59189-1,drug/toxicology mek/crat ur-srto
59189-1,r-sto mek/creat
59189-1,methyl ethyl ketone/creatinine (u) [molar ratio]
59189-1,ketone/creatinine ethyl methyl (u) [molar ratio]
59189-1,substance ratio metyl ethyl kocreatinine(u) rtio] [molr
74322-9,mica*043 igg ab [presence] in serum
74322-9,mica*043 igg [presence] ab in serum
74322-9,mica*043 igg in [presence] immunoglobulin g ab ser
74322-9,mica*043 igg ser ql
74322-9,mica*043 ser igg ql
74322-9,random mica*43 ql se igg
74322-9,mica*043 igg ql (s)
74322-9,immunoglobulin g mica*043 ql ig (s)
74322-9,mica*043 igg ql (s)
23255-3,mycoplasma bovis ab [presence] in serum
23255-3,mycoplasma ab qual bovis [prsence]n sum
23255-3,point in time mycoplasma bovi ab [presence] in serum
23255-3,mp bovis ab ser ql
23255-3,ser bovis ab mp ql
23255-3,mp bovi q mycoplas ser ab
23255-3,mp. bovis ab ql (s)
23255-3,mp. bovis ab aby ql()
23255-3,mp. bovis ql ab (s)
48145-7,mevalonolactone/creatinine [molar ratio] in urine
48145-7,mevalonolactone/creatinine ratio] [molar in urine
48145-7,in [molar ratio] mevalonolactone/creatinine urine
48145-7,mevalonolactone/creat ur-srto
48145-7,mevalonic acid lactone ur-srto mevalonolactone/creat
48145-7,ur-srto mevalonolactone/creat
48145-7,mevalonolactone/creatinine (u) [molar ratio]
48145-7,mevalonolactone/creatnine () [mla creat rtio]
48145-7,mevalonolactone/creatinine (u) [molar crea ratio]
35175-9,saturated fatty acids [moles/volume] in serum or plasma
35175-9,saturated fatty acids [moles/volume] serum in or plasma
35175-9,saturatedfatty acids [moles/volume in srum r plasm
35175-9,sat fa serpl-scnc
35175-9,sat serpl-scnc fa
35175-9,sat plsm serum or plasma-scnc fa
35175-9,saturated fatty acids [moles/vol]
35175-9,pt saturated acids fatty [moles/vol]
35175-9,acids fatty saturated [moles/vol]
46126-9,endomysium iga ab [presence] in serum by immunofluorescence
46126-9,endomysium iga ab [presence] in ser by immunofluorescence acif
46126-9,immunofluorescence ab[presence] in transglutaminase ser by endomysiumiga
46126-9,endomysium iga ser ql if
46126-9,edomsi serqlif iga
46126-9,iga endomysium ser ql if
46126-9,endomysium iga if ql (s)
46126-9,endomysium iga presence immunofluorescence if (s)
46126-9,endomysium iga i immunofluor ql()
71675-3,basophils/leukocytes [pure number fraction] in blood by manual count
71675-3,baophilslukocytes [pure numbe fracio] in blod by manua count
71675-3,[pure basophils/leukocytes number frction] in bd by basos anual count
71675-3,basophils nfr.df bld manual
71675-3,basophils bld nfr.df blood manual
71675-3,basopilsnfr.d mnual quantitative blood
71675-3,basophils/leukocytes manual cnt (bld) [pure # fraction]
71675-3,basophils/leukocytes manual cnt (blood) [pure # fraction]
71675-3,wb basophils/lekocytes manual ct (bld)[pure #fration]
77390-3,respiratory syncytial virus ag [presence] in nasopharynx by immunofluorescence
77390-3,respiratory syncytia vius ag [presene in naspharynx by immunoflorescene
77390-3,respiratory point in time sncyial virus ag [resen] in naspharyn b immunofluorsene
77390-3,rsv ag nph ql if
77390-3,rsv a immunofluorescence nph ql if
77390-3,rsv ag if q nph
77390-3,rsv ag if ql (nph)
77390-3,presence ag if pulmonology rsv (ph)
77390-3,rsv infectious disease if ag ql(nph)
15379-1,haemophilus influenzae b ag [presence] in urine
15379-1,[presence] influenzae b ag haemophilus ordinal in urine
15379-1,haemophilus influenzae b ag [presene] in urne
15379-1,haem influ b ag ur ql
15379-1,haem influ b ur ag ql
15379-1,haem b influ ag ur ql
15379-1,h. influenzae b ag ql (u)
15379-1,h flu h. influenzae b ag ql (u)
15379-1,h. infectiousdisease influenzae b ag (u) ql
24411-1,canine parvovirus ab [presence] in serum by hemagglutination inhibition
24411-1,canine parvovirus ab [presence] hemagglutination serum by in inhibition
24411-1,canin prvovirus ab [presece] in inhibition byhemagglutination serum
24411-1,cpv ab ser ql hai
24411-1,cpv ab serum hi ql hai
24411-1,cpv ser ab ql hai parvo virus
24411-1,canine parvovirus ab hai ql (s)
24411-1,canine parvovirus ab hai ql (s)
24411-1,canine ab parvovirus hai ql (s)
69866-2,process variables for assays - human leukocyte antigen - hla phenx
69866-2,process variables for assays panel.phenx - human leukcyte antigen - hla penx
69866-2,process variables for assays -human hen antige - ha leuocyte
69866-2,process for assays-hla phenx
69866-2,assays-hla for process phenx
69866-2,for process assays-hla phenx
80608-3,cefuroxime [mass/volume] in serum or plasma
80608-3,efuroxime[mas/volume] pl in serm or plasma
80608-3,serum [ass/volume] in efuroxime or plasma
80608-3,cefuroxime serpl-mcnc
80608-3,zinacef serpl-mcnc cefuroxime
80608-3,serpl-mcnc cefuroxime
80608-3,cefuroxime [mass/vol]
80608-3,quant cefuroxime [mass/vol]
80608-3,cefuroxime [mass/vol]
19090-0,colony count [#/volume] in urine
19090-0,abs coln count [/volume] urine in
19090-0,urine cont [/volume] in colony
19090-0,cc # ur
19090-0,random cc ur #
19090-0,ur # cc
19090-0,colony count (u) [#/vol]
19090-0,colony count (u) [#/vol]
19090-0,colony quant [#/vol] (u) count
74427-6,myelocytes.eosinophilic/leukocytes in blood by manual count
74427-6,myelocytes.eosinophilic/leukocytes in blood by count manual
74427-6,myelocytes.eosinophilic/leukocytes in blood by wb manual count
74427-6,myelocytes.eos nfr bld manual
74427-6,bldmanual nfr manl myelocytes.o
74427-6,manual nfr white bld cell bld myelocytes.eos
74427-6,myelocytes.eosinophilic/leukocytes manual cnt (bld)
74427-6,myelocytes.eosinophilic/leukocytes manual cnt random (bld)
74427-6,manual myelocytes.eosinophilic/leukocytes cnt (bld)
85750-8,streptococcus pneumoniae danish serotype 23a dna [cycle threshold #] in specimen by naa with probe detection
85750-8,streptococcus pneumoniae danish serotype 23a dna [cycle threshold #] in specimen by naa with probe detection
85750-8,qbr streptococcus pneumoniae danish serotype 23a dna [cycle threshold #] in specimen by naa with probe detection
85750-8,s pneum da 23a dna ct spec qn naa+probe
85750-8,spec pneum da 23a dna ct s qn naa+probe
85750-8,s pneum da 23a dna ct spec qn naa+probe
85750-8,s. pneumoniae danish type 23a dna naa+probe (specimen) [threshnum]
85750-8,s. naa+probe danish type id 23a dna pneumoniae (specimen) [threshnum]
85750-8,s. pneumonae danish ype 3a dna na+prbe (spcien[threshnum]
71391-7,cms - eye exam panel
71391-7,cms eye pane exam
71391-7,cms pnel eye pt eam -
101216-0,hantavirus sin nombre igm ab [presence] in serum or plasma by line blot
101216-0,hantavrus sinnombre igm ab [prsence] in serum or plasma ylie blot
101216-0,hantavirus sin nombre igm ab [presence] qual in serum or plasma by line blot
101216-0,snv igm serpl ql line blot
101216-0,nv serpl igmserpl lne l blo
101216-0,snv sr igm serpl ql line blot
101216-0,hantavirus sin nombre igm line blot ql
101216-0,hantavirus sin ql igm line blot nombre
101216-0,hantavirus snv sin nombre igm line blot ql
2830-8,potassium renal clearance in 24 hour urine and serum or plasma
2830-8,clearance renal potassium in 24 hour urine and serum or 24hr plasma
2830-8,potassium renal in clearance 24 hour urine and serum or plasma
2830-8,potassium cl 24h ur+serpl-vrate
2830-8,potassium 24h cl ur+serpl-vrate
2830-8,potassium cl ur+serpl-vrate 24h
2830-8,potassium renal clearance (24h u+s/p) [vol/time]
2830-8,potassium rnalclearane serpl (24h u+s/p) [vol/time]
2830-8,potassium renal clearance (24h u+s/p) [vol/time]
5181-3,hepatitis a virus igm ab [units/volume] in serum by immunoassay
5181-3,patitis avirus i ab [units/volume] in serum byimmunossay
5181-3,hepatitis a virus igm ab [units/volume] in serum quantitative by immunoassay
5181-3,hav igm ser ia-acnc
5181-3,enzyme immunoassay hav im sr ia-cnc
5181-3,hav igm ser random ia-acnc
5181-3,hav igm ia qn (s)
5181-3,hav ia igm qn (s)
5181-3,hav igm ia qn (s)
75105-7,fatty acids.very long chain c26:1 (hexacosenoate) [entitic substance] in red blood cells
75105-7,fatty acids.very long chain c26:1 (hexacosenoate) [entitic substance] in red bld cells
75105-7,in acids.very long chain c26:1 (hexacosenoate) [entitic substance] fatty red blood cells
75105-7,vlcfa c26:1 entsub rbc
75105-7,erythrocytes vlcfa c26:1 entsub rbc
75105-7,vlcfa c26:1 entsub rbc vlc
75105-7,fatty acids.very long chain c26:1 (hexacosenoate) (rbc) [entitic substance]
75105-7,(rbc) acids.very long chain c26:1 (hexacosenoate) fatty quan [entitic substance]
75105-7,fatt qnt acids.ver long chain c26:1 (exacosenoate) (rbc) [entitic substance]
22496-4,rubella virus ab [presence] in serum
22496-4,rubella virus ab [pesence] in serum anti
22496-4,rubella viusab [presencein ser
22496-4,rubv ab ser ql
22496-4,rubv ab serum ql sr
22496-4,universallaborders serql ab rubv
22496-4,rubella virus ab ql (s)
22496-4,rubella screen ab virus presence ()
22496-4,rubella virus ql ab (s)
96403-1,renal clearance and renal plasma flow panel - urine and serum or plasma
96403-1,renal clearance and renal plasma flow panel - urine and serum or plasma
96403-1,renal clearance and renl plas low urn pan - urie and serumor lasma
96403-1,renal cl + rpf panel ur+serpl
96403-1,cl dynamic enal rpf panel ur+serpl
96403-1,renalc ur+srpl rpf pnel +
96403-1,renal clearance and renal plasma flow panel (stdy u+s/p)
96403-1,renal clearance and renal plasma flow panel (stdy u+s/p)
96403-1,renal clearance and renal plas flow panel (stdy u+s/p) quant
51982-7,lamotrigine [presence] in serum or plasma
51982-7,lamotrigine [presence] in ser or plasma
51982-7,lamorigine serplas presnce] in serum or plasma
51982-7,lamotrigine serpl ql
51982-7,lamotrgine sp drugs l
51982-7,lamotrigine serpl ql
51982-7,lamotrigine ql
51982-7,presence lamotrigine
51982-7,lamotrigine ql plsm
72260-3,phosphorylated tau 181 [mass/volume] in cerebral spinal fluid by immunoassay
72260-3,phosphorylated tau phospho t181 181 [mass/volume] in cerebral spinal fluid by immunoassay
72260-3,phosphorylated by 181 [mass/voume]n cerebral pinalflui tau mmunossay
72260-3,p-tau181 csf ia-mcnc
72260-3,p-tau181 csf ia-mcc mass concentration
72260-3,p-tau181 csf ia-mcnc
72260-3,phosphorylated tau 181 ia (csf) [mass/vol]
72260-3,phosphorylated point in time tau 181 ia (csf) [mass/vol]
72260-3,posporlated 181 tau ia (csf) [mss/vol] prot
45220-1,lymphocytic choriomeningitis virus igm ab [presence] in serum
45220-1,lymhoytic choriomeningitis infectiousdisease virus rum ab [presence] in igm
45220-1,in choriomeningitis virus igab[presenc lymphocytc immune globulin m serum
45220-1,lcmv igm ser ql
45220-1,lcmv ser igm ql
45220-1,id lcmv igm ser ql
45220-1,lymphocytic choriomeningitis virus igm ql (s)
45220-1,lymphocytic choriomeningitis virus igm ql (s)
45220-1,ymphocytic virusigm hoiomeningti l (s)
82465-6,mosquito identified [type] in environmental specimen
82465-6,in identified [type] mosquito environmental specimen
82465-6,mosquito ientifie [typ] in environmental spcimen
82465-6,mosquito environ spec
82465-6,spec random environ mosquito
82465-6,mosquito environ id spec
82465-6,mosquito identified nom (environmental specimen)
82465-6,specimen) identified nom (environmental mosquito
82465-6,msquio idntified nom secimen enirnental
74409-4,mica igg panel - serum
74409-4,mica - panel igg serum
74409-4,igg mica panel - serum
74409-4,mica igg pnl ser
74409-4,pnl igg mica serum
74409-4,igg mica pnl ser mica igg pnl
74409-4,mica igg panel (s)
74409-4,ic igg panel (s) pnl
74409-4,(s) serology igg panel mica
100843-2,liver fibrosis score in serum or plasma by calculated.agile3+
100843-2,by fibrosis score in ser or plasma liver calculated.agile3+
100843-2,liverfirosis score inserum or plaa by calculated.gle3+
100843-2,liver fibr score serpl agile3+
100843-2,lver fibr serplaie3 score
100843-2,liver agile3+ random score serpl fibr
100843-2,liver fibrosis score calculated.agile3+ [score]
100843-2,liver fibrosis pl score calculated.agile3+ [score]
100843-2,liverfibois core calculate.agile3+ [score]
33709-7,clostridium botulinum toxin a [presence] in specimen
33709-7,clostridium c bot tox botulinum toxin a [ql] in specimen
33709-7,clstridim botulinumti a [pesenc] i spcime
33709-7,c bot tox a spec ql
33709-7,presence bot qualitative tox a spec c
33709-7,c ot spec a misc tx ql
33709-7,c. botulinum toxin a ql (specimen)
33709-7,c. (specimen txin a presence otulinum
33709-7,c. botulinum toxin a presence (specimen) point in time
55898-1,immunoglobulin light chains.free [presence] in serum by immunofixation
55898-1,immunoglobulin lightchains.free [presence by serum in mmunofixaton
55898-1,immunoglobulin light chains.free [presence] immunofixation serum by in
55898-1,bj protein free ser ql ife
55898-1,ser protein free bj ql ife
55898-1,protein bj free ser ql bjp ife
55898-1,immunoglobulin light chains.free immunofixation ql (s)
55898-1,light immunoglobulin chains.free immunofixation ql (s)
55898-1,imuoglobuli ight cains.free munofixation ql (s)
3953-7,phenothiazines [presence] in urine
3953-7,phenothiazine in [presence] rine
3953-7,phenothiazines inurin [presene]
3953-7,phenothiaz ur ql
3953-7,ql ur phenothiaz
3953-7,phenothiaz phenothiazn ur l
3953-7,phenothiazines ql (u)
3953-7,pheothiazines  (u)
3953-7,(u) ql phenothiazines
38430-5,ibuprofen [mass/volume] in serum or plasma --1 hour post dose
38430-5,ibofen [mass/volue in serum r pma--1 hour postdose
38430-5,--1 60 min inserum or plsma ibuprofen[mas/volum] our post ose
38430-5,ibuprofen 1h p serpl-mcnc
38430-5,ibuproen serpmcnc p 1h
38430-5,iburofen 1h p sepl-mcnc
38430-5,ibuprofen 1 hr post dose [mass/vol]
38430-5,post 1 hr ibuprofen dose serp [mass/vol]
38430-5,ibuprofen 1 hr post [mass/vol] dose
27167-6,chlamydia trachomatis igm ab [titer] in cerebral spinal fluid by immunofluorescence
27167-6,clamyia trachomats igm ab [titer] n titer cerebral spinl fluid by immnofluoresence
27167-6,chlamydia trachomatis igm ab [titer] in cerebral spinal fluid by immunofluorescence
27167-6,c trach igm titr csf if
27167-6,c trah igmtitr if csf
27167-6,c trach igm tit csf if
27167-6,c. trachomatis igm if (csf) [titer]
27167-6,c. trachomats im if (cs) [titer]
27167-6,c (csf) if rachomaisigm [titer]
74806-1,lithium [moles/volume] in serum or plasma --trough
74806-1,lithiu in [molevolume qnt serum or plasma --tou
74806-1,lithium [moles/volume] in lithane --trough or plasma serum
74806-1,lithium trough serpl-scnc
74806-1,trough lithium serum or plasma-scnc point in time
74806-1,lithium trough serpl-scnc
74806-1,lithium trough [moles/vol]
74806-1,plsm trough lithium [moles/vol]
74806-1,point in time lithiumtroh[moles/vol]
10898-5,eastern equine encephalitis virus igm ab [titer] in serum by immunofluorescence
10898-5,eastern equine encephalitis virus igm ab [titer] in ser by immunofluorescence
10898-5,ester euine encepalitis virus id igmb [iter] inseum by immunofuorescence
10898-5,eeev igm titr ser if
10898-5,eeev igm titr enc ser if
10898-5,if eee virus gm titr sr eeev
10898-5,eeev igm if (s) [titer]
10898-5,eeev igm if (s) [titer]
10898-5,eeev igm i (s) [titer]
59920-9,lamotrigine [moles/volume] in gastric fluid
59920-9,lamotrigine [moles/volume] gastric in fluid
59920-9,in [mole/volum lamotrigine gastrc gastric contents flud
59920-9,lamotrigine gast-scnc
59920-9,gastscnc random lamotrigine
59920-9,gast-scnc lamotrigine
59920-9,lamotrigine (gast fld) [moles/vol]
59920-9,lamotrigiegast moles/vol] fld)
59920-9,lamotrigine drugs fld) (gast [moles/vol]
23509-3,trypanosoma equiperdum [presence] in body fluid by light microscopy
23509-3,tranosoma lght in bodyfluid by equiperdum[presence] microcopy
23509-3,trypanosoma light [presence] in body fluid by equiperdum microscopy
23509-3,t equiperdum fld ql micro
23509-3,t equiperdum ql fld micro
23509-3,l ld eqipedum micro
23509-3,t. equiperdum lm ql (body fld)
23509-3,t. equiperdum presence lm (body fld)
23509-3,equiperdum t. lm ql body covering disease l)
97535-9,gas panel - central venous blood
97535-9,gas pnel  central venou lood
97535-9,as pane - venous centra blood qnt
97535-9,gas pnl bldcv
97535-9,bldcv pnl gas
97535-9,gas n bldcv
97535-9,gas panel (bldcv)
97535-9,as panel panl (bldcv)
97535-9,gas (bdcv) random panl
14056-6,"carbamazepine 10,11-epoxide free [mass/volume] in serum or plasma"
14056-6,"carbamazepine 10,11-epoxide free [mass/volume] in serpl"
14056-6,carbmazepin 1011-epoxiefre mss/volume] in serum r plasma
14056-6,carbamazepine ep free serpl-mcnc
14056-6,aramazepine ep quantitative free serpl-mcnc
14056-6,carbamazepine ep free serpl-mcnc serp
14056-6,"carbamazepine 10,11-epoxide free [mass/vol]"
14056-6,"carbamazepine free 10,11-epoxide [mass/vol]"
14056-6,"crbamazepin carbamezapine 10,11epxide re[mass/vol]"
60334-0,thiocyanate [moles/volume] in specimen
60334-0,thiocyanate [moles/volume] specimen in
60334-0,thiocyanate [moles/volume] in specimen quant
60334-0,thiocyanate spec-scnc
60334-0,spec-scnc thiocyanate
60334-0,spec-snc thicyaate
60334-0,thiocyanate (specimen) [moles/vol]
60334-0,[moles/vol] (spcen) thiocaate
60334-0,(secimen[moes/vol] thiocyanate
29369-6,n-acetylprocainamide/procainamide [mass ratio] in serum or plasma
29369-6,n-acetylprocainamide/procainamide mass ratio] or acecainide serum in plama
29369-6,n-acetylprocainamide/procainamide [mass or in serum ratio] plasma
29369-6,napa/pa serpl
29369-6,serpl nap/pa
29369-6,npapa sr epl
29369-6,n-acetylprocainamide/procainamide [mass ratio]
29369-6,[mass serpl n-acetylprocainamide/procainamide ratio]
29369-6,n-acetylprocainamide/procainamide pl ratio] [mass
95224-2,myelocytes/leukocytes in stem cell product by manual count
95224-2,cell in stem myelocytes/leukocytes product by manual count
95224-2,mylocts/eukocytes n stem count producbymanual cell
95224-2,myelocytes nfr stem prod manual
95224-2,myelocyts nfr stem rod anual quant
95224-2,mylocytes nfr ste pr wbc mnua
95224-2,myelocytes/leukocytes manual cnt (stem cell product)
95224-2,myelocytes/leukocytes (stem cnt manual cell product)
95224-2,cnt manual myelocytes/leukocytes (stem cell product)
93244-2,complement sc5b-9 [mass/volume] in serum or plasma by immunoassay
93244-2,complement elfa sc5b-9 [mass/volume] nserum or plasmaby immuoassay
93244-2,complement sc5b-9 [mass/volume] by ser or plasma in immunoassay
93244-2,sc5b9 serpl ia-mcnc
93244-2,scb9 erpl ia-mn
93244-2,serpl sc5b9 ia-mcnc
93244-2,complement sc5b-9 ia [mass/vol]
93244-2,complement sc5b-9 eia ia [mass/ol]
93244-2,complement sc5b-9 plas ia [mass/vol]
22219-0,coxsackievirus a7 ab [titer] in cerebral spinal fluid
22219-0,coxckieirus a7 in titer] ab point in time cerebral spinal fluid
22219-0,coxsakevirus a7 a[titer] i cerebral spinal fluid
22219-0,cv a7 ab titr csf
22219-0,7 v ab titr csf
22219-0,cv a7 ab titr spinal flu csf
22219-0,coxsackievirus a7 ab (csf) [titer]
22219-0,coxsackievirus (csf) ab a7 [titer]
22219-0,coxsckievirus a7 ab(cf)[tier]
62280-3,phenx - caffeine protocol 050301
62280-3,caffeine caffn - phenx protocol 050301
62280-3,phenx protocol caffeine - 050301
62280-3,phenx - caffeine protocol
62280-3,phenx - caffeine protocol
62280-3,phen caffeine point in time protool
88223-3,francisella sp dna [presence] in aspirate by naa with probe detection
88223-3,francisella sp dna [ql] in aspirate probe id naa with by detection
88223-3,fancsla sp dna [preence] in aspirate by naa probe with detection
88223-3,francisella sp dna aspirate ql naa+probe
88223-3,probe with ampification francisela sp dna aspirate ql aa+prbe
88223-3,francisella sp dna aspirate amplification ql naa+probe
88223-3,francisella sp dna naa+probe ql (asp)
88223-3,francisella ql dna naa+probe sp (asp)
88223-3,fraisella sp dna naa+probeql (asp)
35094-2,blood pressure panel
35094-2,blood pressure panel
35094-2,panel pressure blood panel.bp
35094-2,bp pnl
35094-2,bp pnl
35094-2,pan pnl bp
59464-8,microbiologist review of results
59464-8,microbiologist review results of interpretation
59464-8,microiologist f reviw impressions result
59464-8,microbiologist review
59464-8,microbiology microbiologist review
59464-8,review misc microbiologist
59464-8,microbiologist review [interp]
59464-8,pt micobiologist review [inter]
59464-8,microbiologist [interp] review
17565-3,salmonella typhi h d ab [presence] in serum by latex agglutination
17565-3,salmonella by h d ab [presence] in serum typhi latex agglutination
17565-3,salmonella typhi h d ab [presence] by ser in latex agglutination
17565-3,s typhi h d ab ser ql la
17565-3,styphihd ab ql serum a
17565-3,s typhi d ab pr sr presence la
17565-3,s. typhi h d ab la ql (s)
17565-3,s. typh h typhoid d ab la ql (s)
17565-3,s. typhi aby h d (s) la ql ab
23557-2,vesicular stomatitis virus ag [presence] in skin by immunoassay
23557-2,viruag stomatitis icular [presence in skn b immunoassay
23557-2,vesicular stomatitis in ag [presence] virus skin by immunoassay
23557-2,vsv ag skin ql ia
23557-2,vsv qlia gski
23557-2,vsv ag skin ql qual ia
23557-2,vesicular stomatitis virus ag ia ql (skin)
23557-2,vesicular stomatitis (skin) ag ia ql virus skn
23557-2,vesiclar toatitis pr virs ag ia ql(skin
56972-3,prolactin [mass/volume] in serum or plasma --post precipitation
56972-3,prolactin [mass/volume] serpl in serpl --post precipitation
56972-3,prolacin [mass/volume] in serumr plasma --post peciitation after
56972-3,prolactin post precipitation serpl-mcnc
56972-3,prolactin post precipitation serpl-mcnc
56972-3,prolactin serpl-mcnc precitation post
56972-3,prolactin post precipitation [mass/vol]
56972-3,serpl prolactin post precipitation [mass/vol]
56972-3,serp prlactin ost pecipitation [mas/vol]
3131-0,xanthine [mass/volume] in serum
3131-0,xanthine [mass/volume] in quan ser
3131-0,serum in anthie[mass/volum] quan
3131-0,xanthine ser-mcnc
3131-0,xathne ser-mcnc
3131-0,random ser-mcnc xantine
3131-0,xanthine (s) [mass/vol]
3131-0,xnthine (s) [mass/vol]
3131-0,xanthine (s) [mass/vol]
4121-0,amobarbital [mass] of dose
4121-0,amobarbital [mass] of dose
4121-0,amobarbital [mass] dose of amobarb
4121-0,amobarbital dose
4121-0,aobarbitl dose
4121-0,amobarbital amytal dose
4121-0,amobarbital (dose) [mass]
4121-0,(dose) amobarbital [mass]
4121-0,[mass] (dose) amobarbital
78918-0,7-hydroxyquetiapine [z-score] in urine
78918-0,ine [-scor]in -hdroxyquetiape
78918-0,7-hydroxyquetiapine urine in [z-score]
78918-0,7oh-quetiapine z-score ur
78918-0,ur z-score 7oh-quetiapine
78918-0,ur z-score qnt 7oh-quetiapine
78918-0,7-hydroxyquetiapine (u) [z-score]
78918-0,7-hydroxyquetiapine [z-score] (u)
78918-0,() 7-hydroxyquetiapine z-score]
91782-3,respiratory syncytial virus [presence] in lower respiratory specimen by organism specific culture
91782-3,respiratory syncytial virus [ql] inlowerrspiraty pecimenbyorganis pecifi culure
91782-3,respiratory breathing syncytial virus [presence] in lower respiratory specimen by organism specific culture
91782-3,rsv lower resp ql cult
91782-3,rsv lower resp presence cult
91782-3,sv wr resp qlcult
91782-3,rsv org specific cx ql (lower resp)
91782-3,rsv resp) specific cx ql (lower rsv org
91782-3,rsv org specific cx lower resp presence (lower resp)
14628-2,bile acid [moles/volume] in serum or plasma
14628-2,bile aci [moles/volume]in seru or point in time plasma
14628-2,bile acid [moles/volume] in serum serp or plasma
14628-2,bile ac serpl-scnc
14628-2,serp-scnc ac bile
14628-2,bile serpl-scnc ac serp
14628-2,bile acid [moles/vol]
14628-2,ile [mols/vol] chemistry aid
14628-2,[moles/vol] acid bile
23504-4,tritrichomonas foetus dna [presence] in specimen by naa with probe detection
23504-4,tritrichomonas foetus dna in [presence] specimen by naa with probe detection
23504-4,ritrihomona fotus dn presenc] naa specimen lat b in th prbe deectin
23504-4,t foet dna spec ql naa+probe
23504-4,tfoet daspec ql aa+prob to be specified in another part of the message
23504-4,t foetdna spec polymerase chain reaction l naa+probe
23504-4,t. foetus dna naa+probe ql (specimen)
23504-4,t. foetus to be specified in another part of the message dna naa+probe (specimen) ql
23504-4,t. foetus dna naa+probe presence (specimen)
34374-9,serotonin/creatinine [molar ratio] in urine
34374-9,ratio] [molar serotonin/creatinine in urine
34374-9,erotonin/creatinine[molarrato] urne in urn
34374-9,serotonin/creat ur-srto
34374-9,ur-srto serotonin/creat
34374-9,quan ur-srto serotonin/creat
34374-9,serotonin/creatinine (u) [molar ratio]
34374-9,serotonin/creatinine (u) ratio] [molar
34374-9,sertonin/creatinine [molar (u) ato]
9832-7,cholesterol in hdl 2 [mass/volume] in serum or plasma
9832-7,cholesterol in hdl 2 [mass/volume] in ser or plasma
9832-7,chlestrol i hdl [mass/volue] quantitative in serpl
9832-7,hdl2c serpl-mcnc
9832-7,hdl2c serpl-mcnc
9832-7,serpl-mcnc hdl2c
9832-7,cholesterol in hdl 2 [mass/vol]
9832-7,clserol in hdl2 cardio mss/vol]
9832-7,cholesterolin quantitative hdl [mass/vol] 2
80183-7,xanthopterin [moles/volume] in serum or plasma
80183-7,xntopterin [moles/volume in serumor plasma
80183-7,xanthopterin plasma in pterins serum or [moles/volume]
80183-7,xanthopterin serpl-scnc
80183-7,serpl-scnc xanthopterin bh4 deficiency
80183-7,serpl-scnc xanthopterin
80183-7,xanthopterin [moles/vol]
80183-7,xanthoterin [moles/vo] serum
80183-7,xanthoterin [moles/vol]
25850-9,ammonia [moles/volume] in 24 hour urine
25850-9,mona hururine moles/volum]in2
25850-9,ammonia [moles/volume] urine 24 hour in
25850-9,ammonia 24h ur-scnc
25850-9,24h ammonia quan ur-scnc
25850-9,ammonia ur-scn 24h chemistry
25850-9,ammonia (24h u) [moles/vol]
25850-9,u) (24h ammonia [moles/vol]
25850-9,ammonia [moles/vol] u) ammon (24h
87454-5,potassium [mass/volume] in specimen
87454-5,otassium [ms/volume] spcien vet in
87454-5,potassium specimen in [mass/volume]
87454-5,potassium spec-mcnc
87454-5,potassium spec-mcnc
87454-5,otassium spec-mcnc
87454-5,potassium (specimen) [mass/vol]
87454-5,ss/vol] (secien) potassium
87454-5,(specimen) potassium [mass/vol]
96302-5,candida auris dna [presence] by naa with non-probe detection in positive blood culture
96302-5,candida auris na [pesence by naa with non-probe detection in positive blod tma culture
96302-5,candida aurisdna [ql] y naa with n-probe in detection potive blood ulture
96302-5,c auris dna bld pos ql naa+non-probe
96302-5,c naa+non-probe dna blood pos ql auris
96302-5,c auris dna naa+non-probe pos ql blood
96302-5,c. auris dna naa+non-probe ql (pos bld culture)
96302-5,dna auris c. naa+non-probe ql (pos blood culture)
96302-5,c. ql dna naa+non-probe uri (pos bldculture)
95528-6,nida quick screen [nida]
95528-6,screen quick nida [nida]
95528-6,nida quick screen survey [nida]
74402-9,lymphocytes/leukocytes in cord blood
74402-9,lymphocytes/leukocytes in cord blood
74402-9,lymphocytes/leukocytes cord in blood
74402-9,lymphocytes nfr bldco
74402-9,gynecology lymphocytes nfr bldco
74402-9,qnt lymphocytes bldco nfr
74402-9,lymphocytes/leukocytes (bldco)
74402-9,white blood cells lympoys/leukocytes (bldco)
74402-9,lymphocytes/leukocytes lkcs (bldco)
98118-3,vascular endothelial growth factor c [mass/volume] in serum or plasma
98118-3,vascular endothelial growth ser c [mass/volume] in factor or plasma
98118-3,vascular endothelial growth factor c [mass/volume] in serum or mass concentration plasma
98118-3,vegf-c serpl-mcnc
98118-3,serpl-mcn vegfc
98118-3,serpl-mcnc vegf-c
98118-3,vascular endothelial growth factor c [mass/vol]
98118-3,vascular endothelial growth factor c [mass/vol]
98118-3,vascular endothelial growth [mass/vol] c factor
104010-4,16-item transportation security index [tsi-16]
104010-4,16tem indx security transpoation [i-16]
104010-4,16-item transportation security index [tsi-16]
92588-3,promis short form - self-efficacy for managing symptoms 8a - version 1.0
92588-3,promis short form - self-efficacy managing for symptoms 8a - version 1.0
92588-3,promis short form - self-efficacy managing for symptoms 8a - version 1.0
41637-0,ebola virus ag [presence] in specimen by immunofluorescence
41637-0,ebola virus ag anticomplement immunofluorescence [presence] in specimen by immunofluorescence
41637-0,antigen ebola virus ag [presence] in specimen by immunofluorescence
41637-0,ebov ag spec ql if
41637-0,ebov if presence anticomplement immunofluorescence agspec
41637-0,to be specified in another part of the message ag ebov spe ql f
41637-0,ebola virus ag if ql (specimen)
41637-0,ag vius ebola if ql (spcimen)
41637-0,ebola ql ag anticomplement immunofluorescence if virus (specimen)
2245-9,estradiol (e2) [moles/mass] in tissue
2245-9,chemistry estradiol (e2) [moles/mass] in tissue
2245-9,estradiol (e2)[moles/mass] isse tissue in
2245-9,estradiol tiss-scnt
2245-9,tiss-cnt estradiol
2245-9,estradiol tiss-scnt
2245-9,e2 (tiss) [moles/mass]
2245-9,[moles/mass] (tiss) e2
2245-9,qnt [moles/mass] (tiss) e2
30447-7,myelocytes/leukocytes in cerebral spinal fluid
30447-7,myelocytes/leukocytes in cerebral spinal fluid
30447-7,myelocytes/leukocytes in fluid spinal cerebral
30447-7,myelocytes nfr csf
30447-7,cerebrospinal fluid hematology/cell counts nfr myelocytes
30447-7,nfr myelocytes csf
30447-7,myelocytes/leukocytes (csf)
30447-7,(csf) melocytesleukocytes spinal fl
30447-7,(csf) myelocytes/leukocytes
77953-8,west nile virus igg ab [presence] in cerebral spinal fluid by immunoassay
77953-8,[presence] nile virsig a west in cerebral spinal fluid immune globulin g bimmunoassay
77953-8,west nile virus igg ab [ql] spinal cerebral in fluid by immunoassay
77953-8,wnv igg csf ql ia
77953-8,wnv iggcf antibody ia ql
77953-8,wnv igg csf ql ia enzyme immunoassay
77953-8,west nile virus igg ia ql (csf)
77953-8,westnile ia ig vrus ql (csf)
77953-8,west virus nile neurology igg ia ql (csf)
73041-6,ceftriaxone induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73041-6,ceftriaxone induced neutrophil igm ab [presence] in (neut) ab serum or flow by plasma cytometry (fc)
73041-6,ceftriaxone inued neutrophil igm neut b[presene in serumor plsma y flow ctometry (fc)
73041-6,ceftriaxone (neut) igm serpl ql fc
73041-6,ceftriaxone (neu) ql serpl igm fc
73041-6,ceftriaxone (neut) igm point in time serpl ql fc
73041-6,ceftriaxone induced neutrophil igm fc ql
73041-6,ceftiaxone induced l igm fc neutrophil
73041-6,ceftrixoneinduced neuthil gm fc l
56548-1,u1 small nuclear ribonucleoprotein igg ab [units/volume] in serum by immunoassay
56548-1,u1 small nuclear ribonucleoprotein igg ab qnt [units/volume] in ser by immunoassay
56548-1,in small nuclear ribonucleoprotein igg ab [units/volume] u1 serum elfa by immunoassay
56548-1,u1 snrnp igg ser ia-acnc
56548-1,ia-acnc snrnp igg serum u1
56548-1,u1 snrnp igg ser ia-acnc
56548-1,u1 small nuclear ribonucleoprotein igg ia qn (s)
56548-1,u1 sallclearribocleprotein igg ia qn (s)
56548-1,nuclearribonuleoproteinig u1small a quantitative qn (s)
64394-0,phenx - perceived stress protocol 180801
64394-0,phex perceived - stres potocol18801 random
64394-0,phenx perceived - stress protocol 180801
64394-0,perceived stress proto
64394-0,erceivedstressproto point in time
64394-0,stressroto pceived panel
76496-9,complement c4 [moles/volume] in serum or plasma
76496-9,omplement c4 [moles/volume] in serp plama serumor
76496-9,cmplement c4 [moles/volue] in srum or plasma
76496-9,c4 serpl-scnc
76496-9,c4 qnt serpl-scnc
76496-9,c4 serpl-scnc
76496-9,complement c4 [moles/vol]
76496-9,c4 complement [moles/vol]
76496-9,complement c4 [moles/vol]
80127-4,aluminum [moles/volume] in cerebral spinal fluid
80127-4,aluminum [moles/volume] in spinal quantitative cerebral fluid
80127-4,aluminum [moles/volu] spinal crebral fluid
80127-4,aluminum csf-scnc
80127-4,csf-scnc qnt alumnm
80127-4,csf-scnc aluminum
80127-4,aluminum (csf) [moles/vol]
80127-4,aluminum (csf) drugs [moles/vol]
80127-4,aluminum (cerebrospinal fluid) aluminium [moles/vol]
12312-5,cyclopropane [mass/volume] in blood
12312-5,cyclopropane [mass/volume] in blood
12312-5,cclopropane [mass/olume] in blood random
12312-5,cyclopropane bld-mcnc
12312-5,blood-mcnc cyclopropane drugs
12312-5,cyclopropane blood-mcnc
12312-5,cyclopropane (bld) [mass/vol]
12312-5,cycloproane [ma/vol] (l)
12312-5,cyclopropane [mass/vol] (bld)
29512-1,beta hydroxybutyrate [mass/volume] in serum or plasma
29512-1,bea yroxbutyrate [mass/volume] in ser orplsa serplas
29512-1,beta hydroxybutyrate [mass/volume] in ser or plasma
29512-1,b-oh-butyr serpl-mcnc
29512-1,serpl-mcnc b-oh-butyr
29512-1,b-oh-uyr serpl-mcnc
29512-1,beta hydroxybutyrate [mass/vol]
29512-1,bet beta hydroxy butyrate [mass/vol] hydroxutyre
29512-1,[mass/vl] betahydroxybutyrte
22606-8,varicella zoster virus igm ab [titer] in serum
22606-8,varicella zoster virus igm ab [titer] in serum
22606-8,zoser varicel virus igm ab [titr] in serum
22606-8,vzv igm titr ser
22606-8,vzvigmtit ser
22606-8,igm vzv titr ser
22606-8,vzv igm (s) [titer]
22606-8,vv im (s [titer]
22606-8,[titer] vzv im(s) vzv
8050-7,venezuelan equine encephalitis virus igg ab [units/volume] in serum
8050-7,venezuelan equine encephalitis virus enc igg ab [units/volume] in serum
8050-7,venezuelan equine encephalitis [units/volume] igg ab virus in serum
8050-7,veev igg ser-acnc
8050-7,veev igg ser-acnc
8050-7,veev igg immune globulin g ser-acnc
8050-7,veev igg qn (s)
8050-7,veev igg qn (s) autoantibody
8050-7,qn igg veev (s)
104399-1,european tick borne encephalitis virus rna [presence] in cerebral spinal fluid by naa with probe detection
104399-1,europan tick borne encephlitis cerebral rna spinal fld preence] n viru spinal fluid by naawith prbe detection
104399-1,european tick borne encephalitis rna virus [presence] in cerebral spinal naat fluid by naa with probe detection
104399-1,tbev rna csf ql naa+probe
104399-1,amplif csf tbevrna ql naa+probe
104399-1,naa+probe rna csf ql tbev
104399-1,european tick borne encephalitis virus rna naa+probe ql (csf)
104399-1,eurean vrus bone encephalitis tck rna naa+probe ql (cerebrospinal fluid)
104399-1,uropan tick ql(csf) encephalitis virus rna naaprobe borne
88148-2,microscopic observation [identifier] in genital specimen by acid fast stain
88148-2,random microscopic observation [identifier] in genital specimen by acid fast stain
88148-2,micscopic observation [identifier] in ial specimen by ad fast stain
88148-2,acid fast stn genital
88148-2,acid fas genital stn
88148-2,acid stn fast genital
88148-2,microscopic observation acid fast stain nom (genital specimen)
88148-2,microscopicobservaton urogenital acid fast stain nom (genitalspecmen)
88148-2,micrscpc obervation acidfatstainno (genital specimn)
31618-2,salmonella paratyphi b h ab [units/volume] in serum
31618-2,paratphi salmonell b h point in time ab[units/volume]in serum
31618-2,salmonella paratyphi abs b h ab [units/volume] in serum
31618-2,s paraty b h ab ser-acnc
31618-2,s aat b h quan ab ser-acc
31618-2,b spary h ab ser-acnc
31618-2,s. paratyphi b h ab qn (s)
31618-2,s. paratyphi b h ab qn (s)
31618-2,s. paratyphi b h ab qn (s)
4083-2,trimipramine [mass/volume] in serum or plasma
4083-2,trimipramine [mass/volume] in ser or plasma
4083-2,trimipramine [mass/volume] in or serum plasma
4083-2,trimipramine serpl-mcnc
4083-2,trimipramine serpl-mcnc serpl
4083-2,mass concentration trmiramine serpl-mcnc
4083-2,trimipramine [mass/vol]
4083-2,mass/vol] random trimipramne
4083-2,[mass/ol] trimiramine mass concentration
56060-7,deprecated phenx measure - height
56060-7,deprecated - measure phenx height panl
56060-7,deprecated phenx measure height -
99708-0,continuous renal replacement therapy mode renal replacement therapy circuit
99708-0,continu renareplacement herapy mode ral replacemen therapy nominal circui
99708-0,continuous renal replacement therapy mode renal replacement therapy circuit random
99708-0,crrt mode rrt circuit
99708-0,crrt moderrt circuit
99708-0,kidney crrtmode rr circui
9809-5,propoxyphene [presence] in gastric fluid
9809-5,propoxyphene in [presence] gastric fluid
9809-5,propoxyphene [ql] in gastric fluid
9809-5,propoxyph gast ql
9809-5,propoxyph gast presence gastric fluid
9809-5,propoxyph ql gast
9809-5,propoxyphene ql (gast fld)
9809-5,propoxypen (gst ql fld)
9809-5,propoxyphene ql distalgesic (gast fld)
2904-1,pyrophosphate crystals [#/volume] in synovial fluid
2904-1,pyrophosphate abs [#/volume] crystals in synovial fluid
2904-1,pyrophosphate crystals in [#/volume] synovial fluid
2904-1,pyrophos cry # snv
2904-1,# cry pyrophos snv
2904-1,cry pyrophos # snv hematology/cell counts
2904-1,pyrophosphate crystals (syn fld) [#/vol]
2904-1,pyrohoshate crystals fld) (sn syn [#/vol]
2904-1,[#vol] (syn fld) pophoshaterystals
90424-3,microorganism preliminary growth detection panel - body fluid by culture
90424-3,- preliminary growth detection panel microorganism body fluid by culture
90424-3,icroorgnsm preliminary growth eection panel- bdy fluid by pnl culture
90424-3,microorg prel grow det pnl fld cult
90424-3,microorg prel grow fld pnl det cult
90424-3,microorg prel grow bod cult pnl fld det
90424-3,microorganism preliminary growth detection panel cx (body fld)
90424-3,microoraism reiminary cx(ody panel growthdetection fd) panel.microbiology
90424-3,detection preliminary growth microorganism panel cx (body fld)
43688-1,16-alpha hydroxypregnenolone/creatinine [mass ratio] in urine
43688-1,16-alpha hydroxypregnenolone/creatinine [mass ratio] in chemistry urine
43688-1,16-alpha hydroxypregnenolone/creatinine [mass ratio] in mass concentration ratio urine
43688-1,16a oh-preg/creat ur
43688-1,16a oh-preg/creat ur alfa
43688-1,16a oh-preg/creat ur
43688-1,16-alpha hydroxypregnenolone/creatinine (u) [mass ratio]
43688-1,16alha hydroxyprgnenolone/ceatnine(u [mass ratio]
43688-1,16-alpha hydroxypregnenolone/creatinine (u) [mass ratio] 16a oh-preg
35413-4,coxsackievirus a4+a16 ab [titer] in serum
35413-4,coxsackievirus a4+a16 ab [titer] serum in
35413-4,coxsackievius a4+a16ab [tit] inserum coxsackie
35413-4,cv a4+a16 ab titr ser
35413-4,id cv a4+a16 ab titr serum
35413-4,ab a4+a16 cv titr ser
35413-4,coxsackievirus a4+a16 ab (s) [titer]
35413-4,coxsackievirus a4+a16 ab (s) [titer]
35413-4,coxsackevirs a4+a1 smqn ab (s) [titer]
6464-2,microscopic observation [identifier] in cervix by gram stain
6464-2,microscopic obervaion identifier] in ervix stain bgra obgyn
6464-2,mioscopic oservation [identfier in cervx b gram stain
6464-2,gram stn cvx
6464-2,cvx stn gram
6464-2,gram cvx stn
6464-2,microscopic observation gram stain nom (cvx)
6464-2,micrococ (x) nominal stain om obsevationgrm
6464-2,microscopiobservation grm stain nm identity or presence cvx)
59584-3,coxsackievirus a7 igg ab [titer] in serum by immunofluorescence
59584-3,coxsackievirus a7 igg antibodies ab by in serum [titer] immunofluorescence
59584-3,coxskievirus a7igg random ab [iter] in serum byimmunofluorescence
59584-3,cv a7 igg titr ser if
59584-3,if a7 igg titr ser cv
59584-3,cv igg a7 titr ser if
59584-3,coxsackievirus a7 igg if (s) [titer]
59584-3,coxsackievirus a7 [titer] if (s) igg
59584-3,coxsacievirus if igg a7 (s[titer
21362-9,legionella pneumophila igg ab [titer] in serum by immunofluorescence
21362-9,antibody legionella pneumophilag ab [titer] inserm byimmunofluorecece
21362-9,leionela neumophila igg ab abs [iter] in serum by imunofluorecence
21362-9,l pneumo igg titr ser if
21362-9,point in time l pneumo igg ser tir if
21362-9,l igg pneumo titr ser if
21362-9,l. pneumophila igg if (s) [titer]
21362-9,[tite] smqn pneumohilaiggif (s) l.
21362-9,l. if igg pneumophila (s) [titer]
104759-6,dohle body [presence] in blood
104759-6,in ody [presence] bod dohle blood
104759-6,dohle inblood [presence] body
104759-6,dohle bod bld ql
104759-6,dohle bod q bd
104759-6,ql bo bld dohle bodies
104759-6,dohle body ql (bld)
104759-6,ql bod body dohle (bld)
104759-6,screen dohle body (bld) ql
5358-7,smooth muscle ab [titer] in serum by immunofluorescence
5358-7,time resolved fluorescence [titer] muscle ab smooth in serum by immunofluorescence
5358-7,smooth muscle ab [titer] in serum by immunofluorescence
5358-7,smooth muscle ab titr ser if
5358-7,ab muscle smooth titr ser if
5358-7,smooth muscle ab antibodies titr ser if
5358-7,smooth muscle ab if (s) [titer]
5358-7,smoothmuscle universallaborders a if (s [titer]
5358-7,smoot musle antby ab if (s) [iter]
15391-6,parainfluenza virus 1 igm ab [titer] in serum
15391-6,parainfluenza virus 1 igm ab [titer] in serum
15391-6,parnflunz virs 1 igmab [titer] pt in seru
15391-6,hpiv1 igm titr ser
15391-6,hpiv1 ttr igm se
15391-6,aby hpiv1 igm titr ser
15391-6,parainfluenza virus 1 igm (s) [titer]
15391-6,igm virus 1 parainfluenza (s) [titer]
15391-6,paainfluenza virus 1 [titer] (s) igm
106629-9,alcohol consumption environment
106629-9,consuption alcohol enronment
106629-9,alcohol environment consumption
106629-9,alcohol consumption envir
106629-9,envir consumption alc alcohol
106629-9,alcohol consumption envir
59676-7,flurazepam [mass/volume] in body fluid
59676-7,flurazepam [mass/volume] in fluid body
59676-7,flurazepam [mass/volume] fluid in body fluid
59676-7,flurazepam fld-mcnc
59676-7,bod fld-mcnc flurazepam
59676-7,mass concentration flurazepam fld-mcnc
59676-7,flurazepam (body fld) [mass/vol]
59676-7,fluraepam (bdy drug/toxicology fld) [massvl
59676-7,flrzepam (body fld) quant [mss/o]
95037-8,fasi v1.0 - availability of unpaid assistance during assessment period [cms assessment]
95037-8,fasi 1.0 - vailailty of unpaid urig assistance assessment period [cms asessent] panel.survey.cms
95037-8,cms v1.0 - avalabiliy of unpaid assistance dung assessment eriod fai assssmnt]
17273-4,methylephedrine [units/volume] in urine
17273-4,[units/volume] methylephedrine in urine
17273-4,in [units/volume] methylephedrine urine
17273-4,me-ephedrine ur-acnc
17273-4,meehedrine ua ur-cnc
17273-4,drugs ur-acnc me-ephedrine
17273-4,methylephedrine qn (u)
17273-4,methylephedrine qn (u)
17273-4,mthylephedrine () qn
38399-2,crystals [type] in peritoneal fluid by light microscopy
38399-2,crystas [type] in peritoneal fluid by ligt microsop
38399-2,crstls [type] micro n peritoneal fluid bylight microsopy
38399-2,crystals prt micro
38399-2,crystals prt micro
38399-2,prt crstals lm micro
38399-2,crystals lm nom (periton fld)
38399-2,crystals random lm nm(piton fld)
38399-2,crystals nom nominal lm (periton fld)
18461-4,3-hydroxypalmitoylcarnitine (c16-oh) [mass/volume] in serum or plasma
18461-4,3-hydroxypalmitoylcarnitine (c16-oh) [mass/volume] in serpl
18461-4,3-hydroxypalmitoylcarnitine (c16-oh) [mass/volume] in ser or serpl plasma
18461-4,3oh-palmitoylcarn serpl-mcnc
18461-4,serpl-mnc 3oh-palmitoylcarn
18461-4,serpl-mcnc 3oh-palmitoylcarn
18461-4,c16-oh [mass/vol]
18461-4,c16-oh[mass/vol] quant
18461-4,3-hydroxyhexadecanoylcarnitine c16-h [mass/ol]
57085-3,organic acid newborn screen panel
57085-3,organic newborn acid screen panel
57085-3,organic acid newborn screen panel
57085-3,oa nb scn pnl dbs
57085-3,oa nb dbs pnl panl scn
57085-3,oa scn nb pnl dbs
57085-3,organic acid nbs panel (dbs)
57085-3,organicacid (dbs) pael bs
57085-3,organic acid nbs oa nb scn pnl panel (dbs)
93509-8,pentacarboxylporphyrin i [moles/time] in 24 hour urine
93509-8,pentacarboxylporphyrin i [moles/time] in 24 hor urine
93509-8,entacarboxylorphyin quantitative in [oles/time i 24hour urine
93509-8,penta-cpi 24h ur-srate
93509-8,pena-cpi 24 chemistry ur-srate
93509-8,penta-cpi 24h ur-srate
93509-8,pentacarboxylporphyrin i (24h u) [moles/time]
93509-8,pentacarboxylporphyrin i (24h u) urn [moles/time]
93509-8,24hr pentacarboxylporphyrin i (24h u) [moles/time]
87978-3,fungus identified in peritoneal dialysis fluid by culture
87978-3,fungus fungi idetifid in pertoneal dialysis fluid by culture
87978-3,fugus fungi identified fluid peritonel dialyss in by cultue
87978-3,fungus diafp cult
87978-3,fungus cult dialysis fluid diafp
87978-3,fungus diafp cult id
87978-3,fungus identified cx nom (perit dial fld)
87978-3,fungus identified cx nom (perit dial fld) diaf
87978-3,fld identified x nom (perit dial fungus
34339-2,metanephrine [moles/volume] in urine
34339-2,metanephrine [moles/volume] urine in
34339-2,urine [moles/ome] in pt metaneprine
34339-2,metaneph ur-scnc
34339-2,metaneph ur-scnc
34339-2,metaneph rscn metaneph
34339-2,metanephrine (u) [moles/vol]
34339-2,[moles/vol] (u) metanephrine
34339-2,mols/vol] (u metanphrine
48772-8,lambda light chains [mass/volume] in cerebral spinal fluid
48772-8,lambda light fluid [ass/volume] in cerebral spinal cains
48772-8,lambda light chains [mass/volume] in immunoglob cerebral spinal fluid
48772-8,lambda lc csf-mcnc
48772-8,lambda ccsf-mcnc
48772-8,lambda cerebrospinal fluid-mcnc lc
48772-8,immunoglobulin light chains.lambda (csf) [mass/vol]
48772-8,immunoglobulin igh quantitative ais.lamba (cerebrospinal fluid [mass/vo]
48772-8,chains.lambda light immunoglobulin (csf) [mass/vol]
79396-8,nadh:ubiquinone reductase [enzymatic activity/mass] in tissue
79396-8,tissue reductase [enzymatic activity/mass] in nadh:ubiquinone
79396-8,nadh:uiquinne reductas [enzymatic activity/ass]intissue
79396-8,nadh ubiq red tiss-ccnt
79396-8,nadh ubiq random red tiss-ccnt
79396-8,nadh ubi tss-ccnt ed
79396-8,nadh:ubiquinone reductase (tiss) [catalytic activity/mass]
79396-8,[cataltic reducae (tiss) nadh:ubquinone dihydronicotinamide adenine dinucleotide-coenzyme q reductase acivitmass]
79396-8,nadh:ubiquinone qnt reductase (tiss) [catalytic activity/mass]
105232-3,influenza virus a+b rna [presence] in sputum by naa with probe detection
105232-3,sputum virus a+b rna [presence] in influenza fluav by naa with probe detection
105232-3,influenza virus a+b rna [presence] in sputum by naa with probe detection
105232-3,fluav+flubv rna spt ql naa+probe
105232-3,flav+flubvrna spt ql naa+probe
105232-3,fu+flubv rna dna nucleic acid probe q spt naa+probe
105232-3,fluav+flubv rna naa+probe ql (sput)
105232-3,fluav+flubv rna ql lat naa+probe (sput)
105232-3,fluav+flubv rna naa+probe ql fluv (sput)
53606-0,neisseria meningitidis dna [presence] in blood by naa with probe detection
53606-0,neisseria meninitidis dn [presnce in blod by naa with probe deection
53606-0,neisseria meningitidis probe [presence] in blood by naa with dna detection
53606-0,n men dna bld ql naa+probe
53606-0,n men dna bld infectious disease ql naa+probe
53606-0,n dna mening men bld ql naa+probe
53606-0,n. meningitidis dna naa+probe ql (bld)
53606-0,n. meningitidis dna (bld) ql naa+probe
53606-0,danaa+probe meningitidis n. q(d)
81308-9,influenza virus a rna [cycle threshold #] in respiratory system specimen by naa with probe detection
81308-9,ifluenza virus rna a [cycle thrshold #] in resiratory system pecimn by aa ith probe detection
81308-9,influenza virus a cycle rna threshold #] in respiratory ystem specimen by naa with probe etection
81308-9,fluav rna ct resp qn naa+probe
81308-9,dna probe ct rna fluav resp qn naa+probe
81308-9,fluav rna naat ct resp qn naa+probe
81308-9,fluav rna naa+probe (respiratory system specimen) [threshnum]
81308-9,fluav rna naa+probe (respiratory syte [threshum] pcr secimen)
81308-9,fluav specimen) naa+probe (respiratory system rna [thresnum] amplification
53188-9,3-hydroxydodecenoylcarnitine (c12:1-oh) [moles/volume] in dbs
53188-9,(c12:1-oh) 3-hydroxydodecenoylcarnitine whole bld [moles/volume] in dbs
53188-9,3-hydroxydodecenoylcarnitine (c12:1-oh) [moles/volume] in dbs
53188-9,3-oh-dodecenoylcarn dbs-scnc
53188-9,level dbs-scnc 3-oh-dodecenoylcarn
53188-9,dbs-scnc quan 3-oh-dodeenolcarn
53188-9,c12:1-oh (dbs) [moles/vol]
53188-9,3-oh-dodecenoylcarn c12:1-oh (bs) [mols/ol]
53188-9,(dbs) c12:1-oh [moles/vol]
35626-1,norpropoxyphene [mass/volume] in serum or plasma by screen method
35626-1,orprpoxyphene quan [mss/vume] i ser or plasmaby screen method
35626-1,plasma [mass/volume] in serum or norpropoxyphene by screen method
35626-1,norpropoxyph serpl scn-mcnc
35626-1,norpropoxyph serpl scnmc
35626-1,norpropoxyph scn-mcnc serpl
35626-1,norpropoxyphene screen [mass/vol]
35626-1,screen level norpropoxyphene [mass/vol]
35626-1,screen norpropoxyphene [mass/vol]
35253-4,urate [mass or moles/volume] in 24 hour urine
35253-4,urate ur in or moles/volume] [mass 24 hour urine
35253-4,urate 24hr [mass or moles/volume] 24 in hour urine
35253-4,urate 24h ur-mscnc
35253-4,urate 24h 1 day ur-mscnc
35253-4,ur-mscnc 24h urte
35253-4,urate (24h u) [mass or moles/vol]
35253-4,urate (24h u) [mass qnt or moles/vol]
35253-4,[mass (24h u) urate or moles/vol]
643-7,microscopic observation [identifier] in pus by gram stain
643-7,microscopic observation [identifier] in stains pus by gram stain
643-7,microscopic [identifier] observation in pus by gram stain
643-7,gram stn pus
643-7,gram stnpus
643-7,pus stn ram
643-7,microscopic observation gram stain nom (pus)
643-7,microscopic observation gram nom stain (pus)
643-7,microscopic gram observation stain nom (pus) gram stn
23435-1,salmonella pullorum dna [presence] in specimen by naa with probe detection
23435-1,salmonella infectious disease uloum dna [presence] in specimen by naawith prbe detection
23435-1,with pullorum dna [presence] in specimen by ql naa salmonella probe detection
23435-1,s pullorum dna spec ql naa+probe
23435-1,s da pullorum spec q naa+obe
23435-1,s pullorum dna spec lat presence naa+probe
23435-1,s. pullorum dna naa+probe ql (specimen)
23435-1,s. pullorum dna naa+probe presence (specimen)
23435-1,s. pullorum dna naa+probe ligase chain reaction ql (specimen)
67827-6,lymphocytes [#/volume] in pericardial fluid
67827-6,lymphocytes [#/volum] cardio i pericardal fuid
67827-6,lymphcytes[#/volume]n percardial quan fluid
67827-6,lymphocytes # pcar
67827-6,# lymphocytes pcar
67827-6,# lymphocytes pcar
67827-6,lymphocytes (pericard fld) [#/vol]
67827-6,fld) (percard lymphocytes [#/vol]
67827-6,ymphocytes (periar fld)[/vol]
21365-2,leptin [mass/volume] in serum or plasma
21365-2,or [mass/voume] inseum epti plas level
21365-2,leptin [mass/volume] in serum plasma or
21365-2,leptin serpl-mcnc
21365-2,serpl-mcnc leptin
21365-2,srpl-mcnc leptin
21365-2,leptin [mass/vol]
21365-2,leptin [mass/vol]
21365-2,leptin [mass/vol]
23931-9,salmonella typhi o d [titer] in serum by immunofluorescence
23931-9,salmonella typhi d [iter] insrum y acif immunoluorescenc
23931-9,salmonlla yph od [ter] in serum by typhoid immuflurescence
23931-9,s typhi o d titr ser if
23931-9,s typhi o d titr ser dextro if
23931-9,s typhi d er titr if
23931-9,s. typhi o d if (s) [titer]
23931-9,anticomplement immunofluorescence if typhi o d s. (s) [titer]
23931-9,s. typhi o d [titer] if(s)
37425-6,abnormal prion protein [presence] in brain by immunoassay
37425-6,elfa abnormal prion protein [presence] in brain by immunoassay
37425-6,brain prion protein [presence] in abnormal by immunoassay
37425-6,abn prion prot brain ql ia
37425-6,an pion prot brain ql ia
37425-6,abn prion prot brain elisa presence ia
37425-6,abnormal prion protein ia ql (brain)
37425-6,abnormal pon protein ia presence (rin)
37425-6,point in time abnrmal pron (brai) a presence prtein
17317-9,n-acetylprocainamide [mass/volume] in urine
17317-9,urn n-acetylprocainamide [mass/volume] in uie
17317-9,n-acetylprocainamide [mass/volume] quantitative in urine
17317-9,napa ur-mcnc
17317-9,ur-mcnc napa random
17317-9,ur-mcnc napa acetylprocanam
17317-9,n-acetylprocainamide (u) [mass/vol]
17317-9,n-acetylprocainamide [mass/vol] (u)
17317-9,[mass/vol] (u) n-acetylprocainamide
38279-6,lymphocyte proliferation stimulated by 2.5 ug/ml candida albicans [units/volume] in blood
38279-6,lymphocyte proliferation lst stimulated by 2.5 ug/ml candida albicans [units/volume] in bld
38279-6,cndida prolifration stimlated by 2.5 ug/ml lympocyte albicans [units/volume] in blood
38279-6,lpt 2.5 ug/ml ca bld-acnc
38279-6,lp 2.5 um ca bld-acnc
38279-6,lpt 2.5 ug/ml ca bld-acnc
38279-6,lymphocyte proliferation stimulated by 2.5 ug/ml candida albicans qn (bld)
38279-6,lymphocyte prolifration .5 stimultedby ug/ml canida albicans qn bld)
38279-6,proliferation lymphocyte stimulated by 2.5 ug/ml candida albicans qn arbitrary concentration (blood)
71624-1,lymphocytes/leukocytes [pure number fraction] in synovial fluid by manual count
71624-1,ynovial [pure joint fld number fraction] in ymphocytes/leukocyes fid by manul count
71624-1,lymphocytes/leukocytes [pure number in fraction] synovial fluid leukocyte by manual count
71624-1,lymphocytes nfr.df snv manual
71624-1,nfr.df lymphocytes snv manual
71624-1,lyphocytes nfr.f snv manual
71624-1,lymphocytes/leukocytes manual cnt (syn fld) [pure # fraction]
71624-1,lymphocytes/leukocytes manual cnt (syn fld) # joint aspirate [pure fraction]
71624-1,lymphocytes/euoctes manulnt ration] fd) [pre # (syn
33200-7,amyloid beta 42 peptide [mass/volume] in plasma
33200-7,amyloid beta 42 peptide [mass/volume] plasma in
33200-7,amod nplasma petide mass/volue] beta42
33200-7,al beta42 plas-mcnc
33200-7,quantitative al beta42 plas-mcnc
33200-7,al plas-mnc be42 ab42 peptide
33200-7,amyloid beta 42 peptide (p) [mass/vol]
33200-7,amyloid beta 42 peptide (p) [mass/vol]
33200-7,amyloid 42 beta pptide (p) [massvol] beta-amyloid
47094-8,calciferol (vit d2) [moles/volume] in serum or plasma
47094-8,calciferol (vit d2) [moles/volume] in chemistry or serum plas
47094-8,[moles/volume] (vit d2) caciferol in serum serp orplasma
47094-8,vitamin d2 serpl-scnc
47094-8,vitamin serp-scc d2
47094-8,vitamin serpl-scnc d2
47094-8,vitamin d2 [moles/vol]
47094-8,d2 vitamin [moles/vol]
47094-8,vitamin d2 [moles/vol]
25269-2,polymyxin b [mass/volume] in specimen
25269-2,polymyxin b [mass/volume] in specimen
25269-2,polymyxin [mass/volume] b in specimen
25269-2,polymyxin b spec-mcnc
25269-2,b polymyxin spec-mcnc
25269-2,polymyxin b spec-mcnc quan
25269-2,polymyxin b (specimen) [mass/vol]
25269-2,polymyxin b (specimen) [mass/vol]
25269-2,polmyxin b [mass/vol level (secimen)
44018-0,basophils [presence] in body fluid by light microscopy
44018-0,bf by [presence] in body fluid basophils light microscopy
44018-0,basophils by in body fluid [presence] light microscopy
44018-0,basophils fld ql micro
44018-0,micro fld ql basophils
44018-0,presence fld basophils micro
44018-0,basophils lm ql (body fld)
44018-0,basopls ql lm (body fld) random
44018-0,basophils (body ql lm fld)
29798-6,eastern equine encephalitis virus igg ab [presence] in cerebral spinal fluid by immunofluorescence
29798-6,easternequine encephalitis vrus ig ab [ql] n cerbrl spinalfluid by immunofluorescence
29798-6,eastern equine encephalitis virus igg immunofluorescence [ql] in cerebral spinal fluid by ab
29798-6,eeev igg csf ql if
29798-6,eeev ql csf igg if
29798-6,csf igg presence eeev presence if
29798-6,eeev igg if ql (csf)
29798-6,eeev igg if ql (csf)
29798-6,eeev igg fa (csf ifql
105522-7,phosphodiesterase 10a igg ab [titer] in cerebral spinal fluid by immunofluorescence
105522-7,phosphodiesterase 10a igg ab [titer] in cerebral spinal fluid by immunofluorescence
105522-7,phophdiesterase 10a fluid ab [titer] incerebal pinal ig by immunoluorescenc
105522-7,pde10a igg titr csf if
105522-7,if igg titr csf pde10a
105522-7,pde10a sfif iggtir
105522-7,phosphodiesterase 10a igg if (csf) [titer]
105522-7,phosphodiesterase 10a igg if [titer] (csf)
105522-7,phosphodiesterase 10a igg if (csf) [titer]
3467-8,chlorpheniramine [presence] in urine
3467-8,in [presnce] chl chlopheniamine urine
3467-8,chlorpeniramin presnce in urie
3467-8,chlorphenir ur ql
3467-8,chlophenir presence r
3467-8,chlorphenirr drugs q
3467-8,chlorpheniramine ql (u)
3467-8,u) chorpheiramineql
3467-8,chlorpheniramine (u) ql random
60111-2,oxyphenbutazone [mass/volume] in urine
60111-2,oxyphenbutazone [mass/volume] in urine
60111-2,oxyphenbutazone [mass/volume] in urine mass concentration
60111-2,oxyphenbutazone ur-mcnc
60111-2,random ur-mnc oxyhebutaze
60111-2,ur-mcnc oxyphenbutazone
60111-2,oxyphenbutazone (u) [mass/vol]
60111-2,oxyphenbutazon(u) [mass/vol]
60111-2,urn oxyphenbutazone (u) [mass/vol]
16802-1,echovirus 30 ab [units/volume] in serum
16802-1,quan echovirus 30 ab [unts/voume] in serum
16802-1,echvirus 3 ab [itsvolume] in srum
16802-1,ecv30 ab ser-acnc
16802-1,ecv30 ab infectiousdisease ser-acnc
16802-1,sr-nc b ecv30
16802-1,echovirus 30 ab qn (s)
16802-1,arbitrary concentration echovirus qn b 30 (s)
16802-1,echovirus (s) ab qn 30
2531-2,lactate dehydrogenase [enzymatic activity/volume] in peritoneal fluid
2531-2,actate ehydrogease [enzymatic activitvolume] in eritoneal fluid
2531-2,lactae dehydrogens [enzyatic actiity/volum]inperitonalfluid
2531-2,ldh prt-ccnc
2531-2,prt-ccnc ldh
2531-2,prt-cnc dh
2531-2,ldh (periton fld) [catalytic activity/vol]
2531-2,ldh (perton fld activiy/vo] [catalytic
2531-2,ldh (periton fld) [catalytic activity/vol]
51661-7,hepatitis a virus ab [presence] in body fluid
51661-7,hepatitis virus a a [presence] in dy fluid
51661-7,hepatits a virusab aby presenc] bod i flid
51661-7,hav ab fld ql
51661-7,hav ab ql autoantibody fld
51661-7,fld ab hav ql
51661-7,hav ab ql (body fld)
51661-7,ql ab hav (body fld)
51661-7,hav ab (body ql fld)
3116-1,valine [mass/volume] in cerebral spinal fluid
3116-1,valine [mass/volume] in cerebral spinal fluid
3116-1,spinal massvolue] qnt in cerebral valine flu
3116-1,valine csf-mcnc
3116-1,spinal fld valine csf-mcnc
3116-1,cerebrospinal fl valine cfmcn
3116-1,valine (csf) [mass/vol]
3116-1,cerebrospinal fl [ass/vol (csf) valin
3116-1,[mass/vol] (cerebrospinal fluid) valine
96825-5,liver [score] sofa
96825-5,liver [score] sofa
96825-5,[score] liver sofa
96825-5,liver score sofa
96825-5,quantitative liver score sofa
96825-5,score liver sofa
31517-6,mycoplasma sp ab [units/volume] in serum
31517-6,mycoplasma sp ab myco [units/volume] in ser
31517-6,mycoplasma sp in [units/volume] ab ser
31517-6,mycoplasma ab ser-acnc
31517-6,mycoplasma ab ser-acnc autoantibodies
31517-6,mycoplasma ab ser-acnc
31517-6,mycoplasma sp ab qn (s)
31517-6,arbitrary concentration mycopl sp ab n (s
31517-6,serum mycoplasma sp ab qn (s)
13642-4,deprecated ethylene glycol
13642-4,ur deprecated ethylene glycol
13642-4,glycol ethylene deprecated
13642-4,deprecated ethylene glycol ur ql
13642-4,deprecated ethyene l r glycol screen
13642-4,deprecated random ql glycol ur ethylene
13642-4,ethylene glycol ql (u)
13642-4,ethylene ql glycol (u) drugs
13642-4,glycol ethylene ql (u) ua
15462-5,bovine diarrhea virus 1 neutralizing antibody [titer] in serum by neutralization test
15462-5,bovine diarrhea virus 1 neutralizing antibody [titer] in ser by ttr neutralization test
15462-5,bovne diarrhea virus 1 neutralizing microbiology antbody [titer] in eru by neuralization test
15462-5,bvdv1 nab titr ser nt
15462-5,bvdv1 nab ser titr nt
15462-5,serum nab titr bvdv1 nt
15462-5,bovine diarrhea virus 1 neut ab neut test (s) [titer]
15462-5,bovine diarrhea irus 1 neut  net test ) [tie]
15462-5,infectiousdisease bovine diarrhea virus 1 neut neut ab test (s) [titer]
40527-4,cocaine [presence] in meconium
40527-4,in [presence] cocaine meconium
40527-4,cocaine universallaborders in [ql] meconium
40527-4,cocaine mec ql
40527-4,cocaine presence mec
40527-4,cocaine universallaborders mec ql
40527-4,cocaine ql (mec)
40527-4,ql cocaine (mec)
40527-4,cocaine ql mec qualitative
73033-3,clindamycin induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
73033-3,clindamycin induced neutrophil or ab [presence] in serum igm plasma by flow cytometry (fc)
73033-3,clindamyin induced neurophil igm ab [ql in sermor lsma by plsm fow cytometry (fc
73033-3,clindamycin (neut) igm serpl ql fc
73033-3,(neut) clindamycin igm pl serpl ql fc
73033-3,cindacin (neut) gm serpl qfc
73033-3,clindamycin induced neutrophil igm fc ql
73033-3,clindaycin induced neutrpl igm anti fcql
73033-3,clindamycin indced nroplim fc ql
13025-2,trichlorotrifluoroethane [mass/volume] in blood
13025-2,trichlorotrifluoroethane [mass/olume] in blod
13025-2,cfc-113 [mass/olume] triclorotrifluoroethane i blood
13025-2,tctfe bld-mcnc
13025-2,bld-mcnc tctfe
13025-2,bld-mcnc tctfe
13025-2,trichlorotrifluoroethane (bld) [mass/vol]
13025-2,[mass/vol] (bld) trichlorotrifluoroethane
13025-2,(ld)[mas/vo] richlororifluoroethane
9458-1,deprecated streptococcus pneumoniae 23 igg ab [units/volume] in serum by immunoassay
9458-1,eprecated pneumoniae streptococcs 23igg ab[nit/volume] n serumby antibodies immunoassay
9458-1,depecated streptococu pneumoniae 23igg ab [nits/volum] pneum inserm b immunoassay
9458-1,deprecated s pneum23 igg ser ia-acnc
9458-1,deprecated s pneum23 immunoglobulin g igg ser ia-acnc
9458-1,serum s pneum23 pneumococcal pneumonia ig deprecated ia-acn
9458-1,s. pneumoniae 23 igg ia qn (s)
9458-1,s. pneumoniae 23 igg ia qn (s)
9458-1,s. ia 23 igg pneumoniae qn (s)
24250-3,adenovirus ab [titer] in serum --2nd specimen
24250-3,specimen ab [titer] in serum --2nd adenovirus
24250-3,aenovirus ab [titer] in seum --nd pecimen pt
24250-3,hadv ab sp2 titr ser
24250-3,hadv ab sp2 titr ser
24250-3,ab hadv sptitr ser adeno virus
24250-3,adenovirus ab spec 2 (s) [titer]
24250-3,adenovirus ab spec 2 (s) [titer]
24250-3,2 ab spec adenovirus (s) [titer]
97215-8,acetyl fentanyl [presence] in cord tissue by confirmatory method
97215-8,acetyl fentanyl [ql] in drugs of abuse cord tissue by confirmatory method
97215-8,method fentanyl [presence] in cord tissue by confirmatory acetyl
97215-8,acetyl fentanyl tissco ql cfm
97215-8,screen acetyl tissco fentanyl ql cfm
97215-8,tissco fenanyl acetyl confirmation ql cfm
97215-8,acetyl fentanyl confirm ql (umb cord tissue)
97215-8,actyl fentanylnfirm ql ord (umb addiction tissu)
97215-8,cord ftanyl confim ql um point in time actl tissu)
45345-6,tick engorgement [presence]
45345-6,tick [presence] engorgement
45345-6,id tick engorgement [presence]
45345-6,engorgement tick ql
45345-6,engorgement tick ql pr
45345-6,tck enorgement q
45345-6,engorgement ql (tick)
45345-6,(tick) pr ql egorgem
45345-6,ordinal engogemntql tick)
30220-8,coxsackievirus b1 ab [presence] in serum
30220-8,coxsackievirus b1 ab [presence] in serum
30220-8,coxsackieviu1 ab [presen] inseru
30220-8,cv b1 ab ser ql
30220-8,cv b1 a erql
30220-8,point in time cv b1 ab ser ql
30220-8,coxsackievirus b1 ab ql (s)
30220-8,b b1 coxsackievirus l (s
30220-8,coxsackievirus b1 ab ql (s) autoantibody
57766-8,histoplasma capsulatum ag [mass/volume] in body fluid
57766-8,histplsma casulatum ag [mass/volue] in bdy luid
57766-8,histopasm capsulatu inbody [mass/voue] ag flui
57766-8,h capsul ag fld-mcnc
57766-8,h ag capsul fld-mcnc
57766-8,h capsl ag fl-mnc
57766-8,h. capsulatum ag (body fld) [mass/vol]
57766-8,h. [mass/vol] ag (body fld) capsulatum
57766-8,h. capulatm ag (body fld) [mass/vol]
80972-3,amikacin free [mass/volume] in serum or plasma
80972-3,akaci [mass/volume] fre in sru o plama
80972-3,amikacn free plasma in serum sr or [mss/volum]
80972-3,amikacin free serpl-mcnc
80972-3,free amikacin serpl-mcnc
80972-3,amikacin free amikin serpl-mcnc
80972-3,amikacin free [mass/vol]
80972-3,drug/toxicology free[ass/vo] amikac
80972-3,amikacin free [mass/vol sr
59631-2,clobazam [mass/mass] in meconium by confirmatory method
59631-2,clobazam by in meconium [mass/mass] confirmatory method
59631-2,clobazam [mass/mass] in meconium y cfirmaor ethod mass content
59631-2,clobazam mec cfm-mcnt
59631-2,cloazam e quant cfm-cnt
59631-2,cloazam mec cfm-mcnt
59631-2,clobazam confirm (mec) [mass/mass]
59631-2,[mass/mass] (mec) clobazamconfirm
59631-2,clobazam urbadan cofirm (mec) [masmass]
6410-5,gardnerella vaginalis rrna [presence] in genital specimen by probe
6410-5,garderella vaginais infectiousdisease rn presence in genitaspec by probe
6410-5,gardnerella vaginalis rrna [presence] in gental speimen by probe
6410-5,g vaginalis rrna genital ql probe
6410-5,g ql rrna genital vaginalis probe
6410-5,vginals rrna urogenital genitl ql probe
6410-5,g. vaginalis rrna probe ql (genital specimen)
6410-5,g. vaginalis rrna probe presence (genital microbiology specimen)
6410-5,ob . vagilis rna (enitalspeimen) probeql
57867-4,pericyazine [moles/volume] in specimen
57867-4,pricyzne point in time specime in [moles/volume]
57867-4,in pericyin[moes/volum specimen
57867-4,pericyazine spec-scnc
57867-4,secscc pericyazin
57867-4,spec-scnc pericyazine
57867-4,pericyazine (specimen) [moles/vol]
57867-4,pericyazin (specimn) [moles/vol]
57867-4,pericyazine (specimen) [moles/vol]
70866-9,rabies virus strain identified in specimen by immunofluorescence
70866-9,rabies virus strain identified immune fluorescence in specimen by immunofluorescence
70866-9,rabies virus strin point in time intifi i simn by immunoluoresence
70866-9,rabv strain spec if
70866-9,immunoflour rabv strain spec if
70866-9,rabv strain spec if anticomplement immunofluorescence
70866-9,rabies virus strain identified if nom (specimen)
70866-9,virus rabie strain idenified i nom (specimen)
70866-9,(specimen) virs strain idenified if nom rabies
18361-6,adenosine monophosphate.cyclic/creatinine [mass ratio] in urine
18361-6,adenosne monophospat.cyclccreatinine [mass ratio] in rine
18361-6,adnosine monophoshat.cyclic/creatinine urne n [massratio
18361-6,camp/creat ur
18361-6,ur camp/creat ur
18361-6,ur camp/creat
18361-6,adenosine monophosphate.cyclic/creatinine (u) [mass ratio]
18361-6,adenosne monophosphaecycli/cretinine [mass (u) ratio] quant
18361-6,adenosine monopophate.cycic/creatinine(u) [mas atio]
33797-2,creatine [moles/time] in 12 hour urine
33797-2,catne 2 in [mols/time] hoururin
33797-2,[mole/time] creatine in 12 hour urine ua
33797-2,creatine 12h ur-srate
33797-2,creatine ur-srate 12h
33797-2,creatine ur-srate 12h
33797-2,creatine (12h u) [moles/time]
33797-2,[mes/time] hu) creatine
33797-2,[moles/time] (12h u) creatine
14068-1,triamterene+hydrochlorothiazide [mass/volume] in serum or plasma
14068-1,triamterene+hydrochlorothiazide [mass/volume] or serum in plasma
14068-1,triamterene+hydrochlorothiazide in [mass/volume] ser or plasma
14068-1,dyazide serpl-mcnc
14068-1,serpl-mcn dyazide
14068-1,serpl-mcnc dyazide
14068-1,triamterene+hydrochlorothiazide [mass/vol]
14068-1,tramterene+hydrochlorotiazide [assol] serp
14068-1,[mass/vol] triamterene+hydrochlorothiazide
5735-6,silver [mass/volume] in urine
5735-6,qnt slvr [mass/volume]in urine
5735-6,silver urine in [mass/volume]
5735-6,silver ur-mcnc
5735-6,ur-mcnc silver ua
5735-6,ag ur-mcnc silver
5735-6,silver (u) [mass/vol]
5735-6,silver (u)[mass/vo]
5735-6,(u) lver quant [mas/vol
30355-2,herpes simplex virus 1+2 igm ab [presence] in serum by immunofluorescence
30355-2,hepe simple irs 12 m ab[presence] in serumby immunofluorecence pr
30355-2,herpes simplex [presence] 1+2 igm ab viu in serumb immunofuorescee
30355-2,hsv1+2 igm ser ql if
30355-2,anti hv1+2 igm ser q if
30355-2,hsv1+2 igm hsv1+2 se presence i
30355-2,hsv 1+2 igm if ql (s)
30355-2,sv immune globulin m 1+2 im if ql (s)
30355-2,hsv 1+2 igm point in time if presence (s)
43210-4,human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68+70 dna [presence] in anal by naa with probe detection
43210-4,human pailloma virs 16+18+31+335+3945+51+52+56+58+5968+70 dna [pesnce]in anal by naa with probe etction
43210-4,human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68+70 dna [ql] in anal by naa with probe human papillomavirus detection
43210-4,hpv i/h risk 3 dna anal ql naa+probe
43210-4,hpv dna risk 3 i/h anal ql naa+probe
43210-4,hpv /hrisk 3 dn anal l naa+probe
43210-4,hpv 16+18+31+33+35+39+45+51+52+56+58+59+68+70 dna naa+probe ql (anal)
43210-4,hpv 16+18+31+33+35+39+45+51+52+56+58+59+68+70 dna presence naa+probe hpv i/h risk 1 (anal)
43210-4,(anal) 16+18+31+33+35+39+45+51+52+56+58+59+68+70 dna naa+probe anus ql hpv
85680-7,haemophilus influenzae ecs gene [cycle threshold #] in specimen by naa with probe detection
85680-7,haemophilus influenzae ecs gene [cycle threshold probe in specimen by naa with #] detection
85680-7,haemphilus influenza ecs gene [cyce threshd #] in spcmen by naa with probe detectin
85680-7,h influen ecs ct spec qn naa+probe
85680-7,h influen lat ecs ct spec qn naa+probe
85680-7,ligase chain reaction h influen ecs naa+probe spec qn ct
85680-7,h. influenzae ecs gene naa+probe (specimen) [threshnum]
85680-7,gene ecs h.nfluezae naa+probe (specmen) [threhnum]
85680-7,unspecified h.nfluenzae [threshnum] gene naa+probe (specime) ecs
10883-7,phenolphthalein [mass/mass] in stool
10883-7,stool [mass/mass] in phenolphthalein
10883-7,[mass/mass] phenolphthalein in stool stool = fecal
10883-7,phenolphthalein stl-mcnt
10883-7,stl-mcnt phenolphthalein
10883-7,stl-mnt henolphthalein
10883-7,phenolphthalein (stl) [mass/mass]
10883-7,bowel movement [mass/ms] penolphthaein(sl)
10883-7,penolphthalein (stl) mas/mass] mass content
22191-1,chlamydia trachomatis igg ab [titer] in serum
22191-1,chlamydia tachomatisigg infectious disease ab ter] in serum
22191-1,chlamydia trachomatis igg in [titer] ab ser
22191-1,c trach igg titr ser
22191-1,c trachomatis c trach igg titr ser
22191-1,trach c ttr igg titr ser
22191-1,c. trachomatis igg (s) [titer]
22191-1,c. trachomatis igg autoantibody (s) [titer]
22191-1,c. trachomatis igg (s) [titer]
46446-1,record id section set naaccr v.11
46446-1,record id sectio setnaaccrv.11
46446-1,record id v.11 set naaccr section
46446-1,record id section naaccr v.11
46446-1,record idsectin naar v.1 random
46446-1,ecord id .1 naacr section
25303-9,alpha 1 antitrypsin [mass/mass] in stool
25303-9,stool 1 antitrysin mass/mass] in lph stool = fecal
25303-9,lpha 1antitrpin [ass/mss n stool
25303-9,a1at stl-mcnt
25303-9,stl-mcnt a1at stool = fecal
25303-9,pulmonary a1at stl-mcnt
25303-9,alpha 1 antitrypsin (stl) [mass/mass]
25303-9,alpha [mass/mass] antitrypsin (stl) 1
25303-9,alph (st)[ass/mass] antitrypsin 1
87405-7,certolizumab ab [units/volume] in serum or plasma by immunoassay
87405-7,ertolizumaab [uits/volume] seum in cimzia or plsmabyimmunoassay
87405-7,certolzuma ab[units/volume] in serum orplasmaby immunoasay
87405-7,certolizumab ab serpl ia-acnc
87405-7,ia-acnc ab serpl certolizumab serpl
87405-7,certolizumab ia-acnc serpl ab
87405-7,certolizumab ab ia qn
87405-7,antby certolizumab ab qn ia
87405-7,certolizumab qn ia ab
86661-6,chlamydia trachomatis+neisseria gonorrhoeae tests - fpar 2.0 set
86661-6,hlamydia trachomatis+neseria gonorrhea set tes fpar .0 gonorhoeae
86661-6,chlamydia trachomatis+neisseria gonorrhoeae tests 2.0 fpar - set
8842-7,high right atrium oxygen saturation
8842-7,high right atrium lung oxygen saturation
8842-7,high to2 saturation atrium oxygen right
8842-7,sao2 % ra.high
8842-7,ra.high % pulmonology sao2
8842-7,ra.high % sao2 cardiology
4588-0,hemoglobin h/hemoglobin.total in blood
4588-0,h/hemoglobin.total hemoglobin in blood
4588-0,h/hemoglobintotal emoglobin hgb in bld
4588-0,hgb h mfr bld
4588-0,hgb h mfr bld
4588-0,hgb mfr h blood
4588-0,hemoglobin h (bld) [mass fraction]
4588-0,hemoglobin h [mass (blood) fraction]
4588-0,hemoglobin h (blood) [mass quan fraction]
24183-6,coxsackievirus b2 neutralizing antibody [titer] in serum by neutralization test --1st specimen
24183-6,coxsackvius b nutralizng antbdy[tter] serum in by neutraiztion test --1stspecimen
24183-6,cosackievirus sr b2 neutralizingantibody[iter] in ser by neuralizatin test --1stpeimen
24183-6,cv b2 nab sp1 titr ser nt
24183-6,cv b2 nab sp1 titr serum nt
24183-6,ser b2 nab sp1 titr cv nt
24183-6,coxsackievirus b2 neut ab spec 1 neut test (s) [titer]
24183-6,b2 coxsackievirus neut ab spec 1 neut test (s) [titer]
24183-6,coxsackievirus b neut [titer] spec 1 neut test (s) ab
101353-1,borrelia burgdorferi ab [interpretation] in serum qualitative by ia.mttt
101353-1,borrelia burgdorferi ab in [interpretation] serum qualitative by ia.mttt
101353-1,borrelia burgdorferi ab [interpretation] in serum qualitative by qualitative ia.mttt
101353-1,b burgdor ab ser ia.mttt-imp
101353-1,b burgdor serum ab ia.mttt-imp
101353-1,abse burgor b ia.mttt-imp
101353-1,b. burgdorferi ab ia.mttt ql (s) [interp]
101353-1,ql b ia.mttt b.burgdorfri (s) [intp]
101353-1,b. burgdorferi ab ia.mttt ql (s) [interp]
76381-3,nursing license type panel [nmmds]
76381-3,nrsing point in time panl licensete [nmmds]
76381-3,nrsing lcense pan type panel nmmds]
18765-8,deprecated podiatry visit note
18765-8,depecatepodiaty visit attach noe
18765-8,deprecated note eval visit podiatry
22138-2,borrelia hermsii igg ab [titer] in serum
22138-2,borrelia hermii dilution factor (titer) igg ab [titer] in serum
22138-2,borrelia hermsi in ab [titer] igg seru
22138-2,b hermsii igg titr ser
22138-2,b hemsii iggtitr ser
22138-2,b hermsii igg titr serum
22138-2,b. hermsii igg (s) [titer]
22138-2,b. hermsii igg [titer] titer (s)
22138-2,b. hermsii igg (s) [titer]
58420-1,anidulafungin [mass/volume] in serum or plasma
58420-1,anidulafungin [mass/volume] or serum in plasma
58420-1,anidulafungin pl [mass/volume] in serum or plasma
58420-1,anidulafungin serpl-mcnc
58420-1,quantitative serpl-mcnc anidulfngin
58420-1,anidulafungin quant serpl-cnc
58420-1,anidulafungin [mass/vol]
58420-1,anidulafunin [mass/vol]
58420-1,ly303366 [mass/vol] anidulafungin
6680-3,microscopic observation [identifier] in tissue by wet preparation
6680-3,microscopic wet [identifier]in tissue by observation prparation
6680-3,microoic obervation infectious disease ientiie] in tssue b wet preparatin
6680-3,wet prep tiss
6680-3,wet pp tiss
6680-3,wet wet mount preptiss
6680-3,microscopic observation wet prep nom (tiss)
6680-3,"microscopic observation wet tissue, unspecified (tiss) nom prep"
6680-3,microscopic nominal observation nom prep wet (tiss)
34982-9,unidentified cells/leukocytes in peritoneal fluid
34982-9,uidentified in cells/leukocytes percent pertoea fld
34982-9,unidentified cells/leukocytes nos ab in peritoneal fluid
34982-9,unident cells nfr prt
34982-9,unident cells nfrprt
34982-9,prt cells ascitis nfr unident
34982-9,unidentified cells/leukocytes (periton fld)
34982-9,ascites unidentified cells/leukocytes (periton fld)
34982-9,undentfed cells/leukocytes (periton prt fld)
105688-6,aspergillus niger dna [presence] in specimen by naa with probe detection
105688-6,apergillus nigedna[pesene]in b pecimen naa with robe detection
105688-6,aspergillus nger dna [presence] in spcimen y naa wih probe dtetio
105688-6,a niger dna spec ql naa+probe
105688-6,a niger dna specql naapob
105688-6,probe amp a nier dnaspel naa+probe
105688-6,a. niger dna naa+probe ql (specimen)
105688-6,a. niger dna naa+probe l(specien)
105688-6,(specimen) niger dna naa+probe ql a.
5641-6,ethanol [mass/volume] in exhaled gas
5641-6,ethaol [mass/olume] i exhaled ga
5641-6,random thnol iexhaled [ass/volue] as
5641-6,ethanol exg-mcnc
5641-6,exg-mnc ethaol point in time
5641-6,exg-mcnc point in time ethanol
5641-6,ethanol (exhl gas) [mass/vol]
5641-6,ethanol (exhl gas) [mass/vol] alc
5641-6,[mass/vol] (exhl exhaled gas gas) ethnol
89515-1,ganglioside gt1b igm ab [presence] in serum by line blot
89515-1,ab gt1b igm ganglioside [presence] in ser by line blot
89515-1,ganglioside gtb igm ab [pesence] blot serum by lie in
89515-1,gt1b ganlg igm ser ql line blot
89515-1,gt1b ganlg igm ser blot line ql
89515-1,gt1 ganlg igm seq line blot
89515-1,ganglioside gt1b igm line blot ql (s)
89515-1,ganioide gt1b ig line blot anti presence (s)
89515-1,ganglioside gt1b igm line blot presence (s)
98965-7,brexpiprazole [mass/volume] in urine by confirmatory method
98965-7,brexpiprazol mass/volue] in uin by confirmatory meto
98965-7,level rexpirazoe[mass/olume]in urine by cnfirmatory ethod
98965-7,brexpiprazole ur cfm-mcnc
98965-7,brexpiprazole cfm-mcnc ur
98965-7,cfm-mcnc ur brexpiprazole
98965-7,brexpiprazole confirm (u) [mass/vol]
98965-7,[mass/vl] confirm (u brexpiprazole conf
98965-7,brexpiprazole confirm (u) drug/toxicology [mass/vol]
73897-1,chronic lyme disease panel - blood by flow cytometry (fc)
73897-1,(fc) lyme disease panel chronic lyme dis pnl - blood by flow cytometry chronic
73897-1,chroni lme - panel diseas bld b flow cytoety (fc)
73897-1,chronic lyme dis pnl bld fc
73897-1,chronic yme dis pnl bld fc
73897-1,chroniclyme c pnl bl ds
73897-1,chronic lyme disease panel fc (bld)
73897-1,sease pt lyme chronic panel fc(bld)
73897-1,panl lyme disease chrnic fc (blood)
23092-0,equine herpesvirus 4 ag [presence] in specimen by immunofluorescence
23092-0,equine herpesvirus 4 ag to be specified in another part of the message resence] i specimn by immunofluorescene
23092-0,equineherpeviru 4 ag [presece] i specimen bimunolurscene
23092-0,ehv4 ag spec ql if
23092-0,ehv4 ag specql if
23092-0,ehv4 if spec ql ag
23092-0,equine herpesvirus 4 ag if ql (specimen)
23092-0,equine herpesvirus 4 veterinary g f ql(specime)
23092-0,eqn herpesvirus  ag if ql (specimen)
19185-8,tissue polypeptide specific ag [units/volume] in pleural fluid
19185-8,tiue plypeptide speific g units/volume] in antigen pleral fuid
19185-8,tissue olypeptide spcific ag [unis/olume] in chemistry pleural fluid
19185-8,tps ag plr-acnc
19185-8,tps ag pracnc quantitative
19185-8,plr-acnc ag point in time tps
19185-8,tissue polypeptide specific ag qn (pleur fld)
19185-8,tissue qn specific ag polypeptide (pleur fld)
19185-8,tissue polypeptid specific a qn (leur quant f)
72631-5,amobarbital [presence] in saliva (oral fluid) by confirmatory method
72631-5,amobarbita [presenc] in saliva (orl flud) y confiratory mtho
72631-5,aobarita [ql]in cnfrm saliva (oral flui) b confirmatory ethd
72631-5,amobarbital sal ql cfm
72631-5,amoabia sal pr l cf
72631-5,cfm salq amobarbital
72631-5,amobarbital confirm ql (sal)
72631-5,ambarbital (sal) drug/toxicology nfimql
72631-5,amobarbital confirm presence confirmation (sal)
14704-1,doxepin [presence] in gastric fluid
14704-1,gastri [resene]in dxepin qual fluid
14704-1,fluid [presence] in gastric doxepin
14704-1,doxepin gast ql
14704-1,gast doxepin ql
14704-1,doxepin ql gast
14704-1,doxepin ql (gast fld)
14704-1,fld) ql (gast doxepin
14704-1,doepin ql ast fld)
70103-7,methotrexate [moles/volume] in serum or plasma --6th specimen
70103-7,methotrxat [moles/volume] in srm r lasa --th pecimen
70103-7,methotrexate plasma in serum or [moles/volume] --6th specimen
70103-7,mtx sp6 serpl-scnc
70103-7,mtx serpl-scnc sp6 mtx
70103-7,mtxp6serp-scnc
70103-7,methotrexate 6th specimen [moles/vol]
70103-7,methotrexate 6th specimen [moles/vol]
70103-7,methotrexate 6th specmen [moles/vol]
101566-8,human coronavirus rna in specimen document
101566-8,human specimen rna in coronavirus document
101566-8,in coronavirus rna human specimen document
101566-8,hcov rna spec doc
101566-8,hcov point in time rna spec doc
101566-8,hcov rna spec doc other
101566-8,hcov rna doc (specimen)
101566-8,hcov rna doc (specimen) document
101566-8,hcov rna do (specimen)
21550-9,synovial lining cells [presence] in synovial fluid by light microscopy
21550-9,synovial lining cells [presence] in synovial fluid by light joint fluid microscopy
21550-9,synovial random lining cells [presence] in synovial fluid by light microscopy
21550-9,synoviocytes snv ql micro
21550-9,synoviocyts snv mcro presence
21550-9,synoviocytes ql snv micro
21550-9,synovial lining cells lm ql (syn fld)
21550-9,synovial (syn cells lm ql lining fld) synovial fluid
21550-9,synovial (syn cells lm joint aspirate presence lining fld)
38287-9,"2,2-dichloropropionate [mass/volume] in water"
38287-9,"2,2-dichloropropionate [mass/volume] in water point in time"
38287-9,in [mass/volume] 22-dicloopropiona random water
38287-9,"2,2-dpa wat-mcnc"
38287-9,",2-dpa wat-mcnc"
38287-9,"wat-mcnc 2,2-dpa"
38287-9,"2,2-dichloropropionate (water) [mass/vol]"
38287-9,"2,2-dichloropropionate (water) [mass/vol]"
38287-9,"[mass/vol] (water) 2,2-dichloropropionate"
86169-0,streptococcus pneumoniae danish serotype 9n igg ab [mass/volume] in serum
86169-0,streptococcus danish pneumoniae serotype 9n igg ab [mass/volume] in serum
86169-0,streptoccus peumoniae pneumo danish serotype 9n [mass/volume] ab igg in seru
86169-0,s pneum da 9n igg ser-mcnc
86169-0,s 9n da pneum igg serum-mcnc
86169-0,s immune globulin g pneu sercnc n igg da
86169-0,s. pneumoniae danish type 9n igg (s) [mass/vol]
86169-0,s. pneumoniae dn type 9n igg (s [as/vol]
86169-0,s. pneumoniae mass concentration danish type 9n igg (s) [mass/vol]
18260-0,zinc [presence] in tissue
18260-0,zi [reence] in tissue
18260-0,zn zinc [presence] in tisue
18260-0,zinc tiss ql
18260-0,zinc ql tiss
18260-0,zinc ql tiss
18260-0,zinc ql (tiss)
18260-0,inc ql (tiss
18260-0,ql tissue zinc (tiss)
53125-1,monocytes+macrophages/leukocytes in bone marrow
53125-1,marrow in bone monocytes+macrophages/leukocytes monos
53125-1,monocytes+macrophage/leukocytes inbone arrow
53125-1,monos+macros nfr mar
53125-1,monos+macos point in time nfr mar
53125-1,monos+macros nfr mar point in time
53125-1,monocytes+macrophages/leukocytes (bm)
53125-1,(bm) monocytes+macrophages/leukocytes
53125-1,(bm) monocytes+macrophages/leukocytes wbc
59239-4,prostate specific ag free [mass/volume] in body fluid
59239-4,prostate ag qnt specific free [mass/volume] in body fluid
59239-4,prostate spec speciic ag free [mas/volume] in body flui
59239-4,psa free fld-mcnc
59239-4,fldmnc free psa
59239-4,psa free fld-mcnc ps
59239-4,free psa (body fld) [mass/vol]
59239-4,free fld) (body psa [ms/vol]
59239-4,free psa (body fld) [mass/vol]
92876-2,human coronavirus 229e+hku1+nl63+oc43 and parainfluenza virus 1+2+3+4 rna panel - lower respiratory specimen by naa with probe detection
92876-2,hua coronavius29e+hk1+nl63+o4 and parifluenza virus 1+2+3+ rna pel -owe respiatory specime bynaa with probe deection
92876-2,human coronavirus 229e+hku1+nl63+oc43 and parainfluenza rna 1+2+3+4 virus panel - lcr lower respiratory specimen by naa with probe detection
92876-2,4 hcovs + hpiv1-4 rna pnl lowresp naa+pr
92876-2,4 hcovs + hpiv1-4 amplification rna pnl lowresp naa+pr
92876-2,4 pnl +hpv1-4 rna hcov lowrespnaa+pr
92876-2,hcov 229e+hku1+nl63+oc43 and parainfluenza virus 1+2+3+4 rna panel naa+probe (lower resp)
92876-2,lat hcov 229e+hku1+nl63+oc43 and parainfluenza virus 1+2+3+4 rna panel naa+probe (lower resp)
92876-2,hcov na+probe(ower an parainflueza vius 1+2+3+4 rna pnel low 229e+ku1+nl63+oc43 res)
56075-5,deprecated phenx measure - pregnancy weight gain
56075-5,deprecate phenx esure - regayweght point in time gain
56075-5,dprected phen measure - pregnancy weight gain
61382-8,human papilloma virus 52 dna [presence] in specimen by naa with probe detection
61382-8,human papilloma virus 52 hpv dna [presence] in specimen by naa with probe detection
61382-8,human naa virus 52 dna [ql] in specimen by papilloma with probe detection
61382-8,hpv52 dna spec ql naa+probe
61382-8,hpv52 sda dna ql spec naa+probe
61382-8,hpv52 naa+probe spec presence dna
61382-8,hpv 52 dna naa+probe ql (specimen)
61382-8,52 hpv dna naa+probe ql (specimen)
61382-8,naa+probe 52 dna hpv ql (specimen)
44395-2,lambda light chains [presence] in 24 hour urine
44395-2,light lambda chains [presence] in 24 hour urine
44395-2,lambda light chains [presence] in urine hour 24
44395-2,lambda lc 24h ur ql
44395-2,ur lc 24h lambda ql
44395-2,ambda lc screen ql ur 24h
44395-2,immunoglobulin light chains.lambda ql (24h u)
44395-2,immunoglobulin light ua chains.lambda (24h presence u)
44395-2,immunoglobulin light u) ql (24h chains.lambda
53295-2,urinalysis type of crystal panel [#/volume] - urine by computer assisted method
53295-2,urinalysis type - crystal panel [#/volume] of urine by absolute computer assisted method
53295-2,urinayis typ ua [#volume] crysta panel of - urine b computer ssisted method
53295-2,ua crystal pnl # ur comp assist
53295-2,ua crystal pnl # number concentration (count/vol) ur comp assist
53295-2,ua urn com pnl # ur crystal assis
53295-2,urinalysis type of crystal panel computer assisted (u) [#/vol]
53295-2,urinalysis computer of crystal panel type assisted (u) [#/vol]
53295-2,automated detection urinalss typeof [#vol] panel computr assisted(u) cytal
14930-2,triiodothyronine (t3) [moles/volume] in serum or plasma
14930-2,triiodothyronine (t3) [moles/volume] in serum or plasma
14930-2,triiodothyroin (3) [moles/volume] in serum or plasma plama or erum
14930-2,t3 serpl-scnc
14930-2,serpl-scnc t3
14930-2,serpl-scnc t
14930-2,t3 [moles/vol]
14930-2,t3 t3 [mols/ol
14930-2,[moesvol] t3
13279-5,rubella virus igg ab [units/volume] in serum --1st specimen
13279-5,rubella virus igg ab [units/volume] in serum --1st antby specimen
13279-5,rubella virus --1st ab qnt [units/volume] in serum igg specimen
13279-5,rubv igg sp1 ser-acnc
13279-5,rubv igg sp1 ser-cn
13279-5,ser-acnc igg sp1 rubv
13279-5,rubella virus igg spec 1 qn (s)
13279-5,rubllavrus gg sec 1 qn (s)
13279-5,immune globulin g rubella virus igg spec 1 qn (s)
6343-8,chlamydia sp ag [presence] in conjunctival specimen by immunoassay
6343-8,chlamydia sp ag [ql] in conjunctival eia specimen by immunoassay
6343-8,chlamydia sp ag [presence] in conjunctival specimen by immunoassay
6343-8,chlamydia ag conjunct ql ia
6343-8,clamdia ag random conjunct ia ql
6343-8,chlamydia ag cnjunt ql infectiousdisease ia
6343-8,chlamydia sp ag ia ql (conj)
6343-8,qual conj) sp ag i presence chlamydia
6343-8,sp chlamydia ag ia ql (conj)
70218-3,triglyceride [moles/volume] in blood
70218-3,triglyceride [moles/volume] in blood
70218-3,triglyceride [moles/volume] bld trigly in
70218-3,trigl bld-scnc
70218-3,bld-scnc trigl level
70218-3,trigld-snc
70218-3,triglyceride (bld) [moles/vol]
70218-3,rglyceride molesvol] random (bd)
70218-3,[moles/vol] (blood) triglyceride
92653-5,trazodone [presence] in urine by confirmatory method
92653-5,trazdone screen [pesence] in urine b confimatoymethod
92653-5,trazodone [ql] in urine by confirmatory meod
92653-5,trazodone ur ql cfm
92653-5,trazodone cfm ql pr ur
92653-5,trazodone u ql cfm
92653-5,trazodone confirm ql (u)
92653-5,cnfrm ql confirm trazodone (u)
92653-5,(u) confirm ql trazodone
4532-8,complement total hemolytic ch50 [units/volume] in serum or plasma
4532-8,complment total hemolytic h50 [units/voume] in serum or pasma
4532-8,complement total hemolytic ch50 [units/volume] in ser or plasma
4532-8,ch50 serpl-acnc
4532-8,serpl-acnc ch50
4532-8,serpl-acnc ch50
4532-8,complement total hemolytic ch50 qn
4532-8,complement otal hemlyi c50 n
4532-8,serp complement hemolytic total ch50 qn
96045-0,osmotic fragility of red blood cells--10% glucose 48 hour 37 degree c incubation
96045-0,osmoti fragility of edblo cels--0 gluco 48 hour 37 degree c incubaton
96045-0,osmotic fragility of red bld cells--10% glucose 48 hour 37 degree c incubation
96045-0,of 10% glu 48h inc nfr rbc
96045-0,of 10% glu 48h inc fr rbc
96045-0,of 10% glu 48h inc nfr fragil rb
96045-0,osmotic fragility 10% glucose 48 hr 37 degree c incubation (rbc)
96045-0,osotc faglity 10% glucose 8 hr37 deree c incubatio (rb)
96045-0,osmotic fragility 10% glucose 48 hr c degree 37 incubation (rbc)
22701-7,salicylates [moles/volume] in urine
22701-7,salicylates urine in [moles/volume]
22701-7,salicylaes moles/olume] urine ortho-hydroxybenzoic acid i
22701-7,salicylates ur-scnc
22701-7,salicylates ur-scnc
22701-7,ur-scnc ortho-hydroxybenzoate salicylates
22701-7,salicylates (u) [moles/vol]
22701-7,2-hydroxybenzoate (u)[molesvol] salicylates
22701-7,2-hydroxybenzoic acid acylats (u) [mols/vol]
60305-0,fluphenazine [moles/volume] in specimen
60305-0,fluphenazine quan in [moles/volume] specimen
60305-0,fluphenazine [moles/volume] drug/toxicology specimen in
60305-0,fluphenazine spec-scnc
60305-0,spe-cnc substance concentration fluphenzine
60305-0,spc-sc fluphenazine
60305-0,fluphenazine (specimen) [moles/vol]
60305-0,(specimen) fluphenazine [moles/vol]
60305-0,[moles/vol] (specimen) fluphenazine
26785-6,ephedrine+pseudoephedrine [mass/volume] in urine
26785-6,urine [mss/volume] in ua ehedrine+pseudoephedrine
26785-6,cenafed ephedrine+seudoephedrine [mass/voume] in urine
26785-6,ephedrin+pseudo ur-mcnc
26785-6,ur ur-mcnc ephedrin+pseudo
26785-6,ur-mcn ephedrin+peudo
26785-6,ephedrine+pseudoephedrine (u) [mass/vol]
26785-6,ephedrine+pseudoephedrine (u) [mass/vol]
26785-6,ephedrine+pseudoephedrine [mass/vol] (u)
90170-2,promis parent proxy item bank - cognitive function - version 1.0
90170-2,promis parent pan proxy item bank - cognitive function - version 1.0
90170-2,promis parent proxy item bank pan - 1.0 function - version cognitive
14678-7,cortisol [moles/volume] in serum or plasma --pm trough specimen
14678-7,[moles/volume] cortisol in serum or plasma --pm trough specimen
14678-7,cortisol[moles/olume] in ser 12am or -pm plasma trough specimen
14678-7,cortis pm serpl-scnc
14678-7,rtis pm serl-scnc pm diurnal trough
14678-7,serpl-scnc pm cortis
14678-7,cortisol pm trough specimen [moles/vol]
14678-7,ortiol pm trugh specimn [moles/o]
14678-7,pm cortisol trough specimen [moles/vol]
2541-1,lactate dehydrogenase 3 [enzymatic activity/volume] in serum or plasma by chemical separation
2541-1,tumor marker lactate dehydrogenase 3 [enzymatic activity/volume] in serum or plasma by chemical separation
2541-1,lactate dehydrogenase 3 [enzymatic activity/volume] in serum or plasma lactic acid by chemical separation
2541-1,ldh3 serpl chem sepn-ccnc
2541-1,l3 sepl hm sepn-cnc dehyrdogenase
2541-1,sr ldh3 serl chem spn-ccnc
2541-1,ldh 3 chemical separation [catalytic activity/vol]
2541-1,ld3 separation cheical pl [catalytic activt/vol]
2541-1,dehyrdogenase dh 3 [catalyicctvity/vol] searaio cheial
72158-9,apo-transcobalamin i [moles/volume] in serum
72158-9,apo-transcobalamin i in [moles/volume] serum
72158-9,apo-trascobalamin i [moles/volume] in serum
72158-9,apo-tc-1 ser-scnc
72158-9,apo-tc-1 ser-scnc
72158-9,ser-scnc apo-tc-1
72158-9,apo-transcobalamin i (s) [moles/vol]
72158-9,[moles/vol] level i (s) apotrnscobalamin
72158-9,apo-transcobalamin i (s) [mes/vol]
40662-9,protein [mass/time] in 12 hour urine --resting
40662-9,prtn [mass/ime]in 12 urine hour nephrology --rsting
40662-9,urine [mass/time] in 12 hour protein --resting
40662-9,prot resting 12h ur-mrate
40662-9,prot restig 12h ur-mre
40662-9,prot 12h resting ur-mrate
40662-9,protein resting (12h u) [mass/time]
40662-9,proteinresting u)[mass/time] (12h urn
40662-9,protein resting (12h u) [mass/time] chemistry
82729-5,natural killer cell cytotoxicity.100:1 effector to target cell ratio/positive control in blood mononuclear cells
82729-5,natural iller cell cytotoxicity.00:1 effector totarget cll ratio/ositive conrl in boodmononuclea cells
82729-5,ntual killer cll cytotoxicity.100:1 effector to target cellratio/posiive pbmc cotrol in blood ononuclear cell
82729-5,nk cytotox.100:1 e:t/pos cntrl bld mc
82729-5,nk ctotox.100: e:t/poctrl blood bld mc
82729-5,bld cytotox.100:1 e:t/os cntrl nk quant mc
82729-5,nk cytotoxicity 100:1 e:t ratio/positive control (bld mc) [rel units/vol]
82729-5,(bld cytotoxicity 100:1 e:t ratio/positive control nk mc) [rel units/vol]
82729-5,nk cytotoxicity 100:1 e:t ratio/positive control units/vol] mc) [rel (blood
50894-5,pentacarboxylporphyrins [moles/mass] in stool
50894-5,pntacarboxylporhyrins [oles/mass] in stool
50894-5,pentacboxylporphyrins [moles/mass] in penta-cp stool
50894-5,penta-cp stl-scnt
50894-5,stl-scnt penta-cp
50894-5,penta-cp stl-scnt
50894-5,pentacarboxylporphyrins (stl) [moles/mass]
50894-5,pentacarboxylporphyrins (stl) quantitative [moles/mass]
50894-5,(stl) pentacarboxylporphyrins [moles/mass]
72457-5,desmin ab [presence] in serum or plasma by immunoblot
72457-5,demin ab [presene]in seum plasma or b imublt
72457-5,immuoblot in seum or plasa by desminab[resence]
72457-5,desmin ab serpl ql ib
72457-5,serum or plasma ab desmin ql ib serum or plasma
72457-5,esmin a serpl ql i
72457-5,desmin ab ib ql
72457-5,desmn west blt ibql ab
72457-5,desmin ab ib abs presence
7822-0,chlamydophila psittaci ab [units/volume] in serum
7822-0,autoantibody hlamydophia psitacia [units/volume] in serum
7822-0,[units/volue] psittci ab chamydophila inserum infectious disease
7822-0,c psittaci ab ser-acnc
7822-0,enzootic abortion of ewes c psittaci ab ser-acnc
7822-0,c psittaci ab seracnc
7822-0,c. psittaci ab qn (s)
7822-0,c ittaci b qn point in time (s
7822-0,c. psittai ab qn point in time (s)
100997-6,"respiratory allergen panel, area 5 - serum"
100997-6,"respiroy allergen panl, area 5 - ser"
100997-6,"respiratory allergen 5 area panel, - serum"
100997-6,"respiratory allergen panel, area 5 ser"
100997-6,"respirtory allergen 5 area panl, ser"
100997-6,"serum allergen panel, area 5 respiratory"
100997-6,"respiratory allergen panel, area 5 (s)"
100997-6,"respiratory allergen panel, alrgen area 5 (s)"
100997-6,respiratory alerge (s) area 5 pael
101754-0,trichophyton tonsurans dna [presence] in specimen by naa with probe detection
101754-0,trichophyon tnsrans dna[presene in speimn by detectin with probe aa
101754-0,trichophyton tonsurans dna [ql] in specimen by naa with probe detection
101754-0,t. tonsurans dna spec ql naa+probe
101754-0,t. tonsurans spec deoxyribonucleic acid dna ql naa+probe
101754-0,t. tonsurans dna spec presence naa+probe deoxyribonucleic acid
101754-0,trichophyton tonsurans dna naa+probe ql (specimen)
101754-0,trichophyton tonsurans dna naa+probe ql (specimen) unspecified
101754-0,trichophyton tonsurans dnanaa+probe l (speimen) sda
25132-2,pyruvate/creatinine [molar ratio] in urine
25132-2,cr [molar pyruvate/creatinine ratio] in urine
25132-2,pyruvate/creatinine [molar ratio] in urine quantitative
25132-2,pyruvate/creat ur-srto
25132-2,ur-srto pyruvate/creat
25132-2,ur-srto pyruvate/creat
25132-2,pyruvate/creatinine (u) [molar ratio]
25132-2,pyruvat/reatinine (u) [molr ratio]
25132-2,pyruvte/reatinine () [molar ratio] ucr
86605-3,alpha hydroxytriazolam/creatinine [mass ratio] in urine by confirmatory method
86605-3,alpha in [mass rato] hyroxytriazolam/creatinine urine by conirmatory method
86605-3,alpha hydroxytriazolam/creatinine [mass potentialforabuse ratio] in urine by confirmatory method
86605-3,a-oh-triazolam/creat ur cfm
86605-3,a-oh-tiazolam/ceatufm
86605-3,cfm ur a-oh-triazolam/creat
86605-3,alpha hydroxytriazolam/creatinine confirm (u) [mass ratio]
86605-3,hydoytriazlam/creatinine alpha confrm (u) [assratio
86605-3,alpha hydroxytriazolam/creatinine confirm (u) ratio] [mass
10546-0,normethsuximide [mass/volume] in serum or plasma
10546-0,normehsuximide[mas/volue] nserum r suximide metabolite plasm
10546-0,norethsuximide [mass/olme] n plsma or serum
10546-0,normethsuximide serpl-mcnc
10546-0,normethsuximie serpl serp-nc
10546-0,normethsuxide serplmcc
10546-0,normethsuximide [mass/vol]
10546-0,norethsuximide [masvol]
10546-0,[mass/vol] normethsuximide
106608-3,streptococcus pyogenes dna [presence] in body fluid by naa with non-probe detection
106608-3,steptococcuspyones dna [prsence] in body luid by na with non-probe deection
106608-3,streptococcus pyogenes dna [presence] in body fluid s pyogenes by naa non-probe with detection
106608-3,s pyo dna fld ql naa+non-probe
106608-3,fld pyo s pyogenes dna s presence naa+non-probe
106608-3,s po dna fld l naa+on-probe
106608-3,s. pyogenes dna naa+non-probe ql (body fld)
106608-3,s. ordinal pyogenes dna na+non-probeql(bdy fld)
106608-3,s. pyogens na+non-probe dna ql (body fld)
97537-5,ph of central venous blood adjusted to patient's actual temperature
97537-5,ph of cental patien's blood adjsted o venous actua tmperatur
97537-5,ph of central s prime adjusted blood venous to patient's actual temperature
97537-5,ph temp adj bldcv
97537-5,bldcv temp adj ph
97537-5,s prime ph temp adj bldcv
97537-5,ph adjusted to patient's actual temperature (bldcv)
97537-5,p adjusted temp to patent'sactal temperature (blv)
97537-5,temperature adjustedtopaten's actual ph temp (bdcv)
1778-0,alkaline phosphatase.intestinal [enzymatic activity/volume] in serum or plasma
1778-0,or phosphatase.intestinal [enzymatic activity/volume] in ser alkaline plasma
1778-0,alkaline phosphatase.intestinal [enzymatic activity/volume] in ser or plasma
1778-0,alp intest serpl-ccnc
1778-0,random alp intest serpl-ccnc
1778-0,intst al srl-ccnc
1778-0,alp intest [catalytic activity/vol]
1778-0,alp intest [catalytic activity/vol]
1778-0,alp intest alp intest [catalytic activity/vol]
54931-1,isovalerylcarnitine+methylbutyrylcarnitine (c5)/creatinine [molar ratio] in urine
54931-1,isovalerylcarnitine+methylbutyrylcarnitine (c5)/creatinine [molar raio] ua in urie
54931-1,[molar (c5)/creatinine isovalerylcarnitine+methylbutyrylcarnitine ratio] in urine
54931-1,isovaleryl+mebutyrylcarn/creat ur-srto
54931-1,ur-srto isovaleryl+mebutyrylcarn/creat
54931-1,isovaleryl+mebyrylcarn/creat ur ur-srto
54931-1,isovalerylcarnitine+methylbutyrylcarnitine (c5)/creatinine (u) [molar ratio]
54931-1,isovalerylcarnitine+methylbutyrylcarnitine ratio] isovaleryl-2-methylbutyrylcarnitine (u) [molar (c5)/creatinine
54931-1,isovalerylcrnitine+methlbutyrylnitine chemistry (c5)/cetinine ratio] olar (u)
42332-7,alpha-1-fetoprotein l3/alpha-1-fetoprotein.total in serum or plasma
42332-7,alpha-1-fetoprotein serum in l3/alpha-1-fetoprotein.total or plasma
42332-7,alpha-1-feopotein in l3/lpha1-fetoprotei.totl erum orplama
42332-7,afp l3 mfr serpl
42332-7,l3 chemistry afp mfr serum or plasma
42332-7,l3 ap serum or plasma mfr serpl
42332-7,afp l3/total afp [mass fraction]
42332-7,rtio] l3/total afp [mass quantitative fp
42332-7,afp l3/total afp [mass fraction]
48061-6,giardia lamblia+cryptosporidium sp ag [presence] in stool by immunofluorescence
48061-6,giardia immunofluorescence sp ag [presence] in stool by lamblia+cryptosporidium
48061-6,giardia b sp g [prsence] in stool lambli+cryptospordium immunouorescence immunoflour
48061-6,g lamblia+cryptosp ag stl ql if
48061-6,gamblia+cryptosp pr ag stl presence if
48061-6,stl lamblia+cryptosp ag presence g presence if
48061-6,g. lamblia+cryptosporidium sp ag if ql (stl)
48061-6,(stl) ifa lambli+cryptosporidim spag ifql g.
48061-6,(stl) lamblia+cryptosporidium sp ag if ql g.
77394-5,human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 dna [presence] in anorectal by naa with probe detection
77394-5,humn papilloma vius 31+33+35+3+45+51+52+56+58+59+668 dna presence] in ligase chain reaction anorectal by naa with probe detection
77394-5,human papilloma virus anorectal dna [presence] in 31+33+35+39+45+51+52+56+58+59+66+68 by naa with probe detection
77394-5,hpv hr 12 dna anorectl ql naa+probe
77394-5,hpv hr 12 dna anorectl ql hpv naa+probe
77394-5,hp ql 12 dna anorctl hr naa+probe
77394-5,hpv 31+33+35+39+45+51+52+56+58+59+66+68 dna naa+probe ql (anorectal)
77394-5,hpv ql dna naa+prob 31+33+35+39+45+51+52+56+58+59+66+ (anorectal) nasba
77394-5,hpv da 1+33+35+39+5+5152+6+58+5966+68 naa+robe rectum q (anorctal)
34887-0,peste des petits ruminants virus ag [presence] in tissue by immunofluorescence
34887-0,peste des tissue pis rumiants virus ag in [resence] tissue bymmunoluorescence
34887-0,peste des petis a[ql] virus rumiants n issue by immunofluorescnce
34887-0,pprv ag tiss ql if
34887-0,pprv ag if ql tiss
34887-0,pprvag ql tiss if
34887-0,peste des petits ruminants virus ag if ql (tiss)
34887-0,peste des petits ruminants (tiss) ag if ql virus ql
34887-0,peste des petits ruminants if ag virus ql ifa (tiss)
88143-3,fungus identified in cornea or conjunctiva by culture
88143-3,by identifidn crnea or conjuntia fungus culture
88143-3,fungs culture inconea or onjunctiva by identified infectiousdisease
88143-3,fungus corn/cnjt cult
88143-3,ungus corn/cnjt clt id
88143-3,corn/cnjt fngus cut
88143-3,fungus identified cx nom (corn/cnjt)
88143-3,fungus identified random cx nom (corn/cnjt)
88143-3,fungi fungus dentified cx nom (corcnjt)
79221-8,steroid fractions panel - serum or plasma
79221-8,steroid fractions panel - ser or plasma
79221-8,steroid frac plasma panel - serum or fractions
79221-8,steroid fract pnl serpl
79221-8,pnl fract steroid serpl
79221-8,serp steroid serpl pnl fract
79221-8,steroid fractions panel
79221-8,fractions steroid panel
79221-8,steroid panel fractions
88301-7,kappa light chains.free [presence] in 24 hour urine by immunofixation
88301-7,kappa light chains.free [presence] in 24 qualitative hour urine by immunofixation
88301-7,kapa ligh chains.free [presence] in 24 o immunoixation b urne
88301-7,kappa lc free 24h ur ql ife
88301-7,hematology appa lc free 24h ur presence ie
88301-7,appac free immuno 2h ife ql ur
88301-7,immunoglobulin light chains.kappa.free immunofixation ql (24h u)
88301-7,(24 lighthains.kappa.freimmunofxation ql immunoglobulin u)
88301-7,u) light chains.kappa.free immunofixation ql (24h immunoglobulin
73948-2,jwh-122 (synthetic cannabinoid) [presence] in blood
73948-2,jwh-122 (synthetic cannabinoid) [ql] in blood
73948-2,jwh-122 (synthetic [presence] cannabinoid) in blood
73948-2,jwh-122 bld ql
73948-2,jwh-2 d presence
73948-2,bdql drugs of abuse jwh-122
73948-2,jwh-122 (synthetic cannabinoid) ql (bld)
73948-2,jwh-122 drugs (synthetic cannabinoid) presence (bld)
73948-2,jwh-122 cannabinoid) (synthetic ql (bld)
30077-2,amylase/creatinine renal clearance [ratio] in urine and serum or plasma
30077-2,amyas/creatiine renal clearnce[ratio] in urin ndserum cr or plasma
30077-2,amylase/cretinine or clearance [rato] in urine an ser rl plasma
30077-2,amylase/cr cl ur+serpl-rto
30077-2,amylase/cr ur+serpl-rto cl
30077-2,amylase/cr ur+serpl-rto amyl cl
30077-2,amylase/creatinine renal clearance (u+s/p) [ratio]
30077-2,(u+s/p) random renal clearance amylase/creatinine [ratio]
30077-2,amas/creatinine renal learance k87 [ratio] (u+s/p)
6473-3,microscopic observation [identifier] in tissue by trichrome stain
6473-3,microbiology microscopic orvation [idetifie] trichrome tissue by in stain
6473-3,microscopic observation [identifier] in tissue by trichrome stain
6473-3,tri stn tiss
6473-3,tiss infectiousdisease ist
6473-3,tri tiss stn
6473-3,microscopic observation trichrome stain nom (tiss)
6473-3,mroscopi obsrvationtrihome infectiousdisease stain nom (tiss)
6473-3,microscopic obevation trihrme no stain (tiss)
32841-9,neisseria meningitidis serogroups c+w135 ag [presence] in specimen
32841-9,neissera meningitidis serogroupsc+3 ag [presece] in specime
32841-9,neisseria in serorpsc+w13 g [resnce] meningitdis scie
32841-9,n men sg c+w135 ag spec ql
32841-9,n mn sg c+w15 ag specql
32841-9,n en s cw135 agspec ql
32841-9,n. meningitidis c+w135 ag ql (specimen)
32841-9,meningitidis n. c+w135 ag presence (specimen)
32841-9,n. meningitidis c+w135 (specimen) ql ag
30028-5,o-ethyl o-(p-nitrophenyl) phenylphosphonothionate [mass/volume] in serum or plasma
30028-5,o-ethyl o-(p-nitrophenyl) phenylphosphonothionate [mass/volume] in serum or plasma drugs
30028-5,o-ethyl o-(p-nitrophenyl) phenylphosphonothionate or in serum [mass/volume] plasma
30028-5,epn serpl-mcnc
30028-5,serpl-mcnc point in time epn
30028-5,pn serpl-mcnc epn
30028-5,o-ethyl o-(p-nitrophenyl) phenylphosphonothionate [mass/vol]
30028-5,o-(p-nitrophenyl) o-ethyl phenylphosphonothionate [mass/vol] point in time
30028-5,o-ethy o-(nitrophenyl) phnylphosphonothionate [ms/vo]
70053-4,hantavirus hantaan igm ab [presence] in serum or plasma by immunofluorescence
70053-4,hantavirus hantaan igm ab [presence] plasma serum or in by immunofluorescence
70053-4,hantavirus anaan igm ab [presence] in ser orplasma by imunfluorescence
70053-4,htnv igm serpl ql if
70053-4,tv igm erpl presence if
70053-4,htnv igm serpl ql point in time if
70053-4,hantavirus hantaan igm if ql
70053-4,hantavirus antaan gm  l
70053-4,presence hantaan igm if hantavirus
63385-9,dna double strand igg ab [units/volume] in body fluid by flow cytometry (fc)
63385-9,double dna strand igg ab [units/volume] in body fluid by flow cytometry (fc)
63385-9,dna flow strand igg ab [units/volume] in body fluid by double cytometry (fc)
63385-9,dsdna igg fld fc-acnc
63385-9,dsdn igfldfc-acnc arbitrary concentration
63385-9,dsdna igg fl fc-acnc
63385-9,dna double strand igg fc qn (body fld)
63385-9,dna (body strand igg fc body fluid qn double fld)
63385-9,dna doble strndiggfc qn (body fld)
11256-5,haemophilus influenzae b igg ab [mass/volume] in serum
11256-5,haemophilus influenzae b igg [mass/volume] ab in ser
11256-5,haemophilus influenae big ab [mas/volume] in serum serum
11256-5,haem influ b igg ser-mcnc
11256-5,hae influ b igg serum-mcnc
11256-5,influ hem b igg ser-mcnc
11256-5,h. influenzae b igg (s) [mass/vol]
11256-5,h. influenzab (s igg [mas/vl]
11256-5,h. influenze b igg (s) mas/vol]
58762-6,coxiella burnetii phase 2 igg ab [units/volume] in cerebral spinal fluid by immunoassay
58762-6,coxiella burnetii phase 2 igg ab immunoassay in cerebral spinal fluid by [units/volume]
58762-6,coxiella burnetii phase 2 igg in [units/volume] ab cerebral spinal fluid by immunoassay
58762-6,c burnet ph2 igg csf ia-acnc
58762-6,cburetph2 i-acnc cs ig
58762-6,c burnet q fev ph2 ig sf ia-acnc
58762-6,c. burnetii phase 2 igg ia qn (csf)
58762-6,c. burnetii qfever phase 2 igg ia qn (cerebrospinal fluid)
58762-6,c. burnetii ia 2 igg phase qn (csf)
55150-7,anaplasma phagocytophilum igg and igm panel - serum qualitative
55150-7,analma phagocytophilum and igg igm pane - erum ualitatve
55150-7,qualitative phagocytophilum igg and igm pan panel - serum anaplasma
55150-7,a phagocytoph igg+igm pnl ser
55150-7,a phagocytoph igg+igm immunoglobulin m pnl ser
55150-7,a phocytoph ig+igm serum pnl
55150-7,a. phagocytophilum igg and igm panel ql (s)
55150-7,a. phagocytophilum igg and igm panel ql (s)
55150-7,a. igm igg and phagocytophilum serum panel ql (s)
13367-8,beta aminoisobutyrate [mass/volume] in cerebral spinal fluid
13367-8,bet aminoisobutyrate massolume] ceeral in spinalflui
13367-8,beta aminoisobutyrate [mass/volume] in fluid spinal cerebral
13367-8,b-aib csf-mcnc
13367-8,csf-mcnc chemistry b-aib
13367-8,b-aib csf-mcnc mass concentration
13367-8,beta aminoisobutyrate (csf) [mass/vol]
13367-8,beta aminosobutyrate 3-aminoisobutyric acid (cs) [as/vl]
13367-8,be aminoioutyate (csf) mass/vol]
5603-6,borate [mass/time] in 24 hour urine
5603-6,in [mass/time] borate 24 hour urine
5603-6,borate drugs [mass/time] in 24 hour urine
5603-6,borate 24h ur-mrate
5603-6,ur-mrte ur 24h bore
5603-6,borate 24h ur-mrate 1 day
5603-6,borate (24h u) [mass/time]
5603-6,borate (24 ) drug/toxicology [mass/time]
5603-6,borat (24h u) [mass/time]
5612-7,cadmium [mass/time] in 24 hour urine
5612-7,cadmium hour in 24 [mass/time] urine
5612-7,[ass/time] cadmiu in 24 hour ur urine
5612-7,cadmium 24h ur-mrate
5612-7,cadmiu ur-mrae 24h
5612-7,cadmium ur-mrate 24h
5612-7,cadmium (24h u) [mass/time]
5612-7,[mass/tme] (24h ) quant cadmium
5612-7,u (24 admium [mass/time]
58682-6,sulfatides [mass/volume] in urine
58682-6,sufatids[mas/volume] in urn urie
58682-6,[mass/volume] sulfatides in urine
58682-6,sulfatides ur-mcnc
58682-6,r-mcn sulfatides
58682-6,ur-mcn sulfatides
58682-6,sulfatides (u) [mass/vol]
58682-6,[mass/vol] level (u) sulfatides
58682-6,sulfatides (u) urn [mass/vl]
27148-6,deprecated streptococcus pneumoniae 19 ab [mass/volume] in serum --1st specimen
27148-6,specimen treptococcus pneumoiae ab [mas/volume] in serum --1st deprecated
27148-6,deprecated streptococcus pneumoniae 19 ab [mass/volume] in pneu serum --1st specimen
27148-6,deprecated s pneum19 ab sp1 ser-mcnc
27148-6,deprecated sp1 pneum19 ab s serum-mcnc
27148-6,deprecated pneum19 s ab sp1 s pneumoniae ser-mcnc
27148-6,s. pneumoniae 19 ab spec 1 (s) [mass/vol]
27148-6,s. pnumoniae 19 ab spec [ms/vol (s)
27148-6,s. pumoniae 19 ab spe1 (s) [mas/vol]
81811-2,3-hydroxydecanoylcarnitine (c10-oh) [moles/volume] in dbs
81811-2,3-hydroxdecanylcarnitine (c10-oh) iii ds in [mole/volme]
81811-2,quant 3-hydroydecaylcanitine (c10-oh) [molesvolum] in db
81811-2,3-oh-decanoylcarn dbs-scnc
81811-2,3-oh-decanoylcarn dbs-scnc random
81811-2,3oh-ecanoylcarn dbs-scnc
81811-2,c10-oh (dbs) [moles/vol]
81811-2,c10-oh (dbs) [moles/vol] c10-oh
81811-2,whole blood c10-oh (dbs) [moles/vol]
23181-1,leptospira interrogans sv hardjo ab [presence] in serum
23181-1,autoantibody leptospira interrogans sv in ab [ql] hardjo serum
23181-1,leptospira interrogans sv hardjo ab in [presence] serum
23181-1,l inter hard ab ser ql
23181-1,l inter hard ser ab ql
23181-1,l inter ser ab hard ql qualitative
23181-1,l. interrogans sv hardjo ab ql (s)
23181-1,ab inerroganss harjo aby l. presence (s)
23181-1,infectious disease l. interrogans sv hardjo a ql (s)
43282-3,heterophile ab [presence] in control serum
43282-3,heterophile ab [ql] in cntrol serum
43282-3,heterophile ab [presence] in serum control
43282-3,heteroph ab ser cont ql
43282-3,ab heteroph er cont ql
43282-3,cont ab serum heteroph ql id
43282-3,heterophile ab ql (s control)
43282-3,ql( mono screen heterohilea control)
43282-3,presence ab heteroph heterophile (s control)
59063-8,lymphocyte proliferation panel - blood
59063-8,lymphocyte proliferation - panel blood
59063-8,lymphocyte oiferation - panel blood blood
59063-8,lymphocyte prolif pnl bld
59063-8,prolif lymphocyte pnl blood
59063-8,lymphocyte prolif pnl bld
59063-8,lymphocyte proliferation panel (bld)
59063-8,lymphocyte proliferation panel (bld)
59063-8,lphocyte pan rolieation panel (bld)
75138-8,succinylaminoimidazole carboxamide riboside/creatinine [molar ratio] in urine
75138-8,succinylainoimiazole caroxamidiboside/creaiine [molar rai] in urine
75138-8,[mola carboxamide rbside/creatinine succinylaminoimidazole rtio] in urine
75138-8,saicar/creat ur-srto
75138-8,ur-srto saicar/cret
75138-8,ur-srto saicar/creat
75138-8,succinylaminoimidazole carboxamide riboside/creatinine (u) [molar ratio]
75138-8,succinylaminoimidazole carboxamide scrto riboside/creatinine [molar (u) ratio]
75138-8,succinylmnoimidazole carboxade (u) ucr riboside/creatiine [molar rato]
49334-6,adenovirus dna [#/volume] (viral load) in serum or plasma by naa with probe detection
49334-6,adenoviru dna [#/voume] (iral load in rum number concentration o plas by na wth probedetecton
49334-6,denovirus dn[#/voume] (virl lod) in serum or plasma by naa with probe etction
49334-6,hadv dna # serpl naa+probe
49334-6,hadv dna # serpl naa+probe
49334-6,hadv dna # serpl naa+probe hadv
49334-6,adenovirus dna naa+probe [#/vol]
49334-6,adenovirus [#/vol] naa+probe dna
49334-6,adenovirus [#vol] a+proe da
17862-4,calcium [mass/volume] in urine
17862-4,calcium [mass/olume] urn i urin
17862-4,calcium [mss/voume] in urine
17862-4,calcium ur-mcnc
17862-4,ur-mcnc level calcium
17862-4,ur-mcnc calcium
17862-4,calcium (u) [mass/vol]
17862-4,(u) calcium [mass/vol]
17862-4,alciu (u) [mss/vol]
90300-5,helminth identified in specimen by naa with probe detection
90300-5,helminth in amplified identiied secimen bynaa withrobe detein
90300-5,with identified in specimen by naa helminth probe detection
90300-5,worm spec naa+probe
90300-5,worm spec naa+probe probe with ampification
90300-5,worm naa+probe spec
90300-5,helminth identified naa+probe nom (specimen)
90300-5,helminth identified naa+probe nom (specimen)
90300-5,helminth identified naa+probe nom worms (specimen)
104457-7,varicella zoster virus iga ab [presence] in cerebral spinal fluid by immunoassay
104457-7,varicella zster viru iga ab [presen] i chickenpox cerebral spinal fluid y mmunssay
104457-7,varicella zoster virus iga ab [presence] in cerebral spinal by fluid immunoassay
104457-7,vzv iga csf ql ia
104457-7,vzv zoster iga csf ql ia
104457-7,vzv ga sf ql ia
104457-7,vzv iga ia ql (csf)
104457-7,meia vzv iga ql ia (csf)
104457-7,immune globulin a vzvigaiaql (csf
16609-0,chlorphentermine [units/volume] in blood
16609-0,[units/volume] chlorphentermine in blood
16609-0,i chlrphentemie[unts/volume] blood blood
16609-0,chlorphentermin bld-acnc
16609-0,clorentermin drugs ld-acnc
16609-0,bld-anc chlorphenrmin
16609-0,chlorphentermine qn (bld)
16609-0,chrphentermine lucofen qn (bld)
16609-0,lucofen chlorphentermine qn (bld
6360-2,clostridioides difficile toxin a [units/volume] in specimen by immunoassay
6360-2,clostidioides difcil toxin a [uitsvolume] in specimen by immunoassa
6360-2,clostridioides difficile toxin a [units/volume] id in specimen by immunoassay
6360-2,c diff tox a spec ia-acnc
6360-2,c diff tox a ia-acnc spec
6360-2,c diff ia-acnc a spec tox
6360-2,c. difficile toxin a ia qn (specimen)
6360-2,c. ifficile txin a ia qn (specmen)
6360-2,c. difficile toxin a ia (specimen) qn
20523-7,chlorpromazine [mass/volume] in urine by confirmatory method
20523-7,hlorpromazine in [mass/volume] urine by confirmatory method
20523-7,chlorpromazine method in urine by confirmatory [mass/volume]
20523-7,chlorpromazine ur cfm-mcnc
20523-7,ur random chlorpromazine cfm-mcnc
20523-7,chlorpromazine cfm-mcnc ur
20523-7,chlorpromazine confirm (u) [mass/vol]
20523-7,[mass/vol] confirm (u) chorproazie
20523-7,chlorpromazine (u) confirm [mass/vol] level
79342-2,carnitine biosynthesis intermediates pattern [interpretation] in urine narrative
79342-2,crnitinebiosynthesis itermediates atern [interpretation] inurine narrative
79342-2,carnitinebiosynthesis [interpretation paern interediates in urine narrative
79342-2,carnitine biosynthesis pattern ur-imp
79342-2,pattern biosynthesis carnitine ur-imp
79342-2,crnitine biosnthesis pattern ur-im
79342-2,carnitine biosynthesis intermediates pattern nar (u) [interp]
79342-2,carnitine pattern intermediates biosynthesis nar (u) [interp] ur
79342-2,nterediate carnitineosynthesis pattern nar( [iterp] report
79233-3,naphyrone cutoff [mass/volume] in urine for confirmatory method
79233-3,naphyrone cutoff [mass/volume] in urine for confirmatory method ua
79233-3,napyrone cutoff [masvolume]in urine for confiratory method
79233-3,naphyrone cto ur cfm-mcnc
79233-3,naphyrone r cto cm-mcnc
79233-3,naphyrone cfm-mcnc ur cto cnfrm
79233-3,naphyrone cutoff confirm (u) [mass/vol]
79233-3,[mass/vol cutoffofirm (u naphyrone cnfr
79233-3,naphyronecutoff (u) onfirm [ass/vl
80330-4,genitourinary assessment panel
80330-4,genitourinar assessmet panel
80330-4,assessment genitourinary panel panel.h&p
80330-4,gu assessment pnl
80330-4,gu assessment point in time pnl
80330-4,pan gu assessment pnl
38338-0,cyanide [mass/volume] in water
38338-0,cyanide water in [mass/volume]
38338-0,canide wate wat in [mass/volume]
38338-0,cyanide wat-mcnc
38338-0,cynie wat-mc
38338-0,wat-mcn cande random
38338-0,cyanide (water) [mass/vol]
38338-0,cyanide [mass/vol] (water)
38338-0,random (water canide ms/vol]
48932-8,"respiratory allergen panel, us - alaska b - serum"
48932-8,"rspiratory - anel, us -alaska b llergen serum universallaborders"
48932-8,"rspiratory allergen random panel, u - alska b - seum"
48932-8,resp allergen ak b pnl ser
48932-8,resp allergen ak pnl b ser
48932-8,pnl allergen ak resp allergen ak b pnl b resp ser
48932-8,"respiratory allergen panel, us - alaska b (s)"
48932-8,"respirtory llergen pnel, panl us - alaskab s)"
48932-8,"respiratory us pne, allergen - laka b s)"
22231-5,coxsackievirus b4 ab [titer] in cerebral spinal fluid
22231-5,coxsackievirus b4 ab [titer] in cerebral spinal fluid
22231-5,coxsackievirus 4 b [titer] incerebral sinalflid
22231-5,cv b4 ab titr csf
22231-5,titr b4 ab cv csf
22231-5,dilution factor c b4 itrcsf ab
22231-5,coxsackievirus b4 ab (csf) [titer]
22231-5,coxsackievirs b4 [tite] (cf) ab
22231-5,cv coxsackievirus b4 ab (csf) [titer]
34226-1,3-alpha-androstanediol glucuronide/creatinine [molar ratio] in urine
34226-1,3-alpha-adrostanediol [mola glucronide/creatinine ratio] quan in urine
34226-1,-aha-androtanediol gluoide/creatinine substance ratio [molar raion urine
34226-1,3a-diol g/creat ur-srto
34226-1,ur-srto 3a-diolg/crea
34226-1,3a-diol g/creat ur-srto
34226-1,3-alpha-androstanediol glucuronide/creatinine (u) [molar ratio]
34226-1,-alpha-androsanediol glucuronide/cratinin rtio] molr (u)
34226-1,3-alpha-androstanediol glucuronide/creatinie (u) mola ratio]
35144-5,neuronal nuclear type 3 ab [titer] in cerebral spinal fluid
35144-5,neuronal nucler tye [titer]in ab 3 cerebra spina fluid
35144-5,neuronal nuclear type ab [tter in cerebral spil fluid neurology
35144-5,hu3 ab titr csf
35144-5,csf tir hu3 nuc
35144-5,hu3 ab ir cf
35144-5,neuronal nuclear type 3 ab (csf) [titer]
35144-5,neuronal nuclear type 3 ab (csf) [titer]
35144-5,neuronal nuclear type [titer] ab (csf) 3
63265-3,jo-1 extractable nuclear ab [presence] in body fluid by immune diffusion (id)
63265-3,(id) extractable nuclear serology ab [presence] in body fluid by immune diffusion jo-1
63265-3,extractable jo-1 nuclear ab [presence] in body fluid by immune imune diffusion (id)
63265-3,ena jo1 ab fld ql id
63265-3,autoantibodies ena fld ab o1 lid
63265-3,ena fld ab jo1 presence id
63265-3,jo-1 extractable nuclear ab immune diff ql (body fld)
63265-3,jo-1 diff nuclear ab immune extractable immunodiffusion ql (body fld)
63265-3,ql extactable nuclear abimmune diff jo-1 (body fl)
73928-4,jwh-250 5-hydroxypentyl (synthetic cannabinoid metabolite) [presence] in blood
73928-4,jwh-250 5-hdroxypentyl (synteic annabioid mebolite ql [preence] in lood
73928-4,jwh-250 in (synthetic cannabinoid metabolite) [presence] 5-hydroxypentyl bld
73928-4,jwh-250 5oh-pentyl bld ql
73928-4,ql bld jwh-2505oh-pentyl
73928-4,blood bld 5oh-pentyl jwh-20 q
73928-4,jwh-250 5-hydroxypentyl ql (bld)
73928-4,jwh-250 (bld) ql 5-hydroxypentyl potentialforabuse
73928-4,jwh-50 potentialforabuse (bld) ql -hydxypentyl
57675-1,legionella pneumophila igg ab [presence] in serum by immunofluorescence --1st specimen
57675-1,legionella pneumophila igg in [presence] ab ser by immunofluorescence --1st specimen
57675-1,egionella pneumophila gg ab [presence] in seum by imunofluoesene --1st specie
57675-1,l pneumo igg sp1 ser ql if
57675-1,l sp1 igg pneumo ser ql if
57675-1,l pneumo igg sp1 ser ql if
57675-1,l. pneumophila igg spec 1 if ql (s)
57675-1,pnemopha igg if serum 1 spec ql (s)
57675-1,if pneumophila igg spec 1 l. ql (s)
54005-4,nuclear membrane pores nuclear ab pattern [presence] in serum by immunofluorescence
54005-4,nulea membneporsnuclear ab atter i [presence] serum by immunoflurescence
54005-4,nuclea pores embrae trf nuclear ab patten [preence]in serum by mmunofluoescenc
54005-4,ana nuclear membrane pores ser ql if
54005-4,ana nucleamembrane pores serum ql if antinuclear antibody
54005-4,ana nuclear membrane pores ql serum if
54005-4,nuclear membrane pores nuclear ab pattern if ql (s)
54005-4,nclear membrane fluorescent antibody ores nuclear ab pattern if qls)
54005-4,nuclear pr membrane pores nuclear ab pattern if ql (s)
14612-6,nuclear ab [titer] in pericardial fluid
14612-6,nuclear ab [titer] pericardial in fluid
14612-6,nuclear ab [titer] ana in pericardial fluid
14612-6,ana titr pcar
14612-6,titr an pca
14612-6,pcar ana titr pcar
14612-6,nuclear ab (pericard fld) [titer]
14612-6,nuclear ab (pericard titered fld) [titer]
14612-6,nuclear ab (pericard fld) random [titer]
48753-8,3-hydroxydodecanoate.free (3-oh-c12:0) [moles/volume] in serum or plasma
48753-8,3-hydroxydoecanoat.free non-protein bound 3oh-c12:0) [oles/olum] in serumor lasma
48753-8,3-hydroxyddecanoate.free (3-h-c2:0) [moes/volume]in serum or plsma
48753-8,3oh-dodecanoate.free serpl-scnc
48753-8,serpl-scnc 3oh-odecanoate.free
48753-8,serpl-scnc 3oh-dodecanoate.free
48753-8,3-hydroxydodecanoate.free (3-oh-c12:0) [moles/vol]
48753-8,[moles/vol] pl (3-h-c1:0) -hydroxydodecnate.free
48753-8,(3-oh-c12:0) 3-hydroxydodecanoate.free [moles/vol]
73566-2,dextrorphan [mass/volume] in urine
73566-2,in [mass/volume] dextrorphan urine
73566-2,quantitative dextrorphan [massvolume] in urne
73566-2,dxo ur-mcnc
73566-2,dxo ur-mcnc
73566-2,ur-mcnc dxo drug/toxicology
73566-2,dextrorphan (u) [mass/vol]
73566-2,dextrorphan [mass/vol] (u)
73566-2,illicit [mass/vol] (u) dextrorphan
21457-7,phorate [mass/volume] in urine
21457-7,phorate [mass/voue in urie
21457-7,level [massolume] horate inurine
21457-7,phorate ur-mcnc
21457-7,ur-mcnc phorate
21457-7,level phorate ur-mcnc
21457-7,phorate (u) [mass/vol]
21457-7,phrate (u) [mass/vol] urn
21457-7,phorate [mass/vol (u)
54067-4,clostridioides difficile toxin genes [presence] in stool by naa with probe detection
54067-4,costrdoides dificle toxin genes [ql] qual in sool by naa with probe detection
54067-4,clotridioids dfficile toxin genes[presence]in stool by naa with probe detection
54067-4,c diff tox gens stl ql naa+probe
54067-4,c diff tox sda gens naa+probe presence stl
54067-4,c diff stl gens tox presence naa+pob
54067-4,c. difficile toxin genes naa+probe ql (stl)
54067-4,c. diicle toxin genes naa+probe presence (stl)
54067-4,c. difficile toxin genes naa+probe ql (stl)
16179-4,polychlorinated biphenyl (pcb) [mass/mass] in tissue
16179-4,polyhlrinat biheny tisue [mass/mass] (pcb)
16179-4,polychlorinated biphenyl (pcb) [mass/mass] polychlorinated biphenyls in tissue
16179-4,pcb tiss-mcnt
16179-4,pcb tiss-mcnt point in time
16179-4,tiss-mcnt pcb
16179-4,polychlorinated biphenyl (pcb) (tiss) [mass/mass]
16179-4,"(pcb) tissue, unspecified bpenyl polychlorinatd (tiss) [mass/mss]"
16179-4,"plychlorinated biphenyl tissue, unspecified (pcb)tiss)[mass/mass]"
22567-2,streptococcus pyogenes enzyme ab [titer] in serum
22567-2,strepoccus enzyme pyogenes ab [titer] in seum
22567-2,streptococcus strept pyogenes enzyme ab in [titer] serum
22567-2,s pyog.enz ab titr ser
22567-2,s pyog.enz ab titr infectiousdisease ser
22567-2,pyog.enzab s titr serum
22567-2,s. pyogenes enzyme ab (s) [titer]
22567-2,s. (s) enzyme ab pyogenes [titer]
22567-2,s. pyogenes enzymeab id (s) [titer]
29921-4,boron [mass/time] in 24 hour urine
29921-4,boron [mass/time] in 24 urine hour
29921-4,boron urn [mass/time] in24 hour urne
29921-4,boron 24h ur-mrate
29921-4,boron ur-mrate 24h
29921-4,quantitative boron 24h ur-mrate
29921-4,boron (24h u) [mass/time]
29921-4,boron (24h u) [mass/time]
29921-4,boron (24h u) quan [mass/time]
58102-5,current number of unhealed (non-epithelialized) pressure injuries at each stage [oasis-c]
58102-5,current number no injuries unhealed (non-epithelialized) pressure of at each stage [oasis-c]
58102-5,curret number of unhealed(non-epithelialized) pressure injuries at eachstage [asisc]
56497-1,choriogonadotropin.beta subunit [units] in 24 hour urine
56497-1,hour subunit [units] in 24 choriogonadotropin.beta urine beta hcg
56497-1,in subunit [units] choriogonadotropin.beta 24 hour urine
56497-1,b-hcg 24h ur
56497-1,b-hcg ur 24h arbitrary rate
56497-1,b-hcg 24h ur b hcg
56497-1,hcg.beta subunit (24h u) [units/time]
56497-1,choriogonadotropins total hcg.beta subunit (24h u) [units/time]
56497-1,[units/time] subunit (24 ua u) hcg.beta
24020-0,streptococcus agalactiae ag [presence] in urine
24020-0,agalactaeag steptococcus point in time [preence] in urine
24020-0,strptococcus agalactiae in [presence] ua a urin
24020-0,gp b strep ag ur ql
24020-0,ag b strep gp ur steptococcus group b ql
24020-0,gp b ql r strepag
24020-0,s. agalactiae ag ql (u)
24020-0,s. (u) ag presence agalactiae
24020-0,agalactiae s. ag ql (u)
33657-8,beta-n-acetylhexosaminidase.a [moles/volume] in leukocytes
33657-8,beta-n-acetylhexosaminidase.a in gm2-gangliosidosis [moles/volume] leukocytes
33657-8,beta-n-acetylhexosminidase.a moles/volm] in eukocytes random
33657-8,hexosaminidase a wbc-scnc
33657-8,hexosaminidase a beta-hexosaminidase subunit alpha wbc-scnc
33657-8,wbc-scn a xosaminidase
33657-8,beta-n-acetylhexosaminidase.a (wbc) [moles/vol]
33657-8,[moles/vol] (wbc) beta-n-acetylhexosaminidase.a
33657-8,(wbc) eta-n-acetylheosamidase.a [moles/vol]
16490-5,brucella suis ab [units/volume] in serum by latex agglutination
16490-5,bucela suis ab [units/volume] in lat sr by latexaggltinatio
16490-5,brucella suis ab [units/volume] in ser by latex agglutination
16490-5,b suis ab ser la-acnc
16490-5,b suis ab random serum la-acnc
16490-5,suis b ab ser la-acnc
16490-5,b. suis ab la qn (s)
16490-5,b. suis qn la ab (s)
16490-5,b. la ab suis qn (s)
34216-2,11-ketoetiocholanolone [moles/volume] in 24 hour urine
34216-2,1-ketotiocolanoone [molesvolum] in 2 hour urine
34216-2,11-ketoetiocholanolone [moles/volume] hour 24 in urine
34216-2,11ketoetioch 24h ur-scnc
34216-2,24h 11ketoetioch ur-scnc
34216-2,11ketotioch 24ur-scn
34216-2,11-ketoetiocholanolone (24h u) [moles/vol]
34216-2,(24h 11-ketoetiocholanolone u) [moles/vol]
34216-2,(24h 11-ketoetiocholanolone u) molesvol]
2553-6,lactose [presence] in urine
2553-6,in [presence] lactose screen urine
2553-6,lactse [presence qual in urine
2553-6,lactose ur ql
2553-6,ur ua lactose ql
2553-6,ql ur lactose
2553-6,lactose ql (u)
2553-6,lactose presence (u)
2553-6,presence (u) presence lactose
101851-4,flunisolide [moles/volume] in urine
101851-4,flunisolide urine in [moles/volume]
101851-4,[moles/volue] flunisolide inurin
101851-4,flunisolide ur-scnc
101851-4,drugs flunisolidur-scnc
101851-4,quan funsolide ur-scnc
101851-4,flunisolide (u) [moles/vol]
101851-4,(u) flunisolide [moles/vol]
101851-4,flunisolide aerobid (u) [mols/v]
101231-9,neuronal nuclear ab [presence] in cerebral spinal fluid by immunoblot
101231-9,neuronal nuclear [presence] ab cerebrospinal fl in cerebral spinal fluid by immunoblot
101231-9,[presence] nuear cerebrospinal fl a neurnl in creral spinal fluid by immunoblot
101231-9,hu ab csf ql ib
101231-9,immunobl qlib abcsf hu
101231-9,hu ab csf presence ib
101231-9,neuronal nuclear ab ib ql (csf)
101231-9,neronal ql ab ib nuclear (csf)
101231-9,neuronal nuclear ab autoantibody ib ql (cerebrospinal fluid)
75086-9,catecholamine metabolites pattern [interpretation] in urine narrative
75086-9,catecholami metabolites narrative [interpretation]in rine report pattern
75086-9,catechoamine etaboites rrative [interpretaio] in ne pattr
75086-9,catecholamine pattern ur-imp
75086-9,ur ur-imp pattern catecholamine
75086-9,catehoamine pattern r-im impression
75086-9,catecholamine metabolites pattern nar (u) [interp]
75086-9,interp catecholamine metabolites pattern (u) nar [interp]
75086-9,(u) mtblites pattrn nar atecholamine [nerp
45127-8,vesicular stomatitis new jersey virus ag [presence] in specimen by immunoassay
45127-8,vesicular stomatitis ag jersey virus new [presence] in specimen by immunoassay
45127-8,vesicular [presence] newjerse viru ag vsv-nj stomatitis inspecimen by immunoassay
45127-8,vsnjv ag spec ql ia
45127-8,vsnjv spec ag ql ia
45127-8,vsnjv spec a presence ia
45127-8,vesicular stomatitis new jersey virus ag ia ql (specimen)
45127-8,stomatitis vsicular new jerse virs ag ia ql (pecimen)
45127-8,vesicular enzyme immunoassay stomatitis new jersey virus ag ia ql (specimen)
15349-4,alkaline phosphatase.liver 2/alkaline phosphatase.total in serum or plasma
15349-4,alkalinephosphtase.liver 2/alkaline hophatse.total n ser rplasma quan
15349-4,alkaline or 2/alkaline phosphatase.total in serum phosphatase.liver plasma
15349-4,alp liver 2 cfr serpl
15349-4,alp liver 2 cfr tot serum or plasma
15349-4,alp liver serpl cfr 2
15349-4,alp liver 2 [catalytic fraction]
15349-4,fraction] liver 2 [catalytic alp plasma
15349-4,ctaytic 2 alpliver frction]
15190-2,leukocytes other [identifier] in blood by automated count
15190-2,leukocytes other [identifier] in blo by electr autmated cont
15190-2,leukocytes other [identifier] in blood count automated by
15190-2,wbc other bld auto
15190-2,wbc other bldauto
15190-2,elec wb oher bld auto
15190-2,wbc other auto nom (bld)
15190-2,wbc (ld) ato white blood cell nom other
15190-2,wc otherauto om (bld)
88527-7,respiratory syncytial virus [presence] in cornea or conjunctiva by organism specific culture
88527-7,respiratoy sncytialvirus [ql] n crnea or conjuntiv by rganis spec specifi ulure
88527-7,respiratory [presence] virus syncyil in cornea or cojunctaby orgaism spcfic cultue
88527-7,rsv corn/cnjt ql cult
88527-7,rsv presence corn/cnjt cult
88527-7,rsv corn/cnjt ql cult
88527-7,rsv org specific cx ql (corn/cnjt)
88527-7,rsv org cult specifccql (corn/cnjt)
88527-7,ql org specific cx rsv (corn/cnjt)
48811-4,protein fractions 3 panel - serum or plasma
48811-4,protein rctions 3 fract pnel - serum or plasma
48811-4,protei ractions 3 panel -serm or plasma
48811-4,protein fractions 3 pnl serpl
48811-4,iii serpl fractions 3 pnl protein
48811-4,protein fractions 3 pnl serpl
48811-4,protein fractions 3 panel
48811-4,prot 3pael fractions proten
48811-4,protein panel 3 fractions
70044-3,granulocytes [#/volume] in pleural fluid by automated count
70044-3,[#/volume] granulocytes in pleural fluid by automated count
70044-3,granulocytes automated in pleural fluid by [#/volume] count
70044-3,granulocytes # plr auto
70044-3,absolutes granulocytes # plr auto
70044-3,granulocytes# auto plr
70044-3,granulocytes auto (pleur fld) [#/vol]
70044-3,fld) auto (pleur granulocytes [#/vol]
70044-3,granulocytes auto (pleur fld) [#/vol] quant
78777-0,alfentanil [mass/mass] in hair
78777-0,[massass] qnt alfetanil in hair
78777-0,hair [mass/mass] in alfentanil quan
78777-0,alfentanil hair-mcnt
78777-0,alfentanil hair-mct
78777-0,alfentanil har-mcnt random
78777-0,alfentanil (hair) [mass/mass]
78777-0,(hair) alfentanil quantitative [mass/mass]
78777-0,[mas/mas] (hair) alfentanil
34299-8,estrone (e1)/creatinine [molar ratio] in urine
34299-8,(e1)/creatnie strone [molar ratio in urin chemistry
34299-8,etrone random (e1)/creatnine rine [molarratio]in
34299-8,estrone/creat ur-srto
34299-8,ur-srto estrone/creat
34299-8,ur-srto estrone/creat
34299-8,e1/creatinine (u) [molar ratio]
34299-8,/creatinine atio] [molar random (u)
34299-8,e1/creatinine [molar (u) ratio]
53353-9,urinalysis other formed elements panel [#/area] - urine by computer assisted method
53353-9,uinalysis oter ored [#area panel eements - uine by ompter assisted method
53353-9,- other formed elements panel [#/area] urinalysis urine by computer assisted method
53353-9,ua othr elem pnl #/area ur comp assist
53353-9,ua othr comp pnl #/area ur elem assist panl
53353-9,ua othr elem pnl #/area ur comp assist
53353-9,urinalysis other formed elements panel computer assisted (u) [#/area]
53353-9,urinalysis other formed elemenspnelomputer assistd(u) [#/area]
53353-9,urinalysis other forme elements pnel comp assist compute asisted (u) [#/area]
6421-2,hepatitis b virus rrna [presence] in specimen by probe
6421-2,virus b heptitis rrna [presene] in specimen by infectious disease probe
6421-2,hepatitis b virus rrna [ql] in specimen by probe
6421-2,hbv rrna spec ql probe
6421-2,ql rrnaspec pr bv pobe
6421-2,ql rrnaspec misc hbv prob
6421-2,hbv rrna probe ql (specimen)
6421-2,hbv rrna probe presence (specimen)
6421-2,hbv rrna probe ql (specimen)
5711-7,pentachlorophenol [mass/volume] in urine
5711-7,urin [mass/olume]in pentaclrphenol
5711-7,pentachlorophenol [mass/volume] in urine
5711-7,pentachlorophen ur-mcnc
5711-7,ur-mcnc pentachlorophen
5711-7,pntachlorophen ur-mcnc mass concentration
5711-7,pentachlorophenol (u) [mass/vol]
5711-7,pentachlorophenol [mass/vol] (u)
5711-7,pentachlorophenol [mass/vol] (u)
17916-8,bacteria # 2 identified in wound shallow by aerobe culture
17916-8,bacteria infectious disease # 2 identified in wound shallow by aerobe culture
17916-8,bacter # 2identiid inwon shalow by aerobe culture
17916-8,bacteria shlw wnd aerobe cult org #2
17916-8,bacteria hlw wd cult aerobe cult org #
17916-8,bacteria shlw wnd cultorg wnd aerobe #2
17916-8,bacteria identified # 2 aer cx nom (shallow wound)
17916-8,bacteria identified cx 2 aer # nom (shallow wound)
17916-8,bactera dentified # 2 aer x nom (shalow woun)
49495-5,hepatitis b virus surface ab actual/negative control in serum or plasma
49495-5,heptitis b vr suface ab acual/negtivcontrol in ser or plaa
49495-5,epatitis plasma virus surfaceab actual/egatve control in serum r b
49495-5,hbv surface ab s serpl
49495-5,hbv ab surface s serpl
49495-5,hbv surface ab s serpl quant
49495-5,hbv surface ab actual/negative control [rel units/vol]
49495-5,actual/negative neg surfae ab hbv cntrol [rel units/vol]
49495-5,cotrl urface a tual/negatve hv [el units/vol]
58229-6,body weight measured --when specimen taken
58229-6,body point in time weight specimen --when measured taken
58229-6,qnt body weight measured --when specimen taken
58229-6,weight when spec taken measured
58229-6,weight measured spec taken when random
58229-6,weight masured spec aken when point in time
22881-7,border disease virus ag [presence] in tissue by immunoassay
22881-7,border diseaseirus tissueby [presence] in ag mmunoasay
22881-7,virus disease border ag [presence] in tissue by immunoassay
22881-7,border dv ag tiss ql ia
22881-7,qlia dv a is brder
22881-7,brder ql ag tiss dv ia
22881-7,border disease virus ag ia ql (tiss)
22881-7,border diseasevus ag pr ia l (tiss)
22881-7,border presence virus disease ag ia presence (tiss)
97623-3,klebsiella aerogenes dna [presence] in synovial fluid by naa with non-probe detection
97623-3,klesiela rgenes dna [esen] with synovial fluid joint aspirate bynaa in no-robe detection
97623-3,klebsiella aerogenes dna [presence] 3sr sr in synovial fluid by naa with non-probe detection
97623-3,k. aerogenes dna snv ql naa+non-probe
97623-3,aerogenes k. dna snv ql naa+non-probe
97623-3,k. dna aerogenes snv strand displacement amplification ql naa+non-probe
97623-3,k. aerogenes dna naa+non-probe ql (syn fld)
97623-3,k. fld infectiousdisease dna naa+non-probe ql (sy aeoees
97623-3,k. aerogenes dna naa+non-probe ql (syn fld)
22460-0,reagin ab [units/volume] in cerebral spinal fluid
22460-0,reagin ab units/volume] arbitrary concentration i ceeral spina fluid
22460-0,reagin ab [units/volume] in cerebral spinal fluid
22460-0,reagin ab csf-acnc
22460-0,reagin csf-acnc ab quant
22460-0,cerebrospinal fluid-acnc random ab reagin
22460-0,reagin ab qn (csf)
22460-0,reagin ab (csf) qn
22460-0,reagin ab infectiousdisease qn (csf)
70533-5,functional assessment of cancer therapy - bladder symptom index questionnaire - 7 items (fblsi) [facit]
70533-5,functonal [faci] o cancer herapy - blader yptm indexquestonnaire - 7 items (fblsi) assssent
70533-5,functiona asssmentof cancer thrapy- bladder smptomindequestionnaire tems - facit - fblsi (fblsi) [facit]
54086-4,hiv 1+2 igg ab [presence] in dbs
54086-4,hiv 1+2 igg in [presence] ab dbs
54086-4,hiv 1+2 in ab [presence] igg abs dbs
54086-4,hiv1+2 igg dbs ql
54086-4,hiv1+2 dbs blood igg ql
54086-4,hiv1+2 infectious disease ql dbs igg
54086-4,hiv 1+2 igg ql (dbs)
54086-4,hiv 1+2 igg aids presence (dbs)
54086-4,1+2 hiv igg presence (dbs)
59169-3,bupropion [presence] in urine
59169-3,urine [presene in bupropo
59169-3,[presence] bupropion in qual urine
59169-3,bupropion ur ql
59169-3,upropion ur l
59169-3,bupropion ur presence
59169-3,bupropion ql (u)
59169-3,bupropion (u) ql
59169-3,bpropion ql (u)
42996-9,leptospira borgpetersenii sv ballum ab [titer] in serum
42996-9,eptospira sr ogpetrseni sv ballum serum [titer]in ab
42996-9,in borgpetersenii sv ballum ab [titer] leptospira serum
42996-9,l borgp ball ab titr ser
42996-9,l titr ab aby borgpall er
42996-9,l borgp ball id ab titr ser
42996-9,l. borgpetersenii sv ballum ab (s) [titer]
42996-9,l. borgpetersenii ab ballum sv (s) [titer]
42996-9,l. borgpetersenii sv [titer] ab (s) ballum
12456-0,histoplasma capsulatum mycelial phase ab [presence] in cerebral spinal fluid
12456-0,hitoplasma psulatum mycelal cerebral ab [resence] in hase spinal fluid
12456-0,hstoplasma capslatum mceial se a [prsenc] in cerebralspinal flud
12456-0,h capsul myc ab csf ql
12456-0,h capsul myc ql cerebrospinal fluid ab random
12456-0,hcapsul myc ab cf ql
12456-0,h. capsulatum mycelial phase ab ql (csf)
12456-0,h. casulatum mycelial phase presence ab (cf)
12456-0,h. capsuaum mcel phse a ql spinal flu cerebrospinal fluid
87963-5,hiv 1 rna tropism [identifier] in cerebral spinal fluid
87963-5,hiv 1 rna tropism fuid in cerebra spinal idntifier
87963-5,hiv 1 rna tropism [idetifier] in cerbral spina fluid
87963-5,hiv1 rna tropism csf
87963-5,hiv1 rna tropism csf
87963-5,hiv1 csf tropism spinal fld rna
87963-5,hiv 1 rna tropism nom (csf)
87963-5,1 hiv rna tropism nom (csf)
87963-5,hiv 1 rna random tropism nom (cerebrospinal fluid)
73169-5,ranitidine induced platelet igm ab [presence] in serum or plasma by flow cytometry (fc)
73169-5,cytometry induced platelet igm ab [presence] in serpl by flow ranitidine (fc)
73169-5,ranitidine induced platelet igm ab [presence] in ser or by plasma flow cytometry (fc)
73169-5,ranitidine ind plt igm serpl ql fc
73169-5,raniidine gm plt ind serum serpl l fc
73169-5,circulating platelet ab ranitidine igm plt ind serpl ql fc
73169-5,ranitidine induced platelet igm fc ql
73169-5,ntidineinduced serum ql im fc patelet
73169-5,ranitidine induced platelet igm fc presence
63386-7,dna double strand igg ab [units/volume] in pleural fluid by flow cytometry (fc)
63386-7,dna double strand igg ab [units/volume] in pleural fluid by flow cytometry (fc)
63386-7,dna double strand gg ab [unitsvolume] inpleura flid by flow cytometry n-dna fc)
63386-7,dsdna igg plr fc-acnc
63386-7,dsdna plr igg fc-acnc
63386-7,dsdna fc-acnc immune globulin g plr igg
63386-7,dna double strand igg fc qn (pleur fld)
63386-7,dna double qn igg fc strand (pleur fld) random
63386-7,da doubl fc igg strand qn ler fld
87780-3,ziprasidone/creatinine [mass ratio] in urine by confirmatory method
87780-3,ziprasidone/creatinine confirmatory ratio] in urine by [mass method
87780-3,ziprsidonecreatinine [mass ratio] urine lc/ms/ms y confirmtor method
87780-3,ziprasidone/creat ur cfm
87780-3,ziprasidone/creat ur point in time cfm
87780-3,cf quant ur ziprasioncreat
87780-3,ziprasidone/creatinine confirm (u) [mass ratio]
87780-3,mass concentration ratio ziprasidone/creatnie confim (u) [mssratio]
87780-3,ziprasidone/creatnne confirm (u) [mass rati] geodon
48652-2,clostridium tetani toxoid igg ab [units/volume] in serum by immunoassay --2nd specimen
48652-2,clostridium tetani toxoid [units/volume] ab igg in serum by immunoassay --2nd specimen
48652-2,clostridium --2nd toxoid igg ab [units/volume] in serum by immunoassay tetani specimen
48652-2,c tetani toxoid igg sp2 ser ia-acnc
48652-2,ia-acnc tetani toxoid igg sp2 serum post immunization c
48652-2,c teani toxoid igsp ia-acnc ser
48652-2,c. tetani toxoid igg spec 2 ia qn (s)
48652-2,ia tetani ooi igg spe 2 c. qn (s)
48652-2,c. an toxoid igg spe 2 ia qn (s)
41759-2,kappa light chains.free/lambda light chains.free [mass ratio] in urine
41759-2,kappa light in light chains.free [mass ratio] chains.free/lambda lambda lc urine
41759-2,in light chains.free/lambda light chains.free [mass ratio] kappa urine
41759-2,kappa lc free/lambda free ur
41759-2,ur lc free/lambda free kappa
41759-2,kappa lc ur re fre/lambda
41759-2,immunoglobulin light chains.kappa.free/immunoglobulin light chains.lambda.free (u) [mass ratio]
41759-2,immunoglobulin light chains.kappa.free/immunoglobulin light chains.lambda.free (u) ratio] [mass
41759-2,immunoglobulin mcrto light chains.kappa.free/immunoglobulin light ratio] (u) [mass chains.lambda.free
17394-8,oxychlordane [mass/volume] in urine
17394-8,oxychlordane in [mass/volume] urine
17394-8,oxychlordane urine in [mass/volume]
17394-8,oxychlordane ur-mcnc
17394-8,ur-mcnc oxychlordane
17394-8,ur-mcnc oxychlordane mass concentration
17394-8,oxychlordane (u) [mass/vol]
17394-8,[mass/vol] (u) level oxychlordane
17394-8,oxychlordae (u) [massvol]
50607-1,neisseria meningitidis serogroups ag panel - specimen by latex agglutination
50607-1,neisseria meningitidis serogroups ag spec panel - agglutination by latex specimen
50607-1,neisseria meningitidis serogroups ag panel - specimen by latex agglutination
50607-1,n men sg ag pnl spec la
50607-1,n sg men ag pnl spec la
50607-1,men n sg ag pnl spec la meningitis
50607-1,n. meningitidis ag panel la (specimen)
50607-1,n. ag meningitidis panel la (specimen)
50607-1,ag meningitidis n. panel la pnl (specimen)
2431-5,homocystine [mass/volume] in urine
2431-5,homocystine in [mass/volume] urine
2431-5,homocystine [mass/volume] in urine level
2431-5,(hcys)2 ur-mcnc
2431-5,ur-mcnc (hcys)2
2431-5,homocystin urcnc (hcys)2
2431-5,homocystine (u) [mass/vol]
2431-5,(u) homocystine [mass/vol] homocyst(e)ine
2431-5,homocytine heart disease (u) [massl]
31266-0,bordetella pertussis ab [units/volume] in specimen
31266-0,bordetella pertussis autoantibody ab [units/volume] in specimen
31266-0,bodtella pertuis a [nts/volue] quant in specimen
31266-0,b pert ab spec-acnc
31266-0,ab autoantibodies bpert spec-cc
31266-0,b pert spec-acnc ab unspecified
31266-0,b. pertussis ab qn (specimen)
31266-0,b. pertusis ab (specimen) qn arbitrary concentration
31266-0,b. pertussis qn ab (specimen)
87456-0,phosphate [mass/volume] in specimen
87456-0,phosphate i phos [mass/volume] in specimen
87456-0,posphate [mass/volume] in specimen inorganic phosphate
87456-0,phosphate spec-mcnc
87456-0,spec-mcnc miscellaneous phosphte
87456-0,phosphat quant spec-cnc
87456-0,phosphate (specimen) [mass/vol]
87456-0,phosphate [mass/vol] (specimen)
87456-0,phosphate(spcimen) [mass/vol]
30469-1,unspecified cells/leukocytes in body fluid
30469-1,quant unpecifid elllukocytes in body fluid
30469-1,unspecified cels/leukocytes in quant body flid
30469-1,unspecified cells nfr fld
30469-1,b/f unspecified fld nfr cells
30469-1,unspecified fluid cells nfr fld
30469-1,unspecified cells/leukocytes (body fld)
30469-1,fld) cells/leukocytes (body unspecified percent
30469-1,unspecified (body cells/leukocytes fld)
17582-8,silver [mass/volume] in dialysis fluid
17582-8,silver [mass/volume] in ag dialysis fluid
17582-8,silver [mass/volume] in fluid dialysis
17582-8,silver dial fld-mcnc
17582-8,dial silver fld-mcnc
17582-8,pt silver dial fld-mcnc
17582-8,silver (dial fld) [mass/vol]
17582-8,siver dl fld) [ma/vl
17582-8,(dia silver fld)[ma/vol]
72997-0,losartan induced neutrophil igm ab [presence] in serum or plasma by flow cytometry (fc)
72997-0,losartan induced neutrophil igm ab [presence] cytometry serum or plasma by flow in (fc) serum
72997-0,losartan induced neutrophil igm ab [presence] in ser or plasma by flow cytometry (fc)
72997-0,losartan (neut) igm serpl ql fc
72997-0,lsara (net) ql neutrophils erp igm fc
72997-0,losartan serpl igm (neut) ql fc
72997-0,losartan induced neutrophil igm fc ql
72997-0,igm induced neutrophil losartan fc ql
72997-0,induced losartan neutrophil igm fc ql
30141-6,igg [presence] in 24 hour urine by immunoelectrophoresis
30141-6,gg [prsence in 24 by urine ur immnoelectrophores
30141-6,igg hour in 24 [presence] urine by immunoelectrophoresis
30141-6,igg 24h ur ql iep
30141-6,igg 24h ur ql iep ur
30141-6,igg ql ur 24h iep
30141-6,igg iep ql (24h u)
30141-6,immunoglobulin g (2h ip l igg u)
30141-6,igg iep (h presence )
17036-5,la crosse virus ab [titer] in serum
17036-5,la in virus ab [titer] random cros ser
17036-5,ab crosse virus la [titer] in ser
17036-5,lacv ab titr ser
17036-5,lacv serum dilution factor titr ab
17036-5,ac a titr serum
17036-5,la crosse virus ab (s) [titer]
17036-5,la virus crosse ab (s) [titer]
17036-5,la crosse virus antibody ab (s) [titer]
4378-6,pemoline [mass] of dose
4378-6,dose [mass] of dose med or substance pemoline
4378-6,pemoline [mass] of dose cylert
4378-6,pemoline dose
4378-6,dose med or substance pemoline dose
4378-6,dose med or substance pemoline dose
4378-6,pemoline (dose) [mass]
4378-6,[mass] pemolin(dose)
4378-6,pemoline (dose) mass]
93859-7,toxoplasma gondii igg ab [presence] in serum from donor by immunoassay
93859-7,toxoplasma gondii point in time igg ab donor in ser from [presence] by immunoassay
93859-7,donor gondii igg ab [presence] in ser from toxoplasma by immunoassay
93859-7,t gondii igg ser donr ql ia
93859-7,t gondii igg ser ordinal donr ql ia
93859-7,t gondii igg ser elfa donr ql ia
93859-7,t. gondii igg ia ql (s donor)
93859-7,t. gondii igg ia ql (s donr)
93859-7,t. gondii igg iaql ( donr)
11468-6,bacillus anthracis ab [units/volume] in specimen by immunofluorescence
11468-6,bacillus immunofluorescence ab [units/volume] in specimen arbitrary concentration by anthracis
11468-6,bacillus anthracis antibody ab immunofluorescence in specimen by [units/volume]
11468-6,b anthracis ab spec if-acnc
11468-6,b anthracis spec ab if-acnc other
11468-6,b aby anthracis ab spec if-acnc
11468-6,b. anthracis ab if qn (specimen)
11468-6,b. anthracis ab if qn (specimen)
11468-6,b. qn splenic fever ab if anthracis (specimen)
46964-3,cryptococcus sp ag [presence] in cerebral spinal fluid by latex agglutination
46964-3,cryptococc p random ag presence] incerebra spinalluid by latex aggluintion
46964-3,cryptococcus sp ag cerebral spinal fluid [presence] in latex spinal flui by cebral gglutination
46964-3,cryptoc ag csf ql la
46964-3,ql ag cerebrospinal fluid cypto la antigens
46964-3,cryptoc ag cf presence la id
46964-3,cryptococcus sp ag la ql (csf)
46964-3,crtococcs species sp agla ql (csf)
46964-3,crytococcus s ag la ql (csf
94367-0,streptococcus pneumoniae dna [presence] in lower respiratory specimen by naa with probe detection
94367-0,streptococcus pneumoniae dna [presence] in lower tma respiratory specimen by naa with probe detection
94367-0,tma streptococcus pneumoniae dna [ql] in lower respiratory specimen by naa with probe detection
94367-0,s pneum dna lower resp ql naa+probe
94367-0,s resp dna lower pneum ql naa+probe
94367-0,naa+probe pneum dna lower resp ql s
94367-0,s. pneumoniae dna naa+probe ql (lower resp)
94367-0,s. pneumoniae ql naa+probe dna (lower resp)
94367-0,s. pneumoniae dna spec naa+probe ql (lower resp)
16970-6,histoplasma capsulatum ab [presence] in serum by complement fixation
16970-6,hitolasma capulatum ab [presence] inserumby complement fixation
16970-6,histoplasma capsulatum ab by in seum [prsence] complement fixatin
16970-6,h capsul ab ser ql cf
16970-6,ser capsul ab id h presence cf
16970-6,ql capsul ab serum h cf
16970-6,h. capsulatum ab cf ql (s)
16970-6,random h. cf ab capsulatum presence (s)
16970-6,serum h. casulatum ab cfql (s)
20579-9,methanol [presence] in serum or plasma by screen method
20579-9,methanol [presence] in serpl drug/toxicology by screen method
20579-9,mehanl [presence] inrum or lasmaby method cren serplas
20579-9,methanol serpl ql scn
20579-9,methanol scn ql serpl
20579-9,plasma methanolserpl cn q
20579-9,methanol screen ql
20579-9,serpl methaol sree ql
20579-9,methanol ql screen
17583-6,sjogrens syndrome-a extractable nuclear ab [presence] in serum by immunofluorescence
17583-6,sjogrens immunofluorescence extractable nuclear ab [presence] in serum by syndrome-a
17583-6,nuclear syndrome-aextratabl sjorens b [presence in serum by imunofluorescence
17583-6,ena ss-a ab ser ql if
17583-6,ena ser ab ss-a ql if qual
17583-6,enass-a ab er qlif
17583-6,sjogrens syndrome-a extractable nuclear ab if ql (s)
17583-6,sjogens serology syndrome-a extractablenuclear ab if l (s)
17583-6,sjogrens syndrome-a extractable nuclear ab if presence (s)
31314-8,coxiella burnetii phase 2 igg ab [presence] in serum
31314-8,coxiella burnetii phase 2 igg ab [ql] in serum
31314-8,serum ab burnetii phase 2 igg coxiella [rsence] in serum
31314-8,c burnet ph2 igg ser ql
31314-8,igg burnet ph2 c ser presence
31314-8,c burnet ph2 gg ser presence
31314-8,c. burnetii phase 2 igg ql (s)
31314-8,c. burnetii 2 phase igg ql (s) infectiousdisease
31314-8,c. burnetiiphse 2 ql igg (s)
89974-0,7-hydroxyfluphenazine [presence] in urine by screen method
89974-0,7-hydroxyfluphenazine [presence] in urine by qualitative screen method
89974-0,7-hydroxyfluphenazine in [presence] urine by screen method
89974-0,7oh-fluphenazine ur ql scn
89974-0,presence ur 7oh-fluphenazine scn
89974-0,ql ur 7oh-fluphenazine scn
89974-0,7-hydroxyfluphenazine screen ql (u)
89974-0,ua 7ydroyfluphenazine (u) ql sceen
89974-0,7-hydroxyfluphenazine urn screen ql (u)
32622-3,hyaluronidase ab [presence] in serum
32622-3,[presence] ab hyaluronidase in anti ser
32622-3,[ql] ab hyaluronidase in serum
32622-3,hyaluronidase ab ser ql
32622-3,hyaluronidase ab presence ser microbiology
32622-3,ab hyaluronidase ser ql
32622-3,hyaluronidase ab ql (s)
32622-3,hyluronidase abql()
32622-3,hyaluronidase ab q ()
87465-1,monensin [mass/mass] in specimen
87465-1,in [mass/mass] monensin specimen
87465-1,monensin specime in mass/mass]
87465-1,monensin spec-mcnt
87465-1,spec-mcnt monensin unspecified
87465-1,moensin spec-mcn
87465-1,monensin (specimen) [mass/mass]
87465-1,(specimen) monensin [mas/mass] qnt
87465-1,monensin (specimen) quan [mass/mass]
75635-3,rheumatoid arthritis disease activity panel - serum or plasma by vectrada
75635-3,serum or plasma rheumatoid rthritis serumorplasma activity panel - disease by vectrada
75635-3,rheumatoid arthritis disease vectrad panel - seru r plasa by activity
75635-3,ra disease activity pnl serpl vectrada
75635-3,ra disease activity chemistry pnl serpl vectrada
75635-3,movements ra serpl activity pnl disease vectrada
75635-3,rheumatoid arthritis disease activity panel vectrada
75635-3,point in time rheumatoid arthritis disease activity panel vectrada
75635-3,heumatoid rthrtisiese activity panel vectada
59383-0,hydroxyproline/creatinine [mass ratio] in 2 hour urine
59383-0,hydroxyproline/reatiine [mass in ato] hor urine
59383-0,hydroxyproline/creatinine 2 ratio] in [mass ucr hour urine
59383-0,oh-proline/creat 2h ur
59383-0,ur 2h oh-proline/creat
59383-0,oh-proline/creat ur quantitative 2h
59383-0,hydroxyproline/creatinine (2h u) [mass ratio]
59383-0,quan atio] [ass hydroyproline/creatinine(2hu)
59383-0,(hu) hdroxyproline/creatinine [ass oh-proline ratio]
52799-4,major treatments used on or 1 day prior to day of death panel
52799-4,major treatments used on or 1 day death to day of prior panel
52799-4,major tatments used o or 1 day prio to day of death pael
86658-2,hpv tests - fpar 2.0 set
86658-2,hpv tests 2.0 fpar - set
86658-2,panl hpv tests - fpar 2.0 set
48368-5,trans-octadecanoate (c18:0) [moles/volume] in serum or plasma
48368-5,trans-octadecanoate (c18:0) or in serum [moles/volume] plasma
48368-5,trans-octadecanoate (c18:0) [moles/volume] in serum or cetylacetic acid plasma
48368-5,trans-octadecanoate serpl-scnc
48368-5,trans-octadecanoate serpl-scnc
48368-5,serpl-scnc stearate trans-octadecanoate
48368-5,trans-octadecanoate (c18:0) [moles/vol]
48368-5,trans-octadecanoate (c18:0) [moles/vol]
48368-5,tas-otadcanoate (c180) [moles/vol]
48138-2,enolase.neuron specific [mass/volume] in serum or plasma by radioimmunoassay (ria)
48138-2,enolase.neuron specific [mass/volume] in serpl by spec radioimmunoassay (ria)
48138-2,eolase.neuron spcific [mass/voume] n rum or plasm by (ria radioimmunoassay
48138-2,nse serpl ria-mcnc
48138-2,serpl radioimmunoassay nse ria-mcn
48138-2,serplria-mcnc gamma-enolase s
48138-2,enolase.neuron specific ria [mass/vol]
48138-2,enolase.neuron ria specific [mass/vol]
48138-2,enolase.neuron quan specific ria [mass/vol]
47721-6,phenylalanine/amino acids.total in hair
47721-6,henylalnin/amino acids.total in phe hair
47721-6,phelalanine/amino i acids.total hair
47721-6,phe sfr hair
47721-6,pe sfr hair
47721-6,sfr phe hair
47721-6,phenylalanine/total aa (hair) [molar fraction]
47721-6,[molar (hair) phenylalanine/totalaa fraction]
47721-6,substance fraction penylaanne/otal aa (hair) mor frction]
85919-9,oasis c2 - current number of unhealed pressure injuries at each stage - soc or roc during assessment period [cms assessment]
85919-9,oasis current - c2 number of unhealed pressure injuries at each stage - soc or roc during assessment period [cms assessment]
85919-9,oasis c2 - current pressre f unhead numbe injurie at each stage - oc o roc duing sesmnt eriod[cm asessment]
6605-0,leptospira interrogans ag [presence] in tissue by immunofluorescence
6605-0,infectiousdisease leptospira interrogans ag [ql] in tissue by immunofluorescence
6605-0,leptospira interrogans ag [presence] in tissue by immunofluorescence
6605-0,l inter ag tiss ql if
6605-0,qlif nter iss l ifa
6605-0,l presence ag tiss inter if
6605-0,l. interrogans ag if ql (tiss)
6605-0,l. interrogans ag (tiss) ql if
6605-0,l. ag interrogans if ql (tiss)
32268-5,ribose [presence] in urine
32268-5,ribose [presece] in urin
32268-5,riose [presence] inurin ql
32268-5,ribose ur ql
32268-5,presence r ribose
32268-5,ribose presence ur
32268-5,ribose ql (u)
32268-5,ribose ql qualitative (u)
32268-5,rboseql (u) pr
57810-4,"hedis 2010, 2011 codes to identify physiologic monitoring tests - blood urea nitrogen (bun) (mpm-a)"
57810-4,"hedis 2010, 2011 codes to identify random physiologic monitoring tests - blood urea nitrogen (bun) (mpm-a)"
57810-4,"edis 2010, 2011 codes to identify physiologicontoring tests - bloodurea nitrogen (bun) (mpm-a)"
57810-4,hedis 2010-11 mpm-a bun
57810-4,hedis 2010-11 bun mpm-a
57810-4,hedis 2010-11 mpm-a bun
57810-4,"hedis 2010, 2011 codes to identify physiologic monitoring tests - blood urea nitrogen (bun) (mpm-a)"
57810-4,"hedis 2010, 2011 codes to identify physiologic bld urea nitrogen monitoring tests - bld urea nitrogen (bun) (mpm-a)"
57810-4,"hedis 2010, 2011 codes to identify physiologic monitoring tests - blood urea nitrogen (bun) (mpm-a)"
6808-0,aspergillus fumigatus 1 ab [presence] in serum by immune diffusion (id)
6808-0,aspergillus fumigatus 1 ab in [presence] serum by immune diffusion (id)
6808-0,spergillus fuigatus1 ab [presnce] iserum by immuediffson (id)
6808-0,a fumigatus1 ab ser ql id
6808-0,a umigas1 aber ql id
6808-0,infectious disease a fmgatus1 serum ql id
6808-0,a. fumigatus 1 ab immune diff ql (s)
6808-0,a. fumigatus sr 1 ab immne dif l (s)
6808-0,a. fumigatus 1 ab immune diff presence (s)
59629-6,clobazam [mass/volume] in body fluid by confirmatory method
59629-6,mthod [mass/vlume] in body luid by confirmatory cobazam frisium
59629-6,clobazam ass/volume inbd by fuid cofirmatory method
59629-6,clobazam fld cfm-mcnc
59629-6,clobazam fld confirmation cfm-mcnc
59629-6,clobazam fld cf-mcnc
59629-6,clobazam confirm (body fld) [mass/vol]
59629-6,clobazam confirm (body fld) bodies [mass/vol]
59629-6,(body confirm clobazam fld) [mass/vol]
33951-5,sodium/creatinine [molar ratio] in urine
33951-5,sodium/creatinine [molar cr ratio] in urine
33951-5,in [molr rato sodiu/cretinine urine ua
33951-5,sodium/creat ur-srto
33951-5,ur-sto sodium/creat
33951-5,ur-srto sodium/creat
33951-5,sodium/creatinine (u) [molar ratio]
33951-5,ur ratio] (u) [molar sodium/creatinine
33951-5,[molar (u) sodium/creatinine ratio]
39795-0,trifluoperazine [moles/volume] in serum or plasma
39795-0,ser trfluoerazine [moles/volume] in ser plas or
39795-0,in [moles/volume] serplas trifluoperazine serum or plasma
39795-0,trifperazine serpl-scnc
39795-0,serpl-scnc trifperazine stelazine
39795-0,trifperazine serum or plasma-scnc
39795-0,trifluoperazine [moles/vol]
39795-0,[molvol] tifluperazine novoflurazine
39795-0,trifluoperazine terfluzine [moles/vol]
72257-9,platelet function.collagen + adenosine diphosphate induced and epinephrine induced panel - blood
72257-9,platelet fnction.collaen + medication stress denosinediphosphate induced and epinephine inucd panel - blood
72257-9,epin platelet functon.colagn +aenoine induc nduced and epnehrine diphosphat panel - blood
72257-9,close tme coll+adp + epinep pnl bld
72257-9,cloe bd coll+adp + eine pl tme
72257-9,close tme coll+adp + epinep pn bld
72257-9,platelet function.collagen + adenosine diphosphate induced and epinephrine induced panel (bld)
72257-9,platelet function.collagen + adenosine diphosphate induced and epinephrine induced (bld) panel
72257-9,epin platelet function.collagn + adenosine dihosphate inducd and epinephrine indued anel blood)
4029-5,secobarbital [presence] in urine
4029-5,potentialforabuse ecorial [presnce] in uine
4029-5,secobarbital [ql] in urine
4029-5,secobarbital ur ql
4029-5,ur barbiturate secobarbital presence
4029-5,ua seobarbialu ql
4029-5,secobarbital ql (u)
4029-5,secobarbital l (u)
4029-5,scobarbital qualitative presence (u)
106506-9,opiates panel - urine by lc/ms/ms
106506-9,opiates random panel - urine by lc/ms/ms
106506-9,opiates ane- urine by lc/m/ms
106506-9,opiates pnl ur lc/ms/ms
106506-9,lc/msms pan nl ur opiate
106506-9,oiates pnl u lc/ms/ms urn
106506-9,opiates panel lc/ms/ms (u)
106506-9,(u) panel lc/ms/ms opiates panel.drug & toxicology
106506-9,opiates panl lc/ms/m op (u)
13209-2,borrelia hermsii igm ab [units/volume] in serum
13209-2,borrelia hermsii igm ab [units/volume] in ser
13209-2,borrelia sr in igm ab [units/volume] hermsii ser
13209-2,b hermsii igm ser-acnc
13209-2,b ermsii igm ser-acnc
13209-2,b ser-acnc igm hermsii
13209-2,b. hermsii igm qn (s)
13209-2,b. hermsii igm qn (s)
13209-2,q(s) hermsii igm b.
6801-5,complement c3 [mass/volume] in body fluid
6801-5,complement c3 mass/ole] in fluid body
6801-5,complement c3 [mass/volume] in body fluid fluid
6801-5,c3 fld-mcnc
6801-5,fld-mcnc c3
6801-5,fld-mcnc c3
6801-5,complement c3 (body fld) [mass/vol]
6801-5,bod complement fld) (body c3 [mass/vol]
6801-5,complement c random (body fld) [mass/vol]
52838-0,population distribution panel [nmmds]
52838-0,population dstribution anel [nmds]
52838-0,[nmmds] disibutionpanel ppulation
22963-3,campylobacter fetus ab [presence] in genital mucus by agglutination
22963-3,campylobacte fetus ab genital in [presnc] mucusby aggutnation
22963-3,campylobacter fetus genital [ql] in ab mucus by agglutination vibriosis
22963-3,c fetus ab genital mucus ql aggl
22963-3,fetus c ab genital mucus ql aggl
22963-3,genital fetus ab gen c mucus ql aggl
22963-3,c. fetus ab aggl ql (genital mucus)
22963-3,c. fetus b gl ql genm (genital muus)
22963-3,c. fetus ab ql aggl (genital mucus)
33204-9,troponin t.cardiac [presence] in serum or plasma
33204-9,troponin trpoin t.cardiac [presence] in eru or plasma
33204-9,troponin n [presence] t.cardiac serum or plas
33204-9,troponin t serpl ql
33204-9,plas troponin t ql serpl
33204-9,troponin t serpl ql
33204-9,troponin t.cardiac ql
33204-9,t.cardiac troponin presence
33204-9,t.cardiacql tropni
56772-7,macrophages/leukocytes in bronchial specimen by flow cytometry (fc)
56772-7,macophages/lukcytes in cytmetry by flw bronialspecimen hematology/cell counts (fc)
56772-7,macrophages/leukocytes in bronchial specimen by point in time flow cytometry (fc)
56772-7,macrophages nfr bronch fc
56772-7,mcrophaes n bronch fc macrophage
56772-7,macrophagesnfr fc bronc
56772-7,macrophages/leukocytes fc (bronch spec)
56772-7,macrophageeukoytes fc (onch spc) quantitative
56772-7,macrophages/leukocytes fc spec) wbc (bronch
12540-1,2-methylcitrate [mass/volume] in serum or plasma
12540-1,2-methylcitrate [mass/volume] in serum plasma or methylmalonic acidemia
12540-1,2-methylcitrate [ss/vome] in serum or plasma
12540-1,2me-citrate serpl-mcnc
12540-1,serpl-mcnc 2me-citrate
12540-1,serpl-mcnc 2me-citrate quant
12540-1,2-methylcitrate [mass/vol]
12540-1,2-methylcitrate [mass/vol] serpl
12540-1,[mass/vol] 2-methylitrate
11570-9,platelet igg ab [units/volume] in serum
11570-9,platelet igg [units/volume] ab in serum
11570-9,platele igga [unts/volume] inserum
11570-9,platelet igg ser-acnc
11570-9,patelet igg ser-acnc
11570-9,platelet serum-acnc igg quant
11570-9,platelet igg qn (s)
11570-9,(s) igg qn platelet
11570-9,latelet igg qn (s)
103605-2,paroxetine metabolite i [mass/volume] in urine by confirmatory method
103605-2,paoxetine metablie [mass/volume] confirmator urne by n method
103605-2,paroxetine urine i [mass/volume] in metabolite by confirmatory method
103605-2,paroxetine m-i ur cfm-mcnc
103605-2,paroxetine cfm-mcnc ur m-i
103605-2,proetin m- ur ur cfm-mcnc
103605-2,paroxetine metabolite i confirm (u) [mass/vol]
103605-2,paroxetine metabolite i confirm (u) [mass/vol]
103605-2,paxetne metabolite i conirm (u) [mass/vol]
32256-0,lysine [moles/volume] in body fluid
32256-0,lysi [mls/olume] ibodyflui
32256-0,lysine [moles/volume] in body fluid
32256-0,lysine fld-scnc
32256-0,fld-scnc lysine
32256-0,ysine fld-scnc body fluid
32256-0,lysine (body fld) [moles/vol]
32256-0,fd)[ole/vol] (body lys lyine
32256-0,(boy lysine fd) [mole/vo]
15171-2,cryoglobulin.iga [units/volume] in serum
15171-2,cryoglobulin.ga immunoglobulin a [units/vlume] iserum
15171-2,quantitative in [units/volume] cryoglobulin.iga serum
15171-2,cryoglob iga ser-acnc
15171-2,er-anc cryogloiga
15171-2,cryoglob quan ser-acnc iga
15171-2,cryoglobulin.iga qn (s)
15171-2,cryoglobuin.iga (s) qn
15171-2,cryoglobulin.iga n (s)
87353-9,deprecated actinobacillus pleuropneumoniae igg ab/positive control by immunoassay
87353-9,deprecated actinobacillus control igg ab/positive pleuropneumoniae by immunoassay qnt
87353-9,deprecated actinobacillus igg pleuropneumoniae suds ab/positive control by immunoassay
87353-9,deprecated a pleuropn igg/pos cntrl ia
87353-9,deprecated a pleuropn igg/pos cntrl random ia
87353-9,igg/pos plerpn deprecatea cntrl ia aby
87353-9,a. pleuropneumoniae igg/positive control ia [relative ratio]
87353-9,a. pleuropneumoniae igg/positive control ia [relative ratio]
87353-9,a. control igg/positive relative ratio pleuropneumoniae ia [relative ratio]
47445-2,influenza virus a h10 ab [titer] in serum
47445-2,influenza virus a titre h10 [titer] ab in serum
47445-2,influnza virus a h10 ab [titer i ser
47445-2,fluav h10 ab titr ser
47445-2,h10abtitr flav serum
47445-2,fluav h10 ab titr fluav h10 serum
47445-2,fluav h10 ab (s) [titer]
47445-2,fluavh10 (s) a [titr
47445-2,ab h10 fluav bird flu (s)[titer]
2181-6,cystinyl aminopeptidase [enzymatic activity/volume] in serum
2181-6,cystinyl aminopeptidase [enzymatic activity/volume] point in time in serum
2181-6,cystinyl oxytocinase aminopeptidas in activit/volum] [enzymatic serum
2181-6,cystinyl ap ser-ccnc
2181-6,se-nc ap ytiny
2181-6,ser-ccnc ap cystinyl sr
2181-6,cystinyl aminopeptidase (s) [catalytic activity/vol]
2181-6,cystiny quantitative aminopeptidase (s) catalytic activity/vl]
2181-6,(s) aminopeptidae cstinyl [catalytic activity/vol]
105931-0,microscopic observation [identifier] in catheter tip by gram stain --3rd specimen
105931-0,microscopic observation [identifier] in catheter tip by gram random stain --3rd specimen
105931-0,micoscopic observation [identifir] by cather tip in gram sain --3rd spcimn
105931-0,sp3 cath tip gram stn
105931-0,sp3 tip cah sp3 gram st
105931-0,sp3 identity or presence cath tip ram stn
105931-0,microscopic observation spec 3 gram stain nom (catheter tip)
105931-0,mirocopic bervatin spec stain gram 3 nm (cathetetip)
105931-0,microscopic observation spec nom gram stain 3 (catheter tip)
26996-9,complement c7 [units/volume] in serum or plasma
26996-9,complement c7 [units/volume] in ser or hematology/cell counts plasma
26996-9,complement c7 [units/volume] in ser or plasma
26996-9,c7 serpl-acnc
26996-9,c7 sepl-acnc
26996-9,c srpl-cnc serpl
26996-9,complement c7 qn
26996-9,complement c7 qn ser or plasma
26996-9,complement c7 qn sr
30556-5,smith extractable nuclear ab+ribonucleoprotein extractable nuclear ab [titer] in serum by immunofluorescence
30556-5,smith extractable nuclear ab+ribonucleoprotein extractable immunofluorescence ab [titer] in serum by nuclear
30556-5,smith anf etractable nuclear ab+riboucleopotin extrctable nuclear ab [iter] in erum by immufluorescnce
30556-5,ena sm+rnp ab titr ser if
30556-5,ena sm+rnp ab immune fluorescence titr ser if
30556-5,ab sm+rnp ena titr serum if
30556-5,smith extractable nuclear ab+ribonucleoprotein extractable nuclear ab if (s) [titer]
30556-5,smithextractable nuclear a+ribonucleoproin exractable nuclear ab if (s) ifa [titer]
30556-5,smith ribonuclear protein extractable nuclear ab+ribonucleoprotein extractable nuclear ab if (s) [titer]
4127-7,ampicillin [mass] of dose
4127-7,ampicillin of [mass] dose
4127-7,mpicillin [mass] of dose quan
4127-7,ampicillin dose
4127-7,dose amcil ampicillin
4127-7,dose ampicillin amcil
4127-7,ampicillin (dose) [mass]
4127-7,ampicllin [mss] dose med or substance (dose)
4127-7,[mass] (dose) ampicillin
99583-7,lysholm knee scoring scale [lkss]
99583-7,lysholm knee scoring scale [lkss]
99583-7,[lkss] knee scoring scal shom
55130-9,physical restraints used in chair or out of bed
55130-9,restraints physical used in chair or out of bed
55130-9,used restraints physical in chair or out of bed
85772-2,enterobacter cloacae complex dna [presence] by naa with non-probe detection in positive blood culture
85772-2,enterobacter cloacae naa dna [presence] by complex with non-probe detection in positive blood culture
85772-2,enterobacter loacae comple dna [presence] by naaith nopobe detectio  positive blood culture
85772-2,e cloac comp dna bld pos naa+non-probe
85772-2,e cloac comp blood dna pos naa+non-probe
85772-2,e loac cmpda pos blood naa+non-pobe
85772-2,e. cloacae complex dna naa+non-probe ql (pos bld culture)
85772-2,e. cloacae (osbld deoxyribonucleic acid dnanaa+non-prbe ql cmplex culture)
85772-2,e. presence complex dna qualitative naa+non-probe cloacae (pos bld culture)
98138-1,amyloid plaques probability score based on clinical and lab data
98138-1,basedo laqes probability qnt score amyloid clinicaland ab dta
98138-1,amyloid plaques probability score based on clinical and lab data quantitative
98138-1,amyloid plaques score from clin+lab data
98138-1,qnt plaques amyloid score from clin+lab data
98138-1,amyloi from score plaques cln+labata
1846-5,"amylo-alpha-1,6-glucosidase [enzymatic activity/volume] in red blood cells"
1846-5,"amylo-alpha-1,6-glucosidase blood activity/volume] in red [enzymatic cells"
1846-5,"amylo-ala-1,-gucsidase [ezymatactity/vume] inred cell blood"
1846-5,agl rbc-ccnc
1846-5,quantitative agl rbc-ccnc
1846-5,catalytic concentration agl rbc-ccn
1846-5,"amylo-alpha-1,6-glucosidase (rbc) [catalytic activity/vol]"
1846-5,"aciity/vol] (rbc) [ataytic amyl-alpha-1,6glucosdase"
1846-5,"amylo-alpha-1,6-glucosidase [catalytic (rbc) activity/vol]"
88165-6,mycobacterium tuberculosis dna [presence] in cornea or conjunctiva by naa with probe detection
88165-6,mycobacterium tuberculosis dna [presence] in cornea or conjunctiva by naa with probe acid fast bacillus detection
88165-6,mycobacterium tuberculosis dna or in cornea [presence] conjunctiva by naa with probe detection
88165-6,m tb dna corn/cnjt ql naa+probe
88165-6,ligation-activated transcription m tb dna corn/cnjt presence naa+probe
88165-6,dn mtb corn/cnjt l naa+probe 3sr sr
88165-6,m. tuberculosis dna naa+probe ql (corn/cnjt)
88165-6,acid fast bacilli . tuberculosis na naa+probeql (con/cjt)
88165-6,3sr sr m. (corn/cnjt) dna naa+proql tuberculosis
23375-9,deprecated porcine respiratory coronavirus ab [presence] in serum
23375-9,autoantibody deprecated porcine respiratory coronavirus in [presence] ab serum
23375-9,deprecatedrcne sr respiratoryoronvirus ab[pesece]in serum
23375-9,deprecated prcov ab ser ql
23375-9,ser prcov ab deprecated ql
23375-9,eprectd autoantibody prov ab presence ser
23375-9,porcine respiratory coronavirus ab ql (s)
23375-9,prine respiratory ronavirus b ql (s)
23375-9,respiratory porcine coronavirus ab ql (s)
85957-9,streptococcus pneumoniae danish serotype 1 igg ab [units/volume] in serum by immunoassay
85957-9,streptococcus ab danish serotype 1 igg pneumoniae [units/volume] in serum by immunoassay
85957-9,streptococcus pneumoniae serotype danish 1 igg ab [units/volume] pneumococcal pneumonia in serum by immunoassay
85957-9,s pneum da 1 igg ser ia-acnc
85957-9,s pneum da  igg serum ia-acnc
85957-9,s antby pneum sria-cnc ig da1
85957-9,s. pneumoniae danish type 1 igg ia qn (s)
85957-9,s.pneumoni danish type 1 gg ia qn (s)
85957-9,s. qn s pneum da 1 igg danish type 1 igg ia pneumoniae (s)
47004-7,6-monoacetylmorphine free [mass/volume] in urine by confirmatory method
47004-7,6-monoacetylmorphine free [mass/volume] confirmatory urine by in method
47004-7,method free [mass/volume] in urine by confirmatory 6-monoacetylmorphine
47004-7,6mam free ur cfm-mcnc
47004-7,ur free 6mam cfm-mcnc
47004-7,6mam ree ur cfm-mcc
47004-7,6-monoacetylmorphine free confirm (u) [mass/vol]
47004-7,6-mnoacetmorphie [mass/vl] confir (u free
47004-7,(u) free confirm 6-monoacetylmorphine [mass/vol]
82453-2,zo ab [presence] in serum by line blot
82453-2,zo b prsence inru by lin sr blot
82453-2,o ab [presnce in erum by line blot
82453-2,zo ab ser ql line blot
82453-2,zo ab ser line presence blot
82453-2,ab zo ser ql line blot
82453-2,zo ab line blot ql (s)
82453-2,blot ab line zo ql (s)
82453-2,ql zo ab line blt ql (s)
29221-9,mercury [mass/volume] in body fluid
29221-9,mercry [mass/ome] in body flid
29221-9,mercury [mass/volume] in body fluid
29221-9,mercury fld-mcnc
29221-9,fld-mcnc mercury
29221-9,ercury fld-cnc
29221-9,mercury (body fld) [mass/vol]
29221-9,mecury level [mass/vol] fld) (body
29221-9,mercur mass concentration [mass/l] fld) (body
46779-5,medium/short chain acyl-coa dehydrogenase deficiency newborn screen interpretation
46779-5,medium/short chin acyl-coa deydrogease deficiency chains nebrn cen iterprtation
46779-5,mdium/short cain impression acyl-coa dehydrogeas dficiency newbor screen itrpretation
46779-5,m/schadd dbs-imp
46779-5,dbs-imp m/schadd
46779-5,m/schadd dbs-imp fp
46779-5,medium/short chain acyl-coa dehydrogenase deficiency (dbs) [interp]
46779-5,[interp] chainacyl-coa scad deficiency deydrogenasdeiiency dbs) medim/hort
46779-5,medium/short dehydrogenase impressions acyl-coa chain deficiency (dbs) [interp]
52899-2,beryllium [moles/volume] in serum or plasma
52899-2,beryllium [moles/volume] in serum plasma or
52899-2,beryllium plas iserum or [moles/volume]
52899-2,beryllium serpl-scnc
52899-2,serpl-scnc beryllium
52899-2,serpl-scnc beryllium
52899-2,beryllium [moles/vol]
52899-2,[moles/vol] beryllium drugs
52899-2,[moles/vol] beryllium
24310-5,mycoplasma pneumoniae ab [titer] in serum --1st specimen
24310-5,mycoplasma pneumoniae in [titer] ab serum --1st specimen
24310-5,mcoplasmapnemoniae ab[titer] n --1st serum serum specimn
24310-5,m pneumo ab sp1 titr ser
24310-5,pneumo se p1 titr ab m pneumoniae
24310-5,m pneumoab serum titr sp1
24310-5,m. pneumoniae ab spec 1 (s) [titer]
24310-5,pneuoniae m. ab spec 1(s)[tier]
24310-5,m. pneumoniae ab spec 1 (s) [titer]
88146-6,microscopic observation [identifier] in placenta by gram stain
88146-6,microscopic observation [identifier] in plcnta by ram microbiology stai
88146-6,[identifier] observation microscopic in lacenta by gram stain
88146-6,gram stn placenta
88146-6,stnplacenta gram
88146-6,gram stn obstetrics placenta
88146-6,microscopic observation gram stain nom (placenta)
88146-6,microscopic stains observation (placenta) stain nom gram
88146-6,microscopic observation gram stain nom infectiousdisease (placenta)
104837-0,protein.monoclonal [mass/volume] in serum or plasma
104837-0,protein.monoclonal prot [mass/volume] or serum in plasma
104837-0,in proten.monoclonl[ms/vlume] ser or plama
104837-0,m protein serpl-mcnc
104837-0,pr m protein serpl-mcnc
104837-0,para protein m protein srpl-mnc
104837-0,protein.monoclonal [mass/vol]
104837-0,monoclonal spike potein.monclonal[mass/vol]
104837-0,[mass/vol] protein.monoclonal
42986-0,neisseria meningitidis serogroup a igg ab [mass/volume] in serum
42986-0,in meningitidis serogroup a igg ab [mass/volume] neisseria serum
42986-0,neisseria meningitidis serogroup neisseria meningitidis type a a igg ab [mass/volume] in serum
42986-0,n men sg a igg ser-mcnc
42986-0,men point in time n sg a igg ser-mcnc
42986-0,n men sg a igg ser-mcnc antby
42986-0,n. meningitidis a igg (s) [mass/vol]
42986-0,meningitidis n. a igg (s) [mass/vol]
42986-0,quant n. meningitidis igg (s) [mass/vol]
59353-3,tapentadol [mass/volume] in body fluid
59353-3,tapentadol [mass/volume] in body fluid
59353-3,tpentadol palexia [mass/volume] i body flui
59353-3,tapentadol fld-mcnc
59353-3,fld-mcnc tapentadol
59353-3,fld-cnc apentadol
59353-3,tapentadol (body fld) [mass/vol]
59353-3,tapentadol(body fld) mass/vol]
59353-3,tapentadol fld) (body mas/vl
42491-1,cannabinoids [presence] in blood by screen method
42491-1,in [presence] cannabinoids blood by screen method
42491-1,cannabinoids [presence] potentialforabuse method blood by screen in
42491-1,cannabinoids bld ql scn
42491-1,ql blood qualitative cannabinoids scn
42491-1,cannabinoids ld q drug/toxicology scn
42491-1,cannabinoids screen ql (bld)
42491-1,(bl) scren ql cannabinoids
42491-1,cannainoidsscreen (bld) bld ql
35149-4,octadecanoate (c18:0) [moles/volume] in serum or plasma
35149-4,octadecanoate (c18:0) [moles/volume] in plasma serum or plasma
35149-4,octadecanoae (c180) moes/volme] insrum r plasma
35149-4,octadecanoate serpl-scnc
35149-4,serpl-scnc octadecanoate
35149-4,serpl-cnc octadecanoate
35149-4,octadecanoate (c18:0) [moles/vol]
35149-4,(c18:0) octadecanoate [moles/vol] stearic acid
35149-4,octadecanoate (c18:0) [moles/vol] 1-heptadecanecarboxylic acid
14260-4,bromoform [mass/volume] in blood
14260-4,roofom [as/volume] in bood
14260-4,bromoform [mas/vlume] bood in
14260-4,bromoform bld-mcnc
14260-4,mass concentration bromoform bl-mcnc
14260-4,bld-mcnc random bromoform
14260-4,bromoform (bld) [mass/vol]
14260-4,(bld) bromoform [mass/vol]
14260-4,[mass/vol] (bl) bromoform
107127-3,exercise intensity panel
107127-3,xrcise ntensty panel
107127-3,eercse panel inensity
107127-3,exercise intensity panel
107127-3,exercise intensiy pnel
107127-3,panel intensity exercise
23088-8,equine herpesvirus 1+4 ab [titer] in serum
23088-8,1+4 herpvirus equine infectiousdisease ab titer in serum
23088-8,equine ser 1+4 ab [titer] in herpesvirus
23088-8,ehv1+4 ab titr ser
23088-8,ehv1+4 i b ttr ser
23088-8,ti ab eh+4 ser
23088-8,equine herpesvirus 1+4 ab (s) [titer]
23088-8,equine herpesviru 1+4 ab (s) [tite]
23088-8,equine herpesvirus 1+4 ab (s) [titer]
16688-4,creatine kinase [enzymatic activity/volume] in body fluid
16688-4,ceatine kinase [ezymatic activity/olume] in body fluid
16688-4,creatine kinase [enzymatic activity/volume] in body fluid
16688-4,ck fld-ccnc
16688-4,k fld-ccnc
16688-4,ckfd-ccn flu
16688-4,ck (body fld) [catalytic activity/vol]
16688-4,ck activity/vol] fld) b/f [catalytic (body
16688-4,ck (bod ld) [catalytic actvity/vol]
61414-9,doxepin/creatinine [mass ratio] in urine
61414-9,doxepin/creatnine mass ratio] inurie
61414-9,doxepin/creatinine [mass in aponal ratio] urine
61414-9,doxepin/creat ur
61414-9,doxepin/creat r
61414-9,quantitative doxepin/creat ur
61414-9,doxepin/creatinine (u) [mass ratio]
61414-9,doxepn/creatini [ass (u) ratio]
61414-9,[mass (u) doxepin/creatinine ratio]
52959-4,clobazam [presence] in urine
52959-4,clobazam in [presence] urine
52959-4,in [presence] clobazam urine clarmyl
52959-4,clobazam ur ql
52959-4,clobazam presence urn ur
52959-4,ur clobazam ql ql
52959-4,clobazam ql (u)
52959-4,random (u) ql clobazam
52959-4,urbanol clobazam presence (u)
4443-8,ticarcillin [mass] of dose
4443-8,ticarcillin dose of [mass]
4443-8,ticarcillin [mass] of timentin dose
4443-8,ticarcillin dose
4443-8,doe tiarcillin
4443-8,ticarcli doe qnt
4443-8,ticarcillin (dose) [mass]
4443-8,quant (dose) ticarcillin [mass]
4443-8,[mass] (dose) quan ticarcillin
22504-5,measles virus igg ab [units/volume] in serum --2nd specimen
22504-5,measles virus id igg ab [units/volume] in serum --2nd specimen
22504-5,mesle abs vius iggab [units/lume] in serum --2nd scimen
22504-5,mev igg sp2 ser-acnc
22504-5,mev point in time igg sp2 ser-acnc
22504-5,ser-acnc igg sp2 mev
22504-5,mev igg spec 2 qn (s)
22504-5,mev spec igg 2 qn (s) anti
22504-5,(s) igg spec 2qn mev
31437-7,influenza virus a igg ab [units/volume] in serum
31437-7,influenza virus a igg quant ab [units/volume] in serum
31437-7,infuenza virus a igab [units/volume] influ i seum
31437-7,fluav igg ser-acnc
31437-7,ig fluav ser-acnc serum
31437-7,fluav igg ser-acnc
31437-7,fluav igg qn (s)
31437-7,s) igg qn flua
31437-7,autoantibodies fluav igg qn (s)
72499-7,oval fat bodies (globules) [#/area] in stool by microscopy low power field
72499-7,oval fat bodies microscpy [#rea] in sool by globules) w power field
72499-7,ovalfat stool (gloules) [#/area] in odies quantitative bmiroscoy low power field
72499-7,oval fat bodies #/area stl lpf
72499-7,ovalfat bodies #/area stl lpf
72499-7,stl fat bodies #/area oval lm lpf
72499-7,oval fat bodies (globules) lm.lpf (stl) [#/area]
72499-7,oval number areic bodies fat (globules) lm.lpf (stl) [#/area]
72499-7,bodies ovalfat (globles) lm.p (stl) [#/are]
94350-6,pca-1 igg ab [titer] in serum by immunofluorescence
94350-6,pca-1 igg byimunoflorescnce [titer] n serum ab
94350-6,pca-1igg ab titer] by inserum imnofluorescence
94350-6,pca-1 igg titr ser if
94350-6,ttr ser igtitr pa-1 if
94350-6,pc-1 igg purkinje cell cytoplasmic antibody tir ser if
94350-6,pca-1 igg if (s) [titer]
94350-6,pca-1 ifa (s) if igg [iter]
94350-6,(s) igg if pca-1 [titer]
35618-8,methadone [mass/volume] in serum or plasma by screen method
35618-8,serp methadone [mass/volume] in serum plas or by screen method
35618-8,methadone [mass/volume] in mtd plasma or serum by screen method
35618-8,methadone serpl scn-mcnc
35618-8,serpl methadone scn-mcc
35618-8,methdoneserpl scn-mcnc
35618-8,methadone screen [mass/vol]
35618-8,screen methdone [mass/ol]
35618-8,methadone screen [mass/vol]
9773-3,ergotamine [mass/volume] in serum or plasma
9773-3,egotmine [mass/vume] in ser or plsm lsma
9773-3,ergomar ergotamine serum in [mass/volume] or plasma
9773-3,ergotamine serpl-mcnc
9773-3,ergotamnserp-mcnc
9773-3,serp-mcnc ergotamine
9773-3,ergotamine [mass/vol]
9773-3,[mass/vol] ergotamine
9773-3,ergamne [mass/vol]
24221-4,parainfluenza virus 2 ab [titer] in serum by complement fixation --2nd specimen
24221-4,parainflueza virus 2 ab [titer] i ser by complementfixation --2nd pecimen
24221-4,paainfluenz vius 2 ab [tter] in srm by comlement fixati -2nd pecimen
24221-4,hpiv2 ab sp2 titr ser cf
24221-4,hpiv2 ab sp2 ser titered titr cf
24221-4,convalescent hpiv2 ab sp2 titr sercf
24221-4,parainfluenza virus 2 ab spec 2 cf (s) [titer]
24221-4,parainfluenza spec 2 ab virus 2 cf (s) [titer] antibodies
24221-4,parainfluenza virus ab 2 spec 2 cf (s) [titer]
35167-6,vaccenate (c18:1w7) [moles/volume] in serum or plasma
35167-6,serpl vaccenate (c18:w7) [oles/vlume] in serumor lasma
35167-6,vaccenate (c18:1w7) [moles/volume] in serum or plasma level
35167-6,vaccenate serpl-scnc
35167-6,serp-scnc vaccenate
35167-6,srpl-scn vacenate
35167-6,vaccenate (c18:1w7) [moles/vol]
35167-6,vaccenate plasma [moles/vol] (c18:1w7)
35167-6,(c18:1w7) vaccenate [moles/vol]
62583-0,deprecated phenx measure - oral health - dry mouth
62583-0,deprecated oral measure - phenx health - dry mouth
62583-0,deprecated penx eaue- oral moth dry health
18234-5,insulin [presence] in unknown substance
18234-5,unnown [presencei insulin substance
18234-5,insulin in [presence] unknown substance
18234-5,insulin usub ql
18234-5,insulin ql usub
18234-5,usub insulin ql
18234-5,insulin ql (unknown substance)
18234-5,insuln ql (unknown subtace)
18234-5,insulinql ultralente stance) (unknon
75375-6,other cells/leukocytes in sputum by manual count
75375-6,other cells/leukocytes sputum in othr by manual count
75375-6,other cells/leukoytes in sputum by manal count
75375-6,other cells nfr spt manual
75375-6,otheell nfr t manual
75375-6,oter mnual nfr spt cells
75375-6,other cells/leukocytes manual cnt (sput)
75375-6,other cells/leukocytes cnt manual (sput) quantitative
75375-6,white bld cell cnt cells/leukoctes manual other (spt)
96430-4,borrelia burgdorferi g39/40 igg bands [#] in specimen by immunoblot
96430-4,borrlia burgdoreri 39/40igg inpecimen riba [#] ads by immuoblo
96430-4,borrelia burgdorferi g39/40 igg bands [#] in autoantibody specimen by immunoblot
96430-4,b burgdor g39/40 igg bands spec ib
96430-4,western blot b burgdor g39/40 igg bands spec ib
96430-4,b burgdor g39/40 spec bands igg ib qnt
96430-4,b. burgdorferi g39/40 igg bands ib (specimen) [#]
96430-4,b. burgdorferi g39/40 igg bands point in time ib (specimen) [#]
96430-4,b. brgdorferi g9/40 igg (specimen) ib autoantibodies bands [#]
70666-3,cold agglutinin [presence] in serum by 22 degree c incubation
70666-3,cold agglutinin [ql] in serum by 22 degree c incubation
70666-3,cold agglutinin [presence] in serum by 22 c degree incubation
70666-3,ca ser ql 22 deg c inc
70666-3,inc sr ql 22deg ca
70666-3, serql 22 deg c inc
70666-3,cold agglutinin 22 degree c incubation ql (s)
70666-3,cold agglutini ql degree c incubation 22 random (s)
70666-3,cold agglutinin presence degree c incubation 22 pr (s)
71848-6,oxygen saturation [pure mass fraction] in arterial cord blood
71848-6,ob oxygen saturation blood mass fraction] in arterial cord [pure
71848-6,oxygen sturton [pure mass fracion] in arterial cord obgyn blod
71848-6,sao2 df bldcoa
71848-6,bdcoa df ob sao2
71848-6,sao2 bldcoa df obstetrics
71848-6,sao2% (bldcoa) [pure mass fraction]
71848-6,so2% bldcoa) quantitative [pur ass fraction
71848-6,sao2% (bdco) [pure mass fraction]
11007-2,borrelia burgdorferi ag [units/volume] in urine
11007-2,rrelia burgdrferi ag i [units/volme] urin
11007-2,borrelia burgdorferi ag in [units/volume] urine
11007-2,b burgdor ag ur-acnc
11007-2,b lymes ag burgdor ur-acnc
11007-2,b burgdor ag ur-nc
11007-2,b. burgdorferi ag qn (u)
11007-2,b. (u) antigens ag qn burgdorferi
11007-2,b. ag urdorferi qn (u)
82914-3,dothiepin [mass/volume] in serum or plasma --trough
82914-3,or [mass/volume] in ser dothiepin plasma --trough mass concentration
82914-3,dothiepin [mass/volume] n plsm serum or plasma-tough
82914-3,dothiepin trough serpl-mcnc
82914-3,dthiepin serplmcc trough
82914-3,dothiepin trough serpl-mcnc ser
82914-3,dothiepin trough [mass/vol]
82914-3,dthipin rough drugs [mass/vol]
82914-3,dothiepin [mass/vol] trough
103188-9,morganella morganii dna [presence] in wound by naa with probe detection
103188-9,morganlla rgaii b [presece] 3 self-sustaining sequence replication in wound dna naawith prbdettion
103188-9,morganella morganii da[presence] in detetion naa ith probe wondby
103188-9,m. morganii dna wnd ql naa+probe
103188-9,morganii deoxyribonucleic acid m. dna wnd ql naa+probe
103188-9,m. morganii ql wnd dna naa+probe
103188-9,morganella morganii dna naa+probe ql (wound)
103188-9,oranii mrganla dna naa+proe ql (wond)
103188-9,morganella morganii dna naa+probe ql (wound)
100851-5,other cells [#/volume] in amniotic fluid by manual count
100851-5,her cells #/olume] in amniotic fluid by manual count count/volume
100851-5,by cells [#/volume] in amniotic fluid amn other manual count
100851-5,other cells # amn manual
100851-5,other count/volume cells # amn manual
100851-5,manual amniotic flu cells # amn other
100851-5,other cells manual cnt (amn fld) [#/vol]
100851-5,other cells manua cnt (amn fld)[#/vol]
100851-5,cells other manual cnt (amn fld) [#/vol]
6429-5,hiv identified in blood by organism specific culture
6429-5,hi idntifie ilood culture organismspecfic by
6429-5,hiv identified in blood by organism specific culture
6429-5,hiv bld cult
6429-5,bld hv ult
6429-5,wb hiv ld cult
6429-5,hiv identified org specific cx nom (bld)
6429-5,blood hiv idenified rg specifi cx nom (ld)
6429-5,nom(blood) identiied infectiousdisease org specific cx hiv
62907-1,deprecated phenx measure - skin cancer
62907-1,deprecated phenx measure skin - cancer
62907-1,caner pnl phenx easure- skin deprecatd
1785-5,alpha amino acid nitrogen [mass/time] in 24 hour urine
1785-5,alpha amino acid nitrogen [mass/time] 24 in hour urine
1785-5,alpha amino 24 hours acid nitrogen [mass/time] in 24 hour urine
1785-5,a-aa nitrogen 24h ur-mrate
1785-5,a-aa ur-mrate 24h nitrogen
1785-5,a-aa nitroge ur-mrae 4h
1785-5,alpha amino acid nitrogen (24h u) [mass/time]
1785-5,acd alpha amino acid nitrogen (24h u) [mass/time]
1785-5,acid amino alpha nitrogen (24h u) [mass/time]
23222-3,lumpy skin disease virus ag [presence] in specimen by immune diffusion (id)
23222-3,lumpy skin disease virus ag [presence] in specimen by immune id diffusion (id)
23222-3,py kin dises virus apreence] inspecimen y immue diffusn (i)
23222-3,lsdv ag spec ql id
23222-3,lumpy skin disease id a specql lsdv
23222-3,lsdv id spec ql ag
23222-3,lumpy skin disease virus ag immune diff ql (specimen)
23222-3,lumpy skin diseasevirs ag imne diff q (specimen)
23222-3,lumpy skin virus disease ag immune diff ql (specimen)
14912-0,smudge cells/leukocytes in blood by manual count
14912-0,wbcs cells/leukocytes smudge in blood by manual count
14912-0,smdge cel/eukocytes in blood by manua count
14912-0,smudge cells nfr bld manual
14912-0,smudge cllsfbld manual
14912-0,percent smudge nfr cells bld manual
14912-0,smudge cells/leukocytes manual cnt (bld)
14912-0,(bld) cells/lukocytes manua cnt smude
14912-0,smudge basket cells cells/leukocytes manual cnt (bld)
40999-5,calcium hydrogen phosphate dihydrate [mass/time] in 24 hour urine
40999-5,calcium hydrogn phosphate ihdrate [mass/time] in 4 hour 1 day urine
40999-5,phosphate total [mas/me] hosphae dihydrate clciumhdrogen in 24hoururine
40999-5,ca h2 phos dihyd 24h ur-mrate
40999-5,ca h2 phos dihyd 24h ur-rate
40999-5,ca ur-mrate mrate phos dihyd 24h h2
40999-5,calcium hydrogen phosphate dihydrate (24h u) [mass/time]
40999-5,calcium hydrogen phosphate u) (24h dihydrate [mass/time] h2
40999-5,calcium hydrogen u) dihydrate (24h phosphate [mass/time]
21412-2,myocardium ab pattern [interpretation] in serum
21412-2,mycardium intermyofibrillar antibodies ab patter [interretation] in seum
21412-2,myocarum ab pattrn [interreation inseum
21412-2,myocardium ab pattern ser-imp
21412-2,serum ab myoardium pattenserimp
21412-2,myocardiu ab patte sr-imp
21412-2,myocardium ab pattern (s) [interp]
21412-2,serology myocardim ab pattern(s) [interp]
21412-2,myocardium aby ab pattern () [interp]
104230-8,mdmb-fubinaca [mass/volume] in urine by confirmatory method
104230-8,mdmb-fubinaca [mass/volume] urine level in by confirmatory method
104230-8,mdmb-fubinaca urine in [mass/volume] by confirmatory method
104230-8,mdmb-fubinaca ur cfm-mcnc
104230-8,ur mdmb-fubinaca cfm-mcnc
104230-8,quan mdmb-fubinaca ur cfm-mcnc
104230-8,mdmb-fubinaca confirm (u) [mass/vol]
104230-8,mdmb-fubinaca confirm (u) [mass/vol]
104230-8,mdmb-fubinaca confirm (u) [mass/vol]
38469-3,chlamydia trachomatis rrna [presence] in blood by probe
38469-3,chlamydia trachomatis rrna [presence] in blood by probe
38469-3,chlamydia in rrna[presence] trachoatis blood by probe
38469-3,c trach rrna bld ql probe
38469-3,c trah rrna blood qual ql probe
38469-3,c trah id rrna bd qlpro
38469-3,c. trachomatis rrna probe ql (bld)
38469-3,c. trachomatis rrna (bld) presence probe
38469-3,ql tachomatis trachoma rrna probe c. (bld)
74610-7,decadienoylcarnitine (c10:2) [enzymatic activity/mass] in fibroblast
74610-7,decadienoylcarnitine (c10:2) in activity/mass] [enzymatic quantitative fibroblast
74610-7,ecadienoylcarnitne (c10:2) [enzymatic catalytic content activit/ass] ifibrblast
74610-7,decadienoylcarn fib-ccnt
74610-7,chemistry fib-cct decadienoylcarn
74610-7,decadienoylcarn fibr fb-ccn
74610-7,c10:2 (fibroblast) [catalytic activity/mass]
74610-7,c10:2(fibroblast) [catalyticactivty/mass] random
74610-7,c10:2 [catalytic (fibroblast) activity/mass]
22556-5,deprecated streptococcus pneumoniae 8 igg ab [units/volume] in serum
22556-5,depecated anti streptococcu pneumoniae 8 igg ab unit/vlume] in ser
22556-5,depreaed autoantibody strpococcus pneumoniae 8 igg b [unit/olum]i erum
22556-5,deprecated s pneum8 igg ser-acnc
22556-5,random deprecated s pneum8 igg ser-acnc
22556-5,deprecated s pneum8 g immune globulin g ser-acnc
22556-5,s. pneumoniae 8 igg qn (s)
22556-5,8 pneumoniae s. igg n (s)
22556-5,s. pneumoniae aby ig qn s)
24237-0,mycoplasma pneumoniae ab [titer] in serum by complement fixation --2nd specimen
24237-0,ycpasmapneumoiae serm [titer] in smqn ab by complementfixain --2nd speimen
24237-0,mycoplasma in ab[ttr] neumonie eum by compleme fiation --2ndspecimen
24237-0,m pneumo ab sp2 titr ser cf
24237-0,m neumo a sp2 tt ser c
24237-0,m ser ab sp2 titr pneumo cf
24237-0,m. pneumoniae ab spec 2 cf (s) [titer]
24237-0,m. pneumoniae ab spec 2 cf titer (s) [titer]
24237-0,antby m. pneumoniae ab spec 2 cf (s) [titer]
3446-2,cefotaxime [mass/volume] in serum or plasma
3446-2,or [mass/volume] in ser cefotaxime plasma
3446-2,cefotaxime [mass/volume] serum in serum plasma or
3446-2,cefotaxime serpl-mcnc
3446-2,cefotaxime serpl-mcnc quant
3446-2,pl cefotaxime serpl-mcnc
3446-2,cefotaxime [mass/vol]
3446-2,[mass/vol] cefotaxime
3446-2,[mas/vol] sr cefoaxime
59981-1,zopiclone [moles/volume] in urine
59981-1,zopiclone urin in [mols/volume
59981-1,in [moles/vlme] zopiclone urine
59981-1,zopiclone ur-scnc
59981-1,ur-scnc oiclone
59981-1,zopiclone ur-scnc
59981-1,zopiclone (u) [moles/vol]
59981-1,imovane zpiclone [molevol] ()
59981-1,[molsvo] u quant zopiclne
33577-8,rheumatoid factor igm [titer] in serum by nephelometry
33577-8,rheumatoid factor igm [titer] in ser smqn by nephelometry
33577-8,rheumatoid facor igm [tier] dilution factor (titer) inserum byepheloetry
33577-8,rf igm titr ser neph
33577-8,igm rf titr ser neph
33577-8,rf light scattering igm ser titr neph
33577-8,rheumatoid factor igm nephelometry (s) [titer]
33577-8,rheumatoid factor igm nephelometry (s) [titer] immune globulin m
33577-8,rheumatoid nephelometry igm factor (s) fact [titer]
79572-4,folate and tryptophan and metabolites panel - cerebral spinal fluid
79572-4,metabolites and tryptophan and folate panel - cerebral spinal fluid
79572-4,folae and tryptophan and metaolite panel - cerebral sinal fluid
79572-4,folate + tryp + metabs pnl csf
79572-4,metab +tryp + folate pnl csf
79572-4,spinal fl folate + tryp + metabs pnl cerebrospinal fluid
79572-4,folate and tryptophan and metabolites panel (csf)
79572-4,folate spinal fluid and tryptophan and (csf) panel metabolites
79572-4,folate and tryptophan and metabolites (csf) folic acid panel
101781-3,candida guilliermondii dna [presence] in specimen by naa with probe detection
101781-3,specimen guilliermondii dna [presence]in cadia by candidiasis naa wit prbedetection
101781-3,candida guilliermondii [ql] dna in specimen by naa with probe detection
101781-3,c guilliermondii dna spec ql naa+probe
101781-3,c guilliemondii dnspec amplification presence naa+probe
101781-3,c guillirmondii da spec presence lcr naa+probe
101781-3,c. guilliermondii dna naa+probe ql (specimen)
101781-3,c presence dnnaa+probe guilliermndii (specimen)
101781-3,c. guilliermondii da aa+probe ql candidiasis (pcmen)
27306-0,testosterone [presence] in saliva (oral fluid)
27306-0,testosterone saliva in [presence] (oral fluid)
27306-0,testosterone [presence] in saliva (oral fluid)
27306-0,testost sal ql
27306-0,sal testos ql
27306-0,tetost sal ql
27306-0,testosterone ql (sal)
27306-0,testosterone ql (sal) testost
27306-0,qual (sal) ql testosterone
30106-9,acetylcholinesterase [presence] in amniotic fluid
30106-9,acetylcholinesterase amniotic in [presence] fluid
30106-9,acetylcholinesterase amniotic in [presence] screen fluid
30106-9,ache amn ql
30106-9,ache amn ql
30106-9,an ahe ql
30106-9,acetylcholinesterase ql (amn fld)
30106-9,acetylcholinesterase ql (amn fld)
30106-9,acetylcolinesterase q (amn fl)
29635-0,albuterol [presence] in urine
29635-0,urie [presence] in albuterl
29635-0,salbutamol in [presence] albuterol urine
29635-0,albuterol ur ql
29635-0,drugs presence albuterolur
29635-0,albuterol qual ur ql
29635-0,albuterol ql (u)
29635-0,albuteol u) proventil ql
29635-0,albuterol (u) ql proventil
17877-2,bacteria # 6 identified in bone by aerobe culture
17877-2,acteria # 6 identfied in bone bact by aerobe culture
17877-2,bacteria identified 6 aerobe # in bone by aerobe culture
17877-2,bacteria bone aerobe cult org #6
17877-2,nominal bacteria bone aerobe cult org #6
17877-2,bacte bact bone aerbe cult og #6
17877-2,bacteria identified # 6 aer cx nom (bone)
17877-2,baceria ietified # 6 identity or presence bne) cx nom aer
17877-2,bacteria id identified # 6 aer cx nom (bone)
